PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Alper, BS; Malone-Moses, M; McLellan, JS; Prasad, K; Manheimer, E				Alper, Brian S.; Malone-Moses, Meghan; McLellan, James S.; Prasad, Kameshwar; Manheimer, Eric			Thrombolysis in acute ischaemic stroke: time for a rethink?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							TISSUE-PLASMINOGEN ACTIVATOR; POOLED ANALYSIS; ALTEPLASE; TRIAL; GUIDELINES; ATLANTIS; THERAPY; TREAT; NINDS; ECASS		[Alper, Brian S.; Malone-Moses, Meghan; McLellan, James S.] EBSCO Hlth, EBSCO Informat Serv, DynaMed, Ipswich, MA 01938 USA; [Prasad, Kameshwar] All India Inst Med Sci, Dept Neurol, New Delhi, India; [Manheimer, Eric] Cochrane Collaborat, Bahrain Branch, Awali, Bahrain	All India Institute of Medical Sciences (AIIMS) New Delhi	Alper, BS (corresponding author), EBSCO Hlth, EBSCO Informat Serv, DynaMed, Ipswich, MA 01938 USA.	balper@EBSCO.com						Altman DG, 1999, BRIT MED J, V319, P1492, DOI 10.1136/bmj.319.7223.1492; Altman Douglas G, 2002, BMC Med Res Methodol, V2, P3, DOI 10.1186/1471-2288-2-3; American Academy of Emergency Medicine Work Group on Thrombolytic Therapy in Stroke, 2002, POS STAT US INTR THR; American College of Emergency Physicians, 2013, Ann Emerg Med, V61, P225, DOI 10.1016/j.annemergmed.2012.11.005; American College of Emergency Physicians, 2015, CLIN POL US INTR TPA; Australasian College for Emergency Medicine, 2014, STAT INTR THROMB ISC; Australian Government Department of Health Therapeutic goods administration, PROD CONS MED INF AC; Bryer Alan, 2010, S Afr Med J, V100, P747; Canadian Association of Emergency Physicians, 2014, POS STAT AC ISCH STR; Canadian Association of Emergency Physicians Committee on Thrombolytic Therapy for Acute Ischemic Stroke, THROMB THER AC ISCH; Electronic Medicines Compendium, SUMM PROD CHAR ACT; Emberson J, 2014, LANCET, V384, P1929, DOI 10.1016/S0140-6736(14)60584-5; FARRELL B, 1991, J NEUROL NEUROSUR PS, V54, P1044, DOI 10.1136/jnnp.54.12.1044; Genentech, ACT ALT; Gilhus NE, 2011, EUROPEAN HDB NEUROLO, V1, P101; Hacke W, 2004, LANCET, V363, P768; Hacke Werner, 2008, N Engl J Med, V359, P1317, DOI 10.1056/NEJMoa0804656; Haute Autorite de Sante, 2009, TREATING TOBACCO USE; Hudson I, 2014, LANCET, V384, P662, DOI 10.1016/S0140-6736(14)61388-X; Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a; Lansberg MG, 2012, CHEST, V141, pE601S, DOI 10.1378/chest.11-2302; Lees Kennedy R, 2010, Lancet, V375, P1695, DOI 10.1016/S0140-6736(10)60491-6; Lindsay MP, 2013, CANADIAN BEST PRACTI; Minematsu K, 2013, J STROKE CEREBROVASC, V22, P571, DOI 10.1016/j.jstrokecerebrovasdis.2013.04.001; National Institute for Health and Care Excellence, 2012, REV TECHN APPR GUID; National Stroke Foundation, 2010, CLIN GUID STROK MAN; New Zealand Faculty of the Australasian College for Emergency Medicine, 2013, CONS STAT THROMB AC; Newcombe RG, 1999, STAT MED, V18, P1293, DOI 10.1002/(SICI)1097-0258(19990530)18:10<1293::AID-SIM175>3.0.CO;2-7; Sandercock P, 2012, LANCET, V379, P2352, DOI 10.1016/S0140-6736(12)60768-5; Sandercock P, 2012, INT J STROKE, V7, P186, DOI 10.1111/j.1747-4949.2012.00782.x; Shy BD, 2014, J EMERG MED, V46, P385, DOI 10.1016/j.jemermed.2012.05.014; Stroke Thrombolysis Trialists' Collaborative Group, 2013, STROKE, V8, P278; van Zuuren EJ, J EVID BASE IN PRESS; Wardlaw JM, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000213.pub3; Xu AD, 2013, CNS NEUROSCI THER, V19, P543, DOI 10.1111/cns.12126	35	38	41	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 17	2015	350								h1075	10.1136/bmj.h1075	http://dx.doi.org/10.1136/bmj.h1075			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CE1KO	25786912				2023-01-03	WOS:000351570700002
J	Zhou, MJ; Daubresse, M; Stafford, RS; Alexander, GC				Zhou, Meijia; Daubresse, Matthew; Stafford, Randall S.; Alexander, G. Caleb			National Trends in the Ambulatory Treatment of Hypertension in the United States, 1997-2012	PLOS ONE			English	Article							ANTIHYPERTENSIVE MEDICATION USE; PLACEBO-LIKE TOLERABILITY; BLOOD-PRESSURE CONTROL; ORAL RENIN INHIBITOR; CLINICAL-PRACTICE; REAL-LIFE; ALISKIREN; MANAGEMENT; ADULTS; EFFICACY	Importance Hypertension is common and costly. Over the past decade, new antihypertensive therapies have been developed, several have lost patent protection and additional evidence regarding the safety and effectiveness of these agents has accrued. Objective To examine trends in the use of antihypertensive therapies in the United States between 1997 and 2012. Design, Setting and Participants We used nationally representative audit data from the IMS Health National Disease and Therapeutic Index to examine the ambulatory pharmacologic treatment of hypertension. Outcome Measures Our primary unit of analysis was a visit where hypertension was a reported diagnosis and treated with a pharmacotherapy (treatment visit). We restricted analyses to the use of six therapeutic classes of antihypertensive medications among individuals 18 years or older. Results Annual hypertension treatment visits increased from 56.9 million treatment visits (95% confidence intervals [CI], 53.9-59.8) in 1997 to 83.3 million visits (CI 79.2-87.3) in 2008, then declined steadily to 70.9 million visits (CI 66.7-75.0) by 2012. Angiotensin receptor blocker utilization increased substantially from 3% of treatment visits in 1997 to 18% by 2012, whereas calcium channel blocker use decreased from 27% to 18% of visits. Rates of diuretic and beta-blocker use remained stable and represented 24%-30% and 14-16% of visits, respectively. Use of direct renin inhibitor accounted for fewer than 2% of annual visits. The proportion of visits treated using fixed-dose combination therapies increased from 28% to 37% of visits. Conclusions Several important changes have occurred in the landscape of antihypertensive treatment in the United States during the past decade. Despite their novel mechanism of action, the adoption rate of direct renin inhibitors remains low.	[Zhou, Meijia; Daubresse, Matthew; Alexander, G. Caleb] Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; [Zhou, Meijia; Daubresse, Matthew; Alexander, G. Caleb] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Drug Safety & Effectiveness, Baltimore, MD USA; [Stafford, Randall S.] Stanford Univ, Sch Med, Stanford Prevent Res Ctr, Program Prevent Outcomes & Practices, Stanford, CA 94305 USA; [Alexander, G. Caleb] Johns Hopkins Med, Div Gen Internal Med, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Stanford University; Johns Hopkins University; Johns Hopkins Medicine	Alexander, GC (corresponding author), Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA.	galexand@jhsph.edu	Stafford, Randall/F-3974-2017	Stafford, Randall/0000-0003-1805-1271	Agency for Healthcare Research and Quality [RO1 HS0189960]	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	Dr. Alexander is supported by the Agency for Healthcare Research and Quality (RO1 HS0189960). The funding sources had no role in the design and conduct of the study, analysis, or interpretation of the data; and preparation or final approval of the manuscript prior to publication.	Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Chauhan D, 2008, J CLIN PHARM THER, V33, P339, DOI 10.1111/j.1365-2710.2008.00925.x; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Fung V, 2007, CLIN THER, V29, P972, DOI 10.1016/j.clinthera.2007.05.010; Go AS, 2014, CIRCULATION, V129, pE28, DOI 10.1161/01.cir.0000441139.02102.80; Gradman AH, 2005, CIRCULATION, V111, P1012, DOI 10.1161/01.CIR.0000156466.02908.ED; Grimm RH, 2011, J CLIN HYPERTENS, V13, P654, DOI 10.1111/j.1751-7176.2011.00510.x; Gu QP, 2012, CIRCULATION, V126, P2105, DOI 10.1161/CIRCULATIONAHA.112.096156; Gu QP, 2006, CIRCULATION, V113, P213, DOI 10.1161/CIRCULATIONAHA.105.542290; Gupta H, 2010, J PHARM BIOALLIED SC, V2, P2, DOI 10.4103/0975-7406.62694; Heidenreich PA, 2011, CIRCULATION, V123, P933, DOI 10.1161/CIR.0b013e31820a55f5; Higashi A, 2011, J GEN INTERN MED, V26, P1465, DOI 10.1007/s11606-011-1796-4; Hoyert DL, 2011, NATL VITAL STAT REP, V61, P1; James PA, 2014, JAMA-J AM MED ASSOC, V311, P507, DOI 10.1001/jama.2013.284427; Kushiro T, 2006, HYPERTENS RES, V29, P997, DOI 10.1291/hypres.29.997; Ma J, 2006, HYPERTENSION, V48, P846, DOI 10.1161/01.HYP.0000240931.90917.0c; Parving HH, 2012, NEW ENGL J MED, V367, P2204, DOI 10.1056/NEJMoa1208799; Psaty BM, 2002, ARCH INTERN MED, V162, P2325, DOI 10.1001/archinte.162.20.2325; Rabbani A, 2008, AM J HYPERTENS, V21, P509, DOI 10.1038/ajh.2008.31; Sica DA, 2002, DRUGS, V62, P443, DOI 10.2165/00003495-200262030-00003; Sosner P, 2013, J HYPERTENS, V31, P1491, DOI 10.1097/HJH.0b013e328360f716; Stafford RS, 2003, J AM COLL CARDIOL, V41, P56, DOI 10.1016/S0735-1097(02)02670-0; Stanton A, 2003, HYPERTENSION, V42, P1137, DOI 10.1161/01.HYP.0000101688.17370.87; Tocci G, 2012, HIGH BLOOD PRESS CAR, V19, P73, DOI 10.2165/11632170-000000000-00000; Verpooten GA, 2011, INT J CLIN PRACT, V65, P54, DOI 10.1111/j.1742-1241.2010.02562.x; Volpe M, 2012, J HYPERTENS, V30, P194, DOI 10.1097/HJH.0b013e32834e1c66; Zell ER, P SURV RES METH SECT	27	14	14	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 4	2015	10	3							e0119292	10.1371/journal.pone.0119292	http://dx.doi.org/10.1371/journal.pone.0119292			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC9JM	25738503	gold, Green Published, Green Submitted			2023-01-03	WOS:000350685900101
J	Lemmens, RJM; Janssen-Potten, YJM; Timmermans, AAA; Smeets, RJEM; Seelen, HAM				Lemmens, Ryanne J. M.; Janssen-Potten, Yvonne J. M.; Timmermans, Annick A. A.; Smeets, Rob J. E. M.; Seelen, Henk A. M.			Recognizing Complex Upper Extremity Activities Using Body Worn Sensors	PLOS ONE			English	Article							PHYSICAL-ACTIVITY; WEARABLE SENSORS; STROKE; ARM; CLASSIFICATION; CHILDREN; LIFE	To evaluate arm-hand therapies for neurological patients it is important to be able to assess actual arm-hand performance objectively. Because instruments that measure the actual quality and quantity of specific activities in daily life are lacking, a new measure needs to be developed. The aims of this study are to a) elucidate the techniques used to identify upper extremity activities, b) provide a proof-of-principle of this method using a set of activities tested in a healthy adult and in a stroke patient, and c) provide an example of the method's applicability in daily life based on readings taken from a healthy adult. Multiple devices, each of which contains a tri-axial accelerometer, a tri-axial gyroscope and a tri-axial magnetometer were attached to the dominant hand, wrist, upper arm and chest of 30 healthy participants and one stroke patient, who all performed the tasks 'drinking', 'eating' and 'brushing hair' in a standardized environment. To establish proof-of-principle, a prolonged daily life recording of 1 participant was used to identify the task 'drinking'. The activities were identified using multi-array signal feature extraction and pattern recognition algorithms and 2D-convolution. The activities 'drinking', 'eating' and 'brushing hair' were unambiguously recognized in a sequence of recordings of multiple standardized daily activities in a healthy participant and in a stroke patient. It was also possible to identify a specific activity in a daily life recording. The long term aim is to use this method to a) identify arm-hand activities that someone performs during daily life, b) determine the quantity of activity execution, i.e. amount of use, and c) determine the quality of arm-hand skill performance.	[Lemmens, Ryanne J. M.; Janssen-Potten, Yvonne J. M.; Smeets, Rob J. E. M.; Seelen, Henk A. M.] Maastricht Univ, Res Sch CAPHRI, Dept Rehabil Med, NL-6200 MD Maastricht, Netherlands; [Lemmens, Ryanne J. M.; Janssen-Potten, Yvonne J. M.; Smeets, Rob J. E. M.; Seelen, Henk A. M.] Adelante, Ctr Expertise Rehabil & Audiol, Hoensbroek, Netherlands; [Timmermans, Annick A. A.] Hasselt Univ, BIOMED Biomed Res Inst, Diepenbeek, Belgium; [Smeets, Rob J. E. M.] Maastricht Univ, Med Ctr, Dept Rehabil Med, NL-6200 MD Maastricht, Netherlands	Maastricht University; Hasselt University; Maastricht University	Lemmens, RJM (corresponding author), Maastricht Univ, Res Sch CAPHRI, Dept Rehabil Med, NL-6200 MD Maastricht, Netherlands.	r.lemmens@adelante-zorggroep.nl	Smeets, Rob JEM/D-1522-2011	Smeets, Rob JEM/0000-0002-9503-366X; Timmermans, Annick/0000-0002-5461-947X	Adelante; Centre of Expertise in Rehabilitation and Audiology; Hoensbroek; Netherlands	Adelante; Centre of Expertise in Rehabilitation and Audiology; Hoensbroek; Netherlands(Netherlands Government)	This paper was funded by Adelante, Centre of Expertise in Rehabilitation and Audiology, Hoensbroek, the Netherlands. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arner M, 2008, J HAND SURG-AM, V33A, P1337, DOI 10.1016/j.jhsa.2008.02.032; Bai J, 2011, ELECTRON J STAT, V6, P559; Broeks JG, 1999, DISABIL REHABIL, V21, P357; CHEN JJJ, 1992, IEEE T BIO-MED ENG, V39, P9, DOI 10.1109/10.108122; Ermes M, 2008, IEEE T INF TECHNOL B, V12, P20, DOI 10.1109/TITB.2007.899496; Gebruers N, 2010, ARCH PHYS MED REHAB, V91, P288, DOI 10.1016/j.apmr.2009.10.025; Gyllensten IC, 2011, IEEE T BIO-MED ENG, V58, P2656, DOI 10.1109/TBME.2011.2160723; Jain AK, 2000, IEEE T PATTERN ANAL, V22, P4, DOI 10.1109/34.824819; Janssen L, 2011, RES DEV DISABIL, V32, P963, DOI 10.1016/j.ridd.2011.02.002; Lemmens RJM, PLOS ONE IN PRESS; Lemmens RJM, 2014, BMC NEUROLOGY, P14; Lemmens RJM, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-21; Leutheuser H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075196; Lyden K, 2014, MED SCI SPORT EXER, V46, P386, DOI 10.1249/MSS.0b013e3182a42a2d; Magill RA, 2007, MOTOR LEARNING CONTR, P2; Min CH, 2008, IEEE ENG MED BIO, P5192, DOI 10.1109/IEMBS.2008.4650384; Nichols-Larsen DS, 2005, STROKE, V36, P1480, DOI 10.1161/01.STR.0000170706.13595.4f; Patel S, 2012, J NEUROENG REHABIL, V9, DOI 10.1186/1743-0003-9-21; Preece SJ, 2009, PHYSIOL MEAS, V30, pR1, DOI 10.1088/0967-3334/30/4/R01; Sokal B, 2013, ARCH PHYS MED REHABI; Strohrmann C, 2013, J NEUROENG REHABIL, V10, DOI 10.1186/1743-0003-10-83; Timmermans Annick A. A., 2009, 2009 IEEE International Conference on Rehabilitation Robotics: Reaching Users & the Community (ICORR), P98, DOI 10.1109/ICORR.2009.5209558; Timmermans AAA, 2009, DISABIL REHABIL, V31, P1344, DOI 10.1080/09638280902823664; Uswatte G, 2009, REHABIL PSYCHOL, V54, P398, DOI 10.1037/a0017501; VANSANT AF, 1988, PHYS THER, V68, P1330, DOI 10.1093/ptj/68.9.1330; Wagner JF, 2006, COGNITION INSTRUCT, V24, P1, DOI 10.1207/s1532690xci2401_1; Wolfe CDA, 2000, BRIT MED BULL, V56, P275, DOI 10.1258/0007142001903120	27	25	27	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2015	10	3							e0118642	10.1371/journal.pone.0118642	http://dx.doi.org/10.1371/journal.pone.0118642			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC4HV	25734641	Green Submitted, Green Published, gold			2023-01-03	WOS:000350314700043
J	Kim, HU; Ryu, JY; Lee, JO; Lee, SY				Kim, Hyun Uk; Ryu, Jae Yong; Lee, Jong Ok; Lee, Sang Yup			A systems approach to traditional oriental medicine	NATURE BIOTECHNOLOGY			English	Article							DRUG-COMBINATIONS; NATURAL-PRODUCT; MECHANISMS; INTEGRATION; TARGETS; IMPACT; CELLS; TCM		[Kim, Hyun Uk; Ryu, Jae Yong; Lee, Jong Ok; Lee, Sang Yup] Korea Adv Inst Sci & Technol, Metab & Biomol Engn Natl Res Lab, Dept Chem & Biomol Engn,Plus Program BK21, Ctr Syst & Synthet Biotechnol,Inst BioCentury, Taejon 305701, South Korea; [Kim, Hyun Uk; Lee, Jong Ok; Lee, Sang Yup] Korea Adv Inst Sci & Technol, BioInformat Res Ctr, Taejon 305701, South Korea; [Lee, Sang Yup] Korea Adv Inst Sci & Technol, BioProc Engn Res Ctr, Taejon 305701, South Korea; [Kim, Hyun Uk; Lee, Sang Yup] Tech Univ Denmark, Novo Nordisk Fdn Ctr Biosustainabil, Horsholm, Denmark	Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST); Technical University of Denmark	Kim, HU (corresponding author), Korea Adv Inst Sci & Technol, Metab & Biomol Engn Natl Res Lab, Dept Chem & Biomol Engn,Plus Program BK21, Ctr Syst & Synthet Biotechnol,Inst BioCentury, Taejon 305701, South Korea.	leesy@kaist.ac.kr	Kim, Hyun Uk/F-4509-2018; Lee, Sang Yup/C-1526-2011	Kim, Hyun Uk/0000-0001-7224-642X; Lee, Sang Yup/0000-0003-0599-3091	Novo Nordisk Fonden [NNF10CC1016517] Funding Source: researchfish; NNF Center for Biosustainability [New Bioactive Compounds] Funding Source: researchfish	Novo Nordisk Fonden(Novo Nordisk Foundation); NNF Center for Biosustainability		Agren R, 2014, MOL SYST BIOL, V10, DOI 10.1002/msb.145122; Blazier AS, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00299; Chen CYC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015939; Cheung F, 2011, NATURE, V480, pS82, DOI 10.1038/480S82a; Dar AC, 2012, NATURE, V486, P80, DOI 10.1038/nature11127; Ding M, 2007, J PHARM PHARMACOL, V59, P1027, DOI 10.1211/jpp.59.7.0016; Dobson PD, 2009, DRUG DISCOV TODAY, V14, P31, DOI 10.1016/j.drudis.2008.10.011; Feng Y, 2010, BRIT J PHARMACOL, V161, P113, DOI 10.1111/j.1476-5381.2010.00826.x; Ganesan A, 2008, CURR OPIN CHEM BIOL, V12, P306, DOI 10.1016/j.cbpa.2008.03.016; Gujral TS, 2014, P NATL ACAD SCI USA, V111, P5048, DOI 10.1073/pnas.1403080111; Hawkes D, 2014, TRENDS PHARMACOL SCI, V35, P111, DOI 10.1016/j.tips.2014.01.002; Hebar A, 2013, EXPERT REV CLIN PHAR, V6, P23, DOI [10.1586/ECP.12.71, 10.1586/ecp.12.71]; Irwin JJ, 2012, J CHEM INF MODEL, V52, P1757, DOI 10.1021/ci3001277; Jayaseelan KV, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-106; Jia J, 2009, NAT REV DRUG DISCOV, V8, P111, DOI 10.1038/nrd2683; Jung JY, 2011, KOR J MED HIST, V20, P1; Kanehisa M, 2012, NUCLEIC ACIDS RES, V40, pD109, DOI 10.1093/nar/gkr988; Keiser MJ, 2009, NATURE, V462, P175, DOI 10.1038/nature08506; Khanna V, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-30; Kim HU, 2012, BIOTECHNOL J, V7, P330, DOI 10.1002/biot.201100159; Kim HU, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2010.115; Kim TY, 2010, METAB ENG, V12, P105, DOI 10.1016/j.ymben.2009.05.004; Knox C, 2011, NUCLEIC ACIDS RES, V39, pD1035, DOI 10.1093/nar/gkq1126; Li S, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-S1-S10; Liu X, 2013, TRENDS PHARMACOL SCI, V34, P620, DOI 10.1016/j.tips.2013.09.004; Ma XH, 2009, DRUG DISCOV TODAY, V14, P579, DOI 10.1016/j.drudis.2009.03.012; Mardinoglu A, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4083; McCarty MF, 2006, MED HYPOTHESES, V66, P1093, DOI 10.1016/j.mehy.2004.11.046; McKnight SL, 2010, SCIENCE, V330, P1338, DOI 10.1126/science.1199908; Oh C, 2013, KOR J MED HIST, V22, P1; Rahman SA, 2009, J CHEMINFORMATICS, V1, DOI 10.1186/1758-2946-1-12; Schmidt BM, 2007, NAT CHEM BIOL, V3, P360, DOI 10.1038/nchembio0707-360; Spink BC, 2003, BIOCHEM PHARMACOL, V66, P2313, DOI 10.1016/j.bcp.2003.08.019; Thiele I, 2013, NAT BIOTECHNOL, V31, P419, DOI 10.1038/nbt.2488; van der Greef J, 2011, NATURE, V480, pS87, DOI 10.1038/480S87a; Wang L, 2008, P NATL ACAD SCI USA, V105, P4826, DOI 10.1073/pnas.0712365105; Xu ZG, 2011, NATURE, V480, pS90, DOI 10.1038/480S90a	37	60	61	0	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2015	33	3					264	268		10.1038/nbt.3167	http://dx.doi.org/10.1038/nbt.3167			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	CD0ME	25748918	Bronze			2023-01-03	WOS:000350766900022
J	Wolf, SM; Berlinger, N; Jennings, B				Wolf, Susan M.; Berlinger, Nancy; Jennings, Bruce			Forty Years of Work on End-of-Life Care - From Patients' Rights to Systemic Reform	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							FEEDING-TUBE INSERTION; DECISION-MAKING; PALLIATIVE CARE; TRANSITIONS; PROJECT; DEATH		[Wolf, Susan M.] Univ Minnesota, Consortium Law & Values Hlth Environm & Life Sci, Minneapolis, MN 55455 USA; [Berlinger, Nancy] Hastings Ctr, Garrison, NY USA; [Jennings, Bruce] Ctr Humans & Nat, Dobbs Ferry, NY USA	University of Minnesota System; University of Minnesota Twin Cities	Wolf, SM (corresponding author), Univ Minnesota, Consortium Law & Values Hlth Environm & Life Sci, Minneapolis, MN 55455 USA.							Abboud C, 2013, BLOOD, V121, P4439, DOI 10.1182/blood-2013-03-490003; American College of Physicians, PAP END LIF CONS PAN; American Medical Association, AMA POL END LIF CAR; American Nurses Association, POS STAT REG NURS RO; [Anonymous], 2014, NY TIMES, pA18; [Anonymous], 2013, IPAL PROJ IMPR PALL; [Anonymous], 2013, ONC IMPR ONC COMM SK; Aulino F, 2001, J ROY SOC MED, V94, P492, DOI 10.1177/014107680109400923; Back AL, 2013, J PALLIAT MED, V16, P1429, DOI 10.1089/jpm.2013.0193; Barfield RC, 2010, AM J BIOETHICS, V10, P28, DOI 10.1080/15265161003632930; Berlinger N., 2013, HASTINGS CTR GUIDELI, V2nd ed; Berlinger N, 2013, PEDIATRICS, V132, P789, DOI 10.1542/peds.2013-1378; Blinderman CD, 2012, JAMA-J AM MED ASSOC, V307, P917, DOI 10.1001/jama.2012.236; Committee on Approaching Death: Addressing Key End of Life Issues, 2014, DYING AM IMPR QUAL H; Feng ZL, 2012, HEALTH AFFAIR, V31, P1251, DOI 10.1377/hlthaff.2012.0129; Field M., 2002, CHILDREN DIE IMPROVI; Field MJ, 1997, APPROACHING DEATH IM; Fins JJ, 2005, HASTINGS CENT REP, V35, P22, DOI 10.1353/hcr.2005.0020; Goodman DC, 2013, TRENDS CANC CARE NEA; Greer JA, 2013, CA-CANCER J CLIN, V63, P349, DOI 10.3322/caac.21192; HAFEMEISTER TL, 1991, ISSUES LAW MED, V7, P53; *HAST CTR, 1987, GUID TERM LIF SUST T; Hurd MD, 2013, NEW ENGL J MED, V368, P1326, DOI 10.1056/NEJMsa1204629; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; LO B, 1995, JAMA-J AM MED ASSOC, V274, P1634, DOI 10.1001/jama.274.20.1634; Lunney J.R., 2003, DESCRIBING DEATH AM; MEISEL A, 2004, RIGHT DIE LAW END LI; Naylor MD, 2011, HEALTH AFFAIR, V30, P746, DOI 10.1377/hlthaff.2011.0041; Pathak EB, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005196; *PRES COMM STUD ET, 1983, DEC FOR LIF SUST TRE; Quill TE, 2013, NEW ENGL J MED, V368, P1173, DOI 10.1056/NEJMp1215620; Schell JO, 2012, SEMIN DIALYSIS, V25, P611, DOI 10.1111/sdi.12017; Schmidt RJ, 2013, CLIN J AM SOC NEPHRO, V8, P1; Teno JM, 2013, JAMA-J AM MED ASSOC, V309, P470, DOI 10.1001/jama.2012.207624; Teno JM, 2011, J AM GERIATR SOC, V59, P881, DOI 10.1111/j.1532-5415.2011.03385.x; Teno JM, 2009, J PALLIAT MED, V12, P359, DOI 10.1089/jpm.2008.0168; Williams MV, 2014, SOUTH MED J, V107, P455, DOI 10.14423/SMJ.0000000000000140; WOLF SM, 1991, NEW ENGL J MED, V325, P1666, DOI 10.1056/NEJM199112053252334; 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI DOI 10.1001/JAMA.1995.03530200027032	39	33	33	1	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 12	2015	372	7					678	682		10.1056/NEJMms1410321	http://dx.doi.org/10.1056/NEJMms1410321			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CA8CK	25671263				2023-01-03	WOS:000349143900017
J	Stein, GY; Alon, D; Korenfeld, R; Fuchs, S				Stein, Gideon Y.; Alon, Danny; Korenfeld, Roman; Fuchs, Shmuel			Clinical Implications of High-Sensitivity Cardiac Troponin Measurements in Hospitalized Medical Patients	PLOS ONE			English	Article							ACUTE CORONARY SYNDROME; MYOCARDIAL-INFARCTION; HEART-FAILURE; MORTALITY; ASSAY; ASSOCIATION; POPULATION; RISK; AGE	Background The increased use of high sensitivity cardiac troponins (hs-cTn), have made the diagnosis of non-ST elevation myocardial infarction (MI) challenging, especially in complex medical patients, in whom the clinical presentation of MI is nonspecific and multiple comorbidities as well as non-ischemic acute conditions may account for elevated hs-cTn levels. The aim of this study was to assess the frequency of both elevated hs-cTn levels and dynamic changes in hospitalized patients. Methods and Findings We conducted a retrospective study identifying all patients hospitalized in the Internal Medicine Division of Rabin Medical Center, Israel between January 2011 to December 2011, for whom at least one hs-cTn T (hs-cTnT) measurement was obtained. Collected data included patient demographics, acute and chronic diagnosis, hs-cTnT and creatinine levels and date of death. Hs-cTnT levels were obtained in 5,696 admissions and was above the 99th percentile (> = 13 ng/L) in 61.6% of the measurements. A relative change of 50% or higher was observed in 24% of the admissions. Among those with elevated hs-cTnT levels, acute coronary syndromes (ACS) accounted for only 6.1% of acute diagnoses. Maximal hs-cTnT levels above 100 ng/L but not dynamic changes discriminated between ACS and non-ACS conditions (positive and negative predictive values of 12% and 96% respectively). The frequency of elevated hs-cTnT levels was age-dependent and over 75% of patients aged >70 yearsold had levels above the 99th percentile. Multivariate analysis identified hs-cTnT levels higher than the 99th percentile, as an independent, strong predictor for 30-day mortality (OR 4.58 [2.8, 7.49], p<0.0001). Conclusions Elevated hs-cTnT levels together with dynamic changes are frequent findings among hospitalized patients and in most cases, are not related to the ACS diagnosis. These findings highlight the diagnostic challenge of ACS in this complex population. Further studies are needed in order to optimize the use of hs-cTnT measurements in hospitalized patients.	[Fuchs, Shmuel] Beilinson Med Ctr, Rabin Med Ctr, Dept Internal Med B, Petah Tiqwa, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel	Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Fuchs, S (corresponding author), Beilinson Med Ctr, Rabin Med Ctr, Dept Internal Med B, Petah Tiqwa, Israel.	shmuelf@clalit.org.il						Baron JM, 2014, AM J CLIN PATHOL, V141, P488, DOI 10.1309/AJCPLVQQY35XTFVN; de Lemos JA, 2011, CLIN CHEM, V57, P826, DOI 10.1373/clinchem.2011.163758; de Lemos JA, 2010, JAMA-J AM MED ASSOC, V304, P2503, DOI 10.1001/jama.2010.1768; deFilippi CR, 2010, JAMA-J AM MED ASSOC, V304, P2494, DOI 10.1001/jama.2010.1708; Eggers KM, 2013, J AM COLL CARDIOL, V61, P1906, DOI 10.1016/j.jacc.2012.12.048; Gore MO, 2014, J AM COLL CARDIOL, V63, P1441, DOI 10.1016/j.jacc.2013.12.032; Haaf P, 2012, CIRCULATION, V126, P31, DOI 10.1161/CIRCULATIONAHA.112.100867; Hammarsten O, 2012, CLIN CHEM, V58, P628, DOI 10.1373/clinchem.2011.171496; Hijazi Z, 2013, CIRCULATION, DOI [10.1161/CIRCULATIONAHA.113.007747, DOI 10.1161/CIRCULATIONAHA.113.007747]; Irfan A, 2012, AM J MED, V125, P491, DOI 10.1016/j.amjmed.2011.10.031; Kelley WE, 2009, CLIN CHEM, V55, P2098, DOI 10.1373/clinchem.2009.130799; Korley FK, 2013, J AM COLL CARDIOL, V61, P1753, DOI 10.1016/j.jacc.2012.09.069; Masson S, 2013, J INTERN MED, V273, P306, DOI 10.1111/joim.12023; McFalls EO, 2011, AM J MED, V124, P630, DOI 10.1016/j.amjmed.2011.02.024; Mishra RK, 2013, AM J KIDNEY DIS, V61, P701, DOI 10.1053/j.ajkd.2012.11.034; Mueller M, 2012, CLIN CHEM, V58, P209, DOI 10.1373/clinchem.2011.171827; Newby LK, 2012, J AM COLL CARDIOL, V60, P2427, DOI 10.1016/j.jacc.2012.08.969; Normann J, 2012, AM HEART J, V164, P698, DOI 10.1016/j.ahj.2012.08.003; Omland T, 2009, NEW ENGL J MED, V361, P2538, DOI 10.1056/NEJMoa0805299; Reichlin T, 2009, NEW ENGL J MED, V361, P858, DOI 10.1056/NEJMoa0900428; Sandoval Y, 2014, J AM COLL CARDIOL, V63, P2079, DOI 10.1016/j.jacc.2014.02.541; Saunders JT, 2011, CIRCULATION, V123, P1367, DOI 10.1161/CIRCULATIONAHA.110.005264; Stein GY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084285; Thygesen K, 2012, EUR HEART J, V33, P2551, DOI 10.1093/eurheartj/ehs184	24	8	8	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2015	10	1							e0117162	10.1371/journal.pone.0117162	http://dx.doi.org/10.1371/journal.pone.0117162			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC9HX	25636061	gold, Green Published, Green Submitted			2023-01-03	WOS:000350680700073
J	Frost, P				Frost, Paul			COMPETENT NOVICE Intravenous fluid therapy in adult inpatients	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							HYDROXYETHYL STARCH; SEVERE SEPSIS; RESUSCITATION; SALINE		[Frost, Paul] Univ Wales Hosp, Crit Care Directorate, Cardiff CF14 4XW, S Glam, Wales; [Frost, Paul] Cardiff Univ, Inst Med Educ, Cardiff CF14 4XN, S Glam, Wales	Cardiff University; Cardiff University	Frost, P (corresponding author), Univ Wales Hosp, Crit Care Directorate, Cardiff CF14 4XW, S Glam, Wales.	Frostp2@cf.ac.uk						Arieff AI, 1999, CHEST, V115, P1371, DOI 10.1378/chest.115.5.1371; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Caironi P, 2014, NEW ENGL J MED, V370, P1412, DOI 10.1056/NEJMoa1305727; Frost PJ, 2012, BMJ-BRIT MED J, V345, P43; Handy JM, 2008, BRIT J ANAESTH, V101, P141, DOI 10.1093/bja/aen148; Hartog CS, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5981; Kaplan LJ, 2005, CRIT CARE, V9, P198, DOI 10.1188/cc2912; Medicines and Healthcare Products Regulatory Agency, 2013, HYDR STARCH INTR INF; Mehanna HM, 2008, BRIT MED J, V336, P1495, DOI 10.1136/bmj.a301; Myburgh JA, 2013, NEW ENGL J MED, V369, P1243, DOI 10.1056/NEJMra1208627; Myburgh JA, 2012, NEW ENGL J MED, V367, P1901, DOI 10.1056/NEJMoa1209759; National Confidential Enquiry into Perioperative Deaths, 1999, EXTR AGE 1999 REP NA; National Institute for Health and Care Excellence, 2013, CLIN GUID 174; Perel P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000567.pub6; Perner A, 2012, NEW ENGL J MED, V367, P124, DOI 10.1056/NEJMoa1204242; Powell-Tuck J, 2008, BRIT CONSENSUS GUIDE; Preau S, 2010, CRIT CARE MED, V38, P819, DOI 10.1097/CCM.0b013e3181c8fe7a; Reynolds RM, 2006, BMJ-BRIT MED J, V332, P702, DOI 10.1136/bmj.332.7543.702; Severs D, 2014, NEPHROL DIAL TRANSPL, DOI [10.1093/ndt/gfu005, DOI 10.1093/NDT/GFU005]; Spasovski G, 2014, INTENS CARE MED, V40, P320, DOI 10.1007/s00134-014-3210-2; Verheij J, 2006, INTENS CARE MED, V32, P1030, DOI 10.1007/s00134-006-0195-5; Woodcock TE, 2012, BRIT J ANAESTH, V108, P384, DOI 10.1093/bja/aer515	22	14	15	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 6	2015	350								g7620	10.1136/bmj.g7620	http://dx.doi.org/10.1136/bmj.g7620			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AZ3LX	25569336				2023-01-03	WOS:000348130100001
J	Santavirta, T; Santavirta, N; Betancourt, TS; Gilman, SE				Santavirta, Torsten; Santavirta, Nina; Betancourt, Theresa S.; Gilman, Stephen E.			Long term mental health outcomes of Finnish children evacuated to Swedish families during the second world war and their non-evacuated siblings: cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PSYCHOSOCIAL SUPPORT; REFUGEE CHILDREN; RISK-FACTORS; CHILDHOOD; WAR; DEPRESSION; DISORDERS; CONFLICT; EXPERIENCES; PREVALENCE	Objectives To compare the risks of admission to hospital for any type of psychiatric disorder and for four specific psychiatric disorders among adults who as children were evacuated to Swedish foster families during the second world war and their non-evacuated siblings, and to evaluate whether these risks differ between the sexes. Design Cohort study. Setting National child evacuation scheme in Finland during the second world war. Participants Children born in Finland between 1933 and 1944 who were later included in a 10% sample of the 1950 Finnish census ascertained in 1997 (n=45 463; women: n=22 021; men: n=23 442). Evacuees in the sample were identified from war time government records. Main outcome measure Adults admitted to hospital for psychiatric disorders recorded between 1971 and 2011 in the Finnish hospital discharge register. Methods We used Cox proportional hazards models to estimate the association between evacuation to temporary foster care in Sweden during the second world war and admission to hospital for a psychiatric disorder between ages 38 and 78 years. Fixed effects methods were employed to control for all unobserved social and genetic characteristics shared among siblings. Results Among men and women combined, the risk of admission to hospital for a psychiatric disorder did not differ between Finnish adults evacuated to Swedish foster families and their non-evacuated siblings (hazard ratio 0.89, 95% confidence interval 0.64 to 1.26). Evidence suggested a lower risk of admission for any mental disorder (0.67, 0.44 to 1.03) among evacuated men, whereas for women there was no association between evacuation and the overall risk of admission for a psychiatric disorder (1.21, 0.80 to 1.83). When admissions for individual psychiatric disorders were analyzed, evacuated girls were significantly more likely than their non-evacuated sisters to be admitted to hospital for a mood disorder as an adult (2.19, 1.10 to 4.33). Conclusions The Finnish evacuation policy was not associated with an increased overall risk of admission to hospital for a psychiatric disorder in adulthood among former evacuees. In fact, evacuation was associated with a marginally reduced risk of admission for any psychiatric disorder among men. Among women who had been evacuated, however, the risk of being admitted to hospital for a mood disorder was increased.	[Santavirta, Torsten] Stockholm Univ, Swedish Inst Social Res, SE-10691 Stockholm, Sweden; [Santavirta, Nina] Univ Helsinki, Inst Behav Sci, Helsinki, Finland; [Betancourt, Theresa S.] Harvard Univ, Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA; [Gilman, Stephen E.] Harvard Univ, Sch Publ Hlth, Massachusetts Gen Hosp, Dept Social & Behav Sci,Dept Psychiat, Boston, MA 02115 USA; [Gilman, Stephen E.] Harvard Univ, Sch Publ Hlth, Massachusetts Gen Hosp, Dept Epidemiol,Dept Psychiat, Boston, MA 02115 USA	Stockholm University; University of Helsinki; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Massachusetts General Hospital	Santavirta, T (corresponding author), Stockholm Univ, Swedish Inst Social Res, SE-10691 Stockholm, Sweden.	torsten.santavirta@sofi.su.se	Gilman, Stephen/E-7632-2010; Santavirta, Torsten/C-3918-2014; Santavirta, Torsten/AAE-1066-2021	Gilman, Stephen/0000-0002-8331-6419; Santavirta, Torsten/0000-0001-6613-3410; 	Academy of Finland; National Institutes of Health [MH087544]; Signe and Ane Gyllenberg Foundation; Tore Browaldh Foundation; Siamon Foundation; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH087544] Funding Source: NIH RePORTER	Academy of Finland(Academy of Finland); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Signe and Ane Gyllenberg Foundation; Tore Browaldh Foundation; Siamon Foundation; NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This work was supported by the Academy of Finland, National Institutes of Health (grant MH087544), and the Signe and Ane Gyllenberg Foundation. TS received additional support from the Tore Browaldh Foundation and the Siamon Foundation.	Almas AN, 2012, P NATL ACAD SCI USA, V109, P17228, DOI 10.1073/pnas.1121256109; Bean TM, 2007, SOC SCI MED, V64, P1204, DOI 10.1016/j.socscimed.2006.11.010; Betancourt TS, 2013, HARVARD REV PSYCHIAT, V21, P70, DOI 10.1097/HRP.0b013e318283bf8f; Betancourt TS, 2012, J ADOLESCENT HEALTH, V51, P544, DOI 10.1016/j.jadohealth.2012.02.010; Betancourt TS, 2012, DISASTERS, V36, P635, DOI 10.1111/j.1467-7717.2012.01280.x; Betancourt TS, 2011, J AM ACAD CHILD PSY, V50, P323, DOI 10.1016/j.jaac.2011.01.008; Betancourt TS, 2011, J ADOLESCENT HEALTH, V49, P21, DOI 10.1016/j.jadohealth.2010.09.021; Betancourt TS, 2008, INT REV PSYCHIATR, V20, P317, DOI 10.1080/09540260802090363; Bound J, 1999, ECON EDUC REV, V18, P169, DOI 10.1016/S0272-7757(98)00048-X; BRAMER G R, 1988, World Health Statistics Quarterly, V41, P32; Cameron CA, 2015, J HUM RESOU IN PRESS; Craig Peter, 2008, BMJ, V337, pa1655, DOI 10.1136/bmj.a1655; Danese A, 2009, ARCH PEDIAT ADOL MED, V163, P1135, DOI 10.1001/archpediatrics.2009.214; Donovan SJ, 2011, INT J EPIDEMIOL, V40, P345, DOI 10.1093/ije/dyr057; Eide K, 2013, ACTA PAEDIATR, V102, P666, DOI 10.1111/apa.12258; Fazel M, 2005, LANCET, V365, P1309, DOI 10.1016/S0140-6736(05)61027-6; Fazel M, 2012, LANCET, V379, P266, DOI 10.1016/S0140-6736(11)60051-2; Feldman R, 2011, J AM ACAD CHILD PSY, V50, P645, DOI 10.1016/j.jaac.2011.03.001; Freud A, 1943, WAR AND CHILDREN; Frisell T, 2012, EPIDEMIOLOGY, V23, P713, DOI 10.1097/EDE.0b013e31825fa230; Gilman SE, 2015, MOL PSYCHIATR, V20, P329, DOI 10.1038/mp.2014.36; Gilman SE, 2003, AM J PSYCHIAT, V160, P939, DOI 10.1176/appi.ajp.160.5.939; Gilman SE, 2007, AM J EPIDEMIOL, V166, P1134, DOI 10.1093/aje/kwm251; Gilman SE, 2014, SOC SCI MED, V118, P191, DOI 10.1016/j.socscimed.2014.06.029; Gilman SE, 2012, AM J EPIDEMIOL, V176, P684, DOI 10.1093/aje/kws228; Green JG, 2010, ARCH GEN PSYCHIAT, V67, P113, DOI 10.1001/archgenpsychiatry.2009.186; Hjern A, 2002, LANCET, V360, P443, DOI 10.1016/S0140-6736(02)09674-5; HOLT JD, 1974, BIOMETRIKA, V61, P17, DOI 10.1093/biomet/61.1.17; Huemer J, 2009, LANCET, V373, P612, DOI 10.1016/S0140-6736(09)60380-9; International Committee of the Red Cross. Central Tracing Agency and Protection Division, 2004, INT GUID PRINC UN SE; Isohanni M, 1997, SOC PSYCH PSYCH EPID, V32, P303, DOI 10.1007/BF00789044; Jaffee SR, 2002, ARCH GEN PSYCHIAT, V59, P215, DOI 10.1001/archpsyc.59.3.215; Kaven P, 2010, THESIS U HELSINKI; Kendler KS, 2002, PSYCHOL MED, V32, P1187, DOI 10.1017/S0033291702006219; Keskimaki I, 1991, INT J HLTH SCI, V2, P15, DOI DOI 10.1177/1403494812456637; Lehtiranta L, 1996, MATKALLA KODISTA KOT; Lomu J, 1974, PUBLICATION SERIES N, p5a; Morgan C, 2007, PSYCHOL MED, V37, P495, DOI 10.1017/S0033291706009330; Ni Bhrolchain M, 2000, EUR SOCIOL REV, V16, P67; NUNNO MA, 1988, CHILD ABUSE NEGLECT, V12, P521, DOI 10.1016/0145-2134(88)90069-5; Panter-Brick C, 2014, J CHILD PSYCHOL PSYC, V55, P313, DOI 10.1111/jcpp.12167; Perala J, 2007, ARCH GEN PSYCHIAT, V64, P19, DOI 10.1001/archpsyc.64.1.19; Pesonen AK, 2007, AM J EPIDEMIOL, V166, P1126, DOI 10.1093/aje/kwm254; Raikkonen K, 2011, J PSYCHIATR RES, V45, P332, DOI 10.1016/j.jpsychires.2010.07.003; Rasanen E, 1992, Acta Paedopsychiatr, V55, P19; ROSENZWEIG MR, 1995, ECONOMETRICA, V63, P303, DOI 10.2307/2951628; Santavirta N, 2014, HEALTH ECON, V23, P253, DOI 10.1002/hec.2913; Santavirta T, 2012, AM ECON J-APPL ECON, V4, P28, DOI 10.1257/app.4.3.28; Sheridan MA, 2012, P NATL ACAD SCI USA, V109, P12927, DOI 10.1073/pnas.1200041109; Skeer M, 2009, DRUG ALCOHOL DEPEN, V104, P65, DOI 10.1016/j.drugalcdep.2009.03.017; Statistics Finland, 2013, HDB STAT FINL, V38; Sund R, 2012, SCAND J PUBLIC HEALT, V40, P505, DOI 10.1177/1403494812456637; TENNANT C, 1982, BRIT J PSYCHIAT, V141, P475, DOI 10.1192/bjp.141.5.475; Tol WA, 2011, LANCET, V378, P1581, DOI 10.1016/S0140-6736(11)61094-5; Tyler KA, 2002, CHILD ABUSE NEGLECT, V26, P1261, DOI 10.1016/S0145-2134(02)00413-1; Vervliet M, 2014, EUR CHILD ADOLES PSY, V23, P337, DOI 10.1007/s00787-013-0463-1; Wilcox HC, 2010, J AM ACAD CHILD PSY, V49, P514, DOI 10.1016/j.jaac.2010.01.020; World Health Organization, 1992, INSTR MAN, V3; World Health Organization, 1965, INT STAT CLASS DIS I; World Health Organization, 1977, MAN INT STAT CLASS D; World Health Organization, 1992, TAB LIST, V2	62	24	25	1	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 5	2015	350								g7753	10.1136/bmj.g7753	http://dx.doi.org/10.1136/bmj.g7753			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AZ3LU	25569841	Green Published, hybrid			2023-01-03	WOS:000348129900003
J	Knorr, RL; Nakatogawa, H; Ohsumi, Y; Lipowsky, R; Baumgart, T; Dimova, R				Knorr, Roland L.; Nakatogawa, Hitoshi; Ohsumi, Yoshinori; Lipowsky, Reinhard; Baumgart, Tobias; Dimova, Rumiana			Membrane Morphology Is Actively Transformed by Covalent Binding of the Protein Atg8 to PE-Lipids	PLOS ONE			English	Article							AUTOPHAGOSOME FORMATION; AMPHIPATHIC HELICES; EARLY STEPS; VESICLES; MECHANISM; DOMAIN	Autophagy is a cellular degradation pathway involving the shape transformation of lipid bilayers. During the onset of autophagy, the water-soluble protein Atg8 binds covalently to phosphatdylethanolamines (PEs) in the membrane in an ubiquitin-like reaction coupled to ATP hydrolysis. We reconstituted the Atg8 conjugation system in giant and nm-sized vesicles with a minimal set of enzymes and observed that formation of Atg8-PE on giant vesicles can cause substantial tubulation of membranes even in the absence of Atg12-Atg5-Atg16. Our findings show that ubiquitin-like processes can actively change properties of lipid membranes and that membrane crowding by proteins can be dynamically regulated in cells. Furthermore we provide evidence for curvature sorting of Atg8-PE. Curvature generation and sorting are directly linked to organelle shapes and, thus, to biological function. Our results suggest that a positive feedback exists between the ubiquitin-like reaction and the membrane curvature, which is important for dynamic shape changes of cell membranes, such as those involved in the formation of autophagosomes.	[Knorr, Roland L.; Lipowsky, Reinhard; Dimova, Rumiana] Max Planck Inst Colloids & Interfaces, Dept Theory & Biosyst, Potsdam, Germany; [Nakatogawa, Hitoshi; Ohsumi, Yoshinori] Tokyo Inst Technol, Frontier Res Ctr, Yokohama, Kanagawa 227, Japan; [Baumgart, Tobias] Univ Penn, Dept Chem, Philadelphia, PA 19104 USA	Max Planck Society; Tokyo Institute of Technology; University of Pennsylvania	Knorr, RL (corresponding author), Max Planck Inst Colloids & Interfaces, Dept Theory & Biosyst, Potsdam, Germany.	knorr@mpikg.mpg.de; dimova@mpikg.mpg.de	Nakatogawa, Hitoshi/D-5155-2015; Dimova, Rumiana/C-4330-2008; Ohsumi, Yoshinori/C-6449-2009	Nakatogawa, Hitoshi/0000-0002-5828-0741; Dimova, Rumiana/0000-0002-3872-8502; Ohsumi, Yoshinori/0000-0003-2384-2166; Lipowsky, Reinhard/0000-0001-8417-8567	German Science Foundation [1524]; NIH [GM 097552]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM097552] Funding Source: NIH RePORTER	German Science Foundation(German Research Foundation (DFG)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The work was supported by the German Science Foundation within the framework of IGRTG 1524 and by NIH grant GM 097552. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANGELOVA MI, 1986, FARADAY DISCUSS, V81, P303, DOI 10.1039/dc9868100303; Baumgart T, 2011, ANNU REV PHYS CHEM, V62, P483, DOI 10.1146/annurev.physchem.012809.103450; Capraro BR, 2010, J AM CHEM SOC, V132, P1200, DOI 10.1021/ja907936c; Dimova R, 2007, SOFT MATTER, V3, P817, DOI 10.1039/b703580b; Galush WJ, 2008, BIOPHYS J, V95, P2512, DOI 10.1529/biophysj.108.131540; Hatzakis NS, 2009, NAT CHEM BIOL, V5, P835, DOI 10.1038/nchembio.213; Ichimura Y, 2004, J BIOL CHEM, V279, P40584, DOI 10.1074/jbc.M405860200; Jensen MB, 2011, J BIOL CHEM, V286, P42603, DOI 10.1074/jbc.M111.271130; Kaufmann A, 2014, CELL, V156, P469, DOI 10.1016/j.cell.2013.12.022; Knorr RL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032753; Knorr RL, 2010, SOFT MATTER, V6, P1990, DOI 10.1039/b925929e; Kochl R, 2006, TRAFFIC, V7, P129, DOI 10.1111/j.1600-0854.2005.00368.x; Kunding AH, 2008, BIOPHYS J, V95, P1176, DOI 10.1529/biophysj.108.128819; LAI MZ, 1985, BIOCHEMISTRY-US, V24, P1654, DOI 10.1021/bi00328a013; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Lipowsky R, 1996, PHYS REV LETT, V77, P1652, DOI 10.1103/PhysRevLett.77.1652; Lipowsky R, 2013, FARADAY DISCUSS, V161, P305, DOI 10.1039/c2fd20105d; Mari M, 2010, J CELL BIOL, V190, P1005, DOI 10.1083/jcb.200912089; Mizushima N, 2009, CURR TOP MICROBIOL, V335, P71, DOI 10.1007/978-3-642-00302-8_3; Nair U, 2011, CELL, V146, P290, DOI 10.1016/j.cell.2011.06.022; Nakatogawa H, 2007, CELL, V130, P165, DOI 10.1016/j.cell.2007.05.021; Nakatogawa H, 2012, AUTOPHAGY, V8, P177, DOI 10.4161/auto.8.2.18373; Nakatogawa H, 2012, METHODS MOL BIOL, V832, P519, DOI 10.1007/978-1-61779-474-2_37; Nath S, 2014, NAT CELL BIOL, V16, P415, DOI 10.1038/ncb2940; Nikolaus J, 2010, BIOPHYS J, V98, P1192, DOI 10.1016/j.bpj.2009.11.042; Rauch J, 2003, J BIOL CHEM, V278, P47508, DOI 10.1074/jbc.M308089200; Romanov J, 2012, EMBO J, V31, P4304, DOI 10.1038/emboj.2012.278; S Nath JD, 2013, BIOPHYSICAL J, V104; Sakoh-Nakatogawa M, 2013, NAT STRUCT MOL BIOL, V20, P433, DOI 10.1038/nsmb.2527; Sorre B, 2012, P NATL ACAD SCI USA, V109, P173, DOI 10.1073/pnas.1103594108; Stachowiak JC, 2012, NAT CELL BIOL, V14, P944, DOI 10.1038/ncb2561; Tian A, 2009, BIOPHYS J, V96, P2676, DOI 10.1016/j.bpj.2008.11.067; WAUGH R, 1979, BIOPHYS J, V26, P115, DOI 10.1016/S0006-3495(79)85239-X; Xie ZP, 2008, MOL BIOL CELL, V19, P3290, DOI 10.1091/mbc.E07-12-1292; Xie ZP, 2009, AUTOPHAGY, V5, P217, DOI 10.4161/auto.5.2.7201; Yamamoto H, 2012, J CELL BIOL, V198, P219, DOI 10.1083/jcb.201202061; Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814	37	45	45	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 18	2014	9	12							e115357	10.1371/journal.pone.0115357	http://dx.doi.org/10.1371/journal.pone.0115357			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA4AC	25522362	gold, Green Published, Green Submitted			2023-01-03	WOS:000348845600037
J	Nunes, VD; Gholitabar, M; Sims, JM; Bewley, S				Nunes, Vanessa Delgado; Gholitabar, Maryam; Sims, Jessica Mai; Bewley, Susan		Guideline Dev Grp	GUIDELINES Intrapartum care of healthy women and their babies: summary of updated NICE guidance	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Nunes, Vanessa Delgado; Gholitabar, Maryam; Sims, Jessica Mai] Royal Coll Obstetricians & Gynaecologists, Natl Collaborating Ctr Womens & Childrens Hlth, London NW1 4RG, England; [Bewley, Susan] Kings Coll London, Womens Hlth Acad Dept, London WC2R 2LS, England	University of London; King's College London	Nunes, VD (corresponding author), Royal Coll Obstetricians & Gynaecologists, Natl Collaborating Ctr Womens & Childrens Hlth, London NW1 4RG, England.	vnunes@rcog.org.uk		Sims, Jessica/0000-0003-1565-7315				Blix E, 2012, SEX REPROD HEALTHC, V3, P147, DOI 10.1016/j.srhc.2012.10.001; Brocklehurst P, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d7400; National Institute for Clinical Excellence (NICE), 2014, INTR CAR CAR HLTH WO; National Institute for Health and Care Excellence, 2007, INTR CAR CAR HLTH WO	4	31	31	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 3	2014	349								g6886	10.1136/bmj.g6886	http://dx.doi.org/10.1136/bmj.g6886			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AW2KN	25472418	Green Published			2023-01-03	WOS:000346116600002
J	Crous-Bou, M; Fung, TT; Prescott, J; Julin, B; Du, M; Sun, Q; Rexrode, KM; Hu, FB; De Vivo, I				Crous-Bou, Marta; Fung, Teresa T.; Prescott, Jennifer; Julin, Bettina; Du, Mengmeng; Sun, Qi; Rexrode, Kathryn M.; Hu, Frank B.; De Vivo, Immaculata			Mediterranean diet and telomere length in Nurses' Health Study: population based cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-HEART-DISEASE; CIGARETTE-SMOKING; CARDIOVASCULAR-DISEASE; PRIMARY PREVENTION; OXIDATIVE STRESS; RISK-FACTORS; ASSOCIATION; MORTALITY; ADHERENCE; PATTERNS	Objective To examine whether adherence to the Mediterranean diet was associated with longer telomere length, a biomarker of aging. Design Population based cohort study. Setting Nurses' Health Study, an ongoing prospective cohort study of 121 700 nurses enrolled in 1976; in 1989-90 a subset of 32 825 women provided blood samples. Participants 4676 disease-free women from nested case-control studies within the Nurses' Health Study with telomere length measured who also completed food frequency questionnaires. Main outcome measure Association between relative telomere lengths in peripheral blood leukocytes measured by quantitative real time polymerase chain reaction and Alternate Mediterranean Diet score calculated from self reported dietary data. Results Greater adherence to the Mediterranean diet was associated with longer telomeres after adjustment for potential confounders. Least squares mean telomere length z scores were -0.038 (SE 0.035) for the lowest Mediterranean diet score groups and 0.072 (0.030) for the highest group (P for trend=0.004). Conclusion In this large study, greater adherence to the Mediterranean diet was associated with longer telomeres. These results further support the benefits of adherence to the Mediterranean diet for promoting health and longevity.	[Crous-Bou, Marta; Prescott, Jennifer; Julin, Bettina; Du, Mengmeng; Sun, Qi; Hu, Frank B.; De Vivo, Immaculata] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA; [Crous-Bou, Marta; Prescott, Jennifer; Julin, Bettina; Du, Mengmeng; Sun, Qi; Rexrode, Kathryn M.; Hu, Frank B.; De Vivo, Immaculata] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Crous-Bou, Marta; Julin, Bettina; Hu, Frank B.; De Vivo, Immaculata] Harvard Univ, Sch Med, Program Genet Epidemiol & Stat Genet, Dept Epidemiol, Boston, MA 02115 USA; [Fung, Teresa T.] Simmons Coll, Dept Nutr, Boston, MA 02115 USA; [Fung, Teresa T.; Sun, Qi; Hu, Frank B.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; [Du, Mengmeng] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA; Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA; [Rexrode, Kathryn M.] Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Simmons University; Harvard University; Harvard T.H. Chan School of Public Health; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Harvard University; Brigham & Women's Hospital	De Vivo, I (corresponding author), Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA.	nhidv@channing.harvard.edu	Rexrode, Kathryn M/I-1177-2018; Crous-Bou, Marta/A-9499-2019	Crous-Bou, Marta/0000-0003-1493-4288; De Vivo, Immaculata/0000-0002-7185-7402; Rexrode, Kathryn/0000-0003-3387-8429	National Cancer Institute, National Institutes of Health [1R01 CA134958, 2R01 CA082838, P01 CA087969, R01 CA49449, CA065725, CA132190, CA139586, CA140790, CA133914, CA132175, CA163451, HL088521, HL60712, U54 CA155626, R01 AR059073, HL34594]; Sara Borrell postdoctoral fellowship from the Spanish Ministry of Health, Carlos III Health Institute; National Cancer Institute [R25 CA94880]; NHLBI [R00HL098459]; NATIONAL CANCER INSTITUTE [R03CA132175, U54CA155626, R01CA065725, R03CA133914, R01CA134958, P01CA087969, R01CA163451, R01CA049449, R03CA139586, R01CA082838, R03CA132190, R25CA094880, K07CA140790] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060712, R01HL088521, R00HL098459, R01HL034594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR059073] Funding Source: NIH RePORTER	National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Sara Borrell postdoctoral fellowship from the Spanish Ministry of Health, Carlos III Health Institute; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The Nurses' Health Study is supported by the National Cancer Institute, National Institutes of Health (1R01 CA134958, 2R01 CA082838, P01 CA087969, R01 CA49449, CA065725, CA132190, CA139586, CA140790, CA133914, CA132175, CA163451, HL088521, HL60712, U54 CA155626, R01 AR059073, HL34594). MC-B is also supported by a Sara Borrell postdoctoral fellowship from the Spanish Ministry of Health, Carlos III Health Institute. MD is supported by grant R25 CA94880 from the National Cancer Institute. QS is supported by an NHLBI sponsored career development award (R00HL098459). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbott A, 2009, NATURE, V461, P706, DOI 10.1038/461706a; ASCHERIO A, 1992, CIRCULATION, V86, P1475, DOI 10.1161/01.CIR.86.5.1475; Aviv A., 2004, SCI AGING KNOWLEDGE, V2004, P43, DOI DOI 10.1126/SAGEKE.2004.51.PE43; Aviv A, 2009, AM J EPIDEMIOL, V169, P323, DOI 10.1093/aje/kwn338; Bekaert S, 2007, AGING CELL, V6, P639, DOI 10.1111/j.1474-9726.2007.00321.x; Benetou V, 2008, BRIT J CANCER, V99, P191, DOI 10.1038/sj.bjc.6604418; Bischoff C, 2006, EPIDEMIOLOGY, V17, P190, DOI 10.1097/01.ede.0000199436.55248.10; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Blasco MA, 2005, NAT REV GENET, V6, P611, DOI 10.1038/nrg1656; Boccardi V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062781; Calado RT, 2009, NEW ENGL J MED, V361, P2353, DOI 10.1056/NEJMra0903373; Cassidy A, 2010, AM J CLIN NUTR, V91, P1273, DOI 10.3945/ajcn.2009.28947; Cawthon RM, 2003, LANCET, V361, P393, DOI 10.1016/S0140-6736(03)12384-7; Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47; Chiuve SE, 2008, CIRCULATION, V118, P947, DOI 10.1161/CIRCULATIONAHA.108.781062; Chiuve SE, 2012, J NUTR, V142, P1009, DOI 10.3945/jn.111.157222; Colditz G A, 1995, J Am Med Womens Assoc (1972), V50, P40; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; De Vivo I, 2009, CANCER EPIDEM BIOMAR, V18, P1152, DOI 10.1158/1055-9965.EPI-08-0998; Devore EE, 2011, NEUROSCI LETT, V492, P15, DOI 10.1016/j.neulet.2011.01.041; di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118; Du MM, 2012, AM J EPIDEMIOL, V175, P414, DOI 10.1093/aje/kwr330; Estruch R, 2018, NEW ENGL J MED, V378, DOI [10.1056/NEJMoa1800389, 10.1056/nejmoa1800389]; Farzaneh-Far R, 2010, JAMA-J AM MED ASSOC, V303, P250, DOI 10.1001/jama.2009.2008; Fung TT, 2009, CIRCULATION, V119, P1093, DOI 10.1161/CIRCULATIONAHA.108.816736; Garcia-Calzon S, 2014, INT J OBESITY, V38, P177, DOI 10.1038/ijo.2013.68; Han JL, 2009, J INVEST DERMATOL, V129, P415, DOI 10.1038/jid.2008.238; HANKINSON SE, 1995, CANCER EPIDEM BIOMAR, V4, P649; Haycock PC, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4227; Henle ES, 1999, J BIOL CHEM, V274, P962, DOI 10.1074/jbc.274.2.962; Hu FB, 2000, AM J CLIN NUTR, V72, P912; Hu FB, 1999, AM J CLIN NUTR, V69, P243; Hunt SC, 2008, AGING CELL, V7, P451, DOI 10.1111/j.1474-9726.2008.00397.x; Jacobs DR, 2009, AM J CLIN NUTR, V89, pS1543, DOI 10.3945/ajcn.2009.26736B; Krauss J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026983; Liang GY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023462; Lopez-Garcia E, 2014, AM J CLIN NUTR, V99, P172, DOI 10.3945/ajcn.113.068106; MANSON JE, 1991, ARCH INTERN MED, V151, P1141, DOI 10.1001/archinte.151.6.1141; Martin-Ruiz CM, 2005, AGING CELL, V4, P287, DOI 10.1111/j.1474-9726.2005.00171.x; Martinez-Gonzalez MA, 2008, BMJ-BRIT MED J, V336, P1348, DOI 10.1136/bmj.39561.501007.BE; McGrath M, 2007, CANCER EPIDEM BIOMAR, V16, P815, DOI 10.1158/1055-9965.EPI-06-0961; Mirabello L, 2009, AGING CELL, V8, P405, DOI 10.1111/j.1474-9726.2009.00485.x; Okereke OI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040516; Ornish D, 2013, LANCET ONCOL, V14, P1112, DOI 10.1016/S1470-2045(13)70366-8; Page JH, 2008, CLIN CHEM, V54, P1190, DOI 10.1373/clinchem.2007.099291; Prescott J, 2012, HUM REPROD, V27, P3622, DOI 10.1093/humrep/des314; Prescott J, 2010, CANCER-AM CANCER SOC, V116, P4275, DOI 10.1002/cncr.25328; Roux AVD, 2009, AGING CELL, V8, P251, DOI 10.1111/j.1474-9726.2009.00470.x; SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858; Samieri C, 2013, ANN INTERN MED, V159, P584, DOI 10.7326/0003-4819-159-9-201311050-00004; Scarmeas N, 2006, ARCH NEUROL-CHICAGO, V63, P1709, DOI 10.1001/archneur.63.12.noc60109; Sofi F, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1344; Sun Q, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038374; TRICHOPOULOU A, 1995, AM J CLIN NUTR, V61, p1346S, DOI 10.1093/ajcn/61.6.1346S; Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039; Trichopoulou Antonia, 2009, BMJ, V338, pb2337, DOI 10.1136/bmj.b2337; Valdes AM, 2005, LANCET, V366, P662, DOI 10.1016/S0140-6736(05)66630-5; Vallabhaneni H, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003639; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; Von Zglinicki T, 2000, FREE RADICAL BIO MED, V28, P64, DOI 10.1016/S0891-5849(99)00207-5; Von Zglinicki T, 2000, ANN NY ACAD SCI, V908, P99, DOI 10.1111/j.1749-6632.2000.tb06639.x; von Zglinicki T, 2002, TRENDS BIOCHEM SCI, V27, P339, DOI 10.1016/S0968-0004(02)02110-2; von Zglinicki T, 2003, NAT BIOTECHNOL, V21, P229, DOI 10.1038/nbt0303-229b; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; Wang H, 2008, MOVEMENT DISORD, V23, P302, DOI 10.1002/mds.21867; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598; WILLETT WC, 1995, AM J CLIN NUTR, V61, p1402S, DOI 10.1093/ajcn/61.6.1402S; Xu Q, 2009, AM J CLIN NUTR, V89, P1857, DOI 10.3945/ajcn.2008.26986; Zhu HD, 2011, J PEDIATR-US, V158, P215, DOI 10.1016/j.jpeds.2010.08.007	69	149	151	0	36	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 2	2014	349								g6674	10.1136/bmj.g6674	http://dx.doi.org/10.1136/bmj.g6674			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AW2KK	25467028	hybrid, Green Published			2023-01-03	WOS:000346116300002
J	Sleddering, MA; Markvoort, AJ; Dharuri, HK; Jeyakar, S; Snel, M; Juhasz, P; Lynch, M; Hines, W; Li, XH; Jazet, IM; Adourian, A; Hilbers, PAJ; Smit, JWA; Van Dijk, KW				Sleddering, Maria A.; Markvoort, Albert J.; Dharuri, Harish K.; Jeyakar, Skhandhan; Snel, Marieke; Juhasz, Peter; Lynch, Moira; Hines, Wade; Li, Xiaohong; Jazet, Ingrid M.; Adourian, Aram; Hilbers, Peter A. J.; Smit, Johannes W. A.; Van Dijk, Ko Willems			Proteomic Analysis in Type 2 Diabetes Patients before and after a Very Low Calorie Diet Reveals Potential Disease State and Intervention Specific Biomarkers	PLOS ONE			English	Article							APOLIPOPROTEIN-A-IV; HORMONE-BINDING GLOBULIN; OBESE-PATIENTS; COMPLEMENT C3; PLASMA-CONCENTRATIONS; GLYCEMIC CONTROL; MELLITUS; INSULIN; PROTEIN; FIBRINOGEN	Very low calorie diets (VLCD) with and without exercise programs lead to major metabolic improvements in obese type 2 diabetes patients. The mechanisms underlying these improvements have so far not been elucidated fully. To further investigate the mechanisms of a VLCD with or without exercise and to uncover possible biomarkers associated with these interventions, blood samples were collected from 27 obese type 2 diabetes patients before and after a 16-week VLCD (Modifast,450 kcal/day). Thirteen of these patients followed an exercise program in addition to the VCLD. Plasma was obtained from 27 lean and 27 obese controls as well. Proteomic analysis was performed using mass spectrometry (MS) and targeted multiple reaction monitoring (MRM) and a large scale isobaric tags for relative and absolute quantitation (iTRAQ) approach. After the 16-week VLCD, there was a significant decrease in body weight and HbA1c in all patients, without differences between the two intervention groups. Targeted MRM analysis revealed differences in several proteins, which could be divided in diabetes-associated (fibrinogen, transthyretin), obesity-associated (complement C3), and diet-associated markers (apolipoproteins, especially apolipoprotein A-IV). To further investigate the effects of exercise, large scale iTRAQ analysis was performed. However, no proteins were found showing an exercise effect. Thus, in this study, specific proteins were found to be differentially expressed in type 2 diabetes patients versus controls and before and after a VLCD. These proteins are potential disease state and intervention specific biomarkers.	[Sleddering, Maria A.; Snel, Marieke; Jazet, Ingrid M.; Smit, Johannes W. A.; Van Dijk, Ko Willems] Leiden Univ, Med Ctr, Dept Gen Internal Med, Leiden, Netherlands; [Sleddering, Maria A.; Snel, Marieke; Jazet, Ingrid M.; Smit, Johannes W. A.; Van Dijk, Ko Willems] Leiden Univ, Med Ctr, Dept Endocrinol & Metab, Leiden, Netherlands; [Dharuri, Harish K.; Van Dijk, Ko Willems] Leiden Univ, Med Ctr, Leiden, Netherlands; [Markvoort, Albert J.; Hilbers, Peter A. J.] Eindhoven Univ Technol, Dept Biomed Engn, NL-5600 MB Eindhoven, Netherlands; [Juhasz, Peter; Lynch, Moira; Hines, Wade; Li, Xiaohong; Adourian, Aram] BG Med Inc, Waltham, MA USA	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Eindhoven University of Technology	Sleddering, MA (corresponding author), Leiden Univ, Med Ctr, Dept Gen Internal Med, Leiden, Netherlands.	m.a.sleddering@lumc.nl	van Dijk, Ko Willems/A-1798-2008; Markvoort, Albert J/A-9833-2013; Markvoort, Albert/AAI-4535-2021; van Dijk, Ko Willems/AAT-4681-2021	van Dijk, Ko Willems/0000-0002-2172-7394; van Dijk, Ko Willems/0000-0002-2172-7394	Roba Metals BV (IJsselstein, The Netherlands); Center for Translational Molecular Medicine (CTMM), project PREDICCt [01C-104]; Center of Medical Systems Biology (CMSB); Netherlands Consortium for Systems Biology (NCSB); Netherlands Genomics Initiative/Netherlands Organization for Scientific Research (NGI/NWO)	Roba Metals BV (IJsselstein, The Netherlands)(Netherlands Government); Center for Translational Molecular Medicine (CTMM), project PREDICCt; Center of Medical Systems Biology (CMSB); Netherlands Consortium for Systems Biology (NCSB); Netherlands Genomics Initiative/Netherlands Organization for Scientific Research (NGI/NWO)(Netherlands Organization for Scientific Research (NWO))	Funding: This study was funded by an unrestricted grant of Roba Metals BV (IJsselstein, The Netherlands). Nutrition & Sante (Antwerp, Belgium) freely supplied the Modifast. This research was furthermore supported by the Center for Translational Molecular Medicine (CTMM), project PREDICCt (grant 01C-104), and by grants from the Center of Medical Systems Biology (CMSB), the Netherlands Consortium for Systems Biology (NCSB) established by The Netherlands Genomics Initiative/Netherlands Organization for Scientific Research (NGI/NWO). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Afolabi PR, 2007, AM J PHYSIOL-ENDOC M, V293, pE1580, DOI 10.1152/ajpendo.00169.2007; Barazzoni R, 2003, DIABETES, V52, P1851, DOI 10.2337/diabetes.52.7.1851; Bates D., 2011, R PACKAGE VERSION 1, P1; Becker A, 2003, NETH J MED, V61, P129; Bertile F, 2009, PROTEOMICS, V9, P148, DOI 10.1002/pmic.200701001; CABALLERO MJ, 1992, EUR J APPL PHYSIOL O, V64, P9, DOI 10.1007/BF00376432; Caballero MJ, 1996, ENDOCR RES, V22, P131, DOI 10.1080/07435809609030502; Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P1066; Ceriello A, 1998, DIABETOLOGIA, V41, P1270, DOI 10.1007/s001250051064; Choe L, 2007, PROTEOMICS, V7, P3651, DOI 10.1002/pmic.200700316; Culnan DM, 2009, OBESITY, V17, P46, DOI 10.1038/oby.2008.428; Danaei G, 2011, LANCET, V378, P31, DOI 10.1016/S0140-6736(11)60679-X; Dandona P, 2002, AM J CARDIOL, V90, p27G; Ding EL, 2009, NEW ENGL J MED, V361, P1152, DOI 10.1056/NEJMoa0804381; Donath MY, 2011, NAT REV IMMUNOL, V11, P98, DOI 10.1038/nri2925; EHNHOLM C, 1994, ATHEROSCLEROSIS, V107, P229, DOI 10.1016/0021-9150(94)90024-8; Engstrom G, 2005, DIABETES, V54, P570, DOI 10.2337/diabetes.54.2.570; ERNST E, 1993, BRIT HEART J, V70, P116; Finucane MM, 2011, LANCET, V377, P557, DOI 10.1016/S0140-6736(10)62037-5; FUJIMOTO K, 1992, AM J PHYSIOL, V262, pG1002, DOI 10.1152/ajpgi.1992.262.6.G1002; Garcia-Ramirez M, 2007, DIABETOLOGIA, V50, P1294, DOI 10.1007/s00125-007-0627-y; GREEN PHR, 1980, J CLIN INVEST, V65, P911, DOI 10.1172/JCI109745; Hammer S, 2008, J AM COLL CARDIOL, V52, P1006, DOI 10.1016/j.jacc.2008.04.068; Herder C, 2011, CLIN PHARMACOL THER, V90, P52, DOI 10.1038/clpt.2011.93; Hernandez-Mijares A, 2007, INT J OBESITY, V31, P927, DOI 10.1038/sj.ijo.0803543; Hess K, 2012, DIABETOLOGIA, V55, P1103, DOI 10.1007/s00125-011-2301-7; HOFFER LJ, 1984, METABOLISM, V33, P820, DOI 10.1016/0026-0495(84)90108-2; Hothorn T, 2008, BIOMETRICAL J, V50, P346, DOI 10.1002/bimj.200810425; JACOBSSON B, 1989, J HISTOCHEM CYTOCHEM, V37, P31, DOI 10.1177/37.1.2642294; Jae SY, 2008, AM J CARDIOL, V102, P700, DOI 10.1016/j.amjcard.2008.05.012; Jazet IM, 2007, DIABETES RES CLIN PR, V77, P70, DOI 10.1016/j.diabres.2006.10.019; Juhasz P, 2011, J PROTEOME RES, V10, P34, DOI 10.1021/pr100659e; KANNEL WB, 1990, AM HEART J, V120, P672, DOI 10.1016/0002-8703(90)90026-T; Karelis AD, 2008, LANCET, V372, P1281, DOI 10.1016/S0140-6736(08)61531-7; KELLEHER PC, 1983, METABOLISM, V32, P95, DOI 10.1016/0026-0495(83)90163-4; Kim HJ, 2007, J PROTEOME RES, V6, P735, DOI 10.1021/pr060489g; Kramer CK, 2013, ANN INTERN MED, V159, P758, DOI 10.7326/0003-4819-159-11-201312030-00008; Kriegel TM, 2009, REPROD BIOMED ONLINE, V19, P660, DOI 10.1016/j.rbmo.2009.07.001; Kronenberg F, 2000, J AM COLL CARDIOL, V36, P751, DOI 10.1016/S0735-1097(00)00775-0; Lyons TJ, 2012, TRANSL RES, V159, P303, DOI 10.1016/j.trsl.2012.01.009; Maris M, 2008, PROTEOM CLIN APPL, V2, P312, DOI 10.1002/prca.200780093; Matthaei S, 2000, ENDOCR REV, V21, P585, DOI 10.1210/er.21.6.585; Missov RM, 1996, DIABETES CARE, V19, P157, DOI 10.2337/diacare.19.2.157; Mokdad AH, 2001, JAMA-J AM MED ASSOC, V286, P1195, DOI 10.1001/jama.286.10.1195; Onat A, 2011, CLIN CHIM ACTA, V412, P1171, DOI 10.1016/j.cca.2011.03.005; PASQUALI R, 1987, METABOLISM, V36, P1141, DOI 10.1016/0026-0495(87)90240-X; Quilliot D, 2001, METABOLISM, V50, P1019, DOI 10.1053/meta.2001.25656; Ramalho R, 2009, OBES SURG, V19, P915, DOI 10.1007/s11695-009-9848-0; Rao PV, 2009, J PROTEOME RES, V8, P239, DOI 10.1021/pr8003776; Riaz S, 2010, DIABETES TECHNOL THE, V12, P979, DOI 10.1089/dia.2010.0078; Riaz S, 2010, J PHARMACEUT BIOMED, V51, P1103, DOI 10.1016/j.jpba.2009.11.016; Ritz P, 2009, OBES SURG, V19, P840, DOI 10.1007/s11695-008-9627-3; SCALFI L, 1987, ANN NUTR METAB, V31, P154, DOI 10.1159/000177262; Shen L, 2007, ENDOCRINOLOGY, V148, P2681, DOI 10.1210/en.2006-1596; Snel M, 2012, OBESITY, V20, P1572, DOI 10.1038/oby.2011.390; Snel M, 2012, J CLIN ENDOCR METAB, V97, P2512, DOI 10.1210/jc.2011-3178; Snel M, 2012, EUR J INTERN MED, V23, P143, DOI 10.1016/j.ejim.2011.07.004; Snel M, 2011, FOOD CHEM TOXICOL, V49, P3104, DOI 10.1016/j.fct.2011.09.032; Sun ZY, 2000, ATHEROSCLEROSIS, V151, P381, DOI 10.1016/S0021-9150(99)00395-0; Takahashi M, 2008, J IMMUNOL, V180, P6132, DOI 10.4049/jimmunol.180.9.6132; Team R.C., 2021, R FOUN DATION STAT C; Tso P, 2004, PHYSIOL BEHAV, V83, P631, DOI 10.1016/j.physbeh.2004.07.032; Tymchuk CN, 1998, NUTR CANCER, V31, P127, DOI 10.1080/01635589809514691; Tymchuk CN, 2000, NUTR CANCER, V38, P158, DOI 10.1207/S15327914NC382_3; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Verges B, 2001, J LIPID RES, V42, P2021; VERGES BL, 1994, DIABETES CARE, V17, P810, DOI 10.2337/diacare.17.8.810; Wang YA, 2011, DIABETES CARE, V34, P2576, DOI 10.2337/dc11-0685; WEINBERG RB, 1990, GASTROENTEROLOGY, V98, P17, DOI 10.1016/0016-5085(90)91285-E; Yang Y, 2006, INT J OBESITY, V30, P439, DOI 10.1038/sj.ijo.0803173; Zhao Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016470	71	17	21	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 21	2014	9	11							e112835	10.1371/journal.pone.0112835	http://dx.doi.org/10.1371/journal.pone.0112835			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX4MM	25415563	Green Published, gold, Green Submitted			2023-01-03	WOS:000346906600019
J	Alpern, JD; Stauffer, WM; Kesselheim, AS				Alpern, Jonathan D.; Stauffer, William M.; Kesselheim, Aaron S.			High-Cost Generic Drugs - Implications for Patients and Policymakers	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Alpern, Jonathan D.; Stauffer, William M.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; [Alpern, Jonathan D.; Stauffer, William M.] Reg Hosp, Dept Med, St Paul, MN USA; [Kesselheim, Aaron S.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Program Regulat Therapeut & Law, Boston, MA 02115 USA; [Kesselheim, Aaron S.] Harvard Univ, Sch Med, Boston, MA USA	University of Minnesota System; University of Minnesota Twin Cities; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Alpern, JD (corresponding author), Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA.		Liles, Nathan W/C-9819-2018; Kesselheim, Aaron/R-6793-2017	Liles, Nathan W/0000-0002-3710-7296; Kesselheim, Aaron/0000-0002-8867-2666				[Anonymous], MICR 2 0 EL VERS; Choudhry NK, 2009, HEALTH AFFAIR, V28, P827, DOI 10.1377/hlthaff.28.3.827; Colliver V, 2014, PRICES SOAR SOME GEN; Government Accountability Office, 2009, BRANDN PRESCR DRUG P	4	82	82	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 13	2014	371	20					1859	1862		10.1056/NEJMp1408376	http://dx.doi.org/10.1056/NEJMp1408376			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AT1RB	25390739	Bronze			2023-01-03	WOS:000344709800002
J	Harrison, MJ; Dusheiko, M; Sutton, M; Gravelle, H; Doran, T; Roland, M				Harrison, Mark J.; Dusheiko, Mark; Sutton, Matt; Gravelle, Hugh; Doran, Tim; Roland, Martin			Effect of a national primary care pay for performance scheme on emergency hospital admissions for ambulatory care sensitive conditions: controlled longitudinal study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FOR-PERFORMANCE; HEALTH-CARE; FINANCIAL INCENTIVES; HIGHER QUALITY; UK QUALITY; OUTCOMES; PROGRAM; ASSOCIATION; POPULATION; MANAGEMENT	Objective To estimate the impact of a national primary care pay for performance scheme, the Quality and Outcomes Framework in England, on emergency hospital admissions for ambulatory care sensitive conditions (ACSCs). Design Controlled longitudinal study. Setting English National Health Service between 1998/99 and 2010/11. Participants Populations registered with each of 6975 family practices in England. Main outcome measures Year specific differences between trend adjusted emergency hospital admission rates for incentivised ACSCs before and after the introduction of the Quality and Outcomes Framework scheme and two comparators: non-incentivised ACSCs and non-ACSCs. Results Incentivised ACSC admissions showed a relative reduction of 2.7% (95% confidence interval 1.6% to 3.8%) in the first year of the Quality and Outcomes Framework compared with ACSCs that were not incentivised. This increased to a relative reduction of 8.0% (6.9% to 9.1%) in 2010/11. Compared with conditions that are not regarded as being influenced by the quality of ambulatory care (non-ACSCs), incentivised ACSCs also showed a relative reduction in rates of emergency admissions of 2.8% (2.0% to 3.6%) in the first year increasing to 10.9% (10.1% to 11.7%) by 2010/11. Conclusions The introduction of a major national pay for performance scheme for primary care in England was associated with a decrease in emergency admissions for incentivised conditions compared with conditions that were not incentivised. Contemporaneous health service changes seem unlikely to have caused the sharp change in the trajectory of incentivised ACSC admissions immediately after the introduction of the Quality and Outcomes Framework. The decrease seems larger than would be expected from the changes in the process measures that were incentivised, suggesting that the pay for performance scheme may have had impacts on quality of care beyond the directly incentivised activities.	[Harrison, Mark J.; Sutton, Matt] Univ Manchester, Inst Populat Hlth, Manchester Ctr Hlth Econ, Manchester M13 9PL, Lancs, England; [Harrison, Mark J.; Gravelle, Hugh] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada; [Harrison, Mark J.] St Pauls Hosp, Ctr Hlth Evaluat & Outcome Sci, Vancouver, BC V6Z 1Y6, Canada; [Dusheiko, Mark] Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England; [Dusheiko, Mark] Univ Lausanne, Inst Hlth Econ & Management, Lausanne, Switzerland; [Roland, Martin] Univ Cambridge, Cambridge Ctr Hlth Serv Res, Cambridge CB2 0SR, England; [Doran, Tim] Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England	University of Manchester; University of British Columbia; St. Paul's Hospital; University of Saskatchewan; University of York - UK; University of Lausanne; University of Cambridge; University of York - UK	Roland, M (corresponding author), Univ Cambridge, Cambridge Ctr Hlth Serv Res, Forvie Site,Robinson Way, Cambridge CB2 0SR, England.	mr108@cam.ac.uk	Harrison, Mark/AFP-1095-2022	Harrison, Mark/0000-0002-2115-2447; Gravelle, Hugh/0000-0002-7753-4233; Sutton, Matt/0000-0002-6635-2127; Roland, Martin/0000-0002-8533-3060	UK Department of Health	UK Department of Health	This study received no direct funding, but it was initiated at a time when the National Primary Care Research and Development Centre at the University of Manchester was receiving core funding from the UK Department of Health. The views expressed are those of the authors and not necessarily those of the Department of Health. The researchers are totally independent of the funders.	Blunt I, 2010, TRENDS EMERGENCY ADM; Bottle A, 2008, J GEN INTERN MED, V23, P135, DOI 10.1007/s11606-007-0390-2; Calderon-Larranaga A, 2011, THORAX, V66, P191, DOI 10.1136/thx.2010.147058; Campbell SM, 2009, NEW ENGL J MED, V361, P368, DOI 10.1056/NEJMsa0807651; Chang RE, 2012, HEALTH AFFAIR, V31, P93, DOI 10.1377/hlthaff.2010.0402; Chen JY, 2010, AM J MANAG CARE, V16, pE11; Chen JY, 2011, AM J MED QUAL, V26, P340, DOI 10.1177/1062860611398303; Chernew ME, 2011, HEALTH AFFAIR, V30, P51, DOI 10.1377/hlthaff.2010.0980; Christianson J, 2009, FINANCIAL INCENTIVES; Conrad DA, 2009, ANNU REV PUBL HEALTH, V30, P357, DOI 10.1146/annurev.publhealth.031308.100243; Damberg CL, 2009, HEALTH AFFAIR, V28, P517, DOI 10.1377/hlthaff.28.2.517; Department of Health, 2000, DEP HLTH NAT FRAM CO; Doran T, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d3590; DUROJAIYE LIA, 1989, PUBLIC HEALTH, V103, P181, DOI 10.1016/S0033-3506(89)80073-3; Dusheiko M, 2011, HEALTH SERV RES, V46, P27, DOI 10.1111/j.1475-6773.2010.01184.x; Emmert M, 2012, EUR J HEALTH ECON, V13, P755, DOI 10.1007/s10198-011-0329-8; Fiorentini G, 2011, EUR J HEALTH ECON, V12, P297, DOI 10.1007/s10198-010-0230-x; Fleetcroft R, 2010, BRIT J GEN PRACT, V60, DOI 10.3399/bjgp10X515359; Flodgren G, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009255; Gillam SJ, 2012, ANN FAM MED, V10, P461, DOI 10.1370/afm.1377; Houle SK, 2012, ANN INTERN MED, V157, P889; Kiran T, 2010, J EPIDEMIOL COMMUN H, V64, P927, DOI 10.1136/jech.2009.098806; Kruse GB, 2012, HEALTH SERV RES, V47, P2118, DOI 10.1111/1475-6773.12003; Martin S, 2011, QUALITY IMPROVEMENTS; Mitchell C, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X572472; National Audit Office, 2013, EM ADM HOSP MAN DEM; Office for National Statistics, 2012, POP EST ENGL WAL MID; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; Purdy S, 2009, PUBLIC HEALTH, V123, P169, DOI 10.1016/j.puhe.2008.11.001; Purdy S, 2011, J HEALTH SERV RES PO, V16, P133, DOI 10.1258/jhsrp.2010.010013; Roland M, 2004, NEW ENGL J MED, V351, P1448, DOI 10.1056/NEJMhpr041294; Roland M, 2014, NEW ENGL J MED, V370, P1944, DOI 10.1056/NEJMhpr1316051; Roland M, 2012, ANN INTERN MED, V157, P912, DOI 10.7326/0003-4819-157-12-201212180-00014; Rosenthal MB, 2005, JAMA-J AM MED ASSOC, V294, P1788, DOI 10.1001/jama.294.14.1788; Serumaga B, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d108; Simpson CR, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X583407; Soljak M, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X613142; Song Z, 2011, NEW ENGL J MED, V365, P909, DOI 10.1056/NEJMsa1101416; Sutton M, 2012, NEW ENGL J MED, V367, P1821, DOI 10.1056/NEJMsa1114951; Sutton M, 2010, HEALTH ECON, V19, P1, DOI 10.1002/hec.1440; Tian Y, 2012, EMERGENCY HOSP ADMIS; Van Herck P, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-247; van Walraven C, 2011, CAN MED ASSOC J, V183, pE391, DOI 10.1503/cmaj.101860; Wagner AK, 2002, J CLIN PHARM THER, V27, P299, DOI 10.1046/j.1365-2710.2002.00430.x; Weinberger M, 1996, NEW ENGL J MED, V334, P1441, DOI 10.1056/NEJM199605303342206; Werner RM, 2009, HEALTH AFFAIR, V28, P1498, DOI 10.1377/hlthaff.28.5.1498	46	87	87	0	33	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 11	2014	349								g6423	10.1136/bmj.g6423	http://dx.doi.org/10.1136/bmj.g6423			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AU2JQ	25389120	Green Published, hybrid			2023-01-03	WOS:000345444900003
J	Barton, SK; Moss, TJM; Hooper, SB; Crossley, KJ; Gill, AW; Kluckow, M; Zahra, V; Wong, FY; Pichler, G; Galinsky, R; Miller, SL; Tolcos, M; Polglase, GR				Barton, Samantha K.; Moss, Timothy J. M.; Hooper, Stuart B.; Crossley, Kelly J.; Gill, Andrew W.; Kluckow, Martin; Zahra, Valerie; Wong, Flora Y.; Pichler, Gerhard; Galinsky, Robert; Miller, Suzanne L.; Tolcos, Mary; Polglase, Graeme R.			Protective Ventilation of Preterm Lambs Exposed to Acute Chorioamnionitis Does Not Reduce Ventilation-Induced Lung or Brain Injury	PLOS ONE			English	Article							SPATIALLY-RESOLVED SPECTROSCOPY; END-EXPIRATORY PRESSURE; WHITE-MATTER INJURY; CEREBRAL-BLOOD-FLOW; BRONCHOPULMONARY DYSPLASIA; TIDAL VOLUME; INTRAAMNIOTIC ENDOTOXIN; SYSTEMIC INFLAMMATION; RISK-FACTOR; DELIVERY	Background: The onset of mechanical ventilation is a critical time for the initiation of cerebral white matter (WM) injury in preterm neonates, particularly if they are inadvertently exposed to high tidal volumes (V-T) in the delivery room. Protective ventilation strategies at birth reduce ventilation-induced lung and brain inflammation and injury, however its efficacy in a compromised newborn is not known. Chorioamnionitis is a common antecedent of preterm birth, and increases the risk and severity of WM injury. We investigated the effects of high V-T ventilation, after chorioamnionitis, on preterm lung and WM inflammation and injury, and whether a protective ventilation strategy could mitigate the response. Methods: Pregnant ewes (n = 18) received intra-amniotic lipopolysaccharide (LPS) 2 days before delivery, instrumentation and ventilation at 12 +/- 1 days gestation. Lambs were either immediately euthanased and used as unventilated controls (LPSUVC; n = 6), or were ventilated using an injurious high V-T strategy (LPSINJ; n = 5) or a protective ventilation strategy (LPSPROT; n = 7) for a total of 90 min. Mean arterial pressure, heart rate and cerebral haemodynamics and oxygenation were measured continuously. Lungs and brains underwent molecular and histological assessment of inflammation and injury. Results: LPSINJ lambs had poorer oxygenation than LPSPROT lambs. Ventilation requirements and cardiopulmonary and systemic haemodynamics were not different between ventilation strategies. Compared to unventilated lambs, LPSINJ and LPSPROT lambs had increases in pro-inflammatory cytokine expression within the lungs and brain, and increased astrogliosis (p<0.02) and cell death (p<0.05) in the WM, which were equivalent in magnitude between groups. Conclusions: Ventilation after acute chorioamnionitis, irrespective of strategy used, increases haemodynamic instability and lung and cerebral inflammation and injury. Mechanical ventilation is a potential contributor to WM injury in infants exposed to chorioamnionitis.	[Barton, Samantha K.; Moss, Timothy J. M.; Hooper, Stuart B.; Crossley, Kelly J.; Zahra, Valerie; Wong, Flora Y.; Galinsky, Robert; Miller, Suzanne L.; Tolcos, Mary; Polglase, Graeme R.] Monash Univ, Inst Med Res, MIMR PHI, Ritchie Ctr, Clayton, Vic 3168, Australia; [Moss, Timothy J. M.; Hooper, Stuart B.; Miller, Suzanne L.; Polglase, Graeme R.] Monash Univ, Dept Obstet & Gynecol, Clayton, Vic 3168, Australia; [Gill, Andrew W.] Univ Western Australia, Sch Womens & Infants Hlth, Nedlands, WA 6009, Australia; [Kluckow, Martin] Royal N Shore Hosp, Dept Neonatal Med, Sydney, NSW 2065, Australia; [Kluckow, Martin] Univ Sydney, Sydney, NSW 2065, Australia; [Pichler, Gerhard] Med Univ Graz, Dept Pediat, A-8036 Graz, Austria	Monash University; Prince Henry's Institute of Medical Research; University of Sydney; Westmead Institute for Medical Research; Monash University; University of Western Australia; Royal North Shore Hospital; University of Sydney; University of Sydney; Medical University of Graz	Polglase, GR (corresponding author), Monash Univ, Inst Med Res, MIMR PHI, Ritchie Ctr, Clayton, Vic 3168, Australia.	graeme.polglase@monash.edu	Moss, Timothy/A-6633-2008; Crossley, Kelly J/I-7407-2013	Moss, Timothy/0000-0002-9408-4027; Crossley, Kelly J/0000-0002-1580-1156; Hooper, Stuart/0000-0003-1676-4825; Pichler, Gerhard/0000-0003-2405-7143; Miller, Suzanne/0000-0002-0451-8304; Kluckow, Martin/0000-0003-1875-7530; Tolcos, Mary/0000-0001-6105-4553; Galinsky, Robert/0000-0002-6374-9372; Barton, Samantha/0000-0001-7601-0238; Polglase, Graeme/0000-0002-8906-614X	Avant Innovative Research Grant - Research Foundation of Cerebral Palsy Alliance; North Shore Heart Research Foundation; National Health and Medical Research Council Research Fellowship [1026890, APP1043294, 545921]; Rebecca L. Cooper Medical Research Foundation Fellowship; Victorian Government's Operational Infrastructure Support Program	Avant Innovative Research Grant - Research Foundation of Cerebral Palsy Alliance; North Shore Heart Research Foundation; National Health and Medical Research Council Research Fellowship(National Health and Medical Research Council (NHMRC) of Australia); Rebecca L. Cooper Medical Research Foundation Fellowship; Victorian Government's Operational Infrastructure Support Program	This research was supported by an Avant Innovative Research Grant awarded by the Research Foundation of Cerebral Palsy Alliance, North Shore Heart Research Foundation, National Health and Medical Research Council Research Fellowship (GRP, 1026890: TJMM, APP1043294: SBH, 545921), Rebecca L. Cooper Medical Research Foundation Fellowship (GRP) and the Victorian Government's Operational Infrastructure Support Program. Chiesi Farmaceutica generously donated the surfactant used in this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Atik A, 2014, PEDIATR RES, V76, P54, DOI 10.1038/pr.2014.55; Bennet L, 2012, P AUSTR PHYSL SOC, V43, P81; Brown AS, 2006, SCHIZOPHRENIA BULL, V32, P200, DOI 10.1093/schbul/sbj052; Chiumello D, 1999, AM J RESP CRIT CARE, V160, P109, DOI 10.1164/ajrccm.160.1.9803046; Di Palma S, 2012, COMP IMMUNOL MICROB, V35, P429, DOI 10.1016/j.cimid.2012.03.009; DUNCAN A, 1995, PHYS MED BIOL, V40, P295, DOI 10.1088/0031-9155/40/2/007; Eklind S, 2005, PEDIATR RES, V58, P112, DOI 10.1203/01.PDR.0000163513.03619.8D; Quilez ME, 2011, CRIT CARE, V15, DOI 10.1186/cc10230; Fahey JO, 2008, J MIDWIFERY WOM HEAL, V53, P227, DOI 10.1016/j.jmwh.2008.01.001; Feng YS, 2008, AM J PHYSIOL-REG I, V296, pR640; Ferriero DM, 2004, NEW ENGL J MED, V351, P1985, DOI 10.1056/NEJMra041996; Fox WW, 1997, PEDIATRICS, V100, part. no., DOI 10.1542/peds.100.5.e5; Gagliardi L, 2009, PAEDIATR PERINAT EP, V23, P582, DOI 10.1111/j.1365-3016.2009.01069.x; Galinsky R, 2013, J PHYSL, V15, P2127; GLEASON CA, 1988, AM J PHYSIOL, V255, pR1049, DOI 10.1152/ajpregu.1988.255.6.R1049; Greisen G, 2005, EARLY HUM DEV, V81, P423, DOI 10.1016/j.earlhumdev.2005.03.005; Grether JK, 1997, JAMA-J AM MED ASSOC, V278, P207, DOI 10.1001/jama.278.3.207; Hagino K, 2005, J THORAC CARDIOV SUR, V130, P384, DOI 10.1016/j.jtcvs.2005.02.058; Hansen A, 1999, AM J OBSTET GYNECOL, V181, P997, DOI 10.1016/S0002-9378(99)70339-X; Herder V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062939; Hillman NH, 2007, AM J RESP CRIT CARE, V176, P575, DOI 10.1164/rccm.200701-051OC; Hillman NH, 2011, AM J PHYSIOL-LUNG C, V301, pL712, DOI 10.1152/ajplung.00157.2011; Hillman NH, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-151; Hillman NH, 2010, PEDIATR RES, V67, P60, DOI 10.1203/PDR.0b013e3181c1b09e; Jobe AH, 2000, AM J RESP CRIT CARE, V162, P1656, DOI 10.1164/ajrccm.162.5.2003044; Jobe AH, 2008, NEONATOLOGY, V94, P190, DOI 10.1159/000143721; Kallapur SG, 2011, AM J PHYSIOL-LUNG C, V301, pL285, DOI 10.1152/ajplung.00446.2010; Khwaja O, 2008, ARCH DIS CHILD-FETAL, V93, pF153, DOI 10.1136/adc.2006.108837; Kramer BW, 2002, AM J RESP CRIT CARE, V165, P463, DOI 10.1164/ajrccm.165.4.2011118; Kramer BW, 2002, AM J PHYSIOL-LUNG C, V283, pL452, DOI 10.1152/ajplung.00407.2001; Kramer BW, 2001, AM J RESP CRIT CARE, V164, P982, DOI 10.1164/ajrccm.164.6.2103061; Lahra MM, 2004, AM J OBSTET GYNECOL, V190, P147, DOI 10.1016/j.ajog.2003.07.012; McAdams RM, 2012, ROLE CYTOKINES INFLA; Moss TJM, 2002, AM J RESP CRIT CARE, V165, P805, DOI 10.1164/ajrccm.165.6.2108053; Newnham JP, 2001, AM J OBSTET GYNECOL, V185, P190, DOI 10.1067/mob.2001.114500; Nitsos I, 2006, J SOC GYNECOL INVEST, V13, P239, DOI 10.1016/j.jsgi.2006.02.011; O'Donnell CPF, 2005, ARCH DIS CHILD-FETAL, V90, pF392, DOI 10.1136/adc.2004.064691; Polglase GR, 2008, PEDIAT RES; Polglase GR, 2008, PEDIATR RES, V64, P517, DOI 10.1203/PDR.0b013e3181841363; Polglase GR, 2008, J APPL PHYSIOL, V105, P603, DOI 10.1152/japplphysiol.00041.2008; Polglase GR, 2014, PEDIATR RES, V75, P682, DOI 10.1038/pr.2014.40; Polglase GR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039535; Polglase GR, 2012, J APPL PHYSIOL, V112, P481, DOI 10.1152/japplphysiol.00995.2011; Polglase GR, 2010, PEDIATR RES, V67, P630, DOI 10.1203/PDR.0b013e3181dbbd18; Polglase GR, 2009, PEDIATR RES, V65, P67, DOI 10.1203/PDR.0b013e318189487e; Poulton DA, 2011, RESUSCITATION, V82, P175, DOI 10.1016/j.resuscitation.2010.10.012; Roehr CC, 2010, RESUSCITATION, V81, P202, DOI 10.1016/j.resuscitation.2009.10.008; Schmolzer GM, 2010, ARCH DIS CHILD-FETAL, V95, pF393, DOI 10.1136/adc.2009.174003; Speer CP, 2006, SEMIN FETAL NEONAT M, V11, P354, DOI 10.1016/j.siny.2006.03.004; Stonestreet BS, 2000, J APPL PHYSIOL, V88, P1672, DOI 10.1152/jappl.2000.88.5.1672; van den Heuij LG, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-89; VANBEL F, 1994, PEDIATR RES, V35, P329; Vigneswaran R, 2000, J PAEDIATR CHILD H, V36, P293, DOI 10.1046/j.1440-1754.2000.00536.x; Viscardi RM, 2010, CLIN PERINATOL, V37, P393, DOI 10.1016/j.clp.2009.12.003; Volpe JJ, 2003, PEDIATRICS, V112, P176, DOI 10.1542/peds.112.1.176; Wallace MJ, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-19; Wang XY, 2006, SEMIN FETAL NEONAT M, V11, P343, DOI 10.1016/j.siny.2006.04.002; Wong FY, 2008, PEDIATRICS, V121, pE604, DOI 10.1542/peds.2007-1487; Wong FY, 2010, ANESTHESIOLOGY, V113, P1385, DOI 10.1097/ALN.0b013e3181fc5567; Wong FY, 2009, INTENS CARE MED, V35, P1464, DOI 10.1007/s00134-009-1486-4; Wu YW, 2000, JAMA-J AM MED ASSOC, V284, P1417, DOI 10.1001/jama.284.11.1417; Yanowitz TD, 2006, PEDIATR RES, V59, P299, DOI 10.1203/01.pdr.0000196738.03171.f1; Yanowitz TD, 2004, PEDIATR RES, V55, p524A; Yanowitz TD, 2002, PEDIATR RES, V51, P310, DOI 10.1203/00006450-200203000-00008; Yanowitz TD, 2004, J PERINATOLOGY, V24, P229	65	21	22	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 7	2014	9	11							e112402	10.1371/journal.pone.0112402	http://dx.doi.org/10.1371/journal.pone.0112402			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT3WF	25379714	Green Published, gold, Green Submitted			2023-01-03	WOS:000344863100083
J	Tibana, RA; Nascimento, DD; de Sousa, NMF; de Souza, VC; Durigan, J; Vieira, A; Bottaro, M; Nobrega, OD; de Almeida, JA; Navalta, JW; Franco, OL; Prestes, J				Tibana, Ramires Alsamir; Nascimento, Dahan da Cunha; Frade de Sousa, Nuno Manuel; de Souza, Vinicius Carolino; Durigan, Joao; Vieira, Amilton; Bottaro, Martim; Nobrega, Otavio de Toledo; de Almeida, Jeeser Alves; Navalta, James Wilfred; Franco, Octavio Luiz; Prestes, Jonato			Enhancing of Women Functional Status with Metabolic Syndrome by Cardioprotective and Anti-Inflammatory Effects of Combined Aerobic and Resistance Training	PLOS ONE			English	Article							PLASMA NITRIC-OXIDE; QUALITY-OF-LIFE; EXERCISE; INFLAMMATION; RISK; OSTEOPROTEGERIN; HYPERTENSION; VALIDATION; OVERWEIGHT; CYTOKINES	These data describe the effects of combined aerobic plus resistance training (CT) with regards to risk factors of metabolic syndrome (MetS), quality of life, functional capacity, and pro-and anti-inflammatory cytokines in women with MetS. In this context, thirteen women (35.4 +/- 6.2 yr) completed 10 weeks of CT consisting of three weekly sessions of similar to 60 min aerobic training (treadmill at 65-70% of reserve heart rate, 30 min) and resistance training (3 sets of 8-12 repetitions maximum for main muscle groups). Dependent variables were maximum chest press strength; isometric hand-grip strength; 30 s chair stand test; six minute walk test; body mass; body mass index; body adiposity index; waist circumference; systolic (SBP), diastolic and mean blood pressure (MBP); blood glucose; HDL-C; triglycerides; interleukins (IL) 6, 10 and 12, osteoprotegerin (OPG) and serum nitric oxide metabolite (NOx); quality of life (SF-36) and Z-Score of MetS. There was an improvement in muscle strength on chest press (p = 0.009), isometric hand-grip strength (p = 0.03) and 30 s chair stand (p = 0.007). There was a decrease in SBP (p = 0.049), MBP (p = 0.041), Z-Score of MetS (p = 0.046), OPG (0.42 +/- 0.26 to 0.38 +/- 0.19 ng/mL, p, 0.05) and NOx (13.3 +/- 2.3 mu mol/L to 9.1 +/- 2.3 mu mol/L; p<0.0005). IL-10 displayed an increase (13.6 +/- 7.5 to 17.2 +/- 12.3 pg/mL, p<0.05) after 10 weeks of training. Combined training also increased the perception of physical capacity (p = 0.011). This study endorses CT as an efficient tool to improve blood pressure, functional capacity, quality of life and reduce blood markers of inflammation, which has a clinical relevance in the prevention and treatment of MetS.	[Tibana, Ramires Alsamir; Nascimento, Dahan da Cunha; de Souza, Vinicius Carolino; de Almeida, Jeeser Alves; Franco, Octavio Luiz; Prestes, Jonato] Univ Catolica Brasilia, Graduat Program Phys Educ, Brasilia, DF, Brazil; [Frade de Sousa, Nuno Manuel] Fac Estacio Vitoria, Exercise Physiol Lab, Espirito Santo, Brazil; [Durigan, Joao; Vieira, Amilton; Bottaro, Martim; Nobrega, Otavio de Toledo; de Almeida, Jeeser Alves] Univ Brasilia, Brasilia, DF, Brazil; [Navalta, James Wilfred] Univ Nevada, Dept Kinesiol & Nutr Sci, Las Vegas, NV 89154 USA; [Franco, Octavio Luiz] Univ Catolica Brasilia, Programa Posgrad Ciencias Genom & Biotecnol, Ctr Anal Proteom & Bioquim, Brasilia, DF, Brazil	Universidade Catolica de Brasilia; Universidade de Brasilia; Nevada System of Higher Education (NSHE); University of Nevada Las Vegas; Universidade Catolica de Brasilia	Tibana, RA (corresponding author), Univ Catolica Brasilia, Graduat Program Phys Educ, Brasilia, DF, Brazil.	ramirestibana@gmail.com	Almeida, Jeeser A/O-2912-2014; Sousa, Nuno/H-8611-2013; Navalta, James/H-6626-2019; da Cunha Nascimento, Dahan/AAP-9675-2021; Tibana, Ramires A./G-2648-2013; Prestes, Jonato/H-2702-2012; Bottaro, Martim/X-1433-2019; Vieira, Amilton/A-7694-2018; Nobrega, Otavio T/J-7738-2012; Durigan, João Luiz Quagliotti/D-1110-2012; Bottaro, Martim/H-9593-2014; Franco, Octavio L/T-3020-2017	Almeida, Jeeser A/0000-0002-3409-8005; Sousa, Nuno/0000-0001-5854-616X; Navalta, James/0000-0002-4445-7614; da Cunha Nascimento, Dahan/0000-0002-6580-9404; Prestes, Jonato/0000-0003-0399-8817; Bottaro, Martim/0000-0002-4315-3176; Vieira, Amilton/0000-0002-6027-4367; Nobrega, Otavio T/0000-0003-1775-7176; Durigan, João Luiz Quagliotti/0000-0002-7511-5289; Franco, Octavio/0000-0001-9546-0525				Aoki A, 2013, CARDIOVASC DIABETOL, V12, DOI 10.1186/1475-2840-12-11; Asl SZ, 2008, CLIN BIOCHEM, V41, P1342, DOI 10.1016/j.clinbiochem.2008.08.076; Bergman RN, 2011, OBESITY, V19, P1083, DOI 10.1038/oby.2011.38; Bruunsgaard H, 2005, J LEUKOCYTE BIOL, V78, P819, DOI 10.1189/jlb.0505247; Ciconelli RM, 1999, REV BRAS REUMATOL, V39, P143, DOI DOI 10.1590/S0482-50042010000300005; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Cohen J., 2013, STAT POWER ANAL BEHA; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; Dallaire P, 2004, CAN J DIABETES, V28, P59; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Eckel RH, 2005, LANCET, V365, P1415, DOI 10.1016/S0140-6736(05)66378-7; Ervin R Bethene, 2009, Natl Health Stat Report, P1; Esposito K, 2004, NUTR METAB CARDIOVAS, V14, P228, DOI 10.1016/S0939-4753(04)80048-6; Festa A, 2000, CIRCULATION, V102, P42, DOI 10.1161/01.CIR.102.1.42; Fyfe JJ, 2014, SPORTS MED, V44, P743, DOI 10.1007/s40279-014-0162-1; Gami AS, 2007, J AM COLL CARDIOL, V49, P403, DOI 10.1016/j.jacc.2006.09.032; Ho SS, 2013, INFLAMMATION, V36, P625, DOI 10.1007/s10753-012-9584-9; Imayama I, 2011, INT J BEHAV NUTR PHY, V25, P8; Imayama I, 2012, CANCER RES, V72, P2314, DOI 10.1158/0008-5472.CAN-11-3092; Kanbak G, 2011, DIABETES METAB SYND, V5, P7, DOI 10.1016/j.dsx.2010.05.006; Kang J, 2014, ACSMS HEALTH FIT J, V18, P9, DOI 10.1249/FIT.0000000000000004; Kim HM, 2007, DIABETES CARE, V30, P701, DOI 10.2337/dc06-1400; Maejima K, 2001, J DIABETES COMPLICAT, V15, P135, DOI 10.1016/S1056-8727(01)00144-1; Mathur N, 2008, MEDIATORS I IN PRESS; Morena M, 2006, J AM SOC NEPHROL, V17, P262, DOI 10.1681/ASN.2005030260; Okosun IS, 2013, DIABETES METAB SYND, V7, P154, DOI 10.1016/j.dsx.2013.06.007; Orozco LJ, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003054.pub3; Pedersen BK, 1997, INT J SPORTS MED, V18, pS2, DOI 10.1055/s-2007-972695; Pereira GB, 2013, CLIN PHYSIOL FUNCT I, V33, P122, DOI 10.1111/cpf.12004; Prestes J, 2013, REV ASSOC MED BRAS, V59, P308, DOI 10.1016/j.ramb.2013.01.009; Prestes J, 2009, J SPORT SCI, V27, P1607, DOI 10.1080/02640410903352923; Rikli RE, 1999, J AGING PHYS ACTIV, V7, P129, DOI 10.1123/japa.7.2.129; Robbie L, 2001, ANN NY ACAD SCI, V947, P167; Schwingshackl L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082853; Shaw K, 2006, COCHRANE DB SYST REV, V8; Stensvold D, 2012, METAB SYNDR RELAT D, V10, P267, DOI 10.1089/met.2011.0140; Tavel ME, 2001, CHEST, V119, P907, DOI 10.1378/chest.119.3.907; Tibana RA, 2013, DIABETOL METAB SYNDR, V5, DOI 10.1186/1758-5996-5-11; Tibana RA, 2012, EINSTEIN-SAO PAULO, V10, P329, DOI 10.1590/S1679-45082012000300013; Topouchian JA, 2005, BLOOD PRESS MONIT, V10, P325, DOI 10.1097/00126097-200512000-00008; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; Vasan RS, 2002, JAMA-J AM MED ASSOC, V287, P1003, DOI 10.1001/jama.287.8.1003; Williamson DA, 2009, ARCH INTERN MED, V169, P163, DOI 10.1001/archinternmed.2008.544; Yoon Y, 2000, CLIN CHEM, V46, P1626	44	14	15	3	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 7	2014	9	11							e110160	10.1371/journal.pone.0110160	http://dx.doi.org/10.1371/journal.pone.0110160			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT3WF	25379699	Green Published, Green Submitted, gold			2023-01-03	WOS:000344863100011
J	Miller, LG; Daum, RS; Creech, CB; Young, D; Downing, MD; Eells, SJ; Pettibone, S; Hoagland, RJ; Chambers, HF				Miller, Loren G.; Daum, Robert S.; Creech, C. Buddy; Young, David; Downing, Michele D.; Eells, Samantha J.; Pettibone, Stephanie; Hoagland, Rebecca J.; Chambers, Henry F.		DMID 07-0051 Team	Clindamycin versus Trimethoprim-Sulfamethoxazole for Uncomplicated Skin Infections	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STAPHYLOCOCCUS-AUREUS SKIN; SOFT-TISSUE INFECTIONS; RESISTANT; PREVENTION; STRATEGIES; CELLULITIS; MANAGEMENT; CHILDREN; VISITS; ADULT	BACKGROUND Skin and skin-structure infections are common in ambulatory settings. However, the efficacy of various antibiotic regimens in the era of community-acquired methicillin-resistant Staphylococcus aureus (MRSA) is unclear. METHODS We enrolled outpatients with uncomplicated skin infections who had cellulitis, abscesses larger than 5 cm in diameter (smaller for younger children), or both. Patients were enrolled at four study sites. All abscesses underwent incision and drainage. Patients were randomly assigned in a 1: 1 ratio to receive either clindamycin or trimethoprim-sulfamethoxazole (TMP-SMX) for 10 days. Patients and investigators were unaware of the treatment assignments and microbiologic test results. The primary outcome was clinical cure 7 to 10 days after the end of treatment. RESULTS A total of 524 patients were enrolled (264 in the clindamycin group and 260 in the TMP-SMX group), including 155 children (29.6%). One hundred sixty patients (30.5%) had an abscess, 280 (53.4%) had cellulitis, and 82 (15.6%) had mixed infection, defined as at least one abscess lesion and one cellulitis lesion. S. aureus was isolated from the lesions of 217 patients (41.4%); the isolates in 167 (77.0%) of these patients were MRSA. The proportion of patients cured was similar in the two treatment groups in the intention-to-treat population (80.3% in the clindamycin group and 77.7% in the TMP-SMX group; difference, -2.6 percentage points; 95% confidence interval [ CI], -10.2 to 4.9; P = 0.52) and in the populations of patients who could be evaluated (466 patients; 89.5% in the clindamycin group and 88.2% in the TMP-SMX group; difference, -1.2 percentage points; 95% CI, -7.6 to 5.1; P = 0.77). Cure rates did not differ significantly between the two treatments in the subgroups of children, adults, and patients with abscess versus cellulitis. The proportion of patients with adverse events was similar in the two groups. CONCLUSIONS We found no significant difference between clindamycin and TMP-SMX, with respect to either efficacy or side-effect profile, for the treatment of uncomplicated skin infections, including both cellulitis and abscesses.	[Miller, Loren G.; Eells, Samantha J.] Harbor UCLA Univ Calif Los Angeles Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA USA; [Miller, Loren G.; Eells, Samantha J.] Harbor UCLA Univ Calif Los Angeles Med Ctr, Div Infect Dis, Torrance, CA USA; [Miller, Loren G.; Eells, Samantha J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Young, David] Univ Calif San Francisco, Div Plast & Reconstruct Surg, San Francisco, CA 94143 USA; [Downing, Michele D.; Chambers, Henry F.] San Francisco Gen Hosp, Div Infect Dis, San Francisco, CA 94110 USA; [Downing, Michele D.; Chambers, Henry F.] UCSF, San Francisco, CA USA; [Daum, Robert S.] Univ Chicago, Div Pediat Infect Dis, Chicago, IL 60637 USA; [Creech, C. Buddy] Vanderbilt Univ, Div Pediat Infect Dis, Nashville, TN 37235 USA; [Pettibone, Stephanie] EMMES Corp, Rockville, MD USA; [Hoagland, Rebecca J.] Cota Enterprises, Meriden, KS USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Lundquist Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of Chicago; Vanderbilt University; Emmes Corporation	Miller, LG (corresponding author), Harbor UCLA Med Ctr, Div Infect Dis, 1000 W Carson St,Box 466, Torrance, CA 90509 USA.	lgmiller@ucla.edu	Rodriguez, Renee/GYR-1896-2022	Self, Wesley/0000-0002-9300-3045; Rodriguez, Robert/0000-0003-1354-1773	National Institute of Allergy and Infectious Diseases; National Center for Advancing Translational Sciences, National Institutes of Health; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000124] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR033176] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Advancing Translational Sciences, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Funded by the National Institute of Allergy and Infectious Diseases and the National Center for Advancing Translational Sciences, National Institutes of Health; ClinicalTrials.gov number, NCT00730028.	Bowen AC, 2012, J CLIN MICROBIOL, V50, P4067, DOI 10.1128/JCM.02195-12; Carratala J, 2003, EUR J CLIN MICROBIOL, V22, P151, DOI 10.1007/s10096-003-0902-x; Chen CJ, 2005, PEDIATR INFECT DIS J, V24, P40, DOI 10.1097/01.inf.0000148926.11227.1c; Chira S, 2010, EPIDEMIOL INFECT, V138, P313, DOI 10.1017/S0950268809990483; CLSI,, 2012, M07A9 CLSI; David MZ, 2010, CLIN MICROBIOL REV, V23, P616, DOI 10.1128/CMR.00081-09; Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), 2013, GUID IND AC BACT SKI; Edelsberg J, 2009, EMERG INFECT DIS, V15, P1516, DOI 10.3201/eid1509.081228; Eells SJ, 2011, EPIDEMIOL INFECT, V139, P606, DOI 10.1017/S0950268810001408; Fritz SA, 2012, CLIN INFECT DIS, V54, P743, DOI 10.1093/cid/cir919; Gorwitz RJ., 2006, STRATEGIES CLIN MANA; Hersh AL, 2008, ARCH INTERN MED, V168, P1585, DOI 10.1001/archinte.168.14.1585; Ho Joanne M-W, 2011, CMAJ, V183, P1851, DOI 10.1503/cmaj.111152; Hyun DY, 2009, PEDIATR INFECT DIS J, V28, P57, DOI 10.1097/INF.0b013e3181826e5e; Itani KMF, 2014, CLIN INFECT DIS, V58, pS4, DOI 10.1093/cid/cit612; Jeng A, 2010, MEDICINE, V89, P217, DOI 10.1097/MD.0b013e3181e8d635; Kyne L, 2002, INFECT CONT HOSP EP, V23, P653, DOI 10.1086/501989; Lee MC, 2004, PEDIATR INFECT DIS J, V23, P123, DOI 10.1097/01.inf.0000109288.06912.21; Lipsky BA, 2010, INFECT CONT HOSP EP, V31, P828, DOI 10.1086/654007; Loo VG, 2011, NEW ENGL J MED, V365, P1693, DOI 10.1056/NEJMoa1012413; Mascitti KB, 2010, AM J INFECT CONTROL, V38, P324, DOI 10.1016/j.ajic.2009.11.007; Miller LG, 2011, 51 ANN INT C ANT AG; Miller LG, 2012, ANTIMICROB AGENTS CH, V56, P1084, DOI 10.1128/AAC.01608-10; Moran GJ, 2006, NEW ENGL J MED, V355, P666, DOI 10.1056/NEJMoa055356; Pallin DJ, 2008, ANN EMERG MED, V51, P291, DOI 10.1016/j.annemergmed.2007.12.004; Pallin DJ, 2013, CLIN INFECT DIS, V56, P1754, DOI 10.1093/cid/cit122; Ray GT, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-252; Schulz KF, 2010, ANN INTERN MED, V152, P726, DOI 10.7326/0003-4819-152-11-201006010-00232; Stevens DL, 2005, CLIN INFECT DIS, V41, P1373, DOI 10.1086/497143; Williams DJ, 2011, PEDIATRICS, V128, pE479, DOI 10.1542/peds.2010-3681	30	115	120	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 19	2015	372	12					1093	1103		10.1056/NEJMoa1403789	http://dx.doi.org/10.1056/NEJMoa1403789			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CD6EZ	25785967	Green Accepted			2023-01-03	WOS:000351183600004
J	Boerner, JL; Nechiporchik, N; Mueller, KL; Polin, L; Heilbrun, L; Boerner, SA; Zoratti, GL; Stark, K; LoRusso, PM; Burger, A				Boerner, Julie L.; Nechiporchik, Nicole; Mueller, Kelly L.; Polin, Lisa; Heilbrun, Lance; Boerner, Scott A.; Zoratti, Gina L.; Stark, Karri; LoRusso, Patricia M.; Burger, Angelika			Protein Expression of DNA Damage Repair Proteins Dictates Response to Topoisomerase and PARP Inhibitors in Triple-Negative Breast Cancer	PLOS ONE			English	Article							BRCA MUTANT-CELLS; POLY(ADP-RIBOSE) POLYMERASE; PERSPECTIVE; DEFECT; TUMORS; ERCC1	Patients with metastatic triple-negative breast cancer (TNBC) have a poor prognosis. New approaches for the treatment of TNBC are needed to improve patient survival. The concept of synthetic lethality, brought about by inactivating complementary DNA repair pathways, has been proposed as a promising therapeutic option for these tumors. The TNBC tumor type has been associated with BRCA mutations, and inhibitors of Poly (ADP-ribose) polymerase (PARP), a family of proteins that facilitates DNA repair, have been shown to effectively kill BRCA defective tumors by preventing cells from repairing DNA damage, leading to a loss of cell viability and clonogenic survival. Here we present preclinical efficacy results of combining the PARP inhibitor, ABT-888, with CPT-11, a topoisomerase I inhibitor. CPT-11 binds to topoisomerase I at the replication fork, creating a bulky adduct that is recognized as damaged DNA. When DNA damage was stimulated with CPT-11, protein expression of the nucleotide excision repair enzyme ERCC1 inversely correlated with cell viability, but not clonogenic survival. However, 4 out of the 6 TNBC cells were synergistically responsive by cell viability and 5 out of the 6 TNBC cells were synergistically responsive by clonogenic survival to the combination of ABT-888 and CPT-11. In vivo, the BRCA mutant cell line MX-1 treated with CPT-11 alone demonstrated significant decreased tumor growth; this decrease was enhanced further with the addition of ABT-888. Decrease in tumor growth correlated with an increase in double strand DNA breaks as measured by y-H2AX phosphorylation. In summary, inhibiting two arms of the DNA repair pathway simultaneously in TNBC cell lines, independent of BRCA mutation status, resulted in un-repairable DNA damage and subsequent cell death.	[Boerner, Julie L.; Nechiporchik, Nicole; Mueller, Kelly L.; Polin, Lisa; Heilbrun, Lance; Boerner, Scott A.; Zoratti, Gina L.; Stark, Karri; LoRusso, Patricia M.; Burger, Angelika] Wayne State Univ, Barbara Ann Karmanos Canc Inst, Dept Oncol, Detroit, MI 48202 USA; [Boerner, Scott A.; LoRusso, Patricia M.] Yale Univ, Dept Oncol, New Haven, CT USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Yale University	Boerner, JL (corresponding author), Wayne State Univ, Barbara Ann Karmanos Canc Inst, Dept Oncol, Detroit, MI 48202 USA.	boernerj@karmanos.org		Boerner, Scott/0000-0003-1388-9665	National Institutes of Health [U01 CA-62487, R21 CA135572-02]; NATIONAL CANCER INSTITUTE [P30CA022453, U01CA062487, R21CA135572, R01CA140314] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by National Institutes of Health grants U01 CA-62487 (PML) and R21 CA135572-02 (PML). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Anders CK, 2011, CANCER-AM CANCER SOC, V117, P1602, DOI 10.1002/cncr.25746; Barnabas N, 2013, INT J BREAST CANCER, V2013, DOI 10.1155/2013/872743; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Chacon RD, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2574; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Ciccia A, 2008, ANNU REV BIOCHEM, V77, P259, DOI 10.1146/annurev.biochem.77.070306.102408; Corbett TH, 1998, INVEST NEW DRUG, V16, P129, DOI 10.1023/A:1006174622061; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Gossage L, 2007, CANCER TREAT REV, V33, P565, DOI 10.1016/j.ctrv.2007.07.001; Graziani G, 2005, PHARMACOL RES, V52, P109, DOI 10.1016/j.phrs.2005.02.013; Helleday T, 2011, MOL ONCOL, V5, P387, DOI 10.1016/j.molonc.2011.07.001; HOLM S, 1979, ACTA MED SCAND, V205, P587; Institute NC., PDQ GEN BREAST OV CA; Korsching E, 2008, J CLIN PATHOL, V61, P553, DOI 10.1136/jcp.2008.055475; Littell RC, 2006, STAT ANAL SYSTEM SAS; Murphy CG, 2010, CANCER J, V16, P39, DOI 10.1097/PPO.0b013e3181cf0204; Olaussen KA, 2006, NEW ENGL J MED, V355, P983, DOI 10.1056/NEJMoa060570; Rasheed ZA, 2003, ONCOGENE, V22, P7296, DOI 10.1038/sj.onc.1206935; Ratnam K, 2007, CLIN CANCER RES, V13, P1383, DOI 10.1158/1078-0432.CCR-06-2260; Santana-Davila R, 2010, J HEMATOL ONCOL, V3, DOI 10.1186/1756-8722-3-42; Starita LM, 2003, CURR OPIN CELL BIOL, V15, P345, DOI 10.1016/S0955-0674(03)00042-5; Tutt ANJ, 2005, COLD SH Q B, V70, P139, DOI 10.1101/sqb.2005.70.012; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Xu J, 2012, MOL BIOL REP, V39, P3097, DOI 10.1007/s11033-011-1073-y; Zhang YW, 2011, NUCLEIC ACIDS RES, V39, P3607, DOI 10.1093/nar/gkq1304	27	16	16	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 16	2015	10	3							e0119614	10.1371/journal.pone.0119614	http://dx.doi.org/10.1371/journal.pone.0119614			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CD6EY	25774912	gold, Green Submitted, Green Published			2023-01-03	WOS:000351183500105
J	Perkins, GD; Lall, R; Quinn, T; Deakin, CD; Cooke, MW; Horton, J; Lamb, SE; Slowther, AM; Woollard, M; Carson, A; Smyth, M; Whitfield, R; Williams, A; Pocock, H; Black, JJM; Wright, J; Han, K; Gates, S				Perkins, Gavin D.; Lall, Ranjit; Quinn, Tom; Deakin, Charles D.; Cooke, Matthew W.; Horton, Jessica; Lamb, Sarah E.; Slowther, Anne-Marie; Woollard, Malcolm; Carson, Andy; Smyth, Mike; Whitfield, Richard; Williams, Amanda; Pocock, Helen; Black, John J. M.; Wright, John; Han, Kyee; Gates, Simon		PARAMEDIC Trial Collaborators	Mechanical versus manual chest compression for out-of-hospital cardiac arrest (PARAMEDIC): a pragmatic, cluster randomised controlled trial	LANCET			English	Article							EUROPEAN RESUSCITATION COUNCIL; CARDIOPULMONARY-RESUSCITATION; SURVIVAL; DEVICE; NONCOMPLIANCE; GUIDELINES; CPR	Background Mechanical chest compression devices have the potential to help maintain high-quality cardiopulmonary resuscitation (CPR), but despite their increasing use, little evidence exists for their effectiveness. We aimed to study whether the introduction of LUCAS-2 mechanical CPR into front-line emergency response vehicles would improve survival from out-of-hospital cardiac arrest. Methods The pre-hospital randomised assessment of a mechanical compression device in cardiac arrest (PARAMEDIC) trial was a pragmatic, cluster-randomised open-label trial including adults with non-traumatic, out-of-hospital cardiac arrest from four UK Ambulance Services (West Midlands, North East England, Wales, South Central). 91 urban and semi-urban ambulance stations were selected for participation. Clusters were ambulance service vehicles, which were randomly assigned (1: 2) to LUCAS-2 or manual CPR. Patients received LUCAS-2 mechanical chest compression or manual chest compressions according to the first trial vehicle to arrive on scene. The primary outcome was survival at 30 days following cardiac arrest and was analysed by intention to treat. Ambulance dispatch staff and those collecting the primary outcome were masked to treatment allocation. Masking of the ambulance staff who delivered the interventions and reported initial response to treatment was not possible. The study is registered with Current Controlled Trials, number ISRCTN08233942. Findings We enrolled 4471 eligible patients (1652 assigned to the LUCAS-2 group, 2819 assigned to the control group) between April 15, 2010 and June 10, 2013. 985 (60%) patients in the LUCAS-2 group received mechanical chest compression, and 11 (<1%) patients in the control group received LUCAS-2. In the intention-to-treat analysis, 30 day survival was similar in the LUCAS-2 group (104 [6%] of 1652 patients) and in the manual CPR group (193 [7%] of 2819 patients; adjusted odds ratio [OR] 0 . 86, 95% CI 0 . 64-1 . 15). No serious adverse events were noted. Seven clinical adverse events were reported in the LUCAS-2 group (three patients with chest bruising, two with chest lacerations, and two with blood in mouth). 15 device incidents occurred during operational use. No adverse or serious adverse events were reported in the manual group. Interpretation We noted no evidence of improvement in 30 day survival with LUCAS-2 compared with manual compressions. On the basis of ours and other recent randomised trials, widespread adoption of mechanical CPR devices for routine use does not improve survival.	[Perkins, Gavin D.; Lall, Ranjit; Cooke, Matthew W.; Horton, Jessica; Lamb, Sarah E.; Slowther, Anne-Marie; Smyth, Mike] Univ Warwick, Warwick Clin Trials Unit, Coventry CV4 7AL, W Midlands, England; [Perkins, Gavin D.] Heart England NHS Fdn Trust, Birmingham, W Midlands, England; [Quinn, Tom; Deakin, Charles D.; Woollard, Malcolm] Univ Surrey, Fac Hlth & Med Sci, Surrey Peri Operat Anaesthesia Crit Care Collabor, Res Grp, Guildford GU2 5XH, Surrey, England; [Deakin, Charles D.; Pocock, Helen; Black, John J. M.] NHS Fdn Trust, South Cent Ambulance Serv, Otterbourne, England; [Deakin, Charles D.] Univ Hosp Southampton NHS Fdn Trust, NIHR Southampton Resp Biomed Res Unit, Southampton, Hants, England; [Lamb, Sarah E.] Univ Oxford, Oxford, England; [Carson, Andy; Smyth, Mike] NHS Fdn Trust, West Midlands Ambulance Serv, Brierley Hill, England; [Whitfield, Richard; Williams, Amanda] Welsh Ambulance Serv NHS Trust, St Asaph, Denbighshire, Wales; [Wright, John; Han, Kyee] NHS Fdn Trust, North East Ambulance Serv, Newcastle Upon Tyne, Tyne & Wear, England; [Wright, John] Royal Victoria Infirm, Newcastle Upon Tyne, Tyne & Wear, England	University of Warwick; Heart of England NHS Foundation Trust; University of Surrey; University of Southampton; University Hospital Southampton NHS Foundation Trust; University of Oxford; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle University - UK	Perkins, GD (corresponding author), Univ Warwick, Warwick Clin Trials Unit, Coventry CV4 7AL, W Midlands, England.	g.d.perkins@warwick.ac.uk	Perkins, Gavin/E-7613-2010	Hulme, Claire/0000-0003-2077-0419; Blair, Laura/0000-0001-9846-9429; Lamb, Sarah/0000-0003-4349-7195; Lall, Ranjit/0000-0003-1737-2866; Pocock, Helen/0000-0001-7648-5313; Quinn, Tom/0000-0002-5116-0034; Perkins, Gavin/0000-0003-3027-7548; McClelland, Graham/0000-0002-4502-5821	National Institute for Health Research's (NIHR) Health Technology Assessment Programme [HTA-07/37/69]; Director of Research for the Intensive Care Foundation; National Institute for Health Research [07/37/69] Funding Source: researchfish	National Institute for Health Research's (NIHR) Health Technology Assessment Programme(National Institute for Health Research (NIHR)); Director of Research for the Intensive Care Foundation; National Institute for Health Research(National Institute for Health Research (NIHR))	This is a summary of independent research funded by the National Institute for Health Research's (NIHR) Health Technology Assessment Programme (Grant Reference Number HTA-07/37/69). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. GDP is supported as a Director of Research for the Intensive Care Foundation. We thank the independent members of the Trial Steering Committee (Jon Nicholl, Helen Snooks, Fionna Moore, Alasdair Gray, Martyn Box, Father Neil Bayliss, and John Long) and the Data Monitoring Committee (Marion Campbell, Jerry Nolan, and Kathy Rowan).	Atwood C, 2005, RESUSCITATION, V67, P75, DOI 10.1016/j.resuscitation.2005.03.021; Brooks SC, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007260.pub3; Christenson J, 2009, CIRCULATION, V120, P1241, DOI 10.1161/CIRCULATIONAHA.109.852202; Deakin CD, 2009, EMERG MED J, V26, P888, DOI 10.1136/emj.2008.064642; Deakin CD, 2010, RESUSCITATION, V81, P1305, DOI 10.1016/j.resuscitation.2010.08.017; Dunn G, 2003, BRIT J PSYCHIAT, V183, P323, DOI 10.1192/bjp.183.4.323; Go AS, 2014, CIRCULATION, V129, pE28, DOI 10.1161/01.cir.0000441139.02102.80; Hallstrom A, 2006, JAMA-J AM MED ASSOC, V295, P2620, DOI 10.1001/jama.295.22.2620; Hewitt CE, 2006, CAN MED ASSOC J, V175, P347, DOI 10.1503/cmaj.051625; Idris AH, 2012, CIRCULATION, V125, P3004, DOI 10.1161/CIRCULATIONAHA.111.059535; Jacobs I, 2004, RESUSCITATION, V63, P233, DOI 10.1016/j.resuscitation.2004.09.008; Koster RW, 2010, RESUSCITATION, V81, P1277, DOI 10.1016/j.resuscitation.2010.08.009; Krarup NH, 2011, RESUSCITATION, V82, P263, DOI 10.1016/j.resuscitation.2010.11.003; Nolan JP, 2010, RESUSCITATION, V81, pE1, DOI 10.1016/j.resuscitation.2010.08.002; Ong MEH, 2010, ANN EMERG MED, V56, P233, DOI 10.1016/j.annemergmed.2010.01.004; Perkins GD, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2435; Perkins GD, 2012, EMERG MED J, V29, P3, DOI 10.1136/emermed-2011-200758; Perkins GD, 2010, SCAND J TRAUMA RESUS, V18, DOI 10.1186/1757-7241-18-58; Rubertsson S, 2014, JAMA-J AM MED ASSOC, V311, P53, DOI 10.1001/jama.2013.282538; Smekal D, 2011, RESUSCITATION, V82, P702, DOI 10.1016/j.resuscitation.2011.01.032; Stiell IG, 2011, NEW ENGL J MED, V365, P787, DOI 10.1056/NEJMoa1010076; Vadeboncoeur T, 2014, RESUSCITATION, V85, P182, DOI 10.1016/j.resuscitation.2013.10.002; Wang HE, 2012, RESUSCITATION, V83, P1343, DOI 10.1016/j.resuscitation.2012.07.013; Wik L, 2014, RESUSCITATION, V85, P741, DOI 10.1016/j.resuscitation.2014.03.005; Yeung J, 2009, RESUSCITATION, V80, P743, DOI 10.1016/j.resuscitation.2009.04.012; Zuercher M, 2010, CRIT CARE MED, V38, P1141, DOI 10.1097/CCM.0b013e3181ce1fe2	26	271	291	2	48	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 14	2015	385	9972					947	955		10.1016/S0140-6736(14)61886-9	http://dx.doi.org/10.1016/S0140-6736(14)61886-9			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CD2EK	25467566	Green Published, Green Accepted, hybrid			2023-01-03	WOS:000350886900029
J	Seth, A; Ritchie, FK; Wibowo, N; Lua, LHL; Middelberg, APJ				Seth, Arjun; Ritchie, Fiona K.; Wibowo, Nani; Lua, Linda H. L.; Middelberg, Anton P. J.			Non-Carrier Nanoparticles Adjuvant Modular Protein Vaccine in a Particle-Dependent Manner	PLOS ONE			English	Article							VIRUS-LIKE PARTICLES; IMMUNE-RESPONSE; PATHOGEN RECOGNITION; L1 CAPSOMERES; IN-VITRO; DELIVERY; SIZE; IMMUNIZATION; PLATFORM; MICROPARTICLES	Nanoparticles are increasingly used to adjuvant vaccine formulations due to their biocompatibility, ease of manufacture and the opportunity to tailor their size, shape, and physicochemical properties. The efficacy of similarly-sized silica (Si-OH), poly (D,L-lactic-co-glycolic acid) (PLGA) and poly caprolactone (PCL) nanoparticles (nps) to adjuvant recombinant capsomere presenting antigenic M2e modular peptide from Influenza A virus (CapM2e) was investigated in vivo. Formulation of CapM2e with Si-OH or PLGA nps significantly boosted the immunogenicity of modular capsomeres, even though CapM2e was not actively attached to the nanoparticles prior to injection (i.e., formulation was by simple mixing). In contrast, PCL nps showed no significant adjuvant effect using this simple-mixing approach. The immune response induced by CapM2e alone or formulated with nps was antibody-biased with very high antigen-specific antibody titer and less than 20 cells per million splenocytes secreting interferon gamma. Modification of silica nanoparticle surface properties through amine functionalization and pegylation did not lead to significant changes in immune response. This study confirms that simple mixing-based formulation can lead to effective adjuvanting of antigenic protein, though with antibody titer dependent on nanoparticle physicochemical properties.	[Seth, Arjun; Ritchie, Fiona K.; Wibowo, Nani; Middelberg, Anton P. J.] Univ Queensland, Australian Inst Bioengn & Nanotechnol, St Lucia, Qld, Australia; [Lua, Linda H. L.] Univ Queensland, Prot Express Facil, St Lucia, Qld, Australia	University of Queensland; University of Queensland	Middelberg, APJ (corresponding author), Univ Queensland, Australian Inst Bioengn & Nanotechnol, St Lucia, Qld, Australia.	a.middelberg@uq.edu.au	Lua, Linda/B-4879-2010	Lua, Linda/0000-0002-9756-7083; Middelberg, Anton/0000-0001-5922-5704; Ritchie, Fiona/0000-0002-4545-6402	Queensland State Government	Queensland State Government	Funding for this study was provided by the Queensland State Government in the form of a Premier's Fellowship to APJM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript	Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Avgoustakis Konstantinos, 2004, Current Drug Delivery, V1, P321, DOI 10.2174/1567201043334605; Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868; Bommakanti G, 2010, P NATL ACAD SCI USA, V107, P13701, DOI 10.1073/pnas.1007465107; Champion JA, 2009, PHARM RES-DORDR, V26, P244, DOI 10.1007/s11095-008-9626-z; Chu CH, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957-4484/22/18/185601; Correia-Pinto JF, 2013, INT J PHARMACEUT, V440, P27, DOI 10.1016/j.ijpharm.2012.04.047; Danhier F, 2012, J CONTROL RELEASE, V161, P505, DOI 10.1016/j.jconrel.2012.01.043; Dey AK, 2011, EXPERT REV VACCINES, V10, P227, DOI 10.1586/ERV.10.142; Diwan M, 2002, J CONTROL RELEASE, V85, P247, DOI 10.1016/S0168-3659(02)00275-4; Fiers W, 2009, VACCINE, V27, P6280, DOI 10.1016/j.vaccine.2009.07.007; Fifis T, 2004, VACCINE, V23, P258, DOI 10.1016/j.vaccine.2004.05.022; Foged C, 2005, INT J PHARMACEUT, V298, P315, DOI 10.1016/j.ijpharm.2005.03.035; Gasteiger E., 2005, PROTEOMICS PROTOCOLS, P571, DOI [10.1385/1-59259-890-0:571, DOI 10.1385/1-59259-890-0:571]; Grgacic EVL, 2006, METHODS, V40, P60, DOI 10.1016/j.ymeth.2006.07.018; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; Hillaireau H, 2009, CELL MOL LIFE SCI, V66, P2873, DOI 10.1007/s00018-009-0053-z; Ibanez LI, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059081; Jennings GT, 2008, BIOL CHEM, V389, P521, DOI 10.1515/BC.2008.064; Kohli AK, 2004, INT J PHARMACEUT, V275, P13, DOI 10.1016/j.ijpharm.2003.10.038; Kushnir N, 2012, VACCINE, V31, P58, DOI 10.1016/j.vaccine.2012.10.083; Liew MWO, 2012, BIOCHEM ENG J, V67, P88, DOI 10.1016/j.bej.2012.05.007; Lua LHL, 2014, BIOTECHNOL BIOENG, V111, P425, DOI 10.1002/bit.25159; Manish M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061885; McCarthy MP, 1998, J VIROL, V72, P32, DOI 10.1128/JVI.72.1.32-41.1998; Middelberg APJ, 2011, VACCINE, V29, P7154, DOI 10.1016/j.vaccine.2011.05.075; Moon JJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031472; Moyano DF, 2012, J AM CHEM SOC, V134, P3965, DOI 10.1021/ja2108905; Murata Y, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-81; Nakanishi T, 1999, J CONTROL RELEASE, V61, P233, DOI 10.1016/S0168-3659(99)00097-8; Neirynck S, 1999, NAT MED, V5, P1157, DOI 10.1038/13484; Niikura K, 2013, ACS NANO, V7, P3926, DOI 10.1021/nn3057005; Noad R, 2003, TRENDS MICROBIOL, V11, P438, DOI 10.1016/S0966-842X(03)00208-7; Otsuka H, 2003, ADV DRUG DELIVER REV, V55, P403, DOI 10.1016/S0169-409X(02)00226-0; Oyewumi MO, 2010, EXPERT REV VACCINES, V9, P1095, DOI [10.1586/erv.10.89, 10.1586/ERV.10.89]; Peek LJ, 2008, ADV DRUG DELIVER REV, V60, P915, DOI 10.1016/j.addr.2007.05.017; Pejawar-Gaddy S, 2010, CANCER IMMUNOL IMMUN, V59, P1685, DOI 10.1007/s00262-010-0895-0; Plotkin SL, 2004, VACCINES-BASEL, V4th, P1, DOI DOI 10.1016/B978-1-4557-0090-5.00017-3; Raghuvanshi RS, 2002, INT J PHARMACEUT, V245, P109, DOI 10.1016/S0378-5173(02)00342-3; Rivera-Hernandez T, 2013, VACCINE, V31, P1950, DOI 10.1016/j.vaccine.2013.02.013; Roldao A, 2010, EXPERT REV VACCINES, V9, P1149, DOI [10.1586/erv.10.115, 10.1586/ERV.10.115]; Rose RC, 1998, J VIROL, V72, P6151, DOI 10.1128/JVI.72.7.6151-6154.1998; Roy S, 2010, LANGMUIR, V26, P18125, DOI 10.1021/la103212d; Sapp M, 2009, VIROLOGY, V384, P400, DOI 10.1016/j.virol.2008.12.022; Sayin B, 2008, INT J PHARMACEUT, V363, P139, DOI 10.1016/j.ijpharm.2008.06.029; Schadlich L, 2009, J VIROL, V83, P7690, DOI 10.1128/JVI.02588-08; Schussek S, 2013, INFECT IMMUN, V81, P3586, DOI 10.1128/IAI.00544-13; Senger T, 2010, VACCINE, V28, P1583, DOI 10.1016/j.vaccine.2009.11.048; Singh J, 2006, METHODS, V38, P96, DOI 10.1016/j.ymeth.2005.11.003; Singh M, 2007, EXPERT REV VACCINES, V6, P797, DOI 10.1586/14760584.6.5.797; Smith DM, 2013, NAT REV IMMUNOL, V13, P592, DOI 10.1038/nri3488; Souza J, 2012, BIOMED RES INT, V2012; Thomas C, 2011, MOL PHARMACEUT, V8, P405, DOI 10.1021/mp100255c; Vallhov H, 2012, SMALL, V8, P2116, DOI 10.1002/smll.201102620; Wibowo N, 2014, VACCINE, V32, P3664, DOI 10.1016/j.vaccine.2014.04.043; Wibowo N, 2013, CHEM ENG SCI, V103, P12, DOI 10.1016/j.ces.2012.04.001; Xiang SD, 2006, METHODS, V40, P1, DOI 10.1016/j.ymeth.2006.05.016; Yan SY, 2013, J COLLOID INTERF SCI, V395, P1, DOI 10.1016/j.jcis.2012.11.061; Zhang WF, 2014, BIOMATERIALS, V35, P6086, DOI 10.1016/j.biomaterials.2014.04.022; Zhao L, 2014, VACCINE, V32, P327, DOI 10.1016/j.vaccine.2013.11.069; Zhou C, 2012, VACCINE, V30, P3463, DOI 10.1016/j.vaccine.2012.03.021	61	13	13	0	44	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 10	2015	10	3							e0117203	10.1371/journal.pone.0117203	http://dx.doi.org/10.1371/journal.pone.0117203			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CD7MX	25756283	Green Published, gold, Green Submitted			2023-01-03	WOS:000351275700015
J	Lee, IS; Lee, YS; Park, HJ; Lee, H; Chae, Y				Lee, In-Seon; Lee, Ye-Seul; Park, Hi-Joon; Lee, Hyejung; Chae, Younbyoung			Evaluation of Phantom-Based Education System for Acupuncture Manipulation	PLOS ONE			English	Article							NEEDLE MANIPULATION; CHINESE ACUPUNCTURE; HAPTIC SIMULATION; SKILLS	Background Although acupuncture manipulation has been regarded as one of the important factors in clinical outcome, it has been difficult to train novice students to become skillful experts due to a lack of adequate educational program and tools. Objectives In the present study, we investigated whether newly developed phantom acupoint tools would be useful to practice-naive acupuncture students for practicing the three different types of acupuncture manipulation to enhance their skills. Methods We recruited 12 novice students and had them practice acupuncture manipulations on the phantom acupoint (5% agarose gel). We used the Acusensor 2 and compared their acupuncture manipulation techniques, for which the target criteria were depth and time factors, at acupoint LI11 in the human body before and after 10 training sessions. The outcomes were depth of needle insertion, depth error from target criterion, time of rotating, lifting, and thrusting, time error from target criteria and the time ratio. Results After 10 training sessions, the students showed significantly improved outcomes in depth of needle, depth error (rotation, reducing lifting/thrusting), thumb-forward time error, thumbbackward time error (rotation), and lifting time (reinforcing lifting/thrusting). Conclusions The phantom acupoint tool could be useful in a phantom-based education program for acupuncture-manipulation training for students. For advanced education programs for acupuncture manipulation, we will need to collect additional information, such as patient responses, acupoint-specific anatomical characteristics, delicate tissue-like modeling, haptic and visual feedback, and data from an acupuncture practice simulator.	[Lee, In-Seon; Lee, Ye-Seul; Park, Hi-Joon; Lee, Hyejung; Chae, Younbyoung] Kyung Hee Univ, Acupuncture & Meridian Sci Res Ctr, Coll Korean Med, Seoul, South Korea	Kyung Hee University	Chae, Y (corresponding author), Kyung Hee Univ, Acupuncture & Meridian Sci Res Ctr, Coll Korean Med, Seoul, South Korea.	ybchae@khu.ac.kr	Park, Hi-Joon/AAG-1196-2021; Chae, Younbyoung/AAM-1243-2020; Lee, In-Seon/AAM-1252-2020	Lee, In-Seon/0000-0001-9275-3111; Lee, Ye-Seul/0000-0001-6127-5401	National Research Foundation of Korea (NRF) - Korea government (MSIP) [2011-0009913, 2013R1A6A6029251]	National Research Foundation of Korea (NRF) - Korea government (MSIP)	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP)(No. 2011-0009913 & 2013R1A6A6029251). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baak JPA, 2002, J PATHOL, V198, P277, DOI 10.1002/path.1233; Gerovich Oleg, 2004, Comput Aided Surg, V9, P243, DOI 10.3109/10929080500190441; Heng PA, 2006, IEEE T INF TECHNOL B, V10, P28, DOI 10.1109/TITB.2005.855567; Hu Yin'e, 2010, Sheng Wu Yi Xue Gong Cheng Xue Za Zhi, V27, P991; Kim GH, 2010, NEUROL RES, V32, pS92, DOI 10.1179/016164109X12537002794327; Lee IS, 2014, J ALTERN COMPLEM MED, V20, P654, DOI 10.1089/acm.2013.0475; Leung KM, 2003, ST HEAL T, V94, P187; Li J, 2013, ACUPUNCT MED, V31, P172, DOI 10.1136/acupmed-2012-010265; Liu Tang-yi, 2008, Zhongguo Zhen Jiu, V28, P356; Luciano C, 2009, VIRTUAL REAL-LONDON, V13, P69, DOI 10.1007/s10055-009-0112-7; Riener R, 2004, IEEE T INF TECHNOL B, V8, P208, DOI 10.1109/TITB.2004.828885; Seo Y, 2014, ACUPUNCT MED, V32, P394, DOI 10.1136/acupmed-2014-010585; Shi GX, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-42; Sturm LP, 2008, ANN SURG, V248, P166, DOI 10.1097/SLA.0b013e318176bf24; Wang Hai-sheng, 2009, Zhongguo Zhen Jiu, V29, P745; White A, 2008, ACUPUNCT MED, V26, P111, DOI 10.1136/aim.26.2.111	16	6	7	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 17	2015	10	2							e0117992	10.1371/journal.pone.0117992	http://dx.doi.org/10.1371/journal.pone.0117992			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC4KQ	25689598	gold, Green Submitted, Green Published			2023-01-03	WOS:000350322700091
J	Tolle, SW; Back, AL; Meier, DE				Tolle, Susan W.; Back, Anthony L.; Meier, Diane E.			End-of-Life Advance Directive	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							STANDARD ONCOLOGY CARE; PALLIATIVE CARE; SUSTAINING TREATMENT; PHYSICIAN ORDERS; ADVANCED CANCER; PREFERENCES; INTEGRATION; PATIENT; PROGRAM		[Tolle, Susan W.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Back, Anthony L.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA; [Meier, Diane E.] Icahn Sch Med Mt Sinai, Ctr Adv Palliat Care, New York, NY 10029 USA	Oregon Health & Science University; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Icahn School of Medicine at Mount Sinai	Tolle, SW (corresponding author), Oregon Hlth & Sci Univ, Portland, OR 97201 USA.							Back AL, 2009, ARCH INTERN MED, V169, P474, DOI 10.1001/archinternmed.2008.583; Barnato AE, 2007, MED CARE, V45, P386, DOI 10.1097/01.mlr.0000255248.79308.41; Bernstein N., 2014, NY TIMES, pA1; Fromme EK, 2014, J AM GERIATR SOC, V62, P1246, DOI 10.1111/jgs.12889; Gawande A, 2014, BEING MORTAL MED WHA; Greer JA, 2013, CA-CANCER J CLIN, V63, P349, DOI 10.3322/caac.21192; Hickman SE, 2010, J AM GERIATR SOC, V58, P1241, DOI 10.1111/j.1532-5415.2010.02955.x; Kelley AS, 2010, NEW ENGL J MED, V363, P781, DOI 10.1056/NEJMe1004139; Krakauer Barak, 2014, J Clin Ethics, V25, P131; Meier DE, 2014, HEALTH AFFAIR, V33, P895, DOI [10.1377/HLTHAFF.2013.0517, 10.1377/hlthaff.2013.0517]; Smith TJ, 2012, J CLIN ONCOL, V30, P880, DOI 10.1200/JCO.2011.38.5161; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Tulsky JA, 2011, ANN INTERN MED, V155, P593, DOI 10.7326/0003-4819-155-9-201111010-00007; Weeks JC, 2012, NEW ENGL J MED, V367, P1616, DOI 10.1056/NEJMoa1204410	14	16	16	2	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 12	2015	372	7					667	670		10.1056/NEJMclde1411152	http://dx.doi.org/10.1056/NEJMclde1411152			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CA8CK	25671262				2023-01-03	WOS:000349143900015
J	Jacomet, C; Allavena, C; Peyrol, F; Pereira, B; Joubert, LM; Bagheri, H; Cotte, L; Garaffo, R; Gerbaud, L; Dellamonica, P				Jacomet, Christine; Allavena, Clotilde; Peyrol, Fleur; Pereira, Bruno; Joubert, Laurence Morand; Bagheri, Haleh; Cotte, Laurent; Garaffo, Rodolphe; Gerbaud, Laurent; Dellamonica, Pierre			Perception of Antiretroviral Generic Medicines: One-Day Survey of HIV-Infected Patients and Their Physicians in France	PLOS ONE			English	Article							PATIENTS ATTITUDES; DRUG SUBSTITUTION; PRESCRIPTION; EXPERIENCES; VIEWS	Background In the interest of cost effectiveness, switching antiretroviral brand name medications to generics is recommended in France since 2013. The study objective was to evaluate the perception of generics per se and antiretroviral generics in HIV-infected patients and their hospital physicians Methods and Findings 556 out of 703 (79%) adult HIV+ outpatients and 116 physicians in 33 clinics were included in a multicentric cross-sectional survey performed in September 2013. Patients completed a self-questionnaire on their perception and acceptability of generics. Physicians completed a questionnaire on their acceptability of switching antiretroviral to generic. Socio-demographic data, medical history and HIV history were collected. Among the 556 patients with a median HIV duration of 13 years, 77% were France native, 59% in active employment, 100% covered by social insurance, 95% on antiretroviral therapy. Seventy-six percent of the patients accepted generics and 55% trusted them overall. Antiretroviral generics were accepted by 44% of them but only by 17% if the pill burden was going to increase. The factor significantly associated with acceptability of antiretroviral generics was acceptance of generics per se (p<0.001). Among the 116 physicians following a median of 100 HIV-patients/year, 75% would prescribe generics, dropping to 26% if the combo had to be broken. Factors significantly associated with willingness to prescribe antiretroviral generics were the absence of concern regarding the chemical entity (OR = 0.33), being aware that the patient would accept generics for other pathologies (OR = 2.04) and would accept antiretroviral generics (OR = 1.94). No factor related to sociodemographic conditions, HIV status or comorbidities was associated with the acceptability of antiretroviral generics. Conclusions Acceptability of antiretroviral generics in this French population was mostly dictated by the patient's and physician's knowledge and use of generics overall. It should be improved with an efficient information of both patients and physicians.	[Jacomet, Christine] CHU Clermont Ferrand, Hop Gabriel Montpied, Serv Malad Infect & Trop, Clermont Ferrand, France; [Allavena, Clotilde] CHU Hotel Dieu, Serv Malad Infect & Trop, Nantes, France; [Peyrol, Fleur; Gerbaud, Laurent] CHU Clermont Ferrand, EA PEPRADE 4681, Clermont Ferrand, France; [Pereira, Bruno] CHU Clermont Ferrand, Serv Biostat, Clermont Ferrand, France; [Joubert, Laurence Morand] CHU St Antoine, INSERM, UMR S 1136, Virol Lab, Paris, France; [Bagheri, Haleh] CHU Toulouse, INSERM, U1027, Toulouse, France; [Cotte, Laurent] Hosp Civils Lyon, INSERM, U1052, Serv Malad Infect & Trop, Lyon, France; [Garaffo, Rodolphe] CHU Pasteur, Nice, France; [Dellamonica, Pierre] CHU Archet, Serv Malad Infect & Trop, Nice, France	CHU Clermont Ferrand; Nantes Universite; CHU de Nantes; CHU Clermont Ferrand; CHU Clermont Ferrand; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Nice; CHU Nice	Jacomet, C (corresponding author), CHU Clermont Ferrand, Hop Gabriel Montpied, Serv Malad Infect & Trop, Clermont Ferrand, France.	cjacomet@chu-clermontferrand.fr	Allavena, Clotilde/AAH-4310-2019; GERBAUD, Laurent/ABY-4952-2022	Pereira, Bruno/0000-0003-3778-7161	Mylan	Mylan	This paper presents independent research by CHU Clermont-Ferrand, the promoter of the survey. Mylan provided funding for data capture. Funding sources were not involved in study design, data collection, analysis, interpretation, medical writing or submission, decision to publish, or preparation of the manuscript.	Agence Nationale de Securite du Medicament et des produits de sante (ANSM), 2012, MED GEN MED PART ENT; Allenet B, 1999, J EC MED, V17, P301; Allenet B, 2013, REV MED SUISSE, V9, P1005; [Anonymous], 2012, ACAD NATL PHARM RAPP; Barrett LL, 2005, PHYS ATTITUDES PRACT; Baudrant-Boga M, 2011, MED MALADIES METABOL, V5, pS73, DOI [10.1038/nutd.2014.45, DOI 10.1038/NUTD.2014.45]; Chong CP, 2011, HEALTH POLICY, V99, P139, DOI 10.1016/j.healthpol.2010.08.002; Collet JP, 2010, LETT CARDIOLOGUE, V341, P16; De Plazaola JP, 2014, TABLEAU EC FRANCAISE; Decollogny A, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-17; Figueiras MJ, 2008, PHARM WORLD SCI, V30, P590, DOI 10.1007/s11096-008-9247-y; Granlund D, 2009, SOC SCI MED, V69, P1643, DOI 10.1016/j.socscimed.2009.09.016; Hakonsen H, 2009, CURR MED RES OPIN, V25, P2515, DOI 10.1185/03007990903192223; Hassali Mohamed A A, 2009, Int J Pharm Pract, V17, P79; Kjoenniksen I, 2006, PHARM WORLD SCI, V28, P284, DOI 10.1007/s11096-006-9043-5; Lagarce L, 2005, THERAPIE, V60, P67, DOI 10.2515/therapie:2005009; Menkes CJ, 2012, B ACAD NAT MED PARIS, V196, P521, DOI 10.1016/S0001-4079(19)31843-6; Ringuier R, 2008, THERAPIE, V63, P11, DOI 10.2515/therapie:2008006; Roos J., 2005, Journal de Pharmacie Clinique, V24, P217; Sarradon-Eck A, 2007, REV EPIDEMIOL SANTE, V55, P179, DOI 10.1016/j.respe.2007.01.026; Shrank WH, 2006, ARCH INTERN MED, V166, P332, DOI 10.1001/archinte.166.3.332; Shrank WH, 2007, J GEN INTERN MED, V22, P1298, DOI 10.1007/s11606-007-0284-3; Valles JA, 2003, HEALTH POLICY, V65, P269, DOI 10.1016/S0168-8510(03)00018-6; WHO, 2010, WOR HEALT REP, P1; Zucman D, 2014, AIDS, V28, P607, DOI 10.1097/QAD.0000000000000170	26	23	23	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2015	10	2							e0117214	10.1371/journal.pone.0117214	http://dx.doi.org/10.1371/journal.pone.0117214			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CB2GK	25658627	gold, Green Published, Green Submitted			2023-01-03	WOS:000349444900118
J	Zengin, G; Uysal, A; Gunes, E; Aktumsek, A				Zengin, Gokhan; Uysal, Ahmet; Gunes, Erdogan; Aktumsek, Abdurrahman			Survey of Phytochemical Composition and Biological Effects of Three Extracts from a Wild Plant (Cotoneaster nummularia Fisch et Mey.): A Potential Source for Functional Food Ingredients and Drug Formulations	PLOS ONE			English	Article							TOTAL PHENOLIC CONTENT; ANTIOXIDANT ACTIVITY; FERULIC ACID; MEDICINAL-PLANTS; AQUEOUS EXTRACTS; ESSENTIAL OIL; IN-VITRO; L.; INHIBITORS; ANTICHOLINESTERASE	This study was focused on the analysis of the phenolic content, antioxidant, antibacterial, anti-cholinesterase, anti-tyrosinase, anti-amylase and anti-glucosidase activity of three solvent extracts from Cotoneaster nummularia. Moreover, water extract was tested in terms of mutagenic/anti-mutagenic effects. The antioxidant activities of these extracts were evaluated by DPPH, ABTS, O-2, metal chelating, phosphomolybdenum, beta-carotene/linoleic acid, ferric and cupric reducing power assays. Enzyme inhibitory activities were also examined with colorimetric methods. Generally, methanol and water extracts exhibited excellent biological activities. These extracts were rich in phenolic and flavonoid content. Furthermore, Cotoneaster extracts indicated appreciable antibacterial properties against human pathogen strains. HPLC analysis showed that ferulic acid, chlorogenic acid, (-) - epicatechin and (+)-catechin were the major phenolics in extracts tested. These data offer that these extracts from C. nummularia may be considered as a potential source of biological agents for developing functional foods or drug formulations.	[Zengin, Gokhan; Gunes, Erdogan; Aktumsek, Abdurrahman] Selcuk Univ, Fac Sci, Dept Biol, Konya, Turkey; [Uysal, Ahmet] Selcuk Univ, Vocat Sch Hlth Serv, Konya, Turkey	Selcuk University; Selcuk University	Uysal, A (corresponding author), Selcuk Univ, Vocat Sch Hlth Serv, Konya, Turkey.	ahuysal@selcuk.edu.tr	Uysal, Ahmet/V-7909-2017; Zengin, Gokhan/GLS-8806-2022; Zengin, Gokhan/K-9393-2015	Uysal, Ahmet/0000-0002-9297-4050; Zengin, Gokhan/0000-0001-6548-7823; Zengin, Gokhan/0000-0001-6548-7823				Adebiyi AO, 2009, PHARM BIOL, V47, P320, DOI 10.1080/13880200902748460; Aksoy L, 2013, SAUDI J BIOL SCI, V20, P235, DOI 10.1016/j.sjbs.2013.02.003; Aktumsek A, 2013, FOOD CHEM TOXICOL, V55, P290, DOI 10.1016/j.fct.2013.01.018; Apak R, 2006, INT J FOOD SCI NUTR, V57, P292, DOI 10.1080/09637480600798132; Berk S, 2011, AFR J BIOTECHNOL, V10, P8902; Borges A, 2013, MICROB DRUG RESIST, V19, P256, DOI 10.1089/mdr.2012.0244; BUENING MK, 1981, CANCER RES, V41, P67; Cakilcioglu U, 2011, J ETHNOPHARMACOL, V137, P469, DOI 10.1016/j.jep.2011.05.046; Caponio F, 1999, FOOD CHEM, V64, P203, DOI 10.1016/S0308-8146(98)00146-0; Chakrabarti R, 2002, CURR SCI INDIA, V83, P1533; Chandini SK, 2008, FOOD CHEM, V107, P707, DOI 10.1016/j.foodchem.2007.08.081; Dalar A, 2013, IND CROP PROD, V44, P383, DOI 10.1016/j.indcrop.2012.11.037; Dasgupta N, 2004, FOOD CHEM, V88, P219, DOI 10.1016/j.foodchem.2004.01.036; DEAN BJ, 1985, MUTAT RES, V153, P57, DOI 10.1016/0165-1110(85)90005-3; EDENHARDER R, 1993, MUTAT RES, V287, P261, DOI 10.1016/0027-5107(93)90019-C; Eldeen IMS, 2005, J ETHNOPHARMACOL, V102, P457, DOI 10.1016/j.jep.2005.08.049; Erdogan-Orhan I, 2010, J SERB CHEM SOC, V75, P1491, DOI 10.2298/JSC100322115E; Fang L, 2008, BIOORG MED CHEM LETT, V18, P2905, DOI 10.1016/j.bmcl.2008.03.073; Gallegos-Tintore S, 2011, J SCI FOOD AGR, V91, P1618, DOI 10.1002/jsfa.4357; Ranilla LG, 2010, BIORESOURCE TECHNOL, V101, P4676, DOI 10.1016/j.biortech.2010.01.093; Goze I, 2009, J MED PLANTS RES, V3, P246; Higdon JV, 2003, CRIT REV FOOD SCI, V43, P89, DOI 10.1080/10408690390826464; Horn RC, 2003, MUTAGENESIS, V18, P113, DOI 10.1093/mutage/18.2.113; Jang HD, 2007, FOOD CHEM, V103, P749, DOI 10.1016/j.foodchem.2006.09.026; Javanmardi J, 2003, FOOD CHEM, V83, P547, DOI 10.1016/S0308-8146(03)00151-1; KAPPUS H, 1986, BIOCHEM PHARMACOL, V35, P1, DOI 10.1016/0006-2952(86)90544-7; Karioti A, 2007, BIOORGAN MED CHEM, V15, P2708, DOI 10.1016/j.bmc.2007.01.035; Khan S, 2009, J ASIAN NAT PROD RES, V11, P44, DOI 10.1080/10286020802435745; Kinghorn AD, 2004, PLANTA MED, V70, P691, DOI 10.1055/s-2004-827198; Koc ZE, 2013, EXCLI J, V12, P396; Leonti M, 2012, GENET RESOUR CROP EV, V59, P1295, DOI 10.1007/s10722-012-9894-7; Mamiya T, 2008, NEUROSCI LETT, V430, P115, DOI 10.1016/j.neulet.2007.10.029; Manian R, 2008, FOOD CHEM, V107, P1000, DOI 10.1016/j.foodchem.2007.09.008; MARON DM, 1983, MUTAT RES, V113, P173, DOI 10.1016/0165-1161(83)90010-9; Matthews VA, 1972, FLORA TURKEY E AEGEA, V4; Mitscher LA, 1996, MUTAT RES-FUND MOL M, V350, P143, DOI 10.1016/0027-5107(95)00099-2; Mori T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055774; Mortelmans K, 2000, MUTAT RES-FUND MOL M, V455, P29, DOI 10.1016/S0027-5107(00)00064-6; Nazir A, 2010, NAT SCI, V8, P57; Negi PS, 2003, FOOD CHEM, V80, P393, DOI 10.1016/S0308-8146(02)00279-0; Okombi S, 2006, BIOORG MED CHEM LETT, V16, P2252, DOI 10.1016/j.bmcl.2006.01.022; Oksana S., 2012, Journal of Medicinal Plants Research, V6, P2526; Ou SY, 2004, J SCI FOOD AGR, V84, P1261, DOI 10.1002/jsfa.1873; OYAIZU M, 1986, Japanese Journal of Nutrition, V44, P307; Ozgen U, 2012, TURK J BIOL, V36, P93, DOI 10.3906/biy-1009-124; Pandey MR, 2007, OUR NAT, V4, P69; PARKE DV, 1991, CAN J PHYSIOL PHARM, V69, P537, DOI 10.1139/y91-081; Polat R, 2013, J ETHNOPHARMACOL, V148, P951, DOI 10.1016/j.jep.2013.05.050; Priya Darsini DT, 2013, FREE RADICAL ANTIOXI, V3, P62, DOI DOI 10.1016/J.FRA.2013.08.001; Rajaei A, 2010, FOOD CHEM TOXICOL, V48, P107, DOI 10.1016/j.fct.2009.09.023; Re R, 1999, FREE RADICAL BIO MED, V26, P1231, DOI 10.1016/S0891-5849(98)00315-3; Roy S, 2013, ENDOCRINE, V44, P369, DOI 10.1007/s12020-012-9868-8; Saija A, 2000, INT J PHARM, V199, P39, DOI 10.1016/S0378-5173(00)00358-6; Sarikurkcu C, 2012, SPECTROSC LETT, V45, P352, DOI 10.1080/00387010.2012.666701; Sarikurkcu C, 2011, AFR J BIOTECHNOL, V10, P831; Shahwar D, 2010, J MED PLANTS RES, V4, P260; Skotti E, 2014, IND CROP PROD, V53, P46, DOI 10.1016/j.indcrop.2013.12.013; SLINKARD K, 1977, AM J ENOL VITICULT, V28, P49; Suhaj M, 2006, J FOOD COMPOS ANAL, V19, P531, DOI 10.1016/j.jfca.2004.11.005; Vladimir-Knezevic S, 2014, MOLECULES, V19, P767, DOI 10.3390/molecules19010767; Zengin G, 2014, IND CROP PROD, V53, P244, DOI 10.1016/j.indcrop.2013.12.043	61	89	89	0	59	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 19	2014	9	11							e113527	10.1371/journal.pone.0113527	http://dx.doi.org/10.1371/journal.pone.0113527			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AU3SG	25409171	gold, Green Published, Green Submitted			2023-01-03	WOS:000345533200134
J	Li, M; Liang, Z; Sun, X; Gong, T; Zhang, ZR				Li, Man; Liang, Zhen; Sun, Xun; Gong, Tao; Zhang, Zhirong			A Polymeric Prodrug of 5-Fluorouracil-1-Acetic Acid Using a Multi-Hydroxyl Polyethylene Glycol Derivative as the Drug Carrier	PLOS ONE			English	Article							DELIVERY SYSTEMS; IN-VIVO; CLINICAL PHARMACOKINETICS; MACROMOLECULAR PRODRUGS; VASCULAR-PERMEABILITY; CANCER-CHEMOTHERAPY; ANTITUMOR-ACTIVITY; LIVER-MICROSOMES; PHASE-I; TUMOR	Purpose: Macromolecular prodrugs obtained by covalently conjugating small molecular drugs with polymeric carriers were proven to accomplish controlled and sustained release of the therapeutic agents in vitro and in vivo. Polyethylene glycol (PEG) has been extensively used due to its low toxicity, low immunogenicity and high biocompatibility. However, for linear PEG macromolecules, the number of available hydroxyl groups for drug coupling does not change with the length of polymeric chain, which limits the application of PEG for drug conjugation purposes. To increase the drug loading and prolong the retention time of 5-fluorouracil (5-Fu), a macromolecular prodrug of 5-Fu, 5-fluorouracil-1 acid-PAE derivative (5-FA-PAE) was synthesized and tested for the antitumor activity in vivo. Methods: PEG with a molecular weight of 38 kDa was selected to synthesize the multi-hydroxyl polyethylene glycol derivative (PAE) through an addition reaction. 5-fluorouracil-1 acetic acid (5-FA), a 5-Fu derivative was coupled with PEG derivatives via ester bond to form a macromolecular prodrug, 5-FA-PAE. The in vitro drug release, pharmacokinetics, in vivo distribution and antitumor effect of the prodrug were investigated, respectively. Results: The PEG-based prodrug obtained in this study possessed an exceedingly high 5-FA loading efficiency of 10.58%, much higher than the maximum drug loading efficiency of unmodified PEG with the same molecular weight, which was 0.98% theoretically. Furthermore, 5-FA-PAE exhibited suitable sustained release in tumors. Conclusion: This study provides a new approach for the development of the delivery to tumors of anticancer agents with PEG derivatives.	[Li, Man; Liang, Zhen; Sun, Xun; Gong, Tao; Zhang, Zhirong] Sichuan Univ, West China Sch Pharm, Key Lab Drug Targeting & Drug Delivery Syst, Minist Educ, Chengdu 610064, Sichuan, Peoples R China	Sichuan University	Gong, T (corresponding author), Sichuan Univ, West China Sch Pharm, Key Lab Drug Targeting & Drug Delivery Syst, Minist Educ, Chengdu 610064, Sichuan, Peoples R China.	gongtaoy@126.com; zrzzl@vip.sina.com		Gong, Tao/0000-0002-9866-9911	National Natural Science Foundation of China [30873167]; National Basic Research Program of China (973 program) [2013CB932504]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China (973 program)(National Basic Research Program of China)	The authors acknowledge the financial support from the National Natural Science Foundation of China (no. 30873167) and the National Basic Research Program of China (973 program, No: 2013CB932504). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arias JL, 2008, MOLECULES, V13, P2340, DOI 10.3390/molecules13102340; AZORI M, 1987, CRIT REV THER DRUG, V4, P39; Burton SC, 1998, J CHROMATOGR A, V796, P273, DOI 10.1016/S0021-9673(97)01020-0; CHUNG SM, 1991, INT J PHARM, V68, P61; D'Souza AJM, 2004, J PHARM SCI-US, V93, P1962, DOI 10.1002/jps.20096; Dang CT, 2006, EXPERT REV ANTICANC, V6, P427, DOI 10.1586/14737140.6.3.427; Deeken JF, 2007, ANTI-CANCER DRUG, V18, P111, DOI 10.1097/CAD.0b013e3280109411; DUSCHINSKY R, 1957, J AM CHEM SOC, V79, P4559, DOI 10.1021/ja01573a087; Goh PP, 2007, CURR CANCER DRUG TAR, V7, P743, DOI 10.2174/156800907783220462; Greenwald RB, 1996, J MED CHEM, V39, P424, DOI 10.1021/jm950475e; Guo Z, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.2556; Gupta Y, 2007, J DRUG TARGET, V15, P231, DOI 10.1080/10611860701289719; Hao AJ, 2006, DRUG DEV IND PHARM, V32, P757, DOI 10.1080/03639040600683436; Hoste K, 2004, INT J PHARMACEUT, V277, P119, DOI 10.1016/j.ijpharm.2003.07.016; Huang YZ, 2010, CURR PHARM DESIGN, V16, P2369, DOI 10.2174/138161210791920441; Hwu WJ, 2006, CANCER-AM CANCER SOC, V106, P2445, DOI 10.1002/cncr.21909; Iyer L, 1999, CANCER INVEST, V17, P494; Kang NI, 2002, POLYM INT, V51, P443, DOI 10.1002/pi.786; KELLOFF GJ, 1993, BASIC LIFE SCI, V61, P373; KINTZEL PE, 1995, CANCER TREAT REV, V21, P33, DOI 10.1016/0305-7372(95)90010-1; Koyama Y, 1996, BIOCONJUGATE CHEM, V7, P298, DOI 10.1021/bc9600123; Macdonald JS, 1999, ONCOLOGY-NY, V13, P33; Maeda H, 2003, INT IMMUNOPHARMACOL, V3, P319, DOI 10.1016/S1567-5769(02)00271-0; Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5; Maeda H, 2009, EUR J PHARM BIOPHARM, V71, P409, DOI 10.1016/j.ejpb.2008.11.010; Malet-Martino M, 2002, ONCOLOGIST, V7, P288, DOI 10.1634/theoncologist.7-4-288; Meada H, 2001, ADV DRUG DELIV REV, V46, P169; Menei P, 1999, CANCER, V86, P325, DOI 10.1002/(SICI)1097-0142(19990715)86:2<325::AID-CNCR17>3.0.CO;2-S; Milano G, 2002, CHRONOBIOL INT, V19, P177, DOI 10.1081/CBI-120002597; Na Y, 2009, J PHARM PHARMACOL, V61, P707, DOI [10.1211/jpp/61.06.0002, 10.1211/jpp.61.06.0002]; OGISO T, 1976, JPN J PHARMACOL, V26, P445, DOI 10.1254/jjp.26.445; OGISO T, 1978, JPN J PHARMACOL, V28, P175, DOI 10.1254/jjp.28.175; Onishi H, 2008, MOLECULES, V13, P2136, DOI 10.3390/molecules13092136; PARKER WB, 1990, PHARMACOL THERAPEUT, V48, P381, DOI 10.1016/0163-7258(90)90056-8; Pasut G, 2007, PROG POLYM SCI, V32, P933, DOI 10.1016/j.progpolymsci.2007.05.008; Pasut G, 2009, ADV DRUG DELIVER REV, V61, P1177, DOI 10.1016/j.addr.2009.02.010; Pazdur R, 1998, ONCOLOGY-NY, V12, P48; RICHTER AW, 1983, INT ARCH ALLER A IMM, V70, P124, DOI 10.1159/000233309; Riebeseel K, 2002, BIOCONJUGATE CHEM, V13, P773, DOI 10.1021/bc010098m; Rowinsky EK, 2003, J CLIN ONCOL, V21, P148, DOI 10.1200/JCO.2003.03.143; Sarkar FH, 2010, MINI-REV MED CHEM, V10, P357; Sartor O, 2010, CLIN GENITOURIN CANC, V8, P23, DOI 10.3816/CGC.2010.n.004; Sawa T, 2000, CANCER RES, V60, P666; SCHALHORN A, 1992, SEMIN ONCOL, V19, P82; Sheridan W, 1998, Stem Cells, V16 Suppl 2, P193; SHUEY DL, 1995, TOXICOLOGY, V102, P207, DOI 10.1016/0300-483X(95)03049-L; SMYTH HF, 1950, J AM PHARM ASSOC SCI, V39, P349, DOI 10.1002/jps.3030390615; TAKAKURA Y, 1995, CRIT REV ONCOL HEMAT, V18, P207, DOI 10.1016/1040-8428(94)00131-C; Thompson N, 2005, CURR OPIN PHARMACOL, V5, P350, DOI 10.1016/j.coph.2005.04.007; Ton NC, 2007, CLIN CANCER RES, V13, P7113, DOI 10.1158/1078-0432.CCR-07-1550; Udo K, 2010, INT J PHARMACEUT, V388, P95, DOI 10.1016/j.ijpharm.2009.12.039; van Kuilenburg ABP, 2004, NUCLEOS NUCLEOT NUCL, V23, P1371, DOI 10.1081/NCN-200027624; Veronese FM, 2002, ADV DRUG DELIVER REV, V54, P453; Wang JX, 2002, EUR J PHARM BIOPHARM, V54, P285, DOI 10.1016/S0939-6411(02)00083-8; Yang ZY, 2000, J RARE EARTH, V18, P140; ZALIPSKY S, 1983, EUR POLYM J, V19, P1177, DOI 10.1016/0014-3057(83)90016-2; Zhao H, 2008, BIOCONJUGATE CHEM, V19, P849, DOI 10.1021/bc700333s; Zuo DS, 2001, MOLECULES, V6, P647, DOI 10.3390/60800647	58	16	16	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2014	9	11							e112888	10.1371/journal.pone.0112888	http://dx.doi.org/10.1371/journal.pone.0112888			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA8CP	25389968	Green Published, gold, Green Submitted			2023-01-03	WOS:000349144400138
J	Costa, SS; Druzian, JI; Machado, BAS; de Souza, CO; Guimaraes, AG				Costa, Samantha Serra; Druzian, Janice Izabel; Souza Machado, Bruna Aparecida; de Souza, Carolina Oliveira; Guimaraes, Alaise Gil			Bi-Functional Biobased Packing of the Cassava Starch, Glycerol, Licuri Nanocellulose and Red Propolis	PLOS ONE			English	Article							BARRIER PROPERTIES; FILMS; WATER	The aim of this study was to characterize and determine the bi-functional efficacy of active packaging films produced with starch (4%) and glycerol (1.0%), reinforced with cellulose nanocrystals (0-1%) and activated with alcoholic extracts of red propolis (0.4 to 1.0%). The cellulose nanocrystals used in this study were extracted from licuri leaves. The films were characterized using moisture, water-activity analyses and water vapor-permeability tests and were tested regarding their total phenolic compounds and mechanical properties. The antimicrobial and antioxidant efficacy of the films were evaluated by monitoring the use of the active films for packaging cheese curds and butter, respectively. The cellulose nanocrystals increased the mechanical strength of the films and reduced the water permeability and water activity. The active film had an antimicrobial effect on coagulase-positive staphylococci in cheese curds and reduced the oxidation of butter during storage.	[Costa, Samantha Serra] Univ Fed Bahia, Fac Pharm, BR-40171970 Salvador, BA, Brazil; [Druzian, Janice Izabel; de Souza, Carolina Oliveira; Guimaraes, Alaise Gil] Univ Fed Bahia, Fac Pharm, Dept Bromatol Anal, BR-40171970 Salvador, BA, Brazil; [Souza Machado, Bruna Aparecida] Serv Nacl Aprendizagem Ind SENAI, SENAI CIMATEC, Fac Technol, BR-41650010 Salvador, BA, Brazil	Universidade Federal da Bahia; Universidade Federal da Bahia; Faculdade de Tecnologia Senai Cimatec	Costa, SS (corresponding author), Univ Fed Bahia, Fac Pharm, Rua Barao de Geremoabo S-N, BR-40171970 Salvador, BA, Brazil.	manthasc@yahoo.com.br	Druzian, Janice Izabel/G-6884-2015; Souza, Carolina O/G-8869-2015; Machado, Bruna Aparecida Souza/C-3130-2016; Machado, Bruna/AAP-6877-2021	Machado, Bruna Aparecida Souza/0000-0003-1655-0325; Oliveira de Souza, Carolina/0000-0002-8028-5418; Druzian, Janice Izabel/0000-0001-8940-6098	CAPES (Coordination of Improvement of Higher Education Personnel)	CAPES (Coordination of Improvement of Higher Education Personnel)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	The research was funded by CAPES (Coordination of Improvement of Higher Education Personnel), through design nanobiotec. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amal AM, 2013, PLOS ONE, V8, P1; American Oil Chemists Society (AOCS), 1997, CD8B90; American Society for Testing and Materials (ASTM), 2005, E96E96M ASTM; ASTM, 2001, D88200 ASTM; Azeredo HMC, 2009, J FOOD SCI, V74, pN31, DOI 10.1111/j.1750-3841.2009.01186.x; Reis LCB, 2015, FOOD BIOPROD PROCESS, V94, P382, DOI 10.1016/j.fbp.2014.05.004; Beck-Candanedo S, 2005, BIOMACROMOLECULES, V6, P1048, DOI 10.1021/bm049300p; Cagri A, 2001, J FOOD SCI, V66, P865, DOI 10.1111/j.1365-2621.2001.tb15188.x; Coutinho Fernanda M. B., 2003, Polímeros, V13, P01, DOI 10.1590/S0104-14282003000100005; de Mesquita JP, 2011, SOFT MATTER, V7, P4405, DOI 10.1039/c0sm01168a; Gill AO, 2002, INT J FOOD MICROBIOL, V73, P83, DOI 10.1016/S0168-1605(01)00712-7; GONTARD N, 1992, J FOOD SCI, V57, P190, DOI 10.1111/j.1365-2621.1992.tb05453.x; Habibi Y, 2010, CHEM REV, V110, P3479, DOI 10.1021/cr900339w; Holt BL, 2010, J MATER CHEM, V20, P10058, DOI 10.1039/c0jm01022g; Kechichian V, 2010, LWT-FOOD SCI TECHNOL, V43, P1088, DOI 10.1016/j.lwt.2010.02.014; Luz JMR, 2013, PLOS ONE, V8, P8, DOI DOI 10.1371/J0URNAL.P0NE.0069386.G003; Massaro FC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081297; Mathlouthi M, 2001, FOOD CONTROL, V12, P409, DOI 10.1016/S0956-7135(01)00032-9; Mohamed AA, 2013, PLOS ONE, V8, P1, DOI DOI 10.1371/annotation/f9aef9a9-5488-4492-8b8c-1cdded2e3d79; Park YK, 1998, BIOSCI BIOTECH BIOCH, V62, P2230, DOI 10.1271/bbb.62.2230; Pelissari FM, 2009, J AGR FOOD CHEM, V57, P7499, DOI 10.1021/jf9002363; Cavalcante DRR, 2011, BRAZ J OTORHINOLAR, V77, P278, DOI 10.1590/S1808-86942011000300002; Rohn S, 2004, J AGR FOOD CHEM, V52, P4725, DOI 10.1021/jf0496797; Rosa MF, 2010, CARBOHYD POLYM, V81, P83, DOI 10.1016/j.carbpol.2010.01.059; Samir MASA, 2005, BIOMACROMOLECULES, V6, P612, DOI 10.1021/bm0493685; Santos FA, 2002, J ETHNOPHARMACOL, V80, P1, DOI 10.1016/S0378-8741(02)00003-X; Silva JBA, 2012, J FOOD SCI, V77, P14; Siripatrawan U, 2010, FOOD HYDROCOLLOID, V24, P770, DOI 10.1016/j.foodhyd.2010.04.003; Souza CO, 2011, J AGR FOOD CHEM, V1, P1; Taketoshi H, 2012, PLOS ONE, V7, P11; Tanja P, 2013, PLOS ONE, V8, P2; Veiga-Santos P, 2007, FOOD CHEM, V103, P255, DOI 10.1016/j.foodchem.2006.07.048; Wenbin G, 2012, PLOS ONE, V7, P5; Zinoviadou KG, 2009, MEAT SCI, V82, P338, DOI 10.1016/j.meatsci.2009.02.004	34	40	41	0	64	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 10	2014	9	11							e112554	10.1371/journal.pone.0112554	http://dx.doi.org/10.1371/journal.pone.0112554			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT3DP	25383783	Green Submitted, Green Published, gold			2023-01-03	WOS:000344816700081
J	Ding, S; Xu, LW; Yang, F; Kong, LC; Zhao, YC; Gao, LC; Wang, W; Xu, RD; Ge, H; Jiang, M; Pu, J; He, B				Ding, Song; Xu, Longwei; Yang, Fan; Kong, Lingcong; Zhao, Yichao; Gao, Lingchen; Wang, Wei; Xu, Rende; Ge, Heng; Jiang, Meng; Pu, Jun; He, Ben			Association between Tissue Characteristics of Coronary Plaque and Distal Embolization after Coronary Intervention in Acute Coronary Syndrome Patients: Insights from a Meta-Analysis of Virtual Histology-Intravascular Ultrasound Studies	PLOS ONE			English	Article							NO-REFLOW PHENOMENON; ACUTE MYOCARDIAL-INFARCTION; PROGNOSTIC VALUE; PRIMARY ANGIOPLASTY; STENT IMPLANTATION; FRAME COUNT; IMPACT; ELEVATION; CALCIFICATION; ANGIOGRAPHY	Background and Objectives: The predictive value of plaque characteristics assessed by virtual histology-intravascular ultrasound (VH-IVUS) including fibrous tissue (FT), fibrofatty (FF), necrotic core (NC) and dense calcium (DC) in identifying distal embolization after percutaneous coronary intervention (PCI) is still controversial. We performed a systematic review and meta-analysis to summarize the association of pre-PCI plaque composition and post-PCI distal embolization in acute coronary syndrome patients. Methods: Studies were identified in PubMed, OVID, EMBASE, the Cochrane Library, the Current Controlled Trials Register, reviews, and reference lists of relevant articles. A meta-analysis using both fixed and random effects models with assessment of study heterogeneity and publication bias was performed. Results: Of the 388 articles screened, 10 studies with a total of 872 subjects (199 with distal embolization and 673 with normal flow) met the eligibility of our study. Compared with normal flow groups, significant higher absolute volume of NC [weighted mean differences (WMD): 5.79 mm(3), 95% CI: 3.02 to 8.55 mm(3); p < 0.001] and DC (WMD: 2.55 mm(3), 95% CI: 0.22 to 4.88 mm(3); p = 0.03) were found in acute coronary syndrome patients with distal embolization. Further subgroup analysis demonstrated that the predictive value of tissue characteristics in determining distal embolization was correlated to clinical scenario of the patients, definition of distal embolization, and whether the percutaneous aspiration thrombectomy was applied. Conclusion: Our study that pooled current evidence showed that plaque components were closely related to the distal embolization after PCI, especially the absolute volume of NC and DC, supporting further studies with larger sample size and high-methodological quality.	[Ding, Song; Xu, Longwei; Yang, Fan; Kong, Lingcong; Zhao, Yichao; Gao, Lingchen; Wang, Wei; Xu, Rende; Ge, Heng; Jiang, Meng; Pu, Jun; He, Ben] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Cardiol, Shanghai 200030, Peoples R China	Shanghai Jiao Tong University	Pu, J (corresponding author), Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Cardiol, Shanghai 200030, Peoples R China.	pujun310@hotmail.com; heben1025@hotmail.com		Xu, Longwei/0000-0001-7097-8299	National Natural Science Foundation of China [81330006, 81170192, 81270282, 81070176, 81400261]; International Cooperation Program of Shanghai Committee of Science and Technology [12410708300]; Shanghai Leading Medical Talents Program; Program for New Century Excellent Talents in University from Ministry of Education of China [NCET-12-0352]; Shanghai Shuguang Program [12SG22]; Key Basic Research Program of Shanghai Committee of Science and Technology [14JC1404500]; Shanghai Jiao Tong University Science and Technology Foundation [YZ1005]; Shanghai Leading Talents Program [LJ10007]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); International Cooperation Program of Shanghai Committee of Science and Technology; Shanghai Leading Medical Talents Program; Program for New Century Excellent Talents in University from Ministry of Education of China; Shanghai Shuguang Program; Key Basic Research Program of Shanghai Committee of Science and Technology; Shanghai Jiao Tong University Science and Technology Foundation; Shanghai Leading Talents Program	This work was supported by the National Natural Science Foundation of China (81330006, 81170192, 81270282, 81070176, and 81400261), International Cooperation Program of Shanghai Committee of Science and Technology (12410708300), Shanghai Leading Medical Talents Program and Shanghai Leading Talents Program (LJ10007), Program for New Century Excellent Talents in University from Ministry of Education of China (NCET-12-0352), Shanghai Shuguang Program (12SG22), Key Basic Research Program of Shanghai Committee of Science and Technology (14JC1404500), and Shanghai Jiao Tong University Science and Technology Foundation (Grant No. YZ1005). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bae JH, 2008, HEART, V94, P1559, DOI 10.1136/hrt.2007.135822; Bose D, 2008, BASIC RES CARDIOL, V103, P587, DOI 10.1007/s00395-008-0745-9; Claessen BE, 2012, JACC-CARDIOVASC IMAG, V5, pS111, DOI 10.1016/j.jcmg.2011.11.018; Cura FA, 2001, AM J CARDIOL, V88, P124, DOI 10.1016/S0002-9149(01)01605-8; Detrano R, 1996, J AM COLL CARDIOL, V27, P285, DOI 10.1016/0735-1097(95)00460-2; Ding S, 2010, CATHETER CARDIO INTE, V75, P722, DOI 10.1002/ccd.22298; Gibson CM, 1996, CIRCULATION, V93, P879, DOI 10.1161/01.CIR.93.5.879; Grines CL, 1999, NEW ENGL J MED, V341, P1949, DOI 10.1056/NEJM199912233412601; Higashikuni Y, 2008, CIRC J, V72, P1235, DOI 10.1253/circj.72.1235; Hong YJ, 2011, EUR HEART J, V32, P2059, DOI 10.1093/eurheartj/ehp034; Hong YJ, 2009, JACC-CARDIOVASC IMAG, V2, P458, DOI 10.1016/j.jcmg.2008.12.020; Iijima R, 2006, AM J CARDIOL, V97, P29, DOI 10.1016/j.amjcard.2005.07.104; Jang JS, 2013, AM J CARDIOL, V111, P968, DOI 10.1016/j.amjcard.2012.12.016; Katayama T, 2006, AM J CARDIOL, V97, P301, DOI 10.1016/j.amjcard.2005.08.043; Kawaguchi R, 2007, J AM COLL CARDIOL, V50, P1641, DOI 10.1016/j.jacc.2007.06.051; Keelan PC, 2001, CIRCULATION, V104, P412, DOI 10.1161/hc2901.093112; Kusama I, 2007, J AM COLL CARDIOL, V50, P1230, DOI 10.1016/j.jacc.2007.07.004; Maehara A, 2009, CIRC-CARDIOVASC INTE, V2, P482, DOI 10.1161/CIRCINTERVENTIONS.109.868398; Morishima I, 2000, J AM COLL CARDIOL, V36, P1202, DOI 10.1016/S0735-1097(00)00865-2; Nakamura Tomohiro, 2007, J Interv Cardiol, V20, P335, DOI 10.1111/j.1540-8183.2007.00282.x; Ohshima K, 2013, INT J CARDIOL, V167, P1000, DOI 10.1016/j.ijcard.2012.03.079; Ohshima K, 2011, J CARDIOL, V57, P36, DOI 10.1016/j.jjcc.2010.08.002; Ohshima K, 2009, J CARDIOL, V54, P205, DOI 10.1016/j.jjcc.2009.05.009; Pu J, 2014, J AM COLL CARDIOL, V63, P2220, DOI 10.1016/j.jacc.2014.02.576; Pu J, 2012, EUR HEART J, V33, P372, DOI 10.1093/eurheartj/ehr387; Pu J, 2011, ATHEROSCLEROSIS, V215, P203, DOI 10.1016/j.atherosclerosis.2010.11.019; Raggi P, 2003, AM J CARDIOL, V92, P827, DOI 10.1016/S0002-9149(03)00892-0; Schmermund A, 2001, ATHEROSCLEROSIS, V155, P499, DOI 10.1016/S0021-9150(00)00598-0; Shaw LJ, 2003, RADIOLOGY, V228, P826, DOI 10.1148/radiol.2283021006; Shin ES, 2011, INT J CARDIOVAS IMAG, V27, P883, DOI 10.1007/s10554-010-9734-9; Steigen TK, 2008, INT J CARDIOVAS IMAG, V24, P453, DOI 10.1007/s10554-007-9285-x; Tanaka A, 2002, CIRCULATION, V105, P2148, DOI 10.1161/01.CIR.0000015697.59592.07; Taylor AJ, 2000, CIRCULATION, V101, P1243, DOI 10.1161/01.CIR.101.11.1243; Virmani R, 2000, ARTERIOSCL THROM VAS, V20, P1262, DOI 10.1161/01.ATV.20.5.1262; Yamada R, 2010, CIRC J, V74, P1658, DOI 10.1253/circj.CJ-09-0992; Zhao XY, 2013, J INT MED RES, V41, P307, DOI 10.1177/0300060513476423	36	10	10	2	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2014	9	11							e106583	10.1371/journal.pone.0106583	http://dx.doi.org/10.1371/journal.pone.0106583			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AS6XM	25375841	Green Published, gold, Green Submitted			2023-01-03	WOS:000344402600004
J	Behringer, K; Goergen, H; Hitz, F; Zijlstra, JM; Greil, R; Markova, J; Sasse, S; Fuchs, M; Topp, MS; Soekler, M; Mathas, S; Meissner, J; Wilhelm, M; Koch, P; Lindemann, HW; Schalk, E; Semrau, R; Kriz, J; Vieler, T; Bentz, M; Lange, E; Mahlberg, R; Hassler, A; Vogelhuber, M; Hahn, D; Mezger, J; Krause, SW; Skoetz, N; Boll, B; von Tresckow, B; Diehl, V; Hallek, M; Borchmann, P; Stein, H; Eich, H; Engert, A				Behringer, Karolin; Goergen, Helen; Hitz, Felicitas; Zijlstra, Josee M.; Greil, Richard; Markova, Jana; Sasse, Stephanie; Fuchs, Michael; Topp, Max S.; Soekler, Martin; Mathas, Stephan; Meissner, Julia; Wilhelm, Martin; Koch, Peter; Lindemann, Hans-Walter; Schalk, Enrico; Semrau, Robert; Kriz, Jan; Vieler, Tom; Bentz, Martin; Lange, Elisabeth; Mahlberg, Rolf; Hassler, Andre; Vogelhuber, Martin; Hahn, Dennis; Mezger, Joerg; Krause, Stefan W.; Skoetz, Nicole; Boell, Boris; von Tresckow, Bastian; Diehl, Volker; Hallek, Michael; Borchmann, Peter; Stein, Harald; Eich, Hans; Engert, Andreas		German Hodgkin Study Grp; Swiss Grp Clinical Canc Res; Arbeitsgemeinschaft Medikamentose	Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial	LANCET			English	Article							2ND MALIGNANCY RISK; RADIATION-THERAPY; COMBINED-MODALITY; FIELD RADIOTHERAPY; CLINICAL-TRIALS; 2 CYCLES; DISEASE; CHEMOTHERAPY; VINBLASTINE; METAANALYSIS	Background The role of bleomycin and dacarbazine in the ABVD regimen (ie, doxorubicin, bleomycin, vinblastine, and dacarbazine) has been questioned, especially for treatment of early-stage favourable Hodgkin's lymphoma, because of the drugs' toxicity. We aimed to investigate whether omission of either bleomycin or dacarbazine, or both, from ABVD reduced the efficacy of this regimen in treatment of Hodgkin's lymphoma. Methods In this open-label, randomised, multicentre trial (HD13) we compared two cycles of ABVD with two cycles of the reduced-intensity regimen variants ABV (doxorubicin, bleomycin, and vinblastine), AVD (doxorubicin, vinblastine, and dacarbazine), and AV (doxorubicin and vinblastine), in patients with newly diagnosed, histologically proven, classic or nodular, lymphocyte predominant Hodgkin's lymphoma. In each treatment group, 30 Gy involved-field radiotherapy (IFRT) was given after both cycles of chemotherapy were completed. From Jan 28, 2003, patients were centrally randomly assigned (1:1:1:1) with a minimisation method to the four groups. Because of high event rates, assignment to the AV and ABV groups stopped early, on Sept 30, 2005, and Feb 10, 2006; assignment to ABVD and AVD continued (1:1) until Sept 30, 2009. Our primary objective was to show non-inferiority of the experimental variants compared with ABVD in terms of freedom from treatment failure (FFTF), by excluding a difference of 6% after 5 years corresponding to a hazard ratio (HR) of 1.72, via a 95% CI. Analyses reported here include qualified patients only, and between-group comparisons include only patients recruited during the same period. The trial was registered, number ISRCTN63474366. Findings Of 1502 qualified patients, 566, 198, 571, and 167 were randomly assigned to receive ABVD, ABV, AVD, or AV, respectively. 5 year FFTF was 93.1%, 81.4%, 89.2%, and 77.1% with ABVD, ABV, AVD, and AV, respectively. Compared with ABVD, inferiority of the dacarbazine-deleted variants was detected with 5 year differences of -11.5% (95% CI -18.3 to -4.7; HR 2.06 [1.21 to 3.52]) for ABV and -15.2% (-23.0 to -7.4; HR 2.57 [1.51 to 4.40]) for AV. Non-inferiority of AVD compared with ABVD could also not be detected (5 year difference -3.9%, -7.7 to -0.1; HR 1.50, 1.00 to 2.26). 178 (33%) of 544 patients given ABVD had WHO grade III or IV toxicity, compared with 53 (28%) of 187 given ABV, 142 (26%) of 539 given AVD, and 40 (26%) of 151 given AV. Leucopenia was the most common event, and highest in the groups given bleomycin. Interpretation Dacarbazine cannot be omitted from ABVD without a substantial loss of efficacy. With respect to our predefined non-inferiority margin, bleomycin cannot be safely omitted either, and the standard of care for patients with early-stage favourable Hodgkin's lymphoma should remain ABVD followed by IFRT.	[Behringer, Karolin; Goergen, Helen; Sasse, Stephanie; Boell, Boris; von Tresckow, Bastian; Diehl, Volker; Borchmann, Peter; Engert, Andreas] Univ Hosp Cologne, Dept Internal Med 1, German Hodgkin Study Grp, D-50924 Cologne, Germany; [Hitz, Felicitas] Cantonal Hosp St Gallen, St Gallen, Switzerland; [Hitz, Felicitas] SAKK Swiss Grp Clin Canc Res, Bern, Switzerland; [Zijlstra, Josee M.] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands; [Greil, Richard] Paracelcus Med Univ, Dept Med 3, Salzburg, Austria; [Markova, Jana] Charles Univ Prague, Univ Hosp Kralovske Vinohrady, Fac Med 3, Prague, Czech Republic; [Topp, Max S.] Univ Hosp Wurzburg, Wurzburg, Germany; [Soekler, Martin] Univ Tubingen, Tubingen, Germany; [Mathas, Stephan] Charite, Campus Virchow Klinikum, D-13353 Berlin, Germany; [Meissner, Julia] Heidelberg Univ, Heidelberg, Germany; [Wilhelm, Martin] Klinikum Nurnberg, Nurnberg, Germany; [Koch, Peter; Kriz, Jan; Eich, Hans] Univ Hosp Munster, Munster, Germany; [Lindemann, Hans-Walter] Kathol Krankenhaus, Hagen, Germany; [Schalk, Enrico] Otto Von Guericke Univ, Dept Haematol & Oncol, Med Ctr, Magdeburg, Germany; [Semrau, Robert] Univ Hosp Cologne, Dept Radiat Oncol, Cologne, Germany; [Vieler, Tom] Univ Klin Schleswig Holstein, Med Klin, Kiel, Germany; [Bentz, Martin] Stadt Klinikum Karlsruhe, Med Klin, Karlsruhe, Germany; [Lange, Elisabeth] Evangel Krankenhaus, Med Klin, Hematol Onkol, Hamm, Germany; [Mahlberg, Rolf] Krankenanstalt Mutterhaus Borromaerinnen, Med Klin, Trier, Germany; [Hassler, Andre] Charite Campus Mitte, Zentrum Innere Med, Hamatol Onkol, Berlin, Germany; [Vogelhuber, Martin] Univ Klin Regensburg, Med Klin, Regensburg, Germany; [Hahn, Dennis] Katharinen Hosp, Klin Onkol, D-70174 Stuttgart, Germany; [Mezger, Joerg] St Vincentius Kliniken GAG, Palliat Med, Med Klin Hamatol, Onkol,Immunol, Karlsruhe, Germany; [Krause, Stefan W.] Univ Erlangen Nurnberg, Dept Internal Med 5, Haematol Oncol, Erlangen, Germany; [Skoetz, Nicole] Univ Hosp Cologne, Cochrane Haematol Malignancies Grp, Dept Internal Med 1, Cologne, Germany; [Hallek, Michael] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany; [Stein, Harald] Berlin Reference Ctr Lymphoma & Haematopathol, Berlin, Germany	University of Cologne; Kantonsspital St. Gallen; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Paracelsus Private Medical University; Charles University Prague; University Hospital Vinohrady; University of Wurzburg; Eberhard Karls University of Tubingen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Ruprecht Karls University Heidelberg; Klinikum Nurnberg Nord; University of Munster; Otto von Guericke University; University of Cologne; University of Kiel; Schleswig Holstein University Hospital; Municipal Hospital Karlsruhe; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Regensburg; Klinikum Stuttgart; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Erlangen Nuremberg; University of Cologne; University of Cologne	Engert, A (corresponding author), Univ Hosp Cologne, Dept Internal Med 1, D-50924 Cologne, Germany.	a.engert@uni-koeln.de	Semrau, Robert/S-2505-2017; sasse, stephanie/AAV-3317-2020; Greil, Richard F/C-7673-2017; Mathas, Stephan/I-5589-2015; Hallek, Michael/Y-3191-2019; Schalk, Enrico/X-9283-2019	sasse, stephanie/0000-0002-1080-4606; Greil, Richard F/0000-0002-4462-3694; Hallek, Michael/0000-0002-7425-4455; Schalk, Enrico/0000-0003-1892-5098; Krause, Stefan/0000-0002-5259-4651	Deutsche Krebshilfe; Swiss State Secretariat for Education and Research	Deutsche Krebshilfe(Deutsche Krebshilfe); Swiss State Secretariat for Education and Research	Deutsche Krebshilfe and Swiss State Secretariat for Education and Research.	AVILES A, 1995, MED PEDIATR ONCOL, V24, P171, DOI 10.1002/mpo.2950240306; Buchler T, 2007, HAEMATOLOGICA, V92, pE120, DOI 10.3324/haematol.11856; Canellos GP, 2004, J CLIN ONCOL, V22, P1532, DOI 10.1200/JCO.2004.99.010; CARDE P, 1993, J CLIN ONCOL, V11, P2258, DOI 10.1200/JCO.1993.11.11.2258; Carde PP, 2012, J CLIN ONCOL, V30; Eghbali H, 2005, BLOOD, V106, p240A; Engert A, 2007, J CLIN ONCOL, V25, P3495, DOI 10.1200/JCO.2006.07.0482; Engert A, 2010, NEW ENGL J MED, V363, P640, DOI 10.1056/NEJMoa1000067; Ferme C, 2007, NEW ENGL J MED, V357, P1916, DOI 10.1056/NEJMoa064601; Franklin J, 2006, ANN ONCOL, V17, P1749, DOI 10.1093/annonc/mdl302; Hamed R H, 2012, Hematol Oncol Stem Cell Ther, V5, P36, DOI 10.5144/1658-3876.2012.36; Herbst C, 2011, COCHRANE DB SYST REV, V2; Hodgson DC, 2011, HEMATOL MALIG, P305, DOI 10.1007/978-3-642-12780-9_22; Horning SJ, 2002, J CLIN ONCOL, V20, P630, DOI 10.1200/JCO.20.3.630; le Maignan C, 2004, BLOOD, V103, P58, DOI 10.1182/blood-2003-05-1611; Loeffler M, 1998, J CLIN ONCOL, V16, P818, DOI 10.1200/JCO.1998.16.3.818; Martin WG, 2005, J CLIN ONCOL, V23, P7614, DOI 10.1200/JCO.2005.02.7243; Meyer RM, 2012, NEW ENGL J MED, V366, P399, DOI 10.1056/NEJMoa1111961; Meyer RM, 2005, J CLIN ONCOL, V23, P4634, DOI 10.1200/JCO.2005.09.085; Nachman JB, 2002, J CLIN ONCOL, V20, P3765, DOI 10.1200/JCO.2002.12.007; Ng AK, 2002, J CLIN ONCOL, V20, P2101, DOI 10.1200/JCO.2002.08.021; Noordijk EM, 2005, J CLIN ONCOL, V23, p561S, DOI 10.1200/jco.2005.23.16_suppl.6505; Press OW, 2001, J CLIN ONCOL, V19, P4238, DOI 10.1200/JCO.2001.19.22.4238; Sharma A, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.8533; Sieniawski M, 2007, J CLIN ONCOL, V25, P2000, DOI 10.1200/JCO.2006.10.1386; Specht L, 1998, J CLIN ONCOL, V16, P830, DOI 10.1200/JCO.1998.16.3.830; Specht L, 2003, BLOOD, V102, p637A; Straus DJ, 2004, BLOOD, V104, P3483, DOI 10.1182/blood-2004-04-1311; TUBIANA M, 1989, BLOOD, V73, P47; van Leeuwen FE, 2000, J CLIN ONCOL, V18, P487, DOI 10.1200/JCO.2000.18.3.487; von Tresckow B, 2013, BLOOD, V122, DOI 10.1182/blood.V122.21.637.637	31	113	113	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 11	2015	385	9976					1418	1427		10.1016/S0140-6736(14)61469-0	http://dx.doi.org/10.1016/S0140-6736(14)61469-0			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CF7EU	25539730				2023-01-03	WOS:000352719800030
J	Zhang, Z; Ferretti, V; Guntan, I; Moro, A; Steinberg, EA; Ye, ZW; Zecharia, AY; Yu, X; Vyssotski, AL; Brickley, SG; Yustos, R; Pillidge, ZE; Harding, EC; Wisden, W; Franks, NP				Zhang, Zhe; Ferretti, Valentina; Guentan, Ilke; Moro, Alessandro; Steinberg, Eleonora A.; Ye, Zhiwen; Zecharia, Anna Y.; Yu, Xiao; Vyssotski, Alexei L.; Brickley, Stephen G.; Yustos, Raquel; Pillidge, Zoe E.; Harding, Edward C.; Wisden, William; Franks, Nicholas P.			Neuronal ensembles sufficient for recovery sleep and the sedative actions of alpha(2) adrenergic agonists	NATURE NEUROSCIENCE			English	Article							VENTROLATERAL PREOPTIC NUCLEUS; LOCUS-COERULEUS NEURONS; BASAL FOREBRAIN; ALPHA(2A)-ADRENERGIC RECEPTOR; GENERAL-ANESTHESIA; GABAERGIC NEURONS; TRANSGENIC MICE; C-FOS; DEXMEDETOMIDINE; RAT	Do sedatives engage natural sleep pathways? It is usually assumed that anesthetic-induced sedation and loss of righting reflex (LORR) arise by influencing the same circuitry to lesser or greater extents. For the alpha 2 adrenergic receptor agonist dexmedetomidine, we found that sedation and LORR were in fact distinct states, requiring different brain areas: the preoptic hypothalamic area and locus coeruleus (LC), respectively. Selective knockdown of alpha 2A adrenergic receptors from the LC abolished dexmedetomidine-induced LORR, but not sedation. Instead, we found that dexmedetomidine-induced sedation resembled the deep recovery sleep that follows sleep deprivation. We used TetTag pharmacogenetics in mice to functionally mark neurons activated in the preoptic hypothalamus during dexmedetomidine-induced sedation or recovery sleep. The neuronal ensembles could then be selectively reactivated. In both cases, non-rapid eye movement sleep, with the accompanying drop in body temperature, was recapitulated. Thus, alpha 2 adrenergic receptor-induced sedation and recovery sleep share hypothalamic circuitry sufficient for producing these behavioral states.	[Zhang, Zhe; Ferretti, Valentina; Guentan, Ilke; Moro, Alessandro; Steinberg, Eleonora A.; Ye, Zhiwen; Zecharia, Anna Y.; Yu, Xiao; Brickley, Stephen G.; Yustos, Raquel; Pillidge, Zoe E.; Harding, Edward C.; Wisden, William; Franks, Nicholas P.] Imperial Coll London, Dept Life Sci, South Kensington, England; [Vyssotski, Alexei L.] Univ Zurich, ETH Zurich, Inst Neuroinformat, Zurich, Switzerland	Imperial College London; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich	Franks, NP (corresponding author), Imperial Coll London, Dept Life Sci, South Kensington, England.	w.wisden@imperial.ac.uk; n.franks@imperial.ac.uk	Wisden, William/A-4071-2011; Harding, Edward/AAD-4566-2020; Ferretti, Valentina/V-2394-2019	Wisden, William/0000-0003-4743-0334; Harding, Edward/0000-0002-5803-2780; Ferretti, Valentina/0000-0002-5747-8852; Brickley, Stephen/0000-0002-0930-7346; Franks, Nicholas/0000-0003-4874-4212; Moro, Alessandro/0000-0001-9793-6216; Vyssotski, Alexei/0000-0002-9021-1471; Guntan, Ilke/0000-0002-6936-537X; Ye, Zhiwen/0000-0003-4311-1037; Yu, Xiao/0000-0001-9441-1705; Zhang, Zhe/0000-0002-0899-8077	Medical Research Council [G0901892, G0800399]; Biotechnology and Biological Sciences Research Council (BBSRC) [G021691, BB/K018159/1]; Wellcome Trust [WT094211MA]; BBSRC CASE studentship; Wellcome Trust Vacation Scholarship; BBSRC doctoral training grant [BB/F017324/1]; UK-China Scholarships; ERASMUS program; BBSRC [BB/K018159/1] Funding Source: UKRI; MRC [G0800399, G0901892, G0601498] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [1100129, BB/K018159/1] Funding Source: researchfish; Medical Research Council [G0601498] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council (BBSRC)(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome Trust); BBSRC CASE studentship(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust Vacation Scholarship(Wellcome Trust); BBSRC doctoral training grant(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); UK-China Scholarships; ERASMUS program; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by the Medical Research Council (G0901892, N.P.F., S.G.B. and W.W.;G0800399, W.W.), the Biotechnology and Biological Sciences Research Council (BBSRC) (G021691 and BB/K018159/1, N.P.F., S.G.B. and W.W.), the Wellcome Trust (WT094211MA, S.G.B., N.P.F. and W.W.), a BBSRC CASE studentship (E.A.S.), a Wellcome Trust Vacation Scholarship ( Z.E.P.), a BBSRC doctoral training grant (BB/F017324/1, E.C.H.), UK-China Scholarships for Excellence/China Scholarship scheme (X.Y. and Z.Y.) and the ERASMUS program (I.G. and A.M.).	Adams R, 2013, BRIT J ANAESTH, V111, P703, DOI 10.1093/bja/aet194; AGHAJANIAN GK, 1982, SCIENCE, V215, P1394, DOI 10.1126/science.6278591; Alam MA, 2014, J NEUROPHYSIOL, V111, P287, DOI 10.1152/jn.00504.2013; Alexander GM, 2009, NEURON, V63, P27, DOI 10.1016/j.neuron.2009.06.014; Berridge CW, 2012, SLEEP MED REV, V16, P187, DOI 10.1016/j.smrv.2011.12.003; Bol CJJG, 1997, J PHARMACOL EXP THER, V283, P1051; Brown RE, 2012, PHYSIOL REV, V92, P1087, DOI 10.1152/physrev.00032.2011; Carter ME, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00043; Carter ME, 2010, NAT NEUROSCI, V13, P1526, DOI 10.1038/nn.2682; CORREASALES C, 1992, ANESTHESIOLOGY, V76, P948, DOI 10.1097/00000542-199206000-00013; DREW GM, 1979, BRIT J PHARMACOL, V67, P133; Franks NP, 2008, NAT REV NEUROSCI, V9, P370, DOI 10.1038/nrn2372; Gallopin T, 2000, NATURE, V404, P992, DOI 10.1038/35010109; Garner AR, 2012, SCIENCE, V335, P1513, DOI 10.1126/science.1214985; Gelegen C, 2014, EUR J NEUROSCI, V40, P2311, DOI 10.1111/ejn.12570; Gerashchenko D, 2008, P NATL ACAD SCI USA, V105, P10227, DOI 10.1073/pnas.0803125105; Gilsbach R, 2009, MOL PHARMACOL, V75, P1160, DOI 10.1124/mol.109.054544; Gong H, 2004, J PHYSIOL-LONDON, V556, P935, DOI 10.1113/jphysiol.2003.056622; Hu FY, 2012, ANESTHESIOLOGY, V117, P1006, DOI 10.1097/ALN.0b013e3182700ab9; Hunter JC, 1997, BRIT J PHARMACOL, V122, P1339, DOI 10.1038/sj.bjp.0701520; Klugmann M, 2005, MOL CELL NEUROSCI, V28, P347, DOI 10.1016/j.mcn.2004.10.002; Krashes MJ, 2011, J CLIN INVEST, V121, P1424, DOI 10.1172/JCI46229; Lakhlani PP, 1997, P NATL ACAD SCI USA, V94, P9950, DOI 10.1073/pnas.94.18.9950; Lu J, 2000, J NEUROSCI, V20, P3830, DOI 10.1523/JNEUROSCI.20-10-03830.2000; MACDONALD E, 1991, J PHARMACOL EXP THER, V259, P848; Mastakov MY, 2001, MOL THER, V3, P225, DOI 10.1006/mthe.2001.0246; MCGINTY DJ, 1968, SCIENCE, V160, P1253, DOI 10.1126/science.160.3833.1253; McGregor R, 2010, NAT NEUROSCI, V13, P1448, DOI 10.1038/nn1210-1448; Modirrousta M, 2004, NEUROSCIENCE, V129, P803, DOI 10.1016/j.neuroscience.2004.07.028; Murray AJ, 2011, NAT NEUROSCI, V14, P297, DOI 10.1038/nn.2751; Nelson LE, 2003, ANESTHESIOLOGY, V98, P428, DOI 10.1097/00000542-200302000-00024; Reijmers L, 2009, FRONT MOL NEUROSCI, V2, DOI 10.3389/neuro.02.027.2009; Reijmers LG, 2007, SCIENCE, V317, P1230, DOI 10.1126/science.1143839; Rihel J, 2013, CURR OPIN NEUROBIOL, V23, P831, DOI 10.1016/j.conb.2013.04.010; Saito YC, 2013, FRONT NEURAL CIRCUIT, V7, DOI 10.3389/fncir.2013.00192; Sanders RD, 2012, ANESTHESIOLOGY, V117, P945, DOI 10.1097/ALN.0b013e3182700c93; Saper CB, 2010, NEURON, V68, P1023, DOI 10.1016/j.neuron.2010.11.032; SEIDEL WF, 1995, J PHARMACOL EXP THER, V275, P263; Sherin JE, 1998, J NEUROSCI, V18, P4705; Sherin JE, 1996, SCIENCE, V271, P216, DOI 10.1126/science.271.5246.216; Stegmeier F, 2005, P NATL ACAD SCI USA, V102, P13212, DOI 10.1073/pnas.0506306102; STERMAN MB, 1962, EXP NEUROL, V6, P103, DOI 10.1016/0014-4886(62)90081-X; Szymusiak R, 2007, SLEEP MED, V8, P291, DOI 10.1016/j.sleep.2007.03.013; Takahashi K, 2010, NEUROSCIENCE, V169, P1115, DOI 10.1016/j.neuroscience.2010.06.009; Takahashi K, 2009, NEUROSCIENCE, V161, P269, DOI 10.1016/j.neuroscience.2009.02.075; Tan CM, 2002, P NATL ACAD SCI USA, V99, P12471, DOI 10.1073/pnas.122368499; Tang W, 2009, J NEUROSCI, V29, P8621, DOI 10.1523/JNEUROSCI.0359-09.2009; Tong QC, 2008, NAT NEUROSCI, V11, P998, DOI 10.1038/nn.2167; Vyssotski AL, 2009, CURR BIOL, V19, P1159, DOI 10.1016/j.cub.2009.05.070; Zecharia AY, 2009, J NEUROSCI, V29, P2177, DOI 10.1523/JNEUROSCI.4997-08.2009	50	138	152	1	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1097-6256	1546-1726		NAT NEUROSCI	Nat. Neurosci.	APR	2015	18	4					553	+		10.1038/nn.3957	http://dx.doi.org/10.1038/nn.3957			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CE4DL	25706476	Green Accepted			2023-01-03	WOS:000351780900017
J	Debettencourt, MT; Cohen, JD; Lee, RF; Norman, KA; Turk-Browne, NB				Debettencourt, Megan T.; Cohen, Jonathan D.; Lee, Ray F.; Norman, Kenneth A.; Turk-Browne, Nicholas B.			Closed-loop training of attention with real-time brain imaging	NATURE NEUROSCIENCE			English	Article							BASAL GANGLIA; TOP-DOWN; SUSTAINED ATTENTION; COMPUTATIONAL MODEL; FMRI NEUROFEEDBACK; PREFRONTAL CORTEX; NEURAL MECHANISMS; PATTERN-ANALYSIS; PERFORMANCE; OBJECTS	Lapses of attention can have negative consequences, including accidents and lost productivity. Here we used closed-loop neurofeedback to improve sustained attention abilities and reduce the frequency of lapses. During a sustained attention task, the focus of attention was monitored in real time with multivariate pattern analysis of whole-brain neuroimaging data. When indicators of an attentional lapse were detected in the brain, we gave human participants feedback by making the task more difficult. Behavioral performance improved after one training session, relative to control participants who received feedback from other participants' brains. This improvement was largest when feedback carried information from a frontoparietal attention network. A neural consequence of training was that the basal ganglia and ventral temporal cortex came to represent attentional states more distinctively. These findings suggest that attentional failures do not reflect an upper limit on cognitive potential and that attention can be trained with appropriate feedback about neural signals.	[Debettencourt, Megan T.; Cohen, Jonathan D.; Lee, Ray F.; Norman, Kenneth A.; Turk-Browne, Nicholas B.] Princeton Univ, Princeton Neurosci Inst, Princeton, NJ 08544 USA; [Cohen, Jonathan D.; Norman, Kenneth A.; Turk-Browne, Nicholas B.] Princeton Univ, Dept Psychol, Princeton, NJ 08544 USA	Princeton University; Princeton University	Turk-Browne, NB (corresponding author), Princeton Univ, Princeton Neurosci Inst, Princeton, NJ 08544 USA.	ntb@princeton.edu			US National Institutes of Health grant [R01EY021755]; US National Science Foundation (NSF) grant [BCS1229597]; NSF fellowship [DGE1148900]; John Templeton Foundation; NATIONAL EYE INSTITUTE [R01EY021755] Funding Source: NIH RePORTER	US National Institutes of Health grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US National Science Foundation (NSF) grant; NSF fellowship(National Science Foundation (NSF)); John Templeton Foundation; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was supported by US National Institutes of Health grant R01EY021755, US National Science Foundation (NSF) grant BCS1229597, NSF fellowship DGE1148900 and the John Templeton Foundation. The opinions expressed in this publication are those of the authors and do not necessarily reflect the views of these funding agencies.	Al-Aidroos N, 2012, P NATL ACAD SCI USA, V109, P14675, DOI 10.1073/pnas.1202095109; Baldauf D, 2014, SCIENCE, V344, P424, DOI 10.1126/science.1247003; Biggs AT, 2014, Q J EXP PSYCHOL, V67, P1335, DOI 10.1080/17470218.2013.859715; Chun MM, 2011, ANNU REV PSYCHOL, V62, P73, DOI 10.1146/annurev.psych.093008.100427; Czeisler CA, 2005, NEW ENGL J MED, V353, P476, DOI 10.1056/NEJMoa041292; deCharms RC, 2005, P NATL ACAD SCI USA, V102, P18626, DOI 10.1073/pnas.0505210102; DINGES DF, 1985, BEHAV RES METH INSTR, V17, P652, DOI 10.3758/BF03200977; Disner SG, 2011, NAT REV NEUROSCI, V12, P467, DOI 10.1038/nrn3027; Drew T, 2008, J NEUROSCI, V28, P4183, DOI 10.1523/JNEUROSCI.0556-08.2008; Foerde K, 2011, NEUROBIOL LEARN MEM, V96, P624, DOI 10.1016/j.nlm.2011.08.006; Frank MJ, 2012, CEREB CORTEX, V22, P509, DOI 10.1093/cercor/bhr114; Haxby JV, 2001, SCIENCE, V293, P2425, DOI 10.1126/science.1063736; Hinds O, 2013, J NEUROPHYSIOL, V109, P1250, DOI 10.1152/jn.00533.2011; Johnson KA, 2007, NEUROPSYCHOLOGIA, V45, P2234, DOI 10.1016/j.neuropsychologia.2007.02.019; Kravitz AV, 2010, NATURE, V466, P622, DOI 10.1038/nature09159; LaConte SM, 2011, NEUROIMAGE, V56, P440, DOI 10.1016/j.neuroimage.2010.06.052; Leber AB, 2008, P NATL ACAD SCI USA, V105, P13592, DOI 10.1073/pnas.0805423105; Mackworth NH, 1948, Q J EXP PSYCHOL, V1, P6, DOI 10.1080/17470214808416738; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Norman KA, 2006, TRENDS COGN SCI, V10, P424, DOI 10.1016/j.tics.2006.07.005; Noudoost B, 2010, CURR OPIN NEUROBIOL, V20, P183, DOI 10.1016/j.conb.2010.02.003; O'Craven KM, 1999, NATURE, V401, P584, DOI 10.1038/44134; O'Reilly RC, 2006, NEURAL COMPUT, V18, P283, DOI 10.1162/089976606775093909; Reddy L, 2009, P NATL ACAD SCI USA, V106, P21447, DOI 10.1073/pnas.0907330106; Redelmeier DA, 1997, NEW ENGL J MED, V336, P453, DOI 10.1056/NEJM199702133360701; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rosenberg M, 2013, ATTEN PERCEPT PSYCHO, V75, P426, DOI 10.3758/s13414-012-0413-x; Sarter M, 2001, BRAIN RES REV, V35, P146, DOI 10.1016/S0165-0173(01)00044-3; Shallice T, 2002, DEV NEUROPSYCHOL, V21, P43, DOI 10.1207/S15326942DN2101_3; Shibata K, 2011, SCIENCE, V334, P1413, DOI 10.1126/science.1212003; Sulzer J, 2013, NEUROIMAGE, V76, P386, DOI 10.1016/j.neuroimage.2013.03.033; Todd MT, 2013, NEUROIMAGE, V77, P157, DOI 10.1016/j.neuroimage.2013.03.039; Turk-Browne NB, 2013, SCIENCE, V342, P580, DOI 10.1126/science.1238409; Weiskopf N, 2004, IEEE T BIO-MED ENG, V51, P966, DOI 10.1109/TBME.2004.827063; Weissman DH, 2006, NAT NEUROSCI, V9, P971, DOI 10.1038/nn1727; Wiecki TV, 2013, PSYCHOL REV, V120, P329, DOI 10.1037/a0031542; Wolfe JM, 2005, NATURE, V435, P439, DOI 10.1038/435439a; Woolgar A, 2011, J NEUROSCI, V31, P14592, DOI 10.1523/JNEUROSCI.2616-11.2011; Yoo JJ, 2012, NEUROIMAGE, V59, P846, DOI 10.1016/j.neuroimage.2011.07.063; YOSS RE, 1970, NEUROLOGY, V20, P545, DOI 10.1212/WNL.20.6.545	40	177	183	3	95	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1097-6256	1546-1726		NAT NEUROSCI	Nat. Neurosci.	MAR	2015	18	3					470	165		10.1038/nn.3940	http://dx.doi.org/10.1038/nn.3940			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CC2SO	25664913	Green Accepted			2023-01-03	WOS:000350195100028
J	Ito, K; Ookawara, S; Ueda, Y; Goto, S; Miyazawa, H; Yamada, H; Kitano, T; Shindo, M; Kaku, Y; Hirai, K; Yoshida, M; Hoshino, T; Nabata, A; Mori, H; Yoshida, I; Kakei, M; Tabei, K				Ito, Kiyonori; Ookawara, Susumu; Ueda, Yuichiro; Goto, Sawako; Miyazawa, Haruhisa; Yamada, Hodaka; Kitano, Taisuke; Shindo, Mitsunobu; Kaku, Yoshio; Hirai, Keiji; Yoshida, Masashi; Hoshino, Taro; Nabata, Aoi; Mori, Honami; Yoshida, Izumi; Kakei, Masafumi; Tabei, Kaoru			Factors Affecting Cerebral Oxygenation in Hemodialysis Patients: Cerebral Oxygenation Associates with pH, Hemodialysis Duration, Serum Albumin Concentration, and Diabetes Mellitus	PLOS ONE			English	Article							CHRONIC-RENAL-FAILURE; BLOOD-FLOW; RISK; HEMOGLOBIN; HEMATOCRIT; METABOLISM; DEMENTIA; SURGERY	Background Patients undergoing hemodialysis (HD) often develop cerebral disease complications. Furthermore, cerebral regional saturation of oxygen (rSO(2)) was previously reported to be significantly lower in HD patients than in healthy subjects. We aimed to identify the factors affecting the cerebral rSO(2) in HD patients. Methods Fifty-four HD patients (38 men and 16 women; mean age, 67.7 +/- 1.2 years, HD duration, 6.5 +/- 1.9 years) were recruited. Cerebral rSO(2) was monitored at the forehead before HD using an INVOS 5100C (Covidien Japan, Tokyo, Japan). Results The rSO(2) levels were significantly lower in HD patients compared with healthy controls (49.5 +/- 1.7% vs. 68.9 +/- 1.6%, p < 0.001). Multiple regression analysis showed that cerebral rSO(2) independently associated with pH (standardized coefficient: - 0.35), HD duration (standardized coefficient: - 0.33), and serum albumin concentration (standardized coefficient: 0.28). Furthermore, the rSO(2) was significantly lower in HD patients with diabetes mellitus (DM), compared with patients without DM (46.8 +/- 1.7% vs. 52.1 +/- 1.8%, p < 0.05). Conclusions In HD patients, cerebral rSO(2) was affected by multiple factors, including pH, HD duration, and serum albumin concentration. Furthermore, this is the first report describing significantly lower levels of rSO(2) in HD patients with DM than in those without DM.				su-ooka@hb.tp1.jp		Tabei, Seyed MohammadBegher/0000-0001-9923-6969				Bouzat P, 2013, CRIT CARE MED, V41, P1316, DOI 10.1097/CCM.0b013e31827ca64e; Calderon-Arnulphi M, 2007, J NEUROSURG, V106, P283, DOI 10.3171/jns.2007.106.2.283; Cosentino F, 2009, STROKE, V40, P306, DOI 10.1161/STROKEAHA.108.520627; Ferrari M, 2004, CAN J APPL PHYSIOL, V29, P463, DOI 10.1139/h04-031; GENNARI FJ, 1984, NEW ENGL J MED, V310, P102, DOI 10.1056/NEJM198401123100207; Hoshino T, 2014, NEPHRON CLIN PRACT, V126, P57, DOI 10.1159/000358432; Jun IG, 2013, TRANSPL P, V45, P245, DOI 10.1016/j.transproceed.2012.10.025; Kanai H, 2001, AM J KIDNEY DIS, V38, pS129, DOI 10.1053/ajkd.2001.27421; Kim YS, 2008, CLIN SCI, V115, P255, DOI 10.1042/CS20070458; KONTOS HA, 1977, STROKE, V8, P358, DOI 10.1161/01.STR.8.3.358; Lemmers PMA, 2008, PEDIATRICS, V121, P142, DOI 10.1542/peds.2007-0925; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; MACKO RF, 1993, STROKE, V24, P1025, DOI 10.1161/01.STR.24.7.1025; McCusker K, 2006, PERFUSION-UK, V21, P149, DOI 10.1191/0267659106pf863oa; Metry G, 1999, J AM SOC NEPHROL, V10, P854; Murray AM, 2006, NEUROLOGY, V67, P216, DOI 10.1212/01.wnl.0000225182.15532.40; Naganuma T, 2005, KIDNEY INT, V67, P2434, DOI 10.1111/j.1523-1755.2005.00351.x; Nakai S, 2013, THER APHER DIAL, V17, P567, DOI 10.1111/1744-9987.12147; Nielsen AL, 1999, BLOOD PURIFICAT, V17, P206, DOI 10.1159/000014397; Ohara T, 2011, NEUROLOGY, V77, P1126, DOI 10.1212/WNL.0b013e31822f0435; Ono M, 2013, CRIT CARE MED, V41, P464, DOI 10.1097/CCM.0b013e31826ab3a1; Ott A, 1999, NEUROLOGY, V53, P1937, DOI 10.1212/WNL.53.9.1937; Parnia S, 2014, CRIT CARE MED, V42, P930, DOI 10.1097/CCM.0000000000000047; Portoles JM, 2008, KIDNEY INT, V74, pS82, DOI 10.1038/ki.2008.524; Prohovnik I, 2007, J CEREBR BLOOD F MET, V27, P1861, DOI 10.1038/sj.jcbfm.9600478; Roach RC, 1999, AM J PHYSIOL-HEART C, V276, pH438, DOI 10.1152/ajpheart.1999.276.2.H438; Stefanidis I, 2005, CLIN NEPHROL, V64, P129; Stenvinkel P, 2000, NEPHROL DIAL TRANSPL, V15, P953, DOI 10.1093/ndt/15.7.953; Tanaka H, 2007, INT MED J, V14, P35; Tobias JD, 2006, EXPERT REV MED DEVIC, V3, P235, DOI 10.1586/17434440.3.2.235; Ulatowski JA, 1998, AM J PHYSIOL-HEART C, V274, pH1933, DOI 10.1152/ajpheart.1998.274.6.H1933; Verdonck O, 2007, J CEREBR BLOOD F MET, V27, P1369, DOI 10.1038/sj.jcbfm.9600443	32	39	40	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 23	2015	10	2							e0117474	10.1371/journal.pone.0117474	http://dx.doi.org/10.1371/journal.pone.0117474			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC9BI	25706868	gold, Green Published, Green Submitted			2023-01-03	WOS:000350662100092
J	Afulani, PA				Afulani, Patience A.			Rural/Urban and Socioeconomic Differentials in Quality of Antenatal Care in Ghana	PLOS ONE			English	Article							MATERNAL MORTALITY; OF-CARE; HEALTH; DELIVERY; SERVICES; STRATEGIES; LEVEL; MODEL; LABOR; TOO	Background Approximately 800 women die of pregnancy-related complications every day. Over half of these deaths occur in sub-Saharan Africa (SSA). Most maternal deaths can be prevented with high quality maternal health services. It is well established that use of maternal health services vary by place of residence and socioeconomic status (SES), but few studies have examined the determinants of quality of maternal health services in SSA. The purpose of this study is to examine the determinants of antenatal care (ANC) quality in Ghana-focusing on the role of place of residence and SES (education and wealth). The analysis also examines the interactions of these variables and the mediating role of ANC timing, frequency, facility type, and provider type. Methods The data are from the Ghana Maternal Health Survey (N = 4,868). Analytic techniques include multilevel linear regression with mediation and moderation analysis. Results Urban residence and higher SES are positively associated with higher ANC quality, but the urban effect is completely explained by sociodemographic factors. Specifically, about half of the urban effect is explained by education and wealth alone, with other variables accounting for the remainder. The effects of education are conditional on wealth and are strongest for poor women. Starting ANC visits early and attending the recommended four visits as well as receiving ANC from a higher level facility and from a skilled provider are associated with higher quality ANC. These factors partially explain the SES differentials.	[Afulani, Patience A.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Community Hlth Sci, Los Angeles, CA 90089 USA; [Afulani, Patience A.] Calif Ctr Populat Res, Los Angeles, CA USA	University of California System; University of California Los Angeles	Afulani, PA (corresponding author), Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Community Hlth Sci, Los Angeles, CA 90089 USA.	pafulani@ucla.edu		Afulani, Patience/0000-0002-6739-234X	Bixby Doctoral Fellowship in Population from the UCLA Bixby Center on Population and Reproductive Health; Celia and Joseph Blann Fellowship from the UCLA School of Public Health; UCLA Affiliates Scholarship from the UCLA Graduate Division	Bixby Doctoral Fellowship in Population from the UCLA Bixby Center on Population and Reproductive Health; Celia and Joseph Blann Fellowship from the UCLA School of Public Health; UCLA Affiliates Scholarship from the UCLA Graduate Division	The author received no funding for this work. She was supported by the following fellowships: the Bixby Doctoral Fellowship in Population from the UCLA Bixby Center on Population and Reproductive Health; the Celia and Joseph Blann Fellowship from the UCLA School of Public Health; and the UCLA Affiliates Scholarship from the UCLA Graduate Division. These fellowship funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adjiwanou V, 2013, SOC SCI MED, V86, P26, DOI 10.1016/j.socscimed.2013.02.047; ADLER NE, 1994, AM PSYCHOL, V49, P15, DOI 10.1037/0003-066X.49.1.15; Andersen HM, 2004, SOC SCI MED, V59, P2003, DOI 10.1016/j.socscimed.2004.03.005; Aneshensel CS, 2013, THEOR BAS DAT AN SOC, DOI [10.1016/j.jfo.2013.06.003, DOI 10.1016/J.JFO.2013.06.003]; [Anonymous], 2008, DEMOGRAPHIC HLTH RES; Appiah-Denkyira E, 2013, INTERVENTIONS HUMAN, DOI [10.1016/j.jfo.2013.06.003, DOI 10.1016/J.JFO.2013.06.003]; Atinga RA, 2013, INT J SOC ECON, V40, P852, DOI 10.1108/IJSE-2011-0075; Basu S, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001244; Bbaale E, 2011, AUSTRALAS MED J, V4, P516, DOI 10.4066/AMJ.2011.849; Boller C, 2003, B WORLD HEALTH ORGAN, V81, P116; Braveman PA, 2005, JAMA-J AM MED ASSOC, V294, P2879, DOI 10.1001/jama.294.22.2879; Bullough C, 2005, BJOG-INT J OBSTET GY, V112, P1180, DOI 10.1111/j.1471-0528.2005.00718.x; Cai TJ, 2013, SOCIOL METHODOL, V43, P178, DOI 10.1177/0081175012460221; Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1; Carroli G, 2001, PAEDIATR PERINAT EP, V15, P1; Crosby R.A., 2006, RES METHODS HLTH PRO; D'Ambruoso L, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-140; Davis J., 1971, ELEMENTARY SURVEY AN; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; DONABEDIAN A, 1966, MILBANK FUND Q, V44, P166, DOI 10.2307/3348969; Duong DV, 2004, SOC SCI MED, V59, P2585, DOI 10.1016/j.socscimed.2004.04.007; Fauveau V, 2006, INT J GYNECOL OBSTET, V94, P179, DOI 10.1016/j.ijgo.2006.05.020; Friberg IK, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000295; Gabrysch S, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-34; Ghana Health Service, 2012, GHAN HHLTH SERV 2011; [Ghana Health Service UNICEF UNFPA WHO AMDD Ghana Ministry of Health], 2011, NAT ASS EM OBST NEWB; Ghana Statistical Service, 2012, 2010 CENS REP; Ghana Statistical Service, 2011, MULT IND CLUST SURV; Ghana Statistical Service Ghana Health Service Macro International, 2009, GHAN MAT HLTH SURV 2; Graham WJ, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001368; Graham WJ, 2012, LANCET, V379, pE5, DOI 10.1016/S0140-6736(10)62267-2; GSS, 2008, MEAS DHS MACR INT GH; Hamilton LC, 2012, STAT STATA VERSION 1, DOI [10.1007/s12070-012-0514-9, DOI 10.1007/S12070-012-0514-9]; Harvey SA, 2007, B WORLD HEALTH ORGAN, V85, P783, DOI 10.2471/BLT.06.038455; Hox J. J., 2010, MULTILEVEL ANAL; Hulton L, 2000, FRAMEWORK EVALUATION; Hutchinson PL, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-203; Joshi C, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-94; Kolenikov S, 2009, REV INCOME WEALTH, V55, P128, DOI 10.1111/j.1475-4991.2008.00309.x; Krull JL, 2001, MULTIVAR BEHAV RES, V36, P249, DOI 10.1207/S15327906MBR3602_06; Kyei NNA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046475; MacKinnon D. P., 2008, INTRO STAT MEDIATION; Ministry of Health Ghana Ghana Health service UNDP, 2011, GHAN MDG ACC FRAM CO; Mood C, 2010, EUR SOCIOL REV, V26, P67, DOI 10.1093/esr/jcp006; Moyer CA, 2014, MIDWIFERY, V30, P262, DOI 10.1016/j.midw.2013.05.006; Moyer CA, 2013, REPROD HEALTH, V10, DOI 10.1186/1742-4755-10-40; Nikiema B, 2009, HEALTH POLICY PLANN, V24, P367, DOI 10.1093/heapol/czp017; Rabe-Hesketh S, 2012, MULTILEVEL LONGITUDI, VII, DOI [10.1007/ s12070- 012- 0514- 9, DOI 10.1007/S12070-012-0514-9]; THADDEUS S, 1994, SOC SCI MED, V38, P1091, DOI 10.1016/0277-9536(94)90226-7; Tran TK, 2012, BMC PLANT BIOL, V12, P0, DOI [10.1186/ 1472- 6963- 12- 40, DOI 10.1186/1471-2229-12-1]; Treiman DJ., 2014, QUANTITATIVE DATA AN; Tuncalp O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044536; United Nations Secretary General, 2010, GLOB STRAT WOM CHILD; van den Broek NR, 2009, BJOG-INT J OBSTET GY, V116, P18, DOI 10.1111/j.1471-0528.2009.02333.x; van Duong D, 2004, INT J QUAL HEALTH C, V16, P447, DOI 10.1093/intqhc/mzh073; Villar J, 2001, LANCET, V357, P1551, DOI 10.1016/S0140-6736(00)04722-X; Wall SN, 2010, SEMIN PERINATOL, V34, P395, DOI 10.1053/j.semperi.2010.09.009; *WHO, 2004, MAK PREG SAF CRIT RO; WHO, 2014, TRENDS MAT MORT 1990; WHO Department of making pregnancy safer, 2006, STAND MAT NEON CAR M; Witter S, 2007, REPROD HEALTH MATTER, V15, P61; Witter S, 2009, GLOBAL HEALTH ACTION, V2, DOI 10.3402/gha.v2i0.1881; World Health Organization, 2005, WORLD HLTH REPORT 20; World Health Organization U, 2003, ANT CA DEV COUNTR PR; World Health Organization (WHO), 2012, TRENDS MAT MORT 1990	65	51	51	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2015	10	2							e0117996	10.1371/journal.pone.0117996	http://dx.doi.org/10.1371/journal.pone.0117996			28	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CC0XE	25695737	Green Published, gold, Green Submitted			2023-01-03	WOS:000350062300037
J	Smeeing, DPJ; Houwert, RM; Briet, JP; Kelder, JC; Segers, MJM; Verleisdonk, EJMM; Leenen, LPH; Hietbrink, F				Smeeing, Diederik P. J.; Houwert, Roderick M.; Briet, Jan Paul; Kelder, Johannes C.; Segers, Michiel J. M.; Verleisdonk, Egbert Jan M. M.; Leenen, Luke P. H.; Hietbrink, Falco			Weight-Bearing and Mobilization in the Postoperative Care of Ankle Fractures: A Systematic Review and Meta-Analysis of Randomized Controlled Trials and Cohort Studies	PLOS ONE			English	Review							INTERNAL-FIXATION; OPERATIVE TREATMENT; OPEN REDUCTION; SURGERY RESEARCH; EARLY MOTION; IMMOBILIZATION; EPIDEMIOLOGY; MANAGEMENT; COST; CAST	Purpose To determine the effectiveness and safety of interventions used for rehabilitation after open reduction and internal fixation of ankle fractures. Methods A systematic review and meta-analysis was performed using both randomized trials and cohort studies. The effect of mobilization, weight-bearing, and unprotected weight-bearing as tolerated on postoperative recovery was compared using the Olerud Molander score, return to work/daily activities, and the rate of complications. Results A total of 25 articles were included. Ankle exercises resulted in earlier return to work and/or daily activities compared to immobilization (mean difference (MD) -20.76 days; 95% confidence interval (CI) -40.02 to -1.50). There was no difference in the rate of complications between exercises and immobilization (risk ratio (RR) 1.22; 95% CI 0.60 to 2.45) or between early and late weight-bearing (RR 1.26; 95% CI 0.56 to 2.85). Interpretation Results of this meta-analysis show that following ankle surgery, 1) active exercises accelerate return to work and daily activities compared to immobilization, 2) early weight-bearing tends to accelerate return to work and daily activities compared to late weight-bearing. Active exercises in combination with immediate weight-bearing may be a safe option.	[Smeeing, Diederik P. J.; Leenen, Luke P. H.; Hietbrink, Falco] Univ Med Ctr Utrecht, Dept Surg, Utrecht, Netherlands; [Houwert, Roderick M.] Univ Med Ctr Utrecht, Ctr Trauma, Utrecht, Netherlands; [Briet, Jan Paul; Verleisdonk, Egbert Jan M. M.] Diakonessenhuis Utrecht, Dept Surg, Utrecht, Netherlands; [Kelder, Johannes C.] St Antonius Hosp Nieuwegein, Dept Epidemiol, Nieuwegein, Netherlands; [Segers, Michiel J. M.] St Antonius Hosp Nieuwegein, Dept Surg, Nieuwegein, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Diakonessenhuis; St. Antonius Hospital Utrecht; St. Antonius Hospital Utrecht	Smeeing, DPJ (corresponding author), Univ Med Ctr Utrecht, Dept Surg, Utrecht, Netherlands.	diederiksmeeing@hotmail.com	Houwert, Roderick/K-7887-2019	Houwert, Roderick/0000-0003-3497-659X				AHL T, 1993, ACTA ORTHOP SCAND, V64, P95, DOI 10.3109/17453679308994541; AHL T, 1988, ACTA ORTHOP SCAND, V59, P302, DOI 10.3109/17453678809149368; AHL T, 1987, ACTA ORTHOP SCAND, V58, P535, DOI 10.3109/17453678709146394; AHL T, 1986, ACTA ORTHOP SCAND, V57, P526, DOI 10.3109/17453678609014785; Antonopoulos CN, 2011, EUR J VASC ENDOVASC, V42, P751, DOI 10.1016/j.ejvs.2011.08.012; Bhandari M, 2004, ACTA ORTHOP SCAND, V75, P100, DOI 10.1080/00016470410001708200; Black J D J, 2013, Foot (Edinb), V23, P78, DOI 10.1016/j.foot.2013.05.002; Christie AD, 1990, PHYSIOTHERAPY, V6, P3; CIMINO W, 1991, CLIN ORTHOP RELAT R, P152; Court-Brown CM, 2006, INJURY, V37, P691, DOI 10.1016/j.injury.2006.04.130; DALY PJ, 1987, ACTA ORTHOP SCAND, V58, P539, DOI 10.3109/17453678709146395; Del Buono A, 2013, BRIT MED BULL, V106, P179, DOI 10.1093/bmb/lds039; Distasio Anthony J. Ii, 1994, Contemporary Orthopaedics, V29, P273; Dogra AS, 1999, INJURY, V30, P417, DOI 10.1016/S0020-1383(99)00110-2; Egol KA, 2000, J BONE JOINT SURG BR, V82B, P246, DOI 10.1302/0301-620X.82B2.10039; FINSEN V, 1989, J BONE JOINT SURG AM, V71A, P23, DOI 10.2106/00004623-198971010-00005; GODSIFF SP, 1993, INJURY, V24, P529, DOI 10.1016/0020-1383(93)90029-6; Gul A, 2007, ACTA ORTHOP BELG, V73, P360; Harager K, 2000, J Orthop Sci, V5, P552, DOI 10.1007/s007760070004; HEDSTROM M, 1994, CLIN ORTHOP RELAT R, P193; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Honigmann P, 2007, ARCH ORTHOP TRAUM SU, V127, P195, DOI 10.1007/s00402-006-0255-x; HUGHES JL, 1979, CLIN ORTHOP RELAT R, P111; Jacobs WCH, 2012, SPINE J, V12, P706, DOI 10.1016/j.spinee.2012.08.424; Jacobs WCH, 2012, SPINE J, V12, P339, DOI 10.1016/j.spinee.2012.01.015; Jain N, 2008, ANN ROY COLL SURG, V90, P483, DOI 10.1308/003588408X301145; Jensen SL, 1998, ACTA ORTHOP SCAND, V69, P48, DOI 10.3109/17453679809002356; Kimmel LA, 2012, INJURY, V43, P766, DOI 10.1016/j.injury.2011.08.031; Lauge-Hansen N, 1942, THESIS MUNKSGAARD; Lehtonen H, 2003, J BONE JOINT SURG AM, V85A, P205, DOI 10.2106/00004623-200302000-00004; Lin CWC, 2008, AUST J PHYSIOTHER, V54, P201; Lin CWC, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005595.pub3; LUNDKRISTENSEN J, 1981, INJURY, V13, P191, DOI 10.1016/0020-1383(81)90237-0; Murray AM, 2011, INJURY, V42, P1226, DOI 10.1016/j.injury.2010.08.023; Nash CE, 2004, J FAM PRACTICE, V53, P706; Nilsson GM, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471-2474-14-109; OLERUD C, 1984, ARCH ORTHOP TRAUM SU, V103, P190, DOI 10.1007/BF00435553; OLERUD C, 1986, INJURY, V17, P23, DOI 10.1016/0020-1383(86)90008-2; Partenheimer A, 2010, UNFALLCHIRURG, V113, P308, DOI 10.1007/s00113-009-1724-9; Reiner M, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-813; Richter J, 1996, CHIRURG, V67, P1255, DOI 10.1007/s001040050135; Seiger C., 2009, EUR J TRAUMA; Simanski CJP, 2006, J ORTHOP TRAUMA, V20, P108, DOI 10.1097/01.bot.0000197701.96954.8c; Smith TO, 2008, EUR J TRAUMA EMERG S, V34, P69, DOI 10.1007/s00068-007-6111-z; SONDENAA K, 1986, ACTA ORTHOP SCAND, V57, P59, DOI 10.3109/17453678608993217; Starkweather MP, 2012, J FOOT ANKLE SURG, V51, P575, DOI 10.1053/j.jfas.2012.05.022; Thomas G, 2009, FOOT ANKLE INT, V30, P666, DOI 10.3113/FAI.2009.0666; Toivanen JAK, 2003, CURR ORTHOPAED, V17, P167, DOI 10.1016/S0268-0890(03)00047-1; TROPP H, 1995, FOOT ANKLE INT, V16, P79, DOI 10.1177/107110079501600205; vanLaarhoven CJHM, 1996, J BONE JOINT SURG BR, V78B, P395, DOI 10.1302/0301-620X.78B3.0780395; Vioreanu M, 2007, FOOT ANKLE INT, V28, P13, DOI 10.3113/FAI.2007.0003; Wetzler M, 1991, ORTHOP T, V15, P719	52	54	55	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2015	10	2							e0118320	10.1371/journal.pone.0118320	http://dx.doi.org/10.1371/journal.pone.0118320			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC0XE	25695796	Green Published, Green Submitted, gold			2023-01-03	WOS:000350062300048
J	Zhang, ZH; Yin, JY; Chen, JDZ				Zhang, Zhaohui; Yin, Jieyun; Chen, Jiande D. Z.			Ameliorating Effects of Auricular Electroacupuncture on Rectal Distention-Induced Gastric Dysrhythmias in Rats	PLOS ONE			English	Article							IMPROVES DYSPEPTIC SYMPTOMS; MYOELECTRICAL ACTIVITY; ELECTRICAL-STIMULATION; SLOW WAVES; ACUPUNCTURE; MECHANISMS; MOTILITY; IMPAIRMENT	Gastric slow waves (GSW) are known to regulate gastric motility and are impaired with rectal distention (RD). Electroacupuncture (EA) at body acupoints, such as ST 36, has been shown to improve gastric dysrhythmias; however, little is known about the possible effects of auricular electroacupuncture (AEA) on GSW. To study effects and possible mechanisms of AEA on RD-induced gastric dysrhythmias in rats, ten male Sprague-Dawley (SD) rats implanted with gastric serosal electrodes were studied in two different experiments in fed state. Four sessions were performed in experiment 1 as follows: control (RD, no stimulation), RD+AEA, RD+EA at body points and RD+sham AEA. Two sessions were included in experiment 2 to study mechanisms of AEA: RD + atropine and RD + atropine + AEA. It was found that 1) RD significantly decreased the percentage of normal GSW from 89.8 +/- 3.5% to 76.0 +/- 3.3% (P<0.05); 2) AEA increased the percentage of normal GSW during RD to 94.0 +/- 2.1% (P<0.05 vs. RD) via a reduction in the percentages of tachygastria and arrhythmia (P<0.05 vs. RD); 3) atropine blocked the ameliorating effect of AEA on RD-induced gastric dysrhythmias. Our results demonstrated that RD induces gastric dysrhythmias in fed state in rats. AEA improves RD-induced gastric dysrhythmias via the vagal pathway. AEA may have a therapeutic potential in treating gastric dysrhythmias.	[Zhang, Zhaohui; Yin, Jieyun; Chen, Jiande D. Z.] Nanjing Med Univ, Affiliated Hosp 1, Dept Acupuncture, Nanjing, Jiangsu, Peoples R China; [Chen, Jiande D. Z.] Ningbo Pace Translat Med Res Ctr, Ningbo, Zhejiang, Peoples R China	Nanjing Medical University	Chen, JDZ (corresponding author), Univ Texas Med Branch, Div Gastroenterol, Galveston, TX 77555 USA.	Jiandedzchen@gmail.com	zhang, zh/GWV-4677-2022		National Institutes of Health (NIH) Program [CA149956]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD) [JX10231801]; NATIONAL CANCER INSTITUTE [R21CA149956] Funding Source: NIH RePORTER	National Institutes of Health (NIH) Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Financial support was received from the National Institutes of Health (NIH) Program (CA149956) and the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD) (JX10231801). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abo M, 2000, DIGEST DIS SCI, V45, P1731, DOI 10.1023/A:1005590413490; Abramochkin DV, 2012, J COMP PHYSIOL B, V182, P101, DOI 10.1007/s00360-011-0602-2; Arrighi N, 2011, PHARMACOL RES, V64, P420, DOI 10.1016/j.phrs.2011.06.009; Browning KN, 2006, AUTON NEUROSCI-BASIC, V126, P2, DOI 10.1016/j.autneu.2006.01.019; Chang FY, 2005, J GASTROEN HEPATOL, V20, P502, DOI 10.1111/j.1440-1746.2004.03751.x; Chen DD, 2008, J GASTROEN HEPATOL, V23, P141, DOI 10.1111/j.1440-1746.2007.05123.x; Chen JDZ, 1998, DIGEST DIS SCI, V43, P80, DOI 10.1023/A:1018876021156; Chen JDZ, 1996, DIGEST DIS SCI, V41, P1538, DOI 10.1007/BF02087897; Chen JDZ, 2003, GASTROENTEROLOGY, V124, P401, DOI 10.1053/gast.2003.50048; Chen JDZ, 2000, ALIMENT PHARM THERAP, V14, P1041, DOI 10.1046/j.1365-2036.2000.00801.x; Chen J, 2008, AM J PHYSIOL-GASTR L, V295, pG614, DOI 10.1152/ajpgi.90322.2008; Choy DSJ, 1998, J ALTERN COMPLEM MED, V4, P399, DOI 10.1089/acm.1998.4.399; Gao XY, 2011, BRAIN RES, V1397, P19, DOI 10.1016/j.brainres.2011.04.034; Gao XY, 2008, AUTON NEUROSCI-BASIC, V138, P50, DOI 10.1016/j.autneu.2007.10.003; Gori L, 2007, EVID-BASED COMPL ALT, V4, P13, DOI 10.1093/ecam/nem106; Guzik Przemyslaw, 2002, Card Electrophysiol Rev, V6, P256, DOI 10.1023/A:1016333109829; Hirsch DP, 2002, ALIMENT PHARM THER, V16, P17, DOI 10.1046/j.1365-2036.2002.01153.x; Hirst GDS, 2004, J PHARMACOL SCI, V96, P1, DOI 10.1254/jphs.CRJ04002X; Inui A, 2004, FASEB J, V18, P439, DOI 10.1096/fj.03-0641rev; Iwa M, 2007, AUTON NEUROSCI-BASIC, V137, P67, DOI 10.1016/j.autneu.2007.08.001; Kima EH, 2001, NEUROSCI LETT, V307, P113, DOI 10.1016/S0304-3940(01)01948-6; Kraus T, 2007, J NEURAL TRANSM, V114, P1485, DOI 10.1007/s00702-007-0755-z; Li H, 2013, ACUPUNCT MED, V31, P57, DOI 10.1136/acupmed-2012-010173; Li MK, 2010, J ALTERN COMPLEM MED, V16, P435, DOI 10.1089/acm.2009.0348; Liu JS, 2012, AM J PHYSIOL-REG I, V303, pR209, DOI 10.1152/ajpregu.00301.2010; Liu S, 2008, NEUROGASTROENT MOTIL, V20, P1204, DOI 10.1111/j.1365-2982.2008.01164.x; Olsson C, 2011, AUTON NEUROSCI-BASIC, V165, P80, DOI 10.1016/j.autneu.2010.07.002; ORGAN AN, 2009, VOPR KURORTOL FIZIOT, V5, P12; Qian L, 2002, DIGEST DIS SCI, V47, P2473, DOI 10.1023/A:1020551824234; Qian LW, 2003, DIGEST DIS SCI, V48, P508, DOI 10.1023/A:1022532515172; Sallam HS, 2010, AM J PHYSIOL-REG I, V299, pR298, DOI 10.1152/ajpregu.00135.2010; Schukro RP, 2014, COMPLEMENT THER MED, V22, P21, DOI 10.1016/j.ctim.2013.10.002; Shi X., 2013, EVID-BASED COMPL ALT, V2013, DOI DOI 10.1155/2013/894096; SHIRAISHI T, 1995, BRAIN RES BULL, V36, P141, DOI 10.1016/0361-9230(94)00179-5; Sima Lei, 2009, Zhongguo Zhen Jiu, V29, P3; Sun Y, 2010, NEUROGASTROENT MOTIL, V22, P1217, DOI 10.1111/j.1365-2982.2010.01565.x; Takahashi T, 2011, NEUROMODULATION, V14, P8, DOI 10.1111/j.1525-1403.2010.00295.x; Takahashi T, 2006, J GASTROENTEROL, V41, P408, DOI 10.1007/s00535-006-1773-6; Wang J, 2010, J CLIN GASTROENTEROL, V44, P335, DOI 10.1097/MCG.0b013e3181d34572; Wang Yan-Gang, 2007, Zhongguo Zhen Jiu, V27, P245; Xu SP, 2006, DIGEST DIS SCI, V51, P2154, DOI 10.1007/s10620-006-9412-x; Xu XH, 2002, DIGEST DIS SCI, V47, P365, DOI 10.1023/A:1013726223531; Xu XH, 2002, DIGEST DIS SCI, V47, P1746, DOI 10.1023/A:1016484226110; Yang AC, 2011, MED HYPOTHESES, V77, P244, DOI 10.1016/j.mehy.2011.04.021; Yin JY, 2011, AM J PHYSIOL-REG I, V301, pR465, DOI 10.1152/ajpregu.00271.2010; Yin JY, 2010, AM J PHYSIOL-GASTR L, V298, pG563, DOI 10.1152/ajpgi.00252.2009	46	12	15	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 2	2015	10	2							e0114226	10.1371/journal.pone.0114226	http://dx.doi.org/10.1371/journal.pone.0114226			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA3QK	25643282	gold, Green Submitted, Green Published			2023-01-03	WOS:000348821200003
J	Zhong, YF; Wang, K; Zhang, XW; Cai, XF; Chen, YP; Deng, YY				Zhong, Yifei; Wang, Ke; Zhang, Xianwen; Cai, Xiaofan; Chen, Yiping; Deng, Yueyi			Nephrokeli, a Chinese Herbal Formula, May Improve IgA Nephropathy through Regulation of the Sphingosine-1-Phosphate Pathway	PLOS ONE			English	Article							TISSUE GROWTH-FACTOR; PROTEIN-COUPLED RECEPTORS; SPHINGOSINE 1-PHOSPHATE; CELL-PROLIFERATION; CANCER CELLS; KINASE; ACTIVATION; EXPRESSION; APIGENIN; FRUITS	Nephrokeli (NPKL) is a Chinese herbal formula that has been used to treat patients with IgA nephropathy (IgAN) for improvement of proteinuria and kidney injury. However, the mechanism remains unclear. Sphingosine-1-phosphate (S1P) and its receptors S1PR2 and S1PR3 are known to play an important role in kidney disease. Here, we tested whether NPKL is able to regulate the S1P pathway in the kidney of IgAN rats. Four groups of rats were included in the study: Control, IgAN, IgAN treated with losartan, and IgAN treated with NPKL. The IgAN model was generated by injection of bovine serum albumin and staphylococcus enterotoxin B. We found that IgAN rats had increased staining for proliferating cell nuclear antigen (PCNA) in the mesangial area and increased mRNA and protein levels of S1PR2 and S1PR3 in the kidney compared to control rats. Connective tissue growth factor (CTGF), a downstream growth factor in the S1P pathway, was also elevated in the kidney of IgAN rats. Treatment with either NPKL or losartan was able to reduce PCNA staining and the expression of both S1PR2 and S1PR3 in the kidney of IgAN rats. However, NPKL (but not losartan treatment) reduced the expression of CTGF in the kidney of IgAN rats. In addition, we treated rat mesangial cells with sera collected from either NPKL-treated rats or control rats and found that NPKL-serum was able to reduce S1P-induced mesangial cell proliferation and the expression of S1PR2/S1PR3 and CTGF. NPKL also attenuates expression of fibrosis, inflammation, and oxidative stress markers in the kidney of IgAN rats. Our studies provide the mechanism by which NPKL attenuates kidney injury in IgAN rats.	[Zhong, Yifei; Zhang, Xianwen; Cai, Xiaofan; Chen, Yiping; Deng, Yueyi] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Dept Nephrol, Shanghai, Peoples R China; [Wang, Ke] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Surg Res Inst Tradit Chinese Med Combined Western, Shanghai, Peoples R China	Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine	Zhong, YF (corresponding author), Shanghai Univ Tradit Chinese Med, Longhua Hosp, Dept Nephrol, Shanghai, Peoples R China.	yifeilily@126.com; dengyueyi@medmail.com.cn	zhang, xian/GYA-0290-2022; Chen, Yi/HIR-2608-2022; Zhang, XZ/HJA-4189-2022		National Natural Science Foundation of China [1999-30901944]; Shanghai Bureau of Science and Technology [2000-10QA1406500]; Shanghai Bureau of Health [2011-XYQ2011059]; Shanghai Pujiang Program [14PJ1408000]; Shanghai Three-Years Development Program for Traditional Chinese Medicine [ZYSNXD-CC-HPGC-JD-003]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Bureau of Science and Technology; Shanghai Bureau of Health; Shanghai Pujiang Program(Shanghai Pujiang Program); Shanghai Three-Years Development Program for Traditional Chinese Medicine	The research conducted in this manuscript was supported by the grants to Dr. Yifei Zhong from the National Natural Science Foundation of China for Young Investigators (1999-30901944), the Shanghai Bureau of Science and Technology for Young Investigator (2000-10QA1406500), and the Shanghai Bureau of Health for Young Investigators (2011-XYQ2011059). Shanghai Pujiang Program (14PJ1408000), Shanghai Three-Years Development Program for Traditional Chinese Medicine (ZYSNXD-CC-HPGC-JD-003). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alemany R, 1999, J BIOL CHEM, V274, P3994, DOI 10.1074/jbc.274.7.3994; Allen AC, 2001, KIDNEY INT, V60, P969, DOI 10.1046/j.1523-1755.2001.060003969.x; An SZ, 1997, FEBS LETT, V417, P279, DOI 10.1016/S0014-5793(97)01301-X; Brizuela L, 2007, J LIPID RES, V48, P2264, DOI 10.1194/jlr.M700291-JLR200; Coppo R, 2010, J NEPHROL, V23, P626; D'Amico G, 2004, SEMIN NEPHROL, V24, P179, DOI 10.1016/j.semnephrol.2004.01.001; EMANCIPATOR SN, 1987, LAB INVEST, V57, P269; Gassmann M, 2009, ELECTROPHORESIS, V30, P1845, DOI 10.1002/elps.200800720; Geoffroy K, 2004, J BIOL CHEM, V279, P34343, DOI 10.1074/jbc.M403273200; Harrison ME, 2014, EXP MOL PATHOL, V97, P211, DOI 10.1016/j.yexmp.2014.07.006; He ZD, 2001, CHEM PHARM BULL, V49, P780, DOI 10.1248/cpb.49.780; Heringdorf DM, 1999, FEBS LETT, V461, P217, DOI 10.1016/S0014-5793(99)01463-5; Huwiler A, 2006, CURR PHARM DESIGN, V12, P4625, DOI 10.2174/138161206779010422; Jin D, 2015, CELL BIOCHEM BIOPHYS, V71, P1349, DOI 10.1007/s12013-014-0355-0; Katsuma S, 2005, FEBS LETT, V579, P2576, DOI 10.1016/j.febslet.2005.03.073; Katsuma S, 2002, GENES CELLS, V7, P1217, DOI 10.1046/j.1365-2443.2002.00594.x; Katsuma S., 2001, Pharmacogenomics Journal, V1, P211; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Li LS, 2004, KIDNEY INT, V66, P920, DOI 10.1111/j.1523-1755.2004.00837.x; Liu RJ, 2014, DIABETES, V63, P2440, DOI 10.2337/db13-1810; Liu Yi, 2005, Di Yi Jun Yi Da Xue Xue Bao, V25, P1308; Liu ZH., 1989, CHINESE J NEPHROL, V5, P6; Novak J, 2001, J CLIN IMMUNOL, V21, P310, DOI 10.1023/A:1012284402054; Olivera A, 2001, PROSTAG OTH LIPID M, V64, P123, DOI 10.1016/S0090-6980(01)00108-3; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Oo ML, 2007, J BIOL CHEM, V282, P9082, DOI 10.1074/jbc.M610318200; Riser BL, 2000, J AM SOC NEPHROL, V11, P25, DOI 10.1681/ASN.V11125; Rithidech KN, 2012, MUTAT RES-GEN TOX EN, V749, P29, DOI 10.1016/j.mrgentox.2012.08.001; Shi LF, 1998, BIOMED CHROMATOGR, V12, P27; Wahab NA, 2001, BIOCHEM J, V359, P77, DOI 10.1042/0264-6021:3590077; Weston BS, 2003, J AM SOC NEPHROL, V14, P601, DOI 10.1097/01.ASN.0000051600.53134.B9; WIDSTAMATTORPS U, 1992, CLIN NEPHROL, V38, P245; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499; Xiao WQ, 2014, INT J MOL SCI, V15, P11957, DOI 10.3390/ijms150711957; XU B, 2011, CHINESE J INTEGRATED, V12, P333; Yamashita H, 2006, J SURG RES, V130, P80, DOI 10.1016/j.jss.2005.08.004; Zhang GF, 1999, GENE, V227, P89, DOI 10.1016/S0378-1119(98)00589-7; Zhang XX, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0110243, 10.1371/journal.pone.0107072]; ZHANG Y, 2007, J GUANGZHOU U TRADIT, V24, P231; Zhong YF, 2013, KIDNEY INT, V84, P1108, DOI 10.1038/ki.2013.276; [周玲 ZHOU Ling], 2008, [中药新药与临床药理, Traditional Chinese Drug Research and Clinical Plarmacology], V19, P259; Zhu WJ, 2012, LIFE SCI, V91, P369, DOI 10.1016/j.lfs.2012.08.013	42	7	7	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 29	2015	10	1							e0116873	10.1371/journal.pone.0116873	http://dx.doi.org/10.1371/journal.pone.0116873			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA0LR	25633986	gold, Green Published, Green Submitted			2023-01-03	WOS:000348609800011
J	Choi, JW; Cho, HJ; Park, JH; Baek, SY; Chung, JW; Kim, DD; Kim, HC				Choi, Jin Woo; Cho, Hyun-Jong; Park, Ju-Hwan; Baek, Song Yi; Chung, Jin Wook; Kim, Dae-Duk; Kim, Hyo-Cheol			Comparison of Drug Release and Pharmacokinetics after Transarterial Chemoembolization Using Diverse Lipiodol Emulsions and Drug-Eluting Beads	PLOS ONE			English	Article							HEPATOCELLULAR-CARCINOMA; DELIVERY SYSTEM; IN-VITRO; DC BEAD; TOXICITY; CANCER; LIVER; MODEL; TACE	In many studies for chemoembolization of hepatocellular carcinoma, the Lipiodol emulsion preparation protocols, especially the mixing steps, were unclear or even unrevealed at all. However, doxorubicin (DOX) release may depend on the composition and volume ratio (Lipiodol to DOX solution) of a Lipiodol emulsion. Therefore, we conducted a preclinical study to compare in-vitro drug release and in-vivo pharmacokinetics of DOX from diverse Lipiodol emulsions and drug-eluting beads (DEBs) and to compare the tumor response in a rabbit VX2 carcinoma model. DOX release profiles of four types of Lipiodol emulsions with different media (normal saline or Pamiray as an iodinated contrast medium), volume ratio (Lipiodol to DOX solution), and DEBs were investigated in-vitro. For the in-vivo study, 15 rabbits bearing VX2 carcinoma in the liver were treated with 4:1 volume ratio Lipiodol emulsion (group A), 1:1 volume ratio Lipiodol emulsion (group B), and DEBs (group C) chemoembolization. Blood and tissue sampling was conducted to evaluate DOX concentration in plasma and tissues, histological changes, and liver toxicity. The most stable emulsion was formed with Pamiray (including DOX) at a 4:1 volume ratio. The AUC value of group A was significantly lower than that of group B (p=0.003) but comparable to that of group C (p=0.071). The C-max value of group A was significantly different compared with those of group B (p=0.004) and C (p=0.015). The tissue drug concentration in group A was comparable to that in group C (p=0.251). No viable tumor was detected in rabbits of group A and B. In group C, viable tumor less than 10% was seen in two of the five rabbits. There were no significant differences in liver enzyme levels after the procedure. In conclusion, DOX release and pharmacokinetics of presented emulsion systems depend substantially on their composition. Therefore, Lipiodol emulsion type should be considered when interpreting data and designing new studies dealing with chemoembolization.	[Choi, Jin Woo; Baek, Song Yi; Chung, Jin Wook; Kim, Hyo-Cheol] Seoul Natl Univ Hosp, Dept Radiol, Seoul 110744, South Korea; [Cho, Hyun-Jong] Kangwon Natl Univ, Coll Pharm, Chunchon, South Korea; [Park, Ju-Hwan; Kim, Dae-Duk] Seoul Natl Univ, Coll Pharm, Seoul, South Korea; [Park, Ju-Hwan; Kim, Dae-Duk] Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul, South Korea	Seoul National University (SNU); Seoul National University Hospital; Kangwon National University; Seoul National University (SNU); Seoul National University (SNU)	Kim, DD (corresponding author), Seoul Natl Univ, Coll Pharm, Seoul, South Korea.	ddkim@snu.ac.kr; angiointervention@gmail.com	Kim, Dae Duk/D-8864-2013	Cho, Hyun-Jong/0000-0002-5070-9371; Kim, Hyo-Cheol/0000-0002-6016-247X; Chung, Jin Wook/0000-0002-1090-6872	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology [2013R1A1A2A10011007]	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology	This study was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2013R1A1A2A10011007). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199; Buijs M, 2008, RADIOLOGY, V249, P346, DOI 10.1148/radiol.2483071902; Chung GE, 2011, RADIOLOGY, V258, P627, DOI 10.1148/radiol.10101058; Chung JW, 1996, RADIOLOGY, V198, P33, DOI 10.1148/radiology.198.1.8539401; CHUNG JW, 1993, RADIOLOGY, V187, P689, DOI 10.1148/radiology.187.3.8388567; deBaere T, 1996, RADIOLOGY, V201, P731, DOI 10.1148/radiology.201.3.8939223; Dhanasekaran R, 2010, J SURG ONCOL, V101, P476, DOI 10.1002/jso.21522; HERESBACH D, 1989, GASTROEN CLIN BIOL, V13, P775; Hong K, 2006, CLIN CANCER RES, V12, P2563, DOI 10.1158/1078-0432.CCR-05-2225; Idee JM, 2013, CRIT REV ONCOL HEMAT, V88, P530, DOI 10.1016/j.critrevonc.2013.07.003; JOHNSON PJ, 1991, J HEPATOL, V13, P120, DOI 10.1016/0168-8278(91)90873-A; Kan ZX, 1997, ACAD RADIOL, V4, P275, DOI 10.1016/S1076-6332(97)80029-3; Kim HC, 2013, J VASC INTERV RADIOL, V24, P274, DOI 10.1016/j.jvir.2012.11.002; KONNO T, 1983, EUR J CANCER CLIN ON, V19, P1053, DOI 10.1016/0277-5379(83)90028-7; Lammer J, 2010, CARDIOVASC INTER RAD, V33, P41, DOI 10.1007/s00270-009-9711-7; Larson AC, 2008, RADIOLOGY, V246, P964, DOI 10.1148/radiol.2463070725; Lencioni R, 2012, CARDIOVASC INTER RAD, V35, P980, DOI 10.1007/s00270-011-0287-7; LEUNG WT, 1992, CANCER CHEMOTH PHARM, V29, P401, DOI 10.1007/BF00686011; Lewis AL, 2006, J VASC INTERV RADIOL, V17, P335, DOI 10.1097/01.RVI.0000195323.46152.B3; Lewis AL, 2006, J VASC INTERV RADIOL, V17, P1335, DOI 10.1097/01.RVI.0000228416.21560.7F; Malagari K, 2008, EXPERT REV ANTICANC, V8, P1643, DOI 10.1586/14737140.8.10.1643; Osuga K, 2012, INT J CLIN ONCOL, V17, P306, DOI 10.1007/s10147-012-0445-1; Park JH, 2014, J CONTROL RELEASE, V174, P98, DOI 10.1016/j.jconrel.2013.11.016; Sakaguchi H, 1991, Gan To Kagaku Ryoho, V18, P1349; Shin SW, 2009, KOREAN J RADIOL, V10, P425, DOI 10.3348/kjr.2009.10.5.425; Song MJ, 2012, J HEPATOL, V57, P1244, DOI 10.1016/j.jhep.2012.07.017; Varela M, 2007, J HEPATOL, V46, P474, DOI 10.1016/j.jhep.2006.10.020; Vogl TJ, 2011, AM J ROENTGENOL, V197, pW562, DOI 10.2214/AJR.10.4379	28	36	37	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2014	9	12							e115898	10.1371/journal.pone.0115898	http://dx.doi.org/10.1371/journal.pone.0115898			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX7UC	25551760	Green Published, gold, Green Submitted			2023-01-03	WOS:000347119100075
J	Sorii, LJJ; Leggett, LE; Lorenzetti, DL; Silvius, J; Robertson, D; Mansell, L; Holroyd-Leduc, J; Noseworthy, TW; Clement, FM				Sorii, Lesley J. J.; Leggett, Laura E.; Lorenzetti, Diane L.; Silvius, James; Robertson, Duncan; Mansell, Lynne; Holroyd-Leduc, Jayna; Noseworthy, Tom W.; Clement, Fiona M.			Effective Use of the Built Environment to Manage Behavioural and Psychological Symptoms of Dementia: A Systematic Review	PLOS ONE			English	Review							LONG-TERM-CARE; INTERVENTIONS; QUALITY; DESIGN; PEOPLE	Objective: To determine the effectiveness of built environment interventions in managing behavioural and psychological symptoms of dementia (BPSD) among residents in long-term care settings. Methods: Systematic review of literature published from 1995-2013. Studies were included if they: were randomized controlled trials, quasi-experimental trials, or comparative cohort studies; were in long-term or specialized dementia care; included residents with dementia and BPSD; and examined effectiveness of a built environment intervention on frequency and/or severity of BPSD. Quality of included studies was assessed using the Downs and Black Checklist. Study design, patient population, intervention, and outcomes were extracted and narratively synthesized. Results: Five low to moderate quality studies were included. Three categories of interventions were identified: change/redesign of existing physical space, addition of physical objects to environment, and type of living environment. One of the two studies that examined change/redesign of physical spaces reported improvements in BPSD. The addition of physical objects to an existing environment (n=1) resulted in no difference in BPSD between treatment and control groups. The two studies that examined relocation to a novel living environment reported decreased or no difference in the severity and/or frequency of BPSD post-intervention. No studies reported worsening of BPSD following a built environment intervention. Conclusions: The range of built environment interventions is broad, as is the complex and multi-dimensional nature of BPSD. There is inconclusive evidence to suggest a built environment intervention which is clinically superior in long-term care settings. Further high-quality methodological and experimental studies are required to demonstrate the feasibility and effectiveness of such interventions.	[Sorii, Lesley J. J.; Leggett, Laura E.; Lorenzetti, Diane L.; Holroyd-Leduc, Jayna; Noseworthy, Tom W.; Clement, Fiona M.] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada; [Sorii, Lesley J. J.; Leggett, Laura E.; Lorenzetti, Diane L.; Noseworthy, Tom W.; Clement, Fiona M.] Univ Calgary, Inst Publ Hlth, Calgary, AB, Canada; [Lorenzetti, Diane L.] Inst Hlth Econ, Edmonton, AB, Canada; [Holroyd-Leduc, Jayna] Univ Calgary, Dept Med, Calgary, AB, Canada; [Silvius, James; Robertson, Duncan; Mansell, Lynne; Holroyd-Leduc, Jayna; Noseworthy, Tom W.] Alberta Hlth Serv, Calgary, AB, Canada	University of Calgary; University of Calgary; University of Calgary; Alberta Health Services (AHS); University of Calgary	Clement, FM (corresponding author), Univ Calgary, Dept Community Hlth Sci, Teaching Res & Wellness Bldg, Calgary, AB, Canada.	fclement@ucalgary.ca		Lorenzetti, Diane L./0000-0001-8423-3458				Alzheimer Society of Canada, 2010, RIS TID IMP DEM CAN; Azermai M, 2012, AGEING RES REV, V11, P78, DOI 10.1016/j.arr.2011.07.002; Ballard CG, 2006, COCHRANE DATABASE SY, V1; Buffington ALH, 2013, J AM OSTEOPATH ASSOC, V113, P768, DOI 10.7556/jaoa.2013.046; Cadieux MA, 2013, AM J ALZHEIMERS DIS, V28, P723, DOI 10.1177/1533317513500840; Calkins M.P., 1988, DESIGN DEMENTIA; Calkins MP, 2009, NEUROREHABILITATION, V25, P145, DOI 10.3233/NRE-2009-0512; Caspi E, 2013, AGGRESSIVE BEHAV RES; Cohen U, 1993, CONT ENV PEOPLE DEME; Cohen U, 1991, HOLDING HOME DESIGNI; Cohen-Mansfield J, 2005, ALZ DIS ASSOC DIS, V19, P37, DOI 10.1097/01.wad.0000155066.39184.61; Conn DK, 2006, CAN J GERIATR, V9, pS59; Corcoran M, 1991, PHYSICAL OCCUPATIONA, V9, P5, DOI DOI 10.1080/J148V09N03_; Cox Helen, 2004, J Gerontol Nurs, V30, P37; Day K, 2000, GERONTOLOGIST, V40, P397, DOI 10.1093/geront/40.4.397; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Edgerton Edward, 2010, Issues Ment Health Nurs, V31, P306, DOI 10.3109/01612840903383976; Fauth EB, 2013, INT J GERIATRIC PSYC; Gitlin LN, 2003, ALZHEIMERS CARE Q, V4, P85; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; Namazi KH, 1992, AM J ALZHEIMERS DIS, V7, P16, DOI DOI 10.1177/153331759200700105; National Collaborating Centre for mental health, 2007, DEMENTIA NICE SCIE G; Ouslander JG, 2003, J AM GERIATR SOC, V51, P1287; Radhakrishnan R, 2012, ADV PSYCHIAT TREATME, V18, P144, DOI DOI 10.1192/APT.BP.110.008268; Reimer MA, 2004, J AM GERIATR SOC, V52, P1085, DOI 10.1111/j.1532-5415.2004.52304.x; Scottish Intercollegiate Guideline Network (SIGN), 2006, MAN PAT DEM NAT CLIN; Seitz DP, 2012, J AM MED DIR ASSOC, V13, P503, DOI 10.1016/j.jamda.2011.12.059; van der Linde RM, 2013, INT J GERIATR PSYCH, V28, P700, DOI 10.1002/gps.3873; van Hoof J, 2010, AM J ALZHEIMERS DIS, V25, P202, DOI 10.1177/1533317509358885; Wilkes L, 2005, AUSTRALAS J AGEING, V24, P141, DOI 10.1111/j.1741-6612.2005.00105.x	30	22	26	1	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 17	2014	9	12							e115425	10.1371/journal.pone.0115425	http://dx.doi.org/10.1371/journal.pone.0115425			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AX9IA	25517508	Green Submitted, gold, Green Published			2023-01-03	WOS:000347215600066
J	Huang, X; Guo, Y; Huang, WH; Zhang, W; Tan, ZR; Peng, JB; Wang, YC; Hu, DL; Ouyang, DS; Xiao, J; Wang, Y; Luo, M; Chen, Y				Huang, Xi; Guo, Ying; Huang, Wei-hua; Zhang, Wei; Tan, Zhi-rong; Peng, Jing-bo; Wang, Yi-cheng; Hu, Dong-li; Ouyang, Dong-sheng; Xiao, Jian; Wang, Yang; Luo, Min; Chen, Yao			Searching the Cytochrome P450 Enzymes for the Metabolism of Meranzin Hydrate: A Prospective Antidepressant Originating from Chaihu-Shugan-San	PLOS ONE			English	Article							HUMAN LIVER-MICROSOMES; SEROTONIN REUPTAKE INHIBITORS; DEPRESSION; POLYMORPHISM; AGOMELATINE; POPULATION; VOLUNTEERS; EXTRACT; CYP2C19; CYP1A2	Meranzin hydrate (MH), an absorbed bioactive compound from the Traditional Chinese Medicine (TCM) Chaihu-Shugan-San (CSS), was first isolated in our laboratory and was found to possess anti-depression activity. However, the role of cytochrome P450s (CYPs) in the metabolism of MH was unclear. In this study, we screened the CYPs for the metabolism of MH in vitro by human liver microsomes (HLMs) or human recombinant CYPs. MH inhibited the enzyme activities of CYP1A2 and CYP2C19 in a concentration-dependent manner in the HLMs. The K-m and V-max values of MH were 10.3 +/- 1.3 mu M and 99.1 +/- 3.3 nmol/mg protein/min, respectively, for the HLMs; 8.0 +/- 1.6 mu M and 112.4 +/- 5.7 nmol/nmol P450/min, respectively, for CYP1A2; and 25.9 +/- 6.6 mu M and 134.3 +/- 12.4 nmol/nmol P450/min, respectively, for CYP2C19. Other human CYP isoforms including CYP2A6, CYP2C9, CYP2D6, CYP2E1 and CYP3A4 showed minimal or no effect on MH metabolism. The results suggested that MH was simultaneously a substrate and an inhibitor of CYP1A2 and CYP2C9, and MH had the potential to perpetrate drug-drug interactions with other CYP1A2 and CYP2C19 substrates.	[Huang, Xi; Guo, Ying; Huang, Wei-hua; Zhang, Wei; Tan, Zhi-rong; Peng, Jing-bo; Wang, Yi-cheng; Hu, Dong-li; Ouyang, Dong-sheng; Chen, Yao] Cent S Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha 410078, Hunan, Peoples R China; [Huang, Xi; Guo, Ying; Huang, Wei-hua; Zhang, Wei; Tan, Zhi-rong; Peng, Jing-bo; Wang, Yi-cheng; Hu, Dong-li; Ouyang, Dong-sheng; Chen, Yao] Cent S Univ, Inst Clin Pharmacol, Hunan Key Lab Pharmacogenet, Changsha 410078, Hunan, Peoples R China; [Huang, Xi; Xiao, Jian; Wang, Yang; Luo, Min; Chen, Yao] Cent S Univ, Xiangya Hosp, Inst Integrated Tradit Chinese & Western Med, Lab Ethnopharmacol, Changsha 410078, Hunan, Peoples R China	Central South University; Central South University; Central South University	Chen, Y (corresponding author), Cent S Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha 410078, Hunan, Peoples R China.	cbohua@163.com	Chen, Yao/AAJ-5658-2020	Huang, Wei-Hua/0000-0003-4167-8304; Chen, Yao/0000-0001-7231-9860	National Scientific Foundation of China [81302850]; China Postdoctoral Science Foundation [2013M531817, 2014T70793, 2013M542146]; Science and Technology Plan Projects of Hunan Province [2014RS4011]; 863 Project [2012AA02A518]; Key Laboratory Funds of Hunan Province [13K003]; Fundamental Research Funds for the Central South University [1681-7608040003]	National Scientific Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Science and Technology Plan Projects of Hunan Province; 863 Project(National High Technology Research and Development Program of China); Key Laboratory Funds of Hunan Province; Fundamental Research Funds for the Central South University	National Scientific Foundation of China (No. 81302850), General Financial Grant from the China Postdoctoral Science Foundation (No. 2013M531817 and 2014T70793), Science and Technology Plan Projects of Hunan Province (2014RS4011) to YC, General Financial Grant from the China Postdoctoral Science Foundation (No. 2013M542146) to JBP, 863 Project (No. 2012AA02A518) to WZ, Key Laboratory Funds of Hunan Province (13K003) and the Fundamental Research Funds for the Central South University (No. 1681-7608040003) to WHH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bourrie M, 1996, J PHARMACOL EXP THER, V277, P321; Chancellor D, 2011, NAT REV DRUG DISCOV, V10, P809, DOI 10.1038/nrd3585; Chen SJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072428; Chen Y, 2009, XENOBIOTICA, V39, P508, DOI 10.1080/00498250902951763; CHING MS, 1995, BIOCHEM PHARMACOL, V50, P833, DOI 10.1016/0006-2952(95)00207-G; De Crescenzo F, 2014, J AFFECT DISORDERS, V152, P39, DOI 10.1016/j.jad.2013.09.019; Gebhardt AC, 1997, HEPATOLOGY, V26, P957, DOI 10.1053/jhep.1997.v26.pm0009328319; Graf H., 2013, PHARM BIOCH BEHAV; GREENBERG PE, 1993, J CLIN PSYCHIAT, V54, P419; Huang W, 2011, J GASTROINTEST SURG, V15, P87, DOI 10.1007/s11605-010-1374-9; Johnson TN, 2009, PHARM STAT, V8, P186, DOI 10.1002/pst.373; Keers R, 2011, EXPERT REV NEUROTHER, V11, P101, DOI [10.1586/ern.10.186, 10.1586/ERN.10.186]; Kim SH, 2005, LIFE SCI, V76, P1297, DOI 10.1016/j.lfs.2004.10.022; Kocsis JH, 2013, EVID-BASED MENT HEAL, V16, P82, DOI 10.1136/eb-2013-101268; Kong WM, 2011, MOLECULES, V16, P7344, DOI 10.3390/molecules16097344; Lee YC, 2013, J CLIN PSYCHOPHARM, V33, P782, DOI 10.1097/JCP.0b013e31829c970e; Li X, 2013, CHEM-BIOL INTERACT, V204, P140, DOI 10.1016/j.cbi.2013.05.007; McInerney M, 2013, J HEALTH ECON, V32, P1090, DOI 10.1016/j.jhealeco.2013.09.002; Plesnicar BK, 2014, PATIENT PREFER ADHER, V8, P603, DOI 10.2147/PPA.S.12789; Qin CZ, 2014, BIOMED CHROMATOGR, V28, P197, DOI 10.1002/bmc.3003; Ring BJ, 1996, BRIT J CLIN PHARMACO, V41, P181, DOI 10.1111/j.1365-2125.1996.tb00180.x; Schurink B, 2014, J CLIN PSYCHOPHARM, V34, P66, DOI 10.1097/JCP.0000000000000055; Song L, 2014, J CLIN PHARM THER, V39, P204, DOI 10.1111/jcpt.12118; Taavitsainen P, 2001, DRUG METAB DISPOS, V29, P217; Tan E, 2013, CAN FAM PHYSICIAN, V59, P263; Tang C, 2005, DRUG METAB DISPOS, V33, P603, DOI 10.1124/dmd.104.003236; Tombal B, 2010, EUR UROL, V57, P396, DOI 10.1016/j.eururo.2009.11.039; Walker J, 2011, PSYCHOSOMATICS, V52, P424, DOI 10.1016/j.psym.2011.02.003; Weeke P, 2012, CLIN PHARMACOL THER, V92, P72, DOI 10.1038/clpt.2011.368; Xie Y, 2013, NEUROPHARMACOLOGY, V67, P318, DOI 10.1016/j.neuropharm.2012.10.003; Xie Y, 2013, AMINO ACIDS, V44, P413, DOI 10.1007/s00726-012-1347-2; Xu C, 2013, DRUG METAB PHARMACOK, V28, P362, DOI 10.2133/dmpk.DMPK-12-RG-124; Yamamoto Y, 2013, THER DRUG MONIT, V35, P305, DOI 10.1097/FTD.0b013e318283b49a	33	9	11	0	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 26	2014	9	11							e113819	10.1371/journal.pone.0113819	http://dx.doi.org/10.1371/journal.pone.0113819			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA8CZ	25427198	Green Submitted, Green Published, gold			2023-01-03	WOS:000349145400089
J	Al-Henhena, N; Ying, RPY; Ismail, S; Najm, W; Khalifa, SAM; El-Seedi, H; Abdulla, MA				Al-Henhena, Nawal; Ying, Rozaida Poh Yuen; Ismail, Salmah; Najm, Wala; Khalifa, Shaden A. M.; El-Seedi, Hesham; Abdulla, Mahmood Ameen			Chemopreventive Efficacy of Andrographis paniculata on Azoxymethane-Induced Aberrant Colon Crypt Foci In Vivo	PLOS ONE			English	Article							TOTAL PHENOLIC CONTENT; COLORECTAL-CANCER; OXIDATIVE STRESS; ANTIOXIDANT; PLANTS; EXTRACT; 5-FLUOROURACIL; CARCINOGENESIS; ABSORPTION; PREVENTION	Andrographis paniculata is a grass-shaped medicinal herb, traditionally used in Southeast Asia. The aim of this study was to evaluate the chemoprotective effects of A. paniculata on colorectal cancer. A. paniculata ethanol extract was tested on azoxymethane (AOM)-induced aberrant crypt foci (ACF) in vivo and in vitro. A. paniculata treated groups showed a significant reduction in the number of ACF of the treated rats. Microscopically, ACF showed remarkably elongated and stratified cells, and depletion of the submucosal glands of AOM group compared to the treated groups. Histologically, staining showed slightly elevated masses above the surrounding mucosa with oval or slit-like orifices. Immunohistochemically, expression of proliferating cell nuclear antigen (PCNA) and beta-catenin protein were down-regulated in the A. paniculata treated groups compared to the AOM group. When colon tissue was homogenized, malondialdehyde (MDA) and nitric oxide (NO) levels were significantly decreased, whereas superoxide dismutase (SOD) activity was increased in the treated groups compared to the AOM group. A. paniculata ethanol extract showed antioxidant and free radical scavenging activity, as elucidated by the measure of oxidative stress markers. Further, the active fractions were assessed against cell lines of CCD841 and HT29 colon cancer cells.	[Al-Henhena, Nawal; Ying, Rozaida Poh Yuen; Najm, Wala; Abdulla, Mahmood Ameen] Univ Malaya, Fac Med, Dept Biomed Sci, Kuala Lumpur 50603, Malaysia; [Khalifa, Shaden A. M.] Karolinska Univ Hosp, Dept Expt Hematol, SE-14186 Huddinge, Sweden; [El-Seedi, Hesham] Uppsala Univ, Dept Med Chem, Div Pharmacognosy, SE-75123 Uppsala, Sweden; [Ismail, Salmah] Univ Malaya, Fac Sci, Inst Biol Sci, Kuala Lumpur 50603, Malaysia	Universiti Malaya; Karolinska Institutet; Karolinska University Hospital; Uppsala University; Universiti Malaya	Abdulla, MA (corresponding author), Univ Malaya, Fac Med, Dept Biomed Sci, Kuala Lumpur 50603, Malaysia.	ammeen@um.edu.my	ISMAIL, SALMAH/B-9680-2010; Ismail, Salmah/A-6504-2016; El-Seedi, Hesham R./C-8627-2018; POH, ROZAIDA Yuen Ying/B-9625-2010	ISMAIL, SALMAH/0000-0001-5595-8222; POH, ROZAIDA Yuen Ying/0000-0002-7893-9929	University of Malaya [PS246-2010B]; Ministry of Higher Education Malaysia [UM-MOHE UM.C/625/1/HIR/MOHE/SC/09]	University of Malaya(Universiti Malaya); Ministry of Higher Education Malaysia(Ministry of Education, Malaysia)	Funding provided by University of Malaya, Grant No. (PS246-2010B) and High Impact Research Grant UM-MOHE UM.C/625/1/HIR/MOHE/SC/09 from the Ministry of Higher Education Malaysia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abhishek Niranjan, 2010, Indian Journal of Natural Products and Resources, V1, P125; Akowuah GA, 2009, FOOD CHEM TOXICOL, V47, P2321, DOI 10.1016/j.fct.2009.06.022; Al Batran R, 2013, BIOMED RES INT 2013, V2013; Al-Bayaty FH, 2012, NAT PROD RES, V26, P423, DOI 10.1080/14786419.2010.496114; Amaryan G, 2003, PHYTOMEDICINE, V10, P271, DOI 10.1078/094471103322004767; Bagchi D, 2000, TOXICOLOGY, V148, P187, DOI 10.1016/S0300-483X(00)00210-9; Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292; BIRD RP, 1987, CANCER LETT, V37, P147, DOI 10.1016/0304-3835(87)90157-1; Calabrese C, 2000, PHYTOTHER RES, V14, P333, DOI 10.1002/1099-1573(200008)14:5&lt;333::AID-PTR584&gt;3.0.CO;2-D; Chan AT, 2010, GASTROENTEROLOGY, V138, P2029, DOI 10.1053/j.gastro.2010.01.057; Cheah PL, 2014, ASIAN PAC J CANCER P, V15, P3287, DOI 10.7314/APJCP.2014.15.7.3287; El-Seedi HR, 2013, J ETHNOPHARMACOL, V145, P746, DOI 10.1016/j.jep.2012.12.007; FRAGA CG, 1987, BIOCHEM PHARMACOL, V36, P717, DOI 10.1016/0006-2952(87)90724-6; Gan RY, 2010, J MED PLANTS RES, V4, P2438; Hosono K, 2010, MOL CARCINOGEN, V49, P662, DOI 10.1002/mc.20637; Ikram EHK, 2009, J FOOD COMPOS ANAL, V22, P388, DOI 10.1016/j.jfca.2009.04.001; Jarukamjorn K, 2008, J HEALTH SCI, V54, P370, DOI 10.1248/jhs.54.370; Jubeh TT, 2006, J DRUG TARGET, V14, P155, DOI 10.1080/10611860600648429; Khalifa SAM, 2014, BIOCHEM BIOPH RES CO, V446, P681, DOI 10.1016/j.bbrc.2013.12.134; Ko HC, 2006, J ETHNOPHARMACOL, V107, P205, DOI 10.1016/j.jep.2006.03.004; Koukourakis M, 2009, COLORECTAL CANC; Lin FL, 2009, PHYTOTHER RES, V23, P958, DOI 10.1002/ptr.2701; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Marotta F, 2003, HEPATO-GASTROENTEROL, V50, P1914; Murthy NS, 2009, J POSTGRAD MED, V55, P45, DOI 10.4103/0022-3859.43549; Neelwarne B., 2012, RED BEET BIOTECHNOLO, DOI [10.1007/978-1-4614-3458-0, DOI 10.1007/978-1-4614-3458-0]; Norwati D, 2014, ASIAN PAC J CANCER P, V15, P2901, DOI 10.7314/APJCP.2014.15.6.2901; OECD, 2005, DOFO OECD GUID TEST; Ohishi T, 2002, CANCER LETT, V177, P49, DOI 10.1016/S0304-3835(01)00767-4; PINEDO HM, 1988, J CLIN ONCOL, V6, P1653, DOI 10.1200/JCO.1988.6.10.1653; Qader SW, 2011, MOLECULES, V16, P3433, DOI 10.3390/molecules16043433; RADERER M, 1995, EUR J CANCER, V31A, P1002, DOI 10.1016/0959-8049(95)00078-X; Rajagopal Sriram, 2003, J Exp Ther Oncol, V3, P147, DOI 10.1046/j.1359-4117.2003.01090.x; Rao NK., 2006, IRAN J PHARM THERAP, V5, P47; Roy S, 2010, WORLD J MICROB BIOT, V26, P85, DOI 10.1007/s11274-009-0146-8; Saha K, 2004, J ETHNOPHARMACOL, V92, P263, DOI [10.1016/j.jep.2004.03.007, 10.1016/j/jep.2004.03.007]; Samy RP, 2008, J ETHNOPHARMACOL, V115, P302, DOI 10.1016/j.jep.2007.10.006; Sathuvan Malairaj, 2012, Asian Pacific Journal of Tropical Biomedicine, V2, pS741; Segui J, 2005, INFLAMM BOWEL DIS, V11, P872, DOI 10.1097/01.MIB.0000183420.25186.7a; Seril DN, 2003, CARCINOGENESIS, V24, P353, DOI 10.1093/carcin/24.3.353; Shafie NH, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/681027; Sharma OP, 2009, FOOD CHEM, V113, P1202, DOI 10.1016/j.foodchem.2008.08.008; Sheeja K, 2007, IMMUNOPHARM IMMUNOT, V29, P81, DOI 10.1080/08923970701282726; Sheeja K, 2006, IMMUNOPHARM IMMUNOT, V28, P129, DOI 10.1080/08923970600626007; Singha PK, 2003, FITOTERAPIA, V74, P692, DOI [10.1016/S0367-326X(03)00159-X, 10.1016/s0367-326X(03)00159-X]; Skrovankova S, 2012, ADV FOOD NUTR RES; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tomimatsu T, 2005, CHEM-BIOL INTERACT, V155, P129, DOI 10.1016/j.cbi.2005.04.001; Traverso G, 2002, LANCET, V359, P403, DOI 10.1016/S0140-6736(02)07591-8; Violette S, 2002, INT J CANCER, V98, P498, DOI 10.1002/ijc.10146; Wasman SQ, 2011, INDIAN J EXP BIOL, V49, P767; Yamaguchi H, 2003, CANCER RES, V63, P1483; Yen GC, 2001, FOOD CHEM, V74, P471, DOI 10.1016/S0308-8146(01)00165-0; Yoopan N, 2007, PLANTA MED, V73, P503, DOI 10.1055/s-2007-967181; Yu CC, 2005, J PLANT PHYSIOL, V162, P1319, DOI 10.1016/j.jplph.2005.02.003; Zhao F, 2008, J ASIAN NAT PROD RES, V10, P473, DOI [10.1080/10286020801948334, 10.1080/10286020801948599]	56	19	21	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2014	9	11							e111118	10.1371/journal.pone.0111118	http://dx.doi.org/10.1371/journal.pone.0111118			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA8CP	25390042	Green Published, gold			2023-01-03	WOS:000349144400018
J	Ghosh, TS; Van Dyke, M; Maffey, A; Whitley, E; Erpelding, D; Wolk, L				Ghosh, Tista S.; Van Dyke, Michael; Maffey, Ali; Whitley, Elizabeth; Erpelding, Dana; Wolk, Larry			Medical Marijuana's Public Health Lessons - Implications for Retail Marijuana in Colorado	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EXPOSURES		[Ghosh, Tista S.; Van Dyke, Michael; Maffey, Ali; Whitley, Elizabeth; Erpelding, Dana; Wolk, Larry] Colorado Dept Publ Hlth & Environm, Denver, CO 80246 USA	Colorado Department of Public Health & Environment	Ghosh, TS (corresponding author), Colorado Dept Publ Hlth & Environm, Denver, CO 80246 USA.							Colorado Department of Public Health and Environment, 2013, HLTH KIDS COL SURV H; Colorado Department of Public Health and Environment, 2014, MON HLTH REL MAR COL; Salomonsen-Sautel S, 2014, DRUG ALCOHOL DEPEN, V140, P137, DOI 10.1016/j.drugalcdep.2014.04.008; Wang GS, 2014, ANN EMERG MED, V63, P684, DOI 10.1016/j.annemergmed.2014.01.017; Wang GS, 2013, JAMA PEDIATR, V167, P630, DOI 10.1001/jamapediatrics.2013.140	5	61	61	0	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 12	2015	372	11					991	993		10.1056/NEJMp1500043	http://dx.doi.org/10.1056/NEJMp1500043			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CD0XK	25760352				2023-01-03	WOS:000350797300002
J	Fan, WZ; Zhang, YQ; Wang, Y; Yao, XH; Yang, JY; Li, JP				Fan, Wenzhe; Zhang, Yingqiang; Wang, Yu; Yao, Xuehua; Yang, Jianyong; Li, Jiaping			Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Survival and Metastasis for Recurrent Hepatocellular Carcinoma after Transarterial Chemoembolization	PLOS ONE			English	Article							PROGNOSTIC VALUE; RESECTION; LIVER; SCORE	Purpose To evaluate whether neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) predict survival and metastasis in patients after transarterial chemoembolization (TACE) for recurrent hepatocellular carcinoma (RHCC). Materials and Methods Clinical and laboratory data from 132 RHCC patients treated with TACE from January 2003 to December 2012 were retrospectively reviewed. Prognostic factors were assessed by multivariate analysis, and the predictive values of NLR and PLR for overall survival (OS) and extrahepatic metastases were compared. Results Pretreatment mean NLR and PLR were 3.1 and 137, respectively. The 0.5-, 1-, and 2-year OS rates were 93.7%, 67.1%, and 10.1% in the low NLR group and 81.1%, 18.9%, and 3.8% in the high NLR group, respectively (P = 0.017). The corresponding OS rates in the low and high PLR groups were 92.5%, 58.1%, and 9.7% and 84.6%, 23.1%, and 2.6%, respectively (P = 0.030). The discriminatory performance predicting 1-year survival probability was significantly poorer for NLR (area under the curve [AUC] = 0.685, 95% confidence interval [CI] 0.598-0.763) than for PLR (AUC = 0.792, 95% CI 0.712-0.857; P = 0.0295), but was good for both ratios for predicting post-TACE extrahepatic metastasis. Multivariate analysis indicated that high PLR (hazard ratio [HR] = 0.373, 95% CI = 0.216-0.644, P < 0.001, vascular invasion (HR = 0.507, 95% CI = 0.310-0.832, P = 0.007), and multiple tumors (HR= 0.553, 95% CI = 0.333-0.919, P = 0.022) were independent prognostic factors for OS. Conclusions High NLR and PLR were both associated with poor prognosis and metastasis in RHCC patients treated with TACE, but high PLR was a better predictor of 1-year OS. High PLR, vascular invasion, and multiple tumors were independent, unfavorable prognostic factors.	[Fan, Wenzhe; Zhang, Yingqiang; Wang, Yu; Yao, Xuehua; Li, Jiaping] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Intervent Oncol, Guangzhou 510275, Guangdong, Peoples R China; [Yang, Jianyong] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Med Imaging, Guangzhou 510275, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University	Li, JP (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Intervent Oncol, Guangzhou 510275, Guangdong, Peoples R China.	lijiaping_2011@126.com			Specialized Research Fund for the Doctoral Program of Higher Education [20130171120083]	Specialized Research Fund for the Doctoral Program of Higher Education(Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP))	This study was supported by a grant from the Specialized Research Fund for the Doctoral Program of Higher Education (No.20130171120083) (http://www.cutech.edu.cn/cn/kyjj/gdxxbsdkyjj/A010301index_1.htm). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Angermayr B, 2003, GUT, V52, P879, DOI 10.1136/gut.52.6.879; Asher V, 2011, CLIN TRANSL ONCOL, V13, P499, DOI 10.1007/s12094-011-0687-9; Bhatti I, 2010, AM J SURG, V200, P197, DOI 10.1016/j.amjsurg.2009.08.041; Chen TM, 2012, J GASTROEN HEPATOL, V27, P553, DOI 10.1111/j.1440-1746.2011.06910.x; Gomez D, 2008, WORLD J SURG, V32, P1757, DOI 10.1007/s00268-008-9552-6; Huang ZL, 2011, J VASC INTERV RADIOL, V22, P702, DOI 10.1016/j.jvir.2010.12.041; KASUGAI H, 1989, GASTROENTEROLOGY, V97, P965, DOI 10.1016/0016-5085(89)91505-9; Kinoshita A, 2012, BRIT J CANCER, V107, P988, DOI 10.1038/bjc.2012.354; Kishi Y, 2009, ANN SURG ONCOL, V16, P614, DOI 10.1245/s10434-008-0267-6; Lai Q, 2014, TRANSPL INT, V27, P32, DOI 10.1111/tri.12191; Lee S, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-350; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Meng MB, 2009, RADIOTHER ONCOL, V92, P184, DOI 10.1016/j.radonc.2008.11.002; Neagoe PE, 2009, GROWTH FACTORS, V27, P335, DOI 10.3109/08977190903155043; OKAZAKI M, 1993, HEPATO-GASTROENTEROL, V40, P320; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Poon RTP, 2000, J SURG ONCOL, V73, P109, DOI 10.1002/(SICI)1096-9098(200002)73:2<109::AID-JSO10>3.3.CO;2-A; Ray-Coquard I, 2009, CANCER RES, V69, P5383, DOI 10.1158/0008-5472.CAN-08-3845; Rougier P, 2007, SEMIN ONCOL, V34, pS12, DOI 10.1053/j.seminoncol.2007.01.007; Sarraf KM, 2009, J THORAC CARDIOV SUR, V137, P425, DOI 10.1016/j.jtcvs.2008.05.046; Shi M, 2010, WORLD J GASTROENTERO, V16, P264, DOI 10.3748/wjg.v16.i2.264; Shuto T, 1996, HEPATO-GASTROENTEROL, V43, P932; Smith RA, 2008, J GASTROINTEST SURG, V12, P1422, DOI 10.1007/s11605-008-0554-3; Sugimachi K, 2001, J Hepatobiliary Pancreat Surg, V8, P410, DOI 10.1007/s005340100002; Tuszynski GP, 1996, BIOESSAYS, V18, P71, DOI 10.1002/bies.950180113; Wada Y, 1998, HEPATOLOGY, V27, P407, DOI 10.1002/hep.510270214; Wang DS, 2012, TUMOR BIOL, V33, P749, DOI 10.1007/s13277-011-0285-z; Wang GY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025295; Yamanaka T, 2007, ONCOLOGY-BASEL, V73, P215, DOI 10.1159/000127412; Yau T, 2008, CANCER, V113, P2742, DOI 10.1002/cncr.23878; Zerbini A, 2010, GASTROENTEROLOGY, V138, P1931, DOI 10.1053/j.gastro.2009.12.051	32	60	64	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 5	2015	10	3							e0119312	10.1371/journal.pone.0119312	http://dx.doi.org/10.1371/journal.pone.0119312			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC9KG	25742141	Green Published, gold, Green Submitted			2023-01-03	WOS:000350688100103
J	Poosti, F; Bansal, R; Yazdani, S; Prakash, J; Post, E; Klok, P; van den Born, J; de Borst, MH; van Goor, H; Poelstra, K; Hillebrands, JL				Poosti, Fariba; Bansal, Ruchi; Yazdani, Saleh; Prakash, Jai; Post, Eduard; Klok, Pieter; van den Born, Jacob; de Borst, Martin H.; van Goor, Harry; Poelstra, Klaas; Hillebrands, Jan-Luuk			Selective delivery of IFN-gamma to renal interstitial myofibroblasts: a novel strategy for the treatment of renal fibrosis	FASEB JOURNAL			English	Article						drug targeting; PDGFR beta; kidney; unilateral ureteral obstruction	CD4(+) T-CELLS; INTERFERON-GAMMA; GROWTH-FACTOR; UP-REGULATION; FIBROBLASTS; DISEASE; HEALTH; LYMPHANGIOGENESIS; ANGIOGENESIS; TRANSITION	Renal fibrosis leads to end-stage renal disease demanding renal replacement therapy because no adequate treatment exists. IFN-gamma is an antifibrotic cytokine that may attenuate renal fibrosis. Systemically administered IFN-gamma causes side effects that may be prevented by specific drug targeting. Interstitial myofibroblasts are the effector cells in renal fibrogenesis. Here, we tested the hypothesis that cell-specific delivery of IFN-gamma to platelet-derived growth factor receptor beta (PDGFR beta)-expressing myofibroblasts attenuates fibrosis in an obstructive nephropathy [unilateral ureteral obstruction (UUO)] mouse model. PEGylated IFN-gamma conjugated to PDGFR beta-recognizing peptide [(PPB)-polyethylene glycol (PEG)-IFN-gamma] was tested in vitro and in vivo for antifibrotic properties and compared with free IFN-gamma. PDGFR beta expression was >3-fold increased (P < 0.05) in mouse fibrotic UUO kidneys and colocalized with alpha-smooth muscle actin-positive (SMA(+)) myofibroblasts. In vitro, PPB-PEG-IFN-gamma significantly inhibited colla1, colla2, and alpha-SMA mRNA expression in TGF-beta-activated NIH3T3 fibroblasts (P < 0.05). In vivo, PPB-PEG-IFN-g gamma specifically accumulated in PDGFR beta-positive myofibroblasts. PPB-PEG-IFN-gamma treatment significantly reduced renal collagen I, fibronectin, and alpha-SMA mRNA and protein expression. Compared with vehicle treatment, PPB-PEG-IFN-gamma preserved tubular morphology, reduced interstitial T-cell infiltration, and attenuated lymphangiogenesis (all P < 0.05) without affecting peritubular capillary density. PPB-PEG-IFN-gamma reducedIFN-gamma-related side effects as manifested by reducedmajor histocompatibility complex class II expression in brain tissue (P < 0.05 vs. free IFN-gamma). Our findings demonstrate that specific targeting of IFN-gamma to PDGFR-beta-expressing myofibroblasts attenuates renal fibrosis and reduces systemic adverse effects.	[Poosti, Fariba; Klok, Pieter; van Goor, Harry; Hillebrands, Jan-Luuk] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Div Pathol, Groningen, Netherlands; [Yazdani, Saleh; van den Born, Jacob; de Borst, Martin H.] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, Div Nephrol, Groningen, Netherlands; [Post, Eduard; Poelstra, Klaas] Univ Groningen, Dept Pharmacokinet Toxicol & Targeting, NL-9700 RB Groningen, Netherlands; [Bansal, Ruchi; Yazdani, Saleh; Prakash, Jai] Univ Twente, MIRA Inst, NL-7500 AE Enschede, Netherlands	University of Groningen; University of Groningen; University of Groningen; University of Twente	Poosti, F (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol Pathol, HPC EA10,POB 30001, NL-9700 RB Groningen, Netherlands.	f.poosti@umcg.nl; j.l.hillebrands@umcg.nl	Yazdani, Saleh/K-9640-2015; Prakash, Jai/C-8015-2014; Bansal, Ruchi/D-4796-2016; van+Goor, Harry/AAS-7712-2020; Bansal, Ruchi/F-4649-2014	Yazdani, Saleh/0000-0002-5162-9904; Prakash, Jai/0000-0003-1050-650X; Bansal, Ruchi/0000-0003-2470-5876; Hillebrands, Jan-Luuk/0000-0003-3135-3274; De Borst, Martin/0000-0002-4127-8733; van Goor, Harry/0000-0002-6670-1577; Post, Eduard/0000-0001-5885-0081	J.K. de Cock Foundation (University Medical Center Groningen); Netherlands Organisation for Health Research and Development (ZonMW) [40-00506-98-9021]; Graduate School of Medical Sciences (University of Groningen, Groningen, The Netherlands); Netherlands Organization for Scientific Research (Veni grant)	J.K. de Cock Foundation (University Medical Center Groningen); Netherlands Organisation for Health Research and Development (ZonMW)(Netherlands Organization for Health Research and Development); Graduate School of Medical Sciences (University of Groningen, Groningen, The Netherlands); Netherlands Organization for Scientific Research (Veni grant)(Netherlands Organization for Scientific Research (NWO))	The authors thank Catharina Reker-Smit, Geert Harms, Marian Bulthuis, and Sippie Huitema for their technical assistance. This work was supported by the J.K. de Cock Foundation (University Medical Center Groningen). Microscopical imaging was performed at the UMCG Imaging Center, which is supported by The Netherlands Organisation for Health Research and Development (ZonMW Grant 40-00506-98-9021). F.P. was supported by the Graduate School of Medical Sciences (University of Groningen, Groningen, The Netherlands). M.H.d.B. was supported by a grant from The Netherlands Organization for Scientific Research (Veni grant).	Ahmed CML, 2003, J CELL SCI, V116, P3089, DOI 10.1242/jcs.00528; Aldigier JC, 2005, J AM SOC NEPHROL, V16, P3306, DOI 10.1681/asn.2004090804; Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708; Bansal R, 2012, MOL CANCER THER, V11, P2419, DOI 10.1158/1535-7163.MCT-11-0758; Bansal R, 2011, J CONTROL RELEASE, V154, P233, DOI 10.1016/j.jconrel.2011.05.027; Bansal R, 2011, HEPATOLOGY, V54, P586, DOI 10.1002/hep.24395; Barisal R, 2011, MOL PHARMACEUT, V8, P1899, DOI 10.1021/mp200263q; Beljaars L, 2003, BIOCHEM PHARMACOL, V66, P1307, DOI 10.1016/S0006-2952(03)00445-3; Boor P, 2010, NAT REV NEPHROL, V6, P643, DOI 10.1038/nrneph.2010.120; Broekema M, 2007, J AM SOC NEPHROL, V18, P165, DOI 10.1681/ASN.2005070730; Chade AR, 2013, COMPR PHYSIOL, V3, P817, DOI 10.1002/cphy.c120012; Chang FC, 2012, J FORMOS MED ASSOC, V111, P589, DOI 10.1016/j.jfma.2012.09.008; Chen YT, 2011, KIDNEY INT, V80, P1170, DOI 10.1038/ki.2011.208; Cleland JL, 1996, PHARMACEUT RES, V13, P1464, DOI 10.1023/A:1016063109373; Duffield JS, 2014, J CLIN INVEST, V124, P2299, DOI 10.1172/JCI72267; Eddy AA, 2000, PEDIATR NEPHROL, V15, P290, DOI 10.1007/s004670000461; Fioretto P, 1998, NEW ENGL J MED, V339, P69, DOI 10.1056/NEJM199807093390202; Floege J, 2008, J AM SOC NEPHROL, V19, P12, DOI 10.1681/ASN.2007050532; Forbes MS, 2012, AM J PHYSIOL-RENAL, V303, pF120, DOI 10.1152/ajprenal.00110.2012; Friedman SL, 2013, J HEPATOL, V58, P1, DOI 10.1016/j.jhep.2012.10.014; GonzalezCuadrado S, 1996, CLIN EXP IMMUNOL, V106, P518, DOI 10.1046/j.1365-2249.1996.d01-864.x; Gu F, 2005, J CONTROL RELEASE, V102, P607, DOI 10.1016/j.jconrel.2004.10.020; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Johnson HM, 1998, BIOCHEM BIOPH RES CO, V244, P607, DOI 10.1006/bbrc.1998.8254; Kerjaschki D, 2014, J CLIN INVEST, V124, P874, DOI 10.1172/JCI74854; Kida Y, 2014, PEDIATR NEPHROL, V29, P333, DOI 10.1007/s00467-013-2430-y; King TE, 2009, LANCET, V374, P222, DOI 10.1016/S0140-6736(09)60551-1; Konda R, 1999, AM J PATHOL, V155, P1587, DOI 10.1016/S0002-9440(10)65475-2; Krensky AM, 2007, NAT CLIN PRACT NEPHR, V3, P164, DOI 10.1038/ncpneph0418; LeBleu VS, 2013, NAT MED, V19, P1047, DOI 10.1038/nm.3218; LeBleu VS, 2011, KIDNEY INT, V80, P1119, DOI 10.1038/ki.2011.300; Lee AS, 2013, KIDNEY INT, V83, P50, DOI 10.1038/ki.2012.312; Lee J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060900; Levey AS, 2007, KIDNEY INT, V72, P247, DOI 10.1038/sj.ki.5002343; Li JH, 2007, STEM CELLS, V25, P697, DOI 10.1634/stemcells.2006-0133; Li JH, 2009, AM J PATHOL, V175, P1380, DOI 10.2353/ajpath.2009.090096; Lin SL, 2011, AM J PATHOL, V178, P911, DOI 10.1016/j.ajpath.2010.10.012; Lin SL, 2008, AM J PATHOL, V173, P1617, DOI 10.2353/ajpath.2008.080433; Lu XL, 2012, UROL RES, V40, P717, DOI 10.1007/s00240-012-0507-x; Ma LJ, 2005, J AM SOC NEPHROL, V16, P966, DOI 10.1681/ASN.2004060492; Meran S, 2011, INT J EXP PATHOL, V92, P158, DOI 10.1111/j.1365-2613.2011.00764.x; MULLER GA, 1991, AM J KIDNEY DIS, V17, P680; Nikolic-Paterson DJ, 2010, KIDNEY INT, V78, P333, DOI 10.1038/ki.2010.182; Oldroyd SD, 1999, KIDNEY INT, V56, P2116, DOI 10.1046/j.1523-1755.1999.00775.x; Ostendorf T, 2012, PEDIATR NEPHROL, V27, P1041, DOI 10.1007/s00467-011-1892-z; Poosti F, 2012, EUR J PHARMACOL, V694, P111, DOI 10.1016/j.ejphar.2012.08.010; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC1, DOI 10.1152/ajpcell.1999.277.1.C1; Rienstra H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009095; RODEMANN HP, 1991, AM J KIDNEY DIS, V17, P684, DOI 10.1016/S0272-6386(12)80352-0; Sakamoto I, 2009, KIDNEY INT, V75, P828, DOI 10.1038/ki.2008.661; Seikrit C, 2013, NEPHROL DIAL TRANSPL, V28, P889, DOI 10.1093/ndt/gfs509; Shao XJ, 2006, J INTERF CYTOK RES, V26, P568, DOI 10.1089/jir.2006.26.568; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Strutz F, 2000, NEPHROL DIAL TRANSPL, V15, P1535, DOI 10.1093/ndt/15.10.1535; Strutz F, 2006, J AM SOC NEPHROL, V17, P2992, DOI 10.1681/ASN.2006050420; Subramaniam PS, 1999, J BIOL CHEM, V274, P403, DOI 10.1074/jbc.274.1.403; Tanaka T, 2013, NAT REV NEPHROL, V9, P211, DOI 10.1038/nrneph.2013.35; Tapmeier TT, 2010, KIDNEY INT, V78, P351, DOI 10.1038/ki.2010.177; Weng HL, 2005, CLIN GASTROENTEROL H, V3, P819, DOI 10.1016/S1542-3565(05)00404-0; Wu MJ, 2006, KIDNEY INT, V69, P2029, DOI 10.1038/sj.ki.5000161; Yao Y, 2011, UROLOGY, V77, DOI 10.1016/j.urology.2010.10.015; Yazdani S, 2014, EXPERT REV MOL MED, V16, DOI 10.1017/erm.2014.18; Yazdani S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050209; Zeisberg EM, 2008, J AM SOC NEPHROL, V19, P2282, DOI 10.1681/ASN.2008050513; Zeisberg M, 2004, J MOL MED, V82, P175, DOI 10.1007/s00109-003-0517-9; Zhang GQ, 2003, J AM SOC NEPHROL, V14, P1234, DOI 10.1097/01.ASN.0000064701.70231.3F	66	54	58	3	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2015	29	3					1029	1042		10.1096/fj.14-258459	http://dx.doi.org/10.1096/fj.14-258459			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CC8QK	25466892	Green Submitted			2023-01-03	WOS:000350633000027
J	Wu, DH; Xu, L; Wen, CP; Xie, GQ; Ji, JJ; Pan, JL; Jiao, YF; Fan, YS				Wu, De-hong; Xu, Li; Wen, Cheng-ping; Xie, Guan-qun; Ji, Jin-jun; Pan, Jie-li; jiao, Yi-feng; Fan, Yong-sheng			The Effects of Jieduquyuzishen Prescription-Treated Rat Serum on the BAFF/BAFF-R Signal Pathway	PLOS ONE			English	Article							SYSTEMIC-LUPUS-ERYTHEMATOSUS; B-LYMPHOCYTE STIMULATOR; NECROSIS-FACTOR FAMILY; GLUCOCORTICOID-INDUCED APOPTOSIS; DISEASE-ACTIVITY; TNF RECEPTOR; BAFF-R; CELLS; BLYS; PATHOGENESIS	Systemic lupus erythematosus (SLE) is a chronic inflammatory disease mainly characterized by B cell hyperactivity. Glucocorticoid (GC) is widely used in SLE for its potent anti-inflammatory and immunosuppressive effects. Despite its important clinical efficacy, highdose or long-term use of GC can cause severe side effects, such as osteoporosis, osteonecrosis, cataracts, hyperglycemia, coronary heart disease and cognitive impairment. Our early clinical studies have shown that Jieduquyuzishen prescription (JP) can effectively reduce the adverse effects and improve the curative effect of GC in the treatment of SLE. The BAFF/BAFF-R signaling pathway plays an important role in the development of SLE and has been regarded as a potential target for the therapy of SLE. In this study, we attempt to investigate the effect of JP on the BAFF/BAFF-R signaling pathway to explore the mechanism of JP in reducing the toxicity and enhancing the efficacy of GC. YAC-1 cells, isolated rat peripheral blood lymphocytes, polymorphonuclear neutrophils and spleen lymphocytes were treated with drug-containing serum. The results of RT-PCR, Western blot and dual-luciferase reporter gene assays indicate that either JP or GC can inhibit the mBAFF-induced up-regulation of BAFF, BAFF-R, Bcl-2, IL-10 and NF-kappa B in YAC-1 cells and WEHI-231 cells. Furthermore, MTS, flow cytometry and CFSE results reveal that the proliferation and survival of lymphocytes activated by mBAFF are suppressed by JP, GC and their combination. Contrary to GC, JP can reduce the apoptosis and raise the survival of polymorphonuclear neutrophils and can't increase the apoptosis of the peripheral blood lymphocytes and spleen lymphocytes. Therefore, it is possible that JP can down-regulate the BAFF/BAFF-R signaling pathway as effectively as GC, which may result in the dosage reduction of GC, thus decreasing the toxicity and improving the efficacy of GC-based treatment of SLE.	[Wu, De-hong; Fan, Yong-sheng] Zhejiang Chinese Med Univ, Clin Med Coll 1, Hangzhou, Zhejiang, Peoples R China; [Xu, Li; Wen, Cheng-ping; Xie, Guan-qun; Ji, Jin-jun; Pan, Jie-li; jiao, Yi-feng] Zhejiang Chinese Med Univ, Coll Basic Med, Hangzhou, Zhejiang, Peoples R China	Zhejiang Chinese Medical University; Zhejiang Chinese Medical University	Fan, YS (corresponding author), Zhejiang Chinese Med Univ, Clin Med Coll 1, Hangzhou, Zhejiang, Peoples R China.	applezjtcm@126.com		chengping, Wen/0000-0001-9254-6235; Wu, De-hong/0000-0001-6107-6154; Xu, Li/0000-0001-6883-6590	National Basic Research Program of China (973 Program) [2014CB543001]; National Natural Science Foundation of China [81202628, 81403289, 81373633]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Basic Research Program of China (973 Program, No. 2014CB543001) and National Natural Science Foundation of China (No. 81202628, No. 81403289, No. 81373633). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amanna IJ, 2003, J IMMUNOL, V170, P4593, DOI 10.4049/jimmunol.170.9.4593; Bishop GA, 2004, NAT REV IMMUNOL, V4, P775, DOI 10.1038/nri1462; Bosch X, 2011, NEW ENGL J MED, V365, P758, DOI 10.1056/NEJMcibr1107085; Chen J, 2014, J HUAZHONG U SCI-MED, V34, P125, DOI 10.1007/s11596-014-1243-y; Courtney PA, 1999, ANN RHEUM DIS, V58, P309, DOI 10.1136/ard.58.5.309; D'Cruz DP, 2007, LANCET, V369, P587, DOI 10.1016/S0140-6736(07)60279-7; Davidson A, 2001, NEW ENGL J MED, V345, P340, DOI 10.1056/NEJM200108023450506; Davidson A, 2006, CURR OPIN RHEUMATOL, V18, P468; Del Poeta G, 2003, BLOOD, V101, P2125, DOI 10.1182/blood-2002-06-1714; Ding XH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088223; [范永升 Fan Yongsheng], 2005, [中华中医药杂志, China Journal of Traditional Chinese Medicine and Pharmacy], V20, P667; Fan Yuan-xun, 2006, Journal of Nanjing University of Science and Technology, V30, P199; Gross JA, 2000, NATURE, V404, P995, DOI 10.1038/35010115; Harless SM, 2001, CURR BIOL, V11, P1986, DOI 10.1016/S0960-9822(01)00598-X; Hsu BL, 2002, J IMMUNOL, V168, P5993, DOI 10.4049/jimmunol.168.12.5993; Isenberg DA, 2005, RHEUMATOLOGY, V44, P902, DOI 10.1093/rheumatology/keh624; Laabi Y, 2000, SCIENCE, V289, P883, DOI 10.1126/science.289.5481.883; Lande R, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001180; Lavie F, 2004, J PATHOL, V202, P496, DOI 10.1002/path.1533; Lentz VM, 1998, J IMMUNOL, V160, P3743; Litinskiy MB, 2002, NAT IMMUNOL, V3, P822, DOI 10.1038/ni829; Mackay F, 1999, J EXP MED, V190, P1697, DOI 10.1084/jem.190.11.1697; McConnell JR, 2002, CLIN EXP RHEUMATOL, V20, P653; MESSER J, 1983, NEW ENGL J MED, V309, P21, DOI 10.1056/NEJM198307073090105; MILLS JA, 1994, NEW ENGL J MED, V330, P1871, DOI 10.1056/NEJM199406303302608; MIYAKE K, 1994, J EXP MED, V180, P1217, DOI 10.1084/jem.180.4.1217; Mok CC, 2003, J CLIN PATHOL, V56, P481, DOI 10.1136/jcp.56.7.481; Moore PA, 1999, SCIENCE, V285, P260, DOI 10.1126/science.285.5425.260; MOTYKA B, 1995, EUR J IMMUNOL, V25, P1865, DOI 10.1002/eji.1830250711; Mukhopadhyay A, 1999, J BIOL CHEM, V274, P15978, DOI 10.1074/jbc.274.23.15978; Nardelli B, 2001, BLOOD, V97, P198, DOI 10.1182/blood.V97.1.198; Ni CZ, 2004, J IMMUNOL, V173, P7394, DOI 10.4049/jimmunol.173.12.7394; Reyes LI, 2008, CYTOKINE, V42, P170, DOI 10.1016/j.cyto.2007.12.005; Schiemann B, 2001, SCIENCE, V293, P2111, DOI 10.1126/science.1061964; Schneider P, 1999, J EXP MED, V189, P1747, DOI 10.1084/jem.189.11.1747; Shu HB, 2000, P NATL ACAD SCI USA, V97, P9156, DOI 10.1073/pnas.160213497; Sionov RV, 2006, CELL CYCLE, V5, P1017, DOI 10.4161/cc.5.10.2738; Sionov RV, 2008, ADV CANCER RES, V101, P127, DOI 10.1016/S0065-230X(08)00406-5; Thompson JS, 2000, J EXP MED, V192, P129, DOI 10.1084/jem.192.1.129; Thompson JS, 2001, SCIENCE, V293, P2108, DOI 10.1126/science.1061965; Vincent FB, 2014, NAT REV RHEUMATOL, V10, P365, DOI 10.1038/nrrheum.2014.33; WADMAN B, 1972, LANCET, V1, P907; Wen C., 2007, CHIN ARCH TRADITI CH, V25, P1599; Wen C., 2007, J ZHEJIANG CHIN MED, V31, P305, DOI [10.16466/j.issn1005-5509.2007.03.024, DOI 10.16466/J.ISSN1005-5509.2007.03.024]; Yan MH, 2001, CURR BIOL, V11, P1547, DOI 10.1016/S0960-9822(01)00481-X; Zhu XJ, 2009, J CLIN IMMUNOL, V29, P603, DOI 10.1007/s10875-009-9303-y; Zilberman Y, 2004, CELL IMMUNOL, V227, P12, DOI 10.1016/j.cellimm.2004.01.005	47	7	9	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 17	2015	10	2							e0118462	10.1371/journal.pone.0118462	http://dx.doi.org/10.1371/journal.pone.0118462			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC4KQ	25689512	gold, Green Published, Green Submitted			2023-01-03	WOS:000350322700116
J	Lin, CJ; Lin, HJ; Chen, TH; Hsu, YA; Liu, CS; Hwang, GY; Wan, L				Lin, Chao-Jen; Lin, Hui-Ju; Chen, Ter-Hsin; Hsu, Yu-An; Liu, Chin-San; Hwang, Guang-Yuh; Wan, Lei			Polygonum cuspidatum and Its Active Components Inhibit Replication of the Influenza Virus through Toll-Like Receptor 9-Induced Interferon Beta Expression	PLOS ONE			English	Article							A VIRUS; H1N1 VIRUS; ACTIVATION; HEMAGGLUTININ; INDUCTION; LACKING; HUMANS; DNA	Influenza virus infection is a global public health issue. The effectiveness of antiviral therapies for influenza has been limited by the emergence of drug-resistant viral strains. Therefore, there is an urgent need to identify novel antiviral therapies. Here we tested the effects of 300 traditional Chinese medicines on the replication of various influenza virus strains in a lung cell line, A549, using an influenza-specific luciferase reporter assay. Of the traditional medicines tested, Polygonum cuspidatum (PC) and its active components, resveratrol and emodin, were found to attenuate influenza viral replication in A549 cells. Furthermore, they preferentially inhibited the replication of influenza A virus, including clinical strains isolated in 2009 and 2011 in Taiwan and the laboratory strain A/WSN/33 (H1N1). In addition to inhibiting the expression of hemagglutinin and neuraminidase, PC, emodin, and resveratrol also increased the expression of interferon beta (IFN-beta) through Toll-like receptor 9 (TLR9). Moreover, the anti-viral activity of IFN-beta or resveratrol was reduced when the A549 cells were treated with neutralizing anti-IFN-beta antibodies or a TLR9 inhibitor, suggesting that IFN-beta likely acts synergistically with resveratrol to inhibit H1N1 replication. This potential antiviral mechanism, involving direct inhibition of virus replication and simultaneous activation of the host immune response, has not been previously described for a single antiviral molecule. In conclusion, our data support the use of PC, resveratrol or emodin for inhibiting influenza virus replication directly and via TLR-9-induced IFN-beta production.	[Lin, Chao-Jen] Changhua Christian Childrens Hosp, Dept Pediat, Changhua, Taiwan; [Lin, Chao-Jen; Hwang, Guang-Yuh] Tunghai Univ, Dept Life Sci, Taichung 40704, Taiwan; [Lin, Chao-Jen] Chung Shan Med Univ, Sch Med, Taichung, Taiwan; [Lin, Hui-Ju] China Med Univ Hosp, Dept Ophthalmol, Taichung, Taiwan; [Lin, Hui-Ju; Wan, Lei] China Med Univ, Sch Chinese Med, Taichung, Taiwan; [Chen, Ter-Hsin] Natl Chung Hsing Univ, Grad Inst Vet Pathobiol, Taichung 40227, Taiwan; [Hsu, Yu-An] Natl Tsing Hua Univ, Inst Mol Med, Hsinchu, Taiwan; [Liu, Chin-San] Changhua Christian Hosp, Dept Neurol, Changhua, Taiwan; [Wan, Lei] Asia Univ, Dept Biotechnol, Taichung, Taiwan; [Wan, Lei] China Med Univ Hosp, Dept Gynecol, Taichung, Taiwan	Tunghai University; Chung Shan Medical University; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; National Chung Hsing University; National Tsing Hua University; Changhua Christian Hospital; Asia University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan	Hwang, GY (corresponding author), Tunghai Univ, Dept Life Sci, Taichung 40704, Taiwan.	gyhwang@thu.edu.tw; leiwan@mail.cmu.edu.tw	Wan, Lei/F-4719-2010	Wan, Lei/0000-0002-9525-3232	Ministry of Science and Technology, Taiwan, R.O.C. (MOST) [101-2320-B-039-038, 102-2320-B-039-043-MY3, 102-2632-B-039-001-MY3]; China Medical University Hospital, Taichung, Taiwan [DMR-103-064]; Changhua Christian Children's Hospital, Changhua, Taiwan [103-CCH-IRP-081]; Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence [DOH102-TDB-111004]	Ministry of Science and Technology, Taiwan, R.O.C. (MOST); China Medical University Hospital, Taichung, Taiwan; Changhua Christian Children's Hospital, Changhua, Taiwan; Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence	This study was supported by Ministry of Science and Technology, Taiwan, R.O.C. (MOST 101-2320-B-039-038, 102-2320-B-039-043-MY3 and 102-2632-B-039-001-MY3), China Medical University Hospital, Taichung, Taiwan (DMR-103-064), Changhua Christian Children's Hospital, Changhua, Taiwan (103-CCH-IRP-081) and in part by Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (DOH102-TDB-111004). The funders had no role in study design, data	Aluyen Julia Khristine, 2012, Journal of Dietary Supplements, V9, P45, DOI 10.3109/19390211.2011.650842; Battegay M, 2020, SWISS MED WKLY, V150, DOI [10.4414/smw.w20203, 10.4414/smw.2020.20203]; Biron CA, 2001, IMMUNITY, V14, P661, DOI 10.1016/S1074-7613(01)00154-6; Bonjardim CA, 2009, IMMUNOL LETT, V122, P1, DOI 10.1016/j.imlet.2008.11.002; Dapat C, 2013, ANTIVIR RES, V99, P261, DOI 10.1016/j.antiviral.2013.06.003; Gamblin SJ, 2010, J BIOL CHEM, V285, P28403, DOI 10.1074/jbc.R110.129809; Gao HN, 2013, NEW ENGL J MED, V368, P2277, DOI 10.1056/NEJMoa1305584; Garcia-Sastre A, 1998, VIROLOGY, V252, P324, DOI 10.1006/viro.1998.9508; Garcia-Sastre A, 2006, SCIENCE, V312, P879, DOI 10.1126/science.1125676; Ghanim H, 2010, J CLIN ENDOCR METAB, V95, pE1, DOI 10.1210/jc.2010-0482; Hacker H, 2000, J EXP MED, V192, P595, DOI 10.1084/jem.192.4.595; Han JH, 2012, IMMUNOPHARM IMMUNOT, V34, P191, DOI 10.3109/08923973.2011.590499; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Honda K, 2006, NAT REV IMMUNOL, V6, P644, DOI 10.1038/nri1900; Jackson RJ, 2011, J INFECTION, V62, P14, DOI 10.1016/j.jinf.2010.10.003; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Lutz A, 2005, J VIROL METHODS, V126, P13, DOI 10.1016/j.jviromet.2005.01.016; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Naikin A. N., 2013, Voprosy Virusologii, V58, P38; Nicholson KG, 2003, LANCET, V362, P1733, DOI 10.1016/S0140-6736(03)14854-4; Opitz B, 2007, CELL MICROBIOL, V9, P930, DOI 10.1111/j.1462-5822.2006.00841.x; Park S, 2013, BIOCHEM BIOPH RES CO, V440, P14, DOI 10.1016/j.bbrc.2013.08.090; Sato M, 1998, FEBS LETT, V425, P112, DOI 10.1016/S0014-5793(98)00210-5; Schafer SL, 1998, J BIOL CHEM, V273, P2714, DOI 10.1074/jbc.273.5.2714; Sohail MN, 2011, ASIAN J ANIM VET ADV, V6, P1125, DOI 10.3923/ajava.2011.1125.1152; Talon J, 2000, J VIROL, V74, P7989, DOI 10.1128/JVI.74.17.7989-7996.2000; Trost BM, 2011, CHEM-EUR J, V17, P3630, DOI 10.1002/chem.201003454; Valarcher JF, 2003, J VIROL, V77, P8426, DOI 10.1128/JVI.77.15.8426-8439.2003; van der Vries E, 2013, ADV PHARMACOL, V67, P217, DOI 10.1016/B978-0-12-405880-4.00006-8; Wang XY, 2000, J VIROL, V74, P11566, DOI 10.1128/JVI.74.24.11566-11573.2000; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.biochem.56.1.365	32	59	63	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2015	10	2							e0117602	10.1371/journal.pone.0117602	http://dx.doi.org/10.1371/journal.pone.0117602			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CB2GK	25658356	Green Published, gold, Green Submitted			2023-01-03	WOS:000349444900188
J	Robert, C; Karaszewska, B; Schachter, J; Rutkowski, P; Mackiewicz, A; Stroiakovski, D; Lichinitser, M; Dummer, R; Grange, F; Mortier, L; Chiarion-Sileni, V; Drucis, K; Krajsova, I; Hauschild, A; Lorigan, P; Wolter, P; Long, GV; Flaherty, K; Nathan, P; Ribas, A; Martin, AM; Sun, P; Crist, W; Legos, J; Rubin, SD; Little, SM; Schadendorf, D				Robert, Caroline; Karaszewska, Boguslawa; Schachter, Jacob; Rutkowski, Piotr; Mackiewicz, Andrzej; Stroiakovski, Daniil; Lichinitser, Michael; Dummer, Reinhard; Grange, Florent; Mortier, Laurent; Chiarion-Sileni, Vanna; Drucis, Kamil; Krajsova, Ivana; Hauschild, Axel; Lorigan, Paul; Wolter, Pascal; Long, Georgina V.; Flaherty, Keith; Nathan, Paul; Ribas, Antoni; Martin, Anne-Marie; Sun, Peng; Crist, Wendy; Legos, Jeff; Rubin, Stephen D.; Little, Shonda M.; Schadendorf, Dirk			Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BRAF-MUTATED MELANOMA; METASTATIC MELANOMA; ACQUIRED-RESISTANCE; MEK INHIBITION; RAF INHIBITION; V600E MUTATION; VEMURAFENIB; OVERCOME; CRITERIA; TUMORS	BACKGROUND The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as mono-therapies in patients with previously untreated metastatic melanoma with BRAF V600E or V600K mutations. Combining dabrafenib and the MEK inhibitor trametinib, as compared with dabrafenib alone, enhanced antitumor activity in this population of patients. METHODS In this open-label, phase 3 trial, we randomly assigned 704 patients with metastatic melanoma with a BRAF V600 mutation to receive either a combination of dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) or vemurafenib (960 mg twice daily) orally as first-line therapy. The primary end point was overall survival. RESULTS At the preplanned interim overall survival analysis, which was performed after 77% of the total number of expected events occurred, the overall survival rate at 12 months was 72% (95% confidence interval [CI], 67 to 77) in the combination-therapy group and 65% (95% CI, 59 to 70) in the vemurafenib group (hazard ratio for death in the combination-therapy group, 0.69; 95% CI, 0.53 to 0.89; P = 0.005). The prespecified interim stopping boundary was crossed, and the study was stopped for efficacy in July 2014. Median progression-free survival was 11.4 months in the combination-therapy group and 7.3 months in the vemurafenib group (hazard ratio, 0.56; 95% CI, 0.46 to 0.69; P< 0.001). The objective response rate was 64% in the combination-therapy group and 51% in the vemurafenib group (P< 0.001). Rates of severe adverse events and study-drug discontinuations were similar in the two groups. Cutaneous squamous-cell carcinoma and keratoacanthoma occurred in 1% of patients in the combination-therapy group and 18% of those in the vemurafenib group. CONCLUSIONS Dabrafenib plus trametinib, as compared with vemurafenib monotherapy, significantly improved overall survival in previously untreated patients with metastatic melanoma with BRAF V600E or V600K mutations, without increased overall toxicity. (Funded by GlaxoSmithKline; ClinicalTrials.gov number, NCT01597908.)	[Robert, Caroline] Gustave Roussy, Villejuif, France; [Robert, Caroline] INSERM, U981, Villejuif, France; [Grange, Florent] CHU Reims, Hop Robert Debre, Reims, France; [Mortier, Laurent] CHU Lille, Hop Claude Huriez, F-59037 Lille, France; [Karaszewska, Boguslawa] Przychodnia Lekarska Komed, Konin, Poland; [Rutkowski, Piotr] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland; [Rutkowski, Piotr] Inst Oncol, Warsaw, Poland; [Mackiewicz, Andrzej] Poznan Univ Med Sci, Med Polonia, Poznan, Poland; [Drucis, Kamil] Swissmed Ctr Zdrowia, Gdansk, Poland; [Drucis, Kamil] Med Univ Gdansk, Gdansk, Poland; [Schachter, Jacob] Chaim Sheba Med Ctr, Ramat, Israel; [Stroiakovski, Daniil] Moscow City Oncol Hosp 62, Moscow, Russia; [Lichinitser, Michael] Russian Acad Med Sci, Canc Res Ctr, Moscow, Russia; [Dummer, Reinhard] Univ Zurich, Zurich, Switzerland; [Chiarion-Sileni, Vanna] Ist Ricovero & Cura Carattere Sci, Ist Oncol Veneto, Padua, Italy; [Krajsova, Ivana] Gen Univ Hosp, Dermatooncol Dept, Prague, Czech Republic; [Hauschild, Axel] Univ Klinikum Schleswig Holstein, Kiel, Germany; [Stroiakovski, Daniil] Univ Hosp Essen, Essen, Germany; [Lorigan, Paul] Christie NHS Fdn Trust, Manchester, Lancs, England; [Nathan, Paul] Mt Vernon Canc Ctr, Northwood, Middx, England; [Wolter, Pascal] Univ Hosp Leuven, Leuven Canc Inst, Leuven, Belgium; [Long, Georgina V.] Univ Sydney, Melanoma Inst Australia, Mater Hosp, Sydney, NSW 2006, Australia; [Flaherty, Keith] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA; [Ribas, Antoni] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA; [Martin, Anne-Marie; Sun, Peng; Crist, Wendy; Legos, Jeff; Rubin, Stephen D.; Little, Shonda M.] GlaxoSmithKline Oncol Res & Dev, Collegeville, PA USA	UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; CHU de Reims; Universite de Lille - ISITE; CHU Lille; Maria Sklodowska-Curie National Research Institute of Oncology; Maria Sklodowska-Curie National Research Institute of Oncology; Poznan University of Medical Sciences; Fahrenheit Universities; Medical University Gdansk; Chaim Sheba Medical Center; Russian Academy of Medical Sciences; University of Zurich; IRCCS Istituto Oncologico Veneto (IOV); General University Hospital Prague; University of Kiel; Schleswig Holstein University Hospital; University of Duisburg Essen; Christie NHS Foundation Trust; Mount Vernon Cancer Centre; KU Leuven; University Hospital Leuven; Melanoma Institute Australia; University of Sydney; Harvard University; Massachusetts General Hospital; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; GlaxoSmithKline	Robert, C (corresponding author), Gustave Roussy, Serv Dermatol, 114 Rue Edouard Vaillant, F-94805 Villejuif, France.	caroline.robert@gustaveroussy.fr	Robert, Caroline/G-6157-2018; Krajsova, Ivana/I-4505-2017; sileni, vanna chiarion/B-9042-2018; Rutkowski, Piotr/B-3907-2013; Schadendorf, Dirk/AAE-8206-2019; Lorigan, Paul/J-6898-2015; Long, Georgina V/C-1771-2013	Robert, Caroline/0000-0002-9493-0238; Krajsova, Ivana/0000-0002-1599-6424; sileni, vanna chiarion/0000-0001-9191-9124; Rutkowski, Piotr/0000-0002-8920-5429; Lorigan, Paul/0000-0002-8875-2164; Long, Georgina V/0000-0001-8894-3545; Nathan, Paul/0000-0002-2327-3250; Drucis, Kamil/0000-0002-7251-3505; Stroyakovskiy, Daniil/0000-0003-1973-1092	GlaxoSmithKline	GlaxoSmithKline(GlaxoSmithKline)	Supported by GlaxoSmithKline.	Boussemart L, 2013, ANN ONCOL, V24, P1691, DOI 10.1093/annonc/mdt015; Carnahan J, 2010, MOL CANCER THER, V9, P2399, DOI 10.1158/1535-7163.MCT-10-0181; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Corcoran RB, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001148; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Flaherty KT, 2012, NEW ENGL J MED, V367, P1694, DOI 10.1056/NEJMoa1210093; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Greger JG, 2012, MOL CANCER THER, V11, P909, DOI 10.1158/1535-7163.MCT-11-0989; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Kim KB, 2013, J CLIN ONCOL, V31, P482, DOI 10.1200/JCO.2012.43.5966; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; LONG GV, 2014, J CLIN ONCOL S, V32; Menzies AM, 2014, CLIN CANCER RES, V20, P2035, DOI 10.1158/1078-0432.CCR-13-2054; Oberholzer PA, 2012, J CLIN ONCOL, V30, P316, DOI 10.1200/JCO.2011.36.7680; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Robert C, 2011, CURR OPIN ONCOL, V23, P177, DOI 10.1097/CCO.0b013e3283436e8c; Shi HB, 2014, CANCER DISCOV, V4, P80, DOI 10.1158/2159-8290.CD-13-0642; Solit DB, 2011, NEW ENGL J MED, V364, P772, DOI 10.1056/NEJMcibr1013704; Su F, 2012, NEW ENGL J MED, V366, P207, DOI 10.1056/NEJMoa1105358; Van Allen EM, 2014, CANCER DISCOV, V4, P94, DOI 10.1158/2159-8290.CD-13-0617; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023	27	1713	1751	8	141	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 1	2015	372	1					30	39		10.1056/NEJMoa1412690	http://dx.doi.org/10.1056/NEJMoa1412690			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AX7MU	25399551	Green Accepted			2023-01-03	WOS:000347100800007
J	Ubel, PA				Ubel, Peter A.			Transplantation Traffic - Geography as Destiny for Transplant Candidates	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Ubel, Peter A.] Duke Univ, Fuqua Sch Business, Sanford Sch Publ Policy, Durham, NC 27706 USA; [Ubel, Peter A.] Duke Univ, Sch Med, Durham, NC 27706 USA	Duke University; Duke University	Ubel, PA (corresponding author), Duke Univ, Fuqua Sch Business, Sanford Sch Publ Policy, Durham, NC 27706 USA.							Merion RM, 2004, AM J TRANSPLANT, V4, P94, DOI 10.1046/j.1600-6135.2003.00282.x; Neergaard L, 2013, MAPPING BETTER ORGAN; Ubel PA, 1999, NEW ENGL J MED, V340, P964	3	6	6	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 25	2014	371	26					2450	2452		10.1056/NEJMp1407639	http://dx.doi.org/10.1056/NEJMp1407639			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AX4RZ	25539104				2023-01-03	WOS:000346920300003
J	Liu, XJ; Zheng, YB; Li, Y; Wu, SY; Zhen, YS				Liu, Xiu-Jun; Zheng, Yan-Bo; Li, Yi; Wu, Shu-Ying; Zhen, Yong-Su			A Multifunctional Drug Combination Shows Highly Potent Therapeutic Efficacy against Human Cancer Xenografts in Athymic Mice	PLOS ONE			English	Article							TUMOR MICROENVIRONMENT; BESTATIN; TARGET; DIPYRIDAMOLE; ANGIOGENESIS; INHIBITOR	The tumor microenvironment plays a crucial role during tumor development. Integrated combination of drugs that target tumor microenvironment is a promising approach to anticancer therapy. Here, we report a multifunctional combination of low-cytotoxic drugs composed of dipyridamole, bestatin and dexamethasone (DBDx) which mainly acts on the tumor microenvironment shows highly potent antitumor efficacy in vivo. In mouse hepatoma H22 model, the triple drug combination showed synergistic and highly potent antitumor efficacy. The combination indices of various combinations of the triple drugs were between 0.2 and 0.5. DBDx inhibited the growth of a panel of human tumor xenografts and showed no obvious systemic toxicity. At tolerated doses, DBDx suppressed the growth of human hepatocellular carcinoma BEL-7402, HepG2, and lung adenocarcinoma A549 xenografts by 94.5%, 93.7% and 96.9%, respectively. Clonogenic assay demonstrated that DBDx showed weak cytotoxicity. Western blot showed that Flk1 and Nos3 were down-regulated in the DBDx-treated group. Proteomic analysis showed that DBDx mainly affected the metabolic process and immune system process; in addition, the angiogenesis and VEGF signaling pathway were also affected. Conclusively, DBDx, a multifunctional drug combination of three low-cytotoxic drugs, shows synergistic and highly potent antitumor efficacy evidently mediated by the modulation of tumor microenvironment. Based on its low-cytotoxic attributes and its broad-spectrum antitumor therapeutic efficacy, this multifunctional combination might be useful in the treatment of cancers, especially those refractory to conventional chemotherapeutics.	[Zhen, Yong-Su] Chinese Acad Med Sci, Inst Med Biotechnol, Beijing 100730, Peoples R China; Peking Union Med Coll, Beijing 100021, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Medicinal Biotechnology - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Zhen, YS (corresponding author), Chinese Acad Med Sci, Inst Med Biotechnol, Beijing 100730, Peoples R China.	zhenysm@126.com		Zheng, Yan-Bo/0000-0001-9552-8411	"Significant new drugs development'' Major Science and Technology Projects of China [2012ZX09301002]; National Natural Science Foundation of China [81201665]	"Significant new drugs development'' Major Science and Technology Projects of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the "Significant new drugs development'' Major Science and Technology Projects of China (No. 2012ZX09301002, http://www.nmp.gov.cn) and the National Natural Science Foundation of China (No. 81201665, http://www.nsfc.gov.cn). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aapro MS, 2013, CANCER TREAT REV, V39, P113, DOI 10.1016/j.ctrv.2012.09.002; Albini A, 2007, NAT REV CANCER, V7, P139, DOI 10.1038/nrc2067; Aozuka Y, 2004, CANCER LETT, V216, P35, DOI 10.1016/j.canlet.2004.06.050; Blansfield JA, 2008, CLIN CANCER RES, V14, P270, DOI 10.1158/1078-0432.CCR-07-1562; CAO SS, 1989, CANCER CHEMOTH PHARM, V24, P181, DOI 10.1007/BF00300240; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Fan Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093264; Fukumura D, 2006, NAT REV CANCER, V6, P521, DOI 10.1038/nrc1910; Furuse K, 1993, Gan To Kagaku Ryoho, V20, P1187; Gus-Brautbar Y, 2012, MOL CELL, V45, P610, DOI 10.1016/j.molcel.2012.01.006; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Lu HT, 2006, MOL CANCER RES, V4, P221, DOI 10.1158/1541-7786.MCR-05-0261; Mangiameli DP, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-38; Mayer LD, 2006, MOL CANCER THER, V5, P1854, DOI 10.1158/1535-7163.MCT-06-0118; OZONO S, 1990, ACTA ONCOL, V29, P813, DOI 10.3109/02841869009093006; Reisfeld Ralph A., 2013, Critical Reviews in Oncogenesis, V18, P115; Spano D, 2013, CLIN EXP METASTAS, V30, P47, DOI 10.1007/s10585-012-9506-0; Swartz MA, 2012, CANCER RES, V72, P2473, DOI 10.1158/0008-5472.CAN-12-0122; TALMADGE JE, 1986, CANCER RES, V46, P4505; Whiteside TL, 2008, ONCOGENE, V27, P5904, DOI 10.1038/onc.2008.271; Yano A, 2006, CLIN CANCER RES, V12, P3003, DOI 10.1158/1078-0432.CCR-05-2085; Zheng Yan-Bo, 2012, Yao Xue Xue Bao, V47, P1593	24	6	6	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 22	2014	9	12							e115790	10.1371/journal.pone.0115790	http://dx.doi.org/10.1371/journal.pone.0115790			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA3ZY	25531414	gold, Green Published, Green Submitted			2023-01-03	WOS:000348845100108
J	Hayes, J; Jackson, JL; McNutt, GM; Hertz, BJ; Ryan, JJ; Pawlikowski, SA				Hayes, John; Jackson, Jeffrey L.; McNutt, Gail M.; Hertz, Brian J.; Ryan, Jeffrey J.; Pawlikowski, Scott A.			Association Between Physician Time-Unlimited vs Time-Limited Internal Medicine Board Certification and Ambulatory Patient Care Quality	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; OF-CARE; HEALTH-CARE; PREVENTION; METAANALYSIS; MAINTENANCE; OUTCOMES; DISEASE; SCORES	IMPORTANCE American Board of Internal Medicine (ABIM) initiatives encourage internists with time-unlimited certificates to recertify. However, there are limited data evaluating differences in performance between internists with time-limited or time-unlimited board certification. OBJECTIVE To determine whether there are differences in primary care quality between physicians holding time-limited or time-unlimited certification. DESIGN, SETTING, AND PARTICIPANTS Retrospective analysis of performance data from 1 year (2012-2013) at 4 Veterans Affairs (VA) medical centers. Participants were internists with time-limited (n = 71) or time-unlimited (n = 34) ABIM certification providing primary care to 68 213 patients. Median physician panel size was 610 patients (range, 19-1316), with no differences between groups (P = .90). MAIN OUTCOMES AND MEASURES Ten primary care performance measures: colorectal screening rates; diabetes with glycated hemoglobin (HbA(1c) level) less than 9.0%; diabetes with blood pressure less than 140/90 mmHg; diabetes with low-density lipoprotein cholesterol (LDL-C) level less than 100 mg/dL; hypertension with blood pressure less than 140/90 mmHg; thiazide diuretics used in multidrug hypertensive regimen; atherosclerotic coronary artery disease and LDL-C level less than 100 mg/dL; post-myocardial infarction use of aspirin; post-myocardial infarction use of beta-blockers; congestive heart failure (CHF) with use of angiotensin-converting enzyme (ACE) inhibitor. RESULTS After adjustment for practice site, panel size, years since certification, and clustering by physician, there were no differences in outcomes for patients cared for by internists with time-limited or time-unlimited certification for any performance measure: colorectal screening (odds ratio [OR], 0.95 [95% CI, 0.89-1.01]); diabetes with HbA1c level less than 9.0% (OR, 0.96 [95% CI, 0.74-1.2]); blood pressure control (OR, 0.99 [95% CI, 0.69-1.4]); LDL-C level less than 100 mg/dL (OR, 1.1 [95% CI, 0.79-1.5]); hypertension with blood pressure less than 140/90 mmHg (OR, 1.0 [95% CI, 0.92-1.2]); thiazide use (OR, 1.0 [95% CI, 0.8-1.3]); atherosclerotic coronary artery disease with LDL-C level less than 100 mg/dL (OR, 1.1 [95% CI, 0.75-1.7]); post-myocardial infarction use of aspirin (OR, 0.98 [95% CI, 0.58-1.68]) or beta-blockers (OR, 1.0 [95% CI, 0.57-1.9]); CHF with use of ACE inhibitor (OR, 0.98 [95% CI, 0.61-1.6]). CONCLUSIONS AND RELEVANCE Among internists providing primary care at 4 VA medical centers, there were no significant differences between those with time-limited ABIM certification and those with time-unlimited ABIM certification on 10 primary care performance measures. Additional research to examine the difference in patient outcomes among holders of time-limited and time-unlimited certificates in non-VA and nonacademic settings and the association with other ABIM goals may help clarify the potential benefit of Maintenance of Certification participation. Copyright 2014 American Medical Association. All rights reserved.	[Hayes, John] Clement J Zablocki VA Med Ctr, Milwaukee, WI 53295 USA; [Jackson, Jeffrey L.] Clement J Zablocki VA Med Ctr, GIM Sect, Milwaukee, WI 53295 USA; [McNutt, Gail M.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA; [Hertz, Brian J.; Pawlikowski, Scott A.] Hines VA Med Ctr, Chicago, IL USA; [Ryan, Jeffrey J.] Jesse Brown VA Med Ctr, Chicago, IL USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center	Hayes, J (corresponding author), Clement J Zablocki VA Med Ctr, 5000 W Natl Ave, Milwaukee, WI 53295 USA.	john.hayes3@va.gov	Jackson, Jeffrey/AAA-3519-2019	Jackson, Jeffrey/0000-0002-9820-5834				Abdulla J, 2006, EUR J HEART FAIL, V8, P90, DOI 10.1016/j.ejheart.2005.03.006; Abdulla J, 2006, EUR J HEART FAIL, V8, P522, DOI 10.1016/j.ejheart.2005.10.012; American Board of Internal Medicine (ABIM), FAQ 2014 PROGR CHANG; American Board of Internal Medicine (ABIM), 2014, RES PROGR PASS RAT 2; American Board of Internal Medicine (ABIM), MAINT CERT GUID; American Board of Medical Specialties (ABMS), 2014, THE VAL OF ABMS MOC; BERNER ES, 1993, ACAD MED, V68, P753, DOI 10.1097/00001888-199310000-00005; Buscemi D, 2013, J COMMUNITY HOSP INT, V2, DOI 10.3402/jchimp.v2i4.19753; Centor RM, 2014, ANN INTERN MED, V161, P226, DOI 10.7326/M14-1014; Chen J, 2006, J GEN INTERN MED, V21, P238, DOI 10.1111/j.1525-1497.2006.00326.x; Choo EH, 2014, HEART, V100, P492, DOI 10.1136/heartjnl-2013-305137; Choudhry NK, 2005, ANN INTERN MED, V142, P260, DOI 10.7326/0003-4819-142-4-200502150-00008; Hennekens CH, 2002, AM J MANAG CARE, V8, pS691; Hess BJ, 2012, ACAD MED, V87, P157, DOI 10.1097/ACM.0b013e31823f3a57; Holmboe ES, 2008, ARCH INTERN MED, V168, P1396, DOI 10.1001/archinte.168.13.1396; Iglehart JK, 2012, NEW ENGL J MED, V367, P2543, DOI 10.1056/NEJMhpr1211043; Johnson DH, 2012, J ONCOL PRACT, V8, P203, DOI 10.1200/JOP.2011.000479; Lipner RS, 2006, ANN INTERN MED, V144, P29, DOI 10.7326/0003-4819-144-1-200601030-00007; National Committee for Quality Assurance (NCQA), HEDIS MEAS; Norcini JJ, 2000, ACAD MED, V75, P1193, DOI 10.1097/00001888-200012000-00016; Pham HH, 2005, JAMA-J AM MED ASSOC, V294, P473, DOI 10.1001/jama.294.4.473; Reid RO, 2010, ARCH INTERN MED, V170, P1442, DOI 10.1001/archinternmed.2010.307; Sharp LK, 2002, ACAD MED, V77, P534, DOI 10.1097/00001888-200206000-00011; Turchin A, 2008, CIRCULATION, V117, P623, DOI 10.1161/CIRCULATIONAHA.107.733949; Vrecer M, 2003, INT J CLIN PHARM TH, V41, P567; Wenghofer E, 2009, MED EDUC, V43, P1166, DOI 10.1111/j.1365-2923.2009.03534.x; Zauber AG, 2012, NEW ENGL J MED, V366, P687, DOI 10.1056/NEJMoa1100370	28	32	32	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	2014	312	22					2358	2363		10.1001/jama.2014.13992	http://dx.doi.org/10.1001/jama.2014.13992			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AW5YB	25490326				2023-01-03	WOS:000346345700010
J	McCartney, M				McCartney, Margaret			NO HOLDS BARRED Margaret McCartney: Stop playing politics with illegal drug use	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												margaret@margaretmccartney.com	mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358				Home Office, 2014, DRUGS INT COMP; Hughes CE, 2010, BRIT J CRIMINOL, V50, P999, DOI 10.1093/bjc/azq038; Johnson A., 2009, GUARDIAN; Light M, 2013, MINISTRY JUSTICE ANA; Nordt C, 2006, LANCET, V367, P1830, DOI 10.1016/S0140-6736(06)68804-1; Nutt DJ, 2009, J PSYCHOPHARMACOL, V23, P3, DOI 10.1177/0269881108099672; Parliament.uk, 2013, 9 PARL UK	7	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 27	2014	349								g7273	10.1136/bmj.g7273	http://dx.doi.org/10.1136/bmj.g7273			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AW2KG	25430933	Green Published, hybrid			2023-01-03	WOS:000346115800010
J	Surma, MA; Szczepaniak, A; Kroliczewski, J				Surma, Michal A.; Szczepaniak, Andrzej; Kroliczewski, Jaroslaw			Comparative Studies on Detergent-Assisted Apocytochrome b(6) Reconstitution into Liposomal Bilayers Monitored by Zetasizer Instruments	PLOS ONE			English	Article							PROTEIN SECONDARY STRUCTURE; ESCHERICHIA-COLI; MEMBRANE-PROTEINS; CYTOCHROME B(6); TRANSBILAYER MOVEMENT; CYTOPLASMIC MEMBRANE; 2-DIMENSIONAL CRYSTALLIZATION; LIPID-MEMBRANES; SOLUBILIZATION; TRANSPORTER	The present paper is a systematic, comparative study on the reconstitution of an apocytochrome b(6) purified from a heterologous system using a detergent-free method and reconstitution into liposomes performed using three different detergents: SDS, Triton X-100 and DM, and two methods of detergent removal by dialysis and using Bio-Beads. The product size, its distribution and zeta potential, and other parameters were monitored throughout the process. We found that zeta potential of proteoliposomes is correlated with reconstitution efficiency and, as such, can serve as a quick and convenient quality control for reconstitution experiments. We also advocate using detergent-free protein purification methods as they allow for an unfettered choice of detergent for reconstitution, which is the most crucial factor influencing the final product parameters.	[Surma, Michal A.; Szczepaniak, Andrzej; Kroliczewski, Jaroslaw] Univ Wroclaw, Fac Biotechnol, PL-50138 Wroclaw, Poland	University of Wroclaw	Kroliczewski, J (corresponding author), Univ Wroclaw, Fac Biotechnol, PL-50138 Wroclaw, Poland.	jarekk@ibmb.uni.wroc.pl	Króliczewski, Jarosław/H-5930-2019; Surma, Michal/B-1955-2016	Króliczewski, Jarosław/0000-0002-5895-5104; Surma, Michal/0000-0001-7833-2214	University of Wroclaw, Poland; Wroclaw Center for Biotechnology program KNOW (National Scientific Leadership Center)	University of Wroclaw, Poland; Wroclaw Center for Biotechnology program KNOW (National Scientific Leadership Center)	This research was supported by the University of Wroclaw, Poland to AS. Publication fee was partially paid by the Wroclaw Center for Biotechnology program KNOW (National Scientific Leadership Center) 2014-2018.	AMALOU Z, 1994, PLANT PHYSIOL, V106, P79, DOI 10.1104/pp.106.1.79; Arnold T., 2001, CURRENT PROTOCOLS PR; BANGHAM AD, 1965, J MOL BIOL, V13, P238, DOI 10.1016/S0022-2836(65)80093-6; Benes M, 2002, BIOL CHEM, V383, P337, DOI 10.1515/BC.2002.037; Boulter JM, 2001, PROTEIN EXPRES PURIF, V22, P337, DOI 10.1006/prep.2001.1440; CRAMER WA, 1994, CURR OPIN STRUC BIOL, V4, P536, DOI 10.1016/S0959-440X(94)90216-X; Dreher C, 2007, FEBS LETT, V581, P2647, DOI 10.1016/j.febslet.2007.05.007; Ehrmann M, 1998, MOL MICROBIOL, V29, P685, DOI 10.1046/j.1365-2958.1998.00915.x; EYTAN GD, 1982, BIOCHIM BIOPHYS ACTA, V694, P185, DOI 10.1016/0304-4157(82)90024-7; Freisleben HJ, 1995, CHEM PHYS LIPIDS, V78, P137, DOI 10.1016/0009-3084(95)02491-Z; Goni FM, 2000, BBA-BIOMEMBRANES, V1508, P51, DOI 10.1016/S0304-4157(00)00011-3; Hanke G, 1999, J EXP BOT, V50, P1715, DOI 10.1093/jexbot/50.341.1715; HELENIUS A, 1975, BIOCHIM BIOPHYS ACTA, V415, P29, DOI 10.1016/0304-4157(75)90016-7; HELENIUS A, 1981, EUR J BIOCHEM, V116, P27, DOI 10.1111/j.1432-1033.1981.tb05296.x; Hochstadt J, 1975, TRANSPORT, P117; HOLLOWAY PW, 1973, ANAL BIOCHEM, V53, P304, DOI 10.1016/0003-2697(73)90436-3; Ishijima S, 2012, BBA-BIOMEMBRANES, V1818, P2202, DOI 10.1016/j.bbamem.2012.04.015; John K, 2002, BIOPHYS J, V83, P1525, DOI 10.1016/S0006-3495(02)73922-2; John K, 2002, BIOPHYS J, V83, P3315, DOI 10.1016/S0006-3495(02)75332-0; JONAS A, 1971, BIOCHEMISTRY-US, V10, P4492, DOI 10.1021/bi00800a022; Knol J, 1998, BIOCHEMISTRY-US, V37, P16410, DOI 10.1021/bi981596u; KRAGHHANSEN U, 1993, BIOCHEMISTRY-US, V32, P1648, DOI 10.1021/bi00057a032; Kroliczewski J, 2005, BIOCHEMISTRY-US, V44, P7570, DOI 10.1021/bi047422w; Kroliczewski J, 2002, BBA-PROTEINS PROTEOM, V1598, P177, DOI 10.1016/S0167-4838(02)00369-2; Kroliczewski J, 1999, THESIS U WROCLAW; Kroliczewski J, 2011, ACTA BIOCHIM POL, V58, P335; Kubelt J, 2002, BIOCHEMISTRY-US, V41, P5605, DOI 10.1021/bi0118714; Lambert O, 1998, BIOPHYS J, V74, P918, DOI 10.1016/S0006-3495(98)74015-9; LEVY D, 1990, BIOCHIM BIOPHYS ACTA, V1025, P179, DOI 10.1016/0005-2736(90)90096-7; LEVY D, 1992, BIOCHIM BIOPHYS ACTA, V1107, P283, DOI 10.1016/0005-2736(92)90415-I; Perez JL, 2009, VACCINE, V27, P205, DOI 10.1016/j.vaccine.2008.10.052; Miller C., 1986, P257; MILSMANN MHW, 1978, BIOCHIM BIOPHYS ACTA, V512, P147, DOI 10.1016/0005-2736(78)90225-0; Montserret R, 2000, BIOCHEMISTRY-US, V39, P8362, DOI 10.1021/bi000208x; Ollivon M, 2000, BBA-BIOMEMBRANES, V1508, P34, DOI 10.1016/S0304-4157(00)00006-X; OLSON F, 1979, BIOCHIM BIOPHYS ACTA, V557, P9, DOI 10.1016/0005-2736(79)90085-3; Pochini L, 2011, BIOCHEM J, V439, P227, DOI 10.1042/BJ20110544; Quiocho FA, 1997, STRUCTURE, V5, P997, DOI 10.1016/S0969-2126(97)00253-0; Ravaud S, 2006, BIOCHEM J, V395, P345, DOI 10.1042/BJ20051719; Rigaud JL, 1998, EUR BIOPHYS J BIOPHY, V27, P305, DOI 10.1007/s002490050138; RIGAUD JL, 1995, BBA-BIOENERGETICS, V1231, P223, DOI 10.1016/0005-2728(95)00091-V; Rigaud JL, 2000, BBA-BIOMEMBRANES, V1508, P112, DOI 10.1016/S0005-2736(00)00307-2; Scherphof GL, 1997, ADV DRUG DELIVER REV, V24, P179, DOI 10.1016/S0169-409X(96)00457-7; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; SREERAMA N, 1994, J MOL BIOL, V242, P497, DOI 10.1006/jmbi.1994.1597; SZOKA F, 1980, ANNU REV BIOPHYS BIO, V9, P467, DOI 10.1146/annurev.bb.09.060180.002343; TORCHILIN V, 1990, LIPOSOMES PRACTICAL; Tunuguntla R, 2013, BIOPHYS J, V105, P1388, DOI 10.1016/j.bpj.2013.07.043; UENO M, 1984, BIOCHEMISTRY-US, V23, P3070, DOI 10.1021/bi00308a034; Wallgren M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061452; Wallin E, 1998, PROTEIN SCI, V7, P1029, DOI 10.1002/pro.5560070420; WEISER HB, 1950, J PHYS COLLOID CHEM, V54, P990, DOI 10.1021/j150481a003; Zak E, 1997, PLANTA, V201, P334, DOI 10.1007/s004250050075; ZIMM BH, 1948, J CHEM PHYS, V16, P1093, DOI 10.1063/1.1746738	55	6	6	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 25	2014	9	11							e111341	10.1371/journal.pone.0111341	http://dx.doi.org/10.1371/journal.pone.0111341			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AU9GL	25423011	Green Submitted, gold, Green Published			2023-01-03	WOS:000345899700005
J	Santana, MB; Halje, P; Simplicio, H; Richter, U; Freire, MAM; Petersson, P; Fuentes, R; Nicolelis, MAL				Santana, Maxwell B.; Halje, Par; Simplicio, Hougelle; Richter, Ulrike; Freire, Marco Aurelio M.; Petersson, Per; Fuentes, Romulo; Nicolelis, Miguel A. L.			Spinal Cord Stimulation Alleviates Motor Deficits in a Primate Model of Parkinson Disease	NEURON			English	Article							DEEP-BRAIN-STIMULATION; SUBTHALAMIC NUCLEUS; RESTORE LOCOMOTION; RELIEVE AKINESIA; PATIENT	Although deep brain electrical stimulation can alleviate the motor symptoms of Parkinson disease (PD), just a small fraction of patients with PD can take advantage of this procedure due to its invasive nature. A significantly less invasive method-epidural spinal cord stimulation (SCS)-has been suggested as an alternative approach for symptomatic treatment of PD. However, the mechanisms underlying motor improvements through SCS are unknown. Here, we show that SCS reproducibly alleviates motor deficits in a primate model of PD. Simultaneous neuronal recordings from multiple structures of the cortico-basal ganglia-thalamic loop in parkinsonian monkeys revealed abnormal highly synchronized neuronal activity within each of these structures and excessive functional coupling among them. SCS disrupted this pathological circuit behavior in a manner that mimics the effects caused by pharmacological dopamine replacement therapy or deep brain stimulation. These results suggest that SCS should be considered as an additional treatment option for patients with PD.	[Santana, Maxwell B.; Simplicio, Hougelle; Freire, Marco Aurelio M.; Fuentes, Romulo; Nicolelis, Miguel A. L.] Edmond & Lily Safra Int Inst Neurosci Natal, BR-590660 Natal, RN, Brazil; [Halje, Par; Richter, Ulrike; Petersson, Per] Lund Univ, Dept Expt Med Sci, Neuronano Res Ctr, S-22184 Lund, Sweden; [Nicolelis, Miguel A. L.] Duke Univ, Durham, NC 27708 USA; [Nicolelis, Miguel A. L.] Duke Univ, Ctr Neuroengn, Durham, NC 27708 USA; [Nicolelis, Miguel A. L.] Duke Univ, Dept Neurobiol, Durham, NC 27708 USA; [Nicolelis, Miguel A. L.] Duke Univ, Dept Psychol & Neurosci, Durham, NC 27708 USA; [Santana, Maxwell B.] Univ Fed Rio Grande do Norte, BR-59072 Natal, RN, Brazil; [Simplicio, Hougelle] State Univ Rio Grande Norte, BR-59607360 Mossoro, RN, Brazil	Lund University; Duke University; Duke University; Duke University; Duke University; Universidade Federal do Rio Grande do Norte; Universidade do Estado do Rio Grande do Norte (UERN)	Nicolelis, MAL (corresponding author), Edmond & Lily Safra Int Inst Neurosci Natal, BR-590660 Natal, RN, Brazil.	nicoleli@neuro.duke.edu	Petersson, Per/A-5740-2010; Freire, Marco/A-1450-2010; Simplicio, Hougelle/B-8737-2013; Petersson, Per/P-1878-2019; Fuentes, Romulo/N-4258-2019; Richter, Ulrike/B-7084-2012; de Santana, Maxwell Barbosa/D-4105-2009; Fuentes, Romulo/AFR-1296-2022	Petersson, Per/0000-0001-6697-0171; Freire, Marco/0000-0002-6483-0498; Simplicio, Hougelle/0000-0001-8794-9769; Petersson, Per/0000-0001-6697-0171; Fuentes, Romulo/0000-0002-6282-7287; Richter, Ulrike/0000-0001-6100-7984; de Santana, Maxwell Barbosa/0000-0001-7725-0970; Fuentes, Romulo/0000-0002-6282-7287	Michael J. Fox Foundation for Parkinson's Research; FINEP [01.06.1092.00]; INCEMAQ-Program of National Institutes of Science and Technology of CNPq/MCT; Swedish Research Council [325-2011-6441]; Swedish Society for Medical Research; Olle Engkvist; Parkinson Research; Crafoord, Ake Wiberg, Magnus Bergvall, Kockska and Segerfalk Foundation; Hjarnfonden; NIH [R01-NS073125-03]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS073125] Funding Source: NIH RePORTER	Michael J. Fox Foundation for Parkinson's Research; FINEP(Financiadora de Inovacao e Pesquisa (Finep)); INCEMAQ-Program of National Institutes of Science and Technology of CNPq/MCT; Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Society for Medical Research; Olle Engkvist; Parkinson Research; Crafoord, Ake Wiberg, Magnus Bergvall, Kockska and Segerfalk Foundation; Hjarnfonden; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Tobias Palmer for developing the video tracking software used for automatic quantification of locomotor behavior, Jim Meloy and Gary Lehew for building recording electrodes, Ivani Brys for statistical discussion, Carlos Eduardo Idalino for support with data analysis, Pedro Calvacanti for support in IHC, and Marcelo Carvalho for technical support. This research was supported by The Michael J. Fox Foundation for Parkinson's Research; FINEP 01.06.1092.00; INCEMAQ-Program of National Institutes of Science and Technology of CNPq/MCT; the Swedish Research Council (325-2011-6441); Swedish Society for Medical Research; the Olle Engkvist, Parkinson Research, Crafoord, Ake Wiberg, Magnus Bergvall, Kockska and Segerfalk Foundation; Hjarnfonden, and an NIH Transformative award (R01-NS073125-03).	Agari T, 2012, NEUROL MED-CHIR, V52, P470, DOI 10.2176/nmc.52.470; ANNETT LE, 1992, BRAIN, V115, P825, DOI 10.1093/brain/115.3.825; Bankiewicz K.S., 2001, CURR PROTOC NEUROSCI, V5, P9; BENABID AL, 1987, APPL NEUROPHYSIOL, V50, P344; Campos-Romo A, 2009, J NEUROSCI METH, V177, P361, DOI 10.1016/j.jneumeth.2008.10.026; Fahn S.R.L.E., 1987, RECENT DEV PARKINSON; Fenelon G, 2012, PARKINSONISM RELAT D, V18, P213, DOI 10.1016/j.parkreldis.2011.07.015; Follett KA, 2010, NEW ENGL J MED, V362, P2077, DOI 10.1056/NEJMoa0907083; Fuentes R, 2010, EUR J NEUROSCI, V32, P1100, DOI 10.1111/j.1460-9568.2010.07417.x; Fuentes R, 2009, SCIENCE, V323, P1578, DOI 10.1126/science.1164901; Halje P, 2012, J NEUROSCI, V32, P16541, DOI 10.1523/JNEUROSCI.3047-12.2012; Hassan S, 2013, J CLIN NEUROSCI, V20, P1155, DOI 10.1016/j.jocn.2012.08.018; Krack P, 2003, NEW ENGL J MED, V349, P1925, DOI 10.1056/NEJMoa035275; Landi A, 2013, NEUROMODULATION, V16, P276, DOI 10.1111/ner.12005; MITCHELL IJ, 1995, BEHAV PHARMACOL, V6, P492; Morgante L, 2007, PARKINSONISM RELAT D, V13, P528, DOI 10.1016/j.parkreldis.2006.12.013; Nicolelis MA, 2010, NEUROLOGY, V75, P1484, DOI 10.1212/WNL.0b013e3181f46f10; Popovych OV, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00058; Stein E, 2013, EXP NEUROL, V245, P52, DOI 10.1016/j.expneurol.2012.07.023; Stephan H., 1980, BRAIN COMMON MARMOSE; Thevathasan W, 2010, NEUROLOGY, V74, P1325, DOI 10.1212/WNL.0b013e3181d9ed58	21	69	71	0	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	NOV 19	2014	84	4					716	722		10.1016/j.neuron.2014.08.061	http://dx.doi.org/10.1016/j.neuron.2014.08.061			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AU2DA	25447740	Green Accepted, Green Submitted, Bronze			2023-01-03	WOS:000345424900009
J	Jubelt, LE; Graham, J; Maeng, DD; Li, HL; Epstein, AJ; Metlay, JP				Jubelt, Lindsay E.; Graham, Jove; Maeng, Daniel D.; Li, Huilin; Epstein, Andrew J.; Metlay, Joshua P.			Patient Ratings of Case Managers in a Medical Home: Associations With Patient Satisfaction and Health Care Utilization	ANNALS OF INTERNAL MEDICINE			English	Article							VOLUNTARY DISENROLLMENT; REPORTED EXPERIENCE; COMMUNICATION; BENEFICIARIES; OUTCOMES; QUALITY; RISK; HOSPITALIZATION; PERCEPTIONS; PREDICTORS	Background: Case managers are employed in medical homes to coordinate care for clinically complex patients. Objective: To measure the association of patient perceptions of case manager performance with overall satisfaction and subsequent health care utilization. Design: Retrospective cohort study. Setting: Integrated health system in Pennsylvania. Patients: Members of the health system-owned health plan who 1) received primary care in the health system's clinics, 2) were exposed to clinic-embedded case managers, and 3) completed a survey of satisfaction with care. Measurements: Survey assessment of case manager performance and overall satisfaction with care and claims-based assessment of case manager performance and subsequent hospitalizations or emergency department visits. Survey measures were dichotomized into very good versus less than very good. Results: A total of 1755 patients (44%) completed the survey and 1415 met study criteria. Survey respondents who reported very good ratings of case manager performance across all items had a higher probability of reporting very good overall satisfaction with care (92.2% vs. 62.5%; P < 0.001) and had a lower incidence of subsequent emergency department visits (incidence rate ratio, 0.79 [95% CI, 0.64 to 0.98]; P = 0.029) but not hospitalizations (incidence rate ratio, 0.92 [CI, 0.75 to 1.11]; P = 0.37) up to 2 years after the survey compared with survey respondents who reported less-than-very good case manager performance on 1 or more questions on the survey. Limitations: Satisfaction data demonstrated substantial ceiling effects. Survey nonresponse may have introduced bias in the results. Conclusion: Patients' favorable perceptions of case managers are associated with higher overall satisfaction with care and may lower risk for future acute care use.	[Epstein, Andrew J.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA; [Li, Huilin] NYU, Langone Med Ctr, Dept Populat Hlth, New York, NY 10016 USA; [Graham, Jove] Geisinger Ctr Hlth Res, Danville, PA 17822 USA; [Maeng, Daniel D.] Geisinger Hlth Syst, Danville, PA 17822 USA; [Metlay, Joshua P.] Massachusetts Gen Hosp, Boston, MA 02114 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; New York University; NYU Langone Medical Center; Geisinger Health System; Harvard University; Massachusetts General Hospital	Jubelt, LE (corresponding author), NYU, Sch Med, Dept Populat Hlth, 1 Pk Ave,10th Floor, New York, NY 10016 USA.	lindsay.jubelt@nyumc.org		Epstein, Andrew/0000-0001-5078-6564; Li, Huilin/0000-0002-8288-7068	Robert Wood Johnson Foundation; U.S. Department of Veterans Affairs; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI073957] Funding Source: NIH RePORTER	Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); U.S. Department of Veterans Affairs(US Department of Veterans Affairs); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Robert Wood Johnson Foundation and the U.S. Department of Veterans Affairs.	Abramowitz S, 1987, QRB Qual Rev Bull, V13, P122; Agency for Healthcare Research and Quality, CAHPS CLIN GROUP SUR; Chang JT, 2006, ANN INTERN MED, V144, P665, DOI 10.7326/0003-4819-144-9-200605020-00010; Chen J., 2000, J OFF STAT, V16, P113; Devoe JE, 2008, J AM BOARD FAM MED, V21, P441, DOI 10.3122/jabfm.2008.05.080054; Elliott MN, 2009, MED CARE, V47, P842, DOI 10.1097/MLR.0b013e318197b22a; Gilfillan RJ, 2010, AM J MANAG CARE, V16, P607; Gray BM, 2012, HEALTH SERV RES, V47, P4, DOI 10.1111/j.1475-6773.2011.01302.x; Griffin SJ, 2004, ANN FAM MED, V2, P595, DOI 10.1370/afm.142; Hargraves JL, 2003, HEALTH SERV RES, V38, P1509; Heller A, 2009, MED CARE, V47, P850, DOI 10.1097/MLR.0b013e318197b661; Hutchinson A, 1999, QUAL HEALTH CARE, V8, P213, DOI 10.1136/qshc.8.4.213; Jackson JL, 2001, SOC SCI MED, V52, P609, DOI 10.1016/S0277-9536(00)00164-7; KAPLAN SH, 1989, MED CARE, V27, pS110, DOI 10.1097/00005650-198903001-00010; Keenan PS, 2009, MED CARE, V47, P882, DOI 10.1097/MLR.0b013e3181a39415; Kellerman R, 2007, AM FAM PHYSICIAN, V76, P774; Kern LM, 2013, AM J MANAG CARE, V19, P403; Kleinman LC, 2009, HEALTH SERV RES, V44, P288, DOI 10.1111/j.1475-6773.2008.00900.x; Larkins AS, 2013, EUR J GASTROEN HEPAT, V25, P44, DOI 10.1097/MEG.0b013e3283589f80; Li PX, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-245; Lied TR, 2003, HEALTH CARE FINANC R, V25, P55; Lin PJ, 2010, AM J MANAG CARE, V16, P191; Maeng DD, 2013, POPUL HEALTH MANAG, V16, P157, DOI 10.1089/pop.2012.0048; Manary MP, 2013, NEW ENGL J MED, V368, P201, DOI 10.1056/NEJMp1211775; Mitchell SE, 2014, J GEN INTERN MED, V29, P349, DOI 10.1007/s11606-013-2647-2; O'Connor SJ, 2003, HEALTH CARE MANAGE R, V28, P21, DOI 10.1097/00004010-200301000-00003; OEHLERT GW, 1992, AM STAT, V46, P27, DOI 10.2307/2684406; Peikes D, 2009, JAMA-J AM MED ASSOC, V301, P603, DOI 10.1001/jama.2009.126; Pope GC, 2011, EVALUATION CMS HCC R; Reid RJ, 2010, HEALTH AFFAIR, V29, P835, DOI 10.1377/hlthaff.2010.0158; Ruiz-Moral R, 2006, PATIENT EDUC COUNS, V64, P242, DOI 10.1016/j.pec.2006.02.010; Safran DG, 2001, J FAM PRACTICE, V50, P130; Tallman Karen, 2007, Perm J, V11, P19; Williams S, 1998, FAM PRACT, V15, P480, DOI 10.1093/fampra/15.5.480; Wofford MM, 2004, ACAD MED, V79, P134, DOI 10.1097/00001888-200402000-00008; Zolnierek KBH, 2009, MED CARE, V47, P826, DOI 10.1097/MLR.0b013e31819a5acc	36	11	11	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 18	2014	161	10		S			S59	S65		10.7326/M13-3007	http://dx.doi.org/10.7326/M13-3007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CW3RR	25402405				2023-01-03	WOS:000364909900009
J	Kumari, P; Sahal, D; Chauhan, VS				Kumari, Pinky; Sahal, Dinkar; Chauhan, Virander S.			Dendrimeric Template of Plasmodium falciparum Histidine Rich Protein II Repeat Motifs Bearing Asp -> Asn Mutation Exhibits Heme Binding and beta-Hematin Formation	PLOS ONE			English	Article							HYDROGEN-BOND ACCEPTORS; ANION-PI INTERACTIONS; MALARIA PIGMENT; AROMATIC RINGS; X-RAY; PEPTIDES; CONFORMATION	Plasmodium falciparum (Pf) employs a crucial PfHRPII catalyzed reaction that converts toxic heme into hemozoin. Understanding heme polymerization mechanism is the first step for rational design of new drugs, targeting this pathway. Heme binding and hemozoin formation have been ascribed to PfHRPII aspartate carboxylate-heme metal ionic interactions. To investigate, if this ionic interaction is indeed pivotal, we examined the comparative heme binding and beta-hematin forming abilities of a wild type dendrimeric peptide BNT1 {harboring the native sequence motif of PfHRPII (AHHAHHAADA)} versus a mutant dendrimeric peptide BNTM {in which ionic Aspartate residues have been replaced by the neutral Asparaginyl residues (AHHAHHAANA)}. UV and IR data reported here reveal that at pH 5, both BNT1 and BNTM exhibit comparable heme binding as well as beta-hematin forming abilities, thus questioning the role of PfHRPII aspartate carboxylate-heme metal ionic interactions in heme binding and beta-hematin formation. Based on our data and information in the literature we suggest the possible role of weak dispersive interactions like N-H center dot center dot center dot pi and lone-pair center dot center dot center dot pi in heme binding and hemozoin formation.	[Kumari, Pinky; Sahal, Dinkar; Chauhan, Virander S.] Int Ctr Genet Engn & Biotechnol, Malaria Res Lab, New Delhi 110067, India	Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi	Sahal, D (corresponding author), Int Ctr Genet Engn & Biotechnol, Malaria Res Lab, Aruna Asaf Ali Marg, New Delhi 110067, India.	dinkar@icgeb.res.in; virander@icgeb.res.in	SAHAL, DINKAR/GYD-7570-2022; Chauhan, Virander S./K-5276-2019		Malaria Core Fund, ICGEB, New Delhi; University Grants Commission, New Delhi, India [10-2(5)/2005(i)-E.U.II]	Malaria Core Fund, ICGEB, New Delhi; University Grants Commission, New Delhi, India(University Grants Commission, India)	This study was supported by Malaria Core Fund, ICGEB, New Delhi. Pinky Kumari got financial assistance from University Grants Commission, New Delhi, India in the form of "CSIR-UGC Research Fellowship, Award No - F.No. 10-2(5)/2005(i)-E.U.II". The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Breman JG, 2001, AM J TROP MED HYG, V64, P1; Choi CYH, 1999, BIOCHEMISTRY-US, V38, P16916, DOI 10.1021/bi991665k; Dauster I, 2008, PHYS CHEM CHEM PHYS, V10, P2827, DOI 10.1039/b717823a; Egan TJ, 2008, MOL BIOCHEM PARASIT, V157, P127, DOI 10.1016/j.molbiopara.2007.11.005; EGLI M, 1995, P NATL ACAD SCI USA, V92, P180, DOI 10.1073/pnas.92.1.180; FITCH CD, 1987, J BIOL CHEM, V262, P15552; Frontera A, 2005, CHEM-EUR J, V11, P6560, DOI 10.1002/chem.200500783; Gallivan JP, 1999, ORG LETT, V1, P103, DOI 10.1021/ol990577p; Jani D, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000053; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; LEVITT M, 1988, J MOL BIOL, V201, P751, DOI 10.1016/0022-2836(88)90471-8; Li Y, 2003, BIOORG MED CHEM LETT, V13, P3261, DOI 10.1016/S0960-894X(03)00662-0; Lynn A, 1999, FEBS LETT, V459, P267, DOI 10.1016/S0014-5793(99)01260-0; MORGAN WT, 1985, BIOCHEMISTRY-US, V24, P1496, DOI 10.1021/bi00327a031; Niles JC, 2009, P NATL ACAD SCI USA, V106, P13266, DOI 10.1073/pnas.0906370106; Ottiger P, 2009, J PHYS CHEM B, V113, P2937, DOI 10.1021/jp8110474; Pagola S, 2000, NATURE, V404, P307, DOI 10.1038/35005132; Pandey AV, 1999, J PHARMACEUT BIOMED, V20, P203, DOI 10.1016/S0731-7085(99)00021-7; PANTON LJ, 1989, MOL BIOCHEM PARASIT, V35, P149, DOI 10.1016/0166-6851(89)90117-5; PERUTZ MF, 1986, J AM CHEM SOC, V108, P1064, DOI 10.1021/ja00265a036; Sarkhel S, 2003, J AM CHEM SOC, V125, P8998, DOI 10.1021/ja0357801; Schneider EL, 2005, BIOCHEMISTRY-US, V44, P979, DOI 10.1021/bi048570p; Schottel BL, 2006, J AM CHEM SOC, V128, P5895, DOI 10.1021/ja0606273; SLATER AFG, 1991, P NATL ACAD SCI USA, V88, P325, DOI 10.1073/pnas.88.2.325; Sullivan DJ, 2002, INT J PARASITOL, V32, P1645, DOI 10.1016/S0020-7519(02)00193-5; Sullivan DJ, 1996, SCIENCE, V271, P219, DOI 10.1126/science.271.5246.219; Tilley L, 2001, INFEC DIS S, P87; WELLEMS TE, 1986, P NATL ACAD SCI USA, V83, P6065, DOI 10.1073/pnas.83.16.6065; WHO, 2011, WORLD MALARIA REPORT 2011, P1; WLODAWER A, 1984, J MOL BIOL, V180, P301, DOI 10.1016/S0022-2836(84)80006-6; Ziegler J, 1999, J AM CHEM SOC, V121, P2395, DOI 10.1021/ja983220+	31	5	5	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 14	2014	9	11							e112087	10.1371/journal.pone.0112087	http://dx.doi.org/10.1371/journal.pone.0112087			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AU4DF	25398028	gold, Green Submitted, Green Published			2023-01-03	WOS:000345558500031
J	Kopp, T; Riedl, E; Bangert, C; Bowman, EP; Greisenegger, E; Horowitz, A; Kittler, H; Blumenschein, WM; McClanahan, TK; Marbury, T; Zachariae, C; Xu, DL; Hou, XS; Mehta, A; Zandvliet, AS; Montgomery, D; van Aarle, F; Khalilieh, S				Kopp, Tamara; Riedl, Elisabeth; Bangert, Christine; Bowman, Edward P.; Greisenegger, Elli; Horowitz, Ann; Kittler, Harald; Blumenschein, Wendy M.; McClanahan, Terrill K.; Marbury, Thomas; Zachariae, Claus; Xu, Danlin; Hou, Xiaoli Shirley; Mehta, Anish; Zandvliet, Anthe S.; Montgomery, Diana; van Aarle, Frank; Khalilieh, Sauzanne			Clinical improvement in psoriasis with specific targeting of interleukin-23	NATURE			English	Article							DENDRITIC CELLS; MONOCLONAL-ANTIBODY; ATOPIC-DERMATITIS; DOUBLE-BLIND; EXPRESSION; PATHOGENESIS; USTEKINUMAB; VULGARIS; SAFETY; SKIN	Psoriasis is a chronic inflammatory skin disorder that affects approximately 2-3% of the population worldwide and has severe effects on patients' physical and psychological well-being(1-3). The discovery that psoriasis is an immune-mediated disease has led to more targeted, effective therapies; recent advances have focused on the interleukin (IL)-12/23p40 subunit shared by IL-12 and IL-23. Evidence suggests that specific inhibition of IL-23 would result in improvement in psoriasis. Here we evaluate tildrakizumab, a monoclonal antibody that targets the IL-23p19 subunit, in a three-part, randomized, placebo-controlled, sequential, rising multiple-dose phase I study in patients with moderate-to-severe psoriasis to provide clinical proof that specific targeting of IL-23p19 results in symptomatic improvement of disease severity in human subjects. A 75% reduction in the psoriasis area and severity index (PASI) score (PASI75) was achieved by all subjects in parts 1 and 3 (pooled) in the 3 and 10 mg kg(-1) groups by day 196. In part 2, 10 out of 15 subjects in the 3 mg kg(-1) group and 13 out of 14 subjects in the 10 mg kg(-1) group achieved a PASI75 by day 112. Tildrakizumab demonstrated important clinical improvement in moderate-to-severe psoriasis patients as demonstrated by improvements in PASI scores and histological samples.	[Kopp, Tamara; Bangert, Christine; Greisenegger, Elli] Univ Vienna, Sch Med, Dept Dermatol, Div Immunol Allergy & Infect Dis, A-1090 Vienna, Austria; [Kopp, Tamara] Juvenis Med Ctr, A-1010 Vienna, Austria; [Riedl, Elisabeth; Kittler, Harald] Univ Vienna, Sch Med, Dept Dermatol, Div Gen Dermatol, A-1090 Vienna, Austria; [Bowman, Edward P.; Horowitz, Ann; Blumenschein, Wendy M.; McClanahan, Terrill K.; Xu, Danlin; Hou, Xiaoli Shirley; Mehta, Anish; Zandvliet, Anthe S.; Montgomery, Diana; van Aarle, Frank; Khalilieh, Sauzanne] Merck & Co Inc, Whitehouse Stn, NJ 08889 USA; [Marbury, Thomas] Orlando Clin Res Ctr, Orlando, FL 32809 USA; [Zachariae, Claus] Univ Copenhagen, Gentofte Hosp, Dept Dermatoallergol, DK-2900 Hellerup, Denmark	University of Vienna; University of Vienna; Merck & Company; University of Copenhagen; Herlev & Gentofte Hospital	Khalilieh, S (corresponding author), Merck & Co Inc, Whitehouse Stn, NJ 08889 USA.	sauzanne.khalilieh@merck.com	Kittler, Harald/AAK-1502-2020; Kittler, Harald/K-7574-2013; Zachariae, Claus Otto Carl/G-6144-2018	Zachariae, Claus Otto Carl/0000-0001-5506-1319; Greisenegger, Elli/0000-0002-6734-054X; KITTLER, HARALD/0000-0002-0051-8016; Montgomery, Diana/0000-0002-1084-4720	Merck Co., Inc.	Merck Co., Inc.(Merck & Company)	The authors thank E. Marcantonio (Merck & Co., Inc.) for his supervision of research and review of this manuscript and J. Pawlowski (Merck & Co., Inc) for editorial and administrative assistance with this manuscript. This study was funded by Merck & Co., Inc.	Ackerman A., 2005, HISTOLOGIC DIAGNOSIS; Bangert C, 2003, J INVEST DERMATOL, V121, P1409, DOI 10.1111/j.1523-1747.2003.12623.x; Bangert C, 2011, DERMATOLOGY, V222, P36, DOI 10.1159/000321711; Bustamante J, 2011, ANN NY ACAD SCI, V1246, P92, DOI 10.1111/j.1749-6632.2011.06273.x; Chan JR, 2006, J EXP MED, V203, P2577, DOI 10.1084/jem.20060244; FREDRIKSSON T, 1978, DERMATOLOGICA, V157, P238, DOI 10.1159/000250839; Guttman-Yassky E, 2008, J IMMUNOL, V181, P7420, DOI 10.4049/jimmunol.181.10.7420; Homey B, 2000, J IMMUNOL, V164, P6621, DOI 10.4049/jimmunol.164.12.6621; Hueber W, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001107; Keijsers RRMC, 2013, BRIT J DERMATOL, V168, P1294, DOI 10.1111/bjd.12236; Krueger G, 2001, ARCH DERMATOL, V137, P280; Krueger JG, 2012, J ALLERGY CLIN IMMUN, V130, P145, DOI 10.1016/j.jaci.2012.04.024; Langley RG, 2012, J EUR ACAD DERMATOL, V26, P21, DOI 10.1111/j.1468-3083.2011.04412.x; Lee E, 2004, J EXP MED, V199, P125, DOI 10.1084/jem.20030451; Leonardi CL, 2008, LANCET, V371, P1665, DOI 10.1016/S0140-6736(08)60725-4; Lew W, 2004, BRIT J DERMATOL, V150, P668, DOI 10.1111/j.0007-0963.2004.05891.x; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Lowes MA, 2007, NATURE, V445, P866, DOI 10.1038/nature05663; Lowes MA, 2014, ANNU REV IMMUNOL, V32, P227, DOI 10.1146/annurev-immunol-032713-120225; Ngiow SF, 2013, TRENDS IMMUNOL, V34, P548, DOI 10.1016/j.it.2013.07.004; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; Papp KA, 2013, BRIT J DERMATOL, V168, P844, DOI 10.1111/bjd.12214; Papp KA, 2008, LANCET, V371, P1675, DOI 10.1016/S0140-6736(08)60726-6; Sa SM, 2007, J IMMUNOL, V178, P2229, DOI 10.4049/jimmunol.178.4.2229; Schon MP, 2005, NEW ENGL J MED, V352, P1899, DOI 10.1056/NEJMra041320; Skvara H, 2008, J CLIN INVEST, V118, P3151, DOI 10.1172/JCI35636; Stary G, 2005, INT ARCH ALLERGY IMM, V138, P278, DOI 10.1159/000088865; Toichi E, 2006, J IMMUNOL, V177, P4917, DOI 10.4049/jimmunol.177.7.4917; Torzicky M, 2012, J INVEST DERMATOL, V132, P1149, DOI 10.1038/jid.2011.420; TROZAK DJ, 1994, INT J DERMATOL, V33, P380, DOI 10.1111/j.1365-4362.1994.tb01073.x; US FDA, 2009, GUID IND ASS DEV IMM; Villanova F, 2014, J INVEST DERMATOL, V134, P984, DOI 10.1038/jid.2013.477; Wolk K, 2009, EUR J IMMUNOL, V39, P3570, DOI 10.1002/eji.200939687	33	163	177	2	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 14	2015	521	7551					222	+		10.1038/nature14175	http://dx.doi.org/10.1038/nature14175			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH9SY	25754330				2023-01-03	WOS:000354377800059
J	Geue, C; Lorgelly, P; Lewsey, J; Hart, C; Briggs, A				Geue, Claudia; Lorgelly, Paula; Lewsey, James; Hart, Carole; Briggs, Andrew			Hospital Expenditure at the End-of-Life: What Are the Impacts of Health Status and Health Risks?	PLOS ONE			English	Article							TIME-TO-DEATH; CARE EXPENDITURE; MEDICAL EXPENDITURES; CIGARETTE-SMOKING; POPULATION; COSTS; MORTALITY; SCOTLAND; RENFREW; MIDSPAN	Background It is important for health policy and expenditure projections to understand the relationship between age, death and expenditure on health care (HC). Research has shown that older age groups incur lower hospital costs than previously anticipated and that remaining time to death (TTD) was a much stronger indicator for expenditure than age. How health behaviour or risk factors impact on HC utilisation and costs at the end of life is relatively unknown. Smoking and Body Mass Index (BMI) have featured most prominently and mixed findings exist as to the exact nature of this association. Methods This paper considers the relationship between TTD, age and expenditure for inpatient care in the last 12 quarters of life; and introduces measures of health status and risks. A longitudinal dataset covering 35 years is utilised, including baseline survey data linked to hospital and death records. The effect of age, TTD and health indicators on expenditure for inpatient care is estimated using a two-part model. Results As individuals approach death costs increase. This effect is highly significant (p<0.01) from the last until the 8th quarter before death and influenced by age. Statistically significant effects on costs were found for: smoking status, systolic blood pressure and lung function (FEV1). On average, smokers incurred lower quarterly costs in their last 12 quarters of life than non-smokers (similar to 7%). Participants' BMI at baseline did show a negative association with probability of HC utilisation however this effect disappeared when costs were estimated. Conclusions Health risk measures obtained at baseline provide a good indication of individuals' probability of needing medical attention later in life and incurring costs, despite the small size of the effect. Utilising a linked dataset, where such measures are available can add substantially to our ability to explain the relationship between TTD and costs.	[Geue, Claudia; Lewsey, James; Briggs, Andrew] Univ Glasgow, Inst Hlth & Wellbeing, Hlth Econ & Hlth Technol Assessment, Glasgow G12 8RZ, Lanark, Scotland; [Lorgelly, Paula] Monash Univ, Ctr Hlth Econ, Clayton, Vic 3800, Australia; Univ Glasgow, Inst Hlth & Wellbeing, Publ Hlth, Glasgow G12 8RZ, Lanark, Scotland	University of Glasgow; Monash University; University of Glasgow	Geue, C (corresponding author), Univ Glasgow, Inst Hlth & Wellbeing, Hlth Econ & Hlth Technol Assessment, 1 Lilybank Gardens, Glasgow G12 8RZ, Lanark, Scotland.	Claudia.Geue@glasgow.ac.uk	Briggs, Andrew/ABA-9009-2020; Harding, Richard/G-9729-2012	Briggs, Andrew/0000-0002-0777-1997; Lorgelly, Paula/0000-0002-8990-9514	Medical Research Council (UK) [G0800122]; Chief Scientist Office [PDF/13/03] Funding Source: researchfish	Medical Research Council (UK)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Chief Scientist Office	This work was funded by a grant from the Medical Research Council (UK). Grant Number: G0800122. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barendregt JJ, 1997, NEW ENGL J MED, V337, P1052, DOI 10.1056/NEJM199710093371506; Breyer F, 2015, EUR J HEALTH ECON, V16, P95, DOI 10.1007/s10198-014-0564-x; Carstairs V., 1991, DEPRIVATION HLTH SCO; Cleves M., 2008, INTRO SURVIVAL ANAL, V2; Geue C, 2014, EUR J HEALTH ECON, V15, P885, DOI 10.1007/s10198-013-0543-7; Geue C, 2012, HEALTH ECON, V21, P1201, DOI 10.1002/hec.1785; Graham B, 2001, PROXIMITY DEATH ACUT; Gray AM, 2012, APPL METHODS COST EF, P72; Hart CL, 2005, INT J EPIDEMIOL, V34, P28, DOI 10.1093/ije/dyh348; HAWTHORNE VM, 1995, SCOT MED J, V40, P102, DOI 10.1177/003693309504000402; HODGSON TA, 1992, MILBANK Q, V70, P81, DOI 10.2307/3350086; ISD Scotland, SCOTT HLTH SERV COST; Miller LS, 1998, PUBLIC HEALTH REP, V113, P447; Moorin R, 2012, J HEALTH SERV RES PO, V17, P197, DOI 10.1258/jhsrp.2012.011130; Moorin RE, 2008, HEALTH POLICY, V85, P380, DOI 10.1016/j.healthpol.2007.08.003; Payne G, 2007, MILBANK Q, V85, P213, DOI 10.1111/j.1468-0009.2007.00485.x; Popham F, 2010, HEALTH PLACE, V16, P759, DOI 10.1016/j.healthplace.2010.03.007; Seshamani M, 2004, AGE AGEING, V33, P556, DOI 10.1093/ageing/afh187; Seshamani M, 2004, HEALTH ECON, V13, P303, DOI 10.1002/hec.826; Smith GD, 1998, J EPIDEMIOL COMMUN H, V52, P399, DOI 10.1136/jech.52.6.399; Stearns SC, 2004, HEALTH ECON, V13, P315, DOI 10.1002/hec.831; Stewart S, 2001, HEART, V86, P516, DOI 10.1136/heart.86.5.516; Wang FF, 2006, J OCCUP ENVIRON MED, V48, P668, DOI 10.1097/01.jom.0000225045.77734.f4; Whitley E, 2014, ANN BEHAV MED, V47, P148, DOI 10.1007/s12160-013-9539-x; Williams A, 1997, BRIT MED J, V314, P820, DOI 10.1136/bmj.314.7083.820; Zweifel P, 2004, GENEVA PAP R I-ISS P, V29, P652, DOI 10.1111/j.1468-0440.2004.00308.x; Zweifel P, 1999, HEALTH ECON, V8, P485, DOI 10.1002/(SICI)1099-1050(199909)8:6<485::AID-HEC461>3.0.CO;2-4	27	7	7	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 6	2015	10	3							e0119035	10.1371/journal.pone.0119035	http://dx.doi.org/10.1371/journal.pone.0119035			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CC9KQ	25746728	Green Published, Green Accepted, gold, Green Submitted			2023-01-03	WOS:000350689400039
J	McGuire, AL; Bennett, SC; Lansley, SM; Popowicz, ND; della Vergiliana, JFV; Wong, D; Lee, YCG; Chakera, A				McGuire, Amanda L.; Bennett, Sophia C.; Lansley, Sally M.; Popowicz, Natalia D.; della Vergiliana, Julius F. Varano; Wong, Daniel; Lee, Y. C. Gary; Chakera, Aron			Preclinical Assessment of Adjunctive tPA and DNase for Peritoneal Dialysis Associated Peritonitis	PLOS ONE			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; INTRAPERITONEAL UROKINASE; PSEUDOMONAS-AERUGINOSA; STAPHYLOCOCCUS-AUREUS; EXTRACELLULAR DNA; BIOFILM FORMATION; OUTCOMES; PATIENT; SURFACE; INFECTIONS	A major complication of peritoneal dialysis is the development of peritonitis, which is associated with reduced technique and patient survival. The inflammatory response elicited by infection results in a fibrin and debris-rich environment within the peritoneal cavity, which may reduce the effectiveness of antimicrobial agents and predispose to recurrence or relapse of infection. Strategies to enhance responses to antimicrobial agents therefore have the potential to improve patient outcomes. This study presents pre-clinical data describing the compatibility of tPA and DNase in combination with antimicrobial agents used for the treatment of PD peritonitis. tPA and DNase were stable in standard dialysate solution and in the presence of antimicrobial agents, and were safe when given intraperitoneally in a mouse model with no evidence of local or systemic toxicity. Adjunctive tPA and DNase may have a role in the management of patients presenting with PD peritonitis.	[McGuire, Amanda L.; Bennett, Sophia C.; Chakera, Aron] Harry Perkins Inst Med Res, Translat Renal Res Grp, Perth, WA, Australia; [McGuire, Amanda L.; Bennett, Sophia C.; Chakera, Aron] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia; [Lansley, Sally M.; Popowicz, Natalia D.; della Vergiliana, Julius F. Varano; Lee, Y. C. Gary] Sch Med & Pharmacol, Ctr Asthma Allergy Resp Res, Lung Inst Western Australia, Pleural Dis Unit, Perth, WA, Australia; [Wong, Daniel] QEII Med Ctr, PathWest Lab Med WA, Dept Anat Pathol, Perth, WA, Australia; [Lee, Y. C. Gary] Sir Charles Gairdner Hosp, Resp Dept, Perth, WA, Australia; [Chakera, Aron] Sir Charles Gairdner Hosp, Renal Dept, Perth, WA, Australia	Harry Perkins Institute of Medical Research; University of Western Australia; University of Western Australia	Chakera, A (corresponding author), Harry Perkins Inst Med Res, Translat Renal Res Grp, Perth, WA, Australia.	aron.chakera@uwa.edu.au	Lee, Y C Gary/H-5264-2014; Popowicz, Natalia/M-7505-2018	Popowicz, Natalia/0000-0003-0200-1819; Lee, Yun Chor Gary/0000-0002-0036-511X; McGuire, Amanda/0000-0002-1261-9236				AHRENHOLZ DH, 1980, SURGERY, V88, P41; Boateng EA, 2011, J RENAL CARE, V37, P190, DOI 10.1111/j.1755-6686.2011.00244.x; Boudville N, 2012, J AM SOC NEPHROL, V23, P1398, DOI 10.1681/ASN.2011121135; Brown F, 2007, PERITON DIALYSIS INT, V27, P565; DASGUPTA MK, 1991, ADV PERIT D, V7, P165; Davies SJ, 2013, NAT REV NEPHROL, V9, P399, DOI 10.1038/nrneph.2013.100; de Boer AW, 1999, PEDIATR NEPHROL, V13, P284, DOI 10.1007/s004670050609; Duch JM, 2001, AM J KIDNEY DIS, V37, P149, DOI 10.1016/S0272-6386(01)80069-X; Eckardt KU, 2013, LANCET, V382, P158, DOI 10.1016/S0140-6736(13)60439-0; Eckhart L, 2007, BRIT J DERMATOL, V156, P1342, DOI 10.1111/j.1365-2133.2007.07886.x; Gadallah M F, 2000, Adv Perit Dial, V16, P233; Ghaffari A, 2013, PD 1 PERITONEAL DIAL; Ghali JR, 2011, PERITON DIALYSIS INT, V31, P651, DOI 10.3747/pdi.2010.00131; Hall-Stoodley L, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-173; Hanlon GW, 2004, J PHARM PHARMACOL, V56, P847, DOI 10.1211/0022357023817; Hurst K, 2012, ANZDATA REGISTRY REP, pXXIII; Ince A, 2002, AM J SURG, V183, P67, DOI 10.1016/S0002-9610(01)00850-9; INNES A, 1994, NEPHROL DIAL TRANSPL, V9, P797; Izano EA, 2008, APPL ENVIRON MICROB, V74, P470, DOI 10.1128/AEM.02073-07; Jager KJ, 2004, AM J KIDNEY DIS, V43, P891, DOI 10.1053/j.ajkd.2003.12.051; Johnson D, 2006, ANZDATA REGISTRY REP, P88; Kim GC, 2000, AM J KIDNEY DIS, V36, P1000, DOI 10.1053/ajkd.2000.19102; Kumar VA, 2013, PERIT DIAL INT; Lamping DL, 2000, LANCET, V356, P1543, DOI 10.1016/S0140-6736(00)03123-8; Li PKT, 2010, PERITON DIALYSIS INT, V30, P393, DOI 10.3747/pdi.2010.00049; Marcus RJ, 2008, EXPERT OPIN BIOL TH, V8, P1159, DOI 10.1517/14712598.8.8.1159 ; Mastrosimone S, 2002, PERITON DIALYSIS INT, V22, P91; MCINTOSH ME, 1985, EUR J CLIN PHARMACOL, V28, P187, DOI 10.1007/BF00609690; Miles R, 2009, KIDNEY INT, V76, P622, DOI 10.1038/ki.2009.202; de Bustillo EM, 2011, NEFROLOGIA, V31, P723, DOI 10.3265/Nefrologia.pre2011.Oct.10987; MURPHY G, 1991, INT J ARTIF ORGANS, V14, P87, DOI 10.1177/039139889101400206; Nemoto K, 2003, CHEMOTHERAPY, V49, P121, DOI 10.1159/000070617; Piccolo F, 2014, ANN AM THORACIC SOC; Pihl M, 2013, PERITON DIALYSIS INT, V33, P51, DOI 10.3747/pdi.2011.00320; Rahman NM, 2011, NEW ENGL J MED, V365, P518, DOI 10.1056/NEJMoa1012740; READ RR, 1989, KIDNEY INT, V35, P614, DOI 10.1038/ki.1989.30; Sepandj F, 2003, PERITON DIALYSIS INT, V23, P77; SHAK S, 1990, P NATL ACAD SCI USA, V87, P9188, DOI 10.1073/pnas.87.23.9188; Shea M, 2001, Adv Perit Dial, V17, P249; Thomas VC, 2008, J BACTERIOL, V190, P5690, DOI 10.1128/JB.00314-08; Tong MKH, 2005, J NEPHROL, V18, P204; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; Walker A, 2013, NEPHROLOGY CARLTON; Wiggins KJ, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005284.pub2; Worland MA, 1998, ANN PHARMACOTHER, V32, P1216, DOI 10.1345/aph.16153; Zorzanello Mary M, 2004, Nephrol Nurs J, V31, P534; Zorzanello MM, 2004, J AM NEPHROLOGY NURS, V31, P534	47	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 5	2015	10	3							e0119238	10.1371/journal.pone.0119238	http://dx.doi.org/10.1371/journal.pone.0119238			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC9KG	25742006	gold, Green Submitted, Green Published			2023-01-03	WOS:000350688100095
J	Ansah, EK; Narh-Bana, S; Affran-Bonful, H; Bart-Plange, C; Cundill, B; Gyapong, M; Whitty, CJM				Ansah, Evelyn K.; Narh-Bana, Solomon; Affran-Bonful, Harriet; Bart-Plange, Constance; Cundill, Bonnie; Gyapong, Margaret; Whitty, Christopher J. M.			The impact of providing rapid diagnostic malaria tests on fever management in the private retail sector in Ghana: a cluster randomized trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COMBINATION THERAPY; FEBRILE ILLNESS; DRUG SHOPS; CARE; CHILDREN; TANZANIA; OVERDIAGNOSIS; PREVENTION; MICROSCOPY; MEDICINES	Objective To examine the impact of providing rapid diagnostic tests for malaria on fever management in private drug retail shops where most poor rural people with fever present, with the aim of reducing current massive overdiagnosis and overtreatment of malaria. Design Cluster randomized trial of 24 clusters of shops. Setting Dangme West, a poor rural district of Ghana. Participants Shops and their clients, both adults and children. Interventions Providing rapid diagnostic tests with realistic training. Main outcome measures The primary outcome was the proportion of clients testing negative for malaria by a double-read research blood slide who received an artemisinin combination therapy or other antimalarial. Secondary outcomes were use of antibiotics and antipyretics, and safety. Results Of 4603 clients, 3424 (74.4%) tested negative by double-read research slides. The proportion of slide-negative clients who received any antimalarial was 590/1854 (32%) in the intervention arm and 1378/1570 (88%) in the control arm (adjusted risk ratio 0.41 (95% CI 0.29 to 0.58), P<0.0001). Treatment was in high agreement with rapid diagnostic test result. Of those who were slide-positive, 690/787 (87.8%) in the intervention arm and 347/392 (88.5%) in the control arm received an artemisinin combination therapy (adjusted risk ratio 0.96 (0.84 to 1.09)). There was no evidence of antibiotics being substituted for antimalarials. Overall, 1954/2641 (74%) clients in the intervention arm and 539/1962 (27%) in the control arm received appropriate treatment (adjusted risk ratio 2.39 (1.69 to 3.39), P<0.0001). No safety concerns were identified. Conclusions Most patients with fever in Africa present to the private sector. In this trial, providing rapid diagnostic tests for malaria in the private drug retail sector significantly reduced dispensing of antimalarials to patients without malaria, did not reduce prescribing of antimalarials to true malaria cases, and appeared safe. Rapid diagnostic tests should be considered for the informal private drug retail sector.	[Ansah, Evelyn K.] Ghana Hlth Serv, Res & Dev Div, Accra, Ghana; [Narh-Bana, Solomon; Gyapong, Margaret] Ghana Hlth Serv, Dodowa Hlth Res Ctr, Accra, Ghana; [Affran-Bonful, Harriet] Ghana Hlth Serv, Dangme West Dist Hlth Directorate, Accra, Ghana; [Bart-Plange, Constance] Ghana Hlth Serv, Natl Malaria Control Programme, Accra, Ghana; [Cundill, Bonnie; Whitty, Christopher J. M.] London Sch Hyg & Trop Med, London WC1, England	Ghana Health Service; Ghana Health Service; Ghana Health Service; Ghana Health Service; University of London; London School of Hygiene & Tropical Medicine	Ansah, EK (corresponding author), Ghana Hlth Serv, Res & Dev Div, POB MB 190, Accra, Ghana.	Ansahekdr@yahoo.co.uk		Affran Bonful, Harriet/0000-0003-0069-3241; Cundill, Bonnie/0000-0002-3648-820X; Narh-Bana, Solomon A./0000-0001-8010-2637; Gyapong, Margaret/0000-0002-4818-3497; Whitty, Christopher/0000-0002-6076-5027; Ansah, Evelyn/0000-0003-0401-8606	Malaria Capacity Development Consortium of the London School of Hygiene & Tropical Medicine; Welcome Trust; Bill and Melinda Gates Foundation; Medical Research Council [MR/K012126/1] Funding Source: researchfish	Malaria Capacity Development Consortium of the London School of Hygiene & Tropical Medicine; Welcome Trust(Wellcome Trust); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The study was sponsored by the Malaria Capacity Development Consortium of the London School of Hygiene & Tropical Medicine with funding from the Welcome Trust and the Bill and Melinda Gates Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abba K, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008122.pub2; Agyepong I, 2006, MED ED RESOURCES AFR, V21, P5; AGYEPONG IA, 1992, SOC SCI MED, V35, P131, DOI 10.1016/0277-9536(92)90160-R; AGYEPONG IA, 1994, ACTA TROP, V58, P317, DOI 10.1016/0001-706X(94)90025-6; Ahorlu CK, 1997, TROP MED INT HEALTH, V2, P488, DOI 10.1046/j.1365-3156.1997.d01-298.x; Albertini A, 2012, TROP MED INT HEALTH, V17, P147, DOI 10.1111/j.1365-3156.2011.02904.x; Amexo M, 2004, LANCET, V364, P1896, DOI 10.1016/S0140-6736(04)17446-1; Amooti-Kaguna B, 2000, SOC SCI MED, V50, P203, DOI 10.1016/S0277-9536(99)00275-0; Ansah EK, 2010, BMJ-BRIT MED J, V5, P340; Ansah EK, 2013, AM J TROP MED HYG, V89, P724, DOI 10.4269/ajtmh.13-0033; Ansah EK, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-258; Ansah EK, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-853; Asenso-Okyere WK, 1998, HEALTH POLICY PLANN, V13, P181, DOI 10.1093/heapol/13.2.181; Baiden F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045556; Bastiaens GJH, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001590; Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275; Chandler CIR, 2008, HEALTH POLICY PLANN, V23, P170, DOI 10.1093/heapol/czm046; Chandler CIR, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-53; Cohen J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048296; Counihan H, 2012, AM J TROP MED HYG, V87, P57, DOI 10.4269/ajtmh.2012.11-0800; D'Acremont V, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-240; D'Acremont V, 2009, PLOS MED, V6, P4, DOI 10.1371/journal.pmed.0050252; Davis BL, 2013, EMERGENCE APPROACH TO SPEECH ACQUISITION: DOING AND KNOWING, P1; English M, 2004, LANCET, V363, P1948, DOI 10.1016/S0140-6736(04)16408-8; Ensor T, 2004, HEALTH POLICY PLANN, V19, P69, DOI 10.1093/heapol/czh009; Fritzsche C, 2013, T ROY SOC TROP MED H, V107, P158, DOI 10.1093/trstmh/trs087; Gething PW, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000301; Hansen KS, 2013, HEALTH POLICY PLANN, V28, P185, DOI 10.1093/heapol/czs048; Hayes RJ, 2009, INTERD STAT, P3; Hill Z, 2003, TROP MED INT HEALTH, V8, P668, DOI 10.1046/j.1365-3156.2003.01058.x; Institute of Medicine (US) Committee on the Economics of Antimalarial Drugs, 2004, SAVING LIVES BUYING; Kangwana BP, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000437; Littrell M, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-327; Malm KL, 2013, J PUBLIC HEALTH POL, V34, P302, DOI 10.1057/jphp.2013.12; Masanja IM, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-221; Mbonye AK, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-131; Moulton Lawrence H, 2004, Clin Trials, V1, P297, DOI 10.1191/1740774504cn024oa; Mtove G, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-290; Mubi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019753; MWENESI H, 1995, SOC SCI MED, V40, P1271, DOI 10.1016/0277-9536(94)00250-W; Nkrumah Bernard, 2011, BMC Res Notes, V4, P529, DOI 10.1186/1756-0500-4-529; Nonvignon J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-188; Nsimba SE, 1999, DRUG INF J, V33, P1025, DOI 10.1177/009286159903300407; Raab GM, 2001, STAT MED, V20, P351, DOI 10.1002/1097-0258(20010215)20:3<351::AID-SIM797>3.0.CO;2-C; Rankin SL, 2001, ANZ J SURG, V71, P544, DOI 10.1046/j.1440-1622.2001.02188.x; Rao VB, 2013, TRENDS PARASITOL, V29, P164, DOI 10.1016/j.pt.2013.01.005; Reyburn H, 2004, BMJ-BRIT MED J, V329, P1212, DOI 10.1136/bmj.38251.658229.55; Reyburn H, 2007, BRIT MED J, V334, P403, DOI 10.1136/bmj.39073.496829.AE; Rutebemberwa E, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-45; SNOW RW, 1992, T ROY SOC TROP MED H, V86, P237, DOI 10.1016/0035-9203(92)90290-S; Van Dillen J, 2007, TROP DOCT, V37, P185, DOI 10.1258/004947507781524845; World Health Organization, 2009, MAL CAS MAN OP MAN, P26; Yeung S, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-243; Yukich JO, 2012, AM J TROP MED HYG, V87, P437, DOI 10.4269/ajtmh.2012.12-0127	54	55	55	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 4	2015	350								h1019	10.1136/bmj.h1019	http://dx.doi.org/10.1136/bmj.h1019			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CC4DS	25739769	Green Accepted, Green Published, hybrid			2023-01-03	WOS:000350301600009
J	Humikowski, CA				Humikowski, Catherine A.			For What It's Worth	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Chicago, Dept Pediat, Sect Crit Care, Chicago, IL 60637 USA	University of Chicago	Humikowski, CA (corresponding author), Univ Chicago, Dept Pediat, Sect Crit Care, Chicago, IL 60637 USA.	cahumiko@uchicago.edu						Ashcraft MH, 2001, J EXP PSYCHOL GEN, V130, P224, DOI 10.1037/0096-3445.130.2.224; Callaway E, 2014, NATURE, V508, P295, DOI 10.1038/508295a; Kuehn BM, 2014, JAMA-J AM MED ASSOC, V311, P2368, DOI 10.1001/jama.2014.5756	3	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 24	2015	313	8					799	800		10.1001/jama.2014.15004	http://dx.doi.org/10.1001/jama.2014.15004			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CB7RY	25710654				2023-01-03	WOS:000349826400011
J	Wessels, MR; Brigham, KS; DeMaria, A				Wessels, Michael R.; Brigham, Kathryn S.; DeMaria, Alfred, Jr.			Case 6-2015: A 16-Year-Old Boy with Coughing Spells	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACELLULAR PERTUSSIS-VACCINE; BORDETELLA-PERTUSSIS; ADVISORY-COMMITTEE; PREVENTING TETANUS; ADULT TETANUS; DIPHTHERIA; RECOMMENDATIONS; IMMUNIZATION; ADOLESCENTS; INFECTION		[Wessels, Michael R.] Boston Childrens Hosp, Dept Med, Boston, MA 02115 USA; [Brigham, Kathryn S.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA; [DeMaria, Alfred, Jr.] Massachusetts Dept Publ Hlth, William A Hinton State Lab Inst, Boston, MA USA; [Wessels, Michael R.; Brigham, Kathryn S.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [DeMaria, Alfred, Jr.] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Massachusetts General Hospital; Massachusetts Department of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Wessels, MR (corresponding author), Boston Childrens Hosp, Dept Med, Boston, MA 02115 USA.							Birkebaek NH, 1999, CLIN INFECT DIS, V29, P1239, DOI 10.1086/313448; Broder Karen R., 2006, Morbidity and Mortality Weekly Report, V55, P1; California Department of Public Health, PERT SUMM REP; Centers for Disease Control and Prevention, PERT SURV REP; Clark TA, 2012, TRENDS MICROBIOL, V20, P211, DOI 10.1016/j.tim.2012.03.003; CODY CL, 1981, PEDIATRICS, V68, P650; DeBolt Chas, 2012, Morbidity and Mortality Weekly Report, V61, P517; Greenberg DP, 2009, PEDIATR INFECT DIS J, V28, P521, DOI 10.1097/INF.0b013e318199d2fc; Hewlett EL, 2005, NEW ENGL J MED, V352, P1215, DOI 10.1056/NEJMcp041025; Irwin RS, 2006, CHEST, V129, P1, DOI 10.1378/chest.129.1.1; Khoshoo V, 2009, CHEST, V136, P811, DOI 10.1378/chest.09-0649; Kirkland K. B., 2007, Morbidity and Mortality Weekly Report, V56, P837; Klein NP, 2013, PEDIATRICS, V131, pE1716, DOI 10.1542/peds.2012-3836; Klein NP, 2012, NEW ENGL J MED, V367, P1012, DOI 10.1056/NEJMoa1200850; Kretsinger Katrina, 2006, Morbidity and Mortality Weekly Report, V55, P1; Mandal S, 2012, PEDIATRICS, V129, pE424, DOI 10.1542/peds.2011-1710; MARCHANT CD, 1994, J INFECT DIS, V169, P1297, DOI 10.1093/infdis/169.6.1297; Menzies SL, 2009, CLIN VACCINE IMMUNOL, V16, P1781, DOI 10.1128/CVI.00248-09; MINK CM, 1992, CLIN INFECT DIS, V14, P464, DOI 10.1093/clinids/14.2.464; Misegades LK, 2012, JAMA-J AM MED ASSOC, V308, P2126, DOI 10.1001/jama.2012.14939; Pawloski LC, 2012, CLIN VACCINE IMMUNOL, V19, P875, DOI 10.1128/CVI.05686-11; Rank C, 2009, PEDIATR INFECT DIS J, V28, P152, DOI 10.1097/INF.0b013e318185608e; Sawyer M, 2013, MMWR-MORBID MORTAL W, V62, P131; Shields MD, 2008, THORAX, V63, P1, DOI 10.1136/thx.2007.077370; SIBER GR, 1991, VACCINE, V9, P735, DOI 10.1016/0264-410X(91)90289-I; Skoff TH, 2012, ARCH PEDIAT ADOL MED, V166, P344, DOI 10.1001/archpediatrics.2011.1093; Tartof SY, 2013, PEDIATRICS, V131, pE1047, DOI 10.1542/peds.2012-1928; Thompson M, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f7027; Wagner JBC, 2013, PEDIATR CLIN N AM, V60, P951, DOI 10.1016/j.pcl.2013.04.004; Waites KB, 2003, PEDIATR PULM, V36, P267, DOI 10.1002/ppul.10346; Ward JI, 2005, NEW ENGL J MED, V353, P1555, DOI 10.1056/NEJMoa050824; Wei SC, 2010, CLIN INFECT DIS, V51, P315, DOI 10.1086/653938; Witt MA, 2013, CLIN INFECT DIS, V56, P1248, DOI 10.1093/cid/cit046; Witt MA, 2012, CLIN INFECT DIS, V54, P1730, DOI 10.1093/cid/cis287; WRIGHT SW, 1995, JAMA-J AM MED ASSOC, V273, P1044, DOI 10.1001/jama.273.13.1044; Yih WK, 2000, J INFECT DIS, V182, P1409, DOI 10.1086/315863; YOUNG S A, 1987, Clinical Microbiology Newsletter, V9, P176, DOI 10.1016/0196-4399(87)90061-4	37	4	4	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 19	2015	372	8					765	773		10.1056/NEJMcpc1411928	http://dx.doi.org/10.1056/NEJMcpc1411928			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CB7PB	25693017				2023-01-03	WOS:000349818700013
J	Barnes, DE; Mehling, W; Wu, E; Beristianos, M; Yaffe, K; Skultety, K; Chesney, MA				Barnes, Deborah E.; Mehling, Wolf; Wu, Eveline; Beristianos, Matthew; Yaffe, Kristine; Skultety, Karyn; Chesney, Margaret A.			Preventing Loss of Independence through Exercise (PLIE): A Pilot Clinical Trial in Older Adults with Dementia	PLOS ONE			English	Article							MINI-MENTAL-STATE; QUALITY-OF-LIFE; ALZHEIMERS-DISEASE; TAI CHI; OUTCOMES; PERFORMANCE; REHABILITATION; MANAGEMENT; INVENTORY; MEMANTINE	Background Current dementia medications have small effect sizes, many adverse effects and do not change the disease course. Therefore, it is critically important to study alternative treatment strategies. The goal of this study was to pilot-test a novel, integrative group exercise program for individuals with mild-to-moderate dementia called Preventing Loss of Independence through Exercise (PLIE), which focuses on training procedural memory for basic functional movements (e.g., sit-to-stand) while increasing mindful body awareness and facilitating social connection. Methods We performed a 36-week cross-over pilot clinical trial to compare PLIE with usual care (UC) at an adult day program for individuals with dementia in San Francisco, CA. Assessments of physical performance, cognitive function, physical function, dementia-related behaviors, quality of life and caregiver burden were performed by blinded assessors at baseline, 18 weeks (cross-over) and 36 weeks. Our primary outcomes were effect sizes based on between-group comparisons of change from baseline to 18 weeks; secondary outcomes were within-group comparisons of change before and after cross-over. Results Twelve individuals enrolled (7 PLIE, 5 UC) and 2 withdrew (1 PLIE, 18 weeks; 1 UC, 36 weeks). Participants were 82% women (mean age, 84 +/- 4 years); caregivers were 82% daughters (mean age, 56 +/- 13 years). Effect sizes were not statistically significant but suggested potentially clinically meaningful (>= 0.25 SDs) improvement with PLIE versus UC for physical performance (Cohen's D: 0.34 SDs), cognitive function (0.76 SDs) and quality of life (0.83 SDs) as well as for caregiver measures of participant's quality of life (0.33 SDs) and caregiver burden (0.49 SDs). Results were similar when within-group comparisons were made before and after cross-over. Conclusions PLIE is a novel, integrative exercise program that shows promise for improving physical function, cognitive function, quality of life and caregiver burden in individuals with mild-to-moderate dementia. Larger randomized, controlled trials are warranted.	[Barnes, Deborah E.; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA; [Barnes, Deborah E.; Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; [Barnes, Deborah E.; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA; [Mehling, Wolf] Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA; [Mehling, Wolf; Wu, Eveline; Chesney, Margaret A.] Univ Calif San Francisco, Osher Ctr Integrat Med, San Francisco, CA 94143 USA; [Wu, Eveline] Calif Inst Integral Studies, San Francisco, CA USA; [Beristianos, Matthew] Northern Calif Inst Res & Educ, San Francisco, CA USA; [Beristianos, Matthew] Calif Sch Profess Psychol, San Francisco, CA USA; [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; [Skultety, Karyn] Inst Aging, San Francisco, CA USA; [Chesney, Margaret A.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Northern California Institute for Research & Education; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Barnes, DE (corresponding author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.	Deborah.barnes@ucsf.edu			UCSF Osher Center for Integrative Medicine	UCSF Osher Center for Integrative Medicine	We thank Drew and Ellen Bradley for their generous support of the UCSF Osher Center for Integrative Medicine, which enabled the development and pilot-testing of the Preventing Loss of Independence through Exercise (PLIE) program.	Acosta D, 2009, WORLD ALZHEIMER REPO; American Dance Therapy Association, 2014, ABOUT DANCE MOVEMENT; American Occupational Therapy Association, 2014, ABOUT OCCUPATIONAL T; American Physical Therapy Association, 2011, TODAYS PHYSICAL THER; American Tai Chi and Qigong Association, 2014, THE OVERVIEW OF TAI; American Yoga Association, 2006, GENERAL YOGA INFORMA; Bezprozvanny I, 2010, DRUG NEWS PERSPECT, V23, P518, DOI 10.1358/dnp.2010.23.8.1500435; Birks J, 2006, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001190.pub2, 10.1002/14651858.CD001190.pub3]; Blankevoort CG, 2010, DEMENT GERIATR COGN, V30, P392, DOI 10.1159/000321357; Cohen J., 1988, STATISTICAL POWER AN, DOI DOI 10.1234/12345678; Cummings JL, 1997, NEUROLOGY, V48, pS10, DOI 10.1212/WNL.48.5_Suppl_6.10S; Doody RS, 2014, NEW ENGL J MED, V370, P311, DOI 10.1056/NEJMoa1312889; Eldridge LL, 2002, BEHAV NEUROSCI, V116, P722, DOI 10.1037//0735-7044.116.4.722; Fagan T, 2012, CLINICAL TRIALS OF I; Fagan T, 2010, LILLY HALTS IDENTITY; Fleischman DA, 2005, BRAIN, V128, P2006, DOI 10.1093/brain/awh559; Fogel A, 2009, THE PSYCHOPHYSIOLOGY; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Forbes D, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006489.pub3; Freiberger E, 2012, AGE AGEING, V41, P712, DOI 10.1093/ageing/afs099; Galasko D, 1997, ALZ DIS ASSOC DIS, V11, pS33; Garcia-Rodriguez B, 2009, J ALZHEIMERS DIS, V18, P541, DOI 10.3233/JAD-2009-1161; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; Guzman-Garcia A, 2013, INT J GERIATR PSYCH, V28, P914, DOI 10.1002/gps.3913; Hansen RA, 2007, DRUG AGING, V24, P155, DOI 10.2165/00002512-200724020-00007; Hazard RG, 2012, SPINE J, V12, P1132, DOI 10.1016/j.spinee.2012.09.003; Healing Yoga Foundation, 2014, HEALING THROUGH YOGA; Heyn P, 2004, ARCH PHYS MED REHAB, V85, P1694, DOI 10.1016/j.apmr.2004.03.019; Heyn PC, 2008, J NUTR HEALTH AGING, V12, P401, DOI 10.1007/BF02982674; Hogan DB, 2008, CAN MED ASSOC J, V179, P1019, DOI 10.1503/cmaj.081103; Howard R, 2012, NEW ENGL J MED, V366, P893, DOI 10.1056/NEJMoa1106668; Hurd MD, 2013, NEW ENGL J MED, V368, P1326, DOI 10.1056/NEJMsa1204629; Jeffrey S, 2013, IVIG FAILS IN PHASE; Krasny-Pacini A., 2013, Annals of Physical and Rehabilitation Medicine, V56, P212, DOI 10.1016/j.rehab.2013.02.002; Lam LCW, 2012, J AM MED DIR ASSOC, V13, DOI 10.1016/j.jamda.2012.03.008; Logsdon RG, 2002, PSYCHOSOM MED, V64, P510, DOI 10.1097/00006842-200205000-00016; Lyttle T.S.K., 1997, J BODYW MOV THER, V1, P262, DOI [10.1016/S1360-8592(97)80061-7, DOI 10.1016/S1360-8592(97)80061-7]; McDowell I, 1997, J CLIN EPIDEMIOL, V50, P377, DOI 10.1016/S0895-4356(97)00060-7; Meekums B., 1996, PROFESSIONAL CARE FO, P119, DOI [10.1007/978-1-4899-3015-6_7, DOI 10.1007/978-1-4899-3015-6_7]; Mehling Wolf E, 2011, Philos Ethics Humanit Med, V6, P6, DOI 10.1186/1747-5341-6-6; Mendelson AD, 2011, HEALTH EDUC RES, V26, P167, DOI 10.1093/her/cyq077; NOVAK M, 1989, GERONTOLOGIST, V29, P798, DOI 10.1093/geront/29.6.798; Oken BS, 2006, ALTERN THER HEALTH M, V12, P40; Pitkala KH, 2013, JAMA INTERN MED, V173, P894, DOI 10.1001/jamainternmed.2013.359; Potter R, 2011, INT J GERIATR PSYCH, V26, P1000, DOI 10.1002/gps.2641; Rikli RE, 1999, J AGING PHYS ACTIV, V7, P129, DOI 10.1123/japa.7.2.129; Rockwood K, 2004, J NEUROL NEUROSUR PS, V75, P677, DOI 10.1136/jnnp.2003.029074; Rolland Y, 2007, J AM GERIATR SOC, V55, P158, DOI 10.1111/j.1532-5415.2007.01035.x; Rosen Method&REG;, 2014, ROSEN METHOD MOVEMEN; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; Salloway S, 2014, NEW ENGL J MED, V370, P322, DOI 10.1056/NEJMoa1304839; Sandlund ES, 2000, INT J STRESS MANAGE, V7, P139, DOI 10.1023/A:1009536319034; Sherrington CS, 1906, THE INTEGRATIVE ACTI, P412; Smith M, 2006, ALZ DIS ASSOC DIS, V20, P133, DOI 10.1097/00002093-200607000-00002; Taylor-Piliae RE, 2010, J AGING PHYS ACTIV, V18, P261, DOI 10.1123/japa.18.3.261; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; Teri L, 2003, JAMA-J AM MED ASSOC, V290, P2015, DOI 10.1001/jama.290.15.2015; The Feldenkrais&REG;Educational Foundation of North America and the FELDENKRAIS GUILD&REG;of North America, 2014, THE FELDENKRAIS METH; Thies W, 2013, ALZHEIMERS DEMENT, V9, P208, DOI 10.1016/j.jalz.2013.02.003; Thorgrimsen L, 2003, ALZ DIS ASSOC DIS, V17, P201, DOI 10.1097/00002093-200310000-00002; Weyer G, 1997, Int Psychogeriatr, V9, P123, DOI 10.1017/S1041610297004298; Wu E, 2014, AGING MENT HEALTH, P1; Yao L, 2013, WESTERN J NURS RES, V35, P281, DOI 10.1177/0193945912443319	63	42	43	2	39	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 11	2015	10	2							e0113367	10.1371/journal.pone.0113367	http://dx.doi.org/10.1371/journal.pone.0113367			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CB3RF	25671576	gold, Green Published			2023-01-03	WOS:000349545300002
J	Ormond-Walshe, S; Furniss, R; Harris, A; Winfield, K; Haigh, DA				Ormond-Walshe, Sarah; Furniss, Richard; Harris, Andrew; Winfield, Katie; Haigh, Dominic A.			Inquests into patients who die while under a deprivation of liberty order	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Ormond-Walshe, Sarah] Inner South London, West London, England; [Ormond-Walshe, Sarah] Inner South London, London, Staffs, England; [Furniss, Richard] 42 Bedford Row Chambers, London, England; [Harris, Andrew] Inner South London, London, England; [Winfield, Katie] Keele Univ, Sch Med, Keele, Staffs, England; [Haigh, Dominic A.] Univ Oradea, Oradea, Romania	Keele University; University of Oradea	Ormond-Walshe, S (corresponding author), Inner South London, West London, England.							[Anonymous], 2014, ANN REPORT; [Anonymous], 2014, GUID 16 DEPR LIB SAF; Anthony D, 2005, CLIN EFFECTIVENESS N, V9, P26; McGhie F, 2014, INQUEST LAW, V30, P13	4	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 9	2015	350								h501	10.1136/bmj.h501	http://dx.doi.org/10.1136/bmj.h501			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CB0LA	25666725				2023-01-03	WOS:000349316200002
J	Wang, HN; Bai, YH; Chen, YC; Zhang, RG; Wang, HH; Zhang, YH; Gan, JL; Peng, ZW; Tan, QR				Wang, Hua-ning; Bai, Yuan-han; Chen, Yun-chun; Zhang, Rui-guo; Wang, Huai-hai; Zhang, Ya-hong; Gan, Jing-li; Peng, Zheng-wu; Tan, Qing-rong			Repetitive Transcranial Magnetic Stimulation Ameliorates Anxiety-Like Behavior and Impaired Sensorimotor Gating in a Rat Model of Post-Traumatic Stress Disorder	PLOS ONE			English	Article							MEDIAL PREFRONTAL CORTEX; ACOUSTIC STARTLE REFLEX; PREPULSE INHIBITION; NUCLEUS-ACCUMBENS; GENE-EXPRESSION; MESSENGER-RNA; DOUBLE-BLIND; PLACEBO; HIPPOCAMPAL; ATTENTION	Background Repetitive transcranial magnetic stimulation (rTMS) has been employed for decades as a non-pharmacologic treatment for post-traumatic stress disorder (PTSD). Although a link has been suggested between PTSD and impaired sensorimotor gating (SG), studies assessing the effects of rTMS against PTSD or PTSD with impaired SG are scarce. Aim To assess the benefit of rTMS in a rat model of PTSD. Methods Using a modified single prolonged stress (SPS&S) rat model of PTSD, behavioral parameters were acquired using open field test (OFT), elevated plus maze test (EPMT), and prepulse inhibition trial (PPI), with or without 7 days of high frequency (10Hz) rTMS treatment of SPS&S rats. Results Anxiety-like behavior, impaired SG and increased plasma level of cortisol were observed in SPS&S animals after stress for a prolonged time. Interestingly, rTMS administered immediately after stress prevented those impairment. Conclusion Stress-induced anxiety-like behavior, increased plasma level of cortisol and impaired PPI occur after stress and high-frequency rTMS has the potential to ameliorate this behavior, suggesting that high frequency rTMS should be further evaluated for its use as a method for preventing PTSD.	[Wang, Hua-ning; Bai, Yuan-han; Chen, Yun-chun; Zhang, Rui-guo; Wang, Huai-hai; Zhang, Ya-hong; Peng, Zheng-wu; Tan, Qing-rong] Fourth Mil Med Univ, Xijing Hosp, Dept Psychiat, Xian 710032, Peoples R China; [Gan, Jing-li] 91 Hosp PLA, Dept Psychiat, Jiaozuo 454150, Peoples R China	Air Force Military Medical University	Peng, ZW (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Psychiat, Xian 710032, Peoples R China.	pengzhengwu1446@163.com; tanqingr@fmmu.edu.cn	Peng, Zheng-wu/ABA-5838-2021	Peng, Zheng-wu/0000-0002-8185-0538; Bai, Yuanhan/0000-0003-3574-1346; Wang, Hua-Ning/0000-0003-1981-4293	National Key Technology R & D Program of China [2009BA177B09]; Natural Science Foundation of China [81201041, 81371478, 81401109]	National Key Technology R & D Program of China(National Key Technology R&D Program); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the National Key Technology R & D Program of China (No. 2009BA177B09) and the Natural Science Foundation of China (No. 81201041, 81371478 and 81401109). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen EA, 2007, SCIENCE, V317, P1918, DOI 10.1126/science.1146426; Baek K, 2012, NEUROSCIENCE, V200, P159, DOI 10.1016/j.neuroscience.2011.09.050; Baisley SK, 2011, PHYSIOL BEHAV, V104, P796, DOI 10.1016/j.physbeh.2011.08.001; Bitsios P, 2005, INT J PSYCHOPHYSIOL, V55, P229, DOI 10.1016/j.ijpsycho.2004.08.002; Boggio PS, 2010, J CLIN PSYCHIAT, V71, P992, DOI 10.4088/JCP.08m04638blu; Braff DL, 2001, PSYCHOPHARMACOLOGY, V156, P234, DOI 10.1007/s002130100810; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Cohen H, 2004, AM J PSYCHIAT, V161, P515, DOI 10.1176/appi.ajp.161.3.515; Conrad KL, 2011, PHYSIOL BEHAV, V104, P248, DOI 10.1016/j.physbeh.2011.03.001; Feng SF, 2012, BEHAV BRAIN RES, V232, P245, DOI 10.1016/j.bbr.2012.04.019; Ferguson SA, 2001, NEUROTOXICOL TERATOL, V23, P57, DOI 10.1016/S0892-0362(00)00115-X; Filion DL, 2003, BIOL PSYCHOL, V64, P283, DOI 10.1016/S0301-0511(03)00077-2; Fitzgerald PB, 2006, CLIN NEUROPHYSIOL, V117, P2584, DOI 10.1016/j.clinph.2006.06.712; Friedman MJ, 2007, J CLIN PSYCHIAT, V68, P711, DOI 10.4088/JCP.v68n0508; George MS, 1996, J NEUROPSYCH CLIN N, V8, P373; Geyer MA, 2001, PSYCHOPHARMACOLOGY, V156, P117, DOI 10.1007/s002130100811; Ghisolfi ES, 2004, INT J PSYCHOPHYSIOL, V51, P209, DOI 10.1016/j.ijpsycho.2003.09.002; Gillette GM, 1997, LIFE SCI, V61, P1421, DOI 10.1016/S0024-3205(97)00688-7; Grillon C, 1996, PSYCHIAT RES, V64, P169, DOI 10.1016/S0165-1781(96)02942-3; HERBERT H, 1991, J COMP NEUROL, V304, P103, DOI 10.1002/cne.903040108; Horger BA, 1996, CRIT REV NEUROBIOL, V10, P395; Imanaka A, 2006, BEHAV BRAIN RES, V173, P129, DOI 10.1016/j.bbr.2006.06.012; Iwamoto Y, 2007, PROG NEURO-PSYCHOPH, V31, P642, DOI 10.1016/j.pnpbp.2006.12.010; JACKSON G, 1991, BRIT MED J, V303, P533, DOI 10.1136/bmj.303.6802.533; Jia M, 2012, JOVE-J VIS EXP, DOI 10.3791/3361; Kanno M, 2003, J NEUROL SCI, V211, P5, DOI 10.1016/S0022-510X(03)00030-3; Keck ME, 2000, EUR J NEUROSCI, V12, P3713, DOI 10.1046/j.1460-9568.2000.00243.x; Khan S, 2004, PSYCHOPHARMACOLOGY, V172, P225, DOI 10.1007/s00213-003-1634-4; Kumari V, 2003, PSYCHIAT RES-NEUROIM, V122, P99, DOI 10.1016/s0925-4927(02)00123-3; Li YN, 2013, J MOL NEUROSCI, V51, P127, DOI 10.1007/s12031-013-9965-z; Liberzon I, 1999, J NEUROENDOCRINOL, V11, P11; Liberzon I, 1997, PSYCHONEUROENDOCRINO, V22, P443, DOI 10.1016/S0306-4530(97)00044-9; Marshall RD, 2001, AM J PSYCHIAT, V158, P1982, DOI 10.1176/appi.ajp.158.12.1982; McAuliffe JJ, 2009, ANESTHESIOLOGY, V111, P533, DOI 10.1097/ALN.0b013e3181b060d3; Meloni EG, 2000, J NEUROSCI, V20, P5374, DOI 10.1523/JNEUROSCI.20-14-05374.2000; Nemeroff CB, 2006, J PSYCHIATR RES, V40, P1, DOI 10.1016/j.jpsychires.2005.07.005; Neylan TC, 1999, BIOL PSYCHIAT, V46, P1656, DOI 10.1016/S0006-3223(99)00047-5; Ramos A, 2008, TRENDS PHARMACOL SCI, V29, P493, DOI 10.1016/j.tips.2008.07.005; Sailer U, 2008, NEUROPSYCHOLOGIA, V46, P2836, DOI 10.1016/j.neuropsychologia.2008.05.022; Sallinen J, 1998, J NEUROSCI, V18, P3035; Seo JH, 2013, MOL MED REP, V7, P389, DOI 10.3892/mmr.2012.1197; Stewart LP, 2008, DEPRESS ANXIETY, V25, P38, DOI 10.1002/da.20255; Swerdlow NR, 2013, NEUROPHARMACOLOGY, V75, P38, DOI 10.1016/j.neuropharm.2013.06.003; Swerdlow NR, 2013, BEHAV BRAIN RES, V257, P118, DOI 10.1016/j.bbr.2013.09.005; SWERDLOW NR, 1991, J PHARMACOL EXP THER, V256, P530; Takahashi K, 2007, BIOL PSYCHIAT, V62, P148, DOI 10.1016/j.biopsych.2006.06.035; Thorne GL, 2005, INT J PSYCHOPHYSIOL, V56, P121, DOI 10.1016/j.ijpsycho.2004.11.006; Tucker P, 2001, J CLIN PSYCHIAT, V62, P860, DOI 10.4088/JCP.v62n1105; Vasterling JJ, 1998, NEUROPSYCHOLOGY, V12, P125, DOI 10.1037/0894-4105.12.1.125; Wang HN, 2010, PHYSIOL RES, V59, P263, DOI 10.33549/physiolres.931756; Wang HY, 2011, J NEUROSCI, V31, P11044, DOI 10.1523/JNEUROSCI.2125-11.2011; Wang HN, 2014, J PSYCHIATR RES, V51, P79, DOI 10.1016/j.jpsychires.2014.01.004; Wang HN, 2009, PROG NEURO-PSYCHOPH, V33, P1458, DOI 10.1016/j.pnpbp.2009.07.031; Wang W, 2008, NEUROSCI LETT, V441, P237, DOI 10.1016/j.neulet.2008.06.031; Weiss SJ, 2007, PERSPECT PSYCHIATR C, V43, P114, DOI 10.1111/j.1744-6163.2007.00120.x; Wen L, 2014, J MOL NEUROSCI; Yamamoto S, 2009, DEPRESS ANXIETY, V26, P1110, DOI 10.1002/da.20629; Yeomans JS, 1995, BRAIN RES REV, V21, P301, DOI 10.1016/0165-0173(96)00004-5; Yue L, 2009, BRAIN RES, V1260, P94, DOI 10.1016/j.brainres.2009.01.009; Zelikowsky M, 2014, J NEUROSCI, V34, P8462, DOI 10.1523/JNEUROSCI.3624-13.2014; Zhao DM, 2014, J MOL NEUROSCI, V54, P147, DOI 10.1007/s12031-014-0263-1	61	17	18	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2015	10	2							e0117189	10.1371/journal.pone.0117189	http://dx.doi.org/10.1371/journal.pone.0117189			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CB2GK	25659132	gold, Green Published			2023-01-03	WOS:000349444900114
J	Rao, JK				Rao, Jaya K.			Engaging Public Health in End-of-Life Issues: It Is Time to Step Up to the Plate	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CARE		Amer Coll Physicians, Philadelphia, PA 19106 USA	American College of Physicians	Rao, JK (corresponding author), Amer Coll Physicians, 190 N Independence Mall West, Philadelphia, PA 19106 USA.	jrao@acponline.org						[Anonymous], 2014, AM IMPR QUAL HON IND; Committee on Care at the End of Life; Institute of Medicine, 1997, APPROACHING DEATH IM; D'Onofrio C, 2003, HASTINGS CENT REP, V33, pS30; Morhaim DK, 2013, AM J PUBLIC HEALTH, V103, pE8, DOI 10.2105/AJPH.2013.301316; Rao JK, 2014, AM J PREV MED, V46, P65, DOI 10.1016/j.amepre.2013.09.008; Rao JK, 2009, PREV CHRONIC DIS, V6; Rao JK, 2005, AM J PREV MED, V29, P453, DOI 10.1016/j.amepre.2005.08.014; Rao JK, 2002, AM J PREV MED, V23, P215, DOI 10.1016/S0749-3797(02)00500-7; Seaman JB, 2014, AM J HOSP PALLIAT CA	9	3	3	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 3	2015	162	3					230	U142		10.7326/M14-2479	http://dx.doi.org/10.7326/M14-2479			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CC1NP	25486456				2023-01-03	WOS:000350108100011
J	Monte, AA; Zane, RD; Heard, KJ				Monte, Andrew A.; Zane, Richard D.; Heard, Kennon J.			The Implications of Marijuana Legalization in Colorado	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MEDICAL MARIJUANA; CANNABINOIDS		[Monte, Andrew A.; Zane, Richard D.; Heard, Kennon J.] Univ Colorado, Dept Emergency Med, Aurora, CO 80045 USA; [Monte, Andrew A.; Heard, Kennon J.] Rocky Mt Poison & Drug Ctr, Denver, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus	Monte, AA (corresponding author), Univ Colorado, Dept Emergency Med, Leprino Bldg,Seventh Floor,Campus Box B-215, Aurora, CO 80045 USA.	andrew.monte@ucdenver.edu			NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K23GM110516] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R56DA038366] Funding Source: NIH RePORTER; NCATS NIH HHS [UL1 TR001082] Funding Source: Medline; NIDA NIH HHS [1R56DA038366-01, R56 DA038366] Funding Source: Medline; NIGMS NIH HHS [K23 GM110516, 1K23GM110516-01] Funding Source: Medline	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baca R, 2014, DENVER POST; Enforcement Division, MED LIC FAC; Esposito G, 2013, PHYTOTHER RES, V27, P633, DOI 10.1002/ptr.4781; Grotenhermen F, 2003, CLIN PHARMACOKINET, V42, P327, DOI 10.2165/00003088-200342040-00003; Hayes MJ, 2014, JAMA INTERN MED, V174, P1673, DOI 10.1001/jamainternmed.2014.2716; Nagarkatti P, 2009, FUTURE MED CHEM, V1, P1333, DOI 10.4155/FMC.09.93; Wang GS, 2013, JAMA PEDIATR, V167, P630, DOI 10.1001/jamapediatrics.2013.140	7	118	118	1	78	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	2015	313	3					241	242		10.1001/jama.2014.17057	http://dx.doi.org/10.1001/jama.2014.17057			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AZ3RS	25486283	Green Accepted			2023-01-03	WOS:000348145000010
J	Ekstrom, MP; Abernethy, AP; Currow, DC				Ekstrom, Magnus P.; Abernethy, Amy P.; Currow, David C.			The management of chronic breathlessness in patients with advanced and terminal illness	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CHRONIC HEART-FAILURE; CHRONIC DYSPNEA; DOUBLE-BLIND; OPIOIDS; PREVALENCE; INTENSITY; MORPHINE; RELIEF; OXYGEN; LIFE		[Ekstrom, Magnus P.] Lund Univ, Div Resp Med & Allergol, Dept Clin Sci, Lund, Sweden; [Ekstrom, Magnus P.; Currow, David C.] Flinders Univ S Australia, Discipline Palliat & Support Serv, Adelaide, SA 5001, Australia; [Abernethy, Amy P.] Duke Univ, Med Ctr, Dept Med, Div Med Oncol, Durham, NC 27710 USA	Lund University; Flinders University South Australia; Duke University	Ekstrom, MP (corresponding author), Blekinge Hosp, Dept Med, Resp Unit, Karlskrona, Sweden.	pmekstrom@gmail.com		Currow, David/0000-0003-1988-1250	Mundipharma; National Institute of Nursing Research; National Cancer Institute; Agency for Healthcare Research and Quality; DARA; Glaxo Smith Kline; Celgene; Helsinn; Dendreon; Pfizer; Genentech; Bristol Myers Squibb; Insys; Kanglaite; American Academy of Hospice & Palliative Medicine	Mundipharma; National Institute of Nursing Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); DARA; Glaxo Smith Kline(GlaxoSmithKline); Celgene(Bristol-Myers SquibbCelgene Corporation); Helsinn; Dendreon; Pfizer(Pfizer); Genentech(Roche HoldingGenentech); Bristol Myers Squibb(Bristol-Myers Squibb); Insys; Kanglaite; American Academy of Hospice & Palliative Medicine	We have read and understood the BMJ policy on declaration of interests and declare the following interests: DCC is on the clinical trials advisory board for Helsinn Pharmaceuticals, is a clinical trials consultant for MaynePharma, and has received research funding from Mundipharma. APA is on the scientific advisory boards for Bristol-Myers Squibb, is a consultant for Bristol-Myers Squibb, Novartis, and Pfizer, has received research funding from National Institute of Nursing Research, National Cancer Institute, Agency for Healthcare Research and Quality, DARA, Glaxo Smith Kline, Celgene, Helsinn, Dendreon, and Pfizer and is due to receive research funding from Genentech, Bristol Myers Squibb, Insys, and Kanglaite. APA has a paid leadership role with American Academy of Hospice & Palliative Medicine (president) and corporate leadership responsibility in Athena Health (health IT company), Advoset (an education company that has a contract with Novartis), and Orange Leaf Associates LLC (an IT development company).	Abernethy AP, 2010, LANCET, V376, P784, DOI 10.1016/S0140-6736(10)61115-4; Abernethy AP, 2003, BRIT MED J, V327, P523, DOI 10.1136/bmj.327.7414.523; Bausewein Claudia, 2010, BMC Palliat Care, V9, P22, DOI 10.1186/1472-684X-9-22; Bolton CE, 2013, THORAX, V68, pii1, DOI 10.1136/thoraxjnl-2013-203808; Campbell ML, 2013, J PAIN SYMPTOM MANAG, V45, P517, DOI 10.1016/j.jpainsymman.2012.02.012; Campbell ML, 2010, J PALLIAT MED, V13, P285, DOI 10.1089/jpm.2009.0229; Carone M, 2007, RESP MED, V101, P2447, DOI 10.1016/j.rmed.2007.07.016; Currow DC, 2011, J PAIN SYMPTOM MANAG, V42, P388, DOI 10.1016/j.jpainsymman.2010.11.021; Currow DC, 2010, J PAIN SYMPTOM MANAG, V39, P680, DOI 10.1016/j.jpainsymman.2009.09.017; Currow DC, 2009, J PAIN SYMPTOM MANAG, V38, P533, DOI 10.1016/j.jpainsymman.2009.01.006; Ekstrom MP, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g445; Higginson IJ, 2014, LANCET RESP MED; Jennings AL, 2002, THORAX, V57, P939, DOI 10.1136/thorax.57.11.939; Johnson MJ, 2013, J PAIN SYMPTOM MANAG, V46, P957, DOI 10.1016/j.jpainsymman.2013.01.011; Johnson MJ, 2013, EUR RESPIR J, V42, P758, DOI 10.1183/09031936.00139812; Johnson MJ, 2002, EUR J HEART FAIL, V4, P753, DOI 10.1016/S1388-9842(02)00158-7; Lecasse Y, 2006, COCHRANE DB SYST REV; Mahler DA, 2013, CHEST, V143, P1378, DOI 10.1378/chest.12-1541; Moens K, 2014, J PAIN SYMPTOM MANAG, V48, P660, DOI 10.1016/j.jpainsymman.2013.11.009; Nava S, 2013, LANCET ONCOL, V14, P219, DOI 10.1016/S1470-2045(13)70009-3; Nishimura K, 2002, CHEST, V121, P1434, DOI 10.1378/chest.121.5.1434; Oxberry SG, 2011, EUR J HEART FAIL, V13, P1006, DOI 10.1093/eurjhf/hfr068; Pedersen F, 2007, INT J CLIN PRACT, V61, P1481, DOI 10.1111/j.1742-1241.2007.01428.x; Pratter MR, 2011, RESP MED, V105, P1014, DOI 10.1016/j.rmed.2010.12.009; PRATTER MR, 1989, ARCH INTERN MED, V149, P2277, DOI 10.1001/archinte.149.10.2277; Schwartzstein RM, 2010, MURRAY NADELS TXB RE; Simon ST, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007354.pub2; Struik FM, 2013, COCHRANE DB SYST REV, V6; Uronis H, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006429.pub2	29	53	53	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 2	2015	349								g7617	10.1136/bmj.g7617	http://dx.doi.org/10.1136/bmj.g7617			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CX2ZF	25556037	Green Published			2023-01-03	WOS:000365564600002
J	Stock, MS; Thompson, BJ				Stock, Matt S.; Thompson, Brennan J.			Effects of Barbell Deadlift Training on Submaximal Motor Unit Firing Rates for the Vastus Lateralis and Rectus Femoris	PLOS ONE			English	Article							RECRUITMENT THRESHOLD; DISCHARGE RATE; STRENGTH; MUSCLE; ADAPTATIONS; STEADINESS; BEHAVIOR; YOUNG; SYNCHRONIZATION; DECOMPOSITION	Previous investigations that have studied motor unit firing rates following strength training have been limited to small muscles, isometric training, or interventions involving exercise machines. We examined the effects of ten weeks of supervised barbell deadlift training on motor unit firing rates for the vastus lateralis and rectus femoris during a 50% maximum voluntary contraction (MVC) assessment. Twenty-four previously untrained men (mean age 524 years) were randomly assigned to training (n = 15) or control (n = 9) groups. Before and following the intervention, the subjects performed isometric testing of the right knee extensors while bipolar surface electromyographic signals were detected from the two muscles. The signals were decomposed into their constituent motor unit action potential trains, and motor units that demonstrated accuracy levels less than 92.0% were not considered for analysis. One thousand eight hundred ninety-two and 2,013 motor units were examined for the vastus lateralis and rectus femoris, respectively. Regression analyses were used to determine the linear slope coefficients (pulses per second [pps]/% MVC) and y-intercepts (pps) of the mean firing rate and firing rate at recruitment versus recruitment threshold relationships. Deadlift training significantly improved knee extensor MVC force (Cohen's d = .70), but did not influence force steadiness. Training had no influence on the slopes and y-intercepts for the mean firing rate and firing rate at recruitment versus recruitment threshold relationships. In agreement with previous cross-sectional comparisons and randomized control trials, our findings do not support the notion that strength training affects the submaximal control of motor units.	[Stock, Matt S.; Thompson, Brennan J.] Texas Tech Univ, Muscular Assessment Lab, Lubbock, TX 79409 USA	Texas Tech University System; Texas Tech University	Stock, MS (corresponding author), Texas Tech Univ, Muscular Assessment Lab, Lubbock, TX 79409 USA.	matt.stock@ttu.edu	Stock, Matt S./G-8308-2018	Stock, Matt S./0000-0003-1156-1084; Thompson, Brennan/0000-0003-3534-8755				Aagaard P, 2002, J APPL PHYSIOL, V93, P1318, DOI 10.1152/japplphysiol.00283.2002; Adam A, 1998, J NEUROPHYSIOL, V80, P1373, DOI 10.1152/jn.1998.80.3.1373; Baechle T.R., 2008, ESSENTIALS STRENGTH; Beck TW, 2011, MUSCLE NERVE, V43, P245, DOI 10.1002/mus.21836; Beck TW., 2011, CLIN KINESIOL, V65, P1; Bilodeau M, 2000, MUSCLE NERVE, V23, P771, DOI 10.1002/(SICI)1097-4598(200005)23:5<771::AID-MUS15>3.0.CO;2-9; Cohen J., 2013, STAT POWER ANAL BEHA; De Luca CJ, 2006, J NEUROPHYSIOL, V96, P1646, DOI 10.1152/jn.00009.2006; De Luca CJ, 2012, J NEUROPHYSIOL, V107, P178, DOI 10.1152/jn.00961.2010; De Luca CJ, 2010, J NEUROPHYSIOL, V104, P1034, DOI 10.1152/jn.01018.2009; DE LUCA CJ, 1982, J PHYSIOL-LONDON, V329, P113, DOI 10.1113/jphysiol.1982.sp014293; DE LUCA CJ, 1982, J PHYSIOL-LONDON, V329, P129, DOI 10.1113/jphysiol.1982.sp014294; Defreitas JM, 2014, MUSCLE NERVE, V49, P575, DOI 10.1002/mus.23978; Dideriksen JL, 2012, J NEUROPHYSIOL, V107, P3357, DOI 10.1152/jn.00938.2011; Duchateau J, 2006, J APPL PHYSIOL, V101, P1766, DOI 10.1152/japplphysiol.00543.2006; Erim Z, 1996, MUSCLE NERVE, V19, P563, DOI 10.1002/(SICI)1097-4598(199605)19:5<563::AID-MUS3>3.0.CO;2-9; Escamilla RF, 2000, MED SCI SPORT EXER, V32, P1265, DOI 10.1097/00005768-200007000-00013; Escamilla RF, 2002, MED SCI SPORT EXER, V34, P682, DOI 10.1097/00005768-200204000-00019; Gabriel DA, 2006, SPORTS MED, V36, P133, DOI 10.2165/00007256-200636020-00004; Hu XG, 2014, J NEURAL ENG, V11, DOI 10.1088/1741-2560/11/2/026015; Hu XG, 2012, IEEE ENG MED BIO, P4116, DOI 10.1109/EMBC.2012.6346872; JOHNSON MA, 1973, J NEUROL SCI, V18, P111, DOI 10.1016/0022-510X(73)90023-3; Kamen G, 2004, J GERONTOL A-BIOL, V59, P1334, DOI 10.1093/gerona/59.12.1334; KEEN DA, 1994, J APPL PHYSIOL, V77, P2648, DOI 10.1152/jappl.1994.77.6.2648; Kidgell DJ, 2006, EXP BRAIN RES, V175, P745, DOI 10.1007/s00221-006-0724-z; KRAEMER WJ, 1995, J APPL PHYSIOL, V78, P976, DOI 10.1152/jappl.1995.78.3.976; Laidlaw DH, 1999, J APPL PHYSIOL, V87, P1786, DOI 10.1152/jappl.1999.87.5.1786; MORITANI T, 1979, AM J PHYS MED REHAB, V58, P115; Nawab SH, 2010, CLIN NEUROPHYSIOL, V121, P1602, DOI 10.1016/j.clinph.2009.11.092; Patten C, 2000, EUR J APPL PHYSIOL, V83, P128, DOI 10.1007/s004210000271; Patten C, 2001, MUSCLE NERVE, V24, P542, DOI 10.1002/mus.1038; Ratamess NA, 2009, MED SCI SPORT EXER, V41, P687, DOI 10.1249/MSS.0b013e3181915670; Rich C, 2000, MED SCI SPORT EXER, V32, P190; Rutherford OM, 1986, J SPORT SCI, V4, P101, DOI 10.1080/02640418608732105; STARON RS, 1994, J APPL PHYSIOL, V76, P1247, DOI 10.1152/jappl.1994.76.3.1247; Stevens J. P., 2007, INTERMEDIATE STAT MO; Stock MS, 2012, MUSCLE NERVE, V45, P100, DOI 10.1002/mus.22266; TANJI J, 1973, EXP NEUROL, V40, P771, DOI 10.1016/0014-4886(73)90111-8; Vila-Cha C, 2010, J APPL PHYSIOL, V109, P1455, DOI 10.1152/japplphysiol.01213.2009; Weir JP, 2005, J STRENGTH COND RES, V19, P231, DOI 10.1519/15184.1; Zaheer F, 2012, PHYSIOL MEAS, V33, P195, DOI 10.1088/0967-3334/33/2/195	41	13	13	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 22	2014	9	12							e115567	10.1371/journal.pone.0115567	http://dx.doi.org/10.1371/journal.pone.0115567			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA3ZY	25531294	Green Published, gold, Green Submitted			2023-01-03	WOS:000348845100077
J	Wiegersma, M; Panman, CMCR; Kollen, BJ; Berger, MY; Lisman-Van Leeuwen, Y; Dekker, JH				Wiegersma, Marian; Panman, Chantal M. C. R.; Kollen, Boudewijn J.; Berger, Marjolein Y.; Lisman-Van Leeuwen, Yvonne; Dekker, Janny H.			Effect of pelvic floor muscle training compared with watchful waiting in older women with symptomatic mild pelvic organ prolapse: randomised controlled trial in primary care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SHORT-FORM; BASE-LINE; TERMINOLOGY; DISORDERS; STANDARDIZATION; PREVALENCE; MANAGEMENT; PFDI-20	Objective To compare the effects of pelvic floor muscle training and watchful waiting on pelvic floor symptoms in a primary care population of women aged 55 years and over with symptomatic mild pelvic organ prolapse. Design Randomised controlled trial. Setting Dutch primary care. Participants Women aged 55 years or over with symptomatic mild prolapse (leading edge above the hymen) were identified by screening. Exclusion criteria were current prolapse treatment or treatment in the previous year, malignancy of pelvic organs, current treatment for another gynaecological disorder, severe/terminal illness, impaired mobility, cognitive impairment, and insufficient command of the Dutch language. Interventions Pelvic floor muscle training versus watchful waiting. Main outcome measures The primary outcome was change in bladder, bowel, and pelvic floor symptoms measured with the Pelvic Floor Distress Inventory-20 (PFDI-20), three months after the start of treatment. Secondary outcomes were changes in condition specific and general quality of life, sexual function, degree of prolapse, pelvic floor muscle function, and patients' perceived change in symptoms. Results Of the 287 women who were randomised to pelvic floor muscle training (n= 145) or watchful waiting (n= 142), 250 (87%) completed follow-up. Participants in the intervention group improved by (on average) 9.1 (95% confidence interval 2.8 to 15.4) points more on the PFDI-20 than did participants in the watchful waiting group (P= 0.005). Of women in the pelvic floor muscle training group, 57% (82/145) reported an improvement in overall symptoms from the start of the study compared with 1(% (18/142) in the watchful waiting group (P< 0.001). Other secondary outcomes showed no significant difference between the groups. Conclusions Although pelvic floor muscle training led to a significantly greater improvement in PFDI-20 score, the difference between the groups was below the presumed level of clinical relevance (15 points). Nevertheless, 57% of the participants in the intervention group reported an improvement of overall symptoms. More studies are needed to identify factors related to success of pelvic floor muscle training and to investigate long term effects.	[Wiegersma, Marian; Panman, Chantal M. C. R.; Kollen, Boudewijn J.; Berger, Marjolein Y.; Lisman-Van Leeuwen, Yvonne; Dekker, Janny H.] Univ Groningen, Univ Med Ctr Groningen, Dept Gen Practice, NL-9700 AD Groningen, Netherlands	University of Groningen	Dekker, JH (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Gen Practice, FA21,POB 196, NL-9700 AD Groningen, Netherlands.	j.h.dekker@umcg.nl		Dekker, Janny/0000-0001-5005-9324; Lisman-van Leeuwen, Yvonne/0000-0003-4126-526X	Netherlands Organization for Health Research and Development (ZonMw) [4201.1001]	Netherlands Organization for Health Research and Development (ZonMw)(Netherlands Organization for Health Research and Development)	This trial is funded by the Netherlands Organization for Health Research and Development (ZonMw), project number 4201.1001. The funder played no role in the study design; in the collection, analysis, and interpretation of data; or in the writing of the report and the decision to submit the article for publication. All researchers were independent from funders.	Barber MD, 2005, AM J OBSTET GYNECOL, V193, P103, DOI 10.1016/j.ajog.2004.12.025; Bo K, 2006, ACTA OBSTET GYN SCAN, V85, P263, DOI 10.1080/00016340500486800; Braekken IH, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.02.037; Bump RC, 1996, AM J OBSTET GYNECOL, V175, P10, DOI 10.1016/S0002-9378(96)70243-0; Burrows LJ, 2004, OBSTET GYNECOL, V104, P982, DOI 10.1097/01.AOG.0000142708.61298.be; Culligan PJ, 2010, INT UROGYNECOL J, V21, P401, DOI 10.1007/s00192-009-1046-z; de Boer TA, 2010, NEUROUROL URODYNAM, V29, P30, DOI 10.1002/nau.20858; Gelhorn HL, 2012, FEMALE PELVIC MED RE, V18, P221, DOI 10.1097/SPV.0b013e31825e6707; Ghroubi S., 2008, Annales de Readaptation et de Medecine Physique, V51, P96, DOI 10.1016/j.annrmp.2007.11.002; Gutman RE, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.07.028; Hagen S, 2010, NEUROUROL URODYNAM, V29, P1055; Hagen S, 2014, LANCET, V383, P796, DOI 10.1016/S0140-6736(13)61977-7; Hagen S, 2009, INT UROGYNECOL J, V20, P45, DOI 10.1007/s00192-008-0726-4; Haylen BT, 2010, NEUROUROL URODYNAM, V29, P4, DOI 10.1002/nau.20798; Kashyap R, 2013, INT J GYNECOL OBSTET, V121, P69, DOI 10.1016/j.ijgo.2012.11.012; Messelink B, 2005, NEUROUROL URODYNAM, V24, P374, DOI 10.1002/nau.20144; Nygaard I, 2008, JAMA-J AM MED ASSOC, V300, P1311, DOI 10.1001/jama.300.11.1311; Piya-Anant Manee, 2003, Journal of the Medical Association of Thailand, V86, P509; Revicki D, 2008, J CLIN EPIDEMIOL, V61, P102, DOI 10.1016/j.jclinepi.2007.03.012; Rogers RG, 2003, INT UROGYNECOL J PEL, V14, P164, DOI 10.1007/s00192-003-1063-2; Romanzi LJ, 1999, J UROLOGY, V161, P581, DOI 10.1016/S0022-5347(01)61957-8; Slieker-ten Hove MCP, 2009, INT UROGYNECOL J, V20, P1037, DOI 10.1007/s00192-009-0902-1; Smith Phillip P, 2005, Curr Urol Rep, V6, P340, DOI 10.1007/s11934-005-0050-1; Stupp L, 2011, INT UROGYNECOL J, V22, P1233, DOI 10.1007/s00192-011-1428-x; Swift S, 2005, AM J OBSTET GYNECOL, V192, P795, DOI 10.1016/j.ajog.2004.10.602; Thakar R, 2002, BRIT MED J, V324, P1258, DOI 10.1136/bmj.324.7348.1258; Utomo E, 2014, INT UROGYNECOL J, V25, P531, DOI 10.1007/s00192-013-2263-z; Vickers AJ, 2001, BMJ-BRIT MED J, V323, P1123, DOI 10.1136/bmj.323.7321.1123; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Ware John E., 2002, SF 12V2TM SCORE VERS; Wiegersma M, 2014, MATURITAS, V77, P168, DOI 10.1016/j.maturitas.2013.10.014; Wu JM, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.03.046	32	48	50	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 22	2014	349								g7378	10.1136/bmj.g7378	http://dx.doi.org/10.1136/bmj.g7378			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AY2UG	25533442	Green Published, hybrid			2023-01-03	WOS:000347443900001
J	Cao, HD; Ye, H; Sun, ZP; Shen, X; Song, ZW; Wu, XC; He, WC; Dai, CS; Yang, JW				Cao, Hongdi; Ye, Hong; Sun, Zhiping; Shen, Xia; Song, Zongwei; Wu, Xiaochun; He, Weichun; Dai, Chunsun; Yang, Junwei			Circulatory Mitochondrial DNA Is a Pro-Inflammatory Agent in Maintenance Hemodialysis Patients	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; CELL-FREE DNA; CARDIOVASCULAR RISK; PLASMA; MORTALITY; SURVIVAL; SEPSIS; INJURY; DYSFUNCTION; FAILURE	Chronic inflammation is highly prevalent in maintenance hemodialysis (MHD) patients, and it has been shown to be a strong predictor of morbidity and mortality. Mitochondrial DNA (mtDNA) released into circulation after cell damage can promote inflammation in patients and animal models. However, the role and mechanisms of circulatory mtDNA in chronic inflammation in MHD patients remain unknown. Sixty MHD patients and 20 health controls were enrolled in this study. The circulatory mtDNA was detected by quantitative real-time PCR assay. Plasma interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) were quantitated by ELISA assay. Dialysis systems in MHD patients and in vitro were used to evaluate the effect of different dialysis patterns on circulatory mtDNA. Circulatory mtDNA was elevated in MHD patients comparing to that of health control. Regression analysis demonstrated that plasma mtDNA was positively associated with TNF-a and the product of serum calcium and phosphorus, while negatively associated with hemoglobin and serum albumin in MHD patients. MtDNA induced the secretion of IL-6 and TNF-alpha in the THP-1 cells. Single high-flux hemodialysis (HF-HD) and on line hemodiafiltration (OL-HDF) but not low-flux hemodialysis (LF-HD) could partially reduce plasma mtDNA in MHD patients. In vitro, both HD and hemofiltration (HF) could fractional remove mtDNA. Collectively, circulatory mtDNA is elevated and its level is closely correlated with chronic inflammation in MHD patients. HF-HD and HDF can partially reduce circulatory mtDNA in MHD patients.	[Cao, Hongdi; Ye, Hong; Sun, Zhiping; Shen, Xia; Song, Zongwei; Wu, Xiaochun; He, Weichun; Dai, Chunsun; Yang, Junwei] Nanjing Med Univ, Affiliated Hosp 2, Ctr Kidney Dis, Nanjing, Jiangsu, Peoples R China	Nanjing Medical University	Yang, JW (corresponding author), Nanjing Med Univ, Affiliated Hosp 2, Ctr Kidney Dis, Nanjing, Jiangsu, Peoples R China.	jwyang@njmu.edu.cn			Jiangsu Province's Science and Technology Programs of Construction; People's Livelihood [BL2013037]; Nanjing Medical University	Jiangsu Province's Science and Technology Programs of Construction; People's Livelihood; Nanjing Medical University	This work was supported by Jiangsu Province's Science and Technology Programs of Construction and the People's Livelihood (BL2013037) to Junwei Yang. Hongdi Cao was supported by the Yong fellowship from the Nanjing Medical University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arizono K, 2004, BLOOD PURIFICAT, V22, P26, DOI 10.1159/000081870; Atamaniuk J, 2012, NEPHROL DIAL TRANSPL, V27, P902, DOI 10.1093/ndt/gfr695; BRAND K, 1991, MOL CELL BIOL, V11, P4732, DOI 10.1128/MCB.11.9.4732; Caglar K, 2002, KIDNEY INT, V62, P1408, DOI 10.1111/j.1523-1755.2002.kid556.x; Che RC, 2014, AM J PHYSIOL-RENAL, V306, pF367, DOI 10.1152/ajprenal.00571.2013; Chiu RWK, 2003, CLIN CHEM, V49, P719, DOI 10.1373/49.5.719; Cunningham J, 2011, CLIN J AM SOC NEPHRO, V6, P913, DOI 10.2215/CJN.06040710; Duranton F, 2012, J AM SOC NEPHROL, V23, P1258, DOI 10.1681/ASN.2011121175; Hung A, 2008, HEMODIAL INT, V12, P236, DOI 10.1111/j.1542-4758.2008.00260.x; Hung AM, 2011, J AM SOC NEPHROL, V22, P437, DOI 10.1681/ASN.2010070760; Jourde-Chiche N, 2009, SEMIN DIALYSIS, V22, P334, DOI 10.1111/j.1525-139X.2009.00576.x; Kimmel PL, 1998, KIDNEY INT, V54, P236, DOI 10.1046/j.1523-1755.1998.00981.x; Korabecna M, 2012, EXPERT OPIN BIOL TH, V12, pS27, DOI 10.1517/14712598.2012.676034; Krauss S, 2003, J CLIN INVEST, V112, P1831, DOI 10.1172/JCI200319774; Kung CT, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-130; Levey AS, 2003, ANN INTERN MED, V139, P137, DOI 10.7326/0003-4819-139-2-200307150-00013; Malaponte G, 2002, NEPHROL DIAL TRANSPL, V17, P1964, DOI 10.1093/ndt/17.11.1964; Morena Marion, 2005, Hemodial Int, V9, P37, DOI 10.1111/j.1492-7535.2005.01116.x; Nakahira K, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001577; Nolan CR, 2005, J AM SOC NEPHROL, V16, pS120, DOI 10.1681/ASN.2005060662; Oka T, 2012, NATURE, V485, P251, DOI 10.1038/nature10992; Puskarich MA, 2012, SHOCK, V38, P337, DOI 10.1097/SHK.0b013e318266a169; Rao M, 2009, J AM SOC NEPHROL, V20, P189, DOI 10.1681/ASN.2007091031; Stenvinkel P, 2002, KIDNEY INT, V62, P1791, DOI 10.1046/j.1523-1755.2002.00637.x; Stenvinkel P, 2008, CLIN J AM SOC NEPHRO, V3, P505, DOI 10.2215/CJN.03670807; Sun SQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059989; Sursal T, 2013, SHOCK, V39, P55, DOI 10.1097/SHK.0b013e318276f4ca; Taanman JW, 1999, BBA-BIOENERGETICS, V1410, P103, DOI 10.1016/S0005-2728(98)00161-3; Tovbin D, 2012, NEPHROL DIAL TRANSPL, V27, P3929, DOI 10.1093/ndt/gfs255; Tsai NW, 2011, CLIN CHIM ACTA, V412, P476, DOI 10.1016/j.cca.2010.11.036; Zhang LX, 2012, LANCET, V379, P815, DOI 10.1016/S0140-6736(12)60033-6; Zhang Q, 2010, SHOCK, V34, P55, DOI 10.1097/SHK.0b013e3181cd8c08; Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780; Zimmermann J, 1999, KIDNEY INT, V55, P648, DOI 10.1046/j.1523-1755.1999.00273.x	34	41	42	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 8	2014	9	12							e113179	10.1371/journal.pone.0113179	http://dx.doi.org/10.1371/journal.pone.0113179			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX4MX	25485699	Green Submitted, gold, Green Published			2023-01-03	WOS:000346907600015
J	Gong, XC; Zhang, Y; Pan, JY; Qu, HB				Gong, Xingchu; Zhang, Ying; Pan, Jianyang; Qu, Haibin			Optimization of the Ethanol Recycling Reflux Extraction Process for Saponins Using a Design Space Approach	PLOS ONE			English	Article							PANAX-NOTOGINSENG; MAILLARD REACTION; SUGAR; WATER; PRECIPITATION; QUALITY; TRANSFORMATION; CHROMATOGRAPHY; GINSENOSIDES; COMPONENTS	A solvent recycling reflux extraction process for Panax notoginseng was optimized using a design space approach to improve the batch-to-batch consistency of the extract. Saponin yields, total saponin purity, and pigment yield were defined as the process critical quality attributes (CQAs). Ethanol content, extraction time, and the ratio of the recycling ethanol flow rate and initial solvent volume in the extraction tank (RES) were identified as the critical process parameters (CPPs) via quantitative risk assessment. Box-Behnken design experiments were performed. Quadratic models between CPPs and process CQAs were developed, with determination coefficients higher than 0.88. As the ethanol concentration decreases, saponin yields first increase and then decrease. A longer extraction time leads to higher yields of the ginsenosides Rb-1 and Rd. The total saponin purity increases as the ethanol concentration increases. The pigment yield increases as the ethanol concentration decreases or extraction time increases. The design space was calculated using a Monte-Carlo simulation method with an acceptable probability of 0.90. Normal operation ranges to attain process CQA criteria with a probability of more than 0.914 are recommended as follows: ethanol content of 79-82%, extraction time of 6.1-7.1 h, and RES of 0.039-0.040 min(-1). Most of the results of the verification experiments agreed well with the predictions. The verification experiment results showed that the selection of proper operating ethanol content, extraction time, and RES within the design space can ensure that the CQA criteria are met.	[Gong, Xingchu; Zhang, Ying; Pan, Jianyang; Qu, Haibin] Zhejiang Univ, Coll Pharmaceut Sci, Pharmaceut Informat Inst, Hangzhou 310058, Zhejiang, Peoples R China	Zhejiang University	Qu, HB (corresponding author), Zhejiang Univ, Coll Pharmaceut Sci, Pharmaceut Informat Inst, Hangzhou 310058, Zhejiang, Peoples R China.	quhb@zju.edu.cn			National S&T Major Project of China [2012ZX09101201-003]; Research Fund for the Doctoral Program of Higher Education of China [20110101120149]	National S&T Major Project of China; Research Fund for the Doctoral Program of Higher Education of China(Research Fund for the Doctoral Program of Higher Education of China (RFDP)Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP))	This work was supported by the National S&T Major Project of China (2012ZX09101201-003) and Research Fund for the Doctoral Program of Higher Education of China (20110101120149). Haibin Qu received the first fund. The website is (http://www.most.gov.cn/). Xingchu Gong received the second fund. The website is (http://www.cutech.edu.cn/cn/kyjj/gdxxbsdkyjj/A010301index_1.htm). Funds were used to buy materials, chemicals, and pay labor costs. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], [No title captured]; Bai Changcai, 2009, Zhongguo Zhong Yao Za Zhi, V34, P677; Bouchard A, 2007, J CHEM ENG DATA, V52, P1838, DOI 10.1021/je700190m; Chen J., 2013, CHINESE J EXPT TRADI, V19, P59; Coca M, 2004, FOOD CHEM, V86, P421, DOI 10.1016/j.foodchem.2003.09.017; Davidek T, 2006, J AGR FOOD CHEM, V54, P6677, DOI 10.1021/jf060668i; Debrus B, 2011, ANAL CHIM ACTA, V691, P33, DOI 10.1016/j.aca.2011.02.035; Dong TTX, 2005, PHYTOTHER RES, V19, P684, DOI 10.1002/ptr.1728; Gong XC, 2014, SEP PURIF TECHNOL, V132, P126, DOI 10.1016/j.seppur.2014.05.014; Gong XC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104493; Gong XC, 2013, SEP PURIF TECHNOL, V107, P273, DOI 10.1016/j.seppur.2013.01.029; Gong XC, 2012, J CHEM ENG DATA, V57, P3264, DOI 10.1021/je300885g; Gong XC, 2011, IND ENG CHEM RES, V50, P7542, DOI 10.1021/ie2004972; Gong XC, 2011, CHINESE J CHEM ENG, V19, P217, DOI 10.1016/S1004-9541(11)60157-2; ICH, 2009, PHARM DEV Q8 R2; Kim JS, 2008, FOOD CHEM, V108, P582, DOI 10.1016/j.foodchem.2007.11.014; Lebrun P, 2012, EUR J PHARM BIOPHARM, V80, P226, DOI 10.1016/j.ejpb.2011.09.014; Li SP, 2013, J CHROMATOGR A, V1313, P302, DOI 10.1016/j.chroma.2013.07.025; Li SX, 2013, J AGR FOOD CHEM, V61, P10599, DOI 10.1021/jf402993a; Li ZX, 2009, PHARM ENG DESIGN, V30, P35; Nistor I, 2013, J PHARMACEUT BIOMED, V74, P273, DOI 10.1016/j.jpba.2012.10.015; Peterson JJ, 2008, J BIOPHARM STAT, V18, P959, DOI 10.1080/10543400802278197; Qu Lin-hai, 2006, Zhong Yao Cai, V29, P593; Rozet E, 2013, TRAC-TREND ANAL CHEM, V42, P157, DOI 10.1016/j.trac.2012.09.007; Rozet E, 2012, BIOANALYSIS, V4, P755, DOI [10.4155/bio.12.47, 10.4155/BIO.12.47]; Sun S, 2011, FOOD CHEM, V125, P1299, DOI 10.1016/j.foodchem.2010.10.049; Sun S, 2010, FOOD CHEM, V118, P307, DOI 10.1016/j.foodchem.2009.04.122; Tsavas P, 2004, IND ENG CHEM RES, V43, P8391, DOI 10.1021/ie049353n; Wan JB, 2006, J PHARMACEUT BIOMED, V41, P1596, DOI 10.1016/j.jpba.2006.01.058; Wang D, 2012, FOOD CHEM, V132, P1808, DOI 10.1016/j.foodchem.2011.12.010; Wang LL, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/652373; Wang YT, 2008, FOOD CHEM, V110, P161, DOI 10.1016/j.foodchem.2008.01.028; Wu M, 2013, J JIANGXI U TCM, V25, P66; Wu W, 2012, J AGR FOOD CHEM, V60, P10007, DOI 10.1021/jf302638f; Yang G., 2012, CHIN MED J RES PRAC, V26, P29; Yu LX, 2008, PHARM RES, V25, P781, DOI 10.1007/s11095-007-9511-1; Zhang L, 2013, AAPS PHARMSCITECH, V14, P277, DOI 10.1208/s12249-012-9919-8; [赵永亮 Zhao Yongliang], 2011, [中南大学学报. 自然科学版, Journal of Central South University of Science and Technology], V42, P38; Zhu JQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087462	39	13	21	0	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 3	2014	9	12							e114300	10.1371/journal.pone.0114300	http://dx.doi.org/10.1371/journal.pone.0114300			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA7WS	25470598	Green Published, Green Submitted, gold			2023-01-03	WOS:000349128700098
J	Zitt, E; Sturm, G; Kronenberg, F; Neyer, U; Knoll, F; Lhotta, K; Weiss, G				Zitt, Emanuel; Sturm, Gisela; Kronenberg, Florian; Neyer, Ulrich; Knoll, Florian; Lhotta, Karl; Weiss, Guenter			Iron Supplementation and Mortality in Incident Dialysis Patients: An Observational Study	PLOS ONE			English	Article							ERYTHROPOIESIS-STIMULATING AGENTS; INTRAVENOUS IRON; HEMODIALYSIS-PATIENTS; BACTERIAL-INFECTIONS; PARENTERAL IRON; RISK-FACTORS; ANEMIA; OVERLOAD; BACTEREMIA; TIME	Background: Studies on the association between iron supplementation and mortality in dialysis patients are rare and conflicting. Methods: In our observational single-center cohort study (INVOR study) we prospectively studied 235 incident dialysis patients. Time-dependent Cox proportional hazards models using all measured laboratory values for up to 7.6 years were applied to study the association between iron supplementation and all-cause mortality, cardiovascular and sepsis-related mortality. Furthermore, the time-dependent association of ferritin levels with mortality in patients with normal C-reactive protein (CRP) levels (<0.5 mg/dL) and elevated CRP levels (>= 0.5 mg/dL) was evaluated by using non-linear P-splines to allow flexible modeling of the association. Results: One hundred and ninety-one (81.3%) patients received intravenous iron, 13 (5.5%) patients oral iron, whereas 31 (13.2%) patients were never supplemented with iron throughout the observation period. Eighty-two (35%) patients died during a median follow-up of 34 months, 38 patients due to cardiovascular events and 21 patients from sepsis. Baseline CRP levels were not different between patients with and without iron supplementation. However, baseline serum ferritin levels were lower in patients receiving iron during follow up (median 93 vs 251 ng/mL, p<0.001). Iron supplementation was associated with a significantly reduced all-cause mortality [HR (95% CI): 0.22 (0.08-0.58); p=0.002] and a reduced cardiovascular and sepsis-related mortality [HR (95% CI): 0.31 (0.09-1.04); p=0.06]. Increasing ferritin concentrations in patients with normal CRP were associated with a decreasing mortality, whereas in patients with elevated CRP values ferritin levels>800 ng/mL were linked with increased mortality. Conclusions: Iron supplementation is associated with reduced all-cause mortality in incident dialysis patients. While serum ferritin levels up to 800 ng/mL appear to be safe, higher ferritin levels are associated with increased mortality in the setting of concomitant inflammation.	[Zitt, Emanuel; Knoll, Florian; Lhotta, Karl] Feldkirch Acad Teaching Hosp, Dept Nephrol & Dialysis, Feldkirch, Austria; [Zitt, Emanuel; Neyer, Ulrich; Lhotta, Karl] Vorarlberg Inst Vasc Invest & Treatment, Feldkirch, Austria; [Sturm, Gisela] Med Univ Innsbruck, Dept Dermatol & Venereol, A-6020 Innsbruck, Austria; [Sturm, Gisela; Kronenberg, Florian] Med Univ Innsbruck, Dept Med Genet Mol & Clin Pharmacol, Div Genet Epidemiol, A-6020 Innsbruck, Austria; [Weiss, Guenter] Med Univ Innsbruck, Dept Internal Med 4, A-6020 Innsbruck, Austria	Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck	Lhotta, K (corresponding author), Feldkirch Acad Teaching Hosp, Dept Nephrol & Dialysis, Feldkirch, Austria.	karl.lhotta@lkhf.at; guenter.weiss@i-med.ac.at	Kronenberg, Florian/B-1736-2008; Zitt, Emanuel/ABE-1926-2020	Kronenberg, Florian/0000-0003-2229-1120; Zitt, Emanuel/0000-0001-6944-6041; Knoll, Florian/0000-0001-5357-8656; Weiss, Guenter/0000-0003-0709-2158	Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT); Austrian National Bank [13662]; Austrian Science Fund FWF [TRP-188]	Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT); Austrian National Bank; Austrian Science Fund FWF(Austrian Science Fund (FWF))	This study was supported by a grant from Hans Drexel to the Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT to KL) and by a grant from the Austrian National Bank (Project 13662 to FK) and the Austrian Science Fund FWF (TRP-188 to GW). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anemia Work Group, 2012, KIDNEY INT, V2, P279, DOI [DOI 10.1038/kisup.2012.37, DOI 10.1093/NDT/GFT033.13]; Bailie GR, 2015, KIDNEY INT, V87, P162, DOI 10.1038/ki.2014.275; Bailie GR, 2013, NEPHROL DIAL TRANSPL, V28, P2570, DOI 10.1093/ndt/gft062; Besarab A, 2000, J AM SOC NEPHROL, V11, P530, DOI 10.1681/ASN.V113530; BOELAERT JR, 1990, NEPHROL DIAL TRANSPL, V5, P130, DOI 10.1093/ndt/5.2.130; Brewster UC, 2004, SEMIN DIALYSIS, V17, P57; Brookhart MA, 2013, J AM SOC NEPHROL, V24, P1151, DOI 10.1681/ASN.2012121164; Canavese C, 2004, KIDNEY INT, V65, P1091, DOI 10.1111/j.1523-1755.2004.00480.x; Carrera F, 2010, NEPHROL DIAL TRANSPL, V25, P4009, DOI 10.1093/ndt/gfq305; Deicher R, 2003, KIDNEY INT, V64, P728, DOI 10.1046/j.1523-1755.2003.00125.x; Deicher R, 2003, CURR OPIN NEPHROL HY, V12, P139, DOI 10.1097/00041552-200303000-00003; Eschbach JW, 1999, KIDNEY INT, V55, pS35, DOI 10.1046/j.1523-1755.1999.055Suppl.69035.x; Feldman HI, 2004, J AM SOC NEPHROL, V15, P1623, DOI 10.1097/01.ASN.0000128009.69594.BE; Feldman HI, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133734; Fell LH, 2014, NEPHROL DIAL TRANSPL, V29, P809, DOI 10.1093/ndt/gft524; Ferrari P, 2011, CLIN J AM SOC NEPHRO, V6, P77, DOI 10.2215/CJN.04190510; Goch J, 1996, NEPHRON, V73, P403; Goodnough LT, 2010, BLOOD, V116, P4754, DOI 10.1182/blood-2010-05-286260; Gupta A, 2010, BMC NEPHROL, V11, DOI 10.1186/1471-2369-11-16; Hoen B, 1998, J AM SOC NEPHROL, V9, P869; HOEN B, 1995, NEPHROL DIAL TRANSPL, V10, P377; Horl WH, 2007, J AM SOC NEPHROL, V18, P382, DOI 10.1681/ASN.2006080856; Horl WH, 2013, NAT REV NEPHROL, V9, P291, DOI 10.1038/nrneph.2013.21; Horl WH, 2005, WIEN KLIN WOCHENSCHR, V117, P69, DOI 10.1007/s00508-005-0486-9; Kalantar-Zadeh K, 2005, J AM SOC NEPHROL, V16, P3070, DOI 10.1681/ASN.2005040423; KESSLER M, 1993, NEPHRON, V64, P95, DOI 10.1159/000187285; Knovich MA, 2009, BLOOD REV, V23, P95, DOI 10.1016/j.blre.2008.08.001; Koch K M, 1976, Proc Eur Dial Transplant Assoc, V12, P362; Koskenkorva-Frank TS, 2013, FREE RADICAL BIO MED, V65, P1174, DOI 10.1016/j.freeradbiomed.2013.09.001; Koulouridis I, 2013, AM J KIDNEY DIS, V61, P44, DOI 10.1053/j.ajkd.2012.07.014; Kshirsagar AV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078930; Lindsay R M, 1973, Clin Nephrol, V1, P24; Litton E, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f4822; Macdougall IC, 2008, CLIN J AM SOC NEPHRO, V3, P200, DOI 10.2215/CJN.03840907; Macdougall IC, 2013, IRAN J KIDNEY DIS, V7, P9; Meuwese CL, 2011, NEPHROL DIAL TRANSPL, V26, P1313, DOI 10.1093/ndt/gfq557; Nairz M, 2013, J EXP MED, V210, P855, DOI 10.1084/jem.20121946; Nairz M, 2010, CELL MICROBIOL, V12, P1691, DOI 10.1111/j.1462-5822.2010.01529.x; Oexle H, 2003, J LEUKOCYTE BIOL, V74, P287, DOI 10.1189/jlb.0802420; Patruta SI, 1998, J AM SOC NEPHROL, V9, P655; Rostoker G, 2012, AM J MED, V125, P991, DOI 10.1016/j.amjmed.2012.01.015; SEIFERT A, 1987, Q J MED, V65, P1015; Sengoelge G, 2003, J AM SOC NEPHROL, V14, P2639, DOI 10.1097/01.ASN.0000087087.61306.4A; Sonnweber T, 2011, NEPHROL DIAL TRANSPL, V26, P977, DOI 10.1093/ndt/gfq483; Stevens PE, 2012, J RENAL CARE, V38, P67, DOI 10.1111/j.1755-6686.2012.00281.x; Sturm G, 2010, NEPHROL DIAL TRANSPL, V25, P2715, DOI 10.1093/ndt/gfq101; Szczech LA, 2008, KIDNEY INT, V74, P791, DOI 10.1038/ki.2008.295; Teehan GS, 2004, CLIN INFECT DIS, V38, P1090, DOI 10.1086/382878; Thomas Christian, 2005, Lab Hematol, V11, P14, DOI 10.1532/LH96.04049; TIELEMANS CL, 1989, NEPHROL DIAL TRANSPL, V4, P883, DOI 10.1093/ndt/4.10.883; Tovbin D, 2002, AM J KIDNEY DIS, V40, P1005, DOI 10.1053/ajkd.2002.36334; VANASBECK BS, 1984, J INFECTION, V8, P232, DOI 10.1016/S0163-4453(84)93955-0; Vaziri ND, 2013, AM J KIDNEY DIS, V61, P992, DOI 10.1053/j.ajkd.2012.10.027; Weiss G, 2005, NEW ENGL J MED, V352, P1011, DOI 10.1056/NEJMra041809; Weiss G, 2003, KIDNEY INT, V64, P572, DOI 10.1046/j.1523-1755.2003.00099.x; Weiss G, 2014, KIDNEY INT IN PRESS; Zitt E, 2011, CLIN J AM SOC NEPHRO, V6, P2650, DOI 10.2215/CJN.03780411	57	25	25	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2014	9	12							e114144	10.1371/journal.pone.0114144	http://dx.doi.org/10.1371/journal.pone.0114144			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AU8TQ	25462819	Green Published, gold, Green Submitted			2023-01-03	WOS:000345869700107
J	Lo, JA; Fisher, DE				Lo, Jennifer A.; Fisher, David E.			The melanoma revolution: From UV carcinogenesis to a new era in therapeutics	SCIENCE			English	Review							FREQUENT SOMATIC MUTATIONS; ULTRAVIOLET-RADIATION; METASTATIC MELANOMA; INHIBITOR RESISTANCE; CONFERS RESISTANCE; IMPROVED SURVIVAL; MEK INHIBITION; BRAF; ONCOGENE; VEMURAFENIB	Melanoma, the deadliest form of skin cancer, is an a ressive disease that is rising in incidence. Although melanoma is a historically treatment-resistant malignancy, in recent years unprecedented breakthroughs in targeted therapies and immunotherapies have revolutionized the standard of care for patients with advanced disease. Here, we provide an overview of recent developments in our understanding of melanoma risk factors, genomics, and molecular pathogenesis and how these insights have driven advances in melanoma treatment. In addition, we review benefits and limitations of current therapies and look ahead to continued progress in melanoma prevention and therapy. Remarkable achievements in the field have already produced a paradigm shift in melanoma treatment: Metastatic melanoma, once considered incurable, can now be treated with potentially curative rather than palliative intent.	[Fisher, David E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cutaneous Biol Res Ctr,Dept Dermatol, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, MGH Canc Ctr, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Fisher, DE (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cutaneous Biol Res Ctr,Dept Dermatol, Boston, MA 02114 USA.	dfisher3@partners.org	Fisher, David/AAH-2878-2019	/0000-0002-9520-6874	NIH [T32GM007753, P01CA163222, R01AR043369, R01CA150226]; Melanoma Research Alliance, the U.S.-Israel Binational Science Foundation; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; NATIONAL CANCER INSTITUTE [R01CA150226, P01CA163222] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043369] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007753] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Melanoma Research Alliance, the U.S.-Israel Binational Science Foundation; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank H. Tsao, C.-H. Won, and I. Kim for clinical images and K Robinson and K. Flaherty for useful comments and discussions. We extend our sincere apologies to those colleagues whose studies were not cited due to space constraints. This work was supported by the NIH under award numbers T32GM007753 (J.A.L.), P01CA163222, R01AR043369, and R01CA150226 and by grants tram the Melanoma Research Alliance, the U.S.-Israel Binational Science Foundation, and the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (D.E.F.).	Albert MR, 2002, J AM ACAD DERMATOL, V47, P930, DOI 10.1067/mjd.2002.127254; ALBINO AP, 1984, NATURE, V308, P69, DOI 10.1038/308069a0; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Atkins MB, 1999, J CLIN ONCOL, V17, P2105, DOI 10.1200/JCO.1999.17.7.2105; Bald T, 2014, NATURE, V507, P109, DOI 10.1038/nature13111; Bardeesy N, 2005, MOL CELL BIOL, V25, P4176, DOI 10.1128/MCB.25.10.4176-4188.2005; Bishop DT, 2009, NAT GENET, V41, P920, DOI 10.1038/ng.411; Boni A, 2010, CANCER RES, V70, P5213, DOI 10.1158/0008-5472.CAN-10-0118; Boniol M, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4757; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Clemente CG, 1996, CANCER, V77, P1303, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.3.CO;2-0; Cui RT, 2007, CELL, V128, P853, DOI 10.1016/j.cell.2006.12.045; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Curtin JA, 2006, J CLIN ONCOL, V24, P4340, DOI 10.1200/JCO.2006.06.2984; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; EVERSON TC, 1956, ANN SURG, V144, P366, DOI 10.1097/00000658-195609000-00007; Fell GL, 2014, CELL, V157, P1527, DOI 10.1016/j.cell.2014.04.032; Flaherty KT, 2012, NEW ENGL J MED, V367, P1694, DOI 10.1056/NEJMoa1210093; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Furge KA, 2001, P NATL ACAD SCI USA, V98, P10722, DOI 10.1073/pnas.191067898; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Garibyan L, 2010, CURR ONCOL REP, V12, P319, DOI 10.1007/s11912-010-0119-y; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Green AC, 2011, J CLIN ONCOL, V29, P257, DOI 10.1200/JCO.2010.28.7078; GREENE MH, 1981, LANCET, V1, P1196, DOI 10.1016/S0140-6736(81)92359-X; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Haq R, 2013, P NATL ACAD SCI USA, V110, P4321, DOI 10.1073/pnas.1205575110; Harbour JW, 2010, SCIENCE, V330, P1410, DOI 10.1126/science.1194472; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Johannessen CM, 2013, NATURE, V504, P138, DOI 10.1038/nature12688; Kraehn GM, 2001, BRIT J CANCER, V84, P72, DOI 10.1054/bjoc.2000.1535; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Kvam E, 1999, J INVEST DERMATOL, V113, P209, DOI 10.1046/j.1523-1747.1999.00653.x; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lin JY, 2007, NATURE, V445, P843, DOI 10.1038/nature05660; Maertens O, 2013, CANCER DISCOV, V3, P338, DOI 10.1158/2159-8290.CD-12-0313; Mayer D, 2012, J AM ACAD DERMATOL, V66, pE9, DOI 10.1016/j.jaad.2010.10.002; Menzies AM, 2012, CLIN CANCER RES, V18, P3242, DOI 10.1158/1078-0432.CCR-12-0052; Mitra D, 2012, NATURE, V491, P449, DOI 10.1038/nature11624; MORTON DL, 1970, SURGERY, V68, P158; Mosher CE, 2010, ARCH DERMATOL, V146, P412, DOI 10.1001/archdermatol.2009.385; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Paraiso KHT, 2011, CANCER RES, V71, P2750, DOI 10.1158/0008-5472.CAN-10-2954; Pleasance ED, 2010, NATURE, V463, P191, DOI 10.1038/nature08658; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Rees JL, 2003, ANNU REV GENET, V37, P67, DOI 10.1146/annurev.genet.37.110801.143233; Ribas A, 2013, NEW ENGL J MED, V368, P1365, DOI 10.1056/NEJMc1302338; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; Robbins PF, 2013, NAT MED, V19, P747, DOI 10.1038/nm.3161; Rosenberg SA, 2011, CLIN CANCER RES, V17, P4550, DOI 10.1158/1078-0432.CCR-11-0116; Sharpe AH, 2009, IMMUNOL REV, V229, P5, DOI 10.1111/j.1600-065X.2009.00784.x; Shi HB, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1727; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Smalley KSM, 2008, MOL CANCER THER, V7, P2876, DOI 10.1158/1535-7163.MCT-08-0431; Stahl JM, 2004, CANCER RES, V64, P7002, DOI 10.1158/0008-5472.CAN-04-1399; Stark M, 2007, CANCER RES, V67, P2632, DOI 10.1158/0008-5472.CAN-06-4152; Stark MS, 2012, NAT GENET, V44, P165, DOI 10.1038/ng.1041; Su F, 2012, NEW ENGL J MED, V366, P207, DOI 10.1056/NEJMoa1105358; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tsao H, 2012, GENE DEV, V26, P1131, DOI 10.1101/gad.191999.112; Van Allen EM, 2014, CANCER DISCOV, V4, P94, DOI 10.1158/2159-8290.CD-13-0617; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; Viros A, 2014, NATURE, V511, P478, DOI 10.1038/nature13298; Whiteman DC, 2001, CANCER CAUSE CONTROL, V12, P69, DOI 10.1023/A:1008980919928; Whittaker SR, 2013, CANCER DISCOV, V3, P350, DOI 10.1158/2159-8290.CD-12-0470; Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369; Yokoyama S, 2011, NATURE, V480, P99, DOI 10.1038/nature10630; Zaidi MR, 2011, NATURE, V469, P548, DOI 10.1038/nature09666	75	258	271	13	140	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 21	2014	346	6212					945	949		10.1126/science.1253735	http://dx.doi.org/10.1126/science.1253735			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AU6EL	25414302	Green Accepted			2023-01-03	WOS:000345696000032
J	Kadri, SS; Danner, RL				Kadri, Sameer S.; Danner, Robert L.			Review: In sepsis, the effect of resuscitation with crystalloid and colloid fluids on mortality varies Commentary	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CRITICALLY-ILL ADULTS; KIDNEY INJURY; ASSOCIATION; ALBUMIN; SALINE		[Kadri, Sameer S.; Danner, Robert L.] NIH, Dept Crit Care Med, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Kadri, SS (corresponding author), NIH, Dept Crit Care Med, Bethesda, MD 20892 USA.		Kadri, Sameer/Q-9081-2019		CLINICAL CENTER [ZIACL008060] Funding Source: NIH RePORTER	CLINICAL CENTER		Caironi P, 2014, NEW ENGL J MED, V370, P1412, DOI 10.1056/NEJMoa1305727; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Raghunathan K, 2014, CRIT CARE MED, V42, P1585, DOI 10.1097/CCM.0000000000000305; Shaw AD, 2012, ANN SURG, V255, P821, DOI 10.1097/SLA.0b013e31825074f5; Yunos NM, 2012, JAMA-J AM MED ASSOC, V308, P1566, DOI 10.1001/jama.2012.13356; Zarychanski R, 2013, JAMA-J AM MED ASSOC, V309, P678, DOI 10.1001/jama.2013.430	6	0	0	2	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 18	2014	161	10							JC12	10.7326/0003-4819-161-10-201411180-02012	http://dx.doi.org/10.7326/0003-4819-161-10-201411180-02012			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AX9TT	25402533				2023-01-03	WOS:000347245600022
J	Lee, TC; Frenette, C; Jayaraman, D; Green, L; Pilote, L				Lee, Todd C.; Frenette, Charles; Jayaraman, Dev; Green, Laurence; Pilote, Louise			Antibiotic Self-stewardship: Trainee-Led Structured Antibiotic Time-outs to Improve Antimicrobial Use	ANNALS OF INTERNAL MEDICINE			English	Article							INFECTIOUS-DISEASES SOCIETY; HEALTH-CARE EPIDEMIOLOGY; GUIDELINES; KNOWLEDGE; AMERICA	Background: Antibiotic use is an important quality improvement target. Nearly 50% of antibiotic use is unnecessary or inappropriate. To combat overuse, the Centers for Disease Control and Prevention (CDC) proposed "time-outs" to reevaluate antibiotics. Objective: To optimize antibiotic use through trainee-led time-outs. Design: Before-after study. Setting: Internal medicine (2 units, 46 beds) at a university hospital. Patients: Inpatients (n = 679). Intervention: From January 2012 until June 2013, while receiving monthly education on antimicrobial stewardship, resident physicians adjusted patients' antibiotic therapy through twice-weekly time-out audits using a structured electronic checklist. Measurements: Antibiotic costs were standardized and compared in the year before and after the audits. Use was measured as World Health Organization defined daily doses (DDDs) per 1000 patient-days. Total antibiotic use and the use of moxifloxacin, carbapenems, antipseudomonal penicillins, and vancomycin were compared by using interrupted time series. Rates of nosocomial Clostridium difficile infection were compared by using incidence rate ratios. Results: Total costs in the units decreased from $149 743CAD (January 2011 to January 2012) to $80 319 (January 2012 to January 2013), for a savings of $69 424 (46% reduction). Of the savings, $54 150 (78%) was related to carbapenems and $15 274 (22%) was due to other antibiotic classes. Adherence with the auditing process was 80%. In the time-series analyses, the only reliable and statistically significant change was a reduction in the rate of moxifloxicin use, by -1.9 DDDs per 1000 patient-days per month (95% CI, -3.8 to -0.02; P = 0.048). Rates of C. difficile infection decreased from 24.2 to 19.6 per 10 000 patient-days (incidence rate ratio, 0.8 [CI, 0.5 to 1.3]). Limitation: Other temporal factors may confound the findings. Conclusions: An antibiotic self-stewardship bundle to implement the CDC's suggested time-outs seems to have reduced overall costs and targeted antibiotic use.	McGill Univ, Ctr Hlth, Montreal, PQ, Canada; McGill Univ, McGill Ctr Qual Improvement, Montreal, PQ, Canada	McGill University; McGill University	Lee, TC (corresponding author), Royal Victoria Hosp, Div Internal Med, 687 Pine Ave West,Room A4-21, Montreal, PQ H3A 1A1, Canada.	todd.lee@mcgill.ca		Lee, Todd/0000-0002-2267-4239; Pilote, Louise/0000-0002-6159-0628	Robert Wood Johnson Foundation	Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF))	This article is part of the Annals supplement "RWJF Clinical Scholars in Pursuit of the Value Proposition: Evaluations of Low-Cost Innovations for Prevention and Management of Conditions." The Robert Wood Johnson Foundation provided funding for publication of this supplement, which is only available online at www.annals.org. Carol M. Mangione, MD, MPH (co-director of the RWJF Clinical Scholars Program at the University of California, Los Angeles); Jaya K. Rao, MD, MHS (Annals Deputy Editor); and Christine Laine, MD, MPH (Annals Editor in Chief), served as editors for this supplement.	Abbo LM, 2013, CLIN INFECT DIS, V57, P631, DOI 10.1093/cid/cit370; Centers for Disease Control and Prevention, COR EL HOSP ANT STEW; Centers for Disease Control and Prevention (CDC), 2012, GET SMART HEALTHC; Dellit TH, 2007, CLIN INFECT DIS, V44, P159, DOI 10.1086/510393; Drew RH, 2009, PHARMACOTHERAPY, V29, P593, DOI 10.1592/phco.29.5.593; Guidos RJ, 2011, CLIN INFECT DIS, V52, pS397, DOI 10.1093/cid/cir153; Johannsson B, 2011, INFECT CONT HOSP EP, V32, P367, DOI 10.1086/658946; Loo VG, 2005, NEW ENGL J MED, V353, P2442, DOI 10.1056/NEJMoa051639; Morel Chantal M, 2010, BMJ, V340, pc2115, DOI 10.1136/bmj.c2115; Polk RE, 2011, CLIN INFECT DIS, V53, P1100, DOI 10.1093/cid/cir672; Srinivasan A, 2004, ARCH INTERN MED, V164, P1451, DOI 10.1001/archinte.164.13.1451; Wagner AK, 2002, J CLIN PHARM THER, V27, P299, DOI 10.1046/j.1365-2710.2002.00430.x; Weiss CH, 2013, CRIT CARE MED, V41, P2563, DOI 10.1097/CCM.0b013e318298291a; Weiss CH, 2011, AM J RESP CRIT CARE, V184, P680, DOI 10.1164/rccm.201101-0037OC; Zimlichman E, 2013, JAMA INTERN MED, V173, P2039, DOI 10.1001/jamainternmed.2013.9763	15	60	61	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 18	2014	161	10		S			S53	S58		10.7326/M13-3016	http://dx.doi.org/10.7326/M13-3016			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CW3RR	25402404				2023-01-03	WOS:000364909900008
J	Zhang, BP; Liu, B; Zhang, H; Wang, JZ				Zhang, Baoping; Liu, Bin; Zhang, Hong; Wang, Jizeng			Erythrocyte Stiffness during Morphological Remodeling Induced by Carbon Ion Radiation	PLOS ONE			English	Article							ATOMIC-FORCE MICROSCOPY; BLOOD-CELL MEMBRANE; BONE-MARROW-CELLS; PERIPHERAL-BLOOD; MECHANICAL-PROPERTIES; VISCOELASTIC PROPERTIES; HEMATOPOIETIC SYNDROME; LARGE-DEFORMATION; BODY IRRADIATION; ELASTIC-MODULI	The adverse effect induced by carbon ion radiation (CIR) is still an unavoidable hazard to the treatment object. Thus, evaluation of its adverse effects on the body is a critical problem with respect to radiation therapy. We aimed to investigate the change between the configuration and mechanical properties of erythrocytes induced by radiation and found differences in both the configuration and the mechanical properties with involving in morphological remodeling process. Syrian hamsters were subjected to whole-body irradiation with carbon ion beams (1, 2, 4, and 6 Gy) or X-rays (2, 4, 6, and 12 Gy) for 3, 14 and 28 days. Erythrocytes in peripheral blood and bone marrow were collected for cytomorphological analysis. The mechanical properties of the erythrocytes were determined using atomic force microscopy, and the expression of the cytoskeletal protein spectrin-alpha 1 was analyzed via western blotting. The results showed that dynamic changes were evident in erythrocytes exposed to different doses of carbon ion beams compared with X-rays and the control (0 Gy). The magnitude of impairment of the cell number and cellular morphology manifested the subtle variation according to the irradiation dose. In particular, the differences in the size, shape and mechanical properties of the erythrocytes were well exhibited. Furthermore, immunoblot data showed that the expression of the cytoskeletal protein spectrin-alpha 1 was changed after irradiation, and there was a common pattern among its substantive characteristics in the irradiated group. Based on these findings, the present study concluded that CIR could induce a change in mechanical properties during morphological remodeling of erythrocytes. According to the unique characteristics of the biomechanical categories, we deduce that changes in cytomorphology and mechanical properties can be measured to evaluate the adverse effects generated by tumor radiotherapy. Additionally, for the first time, the current study provides a new strategy for enhancing the assessment of the curative effects and safety of clinical radiotherapy, as well as reducing adverse effects.	[Zhang, Baoping; Wang, Jizeng] Lanzhou Univ, Sch Civil Engn & Mech, Lanzhou 730000, Peoples R China; [Zhang, Baoping; Wang, Jizeng] Lanzhou Univ, Minist Educ China, Key Lab Mech Disaster & Environm Western China, Lanzhou 730000, Peoples R China; [Zhang, Baoping; Liu, Bin; Wang, Jizeng] Lanzhou Univ, Inst Biomech & Med Engn, Lanzhou 730000, Peoples R China; [Liu, Bin; Zhang, Hong] Chinese Acad Sci, Inst Modern Phys, Dept Heavy Ion Radiat Med, Lanzhou 730000, Peoples R China	Lanzhou University; Lanzhou University; Ministry of Education, China; Lanzhou University; Chinese Academy of Sciences; Institute of Modern Physics, CAS	Wang, JZ (corresponding author), Lanzhou Univ, Sch Civil Engn & Mech, Lanzhou 730000, Peoples R China.	jizengwangibme@gmail.com	Wang, Jizeng/A-2706-2008	Wang, Jizeng/0000-0002-8383-5868	National Natural Science Foundation of China [11032006, 11072094, 11121202]; PhD Program Foundation of the Ministry of Education of China [20100211110022]; New Century Excellent Talents in University [NCET-10-0445]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); PhD Program Foundation of the Ministry of Education of China(Ministry of Education, China); New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET))	This work was supported by grants from the National Natural Science Foundation of China (grants No. 11032006, No. 11072094, and No. 11121202), the PhD Program Foundation of the Ministry of Education of China (grant No. 20100211110022), and New Century Excellent Talents in University (program No. NCET-10-0445). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Afrin R, 2012, CYTOSKELETON, V69, P101, DOI 10.1002/cm.21001; Alonso JL, 2003, LIFE SCI, V72, P2553, DOI 10.1016/S0024-3205(03)00165-6; An X, 2010, TRANSFUS CLIN BIOL, V17, P197, DOI 10.1016/j.tracli.2010.06.009; Baines AJ, 2010, TRANSFUS CLIN BIOL, V17, P95, DOI 10.1016/j.tracli.2010.06.008; Bao G, 2003, NAT MATER, V2, P715, DOI 10.1038/nmat1001; Bao YZ, 2012, MUTAT RES-GEN TOX EN, V743, P67, DOI 10.1016/j.mrgentox.2011.12.025; Blanc L, 2010, BIOCHEMISTRY-US, V49, P4516, DOI 10.1021/bi1003684; Boey SK, 1998, BIOPHYS J, V75, P1573, DOI 10.1016/S0006-3495(98)74075-5; Broderick MJF, 2005, ADV PROTEIN CHEM, V70, P203, DOI 10.1016/S0065-3233(04)70007-8; Buys AV, 2013, CARDIOVASC DIABETOL, V12, DOI 10.1186/1475-2840-12-25; Callan-Jones A, 2012, BIOPHYS J, V103, P2475, DOI 10.1016/j.bpj.2012.11.008; Cardamone L, 2011, P NATL ACAD SCI USA, V108, P13978, DOI 10.1073/pnas.1100549108; Carl P, 2008, PFLUG ARCH EUR J PHY, V457, P551, DOI 10.1007/s00424-008-0524-3; Chan MM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054902; Coates PJ, 2004, MUTAT RES-FUND MOL M, V568, P5, DOI 10.1016/j.mrfmmm.2004.06.042; Corre I, 2010, MUTAT RES-REV MUTAT, V704, P61, DOI 10.1016/j.mrrev.2010.01.014; Daniels G, 2007, VOX SANG, V93, P331, DOI 10.1111/j.1423-0410.2007.00970.x; Darling EM, 2008, J BIOMECH, V41, P454, DOI 10.1016/j.jbiomech.2007.06.019; De Nunzio C, 2012, EUR UROL, V61, P560, DOI 10.1016/j.eururo.2011.11.013; de Oliveira M, 2010, ANN BIOMED ENG, V38, P2956, DOI 10.1007/s10439-010-0040-4; Debaugnies F, 2011, CLIN CHEM LAB MED, V49, P485, DOI 10.1515/CCLM.2011.066; Delaunay J, 2007, BLOOD REV, V21, P1, DOI 10.1016/j.blre.2006.03.005; Dimitriadis EK, 2002, BIOPHYS J, V82, P2798, DOI 10.1016/S0006-3495(02)75620-8; Discher DE, 2001, CELL MOL BIOL LETT, V6, P593; Discher DE, 1998, BIOPHYS J, V75, P1584, DOI 10.1016/S0006-3495(98)74076-7; Dubreuil RR, 2006, J MEMBRANE BIOL, V211, P151, DOI 10.1007/s00232-006-0863-y; Fedosov DA, 2010, COMPUT METHOD APPL M, V199, P1937, DOI 10.1016/j.cma.2010.02.001; Foretz M, 2011, FASEB J, V25, P337, DOI 10.1096/fj.10-169383; Franke RP, 2013, CLIN HEMORHEOL MICRO, V54, P273, DOI 10.3233/CH-131733; Garaj-Vrhovac V, 2011, INT J HYG ENVIR HEAL, V214, P59, DOI 10.1016/j.ijheh.2010.08.003; Gavara N, 2012, NAT NANOTECHNOL, V7, P733, DOI [10.1038/nnano.2012.163, 10.1038/NNANO.2012.163]; Ghorai A, 2014, SCIENTIFICA, V2014, DOI DOI 10.1155/2014/438030; Ghosh S, 2011, MUTAT RES-FUND MOL M, V716, P10, DOI 10.1016/j.mrfmmm.2011.07.015; Grande T, 2006, INT J RADIAT ONCOL, V64, P612, DOI 10.1016/j.ijrobp.2005.09.036; Guo SL, 2006, BIOMACROMOLECULES, V7, P1630, DOI 10.1021/bm0600724; Haghparast SMA, 2013, J BIOSCI BIOENG, V116, P380, DOI 10.1016/j.jbiosc.2013.03.003; Hansen JC, 1996, BIOPHYS J, V70, P146, DOI 10.1016/S0006-3495(96)79556-5; Heinrich V, 2001, BIOPHYS J, V81, P1452, DOI 10.1016/S0006-3495(01)75800-6; Hu SW, 2011, HEALTH PHYS, V101, P67, DOI 10.1097/HP.0b013e31820dba65; Johnson CP, 2007, SCIENCE, V317, P663, DOI 10.1126/science.1139857; JOHNSON KL, 1971, PROC R SOC LON SER-A, V324, P301, DOI 10.1098/rspa.1971.0141; Kabaso D, 2010, BIOPHYS J, V99, P808, DOI 10.1016/j.bpj.2010.04.067; Katira P, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.028103; Ketene AN, 2012, NANOMED-NANOTECHNOL, V8, P93, DOI 10.1016/j.nano.2011.05.012; Ketene AN, 2011, AFM STUDY OVARIAN CE; Kim Y, 2011, MED BIOL ENG COMPUT, V49, P453, DOI 10.1007/s11517-010-0730-y; Koshino I, 2012, J BIOL CHEM, V287, P35244, DOI 10.1074/jbc.M111.305441; Kozlova EK, 2013, MICRON, V44, P218, DOI 10.1016/j.micron.2012.06.012; Kulkarni S, 2010, CURR DRUG TARGETS, V11, P1375, DOI 10.2174/1389450111009011375; Kunda P, 2008, CURR BIOL, V18, P91, DOI 10.1016/j.cub.2007.12.051; Kuriakose S, 2013, SOFT MATTER, V9, P4284, DOI 10.1039/c3sm27683j; Kusunoki H, 2004, STRUCTURE, V12, P645, DOI 10.1016/j.str.2004.02.022; Lara P. C., 2013, CANC LETT; Lekka M, 2005, BIORHEOLOGY, V42, P307; Li J, 2007, P NATL ACAD SCI USA, V104, P4937, DOI 10.1073/pnas.0700257104; Li M, 2012, SCI CHINA LIFE SCI, V55, P968, DOI 10.1007/s11427-012-4399-3; Li QS, 2008, BIOCHEM BIOPH RES CO, V374, P609, DOI 10.1016/j.bbrc.2008.07.078; Li QF, 2014, INT J RADIAT BIOL, V90, P36, DOI 10.3109/09553002.2014.847294; Li W, 2004, EXP HEMATOL, V32, P1088, DOI 10.1016/j.exphem.2004.07.015; Li XJ, 2014, PHILOS T R SOC A, V372, DOI 10.1098/rsta.2013.0389; Liesveld JL, 2014, HEMATOPOIETIC SYSTEM, P623, DOI DOI 10.1007/978-3-540-75863-1; Lim CT, 2011, THEOR APPL MECH LETT, V1, DOI 10.1063/2.1101400; LIN S, 1977, J BIOL CHEM, V252, P5464; Liu F, 2003, CELL BIOCHEM BIOPHYS, V38, P251, DOI 10.1385/CBB:38:3:251; Lu YB, 2006, P NATL ACAD SCI USA, V103, P17759, DOI 10.1073/pnas.0606150103; Ludwig T, 2008, PFLUG ARCH EUR J PHY, V456, P29, DOI 10.1007/s00424-007-0398-9; Ma XF, 2011, MUTAT RES-FUND MOL M, V716, P20, DOI 10.1016/j.mrfmmm.2011.07.016; Machnicka B, 2012, CELL MOL LIFE SCI, V69, P191, DOI 10.1007/s00018-011-0804-5; Machnicka B, 2013, BIOCHIM BIOPHYS ACTA, V1838, P620; Maciaszek JL, 2011, J BIOMECH, V44, P657, DOI 10.1016/j.jbiomech.2010.11.008; Manda K, 2014, MUTAT RES REV MUTAT; MARCHESI V. T., 1968, SCIENCE, V159, P203, DOI 10.1126/science.159.3811.203; Matsunaga A, 2010, CANCER-AM CANCER SOC, V116, P3740, DOI 10.1002/cncr.25134; MOHANDAS N, 1994, ANNU REV BIOPH BIOM, V23, P787, DOI 10.1146/annurev.bb.23.060194.004035; Moroni M, 2014, INT J RADIAT BIOL, V90, P363, DOI 10.3109/09553002.2014.892226; Moroni M, 2011, RADIAT RES, V176, P89, DOI 10.1667/RR2481.1; Mukherjee D, 2013, INT J RADIAT BIOL, V89, P139, DOI 10.3109/09553002.2013.741280; Muravyov AV, 2013, CLIN HEMORHEOL MICRO, V53, P45, DOI 10.3233/CH-2012-1575; Nambiar R, 2009, P NATL ACAD SCI USA, V106, P11972, DOI 10.1073/pnas.0901641106; Nans A, 2011, BIOPHYS J, V101, P2341, DOI 10.1016/j.bpj.2011.09.050; Nikkhah M, 2010, BIOMATERIALS, V31, P4552, DOI 10.1016/j.biomaterials.2010.02.034; Nomura T, 2008, MUTAT RES-GEN TOX EN, V657, P68, DOI 10.1016/j.mrgentox.2008.08.006; Pan CQ, 2012, CELL SIGNAL, V24, P2143, DOI 10.1016/j.cellsig.2012.06.002; Park HJ, 2012, RADIAT RES, V177, P311, DOI 10.1667/RR2773.1; Park Y, 2010, P NATL ACAD SCI USA, V107, P6731, DOI 10.1073/pnas.0909533107; Park YK, 2010, P NATL ACAD SCI USA, V107, P1289, DOI 10.1073/pnas.0910785107; Peng ZL, 2013, P NATL ACAD SCI USA, V110, P13356, DOI 10.1073/pnas.1311827110; Peslak SA, 2011, EXP HEMATOL, V39, P434, DOI 10.1016/j.exphem.2011.01.010; Picas L, 2013, ACS NANO, V7, P1054, DOI 10.1021/nn303824j; Rico F, 2005, PHYS REV E, V72, DOI 10.1103/PhysRevE.72.021914; Rojas-Aguirre Y, 2012, BBA-BIOMEMBRANES, V1818, P738, DOI 10.1016/j.bbamem.2011.11.026; Salomao M, 2006, P NATL ACAD SCI USA, V103, P643, DOI 10.1073/pnas.0507661103; Samanta S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028169; SCHMIDT CF, 1993, SCIENCE, V259, P952, DOI 10.1126/science.8438153; SHEETZ MP, 1980, J BIOL CHEM, V255, P9955; Shi H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061170; Sneddon I.N., 1965, INT J ENG SCI, V3, P47, DOI [10.1016/0020-7225(65)90019-4, DOI 10.1016/0020-7225(65)90019-4]; Sonmez M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076579; Stewart MP, 2012, NAT PROTOC, V7, P143, DOI 10.1038/nprot.2011.434; STREY H, 1995, BIOPHYS J, V69, P478, DOI 10.1016/S0006-3495(95)79921-0; Strobl JS, 2010, BIOMATERIALS, V31, P7043, DOI 10.1016/j.biomaterials.2010.05.023; Suresh S, 2005, ACTA BIOMATER, V1, P15, DOI 10.1016/j.actbio.2004.09.001; Suzuki Y, 2008, J RADIAT RES, V49, P473, DOI 10.1269/jrr.07107; Svelc T, 2012, CELL MOL BIOL LETT, V17, P217, DOI 10.2478/s11658-012-0005-8; Svetina S, 2004, BIOELECTROCHEMISTRY, V62, P107, DOI 10.1016/j.bioelechem.2003.08.002; Swihart AH, 2001, J MICROSC-OXFORD, V204, P212, DOI 10.1046/j.1365-2818.2001.00960.x; Szarama KB, 2012, DEVELOPMENT, V139, P2187, DOI 10.1242/dev.073734; Takeuchi M, 1998, BIOPHYS J, V74, P2171, DOI 10.1016/S0006-3495(98)77926-3; Umegaki K, 2001, FREE RADICAL BIO MED, V31, P1066, DOI 10.1016/S0891-5849(01)00689-X; Wang CS, 2013, INT J RADIAT BIOL, V89, P132, DOI 10.3109/09553002.2013.734947; Wang Y, 2010, FREE RADICAL BIO MED, V48, P348, DOI 10.1016/j.freeradbiomed.2009.11.005; Weng HB, 2014, BBA-BIOMEMBRANES, V1838, P185, DOI 10.1016/j.bbamem.2013.09.014; Xu H, 2012, CANCER BIOTHER RADIO, V27, P113, DOI 10.1089/cbr.2011.1037; Zhang R, 2008, J CHEM PHYS, V129, DOI 10.1063/1.2958268; Zhu Q, 2008, BIOPHYS J, V94, P2529, DOI 10.1529/biophysj.107.119438; Zhu Q, 2007, BIOPHYS J, V93, P386, DOI 10.1529/biophysj.106.094383; Zou S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073499; Zuk A, 2011, INT J NANOMED, V6, P249, DOI 10.2147/IJN.S15802	118	14	15	0	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 17	2014	9	11							e112624	10.1371/journal.pone.0112624	http://dx.doi.org/10.1371/journal.pone.0112624			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT8BL	25401336	Green Published, gold, Green Submitted			2023-01-03	WOS:000345158700059
J	Lendvai, AZ; Ouyang, JQ; Schoenle, LA; Fasanello, V; Haussmann, MF; Bonier, F; Moore, IT				Lendvai, Adam Z.; Ouyang, Jenny Q.; Schoenle, Laura A.; Fasanello, Vincent; Haussmann, Mark F.; Bonier, Frances; Moore, Ignacio T.			Experimental Food Restriction Reveals Individual Differences in Corticosterone Reaction Norms with No Oxidative Costs	PLOS ONE			English	Article							STRESS-INDUCED CORTICOSTERONE; LIFE-HISTORY; BASE-LINE; PHENOTYPIC PLASTICITY; PLASMA-CORTICOSTERONE; REPRODUCTIVE SUCCESS; ANIMAL PERSONALITY; NATURAL-SELECTION; HOUSE SPARROWS; RESPONSES	Highly plastic endocrine traits are thought to play a central role in allowing organisms to respond rapidly to environmental change. Yet, not all individuals display the same degree of plasticity in these traits, and the costs of this individual variation in plasticity are unknown. We studied individual differences in corticosterone levels under varying conditions to test whether there are consistent individual differences in (1) baseline corticosterone levels; (2) plasticity in the hormonal response to an ecologically relevant stressor (food restriction); and (3) whether individual differences in plasticity are related to fitness costs, as estimated by oxidative stress levels. We took 25 wild-caught house sparrows into captivity and assigned them to repeated food restricted and control treatments (60% and 110% of their daily food intake), such that each individual experienced both food restricted and control diets twice. We found significant individual variation in baseline corticosterone levels and stress responsiveness, even after controlling for changes in body mass. However, these individual differences in hormonal responsiveness were not related to measures of oxidative stress. These results have implications for how corticosterone levels may evolve in natural populations and raise questions about what we can conclude from phenotypic correlations between hormone levels and fitness measures.	[Lendvai, Adam Z.; Ouyang, Jenny Q.; Schoenle, Laura A.; Moore, Ignacio T.] Virginia Tech, Dept Biol Sci, Blacksburg, VA USA; [Ouyang, Jenny Q.] Netherlands Inst Ecol NIOO KNAW, Wageningen, Netherlands; [Fasanello, Vincent; Haussmann, Mark F.] Bucknell Univ, Dept Biol, Lewisburg, PA 17837 USA; [Bonier, Frances] Queens Univ, Dept Biol, Kingston, ON K7L 3N6, Canada	Virginia Polytechnic Institute & State University; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute of Ecology (NIOO-KNAW); Bucknell University; Queens University - Canada	Lendvai, AZ (corresponding author), Univ Debrecen, Dept Evolutionary Zool, H-4012 Debrecen, Hungary.	lendvai@vt.edu	Schoenle, Laura/J-7978-2016; Schoenle, Laura A/M-9614-2017; Lendvai, Adam Z/B-8546-2008; Fasanello, Vincent/ABC-8322-2020; KNAW, NIOO-KNAW/A-4320-2012	Schoenle, Laura/0000-0002-9591-1194; Lendvai, Adam Z/0000-0002-8953-920X; KNAW, NIOO-KNAW/0000-0002-3835-159X	U.S. National Science Foundation (NSF) [IOS-1145625]; Natural Sciences and Engineering Research Council of Canada; Eotvos State Grant from the Hungarian Scholarship Board (Balassi Institute); NSF [DBI-1306025]	U.S. National Science Foundation (NSF)(National Science Foundation (NSF)); Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Eotvos State Grant from the Hungarian Scholarship Board (Balassi Institute); NSF(National Science Foundation (NSF))	Funding was provided by a U.S. National Science Foundation (NSF) grant (FB, ITM, and MFH; IOS-1145625), and by the Natural Sciences and Engineering Research Council of Canada Banting Postdoctoral Fellowship (FB). AZL was supported by an Eotvos State Grant from the Hungarian Scholarship Board (Balassi Institute), LS by the Virginia Tech Institute for Critical Technology and Applied Science. During the preparation of the manuscript, JQO was supported by a NSF postdoctoral grant (DBI-1306025). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adkins-Regan E, 2008, PHILOS T R SOC B, V363, P1599, DOI 10.1098/rstb.2007.0005; Angelier F, 2009, P ROY SOC B-BIOL SCI, V276, P3545, DOI 10.1098/rspb.2009.0868; Baugh AT, 2012, GEN COMP ENDOCR, V175, P488, DOI 10.1016/j.ygcen.2011.12.012; Bennett AJ, 2008, DEV PSYCHOBIOL, V50, P48, DOI 10.1002/dev.20263; Biro PA, 2010, TRENDS ECOL EVOL, V25, P653, DOI 10.1016/j.tree.2010.08.003; Bokony V, 2009, AM NAT, V173, P589, DOI 10.1086/597610; Bonier F, 2010, TRENDS ECOL EVOL, V25, P262, DOI 10.1016/j.tree.2010.01.009; Bonier F, 2009, TRENDS ECOL EVOL, V24, P634, DOI 10.1016/j.tree.2009.04.013; Breuner CW, 1999, J EXP ZOOL, V284, P334, DOI 10.1002/(SICI)1097-010X(19990801)284:3<334::AID-JEZ11>3.3.CO;2-R; Brommer JE, 2013, CURR ZOOL, V59, P485, DOI 10.1093/czoolo/59.4.485; Brommer JE, 2013, BEHAV ECOL SOCIOBIOL, V67, P1027, DOI 10.1007/s00265-013-1527-4; Buck CL, 2007, GEN COMP ENDOCR, V150, P430, DOI 10.1016/j.ygcen.2006.10.011; Burnham K. P., 2002, TECHNOMETRICS, V2nd, DOI DOI 10.1007/B97636; Chevin LM, 2013, AM NAT, V182, P13, DOI 10.1086/670613; Cockrem JF, 2010, BRIT POULTRY SCI, V51, P453, DOI 10.1080/00071668.2010.503637; Cockrem JF, 2013, GEN COMP ENDOCR, V181, P45, DOI 10.1016/j.ygcen.2012.11.025; Cockrem JF, 2009, GEN COMP ENDOCR, V163, P158, DOI 10.1016/j.ygcen.2009.03.029; Conti G, 2012, P NATL ACAD SCI USA, V109, P8866, DOI 10.1073/pnas.1205340109; Costantini D, 2008, ECOL LETT, V11, P1238, DOI 10.1111/j.1461-0248.2008.01246.x; Costantini D, 2008, J COMP PHYSIOL B, V178, P829, DOI 10.1007/s00360-008-0270-z; Costantini D, 2011, J COMP PHYSIOL B, V181, P447, DOI 10.1007/s00360-011-0566-2; Crespi EJ, 2013, FUNCT ECOL, V27, P93, DOI 10.1111/1365-2435.12009; Dingemanse NJ, 2013, J ANIM ECOL, V82, P39, DOI 10.1111/1365-2656.12013; Dingemanse NJ, 2010, TRENDS ECOL EVOL, V25, P261, DOI 10.1016/j.tree.2010.01.008; Dingemanse NJ, 2010, TRENDS ECOL EVOL, V25, P81, DOI 10.1016/j.tree.2009.07.013; Dingemanse NJ, 2004, P ROY SOC B-BIOL SCI, V271, P847, DOI 10.1098/rspb.2004.2680; Dingemanse NJ, 2013, ANIM BEHAV; Dochtermann NA, 2013, BEHAV ECOL, V24, P806, DOI 10.1093/beheco/art002; Epel ES, 2009, HORM-INT J ENDOCRINO, V8, P7, DOI 10.14310/horm.2002.1217; Epel ES, 2004, P NATL ACAD SCI USA, V101, P17312, DOI 10.1073/pnas.0407162101; Evans MR, 2006, J EVOLUTION BIOL, V19, P343, DOI 10.1111/j.1420-9101.2005.01034.x; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Fokidis HB, 2012, J EXP BIOL, V215, P2920, DOI 10.1242/jeb.071043; Fokidis HB, 2011, PHYSIOL BIOCHEM ZOOL, V84, P595, DOI 10.1086/662068; Fokidis HB, 2009, GEN COMP ENDOCR, V160, P259, DOI 10.1016/j.ygcen.2008.12.005; Ghalambor CK, 2007, FUNCT ECOL, V21, P394, DOI 10.1111/j.1365-2435.2007.01283.x; Gomez-Mestre I, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2013.1869; Goutte A, 2011, HORM BEHAV, V59, P167, DOI 10.1016/j.yhbeh.2010.11.004; Groscolas R, 2008, HORM BEHAV, V53, P51, DOI 10.1016/j.yhbeh.2007.08.010; Hadfield JD, 2010, J EVOLUTION BIOL, V23, P494, DOI 10.1111/j.1420-9101.2009.01915.x; Hadfield JD, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i02; Haussmann MF, 2012, P ROY SOC B-BIOL SCI, V279, P1447, DOI 10.1098/rspb.2011.1913; Haussmann MF, 2010, CURR ZOOL, V56, P714, DOI 10.1093/czoolo/56.6.714; Hill GE, 2011, ECOL LETT, V14, P625, DOI 10.1111/j.1461-0248.2011.01622.x; Jenkins BR, 2014, P ROY SOC B-BIOL SCI, V281, DOI 10.1098/rspb.2014.1302; Kitaysky AS, 2001, BEHAV ECOL, V12, P619, DOI 10.1093/beheco/12.5.619; Koolhaas JM, 2010, FRONT NEUROENDOCRIN, V31, P307, DOI 10.1016/j.yfrne.2010.04.001; Lendvai AZ, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2013.1734; Lendvai AZ, 2008, HORM BEHAV, V53, P395, DOI 10.1016/j.yhbeh.2007.11.011; Lendvai AZ, 2007, P ROY SOC B-BIOL SCI, V274, P391, DOI 10.1098/rspb.2006.3735; Lessells CM, 2008, PHILOS T R SOC B, V363, P1589, DOI 10.1098/rstb.2007.0008; Love OP, 2008, HORM BEHAV, V54, P496, DOI 10.1016/j.yhbeh.2008.01.006; Love OP, 2014, GEN COMP ENDOCR, V199, P65, DOI 10.1016/j.ygcen.2014.01.001; Love OP, 2013, FUNCT ECOL, V27, P81, DOI 10.1111/j.1365-2435.2012.02040.x; MacDougall-Shackleton SA, 2009, BIOL LETTERS, V5, P746, DOI 10.1098/rsbl.2009.0382; MacDougall-Shackleton SA, 2013, GEN COMP ENDOCR, V190, P188, DOI 10.1016/j.ygcen.2013.05.026; Malueg AL, 2009, BEHAV ECOL SOCIOBIOL, V63, P687, DOI 10.1007/s00265-008-0702-5; Martin LB, 2012, J EXP BIOL, V215, P4097, DOI 10.1242/jeb.073049; Masoro EJ, 2005, MECH AGEING DEV, V126, P913, DOI 10.1016/j.mad.2005.03.012; McGlothlin JW, 2010, AM NAT, V175, P687, DOI 10.1086/652469; Metcalfe NB, 2010, FUNCT ECOL, V24, P984, DOI 10.1111/j.1365-2435.2010.01750.x; Monaghan P, 2009, ECOL LETT, V12, P75, DOI 10.1111/j.1461-0248.2008.01258.x; Narayan EJ, 2013, COMP BIOCHEM PHYS A, V164, P21, DOI 10.1016/j.cbpa.2012.10.001; Nussey DH, 2007, J EVOLUTION BIOL, V20, P831, DOI 10.1111/j.1420-9101.2007.01300.x; Ottinger MA, 2005, MECH AGEING DEV, V126, P967, DOI 10.1016/j.mad.2005.03.017; Ouyang JQ, 2013, J EVOLUTION BIOL, V26, P1988, DOI 10.1111/jeb.12202; Ouyang JQ, 2011, P ROY SOC B-BIOL SCI, V278, P2537, DOI 10.1098/rspb.2010.2490; Overli O, 2005, INTEGR COMP BIOL, V45, P463, DOI 10.1093/icb/45.3.463; Patterson SH, 2014, J EVOLUTION BIOL, V27, P259, DOI 10.1111/jeb.12286; PIGLIUCCI M, 2001, SYN ECO EVO, pR13; Plummer M., 2006, R NEWS, V6, P7; Price TD, 2003, P ROY SOC B-BIOL SCI, V270, P1433, DOI 10.1098/rspb.2003.2372; R Core Team, 2021, R LANG ENV STAT COMP; Rensel MA, 2011, HORM BEHAV, V59, P497, DOI 10.1016/j.yhbeh.2011.01.010; Romero LM, 2008, GEN COMP ENDOCR, V156, P27, DOI 10.1016/j.ygcen.2007.10.001; Romero LM, 2006, GEN COMP ENDOCR, V149, P58, DOI 10.1016/j.ygcen.2006.05.004; Romero LM, 2010, P ROY SOC B-BIOL SCI, V277, P3157, DOI 10.1098/rspb.2010.0678; Schmidt KL, 2014, GEN COMP ENDOCR, V196, P72, DOI 10.1016/j.ygcen.2013.11.014; Schoech SJ, 2013, FUNCT ECOL, V27, P1100, DOI 10.1111/1365-2435.12142; Selman C, 2012, TRENDS ECOL EVOL, V27, P570, DOI 10.1016/j.tree.2012.06.006; Speakman JR, 2014, BIOESSAYS, V36, P93, DOI 10.1002/bies.201300108; Spencer KA, 2009, ENDOCRINOLOGY, V150, P1931, DOI 10.1210/en.2008-1471; Strochlic DE, 2008, COMP BIOCHEM PHYS A, V149, P68, DOI 10.1016/j.cbpa.2007.10.011; Treidel LA, 2013, BIOL LETTERS, V9, DOI 10.1098/rsbl.2013.0684; van de Pol MV, 2009, ANIM BEHAV, V77, P753, DOI 10.1016/j.anbehav.2008.11.006; Wilcoxen TE, 2011, GEN COMP ENDOCR, V173, P461, DOI 10.1016/j.ygcen.2011.07.007; Williams TD, 2008, PHILOS T R SOC B, V363, P1687, DOI 10.1098/rstb.2007.0003; Wingfield JC, 2003, J NEUROENDOCRINOL, V15, P711, DOI 10.1046/j.1365-2826.2003.01033.x; WINGFIELD JC, 1994, PERSPECTIVES IN COMPARATIVE ENDOCRINOLOGY, P520; WINGFIELD JC, 1992, HORM BEHAV, V26, P145, DOI 10.1016/0018-506X(92)90038-W; Wolf M, 2008, P NATL ACAD SCI USA, V105, P15825, DOI 10.1073/pnas.0805473105	91	50	50	0	61	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2014	9	11							e110564	10.1371/journal.pone.0110564	http://dx.doi.org/10.1371/journal.pone.0110564			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT9MC	25386675	Green Published, gold, Green Submitted			2023-01-03	WOS:000345250400010
J	Soong, C; Kurabi, B; Wells, D; Caines, L; Morgan, MW; Ramsden, R; Bell, CM				Soong, Christine; Kurabi, Bochra; Wells, David; Caines, Lesley; Morgan, Matthew W.; Ramsden, Rebecca; Bell, Chaim M.			Do Post Discharge Phone Calls Improve Care Transitions? A Cluster-Randomized Trial	PLOS ONE			English	Article							HOSPITAL DISCHARGE; QUALITY; REHOSPITALIZATION; INTERVENTION; HOME	Importance: The transition from hospital to home can expose patients to adverse events during the post discharge period. Post discharge care including phone calls may provide support for patients returning home but the impact on care transitions is unknown. Objective: To examine the effect of a 72-hour post discharge phone call on the patient's transition of care experience. Design: Cluster-randomized control trial. Setting: Urban, academic medical center. Participants: General medical patients age 18 and older discharged home after hospitalization. Main Outcomes and Measures: Primary outcome measure was the Care Transition Measure (CTM-3) score, a validated measure of the quality of care transitions. Secondary measures included self-reported adherence to medication and follow up plans, and 30-day composite of emergency department (ED) visits and hospital readmission. Results: 328 patients were included in the study over an 6-month period. 114 (69%) received a post discharge phone call, and 214 of all patients in the study completed the follow outcome survey (65% response rate). A small difference in CTM-3 scores was observed between the intervention and control groups (1.87 points, 95% CI 0.47-3.27, p = 0.01). Self-reported adherence to treatment plans, ED visits, and emergency readmission rates were similar between the two groups (odds ratio 0.57, 95% CI 0.13-2.45, 1.20, 95% CI 0.61-2.37, and 1.18, 95% CI 0.53-2.61, respectively). Conclusions and Relevance: A single post discharge phone call had a small impact on the quality of care transitions and no effect on hospital utilization. Higher intensity post discharge support may be required to improve the patient experience upon returning home.	[Soong, Christine; Kurabi, Bochra; Morgan, Matthew W.; Bell, Chaim M.] Univ Toronto, Div Gen Internal Med, Toronto, ON, Canada; [Soong, Christine; Wells, David; Caines, Lesley; Morgan, Matthew W.; Ramsden, Rebecca; Bell, Chaim M.] Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Soong, C (corresponding author), Univ Toronto, Div Gen Internal Med, Toronto, ON, Canada.	christine.soong@utoronto.ca	Bell, Chaim/C-4611-2015	Bell, Chaim/0000-0002-3778-9469	Mount Sinai Hospital Department of Medicine Physician Fund Campaign	Mount Sinai Hospital Department of Medicine Physician Fund Campaign	This study was funded by a grant from the Mount Sinai Hospital Department of Medicine Physician Fund Campaign. The funding agency had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript.	Arbaje AI, 2010, J AM GERIATR SOC, V58, P364, DOI 10.1111/j.1532-5415.2009.02682.x; Braun E, 2009, EUR J INTERN MED, V20, P221, DOI 10.1016/j.ejim.2008.07.021; Burke RE, 2013, JAMA INTERN MED, DOI [10.1001/jamain-ternmed.2013.171., DOI 10.1001/JAMAIN-TERNMED.2013.171]; Cain CH, 2012, J HOSP MED, V7, P382, DOI 10.1002/jhm.1918; Callen J, 2011, BMJ QUAL SAF, V20, P194, DOI 10.1136/bmjqs.2010.044339; Coleman E, 2012, COMMUNICATION; Coleman EA, 2005, MED CARE, V43, P246, DOI 10.1097/00005650-200503000-00007; Dedhia P, 2009, J AM GERIATR SOC, V57, P1540, DOI 10.1111/j.1532-5415.2009.02430.x; Dharmarajan K, 2013, JAMA-J AM MED ASSOC, V309, P355, DOI 10.1001/jama.2012.216476; Dudas V, 2001, AM J MED, V111, P26, DOI 10.1016/S0002-9343(01)00966-4; Forster AJ, 2004, CAN MED ASSOC J, V170, P345; Hansen LO, 2011, ANN INTERN MED, V155, P520, DOI 10.7326/0003-4819-155-8-201110180-00008; Hardin J.W., 2013, GEN ESTIMATING EQUAT, V2nd ed., DOI [https://doi.org/10.1201/b13880, DOI 10.1201/B13880]; Jack BW, 2009, ANN INTERN MED, V150, P178, DOI 10.7326/0003-4819-150-3-200902030-00007; Kangovi S, 2012, J HOSP MED, V7, P709, DOI 10.1002/jhm.1966; Kripalani S, 2012, ANN INTERN MED, V157, P1, DOI 10.7326/0003-4819-157-1-201207030-00003; Maslove DM, 2009, J GEN INTERN MED, V24, P995, DOI 10.1007/s11606-009-1053-2; Mistiaen P, 2006, COCHRANE DB SYST REV, V2006; National Research Corporation Canada, 2014, PAT FAM EXP; Parry C, 2008, MED CARE, V46, P317, DOI 10.1097/MLR.0b013e3181589bdc; Poon EG, 2004, ARCH INTERN MED, V164, P2223, DOI 10.1001/archinte.164.20.2223; Roy CL, 2005, ANN INTERN MED, V143, P121, DOI 10.7326/0003-4819-143-2-200507190-00011; Schillinger D, 2003, ARCH INTERN MED, V163, P83, DOI 10.1001/archinte.163.1.83; Society of Hospital Medicine, 2014, PROJ BOOST BETT OUTC; van Walraven C, 2004, J GEN INTERN MED, V19, P624, DOI 10.1111/j.1525-1497.2004.30082.x	25	32	33	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2014	9	11							e112230	10.1371/journal.pone.0112230	http://dx.doi.org/10.1371/journal.pone.0112230			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT9MC	25386678	Green Submitted, gold, Green Published			2023-01-03	WOS:000345250400052
J	Freeman, JJ; Feng, YJ; Demehri, FR; Dempsey, PJ; Teitelbaum, DH				Freeman, Jennifer J.; Feng, Yongjia; Demehri, Farokh R.; Dempsey, Peter J.; Teitelbaum, Daniel H.			TPN-associated intestinal epithelial cell atrophy is modulated by TLR4/EGF signaling pathways	FASEB JOURNAL			English	Article						apoptosis; epidermal growth factor; epithelial cell proliferation; mucosal atrophy; total parenteral nutrition	TOTAL PARENTERAL-NUTRITION; NF-KAPPA-B; MOUSE MODEL; BARRIER FUNCTION; INTRAEPITHELIAL LYMPHOCYTES; NECROTIZING ENTEROCOLITIS; INDUCED APOPTOSIS; EGF RECEPTOR; PROLIFERATION; TRANSACTIVATION	Recent studies suggest a close interaction between epidermal growth factor (EGF) and TLR signaling in the modulation of intestinal epithelial cell (IEC) proliferation; however, how these signaling pathways adjust IEC proliferation is poorly understood. We utilized a model of total parenteral nutrition (TPN), or enteral nutrient deprivation, to study this interaction as TPN results in mucosal atrophy due to decreased IEC proliferation and increased apoptosis. We identified the novel finding of decreased mucosal atrophy in TLR4 knockout (TLR4KO) mice receiving TPN. We hypothesized that EGF signaling is preserved in TLR4KO-TPN mice and prevents mucosal atrophy. C57Bl/6 and strain-matched TLR4KO mice were provided either enteral feeding or TPN. IEC proliferation and apoptosis were measured. Cytokine and growth factor abundances were detected in both groups. To examine interdependence of these pathways, ErbB1 pharmacologic blockade was used. The marked decline in IEC proliferation with TPN was nearly prevented in TLR4KO mice, and intestinal length was partially preserved. EGF was significantly increased, and TNF-alpha decreased in TLR4KO-TPN versus wild-type (WT)TPN mice. Apoptotic positive crypt cells were 15-fold higher in WT-TPN versus TLR4KO-TPN mice. Bcl-2 was significantly increased in TLR4KO-TPN mice, while Bax decreased 10-fold. ErbB1 blockade prevented this otherwise protective effect in TLR4KO-sTPN mice. TLR4 blockade significantly prevented TPN-associated atrophy by preserving proliferation and preventing apoptosis. This is driven by a reduction in TNF-alpha abundance and increased EGF. Potential manipulation of this regulatory pathway may have significant clinical potential to prevent TPN-associated atrophy.	[Freeman, Jennifer J.; Feng, Yongjia; Demehri, Farokh R.; Teitelbaum, Daniel H.] Univ Michigan, Dept Surg, Pediat Surg Sect, Ann Arbor, MI 48109 USA; [Freeman, Jennifer J.; Teitelbaum, Daniel H.] Univ Michigan, Ctr Organogenesis, Ann Arbor, MI 48109 USA; [Dempsey, Peter J.] Univ Colorado, Sch Med, Dept Pediat, Denver, CO USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Teitelbaum, DH (corresponding author), Univ Michigan, Mott Childrens Hosp, Pediat Surg Sect, 1540 E Hosp Dr,SPC 4211, Ann Arbor, MI 48109 USA.	dttlbm@umich.edu		Freeman, Jennifer/0000-0001-9144-2645	U.S. National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases [2R01AI-44076-15]; NIH National Institute of Diabetes and Digestive and Kidney Diseases [5R01DK093697]; Center for Organogenesis [T32-HD7505]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007505] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044076] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK093697] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases; NIH National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Center for Organogenesis; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by the U.S. National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (2R01AI-44076-15), the NIH National Institute of Diabetes and Digestive and Kidney Diseases (5R01DK093697), and the Center for Organogenesis (T32-HD7505). The authors declare no conflicts of interest.	Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Bhattacharyya S, 2008, AM J PHYSIOL-GASTR L, V295, pG784, DOI 10.1152/ajpgi.90434.2008; Braga M, 2009, CLIN NUTR, V28, P378, DOI 10.1016/j.clnu.2009.04.002; de Oliveira-Marques V, 2007, J IMMUNOL, V178, P3893, DOI 10.4049/jimmunol.178.6.3893; Del Poeta G, 2003, BLOOD, V101, P2125, DOI 10.1182/blood-2002-06-1714; Duro D, 2008, J PEDIATR GASTR NUTR, V47, pS33, DOI 10.1097/MPG.0b013e3181819007; Feng YJ, 2013, J PHYSIOL-LONDON, V591, P3709, DOI 10.1113/jphysiol.2013.253518; Feng YJ, 2012, AM J PHYSIOL-GASTR L, V302, pG236, DOI 10.1152/ajpgi.00142.2011; Feng YJ, 2010, AM J PHYSIOL-GASTR L, V298, pG833, DOI 10.1152/ajpgi.00030.2010; Feng YJ, 2009, J PHYSIOL-LONDON, V587, P641, DOI 10.1113/jphysiol.2008.162719; Frantz AL, 2012, MUCOSAL IMMUNOL, V5, P501, DOI 10.1038/mi.2012.23; Frey MR, 2009, GASTROENTEROLOGY, V136, P217, DOI 10.1053/j.gastro.2008.09.023; Fukata M, 2007, BIOCHEM SOC T, V35, P1473, DOI 10.1042/BST0351473; Fukata M, 2007, GASTROENTEROLOGY, V133, P1869, DOI 10.1053/j.gastro.2007.09.008; Grossmann J, 1998, AM J PATHOL, V153, P53, DOI 10.1016/S0002-9440(10)65545-9; Hsu D, 2010, LAB INVEST, V90, P1295, DOI 10.1038/labinvest.2010.100; Kaiser GC, 1997, GASTROENTEROLOGY, V112, P1231, DOI 10.1016/S0016-5085(97)70135-5; Krug SM, 2009, MOL BIOL CELL, V20, P3713, DOI 10.1091/mbc.E09-01-0080; KUDSK KA, 1992, ANN SURG, V215, P503, DOI 10.1097/00000658-199205000-00013; Leaphart CL, 2007, J IMMUNOL, V179, P4808, DOI 10.4049/jimmunol.179.7.4808; McElroy SJ, 2008, AM J PHYSIOL-GASTR L, V295, pG285, DOI 10.1152/ajpgi.00425.2007; Miyasaka EA, 2013, J IMMUNOL, V190, P6607, DOI 10.4049/jimmunol.1201746; Sodhi CP, 2012, GASTROENTEROLOGY, V143, P708, DOI 10.1053/j.gastro.2012.05.053; Sun SC, 2012, IMMUNOL REV, V246, P125, DOI 10.1111/j.1600-065X.2011.01088.x; Sun XY, 2008, AM J PHYSIOL-GASTR L, V294, pG139, DOI 10.1152/ajpgi.00386.2007; Sun XY, 2006, JPEN-PARENTER ENTER, V30, P474, DOI 10.1177/0148607106030006474; Wildhaber BE, 2002, PEDIATR SURG INT, V18, P570, DOI 10.1007/s00383-002-0869-1; Wildhaber BE, 2003, J SURG RES, V112, P144, DOI 10.1016/S0022-4804(03)00160-4; Williams JM, 2013, DIS MODEL MECH, V6, P1388, DOI 10.1242/dmm.013284; Yamaoka T, 2008, P NATL ACAD SCI USA, V105, P11772, DOI 10.1073/pnas.0801463105; Yang H, 2003, AM J PHYSIOL-GASTR L, V284, pG629, DOI 10.1152/ajpgi.00290.2002; Yang H, 2002, ANN SURG, V236, P226, DOI 10.1097/00000658-200208000-00011; Yang H, 2008, ANN SURG, V248, P849, DOI 10.1097/SLA.0b013e31818a1522; Yu XY, 2009, GASTROENTEROLOGY, V137, P221, DOI 10.1053/j.gastro.2009.03.060; Zhang CJ, 2009, J NUTR, V139, P1315, DOI 10.3945/jn.108.096669	35	22	23	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2015	29	7					2943	2958		10.1096/fj.14-269480	http://dx.doi.org/10.1096/fj.14-269480			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CL3OI	25782989	Green Submitted, Green Published			2023-01-03	WOS:000356859100023
J	Mcnab, S; Duke, T; South, M; Babl, FE; Lee, KJ; Arnup, SJ; Young, S; Turner, H; Davidson, A				McNab, Sarah; Duke, Trevor; South, Mike; Babl, Franz E.; Lee, Katherine J.; Arnup, Sarah J.; Young, Simon; Turner, Hannah; Davidson, Andrew			140 mmol/L of sodium versus 77 mmol/L of sodium in maintenance intravenous fluid therapy for children in hospital (PIMS): a randomised controlled double-blind trial	LANCET			English	Article							SERIOUSLY ILL CHILDREN; ANTI-DIURETIC HORMONE; ANTIDIURETIC-HORMONE; INAPPROPRIATE SECRETION; IATROGENIC HYPONATREMIA; ACQUIRED HYPONATREMIA; SALINE; SURGERY; MENINGITIS; PREVENTION	Background Use of hypotonic intravenous fluid to maintain hydration in children in hospital has been associated with hyponatraemia, leading to neurological morbidity and mortality. We aimed to assess whether use of fluid solutions with a higher sodium concentration reduced the risk of hyponatraemia compared with use of hypotonic solutions. Methods We did a randomised controlled double-blind trial of children admitted to The Royal Children's Hospital (Melbourne, VIC, Australia) who needed intravenous maintenance hydration for 6 h or longer. With an online randomisation system that used unequal block sizes, we randomly assigned patients (1:1) to receive either isotonic intravenous fluid containing 140 mmol/L of sodium (Na140) or hypotonic fluid containing 77 mmol/L of sodium (Na77) for 72 h or until their intravenous fluid rate decreased to lower than 50% of the standard maintenance rate. We stratified assignment by baseline sodium concentrations. Study investigators, treating clinicians, nurses, and patients were masked to treatment assignment. The primary outcome was occurrence of hyponatraemia (serum sodium concentration <135 mmol/L with a decrease of at least 3 mmol/L from baseline) during the treatment period, analysed by intention to treat. The trial was registered with the Australian New Zealand Clinical Trials Registry, number ACTRN1260900924257. Findings Between Feb 2, 2010, and Jan 29, 2013, we randomly assigned 690 patients. Of these patients, primary outcome data were available for 319 who received Na140 and 322 who received Na77. Fewer patients given Na140 than those given Na77 developed hyponatraemia (12 patients [4%] vs 35 [11%]; odds ratio [OR] 0.31, 95% CI 0.16-0.61; p=0.001). No clinically apparent cerebral oedema occurred in either group. Eight patients in the Na140 group (two potentially related to intravenous fluid) and four in the Na77 group (none related to intravenous fluid) developed serious adverse events during the treatment period. One patient in the Na140 had seizures during the treatment period compared with seven who received Na77. Interpretation Use of isotonic intravenous fluid with a sodium concentration of 140 mmol/L had a lower risk of hyponatraemia without an increase in adverse effects than did fluid containing 77 mmol/L of sodium. An isotonic fluid should be used as intravenous fluid for maintenance hydration in children.	[McNab, Sarah; South, Mike] Royal Childrens Hosp, Dept Gen Med, Melbourne, Vic 3052, Australia; [Duke, Trevor] Royal Childrens Hosp, Paediat Intens Care Unit, Melbourne, Vic 3052, Australia; [Davidson, Andrew] Royal Childrens Hosp, Dept Anaesthesia, Melbourne, Vic 3052, Australia; [Babl, Franz E.; Young, Simon] Royal Childrens Hosp, Emergency Dept, Melbourne, Vic 3052, Australia; [McNab, Sarah; Duke, Trevor; South, Mike; Babl, Franz E.; Lee, Katherine J.; Arnup, Sarah J.; Young, Simon; Turner, Hannah; Davidson, Andrew] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [McNab, Sarah; Duke, Trevor; South, Mike; Lee, Katherine J.; Young, Simon; Davidson, Andrew] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia	Royal Children's Hospital Melbourne; Royal Children's Hospital Melbourne; Royal Children's Hospital Melbourne; Royal Children's Hospital Melbourne; Murdoch Children's Research Institute; University of Melbourne	Mcnab, S (corresponding author), Royal Childrens Hosp, Dept Gen Med, Melbourne, Vic 3052, Australia.	sarah.mcnab@rch.org.au	Lee, Katherine J/A-2519-2016	Arnup, Sarah/0000-0002-9497-1902; South, Mike/0000-0002-5530-2722	National Health and Medical Research Council; Murdoch Childrens Research Institute; Royal Children's Hospital; Australian and New Zealand College of Anaesthetists	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Murdoch Childrens Research Institute; Royal Children's Hospital; Australian and New Zealand College of Anaesthetists	National Health and Medical Research Council, Murdoch Childrens Research Institute, The Royal Children's Hospital, and the Australian and New Zealand College of Anaesthetists.	Arieff AI, 1998, PAEDIATR ANAESTH, V8, P1, DOI 10.1046/j.1460-9592.1998.00730.x; ARIEFF AI, 1992, BRIT MED J, V304, P1218, DOI 10.1136/bmj.304.6836.1218; Brazel PW, 1996, SPINE, V21, P724, DOI 10.1097/00007632-199603150-00013; BURROWS FA, 1983, CRIT CARE MED, V11, P527, DOI 10.1097/00003246-198307000-00009; Choong K, 2011, PEDIATRICS, V128, P857, DOI 10.1542/peds.2011-0415; Coulthard MG, 2008, ARCH DIS CHILD, V93, P335, DOI 10.1136/adc.2007.124461; Coulthard MG, 2012, ARCH DIS CHILD, V97, P491, DOI 10.1136/archdischild-2011-300221; DHAWAN A, 1992, ANN TROP PAEDIATR, V12, P455, DOI 10.1080/02724936.1992.11747614; Duke T, 2003, LANCET, V362, P1320, DOI 10.1016/S0140-6736(03)14577-1; FAJARDO JE, 1989, PEDIATR NEUROL, V5, P37, DOI 10.1016/0887-8994(89)90007-6; Foster BA, 2014, J PEDIATR-US, V165, P163, DOI 10.1016/j.jpeds.2014.01.040; Halberthal M, 2001, BRIT MED J, V322, P780, DOI 10.1136/bmj.322.7289.780; Hasegawa H, 2009, PEDIATR NEPHROL, V24, P507, DOI 10.1007/s00467-008-1053-1; HOLLIDAY MA, 1957, PEDIATRICS, V19, P823; Holliday MA, 2005, PEDIATRICS, V115, P193, DOI 10.1542/peds.2004-1769; Holliday MA, 2004, J PEDIATR-US, V145, P584, DOI 10.1016/j.jpeds.2004.06.077; Holliday MA, 2004, LANCET, V363, P241, DOI 10.1016/S0140-6736(03)15333-0; Holliday MA, 2007, ARCH DIS CHILD, V92, P546, DOI 10.1136/adc.2006.106377; Hughes PD, 2003, LANCET, V362, P1320; JUDD BA, 1990, ACTA PAEDIATR SCAND, V79, P461, DOI 10.1111/j.1651-2227.1990.tb11494.x; Kannan L, 2010, PEDIATR NEPHROL, V25, P2303, DOI 10.1007/s00467-010-1600-4; Kellum JA, 2002, CRIT CARE MED, V30, P259, DOI 10.1097/00003246-200201000-00046; Koczmara Christine, 2010, Dynamics, V21, P21; Liamis G, 2008, AM J KIDNEY DIS, V52, P144, DOI 10.1053/j.ajkd.2008.03.004; Luu R, 2013, J PEDIATR-US, V163, P1652, DOI 10.1016/j.jpeds.2013.06.041; Mohan S, 2013, AM J MED, V126, P1127, DOI 10.1016/j.amjmed.2013.07.021; Montanana PA, 2008, PEDIATR CRIT CARE ME, V9, P589, DOI 10.1097/PCC.0b013e31818d3192; Mori J, 2011, PEDIATR INT, V53, P354, DOI 10.1111/j.1442-200X.2010.03264.x; Moritz ML, 2007, NAT CLIN PRACT NEPHR, V3, P374, DOI 10.1038/ncpneph0526; Moritz ML, 2011, PEDIATRICS, V128, P980, DOI 10.1542/peds.2011-2015; National Patient Safety Agency, 2007, PAT SAF AL 22 NPSA 2; Neville KA, 2010, J PEDIATR-US, V156, P313, DOI 10.1016/j.jpeds.2009.07.059; PATWARI AK, 1995, ANN TROP PAEDIATR, V15, P179, DOI 10.1080/02724936.1995.11747769; Playfor S, 2003, ARCH DIS CHILD, V88, P646, DOI 10.1136/adc.88.7.646-a; Rey C, 2011, ACTA PAEDIATR, V100, P1138, DOI 10.1111/j.1651-2227.2011.02209.x; Saba TG, 2011, BMC PEDIATR, V11, DOI 10.1186/1471-2431-11-82; Shaw AD, 2012, ANN SURG, V255, P821, DOI 10.1097/SLA.0b013e31825074f5; Stewart PC, 2007, BRIT J ANAESTH, V98, P406, DOI 10.1093/bja/ael381; Sutherland A, 2013, ARCH DIS CHILD, V98, pe1; Wilkes NJ, 2001, ANESTH ANALG, V93, P811, DOI 10.1097/00000539-200110000-00003; Yung M, 2009, J PAEDIATR CHILD H, V45, P9, DOI 10.1111/j.1440-1754.2007.01254.x	41	104	105	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 28	2015	385	9974					1190	1197		10.1016/S0140-6736(14)61459-8	http://dx.doi.org/10.1016/S0140-6736(14)61459-8			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CE3GQ	25472864				2023-01-03	WOS:000351715100032
J	Prato, M; Magnetto, C; Jose, J; Khadjavi, A; Cavallo, F; Quaglino, E; Panariti, A; Rivolta, I; Benintende, E; Varetto, G; Argenziano, M; Troia, A; Cavalli, R; Guiot, C				Prato, Mauro; Magnetto, Chiara; Jose, Jithin; Khadjavi, Amina; Cavallo, Federica; Quaglino, Elena; Panariti, Alice; Rivolta, Ilaria; Benintende, Emilio; Varetto, Gianfranco; Argenziano, Monica; Troia, Adriano; Cavalli, Roberta; Guiot, Caterina			2H,3H-Decafluoropentane-Based Nanodroplets: New Perspectives for Oxygen Delivery to Hypoxic Cutaneous Tissues	PLOS ONE			English	Article							PHOTOACOUSTIC COMPUTED-TOMOGRAPHY; CHRONIC WOUNDS; BLOOD SUBSTITUTES; SURFACE-CHARGE; IN-VITRO; ULTRASOUND; NANOPARTICLES; THERAPY; HYDROGELS; DEXTRAN	Perfluoropentane (PFP)-based oxygen-loaded nanobubbles (OLNBs) were previously proposed as adjuvant therapeutic tools for pathologies of different etiology sharing hypoxia as a common feature, including cancer, infection, and autoimmunity. Here we introduce a new platform of oxygen nanocarriers, based on 2H,3H-decafluoropentane (DFP) as core fluorocarbon. These new nanocarriers have been named oxygen-loaded nanodroplets (OLNDs) since DFP is liquid at body temperature, unlike gaseous PFP. Dextran-shelled OLNDs, available either in liquid or gel formulations, display spherical morphology, similar to 600 nm diameters, anionic charge, good oxygen carrying capacity, and no toxic effects on human keratinocytes after cell internalization. In vitro OLNDs result more effective in releasing oxygen to hypoxic environments than former OLNBs, as demonstrated by analysis through oxymetry. In vivo, OLNDs effectively enhance oxy-hemoglobin levels, as emerged from investigation by photoacoustic imaging. Interestingly, ultrasound (US) treatment further improves transdermal oxygen release from OLNDs. Taken together, these data suggest that US-activated, DFP-based OLNDs might be innovative, suitable and cost-effective devices to topically treat hypoxia-associated pathologies of the cutaneous tissues.	[Prato, Mauro; Khadjavi, Amina; Guiot, Caterina] Univ Turin, Dipartimento Neurosci, Turin, Italy; [Magnetto, Chiara; Troia, Adriano] Ist Nazl Ric Metrol INRIM, Turin, Italy; [Jose, Jithin] FujiFilm VisualSon, Amsterdam, Netherlands; [Cavallo, Federica; Quaglino, Elena] Univ Turin, Ctr Mol Biotechnol, Dipartimento Biotecnol Mol & Sci Salute, Turin, Italy; [Panariti, Alice; Rivolta, Ilaria] Univ Milano Bicocca, Dipartimento Sci Salute, Monza, Italy; [Benintende, Emilio; Varetto, Gianfranco] Univ Turin, Dipartimento Sci Chirurg, Turin, Italy; [Argenziano, Monica; Cavalli, Roberta] Univ Turin, Dipartimento Sci & Tecnol Farmaco, Turin, Italy	University of Turin; Istituto Nazionale di Ricerca Metrologica (INRIM); Fujifilm Corporation; University of Turin; University of Milano-Bicocca; University of Turin; University of Turin	Prato, M (corresponding author), Univ Turin, Dipartimento Neurosci, Turin, Italy.	mauro.prato@unito.it; caterina.guiot@unito.it	; Cavallo, Federica/C-5666-2011	Varetto, Gianfranco/0000-0003-4262-886X; Cavallo, Federica/0000-0003-4571-1060; Quaglino, Elena/0000-0002-8151-9124	Compagnia di San Paolo (Ateneo-SanPaolo) [ORTO11CE8R]; University of Torino	Compagnia di San Paolo (Ateneo-SanPaolo); University of Torino	Work funded by Compagnia di San Paolo (Ateneo-SanPaolo 2011 ORTO11CE8R grant to C. G.) and University of Torino (ex-60% grant to R. C.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdel-Mottaleb MMA, 2012, J PHARM SCI-US, V101, P4231, DOI 10.1002/jps.23282; Bang JH, 2010, ADV MATER, V22, P1039, DOI 10.1002/adma.200904093; Bisazza A, 2008, IEEE ENG MED BIO, P2067, DOI 10.1109/IEMBS.2008.4649599; Bos GW, 2005, BIOMATERIALS, V26, P3901, DOI 10.1016/j.biomaterials.2004.10.008; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Brimson CH, 2013, J EUR ACAD DERMATOL, V27, P411, DOI 10.1111/j.1468-3083.2012.04650.x; BROOKS DE, 1973, J COLLOID INTERF SCI, V43, P670, DOI 10.1016/0021-9797(73)90413-X; Cabrales P, 2013, ASAIO J, V59, P337, DOI 10.1097/MAT.0b013e318291fbaa; Castro CI, 2010, ARTIF ORGANS, V34, P622, DOI 10.1111/j.1525-1594.2009.00944.x; Cavalli R, 2009, INT J PHARMACEUT, V381, P160, DOI 10.1016/j.ijpharm.2009.07.010; Cavalli R, 2013, INT J PHARMACEUT, V456, P437, DOI 10.1016/j.ijpharm.2013.08.041; Cavalli R, 2012, INT J NANOMED, V7, P3309, DOI 10.2147/IJN.S30912; Cavalli R, 2009, INT J PHARMACEUT, V378, P215, DOI 10.1016/j.ijpharm.2009.05.058; Cumming G, 2007, J CELL BIOL, V177, P7, DOI 10.1083/jcb.200611141; Davis SC, 2007, ARCH DERMATOL, V143, P1252, DOI 10.1001/archderm.143.10.1252; De Backer D, 2012, J CLIN MONIT COMPUT, V26, P361, DOI 10.1007/s10877-012-9383-8; De Groot CJ, 2001, BIOMATERIALS, V22, P1197, DOI 10.1016/S0142-9612(00)00266-0; Dietz I, 2012, MICROBES INFECT, V14, P311, DOI 10.1016/j.micinf.2011.11.003; Dushkin AV, 2013, PHARM CHEM J+, V46, P630, DOI 10.1007/s11094-013-0859-8; Gordillo GM, 2008, CLIN EXP PHARMACOL P, V35, P957, DOI 10.1111/j.1440-1681.2008.04934.x; Gordillo GM, 2009, INT J LOW EXTR WOUND, V8, P105, DOI 10.1177/1534734609335149; Jose J, 2011, OPT EXPRESS, V19, P2093, DOI 10.1364/OE.19.002093; Kagan D, 2012, ANGEW CHEM INT EDIT, V51, P7519, DOI 10.1002/anie.201201902; Kim JW, 2007, CANCER METAST REV, V26, P291, DOI 10.1007/s10555-007-9060-4; KNIGHTON DR, 1981, SURGERY, V90, P262; Kogan Paul, 2010, Bubble Sci Eng Technol, V2, P3, DOI 10.1179/175889610X12730566149100; Kotopoulis S, 2014, MOL IMAGING BIOL, V16, P53, DOI 10.1007/s11307-013-0672-5; Kotopoulis S, 2013, MED PHYS, V40, DOI 10.1118/1.4808149; Krafft MP, 1998, BIOCHIMIE, V80, P489, DOI 10.1016/S0300-9084(00)80016-4; Laser institute of America, 2007, AMERICAN NATIONAL ST; Laufer J, 2007, PHYS MED BIOL, V52, P141, DOI 10.1088/0031-9155/52/1/010; Lee O, 2013, SKIN RES TECHNOL, V19, pE390, DOI 10.1111/j.1600-0846.2012.00656.x; Liu YY, 2006, J CONTROL RELEASE, V114, P89, DOI 10.1016/j.jconrel.2006.05.018; Lopez RFV, 2011, BIOMATERIALS, V32, P933, DOI 10.1016/j.biomaterials.2010.09.060; Lundgren CEG, 2004, UNDERSEA HYPERBAR M, V31, P105; Magnetto C, 2014, RSC ADV, V4, P38433, DOI 10.1039/c4ra03524k; Mathieu Daniel, 2007, Int J Low Extrem Wounds, V6, P273, DOI 10.1177/1534734607310299; Modery-Pawlowski CL, 2013, BIOMACROMOLECULES, V14, P939, DOI 10.1021/bm400074t; Moller S, 2007, BIOMOL ENG, V24, P496, DOI 10.1016/j.bioeng.2007.08.014; PINNICK RG, 1990, APPL OPTICS, V29, P918, DOI 10.1364/AO.29.000918; Postema M, 2011, WORLD J GASTROENTERO, V17, P28, DOI 10.3748/wjg.v17.i1.28; Rapoport NY, 2004, ULTRASONICS, V42, P943, DOI 10.1016/j.ultras.2004.01.087; Resink S, 2011, OPT LETT, V36, P2809, DOI 10.1364/OL.36.002809; Riess JG, 1999, MRS BULL, V24, P42, DOI 10.1557/S0883769400052313; Ryman-Rasmussen JP, 2007, J INVEST DERMATOL, V127, P143, DOI 10.1038/sj.jid.5700508; Said HK, 2005, ARCH SURG-CHICAGO, V140, P998, DOI 10.1001/archsurg.140.10.998; Sen CK, 2009, WOUND REPAIR REGEN, V17, P1, DOI 10.1111/j.1524-475X.2008.00436.x; Sheikh AY, 2000, ARCH SURG-CHICAGO, V135, P1293, DOI 10.1001/archsurg.135.11.1293; Sola A, 2014, ACTA PAEDIATR, V103, P1009, DOI 10.1111/apa.12692; Sze A, 2003, J COLLOID INTERF SCI, V261, P402, DOI 10.1016/S0021-9797(03)00142-5; Takahashi M., 2009, MAT INTEGR, V22, P2; Thackham JA, 2008, WOUND REPAIR REGEN, V16, P321, DOI 10.1111/j.1524-475X.2008.00372.x; Torchilin V, 2009, EUR J PHARM BIOPHARM, V71, P431, DOI 10.1016/j.ejpb.2008.09.026; Wu X, 2010, SKIN PHARMACOL PHYS, V23, P117, DOI 10.1159/000270381; Xia YP, 2001, J INVEST DERMATOL, V116, P50, DOI 10.1046/j.1523-1747.2001.00209.x; Young Robert W, 2012, J Extra Corpor Technol, V44, P241; Zbytek B, 2013, DERM-ENDOCRINOL, V5, P239, DOI 10.4161/derm.22678	57	33	34	2	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 17	2015	10	3							e0119769	10.1371/journal.pone.0119769	http://dx.doi.org/10.1371/journal.pone.0119769			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CD7QC	25781463	Green Submitted, Green Published, gold			2023-01-03	WOS:000351284600090
J	Qi, K; Li, LJ; Li, XD; Zhao, JL; Wang, Y; You, SJ; Hu, FH; Zhang, HT; Cheng, YT; Kang, S; Cui, HH; Duan, L; Jin, C; Zheng, QS; Yang, YJ				Qi, Kang; Li, Lujin; Li, Xiangdong; Zhao, Jinglin; Wang, Yang; You, Shijie; Hu, Fenghuan; Zhang, Haitao; Cheng, Yutong; Kang, Sheng; Cui, Hehe; Duan, Lian; Jin, Chen; Zheng, Qingshan; Yang, Yuejin			Cardiac Microvascular Barrier Function Mediates the Protection of Tongxinluo against Myocardial Ischemia/Reperfusion Injury	PLOS ONE			English	Article							K-ATP CHANNEL; REPERFUSED SWINE HEARTS; NITRIC-OXIDE SYNTHASE; NO-REFLOW PHENOMENON; ANGIOPOIETIN-LIKE 4; VASCULAR-PERMEABILITY; VE-CADHERIN; CARDIOMYOCYTE HYPERTROPHY; ENDOTHELIAL PERMEABILITY; ADHERENS JUNCTIONS	Objective Tongxinluo (TXL) has been shown to decrease myocardial necrosis after ischemia/ reperfusion (I/R) by simulating ischemia preconditioning (IPC). However, the core mechanism of TXL remains unclear. This study was designed to investigate the key targets of TXL against I/R injury (IRI) among the cardiac structure-function network. Materials and Methods To evaluate the severity of lethal IRI, a mathematical model was established according to the relationship between myocardial no-reflow size and necrosis size. A total of 168 miniswine were employed in myocardial I/R experiment. IRI severity among different interventions was compared and IPC and CCB groups were identified as the mildest and severest groups, respectively. Principal component analysis was applied to further determine 9 key targets of IPC in cardioprotection. Then, the key targets of TXL in cardioprotection were confirmed. Results Necrosis size and no-reflow size fit well with the Sigmoid Emaxmodel. Necrosis reduction space (NRS) positively correlates with I/R injury severity and necrosis size (R2= 0.92, R-2= 0.57, P< 0.01, respectively). Functional and structural indices correlate positively with NRS (R-2= 0.64, R-2= 0.62, P< 0.01, respectively). TXL recovers SUR2, iNOS activity, eNOS activity, VE-cadherin, beta-catenin, gamma-catenin and P-selectin with a trend toward the sham group. Moreover, TXL increases PKA activity and eNOS expression with a trend away fromthe sham group. Among the above nine indices, eNOS activity, eNOS, VE-cadherin, beta-catenin and gamma-catenin expression were significantly up-regulated by TXL compared with IPC (P>0.05) or CCB (P<0.05) and these five microvascular barrier-related indices may be the key targets of TXL inminimizing IRI. Conclusions Our study underlines the lethal IRI as one of the causes of myocardial necrosis. Pretreatment with TXL ameliorates myocardial IRI through promoting cardiac microvascular endothelial barrier function by simulating IPC.	[Qi, Kang; Li, Xiangdong; Zhao, Jinglin; You, Shijie; Hu, Fenghuan; Zhang, Haitao; Cheng, Yutong; Kang, Sheng; Cui, Hehe; Duan, Lian; Jin, Chen; Yang, Yuejin] Chinese Acad Med Sci, Natl Ctr Cardiovasc Dis, Fuwai Hosp, State Key Lab Cardiovasc Dis, Beijing 100730, Peoples R China; [Qi, Kang; Li, Xiangdong; Zhao, Jinglin; Wang, Yang; You, Shijie; Hu, Fenghuan; Zhang, Haitao; Cheng, Yutong; Kang, Sheng; Cui, Hehe; Duan, Lian; Jin, Chen; Yang, Yuejin] Peking Union Med Coll, Beijing 100037, Peoples R China; [Li, Lujin; Zheng, Qingshan] Shanghai Univ Chinese Med, Ctr Drug Clin Res, Shanghai 201203, Peoples R China; [Wang, Yang] Chinese Acad Med Sci, Natl Ctr Cardiovasc Dis, Fuwai Hosp, Biol Informat & Stat Ctr, Beijing 100730, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Shanghai University of Traditional Chinese Medicine; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS	Yang, YJ (corresponding author), Chinese Acad Med Sci, Natl Ctr Cardiovasc Dis, Fuwai Hosp, State Key Lab Cardiovasc Dis, Beijing 100730, Peoples R China.	yangyjfw@126.com	Li, Lujin/ABA-6800-2021		National Basic Research Program (973 Program) of China [2012CB518602, 2005CB523303]; National Natural Science Foundation of China [81370223, 30770858, 30572439, 902090038]; Beijing Natural Science Foundation [7042044]; Capital Medical Development Scientific Research Fund [2002-3072]; Postgraduates' Innovative Foundation of Peking Union Medical College, China [2013-1002-39]	National Basic Research Program (973 Program) of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation(Beijing Natural Science Foundation); Capital Medical Development Scientific Research Fund; Postgraduates' Innovative Foundation of Peking Union Medical College, China	This study was supported by National Basic Research Program (973 Program) of China (No. 2012CB518602; No. 2005CB523303, http://www.973.gov.cn/AreaAppl.aspx; KQ, XL, JZ, SY, FH, HZ, YC, SK, HC, LD, CJ, YY), National Natural Science Foundation of China (No. 81370223; No. 30770858; No. 30572439; No. 902090038, http://www.nsfc.gov.cn; KQ, XL, JZ, SY, FH, HZ, YC, SK, HC, LD, CJ, YY), Beijing Natural Science Foundation (No. 7042044, http://www.bjnsf.org; JZ, SY, FH, CJ, YY), Capital Medical Development Scientific Research Fund (No. 2002-3072, http://www. bjhbkj. com; JZ, SY, FH, CJ, YY) and Postgraduates' Innovative Foundation of Peking Union Medical College, China (2013-1002-39; http://graduate. pumc. edu. cn/peiyang/view/86. aspx; KQ). All funders has no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bekkers SCAM, 2010, J AM COLL CARDIOL, V55, P1649, DOI 10.1016/j.jacc.2009.12.037; Bernardo NL, 1999, AM J PHYSIOL-HEART C, V276, pH1323, DOI 10.1152/ajpheart.1999.276.4.H1323; Bolli R, 2004, CIRC RES, V95, P125, DOI 10.1161/01.RES.0000137171.97172.d7; Bouleti C, 2013, EUR HEART J, V34, P3657, DOI 10.1093/eurheartj/eht153; Cheng YT, 2009, CHINESE MED J-PEKING, V122, P1529, DOI 10.3760/cma.j.issn.0366-6999.2009.13.011; Cheng YuTong, 2009, Shandong Medical Journal, V49, P4; Clement LC, 2014, NAT MED, V20, P37, DOI 10.1038/nm.3396; Corada M, 2001, BLOOD, V97, P1679, DOI 10.1182/blood.V97.6.1679; Csonka C, 2010, J PHARMACOL TOX MET, V61, P163, DOI 10.1016/j.vascn.2010.02.014; Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357; Dejana E, 2008, J CELL SCI, V121, P2115, DOI 10.1242/jcs.017897; Duan L, 2010, SHANDONG YI YAO, V50, P3; [段炼 DUAN Lian], 2010, [中国病理生理杂志, Chinese Journal of Pathophysiology], V26, P430; Facundo HTF, 2005, J BIOENERG BIOMEMBR, V37, P75, DOI 10.1007/s10863-005-4130-1; Galaup A, 2006, P NATL ACAD SCI USA, V103, P18721, DOI 10.1073/pnas.0609025103; Galaup A, 2012, CIRCULATION, V125, P140, DOI 10.1161/CIRCULATIONAHA.111.049072; Genda S, 2002, J AM COLL CARDIOL, V40, P1339, DOI 10.1016/S0735-1097(02)02156-3; Gerczuk PZ, 2012, J AM COLL CARDIOL, V59, P969, DOI 10.1016/j.jacc.2011.07.054; Giannotta M, 2013, DEV CELL, V26, P441, DOI 10.1016/j.devcel.2013.08.020; Guo JA, 2011, CIRC-HEART FAIL, V4, P79, DOI 10.1161/CIRCHEARTFAILURE.110.957969; Hausenloy DJ, 2006, CARDIOVASC RES, V70, P240, DOI 10.1016/j.cardiores.2006.01.017; Hausenloy DJ, 2013, J CLIN INVEST, V123, P92, DOI 10.1172/JCI62874; Ikeno F, 2007, CARDIOVASC RES, V73, P699, DOI 10.1016/j.cardiores.2006.12.011; Kang Sheng, 2009, Cardiovascular & Hematological Disorders - Drug Targets, V9, P107; Karalliedde LD, 2009, AM J PHYSIOL-HEART C, V297, pH1967, DOI 10.1152/ajpheart.00944.2009; Kumar P, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001112; Lee WL, 2010, NEW ENGL J MED, V363, P689, DOI 10.1056/NEJMcibr1007320; Lee WW, 2012, J AM COLL CARDIOL, V59, P153, DOI 10.1016/j.jacc.2011.08.066; Li LJ, 2009, PHARMACOL RES, V60, P277, DOI 10.1016/j.phrs.2009.04.001; Li XD, 2013, INT J CARDIOL, V167, P2657, DOI 10.1016/j.ijcard.2012.06.121; Li XD, 2013, CHINESE MED J-PEKING, V126, P1469, DOI 10.3760/cma.j.issn.0366-6999.20130224; Li Xiang-dong, 2012, Zhonghua Xin Xue Guan Bing Za Zhi, V40, P945; Li XD, 2012, ACTA PHARMACOL SIN, V33, P879, DOI 10.1038/aps.2012.27; Li XD, 2012, MICROVASC RES, V84, P44, DOI 10.1016/j.mvr.2012.04.002; Li XD, 2010, AM J PHYSIOL-HEART C, V299, pH1255, DOI 10.1152/ajpheart.00459.2010; Li Z, 2012, BIOCHEM BIOPH RES CO, V425, P630, DOI 10.1016/j.bbrc.2012.07.130; Maeng YS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068659; Milligan PA, 2013, CLIN PHARMACOL THER, V93, P502, DOI 10.1038/clpt.2013.54; Moey M, 2012, CIRC-HEART FAIL, V5, P504, DOI 10.1161/CIRCHEARTFAILURE.112.967489; Muscari C, 2004, LIFE SCI, V74, P1127, DOI 10.1016/j.lfs.2003.10.001; Nicholson JK, 2008, J PROTEOME RES, V7, P3637, DOI 10.1021/pr8005099; O'Rourke B, 2000, CIRC RES, V87, P845, DOI 10.1161/01.RES.87.10.845; OH B, 2013, EUR HEART J, V34, P932, DOI [10.1093/eurheartj/ehs396, DOI 10.1093/EURHEARTJ/EHS396]; Rezkalla SH, 2008, CATHETER CARDIO INTE, V72, P950, DOI 10.1002/ccd.21715; Ruder TD, 2013, FORENSIC SCI MED PAT, V9, P501, DOI 10.1007/s12024-013-9459-x; Swirski FK, 2013, SCIENCE, V339, P161, DOI 10.1126/science.1230719; Weis SM, 2005, NATURE, V437, P497, DOI 10.1038/nature03987; Wu ZQ, 2006, MOL PHARMACOL, V69, P866, DOI 10.1124/mol.106.016501; Xuan YT, 2007, CIRCULATION, V116, P535, DOI 10.1161/CIRCULATIONAHA.107.689471; Yang CJ, 2013, CARDIOVASC RES, V97, P33, DOI 10.1093/cvr/cvs287; Yang YJ, 2006, HEART, V92, P1131, DOI 10.1136/hrt.2005.077164; Yang YJ, 2007, EUR J HEART FAIL, V9, P30, DOI 10.1016/j.ejheart.2006.04.013; Zhang HT, 2010, CHINESE MED J-PEKING, V123, P2858, DOI 10.3760/cma.j.issn.0366-6999.2010.20.021; Zhang Hai-tao, 2009, Zhonghua Yi Xue Za Zhi, V89, P1421; Zhang L, 2009, AM J PHYSIOL-HEART C, V297, pH2004, DOI 10.1152/ajpheart.00208.2009; Zhao JL, 2006, BRIT J PHARMACOL, V149, P243, DOI 10.1038/sj.bjp.0706862; Zhao JL, 2007, MICROVASC RES, V73, P137, DOI 10.1016/j.mvr.2006.09.002; Zhao JL, 2006, CLIN CHIM ACTA, V374, P100, DOI 10.1016/j.cca.2006.05.039; Zhao JL, 2006, CORONARY ARTERY DIS, V17, P463, DOI 10.1097/00019501-200608000-00010; Zhao JL, 2006, CARDIOVASC DRUG THER, V20, P167, DOI 10.1007/s10557-006-8284-9; Zhao Jing-Lin, 2005, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V27, P486; Zhao JL, 2007, INT J CARDIOL, V115, P334, DOI 10.1016/j.ijcard.2006.03.017	62	19	25	0	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 17	2015	10	3							e0119846	10.1371/journal.pone.0119846	http://dx.doi.org/10.1371/journal.pone.0119846			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CD7QC	25781461	gold, Green Submitted, Green Published			2023-01-03	WOS:000351284600100
J	Cao, CN; Luo, JW; Gao, L; Yi, JL; Huang, XD; Wang, K; Zhang, SP; Qu, Y; Li, SY; Xiao, JP; Zhang, Z; Xu, GZ				Cao, Cai-neng; Luo, Jing-wei; Gao, Li; Yi, Jun-lin; Huang, Xiao-dong; Wang, Kai; Zhang, Shi-ping; Qu, Yuan; Li, Su-yan; Xiao, Jian-ping; Zhang, Zhong; Xu, Guo-zhen			Concurrent Chemotherapy for T4 Classification Nasopharyngeal Carcinoma in the Era of Intensity-Modulated Radiotherapy	PLOS ONE			English	Article							POSITIVE PROGNOSTIC-FACTOR; ACUTE ORGAN TOXICITY; RADIATION; OUTCOMES; CANCER; METAANALYSIS; EXPERIENCE; UPDATE; TRIAL	Objective To evaluate concurrent chemotherapy for T4 classification nasopharyngeal carcinoma (NPC) treated by intensity-modulated radiotherapy (IMRT). Methods From July 2004 to June 2011, 180 non-metastatic T4 classification NPC patients were retrospectively analyzed. Of these patients, 117 patients were treated by concurrent chemoradiotherapy (CCRT) using IMRT and 63 cases were treated by IMRT alone. Results The median follow-up time was 58.97 months (range, 2.79-114.92) months. For all the patients, the 1, 3 and 5-year local failure-free survival (LFFS) rates were 97.7%, 89.2% and 85.9%, regional failure free survival (RFFS) rates were 98.9%, 94.4% and 94.4%, distant failure-free survival (DFFS) rates were 89.7%, 79.9% and 76.2%, and overall survival (OS) rates were 92.7%, 78.9% and 65.3%, respectively. No statistically significant difference was observed in LFFS, RFFS, DFFS and OS between the CCRT group and the IMRT alone group. No statistically significant difference was observed in acute toxicity except leukopenia (p = 0.000) during IMRT between the CCRT group and the IMRT alone group. Conclusion IMRT alone for T4 classification NPC achieved similar treatment outcomes in terms of disease local control and overall survival as compared to concurrent chemotherapy plus IMRT. However, this is a retrospective study with a limited number of patients, such results need further investigation in a prospective randomized clinical trial.	[Cao, Cai-neng; Luo, Jing-wei; Gao, Li; Yi, Jun-lin; Huang, Xiao-dong; Wang, Kai; Zhang, Shi-ping; Qu, Yuan; Li, Su-yan; Xiao, Jian-ping; Zhang, Zhong; Xu, Guo-zhen] Chinese Acad Med Sci, Canc Hosp, Peking Union Med Coll, Dept Radiat Oncol, Beijing 100730, Peoples R China; [Cao, Cai-neng] Zhejiang Canc Hosp, Dept Radiat Oncol, Hangzhou, Zhejiang, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; Zhejiang Cancer Hospital	Luo, JW (corresponding author), Chinese Acad Med Sci, Canc Hosp, Peking Union Med Coll, Dept Radiat Oncol, Beijing 100730, Peoples R China.	jingweiluo2013@163.com	Xiao, Jian/GYU-4351-2022					Al-Sarraf M, 1998, J CLIN ONCOL, V16, P1310, DOI 10.1200/JCO.1998.16.4.1310; Baujat B, 2006, INT J RADIAT ONCOL, V64, P47, DOI 10.1016/j.ijrobp.2005.06.037; Bonner JA, 2010, LANCET ONCOL, V11, P21, DOI 10.1016/S1470-2045(09)70311-0; Cao CN, 2013, ORAL ONCOL, V49, P175, DOI 10.1016/j.oraloncology.2012.08.013; DAHL O, 1994, ACTA ONCOL, V33, P409, DOI 10.3109/02841869409098437; Kam MKM, 2007, J CLIN ONCOL, V25, P4873, DOI 10.1200/JCO.2007.11.5501; Kim Tae Hee, 2008, Cancer Res Treat, V40, P62, DOI 10.4143/crt.2008.40.2.62; Kuhnt T, 1998, STRAHLENTHER ONKOL, V174, P257, DOI 10.1007/BF03038718; Langendijk JA, 2004, J CLIN ONCOL, V22, P4604, DOI 10.1200/JCO.2004.10.074; Lee AWM, 2011, RADIOTHER ONCOL, V98, P15, DOI 10.1016/j.radonc.2010.09.023; Lee AWM, 2010, JNCI-J NATL CANCER I, V102, P1188, DOI 10.1093/jnci/djq258; Lee N, 2002, INT J RADIAT ONCOL, V53, P12, DOI 10.1016/S0360-3016(02)02724-4; Lin SJ, 2014, RADIOTHER ONCOL, V110, P385, DOI 10.1016/j.radonc.2014.01.011; Loong HH, 2014, ORAL ONCOL, DOI [10.1016/j.oraloncology.2014.01.010.1016/j.radonc.2012.08.013, DOI 10.1016/J.ORALONCOLOGY.2014.01.0]; Peng G, 2012, RADIOTHER ONCOL, V104, P286, DOI 10.1016/j.radonc.2012.08.013; Pow EHN, 2006, INT J RADIAT ONCOL, V66, P981, DOI 10.1016/j.ijrobp.2006.06.013; Sultanem K, 2000, INT J RADIAT ONCOL, V48, P711, DOI 10.1016/S0360-3016(00)00702-1; Sun XM, 2014, RADIOTHER ONCOL, V110, P398, DOI 10.1016/j.radonc.2013.10.020; Wang TJC, 2012, J RADIOL ONCOL, V1, P129, DOI 10.1007/s13566-012-0020-4; Wolff HA, 2011, RADIOLOGY, V258, P864, DOI 10.1148/radiol.10100705; Wolff HA, 2011, INT J RADIAT ONCOL, V79, P1467, DOI 10.1016/j.ijrobp.2010.01.010	21	15	16	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 6	2015	10	3							e0119101	10.1371/journal.pone.0119101	http://dx.doi.org/10.1371/journal.pone.0119101			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC9KQ	25747589	gold, Green Published, Green Submitted			2023-01-03	WOS:000350689400044
J	Verissimo, P; Timenetsky, KT; Casalaspo, TJA; Goncalves, LHR; Yang, ASY; Eid, RC				Verissimo, Pedro; Timenetsky, Karina T.; Andre Casalaspo, Thaisa Juliana; Rodrigues Goncalves, Louise Helena; Yun Yang, Angela Shu; Eid, Raquel Caserta			High Prevalence of Respiratory Muscle Weakness in Hospitalized Acute Heart Failure Elderly Patients	PLOS ONE			English	Article							TASK-FORCE; DYSFUNCTION; EXERCISE; PRESSURES; STRENGTH; SOCIETY	Introduction Respiratory Muscle Weakness (RMW) has been defined when the maximum inspiratory pressure (MIP) is lower than 70% of the predictive value. The prevalence of RMW in chronic heart failure patients is 30 to 50%. So far there are no studies on the prevalence of RMW in acute heart failure (AHF) patients. Objectives Evaluate the prevalence of RMW in patients admitted because of AHF and the condition of respiratory muscle strength on discharge from the hospital. Methods Sixty-three patients had their MIP measured on two occasions: at the beginning of the hospital stay, after they had reached respiratory, hemodynamic and clinical stability and before discharge from the hospital. The apparatus and technique to measure MIP were adapted because of age-related limitations of the patients. Data on cardiac ejection fraction, ECG, brain natriuretic peptide (BNP) levels and on the use of noninvasive ventilation (NIV) were collected. Results The mean age of the 63 patients under study was 75 years. On admission the mean ejection fraction was 33% (95% CI: 31-35) and the BNP hormone median value was 726.5 pg/ml (range: 217 to 2283 pg/ml); 65% of the patients used NIV. The median value of MIP measured after clinical stabilization was -52.7 cmH2O (range: -20 to -120 cmH(2)O); 76% of the patients had MIP values below 70% of the predictive value. On discharge, after a median hospital stay of 11 days, the median MIP was -53.5 cmH(2)O (range:-20 to -150 cmH(2)O); 71% of the patients maintained their MIP values below 70% of the predictive value. The differences found were not statistically significant. Conclusion Elderly patients admitted with AHF may present a high prevalence of RMW on admission; this condition may be maintained at similar levels on discharge in a large percentage of these patients, even after clinical stabilization of the heart condition.	[Verissimo, Pedro] Hosp Israelita Albert Einstein, Intens Care Unit, Sao Paulo, Brazil; Hosp Israelita Albert Einstein, Coronary Care Unit, Sao Paulo, Brazil	Hospital Israelita Albert Einstein; Hospital Israelita Albert Einstein	Verissimo, P (corresponding author), Hosp Israelita Albert Einstein, Intens Care Unit, Sao Paulo, Brazil.	pedropbusp@yahoo.com.br						Bosnak-Guclu M, 2011, RESP MED, V105, P1671, DOI 10.1016/j.rmed.2011.05.001; Brower Roy G, 2009, Crit Care Med, V37, pS422, DOI 10.1097/CCM.0b013e3181b6e30a; Burtin C, 2009, CRIT CARE MED, V37, P2499, DOI 10.1097/CCM.0b013e3181a38937; Callegaro CC, 2010, RESP PHYSIOL NEUROBI, V171, P31, DOI 10.1016/j.resp.2010.01.009; Caruso P, 1999, CHEST, V115, P1096, DOI 10.1378/chest.115.4.1096; Chiappa GR, 2008, J AM COLL CARDIOL, V51, P1663, DOI 10.1016/j.jacc.2007.12.045; Chung CJ, 2011, PHYSICIAN SPORTSMED, V39, P37, DOI 10.3810/psm.2011.11.1937; Dall'Ago P, 2006, J AM COLL CARDIOL, V47, P757, DOI 10.1016/j.jacc.2005.09.052; De Jonghe B, 2007, CRIT CARE MED, V35, P2007, DOI 10.1097/01.ccm.0000281450.01881.d8; Frankenstein L, 2009, EUR J CARDIOV PREV R, V16, P424, DOI 10.1097/HJR.0b013e3283030a7e; Gosker HR, 2000, AM J CLIN NUTR, V71, P1033; Gosselink R, 2008, INTENS CARE MED, V34, P1188, DOI 10.1007/s00134-008-1026-7; Jonghe B, 2009, CRIT CARE MED, V37, P309; Krumholz HM, 2008, CIRCULATION, V118, P2596, DOI 10.1161/CIRCULATIONAHA.108.191099; MARINI J J, 1986, Journal of Critical Care, V1, P32, DOI 10.1016/S0883-9441(86)80114-9; Mebazaa Alexandre, 2008, Crit Care Med, V36, pS129, DOI 10.1097/01.CCM.0000296274.51933.4C; Meyer FJ, 2001, CIRCULATION, V103, P2153; Montera MW, 2012, ARQ BRAS CARDIOL, V98; Neder JA, 1999, BRAZ J MED BIOL RES, V32, P719, DOI 10.1590/S0100-879X1999000600007; Needham DM, 2008, JAMA-J AM MED ASSOC, V300, P1685, DOI 10.1001/jama.300.14.1685; NISHIMURA Y, 1994, CHEST, V105, P355, DOI 10.1378/chest.105.2.355; OMLAND T, 2008, CRIT CARE MED, V36, P17; Ribeiro Jorge P, 2009, Curr Heart Fail Rep, V6, P95; RIBEIRO JP, 2012, REV BRAS FISIOTER, V16, P261, DOI DOI 10.1590/S1413-35552012005000034; Smart NA, 2013, INT J CARDIOL, V167, P1502, DOI 10.1016/j.ijcard.2012.04.029; Tzanis G, 2011, BMC ANESTHESIOL, V11, DOI 10.1186/1471-2253-11-14; Winkelmann ER, 2009, AM HEART J, V158, DOI 10.1016/j.ahj.2009.09.005; Wohlgemuth M, 2003, EUR RESPIR J, V22, P1001, DOI 10.1183/09031936.03.00028103; Wong E, 2011, HEART LUNG CIRC, V20, P289, DOI 10.1016/j.hlc.2011.01.009; Yosef-Brauner O, 2015, CLIN RESPIR J, V9, P1, DOI 10.1111/crj.12091	30	14	15	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 11	2015	10	2							e0118218	10.1371/journal.pone.0118218	http://dx.doi.org/10.1371/journal.pone.0118218			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CB3RF	25671566	gold, Green Submitted, Green Published			2023-01-03	WOS:000349545300089
J	Lenzer, J				Lenzer, Jeanne			PRESCRIBING California doctors under investigation for prescribing practices	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												jeanne.lenzer@gmail.com						De Sa K., 2014, SAN JOSE MERCUR 1123; De Sa K., 2015, SAN JOSE MERCUR 0112; Ho BC, 2011, ARCH GEN PSYCHIAT, V68, P128, DOI 10.1001/archgenpsychiatry.2010.199; Kumar A, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009582.pub2; Lord S., FOSTER CHILDREN HHS; Stanton T., 2012, DRUGGING OUR CHILDRE; Weber T, 2013, MEDICARE DRUG PROGRA	7	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 29	2015	350								h74	10.1136/bmj.h74	http://dx.doi.org/10.1136/bmj.h74			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CA3AT	25633865				2023-01-03	WOS:000348778700014
J	Meade, BR; Gogoi, K; Hamil, AS; Palm-Apergi, C; van den Berg, A; Hagopian, JC; Springer, AD; Eguchi, A; Kacsinta, AD; Dowdy, CF; Presente, A; Lonn, P; Kaulich, M; Yoshioka, N; Gros, E; Cui, XS; Dowdy, SF				Meade, Bryan R.; Gogoi, Khirud; Hamil, Alexander S.; Palm-Apergi, Caroline; van den Berg, Arjen; Hagopian, Jonathan C.; Springer, Aaron D.; Eguchi, Akiko; Kacsinta, Apollo D.; Dowdy, Connor F.; Presente, Asaf; Loenn, Peter; Kaulich, Manuel; Yoshioka, Naohisa; Gros, Edwige; Cui, Xian-Shu; Dowdy, Steven F.			Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modifications	NATURE BIOTECHNOLOGY			English	Article							SOLID-PHASE SYNTHESIS; CHEMICAL-MODIFICATION; SIRNA DELIVERY; INTERFERENCE; DESIGN; SATE; PHOSPHODIESTER; PHOSPHONATE; PROGRESS; DNA	RNA interference (RNAi) has great potential to treat human disease(1-3). However, in vivo delivery of short interfering RNAs (siRNAs), which are negatively charged double-stranded RNA macromolecules, remains a major hurdle(4-9). Current siRNA delivery has begun to move away from large lipid and synthetic nanoparticles to more defined molecular conjugates(9). Here we address this issue by synthesis of short interfering ribonucleic neutrals (siRNNs) whose phosphate backbone contains neutral phosphotriester groups, allowing for delivery into cells. Once inside cells, siRNNs are converted by cytoplasmic thioesterases into native, charged phosphodiester-backbone siRNAs, which induce robust RNAi responses. siRNNs have favorable drug-like properties, including high synthetic yields, serum stability and absence of innate immune responses. Unlike siRNAs, siRNNs avidly bind serum albumin to positively influence pharmacokinetic properties. Systemic delivery of siRNNs conjugated to a hepatocyte-specific targeting domain induced extended dose-dependent in vivo RNAi responses in mice. We believe that siRNNs represent a technology that will open new avenues for development of RNAi therapeutics.	[Meade, Bryan R.; Gogoi, Khirud; Hamil, Alexander S.; Palm-Apergi, Caroline; van den Berg, Arjen; Hagopian, Jonathan C.; Springer, Aaron D.; Eguchi, Akiko; Kacsinta, Apollo D.; Dowdy, Connor F.; Presente, Asaf; Loenn, Peter; Kaulich, Manuel; Yoshioka, Naohisa; Gros, Edwige; Cui, Xian-Shu; Dowdy, Steven F.] Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; [Presente, Asaf] Univ Calif San Diego, Sch Med, Dept Med, Div Pulm & Crit Care, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Dowdy, SF (corresponding author), Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA.	sdowdy@ucsd.edu	Eguchi, Akiko/E-3086-2010; Kaulich, Manuel/U-4523-2017	Kaulich, Manuel/0000-0002-9528-8822; Palm Apergi, Caroline/0000-0003-2236-2099	Cancer Biology Training grant (NCI); San Diego Foundation; C.I.R.M. Fellowship; Knut and Alice Wallenberg Foundation; Sweden-America Foundation; CT2 training grant (N.C.I.); Swedish Research Council grant; IRACDA Training grant (N.I.H.); W.M. Keck Foundation; Department of Defense; Leukemia & Lymphoma Society; Pardee Foundation; Howard Hughes Medical Institute; NATIONAL CANCER INSTITUTE [T32CA121938, T32CA067754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K12GM068524] Funding Source: NIH RePORTER	Cancer Biology Training grant (NCI); San Diego Foundation; C.I.R.M. Fellowship; Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Sweden-America Foundation; CT2 training grant (N.C.I.); Swedish Research Council grant(Swedish Research Council); IRACDA Training grant (N.I.H.); W.M. Keck Foundation(W.M. Keck Foundation); Department of Defense(United States Department of Defense); Leukemia & Lymphoma Society(Leukemia and Lymphoma Society); Pardee Foundation; Howard Hughes Medical Institute(Howard Hughes Medical Institute); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Y. Tor (UCSD) for critical input, Y. Su (UCSD) for help with mass spectrometry, and Z. Rudolph and L.D.F. Vasconcelos for technical assistance. B.R.M., A.S.H. and A.D.S. were supported by a T32 Cancer Biology Training grant (NCI); A.S.H. was also supported by a Blasker Award from The San Diego Foundation; A. P. was supported by a C.I.R.M. Fellowship; C.P.-A. was supported by fellowships from Knut and Alice Wallenberg Foundation and Sweden-America Foundation; J.C.H. was supported by the CT2 training grant (N.C.I.); P.L. was supported by a Swedish Research Council grant; A.D.K. was supported by a IRACDA Training grant (N.I.H.). This work was supported by the W.M. Keck Foundation (S.F.D.), the Department of Defense (S.F.D.), SCOR grant from the Leukemia & Lymphoma Society (S.F.D.), the Pardee Foundation (S.F.D.), a grant from an anonymous donor (S.F.D.) and the Howard Hughes Medical Institute (S.F.D.).	Beaucage SL, 2008, CURR OPIN DRUG DISC, V11, P203; Behlke MA, 2008, OLIGONUCLEOTIDES, V18, P305, DOI 10.1089/oli.2008.0164; Bologna JC, 1999, EUR J ORG CHEM, V1999, P2353; Bramsen JB, 2011, METHODS MOL BIOL, V721, P77, DOI 10.1007/978-1-61779-037-9_5; BRESLOW R, 1993, P NATL ACAD SCI USA, V90, P1201, DOI 10.1073/pnas.90.4.1201; Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035; Castanotto D, 2009, NATURE, V457, P426, DOI 10.1038/nature07758; Davidson BL, 2011, NAT REV GENET, V12, P329, DOI 10.1038/nrg2968; Dellinger DJ, 2003, J AM CHEM SOC, V125, P940, DOI 10.1021/ja027983f; Eguchi A, 2009, NAT BIOTECHNOL, V27, P567, DOI 10.1038/nbt.1541; Faraj A, 1999, NUCLEOS NUCLEOT, V18, P987, DOI 10.1080/15257779908041623; Gao S, 2009, MOL THER, V17, P1225, DOI 10.1038/mt.2009.91; Gates KS, 2009, CHEM RES TOXICOL, V22, P1747, DOI 10.1021/tx900242k; Grajkowski A, 2001, ORG LETT, V3, P1287, DOI 10.1021/ol0156852; Guzaev A, 1999, NUCLEOS NUCLEOT, V18, P1391, DOI 10.1080/07328319908044727; Joshua-Tor L, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003772; Judge AD, 2006, MOL THER, V13, P494, DOI 10.1016/j.ymthe.2005.11.002; Kanasty R, 2013, NAT MATER, V12, P967, DOI [10.1038/NMAT3765, 10.1038/nmat3765]; Krishna H, 2012, J AM CHEM SOC, V134, P11618, DOI 10.1021/ja3026714; KUIJPERS WHA, 1990, NUCLEIC ACIDS RES, V18, P5197, DOI 10.1093/nar/18.17.5197; LEFEBVRE I, 1995, J MED CHEM, V38, P3941, DOI 10.1021/jm00020a007; Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0; Meade Bryan R, 2009, Discov Med, V8, P253; Pecot CV, 2011, NAT REV CANCER, V11, P59, DOI 10.1038/nrc2966; PERIGAUD C, 1993, BIOORG MED CHEM LETT, V3, P2521, DOI 10.1016/S0960-894X(01)80709-5; Petersen S, 2014, USPTO, Patent No. [8,691,971, 8691971]; Peyrottes S, 2004, MINI-REV MED CHEM, V4, P395; Pon RT, 1997, NUCLEIC ACIDS RES, V25, P3629, DOI 10.1093/nar/25.18.3629; Reese CB, 2005, ORG BIOMOL CHEM, V3, P3851, DOI 10.1039/b510458k; Rettig GR, 2012, MOL THER, V20, P483, DOI 10.1038/mt.2011.263; Robbins M, 2009, OLIGONUCLEOTIDES, V19, P89, DOI 10.1089/oli.2009.0180; Sliedregt LAJM, 1999, J MED CHEM, V42, P609, DOI 10.1021/jm981078h; Tanabe K, 2011, TETRAHEDRON LETT, V52, P7135, DOI 10.1016/j.tetlet.2011.10.109; Tosquellas G, 1998, NUCLEIC ACIDS RES, V26, P2069, DOI 10.1093/nar/26.9.2069; van den Berg A, 2011, CURR OPIN BIOTECH, V22, P888, DOI 10.1016/j.copbio.2011.03.008; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996; Whitehead KA, 2011, ANNU REV CHEM BIOMOL, V2, P77, DOI 10.1146/annurev-chembioeng-061010-114133; Zhou JH, 2013, PHARMACEUTICALS, V6, P85, DOI 10.3390/ph6010085	38	144	168	6	100	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2014	32	12					1256	U122		10.1038/nbt.3078	http://dx.doi.org/10.1038/nbt.3078			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	AW3AD	25402614	Green Accepted			2023-01-03	WOS:000346156800028
J	Yoo, JJ; Lee, JH; Lee, SH; Lee, M; Lee, DH; Cho, Y; Lee, YB; Yu, SJ; Kim, HC; Kim, YJ; Yoon, JH; Kim, CY; Lee, HS				Yoo, Jeong-Ju; Lee, Jeong-Hoon; Lee, Sang Hwan; Lee, Minjong; Lee, Dong Hyeon; Cho, Yuri; Lee, Yun Bin; Yu, Su Jong; Kim, Hyo-Cheol; Kim, Yoon Jun; Yoon, Jung-Hwan; Kim, Chung Yong; Lee, Hyo-Suk			Comparison of the Effects of Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma between Patients with and without Extrahepatic Metastases	PLOS ONE			English	Article							PROMOTES; MANAGEMENT; SORAFENIB; DIAGNOSIS; SURVIVAL; IMPROVE; VEIN	Background/Aims: Sorafenib is a standard treatment for advanced hepatocellular carcinoma (HCC) (Barcelona Clinic Liver Cancer [BCLC] stage C). However, transarterial chemoembolization (TACE) has also been widely used as a treatment for patients with advanced HCC, even if they have extrahepatic metastases (EHM). The aim of this study was to determine the efficacy of TACE for advanced HCC patients with EHM upon initial diagnosis, as compared with those patients without EHM. Methods: This cohort study involved consecutive patients who underwent TACE as an initial treatment for advanced HCC. One hundred seventy-seven patients with EHM (the EHM group) and 205 with portal vein invasion without EHM (the non-EHM group) were included. A survival analysis was performed to compare overall survival between the two groups. Results: The mean age was 54.5 +/- 9.9 years, and median follow-up duration was 13.1 months (range, 0.5-111.0). Overall survival was significantly shorter in the EHM group than the non-EHM group (median, 8.3 vs. 19.1 months; P<0.001). A multivariate analysis showed that the presence of EHM was an independent poor prognostic factor for shorter overall survival (adjusted hazard ratio, 1.74; 95% confidence interval, 1.39-2.17; P<0.001) after adjustment for Child-Pugh classification, intrahepatic tumor T classification, tumor response to TACE, and serum alpha-fetoprotein level. Patients administered TACE and systemic therapy demonstrated a better survival rate than those administered TACE alone in both the EHM (median, 13.5 vs. 7.2 months) and non-EHM groups (median, 27.9 vs. 18.2 months) (both, P<0.05). Conclusions: The prognosis of advanced HCC patients with EHM is significantly worse than those without EHM administered repeated TACE treatments, even if their tumor stage was similar to BCLC stage C. These results suggest that EHM presence means aggressive tumor biology and that BCLC stage C might be subclassified according to EHM presence.	[Yoo, Jeong-Ju; Lee, Jeong-Hoon; Lee, Minjong; Lee, Dong Hyeon; Cho, Yuri; Lee, Yun Bin; Yu, Su Jong; Kim, Yoon Jun; Yoon, Jung-Hwan; Kim, Chung Yong; Lee, Hyo-Suk] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul Natl Univ Hosp, Seoul 151, South Korea; [Yoo, Jeong-Ju; Lee, Jeong-Hoon; Lee, Minjong; Lee, Dong Hyeon; Cho, Yuri; Lee, Yun Bin; Yu, Su Jong; Kim, Yoon Jun; Yoon, Jung-Hwan; Kim, Chung Yong; Lee, Hyo-Suk] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Liver Res Inst, Seoul, South Korea; [Lee, Sang Hwan; Kim, Hyo-Cheol] Seoul Natl Univ, Coll Med, Dept Radiol, Seoul, South Korea; [Lee, Sang Hwan; Kim, Hyo-Cheol] Seoul Natl Univ, Med Res Ctr, Inst Radiat Med, Seoul, South Korea	Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University (SNU)	Lee, JH (corresponding author), Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul Natl Univ Hosp, Seoul 151, South Korea.	pindra@empal.com	Lee, Jeong-Hoon/Q-1055-2018	Lee, Jeong-Hoon/0000-0002-0315-2080; Yoo, Jeong-Ju/0000-0002-7802-0381; Lee, Yun Bin/0000-0002-3193-9745; Kim, Yoon Jun/0000-0001-9141-7773; Yoon, Jung-Hwan/0000-0002-9128-3610; , minjong/0000-0002-3159-5444; Yu, Su Jong/0000-0001-8888-7977; Kim, Hyo-Cheol/0000-0002-6016-247X				Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; Choi GH, 2013, RADIOLOGY, V269, P602, DOI 10.1148/radiol.13130150; Chung GE, 2011, RADIOLOGY, V258, P627, DOI 10.1148/radiol.10101058; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Forner A, 2010, SEMIN LIVER DIS, V30, P61, DOI 10.1055/s-0030-1247133; Kanda M, 2008, LIVER INT, V28, P1256, DOI 10.1111/j.1478-3231.2008.01864.x; Katyal S, 2000, RADIOLOGY, V216, P698, DOI 10.1148/radiology.216.3.r00se24698; Kim HC, 2013, J VASC INTERV RADIOL, V24, P274, DOI 10.1016/j.jvir.2012.11.002; Lee HS, 2011, DIGEST DIS, V29, P333, DOI 10.1159/000327572; Lencioni R, 2010, SEMIN LIVER DIS, V30, P52, DOI 10.1055/s-0030-1247132; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Llovet JM, 2008, J HEPATOL, V48, pS20, DOI 10.1016/j.jhep.2008.01.022; Natsuizaka M, 2005, J GASTROEN HEPATOL, V20, P1781, DOI 10.1111/j.1440-1746.2005.03919.x; Park JW, 2012, J HEPATOL, V56, P1336, DOI 10.1016/j.jhep.2012.01.006; Verslype C, 2012, ANN ONCOL, V23, P41, DOI 10.1093/annonc/mds225; Xia L, 2014, ONCOGENE, V33, P1395, DOI 10.1038/onc.2013.90; Xia LM, 2014, HEPATOLOGY, V59, P958, DOI 10.1002/hep.26735; Yoo DJ, 2011, J GASTROEN HEPATOL, V26, P145, DOI 10.1111/j.1440-1746.2010.06341.x; Zhao FT, 2013, ASIAN PAC J CANCER P, V14, P3831, DOI 10.7314/APJCP.2013.14.6.3831	21	18	19	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 26	2014	9	11							e113926	10.1371/journal.pone.0113926	http://dx.doi.org/10.1371/journal.pone.0113926			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA8CZ	25427152	gold, Green Published, Green Submitted			2023-01-03	WOS:000349145400103
J	Stupple, A				Stupple, Aaron			PERSONAL VIEW Training in communication skills should be integrated with mandatory resuscitation training	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Stupple, A (corresponding author), Beth Israel Deaconess Med Ctr, 330 Brookline Ave, Boston, MA 02215 USA.	astupple@gmail.com						Institute of Medicine, 2014, DYING IN AMERICA IMP	1	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 19	2015	350								h1405	10.1136/bmj.h1405	http://dx.doi.org/10.1136/bmj.h1405			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CE1KV	25791831				2023-01-03	WOS:000351571400003
J	Gentile, MT; Ciniglia, C; Reccia, MG; Volpicelli, F; Gatti, M; Thellung, S; Florio, T; Melone, MAB; Colucci-D'Amato, L				Gentile, Maria Teresa; Ciniglia, Claudia; Reccia, Mafalda G.; Volpicelli, Floriana; Gatti, Monica; Thellung, Stefano; Florio, Tullio; Melone, Mariarosa A. B.; Colucci-D'Amato, Luca			Ruta graveolens L. Induces Death of Glioblastoma Cells and Neural Progenitors, but Not of Neurons, via ERK 1/2 and AKT Activation	PLOS ONE			English	Article							ESTROGEN-BINDING-SITES; IN-VITRO; NATURAL-PRODUCTS; TERMINAL DIFFERENTIATION; SOMATOSTATIN INHIBITION; DRUG DISCOVERY; RET ONCOGENE; GLIOMA-CELLS; EXPRESSION; PROLIFERATION	Glioblastoma multiforme is a highly aggressive brain tumor whose prognosis is very poor. Due to early invasion of brain parenchyma, its complete surgical removal is nearly impossible, and even after aggressive combined treatment (association of surgery and chemo-and radio-therapy) five-year survival is only about 10%. Natural products are sources of novel compounds endowed with therapeutic properties in many human diseases, including cancer. Here, we report that the water extract of Ruta graveolens L., commonly known as rue, induces death in different glioblastoma cell lines (U87MG, C6 and U138) widely used to test novel drugs in preclinical studies. Ruta graveolens' effect was mediated by ERK1/2 and AKT activation, and the inhibition of these pathways, via PD98058 and wortmannin, reverted its antiproliferative activity. Rue extract also affects survival of neural precursor cells (A1) obtained from embryonic mouse CNS. As in the case of glioma cells, rue stimulates the activation of ERK1/2 and AKT in A1 cells, whereas their blockade by pharmacological inhibitors prevents cell death. Interestingly, upon induction of differentiation and cell cycle exit, A1 cells become resistant to rue's noxious effects but not to those of temozolomide and cisplatin, two alkylating agents widely used in glioblastoma therapy. Finally, rutin, a major component of the Ruta graveolens water extract, failed to cause cell death, suggesting that rutin by itself is not responsible for the observed effects. In conclusion, we report that rue extracts induce glioma cell death, discriminating between proliferating/undifferentiated and non-proliferating/differentiated neurons. Thus, it can be a promising tool to isolate novel drugs and also to discover targets for therapeutic intervention.	[Gentile, Maria Teresa; Ciniglia, Claudia; Reccia, Mafalda G.; Colucci-D'Amato, Luca] Univ Naples 2, Dept Environm Biol & Pharmaceut Sci & Technol, Lab Mol & Cellular Pathol, Caserta, Italy; [Volpicelli, Floriana] Univ Naples Federico II, Dept Pharm, Naples, Italy; [Volpicelli, Floriana] CNR, Inst Genet & Biophys Adriano Buzzati Traverso, I-80125 Naples, Italy; [Gatti, Monica; Thellung, Stefano; Florio, Tullio] Univ Genoa, Dept Internal Med, Pharmacol Sect, I-16126 Genoa, Italy; [Gatti, Monica; Thellung, Stefano; Florio, Tullio] Univ Genoa, CEBR, Genoa, Italy; [Melone, Mariarosa A. B.] Univ Naples 2, Dept Clin & Expt Med & Surg, Div Neurol, Naples, Italy; [Melone, Mariarosa A. B.; Colucci-D'Amato, Luca] Univ Naples 2, CIRN, Naples, Italy	Universita della Campania Vanvitelli; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); University of Genoa; University of Genoa; Universita della Campania Vanvitelli; Universita della Campania Vanvitelli	Colucci-D'Amato, L (corresponding author), Univ Naples 2, Dept Environm Biol & Pharmaceut Sci & Technol, Lab Mol & Cellular Pathol, Caserta, Italy.	luca.colucci@unina2.it	terracciano, chiara/C-2955-2018; Melone, Mariarosa Anna Beatrice/N-6788-2015; Thellung, Stefano/L-8802-2015; FLORIO, TULLIO/ABG-3182-2020; Florio, Tullio/A-2211-2012; CINIGLIA, CLAUDIA/D-7053-2017	terracciano, chiara/0000-0002-1853-5578; Melone, Mariarosa Anna Beatrice/0000-0002-7213-9277; Thellung, Stefano/0000-0002-2010-331X; Florio, Tullio/0000-0002-2394-996X; GENTILE, Maria Teresa/0000-0003-4239-5330; Reccia, Mafalda Giovanna/0000-0002-5568-0221; CINIGLIA, CLAUDIA/0000-0001-5819-6921; Monica, Gatti/0000-0002-2016-0285; Volpicelli, Floriana/0000-0003-0618-5504	Progetto Sicurezza, sostenibilita e competitivita nelle produzioni Agroalimentari delle Campania "CARINA"; Network per la salvaguardia e la gestione delle risorse genetiche agro-alimentari "AGRIGENET"; Programma di Ricerca Scientifica di Rilevante Interesse Nazionale (PRIN) [20109MXHMR_004]	Progetto Sicurezza, sostenibilita e competitivita nelle produzioni Agroalimentari delle Campania "CARINA"; Network per la salvaguardia e la gestione delle risorse genetiche agro-alimentari "AGRIGENET"; Programma di Ricerca Scientifica di Rilevante Interesse Nazionale (PRIN)(Ministry of Education, Universities and Research (MIUR))	This work was supported by Progetto Sicurezza, sostenibilita e competitivita nelle produzioni Agroalimentari delle Campania "CARINA" (POR FSE 2007-2013), Network per la salvaguardia e la gestione delle risorse genetiche agro-alimentari "AGRIGENET" (PSR 2007/2013, to CC), and Programma di Ricerca Scientifica di Rilevante Interesse Nazionale (PRIN, 20109MXHMR_004, to MABM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ashida H, 2000, FEBS LETT, V476, P213, DOI 10.1016/S0014-5793(00)01730-0; Auf G, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-597; Barbieri F, 2008, ENDOCRINOLOGY, V149, P4736, DOI 10.1210/en.2007-1762; BASTIDA E, 1984, BLOOD, V64, P177; BENDA P, 1968, SCIENCE, V161, P370, DOI 10.1126/science.161.3839.370; Brower V, 2008, J NATL CANCER I, V100, P838, DOI 10.1093/jnci/djn199; Brzezianska E, 2011, FRONT BIOSCI-LANDMRK, V16, P422, DOI 10.2741/3696; Burrell K, 2014, CANCER RES, V74, P3727, DOI 10.1158/0008-5472.CAN-13-3119; Califano D, 2000, J BIOL CHEM, V275, P19297, DOI 10.1074/jbc.M905866199; Califano D, 1996, P NATL ACAD SCI USA, V93, P7933, DOI 10.1073/pnas.93.15.7933; Chappell WH, 2011, ONCOTARGET, V2, P135, DOI 10.18632/oncotarget.240; Chen CC, 2001, J NAT PROD, V64, P990, DOI 10.1021/np000582y; Cheng Yen-Po, 2014, Surg Neurol Int, V5, P78, DOI 10.4103/2152-7806.133205; Clara CA, 2014, NEUROPATHOLOGY, V34, P343, DOI 10.1111/neup.12111; Colucci-D'Amato GL, 2000, J BIOL CHEM, V275, P19306, DOI 10.1074/jbc.275.25.19306; Colucci-D'Amato GL, 1999, EXP CELL RES, V252, P383, DOI 10.1006/excr.1999.4636; Colucci-D'Amato L, 2003, BIOESSAYS, V25, P1085, DOI 10.1002/bies.10355; CONWAY GA, 1979, J ETHNOPHARMACOL, V1, P241, DOI 10.1016/S0378-8741(79)80014-8; Deschenes-Simard X, 2014, CANCER RES, V74, P412, DOI 10.1158/0008-5472.CAN-13-2381; Fadlalla K, 2011, ANTICANCER RES, V31, P233; Florio T, 1999, MOL ENDOCRINOL, V13, P24, DOI 10.1210/me.13.1.24; Florio T, 2012, DRUG DISCOV TODAY, V17, P1103, DOI 10.1016/j.drudis.2012.06.001; Friedmann-Morvinski D, 2014, EMBO REP, V15, P244, DOI 10.1002/embr.201338254; Friedmann-Morvinski D, 2012, SCIENCE, V338, P1080, DOI 10.1126/science.1226929; Gentile MT, 2012, J NEUROCHEM, V123, P963, DOI 10.1111/jnc.12004; Gong X, 2011, NEUROLOGY, V76, P1126, DOI 10.1212/WNL.0b013e318212a89f; Gronych J, 2014, CELL, V157, P525, DOI 10.1016/j.cell.2014.04.001; Gutierrez-Pajares JL, 2003, REPROD TOXICOL, V17, P667, DOI 10.1016/j.reprotox.2003.07.002; Haghighitalab A, 2014, Z NATURFORSCH C, V69, P99, DOI 10.5560/ZNC.2013-0006; Hilario A, 2014, AM J NEURORADIOL, V35, P1096, DOI 10.3174/ajnr.A3837; Holand K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094132; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Ianora A, 2004, NATURE, V429, P403, DOI 10.1038/nature02526; Ilkanizadeh S, 2014, ADV CANCER RES, V121, P1, DOI 10.1016/B978-0-12-800249-0.00001-9; Jing Y, 2012, TOXICOL SCI, V125, P10, DOI 10.1093/toxsci/kfr256; Johnson BE, 2014, SCIENCE, V343, P189, DOI 10.1126/science.1239947; Kamson DO, 2014, NEURO-ONCOLOGY, V16, P1373, DOI 10.1093/neuonc/nou042; Kuzovkina I, 2004, PHYTOCHEMISTRY, V65, P1095, DOI 10.1016/j.phytochem.2004.03.003; Lee JS, 2014, NEURO-ONCOLOGY, V16, P191, DOI 10.1093/neuonc/not167; Li JWH, 2009, SCIENCE, V325, P161, DOI 10.1126/science.1168243; Li L, 2015, ONCOGENE, V34, P129, DOI 10.1038/onc.2013.534; Li L, 2014, INT J BIOCHEM CELL B, V53, P224, DOI 10.1016/j.biocel.2014.05.021; Luo F, 2014, MOL BIOSYST, V10, P1912, DOI 10.1039/c4mb00105b; Mace TA, 2014, CANCER IMMUNOL IMMUN, V63, P889, DOI 10.1007/s00262-014-1564-5; MARKAVERICH BM, 1984, CANCER RES, V44, P1515; Massa A, 2004, J BIOL CHEM, V279, P29004, DOI 10.1074/jbc.M403573200; McNamara Mairead G, 2013, Cancers (Basel), V5, P1103, DOI 10.3390/cancers5031103; Mielcke TR, 2012, EUR J MED CHEM, V48, P255, DOI 10.1016/j.ejmech.2011.12.023; Nguyen TTT, 2004, CARCINOGENESIS, V25, P647, DOI 10.1093/carcin/bgh052; Oszvald A, 2012, J NEURO-ONCOL, V109, P341, DOI 10.1007/s11060-012-0898-0; Pathak S, 2003, INT J ONCOL, V23, P975; Pollio A, 2008, J ETHNOPHARMACOL, V116, P469, DOI 10.1016/j.jep.2007.12.013; Porcile C, 2014, J CELL PHYSIOL, V229, P1444, DOI 10.1002/jcp.24582; Preethi KC, 2008, ASIAN PAC J CANCER P, V9, P763; Preusser M, 2011, ANN NEUROL, V70, P9, DOI 10.1002/ana.22425; RANELLETTI FO, 1992, INT J CANCER, V50, P486, DOI 10.1002/ijc.2910500326; Ratheesh M, 2013, INFLAMM RES, V62, P367, DOI 10.1007/s00011-013-0588-1; Ratheesh M, 2011, EXP TOXICOL PATHOL, V63, P285, DOI 10.1016/j.etp.2010.01.007; REHEMTULLA A, 1988, BIOCHEM CELL BIOL, V66, P1270, DOI 10.1139/o88-147; Reme T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066574; Rethy B, 2007, PLANTA MED, V73, P41, DOI 10.1055/s-2006-951747; Rizzo C, 1996, J BIOL CHEM, V271, P29497, DOI 10.1074/jbc.271.46.29497; Ruggiero A, 2013, J NEURO-ONCOL, V113, P513, DOI 10.1007/s11060-013-1145-z; Sallam AA, 2014, ORG BIOMOL CHEM, V12, P5295, DOI 10.1039/c4ob00553h; Seo BR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095588; Shi ZZ, 2010, MOL CANCER RES, V8, P615, DOI 10.1158/1541-7786.MCR-09-0264; Shibahara I, 2015, NEURO-ONCOLOGY, V17, P136, DOI 10.1093/neuonc/nou112; Skropeta D, 2014, NAT PROD REP, V31, P999, DOI 10.1039/c3np70118b; Spencer D, 2011, NEUROLOGY, V76, pE69, DOI 10.1212/WNL.0b013e318215b914; Sun YY, 2014, P NATL ACAD SCI USA, V111, P3538, DOI 10.1073/pnas.1313814111; Tamura K, 2014, J NEUROSURG, V120, P1010; van den Bent MJ, 2006, EUR J CANCER, V42, P582, DOI 10.1016/j.ejca.2005.06.031; Velazquez KT, 2014, J NUTR, V144, P868, DOI 10.3945/jn.113.188367; Vredenburgh JJ, 2009, NEURO-ONCOLOGY, V11, P80, DOI 10.1215/15228517-2008-075; Wang CY, 2014, AM J CHINESE MED, V42, P543, DOI 10.1142/S0192415X14500359; Xie J, 2014, ONCOL LETT, V7, P131, DOI 10.3892/ol.2013.1685; Ye Q, 2014, ONCOGENE, V33, P1828, DOI 10.1038/onc.2013.122; Yi L, 2014, NEUROMOL MED, V16, P578, DOI 10.1007/s12017-014-8310-1; Youland RS, 2013, NEURO-ONCOLOGY, V15, P1102, DOI 10.1093/neuonc/not080; Zheng HW, 2008, NATURE, V455, P1129, DOI 10.1038/nature07443; Zhuang WZ, 2012, CANCER SCI, V103, P684, DOI 10.1111/j.1349-7006.2011.02198.x; Zustovich F, 2009, ANTICANCER RES, V29, P4275	82	32	32	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 18	2015	10	3							e0118864	10.1371/journal.pone.0118864	http://dx.doi.org/10.1371/journal.pone.0118864			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE9BN	25785932	Green Published, gold, Green Submitted			2023-01-03	WOS:000352138500053
J	Farooqui, A; Khan, A; Borghetto, I; Kazmi, SU; Rubino, S; Paglietti, B				Farooqui, Amber; Khan, Adnan; Borghetto, Ilaria; Kazmi, Shahana U.; Rubino, Salvatore; Paglietti, Bianca			Synergistic Antimicrobial Activity of Camellia sinensis and Juglans regia against Multidrug-Resistant Bacteria	PLOS ONE			English	Article							INTENSIVE-CARE UNITS; IN-VITRO ACTIVITIES; STAPHYLOCOCCUS-AUREUS; ACINETOBACTER-BAUMANNII; ANTIBACTERIAL ACTIVITY; DRUG-RESISTANCE; COMBINATION; AGENTS; MRSA; CHECKERBOARD	Synergistic combinations of antimicrobial agents with different mechanisms of action have been introduced as more successful strategies to combat infections involving multidrug resistant (MDR) bacteria. In this study, we investigated synergistic antimicrobial activity of Camellia sinensis and Juglans regia which are commonly used plants with different antimicrobial agents. Antimicrobial susceptibility of 350 Gram-positive and Gram-negative strains belonging to 10 different bacterial species, was tested against Camellia sinensis and Juglans regia extracts. Minimum inhibitory concentrations (MICs) were determined by agar dilution and microbroth dilution assays. Plant extracts were tested for synergistic antimicrobial activity with different antimicrobial agents by checkerboard titration, Etest/agar incorporation assays, and time kill kinetics. Extract treated and untreated bacteria were subjected to transmission electron microscopy to see the effect on bacterial cell morphology. Camellia sinensis extract showed higher antibacterial activity against MDR S. Typhi, alone and in combination with nalidixic acid, than to susceptible isolates." We further explore anti-staphylococcal activity of Juglans regia that lead to the changes in bacterial cell morphology indicating the cell wall of Gram-positive bacteria as possible target of action. The synergistic combination of Juglans regia and oxacillin reverted oxacillin resistance of methicillin resistant Staphylococcus aureus (MRSA) strains in vitro. This study provides novel information about antimicrobial and synergistic activity of Camellia sinensis and Juglans regia against MDR pathogens	[Farooqui, Amber; Khan, Adnan; Kazmi, Shahana U.] Univ Karachi, Dept Microbiol, Immunol & Infect Dis Res Lab, Karachi, Pakistan; [Farooqui, Amber; Khan, Adnan; Borghetto, Ilaria; Rubino, Salvatore; Paglietti, Bianca] Univ Sassari, Dept Biomed Sci, I-07100 Sassari, Italy; [Farooqui, Amber] Shantou Univ, Coll Med, Int Inst Infect & Immun, Div Immunol, Shantou, Guangdong, Peoples R China; [Rubino, Salvatore] King Faisal Specialist Hosp & Res Ctr, Dept Infect & Immun, Riyadh 11211, Saudi Arabia	University of Karachi; University of Sassari; Shantou University; King Faisal Specialist Hospital & Research Center	Farooqui, A (corresponding author), Univ Karachi, Dept Microbiol, Immunol & Infect Dis Res Lab, Karachi, Pakistan.	amberfarooqui@hotmail.com	Barac, Aleksandra/W-9785-2019; Rubino, Salvatore/AAC-5848-2022	Farooqui, Amber/0000-0002-6031-9561; PAGLIETTI, Bianca/0000-0002-2568-0642	Higher Education Commission of Pakistan; Sardinian Region [LR7-2008 - CRP1_381]	Higher Education Commission of Pakistan(Higher Education Commission of Pakistan); Sardinian Region(Regione Sardegna)	The study was supported by the grants of Higher Education Commission of Pakistan (http://hec.gov.pk) which were awarded to Amber Farooqui and Adnan Khan for PhD in Science and Technology. Partial support was also provided by the grant of Sardinian Region (grant number LR7-2008 - CRP1_381) awarded to Salvatore Rubino and Bianca Paglietti. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abreu AC, 2012, NAT PROD REP, V29, P1007, DOI 10.1039/c2np20035j; Ahmad A, 2014, MOLECULES, V19, P2896, DOI 10.3390/molecules19032896; Akram Farhana, 2014, ISRN Microbiol, V2014, P469758, DOI 10.1155/2014/469758; Ali NH, 2007, PAK J PHARM SCI, V20, P140; Ali NH, 2010, J INFECT DEV COUNTR, V4, P382, DOI 10.3855/jidc.599; Allegranzi B, 2011, LANCET, V377, P228, DOI 10.1016/S0140-6736(10)61458-4; BECK WD, 1986, J BACTERIOL, V165, P373, DOI 10.1128/jb.165.2.373-378.1986; Begum S, 2012, NAT PROD RES, V26, P2084, DOI 10.1080/14786419.2011.625502; Cetin ES, 2013, JPN J INFECT DIS, V66, P463, DOI 10.7883/yoken.66.463; Chan EWC, 2011, PHARMACOGN RES, V3, P266, DOI 10.4103/0974-8490.89748; Coates ARM, 2011, BRIT J PHARMACOL, V163, P184, DOI 10.1111/j.1476-5381.2011.01250.x; Cockerill FR, 2013, PERFORMANCE STANDARD; Cowan MM, 1999, CLIN MICROBIOL REV, V12, P564, DOI 10.1128/CMR.12.4.564; Ghosh S, 2012, BIOTECHNOL ADV, V30, P1425, DOI 10.1016/j.biotechadv.2012.03.001; Gordon NC, 2010, INT J ANTIMICROB AG, V36, P129, DOI 10.1016/j.ijantimicag.2010.03.025; Grubb WB, 1998, REV MED MICROBIOL, V9, P153; Hamilton-Miller JMT, 2000, J ANTIMICROB CHEMOTH, V46, P852, DOI 10.1093/jac/46.5.852; HAMILTONMILLER JMT, 1995, ANTIMICROB AGENTS CH, V39, P2375, DOI 10.1128/AAC.39.11.2375; Hartmann M, 2010, ANTIMICROB AGENTS CH, V54, P3132, DOI 10.1128/AAC.00124-10; Iyer A, 2014, J INFECT DEV COUNTR, V8, P372, DOI 10.3855/jidc.3589; Jain S, 2013, J INFECT DEV COUNTR, V7, P788, DOI 10.3855/jidc.3030; Klancnik A, 2010, J MICROBIOL METH, V81, P121, DOI 10.1016/j.mimet.2010.02.004; Klitgaard JK, 2008, J ANTIMICROB CHEMOTH, V62, P1215, DOI 10.1093/jac/dkn417; Kristiansen JE, 2007, J ANTIMICROB CHEMOTH, V59, P1271, DOI 10.1093/jac/dkm071; Moellering RC, 2012, J ANTIMICROB CHEMOTH, V67, P4, DOI 10.1093/jac/dkr437; Nariman F, 2004, HELICOBACTER, V9, P146, DOI 10.1111/j.1083-4389.2004.00211.x; Noumi E, 2010, EUR J CLIN MICROBIOL, V29, P81, DOI 10.1007/s10096-009-0824-3; Oliveira I, 2008, FOOD CHEM TOXICOL, V46, P2326, DOI 10.1016/j.fct.2008.03.017; Pereira JA, 2007, FOOD CHEM TOXICOL, V45, P2287, DOI 10.1016/j.fct.2007.06.004; Petersen PJ, 2006, J ANTIMICROB CHEMOTH, V57, P573, DOI 10.1093/jac/dki477; Pinho MG, 2001, J BACTERIOL, V183, P6525, DOI 10.1128/JB.183.22.6525-6531.2001; Rojas Jhon J, 2006, BMC Complement Altern Med, V6, P2, DOI 10.1186/1472-6882-6-2; Shetty Mamatha, 1994, Journal of Communicable Diseases, V26, P147; Sopirala MM, 2010, ANTIMICROB AGENTS CH, V54, P4678, DOI 10.1128/AAC.00497-10; Taguri T, 2004, BIOL PHARM BULL, V27, P1965, DOI 10.1248/bpb.27.1965; Timurkaynak F, 2006, INT J ANTIMICROB AG, V27, P224, DOI 10.1016/j.ijantimicag.2005.10.012; Vernet G, 2014, EMERG INFECT DIS, V20, P434, DOI [10.3201/eid2003.121157, 10.3201/EID2003.121157]; Vincent JL, 2009, JAMA-J AM MED ASSOC, V302, P2323, DOI 10.1001/jama.2009.1754; Yam TS, 1997, FEMS MICROBIOL LETT, V152, P169, DOI 10.1016/S0378-1097(97)00197-3; Zhao WH, 2001, ANTIMICROB AGENTS CH, V45, P1737, DOI 10.1128/AAC.45.6.1737-1742.2001	40	49	52	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 26	2015	10	2							e0118431	10.1371/journal.pone.0118431	http://dx.doi.org/10.1371/journal.pone.0118431			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC2ZH	25719410	gold, Green Published, Green Submitted			2023-01-03	WOS:000350213200054
J	Chen, DF				Chen, Daniel F.			The Other AMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CARE		George Washington Univ, Sch Med & Hlth Sci, Div Geriatr & Palliat Care, Washington, DC 20052 USA	George Washington University	Chen, DF (corresponding author), George Washington Univ, Sch Med & Hlth Sci, Div Geriatr & Palliat Care, Washington, DC 20052 USA.	dfchen@gmail.com						Alfandre D, 2013, JAMA-J AM MED ASSOC, V310, P2393, DOI 10.1001/jama.2013.280887; [Anonymous], HOSP ADJ EXP PER INP; [Anonymous], YOUT RIGHT FAST APP; Beales JL, 2009, CLIN GERIATR MED, V25, P149, DOI 10.1016/j.cger.2008.11.002; Bodenheimer T, 2009, HEALTH AFFAIR, V28, P64, DOI 10.1377/hlthaff.28.1.64; De Jonge KE, 2014, J AM GERIATR SOC, V62, P1825, DOI 10.1111/jgs.12974; Kaboli PJ, 2012, ANN INTERN MED, V157, P837, DOI 10.7326/0003-4819-157-12-201212180-00003; Reuben DB, 2014, NEW ENGL J MED, V370, P694, DOI 10.1056/NEJMp1315568	8	1	1	1	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 17	2015	313	7					671	672		10.1001/jama.2014.13626	http://dx.doi.org/10.1001/jama.2014.13626			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CB2RQ	25688776				2023-01-03	WOS:000349476100010
J	Halpern, SD; Emanuel, EJ				Halpern, Scott D.; Emanuel, Ezekiel J.			Ethical Guidance on the Use of Life-Sustaining Therapies for Patients With Ebola in Developed Countries	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Penn, Leonard Davis Inst Hlth Econ, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Halpern, SD (corresponding author), Univ Penn, 719 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.	shalpern@exchange.upenn.edu						EMANUEL EJ, 1988, NEW ENGL J MED, V318, P1686, DOI 10.1056/NEJM198806233182511; Fowler RA, 2014, AM J RESP CRIT CARE, V190, P733, DOI 10.1164/rccm.201408-1514CP; Halpern SD, 2007, NEW ENGL J MED, V357, P1340, DOI 10.1056/NEJMsb071595; Yealy DM, 2014, NEW ENGL J MED, V370, P1683, DOI 10.1056/NEJMoa1401602; Young MJ, 2012, CRIT CARE MED, V40, P261, DOI 10.1097/CCM.0b013e31822d750d	5	7	7	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 17	2015	162	4					304	305		10.7326/M14-2611	http://dx.doi.org/10.7326/M14-2611			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CC3FU	25545099				2023-01-03	WOS:000350232500021
J	Pasqualim, G; Baldo, G; de Carvalho, TG; Tavares, AMV; Giugliani, R; Matte, U				Pasqualim, Gabriela; Baldo, Guilherme; de Carvalho, Talita Giacomet; Tavares, Angela Maria Vicente; Giugliani, Roberto; Matte, Ursula			Effects of Enzyme Replacement Therapy Started Late in a Murine Model of Mucopolysaccharidosis Type I	PLOS ONE			English	Article							RECOMBINANT ENCAPSULATED CELLS; MPS-I; AORTIC DILATATION; UP-REGULATION; TRANSPLANTATION; LARONIDASE; EFFICACY; IMPROVES; GUIDELINES; MANAGEMENT	Mucopolysaccharidosis type I (MPS I) is a progressive disorder caused by deficiency of alpha L- iduronidase (IDUA), which leads to storage of heparan and dermatan sulphate. It is suggested that early enzyme replacement therapy (ERT) leads to better outcomes, although many patients are diagnosed late and don't receive immediate treatment. This study aims to evaluate the effects of late onset ERT in a MPS I murine model. MPS I mice received treatment from 6 to 8 months of age (ERT 6-8mo) with 1.2mg laronidase/kg every 2 weeks and were compared to 8 months-old wild-type (Normal) and untreated animals (MPS I). ERT was effective in reducing urinary and visceral GAG to normal levels. Heart GAG levels and left ventricular (LV) shortening fraction were normalized but cardiac function was not completely improved. While no significant improvements were found on aortic wall width, treatment was able to significantly reduce heart valves thickening. High variability was found in behavior tests, with treated animals presenting intermediate results between normal and affected mice, without correlation with cerebral cortex GAG levels. Cathepsin D activity in cerebral cortex also did not correlate with behavior heterogeneity. All treated animals developed anti-laronidase antibodies but no correlation was found with any parameters analyzed. However, intermediary results from locomotion parameters analyzed are in accordance with intermediary levels of heart function, cathepsin D, activated glia and reduction of TNF-alpha expression in the cerebral cortex. In conclusion, even if started late, ERT can have beneficial effects on many aspects of the disease and should be considered whenever possible.	[Pasqualim, Gabriela; de Carvalho, Talita Giacomet; Giugliani, Roberto; Matte, Ursula] Univ Fed Rio Grande do Sul, Postgrad Program Genet & Mol Biol PPGBM, Porto Alegre, RS, Brazil; [Pasqualim, Gabriela; Baldo, Guilherme; de Carvalho, Talita Giacomet; Giugliani, Roberto; Matte, Ursula] Hosp Clin Porto Alegre, Expt Res Ctr, Gene Therapy Ctr, Porto Alegre, RS, Brazil; [Baldo, Guilherme] Univ Fed Rio Grande do Sul, Inst Ciencias Basicas Saude, Dept Physiol, Porto Alegre, RS, Brazil; [Tavares, Angela Maria Vicente] Uniritter Laureate Int Univ, Dept Hlth Sci, Porto Alegre, RS, Brazil; [Giugliani, Roberto] Hosp Clin Porto Alegre, Med Genet Serv, Porto Alegre, RS, Brazil; [Giugliani, Roberto; Matte, Ursula] INAGEMP, Porto Alegre, RS, Brazil; [Giugliani, Roberto; Matte, Ursula] Univ Fed Rio Grande do Sul, Inst Biociencias, Dept Genet, BR-90049 Porto Alegre, RS, Brazil	Universidade Federal do Rio Grande do Sul; Universidade Federal do Rio Grande do Sul; Universidade Federal do Rio Grande do Sul	Matte, U (corresponding author), Univ Fed Rio Grande do Sul, Postgrad Program Genet & Mol Biol PPGBM, Porto Alegre, RS, Brazil.	umatte@hcpa.ufrgs.br	Baldo, Guilherme/U-9104-2019; Da Silveira Matte umatte, Ursula/U-3912-2019; Pasqualim, Gabriela/E-5219-2018; Baldo, Guilherme/AAR-5677-2020; Giugliani, Roberto/G-4790-2015; Tavares, Angela Maria Vicente/F-6539-2010	Baldo, Guilherme/0000-0003-1598-5861; Da Silveira Matte umatte, Ursula/0000-0003-4977-6662; Pasqualim, Gabriela/0000-0002-6250-9609; Giugliani, Roberto/0000-0001-9655-3686; Vicente Tavares, Angela Maria/0000-0002-3402-0523	Fundo de Incentivo a Pesquisa e Eventos do Hospital de Clinicas de Porto Alegre (FIPE-HCPA); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul (FAPERGS)/Ministerio da Saude (MS)/Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)/Secretaria de Estado da Saude do RS [1151-2551/13-3]	Fundo de Incentivo a Pesquisa e Eventos do Hospital de Clinicas de Porto Alegre (FIPE-HCPA); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul (FAPERGS)/Ministerio da Saude (MS)/Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)/Secretaria de Estado da Saude do RS	This work was supported by Fundo de Incentivo a Pesquisa e Eventos do Hospital de Clinicas de Porto Alegre (FIPE-HCPA) and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul (FAPERGS)/Ministerio da Saude (MS)/Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)/Secretaria de Estado da Saude do RS (process #1151-2551/13-3). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Archer LD, 2014, J INHERIT METAB DIS, V37, P1, DOI 10.1007/s10545-013-9613-3; Arfi A, 2011, MOL GENET METAB, V103, P18, DOI 10.1016/j.ymgme.2011.01.015; Baldo G, 2014, MED HYPOTHESES, V82, P478, DOI 10.1016/j.mehy.2014.01.029; Baldo G, 2013, MOL GENET METAB, V109, P33, DOI 10.1016/j.ymgme.2013.03.005; Baldo G, 2012, CYTOTHERAPY, V14, P860, DOI 10.3109/14653249.2012.672730; Baldo G, 2012, BEHAV BRAIN RES, V233, P169, DOI 10.1016/j.bbr.2012.04.051; Baldo G, 2012, CELLS TISSUES ORGANS, V195, P323, DOI 10.1159/000327532; Baldo G, 2011, MOL GENET METAB, V104, P608, DOI 10.1016/j.ymgme.2011.08.018; Beck M, 2014, GENET MED, V16, P759, DOI 10.1038/gim.2014.25; Boelens JJ, 2010, PEDIATR CLIN N AM, V57, P123, DOI 10.1016/j.pcl.2009.11.004; Brands MMMG, 2013, J INHERIT METAB DIS, V36, P227, DOI 10.1007/s10545-011-9444-z; Braunlin EA, 2003, AM J CARDIOL, V92, P882, DOI 10.1016/S0002-9149(03)00909-3; Braunlin EA, 2006, AM J CARDIOL, V98, P416, DOI 10.1016/j.amjcard.2006.02.047; Clarke LA, 2009, PEDIATRICS, V123, P229, DOI 10.1542/peds.2007-3847; D'Aco K, 2012, EUR J PEDIATR, V171, P911, DOI 10.1007/s00431-011-1644-x; de Ru MH, 2013, J INHERIT METAB DIS, V36, P247, DOI 10.1007/s10545-012-9538-2; de Ru MH, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-22; de Ru MH, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-55; Dickson P, 2008, J CLIN INVEST, V118, P2868, DOI 10.1172/JCI34676; Dierenfeld AD, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001380; Gabrielli O, 2010, PEDIATRICS, V125, pE183, DOI 10.1542/peds.2009-1728; Giugliani R, 2009, MOL GENET METAB, V96, P13, DOI 10.1016/j.ymgme.2008.10.009; Giugliani R, 2012, J INHERIT METAB DIS, V35, P871, DOI 10.1007/s10545-011-9436-z; Giugliani R, 2010, GENET MOL BIOL, V33, P589, DOI 10.1590/S1415-47572010005000093; Harada H, 2011, MOL GENET METAB, V103, P215, DOI 10.1016/j.ymgme.2011.03.016; Jones JE, 2002, AM J PHYSIOL-HEART C, V283, pH364, DOI 10.1152/ajpheart.00979.2001; Kakkis ED, 2001, NEW ENGL J MED, V344, P182, DOI 10.1056/NEJM200101183440304; Lyons JA, 2011, LAB INVEST, V91, P665, DOI 10.1038/labinvest.2011.7; Ma X, 2008, MOL GENET METAB, V94, P298, DOI 10.1016/j.ymgme.2008.03.018; Martins AM, 2009, J PEDIATR-US, V155, pS32, DOI 10.1016/j.jpeds.2009.07.005; Matthes F, 2012, HUM MOL GENET, V21, P2599, DOI 10.1093/hmg/dds086; Metcalf JA, 2010, MOL GENET METAB, V99, P396, DOI 10.1016/j.ymgme.2009.12.003; Muenzer J, 2011, RHEUMATOLOGY, V50, pV4, DOI 10.1093/rheumatology/ker394; Muenzer J, 2009, PEDIATRICS, V123, P19, DOI 10.1542/peds.2008-0416; Munoz-Rojas MV, 2011, J INHERIT METAB DIS, V34, P1029, DOI 10.1007/s10545-011-9336-2; Neufeld EF, 2001, MUCOPOLYSACCHARIDOSE, P3421, DOI DOI 10.1036/OMMBID.165; Ohmi K, 2003, P NATL ACAD SCI USA, V100, P1902, DOI 10.1073/pnas.252784899; Ou L, 2014, MOL GENET METAB, V111, P116, DOI 10.1016/j.ymgme.2013.09.008; Pan D, 2008, BRAIN RES, V1188, P241, DOI 10.1016/j.brainres.2007.10.036; Sifuentes M, 2007, MOL GENET METAB, V90, P171, DOI 10.1016/j.ymgme.2006.08.007; Tokic V, 2007, EUR J PEDIATR, V166, P727, DOI 10.1007/s00431-006-0316-8; Valayannopoulos V, 2011, RHEUMATOLOGY, V50, pV49, DOI 10.1093/rheumatology/ker396; Vieira T, 2008, AM J MED GENET A, V146A, P1741, DOI 10.1002/ajmg.a.32320; Wilkinson FL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035787; Wolf DA, 2012, BONE MARROW TRANSPL, V47, P1235, DOI 10.1038/bmt.2011.239; Wraith JE, 2007, PEDIATRICS, V120, pE37, DOI 10.1542/peds.2006-2156; Wraith JE, 2004, J PEDIATR-US, V144, P581, DOI 10.1016/j.jpeds.2004.01.046	47	14	14	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2015	10	2							e0117271	10.1371/journal.pone.0117271	http://dx.doi.org/10.1371/journal.pone.0117271			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA3QZ	25646802	gold, Green Submitted, Green Published			2023-01-03	WOS:000348822600062
J	Fumis, RRL; Ranzani, OT; Martins, PS; Schettino, G				Lins Fumis, Renata Rego; Ranzani, Otavio T.; Martins, Paulo Sergio; Schettino, Guilherme			Emotional Disorders in Pairs of Patients and Their Family Members during and after ICU Stay	PLOS ONE			English	Article							INTENSIVE-CARE-UNIT; POSTTRAUMATIC STRESS SYMPTOMS; ILL CANCER-PATIENTS; DEPRESSION SYMPTOMS; CRITICAL ILLNESS; VISITING POLICY; ANXIETY; SPIRITUALITY; RELATIVES; COMMUNICATION	Introduction Patients and family members undergo different experiences of suffering from emotional disorders during ICU stay and after ICU discharge. The purpose of this study was to compare the incidence of anxiety, depression and post-traumatic stress disorder (PTSD) symptoms in pairs (patient and respective family member), during stay at an open visit ICU and at 30 and 90-days post-ICU discharge. We hypothesized that there was a positive correlation with the severity of symptoms among pairs and different patterns of suffering over time. Methods A prospective study was conducted in a 22-bed adult general ICU including patients with >48 hours stay. The Hospital Anxiety and Depression Scale (HADS) was completed by the pairs (patients/respective family member). Interviews were made by phone at 30 and 90-days post-ICU discharge using the Impact of Event Scale (IES) and the HADS. Multivariate models were constructed to predict IES score at 30 days for patients and family members. Results Four hundred and seventy one family members and 289 patients were interviewed in the ICU forming 184 pairs for analysis. Regarding HADS score, patients presented less symptoms than family members of patients who survived and who deceased at 30 and 90-days (p<0.001). However, family members of patients who deceased scored higher anxiety and depression symptoms (p = 0.048) at 90-days when compared with family members of patients who survived. Patients and family members at 30-days had a similar IES score, but it was higher in family members at 90-days (p = 0.019). For both family members and patients, age and symptoms of anxiety and depression during ICU were the major determinants for PTSD at 30-days. Conclusions Anxiety, depression and PTSD symptoms were higher in family members than in the patients. Furthermore, these symptoms in family members persisted at 3 months, while they decreased in patients.	[Lins Fumis, Renata Rego; Martins, Paulo Sergio; Schettino, Guilherme] Hosp Sirio Libanes, Intens Care Unit, BR-01308050 Sao Paulo, Brazil; [Ranzani, Otavio T.] Univ Sao Paulo, Hosp Clin, Inst Heart, Resp Intens Care Unit,Pulm Div, BR-05403900 Sao Paulo, Brazil	Universidade de Sao Paulo	Fumis, RRL (corresponding author), Hosp Sirio Libanes, Intens Care Unit, Rua Dona Adma Jafet 91, BR-01308050 Sao Paulo, Brazil.	regolins@uol.com.br	Ranzani, Otavio T./K-1196-2012; Fumis, R R/J-6993-2015	Ranzani, Otavio T./0000-0002-4677-6862; Fumis, Renata/0000-0003-4780-704X	'Fundacao de Amparo a Pesquisa do Estado de Sao Paulo' - FAPESP [11/05672-1]	'Fundacao de Amparo a Pesquisa do Estado de Sao Paulo' - FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	This study is supported by 'Fundacao de Amparo a Pesquisa do Estado de Sao Paulo' - FAPESP - Process no 11/05672-1. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Azoulay E, 2005, AM J RESP CRIT CARE, V171, P987, DOI 10.1164/rccm.200409-1295OC; Azoulay Elie, 2003, Curr Opin Crit Care, V9, P545; Berwick DM, 2004, JAMA-J AM MED ASSOC, V292, P736, DOI 10.1001/jama.292.6.736; Boscaglia N, 2005, INT J GYNECOL CANCER, V15, P755, DOI 10.1111/j.1525-1438.2005.00248.x; Botega NJ, 1995, REV SAUDE PUBL, V29, P355, DOI 10.1590/S0034-89101995000500004; Curtis JR, 2002, J CRIT CARE, V17, P147, DOI 10.1053/jcrc.2002.35929; da Silva Ramos Fernando Jose, 2013, Ann Intensive Care, V3, P34, DOI 10.1186/2110-5820-3-34; Davidson JE, 2007, CRIT CARE MED, V35, P605, DOI 10.1097/01.CCM.0000254067.14607.EB; de Miranda S, 2011, CRIT CARE MED, V39, P112, DOI 10.1097/CCM.0b013e3181feb824; Fumagalli S, 2006, CIRCULATION, V113, P946, DOI 10.1161/CIRCULATIONAHA.105.572537; Fumis RR, 2013, INTENS CARE MED, V39, P324; Fumis RRL, 2006, INTENS CARE MED, V32, P124, DOI 10.1007/s00134-005-2857-0; Garrouste-Orgeas M, 2008, CRIT CARE MED, V36, P30, DOI 10.1097/01.CCM.0000295310.29099.F8; Jackson JC, 2007, CRIT CARE, V11, DOI 10.1186/cc5707; Janiszewska J, 2013, INT UROL NEPHROL, V45, P1379, DOI 10.1007/s11255-012-0326-6; Jones C, 2007, INTENS CARE MED, V33, P978, DOI 10.1007/s00134-007-0600-8; Lautrette A, 2007, NEW ENGL J MED, V356, P469, DOI 10.1056/NEJMoa063446; Lee MD, 2007, CRIT CARE MED, V35, P497, DOI 10.1097/01.CCM.0000254338.87182.AC; Fumis RRL, 2009, INTENS CARE MED, V35, P899, DOI 10.1007/s00134-009-1406-7; McCoubrie R, 2006, SUPPORT CARE CANCER, V14, P379, DOI 10.1007/s00520-005-0892-6; McKercher C, 2013, NEPHROLOGY, V18, P585, DOI 10.1111/nep.12138; Myhren H, 2010, CRIT CARE, V14, DOI 10.1186/cc8870; Paparrigopoulos T, 2014, INT J PSYCHIAT CLIN, V18, P25, DOI 10.3109/13651501.2013.855793; Peris A, 2011, CRIT CARE, V15, DOI 10.1186/cc10003; Pochard F, 2005, J CRIT CARE, V20, P90, DOI 10.1016/j.jcrc.2004.11.004; Pochard F, 2001, CRIT CARE MED, V29, P1893, DOI 10.1097/00003246-200110000-00007; Rosendahl J, 2013, CRIT CARE MED, V41, P69, DOI 10.1097/CCM.0b013e31826766b0; Schleder LP, 2013, ACTA PAUL ENFERM, V26, P71, DOI 10.1590/S0103-21002013000100012; Silva Adriana Cardoso de Oliveira e, 2010, Rev. psiquiatr. Rio Gd. Sul, V32, P86, DOI 10.1590/S0101-81082010000300005; Steyerberg EW., 2009, CLIN PREDICTION MODE, DOI [10.1007/978-0-387-77244-8, DOI 10.1007/978-0-387-77244-8]; Sukantarat K, 2007, BRIT J HEALTH PSYCH, V12, P65, DOI 10.1348/135910706X94096; Tramm R, 2014, AUST CRIT CARE; Vandijck DM, 2010, HEART LUNG, V39, P137, DOI 10.1016/j.hrtlng.2009.06.001; Wall RJ, 2007, CHEST, V132, P1425, DOI 10.1378/chest.07-0419; Young E, 2005, INTENS CARE MED, V31, P86, DOI 10.1007/s00134-004-2495-y	35	61	66	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2015	10	1							e0115332	10.1371/journal.pone.0115332	http://dx.doi.org/10.1371/journal.pone.0115332			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA7UF	25616059	gold, Green Published, Green Submitted			2023-01-03	WOS:000349122100011
J	Kind, AJH; Jencks, S; Brock, J; Yu, MG; Bartels, C; Ehlenbach, W; Greenberg, C; Smith, M				Kind, Amy J. H.; Jencks, Steve; Brock, Jane; Yu, Menggang; Bartels, Christie; Ehlenbach, William; Greenberg, Caprice; Smith, Maureen			Neighborhood Socioeconomic Disadvantage and 30-Day Rehospitalization	ANNALS OF INTERNAL MEDICINE			English	Article							HOSPITAL READMISSION; ALL-CAUSE; MORTALITY; DISPARITIES; HEALTH; RISK; CARE; INEQUALITIES; COMMUNITIES; COMORBIDITY	Background: Measures of socioeconomic disadvantage may enable improved targeting of programs to prevent rehospitalizations, but obtaining such information directly from patients can be difficult. Measures of U.S. neighborhood socioeconomic disadvantage are more readily available but are rarely used clinically. Objective: To evaluate the association between neighborhood socioeconomic disadvantage at the census block group level, as measured by the Singh validated area deprivation index (ADI), and 30-day rehospitalization. Design: Retrospective cohort study. Setting: United States. Patients: Random 5% national sample of Medicare patients discharged with congestive heart failure, pneumonia, or myocardial infarction between 2004 and 2009 (n = 255 744). Measurements: Medicare data were linked to 2000 census data to construct an ADI for each patient's census block group, which were then sorted into percentiles by increasing ADI. Relationships between neighborhood ADI grouping and 30-day rehospitalization were evaluated using multivariate logistic regression models, controlling for patient sociodemographic characteristics, comorbid conditions and severity, and index hospital characteristics. Results: The 30-day rehospitalization rate did not vary significantly across the least disadvantaged 85% of neighborhoods, which had an average rehospitalization rate of 21%. However, within the most disadvantaged 15% of neighborhoods, rehospitalization rates increased from 22% to 27% with worsening ADI. This relationship persisted after full adjustment, with the most disadvantaged neighborhoods having a rehospitalization risk (adjusted risk ratio, 1.09 [95% CI, 1.05 to 1.12]) similar to that of chronic pulmonary disease (adjusted risk ratio, 1.06 [CI, 1.04 to 1.08]) and greater than that of uncomplicated diabetes (adjusted risk ratio, 0.95 [CI, 0.94 to 0.97]). Limitation: No direct markers of care quality or access. Conclusion: Residence within a disadvantaged U.S. neighborhood is a rehospitalization predictor of magnitude similar to chronic pulmonary disease. Measures of neighborhood disadvantage, such as the ADI, could potentially be used to inform policy and care after hospital discharge.	Univ Wisconsin, Sch Med & Publ Hlth, Geriatr Res Educ & Clin Ctr, William S Middleton Vet Affairs Hosp, Madison, WI 53706 USA; Univ Wisconsin, Sch Nursing, Madison, WI USA; Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA; Telligen, Englewood, CO USA	Geriatric Research Education & Clinical Center; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Kind, AJH (corresponding author), William S Middleton Vet Affairs Hosp, Geriatr Res Educ & Clin Ctr, 2500 Overlook Terrace, Madison, WI 53705 USA.	ajk@medicine.wisc.edu	Ehlenbach, William J./R-5784-2019; Bartels, Christie Michels/ABG-4072-2020	Ehlenbach, William J./0000-0002-2864-5543; Bartels, Christie Michels/0000-0001-6523-0374; Kind, Amy/0000-0002-7183-610X	National Institute on Aging; University of Wisconsin School of Medicine and Public Health's Institute for Clinical and Translational Research and Health Innovation Program; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000427] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025011] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K23AG038352, K23AG034551] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); University of Wisconsin School of Medicine and Public Health's Institute for Clinical and Translational Research and Health Innovation Program; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	National Institute on Aging and University of Wisconsin School of Medicine and Public Health's Institute for Clinical and Translational Research and Health Innovation Program.	Acevedo-Garcia D, 2008, HEALTH AFFAIR, V27, P321, DOI 10.1377/hlthaff.27.2.321; Arbaje AI, 2008, GERONTOLOGIST, V48, P495, DOI 10.1093/geront/48.4.495; Begg MD, 2003, STAT MED, V22, P2591, DOI 10.1002/sim.1524; Berenson Julia, 2012, Issue Brief (Commonw Fund), V34, P1; Berlin JA, 1999, BIOMETRICS, V55, P470, DOI 10.1111/j.0006-341X.1999.00470.x; Blumenshine P, 2010, AM J PREV MED, V39, P263, DOI 10.1016/j.amepre.2010.05.012; Breslow NE, 1980, IARC SCI PUBL, P5; Brock J, 2013, JAMA-J AM MED ASSOC, V309, P381, DOI 10.1001/jama.2012.216607; Bureau U.S. Census, 2012, CART BOUND FIL DESCR; Cederberg M., 2009, THEMATIC REPORT SOCI; Centers for Medicare & Medicaid Services, 2009, CHRON COND DAT WAR; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Federal Reserve System Brookings Institution, 2008, END CHALL CONC POV A; Fleegler EW, 2007, PEDIATRICS, V119, pE1332, DOI 10.1542/peds.2006-1505; Foraker RE, 2011, CIRC-HEART FAIL, V4, P308, DOI 10.1161/CIRCHEARTFAILURE.110.959031; Franco M, 2008, AM J PREV MED, V35, P561, DOI 10.1016/j.amepre.2008.07.003; Gordon D., 1997, BREADLINE BRITAIN 19; HOUSE JS, 1994, J HEALTH SOC BEHAV, V35, P213, DOI 10.2307/2137277; HOUSE JS, 1990, MILBANK Q, V68, P383, DOI 10.2307/3350111; Hsieh C.-C., 1993, CRIMINAL JUSTICE REV, V18, P182, DOI [10.1177/073401689301800203, DOI 10.1177/073401689301800203]; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Joynt KE, 2013, NEW ENGL J MED, V368, P1175, DOI 10.1056/NEJMp1300122; Joynt KE, 2013, JAMA-J AM MED ASSOC, V309, P342, DOI 10.1001/jama.2012.94856; Joynt KE, 2011, JAMA-J AM MED ASSOC, V305, P675, DOI 10.1001/jama.2011.123; Kangovi S, 2011, JAMA-J AM MED ASSOC, V306, P1796, DOI 10.1001/jama.2011.1562; Kansagara D, 2011, JAMA-J AM MED ASSOC, V306, P1688, DOI 10.1001/jama.2011.1515; Kleinman LC, 2009, HEALTH SERV RES, V44, P288, DOI 10.1111/j.1475-6773.2008.00900.x; Kneebone Elizabeth, 2011, METROPOLITAN OPPORTU; Krumholz H., 2008, HOSP 30 DAY HEART FA; Krumholz HM, 2013, NEW ENGL J MED, V368, P100, DOI 10.1056/NEJMp1212324; Krumholz HM, 2008, HOSP 30 DAY ACUTE MY; Krumholz HM., 2008, HOSP 30 DAY PNEUMONI; Lantz PM, 1998, JAMA-J AM MED ASSOC, V279, P1703, DOI 10.1001/jama.279.21.1703; Localio AR, 2007, J CLIN EPIDEMIOL, V60, P874, DOI 10.1016/j.jclinepi.2006.12.001; Ludwig J, 2012, SCIENCE, V337, P1505, DOI 10.1126/science.1224648; Ludwig J, 2011, NEW ENGL J MED, V365, P1509, DOI 10.1056/NEJMsa1103216; Moore LV, 2006, AM J PUBLIC HEALTH, V96, P325, DOI 10.2105/AJPH.2004.058040; National Quality Forum, 2012, PAT OUTC ALL CAUS RE; Neuhaus JM, 1998, BIOMETRICS, V54, P638, DOI 10.2307/3109770; Philbin EF, 2001, AM J CARDIOL, V87, P1367, DOI 10.1016/S0002-9149(01)01554-5; Pope GC, 2004, HEALTH CARE FINANC R, V25, P119; Rau J., 2012, KAISER HLTH NEW 0813; Robert SA, 1999, ANNU REV SOCIOL, V25, P489, DOI 10.1146/annurev.soc.25.1.489; Ross JS, 2012, HEALTH AFFAIR, V31, P1739, DOI 10.1377/hlthaff.2011.1028; Sharma G, 2009, JAMA-J AM MED ASSOC, V301, P1671, DOI 10.1001/jama.2009.517; Shavers VL, 2007, J NATL MED ASSOC, V99, P1013; Singh GK, 2004, CANCER, V101, P1051, DOI 10.1002/cncr.20467; Singh GK, 2003, AM J PUBLIC HEALTH, V93, P1137, DOI 10.2105/AJPH.93.7.1137; Singh GK, 2002, JNCI-J NATL CANCER I, V94, P916, DOI 10.1093/jnci/94.12.916; Singh GK, 2002, INT J EPIDEMIOL, V31, P600, DOI 10.1093/ije/31.3.600; Singh GK, 2013, J URBAN HEALTH, V90, P388, DOI 10.1007/s11524-012-9744-0; Singh GK, 2011, J CANCER EPIDEMIOL, V2011, DOI 10.1155/2011/107497; Spicker P., 2000, WELFARE STATE GEN TH; Sundquist K, 2003, J EPIDEMIOL COMMUN H, V57, P347, DOI 10.1136/jech.57.5.347; U.S. Census Bureau, POV DEF; U.S. Department of Agriculture Economic Research Service, RUR CLASS OV; US Department of Housing & Urban Development, 1996, 1 BIENNIAL REPORT C; van Walraven C, 2013, J HOSP MED, V8, P261, DOI 10.1002/jhm.2025; Washington State Department of Health, 2009, GUID US RUR URB CLAS	59	508	508	1	37	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 2	2014	161	11					765	U36		10.7326/M13-2946	http://dx.doi.org/10.7326/M13-2946			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AX9UJ	25437404	Green Accepted			2023-01-03	WOS:000347247200005
J	Peng, SL; Zhao, Y; Xu, F; Jia, CJ; Xu, YQ; Dai, CL				Peng, Songlin; Zhao, Yang; Xu, Feng; Jia, Changjun; Xu, Yongqing; Dai, Chaoliu			An Updated Meta-Analysis of Randomized Controlled Trials Assessing the Effect of Sorafenib in Advanced Hepatocellular Carcinoma	PLOS ONE			English	Article							PHASE-III TRIAL; CLINICAL-TRIALS; RAF/MEK/ERK PATHWAY; BAY 43-9006; EFFICACY; QUALITY; ANGIOGENESIS; EXPERIENCE; INHIBITOR; TARGETS	Background: The efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma (HCC) remains controversial. Therefore, we conducted a meta-analysis to evaluate the efficacy and safety of sorafenib for treating patients with advanced HCC. Methods: The PubMed, Embase, and Web of Science databases were searched. Eligible studies were randomized controlled trials (RCTs) that assessed sorafenib therapy in patients with advanced HCC. The outcomes included overall survival (OS), time to progression (TTP), overall response rate (ORR), and toxicities. Hazard ratio (HR) and risk ratio (RR) were used for the meta-analysis and were expressed with 95% confidence intervals (CIs). Results: Seven RCTs, with a total of 3807 patients, were included in this metaanalysis. All patients received sorafenib alone, or with other chemotherapeutic regimens. Pooled estimates showed that sorafenib improved the OS (HR=0.74, 95% CI: 0.61, 0.90; P=0.002), or TTP outcomes (HR=0.69, 95% CI: 0.55, 0.86; P=0.001). Subgroup analysis revealed that sorafenib was more effective in the patients with an Eastern Cooperative Oncology Group performance status (ECOG PS) of 1-2 (HR=0.77, 95% CI: 0.60, 1.0; P=0.05), or macroscopic vascular invasion (MVI), and/or extrahepatic spread (EHS) (HR=0.65, 95% CI: 0.46, 0.93; P=0.02), in terms of OS. Patients who received sorafenib did not have a higher ORR (RR=0.85, 95% CI: 0.65, 1.11; P=0.10). In addition, there was a slight increase in toxicity in the sorafenib group. Conclusion: Treatment with sorafenib significantly improved OS and TTP in patients with advanced HCC. Additional large-scale, well-designed RCTs are needed to evaluate the efficacy of sorafenib-based therapy in the treatment of advanced HCC.	[Peng, Songlin; Zhao, Yang; Xu, Feng; Jia, Changjun; Xu, Yongqing; Dai, Chaoliu] China Med Univ, Affiliated Shengjing Hosp, Dept Hepatobiliary Surg, Shenyang 110004, Peoples R China	China Medical University	Dai, CL (corresponding author), China Med Univ, Affiliated Shengjing Hosp, Dept Hepatobiliary Surg, Shenyang 110004, Peoples R China.	daicl@sj-hospital.org	Xu, Feng/L-8097-2019	Xu, Feng/0000-0003-3212-6284	Shengyang science and technology project plan [F13-221-924]	Shengyang science and technology project plan	The study was supported by Shengyang science and technology project plan (F13-221-924). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdel-Rahman O, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0655-z; Abou-Alfa GK, 2006, J CLIN ONCOL, V24, P4293, DOI 10.1200/JCO.2005.01.3441; Abou-Alfa GK, 2010, JAMA-J AM MED ASSOC, V304, P2154, DOI 10.1001/jama.2010.1672; Adnane L, 2006, METHOD ENZYMOL, V407, P597, DOI 10.1016/S0076-6879(05)07047-3; Balsom SM, 2010, ONCOLOGY-BASEL, V78, P210, DOI 10.1159/000313701; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Bruix J, 2012, J HEPATOL, V57, P821, DOI 10.1016/j.jhep.2012.06.014; Brunocilla PR, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0345-2; Carlomagno F, 2006, JNCI-J NATL CANCER I, V98, P326, DOI 10.1093/jnci/djj069; Cheng AL, 2013, J CLIN ONCOL, V31, P4067, DOI 10.1200/JCO.2012.45.8372; Cheng AL, 2012, EUR J CANCER, V48, P1452, DOI 10.1016/j.ejca.2011.12.006; Del Prete S, 2010, CANCER CHEMOTH PHARM, V66, P837, DOI 10.1007/s00280-009-1226-z; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fattovich G, 2004, GASTROENTEROLOGY, V127, pS35, DOI 10.1053/j.gastro.2004.09.014; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Iavarone M, 2011, HEPATOLOGY, V54, P2055, DOI 10.1002/hep.24644; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Johnson PJ, 2013, J CLIN ONCOL, V31, P3517, DOI 10.1200/JCO.2012.48.4410; Kjaergard LL, 2001, ANN INTERN MED, V135, P982, DOI 10.7326/0003-4819-135-11-200112040-00010; Kudo M, 2011, EUR J CANCER, V47, P2117, DOI 10.1016/j.ejca.2011.05.007; Llovet JM, 1999, HEPATOLOGY, V29, P62, DOI 10.1002/hep.510290145; Llovet JM, 1999, SEMIN LIVER DIS, V19, P329, DOI 10.1055/s-2007-1007122; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Llovet JM, 2008, JNCI-J NATL CANCER I, V100, P698, DOI 10.1093/jnci/djn134; Manghisi G, 1998, HEPATOLOGY, V28, P751; MANTEL N, 1959, J NATL CANCER I, V22, P719; Nordenstedt H, 2010, DIGEST LIVER DIS, V42, pS206, DOI 10.1016/S1590-8658(10)60507-5; Pinter M, 2011, ALIMENT PHARM THER, V34, P949, DOI 10.1111/j.1365-2036.2011.04823.x; Semela D, 2004, J HEPATOL, V41, P864, DOI 10.1016/j.jhep.2004.09.006; Song TQ, 2011, EUR J GASTROEN HEPAT, V23, P1233, DOI 10.1097/MEG.0b013e32834bd2d0; Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16; Trojniak MP, 2012, IMMUNOPHARM IMMUNOT, V34, P419, DOI 10.3109/08923973.2011.617373; Wang Z, 2013, ASIAN PAC J CANCER P, V14, P691, DOI 10.7314/APJCP.2013.14.2.691; Wilhelm S, 2006, NAT REV DRUG DISCOV, V5, P835, DOI 10.1038/nrd2130; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Wood, 2006, COMMUNITY ONCOL, V3, P558; Yang YP, 2012, CELL BIOCHEM BIOPHYS, V63, P159, DOI 10.1007/s12013-012-9353-2; Yau T, 2009, CANCER-AM CANCER SOC, V115, P428, DOI 10.1002/cncr.24029; Zhang X, 2012, HEPATOB PANCREAT DIS, V11, P458, DOI 10.1016/S1499-3872(12)60209-4	42	20	26	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2014	9	12							e112530	10.1371/journal.pone.0112530	http://dx.doi.org/10.1371/journal.pone.0112530			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AU8TQ	25460347	Green Submitted, Green Published, gold			2023-01-03	WOS:000345869700018
J	Powles, T; Eder, JP; Fine, GD; Braiteh, FS; Loriot, Y; Cruz, C; Bellmunt, J; Burris, HA; Petrylak, DP; Teng, SL; Shen, XD; Boyd, Z; Hegde, PS; Chen, DS; Vogelzang, NJ				Powles, Thomas; Eder, Joseph Paul; Fine, Gregg D.; Braiteh, Fadi S.; Loriot, Yohann; Cruz, Cristina; Bellmunt, Joaquim; Burris, Howard A.; Petrylak, Daniel P.; Teng, Siew-Leng; Shen, Xiaodong; Boyd, Zachary; Hegde, Priti S.; Chen, Daniel S.; Vogelzang, Nicholas J.			MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer	NATURE			English	Article							TRANSITIONAL-CELL CARCINOMA; ADVANCED UROTHELIAL CARCINOMA; PHASE-II; 2ND-LINE TREATMENT; SINGLE GROUP; VINFLUNINE; TRIAL; PACLITAXEL; CLONING; PLUS	There have been no major advances for the treatment of metastatic urothelial bladder cancer (UBC) in the last 30 years. Chemotherapy is still the standard of care. Patient outcomes, especially for those in whom chemotherapy is not effective or is poorly tolerated, remain poor(1,2). One hallmark of UBC is the presence of high rates of somatic mutations(3,5). These alterations may enhance the ability of the host immune system to recognize tumour cells as foreign owing to an increased number of antigens(6). However, these cancers may also elude immune surveillance and eradication through the expression of programmed death-ligand 1 (PD-Li; also called CD274 or B7-H1) in the tumour microenvironment(7,8). Therefore, we examined the anti-PDLi antibody MPDL3280A, a systemic cancer immunotherapy, for the treatment of metastatic UBC. MPDL3280A is a high-affinity engineered human anti-PD-L1 monoclonal immunoglobulin-Gl antibody that inhibits the interaction of PD-L1 with PD-1 (PDCD1) and B7.1 (CD80)9. Because PD-L1 is expressed on activated T cells, MPDL3280A was engineered with a modification in the Fc domain that eliminates antibody-dependent cellular cytotoxicity at clinically relevant doses to prevent the depletion of T cells expressing PD-Li. Here we show that MPDL3280A has noteworthy activity in metastatic UBC. Responses were often rapid, with many occurring at the time of the first response assessment (6 weeks) and nearly all were ongoing at the data cutoff. This phase I expansion study, with an adaptive design that allowed for biomarker-positive enriched cohorts, demonstrated that tumours expressing PD-L1 -positive tumour-infiltrating immune cells had particularly high response rates. Moreover, owing to the favourable toxicity profile, including a lack of renal toxicity, patients with UBC, who are often older and have a higher incidence of renal impairment, may be better able to tolerate MPDL3280A versus chemotherapy. These results suggest that MPDL3280A may have an important role in treating UBC-the drug received breakthrough designation status by the US Food and Drug Administration (FDA) in June 2014.	[Powles, Thomas] Queen Mary Univ London, Barts Canc Inst, Barts Expt Canc Med Ctr, London EC1M 6BQ, England; [Eder, Joseph Paul; Petrylak, Daniel P.] Yale Canc Ctr, New Haven, CT 06520 USA; [Fine, Gregg D.; Teng, Siew-Leng; Shen, Xiaodong; Boyd, Zachary; Hegde, Priti S.; Chen, Daniel S.] Genentech Inc, San Francisco, CA 94080 USA; [Braiteh, Fadi S.] Comprehens Canc Ctr Nevada, Las Vegas, NV 89169 USA; [Loriot, Yohann] Gustave Roussy, F-94805 Villejuif, France; [Cruz, Cristina] VHIO, Barcelona 08035, Spain; [Cruz, Cristina] Vall dHebron Univ Hosp, Barcelona 08035, Spain; [Bellmunt, Joaquim] Harvard Univ, Sch Med, Bladder Canc Ctr, Dana Farber Brigham & Womens Canc Ctr, Boston, MA 02215 USA; [Burris, Howard A.] Sarah Cannon Res Inst, Nashville, TN 37203 USA; [Vogelzang, Nicholas J.] Univ Nevada, Sch Med, Las Vegas, NV 89169 USA; [Vogelzang, Nicholas J.] Univ Nevada, US Oncol Comprehens Canc Ctr Nevada, Las Vegas, NV 89169 USA	University of London; Queen Mary University London; Yale University; Roche Holding; Genentech; Comprehensive Cancer Centers of Nevada; UNICANCER; Gustave Roussy; Vall d'Hebron Institut d'Oncologia (VHIO); Hospital Universitari Vall d'Hebron; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Sarah Cannon Research Institute; Nevada System of Higher Education (NSHE); University of Nevada Las Vegas; Comprehensive Cancer Centers of Nevada; Nevada System of Higher Education (NSHE); University of Nevada Las Vegas	Powles, T (corresponding author), Queen Mary Univ London, Barts Canc Inst, Barts Expt Canc Med Ctr, London EC1M 6BQ, England.	Thomas.Powles@bartshealth.nhs.uk	Ge, Leeyuan/O-4508-2014; Bellmunt, Joaquim/B-8151-2019; Cruz, Cristina/GLR-3029-2022; Chen, Daniel Shin-Yu/AGD-8923-2022; Loriot, Yohann/W-5572-2019	Bellmunt, Joaquim/0000-0003-2328-3421; Cruz, Cristina/0000-0002-6474-7504; Chen, Daniel Shin-Yu/0000-0001-5085-3579; 				Bellmunt J, 2010, J CLIN ONCOL, V28, P1850, DOI 10.1200/JCO.2009.25.4599; Bellmunt J, 2009, J CLIN ONCOL, V27, P4454, DOI 10.1200/JCO.2008.20.5534; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Chen DS, 2012, CLIN CANCER RES, V18, P6580, DOI 10.1158/1078-0432.CCR-12-1362; Chen G. J., 2013, J CLIN ONCOL S; Choueiri TK, 2012, J CLIN ONCOL, V30, P507, DOI 10.1200/JCO.2011.37.7002; Culine S, 2006, BRIT J CANCER, V94, P1395, DOI 10.1038/sj.bjc.6603118; Dahlberg SE, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju163; De Santis M, 2012, J CLIN ONCOL, V30, P191, DOI 10.1200/JCO.2011.37.3571; Dreicer R, 1996, J UROLOGY, V156, P1606, DOI 10.1016/S0022-5347(01)65459-4; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Gallagher DJ, 2010, J CLIN ONCOL, V28, P1373, DOI 10.1200/JCO.2009.25.3922; Iwai Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002404; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Ko YJ, 2013, LANCET ONCOL, V14, P769, DOI 10.1016/S1470-2045(13)70162-1; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Necchi A, 2012, LANCET ONCOL, V13, P810, DOI 10.1016/S1470-2045(12)70294-2; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; Seront E, 2012, ANN ONCOL, V23, P2663, DOI 10.1093/annonc/mds057; Sonpavde G, 2013, EUR UROL, V63, P717, DOI 10.1016/j.eururo.2012.11.042; Sweeney CJ, 2006, J CLIN ONCOL, V24, P3451, DOI 10.1200/JCO.2005.03.6699; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; van Rooij N, 2013, J CLIN ONCOL, V31, pE439, DOI 10.1200/JCO.2012.47.7521; Vaughn DJ, 2009, CANCER, V115, P4110, DOI 10.1002/cncr.24460; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Wolchok JD, 2009, CLIN CANCER RES, V15, P7412, DOI 10.1158/1078-0432.CCR-09-1624; Wrammert J, 2008, NATURE, V453, P667, DOI 10.1038/nature06890	27	1750	1871	12	328	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 27	2014	515	7528					558	+		10.1038/nature13904	http://dx.doi.org/10.1038/nature13904			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AW4JP	25428503				2023-01-03	WOS:000346247600052
J	Bibault, JE; Nickers, P; Tresch, E; Cordoba, A; Leblanc, E; Comte, P; Lacornerie, T; Lartigau, E				Bibault, Jean-Emmanuel; Nickers, Philippe; Tresch, Emmanuelle; Cordoba, Abel; Leblanc, Eric; Comte, Pauline; Lacornerie, Thomas; Lartigau, Eric			Feasibility Study of Pelvic Helical IMRT for Elderly Patients with Endometrial Cancer	PLOS ONE			English	Article							INTENSITY-MODULATED RADIOTHERAPY; EXTERNAL-BEAM RADIOTHERAPY; RADIATION-THERAPY; POSTOPERATIVE RADIOTHERAPY; ADJUVANT TREATMENT; CARCINOMA; SURGERY; TRIAL; SURVIVAL; IMPACT	Purpose: Standard treatment for early-stage endometrial cancer involves surgery (when possible) followed by brachytherapy or external-beam radiotherapy (EBRT) for high-risk tumors. EBRT is not without toxicity, meaning that it could be difficult to complete for elderly patients, who typically have decreased reserve and resistance to stressors. Patients and methods: Patients aged 70 and over treated between April 2009 and May 2013 for endometrial cancer and received IMRT (Intensity-Modulated Radiation Therapy) were included in this observational study. IMRT could be performed as adjuvant treatment or as an exclusive treatment for patients not amenable to surgery. The primary endpoints of this study were to assess the feasibility and toxicity of pelvic IMRT in this population. Secondary endpoints were to assess disease-specific survival, overall survival, and local control. Predictors of toxicity were also explored. Results: Forty seven consecutive patients were included in the analysis. Median age at diagnosis was 75 years (range, 70-89 years). Eleven patients were aged 80 years and older. Toxicities were found in thirty four patients (72%) during treatment. Among these, toxicity did not exceed grade 2 for 32 patients (68%). Two patients had a grade 3 toxicity (4%). Overall survival rates were 87% and 83% at 1 and 2 years, respectively. Six patients (12.8%) had a local relapse and nine others (19.1%) had distant relapse. Conclusions: Pelvic helical IMRT for patients aged 70 and older is feasible with full standard radiation doses, showing that age greater than 70 should not be considered as a reason not to perform optimal treatment.	[Bibault, Jean-Emmanuel; Nickers, Philippe; Cordoba, Abel; Comte, Pauline; Lacornerie, Thomas; Lartigau, Eric] Oscar Lambret Comprehens Canc Ctr, Acad Radiat Oncol Dept, Lille, France; [Tresch, Emmanuelle] Oscar Lambret Comprehens Canc Ctr, Dept Biostat, Lille, France; [Leblanc, Eric] Oscar Lambret Comprehens Canc Ctr, Gynaecol Oncol Dept, Lille, France; [Bibault, Jean-Emmanuel; Lartigau, Eric] Univ Lille 2, Fac Med, Lille, France; [Bibault, Jean-Emmanuel; Nickers, Philippe; Tresch, Emmanuelle; Cordoba, Abel; Leblanc, Eric; Comte, Pauline; Lacornerie, Thomas; Lartigau, Eric] ONCOLille, Maison Reg Rech Clin, Lille, France	UNICANCER; Centre Oscar Lambret; UNICANCER; Centre Oscar Lambret; UNICANCER; Centre Oscar Lambret; Universite de Lille - ISITE; Universite de Lille	Lartigau, E (corresponding author), Oscar Lambret Comprehens Canc Ctr, Acad Radiat Oncol Dept, 3 Rue Frederic Combemale, Lille, France.	e-lartigau@o-lambret.fr	lartigau, eric/GSI-5327-2022	leblanc, eric/0000-0001-7299-0339; Bibault, Jean-Emmanuel/0000-0002-1728-6776; Lacornerie, Thomas/0000-0001-8994-5999	Accuray	Accuray	The radiation therapy department at the Oscar Lambret Comprehensive Cancer Center has a clinical research program partially funded by Accuray. Dr. Lartigau has been acting Chief Medical Officer at Accuray from April 2014 until September 2014 and has participated in coordination of the study, provided mentorship and edited the manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AALDERS J, 1980, OBSTET GYNECOL, V56, P419; Ahmed A, 2008, GYNECOL ONCOL, V111, P35, DOI 10.1016/j.ygyno.2008.06.026; Alektiar KM, 2003, CANCER-AM CANCER SOC, V98, P2368, DOI 10.1002/cncr.11830; Barillot I, 2014, RADIOTHER ONCOL, V111, P138, DOI 10.1016/j.radonc.2014.01.018; Baumann M, 1998, RADIOTHER ONCOL, V46, P225; Beriwal S, 2006, GYNECOL ONCOL, V102, P195, DOI 10.1016/j.ygyno.2006.01.062; Blake P, 2009, LANCET, V373, P137, DOI 10.1016/S0140-6736(08)61767-5; Boyer AL, 2001, INT J RADIAT ONCOL, V51, P880, DOI 10.1016/S0360-3016(01)01749-7; Creutzberg CL, 2000, LANCET, V355, P1404, DOI 10.1016/S0140-6736(00)02139-5; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Fleming ND, 2011, GYNECOL ONCOL, V120, P189, DOI 10.1016/j.ygyno.2010.10.038; FRICK HC, 1973, AM J OBSTET GYNECOL, V115, P663, DOI 10.1016/0002-9378(73)90615-7; Heron DE, 2003, GYNECOL ONCOL, V91, P39, DOI 10.1016/S0090-8258(03)00461-X; Hsieh CH, 2009, RADIAT ONCOL, V4, DOI 10.1186/1748-717X-4-62; Igdem S, 2009, EUR J GYNAECOL ONCOL, V30, P547; Jolly S, 2006, GYNECOL ONCOL, V103, P87, DOI 10.1016/j.ygyno.2006.01.038; Jutzi L, 2013, GYNECOL ONCOL, V131, P581, DOI 10.1016/j.ygyno.2013.09.012; Keys HM, 2004, GYNECOL ONCOL, V92, P744, DOI 10.1016/j.ygyno.2003.11.048; Klopp AH, 2013, INT J RADIAT ONCOL, V86, P83, DOI 10.1016/j.ijrobp.2013.01.017; Lim K, 2009, INT J RADIAT ONCOL, V74, P304, DOI 10.1016/j.ijrobp.2008.12.043; Nelson NJ, 2000, J NATL CANCER I, V92, P1968, DOI 10.1093/jnci/92.24.1968; Njolstad TS, 2013, GYNECOL ONCOL, V131, P410, DOI 10.1016/j.ygyno.2013.08.032; NOER MC, 2014, ACTA OBSTET GYNECOL, DOI DOI 10.1111/A0GS.12338; Nout RA, 2010, LANCET, V375, P816, DOI 10.1016/S0140-6736(09)62163-2; Nout RA, 2011, J CLIN ONCOL, V29, P1692, DOI 10.1200/JCO.2010.32.4590; Okuma K, 2010, J OBSTET GYNAECOL RE, V36, P757, DOI 10.1111/j.1447-0756.2010.01202.x; Quaglia A, 2009, EUR J CANCER, V45, P1006, DOI 10.1016/j.ejca.2008.11.028; Roeske JC, 2000, INT J RADIAT ONCOL, V48, P1613, DOI 10.1016/S0360-3016(00)00771-9; Small W, 2008, INT J RADIAT ONCOL, V71, P428, DOI 10.1016/j.ijrobp.2007.09.042; Suh DH, 2012, INT J GYNECOL CANCER, V22, P161, DOI 10.1097/IGC.0b013e318234f8d5; Vaknin Z, 2009, INT J GYNECOL CANCER, V19, P879, DOI 10.1111/IGC.0b013e3181a73a12; Wagner A, 2013, GYNECOL ONCOL, V130, P229, DOI 10.1016/j.ygyno.2013.04.052; Wright JD, 2009, CANCER-AM CANCER SOC, V115, P1276, DOI 10.1002/cncr.24160	33	3	3	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 25	2014	9	11							e113279	10.1371/journal.pone.0113279	http://dx.doi.org/10.1371/journal.pone.0113279			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AU9GL	25423024	Green Submitted, Green Published, gold			2023-01-03	WOS:000345899700029
J	Falanga, A; Tarallo, R; Carberry, T; Galdiero, M; Weck, M; Galdiero, S				Falanga, Annarita; Tarallo, Rossella; Carberry, Thomas; Galdiero, Massimiliano; Weck, Marcus; Galdiero, Stefania			Elucidation of the Interaction Mechanism with Liposomes of gH625-Peptide Functionalized Dendrimers	PLOS ONE			English	Article							SIMPLEX-VIRUS TYPE-1; CELL-PENETRATING PEPTIDES; SUPPORTED LIPID-BILAYERS; POLY(AMIDOAMINE) DENDRIMERS; PAMAM DENDRIMERS; PORE FORMATION; INTRACELLULAR DELIVERY; POLYCATIONIC POLYMERS; MOLECULAR-DYNAMICS; HOLE FORMATION	We have demonstrated that amide-based dendrimers functionalized with the membrane-interacting peptide gH625 derived from the herpes simplex virus type 1 (HSV-1) envelope glycoprotein H enter cells mainly through a non-active translocation mechanism. Herein, we investigate the interaction between the peptide-functionalized dendrimer and liposomes composed of PC/Chol using fluorescence spectroscopy, isothermal titration calorimetry, and surface plasmon resonance to get insights into the mechanism of internalization. The affinity for the membrane bilayer is very high and the interaction between the peptide-dendrimer and liposomes took place without evidence of pore formation. These results suggest that the presented peptidodendrimeric scaffold may be a promising material for efficient drug delivery.	[Falanga, Annarita; Galdiero, Stefania] Univ Naples Federico II, Dept Pharm, Naples, Italy; [Falanga, Annarita; Galdiero, Stefania] Univ Naples Federico II, CIRPEB, Naples, Italy; [Falanga, Annarita; Galdiero, Stefania] Univ Naples Federico II, DFM Scarl, Naples, Italy; [Tarallo, Rossella; Carberry, Thomas; Weck, Marcus] NYU, Inst Mol Design, New York, NY USA; [Tarallo, Rossella; Carberry, Thomas; Weck, Marcus] NYU, Dept Chem, New York, NY 10003 USA; [Galdiero, Massimiliano] Univ Naples 2, Dept Expt Med, Naples, Italy	University of Naples Federico II; University of Naples Federico II; University of Naples Federico II; New York University; New York University; Universita della Campania Vanvitelli	Galdiero, S (corresponding author), Univ Naples Federico II, Dept Pharm, Naples, Italy.	stefania.galdiero@unina.it	Galdiero, Stefania/M-3225-2019; galdiero, stefania/B-1357-2010	Galdiero, Stefania/0000-0002-7849-7024; Galdiero, Massimiliano/0000-0002-1576-6290; FALANGA, Annarita/0000-0001-6538-8585; Weck, Marcus/0000-0002-6486-4268	MIUR [PON01_02388]	MIUR(Ministry of Education, Universities and Research (MIUR))	Financial support was provided by MIUR - PON01_02388 "Verso la medicina personalizzata: nuovi sistemi molecolari per la diagnosi e la terapia di patologie oncologiche ad alto impatto sociale'' SALUTE DELL'UOMO E BIOTECNOLOGIE. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Accardo A, 2013, POLYM J, V45, P481, DOI 10.1038/pj.2012.215; Andrushchenko VV, 2008, BBA-BIOMEMBRANES, V1778, P1004, DOI 10.1016/j.bbamem.2007.12.022; Cantor C.R., 1980, BIOPHYS CHEM; Carberry TP, 2012, CHEM-EUR J, V18, P13678, DOI 10.1002/chem.201202358; Castile JD, 1999, INT J PHARM, V182, P101, DOI 10.1016/S0378-5173(99)00069-1; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; Falanga A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032186; Falanga A, 2011, NANOMED-NANOTECHNOL, V7, P925, DOI 10.1016/j.nano.2011.04.009; Falanga A, 2009, PROTEIN PEPTIDE LETT, V16, P751, DOI 10.2174/092986609788681760; Galdiero S, 2005, J BIOL CHEM, V280, P28632, DOI 10.1074/jbc.M505196200; Galdiero S, 2008, J BIOL CHEM, V283, P29993, DOI 10.1074/jbc.M803092200; Galdiero S, 2012, BIOCHEMISTRY-US, V51, P3121, DOI 10.1021/bi201589m; Galdiero S, 2012, CURR DRUG METAB, V13, P93, DOI 10.2174/138920012798356961; Galdiero S, 2010, J BIOL CHEM, V285, P17123, DOI 10.1074/jbc.M110.114819; Galdiero S, 2010, BBA-BIOMEMBRANES, V1798, P579, DOI 10.1016/j.bbamem.2010.01.006; Gardikis K, 2006, INT J PHARM, V318, P118, DOI 10.1016/j.ijpharm.2006.03.023; Gillies ER, 2005, DRUG DISCOV TODAY, V10, P35, DOI 10.1016/S1359-6446(04)03276-3; Guarnieri D, 2013, SMALL, V9, P853, DOI 10.1002/smll.201201870; Hong SP, 2006, BIOCONJUGATE CHEM, V17, P728, DOI 10.1021/bc060077y; Hong S, 2009, BIOCONJUGATE CHEM, V20, P1503, DOI 10.1021/bc900029k; Hong SP, 2004, BIOCONJUGATE CHEM, V15, P774, DOI 10.1021/bc049962b; Ionov M., 2011, ACTA PHYS U COMENIAN, V52, P33; Jain K, 2010, INT J PHARMACEUT, V394, P122, DOI 10.1016/j.ijpharm.2010.04.027; Kelly CV, 2008, J PHYS CHEM B, V112, P9346, DOI 10.1021/jp8013783; Kelly CV, 2009, ACS NANO, V3, P1886, DOI 10.1021/nn900173e; Klajnert B, 2006, BIOCHEM BIOPH RES CO, V345, P21, DOI 10.1016/j.bbrc.2006.04.041; Klajnert B, 2004, BIOELECTROCHEMISTRY, V65, P23, DOI 10.1016/j.bioelechem.2004.06.004; Klajnert B, 2005, INT J PHARMACEUT, V305, P154, DOI 10.1016/j.ijpharm.2005.08.015; Klajnert B, 2006, INT J PHARMACEUT, V327, P145, DOI 10.1016/j.ijpharm.2006.07.018; Lee CC, 2005, NAT BIOTECHNOL, V23, P1517, DOI 10.1038/nbt1171; Lee H, 2008, J PHYS CHEM B, V112, P7778, DOI 10.1021/jp802606y; Lee H, 2006, J PHYS CHEM B, V110, P18204, DOI 10.1021/jp0630830; Leroueil PR, 2007, ACCOUNTS CHEM RES, V40, P335, DOI 10.1021/ar600012y; Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1; Mae M, 2006, CURR OPIN PHARMACOL, V6, P509, DOI 10.1016/j.coph.2006.04.004; Mecke A, 2005, LANGMUIR, V21, P10348, DOI 10.1021/la050629l; Mecke A, 2005, LANGMUIR, V21, P8588, DOI 10.1021/la051800w; Mecke A, 2004, CHEM PHYS LIPIDS, V132, P3, DOI 10.1016/j.chemphyslip.2004.09.001; Mozsolits H, 2001, BBA-BIOMEMBRANES, V1512, P64, DOI 10.1016/S0005-2736(01)00303-0; Newkome G. R., 2001, DENDRIMERS DENDRONS; Ornelas C, 2011, ORG LETT, V13, P976, DOI 10.1021/ol103019z; Ottaviani MF, 1999, LANGMUIR, V15, P1973, DOI 10.1021/la9803068; Ottaviani MF, 1998, J PHYS CHEM B, V102, P6029, DOI 10.1021/jp980715c; Papo N, 2003, BIOCHEMISTRY-US, V42, P458, DOI 10.1021/bi0267846; Pearson RM, 2012, THER DELIV, V3, P941, DOI 10.4155/TDE.12.76; Purohit G, 2001, INT J PHARMACEUT, V214, P71, DOI 10.1016/S0378-5173(00)00635-9; Roberts JC, 1996, J BIOMED MATER RES, V30, P53, DOI 10.1002/(SICI)1097-4636(199601)30:1<53::AID-JBM8>3.0.CO;2-Q; Ruzza P, 2010, PHARMACEUTICALS, V3, P1045, DOI 10.3390/ph3041045; Sanna V, 2014, INT J NANOMED, V9, P467, DOI 10.2147/IJN.S36654; Saovapakhiran A, 2009, BIOCONJUGATE CHEM, V20, P693, DOI 10.1021/bc8002343; SCHWARZ G, 1986, BIOCHIM BIOPHYS ACTA, V861, P141, DOI 10.1016/0005-2736(86)90412-8; Seelig J, 1997, BBA-REV BIOMEMBRANES, V1331, P103, DOI 10.1016/S0304-4157(97)00002-6; Seib FP, 2007, J CONTROL RELEASE, V117, P291, DOI 10.1016/j.jconrel.2006.10.020; SHAI Y, 1990, J BIOL CHEM, V265, P20202; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Shcharbin D, 2006, CELL MOL BIOL LETT, V11, P242, DOI 10.2478/s11658-006-0018-2; Smaldone G, 2013, INT J NANOMED, V8, P2555, DOI 10.2147/IJN.S44186; Smith DK, 2008, CURR TOP MED CHEM, V8, P1187, DOI 10.2174/156802608785849030; Smith PES, 2010, J AM CHEM SOC, V132, P8087, DOI 10.1021/ja101524z; Svenson S, 2005, ADV DRUG DELIVER REV, V57, P2106, DOI 10.1016/j.addr.2005.09.018; Tarallo R, 2013, INT J NANOMED, V8, P521, DOI 10.2147/IJN.S37739; Tarallo R, 2011, CHEM-EUR J, V17, P12659, DOI 10.1002/chem.201101425; Tiriveedhi V, 2011, BBA-BIOMEMBRANES, V1808, P209, DOI 10.1016/j.bbamem.2010.08.017; Torchilin VP, 2006, ANNU REV BIOMED ENG, V8, P343, DOI 10.1146/annurev.bioeng.8.061505.095735; Wenk MR, 1998, BIOCHEMISTRY-US, V37, P3909, DOI 10.1021/bi972615n; Wieprecht T, 1999, BIOCHEMISTRY-US, V38, P10377, DOI 10.1021/bi990913+; Wimley WC, 2011, J MEMBRANE BIOL, V239, P27, DOI 10.1007/s00232-011-9343-0; Wrobel D, 2012, CHEM PHYS LIPIDS, V165, P401, DOI 10.1016/j.chemphyslip.2012.01.008; Wrobel D, 2011, BBA-MOL CELL BIOL L, V1811, P221, DOI 10.1016/j.bbalip.2010.11.007; Yan LT, 2009, ACS NANO, V3, P2171, DOI 10.1021/nn9004236; Yau WM, 1998, BIOCHEMISTRY-US, V37, P14713, DOI 10.1021/bi980809c	71	20	20	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 25	2014	9	11							e112128	10.1371/journal.pone.0112128	http://dx.doi.org/10.1371/journal.pone.0112128			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AU9GL	25423477	gold, Green Published, Green Submitted			2023-01-03	WOS:000345899700009
J	Hanley, N				Hanley, Neil			Closing in on pancreatic beta cells	NATURE BIOTECHNOLOGY			English	Editorial Material							EMBRYONIC STEM-CELLS		[Hanley, Neil] Univ Manchester, Ctr Endocrinol & Diabet, Manchester M13 9PL, Lancs, England; [Hanley, Neil] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester, Lancs, England	University of Manchester; University of Manchester	Hanley, N (corresponding author), Univ Manchester, Ctr Endocrinol & Diabet, Manchester M13 9PL, Lancs, England.	Neil.Hanley@manchester.ac.uk		Hanley, Neil/0000-0003-3234-4038	Wellcome Trust [088566] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aguayo-Mazzucato C, 2013, DIABETES, V62, P1569, DOI 10.2337/db12-0849; Assady S, 2001, DIABETES, V50, P1691, DOI 10.2337/diabetes.50.8.1691; Barton FB, 2012, DIABETES CARE, V35, P1436, DOI 10.2337/dc12-0063; Blum B, 2014, ELIFE, V3, DOI 10.7554/eLife.02809; Hebrok M, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007674; Jennings RE, 2013, DIABETES, V62, P3514, DOI 10.2337/db12-1479; Kroon E, 2008, NAT BIOTECHNOL, V26, P443, DOI 10.1038/nbt1393; Mukhi S, 2009, DEV BIOL, V328, P384, DOI 10.1016/j.ydbio.2009.01.038; Pagliuca FW, 2014, CELL, V159, P428, DOI 10.1016/j.cell.2014.09.040; Rezania A, 2014, NAT BIOTECHNOL, V32, P1121, DOI 10.1038/nbt.3033; Rezania A, 2012, DIABETES, V61, P2016, DOI 10.2337/db11-1711; Rezania A, 2011, DIABETES, V60, P239, DOI 10.2337/db10-0573; Solar M, 2009, DEV CELL, V17, P849, DOI 10.1016/j.devcel.2009.11.003; Stanger BZ, 2013, GASTROENTEROLOGY, V144, P1170, DOI 10.1053/j.gastro.2013.01.074	14	4	10	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2014	32	11					1100	1102		10.1038/nbt.3064	http://dx.doi.org/10.1038/nbt.3064			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	AT5IL	25380444				2023-01-03	WOS:000344977000012
J	Zhao, RQ; Xu, ZG; Zhao, MH				Zhao, Renqing; Xu, Zhengang; Zhao, Meihua			Antiresorptive Agents Increase the Effects of Exercise on Preventing Postmenopausal Bone Loss in Women: A Meta-Analysis	PLOS ONE			English	Article							HORMONE REPLACEMENT THERAPY; MINERAL DENSITY; COMBINED INTERVENTION; IMMUNE REGULATION; JAPANESE WOMEN; FAT MASS; BODY-FAT; ESTROGEN; IMPACT; ISOFLAVONE	Background and Objectives It remains unknown whether the combination of antiresorptive agents and exercise would generate additive effects on bone mineral density (BMD) in postmenopausal women, though their separate roles in preventing bone loss have been well established. This meta-analysis aimed to evaluate the combined impact of antiresorptive treatment and exercise on the lumbar spine and femoral neck BMD in postmenopausal women compared with an exercise-only intervention. Methods A systematic literature search of PubMed, EMBASE, SportDiscus and ProQuest up to Jun 2014 was conducted to identify the influence of antiresorptive agents and exercise on BMD in postmenopausal women. The study quality of the included trials was evaluated. The effect sizes were estimated by calculating the standardized mean difference (SMD). Subgroup analyses were conducted by pharmacological regimens and exercise categories. Results Nine studies with a total of 1,248 postmenopausal women met the inclusion criteria. The heterogeneity between the studies was evident at the spine (I-2 = 78.7%) and hip (I-2 = 41.7%) measurements; random-effects models were used in the data analysis. The pooled effect sizes associated with the combined interventions of antiresorptive agents and exercise were significant at the lumbar spine BMD (SMD = 0.511, 95% CI = 0.118-0.904, p = 0.011). Combining hormone replacement therapy (HRT) and exercise training generated greater beneficial effects on lumbar spine (SMD = 0.729, 95% CI = 0.186-1.273, p = 0.009) and femoral neck BMD (SMD = 0.220, 95% CI = 0.0110-429, p = 0.039) than the exercise-only intervention. Impact exercise was sensitive to antiresorptive agents in preventing postmenopausal bone loss both at the spine (SMD = 1.252, 95% CI = 0.465-2.039, p = 0.002) and hips (SMD = 0.414, 95% CI = 0.106-0.723, p = 0.008). Conclusions Our findings indicate that antiresorptive agents significantly increase the impact of exercise on the prevention of bone loss in postmenopausal women, which implies that the combination of antiresorptive agents and exercise may generate additive effects.	[Zhao, Renqing; Xu, Zhengang; Zhao, Meihua] Zhejiang Normal Univ, Coll Phys Educ & Hlth Sci, Jinhua, Zhejiang, Peoples R China	Zhejiang Normal University	Zhao, RQ (corresponding author), Zhejiang Normal Univ, Coll Phys Educ & Hlth Sci, Jinhua, Zhejiang, Peoples R China.	renzhao@zjnu.cn			Zhejiang Provincial Natural Science Foundation of China [LY14H070001]	Zhejiang Provincial Natural Science Foundation of China(Natural Science Foundation of Zhejiang Province)	This material was based upon work funded by Zhejiang Provincial Natural Science Foundation of China under Grant No. LY14H070001 (http://www.zjnsf.gov.cn/index.aspx). RZ received the funding. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ammann P, 2003, OSTEOPOROSIS INT, V14, pS13, DOI 10.1007/s00198-002-1345-4; Ankrom MA, 1998, BIOCHEM J, V333, P787, DOI 10.1042/bj3330787; Babatunde OO, 2012, OSTEOPOROSIS INT, V23, P109, DOI 10.1007/s00198-011-1801-0; Bassey EJ, 1998, J BONE MINER RES, V13, P1805, DOI 10.1359/jbmr.1998.13.12.1805; Borer KT, 2005, SPORTS MED, V35, P779, DOI 10.2165/00007256-200535090-00004; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; Cheng S, 2002, BONE, V31, P126, DOI 10.1016/S8756-3282(02)00794-9; Chilibeck PD, 2002, CAN J PHYSIOL PHARM, V80, P941, DOI 10.1139/y02-126; Chilibeck PD, 2013, J BONE MINER RES, V28, P780, DOI 10.1002/jbmr.1815; Chuin A, 2009, OSTEOPOROSIS INT, V20, P1253, DOI 10.1007/s00198-008-0798-5; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; Damien E, 1998, J BONE MINER RES, V13, P1275, DOI 10.1359/jbmr.1998.13.8.1275; Going S, 2003, OSTEOPOROSIS INT, V14, P637, DOI 10.1007/s00198-003-1436-x; Gurney EP, 2014, J STEROID BIOCHEM, V142, P4, DOI 10.1016/j.jsbmb.2013.10.009; Hahn S, 2000, STAT MED, V19, P3325, DOI 10.1002/1097-0258(20001230)19:24<3325::AID-SIM827>3.0.CO;2-D; HIGGINS J, 2008, COCHRANE REVIEWERS H, P6472; Howe TE, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000333, 10.1002/14651858.CD000333.pub2]; Ishimi Y, 2000, BIOCHEM BIOPH RES CO, V274, P697, DOI 10.1006/bbrc.2000.3175; Ishimi Y, 2002, BONE, V31, P180, DOI 10.1016/S8756-3282(02)00780-9; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Kelley GA, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-177; KOHRT WM, 1995, J BONE MINER RES, V10, P1303, DOI 10.1002/jbmr.5650100906; Kohrt WM, 1998, J APPL PHYSIOL, V84, P1506, DOI 10.1152/jappl.1998.84.5.1506; Lagari VS, 2014, J STEROID BIOCHEM, V139, P294, DOI 10.1016/j.jsbmb.2012.12.002; Lorrain J, 2003, MENOPAUSE, V10, P228, DOI 10.1097/00042192-200310030-00010; Maddalozzo GF, 2007, BONE, V40, P1244, DOI 10.1016/j.bone.2006.12.059; Martyn-St James M, 2006, OSTEOPOROSIS INT, V17, P1225, DOI 10.1007/s00198-006-0083-4; Martyn-St James M, 2008, BONE, V43, P521, DOI 10.1016/j.bone.2008.05.012; Milliken LA, 2003, CALCIFIED TISSUE INT, V72, P478, DOI 10.1007/s00223-001-1128-5; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; Pildal J, 2007, INT J EPIDEMIOL, V36, P847, DOI 10.1093/ije/dym087; Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140-6736(10)62349-5; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Sugiyama T, 2002, J BONE MINER METAB, V20, P196, DOI 10.1007/s007740200028; Tobias JH, 2003, TRENDS ENDOCRIN MET, V14, P441, DOI 10.1016/j.tem.2003.09.010; Torgerson DJ, 2001, JAMA-J AM MED ASSOC, V285, P2891, DOI 10.1001/jama.285.22.2891; Umland EM, 2000, PHARMACOTHERAPY, V20, P981, DOI 10.1592/phco.20.11.981.35259; Uusi-Rasi K, 2003, BONE, V33, P132, DOI 10.1016/S8756-3282(03)00082-6; Wang QJ, 2004, J CLIN ENDOCR METAB, V89, P1698, DOI 10.1210/jc.2003-031113; Wood L, 2008, BMJ-BRIT MED J, V336, P601, DOI 10.1136/bmj.39465.451748.AD; Wu J, 2006, J BONE MINER RES, V21, P780, DOI 10.1359/JBMR.060208; Wu J, 2006, METABOLISM, V55, P423, DOI 10.1016/j.metabol.2005.10.002; Wu J, 2004, METABOLISM, V53, P942, DOI 10.1016/j.metabol.2004.01.019; Wu J, 2003, J APPL PHYSIOL, V94, P335, DOI 10.1152/japplphysiol.00498.2002; Zhang J, 2014, OSTEOPOROSIS INT, V25, P1585, DOI 10.1007/s00198-014-2644-2; ZHAO R, 2014, EFFICIENCY JUMPING E, P6472; Zhao RQ, 2014, SPORTS MED, V44, P1393, DOI 10.1007/s40279-014-0220-8; Zhao RQ, 2013, EUR J CLIN INVEST, V43, P1195, DOI 10.1111/eci.12158; Zhao RQ, 2012, INT J MED SCI, V9, P825, DOI 10.7150/ijms.5180	49	10	11	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2015	10	1							e0116729	10.1371/journal.pone.0116729	http://dx.doi.org/10.1371/journal.pone.0116729			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA7UF	25615597	Green Published, Green Submitted, gold			2023-01-03	WOS:000349122100039
J	Goroll, AH; Hunt, DP				Goroll, Allan H.; Hunt, Daniel P.			Bridging the Hospitalist-Primary Care Divide through Collaborative Care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Goroll, Allan H.; Hunt, Daniel P.] Massachusetts Gen Hosp, Div Gen Internal Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Goroll, AH (corresponding author), Massachusetts Gen Hosp, Div Gen Internal Med, Boston, MA 02114 USA.		Hunt, Dan/AAL-3807-2021					Kuo Y, 2009, NEW ENGL J MED, V360, P1102, DOI 10.1056/NEJMsa0802381; Turner J, 2014, J GEN INTERN MED, V29, P1004, DOI 10.1007/s11606-013-2754-0; Wachter RM, 2002, DM-DIS MON, V48, P267, DOI 10.1016/S0011-5029(02)90034-9; West CP, 2012, JAMA-J AM MED ASSOC, V308, P2241, DOI 10.1001/jama.2012.47535; White HL, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-58	5	17	17	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 22	2015	372	4					308	309		10.1056/NEJMp1411416	http://dx.doi.org/10.1056/NEJMp1411416			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AZ4PJ	25607426				2023-01-03	WOS:000348204500005
J	Krychowiak, M; Grinholc, M; Banasiuk, R; Krauze-Baranowska, M; Glod, D; Kawiak, A; Krolicka, A				Krychowiak, Marta; Grinholc, Mariusz; Banasiuk, Rafal; Krauze-Baranowska, Miroslawa; Glod, Daniel; Kawiak, Anna; Krolicka, Aleksandra			Combination of Silver Nanoparticles and Drosera binata Extract as a Possible Alternative for Antibiotic Treatment of Burn Wound Infections Caused by Resistant Staphylococcus aureus	PLOS ONE			English	Article							IN-VITRO; NAPHTHOQUINONES; PLUMBAGIN; BACTERIA; SYNERGY; PLANTS; MODEL	Staphylococcus aureus is the most common infectious agent involved in the development of skin infections that are associated with antibiotic resistance, such as burn wounds. As drug resistance is a growing problem it is essential to establish novel antimicrobials. Currently, antibiotic resistance in bacteria is successfully controlled by multi-drug therapies. Here we demonstrate that secondary metabolites present in the extract obtained from Drosera binata in vitro cultures are effective antibacterial agents against S. aureus grown in planktonic culture and in biofilm. Moreover, this is the first report demonstrating the synergistic interaction between the D. binata extract and silver nanoparticles (AgNPs), which results in the spectacular enhancement of the observed bactericidal activity, while having no cytotoxic effects on human keratinocytes. Simultaneous use of these two agents in significantly reduced quantities produces the same effect, i.e. by killing 99.9% of bacteria in inoculum or eradicating the staphylococcal biofilm, as higher amounts of the agents used individually. Our data indicates that combining AgNPs with either the D. binata extract or with its pure compound (3-chloroplumbagin) may provide a safe and highly effective alternative to commonly used antibiotics, which are ineffective towards the antibiotic-resistant S. aureus.	[Krychowiak, Marta; Banasiuk, Rafal; Krolicka, Aleksandra] Univ Gdansk, Intercollegiate Fac Biotechnol, Dept Biotechnol, Lab Biol Act Cpds, PL-80952 Gdansk, Poland; [Krychowiak, Marta; Grinholc, Mariusz; Banasiuk, Rafal; Kawiak, Anna; Krolicka, Aleksandra] Med Univ Gdansk, Gdansk, Poland; [Grinholc, Mariusz] Univ Gdansk, Dept Biotechnol, Lab Mol Diagnost, IFB, Gdansk, Poland; [Krauze-Baranowska, Miroslawa; Glod, Daniel] Med Univ Gdansk, Dept Pharmacognosy Med Plant Garden, Gdansk, Poland; [Kawiak, Anna] Univ Gdansk, Dept Biotechnol, Lab Plant Protect & Biotechnol, IFB, Gdansk, Poland	Fahrenheit Universities; University of Gdansk; Fahrenheit Universities; Medical University Gdansk; Fahrenheit Universities; University of Gdansk; Fahrenheit Universities; Medical University Gdansk; Fahrenheit Universities; University of Gdansk	Krolicka, A (corresponding author), Univ Gdansk, Intercollegiate Fac Biotechnol, Dept Biotechnol, Lab Biol Act Cpds, PL-80952 Gdansk, Poland.	aleksandra.krolicka@biotech.ug.edu.pl	Królicka, Aleksandra/J-4170-2014; Krychowiak-Masnicka, Marta/ABB-2956-2021; Krychowiak-Masnicka, Marta/AAI-3977-2020; Kawiak, Anna/L-6060-2014; Krolicka, Aleksandra/AAC-3958-2019; Grinholc, Mariusz/F-5962-2011; Grinholc, Mariusz/N-8726-2019	Krychowiak-Masnicka, Marta/0000-0002-3617-6572; Krychowiak-Masnicka, Marta/0000-0002-3617-6572; Kawiak, Anna/0000-0001-8105-2555; Krolicka, Aleksandra/0000-0001-5231-283X; Grinholc, Mariusz/0000-0003-4041-0891; Banasiuk, Rafal/0000-0002-3774-1545; Krauze-Baranowska, Miroslawa/0000-0002-0344-7401	National Centre for Research and Development [LIDER/32/36/L-2/10/NCRiR/2011]; EU FP7 project MOBI4Health [GA. 316094]	National Centre for Research and Development(National Centre for Research & Development, Poland); EU FP7 project MOBI4Health	The research was supported by the National Centre for Research and Development (project LIDER/32/36/L-2/10/NCRiR/2011). Publication costs were covered by the EU FP7 project MOBI4Health, GA. 316094. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allaker RP, 2014, INT J ANTIMICROB AG, V43, P95, DOI 10.1016/j.ijantimicag.2013.11.002; BEHRMAN EJ, 1995, J CHEM RES-S, P164; BENDZ G, 1968, ACTA CHEM SCAND, V22, P2722, DOI 10.3891/acta.chem.scand.22-2722; BERENBAUM MC, 1978, J INFECT DIS, V137, P122, DOI 10.1093/infdis/137.2.122; Bringmann G, 2000, PHYTOCHEMISTRY, V53, P339, DOI 10.1016/S0031-9422(99)00543-9; Church D, 2006, CLIN MICROBIOL REV, V19, P403, DOI 10.1128/CMR.19.2.403-434.2006; Clinical and Laboratory Standards Institute (CLSI), 2014, CLIN LAB STANDARDS I; CLSI,, 2012, M07A9 CLSI; Daglia M, 2012, CURR OPIN BIOTECH, V23, P174, DOI 10.1016/j.copbio.2011.08.007; Davis SC, 2008, WOUND REPAIR REGEN, V16, P23, DOI 10.1111/j.1524-475X.2007.00303.x; ENGVILD KC, 1986, PHYTOCHEMISTRY, V25, P781, DOI 10.1016/0031-9422(86)80002-4; Garcia-Barrasa J, 2011, CENT EUR J CHEM, V9, P7, DOI 10.2478/s11532-010-0124-x; Harrison JJ, 2010, NAT PROTOC, V5, P1236, DOI 10.1038/nprot.2010.71; Hernandez-Munoz LS, 2009, ORG BIOMOL CHEM, V7, P1896, DOI 10.1039/b822684a; Higa M, 1998, CHEM PHARM BULL, V46, P1189, DOI 10.1248/cpb.46.1189; Kalishwaralal K, 2010, COLLOID SURFACE B, V79, P340, DOI 10.1016/j.colsurfb.2010.04.014; Kawiak A, 2003, PLANT CELL TISS ORG, V75, P175, DOI 10.1023/A:1025023800304; KREHER B, 1990, PHYTOCHEMISTRY, V29, P605, DOI 10.1016/0031-9422(90)85125-Y; KRISHNAN.V, 1969, PHYTOCHEMISTRY, V8, P1591, DOI 10.1016/S0031-9422(00)85936-1; Krolicka A, 2008, ENZYME MICROB TECH, V42, P216, DOI 10.1016/j.enzmictec.2007.09.011; Kuo PL, 2006, MOL CANCER THER, V5, P3209, DOI 10.1158/1535-7163.MCT-06-0478; LAKSHMI VV, 1987, CURR MICROBIOL, V16, P159; Lowy FD, 2003, J CLIN INVEST, V111, P1265, DOI [10.1172/JCI200318535, 10.1172/JC1200318535]; Machado TB, 2003, INT J ANTIMICROB AG, V21, P279, DOI 10.1016/S0924-8579(02)00349-7; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Murray CK, 2007, J TRAUMA, V62, pS73, DOI 10.1097/TA.0b013e318065af1a; NAIR A G R, 1990, Fitoterapia, V61, P85; RAZZAKOVA DM, 1973, KHIM PRIRODNYK SOEDI, P206; SIDHU GS, 1971, TETRAHEDRON LETT, P2385; Sondi I, 2004, J COLLOID INTERF SCI, V275, P177, DOI 10.1016/j.jcis.2004.02.012; Stewart PS, 2001, LANCET, V358, P135, DOI 10.1016/S0140-6736(01)05321-1; THORNSBERRY C, 1991, ANN OTO RHINOL LARYN, V100, P7, DOI 10.1177/00034894911000S904; Tsymbal A, 2005, LECT NOTES COMPUTER; Wagner H, 2009, PHYTOMEDICINE, V16, P97, DOI 10.1016/j.phymed.2008.12.018; Williamson EM, 2001, PHYTOMEDICINE, V8, P401, DOI 10.1078/0944-7113-00060; Zehl M, 2011, ANAL BIOANAL CHEM, V400, P2565, DOI 10.1007/s00216-011-4690-3	36	44	45	3	56	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2014	9	12							e115727	10.1371/journal.pone.0115727	http://dx.doi.org/10.1371/journal.pone.0115727			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX7UC	25551660	Green Published, Green Submitted, gold			2023-01-03	WOS:000347119100055
J	Magalhaes, GF; Santos, GBND; Rosa, MB; Noblat, LDCB				Magalhaes, Gabriella Fernandes; Noblat de Carvalho Santos, Glaucia Beisl; Rosa, Mario Borges; Costa Beisl Noblat, Lucia de Araujo			Medication Reconciliation in Patients Hospitalized in a Cardiology Unit	PLOS ONE			English	Article							ADMISSION; DISCREPANCIES; ERRORS; IMPACT; TRANSITIONS; ORDERS	Objectives: To compare drugs prescribed on hospital admission with the list of drugs taken prior to admission for adult patients admitted to a cardiology unit and to identify the role of a pharmacist in identifying and resolving medication discrepancies. Method: This study was conducted in a 300 bed university hospital in Brazil. Clinical pharmacists taking medication histories and reconciling medications prescribed on admission with a list of drugs used prior to admission. Discrepancies were classified as justified (e.g., based on the pharmacotherapeutic guidelines of the hospital studied) or unintentional. Treatments were reviewed within 48 hours following hospitalization. Unintentional discrepancies were further classified according to the categorization of medication error severity. Pharmacists verbally contacted the prescriber to recommend actions to resolve the discrepancies. Results: A total of 181 discrepancies were found in 50 patients (86%). Of these discrepancies, 149 (82.3%) were justified changes to the patient's home medication regimen; however, 32 (17.7%) discrepancies found in 24 patients were unintentional. Pharmacists made 31 interventions and 23 (74.2%) were accepted. Among unintentional discrepancies, the most common was a different medication dose on admission (42%). Of the unintentional discrepancies 13 (40.6%) were classified as error without harm, 11 (34.4%) were classified as error without harm but which could affect the patient and require monitoring, 3 (9.4%) as errors could have resulted in harm and 5 (15.6%) were classified as circumstances or events that have the capacity to cause harm. Conclusion: The results revealed a high number of unintentional discrepancies and the pharmacist can play an important role by intervening and correcting medication errors at a hospital cardiology unit.	[Magalhaes, Gabriella Fernandes] Fed Univ Bahia State UFBA, Prof Edgard Santos Univ Hosp, Salvador, BA, Brazil; [Noblat de Carvalho Santos, Glaucia Beisl; Costa Beisl Noblat, Lucia de Araujo] Fed Univ Bahia State UFBA, Prof Edgard Santos Univ Hosp, Salvador, BA, Brazil; [Rosa, Mario Borges] Hosp Fdn Minas Gerais State FHEMIG, Inst Safe Medicat Practices Brazil, Belo Horizonte, MG, Brazil; [Costa Beisl Noblat, Lucia de Araujo] Fed Univ Bahia UFBA, Fac Pharm, Salvador, BA, Brazil	Universidade Federal da Bahia	Magalhaes, GF (corresponding author), Fed Univ Bahia State UFBA, Prof Edgard Santos Univ Hosp, Salvador, BA, Brazil.	gabimagalhaes@yahoo.com.br	Rosa, Mario B/I-8640-2012					ALFAROLARA ER, 2013, ATEN PRIMARIA; Aljadhey H, 2013, INT J QUAL HEALTH C, V25, P648, DOI 10.1093/intqhc/mzt075; BARNSTEINER JH, 2008, PATIENT SAFETY AND Q; BRAGA JF, 2011, REVISTA BRASILEIRA D, V2, P12; Buckley MS, 2013, ANN PHARMACOTHER, V47, P1599, DOI 10.1177/1060028013507428; Coffey Maitreya, 2009, Healthc Q, V12 Spec No Patient, P102; Cornish PL, 2005, ARCH INTERN MED, V165, P424, DOI 10.1001/archinte.165.4.424; Delgado SO, 2007, MED CLIN, V129, P343, DOI DOI 10.1157/13109550; Galvin M, 2013, INT J CLIN PHARM-NET, V35, P14, DOI 10.1007/s11096-012-9696-1; Gleason KM, 2004, AM J HEALTH-SYST PH, V61, P1689, DOI 10.1093/ajhp/61.16.1689; Gleason KM, 2010, J GEN INTERN MED, V25, P441, DOI 10.1007/s11606-010-1256-6; Hellstrom Lina M, 2012, BMC Clin Pharmacol, V12, P9, DOI 10.1186/1472-6904-12-9; *JOINT COMM INT, 2006, USING MEDICATION REC; *JOINT COMM INT, 2013, NATIONAL PATIENT SAF; Ketchum K, 2005, AM J NURS, V105, P78, DOI 10.1097/00000446-200511000-00033; KLIETHERMES MA, 2008, MEDICATION RECONCILI; LEGUELINELBLACH.G, 2014, EUR J INTERN MED, V48, P1298; Lehnbom EC, 2014, ANN PHARMACOTHER, V48, P1298, DOI 10.1177/1060028014543485; Lessard S, 2006, AM J HEALTH-SYST PH, V63, P740, DOI 10.2146/ajhp050291; Messeder AM, 2007, CAD SAUDE PUBLICA, V23, P835, DOI 10.1590/S0102-311X2007000400011; Moriel M C, 2008, Farm Hosp, V32, P65; Morimoto T, 2011, J GEN INTERN MED, V26, P148, DOI 10.1007/s11606-010-1518-3; Mueller SK, 2012, ARCH INTERN MED, V172, P1057, DOI 10.1001/archinternmed.2012.2246; *NICE, 2007, TECHNICAL PATIENT SA; Paez VF., 2010, REV CALID ASIST, V25, P308, DOI DOI 10.1016/J.CALI.2010.03.002; QUAGLIA TP, 2011, REVISTA BRASILEIRA D, V2, P40; Quelennec B, 2013, EUR J INTERN MED, V24, P530, DOI 10.1016/j.ejim.2013.02.007; Reeder TA, 2008, AM J HEALTH-SYST PH, V65, P857, DOI 10.2146/ajhp070292; RIBEIRO AF, 2011, REVISTA BRASILEIRA D, V2, P34; Rogers G, 2006, JT COMM J QUAL PATIE, V32, P37, DOI 10.1016/S1553-7250(06)32006-5; Rozich J., 2001, J CLIN OUTCOMES MANA, V8, P27; Schnipper JL, 2006, ARCH INTERN MED, V166, P565, DOI 10.1001/archinte.166.5.565; Sinvani LD, 2013, J AM MED DIR ASSOC, V14, P668, DOI 10.1016/j.jamda.2013.02.021; *SOC CAT FARM CLIN, 2009, GUIA PARA LA IMPLANT; Tam VC, 2005, CAN MED ASSOC J, V173, P510, DOI 10.1503/cmaj.045311; UNROE KT, 2010, THE AMERICAN JOURNAL, V8, P115, DOI DOI 10.1016/J.AMJOPHARM.2010.04.002; Vira T, 2006, QUAL SAF HEALTH CARE, V15, P122, DOI 10.1136/qshc.2005.015347; *WHO, 2012, PATIENT SAFETY ACTIO	38	22	24	3	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 22	2014	9	12							e115491	10.1371/journal.pone.0115491	http://dx.doi.org/10.1371/journal.pone.0115491			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CA3ZY	25531902	Green Published, gold, Green Submitted			2023-01-03	WOS:000348845100073
J	Petrie, MA; Suneja, M; Faidley, E; Shields, RK				Petrie, Michael A.; Suneja, Manish; Faidley, Elizabeth; Shields, Richard K.			A Minimal Dose of Electrically Induced Muscle Activity Regulates Distinct Gene Signaling Pathways in Humans with Spinal Cord Injury	PLOS ONE			English	Article							HUMAN SKELETAL-MUSCLE; TYPE-2 DIABETES-MELLITUS; PARALYZED SOLEUS MUSCLE; MESSENGER-RNA EXPRESSION; INSULIN-RESISTANCE; DEHYDROGENASE-DEFICIENCY; COMPRESSIVE LOADS; EXERCISE; STIMULATION; INDIVIDUALS	Paralysis after a spinal cord injury (SCI) induces physiological adaptations that compromise the musculoskeletal and metabolic systems. Unlike non-SCI individuals, people with spinal cord injury experience minimal muscle activity which compromises optimal glucose utilization and metabolic control. Acute or chronic muscle activity, induced through electrical stimulation, may regulate key genes that enhance oxidative metabolism in paralyzed muscle. We investigated the short and long term effects of electrically induced exercise on mRNA expression of human paralyzed muscle. We developed an exercise dose that activated the muscle for only 0.6% of the day. The short term effects were assessed 3 hours after a single dose of exercise, while the long term effects were assessed after training 5 days per week for at least one year (adherence 81%). We found a single dose of exercise regulated 117 biological pathways as compared to 35 pathways after one year of training. A single dose of electrical stimulation increased the mRNA expression of transcriptional, translational, and enzyme regulators of metabolism important to shift muscle toward an oxidative phenotype (PGC-1 alpha, NR4A3, IFRD1, ABRA, PDK4). However, chronic training increased the mRNA expression of specific metabolic pathway genes (BRP44, BRP44L, SDHB, ACADVL), mitochondrial fission and fusion genes (MFF, MFN1, MFN2), and slow muscle fiber genes (MYH6, MYH7, MYL3, MYL2). These findings support that a dose of electrical stimulation (similar to 10 minutes/day) regulates metabolic gene signaling pathways in human paralyzed muscle. Regulating these pathways early after SCI may contribute to reducing diabetes in people with longstanding paralysis from SCI.	[Petrie, Michael A.; Faidley, Elizabeth; Shields, Richard K.] Univ Iowa, Carver Coll Med, Dept Phys Therapy & Rehabil Sci, Iowa City, IA 52242 USA; [Suneja, Manish] Univ Iowa, Carver Coll Med, Dept Internal Med, Iowa City, IA USA; [Shields, Richard K.] VA Med Ctr, Dept Vet Affairs, Iowa City, IA USA	University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Shields, RK (corresponding author), Univ Iowa, Carver Coll Med, Dept Phys Therapy & Rehabil Sci, Iowa City, IA 52242 USA.	richard-shields@uiowa.edu		Petrie, Michael/0000-0002-5212-0907; Suneja, Manish/0000-0002-1613-8456; Shields, Richard/0000-0002-5838-9317	National Institute of Child Health and Human Development from National Institue of Health [R01HD062507]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development [1I01RXOOO149-01]; Craig H. Neilsen Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD062507] Funding Source: NIH RePORTER; Veterans Affairs [I01RX000149] Funding Source: NIH RePORTER	National Institute of Child Health and Human Development from National Institue of Health; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development(US Department of Veterans Affairs); Craig H. Neilsen Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Veterans Affairs(US Department of Veterans Affairs)	This study was supported in part by awards to RKS from the National Institute of Child Health and Human Development Grant R01HD062507 from National Institue of Health and Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development Grant 1I01RXOOO149-01, and the Craig H. Neilsen Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams CM, 2011, MUSCLE NERVE, V43, P65, DOI 10.1002/mus.21831; Andresen BS, 1996, HUM MOL GENET, V5, P461, DOI 10.1093/hmg/5.4.461; Arai A, 2002, J BIOL CHEM, V277, P24453, DOI 10.1074/jbc.M202216200; Babraj JA, 2009, BMC ENDOCR DISORD, V9, DOI 10.1186/1472-6823-9-3; Barbour Jayne Alexandra, 2014, Int J Cell Biol, V2014, P156020, DOI 10.1155/2014/156020; Bauman WA, 1999, SPINAL CORD, V37, P765, DOI 10.1038/sj.sc.3100893; BIGLANDRITCHIE B, 1983, J PHYSIOL-LONDON, V340, P335, DOI 10.1113/jphysiol.1983.sp014765; Bjornholm M, 2005, BIOCHEM SOC T, V33, P354; Bricker DK, 2012, SCIENCE, V337, P96, DOI 10.1126/science.1218099; Brown RM, 2004, HUM GENET, V115, P123, DOI 10.1007/s00439-004-1124-8; Chu V, 2006, SPIE; Cragg JJ, 2013, NEUROLOGY, V81, P1864, DOI 10.1212/01.wnl.0000436074.98534.6e; Crameri RM, 2002, SCAND J MED SCI SPOR, V12, P316, DOI 10.1034/j.1600-0838.2002.20106.x; DUCKWORTH WC, 1980, DIABETES, V29, P906, DOI 10.2337/diabetes.29.11.906; Dudley-Javoroski S, 2012, OSTEOPOROSIS INT, V23, P2335, DOI 10.1007/s00198-011-1879-4; Dudley-Javoroski S, 2011, ARCH PHYS MED REHAB, V92, P242, DOI 10.1016/j.apmr.2010.10.031; Egan B, 2013, CELL METAB, V17, P162, DOI 10.1016/j.cmet.2012.12.012; Egan B, 2010, J PHYSIOL-LONDON, V588, P1779, DOI 10.1113/jphysiol.2010.188011; Fritz T, 2011, DIABETIC MED, V28, P1362, DOI 10.1111/j.1464-5491.2011.03348.x; Gaignard P, 2013, AM J HUM GENET, V93, P384, DOI 10.1016/j.ajhg.2013.06.015; Giger JM, 2009, J APPL PHYSIOL, V107, P1204, DOI 10.1152/japplphysiol.00344.2009; GRIMBY G, 1976, SCAND J REHABIL MED, V8, P37; HENNEMAN E, 1985, J EXP BIOL, V115, P105; Iqbal S, 2013, MUSCLE NERVE, V48, P963, DOI 10.1002/mus.23838; Jensen MP, 2012, SPINAL CORD, V50, P373, DOI 10.1038/sc.2011.150; Jin WZ, 2011, J CLIN INVEST, V121, P918, DOI 10.1172/JCI41940; Kawasaki E, 2009, J APPL PHYSIOL, V106, P1826, DOI 10.1152/japplphysiol.90923.2008; Kim JA, 2008, CIRC RES, V102, P401, DOI 10.1161/CIRCRESAHA.107.165472; Kulkarni SS, 2012, METABOLISM, V61, P175, DOI 10.1016/j.metabol.2011.06.014; Lamon S, 2009, J PHYSIOL-LONDON, V587, P1795, DOI 10.1113/jphysiol.2009.168674; LaVela SL, 2006, J SPINAL CORD MED, V29, P387, DOI 10.1080/10790268.2006.11753887; Le WP, 2000, BBA-MOL CELL BIOL L, V1485, P121, DOI 10.1016/S1388-1981(00)00034-2; Little JP, 2011, J APPL PHYSIOL, V111, P1554, DOI 10.1152/japplphysiol.00921.2011; Little JP, 2011, AM J PHYSIOL-REG I, V300, pR1303, DOI 10.1152/ajpregu.00538.2010; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; Micheli L, 2011, J BIOL CHEM, V286, P5691, DOI 10.1074/jbc.M110.162842; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Palikaras K., 2014, EXP GERONTOL; Pearen MA, 2012, MOL ENDOCRINOL, V26, P372, DOI 10.1210/me.2011-1274; Petrie MA, 2014, PHYSIOL REP, V2, DOI 10.1002/phy2.248; Pilegaard H, 2006, DIABETES, V55, P3020, DOI 10.2337/db06-0152; Pruitt K., 2002, NCBI HDB, P307; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shields RK, 2007, NEUROREHAB NEURAL RE, V21, P169, DOI 10.1177/1545968306293447; Shields RK, 2006, J APPL PHYSIOL, V101, P556, DOI 10.1152/japplphysiol.00099.2006; Shields RK, 2006, MUSCLE NERVE, V34, P84, DOI 10.1002/mus.20564; Shields RK, 2006, J NEUROPHYSIOL, V95, P2380, DOI 10.1152/jn.01181.2005; Shields RK, 2006, SPINE, V31, P548, DOI 10.1097/01.brs.0000201303.49308.a8; Shields RK, 1997, J APPL PHYSIOL, V82, P1499, DOI 10.1152/jappl.1997.82.5.1499; SHIELDS RK, 1995, J NEUROPHYSIOL, V73, P2195, DOI 10.1152/jn.1995.73.6.2195; Spriet LL, 2004, J APPL PHYSIOL, V96, P2082, DOI 10.1152/japplphysiol.01318.2003; Spriet LL, 2002, EXERC SPORT SCI REV, V30, P91, DOI 10.1097/00003677-200204000-00009; STRAUSS AW, 1995, P NATL ACAD SCI USA, V92, P10496, DOI 10.1073/pnas.92.23.10496; Stuart CA, 2013, J CLIN ENDOCR METAB, V98, P2027, DOI 10.1210/jc.2012-3876; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sugden MC, 2003, AM J PHYSIOL-ENDOC M, V284, pE855, DOI 10.1152/ajpendo.00526.2002; Wallace MA, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00469; Wallace MA, 2011, J PHYSIOL-LONDON, V589, P2027, DOI 10.1113/jphysiol.2011.205468; Winnick JJ, 2008, J CLIN ENDOCR METAB, V93, P771, DOI 10.1210/jc.2007-1524; Zijdewind I, 2012, J PHYSIOL-LONDON, V590, P1683, DOI 10.1113/jphysiol.2011.220103	61	19	19	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 22	2014	9	12							e115791	10.1371/journal.pone.0115791	http://dx.doi.org/10.1371/journal.pone.0115791			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA3ZY	25531450	Green Submitted, Green Published, gold			2023-01-03	WOS:000348845100109
J	Orozco, JJ; Balkin, ER; Gooley, TA; Kenoyer, A; Hamlin, DK; Wilbur, DS; Fisher, DR; Hylarides, MD; Shadman, M; Green, DJ; Gopal, AK; Press, OW; Pagel, JM				Orozco, Johnnie J.; Balkin, Ethan R.; Gooley, Ted A.; Kenoyer, Aimee; Hamlin, Donald K.; Wilbur, D. Scott; Fisher, Darrell R.; Hylarides, Mark D.; Shadman, Mazyar; Green, Damian J.; Gopal, Ajay K.; Press, Oliver W.; Pagel, John M.			Anti-CD45 Radioimmunotherapy with Y-90 but Not Lu-177 Is Effective Treatment in a Syngeneic Murine Leukemia Model	PLOS ONE			English	Article							TOTAL-BODY IRRADIATION; BONE-MARROW-TRANSPLANTATION; TERM-FOLLOW-UP; PRETARGETED RADIOIMMUNOTHERAPY; MONOCLONAL-ANTIBODY; MYELOID-LEUKEMIA; CELL TRANSPLANTATION; RANDOMIZED-TRIAL; PHASE-I; LYMPHOMA	Radioimmunotherapy (RIT) for treatment of hematologic malignancies has primarily employed monoclonal antibodies (Ab) labeled with I-131 or Y-90 which have limitations, and alternative radionuclides are needed to facilitate wider adoption of RIT. We therefore compared the relative therapeutic efficacy and toxicity of anti-CD45 RIT employing Y-90 and Lu-177 in a syngeneic, disseminated murine myeloid leukemia (B6SJLF1/J) model. Biodistribution studies showed that both Y-90- and Lu-177-anti-murine CD45 Ab conjugates (DOTA-30F11) targeted hematologic tissues, as at 24 hours 48.8 +/- 21.2 and 156 +/- 14.6% injected dose per gram of tissue (% ID/g) of Y-90-DOTA-30F11 and 54.2 +/- 9.5 and 199 +/- 11.7% ID/g of Lu-177-DOTA-30F11 accumulated in bone marrow (BM) and spleen, respectively. However, Y-90-DOTA-30F11 RIT demonstrated a dose-dependent survival benefit: 60% of mice treated with 300 mu Ci Y-90-DOTA-30F11 lived over 180 days after therapy, and mice treated with 100 mu Ci Y-90-DOTA-30F11 had a median survival 66 days. Y-90-anti-CD45 RIT was associated with transient, mild myelotoxicity without hepatic or renal toxicity. Conversely, Lu-177-anti-CD45 RIT yielded no long-term survivors. Thus, Y-90 was more effective than Lu-177 for anti-CD45 RIT of AML in this murine leukemia model.	[Orozco, Johnnie J.; Gooley, Ted A.; Kenoyer, Aimee; Hylarides, Mark D.; Shadman, Mazyar; Green, Damian J.; Gopal, Ajay K.; Press, Oliver W.; Pagel, John M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA; [Orozco, Johnnie J.; Shadman, Mazyar] Univ Washington, Div Hematol, Seattle, WA 98195 USA; [Balkin, Ethan R.; Hamlin, Donald K.; Wilbur, D. Scott; Green, Damian J.; Gopal, Ajay K.; Press, Oliver W.; Pagel, John M.] Univ Washington, Seattle, WA 98195 USA; [Fisher, Darrell R.] Dade Moeller Hlth Grp, Richland, WA USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Pagel, JM (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA.	jpagel@fhcrc.org		Press, Oliver/0000-0002-3147-8037; Gopal, Ajay/0000-0003-3023-6834	National Institutes of Health [R01 CA109663, R01 CA138720, R01 CA076287, R01 CA136639, R01 CA154897, P01 CA044991]; Lymphoma Research Foundation; Damon Runyon Cancer Foundation; Leukemia and Lymphoma Society; American Society of Blood and Marrow Transplantation; NATIONAL CANCER INSTITUTE [R01CA136639, P01CA044991, R01CA154897, R01CA138720, R01CA076287, R01CA109663] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Lymphoma Research Foundation; Damon Runyon Cancer Foundation; Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); American Society of Blood and Marrow Transplantation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Institutes of Health (R01 CA109663, R01 CA138720, R01 CA076287, R01 CA136639, R01 CA154897, P01 CA044991) and awards from the Lymphoma Research Foundation (OWP and JMP), Damon Runyon Cancer Foundation (JMP), Leukemia and Lymphoma Society (OWP, JMP, AKG, and JJO), and the American Society of Blood and Marrow Transplantation (JJO), as well as Frederick Kullman (JMP) and by a gift from James and Sherry Raisbeck. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BEATTY BG, 1994, CANCER, V73, P958, DOI 10.1002/1097-0142(19940201)73:3+<958::AID-CNCR2820731331>3.0.CO;2-E; Bouchet LG, 2000, J NUCL MED, V41, P682; Bunjes DW, 2001, BLOOD, V98, p197A; Burke JM, 2003, BONE MARROW TRANSPL, V32, P549, DOI 10.1038/sj.bmt.1704201; CLIFT RA, 1990, BLOOD, V76, P1867; Clift RA, 1998, BLOOD, V92, P1455, DOI 10.1182/blood.V92.4.1455; CLIFT RA, 1991, BLOOD, V77, P1660; COSSET JM, 1989, RADIOTHER ONCOL, V15, P151, DOI 10.1016/0167-8140(89)90129-1; de Jong M, 2005, J NUCL MED, V46, p13S; FISHER DR, 1991, ANTIBODY IMMUNOCONJ, V4, P655; GOLDENBERG DM, 1991, J CLIN ONCOL, V9, P548, DOI 10.1200/JCO.1991.9.4.548; HUI TE, 1994, CANCER, V73, P951; MATTHEWS DC, 1991, BLOOD, V78, P1864; Matthews DC, 1999, BLOOD, V94, P1237, DOI 10.1182/blood.V94.4.1237.416k34_1237_1247; Mitchell GS, 2011, PHILOS T R SOC A, V369, P4605, DOI 10.1098/rsta.2011.0271; NAKANO A, 1990, ACTA PATHOL JAPON, V40, P107; OMARY MB, 1980, J EXP MED, V152, P842, DOI 10.1084/jem.152.4.842; Pagel JM, 2006, BLOOD, V107, P2184, DOI 10.1182/blood-2005-06-2317; Pagel JM, 2003, BLOOD, V101, P2340, DOI 10.1182/blood-2002-03-0874; Pagel JM, 2008, BLOOD, V111, P2261, DOI 10.1182/blood-2007-06-097451; Pagel JM, 2011, BLOOD, V118, P703, DOI 10.1182/blood-2011-04-347039; PRESS OW, 1993, NEW ENGL J MED, V329, P1219, DOI 10.1056/NEJM199310213291702; Press OW, 2001, BLOOD, V98, P2535, DOI 10.1182/blood.V98.8.2535; Robertson R, 2009, PHYS MED BIOL, V54, pN355, DOI 10.1088/0031-9155/54/16/N01; Robertson R, 2011, J NUCL MED, V52, P1764, DOI 10.2967/jnumed.111.091710; ROSEN ST, 1987, J CLIN ONCOL, V5, P562, DOI 10.1200/JCO.1987.5.4.562; Ruggiero A, 2010, J NUCL MED, V51, P1123, DOI 10.2967/jnumed.110.076521; SCHEINBERG DA, 1990, J CLIN ONCOL, V8, P792, DOI 10.1200/JCO.1990.8.5.792; SCHWARTZ MA, 1993, J CLIN ONCOL, V11, P294, DOI 10.1200/JCO.1993.11.2.294; SHANK B, 1981, INT J RADIAT ONCOL, V7, P1240, DOI 10.1016/0360-3016(81)90567-8; SIEGEL JA, 1994, J NUCL MED, V35, P152; SOCIE G, 1991, INT J RADIAT ONCOL, V20, P397, DOI 10.1016/0360-3016(91)90048-9; TAETLE R, 1991, LEUKEMIA, V5, P309; VANDERJAGT RHC, 1992, CANCER RES, V52, P89; VANOS R, 1993, RADIAT RES, V136, P118, DOI 10.2307/3578648	35	9	9	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2014	9	12							e113601	10.1371/journal.pone.0113601	http://dx.doi.org/10.1371/journal.pone.0113601			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AU8TQ	25460570	Green Published, Green Submitted, gold			2023-01-03	WOS:000345869700039
J	Rudick, CN; Taylor, AK; Yaggie, RE; Schaeffer, AJ; Klumpp, DJ				Rudick, Charles N.; Taylor, Aisha K.; Yaggie, Ryan E.; Schaeffer, Anthony J.; Klumpp, David J.			Asymptomatic Bacteriuria Escherichia coli Are Live Biotherapeutics for UTI	PLOS ONE			English	Article							URINARY-TRACT-INFECTION; RANDOMIZED CONTROLLED-TRIAL; CROSS-TALK; PREVENTION; BLADDER; PLACEBO; EVASION; INTERFERENCE; INDUCTION; WOMEN	Urinary tract infections (UTI) account for approximately 8 million clinic visits annually with symptoms that include acute pelvic pain, dysuria, and irritative voiding. Empiric UTI management with antimicrobials is complicated by increasing antimicrobial resistance among uropathogens, but live biotherapeutics products (LBPs), such as asymptomatic bacteriuria (ASB) strains of E. coli, offer the potential to circumvent antimicrobial resistance. Here we evaluated ASB E. coli as LBPs, relative to ciprofloxacin, for efficacy against infection and visceral pain in a murine UTI model. Visceral pain was quantified as tactile allodynia of the pelvic region in response to mechanical stimulation with von Frey filaments. Whereas ciprofloxacin promoted clearance of uropathogenic E. coli (UPEC), it did not reduce pelvic tactile allodynia, a measure of visceral pain. In contrast, ASB E. coli administered intravesically or intravaginally provided comparable reduction of allodynia similar to intravesical lidocaine. Moreover, ASB E. coli were similarly effective against UTI allodynia induced by Proteus mirabilis, Enterococccus faecalis and Klebsiella pneumoniae. Therefore, ASB E. coli have anti- infective activity comparable to the current standard of care yet also provide superior analgesia. These studies suggest that ASB E. coli represent novel LBPs for UTI symptoms.	[Rudick, Charles N.; Taylor, Aisha K.; Yaggie, Ryan E.; Schaeffer, Anthony J.; Klumpp, David J.] Northwestern Univ, Feinberg Sch Med, Dept Urol, Chicago, IL 60611 USA; [Klumpp, David J.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Klumpp, DJ (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Urol, Chicago, IL 60611 USA.	d-klumpp@northwestern.edu			National Institute of Diabetes and Digestive and Kidney Diseases;  [R01 DK042648];  [U01 DK8234201]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK082342, R01DK042648] Funding Source: NIH RePORTER	National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); ; ; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	These studies were funded by the National Institute of Diabetes and Digestive and Kidney Diseases (http://www.niddk.nih.gov/Pages/default.aspx). Funding was through awards R01 DK042648 and U01 DK8234201 to D.J.K. and A.J.S. Award U01 DK8234201 is within the Multi-Disciplinary Approaches to Chronic Pelvic Pain Research Network (MAPP, www.mappnetwork.org). This work was approved for publication by the MAPP Publications Committee. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANDERSSON P, 1991, INFECT IMMUN, V59, P2915, DOI 10.1128/IAI.59.9.2915-2921.1991; Bergsten G, 2007, CELL MICROBIOL, V9, P1766, DOI 10.1111/j.1462-5822.2007.00912.x; Billips BK, 2008, INFECT IMMUN, V76, P3891, DOI 10.1128/IAI.00069-08; Bleidorn J, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-30; Christiaens TCM, 2002, BRIT J GEN PRACT, V52, P729; Czaja Christopher A, 2007, Infect Dis Obstet Gynecol, V2007, P35387, DOI 10.1155/2007/35387; Darouiche RO, 2011, UROLOGY, V78, P341, DOI 10.1016/j.urology.2011.03.062; Darouiche RO, 2005, CLIN INFECT DIS, V41, P1531, DOI 10.1086/497272; Ferry SA, 2004, SCAND J INFECT DIS, V36, P296, DOI 10.1080/00365540410019642; Fiore C, 2010, REGULATORY CONSIDERA; Foxman B, 2000, ANN EPIDEMIOL, V10, P509, DOI 10.1016/S1047-2797(00)00072-7; Foxman B, 2010, NAT REV UROL, V7, P653, DOI 10.1038/nrurol.2010.190; Gupta K, 1998, J INFECT DIS, V178, P446, DOI 10.1086/515635; Hang L, 2000, J INFECT DIS, V182, P1738, DOI 10.1086/317599; Hooton TM, 2000, NEW ENGL J MED, V343, P992, DOI 10.1056/NEJM200010053431402; HOPKINS WJ, 1995, J INFECT DIS, V171, P462, DOI 10.1093/infdis/171.2.462; Hull R, 2000, J UROLOGY, V163, P872, DOI 10.1016/S0022-5347(05)67823-8; HULTGREN SJ, 1986, INFECT IMMUN, V54, P613, DOI 10.1128/IAI.54.3.613-620.1986; Hunstad DA, 2010, ANNU REV MICROBIOL, V64, P203, DOI 10.1146/annurev.micro.112408.134258; Karlowsky JA, 2002, ANTIMICROB AGENTS CH, V46, P2540, DOI 10.1128/AAC.46.8.2540-2545.2002; Klemm P, 2007, INFECT IMMUN, V75, P3688, DOI 10.1128/IAI.01730-06; Klumpp DJ, 2006, INFECT IMMUN, V74, P5106, DOI 10.1128/IAI.00376-06; Klumpp DJ, 2001, INFECT IMMUN, V69, P6689, DOI 10.1128/IAI.69.11.6689-6695.2001; LINDBERG U, 1975, ACTA PAEDIATR SCAND, V64, P718, DOI 10.1111/j.1651-2227.1975.tb03910.x; Looft T, 2012, GUT MICROBES, V3, P463, DOI 10.4161/gmic.21288; Malykhina AP, 2012, NEUROUROL URODYNAM, V31, P352, DOI 10.1002/nau.21228; McMahon SB, 1978, J PHYSL, V275; Mulvey MA, 1998, SCIENCE, V282, P1494, DOI 10.1126/science.282.5393.1494; Mulvey MA, 2001, INFECT IMMUN, V69, P4572, DOI 10.1128/IAI.69.7.4572-4579.2001; Mulvey MA, 2000, P NATL ACAD SCI USA, V97, P8829, DOI 10.1073/pnas.97.16.8829; Naber KG, 2011, INT J ANTIMICROB AG, V38, P21, DOI 10.1016/j.ijantimicag.2011.09.003; Nelson C, 1999, VITAL HLTH STAT, V13; OLD DC, 1970, J BACTERIOL, V103, P447, DOI 10.1128/JB.103.2.447-456.1970; Parsons CL, 2006, EXPERT OPIN PHARMACO, V7, P411, DOI 10.1517/14656566.7.4.411; Pezzone MA, 2005, GASTROENTEROLOGY, V128, P1953, DOI 10.1053/j.gastro.2005.03.008; Reid G, 2006, WORLD J UROL, V24, P28, DOI 10.1007/s00345-005-0043-1; Rudick CN, 2007, AM J PHYSIOL-REG I, V293, pR1191, DOI 10.1152/ajpregu.00411.2007; Rudick CN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041273; Rudick CN, 2010, J INFECT DIS, V201, P1240, DOI 10.1086/651275; Schaeffer AJ, 2012, CAMPBELL WALSH UROLO, P223; Stapleton A, 2003, INFECT DIS CLIN N AM, V17, P457, DOI 10.1016/S0891-5520(03)00010-2; Stewardson AJ, 2011, CURR OPIN PHARMACOL, V11, P446, DOI 10.1016/j.coph.2011.06.011; Sunden F, 2010, J UROLOGY, V184, P179, DOI 10.1016/j.juro.2010.03.024; Thumbikat P, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000415; Wise BL, 2012, AM J MED, V125, DOI 10.1016/j.amjmed.2012.05.027	45	18	19	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2014	9	11							e109321	10.1371/journal.pone.0109321	http://dx.doi.org/10.1371/journal.pone.0109321			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX7UZ	25405579	Green Published, gold, Green Submitted			2023-01-03	WOS:000347121300005
J	Mann, J; McLean, R; Skeaff, M; Morenga, LT				Mann, Jim; McLean, Rachael; Skeaff, Murray; Morenga, Lisa Te			Low carbohydrate diets: going against the grain	LANCET			English	Editorial Material							RANDOMIZED CONTROLLED-TRIALS; WEIGHT-LOSS; FAT; RISK; DISEASE		[Mann, Jim] Univ Otago, Dept Human Nutr, Dunedin 9054, New Zealand; Univ Otago, Edgar Ctr Diabet & Obes Res, Dunedin 9054, New Zealand	University of Otago; University of Otago	Mann, J (corresponding author), Univ Otago, Dept Human Nutr, POB 56, Dunedin 9054, New Zealand.	jim.mann@otago.ac.nz	Te Morenga, Lisa/C-4459-2011; McLean, Rachael/AAF-7596-2019	Te Morenga, Lisa/0000-0003-3526-0091; McLean, Rachael/0000-0002-0005-328X				Bueno NB, 2013, BRIT J NUTR, V110, P1178, DOI 10.1017/S0007114513000548; Chowdhury R, 2014, ANN INTERN MED, V160, P398, DOI 10.7326/M13-1788; Ford ES, 2007, NEW ENGL J MED, V356, P2388, DOI 10.1056/NEJMsa053935; Hession M, 2009, OBES REV, V10, P36, DOI 10.1111/j.1467-789X.2008.00518.x; Hooper L, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e7666; Hooper L, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002137.pub3; Jakobsen MU, 2009, AM J CLIN NUTR, V89, P1425, DOI 10.3945/ajcn.2008.27124; Johansson I, 2012, NUTR J, V11, DOI 10.1186/1475-2891-11-40; Lindstrom J, 2013, DIABETOLOGIA, V56, P284, DOI 10.1007/s00125-012-2752-5; Mann J, 2007, EUR J CLIN NUTR, V61, pS132, DOI 10.1038/sj.ejcn.1602943; Morenga LT, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.e7492; Nordic Council of Ministers, 2014, NORD NUTR REC 2012 I; Sacks FM, 2009, NEW ENGL J MED, V360, P859, DOI 10.1056/NEJMoa0804748; Schwab U, 2014, FOOD NUTR RES, V58, DOI 10.3402/fnr.v58.25145; Scientific Advisory Committee on Nutrition, 2014, CARB HLTH R IN PRESS; Shai I, 2008, NEW ENGL J MED, V359, P229, DOI 10.1056/NEJMoa0708681; US Department of Agriculture US Department of Health and Human Services, 2020, DIET GUID AM 2020 20; USDA, 2014, SER SYST REV REL DIE; WHO, 2014, GUID FREE S IN PRESS	19	14	14	0	22	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 25	2014	384	9953					1479	1480		10.1016/S0140-6736(14)61413-6	http://dx.doi.org/10.1016/S0140-6736(14)61413-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AR9MO	25390561				2023-01-03	WOS:000343899600004
J	Wentzensen, N; Trabert, B				Wentzensen, Nicolas; Trabert, Britton			Hormone therapy: short-term relief, long-term consequences	LANCET			English	Editorial Material							ESTROGEN PLUS PROGESTIN; NIH-AARP DIET; OVARIAN-CANCER; UNITED-STATES; REPLACEMENT THERAPY; ENDOMETRIAL CANCER; BREAST-CANCER; HEALTH; RISK; WOMEN		[Wentzensen, Nicolas; Trabert, Britton] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wentzensen, N (corresponding author), NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.	wentzenn@mail.nih.gov	Wentzensen, Nicolas/AAG-8522-2019; Trabert, Britton/F-8051-2015	Trabert, Britton/0000-0002-1539-6090				Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Brinton LA, 2008, CANCER EPIDEM BIOMAR, V17, P3150, DOI 10.1158/1055-9965.EPI-08-0435; Collaborative Group on Epidemiological Studies of Ovarian Cancer, 2014, LANCET; Lacey JV, 2002, JAMA-J AM MED ASSOC, V288, P334, DOI 10.1001/jama.288.3.334; Manson JE, 2013, JAMA-J AM MED ASSOC, V310, P1353, DOI 10.1001/jama.2013.278040; Moyer VA, 2013, ANN INTERN MED, V158, P47, DOI 10.7326/0003-4819-158-1-201301010-00553; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Steinkellner AR, 2012, MENOPAUSE, V19, P616, DOI 10.1097/gme.0b013e31824bb039; Trabert B, 2012, BRIT J CANCER, V107, P1181, DOI 10.1038/bjc.2012.397; Trabert B, 2013, INT J CANCER, V132, P417, DOI 10.1002/ijc.27623; WEISS NS, 1976, NEW ENGL J MED, V294, P1259, DOI 10.1056/NEJM197606032942303; Yang HP, 2013, J CLIN ONCOL, V31, P2146, DOI 10.1200/JCO.2012.45.5758	12	14	15	1	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 9	2015	385	9980					1806	1808		10.1016/S0140-6736(14)62458-2	http://dx.doi.org/10.1016/S0140-6736(14)62458-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CH6ZE	25684588	hybrid			2023-01-03	WOS:000354184500005
J	Eldridge, D; Ledoux, M				Eldridge, David; Ledoux, Matthew			Needs more salt: old hydration habits are hard to break	LANCET			English	Editorial Material							SERIOUSLY ILL CHILDREN; HOSPITALIZED CHILDREN; INTRAVENOUS FLUIDS; METAANALYSIS		[Eldridge, David; Ledoux, Matthew] E Carolina Univ, Brody Sch Med, Dept Pediat, Greenville, NC 27834 USA	University of North Carolina; East Carolina University	Eldridge, D (corresponding author), E Carolina Univ, Brody Sch Med, Dept Pediat, Greenville, NC 27834 USA.	eldridged@ecu.edu						ARIEFF AI, 1992, BRIT MED J, V304, P1218, DOI 10.1136/bmj.304.6836.1218; Balasubramanian K, 2012, ACTA PAEDIATR, V101, P236, DOI 10.1111/j.1651-2227.2011.02508.x; Duke T, 2003, LANCET, V362, P1320, DOI 10.1016/S0140-6736(03)14577-1; Foster BA, 2014, J PEDIATR-US, V165, P163, DOI 10.1016/j.jpeds.2014.01.040; Grissinger Matthew, 2013, P T, V38, P575; HOLLIDAY MA, 1957, PEDIATRICS, V19, P823; Holliday MA, 2004, LANCET, V363, P241, DOI 10.1016/S0140-6736(03)15333-0; Kannan L, 2011, INDIAN J PEDIATR, V78, P357, DOI 10.1007/s12098-010-0277-9; Koczmara Christine, 2010, Dynamics, V21, P21; Magder S, 2014, BEST PRAC RES-CL ANA, V28, P235, DOI 10.1016/j.bpa.2014.07.001; McNab S, 2014, LANCET; Wang JJ, 2014, PEDIATRICS, V133, P105, DOI 10.1542/peds.2013-2041	12	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 28	2015	385	9974					1159	1160		10.1016/S0140-6736(14)61741-4	http://dx.doi.org/10.1016/S0140-6736(14)61741-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CE3GQ	25472863				2023-01-03	WOS:000351715100008
J	Prescott, HC; Langa, KM; Iwashyna, TJ				Prescott, Hallie C.; Langa, Kenneth M.; Iwashyna, Theodore J.			Readmission Diagnoses After Hospitalization for Severe Sepsis and Other Acute Medical Conditions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							HEALTH		[Prescott, Hallie C.; Langa, Kenneth M.] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA; [Iwashyna, Theodore J.] Hlth Serv Res & Dev Serv Ctr Innovat, VA Ctr Clin Management Res, Ann Arbor, MI USA	University of Michigan System; University of Michigan	Prescott, HC (corresponding author), Univ Michigan, Dept Med, 2800 Plymouth Rd,North Campus Res Ctr, Ann Arbor, MI 48109 USA.	hprescot@med.umich.edu		Prescott, Hallie/0000-0002-8442-6724; Iwashyna, Theodore/0000-0002-4226-9310; Langa, Kenneth/0000-0002-2798-1836	NHLBI NIH HHS [T32 HL007749] Funding Source: Medline; NIA NIH HHS [U01 AG09740, U01 AG009740, R01 AG030155, R21 AG044752, P30 AG024824, R01 AG0030155] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007749] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [U01AG009740, R01AG030155, R21AG044752, P30AG024824] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Agency for Healthcare Research and Quality, GUID PREV QUAL IND; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Blackwell M, 2009, STATA J, V9, P524, DOI 10.1177/1536867X0900900402; Iwashyna TJ, 2014, MED CARE, V52, pE39, DOI 10.1097/MLR.0b013e318268ac86; Prescott HC, 2014, AM J RESP CRIT CARE, V190, P62, DOI 10.1164/rccm.201403-0471OC; Sonnega A, 2014, INT J EPIDEMIOL, V43, P576, DOI 10.1093/ije/dyu067	6	142	148	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 10	2015	313	10					1055	1057		10.1001/jama.2015.1410	http://dx.doi.org/10.1001/jama.2015.1410			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CC8UE	25756444	Bronze, Green Accepted			2023-01-03	WOS:000350643100023
J	Damgaard, AL; Hansen, BM; Mathiasen, R; Buchvald, F; Lange, T; Greisen, G				Damgaard, Anne Louise; Hansen, Bo Molholm; Mathiasen, Rene; Buchvald, Frederik; Lange, Theis; Greisen, Gorm			Prematurity and Prescription Asthma Medication from Childhood to Young Adulthood: A Danish National Cohort Study	PLOS ONE			English	Article							BRONCHOPULMONARY DYSPLASIA; LUNG-FUNCTION; PRETERM BIRTH; CHILDREN BORN; DISEASE; INFANTS; ASSOCIATION; PATHOLOGY; REGISTERS; PATTERNS	Introduction Preterm birth is associated with increased risk of asthma-like symptoms and purchase of prescription asthma medication in childhood. We investigated whether this association persists into adulthood and whether it is affected by accounting for neonatal respiratory morbidity (acute respiratory disease and bronchopulmonary dysplasia). Methods A national cohort of all infants born in Denmark in the period 1980-2009 was included in this register study. Data on purchase of asthma medication (combination of inhaled beta-2 agonists and other drugs for obstructive airway disease) in 2010-2011 were obtained from the Danish National Prescription Registry. Associations between gestational age (GA), neonatal respiratory morbidity and a cross-sectional evaluation of asthma medication purchase were explored by multivariate logistic regressions. Results A full dataset was obtained on 1,790,241 individuals, 84.6% of all infants born in the period. Odds-ratios (95% CI) for the association between GA and purchase of asthma medication during infancy were: 3.86 (2.46-6.04) in GA 23-27 weeks, 2.37 (1.84-3.04) in GA 28-31 weeks and 1.59 (1.43-1.77) in GA 32-36 weeks compared to term infants with GA 37-42 weeks. Associations weakened in older age groups and became insignificant in young adults born extremely and very preterm with odds-ratios: 1.41 (0.63-3.19) and 1.15 (0.83-1.60) in GA 23-27 and 28-31 respectively. When adjusting for neonatal respiratory morbidity, the associations weakened but persisted both in childhood and adolescence. Conclusion There was a strong dose-response association between gestational age and the purchase of prescription asthma medication in infancy and childhood. This association weakened during adolescence and was mostly non-significant in young adulthood. The increased risk of prescription asthma medication purchase in ex-preterm children could only partly be explained by neonatal respiratory morbidity.	[Damgaard, Anne Louise; Hansen, Bo Molholm; Greisen, Gorm] Rigshosp, Copenhagen Univ Hosp, Dept Neonatol, DK-2100 Copenhagen, Denmark; [Mathiasen, Rene] Rigshosp, Copenhagen Univ Hosp, Dept Pediat & Adolescent Med, DK-2100 Copenhagen, Denmark; [Buchvald, Frederik] Rigshosp, Copenhagen Univ Hosp, Dept Pediat & Adolescent Med, Pulm Serv, DK-2100 Copenhagen, Denmark; [Lange, Theis] Univ Copenhagen, Dept Biostat, Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; University of Copenhagen	Damgaard, AL (corresponding author), Rigshosp, Copenhagen Univ Hosp, Dept Neonatol, DK-2100 Copenhagen, Denmark.	aldamgaard@me.com	de Barros Garioud, Anne Louise/AAQ-3868-2021; Greisen, Gorm/AAA-6463-2022	de Barros Garioud, Anne Louise/0000-0003-1149-9946; Greisen, Gorm/0000-0001-8042-3262; Hansen, Bo Molholm/0000-0002-3087-3983; Lange, Theis/0000-0001-6807-8347	Rigshospitalet Research Funds	Rigshospitalet Research Funds	The study was funded by Rigshospitalet Research Funds and internal funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almqvist C, 2012, CLIN EXP ALLERGY, V42, P1369, DOI 10.1111/j.1365-2222.2012.04021.x; Bancalari E, 2006, SEMIN PERINATOL, V30, P164, DOI 10.1053/j.semperi.2006.05.002; Baraldi E, 2005, AM J RESP CRIT CARE, V171, P68, DOI 10.1164/rccm.200403-298Oc; Bhatia Jatinder, 2009, Neonatology, V95, P362, DOI 10.1159/000209302; Bonnelykke Klaus, 2013, Ugeskr Laeger, V175, P1863; Brostrom EB, 2010, RESP MED, V104, P362, DOI 10.1016/j.rmed.2009.10.008; Crump C, 2011, PEDIATRICS, V127, pE913, DOI 10.1542/peds.2010-2603; Dishop MK, 2010, PEDIAT ALLER IMM PUL, V23, P69, DOI 10.1089/ped.2010.0007; Doyle LW, 2006, PEDIATRICS, V118, P108, DOI 10.1542/peds.2005-2522; Fakhoury KF, 2010, PEDIATRICS, V125, pE1441, DOI 10.1542/peds.2009-0668; Fawke J, 2010, AM J RESP CRIT CARE, V182, P237, DOI 10.1164/rccm.200912-1806OC; Filippone M, 2010, EUR RESPIR J, V35, P1419, DOI 10.1183/09031936.00013310; Goyal NK, 2011, PEDIATRICS, V128, pE830, DOI 10.1542/peds.2011-0809; Helweg-Larsen K, 2011, SCAND J PUBLIC HEALT, V39, P26, DOI 10.1177/1403494811399958; Hjalmarson O, 2002, AM J RESP CRIT CARE, V165, P83, DOI 10.1164/ajrccm.165.1.2107093; Jensen KE, 2008, ACTA OBSTET GYN SCAN, V87, P760, DOI 10.1080/00016340802179814; Jensen VM, 2011, SCAND J PUBLIC HEALT, V39, P91, DOI 10.1177/1403494810394715; Kallen B, 2012, ARCH DIS CHILD; Kildemoes HW, 2011, SCAND J PUBLIC HEALT, V39, P38, DOI 10.1177/1403494810394717; Kindlund K, 2010, THORAX, V65, P146, DOI 10.1136/thx.2009.117101; Larsen CG, 2013, CLIN RESPIR J, V7, P354, DOI 10.1111/crj.12015; Laughon M, 2009, PEDIATRICS, V123, P1124, DOI 10.1542/peds.2008-0862; Lynge E, 2011, SCAND J PUBLIC HEALT, V39, P30, DOI 10.1177/1403494811401482; Marsal K, 1996, ACTA PAEDIATR, V85, P843, DOI 10.1111/j.1651-2227.1996.tb14164.x; McEvoy C, 2013, J PEDIATR-US, V162, P464, DOI 10.1016/j.jpeds.2012.09.042; Moth G, 2007, EUR J CLIN PHARMACOL, V63, P605, DOI 10.1007/s00228-007-0286-4; Narang I, 2006, PEDIATR PULM, V41, P497, DOI 10.1002/ppul.20385; Narayanan M, 2013, AM J RESP CRIT CARE, V187, P1104, DOI 10.1164/rccm.201210-1850OC; NORTHWAY WH, 1990, NEW ENGL J MED, V323, P1793, DOI 10.1056/NEJM199012273232603; Ortqvist AK, 2009, PEDIATRICS, V124, pE737, DOI 10.1542/peds.2009-0305; Pedersen CB, 2011, SCAND J PUBLIC HEALT, V39, P22, DOI 10.1177/1403494810387965; Pelkonen AS, 1997, AM J RESP CRIT CARE, V156, P1178, DOI 10.1164/ajrccm.156.4.9610028; Porsbjerg C, 2009, ASTMA BEHANDLING, P1; Rogvi RA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016668; Stensballe LG, 2012, J PEDIAT; THURLBECK WM, 1982, THORAX, V37, P564, DOI 10.1136/thx.37.8.564; Thygesen LC, 2011, SCAND J PUBLIC HEALT, V39, P12, DOI 10.1177/1403494811399956; Tollanes MC, 2008, J PEDIATR-US, V153, P112, DOI 10.1016/j.jpeds.2008.01.029; Vinding GR, 2013, ACTA DERMATO VENEREO; Vogt H, 2011, PEDIATRICS, V127, P1052, DOI 10.1542/peds.2010-3083; Vrijlandt EJLE, 2007, J PEDIATR-US, V150, P256, DOI 10.1016/j.jpeds.2006.12.007; Wang Lei, 2008, Birth Defects Research, V84, P54, DOI 10.1002/bdrc.20114; Zilmer M, 2011, ACTA PAEDIATR, V100, P385, DOI 10.1111/j.1651-2227.2010.02036.x	43	21	21	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 4	2015	10	2							e0117253	10.1371/journal.pone.0117253	http://dx.doi.org/10.1371/journal.pone.0117253			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA9NG	25651521	Green Published, Green Submitted, gold			2023-01-03	WOS:000349250700011
J	Ness, DL; Johnson, BH				Ness, Debra L.; Johnson, Beverley H.			Dying in America: A Constructive Step Forward and an Opportunity to Deepen Partnerships With Patients and Families	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Ness, Debra L.] Natl Partnership Women & Families, Washington, DC 20009 USA; [Johnson, Beverley H.] Inst Patient & Family Ctr Care, Bethesda, MD 20814 USA		Ness, DL (corresponding author), Natl Partnership Women & Families, 1875 Connecticut Ave NW,Suite 650, Washington, DC 20009 USA.	dness@nationalpartnership.org						[Anonymous], 2014, C REC PARTN PAT FAM; Committee on Approaching Death: Addressing Key End of Life Issues, 2014, DYING AM IMPR QUAL H; Fulmer T, 2014, PARTNERING PATIENTS; Inst. Med, 2013, BEST CAR LOW COST PA; Johnson B. H., 2012, PARTNERING PATIENTS; Weinberger SE, 2014, ANN INTERN MED, V161, P73, DOI 10.7326/M13-2993	6	5	5	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 3	2015	162	3					226	U136		10.7326/M14-2537	http://dx.doi.org/10.7326/M14-2537			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CC1NP	25486367				2023-01-03	WOS:000350108100009
J	Watts, G				Watts, Geoff			Ian George Jacobs Obituary	LANCET			English	Biographical-Item																			0	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 31	2015	385	9966					414	414		10.1016/S0140-6736(15)60145-3	http://dx.doi.org/10.1016/S0140-6736(15)60145-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AZ9CT	25713853	Bronze			2023-01-03	WOS:000348509900015
J	Stewart, AK; Rajkumar, SV; Dimopoulos, MA; Masszi, T; Spicka, I; Oriol, A; Hajek, R; Rosinol, L; Siegel, DS; Mihaylov, GG; Goranova-Marinova, V; Rajnics, P; Suvorov, A; Niesvizky, R; Jakubowiak, AJ; San-Miguel, JF; Ludwig, H; Wang, M; Maisnar, V; Minarik, J; Bensinger, WI; Mateos, MV; Ben-Yehuda, D; Kukreti, V; Zojwalla, N; Tonda, ME; Yang, XQ; Xing, B; Moreau, P; Palumbo, A				Stewart, A. Keith; Rajkumar, S. Vincent; Dimopoulos, Meletios A.; Masszi, Tamas; Spicka, Ivan; Oriol, Albert; Hajek, Roman; Rosinol, Laura; Siegel, David S.; Mihaylov, Georgi G.; Goranova-Marinova, Vesselina; Rajnics, Peter; Suvorov, Aleksandr; Niesvizky, Ruben; Jakubowiak, Andrzej J.; San-Miguel, Jesus F.; Ludwig, Heinz; Wang, Michael; Maisnar, Vladimr; Minarik, Jiri; Bensinger, William I.; Mateos, Maria-Victoria; Ben-Yehuda, Dina; Kukreti, Vishal; Zojwalla, Naseem; Tonda, Margaret E.; Yang, Xinqun; Xing, Biao; Moreau, Philippe; Palumbo, Antonio		ASPIRE Investigators	Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SINGLE-AGENT CARFILZOMIB; LOW-DOSE DEXAMETHASONE; RANDOMIZED PHASE-III; STEM-CELL TRANSPLANTATION; PLUS DEXAMETHASONE; BORTEZOMIB; COMBINATION; SURVIVAL; ESCALATION; PX-171-006	Background Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and dexamethasone has shown efficacy in a phase 1 and 2 study in relapsed multiple myeloma. Methods We randomly assigned 792 patients with relapsed multiple myeloma to carfilzomib with lenalidomide and dexamethasone (carfilzomib group) or lenalidomide and dexamethasone alone (control group). The primary end point was progression-free survival. Results Progression-free survival was significantly improved with carfilzomib (median, 26.3 months, vs. 17.6 months in the control group; hazard ratio for progression or death, 0.69; 95% confidence interval [CI], 0.57 to 0.83; P = 0.0001). The median overall survival was not reached in either group at the interim analysis. The Kaplan-Meier 24-month overall survival rates were 73.3% and 65.0% in the carfilzomib and control groups, respectively (hazard ratio for death, 0.79; 95% CI, 0.63 to 0.99; P = 0.04). The rates of overall response (partial response or better) were 87.1% and 66.7% in the carfilzomib and control groups, respectively (P< 0.001; 31.8% and 9.3% of patients in the respective groups had a complete response or better; 14.1% and 4.3% had a stringent complete response). Adverse events of grade 3 or higher were reported in 83.7% and 80.7% of patients in the carfilzomib and control groups, respectively; 15.3% and 17.7% of patients discontinued treatment owing to adverse events. Patients in the carfilzomib group reported superior health-related quality of life. Conclusions In patients with relapsed multiple myeloma, the addition of carfilzomib to lenalidomide and dexamethasone resulted in significantly improved progression-free survival at the interim analysis and had a favorable risk-benefit profile. (Funded by Onyx Pharmaceuticals; ClinicalTrials.gov number, NCT01080391.)	[Stewart, A. Keith] Mayo Clin, Div Hematol Oncol, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA; [Rajkumar, S. Vincent] Mayo Clin, Div Hematol, Rochester, MN USA; [Dimopoulos, Meletios A.] Alexandra Hosp, Athens, Greece; [Masszi, Tamas] Semmelweis Univ, St Istvan & St Laszlo Hosp, Dept Hematol & Stem Cell Transplantat, H-1085 Budapest, Hungary; [Spicka, Ivan] Gen Univ Hosp, Dept Internal Med, Prague, Czech Republic; [Hajek, Roman] Univ Hosp Brno, Brno, Czech Republic; [Hajek, Roman] Univ Ostrava, Fac Med, Ostrava, Czech Republic; [Maisnar, Vladimr] Charles Univ Prague, Fac Hosp, Hradec Kralove, Czech Republic; [Minarik, Jiri] Univ Hosp Olomouc, Dept Hematol, Olomouc, Czech Republic; [Oriol, Albert] Hosp Badalona Germans Trias & Pujol, Inst Catal Oncol, Dept Clin Hematol, Inst Josep Carreras, Barcelona, Spain; [Rosinol, Laura] Hosp Clin Barcelona, Barcelona, Spain; [San-Miguel, Jesus F.] Univ Navarra Clin, Ctr Invest Med Aplicada, Pamplona, Spain; [Mateos, Maria-Victoria] Hosp Univ Salamanca, Salamanca, Spain; [Siegel, David S.] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA; [Mihaylov, Georgi G.] Queen Joanna Univ Hosp, Sofia, Bulgaria; [Goranova-Marinova, Vesselina] Univ Multiprofile Hosp Act, Hematol Clin, Plovdiv, Bulgaria; [Rajnics, Peter] Mor Kaposi Teaching Hosp, Kaposvar, Hungary; [Suvorov, Aleksandr] First Republican Clin Hosp Udmurtia, Izhevsk, Russia; [Niesvizky, Ruben] Weill Cornell Med Coll, New York, NY USA; [Jakubowiak, Andrzej J.] Univ Chicago Med, Chicago, IL USA; [Ludwig, Heinz] Wilhelminenspital Stadt Wien, Wilhelminen Canc Res Inst, Vienna, Austria; [Wang, Michael] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Bensinger, William I.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; [Ben-Yehuda, Dina] Hadassah Hebrew Univ Med Ctr, Jerusalem, Israel; [Kukreti, Vishal] Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada; [Zojwalla, Naseem; Tonda, Margaret E.; Yang, Xinqun; Xing, Biao] Onyx Pharmaceut, San Francisco, CA USA; [Moreau, Philippe] Univ Nantes, Nantes, France; [Palumbo, Antonio] Univ Turin, Turin, Italy	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Alexandra Hospital; Semmelweis University; General University Hospital Prague; University Hospital Brno; University of Ostrava; Charles University Prague; University Hospital Hradec Kralove; University Hospital Olomouc; Catalan Institute of Oncology; Hospital Germans Trias i Pujol; Institut de Recerca Contra la Leucemia Josep Carreras (IJC); University of Barcelona; Hospital Clinic de Barcelona; University of Navarra; University of Salamanca; Hackensack University Medical Center; Medical University Sofia; Medical University Plovdiv; Cornell University; Wilhelminenspital; University of Texas System; UTMD Anderson Cancer Center; Fred Hutchinson Cancer Center; Hebrew University of Jerusalem; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Nantes Universite; University of Turin	Stewart, AK (corresponding author), Mayo Clin, Div Hematol Oncol, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.	stewart.keith@mayo.edu	Rajkumar, S. Vincent/AAV-1834-2021; Maisnar, Vladimir/Q-8579-2017; Blimark, Cecilie Hveding/AAZ-6423-2021; Minarik, Jiri/GWR-0249-2022; Oriol, Albert/K-9923-2017; San-Miguel, Jesús F./V-8977-2018; Dimopoulos, Meletios Athanasios/AAD-4130-2019; Symeonidis, Argiris/K-2287-2019; Hajek, Roman/I-6639-2017; Gaidano, Gianluca/AAW-2773-2021; FACON, THIERRY/M-9736-2014	Rajkumar, S. Vincent/0000-0002-5862-1833; Maisnar, Vladimir/0000-0003-1738-4920; Blimark, Cecilie Hveding/0000-0003-3297-6019; Minarik, Jiri/0000-0003-0513-326X; Oriol, Albert/0000-0001-6804-2221; San-Miguel, Jesús F./0000-0002-9183-4857; Symeonidis, Argiris/0000-0002-3685-3473; Hajek, Roman/0000-0001-6955-6267; Gaidano, Gianluca/0000-0002-4681-0151; FACON, THIERRY/0000-0001-7705-8460; moreau, philippe/0000-0003-1780-8746; Spicka, Ivan/0000-0002-5451-5283; de Fabritiis, Paolo/0000-0002-1835-0581; Goranova-Marinova, Veselina/0000-0002-7811-162X; Dimopoulos, Meletios/0000-0001-8990-3254; Grasa-Ullrich, Jose-Maria/0000-0002-6023-7590; Masszi, Tamas/0000-0003-2322-9863; nahi, hareth/0000-0003-4711-5094; de la Rubia, Javier/0000-0002-8354-768X	Onyx Pharmaceuticals; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	Onyx Pharmaceuticals; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funded by Onyx Pharmaceuticals; ClinicalTrials.gov number, NCT01080391.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Arnulf B, 2012, HAEMATOL-HEMATOL J, V97, P1925, DOI 10.3324/haematol.2012.067793; Attal M, 2012, NEW ENGL J MED, V366, P1782, DOI 10.1056/NEJMoa1114138; Benboubker L, 2014, NEW ENGL J MED, V371, P906, DOI 10.1056/NEJMoa1402551; Berenson JR, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.8594; Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x; Cocks K, 2011, J CLIN ONCOL, V29, P89, DOI 10.1200/JCO.2010.28.0107; DeMets D L, 1995, Cancer Treat Res, V75, P1; Dimopoulos M, 2009, NEW ENGL J MED, V361, P544; Dimopoulos MA, 2010, LEUKEMIA, V24, P1769, DOI 10.1038/leu.2010.175; Dimopoulos MA, 2009, LEUKEMIA, V23, P2147, DOI 10.1038/leu.2009.147; Durie BGM, 2007, LEUKEMIA, V21, P1134, DOI 10.1038/sj.leu.2404582; Garderet L, 2014, J CLIN ONCOL, V32, P1285; Garderet L, 2012, J CLIN ONCOL, V30, P3429, DOI 10.1200/JCO.2012.46.1848; Garderet L, 2012, J CLIN ONCOL, V30, P2475, DOI 10.1200/JCO.2011.37.4918; Jagannath S, 2012, CL LYMPH MYELOM LEUK, V12, P310, DOI 10.1016/j.clml.2012.08.003; Jakubowiak A. J., 2013, J CLIN ONCOL S, V31, P8543, DOI 10.1200/jco.2013.31.15_suppl.8543; Jakubowiak AJ, 2012, BLOOD, V120, P1801, DOI 10.1182/blood-2012-04-422683; Kumar SK, 2008, BLOOD, V111, P2516, DOI 10.1182/blood-2007-10-116129; Kyle RA, 2009, LEUKEMIA, V23, P3, DOI 10.1038/leu.2008.291; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Lonial S, 2014, LEUKEMIA, V28, P258, DOI 10.1038/leu.2013.220; McCarthy PL, 2012, NEW ENGL J MED, V366, P1770, DOI 10.1056/NEJMoa1114083; Munshi NC, 2011, BLOOD, V117, P4696, DOI 10.1182/blood-2010-10-300970; Niesvizky R, 2013, CLIN CANCER RES, V19, P2248, DOI 10.1158/1078-0432.CCR-12-3352; Orlowski RZ, 2007, J CLIN ONCOL, V25, P3892, DOI 10.1200/JCO.2006.10.5460; Palumbo A, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.8515; Palumbo A, 2012, NEW ENGL J MED, V367, P285; Palumbo A, 2012, NEW ENGL J MED, V366, P1759, DOI 10.1056/NEJMoa1112704; Rajkumar SV, 2010, LANCET ONCOL, V11, P14; Richardson PG, 2014, BLOOD, V123, P1461, DOI 10.1182/blood-2013-07-517276; Siegel D, 2013, HAEMATOLOGICA, V98, P1753, DOI 10.3324/haematol.2013.089334; Siegel DS, 2012, BLOOD, V120, P2817, DOI 10.1182/blood-2012-05-425934; Wang M, 2013, BLOOD, V122, P3122, DOI 10.1182/blood-2013-07-511170; Weber DM, 2007, NEW ENGL J MED, V357, P2133, DOI 10.1056/NEJMoa070596; Zingone A, 2013, BLOOD, V122, P538	36	920	952	1	141	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 8	2015	372	2					142	152		10.1056/NEJMoa1411321	http://dx.doi.org/10.1056/NEJMoa1411321			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AY2UA	25482145				2023-01-03	WOS:000347443300009
J	Skov, AL				Skov, Anne Ladegaard			MATERIALS SCIENCE Like cartilage, but simpler	NATURE			English	Editorial Material									Tech Univ Denmark, Dept Chem & Biochem Engn, Danish Polymer Ctr, DK-2800 Lyngby, Denmark	Technical University of Denmark	Skov, AL (corresponding author), Tech Univ Denmark, Dept Chem & Biochem Engn, Danish Polymer Ctr, DK-2800 Lyngby, Denmark.	al@kt.dtu.dk	Skov, Anne Ladegaard/N-2320-2019; Skov, Anne L/A-1614-2013	Skov, Anne Ladegaard/0000-0003-1223-6638; Skov, Anne L/0000-0003-1223-6638				Cordier P, 2008, NATURE, V451, P977, DOI 10.1038/nature06669; Liu MJ, 2015, NATURE, V517, P68, DOI 10.1038/nature14060; MOW VC, 1992, BIOMATERIALS, V13, P67, DOI 10.1016/0142-9612(92)90001-5; Vudayagiri S, 2014, SMART MATER STRUCT, V23, DOI 10.1088/0964-1726/23/10/105017	4	4	4	2	69	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 1	2015	517	7532					25	26		10.1038/517025a	http://dx.doi.org/10.1038/517025a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX8SI	25557709				2023-01-03	WOS:000347178400024
J	West, KP; Shamim, AA; Mehra, S; Labrique, AB; Ali, H; Shaikh, S; Klemm, RDW; Wu, LSF; Mitra, M; Haque, R; Hanif, AAM; Massie, AB; Merrill, RD; Schulze, KJ; Christian, P				West, Keith P., Jr.; Shamim, Abu Ahmed; Mehra, Sucheta; Labrique, Alain B.; Ali, Hasmot; Shaikh, Saijuddin; Klemm, Rolf D. W.; Wu, Lee S-F.; Mitra, Maithilee; Haque, Rezwanul; Hanif, Abu A. M.; Massie, Allan B.; Merrill, Rebecca Day; Schulze, Kerry J.; Christian, Parul			Effect of Maternal Multiple Micronutrient vs Iron-Folic Acid Supplementation on Infant Mortality and Adverse Birth Outcomes in Rural Bangladesh The JiVitA-3 Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BETA-CAROTENE SUPPLEMENTATION; MIDDLE-INCOME COUNTRIES; FOR-GESTATIONAL-AGE; DOUBLE-BLIND; VITAMIN-A; PRETERM BIRTH; FETAL LOSS; PREGNANCY; WEIGHT; WOMEN	IMPORTANCE Maternal micronutrient deficiencies may adversely affect fetal and infant health, yet there is insufficient evidence of effects on these outcomes to guide antenatal micronutrient supplementation in South Asia. OBJECTIVE To assess effects of antenatal multiple micronutrient vs iron-folic acid supplementation on 6-month infant mortality and adverse birth outcomes. DESIGN, SETTING, AND PARTICIPANTS Cluster randomized, double-masked trial in Bangladesh, with pregnancy surveillance starting December 4, 2007, and recruitment on January 11, 2008. Six-month infant follow-up ended August 30, 2012. Surveillance included 127 282 women; 44 567 became pregnant and were included in the analysis and delivered 28 516 live-born infants. Median gestation at enrollment was 9 weeks (interquartile range, 7-12). INTERVENTIONS Women were provided supplements containing 15 micronutrients or iron-folic acid alone, taken daily from early pregnancy to 12 weeks postpartum. MAIN OUTCOMES AND MEASURES The primary outcome was all-cause infant mortality through 6 months (180 days). Prespecified secondary outcomes in this analysis included stillbirth, preterm birth (<37 weeks), and low birth weight (<2500 g). To maintain overall significance of a=.05, a Bonferroni-corrected a=.01 was calculated to evaluate statistical significance of primary and 4 secondary risk outcomes (.05/5). RESULTS Among the 22 405 pregnancies in the multiple micronutrient group and the 22 162 pregnancies in the iron-folic acid group, there were 14 374 and 14 142 live-born infants, respectively, included in the analysis. At 6 months, multiple micronutrients did not significantly reduce infant mortality; there were 764 deaths (54.0 per 1000 live births) in the iron-folic acid group and 741 deaths (51.6 per 1000 live births) in the multiple micronutrient group (relative risk [RR], 0.95; 95% CI, 0.86-1.06). Multiple micronutrient supplementation resulted in a non-statistically significant reduction in stillbirths (43.1 vs 48.2 per 1000 births; RR, 0.89; 95% CI, 0.81-0.99; P=.02) and significant reductions in preterm births (18.6 vs 21.8 per 100 live births; RR, 0.85; 95% CI, 0.80-0.91; P<.001) and low birth weight (40.2 vs 45.7 per 100 live births; RR, 0.88; 95% CI, 0.85-0.91; P<.001). CONCLUSIONS AND RELEVANCE In Bangladesh, antenatal multiple micronutrient compared with iron-folic acid supplementation did not reduce all-cause infant mortality to age 6 months but resulted in a non-statistically significant reduction in stillbirths and significant reductions in preterm births and low birth weight.	[West, Keith P., Jr.; Shamim, Abu Ahmed; Mehra, Sucheta; Labrique, Alain B.; Ali, Hasmot; Shaikh, Saijuddin; Klemm, Rolf D. W.; Wu, Lee S-F.; Mitra, Maithilee; Massie, Allan B.; Schulze, Kerry J.; Christian, Parul] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Human Nutr, Dept Int Hlth, Baltimore, MD 21205 USA; [Shamim, Abu Ahmed; Ali, Hasmot; Shaikh, Saijuddin; Haque, Rezwanul; Hanif, Abu A. M.] JiVitA Project, Gaibandha, Bangladesh; [Massie, Allan B.] Johns Hopkins Sch Med, Dept Surg, Baltimore, MD USA; [Merrill, Rebecca Day] Ctr Dis Control & Prevent, Atlanta, GA USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; Centers for Disease Control & Prevention - USA	West, KP (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, W2041,615 N Wolfe St, Baltimore, MD 21205 USA.	kwest1@jhu.edu	Hanif, Abu Abdullah Mohammad/AAG-4636-2020; Ali, Hasmot/I-8700-2019	Hanif, Abu Abdullah Mohammad/0000-0001-6274-5612; Ali, Hasmot/0000-0003-0044-1992; Abu Ahmed, Shamim/0000-0002-7071-8558; Labrique, Alain/0000-0003-2502-7819	Global Control of Micronutrient Deficiency from Bill and Melinda Gates Foundation [OPP614]	Global Control of Micronutrient Deficiency from Bill and Melinda Gates Foundation	The JiVitA-3 Trial was funded through grant OPP614 (Global Control of Micronutrient Deficiency) from the Bill and Melinda Gates Foundation (Ellen Piwoz, ScD, Senior Program Officer). Additional assistance was received from the Sight and Life Global Nutrition Research Institute. DSM formulated, prepared, and delivered in-country micronutrient premixes for supplement production gratis and tested supplement potency throughout the trial gratis. Beximco Pharmaceuticals produced, bottled, labeled, and delivered to the field site 16 million study tablets during the trial gratis and delivered an additional 1 million multiple micronutrient supplements gratis to support posttrial antenatal supplement delivery services in the community.	Alexander GR, 1996, OBSTET GYNECOL, V87, P163, DOI 10.1016/0029-7844(95)00386-X; [Anonymous], COMP MULT SUPPL BE U; Arsenault JE, 2013, J NUTR, V143, P197, DOI 10.3945/jn.112.169524; Berti C, 2011, CLIN NUTR, V30, P689, DOI 10.1016/j.clnu.2011.08.004; Bhutta ZA, 2013, LANCET, V382, P452, DOI 10.1016/S0140-6736(13)60996-4; Blencowe H, 2012, LANCET, V379, P2162, DOI 10.1016/S0140-6736(12)60820-4; Christian P, 2003, AM J CLIN NUTR, V78, P1194, DOI 10.1093/ajcn/78.6.1194; Christian P, 2003, J NUTR, V133, P3492, DOI 10.1093/jn/133.11.3492; Christian P, 2003, BMJ-BRIT MED J, V326, P571, DOI 10.1136/bmj.326.7389.571; Christian PS, 2012, ARCH DIS CHILD-FETAL, V97, pF312, DOI 10.1136/adc.2006.114009; Christian P, 2013, AM J CLIN NUTR, V97, P188, DOI 10.3945/ajcn.112.042275; Christian P, 2010, ANNU REV NUTR, V30, P83, DOI 10.1146/annurev.nutr.012809.104813; Cohen J., 1988, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; Cousens S, 2011, LANCET, V377, P1319, DOI 10.1016/S0140-6736(10)62310-0; Gunnsteinsson S, 2010, J HEALTH POPUL NUTR, V28, P509; Haider BA, 2012, COCHRANE DB SYST REV, V11; Hindle LJ, 2006, AM J CLIN NUTR, V84, P1086, DOI 10.1093/ajcn/84.5.1086; Hovdenak N, 2012, EUR J OBSTET GYN R B, V164, P127, DOI 10.1016/j.ejogrb.2012.06.020; Jiang TN, 2005, J NUTR, V135, P1106, DOI 10.1093/jn/135.5.1106; Katz J, 2006, J NUTR, V136, P1389, DOI 10.1093/jn/136.5.1389; Katz J, 2013, LANCET, V382, P417, DOI 10.1016/S0140-6736(13)60993-9; Klemm R, 2008, PEDIATRICS, V120, pe240; Klemm RDW, 2015, MATERN CHILD NUTR, V11, P583, DOI 10.1111/mcn.12041; Labrique AB, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-102; Lee ACC, 2013, LANCET GLOB HEALTH, V1, pE26, DOI 10.1016/S2214-109X(13)70006-8; Lee ACC, 2009, ARCH PEDIAT ADOL MED, V163, P616, DOI 10.1001/archpediatrics.2009.75; Lee SE, 2013, PUBLIC HLTH NUTR, V16, P1340; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Merrill RD, 2012, ASIA PAC J CLIN NUTR, V21, P416; Merrill RD, 2011, J NUTR, V141, P944, DOI 10.3945/jn.111.138628; Mistry HD, 2011, OXID MED CELL LONGEV, V2011, DOI 10.1155/2011/841749; Osrin D, 2005, LANCET, V365, P955, DOI 10.1016/S0140-6736(05)71084-9; Otten JJ, 2008, ESSENTIAL GUIDE NUTR; Palmer AC, 2011, ADV NUTR, V2, P377, DOI 10.3945/an.111.000570; Pathak Priyali, 2004, Indian Journal of Pediatrics, V71, P1007; Persson LA, 2012, JAMA-J AM MED ASSOC, V307, P2050, DOI 10.1001/jama.2012.4061; Poston L, 2011, AM J CLIN NUTR S, V94, p1980S; Ramakrishnan U, 2012, PAEDIATR PERINAT EP, V26, P153, DOI 10.1111/j.1365-3016.2012.01276.x; Roberfroid D, 2010, AM J CLIN NUTR, V91, P1649, DOI 10.3945/ajcn.2009.28855; Romero R, 2003, J NUTR, V133, p1668S, DOI 10.1093/jn/133.5.1668S; Shankar AH, 2008, LANCET, V371, P215, DOI 10.1016/S0140-6736(08)60133-6; Torheim LE, 2010, J NUTR, V140, p2051S, DOI 10.3945/jn.110.123463; Villar J, 2014, LANCET, V384, P857, DOI 10.1016/S0140-6736(14)60932-6; West KP, 2011, JAMA-J AM MED ASSOC, V305, P1986, DOI 10.1001/jama.2011.656; West KP, 1999, BMJ-BRIT MED J, V318, P570, DOI 10.1136/bmj.318.7183.570	45	79	79	2	32	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 24	2014	312	24					2649	2658		10.1001/jama.2014.16819	http://dx.doi.org/10.1001/jama.2014.16819			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AX5KW	25536256				2023-01-03	WOS:000346966100017
J	Osonoi, T; Saito, M; Tamasawa, A; Ishida, H; Tsujino, D; Nishimura, R; Utsunomiya, K				Osonoi, Takeshi; Saito, Miyoko; Tamasawa, Atsuko; Ishida, Hidenori; Tsujino, Daisuke; Nishimura, Rimei; Utsunomiya, Kazunori			Effect of Hemodialysis on Plasma Glucose Profile and Plasma Level of Liraglutide in Patients with Type 2 Diabetes Mellitus and End-Stage Renal Disease: A Pilot Study	PLOS ONE			English	Editorial Material							ANALOG LIRAGLUTIDE; PHARMACOKINETICS; IMPAIRMENT; METABOLISM	The effect of hemodialysis on the plasma glucose profile and liraglutide level after liraglutide injection was investigated in patients with diabetes and end-stage renal disease (ESRD). Either 0.6 mg or 0.9 mg liraglutide was subcutaneously administered daily to 10 Japanese type 2 diabetic patients with ESRD. Hemodialysis was conducted on days 1 and 3. Plasma liraglutide and glucose concentrations were measured by enzyme-linked immunosorbent assay and a continuous glucose monitoring system, respectively. The safety profile of liraglutide was also assessed. Hemodialysis had no effect on the pharmacokinetic parameters of liraglutide in patients with diabetes and ESRD; the maximum plasma concentration (C-max), t(max), area under the concentration-time curve (AUC), and CL/f were unaltered. Similarly, hemodialysis did not affect the mean or minimum glucose levels, AUC, or duration of hyperglycemia (>180 mg/dL) and hypoglycemia (, 70 mg/dL) following liraglutide administration. However, significant increases in mean amplitude of glycemic excursions (MAGE) and standard deviation (SD) as markers of glucose fluctuation, and the maximum glucose level were observed during hemodialysis. No adverse events, including hypoglycemia, were observed after liraglutide injection, either off-hemodialysis (day 2) or on-hemodialysis (day 3). Liraglutide was well tolerated in patients with type 2 diabetes and ESRD undergoing hemodialysis. The present results suggested that hemodialysis did not affect the pharmacokinetic profile of liraglutide or most glycemic indices, with the exception of MAGE, SD, and the maximum glucose level. These results suggested that it may be possible to use liraglutide during hemodialysis for diabetes with ESRD, without dose adjustment.	[Osonoi, Takeshi; Saito, Miyoko; Tamasawa, Atsuko; Ishida, Hidenori] Nakakinen Clin, Dept Internal Med, Naka, Ibaraki, Japan; [Tsujino, Daisuke; Nishimura, Rimei; Utsunomiya, Kazunori] Jikei Univ, Sch Med, Dept Internal Med, Div Diabet Metab & Endocrinol,Minato Ku, Tokyo, Japan; [Nishimura, Rimei] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA	Jikei University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Osonoi, T (corresponding author), Nakakinen Clin, Dept Internal Med, Naka, Ibaraki, Japan.	t-osonoi@kensei-kai.com						Abe M, 2011, CURR DRUG METAB, V12, P57, DOI 10.2174/138920011794520053; Bode B, 2011, AM J MANAG CARE, V17, pS59; Brock CM, 2010, US PHARM, V35, P8; Jacobsen LV, 2009, BRIT J CLIN PHARMACO, V68, P898, DOI 10.1111/j.1365-2125.2009.03536.x; Krepinsky J, 2000, AM J KIDNEY DIS, V35, P500, DOI 10.1016/S0272-6386(00)70204-6; Kuriyama S, 2001, NURSING, V21, P82; Linnebjerg H, 2007, BRIT J CLIN PHARMACO, V64, P317, DOI 10.1111/j.1365-2125.2007.02890.x; Malm-Erjefalt M, 2010, DRUG METAB DISPOS, V38, P1944, DOI 10.1124/dmd.110.034066; Ministry of Health, 2008, ETH GUID CLIN STUD A; Mirani M, 2010, DIABETES TECHNOL THE, V12, P749, DOI 10.1089/dia.2010.0052; Mori Y, 2011, DIABETES TECHNOL THE, V13, P1139, DOI 10.1089/dia.2011.0137; National Institute for Health and Care Excellence, 2010, DIAB TYP 2 LIR TREAT; Nauck M, 2013, DIABETES OBES METAB, V15, P204, DOI 10.1111/dom.12012; Neumiller JJ, 2010, DIABET METAB SYND OB, V3, P215; Schmidt WE, 2010, INT J CLIN PRACT, V64, P12, DOI 10.1111/j.1742-1241.2010.02500.x; Terawaki Y, 2013, DIABETOL METAB SYNDR, V5, DOI 10.1186/1758-5996-5-10	16	17	17	2	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 19	2014	9	12							e113468	10.1371/journal.pone.0113468	http://dx.doi.org/10.1371/journal.pone.0113468			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX8WK	25526642	Green Submitted, gold, Green Accepted, Green Published			2023-01-03	WOS:000347186200068
J	Sacks, FM; Carey, VJ; Anderson, CAM; Miller, ER; Copeland, T; Charleston, J; Harshfield, BJ; Laranjo, N; McCarron, P; Swain, J; White, K; Yee, K; Appel, LJ				Sacks, Frank M.; Carey, Vincent J.; Anderson, Cheryl A. M.; Miller, Edgar R., III; Copeland, Trisha; Charleston, Jeanne; Harshfield, Benjamin J.; Laranjo, Nancy; McCarron, Phyllis; Swain, Janis; White, Karen; Yee, Karen; Appel, Lawrence J.			Effects of Flig,,h vs Low Glycemic Index of Dietary Carbohydrate on Cardiovascula Disease Risk Factors and Insulin Sensitivity The OmniCarb Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WEIGHT-LOSS; BLOOD-PRESSURE; GLYCATED HEMOGLOBIN; MEDITERRANEAN DIET; SERUM-LIPIDS; LOAD; GLUCOSE; METAANALYSIS; PROTEIN; CHOLESTEROL	IMPORTANCE Foods that have similar carbohydrate content can differ in the amount they raise blood glucose. The effects of this property, called the glycemic index, on risk factors for cardiovascular disease and diabetes are not well understood. OBJECTIVE To determine the effect of glycemic index and amount of total dietary carbohydrate on risk factors for cardiovascular disease and diabetes. DESIGN, SETTING, AND PARTICIPANTS Randomized crossover-controlled feeding trial conducted in research units in academic medical centers, in which 163 overweight adults (systolic blood pressure, 120-159 mm Hg) were given 4 complete diets that contained all of their meals, snacks, and calorie-containing beverages, each for 5 weeks, and completed at least 2 study diets. The first participant was enrolled April 1, 2008; the last participant finished December 22, 2010. For any pair of the 4 diets, there were 135 to 150 participants contributing at least 1primary outcome measure. INTERVENTIONS (1) A high-glycemic index (65% on the glucose scale), high-carbohydrate diet (58% energy); (2) a low-glycemic index (40%), high-carbohydrate diet; (3) a high-glycemic index, low-carbohydrate diet (40% energy); and (4) a low-glycemic index, low-carbohydrate diet. Each diet was based on a healthful DASH-type diet. MAIN OUTCOMES AND MEASURES The 5 primary outcomes were insulin sensitivity, determined from the areas under the curves of glucose and insulin levels during an oral glucose tolerance test; levels of low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides; and systolic blood pressure. RESULTS At high dietary carbohydrate content, the low- compared with high-glycemic index level decreased insulin sensitivity from 8.9 to 7.1 units (-20%, P = .002); increased LDL cholesterol from 139 to 147 mg/dL (6%, P <= .001); and did not affect levels of HDL cholesterol, triglycerides, or blood pressure. At low carbohydrate content, the low- compared with high-glycemic index level did not affect the outcomes except for decreasing triglycerides from 91 to 86 mg/dL (-5%, P = .02). In the primary diet contrast, the low-glycemic index, low-carbohydrate diet, compared with the high-glycemic index, high-carbohydrate diet, did not affect insulin sensitivity, systolic blood pressure, LDL cholesterol, or HDL cholesterol but did lower triglycerides from 111 to 86 mg/dL (-23%, P <= .001). CONCLUSIONS AND RELEVANCE In this 5-week controlled feeding study, diets with low glycemic index of dietary carbohydrate, compared with high glycemic index of dietary carbohydrate, did not result in improvements in insulin sensitivity, lipid levels, or systolic blood pressure. In the context of an overall DASH-type diet, using glycemic index to select specific foods may not improve cardiovascular risk factors or insulin resistance.	[Sacks, Frank M.; Carey, Vincent J.; Copeland, Trisha; Harshfield, Benjamin J.; Laranjo, Nancy] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA; [Sacks, Frank M.; Carey, Vincent J.; Copeland, Trisha; Harshfield, Benjamin J.; Laranjo, Nancy] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; [Sacks, Frank M.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; [Anderson, Cheryl A. M.; Charleston, Jeanne; Appel, Lawrence J.] Johns Hopkins Med Inst, Dept Epidemiol, Baltimore, MD 21205 USA; [Miller, Edgar R., III; Charleston, Jeanne; McCarron, Phyllis; White, Karen; Appel, Lawrence J.] Johns Hopkins Med Inst, Div Gen Internal Med, Baltimore, MD 21205 USA; [Miller, Edgar R., III; Charleston, Jeanne; Appel, Lawrence J.] Johns Hopkins Med Inst, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD 21205 USA; [Swain, Janis; Yee, Karen] Brigham & Womens Hosp, Ctr Clin Invest, Boston, MA 02115 USA; [Anderson, Cheryl A. M.] Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Harvard University; Brigham & Women's Hospital; University of California System; University of California San Diego	Sacks, FM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.	fsacks@hsph.harvard.edu	Appel, Larry/GLT-2608-2022		National Heart, Lung, and Blood Institute [R01HL084568]; National Institute of Diabetes and Digestive and Kidney Diseases [R21 DK098720-02]; Harvard Clinical and Translational Science Center from the National Center for Advancing Translational Science [8UL1TR0001750-05]; general clinical research center at Brigham and Women's Hospital [M01-02635]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL084568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK098720] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Harvard Clinical and Translational Science Center from the National Center for Advancing Translational Science; general clinical research center at Brigham and Women's Hospital; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The study was supported by an investigator-initiated grant from the National Heart, Lung, and Blood Institute (R01HL084568) and received additional support from National Institute of Diabetes and Digestive and Kidney Diseases (R21 DK098720-02); the Harvard Clinical and Translational Science Center (8UL1TR0001750-05) from the National Center for Advancing Translational Science; and the general clinical research center at Brigham and Women's Hospital (M01-02635).	Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Appel LJ, 2005, JAMA-J AM MED ASSOC, V294, P2455, DOI 10.1001/jama.294.19.2455; Atkinson FS, 2008, DIABETES CARE, V31, P2281, DOI 10.2337/dc08-1239; Brown L, 1999, AM J CLIN NUTR, V69, P30; de Lorgeril M, 1999, CIRCULATION, V99, P779, DOI 10.1161/01.CIR.99.6.779; De Rougemont A, 2007, BRIT J NUTR, V98, P1288, DOI 10.1017/S0007114507778674; Dong JY, 2011, BRIT J NUTR, V106, P1649, DOI 10.1017/S000711451100540X; Ebbeling CB, 2012, JAMA-J AM MED ASSOC, V307, P2627, DOI 10.1001/jama.2012.6607; Estruch R, 2013, NEW ENGL J MED, V368, P1279, DOI 10.1056/NEJMoa1200303; Fabricatore AN, 2011, DIABETES RES CLIN PR, V92, P37, DOI 10.1016/j.diabres.2010.12.016; Fabricatore AN, 2011, AM J CLIN NUTR, V94, P1519, DOI 10.3945/ajcn.111.020354; Gannon MC, 1998, DIABETES CARE, V21, P1619, DOI 10.2337/diacare.21.10.1619; Gogebakan O, 2011, CIRCULATION, V124, P2829, DOI 10.1161/CIRCULATIONAHA.111.033274; Goff LM, 2013, NUTR METAB CARDIOVAS, V23, P1, DOI 10.1016/j.numecd.2012.06.002; Hartman TJ, 2010, J NUTR, V140, P60, DOI 10.3945/jn.109.114249; Heilbronn LK, 2002, J AM COLL NUTR, V21, P120, DOI 10.1080/07315724.2002.10719204; Jarvi AE, 1999, DIABETES CARE, V22, P10, DOI 10.2337/diacare.22.1.10; Jebb SA, 2010, AM J CLIN NUTR, V92, P748, DOI 10.3945/ajcn.2009.29096; Jenkins DJA, 2008, JAMA-J AM MED ASSOC, V300, P2742, DOI 10.1001/jama.2008.808; Jones G, 2003, DESIGN ANAL CROSS OV; Larsen TM, 2010, NEW ENGL J MED, V363, P2102, DOI 10.1056/NEJMoa1007137; Livesey G, 2008, AM J CLIN NUTR, V87, p258S, DOI 10.1093/ajcn/87.1.258S; Ludbrook J, 2000, CLIN EXP PHARMACOL P, V27, P212, DOI 10.1046/j.1440-1681.2000.03223.x; Matsuda M, 1999, DIABETES CARE, V22, P1462, DOI 10.2337/diacare.22.9.1462; McMillan-Price J, 2006, ARCH INTERN MED, V166, P1466, DOI 10.1001/archinte.166.14.1466; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; Michaud DS, 2005, CANCER EPIDEM BIOMAR, V14, P138, DOI 10.1158/1055-9965.EPI-05-0428; Mirrahimi A, 2012, J AM HEART ASSOC, V1, DOI 10.1161/JAHA.112.000752; Obarzanek E, 2001, AM J CLIN NUTR, V74, P80; Raatz SK, 2005, J NUTR, V135, P2387, DOI 10.1093/jn/135.10.2387; Reynolds RC, 2009, EUR J CLIN NUTR, V63, P872, DOI 10.1038/ejcn.2008.52; Runchey SS, 2012, EUR J CLIN NUTR, V66, P1146, DOI 10.1038/ejcn.2012.107; Schwingshackl L, 2013, NUTR METAB CARDIOVAS, V23, P699, DOI 10.1016/j.numecd.2013.04.008; Selvin E, 2010, NEW ENGL J MED, V362, P800, DOI 10.1056/NEJMoa0908359; Shikany JM, 2009, METABOLISM, V58, P1793, DOI 10.1016/j.metabol.2009.06.006; Sichieri R, 2007, AM J CLIN NUTR, V86, P707, DOI 10.1093/ajcn/86.3.707; Sloth B, 2004, AM J CLIN NUTR, V80, P337, DOI 10.1093/ajcn/80.2.337; Thomas DE, 2010, BRIT J NUTR, V104, P797, DOI 10.1017/S0007114510001534; Vrolix R, 2010, AM J CLIN NUTR, V92, P366, DOI 10.3945/ajcn.2009.28339; White WB, 2001, BLOOD PRESS MONIT, V6, P107, DOI 10.1097/00126097-200104000-00007; Wolever TMS, 2008, AM J CLIN NUTR, V87, P114, DOI 10.1093/ajcn/87.1.114; WOLEVER TMS, 1991, AM J CLIN NUTR, V54, P846, DOI 10.1093/ajcn/54.5.846	42	139	140	4	68	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 17	2014	312	23					2531	2541		10.1001/jama.2014.16658	http://dx.doi.org/10.1001/jama.2014.16658			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AW5YN	25514303	Green Accepted, Green Published			2023-01-03	WOS:000346346900016
J	Masters, SH; Burstein, R; DeCenso, B; Moore, K; Haakenstad, A; Ikilezi, G; Achan, J; Osei, I; Garshong, B; Kisia, C; Njuguna, P; Babigumira, J; Kumar, S; Hanlon, M; Gakidou, E				Masters, Samuel H.; Burstein, Roy; DeCenso, Brendan; Moore, Kelsey; Haakenstad, Annie; Ikilezi, Gloria; Achan, Jane; Osei, Ivy; Garshong, Bertha; Kisia, Caroline; Njuguna, Pamela; Babigumira, Joseph; Kumar, Santosh; Hanlon, Michael; Gakidou, Emmanuela			Pharmaceutical Availability across Levels of Care: Evidence from Facility Surveys in Ghana, Kenya, and Uganda	PLOS ONE			English	Article							ESSENTIAL MEDICINES; AFFORDABILITY; ANTIMALARIALS; SERVICES; DISEASES; QUALITY; OUTLETS; CHOICE; ACCESS	Objective: In this study we use facility-level data from nationally representative surveys conducted in Ghana, Kenya, and Uganda to understand pharmaceutical availability within the three countries. Methods: In 2012, we conducted a survey to capture information on pharmaceuticals and other facility indicators from over 200 facilities in each country. We analyze data on the availability of pharmaceuticals and quantify its association with various facility-level indicators. We analyze both availability of essential medicines, as defined by the various essential medicine lists (EMLs) of each respective country, and availability of all surveyed pharmaceuticals deemed important for treatment of various high-burden diseases, including those on the EMLs. Results: We find that there is heterogeneity with respect to availability across the three countries with Ghana generally having better availability than Uganda and Kenya. To analyze the relationship between facility-level factors and pharmaceutical stock-out we use a binomial regression model. We find that the factors associated with stock-out vary by country, but across all countries both presence of a laboratory at the facility and presence of a vehicle at the facility are significantly associated with reduced stock-out. Conclusion: The results of this study highlight the poor availability of essential medicines across these three countries and suggest more needs to be done to strengthen the supply system so that stock remains uninterrupted.	[Masters, Samuel H.] Univ N Carolina, Dept Hlth Policy & Management, Chapel Hill, NC 27599 USA; [Burstein, Roy; Haakenstad, Annie; Hanlon, Michael] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA; [DeCenso, Brendan] RTI Int, Durham, NC USA; [Ikilezi, Gloria; Achan, Jane] Infect Dis Res Collaborat, Kampala, Uganda; [Osei, Ivy; Garshong, Bertha] Ghana Hlth Serv, Accra, Ghana; [Kisia, Caroline; Njuguna, Pamela] Act Africa Help Int, Nairobi, Kenya; [Babigumira, Joseph] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA; [Kumar, Santosh] Sam Houston State Univ, Dept Econ & Int Business, Huntsville, TX 77340 USA	University of North Carolina; University of North Carolina Chapel Hill; Institute for Health Metrics & Evaluation; University of Washington; University of Washington Seattle; Research Triangle Institute; Ghana Health Service; University of Washington; University of Washington Seattle; Texas State University System; Sam Houston State University	Masters, SH (corresponding author), Univ N Carolina, Dept Hlth Policy & Management, Chapel Hill, NC 27599 USA.	masters@unc.edu	Babigumira, Joseph/T-4208-2019	Masters, Samuel/0000-0001-7581-8219				Babar ZUD, 2007, PLOS MED, V4, P466, DOI 10.1371/journal.pmed.0040082; Bazargani YT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087576; Buabeng KO, 2008, CLIN PHARMACOL THER, V84, P613, DOI 10.1038/clpt.2008.130; Cameron A, 2009, LANCET, V373, P240, DOI 10.1016/S0140-6736(08)61762-6; Cheraghali AM, 2009, PHARM WORLD SCI, V31, P209, DOI 10.1007/s11096-009-9282-3; Cockburn R, 2005, PLOS MED, V2, P302, DOI 10.1371/journal.pmed.0020100; DAVIS BL, 2013, EM APPR SPEECH ACQ, P1, DOI DOI 10.1186/1475-2875-12-135; Ghana National Drugs Program Ministry of Health, 2010, GHAN ESS MED LIST; Hanson K, 2005, HEALTH ECON, V14, P687, DOI 10.1002/hec.959; IHME, 2014, HLTH SERV PROV KEN A; Institute for Health Metrics and Evaluation (IHME), 2013, ACC BOTTL COSTS EQ A; Kangwana BB, 2009, AM J TROP MED HYG, V80, P737, DOI 10.4269/ajtmh.2009.80.737; Kaur H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003403; Kenya Ministry of Medical Services Kenya Ministry of Public Health & Sanitation, 2010, KEN ESS MED LIST; Laing R, 2003, LANCET, V361, P1723, DOI 10.1016/S0140-6736(03)13375-2; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Mendis S, 2007, B WORLD HEALTH ORGAN, V85, P279, DOI 10.2471/BLT.06.033647; Mugisha F, 2004, B WORLD HEALTH ORGAN, V82, P572; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; Nabbuye-Sekandi J, 2011, INT J QUAL HEALTH C, V23, P516, DOI 10.1093/intqhc/mzr040; Pasquet A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013414; Robertson J, 2009, B WORLD HEALTH ORGAN, V87, P231, DOI 10.2471/BLT.08.053645; StataCorp, 2011, BEVOLKING; Tumwine Y, 2010, TROPICAL J PHARM RES, V9; Uganda Ministry of Health, 2011, UG ESS MED LIST; van Mourik MSM, 2010, BMC CARDIOVASC DISOR, V10, DOI 10.1186/1471-2261-10-25; WHO, 2013, WHO MOD LISTS ESS ME; World Health Organization and Health Action International, 2003, MED PRIC NEW APPR ME; Yang H, 2010, HEALTH POLICY PLANN, V25, P219, DOI 10.1093/heapol/czp056	29	23	23	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 11	2014	9	12							e114762	10.1371/journal.pone.0114762	http://dx.doi.org/10.1371/journal.pone.0114762			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AX8FY	25500832	Green Published, gold, Green Submitted			2023-01-03	WOS:000347146700051
J	Shahrin, L; Leung, DT; Matin, N; Pervez, MM; Azim, T; Bardhan, PK; Heffelfinger, JD; Chisti, MJ				Shahrin, Lubaba; Leung, Daniel T.; Matin, Nashaba; Pervez, Mohammed Moshtaq; Azim, Tasnim; Bardhan, Pradip Kumar; Heffelfinger, James D.; Chisti, Mohammod Jobayer			Characteristics and Predictors of Death among Hospitalized HIV-Infected Patients in a Low HIV Prevalence Country: Bangladesh	PLOS ONE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; RISK BEHAVIOR; MORTALITY; AIDS; MIGRATION; ADULTS; HEALTH; HAART; MEN	Background: Predictors of death in hospitalized HIV-infected patients have not been previously reported in Bangladesh. Objective: The primary aim of this study was to determine predictors of death among hospitalized HIV-infected patients at a large urban hospital in Bangladesh. Methods: A study was conducted in the HIV in-patient unit (Jagori Ward) of icddr,b's Dhaka Hospital. Characteristics of patients who died during hospitalization were compared to those of patients discharged from the ward. Bivariate analysis was performed to determine associations between potential risk factors and death. Multivariable logistic regression was used to identify factors independently associated with death. Results: Of 293 patients admitted to the Jagori Ward, 57 died during hospitalization. Most hospitalized patients (67%) were male and the median age was 35 (interquartile range: 2-65) years. Overall, 153 (52%) patients were diagnosed with HIV within 6 months of hospitalization. The most common presumptive opportunistic infections (OIs) identified were tuberculosis (32%), oesophageal candidiasis (9%), Pneumocystis jirovecii pneumonia (PJP) (8%), and histoplasmosis (7%). On multivariable analysis, independent predictors of mortality were CD4 count <= 200 cells/mm(3) (adjusted odds ratio [aOR]: 16.6, 95% confidence interval [CI]: 3.7-74.4), PJP (aOR: 18.5, 95% CI: 4.68-73.3), oesophageal candidiasis (aOR: 27.5, 95% CI: 5.5-136.9), malignancy (aOR: 15.2, 95% CI: 2.3-99.4), and bacteriuria (aOR: 7.9, 95% CI: 1.2-50.5). Being on antiretroviral therapy prior to hospitalization (aOR: 0.2, 95% CI: 0.06-0.5) was associated with decreased mortality. Conclusion: This study showed that most patients who died during hospitalization on the Jagori Ward had HIV-related illnesses which could have been averted with earlier diagnosis of HIV and proper management of OIs. It is prudent to develop a national HIV screening programme to facilitate early identification of HIV.	[Shahrin, Lubaba; Pervez, Mohammed Moshtaq; Bardhan, Pradip Kumar; Chisti, Mohammod Jobayer] Dhaka Hosp, Int Ctr Diarrheal Dis Res, Dhaka, Bangladesh; [Shahrin, Lubaba; Pervez, Mohammed Moshtaq; Chisti, Mohammod Jobayer] Int Ctr Diarrheal Dis Res, CNFS, Dhaka, Bangladesh; [Shahrin, Lubaba; Leung, Daniel T.; Pervez, Mohammed Moshtaq; Azim, Tasnim] Int Ctr Diarrheal Dis Res, Ctr HIV AIDS CHIV, Dhaka, Bangladesh; [Leung, Daniel T.] Int Ctr Diarrheal Dis Res, CVS, Dhaka, Bangladesh; [Matin, Nashaba] Royal London Hosp, Barts Hlth NHS Trust, London E1 1BB, England; [Heffelfinger, James D.] Ctr Dis Control & Prevent CDC, Global Dis Detect Branch, Div Global Hlth Promot, Ctr Global Hlth, Atlanta, GA USA	International Centre for Diarrhoeal Disease Research (ICDDR); International Centre for Diarrhoeal Disease Research (ICDDR); International Centre for Diarrhoeal Disease Research (ICDDR); International Centre for Diarrhoeal Disease Research (ICDDR); Barts Health NHS Trust; Royal London Hospital; Centers for Disease Control & Prevention - USA	Shahrin, L (corresponding author), Dhaka Hosp, Int Ctr Diarrheal Dis Res, Dhaka, Bangladesh.	lubabashahrin@icddrb.org	Chisti, Mohammod J/A-7216-2018; Shahrin, Lubaba/AAF-1019-2020	Shahrin, Lubaba/0000-0002-5676-3280; Leung, Daniel/0000-0001-8401-0801	icddr,b; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI100923] Funding Source: NIH RePORTER	icddr,b; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This research protocol was funded by the icddr,b and its donors who provide unrestricted support to this organization for its infrastructure (such as Dhaka Hospital) and research. Current donors providing unrestricted support include the following: Australian Agency for International Development (AusAID), Government of the People's Republic of Bangladesh, Canadian International Development Agency, Embassy of the Kingdom of Netherlands, Swedish International Development Cooperation Agency, Swiss Agency for Development and Cooperation and Department for International Development, UK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agaba PA, 2011, J INFECT DEV COUNTR, V5, P377, DOI 10.3855/jidc.1096; [Anonymous], 2013, UNAIDS REP GLOB AIDS; Azim T, 2008, INT J STD AIDS, V19, P327, DOI 10.1258/ijsa.2007.007269; Azim T, 2009, 20 YEARS HIV BANGLAD, V2009, P1; Azim T, 2008, J HEALTH POPUL NUTR, V26, P311; Bunnell R, 2008, AIDS, V22, P617, DOI 10.1097/QAD.0b013e3282f56b53; Charles BHEL, 2003, REV HUMAN IMMUNODEFI, P652; Crum NF, 2006, JAIDS-J ACQ IMM DEF, V41, P194, DOI 10.1097/01.qai.0000179459.31562.16; Dhaka Tribune, 2013, WORLD AIDS DAY OBS 3; Fei MW, 2009, THORAX, V64, P1070, DOI 10.1136/thx.2009.117846; HOEPELMAN AIM, 1992, AIDS, V6, P179, DOI 10.1097/00002030-199202000-00006; International Organization for Migration (IOM), 2013, SIT AN MIGR HIV BANG, P1; Jerene D, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-136; Joint United Nations Programme on HIV/AIDS (UNAIDS), 2013, HIV AS PAC UNAIDS RE; Kaplan Jonathan E., 2009, Morbidity and Mortality Weekly Report, V58, P1; Krentz HB, 2006, HIV MED, V7, P457, DOI 10.1111/j.1468-1293.2006.00408.x; Kumarasamy N, 2003, CLIN INFECT DIS, V36, P79, DOI 10.1086/344756; Mamtaz A, 1999, J Prev Soc Med, V18, P74; Matin N, 2011, J HEALTH POPUL NUTR, V29, P14; Mercer A, 2007, SEX TRANSM DIS, V34, P265, DOI 10.1097/01.olq.0000240384.61924.65; Morris A, 2004, EMERG INFECT DIS, V10, P1713, DOI 10.3201/eid1010.030985; Pervez MM, 2013, HLTH SCI B, V11, P15; Pinho Ana Maria Felix De, 1994, Genitourinary Medicine, V70, P30; Sackoff JE, 2006, ANN INTERN MED, V145, P397, DOI 10.7326/0003-4819-145-6-200609190-00003; Sani MU, 2006, J NATL MED ASSOC, V98, P862; Schneider M, 2005, NATURAL HIST MORTALI; UNAIDS, 2021, PREV HIV INF TIM NEW; Weine SM, 2012, AIDS BEHAV, V16, P1605, DOI 10.1007/s10461-012-0183-4; World Bank, 2016, HLTH RISKS PART MATT, P1; World Health Organization, 2013, POCK BOOK HOSP CAR C	30	16	16	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 8	2014	9	12							e113095	10.1371/journal.pone.0113095	http://dx.doi.org/10.1371/journal.pone.0113095			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX4MX	25485634	Green Published, Green Submitted, gold			2023-01-03	WOS:000346907600014
J	Lee, WL; Tan, JWM; Tan, CN; Loo, SCJ				Lee, Wei Li; Tan, Jun Wei Melvin; Tan, Chaoyang Nicholas; Loo, Say Chye Joachim			Modulating Drug Release from Gastric-Floating Microcapsules through Spray-Coating Layers	PLOS ONE			English	Article							RIBOFLAVIN-CONTAINING MICROBALLOONS; IN-VIVO EVALUATION; SUSTAINED-RELEASE; DELIVERY-SYSTEMS; VITRO; MICROSPHERES; PHARMACOKINETICS; BIOAVAILABILITY; MICROPARTICLES; FENOFIBRATE	Floating dosage forms with prolonged gastric residence time have garnered much interest in the field of oral delivery. However, studies had shown that slow and incomplete release of hydrophobic drugs during gastric residence period would reduce drug absorption and cause drug wastage. Herein, a spray-coated floating microcapsule system was developed to encapsulate fenofibrate and piroxicam, as model hydrophobic drugs, into the coating layers with the aim of enhancing and tuning drug release rates. Incorporating fenofibrate into rubbery poly(caprolactone) (PCL) coating layer resulted in a complete and sustained release for up to 8 h, with outermost non-drug-holding PCL coating layer serving as a rate-controlling membrane. To realize a multidrug-loaded system, both hydrophilic metformin HCl and hydrophobic fenofibrate were simultaneously incorporated into these spray-coated microcapsules, with metformin HCl and fenofibrate localized within the hollow cavity of the capsule and coating layer, respectively. Both drugs were observed to be completely released from these coated microcapsules in a sustained manner. Through specific tailoring of coating polymers and their configurations, piroxicam loaded in both the outer polyethylene glycol and inner PCL coating layers was released in a double-profile manner (i.e. an immediate burst release as the loading dose, followed by a sustained release as the maintenance dose). The fabricated microcapsules exhibited excellent buoyancy in simulated gastric fluid, and provided controlled and sustained release, thus revealing its potential as a rate-controlled oral drug delivery system.	[Lee, Wei Li; Tan, Jun Wei Melvin; Tan, Chaoyang Nicholas; Loo, Say Chye Joachim] Nanyang Technol Univ, Sch Mat Sci & Engn, Singapore 639798, Singapore	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Loo, SCJ (corresponding author), Nanyang Technol Univ, Sch Mat Sci & Engn, 50 Nanyang Ave, Singapore 639798, Singapore.	joachimloo@ntu.edu.sg	Loo, Say Chye Joachim/A-2234-2011; Lee, Wei Li/F-9095-2010	Loo, Say Chye Joachim/0000-0001-5300-1275; Lee, Wei Li/0000-0002-9720-3407	Singapore Centre on Environmental Life Sciences Engineering (SCELSE) [M4330001.C70.703012]; School of Materials Science and Engineering [M020070110]; Solar Fuels Laboratory Nanyang Technological University [M060070008]; NTU-National Healthcare Group (NTU-NHG) [ARG/14012]	Singapore Centre on Environmental Life Sciences Engineering (SCELSE); School of Materials Science and Engineering; Solar Fuels Laboratory Nanyang Technological University(Nanyang Technological University); NTU-National Healthcare Group (NTU-NHG)	The authors would also like to acknowledge the financial support from the Singapore Centre on Environmental Life Sciences Engineering (SCELSE) (M4330001.C70.703012), the School of Materials Science and Engineering (M020070110), Solar Fuels Laboratory Nanyang Technological University (M060070008), and the NTU-National Healthcare Group (NTU-NHG) grant (ARG/14012). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali J, 2007, EUR J PHARM BIOPHARM, V67, P196, DOI 10.1016/j.ejpb.2006.12.015; Arifin DY, 2006, ADV DRUG DELIVER REV, V58, P1274, DOI 10.1016/j.addr.2006.09.007; Danki L., 2010, INT J PHARM BIO SCI, V1, P1; Dashevsky A, 2004, EUR J PHARM BIOPHARM, V58, P45, DOI 10.1016/j.ejpb.2004.03.013; DAVIES NM, 1995, DIS COLON RECTUM, V38, P1311, DOI 10.1007/BF02049158; ERNI W, 1987, European Neurology, V27, P21, DOI 10.1159/000116171; Frank A, 2005, J CONTROL RELEASE, V102, P333, DOI 10.1016/j.jconrel.2004.10.019; Girotto C, 2009, SOL ENERG MAT SOL C, V93, P454, DOI 10.1016/j.solmat.2008.11.052; Girotto C, 2009, ORG ELECTRON, V10, P735, DOI 10.1016/j.orgel.2009.03.006; He W, 2011, INT J NANOMED, V6, P521, DOI 10.2147/IJN.S17282; Hwang SJ, 1998, CRIT REV THER DRUG, V15, P243; Joseph NJ, 2002, J CONTROL RELEASE, V79, P71, DOI 10.1016/S0168-3659(01)00507-7; Krishnamachari Y, 2007, INT J PHARM, V338, P238, DOI 10.1016/j.ijpharm.2007.02.015; Kumar A., 2011, PHARM GLOBALE IJCP, V3, P1, DOI DOI 10.7763/IJET.2011.V3.191; Lao LL, 2008, EUR J PHARM BIOPHARM, V70, P796, DOI 10.1016/j.ejpb.2008.05.024; Lee WL, 2013, J MATER CHEM B, V1, P1090, DOI 10.1039/c2tb00495j; Lee WL, 2012, J BIOMED MATER RES A, V100A, P3353, DOI 10.1002/jbm.a.34292; Lee WL, 2012, J PHARM SCI-US, V101, P2787, DOI 10.1002/jps.23191; Lee WL, 2011, J CONTROL RELEASE, V151, P229, DOI 10.1016/j.jconrel.2011.02.012; Liu YF, 2011, INT J PHARMACEUT, V413, P103, DOI 10.1016/j.ijpharm.2011.04.030; Ma NN, 2008, INT J PHARMACEUT, V358, P82, DOI 10.1016/j.ijpharm.2008.02.024; Meka L, 2008, AAPS PHARMSCITECH, V9, P612, DOI 10.1208/s12249-008-9090-4; Naha PC, 2008, J MICROENCAPSUL, V25, P248, DOI [10.1080/02652040801903843, 10.1080/02652040801903843 ]; Nayak A, 2011, MOL PHARMACEUT, V8, P2273, DOI 10.1021/mp2001395; Sastry, 2000, Pharm Sci Technol Today, V3, P138; Sato Y, 2004, J CONTROL RELEASE, V98, P75, DOI 10.1016/j.jconrel.2004.04.021; Sato Y, 2004, INT J PHARM, V275, P97, DOI 10.1016/j.ijpharm.2004.01.036; Sato Y, 2004, EUR J PHARM BIOPHARM, V57, P235, DOI 10.1016/s0939-6411(03)00185-1; Siepmann J, 2001, ADV DRUG DELIVER REV, V48, P139, DOI 10.1016/S0169-409X(01)00112-0; Singh A., 2008, WO Pat., Patent No. [WO/2008/062,440, 2008062440, WO/2008/062440]; Singh BN, 2000, J CONTROL RELEASE, V63, P235, DOI 10.1016/S0168-3659(99)00204-7; Streubel Alexander, 2006, Expert Opin Drug Deliv, V3, P217, DOI 10.1517/17425247.3.2.217; Tang YD, 2007, INT J PHARMACEUT, V336, P159, DOI 10.1016/j.ijpharm.2006.11.060; Van Speybroeck M, 2010, EUR J PHARM SCI, V41, P623, DOI 10.1016/j.ejps.2010.09.002; VERBEECK RK, 1986, J RHEUMATOL, V13, P789; Zhu T, 2010, J CLIN PHARMACOL, V50, P914, DOI 10.1177/0091270009354995	36	14	14	2	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 3	2014	9	12							e114284	10.1371/journal.pone.0114284	http://dx.doi.org/10.1371/journal.pone.0114284			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA7WS	25470374	Green Published, gold			2023-01-03	WOS:000349128700096
J	Brody, H				Brody, Herb			Haemophilia	NATURE			English	Editorial Material																			0	2	2	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 27	2014	515	7528					S157	S157		10.1038/515S157a	http://dx.doi.org/10.1038/515S157a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AW4JP	25427203	Bronze			2023-01-03	WOS:000346247600005
J	Obermeyer, Z; Makar, M; Abujaber, S; Dominici, F; Block, S; Cutler, DM				Obermeyer, Ziad; Makar, Maggie; Abujaber, Samer; Dominici, Francesca; Block, Susan; Cutler, David M.			Association Between the Medicare Hospice Benefit and Health Care Utilization and Costs for Patients With Poor-Prognosis Cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OF-LIFE CARE; NEAR-DEATH; END; CHEMOTHERAPY; BENEFICIARIES; INTENSITY; CLAIMS; BREAST; PLACE	IMPORTANCE More patients with cancer use hospice currently than ever before, but there are indications that care intensity outside of hospice is increasing, and length of hospice stay decreasing. Uncertainties regarding how hospice affects health care utilization and costs have hampered efforts to promote it. OBJECTIVE To compare utilization and costs of health care for patients with poor-prognosis cancers enrolled in hospice vs similar patients without hospice care. DESIGN, SETTING, AND PARTICIPANTS Matched cohort study of patients in hospice and nonhospice care using a nationally representative 20% sample of Medicare fee-for-service beneficiaries who died in 2011. Patients with poor-prognosis cancers (eg, brain, pancreatic, metastatic malignancies) enrolled in hospice before death were matched to similar patients who died without hospice care. EXPOSURES Period between hospice enrollment and death for hospice beneficiaries, and the equivalent period of nonhospice care before death for matched nonhospice patients. MAIN OUTCOMES AND MEASURES Health care utilization including hospitalizations and procedures, place of death, cost trajectories before and after hospice start, and cumulative costs, all during the last year of life. RESULTS Among 86 851 patients with poor-prognosis cancers, median time from first poor-prognosis diagnosis to death was 13 months (interquartile range [IQR], 3-34), and 51 924 (60%) entered hospice before death. Matching yielded a cohort balanced on age, sex, region, time from poor-prognosis diagnosis to death, and baseline care utilization, with 18 165 patients in the hospice group and 18 165 in the nonhospice group. [GRAPHICS] After matching, 11% of nonhospice and 1% of hospice beneficiaries who had cancer-directed therapy after exposure were excluded. Median hospice duration was 11 days. Nonhospice beneficiaries had significantly greater health care utilization, largely for acute conditions not directly related to cancer and higher overall costs. CONCLUSIONS AND RELEVANCE In this sample of Medicare fee-for-service beneficiaries with poor-prognosis cancer, those receiving hospice care vs not (control), had significantly lower rates of hospitalization, intensive care unit admission, and invasive procedures at the end of life, along with significantly lower total costs during the last year of life.	[Obermeyer, Ziad] Harvard Univ, Sch Med, Dept Emergency Med, Boston, MA USA; [Obermeyer, Ziad] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; [Obermeyer, Ziad; Makar, Maggie; Abujaber, Samer] Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA; [Obermeyer, Ziad; Block, Susan] Brigham & Womens Hosp, Ariadne Labs, Boston, MA 02115 USA; [Obermeyer, Ziad; Block, Susan] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; [Dominici, Francesca] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Block, Susan] Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Boston, MA 02115 USA; [Block, Susan] Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA; [Block, Susan] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Cutler, David M.] Harvard Univ, Dept Econ, Cambridge, MA 02138 USA; [Cutler, David M.] Natl Bur Econ Res, Cambridge, MA 02138 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; National Bureau of Economic Research	Obermeyer, Z (corresponding author), Brigham & Womens Hosp, Dept Emergency Med, Neville House,75 Francis St, Boston, MA 02115 USA.	zobermeyer@partners.org		Cutler, David/0000-0002-4949-8917; /0000-0002-1224-4657	National Institutes of Health [DP5 OD012161]; National Cancer Institute [P01 CA134294]; Agency for Healthcare Research and Quality [K18 HS021991]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K18HS021991] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA134294] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP5OD012161] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by National Institutes of Health grant DP5 OD012161 (Dr Obermeyer), National Cancer Institute grant P01 CA134294 (Dr Dominici), and Agency for Healthcare Research and Quality grant K18 HS021991 (Dr Dominici).	Barnato AE, 2004, HEALTH SERV RES, V39, P363, DOI 10.1111/j.1475-6773.2004.00232.x; Bogasky S, 2014, MED MED RES REV, V4, P1; Casarett DJ, 2011, JAMA-J AM MED ASSOC, V305, P1031, DOI 10.1001/jama.2011.271; Du XLL, 2006, MED CARE, V44, P124, DOI 10.1097/01.mlr.0000196978.34283.a6; Gagne JJ, 2011, J CLIN EPIDEMIOL, V64, P749, DOI 10.1016/j.jclinepi.2010.10.004; Glare P, 2008, PROGNOSIS ADV CANC; Harrington SE, 2008, JAMA-J AM MED ASSOC, V299, P2667, DOI 10.1001/jama.299.22.2667; Huskamp HA, 2001, HEALTH AFFAIR, V20, P204, DOI 10.1377/hlthaff.20.3.204; Iacus SM, 2011, J AM STAT ASSOC, V106, P345, DOI 10.1198/jasa.2011.tm09599; Institute of Medicine of the National Academies, 2013, GEOGR VAR HLTH CAR S; Kellehear, 2014, INNER LIFE DYING PER; Kelley AS, 2013, HEALTH AFFAIR, V32, P552, DOI 10.1377/hlthaff.2012.0851; Klabunde CN, 2007, ANN EPIDEMIOL, V17, P584, DOI 10.1016/j.annepidem.2007.03.011; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Meier DE, 2011, MILBANK Q, V89, P343, DOI 10.1111/j.1468-0009.2011.00632.x; National Hospice and Palliative Care Organization, 2012, NHPCO FACTS FIG HOSP; Research Data Assistance Center, CMMI PAYM BUNDL IN; Steinhauser KE, 2000, ANN INTERN MED, V132, P825, DOI 10.7326/0003-4819-132-10-200005160-00011; Taylor DH, 2007, SOC SCI MED, V65, P1466, DOI 10.1016/j.socscimed.2007.05.028; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; Teno JM, 2013, JAMA-J AM MED ASSOC, V309, P470, DOI 10.1001/jama.2012.207624; Tinetti ME, 2012, JAMA-J AM MED ASSOC, V307, P915, DOI 10.1001/jama.2012.229; Warren JL, 2002, MED CARE, V40, P55; Wennberg JE, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f549; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665	25	81	81	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 12	2014	312	18					1888	1896		10.1001/jama.2014.14950	http://dx.doi.org/10.1001/jama.2014.14950			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AS8ZE	25387186	Green Submitted, Green Accepted			2023-01-03	WOS:000344532600018
J	Li, CL; Zhao, K; Li, H; Farah, OI; Wang, JJ; Sun, RZ; Zhang, HP				Li, Cui-ling; Zhao, Kai; Li, Hui; Farah, Omar Ibrahim; Wang, Jiao-jiao; Sun, Rong-ze; Zhang, Hui-ping			Free Preconceptual Screening Examination Service in Rural Areas of Hubei Province, China in 2012	PLOS ONE			English	Article							HEALTH-CARE; UNITED-STATES; WOMEN; RECOMMENDATIONS; PREGNANCY; SURVEILLANCE; SUPPLEMENT; PREDICTORS; TRENDS	Objective: This work aims to collect and summarize the outcomes on free preconceptual screening examination in rural areas of Hubei Province in 2012. Moreover, this review promotes further understanding of the status of this activity to provide the Family Planning Commission valid scientific data upon which to construct effective policies. Methods: Couples, who complied with the family planning policy and were the residents in agricultural areas or lived in a local rural area for more than six months, were encouraged to participate in the free preconceptual screening examination service provided by the Hubei Provincial Population and Family Planning Commission. This service included 19 screening tests. All the data, including forms, manuals, and test results, were collected from 1 January 2012 to 31 December 2012 in rural areas in Hubei Province. Results: A total of 497,860 individuals participated in the free preconceptual screening examination service, with a coverage rate of 97.1%. 4.0% and 4.8% of the participants exhibited with abnormal blood levels of ALT and creatinine, respectively; 0.36% of the participants tested positive for syphilis; 0.44% and 3.6% of the female participants tested positive for Neisseria gonorrhoeae and Chlamydia trachomatis, respectively; and 0.84% and 1.8% of the female participants tested positive for cytomegalovirus (IgM) and Toxoplasma gondii (IgM), respectively. After risk assessment, 59,935 participants might have high-risk of adverse pregnancy outcomes. In 2012, the prevalence of birth defects among the parturient who participated in the preconceptual screening examination service was 0.04%, while the prevalence was 0.08% among those who did not participate in the service. Conclusion: Preconceptual screening examination service may help to address the risk factors that can lead to adverse pregnancy outcome. More studies on the relationship between preconceptual screening examination service and prevalence of birth defect or other adverse pregnancy outcomes should be conducted.	[Li, Cui-ling; Zhao, Kai; Farah, Omar Ibrahim; Wang, Jiao-jiao; Zhang, Hui-ping] Huazhong Univ Sci & Technol, Tongji Med Coll, Family Planning Res Inst, Wuhan, Hunan, Peoples R China; [Li, Hui] Hubei Prov Populat & Family Planning Commiss, Dept Sci, Wuhan, Hunan, Peoples R China; [Li, Hui] Hubei Prov Populat & Family Planning Commiss, Technol Serv, Wuhan, Hunan, Peoples R China; [Sun, Rong-ze] Wuhan Univ, Renmin Hosp, Wuhan, Hunan, Peoples R China	Huazhong University of Science & Technology; Wuhan University	Zhang, HP (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Family Planning Res Inst, Wuhan, Hunan, Peoples R China.	familyplanning2013@163.com	Zhang, Hui/HHN-8494-2022		Foundation of Hubei Provincial Population and Family Planning Commission [JS-2011011]	Foundation of Hubei Provincial Population and Family Planning Commission	The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This study was supported by the Foundation of Hubei Provincial Population and Family Planning Commission (grant no. JS-2011011).	Allaire AD, 1998, EUR J OBSTET GYN R B, V78, P163, DOI 10.1016/S0301-2115(98)00062-1; Boulet SL, 2006, MATERN CHILD HLTH J, V10, pS13, DOI 10.1007/s10995-006-0106-y; Campbell SK, 2012, MATERN CHILD HLTH J, V16, P1284, DOI 10.1007/s10995-011-0889-3; Centre BSR, 2009, PRECONCEPTION HLTH P; Chen Z, 2011, REPORT WOMEN CHILDRE; de Jong-van den Berg LTW, 2005, AM J OBSTET GYNECOL, V192, P121, DOI 10.1016/j.ajog.2004.05.085; de Weerd S, 2002, OBSTET GYNECOL, V99, P45, DOI 10.1016/S0029-7844(01)01573-3; Dunlop AL, 2007, J AM BOARD FAM MED, V20, P81, DOI 10.3122/jabfm.2007.01.060143; Dunlop AL, 2013, AM J HEALTH PROMOT, V27, pS50, DOI 10.4278/ajhp.120116-QUAN-39; Ebrahim SH, 2006, MATERN CHILD HLTH J, V10, pS37, DOI 10.1007/s10995-006-0096-9; Frey KA, 2006, MATERN CHILD HLTH J, V10, pS73, DOI 10.1007/s10995-006-0110-2; Heyes T, 2004, FAM PRACT, V21, P22, DOI 10.1093/fampra/cmh106; Jack BW, 2008, AM J OBSTET GYNECOL, V199, pS266, DOI 10.1016/j.ajog.2008.07.067; Johnson Kay, 2006, Morbidity and Mortality Weekly Report, V55, P1; Li CL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072649; Liu Y, 2006, J PERINATOL, V26, P409, DOI 10.1038/sj.jp.7211537; Livingood WC, 2010, MATERN CHILD HLTH J, V14, P382, DOI 10.1007/s10995-009-0471-4; LOBO I, 2008, NATURE ED, V1; Moos MK, 2008, AM J OBSTET GYNECOL, V199, pS280, DOI 10.1016/j.ajog.2008.08.060; Morin P, 2002, PREV MED, V35, P143, DOI 10.1006/pmed.2002.1041; Tu L, 2012, IRAN J PUBLIC HEALTH, V41, P20; Weisman CS, 2011, WOMEN HEALTH ISS, V21, P265, DOI 10.1016/j.whi.2011.03.007; Witters I, 2010, GENET COUNSEL, V21, P169; Xaverius PK, 2013, J WOMENS HEALTH, V22, P203, DOI 10.1089/jwh.2012.3804	24	2	3	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2014	9	11							e111918	10.1371/journal.pone.0111918	http://dx.doi.org/10.1371/journal.pone.0111918			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AS6XM	25375642	Green Published, Green Submitted, gold			2023-01-03	WOS:000344402600075
J	von Minckwitz, G; Loibl, S				von Minckwitz, Gunter; Loibl, Sibylle			Evolution of adjuvant chemotherapy for breast cancer	LANCET			English	Editorial Material							RANDOMIZED-TRIAL; DOSE-DENSE; EPIRUBICIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; DOCETAXEL; WOMEN		[von Minckwitz, Gunter; Loibl, Sibylle] GBG Forsch GmbH, German Breast Grp, D-63263 Neu Isenburg, Germany	German Breast Group	von Minckwitz, G (corresponding author), GBG Forsch GmbH, German Breast Grp, D-63263 Neu Isenburg, Germany.	gunter.vonminckwitz@germanbreastgroup.de						Albain K, 2012, LANCET, V379, P432, DOI 10.1016/S0140-6736(11)61625-5; Bonilla L, 2010, JNCI-J NATL CANCER I, V102, P1845, DOI 10.1093/jnci/djq409; Budd GT, 2015, J CLIN ONCOL, V33, P58, DOI 10.1200/JCO.2014.56.3296; Citron ML, 2003, J CLIN ONCOL, V21, P1431, DOI 10.1200/JCO.2003.09.081; Del Mastro L, 2015, LANCET; Levine MN, 2005, J CLIN ONCOL, V23, P5166, DOI 10.1200/JCO.2005.09.423; Martin M, 2005, NEW ENGL J MED, V352, P2302, DOI 10.1056/NEJMoa043681; NORTON L, 1986, CANCER TREAT REP, V70, P163; Poole CJ, 2006, NEW ENGL J MED, V355, P1851, DOI 10.1056/NEJMoa052084; Roche H, 2006, J CLIN ONCOL, V24, P5664, DOI 10.1200/JCO.2006.07.3916; Sparano JA, 2008, NEW ENGL J MED, V358, P1663, DOI 10.1056/NEJMoa0707056; von Minckwitz G, 2008, ANN ONCOL, V19, P292, DOI 10.1093/annonc/mdm438	12	3	3	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 9	2015	385	9980					1812	1814		10.1016/S0140-6736(14)62348-5	http://dx.doi.org/10.1016/S0140-6736(14)62348-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CH6ZE	25740287				2023-01-03	WOS:000354184500008
J	Zhou, ZL; Su, YF; Campbell, B; Zhou, ZY; Gao, JM; Yu, Q; Chen, JH; Pan, YS				Zhou, Zhongliang; Su, Yanfang; Campbell, Benjamin; Zhou, Zhiying; Gao, Jianmin; Yu, Qiang; Chen, Jiuhao; Pan, Yishan			The Financial Impact of the 'Zero-Markup Policy for Essential Drugs' on Patients in County Hospitals in Western Rural China	PLOS ONE			English	Article							ESSENTIAL MEDICINES; HEALTH-CARE	Objective With a quasi-experimental design, this study aims to assess whether the Zero-markup Policy for Essential Drugs (ZPED) reduces the medical expense for patients at county hospitals, the major healthcare provider in rural China. Methods Data from Ningshan county hospital and Zhenping county hospital, China, include 2014 outpatient records and 9239 inpatient records. Quantitative methods are employed to evaluate ZPED. Both hospital-data difference-in-differences and individual-data regressions are applied to analyze the data from inpatient and outpatient departments. Results In absolute terms, the total expense per visit reduced by 19.02 CNY (3.12 USD) for outpatient services and 399.6 CNY (65.60 USD) for inpatient services. In relative terms, the expense per visit was reduced by 11% for both outpatient and inpatient services. Due to the reduction of inpatient expense, the estimated reduction of outpatient visits is 2% among the general population and 3.39% among users of outpatient services. The drug expense per visit dropped by 27.20 CNY (4.47 USD) for outpatient services and 278.7 CNY (45.75 USD) for inpatient services. The proportion of drug expense out of total expense per visit dropped by 11.73 percentage points in outpatient visits and by 3.92 percentage points in inpatient visits. Conclusion Implementation of ZPED is a benefit for patients in both absolute and relative terms. The absolute monetary reduction of the per-visit inpatient expense is 20 times of that in outpatient care. According to cross-price elasticity, the substitution between inpatient and outpatient due to the change in inpatient price is small. Furthermore, given that the relative reductions are the same for outpatient and inpatient visits, according to relative thinking theory, the incentive to utilize outpatient or inpatient care attributed to ZPED is equivalent, regardless of the 20-times price difference in absolute terms.	[Zhou, Zhongliang; Gao, Jianmin] Xi An Jiao Tong Univ, Sch Publ Policy & Adm, Xian 710049, Peoples R China; [Su, Yanfang] Harvard Univ, Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA; [Campbell, Benjamin] Bryn Mawr Coll, Bryn Mawr, PA USA; [Zhou, Zhiying] Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Publ Hlth, Xian 710049, Peoples R China; [Yu, Qiang] Ankang Municipal Dev & Reform Commiss, Ankang, Peoples R China; [Chen, Jiuhao] Ningshan Cty Hosp, Ankang, Shaanxi, Peoples R China; [Pan, Yishan] Zhenping Cty Hosp, Ankang, Shaanxi, Peoples R China	Xi'an Jiaotong University; Harvard University; Harvard T.H. Chan School of Public Health; Bryn Mawr College; Xi'an Jiaotong University	Su, YF (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Global Hlth & Populat, 665 Huntington Ave, Boston, MA 02115 USA.	yanfangsu@mail.harvard.edu	Pan, Yi/AAJ-2341-2021	Su, Yanfang/0000-0001-7557-8518	National Natural Science Fund of China [71203177]; Shaanxi Social Science Fund [12Q036]; China Medical Board (CMB)	National Natural Science Fund of China(National Natural Science Foundation of China (NSFC)); Shaanxi Social Science Fund; China Medical Board (CMB)	This study was funded by National Natural Science Fund of China (Serial number: 71203177), Shaanxi Social Science Fund (Serial number: 12Q036) and China Medical Board (CMB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Angrist JD, 2009, MOSTLY HARMLESS ECONOMETRICS: AN EMPIRICISTS COMPANION, P1; Azar O.H., 2007, J SOCIO-ECON, V36, P1, DOI [10.1016/j.socec.2005.12.014, DOI 10.1016/J.SOCEC.2005.12.014]; Center for Health Statistics and Information National Health and Family Planning Commission, 2009, AN REP NAT HLTH SERV; Chen M, 2013, CHINESE HLTH RESOURC, V16, P93; Chen YBB, 2013, CHINESE J HLTH POLIC, V6, P34; Craig SR, 2009, SOC SCI MED, V69, P1681, DOI 10.1016/j.socscimed.2009.08.024; Eggleston K, 2012, MILKEN I REV; Geest Sjaak van der, 1996, ANNU REV ANTHROPOL, V25, P153; Gulliford Martin, 2002, J Health Serv Res Policy, V7, P186, DOI 10.1258/135581902760082517; He P, 2011, CHINESE J HLTH POLIC, V4, P11; Hogerzeil HV, 2004, BRIT MED J, V329, P1169, DOI 10.1136/bmj.329.7475.1169; Hu J, 2007, CHIN J PREVCONTRCHRO, V15, P189; Lagarde M, 2008, B WORLD HEALTH ORGAN, V86, P839, DOI 10.2471/BLT.07.049197; Lee J.W., 2000, FRAMEWORK R D EVALUA; Li L, 2008, CHINESE HLTH EC, V27, P41; Ministry of Health, 2011, STAT B CHIN HLTH SER; Nichter M., 2008, GLOBAL HLTH WHY CULT; Petryna A., 2006, GLOBAL PHARM ETHICS; Potter W, 2009, HLTH CARE IND VS HLT; Ratanawijitrasin S, 2001, SOC SCI MED, V53, P831, DOI 10.1016/S0277-9536(00)00390-7; Shen R, 2013, CHINESE HOSP, V17, P62; [石亚丽 Shi Yali], 2013, [中国药房, China Pharmacy], V24, P300; Song Y, 2012, CHINESE HLTH SERVICE, V8, P586; Song Yan, 2014, J Pharm Policy Pract, V7, P12, DOI 10.1186/2052-3211-7-12; Sun Q, 2012, CHINESE HLTH EC, V31, P65, DOI [10.1016/j.clnu.2011.08.009, DOI 10.1016/J.CLNU.2011.08.009]; Sussmuth-Dyckerhoff C., 2010, HLTH INT, V10, P55; Wagstaff A, 2003, HEALTH ECON, V12, P921, DOI 10.1002/hec.776; Wang H, 2012, CHINESE J HLTH POLIC, V5, P30; Wang J, 2013, CHINA PHARM, V23, P2982, DOI DOI 10.6039/J.ISSN.1001-0408.2012.32.03; WHO, 1988, DEV IMPL NAT DRUG PO; Whyte Susan., 2003, SOCIAL LIVES MED; Wooldridge J., 2005, INTRO ECONOMETRICS M, V3; Yang LP, 2013, HEALTH POLICY PLANN, V28, P750, DOI 10.1093/heapol/czs116; Yip W, 2009, SOC SCI MED, V68, P201, DOI 10.1016/j.socscimed.2008.09.066; [周忠良 Zhou Zhongliang], 2013, [中国卫生政策研究, Chinese Journal of Health Policy], V6, P25; Zhou ZL, 2013, INT J EQUITY HEALTH, V12, DOI 10.1186/1475-9276-12-34; Zhou ZL, 2011, HEALTH POLICY, V103, P255, DOI 10.1016/j.healthpol.2011.09.005; Zhou ZL, 2015, J ASIAN PUBLIC POLIC	38	25	28	0	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2015	10	3							e0121630	10.1371/journal.pone.0121630	http://dx.doi.org/10.1371/journal.pone.0121630			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CD9NQ	25790443	Green Published, Green Submitted, gold			2023-01-03	WOS:000351425400199
J	Ebert, DD; Zarski, AC; Christensen, H; Stikkelbroek, Y; Cuijpers, P; Berking, M; Riper, H				Ebert, David Daniel; Zarski, Anna-Carlotta; Christensen, Helen; Stikkelbroek, Yvonne; Cuijpers, Pim; Berking, Matthias; Riper, Heleen			Internet and Computer-Based Cognitive Behavioral Therapy for Anxiety and Depression in Youth: A Meta-Analysis of Randomized Controlled Outcome Trials	PLOS ONE			English	Article							TEENS-CD-ROM; MENTAL-HEALTH; ADOLESCENT DEPRESSION; YOUNG-PEOPLE; SERVICE USE; DISORDERS; CHILDREN; PSYCHOTHERAPY; COMORBIDITY; CHILDHOOD	Background Anxiety and depression in children and adolescents are undertreated. Computer-and Internet-based cognitive behavioral treatments (cCBT) may be an attractive treatment alternative to regular face-to-face treatment. This meta-analysis aims to evaluate whether cCBT is effective for treating symptoms of anxiety and depression in youth. Methods and Findings We conducted systematic searches in bibliographical databases (Pubmed, Cochrane controlled trial register, PsychInfo) up to December 4, 2013. Only randomized controlled trials in which a computer-, Internet-or mobile-based cognitive behavioral intervention targeting either depression, anxiety or both in children or adolescents up to the age of 25 were compared to a control condition were selected. We employed a random-effects pooling model in overall effect analyses and a mixed effect model for sub-group analyses. Searches resulted in identifying 13 randomized trials, including 796 children and adolescents that met inclusion criteria. Seven studies were directed at treating anxiety, four studies at depression, and two were of a transdiagnostic nature, targeting both anxiety and depression. The overall mean effect size (Hedges' g) of cCBT on symptoms of anxiety or depression at post-test was g=0.72 (95% CI: 0.55-0.90, numbers needed to be treated (NNT)=2.56). Heterogeneity was low (I-2=20.14%, 95% CI: 0-58%). The superiority of cCBT over controls was evident for interventions targeting anxiety (g=0.68; 95% CI: 0.45-0.92; p < .001; NNT=2.70) and for interventions targeting depression (g=0.76; 95% CI: 0.41-0.12; p < .001; NNT=2.44) as well as for transdiagnostic interventions (g=0.94; 95% CI: 0.23-2.66; p < .001; NNT=2.60). Conclusions Results provide evidence for the efficacy of cCBT in the treatment of anxiety and depressive symptoms in youth. Hence, such interventions may be a promising treatment alternative when evidence based face-to-face treatment is not feasible. Future studies should examine long-term effects of treatments and should focus on obtaining patient-level data from existing studies, to perform an individual patient data meta-analysis.	[Ebert, David Daniel; Zarski, Anna-Carlotta; Cuijpers, Pim; Berking, Matthias; Riper, Heleen] Leuphana Univ, Innovat Incubator, Div Hlth Trainings Online, Luneburg, Germany; [Ebert, David Daniel; Berking, Matthias] Univ Erlangen Nurnberg, Dept Psychol Clin Psychol & Psychotherapy, D-91054 Erlangen, Germany; [Christensen, Helen] Black Dog Inst, Sydney, NSW, Australia; [Stikkelbroek, Yvonne] Univ Utrecht, Ctr Child & Adolescent Studies, NL-3508 TC Utrecht, Netherlands; [Cuijpers, Pim; Riper, Heleen] Vrije Univ Amsterdam Med Ctr, Reg Mental Hlth Serv Ctr, GGZ inGeest, Amsterdam, Netherlands; [Ebert, David Daniel; Cuijpers, Pim; Riper, Heleen] Vrije Univ Amsterdam, Dept Clin Psychol, Amsterdam, Netherlands; [Ebert, David Daniel; Cuijpers, Pim; Riper, Heleen] Vrije Univ Amsterdam, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands	Leuphana University Luneburg; University of Erlangen Nuremberg; Black Dog Institute; Utrecht University; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	Ebert, DD (corresponding author), Leuphana Univ, Innovat Incubator, Div Hlth Trainings Online, Luneburg, Germany.	ebert@inkubator.leuphana.de	Stikkelbroek, Yvonne/ABG-8003-2021; Christensen, Helen/F-5053-2012; Cuijpers, Pim/G-1703-2013	Christensen, Helen/0000-0003-0435-2065; Ebert, David Daniel/0000-0001-6820-0146; Cuijpers, Pim/0000-0001-5497-2743	European Union [EFRE: ZW6-80119999, CCI 2007DE161PR001]	European Union(European Commission)	This study is funded by the European Union (EFRE: ZW6-80119999, CCI 2007DE161PR001). The funders played no role in study design, collection, analysis, interpretation of data, writing of the report, or in the decision to submit the paper for publication.	Andersson G., WORLD PSYCH IN PRESS; Andrews G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013196; Angold A, 1998, AM J PUBLIC HEALTH, V88, P75, DOI 10.2105/AJPH.88.1.75; ANGOLD A, 1993, AM J PSYCHIAT, V150, P1779; Axelson DA, 2001, DEPRESS ANXIETY, V14, P67, DOI 10.1002/da.1048; Barrett PM, 1996, J CONSULT CLIN PSYCH, V64, P333, DOI 10.1037/0022-006X.64.2.333; Bodden DHM, 2008, J ABNORM CHILD PSYCH, V36, P487, DOI 10.1007/s10802-007-9194-4; Borenstein M, 2009, INTRO META ANAL, DOI [10.1007/978-3-319-14908-0_2, DOI 10.1002/9780470743386]; BRADY EU, 1992, PSYCHOL BULL, V111, P244, DOI 10.1037/0033-2909.111.2.244; Buntrock C, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/1471-244X-14-25; BURNS BJ, 1995, HEALTH AFFAIR, V14, P147, DOI 10.1377/hlthaff.14.3.147; Calear AL, 2010, MED J AUSTRALIA, V192, pS12; Calear AL, 2009, J CONSULT CLIN PSYCH, V77, P1021, DOI 10.1037/a0017391; Compton SN, 2004, J AM ACAD CHILD PSY, V43, P930, DOI 10.1097/01.chi.0000127589.57468.bf; Costello EJ, 2003, ARCH GEN PSYCHIAT, V60, P837, DOI 10.1001/archpsyc.60.8.837; Cunningham MJ, 2009, EUR CHILD ADOLES PSY, V18, P125, DOI 10.1007/s00787-008-0703-y; Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Ehrenreich JT, 2009, CHILD FAM BEHAV THER, V31, P20, DOI 10.1080/07317100802701228; Essau CA, 2005, DEPRESS ANXIETY, V22, P130, DOI 10.1002/da.20115; Fleming T, 2012, BEHAV COGN PSYCHOTH, V40, P529, DOI 10.1017/S1352465811000695; Ford T, 1999, AIRCR ENG AEROSP TEC, V71, P42, DOI 10.1108/00022669910252169; Gulliver A, 2010, BMC PSYCHIATRY, V10, DOI 10.1186/1471-244X-10-113; Haug T, 2012, CLIN PSYCHOL REV, V32, P425, DOI 10.1016/j.cpr.2012.04.002; Hedman E, 2012, EXPERT REV PHARM OUT, V12, P745, DOI [10.1586/ERP.12.67, 10.1586/erp.12.67]; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hofstra MB, 2002, J AM ACAD CHILD PSY, V41, P182, DOI 10.1097/00004583-200202000-00012; Ioannidis JPA, 2007, BRIT MED J, V335, P914, DOI 10.1136/bmj.39343.408449.80; James AC, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD004690.pub3, 10.1002/14651858.CD004690.pub4]; Kataoka SH, 2002, AM J PSYCHIAT, V159, P1548, DOI 10.1176/appi.ajp.159.9.1548; Kazdin AE, 2002, RES DESIGN CLIN PSYC, P1000; Keller M. A., 2009, THESIS; Khanna MS, 2010, J CONSULT CLIN PSYCH, V78, P737, DOI 10.1037/a0019739; Klein JB, 2007, J AM ACAD CHILD PSY, V46, P1403, DOI 10.1097/chi.0b013e3180592aaa; Kontopantelis E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069930; Kraemer HC, 2006, BIOL PSYCHIAT, V59, P990, DOI 10.1016/j.biopsych.2005.09.014; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; Lin J, 2013, REHABILITATION, V52, P155, DOI 10.1055/s-0033-1343491; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Makarushka MM, 2011, THESIS U OREGON OREG; March S, 2009, J PEDIATR PSYCHOL, V34, P474, DOI 10.1093/jpepsy/jsn099; Merikangas KR, 2010, J AM ACAD CHILD PSY, V49, P980, DOI 10.1016/j.jaac.2010.05.017; Michael KD, 2002, CLIN PSYCHOL REV, V22, P247, DOI 10.1016/S0272-7358(01)00089-7; Orsini N., 2013, HETEROGI STATA MODUL; ORVASCHEL H, 1995, J AM ACAD CHILD PSY, V34, P1525, DOI 10.1097/00004583-199511000-00020; Parker G, 2003, J AFFECT DISORDERS, V74, P131, DOI 10.1016/S0165-0327(02)00002-2; RAO U, 1995, J AM ACAD CHILD PSY, V34, P566, DOI 10.1097/00004583-199505000-00009; Reynolds S, 2012, CLIN PSYCHOL REV, V32, P251, DOI 10.1016/j.cpr.2012.01.005; Rozental A., 2014, INTERNET INTERVENTIO, V1, P12, DOI [10.1016/j.invent.2014.02.001, DOI 10.1016/J.INVENT.2014.02.001]; Sawyer MG, 2001, AUST NZ J PSYCHIAT, V35, P806, DOI 10.1046/j.1440-1614.2001.00964.x; Sethi S, 2010, J TECHNOL HUMAN SERV, V28, P144, DOI 10.1080/15228835.2010.508317; Spence SH, 2011, J CONSULT CLIN PSYCH, V79, P629, DOI 10.1037/a0024512; Stallard P, 2011, BEHAV COGN PSYCHOTH, V39, P273, DOI 10.1017/S135246581000086X; Stasiak K, 2012, BEHAV COGN PSYCHOTH, V20, P1; Storch EA, 2011, PSYCHIAT RES, V189, P407, DOI 10.1016/j.psychres.2011.05.047; Tillfors M, 2008, DEPRESS ANXIETY, V25, P708, DOI 10.1002/da.20416; Tillfors Maria, 2011, Cognitive Behaviour Therapy, V40, P147, DOI 10.1080/16506073.2011.555486; Trosper SE, 2009, CLIN CHILD FAM PSYCH, V12, P234, DOI 10.1007/s10567-009-0043-6; van der Zanden R, 2012, J MED INTERNET RES, V14, P274, DOI 10.2196/jmir.2033; van Zoonen K, 2014, INT J EPIDEMIOL, V43, P318, DOI 10.1093/ije/dyt175; Weisz JR, 2013, JAMA PSYCHIAT, V70, P750, DOI 10.1001/jamapsychiatry.2013.1176; Weisz JR, 2006, PSYCHOL BULL, V132, P132, DOI 10.1037/0033-2909.132.1.132; WEISZ JR, 1995, PSYCHOL BULL, V117, P450, DOI 10.1037/0033-2909.117.3.450; Woodward LJ, 2001, J AM ACAD CHILD PSY, V40, P1086, DOI 10.1097/00004583-200109000-00018; Wuthrich VM, 2012, J AM ACAD CHILD PSY, V51, P261, DOI 10.1016/j.jaac.2011.12.002; Zachrisson HD, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-34	66	262	266	3	114	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 18	2015	10	3							e0119895	10.1371/journal.pone.0119895	http://dx.doi.org/10.1371/journal.pone.0119895			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CE9BN	25786025	gold, Green Published, Green Submitted			2023-01-03	WOS:000352138500142
J	Wisniewski, T; Goni, F				Wisniewski, Thomas; Goni, Fernando			Immunotherapeutic Approaches for Alzheimer's Disease	NEURON			English	Review							AMYLOID-BETA-PEPTIDE; ANTI-TAU ANTIBODIES; REDUCES A-BETA; MOUSE MODEL; PASSIVE-IMMUNIZATION; INTRAVENOUS IMMUNOGLOBULIN; NEUROFIBRILLARY TANGLES; HYPERPHOSPHORYLATED-TAU; MONOCLONAL-ANTIBODIES; SYNAPTIC PLASTICITY	Alzheimer's disease (AD) is the most prevalent form of dementia worldwide and is an emerging global epidemic. It is characterized by an imbalance between production and clearance of amyloid beta (A beta) and tau proteins. Oligomeric forms of A beta and tau are believed to be the most toxic. Dramatic results from AD animal models showed great promise for active and passive immune therapies targeting A beta. However, there is very limited evidence in human studies of the clinical benefits from these approaches. Immunotherapies targeting only tau pathology have had some success but are limited so far to mouse models. The majority of current methods is based on immunological targeting of a self-protein; hence, benefits need to be balanced against risks of stimulating excessive autoimmune toxic inflammation. For greater efficacy the next generation of vaccines needs to focus more on concurrently targeting all the intermediate toxic conformers of oligomeric A beta and tau species.	[Wisniewski, Thomas; Goni, Fernando] NYU, Dept Neurol, Sch Med, Ctr Cognit Neurol,Alexandria ERSP, New York, NY 10016 USA; [Wisniewski, Thomas] NYU, Dept Pathol, Sch Med, Alexandria ERSP, New York, NY 10016 USA; [Wisniewski, Thomas] NYU, Dept Psychiat, Sch Med, Alexandria ERSP, New York, NY 10016 USA	New York University; New York University; New York University	Wisniewski, T (corresponding author), NYU, Dept Neurol, Sch Med, Ctr Cognit Neurol,Alexandria ERSP, 450 East 29th St, New York, NY 10016 USA.	thomas.wisniewski@nyumc.org	Wisniewski, Thomas/Q-6525-2019	Wisniewski, Thomas/0000-0002-3379-8966	NIH [NS073502, AG20245, AG08051]; Alzheimer's Disease Association [IIRG-13-283707]; Seix Dow Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS073502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020245, P30AG008051] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Alzheimer's Disease Association(Alzheimer's Association); Seix Dow Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by NIH grants NS073502, AG20245, and AG08051. It also was supported by the Alzheimer's Disease Association (IIRG-13-283707) and the Seix Dow Foundation.	Adolfsson O, 2012, J NEUROSCI, V32, P9677, DOI 10.1523/JNEUROSCI.4742-11.2012; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; Ashe KH, 2013, PRION, V7, P55, DOI 10.4161/pri.23061; Asuni AA, 2007, J NEUROSCI, V27, P9115, DOI 10.1523/JNEUROSCI.2361-07.2007; Asuni AA, 2006, EUR J NEUROSCI, V24, P2530, DOI 10.1111/j.1460-9568.2006.05149.x; BANCHER C, 1993, NEUROSCI LETT, V162, P179, DOI 10.1016/0304-3940(93)90590-H; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bard F, 2003, P NATL ACAD SCI USA, V100, P2023, DOI 10.1073/pnas.0436286100; Barry AE, 2011, J NEUROSCI, V31, P7259, DOI 10.1523/JNEUROSCI.6500-10.2011; Bayer AJ, 2005, NEUROLOGY, V64, P94, DOI 10.1212/01.WNL.0000148604.77591.67; Bertram L, 2012, PROG MOL BIOL TRANSL, V107, P79, DOI 10.1016/B978-0-12-385883-2.00008-4; Beydoun MA, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-643; Blurton-Jones Mathew, 2006, Current Alzheimer Research, V3, P437, DOI 10.2174/156720506779025242; Boche D, 2008, BRAIN PATHOL, V18, P267, DOI 10.1111/j.1750-3639.2008.00134.x; Bohrmann B, 2012, J ALZHEIMERS DIS, V28, P49, DOI 10.3233/JAD-2011-110977; Bombois S, 2007, ARCH NEUROL-CHICAGO, V64, P583, DOI 10.1001/archneur.64.4.583; Boutajangout Allal, 2013, Int J Cell Biol, V2013, P576383, DOI 10.1155/2013/576383; Boutajangout A, 2014, GERONTOLOGY, V60, P381, DOI 10.1159/000358875; Boutajangout A, 2011, J NEUROCHEM, V118, P658, DOI 10.1111/j.1471-4159.2011.07337.x; Braak H, 2011, ACTA NEUROPATHOL, V121, P171, DOI 10.1007/s00401-010-0789-4; Chai XY, 2011, J BIOL CHEM, V286, P34457, DOI 10.1074/jbc.M111.229633; Chung E, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-130; Clavaguera F, 2009, NAT CELL BIOL, V11, P909, DOI 10.1038/ncb1901; Colby DW, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a006833; Congdon EE, 2013, J BIOL CHEM, V288, P35452, DOI 10.1074/jbc.M113.491001; Crary JF, 2014, ACTA NEUROPATHOL, V128, P755, DOI 10.1007/s00401-014-1349-0; d'Abramo C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062402; D'Andrea MR, 2001, HISTOPATHOLOGY, V38, P120, DOI 10.1046/j.1365-2559.2001.01082.x; DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398; DeMattos RB, 2012, NEURON, V76, P908, DOI 10.1016/j.neuron.2012.10.029; Di Marco LY, 2014, J ALZHEIMERS DIS, V42, P119, DOI 10.3233/JAD-132225; Dodel R, 2013, LANCET NEUROL, V12, P233, DOI 10.1016/S1474-4422(13)70014-0; Doody RS, 2014, NEW ENGL J MED, V370, P311, DOI 10.1056/NEJMoa1312889; Duyckaerts C, 2011, ACTA NEUROPATHOL, V121, P145, DOI 10.1007/s00401-010-0794-7; Eidenmuller J, 2001, BIOCHEM J, V357, P759, DOI 10.1042/0264-6021:3570759; Elobeid A, 2012, ACTA NEUROPATHOL, V123, P97, DOI 10.1007/s00401-011-0906-z; Farlow M, 2012, ALZHEIMERS DEMENT, V8, P261, DOI 10.1016/j.jalz.2011.09.224; Farlow MR, 2013, NEUROL CLIN, V31, P869, DOI 10.1016/j.ncl.2013.03.012; Fath T, 2002, J NEUROSCI, V22, P9733; Ferrer I, 2004, BRAIN PATHOL, V14, P11, DOI 10.1111/j.1750-3639.2004.tb00493.x; Fiala M, 2005, J ALZHEIMERS DIS, V7, P221, DOI 10.3233/jad-2005-7304; Fillit H, 2009, NEUROLOGY, V73, P180, DOI 10.1212/WNL.0b013e3181ae7aaf; FRACKOWIAK J, 1992, ACTA NEUROPATHOL, V84, P225; Gilman S, 2005, NEUROLOGY, V64, P1553, DOI 10.1212/01.WNL.0000159740.16984.3C; Giuffrida ML, 2009, J NEUROSCI, V29, P10582, DOI 10.1523/JNEUROSCI.1736-09.2009; Goni F, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-150; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; Guerreiro R, 2014, NEUROTHERAPEUTICS, V11, P732, DOI 10.1007/s13311-014-0295-9; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hardy J, 2006, NEURON, V52, P3, DOI 10.1016/j.neuron.2006.09.016; Hartley D, 2014, ALZHEIMERS DEMENT; Hickman DT, 2011, J BIOL CHEM, V286, P13966, DOI 10.1074/jbc.M110.186338; Hickman SE, 2014, BIOCHEM PHARMACOL, V88, P495, DOI 10.1016/j.bcp.2013.11.021; Hock C, 2003, NEURON, V38, P547, DOI 10.1016/S0896-6273(03)00294-0; Holtzman DM, 2012, COLD SPRING HARB PER, V2, DOI DOI 10.1101/CSHPERSPECT.A011585; Huang YD, 2012, CELL, V148, P1204, DOI 10.1016/j.cell.2012.02.040; Jack CR, 2013, LANCET NEUROL, V12, P207, DOI 10.1016/S1474-4422(12)70291-0; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Jin JJ, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-23; Jonsson T, 2012, NATURE, V488, P96, DOI 10.1038/nature11283; Jucker M, 2011, ANN NEUROL, V70, P532, DOI 10.1002/ana.22615; Kanekiyo T, 2014, NEURON, V81, P740, DOI 10.1016/j.neuron.2014.01.045; Karch CM, 2014, NEURON, V83, P11, DOI 10.1016/j.neuron.2014.05.041; Kayed R, 2009, CURR OPIN IMMUNOL, V21, P359, DOI 10.1016/j.coi.2009.05.001; Kim DH, 2014, GENE, V545, P185, DOI 10.1016/j.gene.2014.05.031; Lai AY, 2012, FUTUR NEUROL, V7, P165, DOI 10.2217/FNL.12.6; Lambert MP, 2007, J NEUROCHEM, V100, P23, DOI 10.1111/j.1471-4159.2006.04157.x; Lambert MP, 2009, CNS NEUROL DISORD-DR, V8, P65, DOI 10.2174/187152709787601876; Lampron A, 2013, NEURON, V78, P214, DOI 10.1016/j.neuron.2013.04.005; Lee DC, 2013, NEUROPATH APPL NEURO, V39, P69, DOI 10.1111/nan.12002; Lee EB, 2006, J BIOL CHEM, V281, P4292, DOI 10.1074/jbc.M511018200; Lemere CA, 2001, DNA CELL BIOL, V20, P705, DOI 10.1089/10445490152717569; Lemere CA, 2013, MOL NEURODEGENER, V8, DOI 10.1186/1750-1326-8-36; Majumdar A, 2007, MOL BIOL CELL, V18, P1490, DOI 10.1091/mbc.E06-10-0975; Maloney JA, 2014, J BIOL CHEM, V289, P30990, DOI 10.1074/jbc.M114.589069; Mamikonyan G, 2007, J BIOL CHEM, V282, P22376, DOI 10.1074/jbc.M700088200; Masliah E, 2005, NEURON, V46, P857, DOI 10.1016/j.neuron.2005.05.010; Masliah E, 2005, NEUROLOGY, V64, P129, DOI 10.1212/01.WNL.0000148590.39911.DF; Mckee AC, 2008, BRAIN RES, V1207, P225, DOI 10.1016/j.brainres.2008.01.095; Meyer-Luehmann M, 2006, SCIENCE, V313, P1781, DOI 10.1126/science.1131864; Michaud JP, 2013, P NATL ACAD SCI USA, V110, P1941, DOI 10.1073/pnas.1215165110; Moreth J, 2013, IMMUN AGEING, V10, DOI 10.1186/1742-4933-10-18; Moretto N, 2007, J BIOL CHEM, V282, P11436, DOI 10.1074/jbc.M609690200; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Morgan D, 2011, J INTERN MED, V269, P54, DOI 10.1111/j.1365-2796.2010.02315.x; Muhs A, 2007, P NATL ACAD SCI USA, V104, P9810, DOI 10.1073/pnas.0703137104; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Nelson PT, 2012, J NEUROPATH EXP NEUR, V71, P362, DOI 10.1097/NEN.0b013e31825018f7; Nicoll JAR, 2006, J NEUROPATH EXP NEUR, V65, P1040, DOI 10.1097/01.jnen.0000240466.10758.ce; Nicoll JAR, 2003, NAT MED, V9, P448, DOI 10.1038/nm840; Noble W, 2009, PRION, V3, P78, DOI 10.4161/pri.3.2.8820; Oddo S, 2006, J BIOL CHEM, V281, P1599, DOI 10.1074/jbc.M507892200; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Ozudogru SN, 2012, AM J ALZHEIMERS DIS, V27, P296, DOI 10.1177/1533317512452034; Panza F, 2012, IMMUNOTHERAPY-UK, V4, P213, DOI [10.2217/IMT.11.170, 10.2217/imt.11.170]; Potter Huntington, 2012, Int J Alzheimers Dis, V2012, P489428, DOI 10.1155/2012/489428; Pride M, 2008, NEURODEGENER DIS, V5, P194, DOI 10.1159/000113700; Puzzo D, 2008, J NEUROSCI, V28, P14537, DOI 10.1523/JNEUROSCI.2692-08.2008; Rasool S, 2013, J NEUROCHEM, V126, P473, DOI 10.1111/jnc.12305; Reed-Geaghan EG, 2009, J NEUROSCI, V29, P11982, DOI 10.1523/JNEUROSCI.3158-09.2009; Relkin NR, 2009, NEUROBIOL AGING, V30, P1728, DOI 10.1016/j.neurobiolaging.2007.12.021; Ren PH, 2009, NAT CELL BIOL, V11, P219, DOI 10.1038/ncb1830; Rinne JO, 2010, LANCET NEUROL, V9, P363, DOI 10.1016/S1474-4422(10)70043-0; Rosenmann H, 2006, ARCH NEUROL-CHICAGO, V63, P1459, DOI 10.1001/archneur.63.10.1459; Rostagno A, 2005, CELL MOL LIFE SCI, V62, P1814, DOI 10.1007/s00018-005-5092-5; Rozenstein-Tsalkovich L, 2013, EXP NEUROL, V248, P451, DOI 10.1016/j.expneurol.2013.07.006; Ryan JM, 2009, J ALZHEIMERS DIS, V17, P243, DOI 10.3233/JAD-2009-1118; Sadowski M, 2007, CURR PHARM DESIGN, V13, P1943; SAIDO TC, 1995, NEURON, V14, P457, DOI 10.1016/0896-6273(95)90301-1; Salloway S, 2009, NEUROLOGY, V73, P2061, DOI 10.1212/WNL.0b013e3181c67808; Salloway S, 2014, NEW ENGL J MED, V370, P322, DOI 10.1056/NEJMoa1304839; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Schneeberger A, 2009, J NUTR HEALTH AGING, V13, P264, DOI 10.1007/s12603-009-0070-5; Scholtzova H, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0101-2; Schwartz M, 2013, J NEUROSCI, V33, P17587, DOI 10.1523/JNEUROSCI.3241-13.2013; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Shayan G, 2012, ELECTROPHORESIS, V33, P1975, DOI 10.1002/elps.201100660; Sigurdsson EM, 2004, J NEUROSCI, V24, P6277, DOI 10.1523/JNEUROSCI.1344-04.2004; Sigurdsson EM, 2002, DRUG DEVELOP RES, V56, P135, DOI 10.1002/ddr.10068; Small SA, 2008, NEURON, V60, P534, DOI 10.1016/j.neuron.2008.11.007; Solomon B, 1997, P NATL ACAD SCI USA, V94, P4109, DOI 10.1073/pnas.94.8.4109; Soscia SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009505; Sperling R, 2012, LANCET NEUROL, V11, P241, DOI 10.1016/S1474-4422(12)70015-7; Streit WJ, 2014, CURR OPIN IMMUNOL, V29, P93, DOI 10.1016/j.coi.2014.05.005; Tahara K, 2006, BRAIN, V129, P3006, DOI 10.1093/brain/awl249; Terry RD, 1996, J NEUROPATH EXP NEUR, V55, P1023, DOI 10.1097/00005072-199655100-00001; Vidal R, 1999, NATURE, V399, P776; Vollmer J, 2009, ADV DRUG DELIVER REV, V61, P195, DOI 10.1016/j.addr.2008.12.008; Winblad B, 2012, LANCET NEUROL, V11, P597, DOI 10.1016/S1474-4422(12)70140-0; Wingo TS, 2012, ARCH NEUROL-CHICAGO, V69, P59, DOI 10.1001/archneurol.2011.221; WISNIEWSKI HM, 1994, NEUROPATH APPL NEURO, V20, P192; WISNIEWSKI HM, 1992, ACTA NEUROPATHOL, V84, P117, DOI 10.1007/BF00311383; Wisniewski T, 2005, NAT CLIN PRACT NEURO, V1, P84, DOI 10.1038/ncpneuro0019; Wisniewski T, 2005, BRAIN PATHOL, V15, P72; Wisniewski T, 2009, ALZ DEMENTIA, V5, pP113; Wisniewski T, 2014, BIOCHEM PHARMACOL, V88, P499, DOI 10.1016/j.bcp.2013.12.020; Wisniewski T, 2012, LANCET NEUROL, V11, P571, DOI 10.1016/S1474-4422(12)70136-9; Wisniewski T, 2012, EXPERT REV ANTI-INFE, V10, P307, DOI [10.1586/ERI.11.177, 10.1586/eri.11.177]; Wisniewski T, 2010, BBA-MOL BASIS DIS, V1802, P847, DOI 10.1016/j.bbadis.2010.05.004; Yanamandra K, 2013, NEURON, V80, P402, DOI 10.1016/j.neuron.2013.07.046; Yoshiyama Y, 2013, J NEUROL NEUROSUR PS, V84, P784, DOI 10.1136/jnnp-2012-303144	142	206	219	1	127	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	MAR 18	2015	85	6					1162	1176		10.1016/j.neuron.2014.12.064	http://dx.doi.org/10.1016/j.neuron.2014.12.064			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CD8BA	25789753	Bronze, Green Accepted			2023-01-03	WOS:000351319000006
J	Ong, MEH; Anantharaman, V				Ong, Marcus Eng Hock; Anantharaman, Venkataraman			Out-of-hospital cardiac arrest: manual or mechanical CPR?	LANCET			English	Editorial Material							CHEST COMPRESSION DEVICE; CARDIOPULMONARY-RESUSCITATION; QUALITY		[Ong, Marcus Eng Hock; Anantharaman, Venkataraman] Singapore Gen Hosp, Dept Emergency Med, Singapore 169608, Singapore; [Ong, Marcus Eng Hock] Duke NUS Grad Med Sch, Hlth Serv & Syst Res, Singapore 169857, Singapore	Singapore General Hospital; National University of Singapore	Ong, MEH (corresponding author), Singapore Gen Hosp, Dept Emergency Med, Singapore 169608, Singapore.	marcus.ong.e.h@sgh.com.sg						Casner Michael, 2005, Prehosp Emerg Care, V9, P61, DOI 10.1080/10903120590891714; Hallstrom A, 2006, JAMA-J AM MED ASSOC, V295, P2620, DOI 10.1001/jama.295.22.2620; Ong MEH, 2006, JAMA-J AM MED ASSOC, V295, P2629, DOI 10.1001/jama.295.22.2629; Ong MEH, 2013, PREHOSP EMERG CARE, V17, P491, DOI 10.3109/10903127.2013.818176; Ong MEH, 2013, RESUSCITATION, V84, P508, DOI 10.1016/j.resuscitation.2012.07.033; Ong MEH, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-39; Ong MEH, 2010, ANN EMERG MED, V56, P233, DOI 10.1016/j.annemergmed.2010.01.004; Perkins GD, 2014, LANCET; Rubertsson S, 2014, JAMA-J AM MED ASSOC, V311, P53, DOI 10.1001/jama.2013.282538; Russi CS, 2011, PREHOSP EMERG CARE, V15, P410, DOI 10.3109/10903127.2011.561414; Wang HC, 2007, RESUSCITATION, V74, P453, DOI 10.1016/j.resuscitation.2007.01.018; Wik L, 2014, RESUSCITATION, V85, P741, DOI 10.1016/j.resuscitation.2014.03.005	13	5	6	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 14	2015	385	9972					920	922		10.1016/S0140-6736(14)61941-3	http://dx.doi.org/10.1016/S0140-6736(14)61941-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CD2EK	25467563	hybrid			2023-01-03	WOS:000350886900007
J	Zhang, GX; Xiong, N; Zhang, ZT; Liu, L; Huang, JS; Yang, JL; Wu, J; Lin, ZC; Wang, T				Zhang, Guoxin; Xiong, Nian; Zhang, Zhentao; Liu, Ling; Huang, Jinsha; Yang, Jiaolong; Wu, Jing; Lin, Zhicheng; Wang, Tao			Effectiveness of Traditional Chinese Medicine as an Adjunct Therapy for Parkinson's Disease: A Systematic Review and Meta-Analysis	PLOS ONE			English	Article							TAI-CHI; DAYTIME SLEEPINESS; GAIT INITIATION; PREVALENCE; DIAGNOSIS; DEMENTIA; SHANGHAI; BALANCE; XIAN	Background Idiopathic Parkinson disease (PD) is a common neurodegenerative disease that seriously hinders limb activities and affects patients' lives. We performed a meta-analysis aiming to systematically review and quantitatively synthesize the efficacy and safety of traditional Chinese medicine (TCM) as an adjunct therapy for clinical PD patients. Methods An electronic search was conducted in PubMed, Cochrane Controlled Trials Register, China National Knowledge Infrastructure, Chinese Scientific Journals Database and Wanfang data to identify randomized trials evaluating TCM adjuvant therapy versus conventional treatment. The change from baseline of the Unified Parkinson's Disease Rating Scale score (UPDRS) was used to estimate the effectiveness of the therapies. Results Twenty-seven articles involving 2314 patients from 1999 to 2013 were included. Potentially marked improvements were shown in UPDRS I (SMD 0.68, 95%CI 0.38, 0.98), II (WMD 2.41, 95%CI 1.66, 2.62), III (WMD 2.45, 95%CI 2.03, 2.86), IV (WMD 0.32, 95%CI 0.15, 049) and I-IV total scores (WMD 6.18, 95%CI 5.06, 7.31) in patients with TCM plus dopamine replacement therapy (DRT) compared to DRT alone. Acupuncture add-on therapy was markedly beneficial for improving the UPDRS I-IV total score of PD patients (WMD 10.96, 95%CI 5.85, 16.07). However, TCM monotherapy did not improve the score. The effectiveness seemed to be more obvious in PD patients with longer adjunct durations. TCM adjuvant therapy was generally safe and well tolerated. Conclusions Although the data were limited by methodological flaws in many studies, the evidence indicates the potential superiority of TCM as an alternative therapeutic for PD treatment and justifies further high-quality studies.	[Zhang, Guoxin; Xiong, Nian; Liu, Ling; Huang, Jinsha; Yang, Jiaolong; Wang, Tao] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Neurol, Wuhan 430074, Hubei, Peoples R China; [Zhang, Zhentao] Wuhan Univ, Renmin Hosp, Dept Neurol, Wuhan 430072, Hubei, Peoples R China; [Wu, Jing] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Dept Epidemiol & Biostat, Wuhan 430074, Hubei, Peoples R China; [Wu, Jing] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, MOE Key Lab Environm & Hlth, Wuhan 430074, Hubei, Peoples R China; [Lin, Zhicheng] Harvard Univ, McLean Hosp, Sch Med, Dept Psychiat,Div Alcohol & Drug Abuse, Belmont, MA USA; [Lin, Zhicheng] Mailman Neurosci Res Ctr, Belmont, MA USA; [Lin, Zhicheng] Harvard Neuro Discovery Ctr, Boston, MA USA	Huazhong University of Science & Technology; Wuhan University; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Harvard University; McLean Hospital	Wang, T (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Neurol, Wuhan 430074, Hubei, Peoples R China.	wangtaowh@hust.edu.cn	Northcote, Matthew/B-8209-2019; Northcote, Matthew/L-1135-2019	Zhang, Zhentao/0000-0001-6708-1472	National Natural Science Foundation of China [30870866, 81071021, 31171211, 81301082, 81100958, 81200983]; China Medical Foundation [2012B09]; Hubei Molecular Imaging Key Laboratory [0203201343]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Medical Foundation(China Medical University); Hubei Molecular Imaging Key Laboratory	This work was supported by grants 30870866, 81071021 and 31171211 from the National Natural Science Foundation of China (to TW), grant 81200983 from the National Natural Science Foundation of China (to NX), grant 81100958 from the National Natural Science Foundation of China (to ZTZ), grant 81301082 from the National Natural Science Foundation of China (to JSH), grant 2012B09 from China Medical Foundation (to NX) and grant 0203201343 from Hubei Molecular Imaging Key Laboratory (to NX). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amano S, 2013, PARKINSONISM RELAT D, V19, P955, DOI 10.1016/j.parkreldis.2013.06.007; Cao Xue-Bing, 2006, Neurosci Bull, V22, P159; Chaudhuri KR, 2009, LANCET NEUROL, V8, P464, DOI 10.1016/S1474-4422(09)70068-7; Comella CL, 2002, JAMA-J AM MED ASSOC, V287, P509, DOI 10.1001/jama.287.4.509; Fahn S, 2004, NEW ENGL J MED, V351, P2498; Fan Y. P., 2010, TIANJIN J TRADITIONA, V27, P190; Hackney ME, 2008, GAIT POSTURE, V28, P456, DOI 10.1016/j.gaitpost.2008.02.005; Hass CJ, 2004, ARCH PHYS MED REHAB, V85, P1593, DOI 10.1016/j.apmr.2004.01.020; Hobson DE, 2002, JAMA-J AM MED ASSOC, V287, P455, DOI 10.1001/jama.287.4.455; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; Jiang SY, 2009, J LIAONING U TRADITI, V11, P118; Kim TH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035695; Kum WF, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep116; Lam YC, 2008, J ALTERN COMPLEM MED, V14, P662, DOI 10.1089/acm.2007.0011; Li WT, 2012, SHAANXI J TRADITIONA, V33, P549; Lian XF, 2008, J NEW CHINESE MED, V40, P37; Lian Xin-Fu, 2007, Zhongguo Zhong Xi Yi Jie He Za Zhi, V27, P796; Liang JF, 2008, LIAONING J TRADITION, V35, P82; Lohe M, 2010, J NEUROL SCI, V289, P104, DOI 10.1016/j.jns.2009.08.025; Luo XD, 2005, J LIAONING U TCM, V9, P93; Pahwa R, 2006, NEUROLOGY, V66, P983, DOI 10.1212/01.wnl.0000215250.82576.87; Pan WD, 2011, PARKINSONS DIS-US, V2011, DOI 10.4061/2011/789506; Pohjasvaara T, 2000, STROKE, V31, P2952, DOI 10.1161/01.STR.31.12.2952; Shen W, 2006, SHANGHAI J TRADITION, V40, P21; Shen Y, 2008, J ZHEJIANG U TRADITI, V32, P197; [王文同 Wang Wentong], 2004, [中医杂志, Journal of Traditional Chinese Medicine], V45, P274; Wang Y, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/534861; Wang YX, 2013, CLIN J TRADITIONAL C, V25, P758; Wu G, 2002, J AM GERIATR SOC, V50, P746, DOI 10.1046/j.1532-5415.2002.50173.x; Yang DH., 2006, CHIN J CHIN REHABIL, V10, P14, DOI [10.3321/j.issn:1673-8225.2006.19.004, DOI 10.3321/J.ISSN:1673-8225.2006.19.004]; Yang Ming-hui, 2010, Zhong Xi Yi Jie He Xue Bao, V8, P231, DOI 10.3736/jcim20100306; Yuan CX, 2010, SHANGHAI J TRADITION, V44, P3; Yuan H, 2010, NEUROSCI BULL, V26, P66, DOI 10.1007/s12264-010-0302-z; Zhang H, 2008, ACTA CHINESE MED PHA, V36, P34; Zhang HB, 2004, CHINESE J CLIN REHAB; Zhang Xin, 2013, Chinese Journal of Information on Traditional Chinese Medicine, V20, P16; Zhang Y, 2008, LIAONING J TRADITION, V35, P728; Zhang ZX, 2005, ARCH NEUROL-CHICAGO, V62, P447, DOI 10.1001/archneur.62.3.447; Zhang ZX, 2005, LANCET, V365, P595, DOI 10.1016/S0140-6736(05)70801-1; Zhao G.H, 2013, CHINESE J INTEGRATED, V33, P467, DOI [10.1007/s11655-012-1177-9, DOI 10.1007/S11655-012-1177-9]; Zhao Guo-Hua, 2009, Zhongguo Zhong Xi Yi Jie He Za Zhi, V29, P590; [郑春叶 Zheng Chunye], 2006, [中医杂志, Journal of Traditional Chinese Medicine], V47, P516; Zheng CY, 2011, J NEW CHINESE MED, V43, P40; Zhong C, 2012, CHINESE J EXPT TRADI, V18, P343; Zhu XY, 2009, J NEUROLOGY NEUROREH, V6, P114; 钟平, 2012, [中国老年学杂志, Chinese Journal of Gerontology], V32, P2720	46	38	38	0	53	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 10	2015	10	3							e0118498	10.1371/journal.pone.0118498	http://dx.doi.org/10.1371/journal.pone.0118498			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CD7MX	25756963	gold, Green Published, Green Submitted			2023-01-03	WOS:000351275700021
J	Schmeltz, MT; Sembajwe, G; Marcotullio, PJ; Grassman, JA; Himmelstein, DU; Woolhandler, S				Schmeltz, Michael T.; Sembajwe, Grace; Marcotullio, Peter J.; Grassman, Jean A.; Himmelstein, David U.; Woolhandler, Stephanie			Identifying Individual Risk Factors and Documenting the Pattern of Heat-Related Illness through Analyses of Hospitalization and Patterns of Household Cooling	PLOS ONE			English	Article							EMERGENCY-DEPARTMENTS; AMBIENT-TEMPERATURE; CASE-CROSSOVER; PUBLIC-HEALTH; EXTREME HEAT; US CITIES; MORTALITY; WAVE; VULNERABILITY; MORBIDITY	Background As climate change increases the frequency and intensity of extreme heat events researchers and public health officials must work towards understanding the causes and outcomes of heat-related morbidity and mortality. While there have been many studies on both heat-related illness (HRI), there are fewer on heat-related morbidity than on heat-related mortality. Objective To identify individual and environmental risk factors for hospitalizations and document patterns of household cooling. Methods We performed a pooled cross-sectional analysis of secondary U.S. data, the Nationwide Inpatient Sample. Risk ratios were calculated from multivariable models to identify risk factors for hospitalizations. Hierarchical modeling was also employed to identify relationships between individual and hospital level predictors of hospitalizations. Patterns of air conditioning use were analyzed among the vulnerable populations identified. Results Hospitalizations due to HRI increased over the study period compared to all other hospitalizations. Populations at elevated risk for HRI hospitalization were blacks, males and all age groups above the age of 40. Those living in zip-codes in the lowest income quartile and the uninsured were also at an increased risk. Hospitalizations for HRI in rural and small urban clusters were elevated, compared to urban areas. Conclusions Risk factors for HRI include age greater than 40, male gender and hospitalization in rural areas or small urban clusters. Our analysis also revealed an increasing pattern of HRI hospitalizations over time and decreased association between common comorbidities and heat illnesses which may be indicative of underreporting.	[Schmeltz, Michael T.; Sembajwe, Grace; Grassman, Jean A.; Himmelstein, David U.; Woolhandler, Stephanie] CUNY, Sch Publ Hlth, New York, NY 10021 USA; [Sembajwe, Grace; Marcotullio, Peter J.; Himmelstein, David U.; Woolhandler, Stephanie] CUNY, Hunter Coll, New York, NY USA; [Marcotullio, Peter J.] CUNY, Inst Sustainable Cities, New York, NY 10021 USA; [Grassman, Jean A.] CUNY Brooklyn Coll, Hlth & Nutr Sci, Brooklyn, NY 11210 USA	City University of New York (CUNY) System; City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System; City University of New York (CUNY) System; Brooklyn College (CUNY)	Schmeltz, MT (corresponding author), CUNY, Sch Publ Hlth, New York, NY 10021 USA.	mschmeltz@gc.cuny.edu	; Sembajwe, Grace/H-3288-2017	Schmeltz, Michael/0000-0003-4764-9723; Sembajwe, Grace/0000-0002-7163-4743; Marcotullio, Peter/0000-0001-8133-1204	Division Of Behavioral and Cognitive Sci [1229429] Funding Source: National Science Foundation	Division Of Behavioral and Cognitive Sci(National Science Foundation (NSF)NSF - Directorate for Social, Behavioral & Economic Sciences (SBE))		Abrahamson V, 2009, J PUBLIC HEALTH-UK, V31, P119, DOI 10.1093/pubmed/fdn102; Astrom DO, 2011, MATURITAS, V69, P99, DOI 10.1016/j.maturitas.2011.03.008; Barros V, 2014, CLIMATE CHANGE 2014: IMPACTS, ADAPTATION, AND VULNERABILITY, PT A: GLOBAL AND SECTORAL ASPECTS, pIX; Bassil KL, 2008, CAN J PUBLIC HEALTH, V99, P339, DOI 10.1007/BF03403768; Basu R, 2009, ENVIRON HEALTH-GLOB, V8, DOI 10.1186/1476-069X-8-40; Bell ML, 2008, INT J EPIDEMIOL, V37, P796, DOI 10.1093/ije/dyn094; Bouchama A, 2002, NEW ENGL J MED, V346, P1978, DOI 10.1056/NEJMra011089; Chow WTL, 2012, PROF GEOGR, V64, P286, DOI 10.1080/00330124.2011.600225; Conlon KC, 2011, MATURITAS, V69, P197, DOI 10.1016/j.maturitas.2011.04.004; Curriero FC, 2002, AM J EPIDEMIOL, V155, P80, DOI 10.1093/aje/155.1.80; D'lppoliti D, 2010, ENVIRON HEALTH, V9; Deddens JA, 2008, OCCUP ENVIRON MED, V65, P501, DOI 10.1136/oem.2007.034777; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Fouillet A, 2006, INT ARCH OCC ENV HEA, V80, P16, DOI 10.1007/s00420-006-0089-4; Fowler DR, 2013, MMWR-MORBID MORTAL W, V62, P433; Hansen AL, 2008, INT J EPIDEMIOL, V37, P1359, DOI 10.1093/ije/dyn165; Healthcare Cost and Utilization Project (HCUP), 2013, OVERVIEW OF THE NATI; Hess JJ, 2014, ENVIRON HEALTH PERSP, V122, P1209, DOI 10.1289/ehp.1306796; Houchens R, 2007, HCUP METHODS SERIES; Imhoff ML, 2010, REMOTE SENS ENVIRON, V114, P504, DOI 10.1016/j.rse.2009.10.008; Isaac M, 2009, ENERG POLICY, V37, P507, DOI 10.1016/j.enpol.2008.09.051; Johnson DP, 2014, GEOCARTO INT, V29, P65, DOI 10.1080/10106049.2013.799718; Josseran L, 2009, BMC MED INFORM DECIS, V9, DOI 10.1186/1472-6947-9-14; Kalkstein AJ, 2007, INT J BIOMETEOROL, V52, P43, DOI 10.1007/s00484-006-0073-4; Kenny GP, 2010, CAN MED ASSOC J, V182, P1053, DOI 10.1503/cmaj.081050; Kershaw SE, 2012, ENVIRON MONIT ASSESS, V184, P7329, DOI 10.1007/s10661-011-2502-z; Kestens Y, 2011, INT J HEALTH GEOGR, V10, DOI 10.1186/1476-072X-10-7; Khalaj B, 2010, INT ARCH OCC ENV HEA, V83, P833, DOI 10.1007/s00420-010-0534-2; Kilbourne EM, 2002, AM J PREV MED, V22, P328, DOI 10.1016/S0749-3797(02)00412-9; Knowlton K, 2009, ENVIRON HEALTH PERSP, V117, P61, DOI 10.1289/ehp.11594; Knowlton K, 2007, AM J PUBLIC HEALTH, V97, P2028, DOI 10.2105/AJPH.2006.102947; Kondo M, 2013, ENVIRON HEALTH PREV, V18, P251, DOI 10.1007/s12199-012-0313-7; Kovats R. S., 2003, CLIMATE CHANGE HUMAN, P181; Kovats RS, 2008, ANNU REV PUBL HEALTH, V29, P41, DOI 10.1146/annurev.publhealth.29.020907.090843; Kovats RS, 2004, OCCUP ENVIRON MED, V61, P893, DOI 10.1136/oem.2003.012047; Kravchenko J, 2013, AM J PREV MED, V44, P274, DOI 10.1016/j.amepre.2012.11.015; Li B, 2012, CLIMATIC CHANGE, V110, P959, DOI [10.1007/s10584-011-0120-y, 10.1007/s10584-011-0120-v]; Li TT, 2013, NAT CLIM CHANGE, V3, P717, DOI [10.1038/NCLIMATE1902, 10.1038/nclimate1902]; Lugo-Amador NM, 2004, EMERG MED CLIN N AM, V22, P315, DOI 10.1016/j.emc.2004.01.004; Mastrangelo G, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-200; Medina-Ramon M, 2006, ENVIRON HEALTH PERSP, V114, P1331, DOI 10.1289/ehp.9074; Meehl GA, 2004, SCIENCE, V305, P994, DOI 10.1126/science.1098704; Nunes B, 2011, OCCUP ENVIRON MED, V68, P218, DOI 10.1136/oem.2010.058396; O'Neill MS, 2005, J URBAN HEALTH, V82, P191, DOI 10.1093/jurban/jti043; Ostro B, 2010, AM J EPIDEMIOL, V172, P1053, DOI 10.1093/aje/kwq231; Reid CE, 2012, ENVIRON HEALTH PERSP, V120, P715, DOI 10.1289/ehp.1103766; Reid CE, 2009, ENVIRON HEALTH PERSP, V117, P1730, DOI 10.1289/ehp.0900683; Richard L, 2011, HEALTH EDUC RES, V26, P77, DOI 10.1093/her/cyq072; Schwartz J, 2005, EPIDEMIOLOGY, V16, P67, DOI 10.1097/01.ede.0000147114.25957.71; Semenza JC, 1999, AM J PREV MED, V16, P269, DOI 10.1016/S0749-3797(99)00025-2; Semenza JC, 1996, NEW ENGL J MED, V335, P84, DOI 10.1056/NEJM199607113350203; Stafoggia M, 2006, EPIDEMIOLOGY, V17, P315, DOI 10.1097/01.ede.0000208477.36665.34; Steiner Claudia, 2002, Eff Clin Pract, V5, P143; Stone B, 2010, ENVIRON HEALTH PERSP, V118, P1425, DOI 10.1289/ehp.0901879; Tan JG, 2010, INT J BIOMETEOROL, V54, P75, DOI 10.1007/s00484-009-0256-x; United States Census Bureau, 2013, 2010 CENSUS URBAN AN; United States Energy Information Administration (EIA), 2013, RESIDENTIAL ENERGY C; Vaneckova P, 2008, ENVIRON RES, V108, P361, DOI 10.1016/j.envres.2008.07.015; Vaneckova P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055459; Wheeler K, 2013, MMWR-MORBID MORTAL W, V62, P617; Wilby R., 2003, WEATHER, V58, P251, DOI DOI 10.1256/WEA.183.02; Xu ZW, 2012, ENVIRON RES, V117, P120, DOI 10.1016/j.envres.2012.07.002; Ye XF, 2012, ENVIRON HEALTH PERSP, V120, P19, DOI [10.1289/ehp.1003198, 10.1289/ehp.120-a19]; Yeo Theresa Pluth, 2004, AACN Clin Issues, V15, P280, DOI 10.1097/00044067-200404000-00013; Yun GY, 2011, APPL ENERG, V88, P2191, DOI 10.1016/j.apenergy.2011.01.010; Zhang Y, 2013, SCI TOTAL ENVIRON, V442, P1, DOI 10.1016/j.scitotenv.2012.10.042	66	13	15	2	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 5	2015	10	3							e0118958	10.1371/journal.pone.0118958	http://dx.doi.org/10.1371/journal.pone.0118958			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CC9KG	25742021	Green Published, gold			2023-01-03	WOS:000350688100067
J	Freeman, LM; Bloemenkamp, KW; Franssen, MT; Papatsonis, DN; Hajenius, PJ; Hollmann, MW; Woiski, MD; Porath, M; van den Berg, HJ; van Beek, E; Borchert, OWHM; Schuitemaker, N; Sikkema, JM; Kuipers, AHM; Logtenberg, SLM; van der Salm, PCM; Rengerink, KO; Lopriore, E; van den Akker-Van Marle, ME; le Cessie, S; van Lith, JM; Struys, MM; Mol, BJ; Dahan, A; Middeldorp, JM				Freeman, Liv M.; Bloemenkamp, Kitty W.; Franssen, Maureen T.; Papatsonis, Dimitri N.; Hajenius, Petra J.; Hollmann, Markus W.; Woiski, Mallory D.; Porath, Martina; van den Berg, Hans J.; van Beek, Erik; Borchert, Odette W. H. M.; Schuitemaker, Nico; Sikkema, J. Marko; Kuipers, A. H. M.; Logtenberg, Sabine L. M.; van der Salm, Paulien C. M.; Rengerink, Katrien Oude; Lopriore, Enrico; van den Akker-van Marle, M. Elske; le Cessie, Saskia; van Lith, Jan M.; Struys, Michel M.; Mol, Ben Willem J.; Dahan, Albert; Middeldorp, Johanna M.			Patient controlled analgesia with remifentanil versus epidural analgesia in labour: randomised multicentre equivalence trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INTRAVENOUS REMIFENTANIL; METAANALYSIS; IMPUTATION; FENTANYL	Objective To determine women's satisfaction with pain relief using patient controlled analgesia with remifentanil compared with epidural analgesia during labour. Design Multicentre randomised controlled equivalence trial. Setting 15 hospitals in the Netherlands. Participants Women with an intermediate to high obstetric risk with an intention to deliver vaginally. To exclude a clinically relevant difference in satisfaction with pain relief of more than 10%, we needed to include 1136 women. Because of missing values for satisfaction this number was increased to 1400 before any analysis. We used multiple imputation to correct for missing data. Intervention Before the onset of active labour consenting women were randomised to a pain relief strategy with patient controlled remifentanil or epidural analgesia if they requested pain relief during labour. Main outcome measures Primary outcome was satisfaction with pain relief, measured hourly on a visual analogue scale and expressed as area under the curve (AUC), thus providing a time weighted measure of total satisfaction with pain relief. A higher AUC represents higher satisfaction with pain relief. Secondary outcomes were pain intensity scores, mode of delivery, and maternal and neonatal outcomes. Analysis was done by intention to treat. The study was defined as an equivalence study for the primary outcome. Results 1414 women were randomised, of whom 709 were allocated to patient controlled remifentanil and 705 to epidural analgesia. Baseline characteristics were comparable. Pain relief was ultimately used in 65% (447/687) in the remifentanil group and 52% (347/671) in the epidural analgesia group (relative risk 1.32, 95% confidence interval 1.18 to 1.48). Cross over occurred in 7% (45/687) and 8% (51/671) of women, respectively. Of women primarily treated with remifentanil, 13% (53/402) converted to epidural analgesia, while in women primarily treated with epidural analgesia 1% (3/296) converted to remifentanil. The area under the curve for total satisfaction with pain relief was 30.9 in the remifentanil group versus 33.7 in the epidural analgesia group (mean difference -2.8, 95% confidence interval -6.9 to 1.3). For who actually received pain relief the area under the curve for satisfaction with pain relief after the start of pain relief was 25.6 in the remifentanil group versus 36.1 in the epidural analgesia group (mean difference -10.4, -13.9 to -7.0). The rate of caesarean section was 15% in both groups. Oxygen saturation was significantly lower (SpO(2) <92%) in women who used remifentanil (relative risk 1.5, 1.4 to 1.7). Maternal and neonatal outcomes were comparable between both groups. Conclusion In women in labour, patient controlled analgesia with remifentanil is not equivalent to epidural analgesia with respect to scores on satisfaction with pain relief. Satisfaction with pain relief was significantly higher in women who were allocated to and received epidural analgesia.	[Freeman, Liv M.; Bloemenkamp, Kitty W.; Lopriore, Enrico; van den Akker-van Marle, M. Elske; van Lith, Jan M.; Dahan, Albert; Middeldorp, Johanna M.] Leiden Univ Med Ctr, Leiden, Netherlands; [Franssen, Maureen T.] Univ Groningen, Univ Med Ctr Groningen, Dept Obstet & Gynaecol, NL-9713 AV Groningen, Netherlands; [Papatsonis, Dimitri N.] Amphia Hosp, Breda, Netherlands; [Hajenius, Petra J.; Hollmann, Markus W.; Rengerink, Katrien Oude] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; [Woiski, Mallory D.] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Porath, Martina; van den Berg, Hans J.] Maxima Med Ctr, Veldhoven, Netherlands; [van Beek, Erik; Borchert, Odette W. H. M.] St Antonius Hosp, Nieuwegein, Netherlands; [Schuitemaker, Nico] Diakonessen Hosp, Utrecht, Netherlands; [Sikkema, J. Marko; Kuipers, A. H. M.] Hosp Grp Twente, Almelo, Netherlands; [Logtenberg, Sabine L. M.] Onze Lieve Vrouw Hosp, Amsterdam, Netherlands; [van der Salm, Paulien C. M.] Meander Med Ctr, Amersfoort, Netherlands; [Struys, Michel M.] Univ Groningen, Univ Med Ctr Groningen, Dept Anaesthesiol, NL-9713 AV Groningen, Netherlands; [Mol, Ben Willem J.] Univ Adelaide, Sch Paediat & Reprod Hlth, Robinson Inst, Adelaide, SA 5005, Australia	Leiden University; Leiden University Medical Center (LUMC); University of Groningen; Amphia Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Radboud University Nijmegen; Maxima Medical Center; St. Antonius Hospital Utrecht; Diakonessenhuis; Onze Lieve Vrouwe Gasthuis Hospital; Meander Medisch Centrum; University of Groningen; Robinson Research Institute; University of Adelaide	Freeman, LM (corresponding author), Leiden Univ Med Ctr, Leiden, Netherlands.	l.m.freeman@lumc.nl	Woiski, Mallory D/L-4763-2015; Woiski, Mallory D/AAN-6632-2021; Dahan, Albert/B-8845-2008; le+Cessie, Saskia/HGC-8966-2022; Lopriore, Enrico/ABE-3576-2021	Woiski, Mallory D/0000-0002-7553-5929; Woiski, Mallory D/0000-0002-7553-5929; Dahan, Albert/0000-0003-3161-3945; Lopriore, Enrico/0000-0002-3513-5066; Struys, Michel/0000-0003-0421-536X; le Cessie, Saskia/0000-0003-2154-4923; van den Akker-van Marle, M. Elske/0000-0002-5269-509X	ZonMW (Dutch Organization for Health Care Research and Development) [80-82310-97-11039]	ZonMW (Dutch Organization for Health Care Research and Development)	This study was funded by a grant from ZonMW (Dutch Organization for Health Care Research and Development) project No 80-82310-97-11039.	American Society of Anesthiologists, 2015, ASA PHYS STAT CLASS; Barden J, 2004, COCHRANE DB SYST REV, V2; Blair JM, 2005, ANAESTHESIA, V60, P22, DOI 10.1111/j.1365-2044.2004.03975.x; Cappelleri JC, 2009, PAIN PRACT, V9, P348, DOI 10.1111/j.1533-2500.2009.00293.x; Donders ART, 2006, J CLIN EPIDEMIOL, V59, P1087, DOI 10.1016/j.jclinepi.2006.01.014; Douma MR, 2011, INT J OBSTET ANESTH, V20, P118, DOI 10.1016/j.ijoa.2010.11.009; Douma MR, 2010, BRIT J ANAESTH, V104, P209, DOI 10.1093/bja/aep359; Freeman LM, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-63; Greenland S, 1995, AM J EPIDEMIOL, V142, P1255, DOI 10.1093/oxfordjournals.aje.a117592; Kan RE, 1998, ANESTHESIOLOGY, V88, P1467, DOI 10.1097/00000542-199806000-00008; Kranke P, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-139; Liu ZQ, 2014, ANESTH ANALG, V118, P598, DOI 10.1213/ANE.0000000000000077; Marr R, 2013, ANAESTHESIA, V68, P283, DOI 10.1111/anae.12099; Michelsen LG, 1996, J CLIN ANESTH, V8, P679, DOI 10.1016/S0952-8180(96)00179-1; NVOG (Dutch Society of Obstetrics and Gynaecology), 2008, GUID PIJNST TIJD BEV; On Biostatistics and Clinical Trials, 2014, US AR CURV AUC CLIN; Schnabel A, 2012, EUR J ANAESTH, V29, P177, DOI 10.1097/EJA.0b013e32834fc260; Stocki D, 2014, ANESTH ANALG, V118, P589, DOI 10.1213/ANE.0b013e3182a7cd1b; Toms L, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004602.pub2; Ullman R, 2011, COCHRANE DB SYST REV, V10; van der Heijden GJMG, 2006, J CLIN EPIDEMIOL, V59, P1102, DOI 10.1016/j.jclinepi.2006.01.015; Volmanen P, 2008, ACTA ANAESTH SCAND, V52, P249, DOI 10.1111/j.1399-6576.2007.01509.x	22	65	69	1	21	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 23	2015	350								h846	10.1136/bmj.h846	http://dx.doi.org/10.1136/bmj.h846			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CC3YG	25713015	Green Published, hybrid			2023-01-03	WOS:000350286700014
J	Swain, SM; Baselga, J; Kim, SB; Ro, J; Semiglazov, V; Campone, M; Ciruelos, E; Ferrero, JM; Schneeweiss, A; Heeson, S; Clark, E; Ross, G; Benyunes, MC; Cortes, J				Swain, Sandra M.; Baselga, Jose; Kim, Sung-Bae; Ro, Jungsil; Semiglazov, Vladimir; Campone, Mario; Ciruelos, Eva; Ferrero, Jean-Marc; Schneeweiss, Andreas; Heeson, Sarah; Clark, Emma; Ross, Graham; Benyunes, Mark C.; Cortes, Javier		CLEOPATRA Study Grp	Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHASE-II TRIAL; PLUS DOCETAXEL; DOUBLE-BLIND; RECEPTOR; CLEOPATRA; THERAPY; SURVIVAL; EFFICACY; TOLERABILITY; COMBINATION	BACKGROUND In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel, as compared with placebo, trastuzumab, and docetaxel. Overall survival was significantly improved with pertuzumab in an interim analysis without the median being reached. We report final prespecified overall survival results with a median follow-up of 50 months. METHODS We randomly assigned patients with metastatic breast cancer who had not received previous chemotherapy or anti-HER2 therapy for their metastatic disease to receive the pertuzumab combination or the placebo combination. The secondary end points of overall survival, investigator-assessed progression-free survival, independently assessed duration of response, and safety are reported. Sensitivity analyses were adjusted for patients who crossed over from placebo to pertuzumab after the interim analysis. RESULTS The median overall survival was 56.5 months (95% confidence interval [CI], 49.3 to not reached) in the group receiving the pertuzumab combination, as compared with 40.8 months (95% CI, 35.8 to 48.3) in the group receiving the placebo combination (hazard ratio favoring the pertuzumab group, 0.68; 95% CI, 0.56 to 0.84; P<0.001), a difference of 15.7 months. This analysis was not adjusted for crossover to the pertuzumab group and is therefore conservative. Results of sensitivity analyses after adjustment for crossover were consistent. Median progression-free survival as assessed by investigators improved by 6.3 months in the pertuzumab group (hazard ratio, 0.68; 95% CI, 0.58 to 0.80). Pertuzumab extended the median duration of response by 7.7 months, as independently assessed. Most adverse events occurred during the administration of docetaxel in the two groups, with long-term cardiac safety maintained. CONCLUSIONS In patients with HER2-positive metastatic breast cancer, the addition of pertuzumab to trastuzumab and docetaxel, as compared with the addition of placebo, significantly improved the median overall survival to 56.5 months and extended the results of previous analyses showing the efficacy of this drug combination. (Funded by F. Hoffmann-La Roche and Genentech; CLEOPATRA ClinicalTrials. gov number, NCT00567190.)	[Swain, Sandra M.] MedStar Washington Hosp Ctr, Washington Canc Inst, Washington, DC 20010 USA; [Baselga, Jose] Mem Sloan Kettering Canc Ctr, Mem Hosp, New York, NY 10021 USA; [Kim, Sung-Bae] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea; [Ro, Jungsil] Natl Canc Ctr, Ctr Breast Canc, Goyang, South Korea; [Semiglazov, Vladimir] NN Petrov Res Inst Oncol, St Petersburg, Russia; [Campone, Mario] Ctr Rene Gauducheau, F-44035 Nantes, France; [Ferrero, Jean-Marc] Ctr Antoine Lacassagne, F-06054 Nice, France; [Ciruelos, Eva] 12 Octubre Univ Hosp, Dept Med Oncol, Madrid, Spain; [Cortes, Javier] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain; [Schneeweiss, Andreas] Univ Heidelberg Hosp, Natl Ctr Tumor Dis, Heidelberg, Germany; [Heeson, Sarah; Clark, Emma; Ross, Graham] Roche Prod Ltd, Welwyn Garden City, Herts, England; [Benyunes, Mark C.] Genentech Inc, San Francisco, CA 94080 USA	MedStar Washington Hospital Center; Memorial Sloan Kettering Cancer Center; University of Ulsan; Asan Medical Center; National Cancer Center - Korea (NCC); N.N. Petrov Research Institute of Oncology; UNICANCER; Institut de Cancerologie de l'Ouest (ICO); UNICANCER; Centre Antoine Lacassagne; Hospital Universitario 12 de Octubre; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Roche Holding; Roche Holding; Genentech	Swain, SM (corresponding author), MedStar Washington Hosp Ctr, Washington Canc Inst, 110 Irving St, Washington, DC 20010 USA.	sandra.m.swain@medstar.net	Andrade, Jurandyr M/B-2025-2013; Schneeweiss, Andreas/HHS-4098-2022; Watanabe, Junichiro/AAI-8481-2021; de Azevedo, Sergio Jobim/P-5115-2015; MORALES, SERAFIN/L-7216-2019; Yeo, Winnie/R-4792-2018	Andrade, Jurandyr M/0000-0003-3619-0582; Watanabe, Junichiro/0000-0001-9226-895X; MORALES, SERAFIN/0000-0001-7445-4193; Cortes, Javier/0000-0001-7623-1583; Coudert, Bruno/0000-0001-9445-2216; Pienkowski, Tadeusz/0000-0002-0110-5950; Di Leo, Angelo/0000-0002-3665-9056; Yeo, Winnie/0000-0002-0863-8469; Swain, Sandra/0000-0002-1320-3830; Ciruelos, Eva/0000-0002-2796-1042; Biganzoli, Laura/0000-0001-7989-8658	F. Hoffmann-La Roche; Genentech; CLEOPATRA; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	F. Hoffmann-La Roche(Hoffmann-La Roche); Genentech(Roche HoldingGenentech); CLEOPATRA; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funded by F. Hoffmann-La Roche and Genentech; CLEOPATRA ClinicalTrials.gov number, NCT00567190.	Amiri-Kordestani L, 2014, CLIN CANCER RES, V20, P5359, DOI 10.1158/1078-0432.CCR-14-1268; Andersson M, 2011, J CLIN ONCOL, V29, P264, DOI 10.1200/JCO.2010.30.8213; Baselga J, 2014, ANN ONCOL, V25, P592, DOI 10.1093/annonc/mdt543; Baselga J, 2014, J CLIN ONCOL, V32, P3753, DOI 10.1200/JCO.2013.54.5384; Baselga J, 2012, NEW ENGL J MED, V366, P109, DOI 10.1056/NEJMoa1113216; Baselga J, 2010, J CLIN ONCOL, V28, P1138, DOI 10.1200/JCO.2009.24.2024; Blackwell KL, 2012, J CLIN ONCOL, V30, P2585, DOI 10.1200/JCO.2011.35.6725; Cortes J, 2013, ANN ONCOL, V24, P2630, DOI 10.1093/annonc/mdt274; Cortes J, 2012, J CLIN ONCOL, V30, P1594, DOI 10.1200/JCO.2011.37.4207; Dang C, 2014, J CLIN ONCOL; Gianni L, 2011, 34 ANN SAN ANT BREAS; Gianni L, 2012, LANCET ONCOL, V13, P25, DOI 10.1016/S1470-2045(11)70336-9; Marty M, 2005, J CLIN ONCOL, V23, P4265, DOI 10.1200/JCO.2005.04.173; Murthy RK, 2014, CANCER-AM CANCER SOC, V120, P1932, DOI 10.1002/cncr.28689; Nahta R, 2004, CANCER RES, V64, P2343, DOI 10.1158/0008-5472.CAN-03-3856; Negri E, 2014, ONCOLOGIST, V19, P1209, DOI 10.1634/theoncologist.2014-0227; Ross JS, 2009, ONCOLOGIST, V14, P320, DOI 10.1634/theoncologist.2008-0230; Scheuer W, 2009, CANCER RES, V69, P9330, DOI 10.1158/0008-5472.CAN-08-4597; Schneeweiss A, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3690; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Smith TJ, 2006, J CLIN ONCOL, V24, P3187, DOI 10.1200/JCO.2006.06.4451; Swain SM, 2013, LANCET ONCOL, V14, P461, DOI 10.1016/S1470-2045(13)70130-X; Swain SM, 2013, ONCOLOGIST, V18, P257, DOI 10.1634/theoncologist.2012-0448; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Valero V, 2011, J CLIN ONCOL, V29, P149, DOI 10.1200/JCO.2010.28.6450; von Minckwitz G, 2009, J CLIN ONCOL, V27, P1999, DOI 10.1200/JCO.2008.19.6618	26	1224	1272	7	161	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 19	2015	372	8					724	734		10.1056/NEJMoa1413513	http://dx.doi.org/10.1056/NEJMoa1413513			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CB7PB	25693012	Green Published, Green Accepted			2023-01-03	WOS:000349818700006
J	Merkow, RP; Ju, MH; Chung, JW; Hall, BL; Cohen, ME; Williams, MV; Tsai, TC; Ko, CY; Bilimoria, KY				Merkow, Ryan P.; Ju, Mila H.; Chung, Jeanette W.; Hall, Bruce L.; Cohen, Mark E.; Williams, Mark V.; Tsai, Thomas C.; Ko, Clifford Y.; Bilimoria, Karl Y.			Underlying Reasons Associated With Hospital Readmission Following Surgery in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY IMPROVEMENT PROGRAM; SURGICAL-CARE; MEDICARE BENEFICIARIES; 30-DAY READMISSION; AMERICAN-COLLEGE; PATIENT EXPERIENCE; HEART-FAILURE; RISK-FACTORS; RATES; SITE	IMPORTANCE Financial penalties for readmission have been expanded beyond medical conditions to include surgical procedures. Hospitals are working to reduce readmissions; however, little is known about the reasons for surgical readmission. OBJECTIVE To characterize the reasons, timing, and factors associated with unplanned postoperative readmissions. DESIGN, SETTING, AND PARTICIPANTS Patients undergoing surgery at one of 346 continuously enrolled US hospitals participating in the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) between January 1, 2012, and December 31, 2012, had clinically abstracted information examined. Readmission rates and reasons (ascertained by clinical data abstractors at each hospital) were assessed for all surgical procedures and for 6 representative operations: bariatric procedures, colectomy or proctectomy, hysterectomy, total hip or knee arthroplasty, ventral hernia repair, and lower extremity vascular bypass. MAIN OUTCOMES AND MEASURES Unplanned 30day readmission and reason for readmission. RESULTS The unplanned readmission rate for the 498 875 operations was 5.7%. For the individual procedures, the readmission rate ranged from 3.8% for hysterectomy to 14.9% for lower extremity vascular bypass. The most common reason for unplanned readmission was surgical site infection (SSI) overall (19.5%) and also after colectomy or proctectomy (25.8%), ventral hernia repair (26.5%), hysterectomy (28.8%), arthroplasty (18.8%), and lower extremity vascular bypass (36.4%). Obstruction or ileus was the most common reason for readmission after bariatric surgery (24.5%) and the second most common reason overall (10.3%), after colectomy or proctectomy (18.1%), ventral hernia repair (16.7%), and hysterectomy (13.4%). Only 2.3% of patients were readmitted for the same complication they had experienced during their index hospitalization. Only 3.3% of patients readmitted for SSIs had experienced an SSI during their index hospitalization. There was no time pattern for readmission, and early (<= 7 days postdischarge) and late (> 7 days postdischarge) readmissions were associated with the same 3 most common reasons: SSI, ileus or obstruction, and bleeding. Patient comorbidities, index surgical admission complications, nonhome discharge (hazard ratio [HR], 1.40 [95% CI, 1.351.46]), teaching hospital status (HR, 1.14 [95% CI 1.071.21]), and higher surgical volume (HR, 1.15 [95% CI, 1.071.25]) were associated with a higher risk of hospital readmission. CONCLUSIONS AND RELEVANCE Readmissions after surgery were associated with new postdischarge complications related to the procedure and not exacerbation of prior index hospitalization complications, suggesting that readmissions after surgery are a measure of postdischarge complications. These data should be considered when developing quality indicators and any policies penalizing hospitals for surgical readmission.	[Merkow, Ryan P.; Ju, Mila H.; Hall, Bruce L.; Cohen, Mark E.; Ko, Clifford Y.; Bilimoria, Karl Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA; [Merkow, Ryan P.; Ju, Mila H.; Chung, Jeanette W.; Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Dept Surg, SOQIC, Chicago, IL 60611 USA; [Merkow, Ryan P.; Ju, Mila H.; Chung, Jeanette W.; Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Ctr Healthcare Studies, Chicago, IL 60611 USA; [Merkow, Ryan P.; Ju, Mila H.; Chung, Jeanette W.; Bilimoria, Karl Y.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Northwestern Inst Comparat Effectiveness Res Onco, SOQIC, Chicago, IL 60611 USA; [Merkow, Ryan P.] Univ Chicago, Dept Surg, Div Biol Sci, Chicago, IL 60637 USA; [Hall, Bruce L.] Washington Univ, Sch Med, Dept Surg, Barnes Jewish Hosp, St Louis, MO 63110 USA; [Hall, Bruce L.] Washington Univ, Ctr Hlth Policy, Olin Business Sch, St Louis, MO USA; [Hall, Bruce L.] John Cochran Vet Affairs Med Ctr, Dept Surg, St Louis, MO USA; [Hall, Bruce L.] BJC Healthcare, St Louis, MO USA; [Williams, Mark V.] Univ Kentucky, Dept Internal Med, Ctr Hlth Serv Res, Lexington, KY 40506 USA; [Tsai, Thomas C.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; [Tsai, Thomas C.] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA; [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA; [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA	American College of Surgeons; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; University of Chicago; Barnes-Jewish Hospital; Washington University (WUSTL); Washington University (WUSTL); University of Kentucky; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Bilimoria, KY (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Surg, SOQIC, 633 N St Clair St,20th Floor, Chicago, IL 60611 USA.	k-bilimoria@northwestern.edu	Hall, Bruce/HGV-0612-2022	Williams, Mark V/0000-0001-6107-0457	American College of Surgeons Clinical Scholars in Residence Program; Northwestern Institute for Comparative Effectiveness Research in Oncology (NICER-Onc); National Institutes of Health (NIH) [5T32HL094293]; NIH; Agency for Healthcare Research and Quality; American Cancer Society; National Comprehensive Cancer Network; American College of Surgeons; American Board of Surgery; Accreditation Council for Graduate Medical Education; Health Care Services Corporation; Robert H. Lurie Cancer Center of Northwestern University; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL094293] Funding Source: NIH RePORTER	American College of Surgeons Clinical Scholars in Residence Program; Northwestern Institute for Comparative Effectiveness Research in Oncology (NICER-Onc); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); American Cancer Society(American Cancer Society); National Comprehensive Cancer Network; American College of Surgeons; American Board of Surgery; Accreditation Council for Graduate Medical Education; Health Care Services Corporation; Robert H. Lurie Cancer Center of Northwestern University; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Dr Merkow is supported by the American College of Surgeons Clinical Scholars in Residence Program and the Northwestern Institute for Comparative Effectiveness Research in Oncology (NICER-Onc). Dr Ju is supported by the American College of Surgeons Clinical Scholars in Residence Program and National Institutes of Health (NIH) grant 5T32HL094293. Dr Hall is a consultant to the American College of Surgeons. Dr Bilimoria reported support from the NIH, Agency for Healthcare Research and Quality, American Cancer Society, National Comprehensive Cancer Network, American College of Surgeons, American Board of Surgery, Accreditation Council for Graduate Medical Education, Health Care Services Corporation, and the Robert H. Lurie Cancer Center of Northwestern University.	Alper J., 2014, FACILITATING PATIENT; American College of Surgeons, 2012, NAT SURG QUAL IMPR P; American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP), 2013, ACS NSQIP OP MAN; American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP), ACS NSQIP IT WORKS; American Medical Association, 2013, CPT 2013 CURR PROC T; Berenson RA, 2012, NEW ENGL J MED, V366, P1364, DOI 10.1056/NEJMp1201268; Bilimoria KY, 2013, JAMA-J AM MED ASSOC, V310, P1482, DOI 10.1001/jama.2013.280048; Bilimoria KY, 2009, J CLIN ONCOL, V27, P4177, DOI 10.1200/JCO.2008.21.7018; Brand CA, 2012, INT J QUAL HEALTH C, V24, P483, DOI 10.1093/intqhc/mzs044; Chatterjee P, 2012, ARCH INTERN MED, V172, P1204, DOI 10.1001/archinternmed.2012.3158; Cohen ME, 2013, J AM COLL SURGEONS, V217, P336, DOI 10.1016/j.jamcollsurg.2013.02.027; Cowen ME, 1998, MED CARE, V36, P1108, DOI 10.1097/00005650-199807000-00016; Curran T, 2014, J VASC SURG, V60, P1315, DOI 10.1016/j.jvs.2014.05.050; Detsky AS, 2014, JAMA-J AM MED ASSOC, V311, P2169, DOI 10.1001/jama.2014.3695; Dharmarajan K, 2013, JAMA-J AM MED ASSOC, V309, P355, DOI 10.1001/jama.2012.216476; Duffy SQ, 1996, AHCPR PUBLICATION; Fontanarosa PB, 2013, JAMA-J AM MED ASSOC, V309, P398, DOI 10.1001/jama.2013.42; Fox JP, 2013, ANN THORAC SURG, V96, P96, DOI 10.1016/j.athoracsur.2013.03.091; Friese CR, 2010, SURGERY, V147, P602, DOI 10.1016/j.surg.2009.03.014; Girotti ME, 2014, J AM COLL SURGEONS, V218, P423, DOI 10.1016/j.jamcollsurg.2013.12.004; Hawn MT, 2011, ANN SURG, V254, P494, DOI 10.1097/SLA.0b013e31822c6929; Hernandez AF, 2010, JAMA-J AM MED ASSOC, V303, P1716, DOI 10.1001/jama.2010.533; Hospital Compare, HOSP COMP SURV PAT E; Ingraham AM, 2010, J AM COLL SURGEONS, V211, P705, DOI 10.1016/j.jamcollsurg.2010.09.006; Ingraham Angela M, 2010, Adv Surg, V44, P251; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Joynt KE, 2011, JAMA-J AM MED ASSOC, V305, P675, DOI 10.1001/jama.2011.123; Khuri SF, 1998, ANN SURG, V228, P491, DOI 10.1097/00000658-199810000-00006; Khuri SF, 2008, ANN SURG, V248, P329, DOI 10.1097/SLA.0b013e3181823485; Khuri SF, 2007, J AM COLL SURGEONS, V204, P1089, DOI 10.1016/j.jamcollsurg.2007.03.028; Lehrman WG, 2010, MED CARE RES REV, V67, P38, DOI 10.1177/1077558709341323; McCarthy D, 2013, JAMA-J AM MED ASSOC, V309, P351, DOI 10.1001/jama.2013.1; National Quality Foundation (NQF), 2014, VEN THROMB WARF DISC; National Quality Foundation (NQF), 2014, HEART FAIL DET DISCH; QualityNet, OV READM MEAS PUBL R; Royston P, 2006, STATA J, V6, P83, DOI 10.1177/1536867X0600600105; Sacks GD, 2014, JAMA SURG, V149, P759, DOI 10.1001/jamasurg.2014.18; Schmaltz SP, 2011, J HOSP MED, V6, P454, DOI 10.1002/jhm.905; Sellers MM, 2013, J AM COLL SURGEONS, V216, P420, DOI 10.1016/j.jamcollsurg.2012.11.013; Sharma G, 2010, ARCH INTERN MED, V170, P1664, DOI 10.1001/archinternmed.2010.345; Stulberg JJ, 2010, JAMA-J AM MED ASSOC, V303, P2479, DOI 10.1001/jama.2010.841; Tillman M, 2013, J SURG RES, V184, P150, DOI 10.1016/j.jss.2013.03.048; Tsai TC, 2015, JAMA SURG, V150, P59, DOI 10.1001/jamasurg.2014.2071; Tsai TC, 2014, ANN SURG, V259, P1086, DOI 10.1097/SLA.0000000000000326; Tsai TC, 2013, NEW ENGL J MED, V369, P1134, DOI 10.1056/NEJMsa1303118; Werner RM, 2006, JAMA-J AM MED ASSOC, V296, P2694, DOI 10.1001/jama.296.22.2694; Wick EC, 2011, DIS COLON RECTUM, V54, P1475, DOI 10.1097/DCR.0b013e31822ff8f0; Zhang JQ, 2014, J VASC SURG, V59, P1331, DOI 10.1016/j.jvs.2013.12.032	48	506	507	2	57	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	2015	313	5					483	495		10.1001/jama.2014.18614	http://dx.doi.org/10.1001/jama.2014.18614			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CA7AV	25647204				2023-01-03	WOS:000349070300012
J	Huang, CY; Hung, YT; Chang, CM; Juang, SY; Lee, CC				Huang, Chih-Yuan; Hung, Yeh-Ting; Chang, Chun-Ming; Juang, Shiun-Yang; Lee, Ching-Chih			The Association between Individual Income and Aggressive End-of-Life Treatment in Older Cancer Decedents in Taiwan	PLOS ONE			English	Article							ETHNIC-DIFFERENCES; NEW-ZEALAND; LAST YEAR; CARE; DEATH; QUALITY; TRENDS; IMPACT; PLACE; ONTARIO	Objectives To examine the association of individual income and end of life (EOL) care in older cancer decedents in Taiwan. Design Retrospective cohort study. Setting National Health Insurance Research Database (NHIRD) in Taiwan. Participants 28,978 decedents >65 years were diagnosed with cancer and died during 2009-2011 in Taiwan. Of these decedents, 10941, 16535, and 1502 were categorized by individual income as having low, moderate, and high SES, respectively. Main outcome measures Indicators of aggressiveness of EOL care: chemotherapy use before EOL, more than one emergency department (ER) visit, more than one hospital admission, hospital length of stay >4 days, intensive care unit (ICU) admission, and dying in a hospital. Results Low individual income was associated with more aggressive EOL treatment (estimate -0.30 for moderate income, -0.27 for high income, both p<0.01). The major source of aggressiveness was the tendency for older decedents with low income to die in the acute care hospital. The indicators had an increasing trend from 2009 to 2011, except for hospital stay >14 days. Conclusions Low individual income is associated with more aggressive EOL treatment in older cancer decedents. Public health providers should make available appropriate education and hospice resources to these decedents and their families, to reduce the amount of aggressive terminal care such decedents receive.	[Huang, Chih-Yuan] Buddhist Tzu Chi Med Fdn, Dalin Tzu Chi Hosp, Dept Internal Med, Div Nephrol, Chiayi, Taiwan; [Huang, Chih-Yuan] Buddhist Tzu Chi Med Fdn, Dalin Tzu Chi Hosp, Dept Pediat, Chiayi, Taiwan; [Chang, Chun-Ming] Buddhist Tzu Chi Med Fdn, Dalin Tzu Chi Hosp, Dept Surg, Chiayi, Taiwan; [Juang, Shiun-Yang] Buddhist Tzu Chi Med Fdn, Dalin Tzu Chi Hosp, Dept Med Res, Chiayi, Taiwan; [Lee, Ching-Chih] Tzu Chi Univ, Sch Med, Hualien, Taiwan; [Lee, Ching-Chih] Buddhist Tzu Chi Med Fdn, Dalin Tzu Chi Hosp, Dept Otolaryngol, Chiayi, Taiwan; [Lee, Ching-Chih] Buddhist Tzu Chi Med Fdn, Dalin Tzu Chi Hosp, Ctr Clin Epidemiol & Biostat, Chiayi, Taiwan; [Huang, Chih-Yuan; Hung, Yeh-Ting; Chang, Chun-Ming; Juang, Shiun-Yang; Lee, Ching-Chih] Buddhist Tzu Chi Med Fdn, Dalin Tzu Chi Hosp, Ctr Clin Epidemiol & Biostatist, Chiayi 622, Taiwan	Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital; Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital; Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital; Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital; Tzu Chi University; Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital; Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital; Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital	Lee, CC (corresponding author), Tzu Chi Univ, Sch Med, Hualien, Taiwan.	hematcd@hotmail.com						Chang CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044325; Chawla Neetu, 2013, Journal of the National Cancer Institute Monographs, P36, DOI 10.1093/jncimonographs/lgt009; Cheng CL, 2011, PHARMACOEPIDEM DR S, V20, P236, DOI 10.1002/pds.2087; Cohen J, 2010, J CLIN ONCOL, V28, P2267, DOI 10.1200/JCO.2009.23.2850; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Earle CC, 2003, J CLIN ONCOL, V21, P1133, DOI 10.1200/JCO.2003.03.059; Earle CC, 2004, J CLIN ONCOL, V22, P315, DOI 10.1200/JCO.2004.08.136; Earle CC, 2008, J CLIN ONCOL, V26, P3860, DOI 10.1200/JCO.2007.15.8253; Fassbender K, 2009, J PAIN SYMPTOM MANAG, V38, P75, DOI 10.1016/j.jpainsymman.2009.04.007; Felder S, 2000, J HEALTH ECON, V19, P679, DOI 10.1016/S0167-6296(00)00039-4; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Hanchate A, 2009, ARCH INTERN MED, V169, P493, DOI 10.1001/archinternmed.2008.616; Hanratty Barbara, 2007, J Health Serv Res Policy, V12, P90, DOI 10.1258/135581907780279585; Ho TH, 2011, J CLIN ONCOL, V29, P1587, DOI 10.1200/JCO.2010.31.9897; Hogan C, 2001, HEALTH AFFAIR, V20, P188, DOI 10.1377/hlthaff.20.4.188; Hollowell J, 2010, J EVAL CLIN PRACT, V16, P529, DOI 10.1111/j.1365-2753.2009.01154.x; HU W, 2013, J PAIN SYMPTOM MANAG; HUANG WCT, 2009, THESIS NATL DIGITAL; Johnson KS, 2005, J AM GERIATR SOC, V53, P2209, DOI 10.1111/j.1532-5415.2005.00502.x; Kwok J, 2010, CANCER-AM CANCER SOC, V116, P476, DOI 10.1002/cncr.24774; Law HZ, 2011, J ASTHMA, V48, P405, DOI 10.3109/02770903.2011.565849; Lin HC, 2008, STROKE, V39, P2744, DOI 10.1161/STROKEAHA.108.519090; Lin YH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062492; Ministry of Health and Welfare, 2013, 2013 STAT CAUS DEATH; Motiwala SS, 2006, CAN J AGING, V25, P363, DOI 10.1353/cja.2007.0019; Nakamura S, 2010, GERIATR GERONTOL INT, V10, P154, DOI 10.1111/j.1447-0594.2009.00570.x; Perelman J, 2011, J HEALTH SERV RES PO, V16, P197, DOI 10.1258/jhsrp.2011.010047; Reyes-Ortiz CA, 2011, CAN J AGING, V30, P143, DOI 10.1017/S0714980810000796; Riley GF, 2010, HEALTH SERV RES, V45, P565, DOI 10.1111/j.1475-6773.2010.01082.x; Saito AM, 2011, BMC PALLIAT CARE, V10, DOI 10.1186/1472-684X-10-14; Tang ST, 2009, ANN ONCOL, V20, P343, DOI 10.1093/annonc/mdn602; Tang ST, 2012, PALLIATIVE MED, V26, P80, DOI 10.1177/0269216311406989; Tang ST, 2009, J CLIN ONCOL, V27, P4613, DOI 10.1200/JCO.2008.20.5096; Tang ST, 2003, CANCER NURS, V26, P245, DOI 10.1097/00002820-200306000-00012; Tang ST, 2002, CANCER NURS, V25, P158, DOI 10.1097/00002820-200204000-00013; Taylor EJ, 2012, PALLIATIVE MED, V26, P342, DOI 10.1177/0269216311412229; Tseng CH, 2004, DIABETES CARE, V27, P1605, DOI 10.2337/diacare.27.7.1605; Wang HM, 2011, J PAIN SYMPTOM MANAG, V42, P400, DOI 10.1016/j.jpainsymman.2010.12.011; Wang JY, 2014, INT J CARDIOL, V172, P82, DOI 10.1016/j.ijcard.2013.12.082; 2013, ACTA ONCOL, V52, P1062, DOI DOI 10.3109/0284186X.2012.758872; 1975, 4 FACTOR INDEX SOCIA	41	9	9	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 13	2015	10	1							e0116913	10.1371/journal.pone.0116913	http://dx.doi.org/10.1371/journal.pone.0116913			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AZ4OG	25585131	gold, Green Submitted, Green Published			2023-01-03	WOS:000348201300011
J	Stathias, V; Pastori, C; Griffin, TZ; Komotar, R; Clarke, J; Zhang, M; Ayad, NG				Stathias, Vasileios; Pastori, Chiara; Griffin, Tess Z.; Komotar, Ricardo; Clarke, Jennifer; Zhang, Ming; Ayad, Nagi G.			Identifying Glioblastoma Gene Networks Based on Hypergeometric Test Analysis	PLOS ONE			English	Article							DIFFERENTIAL EXPRESSION ANALYSIS; RNA-SEQ; COEXPRESSION NETWORK; BIOLOGICAL NETWORKS; CANCER-CELLS; MICROARRAY; NORMALIZATION; INSIGHTS	Patient specific therapy is emerging as an important possibility for many cancer patients. However, to identify such therapies it is essential to determine the genomic and transcriptional alterations present in one tumor relative to control samples. This presents a challenge since use of a single sample precludes many standard statistical analysis techniques. We reasoned that one means of addressing this issue is by comparing transcriptional changes in one tumor with those observed in a large cohort of patients analyzed by The Cancer Genome Atlas (TCGA). To test this directly, we devised a bioinformatics pipeline to identify differentially expressed genes in tumors resected from patients suffering from the most common malignant adult brain tumor, glioblastoma (GBM). We performed RNA sequencing on tumors from individual GBM patients and filtered the results through the TCGA database in order to identify possible gene networks that are overrepresented in GBM samples relative to controls. Importantly, we demonstrate that hypergeometric-based analysis of gene pairs identifies gene networks that validate experimentally. These studies identify a putative workflow for uncovering differentially expressed patient specific genes and gene networks for GBM and other cancers.	[Stathias, Vasileios] Univ Miami, Miller Sch Med, Dept Human Genet & Genom, Miami, FL 33136 USA; [Stathias, Vasileios; Pastori, Chiara; Ayad, Nagi G.] Univ Miami, Miller Sch Med, Ctr Therapeut Innovat, Dept Psychiat & Behav Sci, Miami, FL 33136 USA; [Griffin, Tess Z.; Zhang, Ming] Univ Georgia, Dept Epidemiol & Biostat, Athens, GA 30602 USA; [Griffin, Tess Z.; Zhang, Ming] Univ Georgia, Inst Bioinformat, Athens, GA 30602 USA; [Komotar, Ricardo] Univ Miami, Miller Sch Med, Dept Neurosurg, Miami, FL 33136 USA; [Clarke, Jennifer] Univ Nebraska, Dept Stat, Dept Food Sci & Technol, Lincoln, NE 68588 USA	University of Miami; University of Miami; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University of Miami; University of Nebraska System; University of Nebraska Lincoln	Ayad, NG (corresponding author), Univ Miami, Miller Sch Med, Ctr Therapeut Innovat, Dept Psychiat & Behav Sci, Miami, FL 33136 USA.	nayad@med.miami.edu	Stathias, Vasileios/AAN-5323-2021	Clarke, Jennifer/0000-0002-2723-7249	National Institutes of Health, National Institutes of Neurological Disease and Stroke;  [1R01NS067289]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS067289] Funding Source: NIH RePORTER	National Institutes of Health, National Institutes of Neurological Disease and Stroke; ; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	1R01NS067289. The funders (National Institutes of Health, National Institutes of Neurological Disease and Stroke)had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Arzate-Mejia RG, 2011, IUBMB LIFE, V63, P881, DOI 10.1002/iub.557; Clarke J, 2013, EPIGENETICS-US, V8, P785, DOI 10.4161/epi.25440; Cline MS, 2007, NAT PROTOC, V2, P2366, DOI 10.1038/nprot.2007.324; Dunn GP, 2012, GENE DEV, V26, P756, DOI 10.1101/gad.187922.112; Erkan EP, 2013, ONCOGENE; Fanelli M, 2008, ONCOGENE, V27, P358, DOI 10.1038/sj.onc.1210642; Foltz G, 2009, ONCOGENE, V28, P2667, DOI 10.1038/onc.2009.122; Franceschini A, 2013, NUCLEIC ACIDS RES, V41, pD808, DOI 10.1093/nar/gks1094; Guo Ya, 2013, PLOS ONE, V8; Haar CP, 2012, NEUROCHEM RES, V37, P1192, DOI 10.1007/s11064-011-0701-1; Hardcastle TJ, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-422; Horvath S, 2006, P NATL ACAD SCI USA, V103, P17402, DOI 10.1073/pnas.0608396103; Hu HY, 2005, BIOINFORMATICS, V21, pI213, DOI 10.1093/bioinformatics/bti1049; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Kim HJ, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-39; Lei M, 2005, CURR CANCER DRUG TAR, V5, P365, DOI 10.2174/1568009054629654; Li J, 2010, PHARMACOGN PERS MED, V3, P111, DOI 10.2147/PGPM.S6852; Nookaew I, 2012, NUCLEIC ACIDS RES, V40, P10084, DOI 10.1093/nar/gks804; Ostrom QT, 2013, NEURO-ONCOLOGY, V15, P1, DOI 10.1093/neuonc/not151; Pastori C, 2014, EPIGENETICS-US, V9, P611, DOI 10.4161/epi.27906; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Seyednasrollah F, 2013, BRIEF BIOINFORM; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Smyth GK., 2004, STAT APPL GENET MOL, V3, DOI [DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Stuart JM, 2003, SCIENCE, V302, P249, DOI 10.1126/science.1087447; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Vartanian A, 2014, NEUROONCOL; Xu X, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S9-S1; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Zhang B, 2005, STAT APPL GENET MOL, V4, DOI 10.2202/1544-6115.1128; Zhao SR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0078644	34	15	15	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2014	9	12							e115842	10.1371/journal.pone.0115842	http://dx.doi.org/10.1371/journal.pone.0115842			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX7UC	25551752	Green Published, gold			2023-01-03	WOS:000347119100068
J	Teshome, W; Assefa, A				Teshome, Wondu; Assefa, Anteneh			Predictors of Immunological Failure of Antiretroviral Therapy among HIV Infected Patients in Ethiopia: A Matched Case-Control Study	PLOS ONE			English	Article							VIROLOGICAL RESPONSES; RECOVERY; ADHERENCE; NONADHERENCE; MORTALITY; AFRICA; ADULTS; SWITCH; HAART; CARE	Background: In resource constrained settings, immunological assessment through CD4 count is used to assess response to first line Highly Active Antiretroviral Therapy (HAART). In this study, we aim to investigate factors associated with immunological treatment failure. Methods: A matched case-control study design was used. Cases were subjects who already experienced immunological treatment failure and controls were those without immunological failure after an exactly or approximately equivalent duration of first line treatment with cases. Data were analyzed using SPSS v16.0. Conditional logistic regression was carried out. Results: A total of 134 cases and 134 controls were included in the study. At baseline, the mean age +/- 1 SD of cases was 37.5 +/- 9.7 years whereas it was 36.9 +/- 9.2 years among controls. The median baseline CD4 counts of cases and controls were 121.0 cells/ml (IQR: 47-183 cells/ml) and 122.0 cells/ml (IQR: 80.0189.8 cells/ml), respectively. The median rate of CD4 cells increase was comparable for the two groups in the first six months of commencing HAART (P50.442). However, the median rate of CD4 increase was significantly different for the two groups in the next 6 months period (M6 to M12). The rate of increment was 8.8 (IQR: 0.5, 14.6) and 1.8 (IQR: 8.8, 11.3) cells/ml/month for controls and cases, respectively (Mann-Whitney U test, P50.003). In conditional logistic regressions grouped baseline CD4 count (P50.028), old age group and higher educational status (P, 0.001) were significant predictors of immunological treatment failure. Conclusion: Subjects with immunological treatment failure have an optimal rate of immunological recovery in the first 6 months of treatment with first line HAART, but relative to the non-failing group the rate declines at a later period, notably between 6 and 12 months. Low baseline CD4 count, old age and higher educational status were associated with immunological treatment failure.	[Teshome, Wondu; Assefa, Anteneh] Hawassa Univ, Coll Med & Hlth Sci, Sch Publ & Environm Hlth, Hawassa, Ethiopia	Hawassa University	Teshome, W (corresponding author), Hawassa Univ, Coll Med & Hlth Sci, Sch Publ & Environm Hlth, Hawassa, Ethiopia.	wondu_teshome@yahoo.com	Asefa, Anteneh/AAG-6341-2020	Asefa, Anteneh/0000-0003-4470-1848; Teshome, Wondu/0000-0001-8292-7026	Hawassa University	Hawassa University	The study was funded by Hawassa University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abrogoua DP, 2012, PATIENT PREFER ADHER, V6, P227, DOI 10.2147/PPA.S26507; Bangsberg DR, 2001, AIDS, V15, P1181, DOI 10.1097/00002030-200106150-00015; Chandy S, 2011, AIDS CARE, V23, P569, DOI 10.1080/09540121.2010.525607; Charles M, 2012, J INT AIDS SOC, V15, DOI 10.7448/IAS.15.2.17375; Esposito A, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-341; Federal Ministry of Health (FMoH) website, GUID MAN OPP INF ANT; FHAPCO website, MONTHL HIV CAR ART U; Grabar S, 2000, ANN INTERN MED, V133, P401, DOI 10.7326/0003-4819-133-6-200009190-00007; Gsponer T, 2012, AIDS, V26, P57, DOI 10.1097/QAD.0b013e32834e1b5f; Gutierrez F, 2008, CURR HIV RES, V6, P100, DOI 10.2174/157016208783885038; Hansana V, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-617; Herrmann S, 2008, INTERN MED J, V38, P8, DOI [10.1111/j.1445-5994.2008.01767.x, 10.1111/j.1445-5994.2007.01477.x]; Johnston V, 2012, JAIDS-J ACQ IMM DEF, V61, P370, DOI 10.1097/QAI.0b013e318266ee3f; Kanapathipillai R, 2011, TROP MED INT HEALTH, V16, P1495, DOI 10.1111/j.1365-3156.2011.02874.x; Kaufmann GR, 2003, ARCH INTERN MED, V163, P2187, DOI 10.1001/archinte.163.18.2187; Koethe JR, 2011, CLIN INFECT DIS, V53, P952, DOI 10.1093/cid/cir606; Landier J, 2011, AIDS CARE, V23, P75, DOI 10.1080/09540121.2010.498867; Langford Simone E, 2007, AIDS Res Ther, V4, P11, DOI 10.1186/1742-6405-4-11; Lawn SD, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-59; Mee P, 2008, AIDS, V22, P1971, DOI 10.1097/QAD.0b013e32830e4cd8; Moore DM, 2005, JAIDS-J ACQ IMM DEF, V40, P288, DOI 10.1097/01.qai.0000182847.38098.d1; Nicastri E, 2005, J MED VIROL, V76, P153, DOI 10.1002/jmv.20352; Palombi L, 2009, CLIN INFECT DIS, V48, P115, DOI 10.1086/593312; Peltzer K, 2013, J HEALTH POPUL NUTR, V31, P150; Rajasuriar R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020713; Tan RM, 2008, JAIDS-J ACQ IMM DEF, V47, P553, DOI 10.1097/QAI.0b013e31816856c5; UNAIDS, TOG WE WILL END AIDS; van Griensven J, 2011, T ROY SOC TROP MED H, V105, P694, DOI 10.1016/j.trstmh.2011.08.007; Viard JP, 2001, J INFECT DIS, V183, P1290, DOI 10.1086/319678; WHO, ANT THER HIV INF AD	30	12	12	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 23	2014	9	12							e115125	10.1371/journal.pone.0115125	http://dx.doi.org/10.1371/journal.pone.0115125			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AZ9UY	25536416	Green Submitted, gold, Green Published			2023-01-03	WOS:000348563300030
J	Tagawa, M; Hamano, T; Nishi, H; Tsuchida, K; Hanafusa, N; Fukatsu, A; Iseki, K; Tsubakihara, Y				Tagawa, Miho; Hamano, Takayuki; Nishi, Hiroshi; Tsuchida, Kenji; Hanafusa, Norio; Fukatsu, Atsushi; Iseki, Kunitoshi; Tsubakihara, Yoshiharu			Mineral Metabolism Markers Are Associated with Myocardial Infarction and Hemorrhagic Stroke but Not Ischemic Stroke in Hemodialysis Patients: A Longitudinal Study	PLOS ONE			English	Article							REGULAR DIALYSIS TREATMENT; MAINTENANCE HEMODIALYSIS; PARATHYROID-HORMONE; ENDOTHELIAL DYSFUNCTION; CARDIOVASCULAR EVENTS; PRACTICE PATTERNS; SERUM-CALCIUM; RISK-FACTORS; DISEASE; MORTALITY	Background/Aims: The associations between phosphate, calcium, and intact parathyroid hormone (PTH) levels and composite cardiovascular end points have been studied. This study examined the associations of these markers with myocardial infarction (MI) and stroke separately. Methods: This is a longitudinal study on 65,849 hemodialysis patients from the Japan Renal Data Registry. Patients with prior events at baseline were excluded. Predictors were phosphate, albumin-corrected calcium, intact PTH, and calcium times phosphate product levels. Outcome was the first episode of MI or stroke during a 1-year observation period. Data were analyzed using multiple logistic regression analyses, adjusted for potential confounders. Results: There were 1,048, 651, and 2,089 events of incident MI, hemorrhagic, and ischemic stroke, respectively. Incident MI was associated with phosphate levels >= 6.5 mg/dL (odds ratio 1.49; confidence interval 1.23-1.80) compared with phosphate levels of 4.7-5.4 mg/dL and intact PTH levels>500 pg/mL (1.35; 1.03-1.79) compared with intact PTH levels of 151-300 pg/mL. Higher albumin-corrected calcium level was positively associated with MI (p=0.04 by trend analysis). Hemorrhagic stroke was associated only with intact PTH levels>500 pg/mL (1.54; 1.10-2.17). Incident ischemic stroke had no association with phosphate, calcium, or intact PTH levels. The association of calcium times phosphate product with outcomes was essentially the same pattern as that of phosphate and outcomes. Conclusions: MI was associated with phosphate, calcium, and intact PTH levels, whereas hemorrhagic stroke was associated only with intact PTH. Ischemic stroke was not associated with any of them. The potential distinct beneficial effect on MI and stroke by managing bone and mineral disease should be investigated in future studies.	[Tagawa, Miho] Kyoto Katsura Hosp, Dept Nephrol, Kyoto, Japan; [Hamano, Takayuki; Nishi, Hiroshi; Tsuchida, Kenji; Hanafusa, Norio; Iseki, Kunitoshi; Tsubakihara, Yoshiharu] Japanese Soc Dialysis Therapy, Comm Renal Data Registry, Tokyo, Japan; [Fukatsu, Atsushi] Kyoto Univ, Grad Sch Med, Dept Nephrol, Kyoto, Japan	Kyoto University	Tagawa, M (corresponding author), Kyoto Katsura Hosp, Dept Nephrol, Kyoto, Japan.	tagawa_miho@yahoo.co.jp	Hamano, TAKAYUKI/AAZ-4837-2021; FUKATSU, ATSUSHI/R-7941-2019	Hamano, TAKAYUKI/0000-0002-2100-9106; 				[Anonymous], 2003, AM J KIDNEY DIS S13, V42, pS1; Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2; Chan KE, 2009, J AM SOC NEPHROL, V20, P2223, DOI 10.1681/ASN.2009030319; Di Marco GS, 2008, AM J PHYSIOL-RENAL, V294, pF1381, DOI 10.1152/ajprenal.00003.2008; Floege J, 2011, NEPHROL DIAL TRANSPL, V26, P1948, DOI 10.1093/ndt/gfq219; Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131; Gokce N, 2003, J AM COLL CARDIOL, V41, P1769, DOI 10.1016/S0735-1097(03)00333-4; Goodkin DA, 2003, J AM SOC NEPHROL, V14, P3270, DOI 10.1097/01.ASN.0000100127.54107.57; Kalantar-Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514; Kawamura M, 1998, AM J KIDNEY DIS, V31, P991, DOI 10.1053/ajkd.1998.v31.pm9631844; Kimata Naoki, 2007, Hemodial Int, V11, P340, DOI 10.1111/j.1542-4758.2007.00190.x; Kumar A, 2009, MAYO CLIN PROC, V84, P917, DOI 10.1016/S0025-6196(11)60509-0; Nakai S, 2008, THER APHER DIAL, V12, P49, DOI 10.1111/j.1744-9987.2007.00540.x; Nakai S, 2009, THER APHER DIAL, V13, P457, DOI 10.1111/j.1744-9987.2009.00789.x; Nakai S, 2008, THER APHER DIAL, V12, P428, DOI 10.1111/j.1744-9987.2008.00634.x; Navarro-Gonzalez JF, 2009, CLIN J AM SOC NEPHRO, V4, P1646, DOI 10.2215/CJN.02420409; ONOYAMA K, 1986, JPN HEART J, V27, P685; PAYNE RB, 1973, BMJ-BRIT MED J, V4, P643, DOI 10.1136/bmj.4.5893.643; Pfeffer MA, 2009, NEW ENGL J MED, V361, P2019, DOI 10.1056/NEJMoa0907845; Rashid G, 2007, AM J PHYSIOL-RENAL, V292, pF1215, DOI 10.1152/ajprenal.00406.2006; Seliger SL, 2003, J AM SOC NEPHROL, V14, P2623, DOI 10.1097/01.ASN.0000088722.56342.A8; Shoji T, 2011, CLIN J AM SOC NEPHRO, V6, P1112, DOI 10.2215/CJN.09961110; Shroff R, 2013, J AM SOC NEPHROL, V24, P179, DOI 10.1681/ASN.2011121191; Shuto E, 2009, J AM SOC NEPHROL, V20, P1504, DOI 10.1681/ASN.2008101106; Slinin Y, 2005, J AM SOC NEPHROL, V16, P1788, DOI 10.1681/ASN.2004040275; Takase B, 2008, CARDIOVASC ULTRASOUN, V6, DOI 10.1186/1476-7120-6-61; Toyoda K, 2005, AM J KIDNEY DIS, V45, P1058, DOI 10.1053/j.ajkd.2005.02.028; Wizemann V, 2010, KIDNEY INT, V77, P1098, DOI 10.1038/ki.2009.477; Young EW, 2005, KIDNEY INT, V67, P1179, DOI 10.1111/j.1523-1755.2005.00185.x	29	14	14	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 10	2014	9	12							e114678	10.1371/journal.pone.0114678	http://dx.doi.org/10.1371/journal.pone.0114678			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AW9YP	25494334	Green Published, gold, Green Submitted			2023-01-03	WOS:000346611400065
J	Lobo, MR; Wang, XY; Gillespie, GY; Woltjer, RL; Pike, MM				Lobo, Merryl R.; Wang, Xiaoyan; Gillespie, G. Yancey; Woltjer, Randall L.; Pike, Martin M.			Combined Efficacy of Cediranib and Quinacrine in Glioma Is Enhanced by Hypoxia and Causally Linked to Autophagic Vacuole Accumulation	PLOS ONE			English	Article							UNFOLDED PROTEIN RESPONSE; TYROSINE KINASE INHIBITOR; CELL-DEATH; TARGETED THERAPIES; INDUCED APOPTOSIS; TUMOR HYPOXIA; GROWTH; GLIOBLASTOMA; VASCULATURE; RESISTANCE	We have previously reported that the in vivo anti-glioma efficacy of the anti-angiogenic receptor tyrosine kinase inhibitor cediranib is substantially enhanced via combination with the late-stage autophagy inhibitor quinacrine. The current study investigates the role of hypoxia and autophagy in combined cediranib/quinacrine efficacy. EF5 immunostaining revealed a prevalence of hypoxia in mouse intracranial 4C8 glioma, consistent with high-grade glioma. MTS cell viability assays using 4C8 glioma cells revealed that hypoxia potentiated the efficacy of combined cediranib/quinacrine: cell viability reductions induced by 1 mu M cediranib +2.5 mu M quinacrine were 78 +/- 7% (hypoxia) vs. 31 +/- 3% (normoxia), p<0.05. Apoptosis was markedly increased for cediranib/quinacrine/hypoxia versus all other groups. Autophagic vacuole biomarker LC3-II increased robustly in response to cediranib, quinacrine, or hypoxia. Combined cediranib/quinacrine increased LC3-II further, with the largest increases occurring with combined cediranib/quinacrine/ hypoxia. Early stage autophagy inhibitor 3-MA prevented LC3-II accumulation with combined cediranib/quinacrine/hypoxia and substantially attenuated the associated reduction in cell viability. Combined efficacy of cediranib with bafilomycin A1, another late-stage autophagy inhibitor, was additive but lacked substantial potentiation by hypoxia. Substantially lower LC3-II accumulation was observed with bafilomycin A1 in comparison to quinacrine. Cediranib and quinacrine each strongly inhibited Akt phosphoryation, while bafilomycin A1 had no effect. Our results provide compelling evidence that autophagic vacuole accumulation plays a causal role in the anti-glioma cytotoxic efficacy of combined cediranib/quinacrine. Such accumulation is likely related to stimulation of autophagosome induction by hypoxia, which is prevalent in the glioma tumor microenvironment, as well as Akt signaling inhibition from both cediranib and quinacrine. Quinacrine's unique ability to inhibit both Akt and autophagic vacuole degradation may enhance its ability to drive cytotoxic autophagic vacuole accumulation. These findings provide a rationale for a clinical evaluation of combined cediranib/quinacrine therapy for malignant glioma.	[Lobo, Merryl R.; Pike, Martin M.] Oregon Hlth & Sci Univ, Adv Imaging Res Ctr, Portland, OR 97201 USA; [Lobo, Merryl R.; Pike, Martin M.] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97201 USA; [Woltjer, Randall L.] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA; [Wang, Xiaoyan] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA; [Gillespie, G. Yancey] Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; University of Alabama System; University of Alabama Birmingham	Pike, MM (corresponding author), Oregon Hlth & Sci Univ, Adv Imaging Res Ctr, Portland, OR 97201 USA.	pikema@ohsu.edu		Gillespie, George/0000-0001-6436-9542	National Institutes of Health, National Cancer Institute [1R21 CA167302-01]; NATIONAL CANCER INSTITUTE [R21CA167302] Funding Source: NIH RePORTER	National Institutes of Health, National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funding was provided by the National Institutes of Health, National Cancer Institute (#1R21 CA167302-01, MMP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amaravadi R, 2009, CANCER BIOL THER, V8, P130, DOI DOI 10.4161/CBT.8.21.10416; Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634; Batchelor TT, 2007, CANCER CELL, V11, P83, DOI 10.1016/j.ccr.2006.11.021; Belloni D, 2010, EXP CELL RES, V316, P1010, DOI 10.1016/j.yexcr.2009.11.005; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Calvo E, 2009, ONCOTARGETS THER, V2, P135; Chiavarina B, 2010, CELL CYCLE, V9, P3534, DOI 10.4161/cc.9.17.12908; Degtyarev M, 2008, J CELL BIOL, V183, P101, DOI 10.1083/jcb.200801099; DYER CA, 1995, J NEUROPATH EXP NEUR, V54, P852, DOI 10.1097/00005072-199511000-00012; Ehsanian R, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-13; Geng Y, 2010, NEURO-ONCOLOGY, V12, P473, DOI 10.1093/neuonc/nop048; Gladson CL, 2010, ANNU REV PATHOL-MECH, V5, P33, DOI 10.1146/annurev-pathol-121808-102109; Guo C, 2009, ONCOGENE, V28, P1151, DOI 10.1038/onc.2008.460; Guo CH, 2011, P NATL ACAD SCI USA, V108, P7968, DOI 10.1073/pnas.1105369108; Gupta A, 2010, P NATL ACAD SCI USA, V107, P14333, DOI 10.1073/pnas.1000248107; Healy SJM, 2009, EUR J PHARMACOL, V625, P234, DOI 10.1016/j.ejphar.2009.06.064; Hellums EK, 2005, NEURO-ONCOLOGY, V7, P213, DOI 10.1215/S1152851705000074; Hu YL, 2012, CANCER RES, V72, P1773, DOI 10.1158/0008-5472.CAN-11-3831; Jensen RL, 2009, J NEURO-ONCOL, V92, P317, DOI 10.1007/s11060-009-9827-2; Jordan BF, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00094; Joshi AD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044372; Kaur B, 2005, NEURO-ONCOLOGY, V7, P134, DOI 10.1215/S1152851704001115; Kaza N, 2012, BRAIN PATHOL, V22, P89, DOI 10.1111/j.1750-3639.2011.00544.x; Koumenis C, 2006, MOL CANCER RES, V4, P423, DOI 10.1158/1541-7786.MCR-06-0150; Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Lefranc F, 2007, ONCOLOGIST, V12, P1395, DOI 10.1634/theoncologist.12-12-1395; Lindberg N, 2012, UPSALA J MED SCI, V117, P92, DOI 10.3109/03009734.2012.654860; Lobo MR, 2013, NEURO-ONCOLOGY, V15, P1673, DOI 10.1093/neuonc/not119; Marceau F, 2009, DRUG METAB DISPOS, V37, P2271, DOI 10.1124/dmd.109.028480; Martinho O, 2013, TRANSL ONCOL, V6, P187, DOI 10.1593/tlo.12400; Mercer RW, 2009, BIODRUGS, V23, P25, DOI 10.2165/00063030-200923010-00003; Mirzoeva OK, 2011, J MOL MED, V89, P877, DOI 10.1007/s00109-011-0774-y; Nazarenko I, 2012, UPSALA J MED SCI, V117, P99, DOI 10.3109/03009734.2012.665097; Nishikawa T, 2010, ANGIOGENESIS, V13, P227, DOI 10.1007/s10456-010-9180-2; Pike MM, 2009, MAGN RESON MED, V61, P615, DOI 10.1002/mrm.21931; Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497; Rahman R, 2010, J ONCOL, V2010, DOI 10.1155/2010/251231; Rong Y, 2006, J NEUROPATH EXP NEUR, V65, P529, DOI 10.1097/00005072-200606000-00001; Rouschop KMA, 2009, CURR MOL MED, V9, P417, DOI 10.2174/156652409788167131; Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shimizu S, 2012, INT J CANCER, V131, P548, DOI 10.1002/ijc.26374; Shingu T, 2009, INT J CANCER, V124, P1060, DOI 10.1002/ijc.24030; Sorensen AG, 2012, CANCER RES, V72, P402, DOI 10.1158/0008-5472.CAN-11-2464; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Takeuchi H, 2004, BRIT J CANCER, V90, P1069, DOI 10.1038/sj.bjc.6601605; Thaker NG, 2009, EXPERT REV NEUROTHER, V9, P1815, DOI 10.1586/ERN.09.116; Wedge SR, 2005, CANCER RES, V65, P4389, DOI 10.1158/0008-5472.CAN-04-4409; Weinmann M, 2004, ONCOGENE, V23, P3757, DOI 10.1038/sj.onc.1207481; Wouters BG, 2008, NAT REV CANCER, V8, P851, DOI 10.1038/nrc2501; Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33; Yung L, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-53; Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200; Zhang RG, 2011, CANCER BIOTHER RADIO, V26, P335, DOI 10.1089/cbr.2010.0814	56	8	8	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2014	9	12							e114110	10.1371/journal.pone.0114110	http://dx.doi.org/10.1371/journal.pone.0114110			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AY3YM	25490024	Green Published, gold, Green Submitted			2023-01-03	WOS:000347515300015
J	Moriuchi, T; Iso, N; Sagari, A; Ogahara, K; Kitajima, E; Tanaka, K; Tabira, T; Higashi, T				Moriuchi, Takefumi; Iso, Naoki; Sagari, Akira; Ogahara, Kakuya; Kitajima, Eiji; Tanaka, Koji; Tabira, Takayuki; Higashi, Toshio			Excitability of the Primary Motor Cortex Increases More Strongly with Slow- than with Normal-Speed Presentation of Actions	PLOS ONE			English	Article							MIRROR-NEURON SYSTEM; TRANSCRANIAL MAGNETIC STIMULATION; VENTRAL PREMOTOR CORTEX; CORTICOSPINAL EXCITABILITY; CORTICAL INTERACTIONS; GRASPING MOVEMENTS; CLINICAL-RELEVANCE; ACTION RECOGNITION; HAND MOVEMENTS; MODULATION	Introduction: The aim of the present study was to investigate how the speed of observed action affects the excitability of the primary motor cortex (M1), as assessed by the size of motor evoked potentials (MEPs) induced by transcranial magnetic stimulation (TMS). Methods: Eighteen healthy subjects watched a video clip of a person catching a ball, played at three different speeds (normal-, half-, and quarter-speed). MEPs were induced by TMS when the model's hand had opened to the widest extent just before catching the ball ("open") and when the model had just caught the ball ("catch"). These two events were locked to specific frames of the video clip ("phases"), rather than occurring at specific absolute times, so that they could easily be compared across different speeds. MEPs were recorded from the thenar (TH) and abductor digiti minimi (ADM) muscles of the right hand. Results: The MEP amplitudes were higher when the subjects watched the video clip at low speed than when they watched the clip at normal speed. A repeated-measures ANOVA, with the factor VIDEO-SPEED, showed significant main effects. Bonferroni's post hoc test showed that the following MEP amplitude differences were significant: TH, normal vs. quarter; ADM, normal vs. half; and ADM, normal vs. quarter. Paired t-tests showed that the significant MEP amplitude differences between TMS phases under each speed condition were TH, "catch" higher than "open" at quarter speed; ADM, "catch" higher than "open" at half speed. Conclusions: These results indicate that the excitability of M1 was higher when the observed action was played at low speed. Our findings suggest that the action observation system became more active when the subjects observed the video clip at low speed, because the subjects could then recognize the elements of action and intention in others.	[Moriuchi, Takefumi; Iso, Naoki; Sagari, Akira; Higashi, Toshio] Nagasaki Univ, Grad Sch Biomed Sci, Unit Rehabil Sci, Nagasaki 852, Japan; [Moriuchi, Takefumi; Iso, Naoki] Tojinkai Miharadai Hosp, Med Corp, Nagasaki, Japan; [Sagari, Akira] Nagasaki Genbaku Hosp, Japanese Red Cross Soc, Nagasaki, Japan; [Ogahara, Kakuya] Kanagawa Univ Human Serv, Fac Hlth & Social Work, Sch Rehabil, Kanagawa, Japan; [Kitajima, Eiji] Nagasaki Univ, Ctr Ind, Univ & Govt Cooperat, Nagasaki 852, Japan; [Tanaka, Koji] Nagasaki Univ, Grad Sch Biomed Sci, Unit Phys & Occupat Therapy, Nagasaki 852, Japan; [Tabira, Takayuki] Nishikyushu Univ, Fac Rehabil Sci, Saga, Japan	Nagasaki University; Nagasaki University; Nagasaki University	Higashi, T (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Unit Rehabil Sci, Nagasaki 852, Japan.	higashi-t@nagasaki-u.ac.jp	Tabira, takayuki/AAS-4222-2021; TANAKA, KOJI/ABC-4601-2021	TANAKA, KOJI/0000-0002-7932-8601				Abdollahi RO, 2013, CEREB CORTEX, V23, P2734, DOI 10.1093/cercor/bhs264; Alaerts K, 2009, CORTEX, V45, P1148, DOI 10.1016/j.cortex.2008.10.005; Allison T, 2000, TRENDS COGN SCI, V4, P267, DOI 10.1016/S1364-6613(00)01501-1; Aziz-Zadeh L, 2006, J NEUROSCI, V26, P2964, DOI 10.1523/JNEUROSCI.2921-05.2006; Aziz-Zadeh L, 2002, EXP BRAIN RES, V144, P127, DOI 10.1007/s00221-002-1037-5; Baldissera F, 2001, EUR J NEUROSCI, V13, P190, DOI 10.1046/j.0953-816x.2000.01368.x; Bang DH, 2013, CLIN REHABIL, V27, P1118, DOI 10.1177/0269215513501528; BARKER AT, 1985, LANCET, V1, P1106; Biagi L, 2010, BRAIN RES BULL, V81, P434, DOI 10.1016/j.brainresbull.2009.12.002; Borroni P, 2008, SOC NEUROSCI-UK, V3, P276, DOI 10.1080/17470910701515269; Bucchioni G, 2013, BRAIN COGNITION, V81, P176, DOI 10.1016/j.bandc.2012.11.001; Buccino G, 2004, BRAIN LANG, V89, P370, DOI 10.1016/S0093-934X(03)00356-0; Buccino G, 2001, EUR J NEUROSCI, V13, P400, DOI 10.1046/j.1460-9568.2001.01385.x; Buccino G, 2006, COGN BEHAV NEUROL, V19, P55, DOI 10.1097/00146965-200603000-00007; Candidi M, 2010, CEREB CORTEX, V20, P2832, DOI 10.1093/cercor/bhq033; Castiello U, 2009, NEUROPSYCHOLOGIA, V47, P835, DOI 10.1016/j.neuropsychologia.2008.12.016; Chong TTJ, 2008, CURR BIOL, V18, P1576, DOI 10.1016/j.cub.2008.08.068; Davare M, 2008, J PHYSIOL-LONDON, V586, P2735, DOI 10.1113/jphysiol.2008.152603; Davare M, 2009, CORTEX, V45, P1050, DOI 10.1016/j.cortex.2009.02.011; Enticott PG, 2011, BRAIN RES BULL, V85, P89, DOI 10.1016/j.brainresbull.2011.03.018; Enticott PG, 2010, NEUROPSYCHOLOGIA, V48, P2675, DOI 10.1016/j.neuropsychologia.2010.05.014; Ertelt D, 2007, NEUROIMAGE, V36, pT164, DOI 10.1016/j.neuroimage.2007.03.043; Ertelt D, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-42; Fadiga L, 2004, J CLIN NEUROPHYSIOL, V21, P157, DOI 10.1097/00004691-200405000-00004; FADIGA L, 1995, J NEUROPHYSIOL, V73, P2608, DOI 10.1152/jn.1995.73.6.2608; Filimon F, 2007, NEUROIMAGE, V37, P1315, DOI 10.1016/j.neuroimage.2007.06.008; Fogassi L, 2005, SCIENCE, V308, P662, DOI 10.1126/science.1106138; Franceschini M, 2012, NEUROREHAB NEURAL RE, V26, P456, DOI 10.1177/1545968311427406; Gallese V, 1996, BRAIN, V119, P593, DOI 10.1093/brain/119.2.593; Gangitano M, 2004, EUR J NEUROSCI, V20, P2193, DOI 10.1111/j.1460-9568.2004.03655.x; Gangitano M, 2001, NEUROREPORT, V12, P1489, DOI 10.1097/00001756-200105250-00038; Gazzola V, 2007, NEUROIMAGE, V35, P1674, DOI 10.1016/j.neuroimage.2007.02.003; Heyes C, 2011, PSYCHOL BULL, V137, P463, DOI 10.1037/a0022288; Iacoboni M, 2005, PLOS BIOL, V3, P529, DOI 10.1371/journal.pbio.0030079; Iacoboni M, 2005, CURR OPIN NEUROBIOL, V15, P632, DOI 10.1016/j.conb.2005.10.010; Iacoboni M, 2006, NAT REV NEUROSCI, V7, P942, DOI 10.1038/nrn2024; Jellema T, 2000, BRAIN COGNITION, V44, P280, DOI 10.1006/brcg.2000.1231; Johnson-Frey SH, 2003, NEURON, V39, P1053, DOI 10.1016/S0896-6273(03)00524-5; Koch G, 2010, NEUROPSYCHOLOGIA, V48, P3513, DOI 10.1016/j.neuropsychologia.2010.07.037; Lago A, 2010, NEUROPSYCHOLOGIA, V48, P1802, DOI 10.1016/j.neuropsychologia.2010.02.030; Maeda F, 2002, J NEUROPHYSIOL, V87, P1329, DOI 10.1152/jn.00773.2000; Maeda F., 2002, INT C SERIES, V1232, P889, DOI [10.1016/S0531-5131(01)00729-4, DOI 10.1016/S0531-5131(01)00729-4]; Montagna M, 2005, EUR J NEUROSCI, V22, P1513, DOI 10.1111/j.1460-9568.2005.04336.x; Nishitani N, 2000, P NATL ACAD SCI USA, V97, P913, DOI 10.1073/pnas.97.2.913; Ogawa K, 2012, EXP BRAIN RES, V216, P61, DOI 10.1007/s00221-011-2908-4; Rizzolatti G, 2001, NEURON, V31, P889, DOI 10.1016/S0896-6273(01)00423-8; Rizzolatti G, 2001, NAT REV NEUROSCI, V2, P661, DOI 10.1038/35090060; Rizzolatti G, 2004, ANNU REV NEUROSCI, V27, P169, DOI 10.1146/annurev.neuro.27.070203.144230; Rizzolatti G, 1996, COGNITIVE BRAIN RES, V3, P131, DOI 10.1016/0926-6410(95)00038-0; Rizzolatti G, 2002, CURR OPIN NEUROBIOL, V12, P149, DOI 10.1016/S0959-4388(02)00308-2; Rizzolatti G, 2009, NAT CLIN PRACT NEURO, V5, P24, DOI 10.1038/ncpneuro0990; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Sartori L, 2013, SOC COGN AFFECT NEUR, V8, P662, DOI 10.1093/scan/nss044; Sartori L, 2013, NEUROREPORT, V24, P63, DOI 10.1097/WNR.0b013e32835c6e6a; Sartori L, 2012, SOC NEUROSCI-UK, V7, P146, DOI 10.1080/17470919.2011.586579; SELTZER B, 1994, J COMP NEUROL, V343, P445, DOI 10.1002/cne.903430308; Senot P, 2011, EXP BRAIN RES, V211, P161, DOI 10.1007/s00221-011-2635-x; Small SL, 2012, DEV PSYCHOBIOL, V54, P293, DOI 10.1002/dev.20504; Strafella AP, 2000, NEUROREPORT, V11, P2289, DOI 10.1097/00001756-200007140-00044; Turella L, 2009, NEUROIMAGE, V46, P844, DOI 10.1016/j.neuroimage.2009.03.002; Turella L, 2009, BRAIN LANG, V108, P10, DOI 10.1016/j.bandl.2007.11.002; Umilta MA, 2001, NEURON, V31, P155, DOI 10.1016/S0896-6273(01)00337-3; Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8; Wilson M, 2005, PSYCHOL BULL, V131, P460, DOI 10.1037/0033-2909.131.3.460; Winter D. A., 2005, BIOMECHANICS MOTOR C, P36	65	9	9	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 5	2014	9	12							e114355	10.1371/journal.pone.0114355	http://dx.doi.org/10.1371/journal.pone.0114355			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX4MS	25479161	Green Published, Green Submitted, gold			2023-01-03	WOS:000346907200075
J	Olin, JT; Wechsler, ME				Olin, J. Tod; Wechsler, Michael E.			Asthma: pathogenesis and novel drugs for treatment	BMJ-BRITISH MEDICAL JOURNAL			English	Review							EXHALED NITRIC-OXIDE; AIRWAY SMOOTH-MUSCLE; STEP-UP THERAPY; INHALED CORTICOSTEROIDS; INTERFERON-GAMMA; CHILDHOOD ASTHMA; DNA METHYLATION; MESSENGER-RNA; BONE-MARROW; T-CELLS	Asthma affects almost 20 million people in the United States and more than 300 million people worldwide. Of these, 10-15% have severe asthma, which is refractory to commonly available drugs. New drugs are needed because those that are currently available cannot control symptoms and exacerbations in all patients and can cause adverse reactions. In the past 10 years, there have been substantial advances in the understanding of asthma genetics, airway biology, and immune cell signaling. These advances have led to the development of small molecule therapeutics and biologic agents that may improve asthma care in tie future. Several new classes of asthma drugs including ultra long acting beta agonists and modulators of the interleukin 4 (IL-4), IL-5, IL-13, and IL-17 pathways have been evaluated in randomized controlled trials. Other new drug classes including dissociated corticosteroids, CXC chemokine receptor 2 antagonists, toll-like receptor 9 agonists, and tyrosine kinase inhibitors remain in earlier phases of development. Despite some preliminary efficacy data, there is insufficient evidence to make strong recommendations about the use of these newer agents. Future research on the clinical efficacy of these biologic agents, tie effect of newer agents on severe asthma in pediatric patients, and the biology of non-eosinophilic and corticosteroid resistant asthma is needed to reduce the morbidity of asthma worldwide.	[Olin, J. Tod] Natl Jewish Hlth, Dept Pediat, Pediat Exercise Tolerance Ctr, Denver, CO USA; [Wechsler, Michael E.] Natl Jewish Hlth, Dept Med, Asthma Program, Denver, CO 80206 USA	National Jewish Health; National Jewish Health	Wechsler, ME (corresponding author), Natl Jewish Hlth, Dept Med, Asthma Program, Denver, CO 80206 USA.	wechslerm@njhealth.org	Wechsler, Michael/AAC-5506-2019					Adamko DJ, 2012, CHEST, V141, P1295, DOI 10.1378/chest.11-2028; Agache I, 2010, RESP MED, V104, P1131, DOI 10.1016/j.rmed.2010.02.018; Akinbami Lara J, 2012, NCHS Data Brief, P1; [Anonymous], 2014, GLOB STRAT ASTHM MAN; Asher MI, 1998, EUR RESPIR J, V12, P315; Bacharier LB, 1998, INT ARCH ALLERGY IMM, V115, P257, DOI 10.1159/000069456; Barnes Peter J, 2009, Lancet, V373, P1905, DOI 10.1016/S0140-6736(09)60326-3; Barnes PJ, 2012, SEMIN RESP CRIT CARE, V33, P685, DOI 10.1055/s-0032-1326965; Barnes PJ, 2011, IMMUNOL REV, V242, P31, DOI 10.1111/j.1600-065X.2011.01020.x; Barnett SBL, 2011, J ALLERGY CLIN IMMUN, V127, P145, DOI 10.1016/j.jaci.2010.10.020; Beeh KM, 2013, J ALLERGY CLIN IMMUN, V131, P866, DOI 10.1016/j.jaci.2012.12.1561; Bonilla S, 2005, J PEDIATR-US, V147, P802, DOI 10.1016/j.jpeds.2005.06.041; Borish LC, 2001, J ALLERGY CLIN IMMUN, V107, P963, DOI 10.1067/mai.2001.115624; Borish LC, 1999, AM J RESP CRIT CARE, V160, P1816, DOI 10.1164/ajrccm.160.6.9808146; BOSLEY CM, 1994, EUR RESPIR J, V7, P504, DOI 10.1183/09031936.94.07030504; Bossley CJ, 2012, J ALLERGY CLIN IMMUN, V129, P974, DOI 10.1016/j.jaci.2012.01.059; Bousquet J., 2007, GLOBAL SURVEILLANCE; Bradding P, 2003, CURR OPIN ALLERGY CL, V3, P45, DOI 10.1097/01.all.0000053267.39029.fd; Brand S, 2012, J ALLERGY CLIN IMMUN, V129, P1602, DOI 10.1016/j.jaci.2011.12.963; Bullens DMA, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-135; Burch J, 2012, PHARMACOECONOMICS, V30, P991, DOI 10.2165/11597160-000000000-00000; BURD PR, 1995, J EXP MED, V181, P1373, DOI 10.1084/jem.181.4.1373; Busse WW, 2013, AM J RESP CRIT CARE, V188, P1294, DOI 10.1164/rccm.201212-2318OC; Busse WW, 2010, J ALLERGY CLIN IMMUN, V125, P1237, DOI 10.1016/j.jaci.2010.04.005; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Carolan BJ, 2013, J ALLERGY CLIN IMMUN, V131, P627, DOI 10.1016/j.jaci.2013.01.010; Castro M, 2011, AM J RESP CRIT CARE, V184, P1125, DOI 10.1164/rccm.201103-0396OC; Chang C, 2012, CARBOHYDRATES COMPRE; Chang TS, 2014, J ALLERGY CLIN IMMUN, V133, P363, DOI 10.1016/j.jaci.2013.09.002; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Clark NA, 2010, ENVIRON HEALTH PERSP, V118, P284, DOI 10.1289/ehp.0900916; Cohen P, 2000, AM J PHYSIOL-LUNG C, V278, pL545, DOI 10.1152/ajplung.2000.278.3.L545; Cohn L, 1997, J EXP MED, V186, P1737, DOI 10.1084/jem.186.10.1737; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Corren J, 2010, AM J RESP CRIT CARE, V181, P788, DOI 10.1164/rccm.200909-1448OC; Cosmi L, 2011, ALLERGY, V66, P989, DOI 10.1111/j.1398-9995.2011.02576.x; COX G, 1995, J IMMUNOL, V154, P4719; Cox G, 2007, NEW ENGL J MED, V356, P1327, DOI 10.1056/NEJMoa064707; Cox PG, 2004, EUR RESPIR J, V24, P659, DOI 10.1183/09031936.04.00054604; Custovic A, 2011, J ALLERGY CLIN IMMUN, V127; Doeing DC, 2013, J APPL PHYSIOL, V114, P834, DOI 10.1152/japplphysiol.00950.2012; DUBUCQUOI S, 1994, J EXP MED, V179, P703, DOI 10.1084/jem.179.2.703; DUFFY DL, 1990, AM REV RESPIR DIS, V142, P1351, DOI 10.1164/ajrccm/142.6_Pt_1.1351; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Erjefalt JS, 1997, THORAX, V52, P1010, DOI 10.1136/thx.52.11.1010; Erkkola M, 2012, PEDIAT ALLERG IMM-UK, V23, P186, DOI 10.1111/j.1399-3038.2012.01272.x; Fish SC, 2005, J IMMUNOL, V174, P7716, DOI 10.4049/jimmunol.174.12.7716; Fitzpatrick AM, 2011, J ALLERGY CLIN IMMUN, V127, DOI DOI 10.1016/LJACI.2010.11.015; Flood-Page P, 2007, AM J RESP CRIT CARE, V176, P1062, DOI 10.1164/rccm.200701-085OC; Fulkerson PC, 2013, NAT REV DRUG DISCOV, V12, P117, DOI 10.1038/nrd3838; Gauvreau GM, 2009, CLIN EXP ALLERGY, V39, P1297, DOI 10.1111/j.1365-2222.2009.03325.x; Gauvreau GM, 2008, AM J RESP CRIT CARE, V177, P952, DOI 10.1164/rccm.200708-1251OC; Gelb AF, 2000, AM J RESP CRIT CARE, V162, P1778, DOI 10.1164/ajrccm.162.5.2001037; Gizycki MJ, 1997, AM J RESP CELL MOL, V16, P664, DOI 10.1165/ajrcmb.16.6.9191468; Goebeler M, 1997, IMMUNOLOGY, V91, P450, DOI 10.1046/j.1365-2567.1997.00263.x; Grainge CL, 2011, NEW ENGL J MED, V364, P2006, DOI 10.1056/NEJMoa1014350; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Guntur VP, 2012, CURR OPIN ALLERGY CL, V12, P68, DOI 10.1097/ACI.0b013e32834ecb4f; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; Hammad H, 2007, ADV IMMUNOL, V93, P265, DOI 10.1016/S0065-2776(06)93007-7; Hanania NA, 2013, AM J RESP CRIT CARE, V187, P804, DOI 10.1164/rccm.201208-1414OC; HER E, 1991, J CLIN INVEST, V88, P1982, DOI 10.1172/JCI115524; Hershey GKK, 2003, J ALLERGY CLIN IMMUN, V111, P677, DOI 10.1067/mai.2003.1333; Hirst SJ, 1996, AM J PHYSIOL-LUNG C, V270, pL415, DOI 10.1152/ajplung.1996.270.3.L415; Hogan SP, 2008, CLIN EXP ALLERGY, V38, P709, DOI 10.1111/j.1365-2222.2008.02958.x; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Holz O, 2010, EUR RESPIR J, V35, P564, DOI 10.1183/09031936.00048509; HUANG SK, 1995, J IMMUNOL, V155, P2688; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; Jeffery PK, 2001, AM J RESP CRIT CARE, V164, pS28, DOI 10.1164/ajrccm.164.supplement_2.2106061; Johansson AK, 2004, EUR J IMMUNOL, V34, P3135, DOI 10.1002/eji.200425043; Joos S, 2008, THORAX, V63, P453, DOI 10.1136/thx.2007.081596; Joubert BR, 2012, ENVIRON HEALTH PERSP, V120, P1425, DOI 10.1289/ehp.1205412; Kallal LE, 2010, EUR J IMMUNOL, V40, P1042, DOI 10.1002/eji.200939778; Kato T, 1995, NAT IMMUN, V14, P198; Kausel L, 2013, SCI WORLD J, DOI 10.1155/2013/937935; Kelly HW, 2012, NEW ENGL J MED, V367, P904, DOI 10.1056/NEJMoa1203229; Kerstjens HAM, 2012, NEW ENGL J MED, V367, P1198, DOI 10.1056/NEJMoa1208606; Kita H, 2013, INT ARCH ALLERGY IMM, V161, P3, DOI 10.1159/000350662; Kroegel C, 1996, EUR RESPIR J, V9, P899, DOI 10.1183/09031936.96.09050899; LaForce C, 2009, CURR MED RES OPIN, V25, P2353, DOI 10.1185/03007990903143143; Lai CKW, 1996, J ALLERGY CLIN IMMUN, V97, P1320, DOI 10.1016/S0091-6749(96)70201-4; Lambrecht BN, 2012, NAT MED, V18, P684, DOI 10.1038/nm.2737; Lambrecht BN, 2012, ANNU REV IMMUNOL, V30, P243, DOI 10.1146/annurev-immunol-020711-075021; Laviolette M, 2013, J ALLERGY CLIN IMMUN, V132; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; Lemanske RF, 2010, NEW ENGL J MED, V362, P975, DOI 10.1056/NEJMoa1001278; Li HM, 1996, J IMMUNOL, V156, P4833; Li-Weber M, 2003, NAT REV IMMUNOL, V3, P534, DOI 10.1038/nri1128; Lipworth BJ, 1999, ARCH INTERN MED, V159, P941, DOI 10.1001/archinte.159.9.941; Lloyd CM, 2013, J ALLERGY CLIN IMMUN, V131, P1267, DOI 10.1016/j.jaci.2013.02.016; Maazi H, 2013, ALLERGY, V68, P695, DOI 10.1111/all.12166; Martinez FD, 2011, J ALLERGY CLIN IMMUN, V128, P939, DOI 10.1016/j.jaci.2011.09.020; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; Molfino NA, 2012, CLIN EXP ALLERGY, V42, P712, DOI 10.1111/j.1365-2222.2011.03854.x; MONTEFORT S, 1993, RESP MED, V87, P9, DOI 10.1016/0954-6111(93)90118-J; Morishima Y, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/609395; Mueller TD, 2002, BBA-MOL CELL RES, V1592, P237, DOI 10.1016/S0167-4889(02)00318-X; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Navarro S, 2011, MUCOSAL IMMUNOL, V4, P53, DOI 10.1038/mi.2010.51; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; Nicolai T, 2003, EUR RESPIR J, V21, P956, DOI 10.1183/09031936.03.00041103a; Normansell R, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003559.pub4; Nutku E, 2003, BLOOD, V101, P5014, DOI 10.1182/blood-2002-10-3058; Nwaru BI, 2013, J ALLERGY CLIN IMMUN, V131, P78, DOI 10.1016/j.jaci.2012.10.028; O'Hehir RE, 2009, AM J RESP CRIT CARE, V180, P936, DOI 10.1164/rccm.200905-0686OC; Ochiai K, 1997, CLIN EXP IMMUNOL, V107, P198, DOI 10.1046/j.1365-2249.1997.d01-884.x; Oh CK, 2010, EUR RESPIR REV, V19, P46, DOI 10.1183/09059180.00007609; Ordonez CL, 2000, AM J RESP CRIT CARE, V161, P1185, DOI 10.1164/ajrccm.161.4.9812061; Otero K, 2010, BLOOD, V116, P2942, DOI 10.1182/blood-2009-12-259903; Partridge Martyn R, 2006, BMC Pulm Med, V6, P13, DOI 10.1186/1471-2466-6-13; Patel AC, 2009, ANNU REV PHYSIOL, V71, P425, DOI 10.1146/annurev.physiol.010908.163253; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Pearce N, 2007, THORAX, V62, P758, DOI 10.1136/thx.2006.070169; Pearlman DS, 2008, ANN ALLERG ASTHMA IM, V101, P90, DOI 10.1016/S1081-1206(10)60840-X; Perera F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004488; Perez-de-Llano LA, 2010, EUR RESPIR J, V35, P1221, DOI 10.1183/09031936.00118809; Peters MC, 2014, J ALLERGY CLIN IMMUN, V133, P388, DOI 10.1016/j.jaci.2013.07.036; Peters SP, 2010, NEW ENGL J MED, V363, P1715, DOI 10.1056/NEJMoa1008770; Philip G, 2009, J ALLERGY CLIN IMMUN, V124, p[699, e8]; Philip G, 2009, J ALLERGY CLIN IMMUN, V124, p[691, e6]; Phillips C, 2003, J LEUKOCYTE BIOL, V73, P165, DOI 10.1189/jlb.0702356; Pichavant M, 2005, J ALLERGY CLIN IMMUN, V115, P771, DOI 10.1016/j.jaci.2004.11.043; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; Rabe KF, 2000, EUR RESPIR J, V16, P802, DOI 10.1183/09031936.00.16580200; Reber L, 2006, EUR J PHARMACOL, V533, P327, DOI 10.1016/j.ejphar.2005.12.067; Reber LL, 2012, J IMMUNOL, V188, P3478, DOI 10.4049/jimmunol.1004227; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Saenz SA, 2010, NATURE, V464, P1362, DOI 10.1038/nature08901; Saglani S, 2013, J ALLERGY CLIN IMMUN, V132, P676, DOI 10.1016/j.jaci.2013.04.012; Sakuishi K, 2007, J IMMUNOL, V179, P3452, DOI 10.4049/jimmunol.179.6.3452; Salazar F, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00356; Schmid-Grendelmeier P, 2002, J IMMUNOL, V169, P1021, DOI 10.4049/jimmunol.169.2.1021; Schoenborn JR, 2007, ADV IMMUNOL, V96, P41, DOI 10.1016/S0065-2776(07)96002-2; Sehmi R, 1997, J CLIN INVEST, V100, P2466, DOI 10.1172/JCI119789; Serra-Batlles J, 1998, EUR RESPIR J, V12, P1322, DOI 10.1183/09031936.98.12061322; Shaw DE, 2007, AM J RESP CRIT CARE, V176, P231, DOI 10.1164/rccm.200610-1427OC; Silverstein MD, 2001, J PEDIATR-US, V139, P278, DOI 10.1067/mpd.2001.115573; Sitkauskiene B, 2004, AM J RESP CELL MOL, V30, P367, DOI 10.1165/rcmb.2002-0311OC; Slager RE, 2012, J ALLERGY CLIN IMMUN, V130, P516, DOI 10.1016/j.jaci.2012.03.030; Sonnappa S, 2011, EUR RESPIR J, V38, P1431, DOI 10.1183/09031936.00164910; Strachan DP, 1998, THORAX, V53, P204, DOI 10.1136/thx.53.3.204; Suissa S, 2001, J ALLERGY CLIN IMMUN, V107, P937, DOI 10.1067/mai.2001.115653; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; Sullivan PW, 2011, J ALLERGY CLIN IMMUN, V127, P363, DOI 10.1016/j.jaci.2010.10.042; Szabo Shelagh M, 2013, Paediatr Respir Rev, V13 Suppl 2, pS9, DOI 10.1016/S1526-0542(12)70161-6; Tyner JW, 2006, J CLIN INVEST, V116, P309, DOI 10.1172/JCI25167; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358, DOI 10.1164/ajrccm.149.2.8306030; Warner SM, 2008, CURR OPIN ALLERGY CL, V8, P44, DOI 10.1097/ACI.0b013e3282f3b5cb; Wechsler ME, 2013, J ALLERGY CLIN IMMUN, V132, P1295, DOI 10.1016/j.jaci.2013.08.009; Wechsler ME, 2009, LANCET, V374, P1754, DOI 10.1016/S0140-6736(09)61492-6; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048; Wenzel SE, 2007, J ALLERGY CLIN IMMUN, V119, P14, DOI 10.1016/j.jaci.2006.10.025; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Wilson RH, 2009, AM J RESP CRIT CARE, V180, P720, DOI 10.1164/rccm.200904-0573OC; Woodcock A, 2013, CHEST, V144, P1222, DOI 10.1378/chest.13-0178; Xiao C, 2011, J ALLERGY CLIN IMMUN, V128, P549, DOI 10.1016/j.jaci.2011.05.038; YING S, 1995, AM J RESP CELL MOL, V12, P477, DOI 10.1165/ajrcmb.12.5.7742012; Zahran Hatice S., 2011, Morbidity and Mortality Weekly Report, V60, P547; Zhang Y, 2014, J ALLERGY CLIN IMMUN, V133; Zimmermann N, 2008, ALLERGY, V63, P1156, DOI 10.1111/j.1398-9995.2008.01709.x; Zimmermann N, 2003, J ALLERGY CLIN IMMUN, V111, P227, DOI 10.1067/mai.2003.139	172	160	169	1	45	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 24	2014	349								g5517	10.1136/bmj.g5517	http://dx.doi.org/10.1136/bmj.g5517			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AW2KC	25420994				2023-01-03	WOS:000346115400001
J	Shuang, F; Hou, SX; Zhu, JL; Ren, DF; Cao, Z; Tang, JG				Shuang, Feng; Hou, Shu-Xun; Zhu, Jia-Liang; Ren, Dong-Feng; Cao, Zheng; Tang, Jia-Guang			Percutaneous Resolution of Lumbar Facet Joint Cysts as an Alternative Treatment to Surgery: A Meta-Analysis	PLOS ONE			English	Article							INTRASPINAL SYNOVIAL CYSTS; INDUCED RADICULAR PAIN; LOW-BACK-PAIN; STEROID INJECTION; FLUOROSCOPIC GUIDANCE; FOLLOW-UP; ASPIRATION; RUPTURE; MANAGEMENT; DIAGNOSIS	Purpose: A comprehensive review of the literature in order to analyze data about the success rate of percutaneous resolution of the lumbar facet joint cysts as a conservative management strategy. Methods: A systematic search for relevant articles published during 1980 to May 2014 was performed in several electronic databases by using the specific MeSH terms and keywords. Most relevant data was captured and pooled for the meta-analysis to achieve overall effect size of treatment along with 95% confidence intervals. Results: 29 studies were included in the meta-analysis. Follow-up duration as mean +/- sd (range) was 16 +/- 10.2 (5 days to 5.7 years). Overall the satisfactory results (after short-or long-term follow-up) were achieved in 55.8 [49.5, 62.08] % (pooled mean and 95% CI) of the 544 patients subjected to percutaneous lumbar facet joint cyst resolution procedures. 38.67 [33.3, 43.95] % of this population underwent surgery subsequently to achieve durable relief. There existed no linear relationship between the increasing average duration of follow-up period of individual studies and percent satisfaction from the percutaneous resolutions procedure. Conclusion: Results shows that the percutaneous cyst resolution procedures have potential to be an alternative to surgical interventions but identification of suitable subjects requires further research.	[Shuang, Feng; Hou, Shu-Xun; Zhu, Jia-Liang; Ren, Dong-Feng; Cao, Zheng; Tang, Jia-Guang] Chinese Peoples Liberat Army Gen Hosp, Affiliated Hosp 1, Dept Orthopaed, Beijing 100853, Peoples R China; [Shuang, Feng] 94th Hosp Chinese PLA, Dept Orthoped, Nanchang, Peoples R China	Chinese People's Liberation Army General Hospital	Hou, SX (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Affiliated Hosp 1, Dept Orthopaed, Beijing 100853, Peoples R China.	houshuxun_2000@163.com; jiaguangtang@yahoo.com.cn			National Natural Science Foundation of China [81071514]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (No. 81071514). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABDULLAH AF, 1984, J NEUROSURG, V60, P617, DOI 10.3171/jns.1984.60.3.0617; Alicioglu B, 2009, Prague Med Rep, V110, P301; Allen TL, 2009, SPINE J, V9, P387, DOI 10.1016/j.spinee.2008.08.008; Amoretti N, 2012, EUR RADIOL, V22, P2836, DOI 10.1007/s00330-012-2533-z; [Anonymous], SURG NEUROL INT S3; Arnold PM, 2009, SPINE J, V9, P919, DOI [10.1016/j.spinee.2009.07.003, 10.1016/j.spinee.2008.08.010]; Ayberk G, 2008, NEUROL MED-CHIR, V48, P298, DOI 10.2176/nmc.48.298; BJORKENGREN AG, 1987, AM J ROENTGENOL, V149, P105, DOI 10.2214/ajr.149.1.105; Boissiere L, 2013, BMJ CASE REP, V2013; Boviatsis EJ, 2008, EUR SPINE J, V17, P831, DOI 10.1007/s00586-007-0563-z; Braza DW, 2005, AM J PHYS MED REHAB, V84, P911, DOI 10.1097/01.phm.0000184216.24478.7e; BUDRIS DM, 1991, ORTHOPEDICS, V14, P618; Bureau NJ, 2001, RADIOLOGY, V221, P179, DOI 10.1148/radiol.2211010213; Cambron SC, 2013, AM J NEURORADIOL, V34, P1661, DOI 10.3174/ajnr.A3441; CARRERA GF, 1980, RADIOLOGY, V137, P665, DOI 10.1148/radiology.137.3.6449717; CASSELMAN ES, 1985, AM J NEURORADIOL, V6, P971; Chang Anthony, 2009, HSS J, V5, P165, DOI 10.1007/s11420-009-9124-9; DePalma MJ, 2009, SPINE J, V9, P921, DOI 10.1016/j.spinee.2009.08.003; Deyo RA, 2001, NEW ENGL J MED, V344, P363, DOI 10.1056/NEJM200102013440508; Foley BS, 2009, AM J PHYS MED REHAB, V88, P1046, DOI 10.1097/PHM.0b013e3181b721ef; Gheyi VK, 1999, CLIN IMAG, V23, P394, DOI 10.1016/S0899-7071(99)00164-3; Gishen P, 2001, CARDIOVASC INTER RAD, V24, P351, DOI 10.1007/s00270-001-0023-9; HONG YY, 1995, ANESTHESIOLOGY, V82, P1061, DOI 10.1097/00000542-199504000-00028; Imai K, 1998, ARCH ORTHOP TRAUM SU, V118, P103, DOI 10.1007/s004020050323; Kennedy DJ, 2009, PAIN MED, V10, P1389, DOI 10.1111/j.1526-4637.2009.00728.x; Kozar S, 2014, RADIOL ONCOL, V48, P35, DOI 10.2478/raon-2013-0024; KURZ LT, 1985, J BONE JOINT SURG AM, V67A, P865, DOI 10.2106/00004623-198567060-00006; Lim AKP, 2001, CLIN RADIOL, V56, P990, DOI 10.1053/crad.2001.0710; Lin TL, 2014, J CHIN MED ASSOC, V77, P213, DOI 10.1016/j.jcma.2014.01.003; Lutz GE, 2002, ARCH PHYS MED REHAB, V83, P1789, DOI 10.1053/apmr.2002.34601; Martha JF, 2009, SPINE J, V9, P899, DOI 10.1016/j.spinee.2009.06.010; Melfi RS, 2005, PAIN MED, V6, P122, DOI 10.1111/j.1526-4637.2005.05021.x; Ortiz AO, 2014, J NEUROINTERV SURG, V6, P790, DOI 10.1136/neurintsurg-2013-010891; Parlier-Cuau C, 1999, RADIOLOGY, V210, P509, DOI 10.1148/radiology.210.2.r99fe60509; Rauchwerger JJ, 2011, PAIN PRACT, V11, P180, DOI 10.1111/j.1533-2500.2010.00411.x; Sabers SR, 2005, ARCH PHYS MED REHAB, V86, P1767, DOI 10.1016/j.apmr.2004.11.051; Sauvage PJ, 2000, J RADIOL, V81, P33; Schulz C, 2011, ORTHOPADE, V40, P600, DOI 10.1007/s00132-011-1744-3; Shah Rinoo V, 2003, Spine J, V3, P479, DOI 10.1016/S1529-9430(03)00148-7; Shin KM, 2012, KOREAN J ANESTHESIOL, V62, P375, DOI 10.4097/kjae.2012.62.4.375; Shipley JA, 1998, J BONE JOINT SURG BR, V80B, P662, DOI 10.1302/0301-620X.80B4.8323; Slipman CW, 2000, ARCH PHYS MED REHAB, V81, P973, DOI 10.1053/apmr.2000.5584; United States Department of Health and Human Services. National Institute of Health, QUAL ASS TOOL OBS CO	43	19	19	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2014	9	11							e111695	10.1371/journal.pone.0111695	http://dx.doi.org/10.1371/journal.pone.0111695			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA8CP	25389771	Green Submitted, Green Published, gold			2023-01-03	WOS:000349144400029
J	Hou, YJ; Wang, Y; Zhao, J; Li, XH; Cui, J; Ding, JQ; Wang, Y; Zeng, XL; Ling, Y; Shen, XH; Chen, SD; Huang, CG; Pei, G				Hou, Yujun; Wang, Ying; Zhao, Jian; Li, Xiaohang; Cui, Jin; Ding, Jianqing; Wang, Ying; Zeng, Xianglu; Ling, Yun; Shen, Xiaoheng; Chen, Shengdi; Huang, Chenggang; Pei, Gang			Smart Soup, a Traditional Chinese Medicine Formula, Ameliorates Amyloid Pathology and Related Cognitive Deficits	PLOS ONE			English	Article							MOUSE MODEL; ALZHEIMERS-DISEASE; MEMORY DEFICITS; BETA; DROSOPHILA; EXPRESSION; OLIGOMERS; EXTRACT; BT-11; BRAIN	Alzheimer's disease (AD) is a progressive neurodegenerative disease that causes substantial public health care burdens. Intensive efforts have been made to find effective and safe disease-modifying treatment and symptomatic intervention alternatives against AD. Smart Soup (SS), a Chinese medicine formula composed of Rhizoma Acori Tatarinowii (AT), Poria cum Radix Pini (PRP) and Radix Polygalae (RP), is a typical prescription against memory deficits. Here, we assessed the efficacy of SS against AD. Oral administration of SS ameliorated the cognitive impairment of AD transgenic mice, with reduced A beta levels, retarded A beta amyloidosis and reduced A beta-induced gliosis and neuronal loss in the brains of AD mice. Consistently, SS treatment reduced amyloid-related locomotor dysfunctions and premature death of AD transgenic Drosophila. Mechanistic studies showed that RP reduced A beta generation, whereas AT and PRP exerted neuroprotective effects against A beta. Taken together, our study indicates that SS could be effective against AD, providing a practical therapeutic strategy against the disease.	[Hou, Yujun; Zhao, Jian; Li, Xiaohang; Cui, Jin; Zeng, Xianglu; Pei, Gang] Chinese Acad Sci, Shanghai Inst Biol Sci, Grad Sch, State Key Lab Cell Biol,Inst Biochem & Cell Biol, Shanghai, Peoples R China; [Wang, Ying; Ding, Jianqing; Chen, Shengdi] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Inst Neurol, Shanghai 200030, Peoples R China; [Wang, Ying] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Neurol, Shanghai 200030, Peoples R China; [Ling, Yun; Huang, Chenggang] Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 200031, Peoples R China; [Shen, Xiaoheng] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Tradit Chinese Med, Shanghai 200030, Peoples R China; [Pei, Gang] Tongji Univ, Sch Life Sci & Technol, Shanghai Key Lab Signaling & Dis Res, Shanghai 200092, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Shanghai Jiao Tong University; Tongji University	Zhao, J (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Grad Sch, State Key Lab Cell Biol,Inst Biochem & Cell Biol, Shanghai, Peoples R China.	jzhao@sibs.ac.cn; gpei@sibs.ac.cn	Hou, Yujun/AFX-2626-2022; Zhao, Jian/E-2008-2019	Zhao, Jian/0000-0002-8862-0591; Hou, Yujun/0000-0003-1778-1176; Li, Xiaohang/0000-0002-7316-2196	National Natural Science Foundation of China [31371419]; Chinese Academy of Sciences [KSCX2-EW-Q-1-01, KSCX2-YW-R-252]; National Science and Technology [2012BAI10B03]; Ministry of Science and Technology [2011CB910202]; Shanghai Municipal Commission for Science and Technology [13401900600]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese Academy of Sciences(Chinese Academy of Sciences); National Science and Technology; Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Shanghai Municipal Commission for Science and Technology	This work was supported by National Natural Science Foundation of China (31371419), Chinese Academy of Sciences (KSCX2-EW-Q-1-01, KSCX2-YW-R-252), National Science and Technology Support Program (2012BAI10B03), the Ministry of Science and Technology (2011CB910202) and Shanghai Municipal Commission for Science and Technology (13401900600). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alamed J, 2006, NAT PROTOC, V1, P1671, DOI 10.1038/nprot.2006.275; Bero AW, 2011, NAT NEUROSCI, V14, P750, DOI 10.1038/nn.2801; Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205; Bilen J, 2005, ANNU REV GENET, V39, P153, DOI 10.1146/annurev.genet.39.110304.095804; BRAND AH, 1993, DEVELOPMENT, V118, P401; Cao DF, 2007, J BIOL CHEM, V282, P36275, DOI 10.1074/jbc.M703561200; Cartier AE, 2009, J NEUROSCI, V29, P7857, DOI 10.1523/JNEUROSCI.1817-09.2009; Chakraborty R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020799; Chen YL, 2004, J ETHNOPHARMACOL, V95, P47, DOI 10.1016/j.jep.2004.06.015; Cheng IH, 2007, J BIOL CHEM, V282, P23818, DOI 10.1074/jbc.M701078200; Cisse M, 2011, NATURE, V469, P47, DOI 10.1038/nature09635; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; Hamilton A, 2012, BRAIN RES, V1449, P83, DOI 10.1016/j.brainres.2012.02.015; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Howes MJR, 2003, PHARMACOL BIOCHEM BE, V75, P513, DOI 10.1016/S0091-3057(03)00128-X; Iijima K, 2008, J ALZHEIMERS DIS, V15, P523; Jankowsky JL, 2004, HUM MOL GENET, V13, P159, DOI 10.1093/hmg/ddh019; Jankowsky JL, 2001, BIOMOL ENG, V17, P157, DOI 10.1016/S1389-0344(01)00067-3; Kraft AW, 2012, FASEB J OFFICIAL PUB; Lazarov O, 2005, CELL, V120, P701, DOI 10.1016/j.cell.2005.01.015; Lee BB, 2003, LIFE SCI, V74, P435, DOI 10.1016/j.lfs.2003.06.034; Lee JY, 2009, NEUROSCI LETT, V454, P111, DOI 10.1016/j.neulet.2009.03.024; Lesne S, 2008, NEUROSCIENCE, V151, P745, DOI 10.1016/j.neuroscience.2007.10.054; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Lin ZH, 2012, EVID-BASED COMPL ALT, V2012, P1, DOI 10.1155/2012/692621; Ling Y, 2013, PHYTOCHEM ANALYSIS, V24, P677, DOI 10.1002/pca.2454; Liu XS, 2013, CELL RES, V23, P351, DOI 10.1038/cr.2012.167; Lu JH, 2011, CHEMBIOCHEM, V12, P615, DOI 10.1002/cbic.201000604; McGeer EG, 2003, PROG NEURO-PSYCHOPH, V27, P741, DOI 10.1016/S0278-5846(03)00124-6; Mhatre SD, 2014, DIS MODEL MECH, V7, P373, DOI 10.1242/dmm.012104; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Muqit MMK, 2002, NAT REV NEUROSCI, V3, P237, DOI 10.1038/nrn751; Park CH, 2002, J NEUROSCI RES, V70, P484, DOI 10.1002/jnr.10429; Reiserer RS, 2007, GENES BRAIN BEHAV, V6, P54, DOI 10.1111/j.1601-183X.2006.00221.x; Selkoe DJ, 2002, J CLIN INVEST, V110, P1375, DOI 10.1172/JCI200216783; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Shin KY, 2009, NEUROSCI LETT, V465, P157, DOI 10.1016/j.neulet.2009.08.033; Stine WB, 2003, J BIOL CHEM, V278, P11612, DOI 10.1074/jbc.M210207200; Teng L, 2010, CELL RES, V20, P138, DOI 10.1038/cr.2010.3; Tian XY, 2012, CHIN J INTEGR MED, V18, P539, DOI 10.1007/s11655-011-0900-2; Tong XG, 2010, J ASIAN NAT PROD RES, V12, P419, DOI 10.1080/10286021003762010; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Walsh DM, 2007, J NEUROCHEM, V101, P1172, DOI 10.1111/j.1471-4159.2006.04426.x; White KE, 2010, FRONT NEUROSCI-SWITZ, V4, DOI 10.3389/fnins.2010.00205; Winslow BT, 2011, AM FAM PHYSICIAN, V83, P1403; Zhao XL, 2010, J NEUROSCI, V30, P1512, DOI 10.1523/JNEUROSCI.3699-09.2010	47	33	37	2	40	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2014	9	11							e111215	10.1371/journal.pone.0111215	http://dx.doi.org/10.1371/journal.pone.0111215			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT9MC	25386946	gold, Green Published, Green Submitted			2023-01-03	WOS:000345250400015
J	Jin, A; Lalonde, CE; Brussoni, M; McCormick, R; George, MA				Jin, Andrew; Lalonde, Christopher E.; Brussoni, Mariana; McCormick, Rod; George, M. Anne			Injury Hospitalizations Due to Unintentional Falls among the Aboriginal Population of British Columbia, Canada: Incidence, Changes over Time, and Ecological Analysis of Risk Markers, 1991-2010	PLOS ONE			English	Article								Background Aboriginal people in British Columbia (BC) have higher injury incidence than the general population. Our project describes variability among injury categories, time periods, and geographic, demographic and socio-economic groups. This report focuses on unintentional falls. Methods We used BC's universal health care insurance plan as a population registry, linked to hospital separation and vital statistics databases. We identified Aboriginal people by insurance premium group and birth and death record notations. We identified residents of specific Aboriginal communities by postal code. We calculated crude incidence and Standardized Relative Risk (SRR) of hospitalization for unintentional fall injury, standardized for age, gender and Health Service Delivery Area (HSDA), relative to the total population of BC. We tested hypothesized associations of geographic, socio-economic, and employment-related characteristics with community SRR of injury by linear regression. Results During 1991 through 2010, the crude rate of hospitalization for unintentional fall injury in BC was 33.6 per 10,000 person-years. The Aboriginal rate was 49.9 per 10,000 and SRR was 1.89 (95% confidence interval 1.85-1.94). Among those living on reserves SRR was 2.00 (95% CI 1.93-2.07). Northern and non-urban HSDAs had higher SRRs, within both total and Aboriginal populations. In every age and gender category, the HSDA-standardized SRR was higher among the Aboriginal than among the total population. Between 1991 and 2010, crude rates and SRRs declined substantially, but proportionally more among the Aboriginal population, so the gap between the Aboriginal and total population is narrowing, particularly among females and older adults. These community characteristics were associated with higher risk: lower income, lower educational level, worse housing conditions, and more hazardous types of employment. Conclusions Over the years, as socio-economic conditions improve, risk of hospitalization due to unintentional fall injury has declined among the Aboriginal population. Women and older adults have benefited more.	[Jin, Andrew] Epidemiol Consultant, Surrey, BC, Canada; [Lalonde, Christopher E.] Univ Victoria, Dept Psychol, Fac Social Sci, Victoria, BC, Canada; [Brussoni, Mariana; George, M. Anne] Univ British Columbia, Dept Pediat, Fac Med, Vancouver, BC V6T 1W5, Canada; [Brussoni, Mariana; George, M. Anne] Child & Family Res Inst, Vancouver, BC, Canada; [Brussoni, Mariana; George, M. Anne] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC V5Z 1M9, Canada; [McCormick, Rod] Thompson Rivers Univ, Fac Human Social & Educ Dev, Kamloops, BC, Canada	University of Victoria; University of British Columbia; Child & Family Research Institute; University of British Columbia	George, MA (corresponding author), Univ No British Columbia, Prince George, BC V2L 5P2, Canada.	ageorge@mail.ubc.ca	Brussoni, Mariana/U-9404-2018; Jin, Andrew/H-5725-2019	Brussoni, Mariana/0000-0002-1495-816X; Jin, Andrew/0000-0002-8708-2381; George, M. Anne/0000-0001-7129-2117; Lalonde, Christopher/0000-0002-0446-0464	Canadian Institutes of Health Research, Institute of Aboriginal Peoples Health [81043]; Child & Family Research Institute; Michael Smith Foundation; British Columbia Region, First Nations and Inuit Health, Health Canada	Canadian Institutes of Health Research, Institute of Aboriginal Peoples Health(Canadian Institutes of Health Research (CIHR)); Child & Family Research Institute; Michael Smith Foundation(Michael Smith Foundation for Health Research); British Columbia Region, First Nations and Inuit Health, Health Canada	Funding: This work was funded by the Canadian Institutes of Health Research, Institute of Aboriginal Peoples Health [grant number AHR # 81043]. Salary support for authors was provided by the Child & Family Research Institute (MAG, MB), by a Michael Smith Foundation for Health Research Scholar Award (MB), and the British Columbia Region, First Nations and Inuit Health, Health Canada (AJ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BC Ministry of Health [creator], 2012, CONS FIL MSP REG PRE; BC Ministry of Health [creator], 2011, DISCH ABSTR DAT HOSP; BC Vital Statistics Agency, 2011, VIT STAT DEATHS; BC Vital Statistics Agency [creator], 2011, VIT STAT BIRTHS; Bell N, 2011, INJURY PREV, V17, P394, DOI 10.1136/ip.2010.030866; Bridges FS, 2005, PSYCHOL REP, V97, P739, DOI 10.2466/pr0.97.3.739-749; *BRIT COL VIT STAT, 2004, REG AN HLTH STAT STA; British Columbia. Provincial Health Officer, 2009, PATHW HLTH HEAL 2 RE; Brussoni M, 2014, PREV SCI; Chandler M. J., 1998, TRANSCULT PSYCHIATRY, V35, P191, DOI DOI 10.1177/136346159803500202; Cloutier E, 2001, EC BURDEN UNINTENTIO; Corporate Information Management Directorate, 2005, INF MAN BRACH BAND C; Desapriya E, 2011, INJURY PREV, V17, P4, DOI 10.1136/ip.2010.026914; Evans RG, 1994, WHY ARE SOME POEPLE; George MA, 2015, HEALTH REP, V26, P3; George MA, 2013, INT J CIRCUMPOL HEAL, V72, P441, DOI 10.3402/ijch.v72i0.21182; Jin A, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-710; Kahn HA, 1989, STAT METHODS EPIDEMI, P95; Penney C, 2012, COMMUNITY WELL BEING; Sayer P, 2009, DEMOGRAPHIC SOCIOECO; Scott V., 2004, PREVENTION FALLS INJ; *SMARTRISK, 2009, EC BURD INJ CAN; Tjepkema Michael, 2011, Health Rep, V22, P25	23	15	15	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2015	10	3							e0121694	10.1371/journal.pone.0121694	http://dx.doi.org/10.1371/journal.pone.0121694			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE8HY	25793298	Green Published, Green Submitted, gold			2023-01-03	WOS:000352083900147
J	Lakhani, M				Lakhani, Mayur			IF I RULED THE NHS Palliative care for everyone with advanced progressive incurable illness	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Natl Council Palliat Care, Alexandria, VA 22314 USA		Lakhani, M (corresponding author), Natl Council Palliat Care, Alexandria, VA 22314 USA.	mk.lakhani@gp-c82644.nhs.uk							0	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 5	2015	350								h605	10.1136/bmj.h605	http://dx.doi.org/10.1136/bmj.h605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CB0JX	25654997				2023-01-03	WOS:000349313100013
J	Huang, H; Li, XY; Zhu, J; Ye, S; Zhang, HY; Wang, W; Wu, XY; Peng, JW; Xu, B; Lin, YC; Cao, YB; Li, HR; Lin, SX; Liu, Q; Lin, TY				Huang, He; Li, Xueying; Zhu, Jun; Ye, Sheng; Zhang, Hongyu; Wang, Wei; Wu, Xiangyuan; Peng, Jiewen; Xu, Bing; Lin, Yingcheng; Cao, Yabing; Li, Haoran; Lin, Suxia; Liu, Qing; Lin, Tongyu			Entecavir vs Lamivudine for Prevention of Hepatitis B Virus Reactivation Among Patients With Untreated Diffuse Large B-Cell Lymphoma Receiving R-CHOP Chemotherapy A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEROPOSITIVE CANCER-PATIENTS; NON-HODGKINS-LYMPHOMA; HBV REACTIVATION; ELDERLY-PATIENTS; HIGH PREVALENCE; PROPHYLACTIC LAMIVUDINE; CYTOTOXIC CHEMOTHERAPY; PREEMPTIVE LAMIVUDINE; PLUS RITUXIMAB; DES-LYMPHOMES	IMPORTANCE Hepatitis B virus (HBV) reactivation is a serious complication for patients with lymphoma treated with rituximab-containing chemotherapies, despite lamivudine prophylaxis treatment. An optimal prophylactic antiviral protocol has not been determined. OBJECTIVE To compare the efficacy of entecavir and lamivudine in preventing HBV reactivation in patients seropositive for the hepatitis B surface antigen with untreated diffuse large B-cell lymphoma receiving chemotherapy treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). DESIGN, SETTING, AND PATIENTS Randomized, open-label, phase 3 study conducted from February 2008 through December 2012 at 10 medical centers in China. This study was a substudy of a parent study designed to compare a 3-week with a 2-week R-CHOP chemotherapy regimen for untreated diffuse large B-cell lymphoma. Patients enrolled in the parent study who were seropositive for the hepatitis B surface antigen and had normal liver function, serum HBV DNA levels of less than 10(3) copies/mL, and no prior antiviral therapy were randomized to entecavir (n = 61) or lamivudine (n = 60). INTERVENTIONS Daily entecavir (0.5 mg) or lamivudine (100 mg) beginning 1week before the initiation of R-CHOP treatment to 6 months after completion of chemotherapy. MAIN OUTCOMES AND MEASURES The primary efficacy end point was the incidence of HBV-related hepatitis. The secondary end points included rates of HBV reactivation, chemotherapy disruption due to hepatitis, and treatment-related adverse events. RESULTS The date of last patient follow-up was May 25, 2013. Incidence of HBV-related hepatitis was significantly lower for the entecavir group vs the lamivudine group. [GRAPHICS] CONCLUSIONS AND RELEVANCE Among patients seropositive for the hepatitis B surface antigen with diffuse large B-cell lymphoma undergoing R-CHOP chemotherapy, the addition of entecavir compared with lamivudine resulted in a lower incidence of HBV-related hepatitis and HBV reactivation. If replicated, these findings support the use of entecavir in these patients.	[Huang, He; Li, Xueying; Li, Haoran; Lin, Tongyu] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou 510060, Guangdong, Peoples R China; [Zhu, Jun] Beijing Canc Hosp, Dept Med Oncol, Beijing, Peoples R China; [Ye, Sheng] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Med Oncol, Guangzhou 510060, Guangdong, Peoples R China; [Zhang, Hongyu] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Med Oncol, Zhuhai, Peoples R China; [Wang, Wei] First Peoples Hosp Foshan, Ctr Canc, Foshan, Peoples R China; [Wu, Xiangyuan] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Med Oncol, Guangzhou 510060, Guangdong, Peoples R China; [Peng, Jiewen] Peoples Hosp Zhongshan, Ctr Canc, Zhongshan, Peoples R China; [Xu, Bing] Southern Med Univ, Dept Hematol, Southern Hosp, Guangzhou, Guangdong, Peoples R China; [Lin, Yingcheng] Shantou Univ, Coll Med, Dept Med Oncol, Canc Hosp, Shantou, Peoples R China; [Cao, Yabing] Kiang Wu Hosp, Ctr Canc, Macau, Peoples R China; [Lin, Suxia] Sun Yat Sen Univ, Ctr Canc, Dept Pathol, Guangzhou 510060, Guangdong, Peoples R China; [Liu, Qing] Sun Yat Sen Univ, Dept Epidemiol & Biostat, Dept Pathol, Guangzhou 510060, Guangdong, Peoples R China	Sun Yat Sen University; Peking University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Southern Medical University - China; Shantou University; Sun Yat Sen University; Sun Yat Sen University	Lin, TY (corresponding author), Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, 651 Dongfeng Rd E, Guangzhou 510060, Guangdong, Peoples R China.	tongyulin@hotmail.com	Cao, Yabing/X-1168-2018		Foundation of 5010 Clinical Trials of Sun Yat-sen University	Foundation of 5010 Clinical Trials of Sun Yat-sen University	This study was supported by a grant from the Foundation of 5010 Clinical Trials of Sun Yat-sen University.	Cancer Therapy Evaluation Program, 2006, COMM TERM CRIT ADV E; Chang TT, 2006, NEW ENGL J MED, V354, P1001, DOI 10.1056/NEJMoa051285; Chen MH, 2008, ANN HEMATOL, V87, P475, DOI 10.1007/s00277-008-0469-9; Cil T, 2008, LEUKEMIA LYMPHOMA, V49, P939, DOI 10.1080/10428190801975568; Coiffier B, 2005, J CLIN ONCOL, V23, P6387, DOI 10.1200/JCO.2005.05.015; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; Coiffier B, 2010, BLOOD, V116, P2040, DOI 10.1182/blood-2010-03-276246; Dai MS, 2004, ANN HEMATOL, V83, P769, DOI 10.1007/s00277-004-0899-y; Espy MJ, 2006, CLIN MICROBIOL REV, V19, P165, DOI 10.1128/CMR.19.1.165-256.2006; Evens AM, 2011, ANN ONCOL, V22, P1170, DOI 10.1093/annonc/mdq583; Feugier P, 2005, J CLIN ONCOL, V23, P4117, DOI 10.1200/JCO.2005.09.131; Hsu CH, 2004, ANTICANCER RES, V24, P3035; Hsu C, 2008, HEPATOLOGY, V47, P844, DOI 10.1002/hep.22106; Huang YH, 2013, J CLIN ONCOL, V31, P2765, DOI 10.1200/JCO.2012.48.5938; Idilman R, 2004, J VIRAL HEPATITIS, V11, P141, DOI 10.1046/j.1365-2893.2003.00479.x; Kang J, 2011, ANN HEMATOL, V90, P159, DOI 10.1007/s00277-010-1055-5; Lai CL, 2006, NEW ENGL J MED, V354, P1011, DOI 10.1056/NEJMoa051287; Lau GKK, 2003, GASTROENTEROLOGY, V125, P1742, DOI 10.1053/j.gastro.2003.09.026; Lee GW, 2003, J KOREAN MED SCI, V18, P849, DOI 10.3346/jkms.2003.18.6.849; Li HR, 2011, J VIRAL HEPATITIS, V18, P877, DOI 10.1111/j.1365-2893.2010.01386.x; Lim LL, 2002, ALIMENT PHARM THER, V16, P1939, DOI 10.1046/j.1365-2036.2002.01364.x; Lok ASF, 2009, HEPATOLOGY, V50, P661, DOI 10.1002/hep.23190; LOK ASF, 1991, GASTROENTEROLOGY, V100, P182, DOI 10.1016/0016-5085(91)90599-G; Long MJ, 2011, BREAST CANCER RES TR, V127, P705, DOI 10.1007/s10549-011-1455-9; Marcellin P, 2009, J HEPATOL, V50, P227, DOI 10.1016/j.jhep.2008.10.001; Marcucci F, 2006, HAEMATOLOGICA, V91, P554; National Comprehensive Cancer Network, 2013, PREV TREATM CANC REL; Park SC, 2008, J MED VIROL, V80, P960, DOI 10.1002/jmv.21168; Pei SN, 2010, ANN HEMATOL, V89, P255, DOI 10.1007/s00277-009-0806-7; Pfreundschuh M, 2008, LANCET ONCOL, V9, P105, DOI 10.1016/S1470-2045(08)70002-0; Pfreundschuh M, 2006, LANCET ONCOL, V7, P379, DOI 10.1016/S1470-2045(06)70664-7; Takai S, 2005, EUR J HAEMATOL, V74, P158, DOI 10.1111/j.1600-0609.2004.00376.x; Wang F, 2007, CANCER-AM CANCER SOC, V109, P1360, DOI 10.1002/cncr.22549; Yeo W, 2004, J CLIN ONCOL, V22, P927, DOI 10.1200/JCO.2004.05.161; Yeo W, 2004, BRIT J CANCER, V90, P1306, DOI 10.1038/sj.bjc.6601699; Yeo W, 2003, J MED VIROL, V70, P553, DOI 10.1002/jmv.10430; Yeo W, 2000, J MED VIROL, V62, P299, DOI 10.1002/1096-9071(200011)62:3&lt;299::AID-JMV1&gt;3.0.CO;2-0; Yeo WN, 2009, J CLIN ONCOL, V27, P605, DOI 10.1200/JCO.2008.18.0182	38	130	133	1	27	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 17	2014	312	23					2521	2530		10.1001/jama.2014.15704	http://dx.doi.org/10.1001/jama.2014.15704			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AW5YN	25514302	Bronze			2023-01-03	WOS:000346346900015
J	van den Bogert, B; Meijerink, M; Zoetendal, EG; Wells, JM; Kleerebezem, M				van den Bogert, Bartholomeus; Meijerink, Marjolein; Zoetendal, Erwin G.; Wells, Jerry M.; Kleerebezem, Michiel			Immunomodulatory Properties of Streptococcus and Veillonella Isolates from the Human Small Intestine Microbiota	PLOS ONE			English	Article							SEGMENTED FILAMENTOUS BACTERIA; TIGHT JUNCTION PROTEINS; PATCH DENDRITIC CELLS; GUT MICROBIOTA; LACTOBACILLUS-PLANTARUM; LY6C(HI) MONOCYTES; GENOME SEQUENCE; ORAL TOLERANCE; IMMUNE-SYSTEM; IN-VIVO	The human small intestine is a key site for interactions between the intestinal microbiota and the mucosal immune system. Here we investigated the immunomodulatory properties of representative species of commonly dominant small-intestinal microbial communities, including six streptococcal strains (four Streptococcus salivarius, one S. equinus, one S. parasanguinis) one Veillonella parvula strain, one Enterococcus gallinarum strain, and Lactobacillus plantarum WCFS1 as a bench mark strain on human monocyte-derived dendritic cells. The different streptococci induced varying levels of the cytokines IL-8, TNF-alpha, and IL-12p70, while the V. parvula strain showed a strong capacity to induce IL-6. E. gallinarum strain was a potent inducer of cytokines and TLR2/6 signalling. As Streptococcus and Veillonella can potentially interact metabolically and frequently co-occur in ecosystems, immunomodulation by pair-wise combinations of strains were also tested for their combined immunomodulatory properties. Strain combinations induced cytokine responses in dendritic cells that differed from what might be expected on the basis of the results obtained with the individual strains. A combination of (some) streptococci with Veillonella appeared to negate IL-12p70 production, while augmenting IL-8, IL-6, IL-10, and TNF-alpha responses. This suggests that immunomodulation data obtained in vitro with individual strains are unlikely to adequately represent immune responses to mixtures of gut microbiota communities in vivo. Nevertheless, analysing the immune responses of strains representing the dominant species in the intestine may help to identify immunomodulatory mechanisms that influence immune homeostasis.	[van den Bogert, Bartholomeus; Zoetendal, Erwin G.; Kleerebezem, Michiel] TIFN, Wageningen, Netherlands; [van den Bogert, Bartholomeus; Zoetendal, Erwin G.] Wageningen Univ, Microbiol Lab, NL-6700 AP Wageningen, Netherlands; [Meijerink, Marjolein; Wells, Jerry M.; Kleerebezem, Michiel] Wageningen Univ, Host Microbe Interact Grp, NL-6700 AP Wageningen, Netherlands; [Kleerebezem, Michiel] NIZO Food Res BV, Ede, Netherlands	Top Institute Food & Nutrition; Wageningen University & Research; Wageningen University & Research; NIZO Food Research	Kleerebezem, M (corresponding author), TIFN, Wageningen, Netherlands.	michiel.kleerebezem@wur.nl	Kleerebezem, Michiel/AAT-2078-2021	Meijerink, Martijn/0000-0002-1500-7294; Kleerebezem, Michiel/0000-0001-8552-2235	Top Institute Food and Nutrition, Wageningen, The Netherlands; Netherlands Bioinformatics Centre (NBIC)	Top Institute Food and Nutrition, Wageningen, The Netherlands(Netherlands Government); Netherlands Bioinformatics Centre (NBIC)	This work was supported by a project from the Top Institute Food and Nutrition, Wageningen, The Netherlands and by The Netherlands Bioinformatics Centre (NBIC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Arias CA, 2012, NAT REV MICROBIOL, V10, P266, DOI 10.1038/nrmicro2761; Benyacoub J, 2005, J NUTR, V135, P1171, DOI 10.1093/jn/135.5.1171; Boleij A, 2011, J INFECT DIS, V203, P1101, DOI 10.1093/infdis/jiq169; Bolotin A, 2004, NAT BIOTECHNOL, V22, P1554, DOI 10.1038/nbt1034; Booijink CCGM, 2010, ENVIRON MICROBIOL, V12, P3213, DOI 10.1111/j.1462-2920.2010.02294.x; Coombes JL, 2008, NAT REV IMMUNOL, V8, P435, DOI 10.1038/nri2335; de Goffau MC, 2014, DIABETOLOGIA, V57, P1569, DOI 10.1007/s00125-014-3274-0; Duerkop BA, 2009, IMMUNITY, V31, P368, DOI 10.1016/j.immuni.2009.08.009; Egland PG, 2004, P NATL ACAD SCI USA, V101, P16917, DOI 10.1073/pnas.0407457101; Gaboriau-Routhiau V, 2009, IMMUNITY, V31, P677, DOI 10.1016/j.immuni.2009.08.020; Hooper LV, 2001, SCIENCE, V291, P881, DOI 10.1126/science.291.5505.881; Ivanov II, 2010, MUCOSAL IMMUNOL, V3, P209, DOI 10.1038/mi.2010.3; Ivanov II, 2012, CELL HOST MICROBE, V12, P496, DOI 10.1016/j.chom.2012.09.009; Jumpertz R, 2011, AM J CLIN NUTR, V94, P58, DOI 10.3945/ajcn.110.010132; Karczewski J, 2010, AM J PHYSIOL-GASTR L, V298, pG851, DOI 10.1152/ajpgi.00327.2009; Kelly D, 2012, IMMUNOL REV, V245, P27, DOI 10.1111/j.1600-065X.2011.01079.x; KIYONO H, 1982, J EXP MED, V155, P605, DOI 10.1084/jem.155.2.605; Kleerebezem M, 2003, P NATL ACAD SCI USA, V100, P1990, DOI 10.1073/pnas.0337704100; Larsen N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009085; Lee YK, 2011, P NATL ACAD SCI USA, V108, P4615, DOI 10.1073/pnas.1000082107; Lelouard H, 2012, GASTROENTEROLOGY, V142, P592, DOI 10.1053/j.gastro.2011.11.039; Lelouard H, 2010, GASTROENTEROLOGY, V138, P173, DOI 10.1053/j.gastro.2009.09.051; Macpherson AJ, 2004, NAT REV IMMUNOL, V4, P478, DOI 10.1038/nri1373; Meijerink M, 2012, FEMS IMMUNOL MED MIC, V65, P488, DOI 10.1111/j.1574-695X.2012.00981.x; Meijerink M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035849; Meijerink M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010632; Morgan E, 2004, CLIN IMMUNOL, V110, P252, DOI 10.1016/j.clim.2003.11.017; Nagano Y, 2012, CURR OPIN IMMUNOL, V24, P392, DOI 10.1016/j.coi.2012.05.007; Neish AS, 2009, GASTROENTEROLOGY, V136, P65, DOI 10.1053/j.gastro.2008.10.080; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; Rivollier A, 2012, J EXP MED, V209, P139, DOI 10.1084/jem.20101387; Rusniok C, 2010, J BACTERIOL, V192, P2266, DOI 10.1128/JB.01659-09; Samuel BS, 2007, P NATL ACAD SCI USA, V104, P10643, DOI 10.1073/pnas.0704189104; Sava IG, 2010, CLIN MICROBIOL INFEC, V16, P533, DOI 10.1111/j.1469-0691.2010.03213.x; Smelt MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047244; Sokol H, 2008, P NATL ACAD SCI USA, V105, P16731, DOI 10.1073/pnas.0804812105; Sonnenburg JL, 2006, PLOS BIOL, V4, P2213, DOI 10.1371/journal.pbio.0040413; Stappenbeck TS, 2002, P NATL ACAD SCI USA, V99, P15451, DOI 10.1073/pnas.202604299; Surana NK, 2012, IMMUNOL REV, V245, P13, DOI 10.1111/j.1600-065X.2011.01075.x; Tanaka K, 2004, HISTOL HISTOPATHOL, V19, P907, DOI 10.14670/HH-19.907; Tims S, 2013, ISME J, V7, P707, DOI 10.1038/ismej.2012.146; Tremaroli V, 2012, NATURE, V489, P242, DOI 10.1038/nature11552; Troy EB, 2010, FRONT BIOSCI-LANDMRK, V15, P25, DOI 10.2741/3603; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; van Baarlen P, 2011, P NATL ACAD SCI USA, V108, P4562, DOI 10.1073/pnas.1000079107; van Baarlen P, 2009, P NATL ACAD SCI USA, V106, P2371, DOI 10.1073/pnas.0809919106; van den Bogert B, 2013, GENOME ANNOUNC, V1; Van den Bogert B, 2011, HDB MOL MICROBIAL EC, VII, P170; Van den Bogert B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083418; van den Bogert B, 2013, FEMS MICROBIOL ECOL, V85, P376, DOI 10.1111/1574-6941.12127; van den Bogert B, 2011, APPL ENVIRON MICROB, V77, P2071, DOI 10.1128/AEM.02477-10; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Vrieze A, 2012, GASTROENTEROLOGY, V143, P913, DOI 10.1053/j.gastro.2012.06.031; Wang M, 2005, FEMS MICROBIOL ECOL, V54, P219, DOI 10.1016/j.femsec.2005.03.012; Wen L, 2008, NATURE, V455, P1109, DOI 10.1038/nature07336; YAMAZAKI S, 1985, IMMUNOLOGY, V56, P43; Zigmond E, 2012, IMMUNITY, V37, P1076, DOI 10.1016/j.immuni.2012.08.026; Zoetendal EG, 2012, ISME J, V6, P1415, DOI 10.1038/ismej.2011.212	59	87	109	3	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 5	2014	9	12							e114277	10.1371/journal.pone.0114277	http://dx.doi.org/10.1371/journal.pone.0114277			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX4MS	25479553	gold, Green Published, Green Submitted			2023-01-03	WOS:000346907200064
J	Hoag, H				Hoag, Hannah			A chance of survival	NATURE			English	Editorial Material							METASTATIC MELANOMA; CANCER; BRAF; VEMURAFENIB; RESISTANCE; IPILIMUMAB; ANTIBODY; SAFETY											Boussemart L, 2014, NATURE, V513, P105, DOI 10.1038/nature13572; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Gray-Schopfer VC, 2005, CANCER METAST REV, V24, P165, DOI 10.1007/s10555-005-5865-1; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Kaufman HL, 2013, NAT REV CLIN ONCOL, V10, P588, DOI 10.1038/nrclinonc.2013.153; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Lipson EJ, 2011, CLIN CANCER RES, V17, P6958, DOI 10.1158/1078-0432.CCR-11-1595; Ribas A, 2014, LANCET ONCOL, V15, P954, DOI 10.1016/S1470-2045(14)70301-8; Robert C, 2014, LANCET, V384, P1109, DOI 10.1016/S0140-6736(14)60958-2; Trunzer K, 2013, J CLIN ONCOL, V31, P1767, DOI 10.1200/JCO.2012.44.7888	14	5	5	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 20	2014	515	7527					S118	S120		10.1038/515S118a	http://dx.doi.org/10.1038/515S118a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AU7HE	25407709	Bronze			2023-01-03	WOS:000345770600005
J	Munari, CC; de Oliveira, PF; Leandro, LF; Pimenta, LM; Ferreira, NH; da Costa, JD; Bastos, JK; Tavares, DC				Munari, Carla Carolina; de Oliveira, Pollyanna Francielli; Leandro, Luis Fernando; Pimenta, Leandra Mara; Ferreira, Natalia Helen; da Costa, Juliana de Carvalho; Bastos, Jairo Kenupp; Tavares, Denise Crispim			In Vivo Assessment of Genotoxic, Antigenotoxic and Anticarcinogenic Activities of Solanum lycocarpum Fruits Glycoalkaloidic Extract	PLOS ONE			English	Article							ST-HILL FRUITS; COMET ASSAY; RESPONSES; NIGRUM; ANTIMUTAGENICITY; CONSUMPTION; TOXICITY; CONDUCT; PLANTS; CELLS	The fruits of Solanum lycocarpum, known as wolf-fruit, are used in folk medicine, and because of that we have evaluated both the genotoxic potential of its glycoalkaloidic extract (SL) and its influence on the genotoxicity induced by methyl methanesulfonate. Furthermore, the potential blocking effect of SL intake in the initial stage of colon carcinogenesis in Wistar rats was investigated in a short-term (4-week) bioassay using aberrant crypt foci (ACF) as biomarker. The genotoxic potential was evaluated using the Swiss mice peripheral blood micronucleus test. The animals were treated with different doses of SL (15, 30 and 60 mg/kg b.w.) for 14 days, and the peripheral blood samples were collected at 48 h, 7 days and 14 days after starting the treatment. For antigenotoxicity assessment, MMS was administered on the 14 th day, and after 24 h the harvesting of bone marrow and liver cells was performed, for the micronucleus and comet assays, respectively. In the ACF assay, male Wistar rats were given four subcutaneous injections of the carcinogen 1,2-dimethylhydrazine (DMH, 40 mg/kg b.w.), twice a week, during two weeks to induce ACF. The treatment with SL (15, 30 and 60 mg/kg b.w.) was given for four weeks during and after carcinogen treatment to investigate the potential beneficial effects of SL on DMH-induced ACF. The results demonstrated that SL was not genotoxic in the mouse micronucleus test. In animals treated with SL and MMS, the frequencies of micronucleus and extensions of DNA damage were significantly reduced in comparison with the animals receiving only MMS. Regarding the ACF assay, SL significantly reduced the frequency of ACF induced by DMH.	[Munari, Carla Carolina] Univ Estadual Paulista, Fac Med Botucatu, Dept Patol, Dist Rubiao Jr, SP, Brazil; [de Oliveira, Pollyanna Francielli; Leandro, Luis Fernando; Pimenta, Leandra Mara; Ferreira, Natalia Helen; Tavares, Denise Crispim] Univ Franca, Franca, SP, Brazil; [da Costa, Juliana de Carvalho; Bastos, Jairo Kenupp] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, Ribeirao Preto, SP, Brazil	Universidade Estadual Paulista; Universidad de Franca; Universidade de Sao Paulo	Munari, CC (corresponding author), Univ Estadual Paulista, Fac Med Botucatu, Dept Patol, Dist Rubiao Jr, SP, Brazil.	camunari@yahoo.com.br	Munari, Carla Carolina/I-2481-2012; da Costa, Juliana/AAL-4204-2021; Tavares, Denise C/C-3396-2012	Tavares, Denise C/0000-0003-4646-5914; Ferreira, Natalia/0000-0002-0052-6139; de Carvalho da Costa, Juliana/0000-0002-2336-7361; Oliveira, Pollyanna/0000-0002-1646-0277; Munari, Carla/0000-0001-6922-369X	Sao Paulo Research Foundation (FAPESP; Brazil) [2011/05732-4]; FAPESP [2009/15871-1]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)	Sao Paulo Research Foundation (FAPESP; Brazil)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	The work was supported by the Sao Paulo Research Foundation (FAPESP; Brazil; grant # 2011/05732-4). C.C. Munari thanks FAPESP for a Doctor's scholarship (grant # 2009/15871-1). The authors are grateful to Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) for their fellowships. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anwikar S, 2012, INT J AYURVEDA RES, V3, P167; Bahgat A, 2008, FUND CLIN PHARMACOL, V22, P693, DOI 10.1111/j.1472-8206.2008.00627.x; BIRD RP, 1987, CANCER LETT, V37, P147, DOI 10.1016/0304-3835(87)90157-1; Burlinson B, 2007, MUTAT RES-GEN TOX EN, V627, P31, DOI 10.1016/j.mrgentox.2006.08.011; Chacon Daniele Roswell, 2002, Cytologia (Tokyo), V67, P417, DOI 10.1508/cytologia.67.417; Choudhary G, 1998, CHEMOSPHERE, V37, P801, DOI 10.1016/S0045-6535(98)00088-5; Collins AR, 2008, MUTAGENESIS, V23, P143, DOI 10.1093/mutage/gem051; Ding X, 2012, J ETHNOPHARMACOL, V139, P599, DOI 10.1016/j.jep.2011.11.058; Farina F, 2010, APPL PHYSIOL NUTR ME, V35, P40, DOI 10.1139/H09-131; Ferguson LR, 2005, MUTAT RES-FUND MOL M, V591, P3, DOI 10.1016/j.mrfmmm.2005.05.017; Gupta RK, 2011, ASIAN PAC J TROP MED, V4, P964, DOI 10.1016/S1995-7645(11)60227-7; Hanausek M, 2001, P NATL ACAD SCI USA, V98, P11551, DOI 10.1073/pnas.191363198; Javed T, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-26; Tiossi RFJ, 2012, J ANAL METHODS CHEM, V2012, DOI 10.1155/2012/947836; Khazir J, 2013, J ASIAN NAT PROD RES, V15, P764, DOI 10.1080/10286020.2013.798314; Krishna G, 2000, MUTAT RES-FUND MOL M, V455, P155, DOI 10.1016/S0027-5107(00)00117-2; Li X, 2011, LIFE SCI, V88, P314, DOI 10.1016/j.lfs.2010.12.006; MACGREGOR JT, 1980, ENVIRON MUTAGEN, V2, P509, DOI 10.1002/em.2860020408; MACGREGOR JT, 1987, MUTAT RES, V189, P103, DOI 10.1016/0165-1218(87)90016-4; Maruo VM, 2003, NEUROTOXICOL TERATOL, V25, P627, DOI 10.1016/S0892-0362(03)00038-2; Maruo VM, 2003, PHYTOMEDICINE, V10, P48, DOI 10.1078/094471103321648656; Munari CC, 2012, FOOD CHEM TOXICOL, V50, P3696, DOI 10.1016/j.fct.2012.07.028; Munari CC, 2013, J NAT MED, V68, P231; Nirmal SA, 2012, J ETHNOPHARMACOL, V142, P91, DOI 10.1016/j.jep.2012.04.019; Patel PK, 2012, J YOUNG PHARM, V4, P164, DOI 10.4103/0975-1483.100022; Peters VM, 2001, CONTRACEPTION, V63, P53, DOI 10.1016/S0010-7824(00)00188-8; Reinhardt HC, 2012, TRENDS GENET, V28, P128, DOI 10.1016/j.tig.2011.12.002; Sa RDDE, 2000, J ETHNOPHARMACOL, V73, P283, DOI 10.1016/S0378-8741(00)00250-6; Seo YR, 2004, EXP MOL MED, V36, P505, DOI 10.1038/emm.2004.64; Soares-Mota MR, 2010, EXP TOXICOL PATHOL, V62, P549, DOI 10.1016/j.etp.2009.07.006; SULTANA S, 1995, J ETHNOPHARMACOL, V45, P189, DOI 10.1016/0378-8741(94)01214-K; Tavares DC, 2011, PLANTA MED, V77, P1489, DOI 10.1055/s-0030-1270886; TOMASI A, 1987, TOXICOL PATHOL, V15, P178, DOI 10.1177/019262338701500208; vandeWater B, 1996, ARCH BIOCHEM BIOPHYS, V327, P71, DOI 10.1006/abbi.1996.0094; WATERS MD, 1990, MUTAT RES, V238, P57, DOI 10.1016/0165-1110(90)90039-E; Weissenberg M, 2001, PHYTOCHEMISTRY, V58, P501, DOI 10.1016/S0031-9422(01)00185-6; Wyatt MD, 2006, CHEM RES TOXICOL, V19, P1580, DOI 10.1021/tx060164e; Yen GC, 2001, FOOD CHEM TOXICOL, V39, P1045, DOI 10.1016/S0278-6915(01)00053-9	38	7	7	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2014	9	11							e111999	10.1371/journal.pone.0111999	http://dx.doi.org/10.1371/journal.pone.0111999			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX7UZ	25405606	gold, Green Published, Green Submitted			2023-01-03	WOS:000347121300019
J	Ovadje, P; Ma, D; Tremblay, P; Roma, A; Steckle, M; Guerrero, JA; Arnason, JT; Pandey, S				Ovadje, Pamela; Ma, Dennis; Tremblay, Phillip; Roma, Alessia; Steckle, Matthew; Guerrero, Jose-Antonio; Arnason, John Thor; Pandey, Siyaram			Evaluation of the Efficacy & Biochemical Mechanism of Cell Death Induction by Piper longum Extract Selectively in In-Vitro and In-Vivo Models of Human Cancer Cells	PLOS ONE			English	Article							N-ACETYLCYSTEINE; APOPTOSIS; INHIBITION	Background: Currently chemotherapy is limited mostly to genotoxic drugs that are associated with severe side effects due to non-selective targeting of normal tissue. Natural products play a significant role in the development of most chemotherapeutic agents, with 74.8% of all available chemotherapy being derived from natural products. Objective: To scientifically assess and validate the anticancer potential of an ethanolic extract of the fruit of the Long pepper (PLX), a plant of the piperaceae family that has been used in traditional medicine, especially Ayurveda and investigate the anticancer mechanism of action of PLX against cancer cells. Materials & Methods: Following treatment with ethanolic long pepper extract, cell viability was assessed using a water-soluble tetrazolium salt; apoptosis induction was observed following nuclear staining by Hoechst, binding of annexin V to the externalized phosphatidyl serine and phase contrast microscopy. Image-based cytometry was used to detect the effect of long pepper extract on the production of reactive oxygen species and the dissipation of the mitochondrial membrane potential following Tetramethylrhodamine or 5,5,6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine chloride staining (JC-1). Assessment of PLX in-vivo was carried out using Balb/C mice (toxicity) and CD-1 nu/nu immunocompromised mice (efficacy). HPLC analysis enabled detection of some primary compounds present within our long pepper extract. Results: Our results indicated that an ethanolic long pepper extract selectively induces caspase-independent apoptosis in cancer cells, without affecting non-cancerous cells, by targeting the mitochondria, leading to dissipation of the mitochondrial membrane potential and increase in ROS production. Release of the AIF and endonuclease G from isolated mitochondria confirms the mitochondria as a potential target of long pepper. The efficacy of PLX in in-vivo studies indicates that oral administration is able to halt the growth of colon cancer tumors in immunocompromised mice, with no associated toxicity. These results demonstrate the potentially safe and non-toxic alternative that is long pepper extract for cancer therapy.	[Ovadje, Pamela; Ma, Dennis; Tremblay, Phillip; Roma, Alessia; Steckle, Matthew; Pandey, Siyaram] Univ Windsor, Dept Chem & Biochem, Windsor, ON N9B 3P4, Canada; [Guerrero, Jose-Antonio; Arnason, John Thor] Univ Ottawa, Dept Biol, Ottawa, ON, Canada	University of Windsor; University of Ottawa	Pandey, S (corresponding author), Univ Windsor, Dept Chem & Biochem, Windsor, ON N9B 3P4, Canada.	spandey@uwindsor.ca	Arnason, John Thor/GXM-3860-2022; Pandey, Siyaram/AAI-5491-2020; Guerrero-Analco, José A./Q-6733-2018	Guerrero-Analco, José A./0000-0003-0998-757X; Roma, Alessia/0000-0002-5592-4724	Windsor & Essex County Cancer Centre Foundation by Seeds4Hope Grant	Windsor & Essex County Cancer Centre Foundation by Seeds4Hope Grant	This study was funded by Windsor & Essex County Cancer Centre Foundation by Seeds4Hope Grant (URL: http://windsorcancerfoundation.org/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bao NRS, 2014, J NAT MED-TOKYO, V68, P211, DOI 10.1007/s11418-013-0773-0; Bezerra DP, 2007, TOXICOL IN VITRO, V21, P1, DOI 10.1016/j.tiv.2006.07.007; Bleske BE, 2013, J CARDIOVASCULAR PHA, V00, P1; Canadian Cancer Society's Steering Committee on Cancer Statistics, 2012, CAN CANC STAT 2012; Casellas P, 2002, NEUROCHEM INT, V40, P475, DOI 10.1016/S0197-0186(01)00118-8; Chandra P, 2014, ANAL METHODS-UK, V6, P4234, DOI 10.1039/c4ay00246f; Davidson D, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00005; Dekhuijzen PNR, 2004, EUR RESPIR J, V23, P629, DOI 10.1183/09031936.04.00016804; Dodd S, 2008, EXPERT OPIN BIOL TH, V8, P1955, DOI [10.1517/14728220802517901, 10.1517/14728220802517901 ]; Earnshaw WC, 1999, NATURE, V397, P387, DOI 10.1038/17015; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Fadeel B, 2005, J INTERN MED, V258, P479, DOI 10.1111/j.1365-2796.2005.01570.x; Fang CD, 2013, CLIN SCI, V124, P709, DOI 10.1042/CS20120517; Fischer A.H., 2008, COLD SPRING HARBOR P, V2008, DOI [10.1101/pdb.prot073411, DOI 10.1101/PDB.PROT073411, DOI 10.1101/PDB.PROT4986, 10.1101/pdb.prot4986]; Foster BC, 2005, ANNU REV PHARMACOL, V45, P203, DOI 10.1146/annurev.pharmtox.45.120403.095950; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Golovine KV, 2013, PROSTATE, V73, P23, DOI 10.1002/pros.22535; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Jarvius M, 2013, BIOCHEM BIOPH RES CO, V431, P117, DOI 10.1016/j.bbrc.2013.01.017; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Lee SE, 2001, CROP PROT, V20, P523, DOI 10.1016/S0261-2194(00)00172-1; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; Mathupala SP, 1997, J BIOENERG BIOMEMBR, V29, P339, DOI 10.1023/A:1022494613613; Meghwal M, 2013, PHYTOTHER RES, V27, P1121, DOI 10.1002/ptr.4972; Newman DJ, 2012, J NAT PROD, V75, P311, DOI 10.1021/np200906s; Raj L, 2012, NATURE, V481, P534, DOI 10.1038/nature10789; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; Thorburn A, 2008, APOPTOSIS, V13, P1, DOI 10.1007/s10495-007-0154-9; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Zhivotovsky B, 2010, EXP CELL RES, V316, P1374, DOI 10.1016/j.yexcr.2010.02.037	32	22	22	2	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 17	2014	9	11							e113250	10.1371/journal.pone.0113250	http://dx.doi.org/10.1371/journal.pone.0113250			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT8BL	25401766	Green Published, gold, Green Submitted			2023-01-03	WOS:000345158700127
J	Hall, ML; Ferreira, VS; Mayberry, RI				Hall, Matthew L.; Ferreira, Victor S.; Mayberry, Rachel I.			Syntactic Priming in American Sign Language	PLOS ONE			English	Article							2ND-LANGUAGE ACQUISITION; 1ST-LANGUAGE ACQUISITION; CRITICAL PERIOD; LEXICAL ACCESS; DEAF SIGNERS; BILINGUALS; AGE; REPRESENTATIONS; COMPREHENSION; ORGANIZATION	Psycholinguistic studies of sign language processing provide valuable opportunities to assess whether language phenomena, which are primarily studied in spoken language, are fundamentally shaped by peripheral biology. For example, we know that when given a choice between two syntactically permissible ways to express the same proposition, speakers tend to choose structures that were recently used, a phenomenon known as syntactic priming. Here, we report two experiments testing syntactic priming of a noun phrase construction in American Sign Language (ASL). Experiment 1 shows that second language (L2) signers with normal hearing exhibit syntactic priming in ASL and that priming is stronger when the head noun is repeated between prime and target (the lexical boost effect). Experiment 2 shows that syntactic priming is equally strong among deaf native L1 signers, deaf late L1 learners, and hearing L2 signers. Experiment 2 also tested for, but did not find evidence of, phonological or semantic boosts to syntactic priming in ASL. These results show that despite the profound differences between spoken and signed languages in terms of how they are produced and perceived, the psychological representation of sentence structure (as assessed by syntactic priming) operates similarly in sign and speech.	[Hall, Matthew L.] Univ Connecticut, Linguist, Storrs, CT 06269 USA; [Ferreira, Victor S.] Univ Calif San Diego, Psychol, San Diego, CA USA; [Mayberry, Rachel I.] Univ Calif San Diego, Linguist, San Diego, CA USA	University of Connecticut; University of California System; University of California San Diego; University of California System; University of California San Diego	Hall, ML (corresponding author), Univ Connecticut, Linguist, Storrs, CT 06269 USA.	matthall.research@gmail.com			National Institutes of Health (NIH) [R01DC012797, HD051030, 5T32DC000041-19]; Rita L. Atkinson Graduate Fellowship; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC012797] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Rita L. Atkinson Graduate Fellowship; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	The research reported here was supported in part by National Institutes of Health (NIH) grants R01DC012797, HD051030, and 5T32DC000041-19 and also by the Rita L. Atkinson Graduate Fellowship. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BAKER CL, 1970, FOUND LANG, V6, P197; Baus C, 2008, COGNITION, V108, P856, DOI 10.1016/j.cognition.2008.05.012; Bellugi U, 1983, Hum Neurobiol, V2, P155; Bernolet S, 2007, J EXP PSYCHOL LEARN, V33, P931, DOI 10.1037/0278-7393.33.5.931; Bernolet S, 2013, COGNITION, V127, P287, DOI 10.1016/j.cognition.2013.02.005; Bernolet S, 2012, BILING-LANG COGN, V15, P503, DOI 10.1017/S1366728911000162; BOCK JK, 1986, COGNITIVE PSYCHOL, V18, P355, DOI 10.1016/0010-0285(86)90004-6; Boudreault P, 2006, LANG COGNITIVE PROC, V21, P608, DOI 10.1080/01690960500139363; Brentari D., 1998, PROSODIC MODEL SIGN; Carreiras M, 2008, J MEM LANG, V58, P100, DOI 10.1016/j.jml.2007.05.004; Cecchetto C, 2004, GLOW NEWSLETTER, V52, P30; Chang F, 2006, PSYCHOL REV, V113, P234, DOI 10.1037/0033-295X.113.2.234; Cleland AA, 2003, J MEM LANG, V49, P214, DOI 10.1016/S0749-596X(03)00060-3; Cormier K, 2012, COGNITION, V124, P50, DOI 10.1016/j.cognition.2012.04.003; DAMASIO A, 1986, NATURE, V322, P363, DOI 10.1038/322363a0; DELL GS, 1986, PSYCHOL REV, V93, P283, DOI 10.1037/0033-295X.93.3.283; Dye M. W. G., 2006, LAB PHONOL, V8, P243; EMMOREY K, 1991, J PSYCHOLINGUIST RES, V20, P365, DOI 10.1007/BF01067970; EMMOREY K, 1990, PERCEPT MOTOR SKILL, V71, P1227, DOI 10.2466/PMS.71.7.1227-1252; EMMOREY K, 1995, APPL PSYCHOLINGUIST, V16, P1, DOI 10.1017/S0142716400006391; Fernald TB., 2000, SIGN LANG LINGUIST, V3, P3, DOI [10.1075/sll.3.1.03fer, DOI 10.1075/SLL.3.1.03FER]; Flett S., 2003 LING POSTGR C U; Geraci Carlo, 2013, RIGHTWARD MOVEMENT C, P211, DOI [10.1075/la.200.08ger, DOI 10.1075/LA.200.08GER]; Greenberg JH, 1966, UNIVERSALS LANG, P73; Hall ML, 2012, SIGN LANG LINGUIST, V15, P104, DOI 10.1075/sll.15.1.05hal; Hickok G, 1996, APHASIOLOGY, V10, P577, DOI 10.1080/02687039608248438; Hickok G, 1996, NATURE, V381, P699, DOI 10.1038/381699a0; Hickok G, 1997, REV NEUROSCIENCE, V8, P205; Hohenberger A., 2002, MODALITY STRUCTURE S, P112; Keenan Edward L., 1976, SUBJECT TOPIC, P303; Lehmann Christian, 1988, AGREEMENT NATURAL LA, P55; Levelt WJM, 1999, BEHAV BRAIN SCI, V22, P1; Liddell S., 1989, SIGN LANGUAGE STUDIE, V64, P197; MacLaughlin D., 1997, THESIS BOSTON U; MacSweeney M, 2006, HUM BRAIN MAPP, V27, P63, DOI 10.1002/hbm.20167; Mayberry RI, 2011, BRAIN LANG, V119, P16, DOI 10.1016/j.bandl.2011.05.007; Mayberry RI, 2002, NATURE, V417, P38, DOI 10.1038/417038a; MAYBERRY RI, 1993, J SPEECH HEAR RES, V36, P1258, DOI 10.1044/jshr.3606.1258; MAYBERRY RI, 1989, MEM COGNITION, V17, P740, DOI 10.3758/BF03202635; MAYBERRY RI, 1991, J MEM LANG, V30, P486, DOI 10.1016/0749-596X(91)90018-F; Meir I, 2007, J LINGUIST, V43, P531, DOI 10.1017/S0022226707004768; Morford JP, 2011, LANG LEARN DEV, V7, P149, DOI 10.1080/15475441.2011.543393; Morford JP, 2011, COGNITION, V118, P286, DOI 10.1016/j.cognition.2010.11.006; Neidle C, 1998, LANGUAGE, V74, P819, DOI 10.2307/417004; Neidle C., 2000, SYNTAX AM SIGN LANGU; Newkirk Don, 1980, ERRORS LINGUISTIC PE, P165; Newman AJ, 2002, NAT NEUROSCI, V5, P76, DOI 10.1038/nn775; NEWPORT EL, 1990, COGNITIVE SCI, V14, P11, DOI 10.1207/s15516709cog1401_2; Orfanidou E, 2009, MEM COGNITION, V37, P302, DOI 10.3758/MC.37.3.302; Pickering MJ, 2008, PSYCHOL BULL, V134, P427, DOI 10.1037/0033-2909.134.3.427; Pickering MJ, 1998, J MEM LANG, V39, P633, DOI 10.1006/jmla.1998.2592; Sakai KL, 2005, BRAIN, V128, P1407, DOI 10.1093/brain/awh465; Sandler W, 2006, SIGN LANGUAGE AND LINGUISTIC UNIVERSALS, P1, DOI 10.2277/ 0521483956; Sandler W., 1989, PHONOLOGICAL REPRESE; Santesteban M, 2010, J MEM LANG, V63, P347, DOI 10.1016/j.jml.2010.07.001; Scheepers C., 2010, 6 INT WORKSH LANG PR; Schoonbaert S, 2007, J MEM LANG, V56, P153, DOI 10.1016/j.jml.2006.10.002; Soderfeldt B, 1997, NEUROLOGY, V49, P82, DOI 10.1212/WNL.49.1.82; Stokoe WC, 1960, STUD LINGUIST, P7; Sutton-Spence R., 1999, LINGUISTICS BRIT SIG; Szekely A, 2004, J MEM LANG, V51, P247, DOI 10.1016/j.jml.2004.03.002; Thompson R, 2005, PSYCHOL SCI, V16, P856, DOI 10.1111/j.1467-9280.2005.01626.x; Tooley KM, 2009, J EXP PSYCHOL LEARN, V35, P19, DOI 10.1037/a0013984; Vinson DP, 2010, PSYCHOL SCI, V21, P1158, DOI 10.1177/0956797610377340	64	17	17	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 18	2015	10	3							e0119611	10.1371/journal.pone.0119611	http://dx.doi.org/10.1371/journal.pone.0119611			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CE9BN	25786230	Green Published, gold, Green Submitted			2023-01-03	WOS:000352138500120
J	De Korte-Verhoef, MC; Pasman, HRW; Schweitzer, BPM; Francke, AL; Onwuteaka-Philipsen, BD; Deliens, L				De Korte-Verhoef, Maria C.; Pasman, H. Roeline W.; Schweitzer, Bart P. M.; Francke, Anneke L.; Onwuteaka-Philipsen, Bregje D.; Deliens, Luc			How Could Hospitalisations at the End of Life Have Been Avoided? A Qualitative Retrospective Study of the Perspectives of General Practitioners, Nurses and Family Carers	PLOS ONE			English	Article							LUNG-CANCER PATIENTS; DEATH; HOME; NETHERLANDS; PLACE; PREFERENCES; POPULATION; REASONS	Background Although many patients prefer to stay and die at home at the end of life, many are hospitalised. Little is known about how to avoid hospitalisations for patients living at home. Aim To describe how hospitalisation at the end of life can be avoided, from the perspective of the GPs, nurses and family carers. Method A qualitative design with face-to-face interviews was used. Taking 30 cases of patients who died non-suddenly, 26 GPs, 15 nurses and 18 family carers were interviewed in depth. Of the 30 patients, 20 were hospitalised and 10 were not hospitalised in the last three months of life. Results Five key themes that could help avoid hospitalisation at the end of life emerged from the interviews. The key themes were: 1) marking the approach of death, and shifting the mindset; 2) being able to provide acute treatment and care at home; 3) anticipatory discussions and interventions to deal with expected severe problems; 4) guiding and monitoring the patient and family in a holistic way through the illness trajectory; 5) continuity of treatment and care at home. If these five key themes are adopted in an interrelated way, this could help avoid hospitalisations, according to GPs, nurses and family carers. Conclusions The five key themes described in this study can be seen as strategies that could help in avoiding hospitalisation at the end of life. It is recommended that for all patients residing at home, GPs and community nurses work together as a team from the moment that it is marked that death is approaching up to the end of life.	[De Korte-Verhoef, Maria C.; Pasman, H. Roeline W.; Francke, Anneke L.; Onwuteaka-Philipsen, Bregje D.; Deliens, Luc] Vrije Univ Amsterdam, Med Ctr, EMGO Inst Hlth & Care Res, Dept Publ & Occupat Hlth, Amsterdam, Netherlands; [De Korte-Verhoef, Maria C.; Pasman, H. Roeline W.; Francke, Anneke L.; Onwuteaka-Philipsen, Bregje D.; Deliens, Luc] Vrije Univ Amsterdam, Med Ctr, Expertise Ctr Palliat Care VUmc, Inst Hlth & Care Res, Amsterdam, Netherlands; [Schweitzer, Bart P. M.] Vrije Univ Amsterdam, Med Ctr, EMGO Inst Hlth & Care Res, Dept Gen Practice, Amsterdam, Netherlands; [Francke, Anneke L.] NIVEL, Netherlands Inst Hlth Serv Res, Utrecht, Netherlands; [Deliens, Luc] Univ Ghent, End of life Care Res Grp, Brussels, Belgium; [Deliens, Luc] Vrije Univ Brussel, Brussels, Belgium	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Netherlands Institute for Health Services Research; Ghent University; Vrije Universiteit Brussel	De Korte-Verhoef, MC (corresponding author), Vrije Univ Amsterdam, Med Ctr, EMGO Inst Hlth & Care Res, Dept Publ & Occupat Hlth, Amsterdam, Netherlands.	eol@vumc.nl	Wu, Hsin-Lung/C-4134-2009	Onwuteaka-Philipsen, Bregje/0000-0002-9440-1248; Deliens, Luc/0000-0002-8158-2422	ZonMw; Netherlands Organization for Health Research and Development [11510005]	ZonMw(Netherlands Organization for Health Research and Development); Netherlands Organization for Health Research and Development(Netherlands Organization for Health Research and Development)	This study is funded by ZonMw, the Netherlands Organization for Health Research and Development (No. 11510005). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abarshi E, 2010, PALLIATIVE MED, V24, P166, DOI 10.1177/0269216309351381; Abel J, 2009, PALLIATIVE MED, V23, P616, DOI 10.1177/0269216309106460; Ahlner-Elmqvist M, 2004, PALLIATIVE MED, V18, P585, DOI 10.1191/0269216304pm924oa; Barbera L, 2008, J PAIN SYMPTOM MANAG, V35, P267, DOI 10.1016/j.jpainsymman.2007.04.019; Borgsteede SD, 2006, BRIT J GEN PRACT, V56, P20; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Brumley Richard D, 2003, J Palliat Med, V6, P715, DOI 10.1089/109662103322515220; Choi J, 2010, SUPPORT CARE CANCER, V18, P1445, DOI 10.1007/s00520-009-0767-3; Claessen SJJ, 2013, BMC FAM PRACT, V14, DOI 10.1186/1471-2296-14-42; de Casterle BD, 2012, INT J NURS STUD, V49, P360, DOI 10.1016/j.ijnurstu.2011.09.012; De Korte-Verhoef MC, 2014, SUPPORT CARE CANCER, V22, P645, DOI 10.1007/s00520-013-2019-9; De Roo ML, 2013, J PAIN SYMPTOM MANAG, V46, P556, DOI 10.1016/j.jpainsymman.2012.09.013; Dumont S, 2009, PALLIATIVE MED, V23, P708, DOI 10.1177/0269216309346546; Gomes B, 2012, ANN ONCOL, V23, P2006, DOI 10.1093/annonc/mdr602; Gott M, 2013, PALLIATIVE MED, V27, P747, DOI 10.1177/0269216312469263; Gott M, 2011, BMJ SUPPORT PALLIAT, V1, P42, DOI [10.1186/1472-684X-12-9, 10.1136/bmj.d1773]; Korte-Verhoef De, 2009, BETER THUIS STERVEN; Meeussen K, 2011, J PAIN SYMPTOM MANAG, V42, P565, DOI 10.1016/j.jpainsymman.2011.01.011; Ratner E, 2001, J AM GERIATR SOC, V49, P778, DOI 10.1046/j.1532-5415.2001.49155.x; Reyniers T, 2014, HEALTH PLACE, V27, P77, DOI 10.1016/j.healthplace.2014.02.002; Royal College of General Practitioners and Royal College of Nursing, 2012, MATT LIF DEATH HELP; Sandelowski M, 2012, QUAL HEALTH RES, V22, P1404, DOI 10.1177/1049732312450368; Schweitzer Bart P M, 2009, BMC Palliat Care, V8, P17, DOI 10.1186/1472-684X-8-17; Shaw KL, 2010, PALLIATIVE MED, V24, P317, DOI 10.1177/0269216310362005; Stajduhar KI, 2008, PALLIATIVE MED, V22, P85, DOI 10.1177/0269216307084612; Thoonsen B, 2011, BMC FAM PRACT, V12, DOI 10.1186/1471-2296-12-123; Van den Block L, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-69; van der Plas AGM, 2014, BMC FAM PRACT, V15, DOI 10.1186/1471-2296-15-14; Vos MS, 2011, LUNG CANCER, V72, P119, DOI 10.1016/j.lungcan.2010.07.007; Walsh EG, 2012, J AM GERIATR SOC, V60, P821, DOI 10.1111/j.1532-5415.2012.03920.x; Wowchuk SM, 2009, J PALLIAT MED, V12, P797, DOI 10.1089/jpm.2009.0048	31	11	11	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 10	2015	10	3							e0118971	10.1371/journal.pone.0118971	http://dx.doi.org/10.1371/journal.pone.0118971			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CD7MX	25756184	Green Published, gold, Green Submitted			2023-01-03	WOS:000351275700033
J	Jain, S; Williams, DJ; Arnold, SR; Ampofo, K; Bramley, AM; Reed, C; Stockmann, C; Anderson, EJ; Grijalva, CG; Self, WH; Zhu, YW; Patel, A; Hymas, W; Chappell, JD; Kaufman, RA; Kan, JH; Dansie, D; Lenny, N; Hillyard, DR; Haynes, LM; Levine, M; Lindstrom, S; Winchell, JM; Katz, JM; Erdman, D; Schneider, E; Hicks, LA; Wunderink, RG; Edwards, KM; Pavia, AT; McCullers, JA; Finelli, L				Jain, Seema; Williams, Derek J.; Arnold, Sandra R.; Ampofo, Krow; Bramley, Anna M.; Reed, Carrie; Stockmann, Chris; Anderson, Evan J.; Grijalva, Carlos G.; Self, Wesley H.; Zhu, Yuwei; Patel, Anami; Hymas, Weston; Chappell, James D.; Kaufman, Robert A.; Kan, J. Herman; Dansie, David; Lenny, Noel; Hillyard, David R.; Haynes, Lia M.; Levine, Min; Lindstrom, Stephen; Winchell, Jonas M.; Katz, Jacqueline M.; Erdman, Dean; Schneider, Eileen; Hicks, Lauri A.; Wunderink, Richard G.; Edwards, Kathryn M.; Pavia, Andrew T.; McCullers, Jonathan A.; Finelli, Lyn		CDC EPIC Study Team	Community-Acquired Pneumonia Requiring Hospitalization among US Children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE-CHAIN-REACTION; PNEUMOCOCCAL CONJUGATE VACCINE; MYCOPLASMA-PNEUMONIAE; VIRAL-INFECTIONS; PCR; DIAGNOSIS; ASSAYS; TESTS; IDENTIFICATION; EPIDEMIOLOGY	BACKGROUND Incidence estimates of hospitalizations for community-acquired pneumonia among children in the United States that are based on prospective data collection are limited. Updated estimates of pneumonia that has been confirmed radiographically and with the use of current laboratory diagnostic tests are needed. METHODS We conducted active population-based surveillance for community-acquired pneumonia requiring hospitalization among children younger than 18 years of age in three hospitals in Memphis, Nashville, and Salt Lake City. We excluded children with recent hospitalization or severe immunosuppression. Blood and respiratory specimens were systematically collected for pathogen detection with the use of multiple methods. Chest radiographs were reviewed independently by study radiologists. RESULTS From January 2010 through June 2012, we enrolled 2638 of 3803 eligible children (69%), 2358 of whom (89%) had radiographic evidence of pneumonia. The median age of the children was 2 years (interquartile range, 1 to 6); 497 of 2358 children (21%) required intensive care, and 3 (<1%) died. Among 2222 children with radiographic evidence of pneumonia and with specimens available for bacterial and viral testing, a viral or bacterial pathogen was detected in 1802 (81%), one or more viruses in 1472 (66%), bacteria in 175 (8%), and both bacterial and viral pathogens in 155 (7%). The annual incidence of pneumonia was 15.7 cases per 10,000 children (95% confidence interval [CI], 14.9 to 16.5), with the highest rate among children younger than 2 years of age (62.2 cases per 10,000 children; 95% CI, 57.6 to 67.1). Respiratory syncytial virus was more common among children younger than 5 years of age than among older children (37% vs. 8%), as were adenovirus (15% vs. 3%) and human metapneumovirus (15% vs. 8%). Mycoplasma pneumoniae was more common among children 5 years of age or older than among younger children (19% vs. 3%). CONCLUSIONS The burden of hospitalization for children with community-acquired pneumonia was highest among the very young, with respiratory viruses the most commonly detected causes of pneumonia.	[Jain, Seema; Bramley, Anna M.; Reed, Carrie; Haynes, Lia M.; Levine, Min; Lindstrom, Stephen; Winchell, Jonas M.; Katz, Jacqueline M.; Erdman, Dean; Schneider, Eileen; Hicks, Lauri A.; Finelli, Lyn] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS A-32, Atlanta, GA 30333 USA; [Williams, Derek J.; Grijalva, Carlos G.; Self, Wesley H.; Zhu, Yuwei; Chappell, James D.; Kan, J. Herman; Edwards, Kathryn M.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; [Williams, Derek J.; Edwards, Kathryn M.] Monroe Carell Jr Childrens Hosp Vanderbilt, Nashville, TN USA; [Williams, Derek J.; Edwards, Kathryn M.] Vanderbilt Vaccine Res Program, Nashville, TN USA; [Arnold, Sandra R.; Patel, Anami; Lenny, Noel; McCullers, Jonathan A.] Le Bonheur Childrens Hosp, Memphis, TN USA; [Arnold, Sandra R.; Patel, Anami; Kaufman, Robert A.; Lenny, Noel; McCullers, Jonathan A.] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA; [Kaufman, Robert A.; McCullers, Jonathan A.] St Jude Childrens Res Hosp, Memphis, TN 38105 USA; [Ampofo, Krow; Stockmann, Chris; Hymas, Weston; Dansie, David; Hillyard, David R.; Pavia, Andrew T.] Univ Utah, Hlth Sci Ctr, Salt Lake City, UT USA; [Anderson, Evan J.; Wunderink, Richard G.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA	Centers for Disease Control & Prevention - USA; Vanderbilt University; Vanderbilt University; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; Utah System of Higher Education; University of Utah; Northwestern University; Feinberg School of Medicine	Jain, S (corresponding author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS A-32, Atlanta, GA 30333 USA.	bwc8@cdc.gov	Finelli, Lyn/AAK-2360-2020; Sherwin, Catherine Mary Turner/B-2888-2012; Levine, Min/ABB-4350-2021; Arnold, Sandra R/O-4712-2014	Sherwin, Catherine Mary Turner/0000-0002-0844-3207; Arnold, Sandra R/0000-0001-6130-8154; Grijalva, Carlos/0000-0002-2329-7797; Kaufman, Robert/0000-0001-7066-5516; Wunderink, Richard/0000-0002-8527-4195; Self, Wesley/0000-0002-9300-3045	Influenza Division of the National Center for Immunization and Respiratory Diseases; NATIONAL CENTER FOR IMMUNICATION AND RESPIRATORY DISEASES [U18IP000299, U18IP000303, U18IP000302, U18IP000301] Funding Source: NIH RePORTER; National Center for Immunization and Respiratory Diseases (NCIRD) [U18IP000490, U18IP000489, U18IP000491, U18IP000488] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI104779] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K23GM110469] Funding Source: NIH RePORTER	Influenza Division of the National Center for Immunization and Respiratory Diseases; NATIONAL CENTER FOR IMMUNICATION AND RESPIRATORY DISEASES(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); National Center for Immunization and Respiratory Diseases (NCIRD)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Funded by the Influenza Division of the National Center for Immunization and Respiratory Diseases.	[Anonymous], 2012, VINT 2012 BRIDG RAC; [Anonymous], 2012, VACCINES; Bartlett RC, 1974, MED MICROBIOLOGY QUA, P24; Blaschke AJ, 2012, DIAGN MICR INFEC DIS, V74, P349, DOI 10.1016/j.diagmicrobio.2012.08.013; Blaschke AJ, 2011, CLIN INFECT DIS, V52, pS331, DOI 10.1093/cid/cir048; Blaschke AJ, 2011, PEDIATR INFECT DIS J, V30, P289, DOI 10.1097/INF.0b013e3182002d14; Bradley JS, 2011, CLIN INFECT DIS, V53, pE25, DOI [10.1093/cid/cir531, 10.1093/cid/cir625]; Caliendo AM, 2014, CLIN INFECT DIS, V58, P1346, DOI 10.1093/cid/ciu092; Caliendo AM, 2013, CLIN INFECT DIS, V57, pS139, DOI 10.1093/cid/cit578; Caliendo AM, 2011, CLIN INFECT DIS, V52, pS326, DOI 10.1093/cid/cir047; Carvalho MDS, 2007, J CLIN MICROBIOL, V45, P2460, DOI 10.1128/JCM.02498-06; Cherian T, 2005, B WORLD HEALTH ORGAN, V83, P353; Dare RK, 2007, J INFECT DIS, V196, P1321, DOI 10.1086/521308; Feikin DR, 2013, CLIN VACCINE IMMUNOL, V20, P113, DOI 10.1128/CVI.00325-12; Fry AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017780; Griffin MR, 2013, NEW ENGL J MED, V369, P155, DOI 10.1056/NEJMoa1209165; Grijalva CG, 2007, LANCET, V369, P1179, DOI 10.1016/S0140-6736(07)60564-9; Hayden FG, 2004, REV MED VIROL, V14, P17, DOI 10.1002/rmv.406; Iwane MK, 2011, J INFECT DIS, V204, P1702, DOI 10.1093/infdis/jir634; Jartti T, 2008, EUR RESPIR J, V32, P314, DOI 10.1183/09031936.00161907; KENDAL AP, 1983, J CLIN MICROBIOL, V18, P930, DOI 10.1128/JCM.18.4.930-934.1983; Lee GE, 2010, PEDIATRICS, V126, P204, DOI 10.1542/peds.2009-3109; Loens K, 2012, J CLIN MICROBIOL, V50, P977, DOI 10.1128/JCM.00200-11; Lu XY, 2008, J CLIN MICROBIOL, V46, P533, DOI 10.1128/JCM.01739-07; Garcia-Garcia ML, 2012, PEDIATR INFECT DIS J, V31, P808, DOI 10.1097/INF.0b013e3182568c67; MacNeil JR, 2011, CLIN INFECT DIS, V53, P1230, DOI 10.1093/cid/cir735; Madhi SA, 2005, CLIN INFECT DIS, V40, P1511, DOI 10.1086/429828; Madhi SA, 2013, PEDIATR INFECT DIS J, V32, pE119, DOI 10.1097/INF.0b013e3182784b26; Michelow IC, 2004, PEDIATRICS, V113, P701, DOI 10.1542/peds.113.4.701; MONTO AS, 1981, J CLIN MICROBIOL, V13, P54, DOI 10.1128/JCM.13.1.54-57.1981; Mullins JA, 2004, EMERG INFECT DIS, V10, P700, DOI 10.3201/eid1004.030555; Nelson JC, 2008, VACCINE, V26, P4947, DOI 10.1016/j.vaccine.2008.07.016; Pavia Andrew T, 2011, Clin Infect Dis, V52 Suppl 4, pS284, DOI 10.1093/cid/cir043; POLLOCK HM, 1983, J CLIN MICROBIOL, V17, P255, DOI 10.1128/JCM.17.2.255-259.1983; Sawatwong P, 2012, CLIN INFECT DIS, V54, P445, DOI 10.1093/cid/cir710; Scott JAG, 2012, CLIN INFECT DIS, V54, pS109, DOI 10.1093/cid/cir1065; Thurman KA, 2011, DIAGN MICR INFEC DIS, V70, P1, DOI 10.1016/j.diagmicrobio.2010.11.014; Waites KB, 2004, CLIN MICROBIOL REV, V17, P697, DOI 10.1128/CMR.17.4.697-728.2004; Wallace Paul S, 2013, Methods Mol Biol, V943, P49, DOI 10.1007/978-1-60327-353-4_3; Weinberg GA, 2004, J INFECT DIS, V189, P706, DOI 10.1086/381456; Werno AM, 2008, CLIN INFECT DIS, V46, P926, DOI 10.1086/528798; World Health Organization, 2011, MAN LAB DIAGN VIR SU	42	977	1092	7	90	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 26	2015	372	9					835	845		10.1056/NEJMoa1405870	http://dx.doi.org/10.1056/NEJMoa1405870			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CB8SQ	25714161	Bronze, Green Accepted			2023-01-03	WOS:000349901700008
J	Nordstrom, P; Gustafson, Y; Michaelsson, K; Nordstrom, A				Nordstrom, Peter; Gustafson, Yngve; Michaelsson, Karl; Nordstrom, Anna			Length of hospital stay after hip fracture and short term risk of death after discharge: a total cohort study in Sweden	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MORTALITY; INTERVENTION; THERAPY; COMPLICATIONS; OUTCOMES; IMPACT	Objective To investigate relation between inpatient length of stay after hip fracture and risk of death after hospital discharge. Setting Population >= 50 years old living in Sweden as of 31 December 2005 with a first hip fracture the years 2006-12. Participants 116 111 patients with an incident hip fracture from a closed nationwide cohort. Main outcome measure Death within 30 days of hospital discharge in relation to hospital length of stay after adjustment for multiple covariates. Results Mean inpatient length of stay after a hip fracture decreased from 14.2 days in 2006 to 11.6 days in 2012 (P<0.001). The association between length of stay and risk of death after discharge was non-linear (P<0.001), with a threshold for this non-linear effect of about 10 days. Thus, for patients with length of stay of <= 10 days (n=59 154), each 1-day reduction in length of stay increased the odds of death within 30 days of discharge by 8% in 2006 (odds ratio 1.08 (95% confidence interval 1.04 to 1.12)), which increased to16% in 2012 (odds ratio 1.16 (1.12 to 1.20)). In contrast, for patients with a length of stay of >= 11 days (n=56 957), a 1-day reduction in length of stay was not associated with an increased risk of death after discharge during any of the years of follow up. Limitations No accurate evaluation of the underlying cause of death could be performed. Conclusion Shorter length of stay in hospital after hip fracture is associated with increased risk of death after hospital discharge, but only among patients with length of stay of 10 days or less. This association remained robust over consecutive years.	[Nordstrom, Peter; Gustafson, Yngve] Umea Univ, Dept Community Med & Rehabil, SE-91087 Umea, Sweden; [Michaelsson, Karl] Uppsala Univ, Sect Orthoped, Dept Surg Sci, SE-75185 Uppsala, Sweden; [Nordstrom, Anna] Umea Univ, SE-91087 Umea, Sweden	Umea University; Uppsala University; Umea University	Nordstrom, P (corresponding author), Umea Univ, Dept Community Med & Rehabil, SE-91087 Umea, Sweden.	peter.nordstrom@germed.umu.se	Nordström, Anna/F-2238-2010; Nordström, Anna/O-2504-2018; Michaelsson, Karl/AAM-9094-2021	Nordström, Anna/0000-0003-3534-456X; Nordström, Anna/0000-0003-3534-456X; Michaelsson, Karl/0000-0003-2815-1217; Nordstrom, Peter/0000-0003-2924-508X	Swedish research council	Swedish research council(Swedish Research CouncilEuropean Commission)	The present study was funded by the Swedish research council. The researchers conducted this study totally independent of the funding bodies.	Aiken LH, 2002, JAMA-J AM MED ASSOC, V288, P1987, DOI 10.1001/jama.288.16.1987; Aiken LH, 2014, LANCET, V383, P1824, DOI 10.1016/S0140-6736(13)62631-8; Bloom D., 2011, GLOBAL EC BURDEN NON, DOI DOI 10.1192/BJP.184.5.393; Centers for Medicare & Medicaid Services, 2013, NAT HLTH EXP PROJ 20; Clarke A, 2001, EUR J PUBLIC HEALTH, V11, P166, DOI 10.1093/eurpub/11.2.166; Ellis G, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006211.pub2; Gedeborg R, 2009, CRIT CARE MED, V37, P449, DOI 10.1097/CCM.0b013e318194b164; Hammar N, 2001, INT J EPIDEMIOL, V30, pS30, DOI 10.1093/ije/30.suppl_1.S30; Harrell Frank E., 2001, REGRESSION MODELING; HOLLINGWORTH W, 1993, BRIT MED J, V307, P903, DOI 10.1136/bmj.307.6909.903; Kaboli PJ, 2012, ANN INTERN MED, V157, P837, DOI 10.7326/0003-4819-157-12-201212180-00003; Karinkanta S, 2010, NAT REV ENDOCRINOL, V6, P396, DOI 10.1038/nrendo.2010.70; Kondo A, 2010, DISABIL REHABIL, V32, P826, DOI 10.3109/09638280903314051; Koster M, 2013, NEUROEPIDEMIOLOGY, V40, P240, DOI 10.1159/000345953; Lawrence VA, 2002, ARCH INTERN MED, V162, P2053, DOI 10.1001/archinte.162.18.2053; Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450; Lundstrom M, 2005, J AM GERIATR SOC, V53, P622, DOI 10.1111/j.1532-5415.2005.53210.x; Mehta SR, 2001, LANCET, V358, P527, DOI 10.1016/S0140-6736(01)05701-4; Michaelsson K, 1998, BMJ-BRIT MED J, V316, P1858; Michaelsson K, 2014, J BONE MINER RES, V29, P424, DOI 10.1002/jbmr.2029; OECD, 2012, HLTH GLANC EUR 2012, P154; Parker M, 2006, BMJ-BRIT MED J, V333, P27, DOI 10.1136/bmj.333.7557.27; Qureshi A, 2003, AGE AGEING, V32, P8, DOI 10.1093/ageing/32.1.8; Rafferty AM, 2007, INT J NURS STUD, V44, P175, DOI 10.1016/j.ijnurstu.2006.08.003; ROCHE J, 2005, BMJ-BRIT MED J, V331, P1374, DOI DOI 10.1136/BMJ.38643.663843.55; Royston P, 2002, STAT MED, V21, P2175, DOI 10.1002/sim.1203; Statistics Sweden Database, 2014, OFF POP STAT; Swedish Association of Local Authorities and Regions, 2013, QUAL EFF SWED HLTH C; United Nation, 2013, WORLD POP PROSP 2012; Vidan M, 2005, J AM GERIATR SOC, V53, P1476, DOI 10.1111/j.1532-5415.2005.53466.x	30	98	99	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 20	2015	350								h696	10.1136/bmj.h696	http://dx.doi.org/10.1136/bmj.h696			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CB8WF	25700551	Green Published, hybrid			2023-01-03	WOS:000349911800005
J	Nanri, A; Mizoue, T; Kurotani, K; Goto, A; Oba, S; Noda, M; Sawada, N; Tsugane, S				Nanri, Akiko; Mizoue, Tetsuya; Kurotani, Kayo; Goto, Atsushi; Oba, Shino; Noda, Mitsuhiko; Sawada, Norie; Tsugane, Shoichiro		Japan Public Hlth Ctr-Based Prospe	Low-Carbohydrate Diet and Type 2 Diabetes Risk in Japanese Men and Women: The Japan Public Health Center-Based Prospective Study	PLOS ONE			English	Article							FOOD FREQUENCY QUESTIONNAIRE; FOLLOW-UP SURVEY; FATTY-ACIDS; COHORT-I; JPHC; REPRODUCIBILITY; METAANALYSIS; VALIDITY; PROTEIN; SCORE	Objective Evidence is sparse and contradictory regarding the association between low-carbohydrate diet score and type 2 diabetes risk, and no prospective study examined the association among Asians, who consume greater amount of carbohydrate. We prospectively investigated the association of low-carbohydrate diet score with type 2 diabetes risk. Methods Participants were 27,799 men and 36,875 women aged 45-75 years who participated in the second survey of the Japan Public Health Center-Based Prospective Study and who had no history of diabetes. Dietary intake was ascertained by using a validated food-frequency questionnaire, and low-carbohydrate diet score was calculated from total carbohydrate, fat, and protein intake. The scores for high animal protein and fat or for high plant protein and fat were also calculated. Odds ratios of self-reported, physician-diagnosed type 2 diabetes over 5-year were estimated by using logistic regression. Results During the 5-year period, 1191 new cases of type 2 diabetes were self-reported. Low-carbohydrate diet score for high total protein and fat was significantly associated with a decreased risk of type 2 diabetes in women (P for trend < 0.001); the multivariable-adjusted odds ratio of type 2 diabetes for the highest quintile of the score were 0.63 (95% confidence interval 0.46-0.84), compared with those for the lowest quintile. Additional adjustment for dietary glycemic load attenuated the association (odds ratio 0.75, 95% confidence interval 0.45-1.25). When the score separated for animal and for plant protein and fat, the score for high animal protein and fat was inversely associated with type 2 diabetes in women, whereas the score for high plant protein and fat was not associated in both men and women. Discussion Low-carbohydrate diet was associated with decreased risk of type 2 diabetes in Japanese women and this association may be partly attributable to high intake of white rice. The association for animal-based and plant-based low-carbohydrate diet warrants further investigation.	[Nanri, Akiko; Mizoue, Tetsuya; Kurotani, Kayo] Natl Ctr Global Hlth & Med, Ctr Clin Sci, Dept Epidemiol & Prevent, Tokyo, Japan; [Goto, Atsushi; Noda, Mitsuhiko] Natl Ctr Global Hlth & Med, Dept Diabet Res, Tokyo, Japan; [Oba, Shino] Natl Inst Publ Hlth, Dept Hlth Promot, Wako, Saitama 3510197, Japan; [Sawada, Norie; Tsugane, Shoichiro] Natl Canc Ctr, Res Ctr Canc Prevent & Screening, Epidemiol & Prevent Grp, Tokyo 104, Japan	National Center for Global Health & Medicine - Japan; National Center for Global Health & Medicine - Japan; National Institute of Public Health - Japan; National Cancer Center - Japan	Nanri, A (corresponding author), Natl Ctr Global Hlth & Med, Ctr Clin Sci, Dept Epidemiol & Prevent, Tokyo, Japan.	nanri@ri.ncgm.go.jp	Oba, Shino/AAC-5473-2021; Noda, Mitsuhiko/W-3905-2019; Tsugane, Shoichiro/A-2424-2015	Oba, Shino/0000-0002-7388-5861; Noda, Mitsuhiko/0000-0003-0413-4631; Tsugane, Shoichiro/0000-0003-4105-2774; Goto, Atsushi/0000-0003-0669-654X	National Cancer Center Research and Development Fund [23-A-31[toku], 26-A-2]; Ministry of Health, Labour and Welfare of Japan	National Cancer Center Research and Development Fund(National Cancer Center - Japan); Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan)	This study was supported by National Cancer Center Research and Development Fund (23-A-31[toku] and 26-A-2) (since 2011) and a Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare of Japan (from 1989 to 2010). The funders had no role in study design, datacollection and analysis, decision to publish, or preparation of the manuscript.	Alhazmi A, 2012, J AM COLL NUTR, V31, P243, DOI 10.1080/07315724.2012.10720425; COLDITZ GA, 1992, AM J CLIN NUTR, V55, P1018, DOI 10.1093/ajcn/55.5.1018; de Koning L, 2011, AM J CLIN NUTR, V93, P844, DOI 10.3945/ajcn.110.004333; Ericson U, 2013, BRIT J NUTR, V109, P1143, DOI 10.1017/S0007114512003017; Forouhi NG, 2014, LANCET DIABETES ENDO, V2, P810, DOI 10.1016/S2213-8587(14)70146-9; Guariguata L, 2014, DIABETES RES CLIN PR, V103, P137, DOI 10.1016/j.diabres.2013.11.002; Halton TL, 2008, AM J CLIN NUTR, V87, P339, DOI 10.1093/ajcn/87.2.339; Halton TL, 2006, NEW ENGL J MED, V355, P1991, DOI 10.1056/NEJMoa055317; Hu EA, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e1454; Huxley R, 2008, EPIDEMIOLOGY DIABETE, P57; Ishihara J, 2003, J EPIDEMIOL, V13, pS134; KADOWAKI T, 1984, DIABETOLOGIA, V26, P44, DOI 10.1007/BF00252262; Kato M, 2009, ENDOCR J, V56, P459, DOI 10.1507/endocrj.K09E-003; Kurotani K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064758; Ministry of Health Labour and Walfare, 2012, NAT HLTH NUTR SURV J; Ministry of Health Labour and Walfare, 2011, NAT HLTH NUTR SURV J; Mitri J, 2011, EUR J CLIN NUTR, V65, P1005, DOI 10.1038/ejcn.2011.118; Nakamura Y, 2014, BRIT J NUTR, V112, P916, DOI 10.1017/S0007114514001627; Nanri A, 2010, AM J CLIN NUTR, V92, P1468, DOI 10.3945/ajcn.2010.29512; Noto H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055030; O'Neil CE, 2012, NUTRIENTS, V4, P2097, DOI 10.3390/nu4122097; Oba S, 2013, NUTR J, V12, DOI 10.1186/1475-2891-12-165; Salmeron J, 2001, AM J CLIN NUTR, V73, P1019; Sasaki S, 2003, J EPIDEMIOL, V13, pS115; Sasaki S, 2003, J EPIDEMIOL, V13, pS13; Schulze MB, 2008, BRIT J NUTR, V99, P1107, DOI 10.1017/S0007114507853360; Simila ME, 2012, EUR J CLIN NUTR, V66, P716, DOI 10.1038/ejcn.2012.24; Sluijs I, 2010, DIABETES CARE, V33, P43, DOI 10.2337/dc09-1321; Tsugane S, 2003, J EPIDEMIOL, V13, pS51; Tsugane S, 2001, J Epidemiol, V11, pS24; Wallin A, 2012, DIABETES CARE, V35, P918, DOI 10.2337/dc11-1631; Willett WC, 1997, AM J CLIN NUTR, V65, P1220, DOI 10.1093/ajcn/65.4.1220S; Wright Jacqueline D, 2010, NCHS Data Brief, P1; Wu JHY, 2012, BRIT J NUTR, V107, pS214, DOI 10.1017/S0007114512001602	34	45	47	3	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2015	10	2							e0118377	10.1371/journal.pone.0118377	http://dx.doi.org/10.1371/journal.pone.0118377			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC0XE	25695497	Green Submitted, Green Published, gold			2023-01-03	WOS:000350062300051
J	Wang, XL; He, YX; Guo, BS; Tsang, MC; Tu, FJ; Dai, Y; Yao, ZH; Zheng, LZ; Xie, XH; Wang, N; Yao, XS; Zhang, G; Qin, L				Wang, Xinluan; He, Yixin; Guo, Baosheng; Tsang, Man-Ching; Tu, Fengjuan; Dai, Yi; Yao, Zhihong; Zheng, Lizhen; Xie, Xinhui; Wang, Nan; Yao, Xinsheng; Zhang, Ge; Qin, Ling			In Vivo Screening for Anti-Osteoporotic Fraction from Extract of Herbal Formula Xianlinggubao in Ovariectomized Mice	PLOS ONE			English	Article							POSTMENOPAUSAL OSTEOPOROSIS; BONE LOSS; BIOCHEMICAL MARKERS; CONTROLLED TRIAL; TOTAL SAPONINS; RADIX-DIPSACI; RATS; FLAVONOIDS; DIFFERENTIATION; IDENTIFICATION	Background and Objectives Traditional Chinese Medicine (TCM) Fufang or formula Xianlinggubao (XLGB) is a prescribed TCM drug in China registered for prevention and treatment of osteoporosis. Fufang in TCM is comprised of a group of herbal compounds contributing in group to the treatment efficacy. The present study aims to identify the bioactive fraction(s) in XLGB extract that account(s) dominantly for its osteogenic effects. Methods The extract of XLGB formula was separated into three fractions using chromatography, i.e., XLGB-A, XLGB-B and XLGB-C. They were administrated to 4-month old ovariectomized (OVX) mice for 6 weeks to determine which bioactive fraction(s) were more effective for preventing OVX-induced bone loss evaluated by microCT, biomechanical testing and biochemical markers. The main peaks of the key fraction were identified using reference compounds isolated from the fraction. In addition, the effects of the composite compounds in XLGB-B on osteoblasts' proliferation and mineralization were evaluated in UMR 106 cells. Results XLGB-B with a yield of 13.0% from herbal Fufang XLGB was identified as the most potential one among the three fractions for prevention of OVX-induced bone loss confirmed with bone mass, bonemicroarchitecture, bone strength and bone turnover markers. Nine compounds in HPLC fingerprint were identified in the XLGB-B fraction, including phenylpropanoids from Herba Epimedii, terpenes from Radix Dipsaci and coumarins from Fructus Psoraleae. In addition, the identified compounds effectively promoted proliferation and/or mineralization of osteoblast-like UMR 106 cells in vitro. Conclusion XLGB-B with defined phytochemical structures was screened as the key fraction that demonstrated preventive effects on OVX-induced bone loss in mice. The present study laid down a foundation towards a new generation of herbal Fufang characterized with "less herbal materials for achieving equal treatment efficacy" in development strategy of TCM for prevention of OVX-induced osteoporosis.	[Wang, Xinluan; Wang, Nan; Qin, Ling] Chinese Acad Sci, Translat Med R&D Ctr, Shenzhen Inst Adv Technol, Inst Biomed Engn & Hlth Tec, Shenzhen 518000, Peoples R China; [Wang, Xinluan; He, Yixin; Guo, Baosheng; Tsang, Man-Ching; Zheng, Lizhen; Xie, Xinhui; Zhang, Ge; Qin, Ling] Chinese Univ Hong Kong, Dept Orthopaed & Traumatol, Musculoskeletal Res Lab, Hong Kong, Hong Kong, Peoples R China; [Tu, Fengjuan; Dai, Yi; Yao, Zhihong; Yao, Xinsheng] Jinan Univ, Coll Pharm, Inst Tradit Chinese Med & Nat Prod, Guangzhou 510632, Guangdong, Peoples R China	Chinese Academy of Sciences; Shenzhen Institute of Advanced Technology, CAS; Chinese University of Hong Kong; Jinan University	Yao, XS (corresponding author), Jinan Univ, Coll Pharm, Inst Tradit Chinese Med & Nat Prod, Guangzhou 510632, Guangdong, Peoples R China.	tyaoxs@jnu.edu.cn; zhangge@hkbu.edu.hk; lingqin@cuhk.edu.hk	Zhang, Ge/K-9118-2019; Qin, Ling/J-9047-2018; GUO, Baosheng/M-6023-2013; Wang, Nan/GRY-3150-2022; Guo, Baosheng/ABD-4800-2021	Zhang, Ge/0000-0002-7807-7695; Qin, Ling/0000-0001-6173-6167; Guo, Baosheng/0000-0002-4510-5418	Ministry of Science and Technology of the People's Republic of China [2011ZX09201-201-01]; National Natural Science Foundation of China [81220108028]; Ministry of Education of the People's Republic of China [B13038]	Ministry of Science and Technology of the People's Republic of China(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Education of the People's Republic of China(Ministry of Education, China)	The work was supported by Ministry of Science and Technology of the People's Republic of China (2011ZX09201-201-01, Prof. Ling Qin), National Natural Science Foundation of China (81220108028, Prof. Xinsheng Yao) and Ministry of Education of the People's Republic of China (B13038, Prof. Xinsheng Yao). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Chen WF, 2011, BRIT J NUTR, V105, P180, DOI 10.1017/S0007114510003247; Cheng TO, 2007, INT J CARDIOL, V121, P9, DOI 10.1016/j.ijcard.2007.01.004; Cremers S, 2006, DRUGS, V66, P2031, DOI 10.2165/00003495-200666160-00001; Deng WM, 2012, J BONE MINER METAB, V30, P517, DOI 10.1007/s00774-012-0351-7; Don MJ, 2012, PHYTOMEDICINE, V19, P551, DOI 10.1016/j.phymed.2012.01.006; Dong GC, 2008, J BIOMED MATER RES A, V84A, P167, DOI 10.1002/jbm.a.31261; Gao XZ, 2010, ASIA PAC TRADIT MED, V6, P142; Guan XY, 2011, J PHARMACEUT BIOMED, V55, P923, DOI 10.1016/j.jpba.2011.03.021; Gui Li, 2007, Zhongguo Xinyao yu Linchuang Zazhi, V26, P619; Hu CX, 2000, CHINESE TRADITIONAL, V22, P246; Huang J., 2004, CHIN J CLIN PHARM TH, V09, P1069; Li QQ, 2010, CHIN MOD MED, V17, P96; [李晓龙 Li Xiaolong], 2010, [药物分析杂志, Chinese Journal of Pharmaceutical Analysis], V30, P891; Li Y, 2014, CHIN J NAT MEDICINES, V12, P204, DOI 10.1016/S1875-5364(14)60034-0; Lim SH, 2009, BRIT J NUTR, V101, P1031, DOI 10.1017/S0007114508066750; Liu CM, 2003, CHEM J CHINESE U, V24, P2215; Liu MJ, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-67; Liu YW, 2012, J ETHNOPHARMACOL, V139, P194, DOI 10.1016/j.jep.2011.11.004; Liu ZG, 2009, J ETHNOPHARMACOL, V123, P74, DOI 10.1016/j.jep.2009.02.025; Lock CA, 2006, OSTEOPOROSIS INT, V17, P20, DOI 10.1007/s00198-005-1942-0; Luo GA, 1997, TRADITIONAL CHINESE, V19, P44; Malaval L, 1998, J BONE MINER RES, V13, P175, DOI 10.1359/jbmr.1998.13.2.175; [茅月娟 MAO Yuejuan], 2006, [中国现代应用药学, Chinese Journal of Modern Applied Pharmacy], V23, P416; Mok SK, 2010, BRIT J PHARMACOL, V159, P939, DOI 10.1111/j.1476-5381.2009.00593.x; Niu YB, 2012, OSTEOPOROSIS INT, V23, P2649, DOI 10.1007/s00198-012-1932-y; Notelovitz M, 1997, AM J MED SCI, V313, P2, DOI 10.1097/00000441-199701000-00002; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Park CK, 2008, BIOCHEM PHARMACOL, V75, P2175, DOI 10.1016/j.bcp.2008.03.007; Qin L, 2005, J BONE MINER METAB, V23, P55, DOI 10.1007/BF03026324; Qin L, 2014, J ORTHOP TRANSL, V2, P43, DOI 10.1016/j.jot.2013.12.001; Reginster JY, 2011, DRUGS, V71, P65, DOI 10.2165/11587570-000000000-00000; Rissanen JP, 2008, CALCIFIED TISSUE INT, V82, P155, DOI 10.1007/s00223-007-9101-6; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Songlin P, 2009, BONE, V45, P534, DOI [DOI 10.1016/J.B0NE.2009.05.022, 10.1016/j.bone.2009.05.022]; Sorensen MG, 2007, BIOMARKERS, V12, P266, DOI 10.1080/13547500601070842; Tan W, 2012, INT J BIOL MACROMOL, V50, P59, DOI 10.1016/j.ijbiomac.2011.09.019; [陶玲 TAO Ling], 2009, [中国医院药学杂志, Chinese Journal of Hospital Pharmacy], V29, P1431; Tsai MH, 2007, AM J CHINESE MED, V35, P669, DOI 10.1142/S0192415X07005168; Varea O, 2010, STEROIDS, V75, P565, DOI 10.1016/j.steroids.2009.09.006; Wang N, 2014, J ORTHOPAEDIC TRANSL, V2, P218; Wang N, 2013, CHIN MED-UK, V8, DOI 10.1186/1749-8546-8-17; Wang XL, 2008, CHEM PHARM BULL, V56, P46, DOI 10.1248/cpb.56.46; Wang XL, 2011, PHYTOMEDICINE, V18, P868, DOI 10.1016/j.phymed.2011.01.022; Wong RWK, 2010, PHYTOTHER RES, V24, pS155, DOI 10.1002/ptr.3049; Wong RWK, 2007, PHYTOTHER RES, V21, P596, DOI 10.1002/ptr.2126; Wu Huichao, 2011, Zhongguo Zhong Yao Za Zhi, V36, P992; Xiao HH, 2011, BRIT J NUTR, V106, P1802, DOI 10.1017/S0007114511002546; Yang Z, 2012, MENOPAUSE, V19, P1156, DOI 10.1097/gme.0b013e3182507e18; Zhang G, 2006, BONE, V38, P818, DOI 10.1016/j.bone.2005.11.019; Zhang G, 2007, J BONE MINER RES, V22, P1072, DOI 10.1359/JBMR.070405; Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617; Zhang RX, 2008, J ETHNOPHARMACOL, V117, P199, DOI 10.1016/j.jep.2008.02.018; Zhu HM, 2012, OSTEOPOROSIS INT, V23, P1317, DOI 10.1007/s00198-011-1577-2; Zhu ZY, 2007, RAPID COMMUN MASS SP, V21, P1855, DOI 10.1002/rcm.3023	54	34	37	1	42	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2015	10	2							e0118184	10.1371/journal.pone.0118184	http://dx.doi.org/10.1371/journal.pone.0118184			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC0XE	25695519	Green Submitted, Green Published, gold			2023-01-03	WOS:000350062300044
J	Lee, BH; Kim, MH; Lee, JH; Seliktar, D; Cho, NJ; Tan, LP				Lee, Bae Hoon; Kim, Myung Hee; Lee, Jae Ho; Seliktar, Dror; Cho, Nam-Joon; Tan, Lay Poh			Modulation of Huh7.5 Spheroid Formation and Functionality Using Modified PEG-Based Hydrogels of Different Stiffness	PLOS ONE			English	Article							MAGNETIC-RESONANCE ELASTOGRAPHY; CELL-LINE; PRIMARY HEPATOCYTES; COLLAGEN SANDWICH; STEM-CELLS; CULTURE; MATRIX; PLATFORM; MODEL; ENCAPSULATION	Physical cues, such as cell microenvironment stiffness, are known to be important factors in modulating cellular behaviors such as differentiation, viability, and proliferation. Apart from being able to trigger these effects, mechanical stiffness tuning is a very convenient approach that could be implemented readily into smart scaffold designs. In this study, fibrinogen-modified poly(ethylene glycol)-diacrylate (PEG-DA) based hydrogels with tunable mechanical properties were synthesized and applied to control the spheroid formation and liver-like function of encapsulated Huh7.5 cells in an engineered, three-dimensional liver tissue model. By controlling hydrogel stiffness (0.1-6 kPa) as a cue for mechanotransduction representing different stiffness of a normal liver and a diseased cirrhotic liver, spheroids ranging from 50 to 200 mu m were formed over a three week time-span. Hydrogels with better compliance (i.e. lower stiffness) promoted formation of larger spheroids. The highest rates of cell proliferation, albumin secretion, and CYP450 expression were all observed for spheroids in less stiff hydrogels like a normal liver in a healthy state. We also identified that the hydrogel modification by incorporation of PEGylated-fibrinogen within the hydrogel matrix enhanced cell survival and functionality possibly owing to more binding of autocrine fibronectin. Taken together, our findings establish guidelines to control the formation of Huh7.5 cell spheroids in modified PEGDA based hydrogels. These spheroids may serve as models for applications such as screening of pharmacological drug candidates.	[Lee, Bae Hoon; Kim, Myung Hee; Lee, Jae Ho; Cho, Nam-Joon; Tan, Lay Poh] Nanyang Technol Univ, Sch Mat Sci & Engn, Singapore 639798, Singapore; [Seliktar, Dror] Technion Israel Inst Technol, Dept Biomed Engn, IL-32000 Haifa, Israel	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Technion Israel Institute of Technology	Cho, NJ (corresponding author), Nanyang Technol Univ, Sch Mat Sci & Engn, Singapore 639798, Singapore.	NJCho@ntu.edu.sg; LPTan@ntu.edu.sg	Tan, LP/A-2229-2011; Cho, Nam-Joon/J-7816-2012	Tan, LP/0000-0002-0172-1569; Cho, Nam-Joon/0000-0002-8692-8955; Seliktar, Dror/0000-0001-6964-8567	National Research Foundation (NRF) Competitive Research Programme grant in Singapore [NRF-CRP10-2012-07]	National Research Foundation (NRF) Competitive Research Programme grant in Singapore	This research is financially supported by the National Research Foundation (NRF) Competitive Research Programme (NRF-CRP10-2012-07) grant in Singapore. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ananthanarayanan A, 2014, MOL PHARMACEUT, V11, P2106, DOI 10.1021/mp500063y; Castell JV, 2006, EXPERT OPIN DRUG MET, V2, P183, DOI 10.1517/17425255.2.2.183; Chang TT, 2009, TISSUE ENG PT A, V15, P559, DOI 10.1089/ten.tea.2007.0434; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Cho NJ, 2009, BIOMED MATER, V4, DOI [10.1088/1748-6041/4/1/011001, 10.1088/1748-6041/25/1/011001]; Dikovsky D, 2006, BIOMATERIALS, V27, P1496, DOI 10.1016/j.biomaterials.2005.09.038; Donato MT, 2008, CELL TRANSPLANT, V17, P1211, DOI 10.3727/096368908787236620; DUNN JCY, 1992, J CELL BIOL, V116, P1043, DOI 10.1083/jcb.116.4.1043; DUNN JCY, 1993, BIOTECHNOL BIOENG, V41, P593, DOI 10.1002/bit.260410512; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Fey SJ, 2012, TOXICOL SCI, V127, P403, DOI 10.1093/toxsci/kfs122; Freudenberg U, 2009, BIOMATERIALS, V30, P5049, DOI 10.1016/j.biomaterials.2009.06.002; Friedrich J, 2009, NAT PROTOC, V4, P309, DOI 10.1038/nprot.2008.226; Georges PC, 2005, J APPL PHYSIOL, V98, P1547, DOI 10.1152/japplphysiol.01121.2004; Godoy P, 2013, ARCH TOXICOL, V87, P1315, DOI 10.1007/s00204-013-1078-5; Hou YT, 2010, J BIOSCI BIOENG, V110, P208, DOI 10.1016/j.jbiosc.2010.01.016; Ivascu A, 2007, INT J ONCOL, V31, P1403; Kamphues C, 2012, ROFO-FORTSCHR RONTG, V184, P1013, DOI 10.1055/s-0032-1313126; Khaitan D, 2006, EXPERT OPIN DRUG DIS, V1, P663, DOI 10.1517/17460441.1.7.663; Klatt D, 2010, BIORHEOLOGY, V47, P133, DOI 10.3233/BIR-2010-0565; Lam CRI, 2014, MOL PHARMACEUT, V11, P2016, DOI 10.1021/mp500059q; Lee BH, 2014, J BIOMAT SCI-POLYM E, V25, P394, DOI 10.1080/09205063.2013.862401; Lee W, 2010, P NATL ACAD SCI USA, V107, P20709, DOI 10.1073/pnas.1005211107; Leong WS, 2010, BIOCHEM BIOPH RES CO, V401, P287, DOI 10.1016/j.bbrc.2010.09.052; Li C.Y., 2014, TISSUE ENG A; Liang Y, 2011, BIOMATERIALS, V32, P9308, DOI 10.1016/j.biomaterials.2011.08.045; Lin Ruei-Zhen, 2008, Biotechnology Journal, V3, P1172, DOI 10.1002/biot.200700228; Lin RZ, 2006, CELL TISSUE RES, V324, P411, DOI 10.1007/s00441-005-0148-2; Lin TY, 2014, BIOMATERIALS, V35, P6898, DOI 10.1016/j.biomaterials.2014.04.118; Mahou R, 2012, J MATER SCI-MATER M, V23, P171, DOI 10.1007/s10856-011-4512-3; Makogonenko E, 2002, BIOCHEMISTRY-US, V41, P7907, DOI 10.1021/bi025770x; Molina-Jimenez F, 2012, VIROLOGY, V425, P31, DOI 10.1016/j.virol.2011.12.021; Mueller S, 2010, HEPATIC MED-EVID RES, V2, P49; Nakazawa K, 2002, INT J ARTIF ORGANS, V25, P51, DOI 10.1177/039139880202500109; Napolitano AP, 2007, TISSUE ENG, V13, P2087, DOI 10.1089/ten.2006.0190; Nelson LJ, 2010, CELLS TISSUES ORGANS, V192, P125, DOI 10.1159/000308893; Nguyen KT, 2002, BIOMATERIALS, V23, P4307, DOI 10.1016/S0142-9612(02)00175-8; Tran NM, 2013, TISSUE ENG PT A, V19, P103, DOI [10.1089/ten.TEA.2012.0139, 10.1089/ten.tea.2012.0139]; Peshwa MV, 1996, IN VITRO CELL DEV-AN, V32, P197; Phelps EA, 2012, ADV MATER, V24, P64, DOI 10.1002/adma.201103574; Ringel M, 2005, TOXICOLOGY, V206, P153, DOI 10.1016/j.tox.2004.07.017; Robinson EE, 2004, MOL BIOL CELL, V15, P973, DOI 10.1091/mbc.E03-07-0528; Semler EJ, 2005, BIOTECHNOL BIOENG, V89, P296, DOI 10.1002/bit.20328; Semler EJ, 2001, BIOTECHNOL BIOENG, V75, P510, DOI 10.1002/bit.10113; STAMATOGLOU SC, 1987, J CELL BIOL, V105, P2417, DOI 10.1083/jcb.105.5.2417; Subramanian K, 2014, STEM CELLS DEV, V23, P124, DOI 10.1089/scd.2013.0097; Tay CY, 2011, SMALL, V7, P1416, DOI 10.1002/smll.201002298; Underhill GH, 2007, BIOMATERIALS, V28, P256, DOI 10.1016/j.biomaterials.2006.08.043; Wang S, 2008, TISSUE ENG PT A, V14, P227, DOI 10.1089/tea.2007.0143; Weber LM, 2006, ACTA BIOMATER, V2, P1, DOI 10.1016/j.actbio.2005.10.005; Wells RG, 2008, HEPATOLOGY, V47, P1394, DOI 10.1002/hep.22193; Williams CM, 2011, TISSUE ENG PT A, V17, P1055, DOI [10.1089/ten.tea.2010.0398, 10.1089/ten.TEA.2010.0398]; Yu HY, 2013, ADV HEALTHC MATER, V2, P442, DOI 10.1002/adhm.201200142	53	46	47	4	48	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 18	2015	10	2							e0118123	10.1371/journal.pone.0118123	http://dx.doi.org/10.1371/journal.pone.0118123			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC0WZ	25692976	Green Published, gold			2023-01-03	WOS:000350061500100
J	Reid, MC; Eccleston, C; Pillemer, K				Reid, M. Carrington; Eccleston, Christopher; Pillemer, Karl			Management of chronic pain in older adults	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PRIMARY-CARE; MUSCULOSKELETAL PAIN; EXERCISE PROGRAM; CHRONIC DISEASE; HEALTH; PREVALENCE; OSTEOARTHRITIS; OUTCOMES; ARTHRITIS; PATIENT		[Reid, M. Carrington] Weill Cornell Med Coll, Dis Geriatr & Palliat Med, New York, NY 10065 USA; [Eccleston, Christopher] Univ Bath, Ctr Pain Res, Bath BA2 7AY, Avon, England; [Pillemer, Karl] Cornell Univ, Dept Human Dev, Ithaca, NY USA	Cornell University; University of Bath; Cornell University	Reid, MC (corresponding author), Weill Cornell Med Coll, Dis Geriatr & Palliat Med, New York, NY 10065 USA.	mcr2004@med.cornell.edu		Eccleston, Christopher/0000-0003-0698-1543; Pillemer, Karl/0000-0002-7700-3563	National Institute on Ageing [P30AG022845]; Agency for Healthcare Quality and Research [R01HS020648]; Howard and Phyllis Schwartz Philanthropic Fund; Endo Pharmaceuticals; UK National Institute for Health Research Cochrane Program; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS020648] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG022845] Funding Source: NIH RePORTER	National Institute on Ageing(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Agency for Healthcare Quality and Research(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Howard and Phyllis Schwartz Philanthropic Fund; Endo Pharmaceuticals; UK National Institute for Health Research Cochrane Program; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We have read and understood the BMJ policy on declaration of interests and declare that: MCR has received funding from the National Institute on Ageing (P30AG022845), the Agency for Healthcare Quality and Research (R01HS020648), Howard and Phyllis Schwartz Philanthropic Fund, and Endo Pharmaceuticals. KP has received research funding from the National Institute on Ageing (P30AG022845). CE has received a grant from the UK National Institute for Health Research Cochrane Program.	Abdulla A, 2013, AGE AGEING, V42, pI1, DOI 10.1093/ageing/afs200; Azevedo LF, 2013, MED CARE, V51, P859, DOI 10.1097/MLR.0b013e3182a53e4e; Broderick JE, 2014, PAIN, V155, P1743, DOI 10.1016/j.pain.2014.05.024; Chodosh J, 2005, ANN INTERN MED, V143, P427, DOI 10.7326/0003-4819-143-6-200509200-00007; Chou R, 2015, ANN INTERN MED, V162, P276, DOI 10.7326/M14-2559; Chou R, 2011, ANN INTERN MED, V154, P181, DOI 10.7326/0003-4819-154-3-201102010-00008; Cooper G, 2013, MEDSCAPE OVERVIEW OS; Dansie EJ, 2013, BRIT J ANAESTH, V111, P19, DOI 10.1093/bja/aet124; Dobscha SK, 2009, JAMA-J AM MED ASSOC, V301, P1242, DOI 10.1001/jama.2009.377; Draguns JG, 2013, PSYCHOLOGIA, V56, P74; Du SZ, 2011, PATIENT EDUC COUNS, V85, pE299, DOI 10.1016/j.pec.2011.02.021; Eccleston C, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010152.pub2; Enck RE, 2010, AM J HOSP PALLIAT ME, V27, P301, DOI 10.1177/1049909110369530; Ferrell B, 2002, J AM GERIATR SOC, V50, pS205, DOI 10.1046/j.1532-5415.50.6s.1.x; Ferrell B, 2009, J AM GERIATR SOC, V57, P1331, DOI 10.1111/j.1532-5415.2009.02376.x; Gilron I, 2005, NEW ENGL J MED, V352, P1324, DOI 10.1056/NEJMoa042580; Guillory J, 2015, CLIN J PAIN; Hadjistavropoulos T, 2007, CLIN J PAIN, V23, pS1, DOI 10.1097/AJP.0b013e31802be869; Henderson JV, 2013, PAIN MED, V14, P1346, DOI 10.1111/pme.12195; Herr K, 2011, PAIN MANAG NURS, V12, P230, DOI 10.1016/j.pmn.2011.10.002; Institute of Medicine (US) Committee on Advancing Pain Research Care and Education Board on Health Sciences Policy, 2011, REL PAIN AM BLUEPR T; International Association for the Study of Pain, 2012, IASP TAX; Jackson T, 2014, CLIN J PAIN, V30, P346, DOI 10.1097/AJP.0b013e31829ea1e3; Keefe FJ, 2004, PAIN, V110, P539, DOI 10.1016/j.pain.2004.03.022; Kroenke K, 2014, JAMA-J AM MED ASSOC, V312, P240, DOI 10.1001/jama.2014.7689; Leadley R M, 2012, J Pain Palliat Care Pharmacother, V26, P310, DOI 10.3109/15360288.2012.736933; Levy SS, 2012, DISABIL HEALTH J, V5, P305, DOI 10.1016/j.dhjo.2012.07.003; Lin EHB, 2003, JAMA-J AM MED ASSOC, V290, P2428, DOI 10.1001/jama.290.18.2428; Lunde LH, 2009, J CLIN PSYCHOL MED S, V16, P254, DOI 10.1007/s10880-009-9162-y; Makris UE, 2014, JAMA-J AM MED ASSOC, V312, P825, DOI 10.1001/jama.2014.9405; Mallen CD, 2013, JAMA INTERN MED, V173, P1119, DOI 10.1001/jamainternmed.2013.962; Martire Lynn M, 2008, Fam Syst Health, V26, P185; McGuire BE, 2014, CURR OPIN PSYCHIATR, V27, P380, DOI 10.1097/YCO.0000000000000090; Messier SP, 2013, JAMA-J AM MED ASSOC, V310, P1263, DOI 10.1001/jama.2013.277669; Morley S, 2013, PAIN, V154, P1929, DOI 10.1016/j.pain.2013.05.049; Nicholas MK, 2013, PAIN, V154, P824, DOI 10.1016/j.pain.2013.02.009; Papaleontiou M, 2010, J AM GERIATR SOC, V58, P1353, DOI 10.1111/j.1532-5415.2010.02920.x; Patel KV, 2013, PAIN, V154, P2649, DOI 10.1016/j.pain.2013.07.029; Reid MC, 2008, PAIN MED, V9, P409, DOI 10.1111/j.1526-4637.2008.00428.x; Reid MC, 2010, PAIN MED, V11, P1063, DOI 10.1111/j.1526-4637.2010.00883.x; Richardson JE, 2013, PAIN MED, V14, P1621, DOI 10.1111/pme.12206; Riddle DL, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-149; Royal College of Physicians British Geriatrics Society and British Pain Society, 2007, CONC GUID GOOD PRACT, V8; Smith AK, 2010, ANN INTERN MED, V153, P563, DOI 10.7326/0003-4819-153-9-201011020-00005; Solano JP, 2006, J PAIN SYMPTOM MANAG, V31, P58, DOI 10.1016/j.jpainsymman.2005.06.007; Tobias KR, 2014, PAIN MANAG NURS, V15, P760, DOI 10.1016/j.pmn.2013.07.013; Towheed TE, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004257.pub2; Trelle S, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.c7086; Tsang A, 2008, J PAIN, V9, P883, DOI 10.1016/j.jpain.2008.05.005; Tse MMY, 2013, J CLIN NURS, V22, P1843, DOI 10.1111/j.1365-2702.2012.04317.x; Warsi A, 2004, ARCH INTERN MED, V164, P1641, DOI 10.1001/archinte.164.15.1641; Wyldea V, 2011, PAIN, V152, P457	52	197	201	1	30	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 13	2015	350								h532	10.1136/bmj.h532	http://dx.doi.org/10.1136/bmj.h532			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CB0MZ	25680884	Green Published			2023-01-03	WOS:000349321700001
J	Zheng, GH; Li, SZ; Huang, MM; Liu, FW; Tao, J; Chen, LD				Zheng, Guohua; Li, Shuzhen; Huang, Maomao; Liu, Feiwen; Tao, Jing; Chen, Lidian			The Effect of Tai Chi Training on Cardiorespiratory Fitness in Healthy Adults: A Systematic Review and Meta-Analysis	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; IMPROVING AEROBIC CAPACITY; TIME PHYSICAL-ACTIVITY; OLDER-ADULTS; CHUAN PRACTITIONERS; EXERCISE INTENSITY; BLOOD-PRESSURE; RISK-FACTORS; WOMEN; MORTALITY	Background Tai Chi may be efficient for healthy adults to improve the cardiorespiratory fitness, but there is no systematic evaluation for its effectiveness. Objective To systematically assess the effectiveness of Tai Chi on cardiorespiratory fitness in healthy adults. Methods Seven electronic databases were searched from their inception to October 2013. The controlled trails including randomized controlled trial (RCT), non-randomized controlled trial (NRCT), self-controlled trial (SCT), and cohort study (CS) testing Tai Chi exercise against non-intervention control conditions in healthy adults that assessed any type cardiorespiratory fitness outcome measures were considered. Two reviewers independently performed the selection of the studies according to predefined criteria. The risk of bias was assessed using Cochrane criteria. RevMan 5.2 software was applied for data analysis. Results Twenty studies (2 RCTs, 8 NRCTs, 3 SCTs, and 7 CSs) with 1868 participants were included, but most of them belonged to low methodological quality. The results of systematic review showed that Tai Chi exercise had positive effect on majority outcomes of cardio function (Blood pressure: n = 536, SPB SMD = -0.93, 95% CI -1.30 to -0.56, P < 0.00001; DBP SMD = -0.54, 95% CI -0.90 to -0.18, P < 0.00001; heart rate at quiet condition: n = 986, SMD = -0.72, 95% CI -1.27 to -0.18, P = 0.010; stroke volume: n = 583, SMD = 0.44, 95% CI 0.28 to 0.61, P < 0.00001; cardio output: n = 583, MD = 0.32 L/ min, 95% CI 0.08 to 0.56, P = 0.009), lung capacity (FVC at quiet condition: n = 1272, MD = 359.16 mL, 95% CI 19.57 to 698.75, P = 0.04 for less than one year intervention, and MD = 442.46 mL, 95% CI 271.24 to 613.68, P<0.0001 for more than one year intervention; V.O(2)peak: n = 246, SMD = 1.33, 95% CI 0.97 to 1.70, P < 0.00001), and cardiorespiratory endurance (O-2 pulse at quiet condition: n = 146, SMD = 1.04; 95% CI 0.69 to 1.39; P < 0.00001; stair test index at quiet condition: n = 679, SMD = 1.34, 95% CI 0.27 to 2.40, p = 0.01). No adverse events were reported. Conclusions The results are encouraging and suggest that Tai Chi may be effective in improving cardiorespiratory fitness in healthy adults. However, concerning the low methodological quality in the included studies, more larger-scale well-designed trails are needed till the specific and accurate conclusions can be perorated.	[Zheng, Guohua; Li, Shuzhen; Huang, Maomao; Liu, Feiwen; Tao, Jing] Fujian Univ Tradit Chinese Med, Coll Rehabil Med, Fuzhou, Peoples R China; [Chen, Lidian] Fujian Univ Tradit Chinese Med, Fuzhou, Peoples R China	Fujian University of Traditional Chinese Medicine; Fujian University of Traditional Chinese Medicine	Chen, LD (corresponding author), Fujian Univ Tradit Chinese Med, Fuzhou, Peoples R China.	lidianchen87@163.com		Li, shuzhen/0000-0002-8336-092X; Tao, Jing/0000-0001-9751-5294; Chen, Lidian/0000-0002-6454-7932	Collaboration Innovation Center for Rehabilitation Technology (number 1 Collaboration Center); Rehabilitation Research Center for Traditional Chinese Medicine, State Administration of Traditional Chinese Medicine of the People's Republic of China	Collaboration Innovation Center for Rehabilitation Technology (number 1 Collaboration Center); Rehabilitation Research Center for Traditional Chinese Medicine, State Administration of Traditional Chinese Medicine of the People's Republic of China	This study is supported by the Collaboration Innovation Center for Rehabilitation Technology (number 1 Collaboration Center (2012)) and Rehabilitation Research Center for Traditional Chinese Medicine, State Administration of Traditional Chinese Medicine of the People's Republic of China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmaidi S, 1998, EUR J APPL PHYSIOL O, V78, P170, DOI 10.1007/s004210050403; Barlow CE, 2006, AM J EPIDEMIOL, V163, P142, DOI 10.1093/aje/kwj019; Birdee GS, 2013, J ALTERN COMPLEM MED, V19, P550, DOI 10.1089/acm.2012.0223; Bu Bin, 2010, J Evid Based Med, V3, P205, DOI 10.1111/j.1756-5391.2010.01107.x; Chan AWK, 2013, COMPLEMENT THER MED, V21, P585, DOI 10.1016/j.ctim.2013.09.008; Chang MY, 2013, AM J HEALTH PROMOT, V28, P16, DOI 10.4278/ajhp.120720-QUAN-356; Chen S. Y., 2013, EVID-BASED COMPL ALT, V2013, DOI [DOI 10.1155/2013/983208, 10.1155/2013/983208]; Cheon SM, 2013, J CLIN NEUROL, V9, P237, DOI 10.3988/jcn.2013.9.4.237; Fu X, 2009, J GANSU NORMAL COLL, V14, P73; Fujie S, 2013, PHYSIOL GENOMICS, V45, P237, DOI 10.1152/physiolgenomics.00089.2012; Gatts Strawberry, 2008, Curr Aging Sci, V1, P68; GOVINDASAMY D, 1992, EUR J APPL PHYSIOL, V65, P203, DOI 10.1007/BF00705082; Han YZ, 2010, STUDY PHASED EVALUAT; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Ho Rainbow T H, 2012, Evid Based Complement Alternat Med, V2012, P923925, DOI 10.1155/2012/923925; Hong YL, 2000, BRIT J SPORT MED, V34, P29, DOI 10.1136/bjsm.34.1.29; Kodama S, 2009, JAMA-J AM MED ASSOC, V301, P2024, DOI 10.1001/jama.2009.681; Laaksonen DE, 2002, DIABETES CARE, V25, P1612, DOI 10.2337/diacare.25.9.1612; LAI JS, 1995, J AM GERIATR SOC, V43, P1222, DOI 10.1111/j.1532-5415.1995.tb07397.x; Lan C, 1998, MED SCI SPORT EXER, V30, P345, DOI 10.1097/00005768-199803000-00003; Lan C, 2004, AM J CHINESE MED, V32, P151, DOI 10.1142/S0192415X04001746; Lan C, 2004, AM J CHINESE MED, V32, P141, DOI 10.1142/S0192415X04001734; Lan C, 1999, MED SCI SPORT EXER, V31, P634, DOI 10.1097/00005768-199905000-00002; Lan C, 2001, MED SCI SPORTS EXERC, V5, P12, DOI [10.1002/bmc.3406, DOI 10.1002/BMC.3406]; Lan C, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/502131; Lan C, 2008, AM J CHINESE MED, V36, P1041, DOI 10.1142/S0192415X08006442; Lan Ching, 2008, V52, P12, DOI 10.1159/000134225; Lang CC, 2007, J CARD FAIL, V13, P672, DOI 10.1016/j.cardfail.2007.05.004; Laukkanen Jari A, 2002, Curr Atheroscler Rep, V4, P468, DOI 10.1007/s11883-002-0052-0; Lee DC, 2010, J PSYCHOPHARMACOL, V24, P27, DOI 10.1177/1359786810382057; Lee LYK, 2013, STRESS HEALTH, V29, P117, DOI 10.1002/smi.2435; Lee MS, 2009, BRIT J SPORT MED, V43, P569, DOI 10.1136/bjsm.2008.053272; Lei XS, 2001, MODERN REKABITLTALIO, V5, P64; Leung RWM, 2013, EXPERT REV RESP MED, V7, P587, DOI 10.1586/17476348.2013.839244; Li JX, 2001, BRIT J SPORT MED, V35, P148, DOI 10.1136/bjsm.35.3.148; [李兴海 LI Xinghai], 2008, [河南师范大学学报. 自然科学版, Journal of Henan Normal University. Natural Science], V36, P123; Liang YW, 2001, J PHYS ED, V8, P64; Liu X., 2010, CHINA PRACTICAL MED, V5, P34; Lo HM, 2012, INT J NURS PRACT, V18, P545, DOI 10.1111/ijn.12006; Lu WA, 2003, MED SCI SPORT EXER, V35, P1972, DOI 10.1249/01.MSS.0000099242.10669.F7; Lu WA, 2012, INT J GERONTOL, V6, P267, DOI 10.1016/j.ijge.2012.01.025; Malagrino PA, 2013, ARQ BRAS ENDOCRINOL, V57, P33, DOI 10.1590/S0004-27302013000100005; Manson J, 2013, BMC GERIATR, V13, DOI 10.1186/1471-2318-13-114; Minton O, 2008, JNCI-J NATL CANCER I, V100, P1155, DOI 10.1093/jnci/djn250; Mossberg KA, 2010, J HEAD TRAUMA REHAB, V25, P173, DOI 10.1097/HTR.0b013e3181dc98ff; Motivala SJ, 2006, J GERONTOL A-BIOL, V61, P1177, DOI 10.1093/gerona/61.11.1177; Nabkasorn C, 2006, EUR J PUBLIC HEALTH, V16, P179, DOI 10.1093/eurpub/cki159; Ng SM, 2012, ALTERN THER HEALTH M, V18, P16; Nguyen MH, 2012, OPEN ACCESS J SPORTS, V3, P7, DOI 10.2147/OAJSM.S27329; Niu RC, 2014, HEART LUNG CIRC, V23, P347, DOI 10.1016/j.hlc.2013.10.057; Peng CZ, 2006, FIGHTING MARTIAL SCI, V6, P32; Prentis JM, 2013, BJU INT, V112, pE13, DOI 10.1111/bju.12219; [荣湘江 RONG Xiangjiang], 2009, [中国康复医学杂志, Chinese Journal of Rehabilitation Medicine], V24, P345; Savovic J, 2014, SYST REV-LONDON, V3, DOI 10.1186/2046-4053-3-37; Singhal N, 2014, J PHYS ACT HEALTH, V11, P296, DOI 10.1123/jpah.2012-0029; Sloan RA, 2013, SINGAP MED J, V54, P576; Snowden CP, 2013, ANN SURG, V257, P999, DOI 10.1097/SLA.0b013e31828dbac2; Swift DL, 2013, CIRC J, V77, P281, DOI 10.1253/circj.CJ-13-0007; Taylor-Piliae Ruth E, 2004, J Cardiovasc Nurs, V19, P48; Taylor-Piliae RE, 2014, ARCH PHYS MED REHAB, V95, P816, DOI 10.1016/j.apmr.2014.01.001; Taylor-Piliae Ruth E., 2008, V52, P40, DOI 10.1159/000134283; Thornton EW, 2004, HEALTH PROMOT INT, V19, P33, DOI 10.1093/heapro/dah105; Tousignant M, 2013, DISABIL REHABIL, V35, P1429, DOI 10.3109/09638288.2012.737084; Tsimaras V, 2003, PERCEPT MOTOR SKILL, V96, P1239, DOI 10.2466/PMS.96.4.1239-1251; Tu HL, 2005, J WUHAN I PHYS ED, V39, P70; Verhagen AP, 2004, FAM PRACT, V21, P107, DOI 10.1093/fampra/cmh122; Wang GJ, 2010, CHINESE J GERONTOLOG, V12, P3802; Xiong KY, 2013, EUR J SPORT SCI, V13, P386, DOI 10.1080/17461391.2011.635706; Xu M, 1997, J CHENGDU PHYS ED I, V3, P79; Yan JH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061672; Yan Y., 2013, J LIAONING NORMAL U, V36, P124; Yan Y, 2010, SCI INFORM, V28, P271; Yeh Gloria Y, 2008, Prev Cardiol, V11, P82; Yeh GY, 2008, EXPLORE-NY, V4, P275, DOI 10.1016/j.explore.2008.04.011; Yeh GY, 2009, J CARDIOPULM REHABIL, V29, P152, DOI 10.1097/HCR.0b013e3181a33379; Yu R, 2013, J SPORT MED PHYS FIT, V53, P680	76	41	45	6	49	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2015	10	2							e0117360	10.1371/journal.pone.0117360	http://dx.doi.org/10.1371/journal.pone.0117360			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC9IO	25680184	Green Published, gold, Green Submitted			2023-01-03	WOS:000350682600062
J	Lavikainen, P; Korhonen, MJ; Huupponen, R; Helin-Salmivaara, A				Lavikainen, Piia; Korhonen, Maarit Jaana; Huupponen, Risto; Helin-Salmivaara, Arja			Accumulation of Cardiovascular and Diabetes Medication among Apparently Healthy Statin Initiators	PLOS ONE			English	Article							PRIMARY PREVENTION; EUROPEAN GUIDELINES; DISEASE PREVENTION; CLINICAL-PRACTICE; ROSUVASTATIN; POPULATION; COHORT	Purpose To characterize accumulation of drug-modifiable cardiovascular (CV) risk factors in statin initiators who had no prior medication or hospitalizations for CV disease or diabetes. Methods A cohort of 45-75-year-old statin initiators in Finland with no prior CV diseases, diabetes or medication for these conditions was followed up for 24 months after statin initiation for accumulation of CV and diabetes drugs. The number of drugs was measured semi-annually since the first statin purchase and analyzed by growth mixture modeling. Results Of the 11 948 apparently healthy statin initiators, 34% purchased at least one additional CV or diabetes drug during the subsequent 24 months. Of those, 20% redeemed no other CV or diabetes drugs at statin initiation but started to accumulate them after 18 months of follow-up, receiving on average 1.3 other drugs at 24 months. The majority, 59%, redeemed on average 0.5 drugs at statin initiation and accumulated 1.5 drugs by the end of 24-month follow-up. Seventeen percent received 1 additional drug at statin initiation, accumulating on average 3 drugs. The remaining 4% with an average of 2 CV or diabetes drugs at statin initiation redeemed 3.5 additional drugs during the follow-up. Conclusions Two years after statin initiation, 2 in 3 apparently healthy initiators could still be defined as such as reflected by CV and diabetes medication use.	[Lavikainen, Piia; Korhonen, Maarit Jaana; Huupponen, Risto; Helin-Salmivaara, Arja] Univ Turku, Dept Pharmacol Drug Dev & Therapeut, Turku, Finland; [Lavikainen, Piia] Univ Turku, Drug Res Doctoral Programme, Turku, Finland; [Korhonen, Maarit Jaana] Univ Turku, Dept Publ Hlth, Turku, Finland; [Huupponen, Risto] Turku Univ Hosp, Dept Clin Pharmacol, FIN-20520 Turku, Finland; [Helin-Salmivaara, Arja] Hosp Dist Helsinki & Uusimaa, Unit Primary Hlth Care, Helsinki, Finland	University of Turku; University of Turku; University of Turku; University of Turku; University of Helsinki; Helsinki University Central Hospital	Lavikainen, P (corresponding author), Univ Turku, Dept Pharmacol Drug Dev & Therapeut, Turku, Finland.	piia.lavikainen@utu.fi		Korhonen, Maarit/0000-0002-2953-4757; Lavikainen, Piia/0000-0003-3560-8860	Academy of Finland [138255]	Academy of Finland(Academy of Finland)	This study was funded by the Academy of Finland (www.aka.fi,decision number 138255). The Academy of Finland had no role in the design, analyses, interpretation of data, writing the report, or in the decision to submit the manuscript.	Andrade SE, 2006, PHARMACOEPIDEM DR S, V15, P565, DOI 10.1002/pds.1230; [Anonymous], 2007, FINN STAT MED 2006; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Crouse JR, 2007, JAMA-J AM MED ASSOC, V297, P1344, DOI 10.1001/jama.297.12.1344; De Backer G, 2003, EUR HEART J, V24, P1601, DOI 10.1016/S0195-668X(03)00347-6; Furu K, 2010, BASIC CLIN PHARMACOL, V106, P86, DOI 10.1111/j.1742-7843.2009.00494.x; Germano G, 2012, EUR HEART J, V33, P137; Graham I, 2007, EUR J CARDIOV PREV R, V14, pS1, DOI 10.1097/01.hjr.0000277983.23934.c9; Greving JP, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1672; Ioannidis JPA, 2014, JAMA-J AM MED ASSOC, V311, P463, DOI 10.1001/jama.2013.284657; Jung T, 2008, SOC PERSONAL PSYCHOL, V2, P302, DOI 10.1111/j.1751-9004.2007.00054.x; Kildemoes HW, 2012, HEALTH POLICY, V108, P216, DOI 10.1016/j.healthpol.2012.08.008; Kildemoes HW, 2012, PHARMACOEPIDEM DR S, V21, P1027, DOI 10.1002/pds.2195; Lazar LD, 2011, CIRCULATION, V124, P146, DOI 10.1161/CIRCULATIONAHA.110.986349; Mitchell Aaron P, 2012, BMC Res Notes, V5, P373, DOI 10.1186/1756-0500-5-373; Muthen L., 2014, MPLUS USERS GUIDE, V7th; Nakamura H, 2006, LANCET, V368, P1155, DOI 10.1016/S0140-6736(06)69472-5; Nylund KL, 2007, STRUCT EQU MODELING, V14, P535, DOI 10.1080/10705510701575396; Prasad V, 2014, ANN INTERN MED, V160, P867, DOI 10.7326/M13-2974; Ray KK, 2010, ARCH INTERN MED, V170, P1024, DOI 10.1001/archinternmed.2010.182; Raymond CB, 2007, CLIN THER, V29, P2107, DOI 10.1016/j.clinthera.2007.09.022; Reinecke J, 2011, ASTA-ADV STAT ANAL, V95, P415, DOI 10.1007/s10182-011-0171-4; Ridker PM, 2008, NEW ENGL J MED, V359, P2195, DOI 10.1056/NEJMoa0807646; Ridker PM, 2013, LANCET, V382, P1762, DOI 10.1016/S0140-6736(13)62388-0; Rikala M, 2013, BASIC CLIN PHARMACOL, V113, P173, DOI 10.1111/bcpt.12075; Sattar N, 2010, LANCET, V375, P735, DOI 10.1016/S0140-6736(09)61965-6; Stone NJ, 2014, J AM COLL CARDIOL, V63, P2889, DOI 10.1016/j.jacc.2013.11.002; Taylor F, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004816.pub5; Vartiainen E, 2013, FINRISKI TUTKIMUS 20; WHO, ATC DDD SYST	30	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2015	10	2							e0117182	10.1371/journal.pone.0117182	http://dx.doi.org/10.1371/journal.pone.0117182			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CB2GK	25658919	gold, Green Published, Green Submitted			2023-01-03	WOS:000349444900112
J	Tappin, D; Bauld, L; Purves, D; Boyd, K; Sinclair, L; MacAskill, S; McKell, J; Friel, B; McConnachie, A; de Caestecker, L; Tannahill, C; Radley, A; Coleman, T				Tappin, David; Bauld, Linda; Purves, David; Boyd, Kathleen; Sinclair, Lesley; MacAskill, Susan; McKell, Jennifer; Friel, Brenda; McConnachie, Alex; de Caestecker, Linda; Tannahill, Carol; Radley, Andrew; Coleman, Tim		Cessation Pregnancy Incentives	Financial incentives for smoking cessation in pregnancy: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							STILLBIRTH	Objective To assess the efficacy of a financial incentive added to routine specialist pregnancy stop smoking services versus routine care to help pregnant smokers quit. Design Phase II therapeutic exploratory single centre, individually randomised controlled parallel group superiority trial. Setting One large health board area with a materially deprived, inner city population in the west of Scotland, United Kingdom. Participants 612 self reported pregnant smokers in NHS Greater Glasgow and Clyde who were English speaking, at least 16 years of age, less than 24 weeks pregnant, and had an exhaled carbon monoxide breath test result of 7 ppm or more. 306 women were randomised to incentives and 306 to control. Interventions The control group received routine care, which was the offer of a face to face appointment to discuss smoking and cessation and, for those who attended and set a quit date, the offer of free nicotine replacement therapy for 10 weeks provided by pharmacy services, and four, weekly support phone calls. The intervention group received routine care plus the offer of up to (sic)400 of shopping vouchers: (sic)50 for attending a face to face appointment and setting a quit date; then another (sic)50 if at four weeks' post-quit date exhaled carbon monoxide confirmed quitting; a further (sic)100 was provided for continued validated abstinence of exhaled carbon monoxide after 12 weeks; a final (sic)200 voucher was provided for validated abstinence of exhaled carbon monoxide at 34-38 weeks' gestation. Main outcome measure The primary outcome was cotinine verified cessation at 34-38 weeks' gestation through saliva (<14.2 ng/mL) or urine (<44.7 ng/mL). Secondary outcomes included birth weight, engagement, and self reported quit at four weeks. Results Recruitment was extended from 12 to 15 months to achieve the target sample size. Follow-up continued until September 2013. Of the 306 women randomised, three controls opted out soon after enrolment; these women did not want their data to be used, leaving 306 intervention and 303 control group participants in the intention to treat analysis. No harms of financial incentives were documented. Significantly more smokers in the incentives group than control group stopped smoking: 69 (22.5%) versus 26 (8.6%). The relative risk of not smoking at the end of pregnancy was 2.63 (95% confidence interval 1.73 to 4.01) P<0.001. The absolute risk difference was 14.0% (95% confidence interval 8.2% to 19.7%). The number needed to treat (where financial incentives need to be offered to achieve one extra quitter in late pregnancy) was 7.2 (95% confidence interval 5.1 to 12.2). The mean birth weight was 3140 g (SD 600 g) in the incentives group and 3120 (SD 590) g in the control group (P=0.67). Conclusion This phase II randomised controlled trial provides substantial evidence for the efficacy of incentives for smoking cessation in pregnancy; as this was only a single centre trial, incentives should now be tested in different types of pregnancy cessation services and in different parts of the United Kingdom.	[Tappin, David] Univ Glasgow, PEACH Unit, Glasgow G3 8SJ, Lanark, Scotland; [Bauld, Linda; Sinclair, Lesley; MacAskill, Susan; McKell, Jennifer] Univ Stirling, Inst Social Mkt, Stirling FK9 4LA, Scotland; [Bauld, Linda; Sinclair, Lesley; MacAskill, Susan; McKell, Jennifer] Univ Stirling, UK Ctr Tobacco & Alcohol Studies, Stirling FK9 4LA, Scotland; [Purves, David] Univ Strathclyde, Glasgow, Lanark, Scotland; [Boyd, Kathleen] Univ Glasgow, Hlth Econ & Hlth Technol Assessment Unit, Inst Hlth & Wellbeing, Glasgow G3 8SJ, Lanark, Scotland; [Friel, Brenda; de Caestecker, Linda] NHS Greater Glasgow & Clyde, Glasgow, Lanark, Scotland; [McConnachie, Alex] Univ Glasgow, Robertson Ctr Biostat, Glasgow G3 8SJ, Lanark, Scotland; [McConnachie, Alex] Univ Glasgow, Glasgow Clin Trials Unit, Glasgow G3 8SJ, Lanark, Scotland; [Tannahill, Carol] Glasgow Ctr Populat Hlth, Glasgow, Lanark, Scotland; [Radley, Andrew] NHS Tayside, Directorate Publ Hlth, Dundee, Scotland; [Coleman, Tim] Univ Nottingham, Div Primary Care, Nottingham NG7 2RD, England; [Coleman, Tim] Univ Nottingham, UK Ctr Tobacco & Alcohol Studies, Nottingham NG7 2RD, England	University of Glasgow; University of Stirling; University of Stirling; University of Strathclyde; University of Glasgow; University of Glasgow; University of Glasgow; University of Dundee; University of Nottingham; University of Nottingham	Tappin, D (corresponding author), Univ Glasgow, PEACH Unit, Yorkhill, Glasgow G3 8SJ, Lanark, Scotland.	david.tappin@glasgow.ac.uk	Radley, Andrew/AAO-7068-2021	Coleman, Tim/0000-0002-7303-4805; Radley, Andrew/0000-0003-4772-2388; McKell, Jennifer/0000-0002-2912-0837; Sinclair, Lesley/0000-0002-2210-8181; Boyd, Kathleen/0000-0002-9764-0113	Chief Scientist Office, Scottish Government; Glasgow Centre for Population Health and the Education; Research Endowment Fund of the Director of Public Health Greater Glasgow and Clyde health board; Yorkhill Children's Charity; Royal Samaritan Endowment Fund; East Midlands Collaboration for Leadership in Applied Health Research and Care; Economic and Social Research Council [ES/G007489/1] Funding Source: researchfish; Medical Research Council [MR/K023195/1, MR/K023195/1B] Funding Source: researchfish; National Institute for Health Research [11/93/01] Funding Source: researchfish; Chief Scientist Office [CZH/4/594] Funding Source: researchfish	Chief Scientist Office, Scottish Government; Glasgow Centre for Population Health and the Education; Research Endowment Fund of the Director of Public Health Greater Glasgow and Clyde health board; Yorkhill Children's Charity; Royal Samaritan Endowment Fund; East Midlands Collaboration for Leadership in Applied Health Research and Care; Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); Chief Scientist Office	The primary funder was the Chief Scientist Office, Scottish Government. Two additional main funders were the Glasgow Centre for Population Health and the Education and Research Endowment Fund of the Director of Public Health Greater Glasgow and Clyde health board. Additional funders were the Yorkhill Children's Charity and the Royal Samaritan Endowment Fund. The funders had no role in writing the manuscript or the decision to submit it for publication. No payment from a pharmaceutical or any other company has been paid to write this article. The corresponding author had full access to all the study data and had the final responsibility for the decision to submit for publication. TC acknowledges the support of East Midlands Collaboration for Leadership in Applied Health Research and Care for his work in general, but no payment was received by him specifically for this study.	[Anonymous], 1997, GEN CONS CLIN TRIALS; Chamberlain Catherine, 2013, Cochrane Database Syst Rev, pCD001055, DOI 10.1002/14651858.CD001055.pub4; Coleman T, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010078; Dietz PM, 2010, AM J PREV MED, V39, P45, DOI 10.1016/j.amepre.2010.03.009; Director of Public Health Greater Glasgow and Clyde NHS Board, 2014, 1252 DIR PUBL HLTH G; Flenady V, 2011, LANCET, V377, P1331, DOI 10.1016/S0140-6736(10)62233-7; Gray R, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b3754; Health and Social Care Information Centre, 2012, INF FEED SURV 2010; HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119; Hoddinott P, 2012, LANCET S30, V380, pS48; Information Services Division NHS National Services Scotland, 2009, BIRTHS BAB SMOK PREG; Jochelson K., 2007, PAYING PATIENT IMPRO; Jurkovic D, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f3676; McGowan A, 2010, MIDWIFERY, V26, pE1, DOI 10.1016/j.midw.2008.05.005; National Institute for Health and Care Excellence, 2010, QUITT SMOK PREGN FOL; National Institute for Health and Care Excellence, GUID METH TECHN APPR; NHS, 2005, SCOTT PROGR CLIN EFF, P35; Office for National Statistics, 2011, STAT B; Radley A, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-343; Tappin D, LANCET ABST IN PRESS; Tappin DM, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-113; Tappin DM, 2010, SUBST ABUSE TREAT PR, V5, DOI 10.1186/1747-597X-5-1; Tappin DM, 2005, BMJ-BRIT MED J, V331, P373, DOI 10.1136/bmj.331.7513.373; US Department of Health and Human Services, 2014, HLTH CONS SMOK 50 YE; Usmani ZC, 2008, SUBST ABUSE TREAT PR, V3, DOI 10.1186/1747-597X-3-4; West R, 2005, ADDICTION, V100, P299, DOI 10.1111/j.1360-0443.2004.00995.x	26	120	120	0	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 27	2015	350								h134	10.1136/bmj.h134	http://dx.doi.org/10.1136/bmj.h134			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CA2ZR	25627664	Green Accepted, Green Published, hybrid			2023-01-03	WOS:000348775700001
J	Chen, YC; Ho, HO; Liu, DZ; Siow, WS; Sheu, MT				Chen, Ying-Chen; Ho, Hsiu-O; Liu, Der-Zen; Siow, Wen-Shian; Sheu, Ming-Thau			Swelling/Floating Capability and Drug Release Characterizations of Gastroretentive Drug Delivery System Based on a Combination of Hydroxyethyl Cellulose and Sodium Carboxymethyl Cellulose	PLOS ONE			English	Article							FLOATING MATRIX TABLETS; SUSTAINED-RELEASE; DOSAGE FORMS; IN-VITRO; HELICOBACTER-PYLORI; GASTRIC RETENTION; BIOADHESIVE; FORMULATION; DESIGN; HYDROCHLORIDE	The aim of this study was to characterize the swelling and floating behaviors of gastroretentive drug delivery system (GRDDS) composed of hydroxyethyl cellulose (HEC) and sodium carboxymethyl cellulose (NaCMC) and to optimize HEC/NaCMC GRDDS to incorporate three model drugs with different solubilities (metformin, ciprofloxacin, and esomeprazole). Various ratios of NaCMC to HEC were formulated, and their swelling and floating behaviors were characterized. Influences of media containing various NaCl concentrations on the swelling and floating behaviors and drug solubility were also characterized. Finally, release profiles of the three model drugs from GRDDS formulation (F1-4) and formulation (F1-1) were examined. Results demonstrated when the GRDDS tablets were tested in simulated gastric solution, the degree of swelling at 6 h was decreased for each formulation that contained NaCMC in comparison to those in de-ionized water (DIW). Of note, floating duration was enhanced when in simulated gastric solution compared to DIW. Further, the hydration of tablets was found to be retarded as the NaCl concentration in the medium increased resulting in smaller gel layers and swelling sizes. Dissolution profiles of the three model drugs in media containing various concentrations of NaCl showed that the addition of NaCl to the media affected the solubility of the drugs, and also their gelling behaviors, resulting in different mechanisms for controlling a drug's release. The release mechanism of the freely water-soluble drug, metformin, was mainly diffusion-controlled, while those of the water-soluble drug, ciprofloxacin, and the slightly water-soluble drug, esomeprazole, were mainly anomalous diffusion. Overall results showed that the developed GRDDS composed of HEC 250HHX and NaCMC of 450 cps possessed proper swelling extents and desired floating periods with sustained-release characteristics.	[Chen, Ying-Chen; Ho, Hsiu-O; Siow, Wen-Shian; Sheu, Ming-Thau] Taipei Med Univ, Sch Pharm, Coll Pharm, Taipei, Taiwan; [Liu, Der-Zen] Taipei Med Univ, Grad Inst Biomed Mat & Engn, Taipei, Taiwan; [Liu, Der-Zen] Hsuan Chuang Univ, Ctr Gen Educ, Hsinchu, Taiwan; [Sheu, Ming-Thau] Taipei Med Univ Hosp, Canc & Chinese Herb Res Ctr, Taipei, Taiwan	Taipei Medical University; Taipei Medical University; Hsuan Chuang University; Taipei Medical University; Taipei Medical University Hospital	Sheu, MT (corresponding author), Taipei Med Univ, Sch Pharm, Coll Pharm, Taipei, Taiwan.	mingsheu@tmu.edu.tw						ALFREY T, 1966, J POLYM SCI POL SYM, P249, DOI 10.1002/polc.5070120119; Arza RAK, 2009, AAPS PHARMSCITECH, V10, P220, DOI 10.1208/s12249-009-9200-y; Atyabi F, 1996, J CONTROL RELEASE, V42, P25, DOI 10.1016/0168-3659(96)01343-0; Atyabi F., 1994, P INT S CONTR REL BI, V21, P806; Bardonnet PL, 2006, J CONTROL RELEASE, V111, P1, DOI 10.1016/j.jconrel.2005.10.031; Basak SC, 2007, PHARMAZIE, V62, P145, DOI 10.1691/ph.2007.2.6108; Bermudez JM, 2008, AAPS PHARMSCITECH, V9, P924, DOI 10.1208/s12249-008-9098-9; Berner B., 2002, U.S. Patent, Patent No. [6,488,962, 6488962]; BOGENTOFT C, 1982, PHARM INT, V3, P366; Chavanpatil MD, 2006, INT J PHARMACEUT, V316, P86, DOI 10.1016/j.ijpharm.2006.02.038; Chen J, 2000, J CONTROL RELEASE, V64, P39, DOI 10.1016/S0168-3659(99)00139-X; Chen J, 1999, J BIOMED MATER RES, V44, P53, DOI 10.1002/(SICI)1097-4636(199901)44:1<53::AID-JBM6>3.3.CO;2-N; Chen RN, 2010, EUR J PHARM SCI, V39, P82, DOI 10.1016/j.ejps.2009.10.015; Chen YC, 2013, INT J PHARMACEUT, V441, P162, DOI 10.1016/j.ijpharm.2012.12.002; Conway BR, 2005, CURR PHARM DESIGN, V11, P775, DOI 10.2174/1381612053381819; de la Torre PM, 2003, BIOMATERIALS, V24, P1459, DOI 10.1016/S0142-9612(02)00541-0; Edgren DE, 2004, US Patent, Patent No. [6,797,283, 6797283]; Flashner-Barak M, 2005, US Patent, Patent No. [6,881,420, 6881420]; Gusler G., 2004, U.S. Patent, Patent No. 6723340; Iannuccelli V, 1998, INT J PHARM, V174, P47, DOI 10.1016/S0378-5173(98)00229-4; ICHIKAWA M, 1991, J PHARM SCI, V80, P1062, DOI 10.1002/jps.2600801113; Jimenez-Martinez I, 2008, INT J PHARMACEUT, V362, P37, DOI 10.1016/j.ijpharm.2008.05.040; JIMENEZCASTELLANOS MR, 1994, INT J PHARM, V105, P65, DOI 10.1016/0378-5173(94)90236-4; Klausner EA, 2002, PHARMACEUT RES, V19, P1516, DOI 10.1023/A:1020412817716; Nur AO, 2000, DRUG DEV IND PHARM, V26, P965, DOI 10.1081/DDC-100101323; Preda M, 2003, J MICROENCAPSUL, V20, P777, DOI 10.1080/02652040310001599742; SHELL JW, 2003, Patent No. 6635280; Sheth PR, 1979, US patent application US Patent, Patent No. 4167558; Streubel A, 2002, INT J PHARMACEUT, V241, P279, DOI 10.1016/S0378-5173(02)00241-7; Streubel Alexander, 2006, Expert Opin Drug Deliv, V3, P217, DOI 10.1517/17425247.3.2.217; Streubel A, 2006, CURR OPIN PHARMACOL, V6, P501, DOI 10.1016/j.coph.2006.04.007; Strubing S, 2008, EUR J PHARM BIOPHARM, V69, P708, DOI 10.1016/j.ejpb.2007.12.009; Strubing S, 2008, J CONTROL RELEASE, V126, P149, DOI 10.1016/j.jconrel.2007.11.013; Sujja-areevath J, 1998, EUR J PHARM SCI, V6, P207, DOI 10.1016/S0928-0987(97)00072-9; Torrado S, 2004, BIOMATERIALS, V25, P917, DOI 10.1016/S0142-9612(03)00579-9; Varshosaz J, 2006, DRUG DELIV, V13, P277, DOI 10.1080/10717540500395106; Zuleger S, 2001, INT J PHARMACEUT, V217, P139, DOI 10.1016/S0378-5173(01)00596-8; [No title captured], Patent No. 4126672	38	33	35	2	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2015	10	1							e0116914	10.1371/journal.pone.0116914	http://dx.doi.org/10.1371/journal.pone.0116914			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC4PT	25617891	Green Published, Green Submitted, gold			2023-01-03	WOS:000350336000030
J	Ansell, SM; Lesokhin, AM; Borrello, I; Halwani, A; Scott, EC; Gutierrez, M; Schuster, SJ; Millenson, MM; Cattry, D; Freeman, GJ; Rodig, SJ; Chapuy, B; Ligon, AH; Zhu, LL; Grosso, JF; Kim, SY; Timmerman, JM; Shipp, MA; Armand, P				Ansell, Stephen M.; Lesokhin, Alexander M.; Borrello, Ivan; Halwani, Ahmad; Scott, Emma C.; Gutierrez, Martin; Schuster, Stephen J.; Millenson, Michael M.; Cattry, Deepika; Freeman, Gordon J.; Rodig, Scott J.; Chapuy, Bjoern; Ligon, Azra H.; Zhu, Lili; Grosso, Joseph F.; Kim, Su Young; Timmerman, John M.; Shipp, Margaret A.; Armand, Philippe			PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STEM-CELL TRANSPLANTATION; T-CELLS; LYMPHOPROLIFERATIVE DISORDERS; ANTI-PD-1 ANTIBODY; RESPONSE CRITERIA; PHASE-II; CANCER; SAFETY; THERAPEUTICS; PIDILIZUMAB	BACKGROUND Preclinical studies suggest that Reed-Sternberg cells exploit the programmed death 1 (PD-1) pathway to evade immune detection. In classic Hodgkin's lymphoma, alterations in chromosome 9p24.1 increase the abundance of the PD-1 ligands, PD-L1 and PD-L2, and promote their induction through Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling. We hypothesized that nivolumab, a PD-1-blocking antibody, could inhibit tumor immune evasion in patients with relapsed or refractory Hodgkin's lymphoma. METHODS In this ongoing study, 23 patients with relapsed or refractory Hodgkin's lymphoma that had already been heavily treated received nivolumab (at a dose of 3 mg per kilogram of body weight) every 2 weeks until they had a complete response, tumor progression, or excessive toxic effects. Study objectives were measurement of safety and efficacy and assessment of the PDL1 and PDL2 (also called CD274 and PDCD1LG2, respectively) loci and PD-L1 and PD-L2 protein expression. RESULTS Of the 23 study patients, 78% were enrolled in the study after a relapse following autologous stem-cell transplantation and 78% after a relapse following the receipt of brentuximab vedotin. Drug-related adverse events of any grade and of grade 3 occurred in 78% and 22% of patients, respectively. An objective response was reported in 20 patients (87%), including 17% with a complete response and 70% with a partial response; the remaining 3 patients (13%) had stable disease. The rate of progression-free survival at 24 weeks was 86%; 11 patients were continuing to participate in the study. Reasons for discontinuation included stem-cell transplantation (in 6 patients), disease progression (in 4 patients), and drug toxicity (in 2 patients). Analyses of pretreatment tumor specimens from 10 patients revealed copy-number gains in PDL1 and PDL2 and increased expression of these ligands. Reed-Sternberg cells showed nuclear positivity of phosphorylated STAT3, indicative of active JAK-STAT signaling. CONCLUSIONS Nivolumab had substantial therapeutic activity and an acceptable safety profile in patients with previously heavily treated relapsed or refractory Hodgkin's lymphoma.	[Ansell, Stephen M.] Mayo Clin, Rochester, MN 55905 USA; [Lesokhin, Alexander M.; Cattry, Deepika] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; [Lesokhin, Alexander M.] Weill Cornell Med Coll, New York, NY 10021 USA; [Borrello, Ivan] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Borrello, Ivan] Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA; [Halwani, Ahmad] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA; [Scott, Emma C.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Scott, Emma C.] Knight Canc Inst, Portland, OR USA; [Gutierrez, Martin] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA; [Zhu, Lili; Grosso, Joseph F.; Kim, Su Young] Bristol Myers Squibb Co, Lawrenceville, NJ USA; [Schuster, Stephen J.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Millenson, Michael M.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; [Freeman, Gordon J.; Chapuy, Bjoern; Shipp, Margaret A.; Armand, Philippe] Dana Farber Canc Inst, Boston, MA 02215 USA; [Rodig, Scott J.; Ligon, Azra H.] Brigham & Womens Hosp, Boston, MA 02115 USA; [Freeman, Gordon J.; Rodig, Scott J.; Chapuy, Bjoern; Ligon, Azra H.; Shipp, Margaret A.; Armand, Philippe] Harvard Univ, Sch Med, Boston, MA USA; [Timmerman, John M.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA	Mayo Clinic; Memorial Sloan Kettering Cancer Center; Cornell University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Oregon Health & Science University; Hackensack University Medical Center; Bristol-Myers Squibb; University of Pennsylvania; Pennsylvania Medicine; Fox Chase Cancer Center; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Ansell, SM (corresponding author), Mayo Clin, 200 First St SW, Rochester, MN 55905 USA.	ansell.stephen@mayo.edu; philippe_armand@dfci.harvard.edu	Rodig, Scott/Y-3889-2019; Zhu, Li/GXH-9801-2022; Freeman, Gordon/AAC-5380-2019	Freeman, Gordon/0000-0002-7210-5616; Halwani, Ahmad/0000-0001-6183-6491	Bristol-Myers Squibb; National Institutes of Health [U54CA163125, P01AI056299, R01CA161026]; Miller Fund; Seattle Genetics; Celldex Therapeutics; Millennium; Idera; Regeneron; Kyowa Hakko Kirin; AbbVie; Genentech; Ventana/Roche; Bayer; Gilead; Merck; Pharmacyclics; Janssen; Sanofi Aventis; NATIONAL CANCER INSTITUTE [R01CA161026, U54CA163125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI056299] Funding Source: NIH RePORTER	Bristol-Myers Squibb(Bristol-Myers Squibb); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Miller Fund; Seattle Genetics; Celldex Therapeutics; Millennium(Takeda Pharmaceutical Company Ltd); Idera; Regeneron(Regeneron); Kyowa Hakko Kirin(Kyowa Kirin Ltd); AbbVie(AbbVie); Genentech(Roche HoldingGenentech); Ventana/Roche; Bayer(Bayer AG); Gilead(Gilead Sciences); Merck(Merck & Company); Pharmacyclics; Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Sanofi Aventis(Sanofi-Aventis); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by Bristol-Myers Squibb, by grants from the National Institutes of Health (U54CA163125 and P01AI056299, to Dr. Freeman; and R01CA161026, to Dr. Shipp), and by a grant from the Miller Fund (to Dr. Shipp).; Dr. Ansell reports receiving grant support from Seattle Genetics, Celldex Therapeutics, Millennium, Idera, and Regeneron; Dr. Lesokhin, receiving consulting fees and grant support from Bristol-Myers Squibb; Dr. Halwani, receiving grant support from Seattle Genetics, Millennium, Kyowa Hakko Kirin, AbbVie, Genentech, and Bristol-Myers Squibb; Dr. Freeman, receiving royalties from patents related to PD-1, PD-L1, and PD-L2 pathways (US 6808710, US 6936704, US 7038013, US7101550, US 7432059, US 7635757, US 7638492, US 7700301, US 7709214, US 8552154, and US 8652465), which are licensed to Bristol-Myers Squibb, Roche, Merck, EMD Serono, Boehringer Ingelheim, Amplimmune, and Novartis; Dr. Rodig, receiving grant support from Bristol-Myers Squibb and Ventana/Roche and having a pending patent application related to anti-PD-L1 monoclonal antibodies and fragments (US 61/895,543); Ms. Zhu, Dr. Grosso, and Dr. Kim, being employees of Bristol-Myers Squibb; Dr. Timmerman, receiving grant support from Bristol-Myers Squibb; Dr. Shipp, receiving fees for serving on advisory boards from Bristol-Myers Squibb, Bayer, Gilead, Merck, Pharmacyclics, and Janssen and receiving grant support from Bristol-Myers Squibb, Sanofi Aventis, and Bayer; and Dr. Armand, receiving consulting fees from Merck. No other potential conflict of interest relevant to this article was reported.	Andorsky DJ, 2011, CLIN CANCER RES, V17, P4232, DOI 10.1158/1078-0432.CCR-10-2660; Arai S, 2013, LEUKEMIA LYMPHOMA, V54, P2531, DOI 10.3109/10428194.2013.798868; Armand P, 2013, J CLIN ONCOL, V31, P4199, DOI 10.1200/JCO.2012.48.3685; Berger R, 2008, CLIN CANCER RES, V14, P3044, DOI 10.1158/1078-0432.CCR-07-4079; Blackburn SD, 2008, P NATL ACAD SCI USA, V105, P15016, DOI 10.1073/pnas.0801497105; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; CARBONE A, 1993, VIRCHOWS ARCH A, V422, P39, DOI 10.1007/BF01605131; Cheson BD, 2007, J CLIN ONCOL, V25, P579, DOI 10.1200/JCO.2006.09.2403; Connors JM, 2005, J CLIN ONCOL, V23, P6400, DOI 10.1200/JCO.2005.05.016; Green MR, 2012, CLIN CANCER RES, V18, P1611, DOI 10.1158/1078-0432.CCR-11-1942; Green MR, 2010, BLOOD, V116, P3268, DOI 10.1182/blood-2010-05-282780; Juszczynski P, 2007, P NATL ACAD SCI USA, V104, P13134, DOI 10.1073/pnas.0706017104; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Lipson EJ, 2013, CLIN CANCER RES, V19, P462, DOI 10.1158/1078-0432.CCR-12-2625; Majhail NS, 2006, BIOL BLOOD MARROW TR, V12, P1065, DOI 10.1016/j.bbmt.2006.06.006; National Cancer Institute, 2009, NIH PUBLICATION; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Steidl C, 2011, NATURE, V471, P377, DOI 10.1038/nature09754; Steidl C, 2010, BLOOD, V116, P418, DOI 10.1182/blood-2009-12-257345; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Weber J, 2010, SEMIN ONCOL, V37, P430, DOI 10.1053/j.seminoncol.2010.09.005; Westin JR, 2014, LANCET ONCOL, V15, P69, DOI 10.1016/S1470-2045(13)70551-5; Wilcox RA, 2009, BLOOD, V114, P2149, DOI 10.1182/blood-2009-04-216671; Yang ZZ, 2006, BLOOD, V107, P3639, DOI 10.1182/blood-2005-08-3376; Younes A, 2012, J CLIN ONCOL, V30, P2183, DOI 10.1200/JCO.2011.38.0410	26	2483	2616	9	465	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 22	2015	372	4					311	319		10.1056/NEJMoa1411087	http://dx.doi.org/10.1056/NEJMoa1411087			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AZ4PJ	25482239	Bronze, Green Accepted			2023-01-03	WOS:000348204500006
J	Pei, RG; Zhou, YF; Wang, GX; Wang, HP; Huang, XY; Yan, XX; Yang, XH				Pei, Renguang; Zhou, Yunfeng; Wang, Guoxiang; Wang, Heping; Huang, Xinyu; Yan, Xiaoxing; Yang, Xiaohua			Outcomes of Bronchial Artery Embolization for Life-Threatening Hemoptysis Secondary to Tuberculosis	PLOS ONE			English	Article							MASSIVE HEMOPTYSIS; PULMONARY TUBERCULOSIS; MANAGEMENT; IMMEDIATE	Objective: To appraise the immediate and long-term outcomes of bronchial arterial embolization for life-threatening hemoptysis secondary to tuberculosis. Methods: 112 patients with life-threatening hemoptysis due to tuberculosis underwent bronchial artery embolization from January 2004 to February 2014. Life-threatening hemoptysis was defined as expectoration of at least 400 ml of blood in 24 hour. The median follow-up is 20 months, ranging from 2 to 52 months. Results: The hemoptysis control rate was 86.6% at 14 days, 84.8% at 30 days, 78.6% at 240 days, 75.9% at 360 days, respectively. None of these characteristics, including gender, age and tuberculosis status, was significantly associated with immediate control of bleeding. Patients with active tuberculosis had a significantly longer recurrence-free duration than did patients with inactive tuberculosis (P=0.040), which was further confirmed by Cox regression hazards model (P=0.046). There was no spinal cord complication or mortality related to bronchial artery embolization. The most common complication was transient chest pain. Conclusion: Bronchial arterial embolization is an effective and safe technique in the management of life-threatening hemoptysis secondary to tuberculosis. Active tuberculosis may be associated with a lower rate of recurrence of hemoptysis.	[Pei, Renguang; Wang, Guoxiang; Wang, Heping; Huang, Xinyu; Yan, Xiaoxing; Yang, Xiaohua] Yijishan Hosp, Wannan Med Coll, Dept Intervent Therapy, Wuhu, Peoples R China; [Zhou, Yunfeng] Yijishan Hosp, Wannan Med Coll, Dept Radiol, Wuhu, Peoples R China	Wannan Medical College; Wannan Medical College	Pei, RG (corresponding author), Yijishan Hosp, Wannan Med Coll, Dept Intervent Therapy, Wuhu, Peoples R China.	mediprg@bjmu.edu.cn						Anuradha C, 2012, DIAGN INTERV RADIOL, V18, P96, DOI 10.4261/1305-3825.DIR.3876-11.2; Chan VL, 2009, INT J TUBERC LUNG D, V13, P1167; Chun JY, 2010, CARDIOVASC INTER RAD, V33, P240, DOI 10.1007/s00270-009-9788-z; Chun JY, 2010, EUR RADIOL, V20, P558, DOI 10.1007/s00330-009-1591-3; CROCCO JA, 1968, ARCH INTERN MED, V121, P495, DOI 10.1001/archinte.121.6.495; DICHIRO G, 1974, RADIOLOGY, V112, P231; FRASER RS, 1993, PATHOL ANNU, V28, P231; Haponik EF, 2000, CHEST, V118, P1431, DOI 10.1378/chest.118.5.1431; HAYAKAWA K, 1992, CARDIOVASC INTER RAD, V15, P154, DOI 10.1007/BF02735578; Hwang HG, 2013, TUBERC RESPIR DIS, V74, P111, DOI 10.4046/trd.2013.74.3.111; Ibrahim WH, 2008, EUR RESPIR J, V32, P1131, DOI 10.1183/09031936.00080108; IM JG, 1993, RADIOLOGY, V186, P653, DOI 10.1148/radiology.186.3.8430169; Jean-Baptiste E, 2000, CRIT CARE MED, V28, P1642, DOI 10.1097/00003246-200005000-00066; KARDJIEV V, 1974, RADIOLOGY, V112, P81, DOI 10.1148/112.1.81; Lee Samuel, 2008, Hong Kong Medical Journal, V14, P14; Mal H, 1999, CHEST, V115, P996, DOI 10.1378/chest.115.4.996; Mossi Francesca, 2003, Radiol Med, V105, P48; Najarian KE, 1998, J THORAC IMAG, V13, P93, DOI 10.1097/00005382-199804000-00004; Osaki S, 2000, RESPIRATION, V67, P412, DOI 10.1159/000029540; RABKIN JE, 1987, RADIOLOGY, V163, P361, DOI 10.1148/radiology.163.2.3562815; REMY J, 1977, RADIOLOGY, V122, P33, DOI 10.1148/122.1.33; REMY J, 1974, ANN RADIOL, V17, P5; Shin BS, 2011, INT J TUBERC LUNG D, V15, P1093, DOI 10.5588/ijtld.10.0659; Sopko David R, 2011, Semin Intervent Radiol, V28, P48, DOI 10.1055/s-0031-1273940; Swanson KL, 2002, CHEST, V121, P789, DOI 10.1378/chest.121.3.789; Tanaka N, 1997, J VASC INTERV RADIOL, V8, P65, DOI 10.1016/S1051-0443(97)70517-7; UFLACKER R, 1985, RADIOLOGY, V157, P637, DOI 10.1148/radiology.157.3.4059552; van den Heuvel MM, 2007, INT J TUBERC LUNG D, V11, P909; Wang LX, 2014, LANCET, V383, P2057, DOI 10.1016/S0140-6736(13)62639-2	29	17	18	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 26	2014	9	12							e115956	10.1371/journal.pone.0115956	http://dx.doi.org/10.1371/journal.pone.0115956			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX9RO	25541693	Green Published, Green Submitted, gold			2023-01-03	WOS:000347239900115
J	Gallo, I; Rattazzi, L; Piras, G; Gobbetti, T; Panza, E; Perretti, M; Dalley, JW; D'Acquisto, F				Gallo, Irene; Rattazzi, Lorenza; Piras, Giuseppa; Gobbetti, Thomas; Panza, Elisabetta; Perretti, Mauro; Dalley, Jeffrey W.; D'Acquisto, Fulvio			Formyl Peptide Receptor as a Novel Therapeutic Target for Anxiety-Related Disorders	PLOS ONE			English	Article							PROTEIN-COUPLED RECEPTOR; SPECIES-TYPICAL BEHAVIORS; INNATE IMMUNE RECOGNITION; MURINE MICROGLIAL CELLS; CHEMOTACTIC PEPTIDE; ENVIRONMENTAL ENRICHMENT; PLASMA-CORTICOSTERONE; DENDRITIC CELLS; GUT MICROBIOTA; BINDING-SITES	Formyl peptide receptors (FPR) belong to a family of sensors of the immune system that detect microbe-associated molecules and inform various cellular and sensorial mechanisms to the presence of pathogens in the host. Here we demonstrate that Fpr2/3-deficient mice show a distinct profile of behaviour characterised by reduced anxiety in the marble burying and light-dark box paradigms, increased exploratory behaviour in an open-field, together with superior performance on a novel object recognition test. Pharmacological blockade with a formyl peptide receptor antagonist, Boc2, in wild type mice reproduced most of the behavioural changes observed in the Fpr2/3(-/)-mice, including a significant improvement in novel object discrimination and reduced anxiety in a light/dark shuttle test. These effects were associated with reduced FPR signalling in the gut as shown by the significant reduction in the levels of p-p38. Collectively, these findings suggest that homeostatic FPR signalling exerts a modulatory effect on anxiety-like behaviours. These findings thus suggest that therapies targeting FPRs may be a novel approach to ameliorate behavioural abnormalities present in neuropsychiatric disorders at the cognitive-emotional interface.	[Gallo, Irene; Rattazzi, Lorenza; Piras, Giuseppa; Gobbetti, Thomas; Perretti, Mauro; D'Acquisto, Fulvio] Queen Mary Univ London, Barts & London Sch Med, William Harvey Res Inst, London, England; [Panza, Elisabetta] Univ Naples Federico II, Dept Expt Pharmacol, Naples, Italy; [Dalley, Jeffrey W.] Univ Cambridge, Dept Psychol, Cambridge, England; [Dalley, Jeffrey W.] Univ Cambridge, Dept Psychiat, Cambridge, England	University of London; Queen Mary University London; University of Naples Federico II; University of Cambridge; University of Cambridge	D'Acquisto, F (corresponding author), Queen Mary Univ London, Barts & London Sch Med, William Harvey Res Inst, London, England.	F.Dacquisto@qmul.ac.uk	D'Acquisto, Fulvio/E-7204-2018	D'Acquisto, Fulvio/0000-0002-4513-1608; Dalley, Jeffrey/0000-0002-2282-3660				Alam A, 2014, MUCOSAL IMMUNOL, V7, P645, DOI 10.1038/mi.2013.84; Anna I, 2002, LAB ANIM-UK, V36, P243, DOI 10.1258/002367702320162379; Anton P, 1998, GUT, V42, P374, DOI 10.1136/gut.42.3.374; Antunes M, 2012, COGN PROCESS, V13, P93, DOI 10.1007/s10339-011-0430-z; Aoki M, 2010, ZOOL SCI, V27, P783, DOI 10.2108/zsj.27.783; Babbin BA, 2007, J IMMUNOL, V179, P8112, DOI 10.4049/jimmunol.179.12.8112; Barr JL, 2011, NEUROSCIENCE, V182, P105, DOI 10.1016/j.neuroscience.2011.03.020; Benaroya-Milshtein N, 2004, EUR J NEUROSCI, V20, P1341, DOI 10.1111/j.1460-9568.2004.03587.x; Bourin M, 2003, EUR J PHARMACOL, V463, P55, DOI 10.1016/S0014-2999(03)01274-3; Bourin M, 2007, FUND CLIN PHARMACOL, V21, P567, DOI 10.1111/j.1472-8206.2007.00526.x; Carpenter AC, 2012, DEV NEUROSCI-BASEL, V34, P250, DOI 10.1159/000336824; Cattaneo F, 2010, NEUROCHEM RES, V35, P2018, DOI 10.1007/s11064-010-0301-5; Chen KD, 2013, J CLIN INVEST, V123, P1694, DOI 10.1172/JCI65569; Chen KQ, 2007, J IMMUNOL, V178, P1759, DOI 10.4049/jimmunol.178.3.1759; Christakis DA, 2012, SCI REP-UK, V2, DOI 10.1038/srep00546; CONDO GT, 1991, PHYS REV D, V43, P2787, DOI 10.1103/PhysRevD.43.2787; Cooray SN, 2013, P NATL ACAD SCI USA, V110, P18232, DOI 10.1073/pnas.1308253110; Costa-Pinto FA, 2010, NEUROIMMUNOMODULAT, V17, P196, DOI 10.1159/000258722; Cryan JF, 2011, NEUROGASTROENT MOTIL, V23, P187, DOI 10.1111/j.1365-2982.2010.01664.x; Cryan JF, 2012, NAT REV NEUROSCI, V13, P701, DOI 10.1038/nrn3346; Cui YH, 2002, NEUROBIOL DIS, V10, P366, DOI 10.1006/nbdi.2002.0517; Cui YH, 2002, J IMMUNOL, V168, P434, DOI 10.4049/jimmunol.168.1.434; De Palma G, 2014, J PHYSL; Deacon RMJ, 2005, BEHAV BRAIN RES, V156, P241, DOI 10.1016/j.bbr.2004.05.027; Deacon RMJ, 2002, BEHAV BRAIN RES, V132, P203, DOI 10.1016/S0166-4328(01)00401-6; Deacon RMJ, 2006, NAT PROTOC, V1, P122, DOI 10.1038/nprot.2006.20; Derian CK, 1996, BIOCHEMISTRY-US, V35, P1265, DOI 10.1021/bi952087k; Dufton N, 2010, PHARMACOL THERAPEUT, V127, P175, DOI 10.1016/j.pharmthera.2010.04.010; Dufton N, 2010, J IMMUNOL, V184, P2611, DOI 10.4049/jimmunol.0903526; El Kebir D, 2008, J LEUKOCYTE BIOL, V84, P600, DOI 10.1189/jlb.1107765; Fediuc S, 2006, J APPL PHYSIOL, V100, P1867, DOI 10.1152/japplphysiol.01416.2005; Foster JA, 2013, TRENDS NEUROSCI, V36, P305, DOI 10.1016/j.tins.2013.01.005; Ganella DE, 2014, BRIT J PHARMACOL, V171, P4556, DOI 10.1111/bph.12643; Gao JL, 2011, BEHAV GENET, V41, P724, DOI 10.1007/s10519-011-9467-0; Gareau MG, 2011, GUT, V60, P307, DOI 10.1136/gut.2009.202515; Gavins FNE, 2012, FASEB J, V26, P4977, DOI 10.1096/fj.12-205971; Gavins FNE, 2003, BLOOD, V101, P4140, DOI 10.1182/blood-2002-11-3411; Gemperle C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050195; Heijtza RD, 2011, P NATL ACAD SCI USA, V108, P3047, DOI 10.1073/pnas.1010529108; Heo SC, 2014, STEM CELLS, V32, P779, DOI 10.1002/stem.1578; Ihara S, 2013, NEUROSCIENCE, V254, P45, DOI 10.1016/j.neuroscience.2013.08.063; Jahng JW, 2011, HORM BEHAV, V59, P213, DOI 10.1016/j.yhbeh.2010.11.010; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Kasai RS, 2011, J CELL BIOL, V192, P463, DOI 10.1083/jcb.201009128; Kedia S, 2014, J NEUROSCI METHODS; Keitoku M, 1997, J MOL CELL CARDIOL, V29, P881, DOI 10.1006/jmcc.1996.0291; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; Leasure JL, 2008, NEUROSCIENCE, V156, P456, DOI 10.1016/j.neuroscience.2008.07.041; Liberles SD, 2009, P NATL ACAD SCI USA, V106, P9842, DOI 10.1073/pnas.0904464106; Lim H, 2012, BIOMOL THER, V20, P418, DOI 10.4062/biomolther.2012.20.4.418; Luisi R, 2009, J NEUROCHEM, V109, P168, DOI 10.1111/j.1471-4159.2009.05945.x; Marashi V, 2003, HORM BEHAV, V43, P281, DOI 10.1016/S0018-506X(03)00002-3; Marquez C, 2006, BEHAV BRAIN RES, V168, P13, DOI 10.1016/j.bbr.2005.10.004; McIlwain KL, 2001, PHYSIOL BEHAV, V73, P705, DOI 10.1016/S0031-9384(01)00528-5; Medzhitov R, 2000, IMMUNOL REV, V173, P89, DOI 10.1034/j.1600-065X.2000.917309.x; Miceli F, 2009, NEUROBIOL DIS, V34, P501, DOI 10.1016/j.nbd.2009.03.009; Molloy MJ, 2013, CELL HOST MICROBE, V14, P318, DOI 10.1016/j.chom.2013.08.003; Mou HW, 2012, INFLAMMATION, V35, P656, DOI 10.1007/s10753-011-9358-9; Munger SD, 2009, NATURE, V459, P521, DOI 10.1038/459521a; Neufeld KM, 2011, NEUROGASTROENT MOTIL, V23, DOI 10.1111/j.1365-2982.2010.01620.x; Onnela JP, 2012, PHYS REV E, V85, DOI 10.1103/PhysRevE.85.036106; Panaro MA, 2006, IMMUNOPHARM IMMUNOT, V28, P103, DOI 10.1080/08923970600625975; Park S, 2014, BIOCHEM BIOPH RES CO, V450, P13, DOI 10.1016/j.bbrc.2014.05.049; PELLOW S, 1985, PHYSIOL BEHAV, V35, P587, DOI 10.1016/0031-9384(85)90145-3; Perretti M, 2009, NAT REV IMMUNOL, V9, P62, DOI 10.1038/nri2470; Rane MJ, 1997, J IMMUNOL, V159, P5070; Riviere S, 2009, NATURE, V459, P574, DOI 10.1038/nature08029; Saigo M, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.091601; Sallusto F, 2010, IMMUNITY, V33, P451, DOI 10.1016/j.immuni.2010.10.008; Santos-Soto IJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081459; Sato AK, 2006, CURR OPIN BIOTECH, V17, P638, DOI 10.1016/j.copbio.2006.10.002; Sato T, 2010, FORENSIC SCI INT, V194, P77, DOI 10.1016/j.forsciint.2009.10.014; Schoenfeld TJ, 2012, EXP NEUROL, V233, P12, DOI 10.1016/j.expneurol.2011.01.008; Spurr L, 2011, INT IMMUNOPHARMACOL, V11, P55, DOI 10.1016/j.intimp.2010.10.006; Stenfeldt AL, 2007, INFLAMMATION, V30, P224, DOI 10.1007/s10753-007-9040-4; Strohle A, 2003, PHARMACOPSYCHIATRY, V36, pS207; Su SB, 1999, J EXP MED, V189, P395, DOI 10.1084/jem.189.2.395; Sutton LM, 2013, HUM MOL GENET, V22, P452, DOI 10.1093/hmg/dds441; Taglialatela G, 2009, BEHAV BRAIN RES, V200, P95; Touma C, 2008, PSYCHONEUROENDOCRINO, V33, P839, DOI 10.1016/j.psyneuen.2008.03.013; van Gaalen MM, 2002, GENES BRAIN BEHAV, V1, P174, DOI 10.1034/j.1601-183X.2002.10305.x; WALSH RN, 1976, PSYCHOL BULL, V83, P482, DOI 10.1037/0033-2909.83.3.482; Wang QS, 2012, BEHAV BRAIN RES, V230, P167, DOI 10.1016/j.bbr.2012.01.051; Wentworth CC, 2011, J BIOL CHEM, V286, P38448, DOI 10.1074/jbc.M111.268938; Wentworth CC, 2010, AM J PATHOL, V177, P2782, DOI 10.2353/ajpath.2010.100529; Yang D, 2002, J LEUKOCYTE BIOL, V72, P598; Yang D, 2001, J IMMUNOL, V166, P4092, DOI 10.4049/jimmunol.166.6.4092; Yang D, 2000, J EXP MED, V192, P1069, DOI 10.1084/jem.192.7.1069; Ye RD, 2009, PHARMACOL REV, V61, P119, DOI 10.1124/pr.109.001578; Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780	90	24	25	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 17	2014	9	12							e114626	10.1371/journal.pone.0114626	http://dx.doi.org/10.1371/journal.pone.0114626			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX9IA	25517119	Green Published, Green Submitted, gold			2023-01-03	WOS:000347215600024
J	Chi, NF; Liu, HL; Yang, JT; Lin, JR; Liao, SL; Peng, BH; Lee, YT; Lee, TH				Chi, Nai-Fang; Liu, Ho-Ling; Yang, Jen-Tsung; Lin, Jr-Rung; Liao, Shu-Li; Peng, Bo-Han; Lee, Yen-Tung; Lee, Tsong-Hai			Neuroprotective Mechanism of BNG-1 against Focal Cerebral Ischemia: A Neuroimaging and Neurotrophin Study	PLOS ONE			English	Article							NERVE GROWTH-FACTOR; SCUTELLARIA-BAICALENSIS; DIFFUSION-PERFUSION; ACUTE STROKE; BLOOD-FLOW; IN-VIVO; RATS; BRAIN; EXPRESSION; HYPERPERFUSION	BNG-1 is a herb complex used in traditional Chinese medicine to treat stroke. In this study, we attempted to identify the neuroprotective mechanism of BNG-1 by using neuroimaging and neurotrophin analyses of a stroke animal model. Rats were treated with either saline or BNG-1 for 7 d after 60-min middle cerebral artery occlusion by filament model. The temporal change of magnetic resonance (MR) imaging of brain was studied using a 7 Tesla MR imaging (MRI) system and the temporal expressions of neurotrophin-3 (NT-3), brain-derived neurotrophic factor (BDNF), and nerve growth factor (NGF) in brain were analyzed before operation and at 4 h, 2 d, and 7 d after operation. Compared with the saline group, the BNG-1 group exhibited a smaller infarction volume in the cerebral cortex in T2 image from as early as 4 h to 7 d, less edema in the cortex in diffusion weighted image from 2 to 7 d, earlier reduction of postischemic hyperperfusion in both the cortex and striatum in perfusion image at 4 h, and earlier normalization of the ischemic pattern in the striatum in susceptibility weighted image at 2 d. NT-3 and BDNF levels were higher in the BNG-1 group than the saline group at 7 d. We concluded that the protective effect of BNG-1 against cerebral ischemic injury might act through improving cerebral hemodynamics and recovering neurotrophin generation.	[Chi, Nai-Fang] Taipei Med Univ, Shuang Ho Hosp, Dept Neurol, New Taipei City, Taiwan; [Chi, Nai-Fang] Taipei Med Univ, Coll Med, Sch Med, Dept Neurol, Taipei, Taiwan; [Liu, Ho-Ling] Chang Gung Univ, Coll Med, Dept Med Imaging & Radiol Sci, Taoyuan, Taiwan; [Yang, Jen-Tsung] Chiayi Chang Gung Mem Hosp, Dept Neurosurg, Chiayi, Taiwan; [Yang, Jen-Tsung] Chang Gung Univ, Coll Med, Dept Neurosurg, Taoyuan, Taiwan; [Lin, Jr-Rung] Chang Gung Univ, Clin Informat & Med Stat Res Ctr, Taoyuan, Taiwan; [Liao, Shu-Li] Minist Hlth & Welf, Taoyuan Gen Hosp, Dept Tradit Chinese Med, Taoyuan, Taiwan; [Peng, Bo-Han] Chang Gung Mem Hosp, Linkou Med Ctr, Dept Tradit Chinese Med, Taoyuan, Taiwan; [Lee, Yen-Tung] En Chu Kong Hosp, Dept Tradit Chinese Med, New Taipei City, Taiwan; [Lee, Tsong-Hai] Chang Gung Mem Hosp, Linkou Med Ctr, Stroke Ctr, Taoyuan, Taiwan; [Lee, Tsong-Hai] Chang Gung Univ, Coll Med, Taoyuan, Taiwan	Taipei Medical University; Taipei Medical University; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University; Chang Gung Memorial Hospital; En Chu Kong Hospital; Chang Gung Memorial Hospital; Chang Gung University	Lee, TH (corresponding author), Chang Gung Mem Hosp, Linkou Med Ctr, Stroke Ctr, Taoyuan, Taiwan.	thlee@adm.cgmh.org.tw	Chi, Nai-Fang/G-3561-2016; Chi, Nai-Fang/E-2851-2017	Chi, Nai-Fang/0000-0002-2204-4923; Chi, Nai-Fang/0000-0002-2204-4923; Lin, Jr-Rung/0000-0002-8522-6601	National Science Council, Taiwan [NSC 97-2314-B-182A-049, NSC 98-2314-B-182-054, NSC 99-2628-B-182-027, 103-2314-B-182A-030-MY2]; Chang Gung Memorial Hospital Medical Research Project, Taiwan (Animal Molecular Imaging Center) [CMRPG340203]	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); Chang Gung Memorial Hospital Medical Research Project, Taiwan (Animal Molecular Imaging Center)	This work was supported by the National Science Council, Taiwan (NSC 97-2314-B-182A-049, NSC 98-2314-B-182-054, NSC 99-2628-B-182-027, 103-2314-B-182A-030-MY2) and Chang Gung Memorial Hospital Medical Research Project, Taiwan (Animal Molecular Imaging Center CMRPG340203). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1995, NEW ENGLAND J MED, V333, P1581; Baik SK, 2012, CEREBROVASC DIS, V34, P206, DOI 10.1159/000342148; Baird AE, 1998, J CEREBR BLOOD F MET, V18, P583, DOI 10.1097/00004647-199806000-00001; Bereczki D, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000480.pub2; Bonoczk Peter, 2002, Eur J Ultrasound, V15, P85, DOI 10.1016/S0929-8266(02)00006-X; Chan S, 2011, CURR OPIN PHARMACOL, V11, P720, DOI 10.1016/j.coph.2011.09.002; Cheng FC, 2005, AM J CHINESE MED, V33, P61, DOI 10.1142/S0192415X05002667; Geisler BS, 2006, STROKE, V37, P1778, DOI 10.1161/01.STR.0000226738.97426.6f; Jeong JC, 2005, J ETHNOPHARMACOL, V98, P259, DOI 10.1016/j.jep.2004.12.034; Kidwell CS, 2001, NEUROLOGY, V57, P2015, DOI 10.1212/WNL.57.11.2015; Kim YO, 2001, J ETHNOPHARMACOL, V77, P183, DOI 10.1016/S0378-8741(01)00283-5; Lee JT, 2014, NEUROSCIENCE, V257, P31, DOI 10.1016/j.neuroscience.2013.10.066; Lee TH, 2004, J NEUROSCI RES, V76, P705, DOI 10.1002/jnr.20097; Lee TH, 1998, STROKE, V29, P1687, DOI 10.1161/01.STR.29.8.1687; LEE TH, 1994, STROKE, V25, P1425, DOI 10.1161/01.STR.25.7.1425; Lee TH, 2008, BRAIN RES, V1187, P1, DOI 10.1016/j.brainres.2007.09.078; Lee TH, 2011, EXP NEUROL, V227, P314, DOI 10.1016/j.expneurol.2010.12.003; Li RL, 2010, CURR NEUROVASC RES, V7, P213, DOI 10.2174/156720210792231796; Lin TN, 2002, STROKE, V33, P2985, DOI 10.1161/01.STR.0000037675.97888.9D; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu CN, 2012, INT IMMUNOPHARMACOL, V14, P121, DOI 10.1016/j.intimp.2012.06.010; Lu ZF, 2010, J ASIAN NAT PROD RES, V12, P265, DOI 10.1080/10286021003689791; MACFARLANE R, 1991, J NEUROSURG, V75, P845, DOI 10.3171/jns.1991.75.6.0845; Mao QQ, 2010, J ETHNOPHARMACOL, V131, P182, DOI 10.1016/j.jep.2010.06.019; Marchal G, 1996, BRAIN, V119, P409, DOI 10.1093/brain/119.2.409; Medina AE, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00021; Oliveira GB, 2014, BRAIN RES, V1561, P23, DOI 10.1016/j.brainres.2014.03.005; Ostergaard L, 1996, MAGN RESON MED, V36, P715, DOI 10.1002/mrm.1910360510; Park JS, 2012, J PHARMACOL EXP THER, V341, P59, DOI 10.1124/jpet.111.189035; Schweinhardt P, 2003, J NEUROSCI METH, V129, P105, DOI 10.1016/S0165-0270(03)00192-4; Shin JW, 2012, AM J CHINESE MED, V40, P85, DOI 10.1142/S0192415X12500073; Tanabe H, 2006, PHYTOMEDICINE, V13, P334, DOI 10.1016/j.phymed.2005.02.001; Wahlgren N, 2007, LANCET, V369, P275, DOI 10.1016/S0140-6736(07)60149-4; Xu XL, 2008, PHYTOTHER RES, V22, P389, DOI 10.1002/ptr.2332; Yan BC, 2014, J NEUROSCI RES, V92, P795, DOI 10.1002/jnr.23360; Ye RD, 2011, NEUROPHARMACOLOGY, V61, P815, DOI 10.1016/j.neuropharm.2011.05.029; Yin YY, 2010, AM J CHINESE MED, V38, P517, DOI 10.1142/S0192415X10008020; Yu XQ, 2008, LIFE SCI, V82, P68, DOI 10.1016/j.lfs.2007.10.019; Zhang L, 2009, YAKUGAKU ZASSHI, V129, P855, DOI 10.1248/yakushi.129.855	39	5	6	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 15	2014	9	12							e114909	10.1371/journal.pone.0114909	http://dx.doi.org/10.1371/journal.pone.0114909			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AW9WY	25506838	Green Submitted, Green Published, gold			2023-01-03	WOS:000346607100033
J	Knutson, SK; Warholic, NM; Johnston, LD; Klaus, CR; Wigle, TJ; Iwanowicz, D; Littlefield, BA; Porter-Scott, M; Smith, JJ; Moyer, MP; Copeland, RA; Pollock, RM; Kuntz, KW; Raimondi, A; Keilhack, H				Knutson, Sarah K.; Warholic, Natalie M.; Johnston, L. Danielle; Klaus, Christine R.; Wigle, Tim J.; Iwanowicz, Dorothy; Littlefield, Bruce A.; Porter-Scott, Margaret; Smith, Jesse J.; Moyer, Mikel P.; Copeland, Robert A.; Pollock, Roy M.; Kuntz, Kevin W.; Raimondi, Alejandra; Keilhack, Heike			Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas	PLOS ONE			English	Article							B-CELL LYMPHOMA; PROTEIN METHYLTRANSFERASES; SELECTIVE-INHIBITION; MOLECULAR SUBTYPES; SOMATIC MUTATIONS; DRUG DISCOVERY; MECHANISMS; CANCER; RESISTANCE; APOPTOSIS	Patients with non-Hodgkin lymphoma (NHL) are treated today with a cocktail of drugs referred to as CHOP (Cyclophosphamide, Hydroxyldaunorubicin, Oncovin, and Prednisone). Subsets of patients with NHL of germinal center origin bear oncogenic mutations in the EZH2 histone methyltransferase. Clinical testing of the EZH2 inhibitor EPZ-6438 has recently begun in patients. We report here that combining EPZ-6438 with CHOP in preclinical cell culture and mouse models results in dramatic synergy for cell killing in EZH2 mutant germinal center NHL cells. Surprisingly, we observe that much of this synergy is due to Prednisolone - a glucocorticoid receptor agonist (GRag) component of CHOP. Dramatic synergy was observed when EPZ-6438 is combined with Prednisolone alone, and a similar effect was observed with Dexamethasone, another GRag. Remarkably, the anti-proliferative effect of the EPZ-6438+GRag combination extends beyond EZH2 mutant-bearing cells to more generally impact germinal center NHL. These preclinical data reveal an unanticipated biological intersection between GR-mediated gene regulation and EZH2-mediated chromatin remodeling. The data also suggest the possibility of a significant and practical benefit of combining EZH2 inhibitors and GRag that warrants further investigation in a clinical setting.	[Knutson, Sarah K.; Warholic, Natalie M.; Johnston, L. Danielle; Klaus, Christine R.; Wigle, Tim J.; Iwanowicz, Dorothy; Porter-Scott, Margaret; Smith, Jesse J.; Moyer, Mikel P.; Copeland, Robert A.; Pollock, Roy M.; Kuntz, Kevin W.; Raimondi, Alejandra; Keilhack, Heike] Epizyme Inc, Res & Dev, Cambridge, MA 02139 USA; [Littlefield, Bruce A.] Eisai Inc, Oncol, Andover, MA USA	Eisai Co Ltd	Keilhack, H (corresponding author), Epizyme Inc, Res & Dev, Cambridge, MA 02139 USA.	hkeilhack@epizyme.com			Eisai Inc.	Eisai Inc.(Eisai Co Ltd)	This work was funded by Eisai Inc. through collaboration between Epizyme and Eisai. The funding entity had no input in study design, data collection and analysis and decision to publish. The funders were not involved in the preparation of the manuscript, but did review and approve it.	Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Ayroldi E, 2009, FASEB J, V23, P3649, DOI 10.1096/fj.09-134684; Badeaux AI, 2013, NAT REV MOL CELL BIO, V14, P211, DOI 10.1038/nrm3545; Barrett-Lee PJ, 2009, ANN ONCOL, V20, P816, DOI 10.1093/annonc/mdn728; Beguelin W, 2013, CANCER CELL, V23, P677, DOI 10.1016/j.ccr.2013.04.011; Budanov AV, 2008, CELL, V134, P451, DOI 10.1016/j.cell.2008.06.028; Chapuy B, 2013, CANCER CELL, V24, P777, DOI 10.1016/j.ccr.2013.11.003; Choi WWL, 2009, CLIN CANCER RES, V15, P5494, DOI 10.1158/1078-0432.CCR-09-0113; Clements WK, 2013, NAT REV IMMUNOL, V13, P336, DOI 10.1038/nri3443; Copeland RA, 2013, ONCOGENE, V32, P939, DOI 10.1038/onc.2012.552; Copeland RA, 2013, EVALUATION OF ENZYME INHIBITORS IN DRUG DISCOVERY: A GUIDE FOR MEDICINAL CHEMISTS AND PHARMACOLOGISTS, 2ND EDITION, P1, DOI 10.1002/9781118540398; Copeland RA, 2009, NAT REV DRUG DISCOV, V8, P724, DOI 10.1038/nrd2974; Daigle SR, 2011, CANCER CELL, V20, P53, DOI 10.1016/j.ccr.2011.06.009; Furusawa C, 2012, SCIENCE, V338, P215, DOI 10.1126/science.1224311; Garapaty-Rao S, 2013, CHEM BIOL, V20, P1329, DOI 10.1016/j.chembiol.2013.09.013; George AA, 2009, INT J BIOCHEM CELL B, V41, P214, DOI 10.1016/j.biocel.2008.09.019; Hans CP, 2004, BLOOD, V103, P275, DOI 10.1182/blood-2003-05-1545; John S, 2008, MOL CELL, V29, P611, DOI 10.1016/j.molcel.2008.02.010; Knutson SK, 2014, MOL CANCER THER, V13, P842, DOI 10.1158/1535-7163.MCT-13-0773; Knutson SK, 2013, P NATL ACAD SCI USA, V110, P7922, DOI 10.1073/pnas.1303800110; Knutson SK, 2012, NAT CHEM BIOL, V8, P890, DOI [10.1038/NCHEMBIO.1084, 10.1038/nchembio.1084]; Konze KD, 2013, ACS CHEM BIOL, V8, P1324, DOI [10.1021/cb400133J, 10.1021/cb400133j]; Lenz G, 2008, P NATL ACAD SCI USA, V105, P13520, DOI 10.1073/pnas.0804295105; Lenz G, 2007, J EXP MED, V204, P633, DOI 10.1084/jem.20062041; Lohr JG, 2012, P NATL ACAD SCI USA, V109, P3879, DOI 10.1073/pnas.1121343109; Maxwell SA, 2013, EXP BIOL MED, V238, P971, DOI 10.1177/1535370213498985; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; Morin RD, 2011, NATURE, V476, P298, DOI 10.1038/nature10351; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Nastoupil LJ, 2012, ONCOLOGY-NY, V26, P488; Niitsu N, 2010, INT J HEMATOL, V92, P231, DOI 10.1007/s12185-010-0666-x; Oakley RH, 2013, J ALLERGY CLIN IMMUN, V132, P1033, DOI 10.1016/j.jaci.2013.09.007; Qi W, 2012, P NATL ACAD SCI USA, V109, P21360, DOI 10.1073/pnas.1210371110; Ramamoorthy S, 2013, ENDOCR DEV, V24, P41, DOI 10.1159/000342502; Rutz HP, 2004, CANCER BIOL THER, V3, P715, DOI 10.4161/cbt.3.8.966; Rutz HP, 2002, LANCET, V360, P1969, DOI 10.1016/S0140-6736(02)11922-2; Schenone M, 2013, NAT CHEM BIOL, V9, P232, DOI [10.1038/nchembio.1199, 10.1038/NCHEMBIO.1199]; Schlossmacher G, 2011, J ENDOCRINOL, V211, P17, DOI 10.1530/JOE-11-0135; Sionov RV, 2008, ADV CANCER RES, V101, P127, DOI 10.1016/S0065-230X(08)00406-5; Van Bogaert T, 2010, CYTOKINE GROWTH F R, V21, P275, DOI 10.1016/j.cytogfr.2010.04.003; van Horssen R, 2006, ONCOLOGIST, V11, P397, DOI 10.1634/theoncologist.11-4-397; Wigle TJ, 2013, CURR OPIN CHEM BIOL, V17, P369, DOI 10.1016/j.cbpa.2013.03.035	42	52	64	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 10	2014	9	12							e111840	10.1371/journal.pone.0111840	http://dx.doi.org/10.1371/journal.pone.0111840			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AW9YP	25493630	Green Published, gold, Green Submitted			2023-01-03	WOS:000346611400005
J	Wu, CT; Lai, JN; Tsai, YT				Wu, Chien-Tung; Lai, Jung-Nien; Tsai, Yueh-Ting			The Prescription Pattern of Chinese Herbal Products That Contain Dang-Qui and Risk of Endometrial Cancer among Tamoxifen-Treated Female Breast Cancer Survivors in Taiwan: A Population-Based Study	PLOS ONE			English	Article							NATIONAL-HEALTH INSURANCE; SURGICAL ADJUVANT BREAST; PROJECT NSABP B-14; ALTERNATIVE MEDICINE; THERAPY; PREVENTION; CARCINOMA; METHYLTRANSFERASE; COMPLEMENTARY; TRIALS	Purpose: The increased practice of traditional Chinese medicine worldwide has raised concerns regarding herb-drug interactions. We analyzed the usage of Chinese herbal products containing dang-qui and investigated whether dang-qui therapy increases endometrial cancer risk among tamoxifen-treated breast cancer survivors in Taiwan. Methods: All patients newly diagnosed with invasive breast cancer who received tamoxifen treatment from January 1, 1998, to December 31, 2008 were selected from the National Health Insurance Research Database. The usage, frequency of service and type of Chinese herbal products containing dang-qui prescribed across the 31,970 survivors were evaluated. Logistic regression method was employed to estimate the odds ratios for utilization of Chinese herbal products containing dang-qui. Cox proportional hazard regression was performed to calculate the hazard ratio of endometrial cancer associated with dang-qui use within the cohort. Results: Almost one in two study subjects had used dang-qui. Among 31,938 tamoxifen-treated breast cancer survivors, 157 cases of subsequent endometrial cancer were identified. The hazard ratio for development of endometrial cancer among breast cancer survivors aged 20-79 years who had taken dang-qui after tamoxifen treatment was decreased compared to survivors who had never used dang-qui (HR: 0.61, 95% CI: 0.44-0.84). To minimise potential confounding factors, women with breast cancer in the reproductive age were excluded from further analysis, and the negative relationship between dang-qui consumption and subsequent endometrial cancer among breast cancer survivors aged 55-79 years was still observed, although not significantly (HR: 0.74, 95% CI: 0.46-1.17). Conclusions: Dang-qui consumption is common among breast cancer survivors aged 20-79 years and seems decrease the risk of subsequent endometrial cancer after less than a cumulative dose of 7,500 mg of tamoxifen treatment.	[Wu, Chien-Tung; Lai, Jung-Nien; Tsai, Yueh-Ting] Natl Yang Ming Univ, Sch Med, Inst Tradit Med, Taipei 112, Taiwan; [Lai, Jung-Nien] Taipei City Hosp, Dept Chinese Med, Yangming Branch, Taipei, Taiwan; [Wu, Chien-Tung; Lai, Jung-Nien; Tsai, Yueh-Ting] Taiwan Assoc Tradit Chinese Med Family, Taipei, Taiwan	National Yang Ming Chiao Tung University; Taipei City Hospital	Tsai, YT (corresponding author), Natl Yang Ming Univ, Sch Med, Inst Tradit Med, Taipei 112, Taiwan.	kareny@ms10.hinet.net			National Science Council [NSC-102WFA2200187]; National Research Institutes of Chinese Medicine [NRICM-10002]; Ministry of Health and Welfare	National Science Council(Ministry of Science and Technology, Taiwan); National Research Institutes of Chinese Medicine; Ministry of Health and Welfare(Ministry of Health, Labour and Welfare, Japan)	The study was partially supported by the National Science Council (NSC-102WFA2200187), the National Research Institutes of Chinese Medicine (NRICM-10002), and the Ministry of Health and Welfare (http://www.mohw.gov.tw/EN/Ministry/Index.aspx). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANDERSSON M, 1991, J NATL CANCER I, V83, P1013, DOI 10.1093/jnci/83.14.1013; [Anonymous], 2013, LIST 100 UN FORM; Bergman L, 2000, LANCET, V356, P881, DOI 10.1016/S0140-6736(00)02677-5; Bernstein L, 1999, J NATL CANCER I, V91, P1654, DOI 10.1093/jnci/91.19.1654; Bonneterre J, 2000, J CLIN ONCOL, V18, P3748, DOI 10.1200/JCO.2000.18.22.3748; BUSH TL, 1993, EPIDEMIOL REV, V15, P233, DOI 10.1093/oxfordjournals.epirev.a036110; Centers for Disease Control and Prevention, 2013, INT CLASS DIS; Chen Ming-Chen, 2013, J Tradit Complement Med, V3, P256, DOI 10.4103/2225-4110.119734; Clarke M, 1998, LANCET, V351, P1451; COOK LS, 1995, J NATL CANCER I, V87, P1359, DOI 10.1093/jnci/87.18.1359; Curtis RE, 2004, JNCI-J NATL CANCER I, V96, P70, DOI 10.1093/jnci/djh007; Curtis RE, 1996, J NATL CANCER I, V88, P832, DOI 10.1093/jnci/88.12.832; Cuzick J, 2003, LANCET, V361, P296, DOI 10.1016/S0140-6736(03)12342-2; Department of Chinese Medicine and Pharmacy Ministry of Health and Welfare, 2014, LIST 21 MOST IMP ANC; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; FORNANDER T, 1989, LANCET, V1, P117; Gelmon K, 2000, LANCET, V356, P868, DOI 10.1016/S0140-6736(00)02670-2; HARDELL L, 1988, LANCET, V2, P1432; Hsieh SC, 2008, PHARMACOEPIDEM DR S, V17, P609, DOI 10.1002/pds.1611; Kuo CC, 2007, INT J CANCER, V121, P2293, DOI 10.1002/ijc.22927; Lai JN, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/697893; Lai JN, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/891893; Lee YC, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-225; LOVE RR, 1994, J NATL CANCER I, V86, P1025, DOI 10.1093/jnci/86.13.1025; Mignotte H, 1998, INT J CANCER, V76, P325, DOI 10.1002/(SICI)1097-0215(19980504)76:3<325::AID-IJC7>3.0.CO;2-X; NAYFIELD SG, 1991, J NATL CANCER I, V83, P1450, DOI 10.1093/jnci/83.20.1450; Rakovitch E, 2005, BREAST CANCER RES TR, V90, P139, DOI 10.1007/s10549-004-3779-1; Reyes-Gibby CC, 2008, LANCET ONCOL, V9, P777, DOI 10.1016/S1470-2045(08)70197-9; Rubino C, 2003, BRIT J CANCER, V89, P840, DOI 10.1038/sj.bjc.6601138; RUTQVIST LE, 1995, J NATL CANCER I, V87, P645, DOI 10.1093/jnci/87.9.645; Sasco AJ, 1996, LANCET, V347, P761, DOI 10.1016/S0140-6736(96)90111-7; SUNDERLAND MC, 1991, J CLIN ONCOL, V9, P1283, DOI 10.1200/JCO.1991.9.7.1283; Swerdlow AJ, 2005, JNCI-J NATL CANCER I, V97, P375, DOI 10.1093/jnci/dji057; Tagliaferri M, 2001, SEMIN ONCOL, V28, P121, DOI 10.1053/sonc.2001.20749; VANLEEUWEN FE, 1994, LANCET, V343, P448, DOI 10.1016/S0140-6736(94)92692-1; Yu YL, 2010, J AGR FOOD CHEM, V58, P1630, DOI 10.1021/jf903043r	36	17	18	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 8	2014	9	12							e113887	10.1371/journal.pone.0113887	http://dx.doi.org/10.1371/journal.pone.0113887			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX4MX	25485843	Green Submitted, gold, Green Published			2023-01-03	WOS:000346907600029
J	Chakraborty, M; McGreal, EP; Williams, A; Davies, PL; Powell, W; Abdulla, S; Voitenok, NN; Hogwood, J; Gray, E; Spiller, B; Chambers, RC; Kotecha, S				Chakraborty, Mallinath; McGreal, Eamon P.; Williams, Andrew; Davies, Philip L.; Powell, Wendy; Abdulla, Salima; Voitenok, Nikolai N.; Hogwood, John; Gray, Elaine; Spiller, Brad; Chambers, Rachel C.; Kotecha, Sailesh			Role of Serine Proteases in the Regulation of Interleukin-8(77) during the Development of Bronchopulmonary Dysplasia in Preterm Ventilated Infants	PLOS ONE			English	Article							CHRONIC LUNG-DISEASE; RESPIRATORY-DISTRESS SYNDROME; NEUTROPHIL CHEMOTACTIC FACTOR; BRONCHOALVEOLAR LAVAGE FLUID; TERMINAL SEQUENCE; TISSUE FACTOR; AMINO-ACID; IN-VITRO; ELASTASE; INHIBITORS	Rationale: The chemokine interleukin-8 is implicated in the development of bronchopulmonary dysplasia in preterm infants. The 77-amino acid isoform of interleukin-8 (interleukin-8(77)) is a less potent chemoattractant than other shorter isoforms. Although interleukin-8(77) is abundant in the preterm circulation, its regulation in the preterm lung is unknown. Objectives: To study expression and processing of pulmonary interleukin-8(77) in preterm infants who did and did not develop bronchopulmonary dysplasia. Methods: Total interleukin-8 and interleukin-8(77) were measured in bronchoalveolar lavage fluid from preterm infants by immunoassay. Neutrophil serine proteases were used to assess processing. Neutrophil chemotaxis assays and degranulation of neutrophil matrix metalloproteinase-9 were used to assess interleukin-8 function. Main Results: Peak total interleukin-8 and interleukin-8(77) concentrations were increased in infants who developed bronchopulmonary dysplasia compared to those who did not. Shorter forms of interleukin-8 predominated in the preterm lung (96.3% No-bronchopulmonary dysplasia vs 97.1% bronchopulmonary dysplasia, p>0.05). Preterm bronchoalveolar lavage fluid significantly converted exogenously added interleukin-8(77) to shorter isoforms (p, 0.001). Conversion was greater in bronchopulmonary dysplasia infants (p<0.05). This conversion was inhibited by alpha-1 antitrypsin and antithrombin III (p<0.01). Purified neutrophil serine proteases efficiently converted interleukin-8(77) to shorter isoforms in a time- and dose-dependent fashion; shorter interleukin-8 isoforms were primarily responsible for neutrophil chemotaxis (p<0.001). Conversion by proteinase-3 resulted in significantly increased interleukin-8 activity in vitro (p<0.01). Conclusions: Shorter, potent, isoforms interleukin-8 predominate in the preterm lung, and are increased in infants developing bronchopulmonary dysplasia, due to conversion of interleukin-8(77) by neutrophil serine proteases and thrombin. Processing of interleukin-8 provides an attractive therapeutic target to prevent development of bronchopulmonary dysplasia.	[Chakraborty, Mallinath; McGreal, Eamon P.; Davies, Philip L.; Powell, Wendy; Abdulla, Salima; Spiller, Brad; Kotecha, Sailesh] Cardiff Univ, Sch Med, Dept Child Hlth, Cardiff CF10 3AX, S Glam, Wales; [Williams, Andrew; Chambers, Rachel C.] UCL, Rayne Inst, Ctr Inflammat & Tissue Repair, London, England; [Voitenok, Nikolai N.] Fund Mol Haematol & Immunol, Moscow, Russia; [Hogwood, John; Gray, Elaine] Natl Inst Biol Stand & Controls, Div Haematol, Potters Bar, Herts, England	Cardiff University; University of London; King's College London; University College London; National Institute for Biological Standards & Control	Kotecha, S (corresponding author), Cardiff Univ, Sch Med, Dept Child Hlth, Cardiff CF10 3AX, S Glam, Wales.	kotechas@cardiff.ac.uk	Spiller, Owen Brad/AAC-2474-2020	Spiller, Owen Brad/0000-0002-9117-6911; Chakraborty, Mallinath/0000-0002-1721-6532; Chambers, Rachel/0000-0003-1370-9417; Kotecha, Sailesh/0000-0003-3535-7627	Sparks, The Children's Medical Research Charity; Arriva Pharmaceuticals	Sparks, The Children's Medical Research Charity; Arriva Pharmaceuticals	This work was supported by Sparks, The Children's Medical Research Charity (http://www.sparks.org.uk/) and by Arriva Pharmaceuticals. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altiok O, 2006, AM J RESP CRIT CARE, V173, P318, DOI 10.1164/rccm.200503-425OC; Ambalavanan N, 2009, PEDIATRICS, V123, P1132, DOI 10.1542/peds.2008-0526; Bacon K, 2003, CYTOKINE, V21, P48, DOI 10.1016/S1043-4666(02)00493-3; Beeton ML, 2011, EUR RESPIR J, V37, P1424, DOI 10.1183/09031936.00037810; Bergin DA, 2010, J CLIN INVEST, V120, P4236, DOI 10.1172/JCI41196; Cederqvist K, 2001, PEDIATRICS, V108, P686, DOI 10.1542/peds.108.3.686; Chakraborty M, 2010, PAEDIATR RESPIR REV, V11, P162, DOI 10.1016/j.prrv.2010.03.002; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; Coalson Jacqueline J, 2003, Semin Neonatol, V8, P73, DOI 10.1016/S1084-2756(02)00193-8; Davies PL, 2010, THORAX, V65, P246, DOI 10.1136/thx.2009.116061; de Blic J, 2000, EUR RESPIR J, V15, P217; De Dooy J, 2007, PEDIATR PULM, V42, P193, DOI 10.1002/ppul.20511; DETMERS PA, 1991, J IMMUNOL, V147, P4211; Dik WA, 2003, PEDIATR PULM, V35, P34, DOI 10.1002/ppul.10219; Ekekezie II, 2004, PEDIATRICS, V113, P1709, DOI 10.1542/peds.113.6.1709; GIMBRONE MA, 1989, SCIENCE, V246, P1601, DOI 10.1126/science.2688092; Goodman RB, 1998, AM J PHYSIOL-LUNG C, V275, pL87, DOI 10.1152/ajplung.1998.275.1.L87; Gortner L, 2011, NEONATOLOGY, V99, P112, DOI 10.1159/000313024; GREGORY H, 1988, BIOCHEM BIOPH RES CO, V151, P883, DOI 10.1016/S0006-291X(88)80364-4; HASLETT C, 1985, AM J PATHOL, V119, P101; HEBERT CA, 1990, J IMMUNOL, V145, P3033; Hilgendorff A, 2011, AM J RESP CRIT CARE, V184, P537, DOI 10.1164/rccm.201012-2010OC; Imokawa S, 1997, AM J RESP CRIT CARE, V156, P631, DOI 10.1164/ajrccm.156.2.9608094; Jobe Alan H., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1723; Kambas K, 2011, J IMMUNOL, V186, P6568, DOI 10.4049/jimmunol.1003756; Konrad FM, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/740987; KOTECHA S, 1995, ARCH DIS CHILD-FETAL, V72, pF90, DOI 10.1136/fn.72.2.F90; Kotecha SJ, 2013, THORAX, V68, P760, DOI 10.1136/thoraxjnl-2012-203079; Leavell KJ, 1997, J LEUKOCYTE BIOL, V61, P361, DOI 10.1002/jlb.61.3.361; Lee WL, 2001, AM J RESP CRIT CARE, V164, P896, DOI 10.1164/ajrccm.164.5.2103040; Leverence JT, 2011, CHEM-BIOL INTERACT, V189, P72, DOI 10.1016/j.cbi.2010.09.026; Lipinski S, 2011, HAMOSTASEOLOGIE, V31, P94, DOI 10.5482/ha-1134; Mackman N, 2009, J THROMB HAEMOST, V7, P136, DOI 10.1111/j.1538-7836.2009.03368.x; Maheshwari A, 2009, CYTOKINE, V46, P12, DOI 10.1016/j.cyto.2008.12.022; McGreal EP, 2010, BBA-MOL BASIS DIS, V1802, P649, DOI 10.1016/j.bbadis.2010.04.005; MERRITT TA, 1983, J CLIN INVEST, V72, P656, DOI 10.1172/JCI111015; Mortier A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023913; Mortier A, 2011, EXP CELL RES, V317, P642, DOI 10.1016/j.yexcr.2010.11.016; Munshi UK, 1997, PEDIATR PULM, V24, P331; NAKAGAWA H, 1991, FEBS LETT, V282, P412, DOI 10.1016/0014-5793(91)80526-9; Nashkevich NN, 2002, J IMMUNOL METHODS, V270, P37, DOI 10.1016/S0022-1759(02)00279-X; NOURSHARGH S, 1992, J IMMUNOL, V148, P106; OGDEN BE, 1984, AM REV RESPIR DIS, V130, P817; PADRINES M, 1994, FEBS LETT, V352, P231, DOI 10.1016/0014-5793(94)00952-X; Proost P, 2008, J EXP MED, V205, P2085, DOI 10.1084/jem.20080305; Remick DG, 2005, CRIT CARE MED, V33, pS466, DOI 10.1097/01.CCM.0000186783.34908.18; SCHRODER JM, 1990, J IMMUNOL, V144, P2223; Scotton CJ, 2009, J CLIN INVEST, V119, P2550, DOI 10.1172/JCI33288; SPEER CP, 1993, PEDIATRICS, V91, P794; STANDIFORD TJ, 1990, J CLIN INVEST, V86, P1945, DOI 10.1172/JCI114928; Sveger T, 2002, ACTA PAEDIATR, V91, P934, DOI 10.1080/080352502760272614; Van den Steen PE, 2000, BLOOD, V96, P2673, DOI 10.1182/blood.V96.8.2673.h8002673_2673_2681; VANDAMME J, 1989, EUR J BIOCHEM, V181, P337; VANDAMME J, 1988, J EXP MED, V167, P1364, DOI 10.1084/jem.167.4.1364; WALZ A, 1987, BIOCHEM BIOPH RES CO, V149, P755, DOI 10.1016/0006-291X(87)90432-3; YOSHIMURA T, 1989, MOL IMMUNOL, V26, P87	56	3	3	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 4	2014	9	12							e114524	10.1371/journal.pone.0114524	http://dx.doi.org/10.1371/journal.pone.0114524			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AW6MB	25474412	Green Published, gold, Green Submitted			2023-01-03	WOS:000346382500044
J	Herbst, RS; Soria, JC; Kowanetz, M; Fine, GD; Hamid, O; Gordon, MS; Sosman, JA; McDermott, DF; Powderly, JD; Gettinger, SN; Kohrt, HEK; Horn, L; Lawrence, DP; Rost, S; Leabman, M; Xiao, YY; Mokatrin, A; Koeppen, H; Hegde, PS; Mellman, I; Chen, DS; Hodi, FS				Herbst, Roy S.; Soria, Jean-Charles; Kowanetz, Marcin; Fine, Gregg D.; Hamid, Omid; Gordon, Michael S.; Sosman, Jeffery A.; McDermott, David F.; Powderly, John D.; Gettinger, Scott N.; Kohrt, Holbrook E. K.; Horn, Leora; Lawrence, Donald P.; Rost, Sandra; Leabman, Maya; Xiao, Yuanyuan; Mokatrin, Ahmad; Koeppen, Hartmut; Hegde, Priti S.; Mellman, Ira; Chen, Daniel S.; Hodi, F. Stephen			Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients	NATURE			English	Article							T-CELLS; IN-VIVO; SAFETY; TUMORS; PD-1; MELANOMA; CRITERIA; PATHWAY; DISEASE; B7-H1	The development of human cancer is a multistep process characterized by the accumulation of genetic and epigenetic alterations that drive or reflect tumour progression. These changes distinguish cancer cells from their normal counterparts, allowing tumours to be recognized as foreign by the immune system(1-4). However, tumours are rarely rejected spontaneously, reflecting their ability to maintain an immunosuppressive microenvironmen(5). Programmed death-ligand 1 (PD-Li; also called B7-H1 or CD274), which is expressed on many cancer and immune cells, plays an important part in blocking the 'cancer immunity cycle' by binding programmed death-1 (PD-1) and B7.1 (CD80), both of which are negative regulators of T-lymphocyte activation. Binding of PD-L1 to its receptors suppresses T-cell migration, proliferation and secretion of cytotoxic mediators, and restricts tumour cell killing(6-10). The PD -LI-PD -1 axis protects the host from overactive T-effector cells not only in cancer but also during microbial infections(11). Blocking PD-L1 should therefore enhance anticancer immunity, but little is known about predictive factors of efficacy. This study was designed to evaluate the safety, activity and biomarkers of PD-L1 inhibition using the engineered humanized antibody MPDL3280A. Here we show that across multiple cancer types, responses (as evaluated by Response Evaluation Criteria in Solid Tumours, version 1.1) were observed in patients with tumours expressing high levels of PD-L1, especially when PD-L1 was expressed by tumour-infiltrating immune cells. Furthermore, responses were associated with T-helper type 1 (T(H)1) gene expression, CTLA4 expression and the absence of fractalkine (CX3CL1) in baseline tumour specimens. Together, these data suggest that MPDL3280A is most effective in patients in which pre-existing immunity is suppressed by PD-L1, and is re-invigorated on antibody treatment.	[Herbst, Roy S.; Gettinger, Scott N.] Yale Univ, Sch Med, Yale Comprehens Canc Ctr, New Haven, CT 06520 USA; [Soria, Jean-Charles] Gustave Roussy South Paris Univ, F-94805 Villejuif, France; [Kowanetz, Marcin; Fine, Gregg D.; Rost, Sandra; Leabman, Maya; Xiao, Yuanyuan; Mokatrin, Ahmad; Koeppen, Hartmut; Hegde, Priti S.; Mellman, Ira; Chen, Daniel S.] Genentech Inc, San Francisco, CA 94080 USA; [Hamid, Omid] Angeles Clin & Res Inst, Los Angeles, CA 90025 USA; [Gordon, Michael S.] Pinnacle Oncol Hematol, Scottsdale, AZ 85258 USA; [Sosman, Jeffery A.; Horn, Leora] Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA; [McDermott, David F.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Powderly, John D.] Carolina BioOncol Inst, Huntersville, NC 28078 USA; [Kohrt, Holbrook E. K.] Stanford Univ, Stanford, CA 94305 USA; [Lawrence, Donald P.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Hodi, F. Stephen] Dana Farber Brigham & Womens Canc Ctr, Boston, MA 02215 USA	Yale University; Roche Holding; Genentech; Angeles Clinic & Research Institute; Vanderbilt University; Harvard University; Beth Israel Deaconess Medical Center; Stanford University; Harvard University; Massachusetts General Hospital; Harvard University; Dana-Farber Cancer Institute	Herbst, RS (corresponding author), Yale Univ, Sch Med, Yale Comprehens Canc Ctr, 333 Cedar St,WWW221, New Haven, CT 06520 USA.	roy.herbst@yale.edu	Soria, Jean-Charles/F-3619-2014; Chen, Daniel Shin-Yu/AGD-8923-2022; Mellman, Ira/ABG-5896-2020	Chen, Daniel Shin-Yu/0000-0001-5085-3579; 	NCI [1R01CA155196, P30 CA 016359]; NATIONAL CANCER INSTITUTE [P30CA016359, R01CA155196] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the patients and their families. We also thank all of the investigators and their staff, including A. Balmanoukian and P. Boasberg from The Angeles Clinic and Research Institute; T. Powles from Barts Cancer Institute, QMUL, Barts Health NHS Trust; D. Cho from NYU Langone Medical Center; P. Cassier from Centre Leon-Berard; F. Braiteh from USON Research Network, Comprehensive Cancer Centers of Nevada; N. Vogelzang from USON Research Network, Comprehensive Cancer Centers of Nevada and University of Nevada; T. Choueiri, L. Gandhi, N. Ibrahim and P. Ott from Dana-Farber Cancer Institute; J.-P. Delord and C. Gomez-Rocca from Institut Claudius Regaud; A. Hollebecque and R. Bahleda from Gustave Roussy; L. Emens from Johns Hopkins Medicine, The Sidney Kimmel Comprehensive Cancer Center; K. Flaherty and R. Sullivan from Massachusetts General Hospital; S. Antonia from Moffitt Cancer Center; H. Burris, J. Infante and D. Spigel from Sarah Cannon Research Institute; G. Fisher from Stanford Medicine, Cancer Institute; P. Conkling and L. Garbo from US Oncology Research, Inc.; C. Cruz and J. Tabenero from Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital; W. Pao and I. Puzanov from Vanderbilt-Ingram Cancer Center; P. Eder, H. Kluger and M. Sznol from Yale Cancer Center. From Genentech, we thank M. Anderson, M. Boe, Z. Boyd, C. Chappey, M. Denker, R. Desai, L. Fu, B. Irving, D. Jin, W. Kadel, R. Nakamura, I. Rhee, X. Shen, M. Stroh, T. Sumiyoshi, J. Wu,Y. Xin and J. Yi. Support for third-party writing assistance for this manuscript was provided by F. Hoffmann-La Roche Ltd. NCI grants 1R01CA155196 (Battle-2) and P30 CA 016359 (CCSG) to R.S.H. helped support the infrastructure for this trial and program.	Akbari O, 2010, MUCOSAL IMMUNOL, V3, P81, DOI 10.1038/mi.2009.112; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Butte MJ, 2007, IMMUNITY, V27, P111, DOI 10.1016/j.immuni.2007.05.016; Chen DK, 2012, ATMOS OCEAN, V50, P1, DOI 10.1080/07055900.2012.741787; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Cole KE, 1998, J EXP MED, V187, P2009, DOI 10.1084/jem.187.12.2009; Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115; Dong HD, 1999, NAT MED, V5, P1365; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Gros A, 2014, J CLIN INVEST, V124, P2246, DOI [10.1172/JC173639, 10.1172/JCI73639]; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Han A, 2013, P NATL ACAD SCI USA, V110, P13073, DOI 10.1073/pnas.1311861110; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Isaacs JD, 1996, CLIN EXP IMMUNOL, V106, P427, DOI 10.1046/j.1365-2249.1996.d01-876.x; Matsumoto K, 2008, BIOCHEM BIOPH RES CO, V365, P170, DOI 10.1016/j.bbrc.2007.10.156; Mellman I, 2011, NATURE, V480, P480, DOI 10.1038/nature10673; Park HJ, 2012, CELL IMMUNOL, V278, P76, DOI 10.1016/j.cellimm.2012.07.001; Park JJ, 2010, BLOOD, V116, P1291, DOI 10.1182/blood-2010-01-265975; Paterson AM, 2011, J IMMUNOL, V187, P1097, DOI 10.4049/jimmunol.1003496; Powles T., 2014, NATURE; Schleifman EB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088401; Spranger S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006504; Taube JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003689; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; van Rooij N, 2013, J CLIN ONCOL, V31, pE439, DOI 10.1200/JCO.2012.47.7521; Warncke M, 2012, J IMMUNOL, V188, P4405, DOI 10.4049/jimmunol.1200090; Wolchok JD, 2009, CLIN CANCER RES, V15, P7412, DOI 10.1158/1078-0432.CCR-09-1624; Wrammert J, 2008, NATURE, V453, P667, DOI 10.1038/nature06890; Yang J, 2011, J IMMUNOL, V187, P1113, DOI 10.4049/jimmunol.1100056	31	3515	3710	24	547	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 27	2014	515	7528					563	+		10.1038/nature14011	http://dx.doi.org/10.1038/nature14011			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AW4JP	25428504	Green Accepted			2023-01-03	WOS:000346247600053
J	Zhou, H; Qu, Z; Mossine, VV; Nknolise, DL; Li, JL; Chen, ZZ; Cheng, JL; Greenlief, CM; Mawhinney, TP; Brown, PN; Fritsche, KL; Hannink, M; Lubahn, DB; Sun, GY; Gu, ZZ				Zhou, Hui; Qu, Zhe; Mossine, Valeri V.; Nknolise, Dineo L.; Li, Jilong; Chen, Zhenzhou; Cheng, Jianlin; Greenlief, C. Michael; Mawhinney, Thomas P.; Brown, Paula N.; Fritsche, Kevin L.; Hannink, Mark; Lubahn, Dennis B.; Sun, Grace Y.; Gu, Zezong			Proteomic Analysis of the Effects of Aged Garlic Extract and Its FruArg Component on Lipopolysaccharide-Induced Neuroinflammatory Response in Microglial Cells	PLOS ONE			English	Article							FACTOR-KAPPA-B; OXIDATIVE STRESS; NITRIC-OXIDE; NEURODEGENERATIVE DISEASES; ANTIOXIDANT PROPERTIES; ALZHEIMERS-DISEASE; SIGNALING PATHWAY; S-ALLYLCYSTEINE; IN-VITRO; INFLAMMATION	Aged garlic extract (AGE) is widely used as a dietary supplement, and is claimed to promote human health through anti-oxidant/anti-inflammatory activities with hypolipidemic, antiplatelet and neuroprotective effects. Prior studies of AGE have mainly focused on its organosulfur compounds, with little attention paid to its carbohydrate derivatives, such as N-alpha-(1-deoxy-D-fructos-1-yl)-L-arginine (FruArg). The goal of this study is to investigate actions of AGE and FruArg on antioxidative and neuroinflammatory responses in lipopolysaccharide (LPS)-activated murine BV-2 microglial cells using a proteomic approach. Our data show that both AGE and FruArg can significantly inhibit LPS-induced nitric oxide (NO) production in BV-2 cells. Quantitative proteomic analysis by combining two dimensional differential in-gel electrophoresis (2D-DIGE) with mass spectrometry revealed that expressions of 26 proteins were significantly altered upon LPS exposure, while levels of 20 and 21 proteins exhibited significant changes in response to AGE and FruArg treatments, respectively, in LPS-stimulated BV-2 cells. Notably, approximate78% of the proteins responding to AGE and FruArg treatments are in common, suggesting that FruArg is a major active component of AGE. MULTICOM-PDCN and Ingenuity Pathway Analyses indicate that the proteins differentially affected by treatment with AGE and FruArg are involved in inflammatory responses and the Nrf2-mediated oxidative stress response. Collectively, these results suggest that AGE and FruArg attenuate neuroinflammatory responses and promote resilience in LPS-activated BV-2 cells by suppressing NO production and by regulating expression of multiple protein targets associated with oxidative stress.	[Zhou, Hui; Qu, Zhe; Nknolise, Dineo L.; Chen, Zhenzhou; Sun, Grace Y.; Gu, Zezong] Univ Missouri, Sch Med, Dept Pathol & Anat Sci, Columbia, MO 65211 USA; [Mossine, Valeri V.; Mawhinney, Thomas P.; Hannink, Mark; Lubahn, Dennis B.; Sun, Grace Y.] Univ Missouri, Sch Med, Dept Biochem, Columbia, MO USA; [Zhou, Hui; Qu, Zhe; Nknolise, Dineo L.; Chen, Zhenzhou; Sun, Grace Y.; Gu, Zezong] Univ Missouri, Sch Med, Ctr Translat Neurosci, Columbia, MO USA; [Li, Jilong; Cheng, Jianlin] Univ Missouri, Dept Comp Sci, Inst Informat, Columbia, MO USA; [Greenlief, C. Michael] Univ Missouri, Dept Chem, Columbia, MO 65211 USA; [Fritsche, Kevin L.] Univ Missouri, Div Anim Sci, Columbia, MO USA; [Gu, Zezong] Harry S Truman Mem Vet Hosp, Columbia, MO 65201 USA; [Brown, Paula N.] British Columbia Inst Technol, Vancouver, BC, Canada	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harry S. Truman Memorial Veterans' Hospital; British Columbia Institute of Technology	Gu, ZZ (corresponding author), Univ Missouri, Sch Med, Dept Pathol & Anat Sci, Columbia, MO 65211 USA.	guze@health.missouri.edu	Cheng, Jianlin/N-8209-2013	Cheng, Jianlin/0000-0003-0305-2853; Mawhinney, Thomas/0000-0002-1807-2550	National Institute of Environmental Health Sciences Centers for Neurodegeneration Science [P01 1P01ES016738]; University of Missouri Department of Pathology and Anatomical Sciences; University of Missouri South African Education Program; National Center for Complementary and Alternative Medicines (NCCAM) [P50AT006273]; Office of Dietary Supplements (ODS); National Cancer Institute (NCI); NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE [P50AT006273] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES016738] Funding Source: NIH RePORTER	National Institute of Environmental Health Sciences Centers for Neurodegeneration Science; University of Missouri Department of Pathology and Anatomical Sciences; University of Missouri South African Education Program; National Center for Complementary and Alternative Medicines (NCCAM)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); Office of Dietary Supplements (ODS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported in part by funding from the National Institute of Environmental Health Sciences Centers for Neurodegeneration Science P01 1P01ES016738 Missouri Consortium and the University of Missouri Department of Pathology and Anatomical Sciences (to ZG), and the University of Missouri South African Education Program (to DLN). This project was made possible by Grant Number P50AT006273 from the National Center for Complementary and Alternative Medicines (NCCAM), the Office of Dietary Supplements (ODS), and the National Cancer Institute (NCI). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amagase H, 2006, J NUTR, V136, p716S, DOI 10.1093/jn/136.3.716S; Amor S, 2010, IMMUNOLOGY, V129, P154, DOI 10.1111/j.1365-2567.2009.03225.x; Araki E, 2001, STROKE, V32, P2370, DOI 10.1161/hs1001.096057; Asehnoune K, 2004, J IMMUNOL, V172, P2522, DOI 10.4049/jimmunol.172.4.2522; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; Blasko I, 2004, AGING CELL, V3, P169, DOI 10.1111/j.1474-9728.2004.00101.x; BOCCHINI V, 1992, J NEUROSCI RES, V31, P616, DOI 10.1002/jnr.490310405; Borek C, 2001, J NUTR, V131, p1010S, DOI 10.1093/jn/131.3.1010S; Cribbs DH, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-179; DENISEVITCH TV, 1995, EXP ONCOL, V17, P111; Dillon SA, 2002, J NUTR, V132, P168, DOI 10.1093/jn/132.2.168; Dillon SA, 2003, LIFE SCI, V72, P1583, DOI 10.1016/S0024-3205(02)02475-X; Gao FF, 2012, LWT-FOOD SCI TECHNOL, V49, P34, DOI 10.1016/j.lwt.2012.04.022; Garden GA, 2006, J NEUROIMMUNE PHARM, V1, P127, DOI 10.1007/s11481-006-9015-5; Geng ZH, 1997, FREE RADICAL BIO MED, V23, P345, DOI 10.1016/S0891-5849(97)00006-3; Griffiths MR, 2009, J NEUROPATH EXP NEUR, V68, P217, DOI 10.1097/NEN.0b013e3181996688; Gu Z, 2005, CELL DEATH DIFFER, V12, P1202, DOI 10.1038/sj.cdd.4401705; Gu ZZ, 2010, MOL NEUROBIOL, V41, P55, DOI 10.1007/s12035-010-8113-9; Guijarro-Munoz I, 2014, J BIOL CHEM, V289, P2457, DOI 10.1074/jbc.M113.521161; Ide N, 1999, J NUTR BIOCHEM, V10, P372, DOI 10.1016/S0955-2863(99)00021-2; Ide N, 2001, J NUTR, V131, p1020S, DOI 10.1093/jn/131.3.1020S; Jiang JH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089748; Jung JS, 2013, BBA-MOL CELL BIOL L, V1831, P1016, DOI 10.1016/j.bbalip.2013.01.020; Kalayarasan S, 2008, J APPL TOXICOL, V28, P908, DOI 10.1002/jat.1355; Kaneko YS, 2012, NEURODEGENER DIS, V10, P100, DOI 10.1159/000332936; Kannappan R, 2011, MOL NEUROBIOL, V44, P142, DOI 10.1007/s12035-011-8168-2; Karp NA, 2008, PROTEOMICS, V8, P948, DOI 10.1002/pmic.200700812; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Kyo E, 2001, J NUTR, V131, p1075S, DOI 10.1093/jn/131.3.1075S; Lawal AO, 2011, ENVIRON TOXICOL PHAR, V32, P266, DOI 10.1016/j.etap.2011.05.012; Lawson LD, 2005, J AGR FOOD CHEM, V53, P6254, DOI 10.1021/jf050536+; Liu B, 2002, ANN NY ACAD SCI, V962, P318, DOI 10.1111/j.1749-6632.2002.tb04077.x; LOWY PH, 1956, J AM CHEM SOC, V78, P3175, DOI 10.1021/ja01594a054; Maldonado PD, 2011, J PHYS CHEM B, V115, P13408, DOI 10.1021/jp208233f; Matsutomo T, 2013, J AGR FOOD CHEM, V61, P3059, DOI 10.1021/jf305549g; Matsuura Y., 1994, J TRAD MED, V18, P204; Morihara N, 2006, J NUTR, V136, p777S, DOI 10.1093/jn/136.3.777S; Morihara N, 2002, LIFE SCI, V71, P509, DOI 10.1016/S0024-3205(02)01706-X; Morihara N, 2011, PLANT FOOD HUM NUTR, V66, P17, DOI 10.1007/s11130-011-0216-6; Moss DW, 2001, EUR J NEUROSCI, V13, P529, DOI 10.1046/j.1460-9568.2001.01418.x; Mossine VV, 2010, MAILLARD REACTION: INTERFACE BETWEEN AGING, NUTRITION AND METABOLISM, P170; Mossine VV, 2008, CANCER RES, V68, P4384, DOI 10.1158/0008-5472.CAN-08-0108; Mossine VV, 2007, J AGR FOOD CHEM, V55, P10373, DOI 10.1021/jf072092i; Mossine VV, 2010, ADV CARBOHYD CHEM BI, V64, P291, DOI 10.1016/S0065-2318(10)64006-1; Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200; Park HJ, 2012, ACTA PHYSIOL, V205, P61, DOI 10.1111/j.1748-1716.2012.02425.x; Rojo LE, 2008, ARCH MED RES, V39, P1, DOI 10.1016/j.arcmed.2007.10.001; Ryu K, 2003, ACS SYM SER, V859, P258; Ryu K, 2001, J NUTR, V131, p972S, DOI 10.1093/jn/131.3.972S; Saijo K, 2011, NAT REV IMMUNOL, V11, P775, DOI 10.1038/nri3086; Sethy NK, 2011, FUNCT INTEGR GENOMIC, V11, P119, DOI 10.1007/s10142-010-0195-y; Shen SM, 2005, NEUROCHEM INT, V47, P298, DOI 10.1016/j.neuint.2005.03.007; Sumi S, 2001, J NUTR, V131, p1096S, DOI 10.1093/jn/131.3.1096S; Tamawski M, 2007, INT IMMUNOPHARMACOL, V7, P1577, DOI 10.1016/j.intimp.2007.08.004; Wang Z, 2010, BIOINFORMATICS, V26, P882, DOI 10.1093/bioinformatics/btq058; Wilms H, 2007, CURR PHARM DESIGN, V13, P1925; Zhao L, 2011, NUTR REV, V69, P310, DOI 10.1111/j.1753-4887.2011.00394.x	57	15	15	4	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 24	2014	9	11							e113531	10.1371/journal.pone.0113531	http://dx.doi.org/10.1371/journal.pone.0113531			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX2IM	25420111	Green Submitted, gold, Green Published			2023-01-03	WOS:000346766900048
J	Ngandu, T; Lehtisalo, J; Solomon, A; Levalahti, E; Ahtiluoto, S; Antikainen, R; Backman, L; Hanninen, T; Jula, A; Laatikainen, T; Lindstrom, J; Mangialasche, F; Paajanen, T; Pajala, S; Peltonen, M; Rauramaa, R; Stigsdotter-Neely, A; Strandberg, T; Tuomilehto, J; Soininen, H; Kivipelto, M				Ngandu, Tiia; Lehtisalo, Jenni; Solomon, Alina; Levalahti, Esko; Ahtiluoto, Satu; Antikainen, Riitta; Backman, Lars; Hanninen, Tuomo; Jula, Antti; Laatikainen, Tiina; Lindstrom, Jaana; Mangialasche, Francesca; Paajanen, Teemu; Pajala, Satu; Peltonen, Markku; Rauramaa, Rainer; Stigsdotter-Neely, Anna; Strandberg, Timo; Tuomilehto, Jaakko; Soininen, Hilkka; Kivipelto, Miia			A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial	LANCET			English	Article							FINNISH GERIATRIC INTERVENTION; ALZHEIMERS-DISEASE; IMPAIRMENT; FITNESS	Background Modifiable vascular and lifestyle-related risk factors have been associated with dementia risk in observational studies. In the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER), a proof-of-concept randomised controlled trial, we aimed to assess a multidomain approach to prevent cognitive decline in at-risk elderly people from the general population. Methods In a double-blind randomised controlled trial we enrolled individuals aged 60-77 years recruited from previous national surveys. Inclusion criteria were CAIDE (Cardiovascular Risk Factors, Aging and Dementia) Dementia Risk Score of at least 6 points and cognition at mean level or slightly lower than expected for age. We randomly assigned participants in a 1: 1 ratio to a 2 year multidomain intervention (diet, exercise, cognitive training, vascular risk monitoring), or a control group (general health advice). Computer-generated allocation was done in blocks of four (two individuals randomly allocated to each group) at each site. Group allocation was not actively disclosed to participants and outcome assessors were masked to group allocation. The primary outcome was change in cognition as measured through comprehensive neuropsychological test battery (NTB) Z score. Analysis was by modified intention to treat (all participants with at least one post-baseline observation). This trial is registered at ClinicalTrials.gov, number NCT01041989. Findings Between Sept 7, 2009, and Nov 24, 2011, we screened 2654 individuals and randomly assigned 1260 to the intervention group (n=631) or control group (n=629). 591 (94%) participants in the intervention group and 599 (95%) in the control group had at least one post-baseline assessment and were included in the modified intention-to-treat analysis. Estimated mean change in NTB total Z score at 2 years was 0.20 (SE 0.02, SD 0.51) in the intervention group and 0.16 (0.01, 0.51) in the control group. Between-group difference in the change of NTB total score per year was 0.022 (95% CI 0.002-0.042, p=0.030). 153 (12%) individuals dropped out overall. Adverse events occurred in 46 (7%) participants in the intervention group compared with six (1%) participants in the control group; the most common adverse event was musculoskeletal pain (32 [5%] individuals for intervention vs no individuals for control). Interpretation Findings from this large, long-term, randomised controlled trial suggest that a multidomain intervention could improve or maintain cognitive functioning in at-risk elderly people from the general population.	[Ngandu, Tiia; Lehtisalo, Jenni; Levalahti, Esko; Ahtiluoto, Satu; Jula, Antti; Laatikainen, Tiina; Lindstrom, Jaana; Peltonen, Markku; Tuomilehto, Jaakko; Kivipelto, Miia] Natl Inst Hlth & Welf, Chron Dis Prevent Unit, Helsinki, Finland; [Pajala, Satu] Natl Inst Hlth & Welf, Welf & Hlth Promot Unit, Helsinki, Finland; [Ngandu, Tiia; Solomon, Alina; Kivipelto, Miia] Karolinska Inst, Ctr Alzheimer Res, S-11330 Stockholm, Sweden; [Solomon, Alina; Soininen, Hilkka; Kivipelto, Miia] Univ Eastern Finland, Inst Clin Med Neurol, Kuopio, Finland; [Laatikainen, Tiina] Univ Eastern Finland, Inst Publ Hlth & Clin Nutr, Kuopio, Finland; [Solomon, Alina; Backman, Lars; Mangialasche, Francesca; Kivipelto, Miia] Stockholm Univ, Karolinska Inst, Aging Res Ctr, S-10691 Stockholm, Sweden; [Antikainen, Riitta; Strandberg, Timo] Univ Oulu, Inst Hlth Sci Geriatr, Oulu, Finland; [Antikainen, Riitta; Strandberg, Timo] Oulu Univ Hosp, Oulu, Finland; [Antikainen, Riitta] Oulu Univ Hosp, Med Res Ctr Oulu, Oulu, Finland; [Antikainen, Riitta] Oulu City Hosp, Oulu, Finland; [Hanninen, Tuomo; Soininen, Hilkka] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland; [Rauramaa, Rainer] Kuopio Univ Hosp, Dept Clin Physiol & Nucl Med, SF-70210 Kuopio, Finland; [Paajanen, Teemu] Finnish Inst Occupat Hlth, Helsinki, Finland; [Rauramaa, Rainer] Kuopio Res Inst Exercise Med, Kuopio, Finland; [Stigsdotter-Neely, Anna] Umea Univ, Dept Psychol, S-90187 Umea, Sweden; [Strandberg, Timo] Univ Helsinki, Cent Hosp, Dept Med, Geriatr Clin, Helsinki, Finland; [Tuomilehto, Jaakko] Univ Helsinki, Cent Hosp, HJELT Inst, Dept Publ Hlth, Helsinki, Finland; [Tuomilehto, Jaakko] South Ostrobothnia Cent Hosp, Seinajoki, Finland; [Tuomilehto, Jaakko] Danube Univ Krems, Ctr Vasc Prevent, Krems, Austria; [Tuomilehto, Jaakko] King Abdulaziz Univ, Diabet Res Grp, Jeddah 21413, Saudi Arabia	Finland National Institute for Health & Welfare; Finland National Institute for Health & Welfare; Karolinska Institutet; University of Eastern Finland; University of Eastern Finland; Karolinska Institutet; Stockholm University; University of Oulu; University of Oulu; University of Oulu; Kuopio University Hospital; University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland; Finnish Institute of Occupational Health; Umea University; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; Danube University Krems; King Abdulaziz University	Kivipelto, M (corresponding author), Karolinska Inst, Ctr Alzheimer Res, S-11330 Stockholm, Sweden.	miia.kivipelto@ki.se	Kivipelto, Miia/AAS-3557-2021; Laatikainen, Tiina/ABD-6622-2021; Peltonen, Markku/F-3037-2015	Laatikainen, Tiina/0000-0002-6614-4782; Peltonen, Markku/0000-0002-3767-4223; Ngandu, Tiia/0000-0002-3698-2021; Mangialasche, Francesca/0000-0002-2686-3926; Lindstrom, Jaana/0000-0001-9255-020X; Solomon, Alina/0000-0002-7166-9903; Lehtisalo, Jenni/0000-0002-8818-0848	Academy of Finland [120676, 11745, 251645]; La Carita Foundation; Alzheimer Association [HAT-10 173121]; Alzheimer's Research and Prevention Foundation; Juho Vainio Foundation; Novo Nordisk Foundation; Finnish Social Insurance Institution; Ministry of Education and Culture; Salama bint Hamdan Al Nahyan Foundation; Axa Research Fund; EVO; Swedish Research Council; Swedish Research Council for Health, Working Life and Welfare; af Jochnick Foundation; Academy of Finland's Responding to Public Health Challenges Research Programme (SALVE) [129395, 129397, 129459, 129421, 129416, 129511, 129401, 259615]; Axa Research Grant; EVO of University Hospital of Kuopio; EVO of University Hospital of Oulu; EVO of University Hospital of Turku; EVO of Seinajoki Central Hospital; EVO of Oulu City Hospital; Swedish Society for Medical Research; Saastamoinen Foundation; Loo och Hans Osterman Foundation; Stiftelsen Dementia; Gustaf o Victoria Frimurarestiftelse; Alexander von Humboldt Research award; Novo Nordisk Fonden [NNF12OC1016402, NNF11OC1014884] Funding Source: researchfish	Academy of Finland(Academy of Finland); La Carita Foundation; Alzheimer Association(Alzheimer's AssociationBrightFocus Foundation); Alzheimer's Research and Prevention Foundation; Juho Vainio Foundation; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Finnish Social Insurance Institution; Ministry of Education and Culture; Salama bint Hamdan Al Nahyan Foundation; Axa Research Fund(AXA Research Fund); EVO; Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Research Council for Health, Working Life and Welfare(Swedish Research CouncilSwedish Research Council for Health Working Life & Welfare (Forte)); af Jochnick Foundation; Academy of Finland's Responding to Public Health Challenges Research Programme (SALVE)(Academy of Finland); Axa Research Grant(AXA Research Fund); EVO of University Hospital of Kuopio; EVO of University Hospital of Oulu; EVO of University Hospital of Turku; EVO of Seinajoki Central Hospital; EVO of Oulu City Hospital; Swedish Society for Medical Research; Saastamoinen Foundation; Loo och Hans Osterman Foundation; Stiftelsen Dementia; Gustaf o Victoria Frimurarestiftelse; Alexander von Humboldt Research award(Alexander von Humboldt Foundation); Novo Nordisk Fonden(Novo Nordisk Foundation)	Academy of Finland, La Carita Foundation, Alzheimer Association, Alzheimer's Research and Prevention Foundation, Juho Vainio Foundation, Novo Nordisk Foundation, Finnish Social Insurance Institution, Ministry of Education and Culture, Salama bint Hamdan Al Nahyan Foundation, Axa Research Fund, EVO funding for University Hospitals of Kuopio, Oulu, and Turku and for Seinajoki Central Hospital and Oulu City Hospital, Swedish Research Council, Swedish Research Council for Health, Working Life and Welfare, and af Jochnick Foundation.; We sincerely thank all participants of the FINGER study. This study was supported by Academy of Finland's Responding to Public Health Challenges Research Programme (SALVE) grants 129395, 129397, 129459, 129421, 129416, 129511, 129401, and 259615, La Carita Foundation, Alzheimer Association grant (HAT-10 173121), Alzheimer's Research and Prevention Foundation, Juho Vainio Foundation, Novo Nordisk Foundation, Finnish Social Insurance Institution, Ministry of Education and Culture Research Grant, Salama bint Hamdan Al Nahyan Foundation, Axa Research Grant, and EVO grants of University Hospitals of Kuopio, Oulu, and Turku, Seinajoki Central Hospital and Oulu City Hospital, as well as personal grants from Academy of Finland 120676 and 11745 (MK), 251645 (AS), Swedish Society for Medical Research (TN), Saastamoinen Foundation (AS), Loo och Hans Osterman Foundation (AS), Stiftelsen Dementia (AS), and Gustaf o Victoria Frimurarestiftelse (TS). LB was supported by grants from the Swedish Research Council, the Swedish Research Council for Health, Working Life, and Welfare, an Alexander von Humboldt Research award, and a donation from the af Jochnick Foundation. The blood pressure monitoring devices were provided by Microlife (Vilnius, Lithuania). We thank Aulikki Nissinen, Erkki Vartiainen, Pekka Puska, Juhani Eskola, Bengt Winblad, and Laura Fratiglioni for their support and valuable feedback. We thank our study nurses, psychologists, physicians, nutritionists, and physiotherapists for their efforts in the conduct of the field work. We thank Liisa Saarikoski, Marko Gronholm, Pirjo Saastamoinen, Laura Lund, Pauliina Pippola, Tony Qwillbard, and all other members of the FINGER study group for their cooperation in data collection and management.	Brookmeyer R, 1998, AM J PUBLIC HEALTH, V88, P1337, DOI 10.2105/AJPH.88.9.1337; Colcombe S, 2003, PSYCHOL SCI, V14, P125, DOI 10.1111/1467-9280.t01-1-01430; Dahlin E, 2008, SCIENCE, V320, P1510, DOI 10.1126/science.1155466; Duff K, 2011, AM J GERIAT PSYCHIAT, V19, P932, DOI 10.1097/JGP.0b013e318209dd3a; Gaede P, 2008, NEW ENGL J MED, V358, P580, DOI 10.1056/NEJMoa0706245; Hanninen Tuomo, 2010, Duodecim, V126, P2013; Harrison J, 2007, ARCH NEUROL-CHICAGO, V64, P1323, DOI 10.1001/archneur.64.9.1323; Kivipelto M, 2006, LANCET NEUROL, V5, P735, DOI 10.1016/S1474-4422(06)70537-3; Kivipelto M, 2013, ALZHEIMERS DEMENT, V9, P657, DOI 10.1016/j.jalz.2012.09.012; Komulainen P, 2010, EUR GERIATR MED, V1, P266, DOI 10.1016/j.eurger.2010.08.001; Lampit A, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001756; Lindenberger U, 2014, SCIENCE, V346, P572, DOI 10.1126/science.1254403; Mormino EC, 2014, JAMA NEUROL, V71, P1379, DOI 10.1001/jamaneurol.2014.2031; MORRIS JC, 1989, NEUROLOGY, V39, P1159, DOI 10.1212/wnl.43.12.2457; National Nutrition Council, 2005, FINN NUTR REC DIET P; Nelson ME, 2007, MED SCI SPORT EXER, V39, P1435, DOI [10.1249/mss.0b013e3180616aa2, 10.1161/CIRCULATIONAHA.107.185650]; Ngandu T, 2014, INT J ENV RES PUB HE, V11, P9345, DOI 10.3390/ijerph110909345; Norton S, 2014, LANCET NEUROL, V13, P788, DOI 10.1016/S1474-4422(14)70136-X; Roig M, 2013, NEUROSCI BIOBEHAV R, V37, P1645, DOI 10.1016/j.neubiorev.2013.06.012; Saaristo T, 2007, INT J CIRCUMPOL HEAL, V66, P101, DOI 10.3402/ijch.v66i2.18239; Salthouse TA, 2014, J GERONTOL B, DOI 10.1093/geronb/gbu063; Singh MAF, 2014, J AM MED DIR ASSOC, V15, P873, DOI 10.1016/j.jamda.2014.09.010; Smith PJ, 2010, PSYCHOSOM MED, V72, P239, DOI 10.1097/PSY.0b013e3181d14633; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; Vartiainen E, 2010, INT J EPIDEMIOL, V39, P504, DOI 10.1093/ije/dyp330; Vellas B, 2011, LANCET NEUROL, V10, P297, DOI 10.1016/S1474-4422(08)70087-5; Williams John W, 2010, Evid Rep Technol Assess (Full Rep), P1; Willis SL, 2006, JAMA-J AM MED ASSOC, V296, P2805, DOI 10.1001/jama.296.23.2805; Working group appointed by the Finnish Medical Society Duodecim and the Finnish Hypertension Society, 2009, HYP CURR CAR SUMM; Working group appointed by the Finnish Medical Society Duodecim and the Medical Advisory Board of the Finnish Diabetes Society, 2007, DIAB CURR CAR SUMM; Working group set up by the Finnish Medical Society Duodecim and Finnish Society of Internal Medicine, 2009, DYSL CURR CAR SUMM; World Health Organization, 2012, DEM PUBL HLTH PRIOR	32	1551	1617	32	467	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 6	2015	385	9984					2255	2263		10.1016/S0140-6736(15)60461-5	http://dx.doi.org/10.1016/S0140-6736(15)60461-5			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CK1CR	25771249				2023-01-03	WOS:000355943500027
J	Nishi, SPE; Zhang, W; Kuo, YF; Sharma, G				Nishi, Shawn P. E.; Zhang, Wei; Kuo, Yong-Fang; Sharma, Gulshan			Oxygen Therapy Use in Older Adults with Chronic Obstructive Pulmonary Disease	PLOS ONE			English	Article							GENDER-DIFFERENCE; SEX-DIFFERENCES; COPD; REHABILITATION; CARE; ADHERENCE	Rationale Oxygen therapy improves survival and function in severely hypoxemic chronic obstructive pulmonary disease (COPD) patients based on two landmark studies conducted over 40 years ago. We hypothesize that oxygen users in the current era may be very different. We examined trends and subject characteristics associated with oxygen therapy use from 2001-2010 in the United States. Methods We examined Medicare beneficiaries with COPD who received oxygen from 2001 to 2010. COPD subjects were identified by: 1) >= 2 outpatient visits >30 days apart within one year with an encounter diagnosis of COPD; or 2) an acute care hospitalization with COPD as the primary or secondary discharge diagnosis. Oxygen therapy and sustained oxygen therapy were defined as >= 1 and >= 11 claims for oxygen, respectively, in the durable medical equipment file in a calendar year. Primary outcome measures were factors associated with oxygen therapy and sustained oxygen therapy over the study period. Results Oxygen therapy increased from 33.7% in 2001 to 40.5% in 2010 (p-value of trend <0.001). Sustained oxygen therapy use increased from 19.5% in 2001, peaked in 2008 to 26.9% and declined to 18.5% in 2010. The majority of subjects receiving oxygen therapy and sustained oxygen therapy were female. Besides gender, factors associated with any oxygen use or sustained oxygen therapy were non-Hispanic white race, low socioeconomic status and >= 2 comorbidities. Conclusions Any oxygen use among fee-for service Medicare beneficiaries with COPD is high. Current users of oxygen are older females with multiple comorbidities. Decline in sustained oxygen therapy use after 2008 may be related to reimbursement policy change.	[Nishi, Shawn P. E.; Zhang, Wei; Sharma, Gulshan] Univ Texas Med Branch, Dept Internal Med, Div Pulm Crit Care & Sleep Med, Galveston, TX 77555 USA; [Kuo, Yong-Fang; Sharma, Gulshan] Univ Texas Med Branch, Sealy Ctr Aging, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Nishi, SPE (corresponding author), Univ Texas Med Branch, Dept Internal Med, Div Pulm Crit Care & Sleep Med, Galveston, TX 77555 USA.	spnishi@utmb.edu	Nishi, Shawn/AAH-6998-2019; Sharma, Gulshan/AAC-5804-2019	Nishi, Shawn/0000-0002-7510-2664	Agency for Healthcare Research and Quality [R01-HS020642]; Patient Centered Outcomes Research Institute [HS02213401]; National Center for Advancing Translational Sciences [UL1TR000071]; Claude D. Pepper OAIC grant [5P30-AG024832]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS020642] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG024832] Funding Source: NIH RePORTER	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Patient Centered Outcomes Research Institute(Patient-Centered Outcomes Research Institute - PCORI); National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Claude D. Pepper OAIC grant; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by the Agency for Healthcare Research and Quality (R01-HS020642) and by the Patient Centered Outcomes Research Institute (HS02213401). Clinical and Translational Science Award (UL1TR000071) from the National Center for Advancing Translational Sciences. Claude D. Pepper OAIC grant # 5P30-AG024832. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AKPUNONU B, 1994, AM J MED SCI, V308, P244; [Anonymous], 1980, ANN INTERN MED, V93, P391; [Anonymous], 2013, DETAILS EXPANSION CO; [Anonymous], AM REV RESP DIS, P721; Borak J, 1996, Monaldi Arch Chest Dis, V51, P7; C. f. D. C. a. P. U. S. D. o. H. a. H. Services, 2011, BEH RISK FACT SURV U; Chaney JC, 2002, CHEST, V122, P1661, DOI 10.1378/chest.122.5.1661; Chapman KR, 2004, CLIN CHEST MED, V25, P331, DOI 10.1016/j.ccm.2004.01.003; Doherty DE, 2006, RESPIR CARE, V51, P519; Dransfield MT, 2006, RESP MED, V100, P1110, DOI 10.1016/j.rmed.2005.09.019; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; FLENLEY DC, 1981, LANCET, V1, P681; GOLD, 2011, GLOB STRAT DIAGN MAN; Guyatt GH, 2000, CHEST, V118, P1303, DOI 10.1378/chest.118.5.1303; Han MK, 2007, CHEST, V132, P403, DOI 10.1378/chest.06-2846; Hayton C, 2013, RESP MED, V107, P401, DOI 10.1016/j.rmed.2012.11.016; Johnston K, 2010, PHYSIOTHER CAN, V62, P368, DOI 10.3138/physio.62.4.368; Keating A, 2011, CHRON RESP DIS, V8, P89, DOI 10.1177/1479972310393756; Langhammer A, 2003, EUR RESPIR J, V21, P1017, DOI 10.1183/09031936.03.00053202; Mannino David M, 2007, Proc Am Thorac Soc, V4, P502, DOI 10.1513/pats.200701-001FM; MEDICARE HOME OXYGEN, 2011, REF PAYM METH HAS PO; MORRISON D, 1995, THORAX, V50, P1103, DOI 10.1136/thx.50.10.1103; Mularski RA, 2006, CHEST, V130, P1844, DOI 10.1378/chest.130.6.1844; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Oba Y, 2000, Respir Care, V45, P401; ODONOHUE WJ, 1995, CHEST, V107, P301, DOI 10.1378/chest.107.2.301; Prescott E, 1997, EUR RESPIR J, V10, P822; Ringbaek TJ, 2006, RESP MED, V100, P218, DOI 10.1016/j.rmed.2005.04.023; Ringbaek TJ, 2013, RESP MED; Strom K, 1993, Monaldi Arch Chest Dis, V48, P473; Suh DC, 2008, RESP CARE, V53, P1461; Wisely C, 2013, 5 THINGS PHYS PATIEN; XU X, 1994, EUR RESPIR J, V7, P477, DOI 10.1183/09031936.94.07030477; Zielinski J, 1998, CHEST, V113, P65, DOI 10.1378/chest.113.1.65	34	19	20	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 18	2015	10	3							e0120684	10.1371/journal.pone.0120684	http://dx.doi.org/10.1371/journal.pone.0120684			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE9BN	25785586	Green Published, gold, Green Submitted			2023-01-03	WOS:000352138500187
J	Henry, P				Henry, Patrick			In rotator cuff tears, primary tendon repair was better than physiotherapy for some measures of function at 5 years	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Henry, P (corresponding author), Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada.							Kuhn JE, 2013, J SHOULDER ELB SURG, V22, P1371, DOI 10.1016/j.jse.2013.01.026	1	0	0	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 17	2015	162	6							JC11	10.7326/ACPJC-2015-162-6-011	http://dx.doi.org/10.7326/ACPJC-2015-162-6-011			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CD7OH	25775342				2023-01-03	WOS:000351279600010
J	Lam, CS; Tipoe, GL; So, KF; Fung, ML				Lam, Chun-Sing; Tipoe, George Lim; So, Kwok-Fai; Fung, Man-Lung			Neuroprotective Mechanism of Lycium barbarum Polysaccharides against Hippocampal-Dependent Spatial Memory Deficits in a Rat Model of Obstructive Sleep Apnea	PLOS ONE			English	Article							RETINAL GANGLION-CELLS; ISCHEMIC BRAIN-INJURY; BCL-2 FAMILY-MEMBERS; INTERMITTENT HYPOXIA; OXIDATIVE STRESS; DNA-DAMAGE; APOPTOSIS; PROTECTS; DEATH; ACTIVATION	Chronic intermittent hypoxia (CIH) is a hallmark of obstructive sleep apnea (OSA), which induces hippocampal injuries mediated by oxidative stress. This study aims to examine the neuroprotective mechanism of Lycium barbarum polysaccharides (LBP) against CIH-induced spatial memory deficits. Adult Sprague-Dawley rats were exposed to hypoxic treatment resembling a severe OSA condition for a week. The animals were orally fed with LBP solution (1mg/kg) daily 2 hours prior to hypoxia or in air for the control. The effect of LBP on the spatial memory and levels of oxidative stress, inflammation, endoplasmic reticulum (ER) stress, apoptosis and neurogenesis in the hippocampus was examined. There was a significant deficit in the spatial memory and an elevated level of malondialdehyde with a decreased expression of antioxidant enzymes (SOD, GPx-1) in the hypoxic group when compared with the normoxic control. In addition, redox-sensitive nuclear factor kappa B (NF kappa B) canonical pathway was activated with a translocation of NF kappa B members (p65, p50) and increased expression levels of NF kappa B-dependent inflammatory cytokines and mediator (TNF alpha, IL-1 beta, COX-2); also, a significantly elevated level of ER stress (GRP78/Bip, PERK, CHOP) and autophagic flux in the hypoxic group, leading to neuronal apoptosis in hippocampal subfields (DG, CA1, CA3). Remarkably, LBP administration normalized the elevated level of oxidative stress, neuroinflammation, ER stress, autophagic flux and apoptosis induced by hypoxia. Moreover, LBP significantly mitigated both the caspase-dependent intrinsic (Bax, Bcl2, cytochrome C, cleaved caspase-3) and extrinsic (FADD, cleaved caspase-8, Bid) signaling apoptotic cascades. Furthermore, LBP administration prevented the spatial memory deficit and enhanced the hippocampal neurogenesis induced by hypoxia. Our results suggest that LBP is neuroprotective against CIH-induced hippocampal-dependent spatial memory deficits by promoting hippocampal neurogenesis and negatively modulating the apoptotic signaling cascades activated by oxidative stress and inflammation.	[Lam, Chun-Sing; Fung, Man-Lung] Univ Hong Kong, Dept Physiol, Hong Kong, Hong Kong, Peoples R China; [Tipoe, George Lim; So, Kwok-Fai] Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China; [So, Kwok-Fai] Univ Hong Kong, Dept Ophthalmol, Hong Kong, Hong Kong, Peoples R China; [Tipoe, George Lim; So, Kwok-Fai; Fung, Man-Lung] Univ Hong Kong, Li Ka Shing Fac Med, Res Ctr Heart Brain Hormone & Hlth Aging, Hong Kong, Hong Kong, Peoples R China; [So, Kwok-Fai] Univ Hong Kong, Li Ka Shing Fac Med, State Key Lab Brain & Cognit Sci, Hong Kong, Hong Kong, Peoples R China; [So, Kwok-Fai] Jinan Univ, Guangdong HongKong Macau Inst CNS Regenerat, Jinan, Guangdong, Peoples R China; [So, Kwok-Fai] Jinan Univ, Guangdong Key Lab Brain Funct & Dis, Guangzhou 510632, Guangdong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong; Jinan University; University of Jinan; Jinan University	Fung, ML (corresponding author), Univ Hong Kong, Dept Physiol, Hong Kong, Hong Kong, Peoples R China.	fungml@hku.hk		So, Kwok-Fai/0000-0003-4039-4246; George, Tipoe/0000-0002-2603-0625	HKU URC grants [SFPBR 201210159040, SFPBR 201311159037]	HKU URC grants	HKU URC grants: SFPBR 201210159040, SFPBR 201311159037. URL: http://www.rss.hku.hk/about-us/urc. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abarikwu SO, 2012, BASIC CLIN PHARMACOL, V110, P441, DOI 10.1111/j.1742-7843.2011.00834.x; Abdel-Wahab BA, 2012, PHYTOMEDICINE, V19, P444, DOI 10.1016/j.phymed.2011.11.011; Amagase H, 2009, NUTR RES, V29, P19, DOI 10.1016/j.nutres.2008.11.005; Bartley J, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-15; Bossenmeyer-Pourie C, 2002, NEUROSCIENCE, V114, P869, DOI 10.1016/S0306-4522(02)00324-X; Burckhardt IC, 2008, AM J RESP CRIT CARE, V177, P1135, DOI 10.1164/rccm.200701-110OC; Cai XH, 2010, ACTA NEUROBIOL EXP, V70, P279; Carpagnano GE, 2002, CHEST, V122, P1162, DOI 10.1378/chest.122.4.1162; Chan HC, 2007, EXP NEUROL, V203, P269, DOI 10.1016/j.expneurol.2006.05.031; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Chang NC, 2010, EMBO J, V29, P606, DOI 10.1038/emboj.2009.369; Chang RCC, 2008, CELL MOL NEUROBIOL, V28, P643, DOI 10.1007/s10571-007-9181-x; Chen WW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088076; Chipuk JE, 2008, P NATL ACAD SCI USA, V105, P20327, DOI 10.1073/pnas.0808036105; Chiu K, 2010, J CELL BIOCHEM, V110, P311, DOI 10.1002/jcb.22539; Chiu SC, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-29; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96; Gozal D, 2001, J NEUROSCI, V21, P2442, DOI 10.1523/JNEUROSCI.21-07-02442.2001; He MH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084800; Ho YS, 2010, J ALZHEIMERS DIS, V19, P813, DOI 10.3233/JAD-2010-1280; Ho YS, 2009, CELL MOL NEUROBIOL, V29, P1233, DOI 10.1007/s10571-009-9419-x; Hu XM, 2005, J NEUROCHEM, V93, P26, DOI 10.1111/j.1471-4159.2004.02968.x; Hu XM, 2003, INT J DEV NEUROSCI, V21, P371, DOI 10.1016/S0736-5748(03)00089-3; Hung MW, 2008, J PINEAL RES, V44, P214, DOI 10.1111/j.1600-079X.2007.00514.x; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Karmakar S, 2007, APOPTOSIS, V12, P671, DOI 10.1007/s10495-006-0024-x; Kirkland RA, 2010, J NEUROSCI, V30, P16114, DOI 10.1523/JNEUROSCI.2862-10.2010; Kokturk O, 2005, INT HEART J, V46, P801, DOI 10.1536/ihj.46.801; Konig HG, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-7; Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035; Lau BWM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033374; Li HY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068881; Li RC, 2003, AM J RESP CRIT CARE, V168, P469, DOI 10.1164/rccm.200211-1264OC; Li Z, 2004, BRAIN RES, V1021, P8, DOI 10.1016/j.brainres.2004.05.115; Lin NC, 2011, J AGR FOOD CHEM, V59, P10088, DOI 10.1021/jf2021754; Liu DX, 2014, PHARMACOL BIOCHEM BE, V116, P55, DOI 10.1016/j.pbb.2013.11.009; Lu SP, 2010, INT J BIOL MACROMOL, V47, P681, DOI 10.1016/j.ijbiomac.2010.08.016; Luo Q, 2006, LIFE SCI, V79, P613, DOI 10.1016/j.lfs.2006.02.012; Luo Q, 2014, J ETHNOPHARMACOL, V154, P249, DOI 10.1016/j.jep.2014.04.013; Martinou JC, 2011, DEV CELL, V21, P92, DOI 10.1016/j.devcel.2011.06.017; Miles DK, 2008, HIPPOCAMPUS, V18, P793, DOI 10.1002/hipo.20439; Morrell MJ, 2006, ADV EXP MED BIOL, V588, P75; Niu AJ, 2008, INT J BIOL MACROMOL, V42, P447, DOI 10.1016/j.ijbiomac.2008.02.003; Pack AI, 2006, AM J RESP CRIT CARE, V173, P7, DOI 10.1164/rccm.200509-1478OE; Pae EK, 2005, NEUROSCI LETT, V375, P123, DOI 10.1016/j.neulet.2004.10.091; Pei YH, 2007, APOPTOSIS, V12, P1681, DOI 10.1007/s10495-007-0091-7; Punjabi Naresh M, 2008, Proc Am Thorac Soc, V5, P136, DOI 10.1513/pats.200709-155MG; Row BW, 2003, AM J RESP CRIT CARE, V167, P1548, DOI 10.1164/rccm.200209-1050OC; Ryan S, 2006, AM J RESP CRIT CARE, V174, P824, DOI 10.1164/rccm.200601-066OC; Valencia A, 2004, FREE RADICAL BIO MED, V36, P1112, DOI 10.1016/j.freeradbiomed.2004.02.013; Veasey Sigrid C, 2012, Front Neurol, V3, P139, DOI 10.3389/fneur.2012.00139; Wang CC, 2009, FOOD CHEM, V116, P595, DOI 10.1016/j.foodchem.2009.03.015; Wang TF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090780; Aviles-Reyes RX, 2010, J NEUROCHEM, V112, P854, DOI 10.1111/j.1471-4159.2009.06535.x; Xiao J, 2013, NUTR DIABETES, V3, DOI 10.1038/nutd.2013.22; Xiao J, 2012, J ETHNOPHARMACOL, V139, P462, DOI 10.1016/j.jep.2011.11.033; Yamaguchi A, 2001, J BIOL CHEM, V276, P5256, DOI 10.1074/jbc.M008552200; Yang D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033596; Zhan GX, 2005, AM J RESP CRIT CARE, V171, P1414, DOI 10.1164/rccm.200411-1564OC; Zhang LL, 2013, AFR J TRADIT COMPLEM, V10, P494, DOI 10.4314/ajtcam.v10i6.18; Zhu Y, 2008, J NEUROSCI, V28, P2168, DOI 10.1523/JNEUROSCI.5232-07.2008	62	33	36	1	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2015	10	2							e0117990	10.1371/journal.pone.0117990	http://dx.doi.org/10.1371/journal.pone.0117990			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC2IM	25714473	Green Submitted, Green Published, gold			2023-01-03	WOS:000350168700047
J	Zhao, L; Feng, CH; Hou, CT; Hu, LY; Wang, QC; Wu, YF				Zhao, Lei; Feng, Chaohong; Hou, Caiting; Hu, Lingyun; Wang, Qiaochun; Wu, Yunfeng			First Discovery of Acetone Extract from Cottonseed Oil Sludge as a Novel Antiviral Agent against Plant Viruses	PLOS ONE			English	Article							TOBACCO-MOSAIC-VIRUS; BETA-SITOSTEROL; ANTIBACTERIAL ACTIVITY; CANCER CELLS; GOSSYPOL; DERIVATIVES; CHEMISTRY; APOPTOSIS; RATS; ROOT	A novel acetone extract from cottonseed oil sludge was firstly discovered against plant viruses including Tobacco mosaic virus (TMV), Rice stripe virus (RSV) and Southern rice black streaked dwarf virus (SRBSDV). Gossypol and beta-sitosterol separated from the acetone extract were tested for their effects on anti-TMV and analysed by nuclear magnetic resonance (NMR) assay. In vivo and field trials in different geographic distributions and different host varieties declared that this extract mixture was more efficient than the commercial agent Ningnanmycin with a broad spectrum of anti-plant-viruses activity. No phytotoxic activity was observed in the treated plants and environmental toxicology showed that this new acetone extract was environmentally friendly, indicating that this acetone extract has potential application in the control of plant virus in the future.	[Zhao, Lei; Hou, Caiting; Wu, Yunfeng] Northwest A&F Univ, Minist Educ, Coll Plant Protect,Minist Agr,Key Lab Plant Protec, State Key Lab Crop Stress Biol Arid Areas,Key Lab, Yangling, Shaanxi, Peoples R China; [Feng, Chaohong; Hu, Lingyun; Wang, Qiaochun] Northwest A&F Univ, Minist Educ, Coll Hort,Minist Agr,Key Lab Plant Protect Resourc, State Key Lab Crop Stress Biol Arid Areas,Key Lab, Yangling, Shaanxi, Peoples R China	Ministry of Agriculture & Rural Affairs; Northwest A&F University - China; Ministry of Agriculture & Rural Affairs; Northwest A&F University - China	Wu, YF (corresponding author), Northwest A&F Univ, Minist Educ, Coll Plant Protect,Minist Agr,Key Lab Plant Protec, State Key Lab Crop Stress Biol Arid Areas,Key Lab, Yangling, Shaanxi, Peoples R China.	qiaochunwang@nwsuaf.edu.cn; wuyf@nwsuaf.edu.cn			Special Fund for Agro-scientific Research in the Public Interest [200903052]; Education Ministry of China [B07049]	Special Fund for Agro-scientific Research in the Public Interest; Education Ministry of China(Ministry of Education, China)	The study was supported by the Special Fund for Agro-scientific Research in the Public Interest (No. 200903052) and the 111 Project from the Education Ministry of China (No. B07049). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	An T, 2012, ANTIVIR RES, V94, P276, DOI 10.1016/j.antiviral.2012.02.014; Awad AB, 2000, INT J MOL MED, V5, P541; Baskar AA, 2012, J MED FOOD, V15, P335, DOI 10.1089/jmf.2011.1780; Bauer JA, 2005, MOL CANCER THER, V4, P1096, DOI 10.1158/1535-7163.MCT-05-0081; Beltrame FL, 2002, BRAZ ARCH BIOL TECHN, V45, P21, DOI 10.1590/S1516-89132002000100004; Bouic PJD, 1996, INT J IMMUNOPHARMACO, V18, P693, DOI 10.1016/S0192-0561(97)85551-8; Cheng ZB, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-307; Chou CH, 1999, CRIT REV PLANT SCI, V18, P609, DOI 10.1016/S0735-2689(99)00393-7; Gebre-Mariam T, 2006, J ETHNOPHARMACOL, V104, P182, DOI 10.1016/j.jep.2005.08.071; GOODING GV, 1967, PHYTOPATHOLOGY, V57, P1285; Hari V, 1998, PLANT VIRUS DISEASE CONTROL, P417; Huang HungChang, 2005, Plant Pathology Bulletin, V14, P1; JANERO DR, 1988, BIOCHEM PHARMACOL, V37, P3335, DOI 10.1016/0006-2952(88)90647-8; Karen-Beth G, 2011, MOL PLANT PATHOL, V12, P938, DOI [10.1111/j.1364-3703.2011.00752.x, DOI 10.1111/J.1364-3703.2011.00752.X]; Keller PA, 2003, J MOL GRAPH MODEL, V21, P365, DOI 10.1016/S1093-3263(02)00183-3; Lall N, 2000, J ETHNOPHARMACOL, V72, P313, DOI 10.1016/S0378-8741(00)00231-2; Lin CW, 2005, ANTIVIR RES, V68, P36, DOI 10.1016/j.antiviral.2005.07.002; LIN TS, 1993, BIOCHEM PHARMACOL, V46, P251, DOI 10.1016/0006-2952(93)90411-O; Ouyang MA, 2007, J AGR FOOD CHEM, V55, P6460, DOI 10.1021/jf0709808; Park C, 2007, BIOL PHARM BULL, V30, P1317, DOI 10.1248/bpb.30.1317; Peres MTLP, 1997, J ETHNOPHARMACOL, V56, P223, DOI 10.1016/S0378-8741(97)00039-1; Prieto JM, 2006, B LATINOAM CARIBE PL, V5, P57; Qian XH, 2010, J AGR FOOD CHEM, V58, P2613, DOI 10.1021/jf904098w; Scholthof KBG, 2004, ANNU REV PHYTOPATHOL, V42, P13, DOI 10.1146/annurev.phyto.42.040803.140322; Seiber JN, 2011, J AGR FOOD CHEM, V59, P1, DOI 10.1021/jf1046078; SUGANO M, 1977, J NUTR, V107, P2011, DOI 10.1093/jn/107.11.2011; Vivancos M, 2005, FREE RADICAL BIO MED, V39, P91, DOI 10.1016/j.freeradbiomed.2005.02.025; Wang ZW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052933; Wei TY, 2009, J GEN VIROL, V90, P1025, DOI 10.1099/vir.0.006858-0; Yang JQ, 2010, J AGR FOOD CHEM, V58, P2730, DOI 10.1021/jf902861m; Yang J, 2012, BIOORG MED CHEM LETT, V22, P1415, DOI 10.1016/j.bmcl.2011.12.076; Yasuhara-Bell J, 2010, ANTIVIR RES, V86, P231, DOI 10.1016/j.antiviral.2010.03.009; Zak A, 1990, Cas Lek Cesk, V129, P1320	33	13	15	2	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 23	2015	10	2							e0117496	10.1371/journal.pone.0117496	http://dx.doi.org/10.1371/journal.pone.0117496			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC9BI	25705894	Green Published, Green Submitted, gold			2023-01-03	WOS:000350662100095
J	Lim, D; Condon, P; DeSteno, D				Lim, Daniel; Condon, Paul; DeSteno, David			Mindfulness and Compassion: An Examination of Mechanism and Scalability	PLOS ONE			English	Article							MEDITATION; EMOTION; ATTENTION; INCREASES; RESPONSES; GRATITUDE	Emerging evidence suggests that meditation engenders prosocial behaviors meant to benefit others. However, the robustness, underlying mechanisms, and potential scalability of such effects remain open to question. The current experiment employed an ecologically valid situation that exposed participants to a person in visible pain. Following three-week, mobile-app based training courses in mindfulness meditation or cognitive skills (i.e., an active control condition), participants arrived at a lab individually to complete purported measures of cognitive ability. Upon entering a public waiting area outside the lab that contained three chairs, participants seated themselves in the last remaining unoccupied chair; confederates occupied the other two. As the participant sat and waited, a third confederate using crutches and a large walking boot entered the waiting area while displaying discomfort. Compassionate responding was assessed by whether participants gave up their seat to allow the uncomfortable confederate to sit, thereby relieving her pain. Participants' levels of empathic accuracy was also assessed. As predicted, participants assigned to the mindfulness meditation condition gave up their seats more frequently than did those assigned to the active control group. In addition, empathic accuracy was not increased by mindfulness practice, suggesting that mindfulness-enhanced compassionate behavior does not stem from associated increases in the ability to decode the emotional experiences of others.	[Lim, Daniel; Condon, Paul; DeSteno, David] Northeastern Univ, Dept Psychol, Boston, MA 02115 USA	Northeastern University	DeSteno, D (corresponding author), Northeastern Univ, Dept Psychol, Boston, MA 02115 USA.	d.desteno@gmail.com	Lim, Daniel/Y-3206-2019		Headspace, Inc.	Headspace, Inc.	Headspace, Inc. provided the authors with free subscription accounts for participants so that participants would have free access to the web-based meditation sessions.	Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1111/1469-7610.00715; Bartlett MY, 2006, PSYCHOL SCI, V17, P319, DOI 10.1111/j.1467-9280.2006.01705.x; Cahn BR, 2006, PSYCHOL BULL, V132, P180, DOI 10.1037/0033-2909.132.2.180; Condon P, 2013, PSYCHOL SCI, V24, P2125, DOI 10.1177/0956797613485603; DARLEY JM, 1968, J PERS SOC PSYCHOL, V8, P377, DOI 10.1037/h0025589; Davidson RJ, 2010, EMOTION, V10, P8, DOI 10.1037/a0018480; DeSteno D, 2010, EMOTION, V10, P289, DOI 10.1037/a0017883; Ekman P, 1971, NEBRASKA S MOTIVATIO, V19, P207, DOI DOI 10.1037/0022-3514.53.4.712; Gethin R., 1998, FDN BUDDHISM; Holzel BK, 2011, PERSPECT PSYCHOL SCI, V6, P537, DOI 10.1177/1745691611419671; Holzel BK, 2011, PSYCHIAT RES-NEUROIM, V191, P36, DOI 10.1016/j.pscychresns.2010.08.006; Hofmann SG, 2010, J CONSULT CLIN PSYCH, V78, P169, DOI 10.1037/a0018555; Jacobs TL, 2011, PSYCHONEUROENDOCRINO, V36, P664, DOI 10.1016/j.psyneuen.2010.09.010; Klimecki OM, 2014, SOC COGN AFFECT NEUR, V9, P873, DOI 10.1093/scan/nst060; Leiberg S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017798; Lutz A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001897; Lutz A, 2008, TRENDS COGN SCI, V12, P163, DOI 10.1016/j.tics.2008.01.005; Lutz A, 2009, J NEUROSCI, V29, P13418, DOI 10.1523/JNEUROSCI.1614-09.2009; MacLean KA, 2010, PSYCHOL SCI, V21, P829, DOI 10.1177/0956797610371339; Mascaro JS, 2013, SOC COGN AFFECT NEUR, V8, P48, DOI 10.1093/scan/nss095; Scherer KR, 2011, J NONVERBAL BEHAV, V35, P305, DOI 10.1007/s10919-011-0115-4; Scherer KR, 2001, J CROSS CULT PSYCHOL, V32, P76, DOI 10.1177/0022022101032001009; Slagter HA, 2007, PLOS BIOL, V5, P1228, DOI 10.1371/journal.pbio.0050138; Vago DR, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00296; Weng HY, 2013, PSYCHOL SCI, V24, P1171, DOI 10.1177/0956797612469537	25	122	122	5	59	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 17	2015	10	2							e0118221	10.1371/journal.pone.0118221	http://dx.doi.org/10.1371/journal.pone.0118221			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CC4KQ	25689827	Green Published, gold, Green Submitted			2023-01-03	WOS:000350322700106
J	Karsch-Volk, M; Barrett, B; Linde, K				Karsch-Voelk, Marlies; Barrett, Bruce; Linde, Klaus			Echinacea for Preventing and Treating the Common Cold	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Karsch-Voelk, Marlies; Linde, Klaus] Tech Univ Munich, Klinikum Rechts Isar, Inst Gen Practice, D-81667 Munich, Germany; [Barrett, Bruce] Univ Wisconsin, Dept Family Med, Madison, WI 53706 USA	Technical University of Munich; University of Wisconsin System; University of Wisconsin Madison	Karsch-Volk, M (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Inst Gen Practice, Orleansstr 47, D-81667 Munich, Germany.	karsch@tum.de		Linde, Klaus/0000-0002-2902-970X	NCCIH NIH HHS [K24 AT006543] Funding Source: Medline; National Center for Complementary & Integrative Health [K24AT006543] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		[Anonymous], TREATM GUID UPP RESP; Barrett B, 2003, PHYTOMEDICINE, V10, P66, DOI 10.1078/094471103321648692; Karsch-Volk M, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000530.pub3; National Institute for Health and Care Excellence, CLIN KNOWL SUMM COMM; Pratter MR, 2006, CHEST, V129, p72S, DOI 10.1378/chest.129.1_suppl.72S	5	26	26	0	55	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	2015	313	6					618	619		10.1001/jama.2014.17145	http://dx.doi.org/10.1001/jama.2014.17145			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CA7AZ	25668266	Green Accepted			2023-01-03	WOS:000349070700022
J	Lenzer, J				Lenzer, Jeanne			Chief architect of Obamacare sparks furore over wish to "die at 75"	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												jeanne.lenzer@gmail.com						Emanuel EJ., 2014, ATLANTIC	1	0	0	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 19	2015	350								h292	10.1136/bmj.h292	http://dx.doi.org/10.1136/bmj.h292			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AZ7YY	25600164				2023-01-03	WOS:000348432800003
J	Bentler, SE; Morgan, RO; Virnig, BA; Wolinsky, FD				Bentler, Suzanne E.; Morgan, Robert O.; Virnig, Beth A.; Wolinsky, Fredric D.			The Association of Longitudinal and Interpersonal Continuity of Care with Emergency Department Use, Hospitalization, and Mortality among Medicare Beneficiaries	PLOS ONE			English	Article							HEALTH; PHYSICIAN; ACCESS; DIMENSION; OUTCOMES; MODEL	Background: Continuity of medical care is widely believed to lead to better health outcomes and service utilization patterns for patients. Most continuity studies, however, have only used administrative claims to assess longitudinal continuity with a provider. As a result, little is known about how interpersonal continuity (the patient's experience at the visit) relates to improved health outcomes and service use. Methods: We linked claims-based longitudinal continuity and survey-based self-reported interpersonal continuity indicators for 1,219 Medicare beneficiaries who completed the National Health and Health Services Use Questionnaire. With these linked data, we prospectively evaluated the effect of both types of continuity of care indicators on emergency department use, hospitalization, and mortality over a five-year period. Results: Patient-reported continuity was associated with reduced emergency department use, preventable hospitalization, and mortality. Most of the claims-based measures, including those most frequently used to assess continuity, were not associated with reduced utilization or mortality. Conclusion: Our results indicate that the patient-and claims-based indicators of continuity have very different effects on these important health outcomes, suggesting that reform efforts must include the patient-provider experience when evaluating health care quality.	[Bentler, Suzanne E.] Univ Iowa, Publ Policy Ctr, Iowa City, IA 52242 USA; [Morgan, Robert O.] Univ Texas Houston, Sch Publ Hlth, Div Management Policy & Community Hlth, Houston, TX 77030 USA; [Virnig, Beth A.] Univ Minnesota, Sch Publ Hlth, Div Hlth Serv Res & Policy, Minneapolis, MN 55455 USA; [Wolinsky, Fredric D.] Univ Iowa, Coll Publ Hlth, Dept Hlth Management & Policy, Iowa City, IA 52246 USA	University of Iowa; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Minnesota System; University of Minnesota Twin Cities; University of Iowa	Bentler, SE (corresponding author), Univ Iowa, Publ Policy Ctr, 217 South Quad, Iowa City, IA 52242 USA.	suzanne-bentler@uiowa.edu	Wolinsky, Fredric D/F-9231-2011	Wolinsky, Fredric/0000-0002-0916-4955	Alvin R. Tarlov & John E. Ware Jr. Doctoral Dissertation Award; University of Iowa John W. Colloton Chair awarded	Alvin R. Tarlov & John E. Ware Jr. Doctoral Dissertation Award; University of Iowa John W. Colloton Chair awarded	This work was supported by an Alvin R. Tarlov & John E. Ware Jr. Doctoral Dissertation Award (http://www.hal-health.org/awards.htm#tarlov) awarded to SB and funds from the University of Iowa John W. Colloton Chair awarded to FW. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	*AG HEALTHC RES QU, 2011, AHRQ QUAL IND VERS 4; *AM MED ASS, 2003, CURR PROC TERM 2004; Andersen R. M., 1968, THESIS; ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; ASPER F, 2007, RESDAC PUB, V9; Austin PC, 2010, J CLIN EPIDEMIOL, V63, P46, DOI 10.1016/j.jclinepi.2009.03.012; BENSIRA Z, 1980, J HEALTH SOC BEHAV, V21, P170, DOI 10.2307/2136736; Bentler SE, 2014, MED CARE RES REV, V71, P156, DOI 10.1177/1077558713505909; Bentler SE, 2014, QUAL LIFE RES, V23, P185, DOI 10.1007/s11136-013-0472-z; BICE TW, 1977, MED CARE, V15, P347, DOI 10.1097/00005650-197704000-00010; BINDMAN AB, 1995, JAMA-J AM MED ASSOC, V274, P305, DOI 10.1001/jama.274.4.305; Boyer CA, 2010, J HEALTH SOC BEHAV, V51, pS80, DOI 10.1177/0022146510383489; BRESLAU N, 1975, J MED EDUC, V50, P965; Cabana MD, 2004, J FAM PRACTICE, V53, P974; EJLERTSSON G, 1984, MED CARE, V22, P231, DOI 10.1097/00005650-198403000-00006; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; ERIKSSON EA, 1983, MED CARE, V21, P858, DOI 10.1097/00005650-198309000-00003; Freeman GK, 2003, FAM PRACT, V20, P623, DOI 10.1093/fampra/cmg601; GINSBURG PB, 2008, POLICY PERSPECTIVE, V1; Gruneir A, 2011, MED CARE RES REV, V68, P131, DOI 10.1177/1077558710379422; Gulliford MC, 2006, ANN FAM MED, V4, P548, DOI 10.1370/afm.578; Gupta R, 2013, JAMA INTERN MED, V173, P1885, DOI 10.1001/jamainternmed.2013.7341; Haggerty JL, 2003, BRIT MED J, V327, P1219, DOI 10.1136/bmj.327.7425.1219; Institute of Medicine (IOM), 2003, PRIOR AR NAT ACT TRA; *IOM, 1996, PRIM CAR AM HLTH NEW; Jee SH, 2006, MED CARE RES REV, V63, P158, DOI 10.1177/1077558705285294; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Kalbfleisch J.D., 2002, STAT ANAL FAILURE TI; Leleu H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071669; MAGILL MK, 1987, J FAM PRACTICE, V24, P165; Mainous AG, 1998, AM J PUBLIC HEALTH, V88, P1539, DOI 10.2105/AJPH.88.10.1539; *MEDPAC, 2005, REPORT TO THE CONGRE, P83; Morgan RO, 2008, J AM GERIATR SOC, V56, P2053, DOI 10.1111/j.1532-5415.2008.01993.x; Nutting Paul A, 2003, Ann Fam Med, V1, P149, DOI 10.1370/afm.63; Nyweide DJ, 2013, JAMA INTERN MED, V173, P1879, DOI 10.1001/jamainternmed.2013.10059; Pandhi N, 2007, FAM MED, V39, P266; Parchman ML, 2002, MED CARE, V40, P137, DOI 10.1097/00005650-200202000-00008; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Rodriguez HP, 2008, J GEN INTERN MED, V23, P1499, DOI 10.1007/s11606-008-0692-z; Saultz John W, 2003, Ann Fam Med, V1, P134, DOI 10.1370/afm.23; Saultz JW, 2005, ANN FAM MED, V3, P159, DOI 10.1370/afm.285; SMEDBY O, 1986, MED CARE, V24, P511; Starfield B, 2005, MILBANK Q, V83, P457, DOI 10.1111/j.1468-0009.2005.00409.x; STEINWACHS DM, 1979, MED CARE, V17, P551, DOI 10.1097/00005650-197906000-00001; Sturmberg J P, 2001, Aust Fam Physician, V30, P513; Sturmberg JP, 2002, FAM PRACT, V19, P85, DOI 10.1093/fampra/19.1.85; Uijen AA, 2011, J CLIN EPIDEMIOL, V64, P1391, DOI 10.1016/j.jclinepi.2011.03.006; van Walraven C, 2010, J EVAL CLIN PRACT, V16, P947, DOI 10.1111/j.1365-2753.2009.01235.x; Ware JE, 2001, CORE INTERPRET SINGL; Wolinsky FD, 2007, J GERONTOL B-PSYCHOL, V62, pS160, DOI 10.1093/geronb/62.3.S160; Wolinsky FD, 2010, J GERONTOL A-BIOL, V65, P421, DOI 10.1093/gerona/glp188; [No title captured]; [No title captured]	53	27	27	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 22	2014	9	12							e115088	10.1371/journal.pone.0115088	http://dx.doi.org/10.1371/journal.pone.0115088			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CA3ZY	25531108	gold, Green Published			2023-01-03	WOS:000348845100036
J	Jiang, LB; Jiang, SY; Zhang, M; Zheng, ZJ; Ma, YF				Jiang, Libing; Jiang, Shouyin; Zhang, Mao; Zheng, Zhongjun; Ma, Yuefeng			Albumin versus Other Fluids for Fluid Resuscitation in Patients with Sepsis: A Meta-Analysis	PLOS ONE			English	Article							CRITICALLY-ILL PATIENTS; EXTRAVASCULAR LUNG WATER; ACUTE KIDNEY INJURY; HYDROXYETHYL STARCH; SEVERE MALARIA; PULMONARY PERMEABILITY; CAPILLARY LEAKAGE; INFORMATION SIZE; VOLUME EXPANSION; ORGAN FUNCTION	Background: Early fluid resuscitation is vital to patients with sepsis. However, the choice of fluid has been a hot topic of discussion. The objective of this study was to evaluate whether the use of albumin-containing fluids for resuscitation in patients with sepsis was associated with a decreased mortality rate. Methods: We systematically searched PubMed, EMBASE and Cochrane library for eligible randomized controlled trials (RCTs) up to March 2014. The selection of eligible studies, assessment of methodological quality, and extraction of all relevant data were conducted by two authors independently. Results: In total, 15 RCTs were eligible for analysis. After pooling the data, we found there was no significant effect of albumin-containing fluids on mortality in patients with sepsis of any severity (RR: 0.94, 95% CI: 0.87, 1.02 and RD: -0.01, 95% CI: -0.03, 0.01). The results were robust to subgroup analyses, sensitivity analyses and trial sequential analyses. Conclusion: The present meta-analysis did not demonstrate significant advantage of using albumin-containing fluids for resuscitation in patients with sepsis of any severity. Given the cost-effectiveness of using albumin, crystalloids should be the first choice for fluid resuscitation in septic patients.	[Zhang, Mao] Zhejiang Univ, Dept Emergency Med, Sch Med, Affiliated Hosp 2, Hangzhou 310003, Zhejiang, Peoples R China; Zhejiang Univ, Inst Emergency Med, Hangzhou 310003, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University	Zhang, M (corresponding author), Zhejiang Univ, Dept Emergency Med, Sch Med, Affiliated Hosp 2, Hangzhou 310003, Zhejiang, Peoples R China.	zmhzjzk@163.com; mayuefengbj@163.com	ma, yue/GXE-9897-2022					Akech S, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010021; Angus DC, 2013, NEW ENGL J MED, V369, P2063, DOI 10.1056/NEJMc1312359; Annane D, 2013, JAMA-J AM MED ASSOC, V310, P1809, DOI 10.1001/jama.2013.280502; [Anonymous], CRIT CARE MED; Boyd JH, 2011, CRIT CARE MED, V39, P259, DOI 10.1097/CCM.0b013e3181feeb15; Brok J, 2008, J CLIN EPIDEMIOL, V61, P763, DOI 10.1016/j.jclinepi.2007.10.007; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Caironi P, 2014, NEW ENGL J MED, V370, P1412, DOI 10.1056/NEJMoa1305727; Chou CD, 2009, J CHIN MED ASSOC, V72, P243, DOI 10.1016/S1726-4901(09)70064-4; Delaney AP, 2011, CRIT CARE MED, V39, P386, DOI 10.1097/CCM.0b013e3181ffe217; Dellinger R. P., 2013, INTENS CARE MED, V41, P580, DOI [DOI 10.1007/s00134-012-2769-8, 10.1007/s00134-012-2769-8]; Dellinger RP, 2013, INTENS CARE MED, V41, P580, DOI DOI 10.1007/s00134-012-2769-8; Dolecek M, 2009, HEPATO-GASTROENTEROL, V56, P1622; Dombrovskiy VY, 2007, CRIT CARE MED, V35, P1244, DOI 10.1097/01.CCM.0000261890.41311.E9; Dubois MJ, 2006, CRIT CARE MED, V34, P2536, DOI 10.1097/01.CCM.0000239119.57544.0C; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; Finfer S, 2013, CURR OPIN CRIT CARE, V19, P315, DOI 10.1097/MCC.0b013e3283632e42; Finfer S, 2011, INTENS CARE MED, V37, P86, DOI 10.1007/s00134-010-2039-6; Friedman G, 2008, J CLIN ANESTH, V20, P528, DOI 10.1016/j.jclinane.2008.05.022; Haase N, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f839; Hayashino Y, 2005, J EPIDEMIOL, V15, P235, DOI 10.2188/jea.15.235; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Karakala N, 2013, CURR OPIN CRIT CARE, V19, P537, DOI 10.1097/MCC.0000000000000028; Latour-Perez J, 2013, CRIT CARE MED, V41, pE289, DOI 10.1097/CCM.0b013e31828ced28; Lyu PF, 2014, CURR OPIN CRIT CARE, V20, P402, DOI 10.1097/MCC.0000000000000117; Maitland K, 2005, CLIN INFECT DIS, V40, P538, DOI 10.1086/427505; Maitland K, 2005, BRIT J HAEMATOL, V128, P393, DOI 10.1111/j.1365-2141.2004.05312.x; Maitland K, 2004, ACTA TROP, V90, P131, DOI 10.1016/j.actatropica.2003.11.010; Maitland K, 2011, NEW ENGL J MED, V364, P2483, DOI 10.1056/NEJMoa1101549; Margarido CB, 2007, SHOCK, V27, P390, DOI 10.1097/01.shk.0000245026.01365.55; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; Martin GS, 2005, CRIT CARE, V9, pR74, DOI 10.1186/cc3025; Marx G, 2004, SHOCK, V21, P336, DOI 10.1097/00024382-200404000-00008; Marx G, 2006, CRIT CARE MED, V34, P3005, DOI 10.1097/01.CCM.0000242755.74063.ED; METILDI LA, 1984, SURG GYNECOL OBSTET, V158, P207; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Murphy CV, 2009, CHEST, V136, P102, DOI 10.1378/chest.08-2706; Ospina-Tascon G, 2010, INTENS CARE MED, V36, P949, DOI 10.1007/s00134-010-1843-3; Palumbo D, 2006, MINERVA ANESTESIOL, V72, P655; Pandey NR, 2014, WORLD J EMERG MED, V5, P42, DOI [10.5847/wjem.j.1920-8642.2014.01.007, 10.5847/wjem.j.issn.1920-8642.2014.01.007]; Perner A, 2012, NEW ENGL J MED, V367, P124, DOI 10.1056/NEJMoa1204242; RACKOW EC, 1983, CRIT CARE MED, V11, P839, DOI 10.1097/00003246-198311000-00001; RACKOW EC, 1989, CRIT CARE MED, V17, P394, DOI 10.1097/00003246-198905000-00003; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Roberts I, 1998, BMJ-BRIT MED J, V317, P235; Schulz KF, 2010, BMJ-BRIT MED J, V340, DOI [10.1136/bmj.c332, 10.1186/1741-7015-8-18]; Trof RJ, 2010, INTENS CARE MED, V36, P697, DOI 10.1007/s00134-010-1776-x; Uhlig C, 2014, CRIT CARE, V18, DOI 10.1186/cc13187; van der Heijden M, 2009, CRIT CARE MED, V37, P1275, DOI 10.1097/CCM.0b013e31819cedfd; Veneman TF, 2004, WIEN KLIN WOCHENSCHR, V116, P305, DOI 10.1007/BF03040900; Verheij J, 2006, BRIT J ANAESTH, V96, P21, DOI 10.1093/bja/aei286; Vincent JL, 2011, MINERVA ANESTESIOL, V77, P1190; Vincent Jean-Louis, 2004, Crit Care Med, V32, pS451, DOI 10.1097/01.CCM.0000142984.44321.A4; Vincent JL, 2004, CRIT CARE MED, V32, P2029, DOI 10.1097/01.CCM.0000142574.00425.E9; Vincent JL, 2003, ANN SURG, V237, P319, DOI 10.1097/00000658-200303000-00005; Wetterslev J, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-86; Wiedermann CJ, 2010, CRIT CARE, V14, DOI 10.1186/cc9308; Zampieri FG, 2013, SHOCK, V39, P42, DOI 10.1097/SHK.0b013e31828faf82; Zarychanski R, 2013, JAMA-J AM MED ASSOC, V309, P678, DOI 10.1001/jama.2013.430; [郑岩 Zheng Yan], 2013, [中国急救医学, Chinese Journal of Critical Care Medicine], V33, P101; [No title captured]	62	27	30	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 4	2014	9	12							e114666	10.1371/journal.pone.0114666	http://dx.doi.org/10.1371/journal.pone.0114666			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AW6MB	25474401	Green Submitted, gold, Green Published			2023-01-03	WOS:000346382500053
J	Wan, WB; Cao, L; Liu, LM; Kalionis, B; Chen, C; Tai, XT; Li, YM; Xia, SJ				Wan, Wen-bin; Cao, Lan; Liu, Lu-mei; Kalionis, Bill; Chen, Chuan; Tai, Xian-tao; Li, Ya-ming; Xia, Shi-jin			EGb761 Provides a Protective Effect against A beta(1-42) Oligomer-Induced Cell Damage and Blood-Brain Barrier Disruption in an In Vitro bEnd.3 Endothelial Model	PLOS ONE			English	Article							GLYCATION END-PRODUCTS; AMYLOID-BETA PEPTIDE; GINKGO-BILOBA; TIGHT JUNCTIONS; MOUSE MODEL; EXPRESSION; RAGE; RECEPTOR; ASTROCYTES; DEPOSITION	Alzheimer's disease (AD) is the most common form of senile dementia which is characterized by abnormal amyloid beta (A beta) accumulation and deposition in brain parenchyma and cerebral capillaries, and leads to blood-brain barrier (BBB) disruption. Despite great progress in understanding the etiology of AD, the underlying pathogenic mechanism of BBB damage is still unclear, and no effective treatment has been devised. The standard Ginkgo biloba extract EGb761 has been widely used as a potential cognitive enhancer for the treatment of AD. However, the cellular mechanism underlying the effect remain to be clarified. In this study, we employed an immortalized endothelial cell line (bEnd.3) and incubation of A beta(1-42) oligomer, to mimic a monolayer BBB model under conditions found in the AD brain. We investigated the effect of EGb761 on BBB and found that A beta(1-42) oligomer-induced cell injury, apoptosis, and generation of intracellular reactive oxygen species (ROS), were attenuated by treatment with EGb761. Moreover, treatment of the cells with EGb761 decreased BBB permeability and increased tight junction scaffold protein levels including ZO-1, Claudin-5 and Occludin. We also found that the A beta(1-42) oligomer-induced upregulation of the receptor for advanced glycation end-products (RAGE), which mediates Ab cytotoxicity and plays an essential role in AD progression, was significantly decreased by treatment with EGb761. To our knowledge, we provide the first direct in vitro evidence of an effect of EGb761 on the brain endothelium exposed to A beta(1-42) oligomer, and on the expression of tight junction (TJ) scaffold proteins and RAGE. Our results provide a new insight into a possible mechanism of action of EGb761. This study provides a rational basis for the therapeutic application of EGb761 in the treatment of AD.	[Wan, Wen-bin] Fudan Univ, Zhongshan Hosp, Dept Neurol, Shanghai 200433, Peoples R China; [Cao, Lan] Fudan Univ, Sch Basic Med Sci, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China; [Liu, Lu-mei; Li, Ya-ming] Fudan Univ, Huadong Hosp, Geriatr Dept Tradit Chinese Med, Shanghai 200433, Peoples R China; [Kalionis, Bill] Pregnancy Res Ctr, Dept Perinatal Med, Parkville, Vic, Australia; [Kalionis, Bill] Univ Melbourne, Royal Womens Hosp, Dept Obstet & Gynaecol, Parkville, Vic 3052, Australia; [Chen, Chuan] Shanghai Geriatr Inst Chinese Med, Shanghai, Peoples R China; [Tai, Xian-tao] Yunnan Univ Tradit Chinese Med, Sch Acupuncture Massage & Rehabil, Kunming, Peoples R China; [Xia, Shi-jin] Fudan Univ, Huadong Hosp, Shanghai Inst Geriatr, Shanghai 200433, Peoples R China	Fudan University; Fudan University; Fudan University; University of Melbourne; Yunnan University of Chinese Medicine; Fudan University	Li, YM (corresponding author), Fudan Univ, Huadong Hosp, Geriatr Dept Tradit Chinese Med, Shanghai 200433, Peoples R China.	doctorymli@163.com; xiashijinhd@163.com	KALIONIS, BILL/B-4766-2011		National Natural Science Foundation of China [81473739, 31171129, 81460748]; Shanghai Committee of Science and Technology, China [12401904500]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Committee of Science and Technology, China(Shanghai Science & Technology Committee)	The authors gratefully acknowledge the financial support of this study by National Natural Science Foundation of China (Grant No. 81473739), and Shanghai Committee of Science and Technology, China (Grant No. 12401904500), YML received the funding, (http://www.nsfc.gov.cn/) and (http://www.stcsm.gov.cn/), respectively; by National Natural Science Foundation of China (Grant No. 31171129, Grant No. 81460748), SJX received the funding, (http://www.nsfc.gov.cn/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bednarczyk J, 2011, ACTA NEUROBIOL EXP, V71, P393; Biron KE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023789; Carrano A, 2011, ANTIOXID REDOX SIGN, V15, P1167, DOI 10.1089/ars.2011.3895; Chen X, 2012, NEUROSCIENCE, V226, P89, DOI 10.1016/j.neuroscience.2012.08.043; Chen Y, 2012, PLANTA MED, V78, P1337, DOI 10.1055/s-0032-1314965; Choi BR, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2013.147; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; Deane R, 2009, CNS NEUROL DISORD-DR, V8, P16, DOI 10.2174/187152709787601867; Deane R, 2003, NAT MED, V9, P907, DOI 10.1038/nm890; Deane R, 2007, CURR ALZHEIMER RES, V4, P191, DOI 10.2174/156720507780362245; Deane R, 2012, J CLIN INVEST, V122, P1377, DOI 10.1172/JCI58642; Deane RJ, 2012, FUTURE MED CHEM, V4, P915, DOI [10.4155/FMC.12.51, 10.4155/fmc.12.51]; Evans JR, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001775.pub2; Gonzalez-Mariscal L, 2011, ANTIOXID REDOX SIGN, V15, P1235, DOI 10.1089/ars.2011.3913; Han SH, 2011, MOL CELLS, V31, P91, DOI 10.1007/s10059-011-0030-x; Jahanshahi M, 2012, ANAT CELL BIOL, V45, P92, DOI 10.5115/acb.2012.45.2.92; Kehr J, 2012, INT PSYCHOGERIATR, V24, pS25, DOI 10.1017/S1041610212000567; Kis B, 2001, NEUROREPORT, V12, P4139, DOI 10.1097/00001756-200112210-00055; Kook SY, 2013, TISSUE BARRIERS, V1, DOI 10.4161/tisb.23993; Kook SY, 2012, J NEUROSCI, V32, P8845, DOI 10.1523/JNEUROSCI.6102-11.2012; Li B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022920; Liu WY, 2012, CNS NEUROSCI THER, V18, P609, DOI 10.1111/j.1755-5949.2012.00340.x; Love S, 2009, FRONT BIOSCI-LANDMRK, V14, P4778, DOI 10.2741/3567; Marco S, 2006, NEUROSCI LETT, V401, P219, DOI 10.1016/j.neulet.2006.03.047; Mashayekh A, 2011, NEURORADIOLOGY, V53, P185, DOI 10.1007/s00234-010-0790-6; Meyer-Luehmann M, 2008, NATURE, V451, P720, DOI 10.1038/nature06616; Muller WE, 2012, INT PSYCHOGERIATR, V24, pS21, DOI 10.1017/S1041610212000592; Nakagawa S, 2007, CELL MOL NEUROBIOL, V27, P687, DOI 10.1007/s10571-007-9195-4; Paul J, 2007, J EXP MED, V204, P1999, DOI 10.1084/jem.20070304; Perrone Lorena, 2012, Int J Alzheimers Dis, V2012, P734956, DOI 10.1155/2012/734956; Pomara N, 2010, NEW ENGL J MED, V362, P1844, DOI 10.1056/NEJMc1002323; Ramasamy R, 2012, AMINO ACIDS, V42, P1151, DOI 10.1007/s00726-010-0773-2; Silverberg GD, 2010, J NEUROPATH EXP NEUR, V69, P98, DOI 10.1097/NEN.0b013e3181c8ad2f; Slowik A, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-55; Wan WB, 2014, INT J NEUROSCI, V124, P75, DOI 10.3109/00207454.2013.825258; Weinmann S, 2010, BMC GERIATR, V10, DOI 10.1186/1471-2318-10-14; Xiao QA, 2010, EUR J PHARMACOL, V647, P48, DOI 10.1016/j.ejphar.2010.08.002; Yan FL, 2008, ACTA NEUROPATHOL, V116, P529, DOI 10.1007/s00401-008-0435-6; Yan SD, 2000, BBA-MOL BASIS DIS, V1502, P145, DOI 10.1016/S0925-4439(00)00041-7; Zehendner CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082823; Zhang CY, 2013, BIOL TRACE ELEM RES, V153, P229, DOI 10.1007/s12011-013-9645-4; Zhou T, 2014, BIOCHEM BIOPH RES CO, V445, P352, DOI 10.1016/j.bbrc.2014.01.194	42	34	39	2	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 26	2014	9	11							e113126	10.1371/journal.pone.0113126	http://dx.doi.org/10.1371/journal.pone.0113126			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA8CZ	25426944	Green Published, gold			2023-01-03	WOS:000349145400034
J	Frisch, S				Frisch, Suzy			Medical cannabis: US researchers battle for access to the plant	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												suzyfrisch@yahoo.com						Abrams DI, 2007, CLIN PHARMACOL THER, V82, P572, DOI 10.1038/sj.clpt.6100200; Aggarwal Sunil K, 2009, J Opioid Manag, V5, P153; Borgelt LM, 2013, PHARMACOTHERAPY, V33, P195, DOI 10.1002/phar.1187; Charuvastra A, 2005, J ADDICT DIS, V24, P87, DOI 10.1300/J069v24n03_07; Drug Enforcement Administration, 2011, DEA POS MAR; Drug Enforcement Administration, DRUG SCHED; Drug Policy Alliance, DEA 4 DEC IMP REJ SC; FRISCH S, MED CANNABIS US RES; Grant I, 2010, REPORT LEGISLATURE G; Hotakeinen R, 2014, FEDS ACCUSED STEERIN; ProCon, 2014, SUMM CHART 23 STAT D; ProConorg, 2014, NUMB LEG MED MAR PAT; Rappold RS, 2014, WEBMD HLTH NEWS 0402	13	2	2	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 21	2014	349								g6997	10.1136/bmj.g6997	http://dx.doi.org/10.1136/bmj.g6997			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AU2KB	25416312				2023-01-03	WOS:000345446000003
J	Mayer, KH				Mayer, Kenneth H.			Advancing HIV prevention science: the roads from Cape Town	LANCET			English	Editorial Material							ANTIRETROVIRAL PROPHYLAXIS; PREEXPOSURE PROPHYLAXIS; INFECTION; THAILAND; TRIAL; WOMEN; MEN		Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Fenway Hlth, Boston, MA 02215 USA	Fenway Health; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Mayer, KH (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Fenway Hlth, Boston, MA 02215 USA.	khmayer@gmail.com			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI060354] Funding Source: NIH RePORTER; NIAID NIH HHS [P30 AI060354] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 2013, UNAIDS REP GLOB AIDS; Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524; Beyrer C, 2013, AIDS, V27, P2665, DOI 10.1097/01.aids.0000432449.30239.fe; Choopanya K, 2013, LANCET, V381, P2083, DOI 10.1016/S0140-6736(13)61127-7; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Graham BS, 2014, HIV RES PREV 2014 OC; Grant RM, 2014, LANCET INFECT DIS, V14, P820, DOI 10.1016/S1473-3099(14)70847-3; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425; Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748; Marrazzo JM, 2013, 20 C RETR OPP INF CR; Mensch BS, 2014, AIDS RES HUM RETROV, V30, pA252; PROUD study, 2014, PROUD STUD INT AN FI; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; Tanser F, 2014, HIV RES PREV 2014 OC; Thigpen MC, 2013, NEW ENGL J MED, V368, P82, DOI 10.1056/NEJMc1210464; Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711; Young B, 2014, CLIN INFECT DIS, V59, pS1, DOI 10.1093/cid/ciu298	18	0	0	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 15	2014	384	9956					1725	1727		10.1016/S0140-6736(14)62036-5	http://dx.doi.org/10.1016/S0140-6736(14)62036-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AT7KX	25455236	Green Accepted			2023-01-03	WOS:000345116400006
J	Liu, H; Liang, JP; Li, PB; Peng, W; Peng, YY; Zhang, GM; Xie, CS; Long, CF; Su, WW				Liu, Hong; Liang, Jie-ping; Li, Pei-bo; Peng, Wei; Peng, Yao-yao; Zhang, Gao-min; Xie, Cheng-shi; Long, Chao-feng; Su, Wei-wei			Core Bioactive Components Promoting Blood Circulation in the Traditional Chinese Medicine Compound Xueshuantong Capsule (CXC) Based on the Relevance Analysis between Chemical HPLC Fingerprint and In Vivo Biological Effects	PLOS ONE			English	Article							GREY RELATIONAL ANALYSIS; GINSENOSIDE-RD; CELLS; COAGULATION; RECEPTOR; FLOW	Compound xueshuantong capsule (CXC) is an oral traditional Chinese herbal formula (CHF) comprised of Panax notoginseng (PN), Radix astragali (RA), Salvia miltiorrhizae (SM), and Radix scrophulariaceae (RS). The present investigation was designed to explore the core bioactive components promoting blood circulation in CXC using high-performance liquid chromatography (HPLC) and animal studies. CXC samples were prepared with different proportions of the 4 herbs according to a four-factor, nine-level uniform design. CXC samples were assessed with HPLC, which identified 21 components. For the animal experiments, rats were soaked in ice water during the time interval between two adrenaline hydrochloride injections to reduce blood circulation. We assessed whole-blood viscosity (WBV), erythrocyte aggregation and red corpuscle electrophoresis indices (EAI and RCEI, respectively), plasma viscosity (PV), maximum platelet aggregation rate (MPAR), activated partial thromboplastin time (APTT), and prothrombin time (PT). Based on the hypothesis that CXC sample effects varied with differences in components, we performed grey relational analysis (GRA), principal component analysis (PCA), ridge regression (RR), and radial basis function (RBF) to evaluate the contribution of each identified component. Our results indicate that panaxytriol, ginsenoside Rb1, angoroside C, protocatechualdehyde, ginsenoside Rd, and calycosin-7-O-beta-D-glucoside are the core bioactive components, and that they might play different roles in the alleviation of circulation dysfunction. Panaxytriol and ginsenoside Rb1 had close relevance to red blood cell (RBC) aggregation, angoroside C was related to platelet aggregation, protocatechualdehyde was involved in intrinsic clotting activity, ginsenoside Rd affected RBC deformability and plasma proteins, and calycosin-7-O-beta-D-glucoside influenced extrinsic clotting activity. This study indicates that angoroside C, calycosin-7-O-beta-D-glucoside, panaxytriol, and protocatechualdehyde may have novel therapeutic uses.	[Liu, Hong; Liang, Jie-ping; Li, Pei-bo; Peng, Wei; Peng, Yao-yao; Zhang, Gao-min; Su, Wei-wei] Sun Yat Sen Univ, Sch Life Sci, Guangdong Key Lab Plant Resources, Guangzhou Qual R&D Ctr Tradit Chinese Med, Guangzhou 510275, Guangdong, Peoples R China; [Xie, Cheng-shi; Long, Chao-feng] Guangdong Zhongsheng Pharmaceut Co Ltd, Dongguan, Peoples R China	Sun Yat Sen University	Su, WW (corresponding author), Sun Yat Sen Univ, Sch Life Sci, Guangdong Key Lab Plant Resources, Guangzhou Qual R&D Ctr Tradit Chinese Med, Guangzhou 510275, Guangdong, Peoples R China.	lsssww@126.com	su, wei/GZM-3986-2022	Liu, Hong/0000-0002-7320-0260	National Science and Technology Major Projects of Significant Drug Discovery of China [2011ZX09201-201-22]; Science and Technology Project for Medical and Health Units of Dongguan city [2012105102004]	National Science and Technology Major Projects of Significant Drug Discovery of China; Science and Technology Project for Medical and Health Units of Dongguan city	This work is financially supported by the National Science and Technology Major Projects of Significant Drug Discovery of China (No 2011ZX09201-201-22), and Science and Technology Project for Medical and Health Units of Dongguan city (No 2012105102004). Guangdong Zhongsheng Pharmaceutical Co., Ltd., provided support in the form of the supply of 4 herbs (PN, RA, SM, and RS), but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bajaj SP, 1999, SEMIN THROMB HEMOST, V25, P407, DOI 10.1055/s-2007-994943; Bensky D, 2004, CHINESE HERBAL MED M, P265; Chen Q., 2006, TRADITIONAL CHINESE; Chiu CC, 2002, COMPUT METH PROG BIO, V69, P1, DOI 10.1016/S0169-2607(01)00181-X; Diaz AM, 2004, LIFE SCI, V74, P2515, DOI 10.1016/j.lfs.2003.10.008; Fan Y, 2003, EUR J PHARMACOL, V481, P33, DOI 10.1016/j.ejphar.2003.09.007; GACHET C, 1991, NOUV REV FR HEMATOL, V33, P347; Guan YY, 2006, EUR J PHARMACOL, V548, P129, DOI 10.1016/j.ejphar.2006.08.001; He F Y, 2004, WORLD SCI TECHNOL MO, V6, P44; He XQ, 2011, APPL REGRESSION ANAL, P169; Kamal AH, 2007, MAYO CLIN PROC, V82, P864, DOI 10.4065/82.7.864; Kesmarky G, 2006, CLIN HEMORHEOL MICRO, V35, P67; Kim YS, 2007, EUR J PHARMACOL, V569, P171, DOI 10.1016/j.ejphar.2007.05.054; Kong WJ, 2011, FOOD CHEM, V127, P1342, DOI 10.1016/j.foodchem.2011.01.095; Kuo Y, 2008, COMPUT IND ENG, V55, P80, DOI 10.1016/j.cie.2007.12.002; Li J, 2011, EUR J PHARMACOL, V652, P104, DOI 10.1016/j.ejphar.2010.11.017; Li R, 2002, J ED CHINESE MED, V21, P62; Liang JP, 2012, J CHINESE MED MAT, V35, P146; Liang YZ, 2001, CHEMOMETR INTELL LAB, V58, P43, DOI 10.1016/S0169-7439(01)00139-3; Liu L, 2012, J ETHNOPHARMACOL, V139, P381, DOI 10.1016/j.jep.2011.11.016; Lu HM, 2006, CHEM PHARM BULL, V54, P725, DOI 10.1248/cpb.54.725; Mchedlishvili G, 1998, CLIN HEMORHEOL MICRO, V19, P315; Ng F, 2008, TETRAHEDRON LETT, V49, P7178, DOI 10.1016/j.tetlet.2008.09.169; Ngo SH, 2003, CHEMOMETR INTELL LAB, V67, P69, DOI 10.1016/S0169-7439(03)00062-5; Ning LiLi, 2000, Acta Pharmaceutica Sinica, V35, P131; Normile D, 2003, SCIENCE, V299, P188, DOI 10.1126/science.299.5604.188; QIN R, 1999, HEMORRHEOLOGY, P45; Qu N, 2007, EUR J PHARM SCI, V31, P156, DOI 10.1016/j.ejps.2007.03.006; Shao ML, 2010, PHARM PEOPLES REPUBL, P909; Shibahara N, 1996, J AUTONOM NERV SYST, V61, P109, DOI 10.1016/S0165-1838(96)00065-3; Song QB, 2011, EXPERT SYST APPL, V38, P7302, DOI 10.1016/j.eswa.2010.12.005; Sun K, 2007, LIFE SCI, V81, P509, DOI 10.1016/j.lfs.2007.06.008; Thrall G, 2005, THROMB RES, V115, P171, DOI 10.1016/j.thromres.2004.08.021; Tian Y, 2010, J ETHNOPHARMACOL, V129, P1, DOI 10.1016/j.jep.2010.02.023; Tziakas DN, 2007, ATHEROSCLEROSIS, V193, P196, DOI 10.1016/j.atherosclerosis.2006.06.016; Wang XC, 1989, APPL GREY SYSTEM MOD, P1; Wen ZY, 2000, CLIN HEMORHEOL MICRO, V23, P51; [肖小河 XIAO Xiao-he], 2010, [中草药, Chinese Traditional and Herbal Drugs], V41, P505; Xue TH, 2003, SCIENCE, V300, P740, DOI 10.1126/science.300.5620.740; Ye RD, 2011, NEUROPHARMACOLOGY, V61, P815, DOI 10.1016/j.neuropharm.2011.05.029; Ye RD, 2011, NEUROCHEM INT, V58, P391, DOI 10.1016/j.neuint.2010.12.015; Yu DH, 2009, BIOMED ENVIRON SCI, V22, P50, DOI 10.1016/S0895-3988(09)60022-2	42	15	23	1	63	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 14	2014	9	11							e112675	10.1371/journal.pone.0112675	http://dx.doi.org/10.1371/journal.pone.0112675			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AU4DF	25396725	Green Submitted, gold, Green Published			2023-01-03	WOS:000345558500075
J	Jin, J; Sui, BW; Gou, JX; Liu, JS; Tang, X; Xu, H; Zhang, Y; Jin, XQ				Jin, Jian; Sui, Bowen; Gou, Jingxin; Liu, Jingshuo; Tang, Xing; Xu, Hui; Zhang, Yu; Jin, Xiangqun			PSMA Ligand Conjugated PCL-PEG Polymeric Micelles Targeted to Prostate Cancer Cells	PLOS ONE			English	Article							BLOCK-COPOLYMER MICELLES; MEMBRANE ANTIGEN; DRUG-DELIVERY; NANOPARTICLES; EXPRESSION; BIODISTRIBUTION; EFFICACY; HYDROGEL; BEHAVIOR	In this content, a small molecular ligand of prostate specific membrane antigen (SMLP) conjugated poly (caprolactone) (PCL)-b-poly (ethylene glycol) (PEG) copolymers with different block lengths were synthesized to construct a satisfactory drug delivery system. Four different docetaxel-loaded polymeric micelles (DTX-PMs) were prepared by dialysis with particle sizes less than 60 nm as characterized by dynamic light scattering (DLS) and transmission electron microscope (TEM). Optimization of the prepared micelles was conducted based on short-term stability and drug-loading content. The results showed that optimized systems were able to remain stable over 7 days. Compared with Taxotere, DTX-PMs with the same ratio of hydrophilic/hydrophobic chain length displayed similar sustained release behaviors. The cytotoxicity of the optimized targeted DTX-PCL12K-PEG(5K)-SMLP micelles (DTX-PMs2) and non-targeted DTX-PCL12K-mPEG(5K) micelles (DTX-PMs1) were evaluated by MTT assays using prostate specific membrane antigen (PSMA) positive prostate adenocarcinoma cells (LNCaP). The results showed that the targeted micelles had a much lower IC50 than their non-targeted counterparts (48 h: 0.87 +/- 0.27 vs 13.48 +/- 1.03 mu g/ml; 72 h: 0.02 +/- 0.008 vs 1.35 +/- 0.54 mu g/ml). In vitro cellular uptake of PMs2 showed 5-fold higher fluorescence intensity than that of PMs1 after 4 h incubation. According to these results, the novel nano-sized drug delivery system based on DTX-PCL-PEG-SMLP offers great promise for the treatment of prostatic cancer.	[Jin, Jian; Sui, Bowen; Liu, Jingshuo; Jin, Xiangqun] Jilin Univ, Coll Pharm Sci, Dept Pharmaceut, Changchun 130023, Peoples R China; [Gou, Jingxin; Tang, Xing; Xu, Hui; Zhang, Yu] Shenyang Pharmaceut Univ, Dept Pharmaceut, Shenyang, Peoples R China	Jilin University; Shenyang Pharmaceutical University	Jin, XQ (corresponding author), Jilin Univ, Coll Pharm Sci, Dept Pharmaceut, Changchun 130023, Peoples R China.	jinxq@jlu.edu.cn						Alexis F, 2008, MOL PHARMACEUT, V5, P505, DOI 10.1021/mp800051m; Bae SJ, 2005, MACROMOLECULES, V38, P5260, DOI 10.1021/ma050489m; Branco MC, 2009, ACTA BIOMATER, V5, P817, DOI 10.1016/j.actbio.2008.09.018; Chang SS, 1999, CLIN CANCER RES, V5, P2674; Chung YM, 2002, BIOMACROMOLECULES, V3, P511, DOI 10.1021/bm0156431; Colombatti M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004608; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Davis ME, 2008, NAT REV DRUG DISCOV, V7, P771, DOI 10.1038/nrd2614; Denmeade SR, 2003, PROSTATE, V54, P249, DOI 10.1002/pros.10199; Dhar S, 2008, J AM CHEM SOC, V130, P11467, DOI 10.1021/ja803036e; Esmaeili F, 2009, J PHARM SCI-US, V98, P2718, DOI 10.1002/jps.21599; Farokhzad OC, 2004, CANCER RES, V64, P7668, DOI 10.1158/0008-5472.CAN-04-2550; Farokhzad OC, 2006, P NATL ACAD SCI USA, V103, P6315, DOI 10.1073/pnas.0601755103; Gaucher G, 2005, J CONTROL RELEASE, V109, P169, DOI 10.1016/j.jconrel.2005.09.034; Ghosh A, 2004, J CELL BIOCHEM, V91, P528, DOI 10.1002/jcb.10661; Gou ML, 2009, J PHYS CHEM B, V113, P12928, DOI 10.1021/jp905781g; Gu PF, 2012, INT J NANOMED, V7, P109, DOI 10.2147/IJN.S27475; Haag R, 2004, ANGEW CHEM INT EDIT, V43, P278, DOI 10.1002/anie.200301694; Hinterwirth H, 2012, ANAL CHIM ACTA, V733, P90, DOI 10.1016/j.aca.2012.04.036; Hrkach J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003651; Hu Y, 2004, BIOMACROMOLECULES, V5, P1756, DOI 10.1021/bm049845j; Huang W, 2010, ACTA BIOMATER, V6, P3927, DOI 10.1016/j.actbio.2010.04.021; ISRAELI RS, 1994, CANCER RES, V54, P1807; KATAOKA K, 1993, J CONTROL RELEASE, V24, P119; Li J, 2006, BIOMATERIALS, V27, P4132, DOI 10.1016/j.biomaterials.2006.03.025; Li JM, 2012, J BIOMED NANOTECHNOL, V8, P809, DOI 10.1166/jbn.2012.1433; Liu CB, 2007, COLLOID SURFACE A, V302, P430, DOI 10.1016/j.colsurfa.2007.03.006; Maresca KP, 2009, J MED CHEM, V52, P347, DOI 10.1021/jm800994j; Murphy GP, 1998, CANCER-AM CANCER SOC, V83, P2259, DOI 10.1002/(SICI)1097-0142(19981201)83:11<2259::AID-CNCR5>3.0.CO;2-T; Nie SF, 2011, INT J NANOMED, V6, P151, DOI 10.2147/IJN.S15057; Qi RG, 2011, J CONTROL RELEASE, V152, pE167, DOI 10.1016/j.jconrel.2011.08.067; Rofstad EK, 2006, CANCER RES, V66, P6699, DOI 10.1158/0008-5472.CAN-06-0983; Samarajeewa S, 2013, MOL PHARMACEUT, V10, P1092, DOI 10.1021/mp3005897; Sanna V, 2011, MOL PHARMACEUT, V8, P748, DOI 10.1021/mp100360g; Savic R, 2006, J DRUG TARGET, V14, P343, DOI 10.1080/10611860600874538; Saxena V, 2013, J BIOMED NANOTECHNOL, V9, P1146, DOI 10.1166/jbn.2013.1632; Torchilin V, 2011, ADV DRUG DELIVER REV, V63, P131, DOI 10.1016/j.addr.2010.03.011; Wang YJ, 2012, J BIOMED NANOTECHNOL, V8, P450, DOI 10.1166/jbn.2012.1390; Wolf P, 2010, PROSTATE, V70, P562, DOI 10.1002/pros.21090; Yamamichi F, 2012, UROLOGY, V80, DOI 10.1016/j.urology.2012.06.023; Zamani S, 2012, POLYMER, V53, P5723, DOI 10.1016/j.polymer.2012.09.051	41	34	34	1	61	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2014	9	11							e112200	10.1371/journal.pone.0112200	http://dx.doi.org/10.1371/journal.pone.0112200			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT9MC	25386942	gold, Green Published, Green Submitted			2023-01-03	WOS:000345250400049
J	Shah, N; Singh, R; Sarangi, U; Saxena, N; Chaudhary, A; Kaur, G; Kaul, SC; Wadhwa, R				Shah, Navjot; Singh, Rumani; Sarangi, Upasana; Saxena, Nishant; Chaudhary, Anupama; Kaur, Gurcharan; Kaul, Sunil C.; Wadhwa, Renu			Combinations of Ashwagandha Leaf Extracts Protect Brain-Derived Cells against Oxidative Stress and Induce Differentiation	PLOS ONE			English	Article							WITHANIA-SOMNIFERA; MITOCHONDRIAL DYSFUNCTION; WITHAFERIN-A; CANCER-CELLS; ALCOHOLIC EXTRACT; GLUTAMATE; IDENTIFICATION; CONCOMITANT; COMPONENTS; INHIBITOR	Background Ashwagandha, a traditional Indian herb, has been known for its variety of therapeutic activities. We earlier demonstrated anticancer activities in the alcoholic and water extracts of the leaves that were mediated by activation of tumor suppressor functions and oxidative stress in cancer cells. Low doses of these extracts were shown to possess neuroprotective activities in vitro and in vivo assays. Methodology/Principal Findings We used cultured glioblastoma and neuroblastoma cells to examine the effect of extracts (alcoholic and water) as well as their bioactive components for neuroprotective activities against oxidative stress. Various biochemical and imaging assays on the marker proteins of glial and neuronal cells were performed along with their survival profiles in control, stressed and recovered conditions. We found that the extracts and one of the purified components, withanone, when used at a low dose, protected the glial and neuronal cells from oxidative as well as glutamate insult, and induced their differentiation per se. Furthermore, the combinations of extracts and active component were highly potent endorsing the therapeutic merit of the combinational approach. Conclusion Ashwagandha leaf derived bioactive compounds have neuroprotective potential and may serve as supplement for brain health.	[Shah, Navjot; Singh, Rumani; Sarangi, Upasana; Saxena, Nishant; Chaudhary, Anupama; Kaul, Sunil C.; Wadhwa, Renu] Natl Inst Adv Ind Sci & Technol, Cell Proliferat Res Grp, Tsukuba, Ibaraki 3058562, Japan; [Shah, Navjot; Singh, Rumani; Sarangi, Upasana; Saxena, Nishant; Chaudhary, Anupama; Kaul, Sunil C.; Wadhwa, Renu] Natl Inst Adv Ind Sci & Technol, DBT AIST Int Lab Adv Biomed DAILAB, Tsukuba, Ibaraki 3058562, Japan; [Kaur, Gurcharan] Guru Nanak Dev Univ, Dept Biotechnol, Amritsar 143005, Punjab, India	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST); Guru Nanak Dev University	Kaul, SC (corresponding author), Natl Inst Adv Ind Sci & Technol, Cell Proliferat Res Grp, Tsukuba, Ibaraki 3058562, Japan.	s-kaul@aist.go.jp; renu-wadhwa@aist.go.jp	Chaudhary, Anupama/AAF-8156-2020; Wadhwa, Renu/L-8898-2018; Kaul, Sunil C/L-8671-2018; Kaur, Gurcharan/V-6033-2019	Chaudhary, Anupama/0000-0001-9619-8813; Wadhwa, Renu/0000-0001-8248-5192; Kaul, Sunil C/0000-0002-0046-3916; 	Department of Biotechnology (India)-National Institute of Advanced Industrial Science & Technology (Japan) Bilateral Project Grant; Ministry of Education, Culture, Sports, Science & Technology (MEXT) Scholarships, Japan	Department of Biotechnology (India)-National Institute of Advanced Industrial Science & Technology (Japan) Bilateral Project Grant; Ministry of Education, Culture, Sports, Science & Technology (MEXT) Scholarships, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	The study was supported by Department of Biotechnology (India)-National Institute of Advanced Industrial Science & Technology (Japan) Bilateral Project Grant. Navjot Shah and Rumani Singh were supported by the Ministry of Education, Culture, Sports, Science & Technology (MEXT) Scholarships, Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Di Carlo M, 2012, FREE RADICAL RES, V46, P1327, DOI 10.3109/10715762.2012.714466; Dobrek L, 2011, POSTEP HIG MED DOSW, V65, P338; Gautam A, 2013, NEUROBIOL LEARN MEM, V106, P177, DOI 10.1016/j.nlm.2013.08.009; Grover A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030890; Grover A, 2012, INT J BIOCHEM CELL B, V44, P496, DOI 10.1016/j.biocel.2011.11.021; Gupta MS, 2006, PHARM BIOL, V44, P263, DOI 10.1080/13880200600713949; Hahm ER, 2013, JNCI-J NATL CANCER I, V105, P1111, DOI 10.1093/jnci/djt153; Hahm ER, 2013, CANCER LETT, V334, P101, DOI 10.1016/j.canlet.2012.08.026; Hahm ER, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023354; Hamilton NB, 2010, NAT REV NEUROSCI, V11, P227, DOI 10.1038/nrn2803; Hynd MR, 2004, NEUROCHEM INT, V45, P583, DOI 10.1016/j.neuint.2004.03.007; Jain S, 2001, PHYTOTHER RES, V15, P544, DOI 10.1002/ptr.802; Jeyanthi Thangavel, 2010, Journal of Basic and Clinical Physiology and Pharmacology, V21, P61; Kaileh M, 2007, J BIOL CHEM, V282, P4253, DOI 10.1074/jbc.M606728200; Kataria H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055316; Kataria H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037080; Kataria H, 2011, EVID-BASED COMPL ALT, V2011, DOI 10.1093/ecam/nep188; Konar A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027265; Kulkarni SK, 2008, PROG NEURO-PSYCHOPH, V32, P1093, DOI 10.1016/j.pnpbp.2007.09.011; Mah LJ, 2010, LEUKEMIA, V24, P679, DOI 10.1038/leu.2010.6; Malik F, 2007, APOPTOSIS, V12, P2115, DOI 10.1007/s10495-007-0129-x; Malik F, 2009, EUR J CANCER, V45, P1494, DOI 10.1016/j.ejca.2009.01.034; Matute C, 2011, J ANAT, V219, P53, DOI 10.1111/j.1469-7580.2010.01339.x; Nakatsu Y, 2009, TOXICOL APPL PHARM, V240, P292, DOI 10.1016/j.taap.2009.06.024; Pedrazzi M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044518; Priyandoko D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019552; Roy RV, 2013, J NAT PROD, V76, P1909, DOI 10.1021/np400441f; Ryu J, 2014, J BIOL CHEM, V289, P24832, DOI 10.1074/jbc.M114.565929; Saito Y, 2010, FREE RADICAL BIO MED, V49, P1542, DOI 10.1016/j.freeradbiomed.2010.08.016; Shah N, 2009, CANCER SCI, V100, P1740, DOI 10.1111/j.1349-7006.2009.01236.x; Shih YY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026236; Shukla V, 2011, ADV PHARMACOL SCI, V2011, DOI 10.1155/2011/572634; Sinha P, 2013, CANCER IMMUNOL IMMUN, V62, P1663, DOI 10.1007/s00262-013-1470-2; Thaiparambil JT, 2011, INT J CANCER, V129, P2744, DOI 10.1002/ijc.25938; Trushina E, 2007, NEUROSCIENCE, V145, P1233, DOI 10.1016/j.neuroscience.2006.10.056; Uttara B, 2009, CURR NEUROPHARMACOL, V7, P65, DOI 10.2174/157015909787602823; Vaishnavi K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044419; Wadegaonkar VP, 2013, J BIOTECHNOL, V168, P229, DOI 10.1016/j.jbiotec.2013.08.028; Wadhwa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077189; Widodo N, 2008, CANCER LETT, V262, P37, DOI 10.1016/j.canlet.2007.11.037; Widodo N, 2007, CLIN CANCER RES, V13, P2298, DOI 10.1158/1078-0432.CCR-06-0948; Widodo N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013536; Widodo N, 2009, J GERONTOL A-BIOL, V64, P1031, DOI 10.1093/gerona/glp088; Yan J, 2010, BRAIN RES, V1347, P132, DOI 10.1016/j.brainres.2010.05.074; Yu Y, 2009, BIOCHEM PHARMACOL, V79, P542; Zheng XY, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/457079	46	22	22	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2015	10	3							e0120554	10.1371/journal.pone.0120554	http://dx.doi.org/10.1371/journal.pone.0120554			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CD9NQ	25789768	Green Submitted, Green Published, gold			2023-01-03	WOS:000351425400162
J	Zhao, BS; Song, XR; Hu, PY; Meng, LX; Tan, YH; She, YJ; Ding, YY				Zhao, Bai-Song; Song, Xing-Rong; Hu, Pei-Ying; Meng, Ling-Xin; Tan, Yong-Hong; She, Ying-Jun; Ding, Yuan-Yuan			Hyperbaric Oxygen Treatment at Various Stages following Chronic Constriction Injury Produces Different Antinociceptive Effects via Regulation of P2X(4)R Expression and Apoptosis	PLOS ONE			English	Article							PREDOMINANTLY NEUROPATHIC ORIGIN; SPINAL-CORD-INJURY; QUALITY-OF-LIFE; CHRONIC PAIN; GENERAL-POPULATION; NERVE INJURY; P2X4 RECEPTORS; UP-REGULATION; RAT MODEL; MICROGLIA	Purpose The aims of this study were to investigate the effect of hyperbaric oxygen (HBO) treatment at various stages following chronic constriction injury (CCI) and to explore the underlying mechanisms of HBO treatment. Methods Forty adult male Sprague-Dawley rats were randomly assigned to five groups (n = 8 for each group): the sham group, CCI group, HBO1 group, HBO2 group, and HBO3 group. Neuropathic pain was induced by CCI of the sciatic nerve. HBO treatment began on postoperative days 1, 6, and 11 and continued for 5 days. The mechanical withdrawal threshold and thermal withdrawal latency were tested on preoperative day 3 and postoperative days 1, 3, 5, 7, 10, 14, and 21. The expression of P2X(4)R was determined by immunohistochemistry and western blot analysis. Cell apoptosis was measured using TUNEL staining. The expression of caspase 3 was measured using reverse transcription polymerase chain reaction (RT-PCR). Electron microscopy was used to determine the ultrastructural changes. Results Early HBO treatment beginning on postoperative day 1 produced a persistent antinociceptive effect and inhibited the CCI-induced increase in the expression of P2X(4)R without changing CCI-induced apoptosis. In contrast, late HBO treatment beginning on postoperative day 11 produced a persistent antinociceptive effect and inhibited CCI-induced apoptosis and upregulation of caspase-3 without changing the expression of P2X(4)R. In addition, late HBO treatment reduced CCI-induced ultrastructural damage. However, HBO treatment beginning on postoperative day 6 produced a transient antinociceptive effect without changing the expression of P2X(4)R or CCI-induced apoptosis. Conclusion HBO treatment at various stages following CCI can produce antinociceptive effects via different mechanisms. Early HBO treatment is associated with inhibition of P2X(4)R expression, and late HBO treatment is associated with inhibition of cell apoptosis.	[Zhao, Bai-Song; Song, Xing-Rong; Hu, Pei-Ying; Tan, Yong-Hong; She, Ying-Jun] Guangzhou Women & Childrens Med Ctr, Dept Anesthesiol, Guangzhou 510623, Guangdong, Peoples R China; [Meng, Ling-Xin; Ding, Yuan-Yuan] China Med Univ, Shengjing Hosp, Dept Pain, Shenyang 110004, Peoples R China	China Medical University	Song, XR (corresponding author), Guangzhou Women & Childrens Med Ctr, Dept Anesthesiol, Guangzhou 510623, Guangdong, Peoples R China.	zhaobaisong819@163.com	ding, yy/HHS-9589-2022		BBraun Anesthesia Scientific Research Fund [F10-205-1-41, BBF 2012-012]; Science and Technology Plan Project	BBraun Anesthesia Scientific Research Fund; Science and Technology Plan Project	This work is supported by the Science and Technology Plan Project and BBraun Anesthesia Scientific Research Fund (grant no. F10-205-1-41 and BBF 2012-012). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Waili NS, 2005, ADV THER, V22, P659, DOI 10.1007/BF02849960; Attal N, 2011, PAIN, V152, P2836, DOI 10.1016/j.pain.2011.09.014; Beggs S, 2012, NAT NEUROSCI, V15, P1068, DOI 10.1038/nn.3155; BENNETT GJ, 1988, PAIN, V33, P87, DOI 10.1016/0304-3959(88)90209-6; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Bouhassira D, 2008, PAIN, V136, P380, DOI 10.1016/j.pain.2007.08.013; Bridges D, 2001, BRIT J ANAESTH, V87, P12, DOI 10.1093/bja/87.1.12; Costigan M, 2009, ANNU REV NEUROSCI, V32, P1, DOI 10.1146/annurev.neuro.051508.135531; Dayan K, 2012, LIFE SCI, V90, P360, DOI 10.1016/j.lfs.2011.12.005; Doth AH, 2010, PAIN, V149, P338, DOI 10.1016/j.pain.2010.02.034; Erturk A, 2014, J NEUROSCI, V34, P1672, DOI 10.1523/JNEUROSCI.3121-13.2014; Gibbons CR, 2013, BRAIN RES, V1537, P111, DOI 10.1016/j.brainres.2013.08.050; Gu N, 2012, EUR J PAIN, V16, P1094, DOI 10.1002/j.1532-2149.2012.00113.x; Haanpaa M, 2011, PAIN, V152, P14, DOI 10.1016/j.pain.2010.07.031; Helms A, 2011, UNDERSEA HYPERBAR M, V38, P309; Inoue K, 2012, CNS NEUROL DISORD-DR, V11, P699, DOI 10.2174/187152712803581065; Ishihara H, 2001, J Orthop Sci, V6, P385, DOI 10.1007/s007760170003; Li FH, 2011, ANESTH ANALG, V113, P626, DOI 10.1213/ANE.0b013e31821f9544; Milligan ED, 2009, NAT REV NEUROSCI, V10, P23, DOI 10.1038/nrn2533; Nakai K, 2010, NEUROREPORT, V21, P559, DOI 10.1097/WNR.0b013e32833980b2; Ohayon MM, 2012, J PSYCHIATR RES, V46, P444, DOI 10.1016/j.jpsychires.2012.01.001; Sanchez EC, 2007, NEUROL RES, V29, P184, DOI 10.1179/016164107X181824; Schwab JM, 2005, J NEUROIMMUNOL, V163, P185, DOI 10.1016/j.jneuroim.2005.02.016; Sekiguchi M, 2009, EUR SPINE J, V18, P1978, DOI 10.1007/s00586-009-1064-z; Smith BH, 2007, CLIN J PAIN, V23, P143, DOI 10.1097/01.ajp.0000210956.31997.89; Smith BH, 2012, CURR PAIN HEADACHE R, V16, P191, DOI 10.1007/s11916-012-0256-0; SUGIMOTO T, 1990, PAIN, V42, P205, DOI 10.1016/0304-3959(90)91164-E; Tanga FY, 2004, NEUROCHEM INT, V45, P397, DOI 10.1016/j.neuint.2003.06.002; Torrance N, 2006, J PAIN, V7, P281, DOI 10.1016/j.jpain.2005.11.008; Treede RD, 2008, NEUROLOGY, V70, P1630, DOI 10.1212/01.wnl.0000282763.29778.59; Tsuda M, 2003, NATURE, V424, P778, DOI 10.1038/nature01786; Ulmann L, 2008, J NEUROSCI, V28, P11263, DOI 10.1523/JNEUROSCI.2308-08.2008; Ulmann L, 2013, GLIA, V61, P1306, DOI 10.1002/glia.22516; Yamada K, 2014, AM J PATHOL, V184, P753, DOI 10.1016/j.ajpath.2013.11.010; Yamashita S, 2009, BRAIN RES, V1301, P171, DOI 10.1016/j.brainres.2009.08.096; Zhang John H, 2005, Pathophysiology, V12, P63, DOI 10.1016/j.pathophys.2005.01.003; Zhang Z, 2008, NEUROSCIENCE, V152, P495, DOI 10.1016/j.neuroscience.2007.12.042; Zhao BS, 2014, J MOL NEUROSCI, V53, P251, DOI 10.1007/s12031-013-0213-3	38	13	19	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2015	10	3							e0120122	10.1371/journal.pone.0120122	http://dx.doi.org/10.1371/journal.pone.0120122			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CD9NQ	25789619	Green Submitted, gold, Green Published			2023-01-03	WOS:000351425400131
J	Yang, GY; Wang, LQ; Ren, J; Zhang, Y; Li, ML; Zhu, YT; Luo, J; Cheng, YJ; Li, WY; Wayne, PM; Liu, JP				Yang, Guo-Yan; Wang, Li-Qiong; Ren, Jun; Zhang, Yan; Li, Meng-Ling; Zhu, Yu-Ting; Luo, Jing; Cheng, Yan-Jun; Li, Wen-Yuan; Wayne, Peter M.; Liu, Jian-Ping			Evidence Base of Clinical Studies on Tai Chi: A Bibliometric Analysis	PLOS ONE			English	Article							AEROBIC CAPACITY; ELDERLY-PEOPLE; EXERCISE; FEAR	Background The safety and health benefits of Tai Chi mind-body exercise has been documented in a large number of clinical studies focused on specific diseases and health conditions. The objective of this systematic review is to more comprehensively summarize the evidence base of clinical studies of Tai Chi for healthcare. Methods and Findings We searched for all types of clinical studies on Tai chi in PubMed, the Cochrane Library and four major Chinese electronic databases from their inception to July 2013. Data were analyzed using SPSS17.0 software. A total of 507 studies published between 1958 and 2013 were identified, including 43 (8.3%) systematic reviews of clinical studies, 255 (50.3%) randomized clinical trials, 90 (17.8%) non-randomized controlled clinical studies, 115 (22.7%) case series and 4 (0.8%) case reports. The top 10 diseases/conditions was hypertension, diabetes, osteoarthritis, osteoporosis or osteopenia, breast cancer, heart failure, chronic obstructive pulmonary disease, coronary heart disease, schizophrenia, and depression. Many healthy participants practiced Tai Chi for the purpose of health promotion or preservation. Yang style Tai Chi was the most popular, and Tai Chi was frequently practiced two to three 1-hour sessions per week for 12 weeks. Tai Chi was used alone in more than half of the studies (58.6%), while in other studies Tai Chi was applied in combination with other therapies including medications, health education and other physical therapies. The majority of studies (94.1%) reported positive effects of Tai Chi, 5.1% studies reported uncertain effects and 0.8% studies reported negative effects. No serious adverse events related to Tai Chi were reported. Conclusions The quantity and evidence base of clinical studies on Tai Chi is substantial. However, there is a wide variation in Tai Chi intervention studied and the reporting of Tai Chi intervention needs to be improved. Further well-designed and reported studies are recommended to confirm the effects of Tai Chi for the frequently reported diseases/conditions.	[Yang, Guo-Yan; Wang, Li-Qiong; Ren, Jun; Li, Wen-Yuan; Liu, Jian-Ping] Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing, Peoples R China; [Zhang, Yan; Li, Meng-Ling; Zhu, Yu-Ting; Luo, Jing; Cheng, Yan-Jun; Liu, Jian-Ping] Beijing Univ Chinese Med, Sch Basic Med Sci, Beijing, Peoples R China; [Luo, Jing] China Acad Chinese Med Sci, Xiyuan Hosp, Beijing, Peoples R China; [Cheng, Yan-Jun] China Acad Chinese Med Sci, Guanganmen Hosp, Beijing, Peoples R China; [Wayne, Peter M.] Brigham & Womens Hosp, Osher Ctr Integrat Med, Boston, MA 02115 USA; [Wayne, Peter M.] Harvard Univ, Sch Med, Boston, MA USA	Beijing University of Chinese Medicine; Beijing University of Chinese Medicine; China Academy of Chinese Medical Sciences; Xiyuan Hospital, CACMS; China Academy of Chinese Medical Sciences; Guang'anmen Hospital, CACMS; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Liu, JP (corresponding author), Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing, Peoples R China.	Liujp@bucm.edu.cn	Yang, Guoyan/AAG-7873-2021; 罗, 静/HCH-9782-2022	Yang, Guoyan/0000-0002-8012-2379; Luo, Jing/0000-0002-2454-2168; Liu, Jianping/0000-0002-0320-061X	Beijing University of Chinese Medicine [2011-CXTD-09]	Beijing University of Chinese Medicine	This work was supported by the Program of Innovative Research Team of Beijing University of Chinese Medicine (2011-CXTD-09). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2010, INTERNATIONAL STATIS; Gu L., 2007, CVPR, P1; Kang JW, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2010-000035; Lan C, 2008, AM J CHINESE MED, V36, P1041, DOI 10.1142/S0192415X08006442; Li FZ, 2007, J AGING PHYS ACTIV, V15, P139, DOI 10.1123/japa.15.2.139; Li JY, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep022; Liu B, 2011, J TRADIT CHIN MED, V31, P141, DOI 10.1016/S0254-6272(11)60029-0; Maciaszek J, 2010, AM J CHINESE MED, V38, P219, DOI 10.1142/S0192415X10007798; MacPherson H, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000261; McGibbon CA, 2005, BMC NEUROL, V5, DOI 10.1186/1471-2377-5-3; Pan L, 2013, EUR J HEART FAIL, V15, P316, DOI 10.1093/eurjhf/hfs170; Sjosten N, 2008, AGING MENT HEALTH, V12, P30, DOI 10.1080/13607860701366079; Song QP, 2014, RES SPORTS MED, V22, P172, DOI 10.1080/15438627.2014.881823; Song R, 2010, J ALTERN COMPLEM MED, V16, P227, DOI 10.1089/acm.2009.0165; Su, 2012, STUDY ON TAI CHI, P1; Sun YX, 1988, CHINESE JOURNAL OF R, V8, P2; Tang H, 2012, STUDY ON TAI CHI, P3; Taylor-Piliae Ruth E., 2008, V52, P40, DOI 10.1159/000134283; Wang D, 1958, CHINESE JOURNAL OF A, V5, P33; Wayne PM, 2014, ARCH PHYS MED REHAB, V95, P2470, DOI 10.1016/j.apmr.2014.05.005; Yan JH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061806; Yan JH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061672; Yeh Gloria Y, 2008, Prev Cardiol, V11, P82; Yeh GY, 2009, J CARDIOPULM REHABIL, V29, P152, DOI 10.1097/HCR.0b013e3181a33379; Yu W, 1997, CHINESE JOURNAL OF C, V6, P78; [曾永红 Zeng Yonghong], 2012, [中国康复理论与实践, Chinese Journal of Rehabilitation Theory and Practice], V18, P1148; Zou WL, 1995, ANTHOLOGY OF MEDICIN, V16, P19	27	60	63	3	70	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 16	2015	10	3							e0120655	10.1371/journal.pone.0120655	http://dx.doi.org/10.1371/journal.pone.0120655			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CD6EY	25775125	Green Published, Green Submitted, gold			2023-01-03	WOS:000351183500188
J	Lu, JY; Cheung, MLM; Huang, BT; Wu, LL; Xie, WJ; Chen, ZJ; Li, DR; Xie, LX				Lu, Jia-Yang; Cheung, Michael Lok-Man; Huang, Bao-Tian; Wu, Li-Li; Xie, Wen-Jia; Chen, Zhi-Jian; Li, De-Rui; Xie, Liang-Xi			Improving Target Coverage and Organ-at-Risk Sparing in Intensity-Modulated Radiotherapy for Cervical Oesophageal Cancer Using a Simple Optimisation Method	PLOS ONE			English	Article							SIMULTANEOUS INTEGRATED BOOST; DIRECT APERTURE OPTIMIZATION; 3D CONFORMAL RADIOTHERAPY; RADIATION-THERAPY; LUNG-CANCER; IMRT; PLANS; HEAD; NECK; CHEMORADIOTHERAPY	Purpose To assess the performance of a simple optimisation method for improving target coverage and organ-at-risk (OAR) sparing in intensity-modulated radiotherapy (IMRT) for cervical oesophageal cancer. Methods For 20 selected patients, clinically acceptable original IMRT plans (Original plans) were created, and two optimisation methods were adopted to improve the plans: 1) a base dose function (BDF)-based method, in which the treatment plans were re-optimised based on the original plans, and 2) a dose-controlling structure (DCS)-based method, in which the original plans were re-optimised by assigning additional constraints for hot and cold spots. The Original, BDF-based and DCS-based plans were compared with regard to target dose homogeneity, conformity, OAR sparing, planning time and monitor units (MUs). Dosimetric verifications were performed and delivery times were recorded for the BDF-based and DCS-based plans. Results The BDF-based plans provided significantly superior dose homogeneity and conformity compared with both the DCS-based and Original plans. The BDF-based method further reduced the doses delivered to the OARs by approximately 1-3%. The re-optimisation time was reduced by approximately 28%, but the MUs and delivery time were slightly increased. All verification tests were passed and no significant differences were found. Conclusion The BDF-based method for the optimisation of IMRT for cervical oesophageal cancer can achieve significantly better dose distributions with better planning efficiency at the expense of slightly more MUs.	[Lu, Jia-Yang; Huang, Bao-Tian; Wu, Li-Li; Xie, Wen-Jia; Chen, Zhi-Jian; Li, De-Rui; Xie, Liang-Xi] Shantou Univ, Dept Radiat Oncol, Canc Hosp, Coll Med, Shantou, Peoples R China; [Cheung, Michael Lok-Man] Prince Wales Hosp, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China	Shantou University; Chinese University of Hong Kong; Prince of Wales Hospital	Xie, LX (corresponding author), Shantou Univ, Dept Radiat Oncol, Canc Hosp, Coll Med, Shantou, Peoples R China.	xieliangxi1@qq.com			National Natural Science Foundation of China [81171994]; Shantou University Medical College Clinical Research Enhancement Initiative [201425]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shantou University Medical College Clinical Research Enhancement Initiative	Funding: This work was sponsored in part by both National Natural Science Foundation of China (Grant No. 81171994) and Shantou University Medical College Clinical Research Enhancement Initiative (Grant No. 201425). No additional external funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahn SJ, 2005, INT J RADIAT ONCOL, V61, P335, DOI 10.1016/j.ijrobp.2004.06.014; Broderick M, 2009, RADIAT ONCOL, V4, DOI 10.1186/1748-717X-4-8; Budrukkar Ashwini N, 2004, Australas Radiol, V48, P45, DOI 10.1111/j.1440-1673.2004.01241.x; Cao CN, 2014, JAMA OTOLARYNGOL, V140, P918, DOI 10.1001/jamaoto.2014.2013; Cheng MC, 2014, MED DOSIM, V39, P246, DOI 10.1016/j.meddos.2014.03.003; Cooper JS, 1999, JAMA-J AM MED ASSOC, V281, P1623, DOI 10.1001/jama.281.17.1623; Dobler B, 2007, RADIAT ONCOL, V2, DOI 10.1186/1748-717X-2-33; Dogan N, 2006, MED PHYS, V33, P4033, DOI 10.1118/1.2357835; Ezzell GA, 2009, MED PHYS, V36, P5359, DOI 10.1118/1.3238104; Fenkell L, 2008, RADIOTHER ONCOL, V89, P287, DOI 10.1016/j.radonc.2008.08.008; Freilich J, 2014, DIS ESOPHAG IN PRESS; Guckenberger M, 2010, RADIOTHER ONCOL, V97, P65, DOI 10.1016/j.radonc.2010.04.027; Hall EJ, 2003, INT J RADIAT ONCOL, V56, P83, DOI 10.1016/S0360-3016(03)00073-7; Hodapp N, 2012, STRAHLENTHER ONKOL, V188, P97, DOI 10.1007/s00066-011-0015-x; Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437; Jeraj R, 2002, PHYS MED BIOL, V47, P391, DOI 10.1088/0031-9155/47/3/303; Jones S, 2008, MED DOSIM, V33, P86, DOI 10.1016/j.meddos.2007.04.002; Kumar G, 2012, JPN J RADIOL, V30, P18, DOI 10.1007/s11604-011-0002-2; Kwint M, 2012, INT J RADIAT ONCOL, V84, pE223, DOI 10.1016/j.ijrobp.2012.03.027; Lin SH, 2012, INT J RADIAT ONCOL, V84, P1078, DOI 10.1016/j.ijrobp.2012.02.015; Lu JY, 2015, BRIT J RADIOL, V88, DOI 10.1259/bjr.20140654; Nicolini G, 2012, INT J RADIAT ONCOL, V84, P553, DOI 10.1016/j.ijrobp.2011.12.041; Nutting CM, 2001, RADIOTHER ONCOL, V61, P157, DOI 10.1016/S0167-8140(01)00438-8; Paddick I, 2000, J NEUROSURG, V93, P219, DOI 10.3171/jns.2000.93.supplement_3.0219; Shridhar R, 2012, J RADIOL ONCOL, V1, P347, DOI 10.1007/s13566-012-0048-5; Shridhar R, 2013, CANCER CONTROL, V20, P97, DOI 10.1177/107327481302000203; Suss P, 2013, PHYS MED BIOL, V58, P1855, DOI 10.1088/0031-9155/58/6/1855; Tucker SL, 2006, INT J RADIAT ONCOL, V66, P754, DOI 10.1016/j.ijrobp.2006.06.002; Verbakel WFAR, 2012, INT J RADIAT ONCOL, V83, pE297, DOI 10.1016/j.ijrobp.2011.12.059; Vineberg KA, 2002, INT J RADIAT ONCOL, V52, P1159, DOI 10.1016/S0360-3016(01)02800-0; Werner-Wasik M, 2010, INT J RADIAT ONCOL, V76, pS86, DOI 10.1016/j.ijrobp.2009.05.070; Xhaferllari I, 2013, J APPL CLIN MED PHYS, V14, P176, DOI 10.1120/jacmp.v14i1.4052; Yu WW, 2014, STRAHLENTHER ONKOL, V190, P979, DOI 10.1007/s00066-014-0636-y	33	4	4	2	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 13	2015	10	3							e0121679	10.1371/journal.pone.0121679	http://dx.doi.org/10.1371/journal.pone.0121679			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CD7NO	25768733	Green Published, Green Submitted, gold			2023-01-03	WOS:000351277500145
J	Wang, XF; Zhang, RW; Gu, LQ; Zhang, YY; Zhao, X; Bi, KS; Chen, XH				Wang, Xiaofan; Zhang, Ruowen; Gu, Liqiang; Zhang, Yuanyuan; Zhao, Xu; Bi, Kaishun; Chen, Xiaohui			Cell-Based Screening Identifies the Active Ingredients from Traditional Chinese Medicine Formula Shixiao San as the Inhibitors of Atherosclerotic Endothelial Dysfunction	PLOS ONE			English	Article							NF-KAPPA-B; HYDROGEN-PEROXIDE; NITRIC-OXIDE; EXPRESSION; FLAVONOIDS; CONSTITUENTS; ACTIVATION; APOPTOSIS; OXIDATION; EXTRACTS	In this study, we performed a phenotypic screening in human endothelial cells exposed to oxidized low density lipoprotein (an in vitro model of atherosclerotic endothelial dysfunction) to identify the effective compounds in Shixiao San. After investigating the suitability and reliability of the cell-based screening method using atorvastatin as the positive control drug, this method was applied in screening Shixiao San and its extracts. The treatment of n-butanol fraction on endothelial cells exhibited stronger healing effects against oxidized low density lipoprotein-induced insult when compared with other fractions. Cell viability, the level of nitric oxide, endothelial nitric oxide synthase and endothelin-1 were measured, respectively. The assays revealed n-butanol fraction significantly elevated the survival ratio of impaired cells in culture. In parallel, n-butanol fraction exhibited the highest inhibition of inflammation. The generation of prostaglandin-2 and adhesion molecule (soluble intercellular adhesion molecule-1) was obviously declined. Furthermore, n-butanol fraction suppressed the production of reactive oxygen species and malondialdehyde, and restored the activity of superoxide dismutase. Compounds identification of the n-butanol fraction was carried out by ultra high liquid chromatography coupled to quadrupole time-of-flight tandem mass spectrometry. The active ingredients including quercetin-3-O-(2(G)-alpha-l-rhamnosyl)-rutinoside, quercetin-3-O-neohesperidoside, isorhamnetin-3-O-neohesperidoside and isorhamnetin-3-O-rutinoside revealed the ability of anti-atherosclerosis after exposing on endothelial cells. The current work illustrated the pharmacology effect of Shixiao San and clearly indicated the major active components in Shixiao San. More importantly, the proposed cell-based screening method might be particularly suitable for fast evaluating the anti-atherosclerosis efficacy of Traditional Chinese Medicines and screening out the interesting ingredients of Traditional Chinese Medicines.	[Wang, Xiaofan; Gu, Liqiang; Zhang, Yuanyuan; Bi, Kaishun; Chen, Xiaohui] Shenyang Pharmaceut Univ, Sch Pharm, Shenyang, Peoples R China; [Zhang, Ruowen] Univ N Dakota, Sch Med & Hlth Sci, Dept Pathol, Grand Forks, ND 58201 USA; [Zhao, Xu] Shenyang Pharmaceut Univ, Sch Tradit Chinese Mat Med, Shenyang, Peoples R China	Shenyang Pharmaceutical University; University of North Dakota Grand Forks; Shenyang Pharmaceutical University	Chen, XH (corresponding author), Shenyang Pharmaceut Univ, Sch Pharm, Shenyang, Peoples R China.	cxh_syphu@hotmail.com	chen, xia/GXM-5435-2022; chen, xia/GYR-3948-2022; zhang, yuanyuan/GYA-4428-2022	Zhang, Ruowen/0000-0003-1403-2356				Ahmadi N, 2010, AM J CARDIOL, V105, P459, DOI 10.1016/j.amjcard.2009.09.052; Boudjeltia KZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038810; Bouhlel I, 2010, J APPL TOXICOL, V30, P551, DOI 10.1002/jat.1525; Bouhlel I, 2009, DRUG CHEM TOXICOL, V32, P258, DOI 10.1080/01480540902882192; Chao CY, 2011, J AGR FOOD CHEM, V59, P5263, DOI 10.1021/jf104003y; Chen CY, 2007, LIFE SCI, V81, P1602, DOI 10.1016/j.lfs.2007.09.028; Chen XF, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0091830, 10.1371/journal.pone.0115462, 10.1371/journal.pone.0085716, 10.1371/journal.pone.0103330, 10.1371/journal.pone.0091809, 10.1371/journal.pone.0087752]; Chunye C, 2011, CELL BIOCH BIOPHYS, V61, P337, DOI [10.1007/s12013-011-9216-2, DOI 10.1007/S12013-011-9216-2]; Fang X, 1998, CIRC RES, V82, P1289, DOI 10.1161/01.RES.82.12.1289; Garg AK, 2002, MOL IMMUNOL, V39, P509, DOI 10.1016/S0161-5890(02)00207-9; Guo S, 2012, CIRC RES, V110, P948, DOI 10.1161/CIRCRESAHA.111.263715; Haendeler J, 1999, VITAM HORM, V57, P49; Heizter T, 2000, CIRC RES, V86, P36; Hirase T, 2012, AM J PHYSIOL-HEART C, V302, pH499, DOI 10.1152/ajpheart.00325.2011; Iljin K, 2009, CLIN CANCER RES, V15, P6070, DOI 10.1158/1078-0432.CCR-09-1035; Jia LQ, 2012, J ETHNOPHARMACOL, V143, P100, DOI 10.1016/j.jep.2012.06.007; Jiang Y, 2010, ANAL CHIM ACTA, V657, P9, DOI 10.1016/j.aca.2009.10.024; Kang YH, 2001, MOL CELL BIOCHEM, V216, P37, DOI 10.1023/A:1011040026620; Kuruppu S, 2012, FEBS LETT, V586, P2212, DOI 10.1016/j.febslet.2012.06.020; Li HG, 2000, J PATHOL, V190, P244, DOI 10.1002/(SICI)1096-9896(200002)190:3<244::AID-PATH575>3.0.CO;2-8; Lopez-Alarcon C, 2013, ANAL CHIM ACTA, V763, P1, DOI 10.1016/j.aca.2012.11.051; MARSDEN PA, 1992, AM J PHYSIOL, V262, pC854, DOI 10.1152/ajpcell.1992.262.4.C854; Minuz P, 2006, BRIT J CLIN PHARMACO, V61, P774, DOI 10.1111/j.1365-2125.2006.02681.x; Morales AI, 2006, TOXICOL APPL PHARM, V210, P128, DOI 10.1016/j.taap.2005.09.006; Non AL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094474; PHIPPS RP, 1991, IMMUNOL TODAY, V12, P349, DOI 10.1016/0167-5699(91)90064-Z; RiceEvans CA, 1996, FREE RADICAL BIO MED, V20, P933, DOI 10.1016/0891-5849(95)02227-9; Seto Y, 2010, J PHARMACEUT BIOMED, V52, P781, DOI 10.1016/j.jpba.2010.02.029; Shibano M, 2008, J NAT MED-TOKYO, V62, P349, DOI 10.1007/s11418-008-0244-1; Sreelatha S, 2009, FOOD CHEM TOXICOL, V47, P702, DOI 10.1016/j.fct.2008.12.022; Tian Long, 2004, Zhonghua Yi Xue Za Zhi, V84, P954; Tsakadze NL, 2004, AM J PHYSIOL-CELL PH, V287, pC55, DOI 10.1152/ajpcell.00585.2003; Wakabayashi I, 2000, EUR J PHARMACOL, V406, P477, DOI 10.1016/S0014-2999(00)00695-6; Wang X, 2014, ASIAN J PHARM SCI, V9, P17, DOI 10.1016/j.ajps.2013.11.008; Wang XF, 2014, J CHROMATOGR B, V953, P1, DOI 10.1016/j.jchromb.2014.01.042; Wang YK, 2005, PHARMACOL RES, V52, P174, DOI 10.1016/j.phrs.2005.02.023; Weller CL, 2007, P NATL ACAD SCI USA, V104, P11712, DOI 10.1073/pnas.0701700104; Wolfrum S, 2003, ARTERIOSCL THROM VAS, V23, P729, DOI 10.1161/01.ATV.0000063385.12476.A7; Xue X, 2013, J CHROMATOGR A, V1280, P75, DOI 10.1016/j.chroma.2013.01.033; Yan XT, 2014, BIOORG MED CHEM LETT, V24, P1397, DOI 10.1016/j.bmcl.2014.01.028; Yi L, 2011, INT J MOL SCI, V12, P5471, DOI 10.3390/ijms12095471; Zheng ZG, 2013, J PHARMACEUT BIOMED, V77, P44, DOI 10.1016/j.jpba.2013.01.003; Zhou W, 2010, MOLECULES, V15, P6217, DOI 10.3390/molecules15096217; Zhu Z, 2011, PLOS ONE, V6, DOI [10.1371/ journal. pone. 0023554, DOI 10.1371/J0URNAL.P0NE.0023554]	44	13	17	0	40	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2015	10	2							e0116601	10.1371/journal.pone.0116601	http://dx.doi.org/10.1371/journal.pone.0116601			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CB7EQ	25699522	Green Published, gold, Green Submitted			2023-01-03	WOS:000349789800012
J	Corrales-Medina, VF; Alvarez, KN; Weissfeld, LA; Angus, DC; Chirinos, JA; Chang, CCH; Newman, A; Loehr, L; Folsom, AR; Elkind, MS; Lyles, MF; Kronmal, RA; Yende, S				Corrales-Medina, Vicente F.; Alvarez, Karina N.; Weissfeld, Lisa A.; Angus, Derek C.; Chirinos, Julio A.; Chang, Chung-Chou H.; Newman, Anne; Loehr, Laura; Folsom, Aaron R.; Elkind, Mitchell S.; Lyles, Mary F.; Kronmal, Richard A.; Yende, Sachin			Association Between Hospitalization for Pneumonia and Subsequent Risk of Cardiovascular Disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-HEART-DISEASE; INFLAMMATORY MARKERS; ATHEROSCLEROSIS RISK; ACUTE INFECTION; STROKE; MORTALITY; SEPSIS; POPULATION; SURVIVAL; HEALTH	IMPORTANCE The risk of cardiovascular disease (CVD) after infection is poorly understood. OBJECTIVE To determine whether hospitalization for pneumonia is associated with an increased short-term and long-term risk of CVD. DESIGN, SETTINGS, AND PARTICIPANTS We examined 2 community-based cohorts: the Cardiovascular Health Study (CHS, n = 5888; enrollment age, >= 65 years; enrollment period, 1989-1994) and the Atherosclerosis Risk in Communities study (ARIC, n = 15 792; enrollment age, 45-64 years; enrollment period, 1987-1989). Participants were followed up through December 31, 2010. We matched each participant hospitalized with pneumonia to 2 controls. Pneumonia cases and controls were followed for occurrence of CVD over 10 years after matching. We estimated hazard ratios (HRs) for CVD at different time intervals, adjusting for demographics, CVD risk factors, subclinical CVD, comorbidities, and functional status. EXPOSURES Hospitalization for pneumonia. MAIN OUTCOMES AND MEASURES Incident CVD (myocardial infarction, stroke, and fatal coronary heart disease). RESULTS Of 591 pneumonia cases in CHS, 206 had CVD events over 10 years after pneumonia hospitalization. Compared with controls, CVD risk among pneumonia cases was highest during the first year after hospitalization and remained significantly higher than among controls through 10 years. In ARIC, of 680 pneumonia cases, 112 had CVD events over 10 years after hospitalization. After the second year, CVD risk among pneumonia cases was not significantly higher than among controls. [GRAPHICS] CONCLUSIONS AND RELEVANCE Hospitalization for pneumonia was associated with increased short-term and long-term risk of CVD, suggesting that pneumonia may be a risk factor for CVD.	[Corrales-Medina, Vicente F.] Univ Ottawa, Dept Med, Ottawa, ON, Canada; [Corrales-Medina, Vicente F.] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada; [Alvarez, Karina N.; Weissfeld, Lisa A.; Angus, Derek C.; Yende, Sachin] Univ Pittsburgh, Dept Crit Care Med, Clin Res Invest & Syst Modeling Acute Illness CRI, Pittsburgh, PA 15261 USA; [Weissfeld, Lisa A.; Chang, Chung-Chou H.] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA; [Chirinos, Julio A.] Univ Penn, Philadelphia, PA 19104 USA; [Chirinos, Julio A.] Philadelphia Vet Affairs Med Ctr, Div Cardiol, Philadelphia, PA USA; [Chang, Chung-Chou H.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15261 USA; [Newman, Anne] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; [Loehr, Laura] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA; [Folsom, Aaron R.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA; [Elkind, Mitchell S.] Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY USA; [Elkind, Mitchell S.] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY USA; [Lyles, Mary F.] Wake Forest Univ, Dept Med, Winston Salem, NC 27109 USA; [Kronmal, Richard A.] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA; [Yende, Sachin] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA	University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of North Carolina; University of North Carolina Chapel Hill; University of Minnesota System; University of Minnesota Twin Cities; Columbia University; Columbia University; Wake Forest University; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System	Yende, S (corresponding author), Univ Pittsburgh, Dept Crit Care Med, Clin Res Invest & Syst Modeling Acute Illness CRI, 606D Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	angusdc@upmc.edu; yendes@upmc.edu	Newman, Anne B./C-6408-2013; Angus, Derek C/E-9671-2012	Newman, Anne B./0000-0002-0106-1150; Loehr, Laura/0000-0002-9054-1825; Corrales-Medina, Vicente/0000-0002-9691-491X	National Heart, Lung, and Blood Institute (NHLBI) [HHSN268201200036C, HHSN268200800007C, N01 HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, HL080295]; National Institute on Aging (NIA) [AG023629]; NHLBI [HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, HHSN268201100012C]; Department of Medicine of The Ottawa Hospital; Ottawa Hospital Research Institute in Ottawa, Ontario, Canada; National Institute of General Medical Sciences [K23GM083215, R01GM097471]; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085081, N01HC085082, N01HC085086, N01HC085083, N01HC085080, N01HC055222, N01HC055019, N01HC085079] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [TL1TR000145, UL1TR000005] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL080295, R01HL080295, R01HL085083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM097471, K23GM083215] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R56AG023629, R01AG023629] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute on Aging (NIA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Department of Medicine of The Ottawa Hospital; Ottawa Hospital Research Institute in Ottawa, Ontario, Canada; National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The Cardiovascular Health Study (CHS) was supported by contracts HHSN268201200036C, HHSN268200800007C, N01 HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, and grant HL080295 from the National Heart, Lung, and Blood Institute (NHLBI), with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided by grant AG023629 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHS- NHLBI. org. The Atherosclerosis Risk in Communities study was supported by contracts HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C from the NHLBI. This article is also supported by a Junior Investigator Award from the Department of Medicine of The Ottawa Hospital and the Ottawa Hospital Research Institute in Ottawa, Ontario, Canada (Dr Corrales- Medina) and by K23GM083215 and R01GM097471 from the National Institute of General Medical Sciences (Dr Yende).	Corrales-Medina VF, 2013, LANCET, V381, P496, DOI 10.1016/S0140-6736(12)61266-5; Corrales-Medina VF, 2010, LANCET INFECT DIS, V10, P83, DOI 10.1016/S1473-3099(09)70331-7; Corrales-Medina VF, 2009, MEDICINE, V88, P154, DOI 10.1097/MD.0b013e3181a692f0; Elkind MSV, 2011, STROKE, V42, P1851, DOI 10.1161/STROKEAHA.110.608588; Foley RN, 2004, J AM SOC NEPHROL, V15, P1038, DOI 10.1097/01.ASN.0000119144.95922.C4; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; Go AS, 2013, CIRCULATION, V127, pE6, DOI 10.1161/CIR.0b013e31828124ad; Guevara RE, 1999, AM J EPIDEMIOL, V149, P282, DOI 10.1093/oxfordjournals.aje.a009804; Hall M.J., 2010, NATL HLTH STAT REPOR, P24; Halm EA, 1998, JAMA-J AM MED ASSOC, V279, P1452, DOI 10.1001/jama.279.18.1452; Ives Diane G., 1995, Annals of Epidemiology, V5, P278, DOI 10.1016/1047-2797(94)00093-9; Iwashyna TJ, 2012, J AM GERIATR SOC, V60, P1070, DOI 10.1111/j.1532-5415.2012.03989.x; Kaptoge S, 2014, EUR HEART J, V35, P578, DOI 10.1093/eurheartj/eht367; Kasal J, 2004, CRIT CARE MED, V32, P700, DOI 10.1097/01.CCM.0000114819.37569.4B; Kellum JA, 2007, ARCH INTERN MED, V167, P1655, DOI 10.1001/archinte.167.15.1655; KULLER L, 1994, AM J EPIDEMIOL, V139, P1164, DOI 10.1093/oxfordjournals.aje.a116963; Lindenauer PK, 2012, JAMA-J AM MED ASSOC, V307, P1405, DOI 10.1001/jama.2012.384; Loeb Mark, 2010, BMJ Clin Evid, V2010; Maclure M, 2000, ANNU REV PUBL HEALTH, V21, P193, DOI 10.1146/annurev.publhealth.21.1.193; Madjid M, 2007, TEX HEART I J, V34, P11; Murugan R, 2010, KIDNEY INT, V77, P527, DOI 10.1038/ki.2009.502; Naghavi M, 2003, CIRCULATION, V107, P762, DOI 10.1161/01.CIR.0000048190.68071.2B; NHLBI, MORBIDITY AND MORTAL; O'Meara ES, 2005, J AM GERIATR SOC, V53, P1108, DOI 10.1111/j.1532-5415.2005.53352.x; Price T R, 1993, Ann Epidemiol, V3, P504; Quartin AA, 1997, JAMA-J AM MED ASSOC, V277, P1058, DOI 10.1001/jama.277.13.1058; Rosamond WD, 1999, STROKE, V30, P736, DOI 10.1161/01.STR.30.4.736; Shah FA, 2013, AM J RESP CRIT CARE, V188, P586, DOI 10.1164/rccm.201212-2154OC; Smeeth L, 2004, NEW ENGL J MED, V351, P2611, DOI 10.1056/NEJMoa041747; Stevens LA, 2006, NEW ENGL J MED, V354, P2473, DOI 10.1056/NEJMra054415; Town Machell, 2006, Prev Chronic Dis, V3, pA53; Tracy RP, 1997, ARTERIOSCL THROM VAS, V17, P1121, DOI 10.1161/01.ATV.17.6.1121; Wang MH, 2009, CANCER EPIDEM BIOMAR, V18, P706, DOI 10.1158/1055-9965.EPI-08-0839; Whitaker HJ, 2009, STAT METHODS MED RES, V18, P7, DOI 10.1177/0962280208092342; White AD, 1996, J CLIN EPIDEMIOL, V49, P223, DOI 10.1016/0895-4356(95)00041-0; WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184; Yende S, 2008, AM J RESP CRIT CARE, V177, P1242, DOI 10.1164/rccm.200712-1777OC; Yende S, 2007, J AM GERIATR SOC, V55, P518, DOI 10.1111/j.1532-5415.2007.01100.x; Yende S, 2013, CHEST, V144, P1008, DOI 10.1378/chest.12-2818; Yende S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022847	40	328	335	3	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	2015	313	3					264	274		10.1001/jama.2014.18229	http://dx.doi.org/10.1001/jama.2014.18229			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AZ3RS	25602997	Green Accepted, Bronze, Green Submitted			2023-01-03	WOS:000348145000018
J	Ma, QF; Chu, CB; Song, HQ				Ma, Qing-feng; Chu, Chang-biao; Song, Hai-qing			Intravenous versus Intra-Arterial Thrombolysis in Ischemic Stroke: A Systematic Review and Meta-Analysis	PLOS ONE			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; RECANALIZATION; OCCLUSION; TIME; PROUROKINASE; IMPROVEMENT; PREDICTORS; HEMORRHAGE; EXPERIENCE; PROACT	Background: Reperfusion following ischemic stroke can be attained by either intravenous thrombolysis (IVT) or intra-arterial thrombolysis (IAT). Only a limited number of randomized prospective studies have compared the efficacy and safety of IVT and IAT. This meta-analysis investigated possible clinical benefits of IAT relative to IVT in patients with acute ischemic stroke. Methods: We searched the PubMed, Cochrane, and Google Scholar databases through October 2013 for manuscripts that describe the findings of randomized controlled or prospective studies that evaluated the outcomes of patients with ischemic stroke who were treated with IVT or IAT. The clinical outcome measures were score on the modified Rankin scale (mRS) and mortality at 90 days. A favorable outcome was defined as an mRS score of 0 to 2. Results: For the mRS, the combined odds ratio (OR) of 3.28 (95% confidence interval (CI), 1.91 to 5.65, P < 0.001) indicated that patients who received IAT had a significantly higher chance for a favorable outcome than did those who received IVT. For mortality, the OR indicated that IAT therapy significantly reduced the proportion of patients who died within 90 days of the procedure (combined OR, 0.40; 95% CI, 0.17 to 0.92; P = 0.032). Conclusion: This meta-analysis determined that IAT conferred a significantly greater probability of achieving a favorable outcome compared with IVT. There was also a significant difference in mortality rates between IAT and IVT. The studies included in this analysis were small and heterogeneous; therefore, larger randomized prospective clinical studies are necessary to further investigate this issue.	[Ma, Qing-feng; Chu, Chang-biao; Song, Hai-qing] Capital Med Univ, Xuan Wu Hosp, Dept Neurol, Beijing, Peoples R China	Capital Medical University	Song, HQ (corresponding author), Capital Med Univ, Xuan Wu Hosp, Dept Neurol, Beijing, Peoples R China.	songhq@vip.sina.com						Arnold M, 2013, NEW ENGL J MED, V368, P2431, DOI [10.1056/NEJMc1304759, 10.1056/NEJMoa1213701]; Bhatia R, 2010, STROKE, V41, P2254, DOI 10.1161/STROKEAHA.110.592535; Bivard A, 2013, J STROKE, V15, P90, DOI 10.5853/jos.2013.15.2.90; Christoforidis GA, 2010, INTERV NEURORADIOL, V16, P297, DOI 10.1177/159101991001600312; Christou I, 2002, J NEUROIMAGING, V12, P119, DOI 10.1111/j.1552-6569.2002.tb00107.x; Ciccone A, 2010, J NEUROINTERV SURG, V2, P74, DOI 10.1136/jnis.2009.001388; del Zoppo GJ, 1998, STROKE, V29, P4, DOI 10.1161/01.STR.29.1.4; DELZOPPO GJ, 2009, STROKE, V40, P2945, DOI [10.1161/STROKEAHA.109.192535, DOI 10.1161/STR0KEAHA.109.192535]; Ducrocq X, 2005, J NEURORADIOLOGY, V32, P26, DOI 10.1016/S0150-9861(05)83018-4; Endo S, 1998, AM J NEURORADIOL, V19, P1169; Furlan A, 1999, JAMA-J AM MED ASSOC, V282, P2003, DOI 10.1001/jama.282.21.2003; Heo JH, 2003, NEUROLOGY, V60, P1684, DOI 10.1212/01.WNL.0000063323.23493.98; Khatri P, 2009, NEUROLOGY, V73, P1066, DOI 10.1212/WNL.0b013e3181b9c847; Kim JW, 2012, CLIN NEUROL NEUROSUR, V114, P1316, DOI 10.1016/j.clineuro.2012.04.022; Lees KR, 2010, LANCET, V375, P1695, DOI 10.1016/S0140-6736(10)60491-6; Lewandowski CA, 1999, STROKE, V30, P2598, DOI 10.1161/01.STR.30.12.2598; Mattle HP, 2008, STROKE, V39, P379, DOI 10.1161/STROKEAHA.107.492348; Mullen MT, 2012, STROKE, V43, P2350, DOI 10.1161/STROKEAHA.111.639211; Nam J, 2015, INT J STROKE, V10, P13, DOI 10.1111/j.1747-4949.2012.00914.x; Natarajan SK, 2009, STROKE, V40, P3269, DOI 10.1161/STROKEAHA.109.555102; Qureshi AI, 2006, NEUROSURGERY, V59, P789, DOI 10.1227/01.NEU.0000232862.06246.3D; Qureshi AI, 2004, LANCET, V363, P804, DOI 10.1016/S0140-6736(04)15697-3; Rabinstein AA, 2002, AM J NEURORADIOL, V23, P1596; Rha JH, 2007, STROKE, V38, P967, DOI 10.1161/01.STR.0000258112.14918.24; Saqqur M, 2007, STROKE, V38, P948, DOI 10.1161/01.STR.0000257304.21967.ba; Sen S, 2009, NEUROCRIT CARE, V11, P76, DOI 10.1007/s12028-009-9204-1; Smith WS, 2008, STROKE, V39, P1205, DOI 10.1161/STROKEAHA.107.497115; Suarez JI, 1999, STROKE, V30, P2094, DOI 10.1161/01.STR.30.10.2094; Sutton AJ, 2000, BMJ-BRIT MED J, V320, P1574, DOI 10.1136/bmj.320.7249.1574; Tomsick T, 1996, AM J NEURORADIOL, V17, P79; van Houwelingen HC, 2002, STAT MED, V21, P589, DOI 10.1002/sim.1040; Wardlaw JM, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000514.pub3; Wardlaw JM, 2012, LANCET, V379, P2364, DOI 10.1016/S0140-6736(12)60738-7; Zangerle A, 2007, NEUROLOGY, V68, P39, DOI 10.1212/01.wnl.0000250341.38014.d2; Zhang B, 2010, CAN J NEUROL SCI, V37, P240, DOI 10.1017/S0317167100009999	35	35	35	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 8	2015	10	1							e0116120	10.1371/journal.pone.0116120	http://dx.doi.org/10.1371/journal.pone.0116120			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AZ4BT	25569136	Green Published, Green Submitted, gold			2023-01-03	WOS:000348168000004
J	Tolaney, SM; Barry, WT; Dang, CT; Yardley, DA; Moy, B; Marcom, PK; Albain, KS; Rugo, HS; Ellis, M; Shapira, I; Wolff, AC; Carey, LA; Overmoyer, BA; Partridge, AH; Guo, H; Hudis, CA; Krop, IE; Burstein, HJ; Winer, EP				Tolaney, Sara M.; Barry, William T.; Dang, Chau T.; Yardley, Denise A.; Moy, Beverly; Marcom, P. Kelly; Albain, Kathy S.; Rugo, Hope S.; Ellis, Matthew; Shapira, Iuliana; Wolff, Antonio C.; Carey, Lisa A.; Overmoyer, Beth A.; Partridge, Ann H.; Guo, Hao; Hudis, Clifford A.; Krop, Ian E.; Burstein, Harold J.; Winer, Eric P.			Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MONOCLONAL-ANTIBODY; CHEMOTHERAPY; EFFICACY; OVEREXPRESSION; ONCOGENE; SAFETY; WOMEN; RISK	BACKGROUND No single standard treatment exists for patients with small, node-negative, human epidermal growth factor receptor type 2 (HER2)-positive breast cancers, because most of these patients have been ineligible for the pivotal trials of adjuvant trastuzumab. METHODS We performed an uncontrolled, single-group, multicenter, investigator-initiated study of adjuvant paclitaxel and trastuzumab in 406 patients with tumors measuring up to 3 cm in greatest dimension. Patients received weekly treatment with paclitaxel and trastuzumab for 12 weeks, followed by 9 months of trastuzumab monotherapy. The primary end point was survival free from invasive disease. RESULTS The median follow-up period was 4.0 years. The 3-year rate of survival free from invasive disease was 98.7% (95% confidence interval [CI], 97.6 to 99.8). Among the 12 relapses seen, 2 were due to distant metastatic breast cancer. Excluding contralateral HER2-negative breast cancers and nonbreast cancers, 7 disease-specific events were noted. A total of 13 patients (3.2%; 95% CI, 1.7 to 5.4) reported at least one episode of grade 3 neuropathy, and 2 had symptomatic congestive heart failure (0.5%; 95% CI, 0.1 to 1.8), both of whom had normalization of the left ventricular ejection fraction after discontinuation of trastuzumab. A total of 13 patients had significant asymptomatic declines in ejection fraction (3.2%; 95% CI, 1.7 to 5.4), as defined by the study, but 11 of these patients were able to resume trastuzumab therapy after a brief interruption. CONCLUSIONS Among women with predominantly stage I HER2-positive breast cancer, treatment with adjuvant paclitaxel plus trastuzumab was associated with a risk of early recurrence of about 2%; 6% of patients withdrew from the study because of protocol-specified adverse events. (Funded by Genentech; ClinicalTrials.gov number, NCT00542451.)	[Tolaney, Sara M.; Overmoyer, Beth A.; Partridge, Ann H.; Krop, Ian E.; Burstein, Harold J.; Winer, Eric P.] Massachusetts Gen Hosp, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02114 USA; [Barry, William T.; Guo, Hao] Massachusetts Gen Hosp, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02114 USA; [Moy, Beverly] Massachusetts Gen Hosp, Dept Hematol Oncol, Boston, MA 02114 USA; [Dang, Chau T.; Hudis, Clifford A.] Mem Sloan Kettering Canc Ctr, Solid Tumor Div, Dept Med, Breast Canc Med Serv, New York, NY 10021 USA; [Dang, Chau T.; Hudis, Clifford A.] Weill Cornell Med Ctr, Dept Med, New York, NY USA; [Shapira, Iuliana] Hofstra North Shore LIJ Sch Med, Dept Med Oncol, New Hyde Pk, NY USA; [Yardley, Denise A.] Sarah Cannon Canc Ctr, Dept Med Oncol, Nashville, TN USA; [Marcom, P. Kelly] Duke Canc Inst, Dept Med, Div Med Oncol, Durham, NC USA; [Carey, Lisa A.] Univ N Carolina, Dept Med Oncol, Chapel Hill, NC USA; [Albain, Kathy S.] Loyola Univ Chicago Stritch Sch Med, Div Hematol Oncol, Dept Med, Cardinal Bernardin Canc Ctr, Maywood, IL USA; [Rugo, Hope S.] Univ Calif San Francisco, Div Oncol, Dept Med, Ctr Comprehens Canc, San Francisco, CA 94143 USA; [Ellis, Matthew] Washington Univ, Dept Med Oncol, St Louis, MO 63130 USA; [Wolff, Antonio C.] Johns Hopkins Kimmel Canc Ctr, Dept Oncol, Baltimore, MD USA	Harvard University; Dana-Farber Cancer Institute; Massachusetts General Hospital; Harvard University; Dana-Farber Cancer Institute; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Memorial Sloan Kettering Cancer Center; Cornell University; Hofstra University; Northwell Health; Sarah Cannon Research Institute; Duke University; University of North Carolina; University of North Carolina Chapel Hill; Loyola University Chicago; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Washington University (WUSTL); Johns Hopkins University; Johns Hopkins Medicine	Winer, EP (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA.	ewiner@-partners.org	Guo, Hao/E-8921-2015; Wolff, Antonio C./T-8796-2019; Marcom, Paul/AAE-4761-2020; Hudis, Clifford/AAW-9482-2021; Marcom, Paul/M-4516-2019	Guo, Hao/0000-0003-1658-0989; Wolff, Antonio C./0000-0003-3734-1063; Marcom, Paul/0000-0001-5302-6368; Hudis, Clifford/0000-0001-7144-8791; 	Genentech; NATIONAL CANCER INSTITUTE [P30CA006973] Funding Source: NIH RePORTER	Genentech(Roche HoldingGenentech); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funded by Genentech; ClinicalTrials.gov number, NCT00542451.	Albain K, 2012, LANCET, V379, P432, DOI 10.1016/S0140-6736(11)61625-5; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Chia S, 2008, J CLIN ONCOL, V26, P5697, DOI 10.1200/JCO.2007.15.8659; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Curigliano G, 2009, J CLIN ONCOL, V27, P5693, DOI 10.1200/JCO.2009.22.0962; Fehrenbacher L, 2014, J CLIN ONCOL, V32, P2151, DOI 10.1200/JCO.2013.52.0858; Goldhirsch A, 2013, LANCET, V382, P1021, DOI 10.1016/S0140-6736(13)61094-6; Gonzalez-Angulo AM, 2009, J CLIN ONCOL, V27, P5700, DOI 10.1200/JCO.2009.23.2025; Hudis CA, 2007, J CLIN ONCOL, V25, P2127, DOI 10.1200/JCO.2006.10.3523; McArthur HL, 2011, CANCER-AM CANCER SOC, V117, P5461, DOI 10.1002/cncr.26171; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; PRESS MF, 1993, CANCER RES, V53, P4960; Romond E, 2012, SAN ANT BREAST CANC; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; SESHADRI R, 1993, J CLIN ONCOL, V11, P1936, DOI 10.1200/JCO.1993.11.10.1936; Slamon D, 2011, NEW ENGL J MED, V365, P1273, DOI 10.1056/NEJMoa0910383; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Vaz-Luis I, 2014, J CLIN ONCOL, V32, P2142, DOI 10.1200/JCO.2013.53.1608; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719	19	449	475	0	43	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 8	2015	372	2					134	141		10.1056/NEJMoa1406281	http://dx.doi.org/10.1056/NEJMoa1406281			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AY2UA	25564897	Green Published, Green Accepted, Bronze			2023-01-03	WOS:000347443300008
J	Liu, MJ; Ishida, Y; Ebina, Y; Sasaki, T; Hikima, T; Takata, M; Aida, T				Liu, Mingjie; Ishida, Yasuhiro; Ebina, Yasuo; Sasaki, Takayoshi; Hikima, Takaaki; Takata, Masaki; Aida, Takuzo			An anisotropic hydrogel with electrostatic repulsion between cofacially aligned nanosheets	NATURE			English	Article							LONG-RANGE; CLAY; DIFFUSION; ALIGNMENT	Machine technology frequently puts magnetic or electrostatic repulsive forces to practical use, as in maglev trains, vehicle suspensions or non-contact bearings(1,2). In contrast, materials design overwhelmingly focuses on attractive interactions, such as in the many advanced polymer-based composites, where inorganic fillers interact with a polymer matrix to improve mechanical properties. However, articular cartilage strikingly illustrates how electrostatic repulsion can be harnessed to achieve unparalleled functional efficiency: it permits virtually friction-less mechanical motion within joints, even under high compression(3,4). Here we describe a composite hydrogel with anisotropic mechanical properties dominated by electrostatic repulsion between negatively charged unilamellar titanate nanosheets(5) embedded within it. Crucial to the behaviour of this hydrogel is the serendipitous discovery of cofacial nanosheet alignment in aqueous colloidal dispersions subjected to a strong magnetic field, which maximizes electrostatic repulsion(6) and thereby induces a quasi-crystalline structural ordering(7,8) over macroscopic length scales and with uniformly large face-to-face nanosheet separation. We fix this transiently induced structural order by transforming the dispersion into a hydrogel(9,10) using light-triggered in situ vinyl polymerization(11). The resultant hydrogel, containing charged inorganic structures that align cofacially in a magnetic flux(12-19), deforms easily under shear forces applied parallel to the embedded nanosheets yet resists compressive forces applied orthogonally. We anticipate that the concept of embedding anisotropic repulsive electrostatics within a composite material, inspired by articular cartilage, will open up new possibilities for developing soft materials with unusual functions.	[Liu, Mingjie; Ishida, Yasuhiro; Aida, Takuzo] RIKEN Ctr Emergent Matter Sci, Wako, Saitama 3510198, Japan; [Ebina, Yasuo; Sasaki, Takayoshi] Int Ctr Mat Nanoarchitecton, Natl Inst Mat Sci, Tsukuba, Ibaraki 3050044, Japan; [Hikima, Takaaki; Takata, Masaki] RIKEN SPring 8 Ctr, Sayo, Hyogo 6795198, Japan; [Aida, Takuzo] Univ Tokyo, Dept Chem & Biotechnol, Sch Engn, Bunkyo Ku, Tokyo 1138656, Japan	RIKEN; National Institute for Materials Science; RIKEN; University of Tokyo	Ishida, Y (corresponding author), RIKEN Ctr Emergent Matter Sci, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	y-ishida@riken.jp; aida@macro.t.u-tokyo.ac.jp	Ishida, Yasuhiro/I-8204-2012; EBINA, Yasuo/H-2730-2011; Aida, Takuzo/I-9117-2012; Liu, Mingjie/G-1109-2010; SASAKI, Takayoshi/H-2956-2011	EBINA, Yasuo/0000-0003-3471-9825; Liu, Mingjie/0000-0003-0824-9858; liu, ming jie/0000-0002-8399-2134	 [25000005]		This work was financially supported by a Grant-in-Aid for Specially Promoted Research (25000005) on "Physically Perturbed Assembly for Tailoring High-Performance Soft Materials with Controlled Macroscopic Structural Anisotropy''. We also acknowledge the ImPACT Program of Council for Science, Technology and Innovation (Cabinet Office, Government of Japan). The synchrotron X-ray diffraction experiments were performed at BL45XUin SPring-8 with the approval of the RIKEN SPring-8 Center (proposal 20140073).	ANANDARAJAH A, 1991, INT J NUMER ANAL MET, V15, P683, DOI 10.1002/nag.1610151002; Budtova T, 1997, MACROMOLECULES, V30, P6556, DOI 10.1021/ma970304e; Cui HG, 2010, SCIENCE, V327, P555, DOI 10.1126/science.1182340; Dean D, 2006, J BIOMECH, V39, P2555, DOI 10.1016/j.jbiomech.2005.09.007; Eguchi M, 2008, J PHYS CHEM C, V112, P11280, DOI 10.1021/jp802702m; Erb RM, 2012, SCIENCE, V335, P199, DOI 10.1126/science.1210822; Feng S, 2009, MACROMOLECULES, V42, P281, DOI 10.1021/ma8015932; Haque MA, 2010, ADV MATER, V22, P5110, DOI 10.1002/adma.201002509; Hull JR, 2000, SUPERCOND SCI TECH, V13, pR1, DOI 10.1088/0953-2048/13/2/201; Ida S, 2008, J AM CHEM SOC, V130, P7052, DOI 10.1021/ja7114772; Kleinschmidt F, 2005, MACROMOLECULES, V38, P9772, DOI 10.1021/ma051479o; Liu MJ, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3029; Lowen H, 2001, J PHYS-CONDENS MAT, V13, pR415, DOI 10.1088/0953-8984/13/24/201; MARET G, 1985, TOP APPL PHYS, V57, P143; Munch E, 2008, SCIENCE, V322, P1516, DOI 10.1126/science.1164865; Osada M, 2006, PHYS REV B, V73, DOI 10.1103/PhysRevB.73.153301; Palmer LC, 2014, J AM CHEM SOC, V136, P14377, DOI [10.1021/ja5082519, 10.1021/ja50825191]; Podsiadlo P, 2007, SCIENCE, V318, P80, DOI 10.1126/science.1143176; Prosser RS, 1996, J AM CHEM SOC, V118, P269, DOI 10.1021/ja953598x; RHIM WK, 1993, REV SCI INSTRUM, V64, P2961, DOI 10.1063/1.1144475; Sasaki T, 1996, J AM CHEM SOC, V118, P8329, DOI 10.1021/ja960073b; Scott JE, 2003, J PHYSIOL-LONDON, V553, P335, DOI 10.1113/jphysiol.2003.050179; Tamesue S, 2013, J AM CHEM SOC, V135, P15650, DOI 10.1021/ja408547g; Tan CB, 2002, J AM CHEM SOC, V124, P11827, DOI 10.1021/ja027079n; TORBET J, 1981, NATURE, V289, P91, DOI 10.1038/289091a0; UYEDA C, 1993, PHYS CHEM MINER, V20, P77; Verwey E.J.W, 1948, THEORY STABILITY LYO; Wang Q, 2010, NATURE, V463, P339, DOI 10.1038/nature08693; Wu JJ, 2012, SOFT MATTER, V8, P3620, DOI 10.1039/c2sm07411g; Wu ZL, 2011, MACROMOLECULES, V44, P3535, DOI 10.1021/ma2001228	30	347	363	63	1435	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 1	2015	517	7532					68	72		10.1038/nature14060	http://dx.doi.org/10.1038/nature14060			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX8SI	25557713				2023-01-03	WOS:000347178400036
J	Domingues, CSB; Waldman, EA				Bruniera Domingues, Carmen-Silvia; Waldman, Eliseu Alves			Causes of Death among People Living with AIDS in the Pre- and Post-HAART Eras in the City of S(a)over-tildeo Paulo, Brazil	PLOS ONE			English	Article							HIV-INFECTED INDIVIDUALS; ACTIVE ANTIRETROVIRAL THERAPY; SURVEYS ANRS EN19; RIO-DE-JANEIRO; INTERNATIONAL CLASSIFICATION; MORTALITY-RATES; PERSISTENT ROLE; UNITED-STATES; DISEASES; CANCERS	Objective: We examine the trend in causes of death among people living with AIDS in the city of S (a) over tildeo Paulo, Brazil, in the periods before and after the introduction of highly active antiretroviral therapy (HAART), and we investigate potential disparities across districts of residence. Methods: Descriptive study of three periods: pre-HAART (1991-1996); early post-HAART (1997-1999); and late post-HAART (2000-2006). The data source was the S (a) over tildeo Paulo State STD/AIDS Program and S (a) over tildeo Paulo State Data Analysis Foundation. Causes of death were classified by the ICD-9 (1991-1995) and ICD-10 (1996-2006). We estimated age-adjusted mortality rates for leading underlying causes of death and described underlying and associated causes of death according to sociodemographic characteristics and area of residence. We used Pearson's chi-square test or Fisher's exact test to compare categorical variables. Areas of residence were categorized using a socioeconomic index. To analyze trends we apply generalized linear model with Poisson regression. Results: We evaluated 32,808 AIDS-related deaths. Between the pre- and late post-HAART periods, the proportion of deaths whose underlying causes were non-AIDS-related diseases increased from 0.2% to 9.6% (p < 0.001): from 0.01% to 1.67% (p < 0.001) for cardiovascular diseases; 0.01% to 1.62% (p < 0.001) for bacterial/unspecified pneumonia; and 0.03% to 1.46% (p < 0.001) for non-AIDS-defining cancers. In the late post-HAART period, the most common associated causes of death were bacterial/unspecified pneumonia (35.94%), septicemia (33.46%), cardiovascular diseases (10.11%) and liver diseases (8.0%); and common underlying causes, besides AIDS disease, included non-AIDS-defining cancers in high-income areas, cardiovascular diseases in middle-income areas and assault in low-income areas. Conclusions: The introduction of HAART has shifted the mortality profile away from AIDS-related conditions, suggesting changes in the pattern of morbidity, but heterogeneously according to area of residence. There is a need for public policies aimed at adapting health care services to address the new scenario.	[Bruniera Domingues, Carmen-Silvia] Referral & Training Ctr, Sao Paulo State Dept Hlth STD & AIDS, Sao Paulo State Program STDs & AIDS, Sao Paulo, Brazil; [Bruniera Domingues, Carmen-Silvia; Waldman, Eliseu Alves] Univ Sao Paulo, Sch Publ Hlth, Dept Epidemiol, Sao Paulo, Brazil	Universidade de Sao Paulo	Waldman, EA (corresponding author), Univ Sao Paulo, Sch Publ Hlth, Dept Epidemiol, Sao Paulo, Brazil.	eawaldma@usp.br	Waldman, Eliseu A/I-9401-2012	Waldman, Eliseu A/0000-0001-7807-6898	Brazilian Conselho Nacional de Desenvolvimento Cientifico e Tecnolo3gico (CNPq, National Council for Scientific and Technological Development) [309502/2003-9]	Brazilian Conselho Nacional de Desenvolvimento Cientifico e Tecnolo3gico (CNPq, National Council for Scientific and Technological Development)	Financial support for this research was provided by a grant from the Brazilian Conselho Nacional de Desenvolvimento Cientifico e Tecnolo3gico (CNPq, National Council for Scientific and Technological Development; Grant no. 309502/2003-9 to EAW). The funder had no role in the data collection, data analysis, preparation of the manuscript or decision to publish. No additional external funding was received for this study.	Adih William K, 2011, J Int Assoc Physicians AIDS Care (Chic), V10, P5, DOI 10.1177/1545109710384505; Bloomfield GS, 2014, JAIDS-J ACQ IMM DEF, V67, pS40, DOI 10.1097/QAI.0000000000000257; Bonnet F, 2009, CLIN INFECT DIS, V48, P633, DOI 10.1086/596766; Crabtree-Ramirez B, 2014, JAIDS-J ACQ IMM DEF, V67, pS96, DOI 10.1097/QAI.0000000000000261; Crum NF, 2006, JAIDS-J ACQ IMM DEF, V41, P194, DOI 10.1097/01.qai.0000179459.31562.16; Crum-Cianflone N, 2009, AIDS, V23, P41, DOI 10.1097/QAD.0b013e328317cc2d; Fazito E, 2012, SEX TRANSM INFECT, V88, pI86, DOI 10.1136/sextrans-2012-050632; Ferreira MP, 2006, SAO PAULO PERSPECT, V20, P5; Galvao J, 2002, LANCET, V360, P1862, DOI 10.1016/S0140-6736(02)11775-2; Gopal M, 2009, CURR CARDIOL REV, V5, P149, DOI 10.2174/157340309788166705; Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768; Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494; Hacker MA, 2007, CAD SAUDE PUBLICA, V23, pS345, DOI 10.1590/S0102-311X2007001500003; Hessamfar-Bonarek M, 2010, INT J EPIDEMIOL, V39, P135, DOI 10.1093/ije/dyp300; Khunnawat C, 2008, AM J CARDIOL, V102, P635, DOI 10.1016/j.amjcard.2008.04.035; Krentz HB, 2005, HIV MED, V6, P99, DOI 10.1111/j.1468-1293.2005.00271.x; Rezende ELLF, 2010, BRAZ J INFECT DIS, V14, P558, DOI [10.1016/S1413-8670(10)70112-4, 10.1590/S1413-86702010000600003]; Lewden C, 2005, INT J EPIDEMIOL, V34, P121, DOI 10.1093/ije/dyh307; Lewden C, 2008, JAIDS-J ACQ IMM DEF, V48, P590, DOI 10.1097/QAI.0b013e31817efb54; Martinez E, 2009, CURR OPIN INFECT DIS, V22, P28, DOI 10.1097/QCO.0b013e328320a849; Melo VH, 2014, J LOW GENIT TRACT DI, V18, P128, DOI 10.1097/LGT.0b013e31829ee855; Ministerio da Saude do Brasil Secretaria de Politicas de Saude Coordenacao Nacional de DST e Aids, 2002, VIG HIV BRAS NOV DIR; Ministerio da Saude do Brasil Secretaria de Vigilancia em Saude Departamento de DST Aids e Hepatites Virais, 2010, B EPIDEMIOLOGICO AID, VVI, P8; Ministerio da Saude do Brasil Secretaria de Vigilancia em Saude Programa Nacional de DST e Aids, 2004, CRIT DEF CAS AIDS AD; Pacheco AG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001531; Pacheco AG, 2011, AIDS RES HUM RETROV, V27, P25, DOI 10.1089/aid.2010.0089; Pacheco AG, 2009, JAIDS-J ACQ IMM DEF, V51, P624, DOI 10.1097/QAI.0b013e3181a4ecf5; Palella FJ, 2006, JAIDS-J ACQ IMM DEF, V43, P27, DOI 10.1097/01.qai.0000233310.90484.16; Paula AA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094636; Prefeitura da Cidade de Sao Paulo, 2002, SECR MUN DES TRAB SO; Prefeitura da Cidade de Sao Paulo. Secretaria Municipal de Saude, 2010, B EPIDEMIOLOGICO AID, VXIV, P17; Sackoff JE, 2006, ANN INTERN MED, V145, P397, DOI 10.7326/0003-4819-145-6-200609190-00003; Santo AH, 2000, REV SAUDE PUBL, V34, P21, DOI 10.1590/S0034-89102000000100005; Santo AH, 1999, REV BRASIL EPIDEMIOL, P90; Santos SS, 2013, J INT AIDS SOC, V16, P17344; Selik RM, 2002, J ACQ IMMUN DEF SYND, V29, P378, DOI 10.1097/00126334-200204010-00009; Shiels MS, 2009, JAIDS-J ACQ IMM DEF, V52, P611, DOI 10.1097/QAI.0b013e3181b327ca; Simard EP, 2010, CLIN INFECT DIS, V51, P957, DOI 10.1086/656416; Suarez LC, 2006, REV ESP SALUD PUBLIC, V80, P157, DOI [10.1590/s1135-57272006000200005, 10.1590/S1135-57272006000200005]; Peres MFT, 2011, REV PANAM SALUD PUBL, V29, P17, DOI 10.1590/S1020-49892011000100003; Waldvogel BC, 2010, DADOS REPENSAR AIDS, P9; Waldvogel Bernadette Cunha, 2006, Rev. bras. estud. popul., V23, P187, DOI 10.1590/S0102-30982006000100011	42	13	13	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 11	2014	9	12							e114661	10.1371/journal.pone.0114661	http://dx.doi.org/10.1371/journal.pone.0114661			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX8FY	25500837	Green Published, gold, Green Submitted			2023-01-03	WOS:000347146700041
J	Liu, HL; Huang, CY; Chen, JY; Wang, HYJ; Chen, PY; Wei, KC				Liu, Hao-Li; Huang, Chiung-Yin; Chen, Ju-Yu; Wang, Hay-Yan Jack; Chen, Pin-Yuan; Wei, Kuo-Chen			Pharmacodynamic and Therapeutic Investigation of Focused Ultrasound-Induced Blood-Brain Barrier Opening for Enhanced Temozolomide Delivery in Glioma Treatment	PLOS ONE			English	Article							ANTITUMOR AGENT TEMOZOLOMIDE; GLIOBLASTOMA-MULTIFORME; HUMAN PLASMA; ADJUVANT TEMOZOLOMIDE; PHASE-III; RAT; DISRUPTION; RADIATION; TUMOR; DRUG	Focused ultrasound (FUS) exposure with the presence of microbubbles has been shown to transiently open the blood-brain barrier (BBB), and thus has potential to enhance the delivery of various kinds of therapeutic agents into brain tumors. The purpose of this study was to assess the preclinical therapeutic efficacy of FUS-BBB opening for enhanced temozolomide (TMZ) delivery in glioma treatment. FUS exposure with microbubbles was delivered to open the BBB of nude mice that were either normal or implanted with U87 human glioma cells. Different TMZ dose regimens were tested, ranging from 2.5 to 25 mg/kg. Plasma and brain samples were obtained at different time-points ranging from 0.5 to 4 hours, and the TMZ concentration within samples was quantitated via a developed LC-MS/MS procedure. Tumor progression was followed with T2-MRI, and animal survival and brain tissue histology were conducted. Results demonstrated that FUS-BBB opening caused the local TMZ accumulation in the brain to increase from 6.98 to 19 ng/mg. TMZ degradation time in the tumor core was found to increase from 1.02 to 1.56 hours. Improved tumor progression and animal survival were found at different TMZ doses (up to 15% and 30%, respectively). In conclusion, this study provides preclinical evidence that FUS-BBB opening increases the local concentration of TMZ to improve the control of tumor progression and animal survival, suggesting the potential for clinical application to improve current brain tumor treatment.	[Liu, Hao-Li; Chen, Ju-Yu] Chang Gung Univ, Dept Elect Engn, Taoyuan, Taiwan; [Huang, Chiung-Yin; Chen, Pin-Yuan; Wei, Kuo-Chen] Chang Gung Mem Hosp, Dept Neurosurg, Linkou, Taiwan; [Wang, Hay-Yan Jack] Natl Sun Yat Sen Univ, Dept Biol Sci, Kaohsiung 80424, Taiwan; [Liu, Hao-Li] Chang Gung Univ, Hlth Aging Res Ctr, Taoyuan, Taiwan	Chang Gung University; Chang Gung Memorial Hospital; National Sun Yat Sen University; Chang Gung University	Liu, HL (corresponding author), Chang Gung Univ, Dept Elect Engn, Taoyuan, Taiwan.	haoliliu@mail.cgu.edu.tw; kuochenwei@adm.cgmh.org.tw		Wei, Kuochen/0000-0003-3505-2196; Chen, Ju-Yu/0000-0001-8064-9392	Ministry of Science and Technology, Taiwan [101-2221-E-182-002-MY3, 102-2221-E-182-020-MY3, 103-2622-B-182A-001, 103-2325-B-182A-007]; Chang-Gung Memorial Hospital, Taiwan [CMRPD2A0031-33, CMRPG380041]	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); Chang-Gung Memorial Hospital, Taiwan(Chang Gung Memorial Hospital)	This research was supported by the Ministry of Science and Technology, Taiwan, grant nos. 101-2221-E-182-002-MY3, 102-2221-E-182-020-MY3, 103-2622-B-182A-001, 103-2325-B-182A-007, and Chang-Gung Memorial Hospital, Taiwan, grant nos. CMRPD2A0031-33 and CMRPG380041. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baker SD, 1999, CLIN CANCER RES, V5, P309; BURGER PC, 1987, MAYO CLIN PROC, V62, P527, DOI 10.1016/S0025-6196(12)65479-2; Chowdhury SK, 1999, J PHARMACEUT BIOMED, V19, P659, DOI 10.1016/S0731-7085(98)00198-8; DENNY BJ, 1994, BIOCHEMISTRY-US, V33, P9045, DOI 10.1021/bi00197a003; Ewing JR, 2006, J CEREBR BLOOD F MET, V26, P310, DOI 10.1038/sj.jcbfm.9600189; Galanis E, 2000, BRIT J CANCER, V82, P1371, DOI 10.1054/bjoc.1999.1075; GROOTHUIS DR, 1982, J NEUROPATH EXP NEUR, V41, P164, DOI 10.1097/00005072-198203000-00006; Grossman SA, 2004, SEMIN ONCOL, V31, P635, DOI 10.1053/j.seminoncol.2004.07.005; Grossman SA, 2003, J CLIN ONCOL, V21, P1485, DOI 10.1200/JCO.2003.10.035; Gupta Vinay, 2006, Neurosurg Focus, V20, pE20, DOI 10.3171/foc.2006.20.4.13; HALPERIN EC, 1988, INT J RADIAT ONCOL, V15, P505, DOI 10.1016/S0360-3016(98)90036-0; Hammond LA, 1999, J CLIN ONCOL, V17, P2604, DOI 10.1200/JCO.1999.17.8.2604; Hassouna I, 2008, INT J RADIAT ONCOL, V72, P927, DOI 10.1016/j.ijrobp.2008.06.1923; Hynynen K, 2005, NEUROIMAGE, V24, P12, DOI 10.1016/j.neuroimage.2004.06.046; Hynynen K, 2003, ACT NEUR S, V86, P555; Hynynen K, 2001, RADIOLOGY, V220, P640, DOI 10.1148/radiol.2202001804; Kim H, 2001, J PHARMACEUT BIOMED, V24, P461, DOI 10.1016/S0731-7085(00)00466-0; Kim HK, 1997, J CHROMATOGR B, V703, P225, DOI 10.1016/S0378-4347(97)00431-3; Liu HL, 2010, RADIOLOGY, V255, P415, DOI 10.1148/radiol.10090699; McDannold N, 2005, ULTRASOUND MED BIOL, V31, P1527, DOI 10.1016/j.ultrasmedbio.2005.07.010; Mesiwala AH, 2002, ULTRASOUND MED BIOL, V28, P389, DOI 10.1016/S0301-5629(01)00521-X; NEUWELT EA, 1982, P NATL ACAD SCI-BIOL, V79, P4420, DOI 10.1073/pnas.79.14.4420; NEUWELT EA, 1986, NEUROSURGERY, V19, P573, DOI 10.1227/00006123-198610000-00011; NEUWELT EA, 1985, CANCER RES, V45, P2827; NEUWELT EA, 1986, CANCER, V58, P1609, DOI 10.1002/1097-0142(19861015)58:8<1609::AID-CNCR2820580805>3.0.CO;2-7; Portnow J, 2009, CLIN CANCER RES, V15, P7092, DOI 10.1158/1078-0432.CCR-09-1349; Reyderman L, 2004, XENOBIOTICA, V34, P487, DOI 10.1080/00498250410001685737; SHEN F, 1995, J CHROMATOGR B, V667, P291, DOI 10.1016/0378-4347(95)00040-P; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; STEVENS MFG, 1987, CANCER RES, V47, P5846; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Tralins KS, 2002, J NUCL MED, V43, P1667; Von Hoff DD, 2004, HDB ANTICANCER PHARM, P57992; Wei KC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058995	35	63	65	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2014	9	12							e114311	10.1371/journal.pone.0114311	http://dx.doi.org/10.1371/journal.pone.0114311			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AY3YM	25490097	Green Submitted, gold, Green Published			2023-01-03	WOS:000347515300026
J	Hao, J; Zhen, Y; Wang, H; Yang, DY; Wang, NL				Hao, Jie; Zhen, Yi; Wang, Hao; Yang, Diya; Wang, Ningli			The Effect of Lateral Decubitus Position on Nocturnal Intraocular Pressure over a Habitual 24-Hour Period in Healthy Adults	PLOS ONE			English	Article							OPEN-ANGLE GLAUCOMA; TENSION GLAUCOMA; POSTURAL CHANGE; YOUNG SUBJECTS; BODY POSITION; PATTERN; POPULATION; SLEEP; EYE	Purpose: To investigate the effect of lateral decubitus position (LDP) on nocturnal intraocular pressure (IOP) and the effect of LDP on 24-hour habitual IOP pattern in healthy subjects. Methods: Intraocular pressure was measured every 2-hours using an Accupen Applanation Tonometer (Accutome, USA). During the diurnal period (7:30 am, 9:30 am, 11:30 am, 1:30 pm, 3:30 pm, 5:30 pm, 7:30 pm, and 9:30 pm), IOP was measured in the sitting position under bright light (500-1000 lux) after the subjects had been seated for 5 min. The nocturnal IOP was measured in the supine position, right LDP, and left LDP, with randomized sequences, under dim light (<10 lux) at 11:30 pm, 1:30 am, 3:30 am, and 5:30 am. The subjects were awakened and maintained each position for 5 min before the measurement. The 24-hour habitual IOP patterns were obtained according to the nocturnal position (supine, right LDP and left LDP) for either eye. P < 0.05 was considered to be significant. Results: Nineteen healthy subjects were included with a mean age of 51.3 +/- 5.8 years. During the nocturnal period, a significant IOP difference was found between the dependent eye (the eye on the lower side) of LDP and the supine position, but not for all the nocturnal time points. Over a 24-hour period, the effect of LDP on habitual IOP pattern was not statistically significant, although the mean nocturnal IOP and the diurnal-nocturnal IOP change for the right and the left eye in the LDP pattern was slightly higher than that in the sitting-supine pattern. Conclusion: Significant nocturnal IOP differences existed between the dependent eye and the supine, but did not occur consistently for all time points. Over a 24-hour period, the effect of LDP on habitual IOP pattern was not statistically significant in healthy subjects.	[Hao, Jie; Zhen, Yi; Yang, Diya; Wang, Ningli] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Ophthalmol & Visual Sci Key Lab, Beijing, Peoples R China; [Wang, Hao] Hebei Eye Hosp, Hebei Key Lab Ophthalmol, Xingtai, Peoples R China	Capital Medical University	Wang, NL (corresponding author), Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Ophthalmol & Visual Sci Key Lab, Beijing, Peoples R China.	wningli@vip.163.com			Research Special Fund of Ministry of Health of the People's Republic of China [201002019]	Research Special Fund of Ministry of Health of the People's Republic of China	This study was supported by a grant from the Research Special Fund of Ministry of Health of the People's Republic of China. Grant number: 201002019. URL: http://wsb.moh.gov.cn/mohkjjys/index.shtml. NW received the funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barkana Y, 2014, J GLAUCOMA, V23, pE23, DOI 10.1097/IJG.0b013e3182a0762f; BILL A, 1978, GLAUCOMA CONCEPTIONS, P97; Blondeau P, 2001, J GLAUCOMA, V10, P18, DOI 10.1097/00061198-200102000-00005; DEKONINCK J, 1992, SLEEP, V15, P143, DOI 10.1093/sleep/15.2.143; DZVONIK ML, 1986, SLEEP, V9, P484, DOI 10.1093/sleep/9.4.484; Fogagnolo P, 2009, INVEST OPHTH VIS SCI, V50, P2209, DOI 10.1167/iovs.08-2889; Kim KN, 2013, OPHTHALMOLOGY, V120, P731, DOI 10.1016/j.ophtha.2012.09.021; Lee JY, 2013, AM J OPHTHALMOL, V155, P329, DOI 10.1016/j.ajo.2012.08.003; Lee JY, 2012, ACTA OPHTHALMOL, V90, pE68, DOI 10.1111/j.1755-3768.2011.02208.x; Lee TE, 2013, OPHTHALMOLOGY, V120, P1565, DOI 10.1016/j.ophtha.2013.01.011; Lee YR, 2012, INVEST OPHTH VIS SCI, V53, P881, DOI 10.1167/iovs.11-7846; Liang YB, 2011, INVEST OPHTH VIS SCI, V52, P8672, DOI 10.1167/iovs.11-7480; Liu JHK, 2005, OPHTHALMOLOGY, V112, P1670, DOI 10.1016/j.ophtha.2005.05.007; Liu JHK, 2003, INVEST OPHTH VIS SCI, V44, P1586, DOI 10.1167/iovs.02-0666; Liu JHK, 1998, INVEST OPHTH VIS SCI, V39, P2707; Liu JHK, 1999, INVEST OPHTH VIS SCI, V40, P2912; Malihi M, 2012, OPHTHALMOLOGY, V119, P987, DOI 10.1016/j.ophtha.2011.11.024; NELSON W, 1979, CHRONOBIOLOGIA, V6, P305; Prata TS, 2010, SURV OPHTHALMOL, V55, P445, DOI 10.1016/j.survophthal.2009.12.002; TSUKAHARA S, 1984, BRIT J OPHTHALMOL, V68, P389, DOI 10.1136/bjo.68.6.389	20	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 25	2014	9	11							e113590	10.1371/journal.pone.0113590	http://dx.doi.org/10.1371/journal.pone.0113590			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AU9GL	25423190	gold, Green Published, Green Submitted			2023-01-03	WOS:000345899700040
J	Wang, WJ; Li, YH; Wang, HM; Zu, YG				Wang, Wenjie; Li, Yanhong; Wang, Huimei; Zu, Yuangang			Differences in the Activities of Eight Enzymes from Ten Soil Fungi and Their Possible Influences on the Surface Structure, Functional Groups, and Element Composition of Soil Colloids	PLOS ONE			English	Article							ACID-PHOSPHATASE; ENZYMATIC-ACTIVITY; CHITINASE ACTIVITY; MYCORRHIZAL FUNGI; FOREST SOILS; ECTOMYCORRHIZAL; PLANT; BIODIVERSITY; VARIABILITY; PHOSPHORUS	How soil fungi function in soil carbon and nutrient cycling is not well understood by using fungal enzymatic differences and their interactions with soil colloids. Eight extracellular enzymes, EEAs (chitinase, carboxymethyl cellulase, beta-glucosidase, protease, acid phosphatase, polyphenol oxidase, laccase, and guaiacol oxidase) secreted by ten fungi were compared, and then the fungi that showed low and high enzymatic activity were co-cultured with soil colloids for the purpose of finding fungi-soil interactions. Some fungi (Gomphidius rutilus, Russula integra, Pholiota adiposa, and Geastrum mammosum) secreted 3-4 enzymes with weak activities, while others (Cyathus striatus, Suillus granulate, Phallus impudicus, Collybia dryophila, Agaricus sylvicola, and Lactarius deliciosus) could secret over 5 enzymes with high activities. The differences in these fungi contributed to the alterations of functional groups (stretching bands of O-H, N-H, C-H, C = O, COO-decreased by 11-60%, while P = O, C-O stretching, O-H bending and Si-O-Si stretching increased 9-22%), surface appearance (disappearance of adhesive organic materials), and elemental compositions (11-49% decreases in C1s) in soil colloids. Moreover, more evident changes were generally in high enzymatic fungi (C. striatus) compared with low enzymatic fungi (G. rutilus). Our findings indicate that inter-fungi differences in EEA types and activities might be responsible for physical and chemical changes in soil colloids (the most active component of soil matrix), highlighting the important roles of soil fungi in soil nutrient cycling and functional maintenance.	[Wang, Wenjie; Li, Yanhong; Wang, Huimei; Zu, Yuangang] Minist Educ, Key Lab Forest Plant Ecol, Harbin, Heilongjiang Pr, Peoples R China		Wang, HM (corresponding author), Minist Educ, Key Lab Forest Plant Ecol, Harbin, Heilongjiang Pr, Peoples R China.	whm0709@hotmail.com	wang, wenjie/G-9041-2014; li, yan/GTI-4638-2022	wang, wenjie/0000-0003-0465-686X; 	China's Ministry of Science and Technology [2011CB403205]; Fundamental Research Funds for the Central Universities [2572014EA01]; China's National Foundation of Natural Sciences [31170575, 41373075]	China's Ministry of Science and Technology(Ministry of Science and Technology, China); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); China's National Foundation of Natural Sciences	This study was supported financially by the China's Ministry of Science and Technology (2011CB403205), Fundamental Research Funds for the Central Universities (2572014EA01), China's National Foundation of Natural Sciences (31170575, 41373075). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aleksieva P, 2003, Z NATURFORSCH C, V58, P239; Baldrian P, 2011, PLANT SOIL, V338, P111, DOI 10.1007/s11104-010-0324-3; Bandick AK, 1999, SOIL BIOL BIOCHEM, V31, P1471, DOI 10.1016/S0038-0717(99)00051-6; Barton CD, 2003, WATER AIR SOIL POLL, V143, P3, DOI 10.1023/A:1022886225564; BOLAN NS, 1991, PLANT SOIL, V134, P189, DOI 10.1007/BF00012037; Bridge P, 2001, PLANT SOIL, V232, P147, DOI 10.1023/A:1010346305799; Buee M, 2009, NEW PHYTOL, V184, P449, DOI 10.1111/j.1469-8137.2009.03003.x; Burke RM, 2002, MYCORRHIZA, V12, P105, DOI 10.1007/s00572-002-0162-0; Cairney JWG, 1998, PLANT SOIL, V205, P181, DOI 10.1023/A:1004376731209; Caldwell BA, 2005, PEDOBIOLOGIA, V49, P637, DOI 10.1016/j.pedobi.2005.06.003; Carter DO, 2007, PEDOBIOLOGIA, V51, P295, DOI 10.1016/j.pedobi.2007.05.002; CHEN KS, 1994, ELECTROPHORESIS, V15, P662, DOI 10.1002/elps.1150150193; Clemmensen KE, 2013, SCIENCE, V339, P1615, DOI 10.1126/science.1231923; Cosgrove DJ, 1977, MICROBIAL TRANSFORMA, P95; Cullings K, 2008, OECOLOGIA, V158, P77, DOI 10.1007/s00442-008-1119-6; DeNovio NM, 2004, VADOSE ZONE J, V3, P338, DOI 10.2113/3.2.338; Desai S, 2014, MYCORRHIZA, V24, P369, DOI 10.1007/s00572-013-0548-1; Dirks-Hofmeister ME, 2012, PLANT MOL BIOL, V80, P203, DOI 10.1007/s11103-012-9943-9; Ekenler M, 2003, SOIL BIOL BIOCHEM, V35, P871, DOI 10.1016/S0038-0717(03)00094-4; Fansler SJ, 2005, BIOL FERT SOILS, V42, P17, DOI 10.1007/s00374-005-0867-2; Fierer N, 2012, P NATL ACAD SCI USA, V109, P21390, DOI 10.1073/pnas.1215210110; GELLERSTEDT G, 1989, WOOD SCI TECHNOL, V23, P75, DOI 10.1007/BF00350609; GIANFREDA L, 1993, SOIL BIOL BIOCHEM, V25, P671, DOI 10.1016/0038-0717(93)90106-L; HAZEN GG, 1965, ANN NY ACAD SCI, V130, P761, DOI 10.1111/j.1749-6632.1965.tb12620.x; Hilszczanska D, 2008, POL J ENVIRON STUD, V17, P881; Huang QY, 2005, COLLOID SURFACE B, V45, P209, DOI 10.1016/j.colsurfb.2005.08.011; Jarosz-Wilkolazka A, 2002, ENZYME MICROB TECH, V30, P566, DOI 10.1016/S0141-0229(02)00022-4; Johnson CT, 1996, METHODS SOIL ANAL 3; Kelleher BP, 2003, LANGMUIR, V19, P9411, DOI 10.1021/la034971e; Klose S, 2003, WATER AIR SOIL POLL, V142, P3, DOI 10.1023/A:1022075130048; Leduc SD, 2013, OECOLOGIA, V172, P257, DOI 10.1007/s00442-012-2471-0; Li Yan-Hong, 2013, Bulletin of Botanical Research, V33, P404, DOI 10.7525/j.issn.1673-5102.2013.04.004; Li YH, 2013, SCI WORLD J, DOI 10.1155/2013/698752; Marcote I, 2001, BIORESOURCE TECHNOL, V79, P147, DOI 10.1016/S0960-8524(01)00048-7; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; MILLER GL, 1959, ANAL CHEM, V31, P426, DOI 10.1021/ac60147a030; Mucha J, 2006, ARCH MICROBIOL, V185, P69, DOI 10.1007/s00203-005-0068-2; NICHOLSORIANS C, 1991, J CHEM ECOL, V17, P1811, DOI 10.1007/BF00993730; Ohnuma T, 2011, FEBS J, V278, P3991, DOI 10.1111/j.1742-4658.2011.08301.x; Olander LP, 2000, BIOGEOCHEMISTRY, V49, P175, DOI 10.1023/A:1006316117817; Pointing SB, 2001, APPL MICROBIOL BIOT, V57, P20; Rao MA, 2000, SOIL BIOL BIOCHEM, V32, P1007, DOI 10.1016/S0038-0717(00)00010-9; Redlak K, 2001, BIOL FERT SOILS, V33, P83, DOI 10.1007/s003740000295; Rousk J, 2010, ISME J, V4, P1340, DOI 10.1038/ismej.2010.58; Schreiner RP, 1997, PLANT SOIL, V188, P199, DOI 10.1023/A:1004271525014; Shaik NM, 2013, MOL BIOL REP, V40, P1351, DOI 10.1007/s11033-012-2179-6; Shao L.P., 1997, FOREST MUSHROOM CHIN; Smith S.E., 2008, MYCORRHIZAL SYMBIOSI, VThird; Snajdr J, 2011, FEMS MICROBIOL ECOL, V75, P291, DOI 10.1111/j.1574-6941.2010.00999.x; Srinivasulu M, 2013, INT J ENVIRON SCI TE, V10, P341, DOI 10.1007/s13762-012-0133-8; van der Heijden MGA, 1998, NATURE, V396, P69, DOI 10.1038/23932; Vitousek PM, 2010, ECOL APPL, V20, P5, DOI 10.1890/08-0127.1; Wang WJ, 2011, PLANT SOIL, V339, P177, DOI 10.1007/s11104-010-0565-1; WOLF DC, 1989, J ENVIRON QUAL, V18, P39, DOI 10.2134/jeq1989.00472425001800010007x; [谢丽源 Xie Liyuan], 2010, [食品工业科技, Science & Technology of Food Industry], V31, P183; Xu Y, 2009, ADV ATMOS SCI, V26, P783, DOI 10.1007/s00376-009-9034-2; [于富强 Yu Fuqiang], 2002, [生态学报, Acta Ecologica Sinica], V22, P2217; Zhou DM, 2011, J SOIL SEDIMENT, V11, P491, DOI 10.1007/s11368-010-0331-2; Zifcakova L, 2011, FUNGAL ECOL, V4, P427, DOI 10.1016/j.funeco.2011.04.002	59	14	14	1	62	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 14	2014	9	11							e111740	10.1371/journal.pone.0111740	http://dx.doi.org/10.1371/journal.pone.0111740			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AU4DF	25398013	gold, Green Published, Green Submitted			2023-01-03	WOS:000345558500024
J	Yu, YJ; Wu, IW; Huang, CY; Hsu, KH; Lee, CC; Sun, CY; Hsu, HJ; Wu, MS				Yu, Yu-Jen; Wu, I-Wen; Huang, Chun-Yu; Hsu, Kuang-Hung; Lee, Chin-Chan; Sun, Chio-Yin; Hsu, Heng-Jung; Wu, Mai-Szu			Multidisciplinary Predialysis Education Reduced the Inpatient and Total Medical Costs of the First 6 Months of Dialysis in Incident Hemodialysis Patients	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; CARE; MORTALITY; SURVIVAL; IMPACT; TAIWAN; COHORT; TRENDS	Background: The multidisciplinary pre-dialysis education (MPE) retards renal progression, reduce incidence of dialysis and mortality of CKD patients. However, the financial benefit of this intervention on patients starting hemodialysis has not yet been evaluated in prospective and randomized trial. Methods: We studied the medical expenditure and utilization incurred in the first 6 months of dialysis initiation in 425 incident hemodialysis patients who were randomized into MPE and non-MPE groups before reaching end-stage renal disease. The content of the MPE was standardized in accordance with the National Kidney Foundation Dialysis Outcomes Quality Initiative guidelines. Results: The mean age of study patients was 63.8 +/- 13.2 years, and 221 (49.7%) of them were men. The mean serum creatinine level and estimated glomerular filtration rate was 6.1 +/- 4.0 mg/dL and 7.6 +/- 2.9 mL.min(-1).1.73 m 22, respectively, at dialysis initiation. MPE patients tended to have lower total medical cost in the first 6 months after hemodialysis initiation (9147.6 +/- 0.1 USD/patient vs. 11190.6 +/- 0.1 USD/patient, p = 0.003), fewer in numbers [0 (1) vs. 1 (2), p<0.001] and length of hospitalization [0 (15) vs. 8 (27) days, p<0.001], and also lower inpatient cost [0 (2617.4) vs. 1559,4 (5019.6) USD/patient, p<0.001] than non-MPE patients, principally owing to reduced cardiovascular hospitalization and vascular access-related surgeries. The decreased inpatient and total medical cost associated with MPE were independent of patients' demographic characteristics, concomitant disease, baseline biochemistry and use of double-lumen catheter at initiation of hemodialysis. Conclusions: Participation of multidisciplinary education in pre-dialysis period was independently associated with reduction in the inpatient and total medical expenditures of the first 6 months post-dialysis owing to decreased inpatient service utilization secondary to cardiovascular causes and vascular access-related surgeries.	[Yu, Yu-Jen; Wu, I-Wen; Lee, Chin-Chan; Sun, Chio-Yin; Hsu, Heng-Jung; Wu, Mai-Szu] Chang Gung Mem Hosp, Dept Nephrol, Keelung, Taiwan; [Yu, Yu-Jen; Wu, I-Wen; Lee, Chin-Chan; Sun, Chio-Yin; Hsu, Heng-Jung] Chang Gung Univ, Coll Med, Taoyuan, Taiwan; [Huang, Chun-Yu; Hsu, Kuang-Hung] Chang Gung Univ, Dept Hlth Care Management, Lab Epidemiol, Taoyuan, Taiwan; [Wu, Mai-Szu] Taipei Med Univ Hosp, Div Nephrol, Taipei, Taiwan; [Wu, Mai-Szu] Taipei Med Univ, Sch Med, Taipei, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University; Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University	Wu, MS (corresponding author), Chang Gung Mem Hosp, Dept Nephrol, Keelung, Taiwan.	maiszuwu@gmail.com		WU, I-WEN/0000-0001-8535-3582; Hsu, Kuang-Hung/0000-0003-2642-7689	Chang Gung Memorial Hospital at Keelung [CMRPG260323, CMRPG2A0422]	Chang Gung Memorial Hospital at Keelung	Chang Gung Memorial Hospital at Keelung provided grant support for this research (CMRPG260323/CMRPG2A0422). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bradbury BD, 2007, CLIN J AM SOC NEPHRO, V2, P89, DOI 10.2215/CJN.01170905; Chen SH, 2011, NEPHROL DIAL TRANSPL, V26, P3560, DOI 10.1093/ndt/gfr047; Chen YR, 2013, NEPHROL DIAL TRANSPL, V28, P671, DOI 10.1093/ndt/gfs469; Cho EJ, 2012, NEPHROLOGY, V17, P472, DOI 10.1111/j.1440-1797.2012.01598.x; Collins A, 2014, AM J KIDNEY DIS, V63, pE1; Department of Health, 2014, NAT HLTH INS ANN STA; Devins GM, 2005, AM J KIDNEY DIS, V46, P1088, DOI 10.1053/j.ajkd.2005.08.017; Dogan E, 2005, NEPHROLOGY, V10, P516, DOI 10.1111/j.1440-1797.2005.00433.x; El Nahas AM, 2005, LANCET, V365, P331, DOI 10.1016/S0140-6736(05)17789-7; Goldstein M, 2004, AM J KIDNEY DIS, V44, P706, DOI 10.1053/j.ajkd.2004.06.012; Hwang SJ, 2010, NEPHROLOGY, V15, P3, DOI 10.1111/j.1440-1797.2010.01304.x; Jungers P, 2001, NEPHROL DIAL TRANSPL, V16, P2357, DOI 10.1093/ndt/16.12.2357; Lysaght MJ, 2002, J AM SOC NEPHROL, V13, pS37; Muntner P, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133745; Stroupe KT, 2011, MED CARE, V49, P248, DOI 10.1097/MLR.0b013e31820192ba; Tseng CL, 2008, ARCH INTERN MED, V168, P55, DOI 10.1001/archinternmed.2007.9; US Renal Data System (USRDS), 2013, CKD CHILDR AD; Wei SY, 2010, NEPHROLOGY, V15, P108, DOI 10.1111/j.1440-1797.2009.01154.x; Wu IW, 2009, NEPHROL DIAL TRANSPL, V24, P3426, DOI 10.1093/ndt/gfp259; Wu MS, 2003, PERITON DIALYSIS INT, V23, P39; Wu MS, 2011, ACTA NEPHROL, V25, P148; Yang WC, 2008, NEPHROL DIAL TRANSPL, V23, P3977, DOI 10.1093/ndt/gfn406	22	34	34	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 14	2014	9	11							e112820	10.1371/journal.pone.0112820	http://dx.doi.org/10.1371/journal.pone.0112820			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AU4DF	25398129	Green Published, gold, Green Submitted			2023-01-03	WOS:000345558500094
J	Carrieri, PM; Michel, L; Lions, C; Cohen, J; Vray, M; Mora, M; Marcellin, F; Spire, B; Morel, A; Roux, P				Carrieri, Patrizia Maria; Michel, Laurent; Lions, Caroline; Cohen, Julien; Vray, Muriel; Mora, Marion; Marcellin, Fabienne; Spire, Bruno; Morel, Alain; Roux, Perrine		Methaville Study Grp	Methadone Induction in Primary Care for Opioid Dependence: A Pragmatic Randomized Trial (ANRS Methaville)	PLOS ONE			English	Article							BUPRENORPHINE TREATMENT; SUBSTITUTION TREATMENT; RETROSPECTIVE COHORT; HEROIN DEPENDENCE; DRUG-USERS; MAINTENANCE; EXPERIENCE; RETENTION; INJECTION; METAANALYSIS	Objective: Methadone coverage is poor in many countries due in part to methadone induction being possible only in specialized care (SC). This multicenter pragmatic trial compared the effectiveness of methadone treatment between two induction models: primary care (PC) and SC. Methods: In this study, registered at ClinicalTrials.Gov (NCT00657397), opioid-dependent individuals not on methadone treatment for at least one month or receiving buprenorphine but needing to switch were randomly assigned to start methadone in PC (N = 155) or in SC (N = 66) in 10 sites in France. Visits were scheduled at months M0, M3, M6 and M12. The primary outcome was self-reported abstinence from street-opioids at 12 months (M12) (with an underlying 15% non-inferiority hypothesis for PC). Secondary outcomes were abstinence during follow-up, engagement in treatment (i.e. completing the induction period), retention and satisfaction with the explanations provided by the physician. Primary analysis used intention to treat (ITT). Mixed models and the log-rank test were used to assess the arm effect (PC vs. SC) on the course of abstinence and retention, respectively. Results: In the ITT analysis (n = 155 in PC, 66 in SC), which compared the proportions of street-opioid abstinent participants, 85/155 (55%) and 22/66 (33%) of the participants were classified as street-opioid abstinent at M12 in PC and SC, respectively. This ITT analysis showed the non-inferiority of PC (21.5 [7.7; 35.3]). Engagement in treatment and satisfaction with the explanations provided by the physician were significantly higher in PC than SC. Retention in methadone and abstinence during follow-up were comparable in both arms (p = 0.47, p = 0.39, respectively). Conclusions: Under appropriate conditions, methadone induction in primary care is feasible and acceptable to both physicians and patients. It is as effective as induction in specialized care in reducing street-opioid use and ensuring engagement and retention in treatment for opioid dependence.	[Carrieri, Patrizia Maria; Lions, Caroline; Cohen, Julien; Mora, Marion; Marcellin, Fabienne; Spire, Bruno; Roux, Perrine] INSERM, SESSTIM, UMR912, F-13258 Marseille, France; [Carrieri, Patrizia Maria; Lions, Caroline; Cohen, Julien; Mora, Marion; Marcellin, Fabienne; Spire, Bruno; Roux, Perrine] Aix Marseille Univ, UMR S912, Marseille, France; [Carrieri, Patrizia Maria; Lions, Caroline; Cohen, Julien; Mora, Marion; Marcellin, Fabienne; Spire, Bruno; Roux, Perrine] ORS PACA, Marseille, France; [Michel, Laurent] INSERM, Res Unit 669, Paris, France; [Michel, Laurent] Univ Paris 11, Paris, France; [Michel, Laurent] Univ Paris 05, UMR S0669, Paris, France; [Michel, Laurent] Ctr Pierre Nicole, Paris, France; [Vray, Muriel] Inst Pasteur, Unite Rech & Expertise Epidemiol Malad Emergentes, Paris, France; [Vray, Muriel] INSERM, Paris, France; [Morel, Alain] Oppelia, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm)	Carrieri, PM (corresponding author), INSERM, SESSTIM, UMR912, F-13258 Marseille, France.	pmcarrieri@aol.com	Vray, Muriel/M-7947-2018; Roux, Perrine/P-1306-2016; Spire, Bruno/F-5546-2013	Roux, Perrine/0000-0002-5069-4982; Spire, Bruno/0000-0002-3546-8020; MICHEL, laurent/0000-0002-2000-7838; Marcellin, Fabienne/0000-0001-8853-3829; Carrieri, Patrizia/0000-0002-6794-4837	French National Agency for Research on Aids and Viral Hepatitis (ANRS); French Ministry of Health	French National Agency for Research on Aids and Viral Hepatitis (ANRS)(ANRSFrench National Research Agency (ANR)); French Ministry of Health	The study received external funding by the French National Agency for Research on Aids and Viral Hepatitis (ANRS) and the French Ministry of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Auriacombe M, 2004, AM J ADDICTION, V13, pS17, DOI 10.1080/10550490490440780; Bouvenot G, 2006, ESSAIS CLIN THEORIE; Brands B, 2008, J ADDICT DIS, V27, P37, DOI 10.1080/10550880802122620; Cadet-Tairou A, 2004, RAPPORT 2004 APPROCH, P28; Carrieri MP, 2006, CLIN INFECT DIS, V43, pS197, DOI 10.1086/508184; Coons SJ, 2011, CLIN PHARMACOL THER, V90, P743, DOI 10.1038/clpt.2011.203; DARKE S, 1992, BRIT J ADDICT, V87, P733; del Giudice P, 2004, BRIT J DERMATOL, V150, P1, DOI 10.1111/j.1365-2133.2004.05607.x; Fareed A, 2010, J ADDICT DIS, V29, P1, DOI 10.1080/10550880903436010; Farre M, 2002, DRUG ALCOHOL DEPEN, V65, P283, DOI 10.1016/S0376-8716(01)00171-5; Fiellin DA, 2001, JAMA-J AM MED ASSOC, V286, P1724, DOI 10.1001/jama.286.14.1724; Fransen GAJ, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-16; Gibson AE, 2003, MED J AUSTRALIA, V179, P38, DOI 10.5694/j.1326-5377.2003.tb05417.x; Hamer RM, 2009, AM J PSYCHIAT, V166, P639, DOI 10.1176/appi.ajp.2009.09040458; Hser YI, 2014, ADDICTION, V109, P79, DOI 10.1111/add.12333; Keen J, 2003, BRIT J GEN PRACT, V53, P461; Kerr T, 2007, DRUG ALCOHOL DEPEN, V87, P39, DOI 10.1016/j.drugalcdep.2006.07.009; MacArthur GJ, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5945; MacGowan RJ, 1996, J PSYCHOACTIVE DRUGS, V28, P259, DOI 10.1080/02791072.1996.10472487; McCowan C, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b2225; Nosyk B, 2012, ADDICTION, V107, P1621, DOI 10.1111/j.1360-0443.2012.03870.x; O'Connor PG, 1998, AM J MED, V105, P100, DOI 10.1016/S0002-9343(98)00194-6; Roux P, 2008, ADDICTION, V103, P1828, DOI 10.1111/j.1360-0443.2008.02323.x; Roux P, 2008, DRUG ALCOHOL DEPEN, V97, P105, DOI 10.1016/j.drugalcdep.2008.03.025; Roux P, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-488; Schwartz RP, 2007, DRUG ALCOHOL DEPEN, V86, P30, DOI 10.1016/j.drugalcdep.2006.04.017; Schwartz RP, 2012, ADDICTION, V107, P943, DOI 10.1111/j.1360-0443.2011.03700.x; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Snyder CF, 2011, J CLIN ONCOL, V29, P1216, DOI 10.1200/JCO.2010.33.2080; Soyka M, 2011, WORLD J BIOL PSYCHIA, V12, P160, DOI 10.3109/15622975.2011.561872; Strain EC, 1999, JAMA-J AM MED ASSOC, V281, P1000, DOI 10.1001/jama.281.11.1000; Teesson M, 2006, DRUG ALCOHOL DEPEN, V83, P174, DOI 10.1016/j.drugalcdep.2005.11.009; Vray M, 1996, J CLIN EPIDEMIOL, V49, P949, DOI 10.1016/0895-4356(96)00047-9; Weinrich M, 2000, JAMA-J AM MED ASSOC, V283, P1343, DOI 10.1001/jama.283.10.1343; Wittchen HU, 2008, DRUG ALCOHOL DEPEN, V95, P245, DOI 10.1016/j.drugalcdep.2008.01.015; Wolfe D, 2010, LANCET, V376, P355, DOI 10.1016/S0140-6736(10)60832-X	36	31	31	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2014	9	11							e112328	10.1371/journal.pone.0112328	http://dx.doi.org/10.1371/journal.pone.0112328			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AY6YT	25393311	gold, Green Submitted, Green Published			2023-01-03	WOS:000347709300052
J	El-Merahbi, R; Liu, YN; Eid, A; Daoud, G; Hosry, L; Monzer, A; Mouhieddine, TH; Hamade, A; Najjar, F; Abou-Kheir, W				El-Merahbi, Rabih; Liu, Yen-Nien; Eid, Assaad; Daoud, Georges; Hosry, Leina; Monzer, Alissar; Mouhieddine, Tarek H.; Hamade, Aline; Najjar, Fadia; Abou-Kheir, Wassim			Berberis libanotica Ehrenb Extract Shows Anti-Neoplastic Effects on Prostate Cancer Stem/Progenitor Cells	PLOS ONE			English	Article							STEM-CELLS; ANTITUMOR ACTIVITIES; RESISTANCE; APOPTOSIS; DEPLETION; VULGARIS; INVASION; THERAPY; ARREST; TARGET	Cancer stem cells (CSCs), including those of advanced prostate cancer, are a suggested reason for tumor resistance toward conventional tumor therapy. Therefore, new therapeutic agents are urgently needed for targeting CSCs. Despite the minimal understanding of their modes of action, natural products and herbal therapies have been commonly used in the prevention and treatment of many cancers. Berberis libanotica Ehrenb (BLE) is a plant rich in alkaloids which may possess anti-cancer activity and a high potential for eliminating CSCs. We tested the effect of BLE on prostate cancer cells and our data indicated that this extract induced significant reduction in cell viability and inhibited the proliferation of human prostate cancer cell lines (DU145, PC3 and 22Rv1) in a dose- and time-dependent manner. BLE extract induced a perturbation of the cell cycle, leading to a G0-G1 arrest. Furthermore, we noted 50% cell death, characterized by the production of high levels of reactive oxidative species (ROS). Inhibition of cellular migration and invasion was also achieved upon treatment with BLE extract, suggesting a role in inhibiting metastasis. Interestingly, BLE extract had a major effect on CSCs. Cells were grown in a 3D sphere-formation assay to enrich for a population of cancer stem/progenitor cells. Our results showed a significant reduction in sphere formation ability. Three rounds of treatment with BLE extract were sufficient to eradicate the self-renewal ability of highly resistant CSCs. In conclusion, our results suggest a high therapeutic potential of BLE extract in targeting prostate cancer and its CSCs.	[El-Merahbi, Rabih; Eid, Assaad; Daoud, Georges; Monzer, Alissar; Mouhieddine, Tarek H.; Abou-Kheir, Wassim] Amer Univ Beirut, Fac Med, Dept Anat Cell Biol & Physiol Sci, Beirut, Lebanon; [Hosry, Leina] Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Canc Biol & Drug Discovery, Taipei, Taiwan; [Hamade, Aline] Lebanese Univ, Fac Sci 2, Dept Biol, Fanar, Lebanon; [Najjar, Fadia] Lebanese Univ, Fac Sci 2, Dept Chem & Biochem, Fanar, Lebanon	American University of Beirut; Taipei Medical University; Lebanese University; Lebanese University	Hamade, A (corresponding author), Lebanese Univ, Fac Sci 2, Dept Biol, Fanar, Lebanon.	alinehamade@gmail.com; Fadia.najjar@gmail.com; wa12@aub.edu.lb	Abou-Kheir, Wassim/AAP-2587-2020; Liu, Yen-Nien/AAW-4698-2021	Abou-Kheir, Wassim/0000-0001-9719-9324; Mouhieddine, Tarek/0000-0002-1190-5978; Daoud, Georges/0000-0001-8043-3882	Medical Practice Plan-MPP (AUB-FM); Lebanese National Council for Scientific Research (CNRS)	Medical Practice Plan-MPP (AUB-FM); Lebanese National Council for Scientific Research (CNRS)(Centre National de la Recherche Scientifique (CNRS))	This research was supported by funding from the Medical Practice Plan-MPP (AUB-FM) and the Lebanese National Council for Scientific Research (CNRS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abou-Kheir W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026112; Abou-Kheir WG, 2010, STEM CELLS, V28, P2129, DOI 10.1002/stem.538; Aniszewski T, 2007, ALKALOIDS SECRETS LI; Bonesi M, 2013, J PHARM PHARMACOL, V65, P1726, DOI 10.1111/jphp.12172; Bournine L, 2013, PHYTOMEDICINE; Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698; Corcoran C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050999; Domingo-Domenech J, 2012, CANCER CELL, V22, P373, DOI 10.1016/j.ccr.2012.07.016; Eid AA, 2013, DIABETES, V62, P2935, DOI 10.2337/db12-1504; Esseily F, 2012, MINERVA BIOTECNOL, V24, P129; Fetsch PA, 2006, CANCER LETT, V235, P84, DOI 10.1016/j.canlet.2005.04.024; Foster BA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055062; Ho YT, 2009, PHYTOMEDICINE, V16, P887, DOI 10.1016/j.phymed.2009.02.015; Huang M, 2007, CLIN CANCER RES, V13, P1298, DOI 10.1158/1078-0432.CCR-06-1277; Imanshahidi M, 2008, PHYTOTHER RES, V22, P999, DOI 10.1002/ptr.2399; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kaseb AO, 2007, CANCER RES, V67, P7782, DOI 10.1158/0008-5472.CAN-07-1483; Kim S, 2008, MOLECULES, V13, P2975, DOI 10.3390/molecules13122975; Koncic MZ, 2010, FOOD CHEM TOXICOL, V48, P2176, DOI 10.1016/j.fct.2010.05.025; Li WH, 2007, CANCER BIOL THER, V6, P787, DOI 10.4161/cbt.6.5.4006; Liu B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021416; Lou H, 2007, ONCOGENE, V26, P1357, DOI 10.1038/sj.onc.1210200; Luk SU, 2011, INT J CANCER, V128, P2182, DOI 10.1002/ijc.25546; Luk SU, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019804; Ma I, 2011, STEM CELL REV REP, V7, P292, DOI 10.1007/s12015-010-9208-4; Maitland NJ, 2008, J CLIN ONCOL, V26, P2862, DOI 10.1200/JCO.2007.15.1472; Marc EB, 2008, J ETHNOPHARMACOL, V120, P315, DOI 10.1016/j.jep.2008.08.024; Peng PL, 2006, TOXICOL APPL PHARM, V214, P8, DOI 10.1016/j.taap.2005.11.010; Rafi MM, 2002, J AGR FOOD CHEM, V50, P677, DOI 10.1021/jf010774e; Refaat A, 2013, ONCOL LETT, V6, P840, DOI 10.3892/ol.2013.1434; Roberts M.F., 1998, ALKALOIDS BIOCH ECOL; Schroeder A, 2013, CANC RES; Sharifi N, 2006, CANCER BIOL THER, V5, P901, DOI 10.4161/cbt.5.8.2949; Singh J, 2009, J ETHNOPHARMACOL, V123, P22, DOI 10.1016/j.jep.2009.02.038; Singh T, 2011, CARCINOGENESIS, V32, P86, DOI 10.1093/carcin/bgq215; Slaninova I, 2013, PHYTOCHEM REV, P1; Wang Y, 2012, MUTAT RES-FUND MOL M, V734, P20, DOI 10.1016/j.mrfmmm.2012.04.005; Yu Jun, 2013, Curr Ther Res Clin Exp, V75, P8, DOI 10.1016/j.curtheres.2013.04.001; Zhang LL, 2012, CANCER LETT, V323, P48, DOI 10.1016/j.canlet.2012.03.037	39	34	35	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 7	2014	9	11							e112453	10.1371/journal.pone.0112453	http://dx.doi.org/10.1371/journal.pone.0112453			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT3WF	25380390	Green Published, Green Submitted, gold			2023-01-03	WOS:000344863100099
J	Liyanage, T; Ninomiya, T; Jha, V; Neal, B; Patrice, HM; Okpechi, I; Zhao, MH; Lv, JC; Garg, AX; Knight, J; Rodgers, A; Gallagher, M; Kotwal, S; Cass, A; Perkovic, V				Liyanage, Thaminda; Ninomiya, Toshiharu; Jha, Vivekanand; Neal, Bruce; Patrice, Halle Marie; Okpechi, Ikechi; Zhao, Ming-hui; Lv, Jicheng; Garg, Amit X.; Knight, John; Rodgers, Anthony; Gallagher, Martin; Kotwal, Sradha; Cass, Alan; Perkovic, Vlado			Worldwide access to treatment for end-stage kidney disease: a systematic review	LANCET			English	Review							RENAL-DISEASE; CARE; PROGRESSION; DIALYSIS; FAILURE; PROGRAM	Background End-stage kidney disease is a leading cause of morbidity and mortality worldwide. Prevalence of the disease and worldwide use of renal replacement therapy (RRT) are expected to rise sharply in the next decade. We aimed to quantify estimates of this burden. Methods We systematically searched Medline for observational studies and renal registries, and contacted national experts to obtain RRT prevalence data. We used Poisson regression to estimate the prevalence of RRT for countries without reported data. We estimated the gap between needed and actual RRT, and projected needs to 2030. Findings In 2010, 2.618 million people received RRT worldwide. We estimated the number of patients needing RRT to be between 4.902 million (95% CI 4.438-5.431 million) in our conservative model and 9.701 million (8.544-11.021 million) in our high-estimate model, suggesting that at least 2.284 million people might have died prematurely because RRT could not be accessed. We noted the largest treatment gaps in low-income countries, particularly Asia (1.907 million people needing but not receiving RRT; conservative model) and Africa (432 000 people; conservative model). Worldwide use of RRT is projected to more than double to 5.439 million (3.899-7.640 million) people by 2030, with the most growth in Asia (0.968 million to a projected 2.162 million [1.571-3.014 million]). Interpretation The large number of people receiving RRT and the substantial number without access to it show the need to both develop low-cost treatments and implement effective population-based prevention strategies.	[Liyanage, Thaminda; Ninomiya, Toshiharu; Neal, Bruce; Knight, John; Rodgers, Anthony; Gallagher, Martin; Kotwal, Sradha; Cass, Alan; Perkovic, Vlado] Univ Sydney, George Inst Global Hlth, Sydney, NSW 2050, Australia; [Liyanage, Thaminda; Perkovic, Vlado] Royal N Shore Hosp, Sydney, NSW, Australia; [Jha, Vivekanand] George Inst Global Hlth, Splendor Forum, Jasola New Delhi, India; [Jha, Vivekanand] Postgrad Inst Med Educ & Res, Dept Nephrol, Chandigarh 160012, India; [Jha, Vivekanand] Univ Oxford, Nuffield Dept Populat Hlth, Oxford, England; [Patrice, Halle Marie] Univ Douala, Fac Med, Dept Clin Sci, Douala, Cameroon; [Okpechi, Ikechi] Univ Cape Town, Div Internal Med, ZA-7925 Cape Town, South Africa; [Zhao, Ming-hui; Lv, Jicheng] Peking Univ, Dept Med, Div Renal, Hosp 1, Beijing 100871, Peoples R China; [Garg, Amit X.] Univ Western Ontario, Dept Med, London, ON, Canada; [Garg, Amit X.] Univ Western Ontario, Dept Epidemiol & Biostat, London, ON, Canada; [Cass, Alan] Charles Darwin Univ, Menzies Sch Hlth Res, Darwin, NT 0909, Australia	George Institute for Global Health; University of Sydney; Royal North Shore Hospital; University of Sydney; Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; University of Oxford; University of Cape Town; Peking University; Western University (University of Western Ontario); Western University (University of Western Ontario); Charles Darwin University; Menzies School of Health Research	Perkovic, V (corresponding author), Univ Sydney, George Inst Global Hlth, Sydney, NSW 2050, Australia.	vperkovic@georgeinstitute.org.au	Perkovic, Vlado/AAY-1933-2021; Garg, Amit X/G-3295-2011	Cass, Alan/0000-0002-3923-3173; Jha, Vivekanand/0000-0002-8015-9470; Gallagher, Martin/0000-0001-9187-6187; Neal, Bruce/0000-0002-0490-7465; Perkovic, Vlado/0000-0002-4257-7620; Kotwal, Sradha/0000-0002-3294-4087; Rodgers, Anthony/0000-0003-1282-1896	Australian National Health and Medical Research Council Program Grant [105255]	Australian National Health and Medical Research Council Program Grant(National Health and Medical Research Council (NHMRC) of Australia)	Australian National Health and Medical Research Council.; This work was supported by an Australian National Health and Medical Research Council Program Grant (ID number 105255).	Anand S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072860; Barros Aluisio J D, 2003, BMC Med Res Methodol, V3, P21, DOI 10.1186/1471-2288-3-21; Bedford M, 2012, AM J KIDNEY DIS, V59, P485, DOI 10.1053/j.ajkd.2011.09.010; Ehrich JHH, 2005, NEPHROL DIAL TRANSPL, V20, P297, DOI 10.1093/ndt/gfh299; Frederick S., COUNTR PROF; Grassmann A, 2005, NEPHROL DIAL TRANSPL, V20, P2587, DOI 10.1093/ndt/gfi159; Hemmelgarn BR, 2012, JAMA-J AM MED ASSOC, V307, P2507, DOI 10.1001/jama.2012.6455; International Diabetes Federation, 2013, IDF DIABETES ATLAS, Vsixth; International Monetary Fund, WORLD EC OUTL DAT; International Society of Nephrology, J INT SOC NEPHROL, V3, P1; Jha V, 2004, RENAL FAILURE, V26, P201, DOI 10.1081/JDI-120039516; Jha V, 2013, LANCET, V382, P260, DOI 10.1016/S0140-6736(13)60687-X; Joshi R, 2008, J AM COLL CARDIOL, V52, P1817, DOI 10.1016/j.jacc.2008.08.049; Kearney PM, 2005, LANCET, V365, P217, DOI 10.1016/S0140-6736(05)70151-3; Lin CM, 2013, J FORMOS MED ASSOC, V112, P773, DOI 10.1016/j.jfma.2013.10.021; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Lv JC, 2013, CAN MED ASSOC J, V185, P949, DOI 10.1503/cmaj.121468; Lysaght MJ, 2002, J AM SOC NEPHROL, V13, pS37; Mazzuchi N, 2006, RENAL FAILURE, V28, P617, DOI 10.1080/08860220600925677; Perkovic V, 2013, KIDNEY INT, V83, P517, DOI 10.1038/ki.2012.401; Rayner HC, 2014, NEPHROL DIAL TRANSPL, V29, P644, DOI 10.1093/ndt/gft486; Sparke C, 2013, AM J KIDNEY DIS, V61, P413, DOI 10.1053/j.ajkd.2012.10.012; Steyerberg EW, 2004, STAT MED, V23, P2567, DOI 10.1002/sim.1844; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; The World Bank, GNI PER CAP ATL METH; United Nations' Department of Economic and Social Affairs, WORLD POP PROSP 2012; United States Renal Data System, 2012, USRDS 2012 ANN DAT R; Wei SY, 2010, NEPHROLOGY, V15, P108, DOI 10.1111/j.1440-1797.2009.01154.x; White SL, 2008, B WORLD HEALTH ORGAN, V86, P229, DOI 10.2471/BLT.07.041715; Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047; World Health Organization, GLOB HLTH OBS DAT RE	31	1046	1108	6	129	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 16	2015	385	9981					1975	1982		10.1016/S0140-6736(14)61601-9	http://dx.doi.org/10.1016/S0140-6736(14)61601-9			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CI1YR	25777665				2023-01-03	WOS:000354541700031
J	Yadav, D; Dhillon, P				Yadav, Diwakar; Dhillon, Preeti			Assessing the Impact of Family Planning Advice on Unmet Need and Contraceptive Use among Currently Married Women in Uttar Pradesh, India	PLOS ONE			English	Article							FEMALE SEX WORKERS; CHILD HEALTH; MATERNAL HEALTH; ANTENATAL CARE; SERVICE UTILIZATION; PROPENSITY SCORES; DISTRICT; RISK	Background Counseling/advice is one of the key interventions to promote family planning (FP) in developing countries, including India. It helps to improve the quality of care and reduce maternal deaths. This paper investigates the continuity of maternal health (MH) service utilization from antenatal care to post-natal care and the impact this service utilization has on contraceptive use and on meeting the demand for family planning among currently married women in rural Uttar Pradesh, India. Methods and Findings The study assesses the impact of FP advice on unmet need and contraceptive use by adopting the propensity score matching method. It uses data from the District Level Household Survey (DLHS) (2007-08) that covered 76,147 currently married women (CMW) in the age group 15-44 years in Uttar Pradesh. Results show that the utilization of MH services [Antenatal care (ANC), institutional delivery, Postnatal care (PNC)] and FP advice during ANC and PNC has led to increase in current use of contraception by 3.7% (p<.01), 7.3% (p<.01) and 6.8% (p<.01), respectively. However, a greater utilization of these services has not translated into a reduction of unmet need for contraception at a similar manner. Conclusion MH service utilization including FP advice is more effective in increasing current use of spacing methods as compared to limiting methods. Findings support the need for "effective FP advice" interventions to reduce unintended births and unmet need. However, women from Scheduled Caste/Scheduled Tribe communities are less likely to receive MH services. Thus, efforts are required to ensure that currently married women across socio-economic backgrounds have equal opportunity to receive MH services and information on contraceptive use to meet the demand for family planning methods.	[Yadav, Diwakar] Populat Serv Int, 2-105 Vijayant Khand, Lucknow, Uttar Pradesh, India; [Dhillon, Preeti] Save Children, New Delhi, India	Save the Children	Yadav, D (corresponding author), Populat Serv Int, 2-105 Vijayant Khand, Lucknow, Uttar Pradesh, India.	yadavdiwakar7@gmail.com	Dhillon, Preeti/ABC-7955-2020	Dhillon, Preeti/0000-0001-9757-6492				Ahmed S, 2002, DEMOGRAPHY, V39, P75, DOI 10.1353/dem.2002.0001; Ahmed S, 2012, LANCET, V380, P111, DOI 10.1016/S0140-6736(12)60478-4; [Anonymous], 2001, ASIA PAC POPUL J, DOI DOI 10.1136/BMJ.I2851; Anwar A., 2004, BANGLADESH INEQUALIT; Bhattacharjee P, 2013, AIDS CARE, V25, pS46, DOI 10.1080/09540121.2012.736607; Birungi H, 2006, ACCEPTABILITY SUSTAI; Briggs CJ, 2001, COCHRANE DB SYST REV, V4, DOI [10.1002/14651858.CD003318PMID:11687187, DOI 10.1002/14651858.CD003318]; Commission P, 2011, IND HUM DEV REPR; Dhakal Sulochana, 2007, BMC Pregnancy Childbirth, V7, P19, DOI 10.1186/1471-2393-7-19; Dixit P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066175; Do M, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-6; Fagan EB, 2009, SOUTH MED J, V102, P260, DOI 10.1097/SMJ.0b013e318197fae4; Glasier AF, 1996, CONTRACEPTION, V53, P217, DOI 10.1016/0010-7824(96)00040-6; Guha M, 2012, J EPIDEMIOL COMMUN H, V66, pII55, DOI 10.1136/jech-2011-200562; Hotchkiss DR, 2005, POPUL RES POLICY REV, V24, P543, DOI 10.1007/s11113-005-4852-0; Hotchkiss DR, 1999, J BIOSOC SCI, V31, P145, DOI 10.1017/S0021932099001455; Howe LD, 2009, J EPIDEMIOL COMMUN H, V63, P871, DOI 10.1136/jech.2009.088021; HUNTINGTON D, 1994, STUD FAMILY PLANN, V25, P176, DOI 10.2307/2137943; India Go, 2011, 1 OFF REG GEN CENS C, V1; International Institute for Population Sciences (IIPS), 2010, DISTR LEV HOUS FAC S, DOI [10.1371/journal.pone.0071584, DOI 10.1371/JOURNAL.PONE.0071584]; International Institute for Population Sciences (IIPS) and Macro International, 2007, NAT FAM HLTH SURV NF; Jat TR, 2011, INT J EQUITY HEALTH, V10, DOI 10.1186/1475-9276-10-59; Joshi S., 2007, FAMILY PLANNING INVE; Juneja S, 2013, AIDS BEHAV, V17, P1040, DOI 10.1007/s10461-012-0314-y; KOENIG MA, 1992, STUD FAMILY PLANN, V23, P352, DOI 10.2307/1966893; Lechner M, 2002, J R STAT SOC A STAT, V165, P59, DOI 10.1111/1467-985X.0asp2; Lee JK, 2011, J GEN INTERN MED, V26, P731, DOI 10.1007/s11606-011-1647-3; Levitt C, 2004, BIRTH-ISS PERINAT C, V31, P203, DOI 10.1111/j.0730-7659.2004.00306.x; Liu L, 2008, POP STUD-J DEMOG, V62, P191, DOI 10.1080/00324720801897796; Lopez LM, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001863.pub3; Magoma M, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-64; Magoma M, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-13; Ministry of Health and Family Welfare (MoHFW), 2005, NAT RUR HLTH MISS 20; Mistry R, 2009, SOC SCI MED, V69, P926, DOI 10.1016/j.socscimed.2009.07.008; MoHFW, 1997, REPR CHILD HLTH PROG; *MOHFW, 2000, NAT POP POL 2000; MoHFW, 2002, NAT HLTH POL 2002; Nikiema B, 2009, HEALTH POLICY PLANN, V24, P367, DOI 10.1093/heapol/czp017; Oakes JM, 2006, METHODS SOCIAL EPIDE, V1st; Ozvaris SB, 1997, ADV CONTRACEPTIVE DE, V13, P63; Pallikadavath S, 2004, SOC SCI MED, V59, P1147, DOI 10.1016/j.socscimed.2003.11.045; Pembe AB, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-12; Ram F, 2006, J BIOSOC SCI, V38, P433, DOI 10.1017/S0021932005026453; Renkert S, 2001, HEALTH PROMOT INT, V16, P381, DOI 10.1093/heapro/16.4.381; RGI, 2011, SAMPL REG SYST SRS; Ringheim K, 2011, INTEGRATING FAMILY P; Rodriguez-Barocio R., 1980, INT FAM PLAN PERSPEC, V6, P2, DOI [10.2307/2947963, DOI 10.2307/2947963]; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; ROSENBAUM PR, 1985, AM STAT, V39, P33, DOI 10.2307/2683903; Rubin DB, 1996, BIOMETRICS, V52, P249, DOI 10.2307/2533160; Seiber EE, 2005, SOC SCI MED, V61, P279, DOI 10.1016/j.socscimed.2004.11.068; Sines E., 2007, POSTNATAL CARE CRITI; Singh A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044931; Singh A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037037; Singh S, 2009, ADDING IT COSTS BENE; StataCorp, 2009, STAT STAT SOFTW REL; Stuart EA, 2010, STAT SCI, V25, P1, DOI 10.1214/09-STS313; Sugathan KS, 2001, PROMOTING I DELIVRIE; Taylor C. E., 1987, Health Policy and Planning, V2, P150, DOI 10.1093/heapol/2.2.150; Toth C, 2008, RIGHT MESSAGE RIGHT; Vyas S, 2006, HEALTH POLICY PLANN, V21, P459, DOI 10.1093/heapol/czl029; Waddington C, 2008, INTEGRATED HLTH SERV; WHO, 2003, WORKING WITH INDIVID; Williamson E, 2012, STAT METHODS MED RES, V21, P273, DOI 10.1177/0962280210394483; World Health Organization, 2004, REPR HLTH STRAT ACC; Yadav D, 2012, STUDY SYNERGIES MATE; Yadav D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078361; Zerai A, 2001, Afr J Reprod Health, V5, P68, DOI 10.2307/3583432	68	15	15	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 4	2015	10	3							e0118584	10.1371/journal.pone.0118584	http://dx.doi.org/10.1371/journal.pone.0118584			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CC9JM	25738707	Green Published, Green Submitted, gold			2023-01-03	WOS:000350685900049
J	Zanette, RA; Bitencourt, PER; Kontoyiannis, DP; Fighera, RA; Flores, MM; Kommers, GD; Silva, PS; Ludwig, A; Moretto, MB; Alves, SH; Santurio, JM				Zanette, Regis A.; Bitencourt, Paula E. R.; Kontoyiannis, Dimitrios P.; Fighera, Rafael A.; Flores, Mariana M.; Kommers, Glaucia D.; Silva, Priscila S.; Ludwig, Aline; Moretto, Maria B.; Alves, Sydney H.; Santurio, Janio M.			Complex Interaction of Deferasirox and Pythium insidiosum: Iron-Dependent Attenuation of Growth In Vitro and Immunotherapy-Like Enhancement of Immune Responses In Vivo	PLOS ONE			English	Article							PYTHIOSIS; LYMPHOCYTES; MODEL	Pythium insidiosum iron acquisition mechanisms are unknown. We previously showed that the iron chelator deferasirox had weak activity in vitro and in rabbits with experimental pythiosis. Here we show that deferasirox causes damage to P. insidiosum hyphae in vitro, but that activity is diminished in the presence of exogenous iron. The tissue activity of the proinflammatory enzyme adenosine deaminase and the histological pattern observed in pythiosis lesions of rabbits treated with deferasirox were similar to the ones in animals treated with immunotherapy.	[Zanette, Regis A.; Ludwig, Aline; Alves, Sydney H.; Santurio, Janio M.] Fed Univ Santa Maria UFSM, Hlth Sci Ctr, Grad Program Pharmacol, Santa Maria, RS, Brazil; [Bitencourt, Paula E. R.; Silva, Priscila S.; Moretto, Maria B.; Alves, Sydney H.] Univ Fed Santa Maria, Hlth Sci Ctr, Grad Program Pharmaceut Sci, Santa Maria, RS, Brazil; [Kontoyiannis, Dimitrios P.] Univ Texas MD Anderson Canc Ctr, Dept Infect Dis Infect Control & Employee Hlth, Houston, TX 77030 USA; [Fighera, Rafael A.; Flores, Mariana M.; Kommers, Glaucia D.] Univ Fed Santa Maria, Hlth Sci Ctr, Grad Program Vet Med, Santa Maria, RS, Brazil	Universidade Federal de Santa Maria (UFSM); Universidade Federal de Santa Maria (UFSM); University of Texas System; UTMD Anderson Cancer Center; Universidade Federal de Santa Maria (UFSM)	Santurio, JM (corresponding author), Fed Univ Santa Maria UFSM, Hlth Sci Ctr, Grad Program Pharmacol, Santa Maria, RS, Brazil.	janio.santurio@gmail.com	Alves, Severino/L-8963-2013; ludwig, Aline/W-7037-2018; Zanette, RA/C-3139-2014; Santurio, Janio Morais/J-2392-2012; Alves, Sydney H/N-4159-2014	ludwig, Aline/0000-0002-0904-4953; Zanette, RA/0000-0003-4432-2231; Santurio, Janio Morais/0000-0001-6286-9076; Alves, Sydney H/0000-0001-5740-387X; Bitencourt, Paula/0000-0001-7828-518X	National Council for Scientific and Technological Development-CNPq [471114/2010-3]; Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul-CAPES/FAPERGS	National Council for Scientific and Technological Development-CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul-CAPES/FAPERGS	This work was supported by the National Council for Scientific and Technological Development-CNPq (grant number 471114/2010-3 to SHA) and Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul-CAPES/FAPERGS (to RAZ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Antonioli L, 2012, CURR DRUG TARGETS, V13, P842, DOI 10.2174/138945012800564095; Azevedo MI, 2012, VET MICROBIOL, V159, P141, DOI 10.1016/j.vetmic.2012.03.030; Bach BC, 2013, CELL BIOCHEM FUNCT, V31, P476, DOI 10.1002/cbf.2921; Belle LP, 2011, CELL BIOCHEM BIOPHYS, V61, P297, DOI 10.1007/s12013-011-9212-6; Ben-Ami R, 2010, ANTIMICROB AGENTS CH, V54, P484, DOI 10.1128/AAC.00956-09; Casanova V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051287; GiustiG HV, 1974, METHODS ENZYMATIC AN, P1092, DOI DOI 10.1016/B978-0-12-091302-2.50108-0; Ibrahim AS, 2007, J CLIN INVEST, V117, P2649, DOI 10.1172/JCI32338; Kontoyiannis DP, 2007, CANCER-AM CANCER SOC, V110, P1303, DOI 10.1002/cncr.22909; Krajaejun T, 2011, FUNGAL BIOL-UK, V115, P683, DOI 10.1016/j.funbio.2011.05.001; Lewis RE, 2011, ANTIMICROB AGENTS CH, V55, P411, DOI 10.1128/AAC.00792-10; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Martins TB, 2012, J COMP PATHOL, V146, P122, DOI 10.1016/j.jcpa.2011.06.006; Minn Y, 1997, MYCOPATHOLOGIA, V138, P29, DOI 10.1023/A:1006889108673; Pan JH, 2014, INT J SURG CASE REP, V5, P677, DOI 10.1016/j.ijscr.2014.05.018; Pereira DIB, 2008, J MYCOL MED, V18, P129, DOI 10.1016/j.mycmed.2008.05.001; Pires L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085431; Schaible ME, 2004, NAT REV MICROBIOL, V2, P946, DOI 10.1038/nrmicro1046; Schloemer N.J., 2013, INFECT DIS CLIN PRAC, V21, pe24, DOI [10.1097/IPC.0b013e318278f3b5, DOI 10.1097/IPC.0B013E318278F3B5]; Sudjaritruk T, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-33; Zanette RA, 2013, J ANTIMICROB CHEMOTH, V68, P1144, DOI 10.1093/jac/dks534	21	9	9	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 4	2015	10	3							e0118932	10.1371/journal.pone.0118932	http://dx.doi.org/10.1371/journal.pone.0118932			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC9JM	25738758	Green Published, gold, Green Submitted			2023-01-03	WOS:000350685900086
J	Haffajee, RL; Jena, AB; Weiner, SG				Haffajee, Rebecca L.; Jena, Anupam B.; Weiner, Scott G.			Mandatory Use of Prescription Drug Monitoring Programs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Haffajee, Rebecca L.] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA 02215 USA; [Haffajee, Rebecca L.] Harvard Pilgrim Hlth Care Inst, Boston, MA USA; [Jena, Anupam B.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; [Jena, Anupam B.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Jena, Anupam B.] Natl Bur Econ Res, Cambridge, MA 02138 USA; [Weiner, Scott G.] Brigham & Womens Hosp, Div Hlth Policy Res Translat, Dept Emergency Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; National Bureau of Economic Research; Harvard University; Brigham & Women's Hospital	Haffajee, RL (corresponding author), Harvard Univ, Sch Med, Dept Populat Med, 133 Brookline Ave,Sixth Floor, Boston, MA 02215 USA.	haffajee@fas.harvard.edu		Weiner, Scott/0000-0002-4672-5184	NIH HHS [1DP5OD017897-01, DP5 OD017897] Funding Source: Medline; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP5OD017897] Funding Source: NIH RePORTER	NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Commonwealth of Massachusetts Department of Public Health, PRESCR MON PROGR; Haegerich TM, 2014, DRUG ALCOHOL DEPEN, V145, P34, DOI 10.1016/j.drugalcdep.2014.10.001; Kreiner P, BUREAU JUSTICE ASSIS; National Alliance for Model State Drug Laws, STAT REQ PRESCR DISP; National Alliance for Model State Drug Laws, STAT REQ ALL LIC PRE; Perrone J, 2012, NEW ENGL J MED, V366, P2341, DOI 10.1056/NEJMp1204493; Prescription Drug Monitoring Program Center of Excellence at Brandeis, COE BRIEF; Substance Abuse and Mental Health Services Administration, DAWN REP; Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality, RES 2013 NAT SURV DR; Warner M, 2014, TRENDS DRUG POISONIN	10	150	151	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	2015	313	9					891	892		10.1001/jama.2014.18514	http://dx.doi.org/10.1001/jama.2014.18514			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CC3FN	25622279	Green Accepted			2023-01-03	WOS:000350231800007
J	Pardo-De-Santayana, M; Macia, MJ				Pardo-de-Santayana, Manuel; Macia, Manuel J.			BIODIVERSITY The benefits of traditional knowledge	NATURE			English	Editorial Material									[Pardo-de-Santayana, Manuel; Macia, Manuel J.] Univ Autonoma Madrid, Dept Biol Bot, E-28049 Madrid, Spain	Autonomous University of Madrid	Pardo-De-Santayana, M (corresponding author), Univ Autonoma Madrid, Dept Biol Bot, E-28049 Madrid, Spain.	manuel.pardo@uam.es	Macia, Manuel J/H-4631-2012; Pardo-de-Santayana, Manuel/A-1123-2012	Macia, Manuel J/0000-0002-4676-612X; Pardo-de-Santayana, Manuel/0000-0001-9406-4758				Hunn E, 2014, ETHNOBIOL LETT, V5, P146, DOI 10.14237/ebl.5.2014.297; Johns T., 2000, EATING ON THE WILD S, P46; Macia M. J., 2014, J ETHNOPHARMACOL, V158, P58; Menendez-Baceta G, 2015, J ETHNOPHARMACOL, V161, P116, DOI 10.1016/j.jep.2014.12.007; Moerman DE, 2002, ANN INTERN MED, V136, P471, DOI 10.7326/0003-4819-136-6-200203190-00011; Pardo-de-Santayana M., 2010, ETHNOBOTANY IN THE N; Quave CL, 2015, NAT PLANTS, V1, P1, DOI [10.1038/NPLANTS.2014.21, 10.1038/nplants.2014.21]; Reyes-Garcia V, 2013, EVOL HUM BEHAV, V34, P249, DOI 10.1016/j.evolhumbehav.2013.03.002; Schultes R.E., 1995, ETHNOBOTANY EVOLUTIO; Verschuuren B., 2010, SACRED NATURAL SITES	10	38	41	1	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 26	2015	518	7540					487	488		10.1038/518487a	http://dx.doi.org/10.1038/518487a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CC1JP	25719661				2023-01-03	WOS:000350097300033
J	Zarzar, LD; Sresht, V; Sletten, EM; Kalow, JA; Blankschtein, D; Swager, TM				Zarzar, Lauren D.; Sresht, Vishnu; Sletten, Ellen M.; Kalow, Julia A.; Blankschtein, Daniel; Swager, Timothy M.			Dynamically reconfigurable complex emulsions via tunable interfacial tensions	NATURE			English	Article							MULTIPLE EMULSIONS; PHASE-SEPARATION; AIR-WATER; SURFACTANTS; MICROFLUIDICS; FABRICATION; ADSORPTION; PARTICLES; RELEASE; HEXANE	Emulsification is a powerful, well-known technique for mixing and dispersing immiscible components within a continuous liquid phase. Consequently, emulsions are central components of medicine, food and performance materials. Complex emulsions, including Janus droplets (that is, droplets with faces of differing chemistries) and multiple emulsions, are of increasing importance' in pharmaceuticals and medical diagnostics', in the fabrication of microparticles and capsules' for food', in chemical separations', in cosmetics', and in dynamic optics'. Because complex emulsion properties and functions are related to the droplet geometry and composition, the development of rapid, simple fabrication approaches allowing precise control over the droplets' physical and chemical characteristics is critical. Significant advances in the fabrication of complex emulsions have been made using a number of procedures, ranging from largescale, less precise techniques that give compositional heterogeneity using high-shear mixers and membranes'', to small-volume but more precise microfluidic methodsn'''. However, such approaches have yet to create droplet morphologies that can be controllably altered after emulsification. Reconfigurable complex liquids potentially have great utility as dynamically tunable materials. Here we describe an approach to the one-step fabrication of three- and four-phase complex emulsions with highly controllable and reconfigurable morphologies. The fabrication makes use of the temperature-sensitive miscibility of hydrocarbon, silicone and fluorocarbon liquids, and is applied to both the microfluidic and the scalable batch production of complex droplets. We demonstrate that droplet geometries can be alternated between encapsulated and Janus configurations by varying the interfacial tensions using hydrocarbon and fluorinated surfactants including stimuli-responsive and cleavable surfactants. This yields a generalizable strategy for the fabrication of multiphase emulsions with controllably reconfigurable morphologies and the potential to create a wide range of responsive materials.	[Zarzar, Lauren D.; Sletten, Ellen M.; Kalow, Julia A.; Swager, Timothy M.] MIT, Dept Chem, Cambridge, MA 02139 USA; [Zarzar, Lauren D.; Sletten, Ellen M.; Kalow, Julia A.; Swager, Timothy M.] MIT, Inst Soldier Nanotechnol, Cambridge, MA 02139 USA; [Sresht, Vishnu; Blankschtein, Daniel] MIT, Dept Chem Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Blankschtein, D (corresponding author), MIT, Dept Chem Engn, Cambridge, MA 02139 USA.	dblank@mit.edu; tswager@mit.edu	Kalow, Julia A/C-7353-2016; Zarzar, Lauren D./C-4239-2019	Kalow, Julia A/0000-0001-9215-520X; /0000-0002-5764-9383; Zarzar, Lauren/0000-0002-3287-3602; /0000-0002-4449-9566	Eni S.p.A. under Eni-MIT Alliance Solar Frontiers Program; US Army Research Laboratory; US Army Research Office through Institute for Soldier Nanotechnologies [W911NF-13-D-0001]; F32 Ruth L. Kirschtein NRSA Fellowships [EB014682, GM106550]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [F32EB014682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM106550] Funding Source: NIH RePORTER	Eni S.p.A. under Eni-MIT Alliance Solar Frontiers Program; US Army Research Laboratory(United States Department of DefenseUS Army Research Laboratory (ARL)); US Army Research Office through Institute for Soldier Nanotechnologies; F32 Ruth L. Kirschtein NRSA Fellowships; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Financial support from Eni S.p.A. under the Eni-MIT Alliance Solar Frontiers Program and by the US Army Research Laboratory and the US Army Research Office through the Institute for Soldier Nanotechnologies under contract number W911NF-13-D-0001 is acknowledged. EMS. and J.A.K. were supported by F32 Ruth L. Kirschtein NRSA Fellowships under award numbers EB014682 (E.M.S.) and GM106550 (J.A.K.). We thank L Arriaga for introducing us to the fabrication of capillary microfluidic devices.	Aserin A., 2008, MULTIPLE EMULSIONS T; Augustin MA, 2009, CHEM SOC REV, V38, P902, DOI 10.1039/b801739p; BEDFORD RG, 1958, J AM CHEM SOC, V80, P282, DOI 10.1021/ja01535a007; Brown P, 2013, SOFT MATTER, V9, P2365, DOI 10.1039/c3sm27716j; CHAKRAVARTI AK, 1995, COLLOID SURFACE A, V103, P59, DOI 10.1016/0927-7757(95)03201-N; Chen LJ, 2014, ADV OPT MATER, V2, P845, DOI 10.1002/adom.201400166; Chevallier E, 2011, SOFT MATTER, V7, P7866, DOI 10.1039/c1sm05378g; Choi CH, 2014, CHEMPHYSCHEM, V15, P21, DOI 10.1002/cphc.201300821; Choi CH, 2013, ADV MATER, V25, P2536, DOI 10.1002/adma.201204657; Duncanson WJ, 2014, LANGMUIR, V30, P13765, DOI 10.1021/la502473w; Gladysz J. A., 2004, HDB FLUOROUS CHEM, V18-20, P521; GRESHAM PA, 1971, NATURE, V234, P149, DOI 10.1038/234149a0; Guzowski J., 2012, SOFT MATTER, V8, P7269; Haase MF, 2014, ANGEW CHEM INT EDIT, V53, P11793, DOI 10.1002/anie.201406040; Kim J.W., 2007, ANGEW CHEM INT EDIT, V119, P1851, DOI DOI 10.1002/ANGE.200604206; Li MS, 2010, J ORG CHEM, V75, P6149, DOI 10.1021/jo100954q; Li XF, 2010, CHEMPHYSCHEM, V11, P3074, DOI 10.1002/cphc.201000500; Lone S, 2014, RSC ADV, V4, P13322, DOI 10.1039/c4ra00158c; McClain BR, 1999, EUR PHYS J B, V10, P45, DOI 10.1007/s100510050828; MUKERJEE P, 1981, J PHYS CHEM-US, V85, P2298, DOI 10.1021/j150615a032; Patravale V. B., 2008, International Journal of Cosmetic Science, V30, P19, DOI 10.1111/j.1468-2494.2008.00416.x; Rosen MJ, 2012, SURFACTANTS AND INTERFACIAL PHENOMENA, 4TH EDITION, P235; Rowlinson J. S., 1982, MOL THEORY CAPILLARI, P209; Shah RK, 2008, MATER TODAY, V11, P18, DOI 10.1016/S1369-7021(08)70053-1; Shum HC, 2010, MACROMOL RAPID COMM, V31, P108, DOI 10.1002/marc.200900590; Sletten EM, 2014, J AM CHEM SOC, V136, P13574, DOI 10.1021/ja507848f; Song Y, 2012, LANGMUIR, V28, P12054, DOI 10.1021/la3026599; van der Graaf S, 2005, J MEMBRANE SCI, V251, P7, DOI 10.1016/j.memsci.2004.12.013; Wong TS, 2011, NATURE, V477, P443, DOI 10.1038/nature10447; Yang Y, 2013, SOFT MATTER, V9, P1458, DOI 10.1039/c2sm27288a; Zhao CX, 2009, ANGEW CHEM INT EDIT, V48, P7208, DOI 10.1002/anie.200902485	31	260	265	48	828	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 26	2015	518	7540					520	524		10.1038/nature14168	http://dx.doi.org/10.1038/nature14168			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC1JP	25719669	Green Accepted, Green Submitted			2023-01-03	WOS:000350097300043
J	Roth, RB; Hess, E; Kaminsky, AF				Roth, Russell B.; Hess, Elmer; Kaminsky, Anthony F.			Of Fires and Frying Pans (Reprinted from vol 155, pg 302, 1954)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Reprint											Roth, RB (corresponding author), 501 Commerce Bldg, Erie, PA USA.							ROTH RB, 1954, JAMA-J AM MED ASSOC, V155, P302, DOI 10.1001/jama.1954.03690210080021	1	0	0	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	2015	313	6					632	632		10.1001/jama.2014.11576	http://dx.doi.org/10.1001/jama.2014.11576			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CA7AZ	25668278				2023-01-03	WOS:000349070700033
J	Mengist, HM; Taye, B; Tsegaye, A				Mengist, Hylemariam Mihiretie; Taye, Bineyam; Tsegaye, Aster			Intestinal Parasitosis in Relation to CD4+T Cells Levels and Anemia among HAART Initiated and HAART Naive Pediatric HIV Patients in a Model ART Center in Addis Ababa, Ethiopia	PLOS ONE			English	Article							INFECTION; CHILDREN; PROFILE	Background Intestinal parasites (IPs) are major concerns in most developing countries where HIV/AIDS cases are concentrated and almost 80% of AIDS patients die of AIDS-related infections. In the absence of highly active antiretroviral therapy (HAART), HIV/AIDS patients in developing countries unfortunately continue to suffer from the consequences of opportunistic and other intestinal parasites. The aim of the study was to determine the prevalence of intestinal parasites in relation to CD4+T cells levels and anemia among HAART initiated and HAART naive pediatric HIV patients in a Model ART center in Addis Ababa, Ethiopia. Methods A prospective comparative cross-sectional study was conducted among HAART initiated and HAART naive pediatric HIV/AIDS patients attending a model ART center at Zewditu Memorial Hospital between August 05, 2013 and November 25, 2013. A total of 180 (79 HAART initiated and 101 HAART naive) children were included by using consecutive sampling. Stool specimen was collected and processed using direct wet mount, formol-ether concentration and modified Ziehl-Neelsen staining techniques. A structured questionnaire was used to collect data on socio-demographic and associated risk factors. CD4+T cells and complete blood counts were performed using BD FACScalibur and Cell-Dyn 1800, respectively. The data was analyzed by SPSS version 16 software. Logistic regressions were applied to assess any association between explanatory factors and outcome variables. P values < 0.05 were taken as statistically significant. Results The overall prevalence of IPs was 37.8% where 27.8% of HAART initiated and 45.5% of HAART naive pediatric HIV/AIDS patients were infected (p < 0.05). Cryptosporidium species, E. histolytica/dispar, Hook worm and Taenia species were IPs associated with CD4+T cell counts < 350 cells/mu mu L in HAART naive patients. The overall prevalence of anemia was 10% in HAART and 31.7% in non-HAART groups. Hook worm, S. stercoralis and H. nana were helminthes significantly associated with anemia in non-HAART patients [AOR, 95% CI: 4.5(1.3, 15.2), P<0.05]. The prevalence of IPs in non-HAART patients was significantly associated with eating unwashed/raw fruit [AOR, 95% CI: 6.3(1.2, 25.6), P<0.05], open field defecation [AOR, 95% CI: 9.3(1.6, 53.6), P<0.05] and diarrhea [AOR, 95% CI: 5.2(1.3, 21.3), P<0.05]. IPs significantly increased in rural residents [AOR, 95% CI: 0.4(0.1, 0.9, P<0.05)]. Conclusion The overall prevalence of intestinal parasites significantly differed by HAART status and cryptosporidium species were found only in HAART naive patients with low CD4+T cell counts. Anemia was also more prevalent and significantly associated with IPs in non-HAART patients. This study identified some environmental and associated risk factors for intestinal parasitic infections. Therefore, Public health measures should continue to emphasize the importance of environmental and personal hygiene to protect HIV/AIDS patients from infections with intestinal parasites and maximize the benefits of HAART.	[Mengist, Hylemariam Mihiretie] Wollega Univ, Fac Med & Hlth Sci, Dept Med Lab Sci, Nekemte, Ethiopia; [Mengist, Hylemariam Mihiretie; Taye, Bineyam; Tsegaye, Aster] Univ Addis Ababa, Coll Hlth Sci, Sch Allied Hlth Sci, Dept Med Lab Sci, Addis Ababa, Ethiopia	Addis Ababa University	Mengist, HM (corresponding author), Wollega Univ, Fac Med & Hlth Sci, Dept Med Lab Sci, Nekemte, Ethiopia.	hylemariam@gmail.com	Mengist, Hylemariam Mihiretie/AAA-6133-2022; Tsegaye, Aster/AAH-7028-2020	Tsegaye, Aster/0000-0002-9026-4629; Mengist, Hylemariam Mihiretie/0000-0002-8467-6985	Addis Ababa University	Addis Ababa University	Addis Ababa University sponsored for this work. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adamu H, 2009, ETHIOP J HEALTH DEV, V23, P133; Adjei A, 2003, East Afr Med J, V80, P369; Akinbo F. O., 2011, Genomic Medicine, Biomarkers and Health Sciences, V3, P119; Akinbol AO, 2011, TANZANIA J HLTH RES, V13, P10; [Anonymous], 1987, B WORLD HEALTH ORGAN, V65, P575; Anteneh T, 2008, MANUAL INTESTINAL PA, P6; Asma L, 2011, TROP BIOMED, V28, P400; Awole M., 2003, ETHIOP J HEALTH DEV, V17, P71; Cheesbrough M, 1999, DISTRICT LAB PRACT 1, P193; Dufera M., 2008, ETHIOP J HLTH BIOMED, V1, P11; Farthing M, 2009, MANSONS TROPICAL DIS; Habib MK, 2001, I STAT MIMEO, V1840, P1; Huruy K, 2008, JPN J INFECT DIS, V61, P205; Idris NS, 2010, J INFECT DEV COUNTR, V4, P309, DOI 10.3855/jidc.275; Kassu A, 2003, CLIN EXP IMMUNOL, V132, P113, DOI 10.1046/j.1365-2249.2003.02106.x; Le HT, 2007, ASIA PAC J CLIN NUTR, V16, P716; Missaye A, 2013, AIDS RES THER, V10, DOI 10.1186/1742-6405-10-7; Mohammed H, 2010, EHNRI, V11, P1; Rao VG, 2006, PUBLIC HEALTH NUTR, V9, P19, DOI 10.1079/PHN2005761; Bachur TPR, 2008, BRAZ J INFECT DIS, V12, P115, DOI 10.1590/S1413-86702008000200004; Telele NF, 2010, REV ANT INFEC DIS, V3, P7; Tian LG, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-36; WHO, 2011, HEM CONC DIAGN AN AS, P3; WHO, 2005, INT WHO CLIN STAG HI, P8; WHO, 1998, 749 WHO, V749, P1; Zeynudin A, 2013, EUR REV MED PHARMACO, V17, P513	26	33	33	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2015	10	2							e0117715	10.1371/journal.pone.0117715	http://dx.doi.org/10.1371/journal.pone.0117715			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CB2GK	25658626	Green Published, gold, Green Submitted			2023-01-03	WOS:000349444900208
J	Dickson, DR; Dickson, CCL; Farnell, R				Dickson, David Robin; Dickson, Claire C. L.; Farnell, Robert			10-MINUTE CONSULTATION Pain at the base of the thumb	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Dickson, David Robin; Farnell, Robert] Leeds Gen Infirm, Hand Unit, Leeds LS1 3EX, W Yorkshire, England; [Dickson, Claire C. L.] Wetherby Surg, Wetherby, W Yorkshire, England	Leeds General Infirmary; University of Leeds	Dickson, DR (corresponding author), Leeds Gen Infirm, Hand Unit, Leeds LS1 3EX, W Yorkshire, England.	davidrdickson@hotmail.com						Anakwe RE, 2011, BMJ-BRIT MED J, V343, P1160; Berggren M, 2001, SCAND J PLAST RECONS, V35, P415; Dziedzic K, 2015, ANN RHEUM DIS, V74, P108, DOI 10.1136/annrheumdis-2013-203938; Maarse W, 2009, J HAND SURG-ASIAN-PA, V14, P99, DOI 10.1142/S0218810409004311; National Institute for Health and Care Excellence, 2014, 177 CG NAT I HLTH CA, V177	5	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 3	2015	350								h182	10.1136/bmj.h182	http://dx.doi.org/10.1136/bmj.h182			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CB0IL	25647321				2023-01-03	WOS:000349309100001
J	Wharam, JF; Graves, AJ; Kozhimannil, KB				Wharam, J. Frank; Graves, Amy J.; Kozhimannil, Katy B.			Navigating the Rise of High-Deductible Health Insurance Childbirth in the Bronze Age	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Wharam, J. Frank] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA 02114 USA; [Wharam, J. Frank] Harvard Pilgrim Hlth Care Inst, Boston, MA 02114 USA; [Graves, Amy J.] Vanderbilt Univ, Med Ctr, Dept Urol Surg, Nashville, TN USA; [Kozhimannil, Katy B.] Univ Minnesota, Sch Publ Hlth, Div Hlth Policy & Management, Minneapolis, MN USA	Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Vanderbilt University; University of Minnesota System; University of Minnesota Twin Cities	Wharam, JF (corresponding author), Harvard Univ, Sch Med, Dept Populat Med, 133 Brookline Ave,Sixth Floor, Boston, MA 02114 USA.	jwharam@post.harvard.edu		Wharam, James/0000-0003-2053-0757	NCI NIH HHS [1R01CA172639, R01 CA172639] Funding Source: Medline; NICHD NIH HHS [K12HD055887] Funding Source: Medline; NIDDK NIH HHS [R01 DK100304, 1R01DK100304] Funding Source: Medline; NCCDPHP CDC HHS [1U58DP02719] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD055887] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA172639] Funding Source: NIH RePORTER; NATIONAL CENTER FOR CHRONIC DISEASE PREV AND HEALTH PROMO [U58DP002719] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK100304] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCCDPHP CDC HHS; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR CHRONIC DISEASE PREV AND HEALTH PROMO(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Childbirth Connection; Catalyst for Payment Reform; Center for Healthcare Quality and Payment Reform, 2013, COST HAV BAB US; Kaiser Family Foundation and Health Research & Educational Trust, EMPL HLTH BEN 2014 A; Kozhimannil KB, 2011, AM J MANAG CARE, V17, P17; LearnVest; Chase Blueprint, FAC PERS FIN; Livingston Gretchen, 2012, US BIRTH RATE FALLS; Patient Protection and Affordable Care Act, 2013, FED REG, V78; Reinhardt UE, 2013, JAMA-J AM MED ASSOC, V310, P1927, DOI 10.1001/jama.2013.281854; Wharam JF, 2013, NEW ENGL J MED, V369, P1481, DOI 10.1056/NEJMp1309490	8	7	8	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	2015	313	3					245	246		10.1001/jama.2014.16085	http://dx.doi.org/10.1001/jama.2014.16085			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AZ3RS	25602991				2023-01-03	WOS:000348145000012
J	Lyon, GM; Mehta, AK; Varkey, JB; Brantly, K; Plyler, L; McElroy, AK; Kraft, CS; Towner, JS; Spiropoulou, C; Stroher, U; Uyeki, TM; Ribner, BS				Lyon, G. Marshall; Mehta, Aneesh K.; Varkey, Jay B.; Brantly, Kent; Plyler, Lance; McElroy, Anita K.; Kraft, Colleen S.; Towner, Jonathan S.; Spiropoulou, Christina; Stroeher, Ute; Uyeki, Timothy M.; Ribner, Bruce S.		Emory Serious Communicable Dis	Clinical Care of Two Patients with Ebola Virus Disease in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEMORRHAGIC-FEVER; INFECTION; FEATURES; KIKWIT; UGANDA; CONGO	West Africa is currently experiencing the largest outbreak of Ebola virus disease (EVD) in history. Two patients with EVD were transferred from Liberia to our hospital in the United States for ongoing care. Malaria had also been diagnosed in one patient, who was treated for it early in the course of EVD. The two patients had substantial intravascular volume depletion and marked electrolyte abnormalities. We undertook aggressive supportive measures of hydration (typically, 3 to 5 liters of intravenous fluids per day early in the course of care) and electrolyte correction. As the patients' condition improved clinically, there was a concomitant decline in the amount of virus detected in plasma.	[Lyon, G. Marshall; Mehta, Aneesh K.; Varkey, Jay B.; Kraft, Colleen S.; Ribner, Bruce S.] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA USA; [Kraft, Colleen S.] Emory Univ, Sch Med, Dept Pathol, Div Infect Dis, Atlanta, GA 30322 USA; [McElroy, Anita K.] Emory Univ, Sch Med, Dept Pediat, Div Infect Dis, Atlanta, GA USA; [McElroy, Anita K.; Towner, Jonathan S.; Spiropoulou, Christina; Stroeher, Ute; Uyeki, Timothy M.] Ctr Dis Control & Prevent, Atlanta, GA USA; [Brantly, Kent; Plyler, Lance] Samaritans Purse, Boone, NC USA	Emory University; Emory University; Emory University; Centers for Disease Control & Prevention - USA	Lyon, GM (corresponding author), 101 Woodruff Cir,WMB 2101, Atlanta, GA 30322 USA.	gmlyon@emory.edu	Kraft, Colleen S/M-2347-2013; Mehta, Aneesh/B-8054-2012; Towner, Jonathan/ABC-3780-2020	Kraft, Colleen S/0000-0003-1757-8477; Mehta, Aneesh/0000-0002-6552-9162; McElroy, Anita/0000-0001-6764-7536	CDC	CDC(Centre National de la Recherche Scientifique (CNRS)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	Supported by the CDC.	Burke J, 1978, B WORLD HEALTH ORGAN, V56, P271; Bwaka MA, 1999, J INFECT DIS, V179, pS1, DOI 10.1086/514308; Del Rio C, 2014, ANN INTERN MED; Feldmann H., 2013, FIELDS VIROLOGY, V1, P923; Geisbert TW, 2003, J INFECT DIS, V188, P1618, DOI 10.1086/379724; Kortepeter MG, 2011, J INFECT DIS, V204, pS810, DOI 10.1093/infdis/jir299; Ksiazek TG, 1999, J INFECT DIS, V179, pS177, DOI 10.1086/514321; MacNeil A, 2010, EMERG INFECT DIS, V16, P1969, DOI 10.3201/eid1612.100627; McElroy AK, 2014, J INFECT DIS, V210, P558, DOI 10.1093/infdis/jiu088; Mupapa K, 1999, J INFECT DIS, V179, pS18, DOI 10.1086/514298; Okware SI, 2002, TROP MED INT HEALTH, V7, P1068, DOI 10.1046/j.1365-3156.2002.00944.x; Peters C.J., 2010, MANDELL DOUGLAS BENN, P2259; Qiu XG, 2014, NATURE, V514, P47, DOI 10.1038/nature13777; Rao SSC, 2006, JPEN-PARENTER ENTER, V30, P433, DOI 10.1177/0148607106030005433; Rollin PE, 2007, J INFECT DIS, V196, pS364, DOI 10.1086/520613; Seas C, 2010, MANDELL DOUGLAS BENN, P2777; Sobarzo A, 2013, NEW ENGL J MED, V369, P492, DOI 10.1056/NEJMc1300266; WHO, 2014, GLOB AL RESP EB VIR; WHO Blood Regulators Network, 2014, POS PAP COLL US CONV; Wong G, 2014, TRENDS MICROBIOL, V22, P456, DOI 10.1016/j.tim.2014.04.002; World Health Organization, 2014, EB RESP ROADM SIT RE	21	254	277	0	95	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 18	2014	371	25					2402	2409		10.1056/NEJMoa1409838	http://dx.doi.org/10.1056/NEJMoa1409838			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AW7DX	25390460	Bronze			2023-01-03	WOS:000346425800009
J	Mao, Y; Qu, Q; Zhang, YZ; Liu, JJ; Chen, XS; Shen, KW				Mao, Yan; Qu, Qing; Zhang, Yuzi; Liu, Junjun; Chen, Xiaosong; Shen, Kunwei			The Value of Tumor Infiltrating Lymphocytes (TILs) for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer: A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							PATHOLOGICAL COMPLETE RESPONSE; SURGICAL ADJUVANT BREAST; PREOPERATIVE CHEMOTHERAPY; T-CELLS; SURVIVAL; PROGNOSIS; THERAPY; TRASTUZUMAB; DOXORUBICIN; DOCETAXEL	Background: We carried out a systematic review and meta-analysis to evaluate the predictive roles of tumor infiltrating lymphocytes (TILs) in response to neoadjuvant chemotherapy (NAC) in breast cancer. Method: A PubMed and Web of Science literature search was designed. Random or fixed effect models were adopted to estimate the summary odds ratio (OR). Heterogeneity and sensitivity analyses were performed to explore heterogeneity among studies and to assess the effects of study quality. Publication bias was evaluated using a funnel plot, Egger's test and Begg's test. We included studies where the predictive significance of TILs, and/or TILs subset on the pathologic complete response (pCR) were determined in NAC of breast cancer. Results: A total of 13 published studies (including 3251 patients) were eligible. In pooled analysis, the detection of higher TILs numbers in pre-treatment biopsy was correlated with better pCR to NAC (OR=3.93, 95% CI, 3.26-4.73). Moreover, TILs predicted higher pCR rates in triple negative (OR=2.49, 95% CI: 1.61-3.83), HER2 positive (OR=5.05, 95% CI: 2.86-8.92) breast cancer, but not in estrogen receptor (ER) positive (OR=6.21, 95% CI: 0.86-45.15) patients. In multivariate analysis, TILs were still an independent marker for high pCR rate (OR=1.41, 95% CI: 1.19-1.66). For TILs subset, higher levels of CD8+ and FOXP3+ T-lymphocytes in pretreatment biopsy respectively predicted better pathological response to NAC (OR=6.44, 95% CI: 2.52-16.46; OR=2.94, 95% CI: 1.05-8.26). Only FOXP3+ lymphocytes in post-NAC breast tissue were a predictive marker for low pCR rate in univariate (OR=0.41, 95% CI: 0.21-0.80) and multivariate (OR=0.36, 95% CI: 0.13-0.95) analysis. Conclusion: Higher TILs levels in pre-treatment biopsy indicated higher pCR rates for NAC. TILs subset played different roles in predicting response to NAC.	[Mao, Yan; Zhang, Yuzi; Liu, Junjun; Chen, Xiaosong; Shen, Kunwei] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Comprehens Breast Hlth Ctr, Shanghai 200030, Peoples R China; [Qu, Qing] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Oncol, Shanghai 200030, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Shen, KW (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Comprehens Breast Hlth Ctr, Shanghai 200030, Peoples R China.	kunwshenrj@163.com			National Natural funding of China [81202087, 81202088, 81172520]; Shanghai Municipal Science and Technology Commission funding [12ZR1446400, 12140901503]; Doctor Innovation funding of Shanghai Jiao Tong University School of Medicine [BXJ201213]	National Natural funding of China; Shanghai Municipal Science and Technology Commission funding; Doctor Innovation funding of Shanghai Jiao Tong University School of Medicine	This study was supported by the National Natural funding of China (81202087,81202088, 81172520), Shanghai Municipal Science and Technology Commission funding (12ZR1446400, 12140901503); Doctor Innovation funding of Shanghai Jiao Tong University School of Medicine (BXJ201213). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andre F, 2013, CLIN CANCER RES, V19, P28, DOI 10.1158/1078-0432.CCR-11-2701; Aruga T, 2009, ONCOL REP, V22, P273, DOI 10.3892/or_00000434; Bear HD, 2003, J CLIN ONCOL, V21, P4165, DOI 10.1200/JCO.2003.12.005; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Bhargava R, 2010, CANCER-AM CANCER SOC, V116, P1431, DOI 10.1002/cncr.24876; Caras I, 2004, CANCER IMMUNOL IMMUN, V53, P1146, DOI 10.1007/s00262-004-0556-2; Carey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078-0432.CCR-06-1109; de Jong RA, 2009, GYNECOL ONCOL, V114, P105, DOI 10.1016/j.ygyno.2009.03.022; Denkert C, 2013, ANN ONCOL, V24, P2786, DOI 10.1093/annonc/mdt350; Denkert C, 2013, CANC RES S, V73; Denkert C, 2010, J CLIN ONCOL, V28, P105, DOI 10.1200/JCO.2009.23.7370; Di Cosimo S, 2013, CANC RES S, V73; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fasching PA, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-486; Fisher B, 1997, J CLIN ONCOL, V15, P2483, DOI 10.1200/JCO.1997.15.7.2483; Fisher B, 1998, J CLIN ONCOL, V16, P2672, DOI 10.1200/JCO.1998.16.8.2672; Fisher CS, 2012, ANN SURG ONCOL, V19, P253, DOI 10.1245/s10434-011-1877-y; Garcia-Martinez E, 2013, CANCER RES, V73, DOI 10.1158/0008-5472.SABCS13-P5-01-08; Giatromanolaki A, 2008, GYNECOL ONCOL, V110, P216, DOI 10.1016/j.ygyno.2008.04.021; Hayes DF, 2006, BREAST CANCER RES TR, V100, P237, DOI 10.1007/s10549-006-9253-5; Hornychova H, 2008, CANCER INVEST, V26, P1024, DOI 10.1080/07357900802098165; Ino K, 2008, CLIN CANCER RES, V14, P2310, DOI 10.1158/1078-0432.CCR-07-4144; Ismael G, 2012, LANCET ONCOL, V13, P869, DOI 10.1016/S1470-2045(12)70329-7; Issa-Nummer Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079775; Kondratiev S, 2004, CLIN CANCER RES, V10, P4450, DOI 10.1158/1078-0432.CCR-0732-3; Kong XN, 2011, EUR J CANCER, V47, P2084, DOI 10.1016/j.ejca.2011.06.014; Ladoire S, 2008, CLIN CANCER RES, V14, P2413, DOI 10.1158/1078-0432.CCR-07-4491; Lee HJ, 2013, J BREAST CANCER, V16, P32, DOI 10.4048/jbc.2013.16.1.32; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Liu FF, 2012, BREAST CANCER RES TR, V135, P459, DOI 10.1007/s10549-012-2132-3; Loi S, 2014, ANN ONCOL, V25, P1544, DOI 10.1093/annonc/mdu112; Loi S, 2013, J CLIN ONCOL, V31, P860, DOI 10.1200/JCO.2011.41.0902; Mahmoud SMA, 2011, J CLIN ONCOL, V29, P1949, DOI 10.1200/JCO.2010.30.5037; Mauri D, 2005, JNCI-J NATL CANCER I, V97, P188, DOI 10.1093/jnci/dji021; McShane LM, 2005, BRIT J CANCER, V93, P387, DOI 10.1038/sj.bjc.6602678; Mei Z, 2014, BRIT J CANCER, V110, P1595, DOI 10.1038/bjc.2014.46; Melichar B, 2012, MED ONCOL, V29, P2577, DOI 10.1007/s12032-012-0195-y; Menard S, 1997, CLIN CANCER RES, V3, P817; Mohammed ZMA, 2012, BRIT J CANCER, V107, P864, DOI 10.1038/bjc.2012.347; Montagna E, 2010, BREAST CANCER RES TR, V124, P689, DOI 10.1007/s10549-010-1027-4; Oda N, 2012, BREAST CANCER RES TR, V136, P107, DOI 10.1007/s10549-012-2245-8; Ohno S, 2013, BREAST CANCER RES TR, V142, P69, DOI 10.1007/s10549-013-2691-y; Ono M, 2012, BREAST CANCER RES TR, V132, P793, DOI 10.1007/s10549-011-1554-7; Seo AN, 2013, BRIT J CANCER, V109, P2705, DOI 10.1038/bjc.2013.634; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Straver ME, 2010, ANN SURG ONCOL, V17, P2411, DOI 10.1245/s10434-010-1008-1; Tan MC, 2009, AM J SURG, V198, P520, DOI 10.1016/j.amjsurg.2009.06.004; Tomsova M, 2008, GYNECOL ONCOL, V108, P415, DOI 10.1016/j.ygyno.2007.10.016; van der Hage JA, 2001, J CLIN ONCOL, V19, P4224, DOI 10.1200/JCO.2001.19.22.4224; West NR, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3072; Yamagami W, 2011, INT J GYNECOL CANCER, V21, P1628, DOI 10.1097/IGC.0b013e31822c271f; Yamaguchi R, 2012, HUM PATHOL, V43, P1688, DOI 10.1016/j.humpath.2011.12.013; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177	53	129	132	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2014	9	12							e115103	10.1371/journal.pone.0115103	http://dx.doi.org/10.1371/journal.pone.0115103			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AW6JI	25501357	Green Published, gold, Green Submitted			2023-01-03	WOS:000346375400072
J	Jung, ME; Bourne, JE; Little, JP				Jung, Mary E.; Bourne, Jessica E.; Little, Jonathan P.			Where Does HIT Fit? An Examination of the Affective Response to High-Intensity Intervals in Comparison to Continuous Moderate- and Continuous Vigorous-Intensity Exercise in the Exercise Intensity-Affect Continuum	PLOS ONE			English	Article							PHYSICAL-ACTIVITY; INTERMITTENT EXERCISE; HYPERGLYCEMIA; BODY	Affect experienced during an exercise session is purported to predict future exercise behaviour. Compared to continuous moderate-intensity exercise (CMI), the affective response to continuous vigorous-intensity exercise (CVI) has consistently been shown to be more aversive. The affective response, and overall tolerability to high-intensity interval training (HIT), is less studied. To date, there has yet to be a comparison between HIT, CVI, and CMI. The purpose of this study was to compare the tolerability and affective responses during HIT to CVI and CMI. This study utilized a repeated measures, randomized, counter-balanced design. Forty-four participants visited the laboratory on four occasions. Baseline fitness testing was conducted to establish peak power output in Watts (Wpeak). Three subsequent visits involved a single bout of a) HIT, corresponding to 1-minute at similar to 100% Wpeak and 1-minute at similar to 20% Wpeak for 20 minutes, b) CMI, corresponding to similar to 40% Wpeak for 40 minutes, and c) CVI, corresponding to similar to 80% Wpeak for 20 minutes. The order of the sessions was randomized. Affective responses were measured before, during and after each session. Task self-efficacy, intentions, enjoyment and preference were measured after sessions. Participants reported greater enjoyment of HIT as compared to CMI and CVI, with over 50% of participants reporting a preference to engage in HIT as opposed to either CMI or CVI. HIT was considered more pleasurable than CVI after exercise, but less pleasurable than CMI at these times. Despite this participants reported being just as confident to engage in HIT as they were CMI, but less confident to engage in CVI. This study highlights the utility of HIT in inactive individuals, and suggests that it may be a viable alternative to traditionally prescribed continuous modalities of exercise for promoting self-efficacy and enjoyment of exercise.	[Jung, Mary E.; Bourne, Jessica E.; Little, Jonathan P.] Univ British Columbia, Sch Hlth & Exercise Sci, Okanagan, BC, Canada	University of British Columbia; University of British Columbia Okanagan	Jung, ME (corresponding author), Univ British Columbia, Sch Hlth & Exercise Sci, Okanagan, BC, Canada.	mary.jung@ubc.ca	Little, Jonathan P./T-4076-2019	Little, Jonathan P./0000-0002-9796-2008	UBC (Hampton Research Fund)	UBC (Hampton Research Fund)	Funding: This research was funded by an internal UBC grant (Hampton Research Fund). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bandura A, 1997, EFFICACY EXERCISE CO; Bartlett JD, 2011, J SPORT SCI, V29, P547, DOI 10.1080/02640414.2010.545427; Blanchard CM, 2001, J SCI MED SPORT, V4, P30, DOI 10.1016/S1440-2440(01)80005-0; Borg G., 1998, CHAMPAIGN; Brewer BW, 2000, J SPORT EXERCISE PSY, V22, P119, DOI 10.1123/jsep.22.2.119; Canadian Society for Exercise Physiology (CSEP), 2002, PHYS ACT READ QUEST; Ekkekakis P, 2005, PSYCHOL SPORT EXERC, V6, P83, DOI 10.1016/j.psychsport.2003.10.005; Ekkekakis P, 2003, COGNITION EMOTION, V17, P213, DOI 10.1080/02699930302292; Ekkekakis P, 2002, PSYCHOL SPORT EXERC, V3, P35, DOI 10.1016/S1469-0292(01)00028-0; Ekkekakis P, 2009, SPORTS MED, V39, P857, DOI 10.2165/11315210-000000000-00000; EMMONS RA, 1986, J RES PERS, V20, P309, DOI 10.1016/0092-6566(86)90137-6; Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb; Gibala MJ, 2008, EXERC SPORT SCI REV, V36, P58, DOI 10.1097/JES.0b013e318168ec1f; Gillen JB, 2012, DIABETES OBES METAB, V14, P575, DOI 10.1111/j.1463-1326.2012.01564.x; Godin G, 1997, MED SCI SPORTS EXERC, V29, P36, DOI DOI 10.1097/00005768-199706001-00009; Hall EE, 2002, BRIT J HEALTH PSYCH, V7, P47, DOI 10.1348/135910702169358; HARDY CJ, 1989, J SPORT EXERCISE PSY, V11, P304, DOI 10.1123/jsep.11.3.304; Heydari M, 2012, J OBES, V2012, DOI 10.1155/2012/480467; Hood MS, 2011, MED SCI SPORT EXER, V43, P1849, DOI 10.1249/MSS.0b013e3182199834; KENDZIERSKI D, 1991, J SPORT EXERCISE PSY, V13, P50, DOI 10.1123/jsep.13.1.50; Kilpatrick M, 2003, RES Q EXERCISE SPORT, V74, P353, DOI 10.1080/02701367.2003.10609103; Little JP, 2011, J APPL PHYSIOL, V111, P1554, DOI 10.1152/japplphysiol.00921.2011; Little JP, 2010, J PHYSIOL-LONDON, V588, P1011, DOI 10.1113/jphysiol.2009.181743; Little JP, APPL PHYSL IN PRESS; MCAULEY E, 1998, ADV SPORT EXERCISE P, P371; MORGAN WP, 1994, MED SCI SPORT EXER, V26, P1071, DOI 10.1249/00005768-199409000-00001; O'Connor PJ, 2005, MED SCI SPORT EXER, V37, P299, DOI 10.1249/01.MSS.0000152802.89770.CF; Oliveira BRR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079965; Parfitt G, 2009, J EXERC SCI FIT, V7, pS34, DOI 10.1016/S1728-869X(09)60021-6; Physical Activity Guidelines Advisory Committee, 2008, PHYS ACT GUID ADV CO; STORER TW, 1990, MED SCI SPORT EXER, V22, P704, DOI 10.1249/00005768-199010000-00024; Tate AK, 1995, J SPORT MED PHYS FIT, V35, P295; Thayer R.E., 1989, BIOPSYCHOLOGY MOOD A; Trapp EG, 2008, INT J OBESITY, V32, P684, DOI 10.1038/sj.ijo.0803781; Tremblay M.S., 2011, HLTH REPORTS, V22, P7; Tritter A, 2013, PSYCHOL SPORT EXERC, V14, P886, DOI 10.1016/j.psychsport.2013.08.002; Trost SG, 2002, MED SCI SPORT EXER, V34, P1996, DOI 10.1097/00005768-200212000-00020; Warburton DER, 2010, INT J BEHAV NUTR PHY, V7, DOI 10.1186/1479-5868-7-39; Warburton DER, 2006, CAN MED ASSOC J, V174, P801, DOI 10.1503/cmaj.051351; Williams DM, 2008, PSYCHOL SPORT EXERC, V9, P231, DOI 10.1016/j.psychsport.2007.04.002; Williams DM, 2012, ANN BEHAV MED, V44, P43, DOI 10.1007/s12160-012-9362-9	41	190	193	1	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 8	2014	9	12							e114541	10.1371/journal.pone.0114541	http://dx.doi.org/10.1371/journal.pone.0114541			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AX4MX	25486273	Green Submitted, Green Published, gold			2023-01-03	WOS:000346907600074
J	Moberly, T				Moberly, Tom			PRESCRIBING Physician, don't heal thyself: the perils of self prescribing	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												tmoberly@bmj.com						Christie JD, 1998, JAMA-J AM MED ASSOC, V280, P1253, DOI 10.1001/jama.280.14.1253; Frank E, 2009, CAN FAM PHYSICIAN, V55, P810; Hem E, 2005, BMC MED, V3, DOI 10.1186/1741-7015-3-16; NHS England, TREAT YOURS FAM MEMB	4	4	4	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 8	2014	349								g7401	10.1136/bmj.g7401	http://dx.doi.org/10.1136/bmj.g7401			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AY5RE	25487279				2023-01-03	WOS:000347628600001
J	Johnson, SC				Johnson, Simon C.			A target for pharmacological intervention in an untreatable human disease	SCIENCE			English	Article							MTOR		Albert Einstein Coll Med, Bronx, NY 10462 USA	Yeshiva University; Albert Einstein College of Medicine	Johnson, SC (corresponding author), Albert Einstein Coll Med, 1301 Morris Pk Ave,Room 469, Bronx, NY 10462 USA.	simon.johnson@einstein.yu.edu		Johnson, Simon/0000-0002-1942-3674				Johnson SC, 2013, SCIENCE, V342, P1524, DOI 10.1126/science.1244360; Johnson SC, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007316; Johnson SC, 2013, NATURE, V493, P338, DOI 10.1038/nature11861; Schleit J, 2013, AGING CELL, V12, P1050, DOI 10.1111/acel.12130	4	6	6	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 5	2014	346	6214								10.1126/science.aaa1811	http://dx.doi.org/10.1126/science.aaa1811			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CB7UV	25477449				2023-01-03	WOS:000349834700001
J	Khvorova, A; Osborn, MF; Hassler, MR				Khvorova, Anastasia; Osborn, Maire F.; Hassler, Matthew R.			Taking charge of siRNA delivery	NATURE BIOTECHNOLOGY			English	Editorial Material									[Khvorova, Anastasia; Osborn, Maire F.; Hassler, Matthew R.] Univ Massachusetts, Sch Med, RNA Therapeut Inst, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Khvorova, A (corresponding author), Univ Massachusetts, Sch Med, RNA Therapeut Inst, Worcester, MA 01655 USA.	Anastasia.Khvorova@umassmed.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM108803] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM108803] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 2014, RNAI ROUNDTABLE ADV; Eguchi A, 2009, NAT BIOTECHNOL, V27, P567, DOI 10.1038/nbt.1541; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Gait MJ, 2003, CELL MOL LIFE SCI, V60, P844, DOI 10.1007/s00018-003-3044-5; HANGELAND JJ, 1995, BIOCONJUGATE CHEM, V6, P695, DOI 10.1021/bc00036a006; Meade BR, 2014, NAT BIOTECHNOL, V32, P1256, DOI 10.1038/nbt.3078; Morrissey DV, 2005, HEPATOLOGY, V41, P1349, DOI 10.1002/hep.20702; PERIGAUD C, 1993, BIOORG MED CHEM LETT, V3, P2521, DOI 10.1016/S0960-894X(01)80709-5; Wiesler WT, 1996, J ORG CHEM, V61, P4272, DOI 10.1021/jo960274y	9	17	19	1	33	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2014	32	12					1197	1198		10.1038/nbt.3091	http://dx.doi.org/10.1038/nbt.3091			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	AW3AD	25489835				2023-01-03	WOS:000346156800019
J	Babeluk, R; Jutz, S; Mertlitz, S; Matiasek, J; Klaus, C				Babeluk, Rita; Jutz, Sabrina; Mertlitz, Sarah; Matiasek, Johannes; Klaus, Christoph			Hand Hygiene - Evaluation of Three Disinfectant Hand Sanitizers in a Community Setting	PLOS ONE			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; HEALTH-CARE; ALCOHOL; EFFICACY; INFECTION; INTERVENTION; PROGRAM; RISK; SOAP; RUBS	Hand hygiene is acknowledged as the single most important measure to prevent nosocomial infections in the healthcare setting. Similarly, in non-clinical settings, hand hygiene is recognised as a key element in helping prevent the spread of infectious diseases. The aim of this study was to evaluate the efficacy of three different disinfectant hand sanitizers in reducing the burden of bacterial hand contamination in 60 healthy volunteers in a community setting, both before and after education about the correct use of hand sanitizers. The study is the first to evaluate the efficacy and ease of use of different formulations of hand rubs used by the general population. The products tested were: Sterillium (perfumed, liquid), desderman pure gel (odorless, gel) and Lavit (perfumed, spray). Sterillium and desderman are EN1500 (hygienic hand rub) certified products (available in pharmacy) and Lavit is non EN1500 certified and available in supermarkets. The two EN1500 certified products were found to be significantly superior in terms of reducing bacterial load. desderman pure gel, Sterillium and Lavit reduced the bacterial count to 6.4%, 8.2% and 28.0% respectively. After education in the correct use of each hand rub, the bacterial load was reduced even further, demonstrating the value of education in improving hand hygiene. Information about the testers' perceptions of the three sanitizers, together with their expectations of a hand sanitizer was obtained through a questionnaire. Efficacy, followed by skin compatibility were found to be the two most important attributes of a hand disinfectant in our target group.	[Babeluk, Rita] Med Univ Vienna, Dept Surg, Vienna, Austria; [Jutz, Sabrina; Mertlitz, Sarah] Univ Appl Sci Campus Vienna, Dept Biotechnol, Vienna, Austria; [Matiasek, Johannes] Wilhelminen Hosp Vienna, Dept Plast Aesthet & Reconstruct Surg, Vienna, Austria; [Klaus, Christoph] Schulke & Mayr GmbH, Int Sci Affairs, Vienna, Austria	Medical University of Vienna; Wilhelminenspital	Klaus, C (corresponding author), Schulke & Mayr GmbH, Int Sci Affairs, Vienna, Austria.	christoph.klaus@schuelke.com		Mertlitz, Sarah/0000-0002-7245-5616	Schulke Mayr	Schulke Mayr	HYCON plates PA (Merck) were provided by Schulke & Mayr Ges.m.b.H. Schulke & Mayr provided support in the form of salaries for author CK, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Aiello AE, 2008, AM J PUBLIC HEALTH, V98, P1372, DOI 10.2105/AJPH.2007.124610; [Anonymous], DIN EN 1500 2013; Barbut F, 2007, J HOSP INFECT, V66, P167, DOI 10.1016/j.jhin.2007.03.021; Best M, 2004, QUAL SAF HEALTH CARE, V13, P233, DOI 10.1136/qshc.2004.010918; Cartner T, 2013, HIGH COMPLIANCE ALCO; COREN S, 1977, SCIENCE, V198, P631, DOI 10.1126/science.335510; Curtis V, 2003, LANCET INFECT DIS, V3, P275, DOI 10.1016/S1473-3099(03)00606-6; Erasmus V, 2010, J HOSP INFECT, V76, P161, DOI 10.1016/j.jhin.2010.04.024; Harrington G, 2007, INFECT CONT HOSP EP, V28, P837, DOI 10.1086/518844; Hilburn J, 2003, AM J INFECT CONTROL, V31, P109, DOI 10.1067/mic.2003.15; Johnson PDR, 2005, MED J AUSTRALIA, V183, P509, DOI 10.5694/j.1326-5377.2005.tb07151.x; Judah G, 2009, AM J PUBLIC HEALTH, V99, pS405, DOI 10.2105/AJPH.2009.164160; Kampf G, 2004, CLIN MICROBIOL REV, V17, P863, DOI 10.1128/CMR.17.4.863-893.2004; Kramer A, 2002, LANCET, V359, P1489, DOI 10.1016/S0140-6736(02)08426-X; Larson EL, 2000, BEHAV MED, V26, P14, DOI 10.1080/08964280009595749; Larson EL, 1998, AM J INFECT CONTROL, V26, P513, DOI 10.1016/S0196-6553(98)70025-2; LAUHARANTA J, 1991, J HOSP INFECT, V17, P207, DOI 10.1016/0195-6701(91)90232-W; Loffler H, 2007, BRIT J DERMATOL, V157, P74, DOI 10.1111/j.1365-2133.2007.07944.x; Nagtegaal MJC, 2012, CONTACT DERMATITIS, V67, P28, DOI 10.1111/j.1600-0536.2012.02055.x; Neuhauser D, 2003, QUAL SAF HEALTH CARE, V12, P317, DOI 10.1136/qhc.12.4.317; Pittet D, 2000, LANCET, V356, P1307, DOI 10.1016/S0140-6736(00)02814-2; Pittet D, 2009, INFECT CONT HOSP EP, V30, P611, DOI 10.1086/600379; Randle J, 2013, J HOSP INFECT, V85, P220, DOI 10.1016/j.jhin.2013.07.013; Randle J, 2010, J HOSP INFECT, V76, P252, DOI 10.1016/j.jhin.2010.06.027; Son C, 2011, AM J INFECT CONTROL, V39, P716, DOI 10.1016/j.ajic.2010.12.008; Suchomel M, 2013, J HOSP INFECT, V83, P284, DOI 10.1016/j.jhin.2012.11.030; Tambekar D, 2007, CONT J BIOMED SCI, V1, P6; WHO, 2000, WORLD HLTH REP 2000, P164; Winnefeld M, 2000, BRIT J DERMATOL, V143, P546	29	24	24	0	79	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 7	2014	9	11							e111969	10.1371/journal.pone.0111969	http://dx.doi.org/10.1371/journal.pone.0111969			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT3WF	25379773	Green Submitted, Green Published, gold			2023-01-03	WOS:000344863100049
J	Wang, RZ; Tan, Y; Wang, XY; Ma, LL; Wang, DM; Hu, YH; Qin, YH; Liu, K; Chang, C; Yu, JM				Wang, Ruozheng; Tan, Yao; Wang, Xiyan; Ma, Lingling; Wang, Duoming; Hu, Yunhui; Qin, Yonghui; Liu, Kai; Chang, Cheng; Yu, Jinming			Prognoses and Long-Term Outcomes of Nasopharyngeal Carcinoma in Han and Uyghur Patients Treated with Intensity-Modulated Radiotherapy in the Xinjiang Autonomous Region of China	PLOS ONE			English	Article							SURVIVAL; PATTERNS; FAILURE; AGE	Objectives: The objective of this study was to investigate the long-term outcomes and prognostic factors for nasopharyngeal carcinoma (NPC) in Han and Uyghur patients treated with intensity-modulated radiotherapy (IMRT) in the Xinjiang region of China. Materials and Methods: One hundred twenty-one Han and 60 Uyghur patients with newly diagnosed NPC without distant metastasis received IMRT at the Affiliated Tumor Hospital of Xinjiang Medical University between 2005 and 2008. The Kaplan-Meier method was used to estimate survival rates, and the log-rank test was used to evaluate differences in survival. Results: Comparing Han and Uyghur patients, the 5-year overall survival (OS), disease-free survival (DFS), local control (LC), regional control (RC), and distant metastasis-free survival (DMFS) rates were 81.9% vs 77.6% (P = 0.297), 72.1% vs 65.6% (P = 0.493), 88.3% vs 86.5% (P = 0.759), 95.0% vs 94.6% (P = 0.929), and 79.1% vs 75.2% (P = 0.613), respectively. Multivariate Cox proportional hazards regression identified the following independent prognostic factors in Han patients: N stage (P = 0.007) and age (P = 0.028) for OS, and age (P = 0.028) for DFS. OS differed significantly between Han and Uyghur patients >60 years old group (P = 0.036). Among Uyghur patients, the independent prognostic factors were age for OS (P = 0.033), as well as N stage (P = 0.037) and age (P = 0.021) for DFS. Additionally, Uyghur patients were less likely to experience mucositis and dermatitis than Han patients. Conclusion: Han and Uyghur patients with NPC had statistically significant differences in age, smoking history, and N staging. There was no significant difference in overall treatment outcomes with IMRT between these 2 ethnic populations in Xinjiang, China.	[Wang, Ruozheng] Tianjin Med Univ, Tianjin, Peoples R China; [Wang, Ruozheng; Tan, Yao; Wang, Xiyan; Ma, Lingling; Wang, Duoming; Hu, Yunhui; Qin, Yonghui; Liu, Kai; Chang, Cheng] Xinjiang Med Univ, Affiliated Tumor Hosp, Dept Radiat Oncol, Urumqi, Xinjiang, Peoples R China; [Yu, Jinming] Tumor Hosp Shandong, Dept Radiat Oncol, Jinnan, Shandong, Peoples R China	Tianjin Medical University; Xinjiang Medical University	Yu, JM (corresponding author), Tumor Hosp Shandong, Dept Radiat Oncol, Jinnan, Shandong, Peoples R China.	wrz8526@163.com			Department of International Cooperation Project [2012DFA31560]; Chinese Nature Science Foundation [81160327, 30960432]; Xinjiang International Collaboration Fund [101141038, 20126024]; Special Fund on Urumqi Talent Project [P08131002]; Youth Science Foundation of Xinjiang Uygur Autonomous Region [2011211B22]; Xinjiang Science and Technology Infrastructure Project [PT1401]	Department of International Cooperation Project; Chinese Nature Science Foundation; Xinjiang International Collaboration Fund; Special Fund on Urumqi Talent Project; Youth Science Foundation of Xinjiang Uygur Autonomous Region; Xinjiang Science and Technology Infrastructure Project	This study received funding from the Department of International Cooperation Project (2012DFA31560), the Chinese Nature Science Foundation (81160327, 30960432), the Xinjiang International Collaboration Fund (101141038, 20126024), the Special Fund on Urumqi Talent Project (P08131002), the Youth Science Foundation of Xinjiang Uygur Autonomous Region (2011211B22), and the Xinjiang Science and Technology Infrastructure Project (PT1401). The funders had roles in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Cao Su-Mei, 2011, Chin J Cancer, V30, P114; Chen R, 1993, Yi Chuan Xue Bao, V20, P389; Han Lu, 2010, Chin J Cancer, V29, P145; Itzhaki O, 2004, BBA-MOL BASIS DIS, V1688, P145, DOI 10.1016/j.bbadis.2003.11.009; Ji XM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056208; Jin J, 2010, XINJIANG STAT YB; Kam MKM, 2004, INT J RADIAT ONCOL, V60, P1440, DOI 10.1016/j.ijrobp.2004.05.022; Kwong DLW, 2004, CANCER, V101, P1584, DOI 10.1002/cncr.20552; Lai SZ, 2011, INT J RADIAT ONCOL, V80, P661, DOI 10.1016/j.ijrobp.2010.03.024; Lin SJ, 2009, INT J RADIAT ONCOL, V75, P1071, DOI 10.1016/j.ijrobp.2008.12.015; MK Su, 2004, J MOD ONCOL, V12, P589; MK Su, 2001, J XINJIANG MED U, V24, P371; Ng WT, 2011, INT J RADIAT ONCOL, V79, P420, DOI 10.1016/j.ijrobp.2009.11.024; Su Sheng-Fa, 2011, Chin J Cancer, V30, P565, DOI 10.5732/cjc.010.10547; Sze HCK, 2012, ORAL ONCOL, V48, P162, DOI 10.1016/j.oraloncology.2011.08.019; Wang DM, 2008, J XINJIANG MED U, V31, P1504; Wang JH, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-2; Xiao GL, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-226; Xue WQ, 2013, AM J EPIDEMIOL, V178, P325, DOI 10.1093/aje/kws479; Yeh SA, 2005, INT J RADIAT ONCOL, V62, P672, DOI 10.1016/j.ijrobp.2004.11.002	20	2	4	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2014	9	11							e111145	10.1371/journal.pone.0111145	http://dx.doi.org/10.1371/journal.pone.0111145			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AS6XM	25375129	Green Published, Green Submitted, gold			2023-01-03	WOS:000344402600026
J	Bashar, K; Healy, DA; Elsheikh, S; Browne, LD; Walsh, MT; Clarke-Moloney, M; Burke, PE; Kavanagh, EG; Walsh, SR				Bashar, Khalid; Healy, Donagh A.; Elsheikh, Sawsan; Browne, Leonard D.; Walsh, Michael T.; Clarke-Moloney, Mary; Burke, Paul E.; Kavanagh, Eamon G.; Walsh, Stewart R.			One-Stage vs. Two-Stage Brachio-Basilic Arteriovenous Fistula for Dialysis Access: A Systematic Review and a Meta-Analysis	PLOS ONE			English	Article							VEIN TRANSPOSITION; VASCULAR ACCESS; OUTCOMES; HEMODIALYSIS; MANAGEMENT; PREDICTORS	Introduction A brachiobasilic arteriovenous fistula (BB-AVF) can provide access for haemodialysis in patients who are not eligible for a more superficial fistula. However, it is unclear whether one-or two-stage BB-AVF is the best option for patients. Aim To systematically assess the difference between both procedures in terms of access maturation, patency and postoperative complications. Methods Online search for randomised controlled trials (RCTs) and observational studies that compared the one-stage versus the two-stage technique for creating a BB-AVF. Results Eight studies were included (849 patients with 859 fistulas), 366 created using a one-stage technique, while 493 in a two-stage approach. There was no statistically significant difference between the two groups in the rate of successful maturation (Pooled risk ratio = 0.95 [0.82, 1.11], P = 0.53). Similarly, the incidence of postoperative haematoma (Pooled risk ratio = 0.73 [0.34, 1.58], P = 0.43), wound infection (Pooled risk ratio = 0.77 [0.35, 1.68], P = 0.51) and steal syndrome (Pooled risk ratio = 0.65 [0.27, 1.53], P = 0.32) were statistically comparable. Conclusion Although more studies seem to favour the two-stage BVT approach, evidence in the literature is not sufficient to draw a final conclusion as the difference between the one-stage and the two-stage approaches for creation of a BB-AVF is not statistically significant in terms of the overall maturation rate and postoperative complications. Patency rates (primary, assisted primary and secondary) were comparable in the majority of studies. Large randomised properly conducted trials with superior methodology and adequate sub-group analysis are needed before making a final recommendation.	[Bashar, Khalid; Healy, Donagh A.; Clarke-Moloney, Mary; Burke, Paul E.; Kavanagh, Eamon G.] Univ Hosp Limerick, Dept Vasc Surg, Limerick, Ireland; [Elsheikh, Sawsan] James Connolly Mem Hosp, Dept Acute Med, Dublin, Ireland; [Browne, Leonard D.; Walsh, Michael T.] Univ Limerick, CABER, Dept Mech Aeronaut & Biomed Engn, Mat & Surface Sci Inst, Limerick, Ireland; [Walsh, Stewart R.] Natl Univ Ireland, Dept Surg, Galway, Ireland	University of Limerick; University of Limerick; Ollscoil na Gaillimhe-University of Galway	Bashar, K (corresponding author), Univ Hosp Limerick, Dept Vasc Surg, Limerick, Ireland.	khalid@live.ie	Walsh, Michael T/C-1405-2010; Walsh, Stewart R/AAC-1229-2021	Walsh, Michael T/0000-0002-1672-8106; Walsh, Stewart/0000-0002-1006-9541; Browne, Leonard/0000-0002-9203-1212				Agarwal A, 2014, SEMIN DIALYSIS, V27, P298, DOI 10.1111/sdi.12170; Allon M, 2007, CLIN J AM SOC NEPHRO, V2, P786, DOI 10.2215/CJN.00860207; Anaya-Ayala JE, 2011, J VASC SURG, V53, P720, DOI 10.1016/j.jvs.2010.09.072; [Anonymous], 1997, Am J Kidney Dis, V30, pS150; Bashar K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104931; Centofanti Guilherme, 2011, Int Arch Med, V4, P16, DOI 10.1186/1755-7682-4-16; DAGHER F, 1976, J SURG RES, V20, P373, DOI 10.1016/0022-4804(76)90029-9; DERSIMONIAN R, 1983, HARVARD EDUC REV, V53, P1; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Effat M, 2013, STAGING BRACHIOBASIL, P9; El Mallah S, 1998, INT ANGIOL, V17, P65; Ethier J, 2008, NEPHROL DIAL TRANSPL, V23, P3219, DOI 10.1093/ndt/gfn261; Feldman HI, 2003, AM J KIDNEY DIS, V42, P1000, DOI 10.1016/j.ajkd.2003.07.003; Fluck R, 2011, NEPHRON CLIN PRACT, V118, pC225, DOI 10.1159/000328071; Frankel A, 2006, EUR J VASC ENDOVASC, V31, P417, DOI 10.1016/j.ejvs.2005.10.003; Glickman M, 2014, J VASC ACCESS, V15, pS81, DOI 10.5301/jva.5000260; Harper SJF, 2008, EUR J VASC ENDOVASC, V36, P237, DOI 10.1016/j.ejvs.2008.02.012; Heye S, 2010, EUR J VASC ENDOVASC, V39, P340, DOI 10.1016/j.ejvs.2009.11.036; Hirth RA, 1996, JAMA-J AM MED ASSOC, V276, P1303; Hossny A, 2003, J VASC SURG, V37, P821, DOI 10.1067/mva.2003.181; Ilhan G, 2013, J VASC ACCESS, V14, P83, DOI 10.5301/jva.5000097; Jindal KK, 1999, J AM SOC NEPHROL, V10, pS297; Kakkos SK, 2010, EUR J VASC ENDOVASC, V39, P612, DOI 10.1016/j.ejvs.2010.01.006; Koksoy C, 2009, J VASC SURG, V49, P171, DOI 10.1016/j.jvs.2008.08.002; Lauvao LS, 2009, J VASC SURG, V49, P1499, DOI 10.1016/j.jvs.2009.02.018; Leblanc M, 2003, J Vasc Access, V4, P39; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Lynch JR, 2011, CURR OPIN NEPHROL HY, V20, P583, DOI 10.1097/MNH.0b013e32834b33c4; Maya ID, 2009, CLIN J AM SOC NEPHRO, V4, P86, DOI 10.2215/CJN.02910608; McCann M, 2008, J REN CARE, V34, P77, DOI 10.1111/j.1755-6686.2008.00022.x; Mendes RR, 2002, J VASC SURG, V36, P460, DOI 10.1067/mva.2002.126544; NKF-KDOQI, 2006, 2006 UPD CLIN PRACT; Ozcan S, 2013, CARDIOVASC J AFR, V24, P364, DOI 10.5830/CVJA-2013-077; Pisoni RL, 2002, KIDNEY INT, V61, P305, DOI 10.1046/j.1523-1755.2002.00117.x; Rayner HC, 2003, KIDNEY INT, V63, P323, DOI 10.1046/j.1523-1755.2003.00724.x; Sidawy AN, 2002, J VASC SURG, V35, P603, DOI 10.1067/mva.2002.122025; Spergel LM, 2007, J NEPHROL, V20, P388; Sterne JAC, 2011, COCHRANE HDB SYSTEMA; Sultan S, 2012, VASC ENDOVASC SURG, V46, P624, DOI 10.1177/1538574412462635; Syed FA, 2012, ANN VASC SURG, V26, P852, DOI 10.1016/j.avsg.2011.12.013; Taghizadeh A, 2003, EUR J VASC ENDOVASC, V26, P670, DOI 10.1016/j.ejvs.2003.09.002; The Nordic Cochrane Centre TCc, 2012, REV MAN REVMAN; Vrakas G, 2013, J VASC SURG, V58, P1300, DOI 10.1016/j.jvs.2013.05.030	43	20	20	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 9	2015	10	3							e0120154	10.1371/journal.pone.0120154	http://dx.doi.org/10.1371/journal.pone.0120154			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC9LT	25751655	Green Published, gold			2023-01-03	WOS:000350692700035
J	Moore, HCF; Unger, JM; Phillips, KA; Boyle, F; Hitre, E; Porter, D; Francis, PA; Goldstein, LJ; Gomez, HL; Vallejos, CS; Partridge, AH; Dakhil, SR; Garcia, AA; Gralow, J; Lombard, JM; Forbes, JF; Martino, S; Barlow, WE; Fabian, CJ; Minasian, L; Meyskens, FL; Gelber, RD; Hortobagyi, GN; Albain, KS				Moore, Halle C. F.; Unger, Joseph M.; Phillips, Kelly-Anne; Boyle, Frances; Hitre, Erika; Porter, David; Francis, Prudence A.; Goldstein, Lori J.; Gomez, Henry L.; Vallejos, Carlos S.; Partridge, Ann H.; Dakhil, Shaker R.; Garcia, Agustin A.; Gralow, Julie; Lombard, Janine M.; Forbes, John F.; Martino, Silvana; Barlow, William E.; Fabian, Carol J.; Minasian, Lori; Meyskens, Frank L., Jr.; Gelber, Richard D.; Hortobagyi, Gabriel N.; Albain, Kathy S.		POEMS S0230 Investigators	Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FERTILITY PRESERVATION; HORMONE AGONISTS; SUPPRESSION; AMENORRHEA; WOMEN; TRIPTORELIN; PREVENTION	BACKGROUND Ovarian failure is a common toxic effect of chemotherapy. Studies of the use of gonadotropin-releasing hormone (GnRH) agonists to protect ovarian function have shown mixed results and lack data on pregnancy outcomes. METHODS We randomly assigned 257 premenopausal women with operable hormone-receptor-negative breast cancer to receive standard chemotherapy with the GnRH agonist goserelin (goserelin group) or standard chemotherapy without goserelin (chemotherapy-alone group). The primary study end point was the rate of ovarian failure at 2 years, with ovarian failure defined as the absence of menses in the preceding 6 months and levels of follicle-stimulating hormone (FSH) in the postmenopausal range. Rates were compared with the use of conditional logistic regression. Secondary end points included pregnancy outcomes and disease-free and overall survival. RESULTS At baseline, 218 patients were eligible and could be evaluated. Among 135 with complete primary end-point data, the ovarian failure rate was 8% in the goserelin group and 22% in the chemotherapy-alone group (odds ratio, 0.30; 95% confidence interval, 0.09 to 0.97; two-sided P = 0.04). Owing to missing primary end-point data, sensitivity analyses were performed, and the results were consistent with the main findings. Missing data did not differ according to treatment group or according to the stratification factors of age and planned chemotherapy regimen. Among the 218 patients who could be evaluated, pregnancy occurred in more women in the goserelin group than in the chemotherapy-alone group (21% vs. 11%, P = 0.03); women in the goserelin group also had improved disease-free survival (P = 0.04) and overall survival (P = 0.05). CONCLUSIONS Although missing data weaken interpretation of the findings, administration of goserelin with chemotherapy appeared to protect against ovarian failure, reducing the risk of early menopause and improving prospects for fertility. (Funded by the National Cancer Institute and others; POEMS/S0230 ClinicalTrials.gov number, NCT00068601.)	[Moore, Halle C. F.] Cleveland Clin Fdn, Cleveland, OH 44195 USA; [Unger, Joseph M.; Barlow, William E.] Fred Hutchinson Canc Res Ctr, SWOG Canc Res Grp Stat Ctr, Seattle, WA 98104 USA; [Gralow, Julie] Seattle Canc Care Alliance, Seattle, WA USA; [Gralow, Julie] Univ Washington, Seattle, WA 98195 USA; [Phillips, Kelly-Anne; Francis, Prudence A.] Univ Melbourne, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Phillips, Kelly-Anne; Francis, Prudence A.; Forbes, John F.] New Zealand Breast Canc Trials Grp ANZBCTG, Newcastle, NSW, Australia; [Boyle, Frances; Lombard, Janine M.; Forbes, John F.] Calvary Mater Hosp, Newcastle, NSW, Australia; [Boyle, Frances] Univ Sydney, Sydney, NSW 2006, Australia; [Phillips, Kelly-Anne; Francis, Prudence A.] IBCSG, Bern, Switzerland; [Hitre, Erika] Natl Inst Oncol, Budapest, Hungary; [Porter, David] Auckland Reg Canc & Blood Serv, Auckland, New Zealand; [Goldstein, Lori J.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; [Gomez, Henry L.] Inst Enfermedades Neoplas, Lima, Peru; [Vallejos, Carlos S.] Oncosalud SAC, Lima, Peru; [Partridge, Ann H.; Gelber, Richard D.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Gelber, Richard D.] IBCSG Stat Ctr, Boston, MA USA; [Dakhil, Shaker R.] Wichita Community Clin Oncol Program, Wichita, KS USA; [Fabian, Carol J.] Univ Kansas, Westwood, KS USA; [Garcia, Agustin A.] Univ So Calif, Norris Canc Ctr, Los Angeles, CA USA; [Martino, Silvana] Angeles Clin, Santa Monica, CA USA; [Martino, Silvana] Res Inst, Santa Monica, CA USA; [Meyskens, Frank L., Jr.] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Orange, CA 92668 USA; [Minasian, Lori] NCI, Canc Prevent Div, Bethesda, MD 20892 USA; [Hortobagyi, Gabriel N.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Albain, Kathy S.] Loyola Univ, Med Ctr, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA	Cleveland Clinic Foundation; Fred Hutchinson Cancer Center; Southwest Oncology Group; Seattle Cancer Care Alliance; University of Washington; University of Washington Seattle; Peter Maccallum Cancer Center; University of Melbourne; Calvary Mater Newcastle Hospital; University of Sydney; National Institute of Oncology Hungary; Fox Chase Cancer Center; Instituto Nacional de Enfermedades Neoplasicas; Harvard University; Dana-Farber Cancer Institute; University of Kansas; University of Southern California; Angeles Clinic & Research Institute; University of California System; University of California Irvine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; UTMD Anderson Cancer Center; Loyola University Chicago	Moore, HCF (corresponding author), Cleveland Clin Fdn, Taussig Canc Inst, R35,9500 Euclid Ave, Cleveland, OH 44195 USA.	mooreh1@ccf.org	Unger, Joseph/O-7457-2019; Francis, Prudence A/J-4003-2012	Francis, Prudence A/0000-0002-7207-9286; Vallejos, Carlos/0000-0002-7872-3693; Gomez, Henry/0000-0003-2660-1843; Phillips, Kelly-Anne/0000-0002-0475-1771	National Cancer Institute; National Breast Cancer Foundation [PRAC-13-04] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [U10CA031946, UG1CA189808, UG1CA189954, UG1CA189957, UG1CA189858, UG1CA189974, U10CA180801, U10CA180819, U10CA180888, U10CA180820, UG1CA189822, U24CA075362, U10CA180821, U10CA180858, U10CA027525, U10CA180830, UG1CA189872, UG1CA189953, UG1CA189972] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Breast Cancer Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funded by the National Cancer Institute and others; POEMS/S0230 ClinicalTrials.gov number, NCT00068601.	Albain KS, 2009, LANCET, V374, P2055, DOI 10.1016/S0140-6736(09)61523-3; Albain KS, 2002, ASCO ANN M ORL FL MA; Badawy A, 2009, FERTIL STERIL, V91, P694, DOI 10.1016/j.fertnstert.2007.12.044; Buchholz S, 2009, INT J ONCOL, V35, P789, DOI 10.3892/ijo_00000391; Del Mastro L, 2014, CANCER TREAT REV, V40, P675, DOI 10.1016/j.ctrv.2013.12.001; Del Mastro L, 2011, JAMA-J AM MED ASSOC, V306, P269, DOI 10.1001/jama.2011.991; Elgindy EA, 2013, OBSTET GYNECOL, V121, P78, DOI [10.1097/AOG.0b013e31827374e2, http://10.1097/AOG.0b013e31827374e2]; Francis PA, 2015, NEW ENGL J MED, V372, P436, DOI 10.1056/NEJMoa1412379; Gerber B, 2011, J CLIN ONCOL, V29, P2334, DOI 10.1200/JCO.2010.32.5704; Grundker C, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2606; Lee SJ, 2006, J CLIN ONCOL, V24, P2917, DOI 10.1200/JCO.2006.06.5888; Munster PN, 2012, J CLIN ONCOL, V30, P533, DOI 10.1200/JCO.2011.34.6890; National Cancer Institute National Institutes of Health, COMM TERM CRIT ADV E; Oktay K, 2007, ONCOLOGIST, V12, P1055, DOI 10.1634/theoncologist.12-9-1055; Pagani O, 1998, EUR J CANCER, V34, P632, DOI 10.1016/S0959-8049(97)10036-3; Pagani O, 2014, NEW ENGL J MED, V371, P107, DOI 10.1056/NEJMoa1404037; Poikonen P, 2000, EUR J CANCER, V36, P43, DOI 10.1016/S0959-8049(99)00225-7; Ruddy KJ, 2014, J CLIN ONCOL, V32, P1151, DOI 10.1200/JCO.2013.52.8877; Schubert A, 2011, BREAST CANCER RES TR, V130, P783, DOI 10.1007/s10549-011-1358-9; Senkus E, 2014, PSYCHO-ONCOLOGY, V23, P173, DOI 10.1002/pon.3384; Sverrisdottir A, 2009, BREAST CANCER RES TR, V117, P561, DOI 10.1007/s10549-009-0313-5; Swain SM, 2010, NEW ENGL J MED, V362, P2053, DOI 10.1056/NEJMoa0909638; Turner NH, 2013, ANN ONCOL, V24, P2224, DOI 10.1093/annonc/mdt196	23	330	363	4	58	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 5	2015	372	10					923	932		10.1056/NEJMoa1413204	http://dx.doi.org/10.1056/NEJMoa1413204			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CC4EU	25738668	Bronze, Green Published, Green Accepted			2023-01-03	WOS:000350304500008
J	Demarque, DP; Fitts, SMF; Boaretto, AG; da Silva, JCL; Vieira, MC; Franco, VNP; Teixeira, CB; Toffoli-Kadri, MC; Carollo, CA				Demarque, Daniel P.; Fitts, Sonia Maria F.; Boaretto, Amanda G.; Leite da Silva, Julio Cesar; Vieira, Maria C.; Franco, Vanessa N. P.; Teixeira, Caroline B.; Toffoli-Kadri, Monica C.; Carollo, Carlos A.			Optimization and Technological Development Strategies of an Antimicrobial Extract from Achyrocline alata Assisted by Statistical Design	PLOS ONE			English	Article							ACCELERATED SOLVENT-EXTRACTION; KINASE-C ACTIVATORS; KUNTH DC.; ANTIOXIDANT; DERIVATIVES; MECHANISMS; EXPRESSION; ASTERACEAE; FRUCTUS; SOUTH	Achyrocline alata, known as Jatei-ka-ha, is traditionally used to treat several health problems, including inflammations and infections. This study aimed to optimize an active extract against Streptococcus mutans, the main bacteria that causes caries. The extract was developed using an accelerated solvent extraction and chemometric calculations. Factorial design and response surface methodologies were used to determine the most important variables, such as active compound selectivity. The standardized extraction recovered 99% of the four main compounds, gnaphaliin, helipyrone, obtusifolin and lepidissipyrone, which represent 44% of the extract. The optimized extract of A. alata has a MIC of 62.5 mu g/mL against S. mutans and could be used in mouth care products.	[Demarque, Daniel P.; Boaretto, Amanda G.; Carollo, Carlos A.] Univ Fed Mato Grosso do Sul, Lab Farmacognosia, Ctr Ciencias Biol & Saude, Campo Grande, MS, Brazil; [Fitts, Sonia Maria F.; Teixeira, Caroline B.] Univ Fed Mato Grosso do Sul, Lab Microbiol, Ctr Ciencias Biol & Saude, Campo Grande, MS, Brazil; [Leite da Silva, Julio Cesar] Univ Fed Mato Grosso do Sul, Fac Odontol, Campo Grande, MS, Brazil; [Vieira, Maria C.] Fundacao Univ Fed Grande Dourados, Fac Ciencias Agr, Dourados, MS, Brazil; [Franco, Vanessa N. P.; Toffoli-Kadri, Monica C.] Univ Fed Mato Grosso do Sul, Lab Farmacol & Inflamacao, Ctr Ciencias Biol & Saude, Setor Biofisiofarmacol, Campo Grande, MS, Brazil	Universidade Federal de Mato Grosso do Sul; Universidade Federal de Mato Grosso do Sul; Universidade Federal de Mato Grosso do Sul; Universidade Federal da Grande Dourados; Universidade Federal de Mato Grosso do Sul	Carollo, CA (corresponding author), Univ Fed Mato Grosso do Sul, Lab Farmacognosia, Ctr Ciencias Biol & Saude, Campo Grande, MS, Brazil.	carlos.carollo@ufms.br	Demarque, Daniel Pecoraro/K-7325-2014; Kadri, Mônica/AAH-4495-2021; Toffoli-Kadri, Mônica C/D-4972-2014	Demarque, Daniel Pecoraro/0000-0002-3576-5148; Kadri, Mônica/0000-0003-4160-4444; Toffoli-Kadri, Mônica C/0000-0003-4160-4444	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); Fundacao de Apoio ao Desenvolvimento do Ensino, Ciencia e Tecnologia do Estado de Mato Grosso do Sul (FUNDECT); Instituto Nacional de Areas Umidas (INAU)	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Fundacao de Apoio ao Desenvolvimento do Ensino, Ciencia e Tecnologia do Estado de Mato Grosso do Sul (FUNDECT)(Fundacao de Apoio ao Desenvolvimento do Ensino Ciencia e Tecnologia do Estado de Mato Grosso do Sul (FUNDECT MS)); Instituto Nacional de Areas Umidas (INAU)	The authors express their gratitude to Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Fundacao de Apoio ao Desenvolvimento do Ensino, Ciencia e Tecnologia do Estado de Mato Grosso do Sul (FUNDECT) and Instituto Nacional de Areas Umidas (INAU) for their support in carrying out the study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADAMS DO, 1984, ANNU REV IMMUNOL, V2, P283, DOI 10.1146/annurev.immunol.2.1.283; Adedapo AA, 2009, BMC COMPLEM ALTERN M, V9, DOI 10.1186/1472-6882-9-21; Aiyegoro OA, 2009, INT J MOL SCI, V10, P4990, DOI 10.3390/ijms10114990; [Anonymous], 2003, M7A6 CLSI, V23, P2; BOHLMANN F, 1980, PHYTOCHEMISTRY, V19, P2475, DOI 10.1016/S0031-9422(00)91058-6; Calabrese EJ, 2005, CRIT REV TOXICOL, V35, P89, DOI 10.1080/10408440590917044; Carlos IZ, 2009, REV BRAS FARMACOGN, V19, P847, DOI 10.1590/S0102-695X2009000600009; Cotoras M, 2011, MOLECULES, V16, P3885, DOI 10.3390/molecules16053885; Czaika VA, 2013, MYCOSES, V56, P16, DOI 10.1111/myc.12055; de Souza GC, 2004, J ETHNOPHARMACOL, V90, P135, DOI 10.1016/j.jep.2003.09.039; DING AH, 1988, J IMMUNOL, V141, P2407; Amorim Crystiane Venditi Gomes do, 2004, Braz. oral res., V18, P242, DOI 10.1590/S1806-83242004000300012; Gao FY, 2013, FOOD CHEM, V141, P1962, DOI 10.1016/j.foodchem.2013.05.013; Grassi-Zampieron R, 2010, REV BRAS FARMACOGN, V20, P575, DOI 10.1590/S0102-695X2010000400017; Grassi-Zampieron RF, 2009, REV BRAS FARMACOGN, V19, P572, DOI 10.1590/S0102-695X2009000400011; HANSEL R, 1970, Z NATURFORSCH PT B, VB 25, P989, DOI 10.1515/znb-1970-0916; Herald TJ, 2012, J SCI FOOD AGR, V92, P2326, DOI 10.1002/jsfa.5633; Herrero M, 2005, FOOD CHEM, V93, P417, DOI 10.1016/j.foodchem.2004.09.037; Hossain MB, 2011, FOOD CHEM, V126, P339, DOI 10.1016/j.foodchem.2010.10.076; ICH-4, 1994, METHODOLOGY; JAKUPOVIC J, 1989, PHYTOCHEMISTRY, V28, P1119, DOI 10.1016/0031-9422(89)80195-5; LINNER KM, 1993, J PHARMACOL EXP THER, V267, P1566; Liu J, 2012, ANTIMICROB AGENTS CH, V56, P4532, DOI 10.1128/AAC.00885-12; Lopes FCM, 2011, NAT PROD RES, V25, P1796, DOI 10.1080/14786419.2010.488624; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nothnick WB, 1998, AM J REPROD IMMUNOL, V40, P364; OFLAHERTY JT, 1990, J IMMUNOL, V144, P1909; OFLAHERTY JT, 1989, J BIOL CHEM, V264, P6836; OPITZ L, 1970, TETRAHEDRON LETT, P3369; Palombo EA, 2011, EVID-BASED COMPL ALT, V2011, DOI 10.1093/ecam/nep067; Pankey GA, 2004, CLIN INFECT DIS, V38, P864, DOI 10.1086/381972; Pezzuto JM, 1997, BIOCHEM PHARMACOL, V53, P121, DOI 10.1016/S0006-2952(96)00654-5; PICK E, 1980, J IMMUNOL METHODS, V38, P161, DOI 10.1016/0022-1759(80)90340-3; Raynie DE, 2010, ANAL CHEM, V82, P4911, DOI 10.1021/ac101223c; Richter BE, 1996, ANAL CHEM, V68, P1033, DOI 10.1021/ac9508199; RIOS JL, 1991, J ETHNOPHARMACOL, V33, P51, DOI 10.1016/0378-8741(91)90160-F; Sala A, 2003, EUR J PHARMACOL, V461, P53, DOI 10.1016/S0014-2999(02)02953-9; Schorr K, 2005, PHYTOCHEM ANALYSIS, V16, P161, DOI 10.1002/pca.836; Sohn HY, 2004, PHYTOMEDICINE, V11, P666, DOI 10.1016/j.phymed.2003.09.005; Toffoli-Kadri MC, 2014, J ETHNOPHARMACOL, V153, P461, DOI 10.1016/j.jep.2014.03.008; Tsuchiya H, 2000, PHYTOMEDICINE, V7, P161, DOI 10.1016/S0944-7113(00)80089-6; Vilkhu K, 2008, INNOV FOOD SCI EMERG, V9, P161, DOI 10.1016/j.ifset.2007.04.014; Yan M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064000; Zhao LC, 2012, MOLECULES, V17, P3618, DOI 10.3390/molecules17043618	44	5	5	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 24	2015	10	2							e0118574	10.1371/journal.pone.0118574	http://dx.doi.org/10.1371/journal.pone.0118574			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC9IY	25710523	Green Published, Green Submitted, gold			2023-01-03	WOS:000350683900062
J	Maxwell, L; Devries, K; Zionts, D; Alhusen, JL; Campbell, J				Maxwell, Lauren; Devries, Karen; Zionts, Danielle; Alhusen, Jeanne L.; Campbell, Jacquelyn			Estimating the Effect of Intimate Partner Violence on Women's Use of Contraception: A Systematic Review and Meta-Analysis	PLOS ONE			English	Article							SOUTH-AFRICAN WOMEN; DOMESTIC VIOLENCE; PREGNANCY; HIV; PREVALENCE; PREVENTION; HEALTH; RISK; HETEROGENEITY; EXPERIENCES	Background Intimate partner violence (IPV) is an important global public health problem. While there is a growing literature on the association between IPV and women's reproductive health (RH) outcomes, most studies are cross-sectional-which weakens inference about the causal effect of IPV on women's RH. This systematic review synthesizes existing evidence from the strongest study designs to estimate the impact of IPV on women's use of contraception. Methods We searched 11 electronic databases from January of 1980 to 3 December 2013 and reviewed reference lists from systematic reviews for studies examining IPV and contraceptive use. To be able to infer causality, we limited our review to studies that had longitudinal measures of either IPV or women's use of contraception. Results Of the 1,574 articles identified by the search, we included 179 articles in the full text review and extracted data from 12 studies that met our inclusion criteria. We limited the meta-analysis to seven studies that could be classified as subject to low or moderate levels of bias. Women's experience of IPV was associated with a significant reduction in the odds of using contraception (n = 14,866; OR: 0.47; 95% CI: 0.25, 0.85; I-2 = 92%; 95% CII2 2: 87%, 96%). Restricting to studies that measured the effect of IPV on women's use of partner dependent contraceptive methods was associated with a reduction in the heterogeneity of the overall estimate. In the three studies that examined women's likelihood of using male condoms with their partners, experience of IPV was associated with a significant decrease in condom use (OR: 0.48; 95% CIOR: 0.32, 0.72; I-2 = 51%; 95% CI(I)2: 0%, 86%). Conclusions IPV is associated with a reduction in women's use of contraception; women who experience IPV are less likely to report using condoms with their male partners. Family planning and HIV prevention programs should consider women's experiences of IPV.	[Maxwell, Lauren; Zionts, Danielle] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada; [Devries, Karen] London Sch Hyg & Trop Med, Dept Global Hlth & Dev, Social & Math Epidemiol Grp, London WC1, England; [Devries, Karen] London Sch Hyg & Trop Med, Gender Violence & Hlth Ctr, Dept Global Hlth & Dev, London WC1, England; [Alhusen, Jeanne L.; Campbell, Jacquelyn] Johns Hopkins Univ, Sch Nursing, Dept Community Publ Hlth, Baltimore, MD USA	McGill University; University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; Johns Hopkins University	Maxwell, L (corresponding author), McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada.	lauren.maxwell@mail.mcgill.ca	Devries, Karen/K-1083-2016	Devries, Karen/0000-0001-8935-2181; Alhusen, Jeanne/0000-0001-9492-1932; Maxwell, Lauren/0000-0002-0777-2092	Maternal and Child Health Equity Project (MACHEquity) - Canadian Institutes of Health Research	Maternal and Child Health Equity Project (MACHEquity) - Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	Funding support for the preparation of this manuscript was provided by the Maternal and Child Health Equity Project (MACHEquity), funded by the Canadian Institutes of Health Research. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abramsky T, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-109; Alio AP, 2009, INT J GYNECOL OBSTET, V107, P35, DOI 10.1016/j.ijgo.2009.05.002; Alkema L, 2013, LANCET, V381, P1642, DOI 10.1016/S0140-6736(12)62204-1; [Anonymous], 2013, Obstet Gynecol, V121, P411, DOI 10.1097/01.AOG.0000426427.79586.3b; Baker WL, 2009, INT J CLIN PRACT, V63, P1426, DOI 10.1111/j.1742-1241.2009.02168.x; Borenstein M., 2009, INTRO META ANAL; Campbell JC, 2002, LANCET, V359, P1331, DOI 10.1016/S0140-6736(02)08336-8; Chamberlain L., 2013, ADDRESSING INTIMATE; Clark LE, 2013, AM J OBSTET GYNECOL, DOI [10.1097/IGC.0000000000000339, DOI 10.1097/IGC.0000000000000339]; Coggins Margi, 2003, Issues Ment Health Nurs, V24, P723; Coker AL, 2007, TRAUMA VIOLENCE ABUS, V8, P149, DOI 10.1177/1524838007301162; Commodity Security Branch UNPF, 2011, NIC COUNTR PROF; de Bocanegra HT, 2010, VIOLENCE AGAINST WOM, V16, P601, DOI 10.1177/1077801210366965; Deeks J, 2011, COCHRANE HDB SYSTEMA, V5; Devries KM, 2013, SCIENCE, V340, P1527, DOI 10.1126/science.1240937; Devries KM, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001439; Dude AM, 2011, AIDS BEHAV, V15, P142, DOI 10.1007/s10461-009-9526-1; Dutton Mary Ann, 2005, Violence Vict, V20, P483, DOI 10.1891/088667005780927520; Egger M, 1998, BRIT MED J, V316, P140; El-Bassel N, 2005, SOC SCI MED, V61, P171, DOI 10.1016/j.socscimed.2004.11.035; Ellsberg M, 2002, LANCET, V359, P1599, DOI 10.1016/S0140-6736(02)08521-5; Ellsberg M, 2001, STUD FAMILY PLANN, V32, P1, DOI 10.1111/j.1728-4465.2001.00001.x; Ely GE, 2011, J INTERPERS VIOLENCE, V26, P3248, DOI 10.1177/0886260510393004; Fanslow J, 2008, AUST NZ J OBSTET GYN, V48, P83, DOI 10.1111/j.1479-828X.2007.00805.x; Fantasia HC, 2012, CONTRACEPTION, V86, P530, DOI 10.1016/j.contraception.2012.03.005; Field A. P., 2003, UNDERSTANDING STAT, V2, P105, DOI DOI 10.1207/S15328031US0202_02; Gee RE, 2009, AM J OBSTET GYNECOL, V201, DOI 10.1016/j.ajog.2009.04.048; Gracia E, 2004, J EPIDEMIOL COMMUN H, V58, P536, DOI 10.1136/jech.2003.019604; Hall M, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001581; Hathaway Jeanne E, 2005, J Am Med Womens Assoc (1972), V60, P42; Friedman SH, 2007, J WOMENS HEALTH, V16, P471, DOI 10.1089/jwh.2006.0115; Hernan MA, 2002, AM J EPIDEMIOL, V155, P176, DOI 10.1093/aje/155.2.176; Hernan MA, 2004, EPIDEMIOLOGY, V15, P615, DOI 10.1097/01.ede.0000135174.63482.43; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Hindin M.J., 2008, INTIMATE PARTNER VIO; Howards PP, 2012, AM J EPIDEMIOL, V176, P506, DOI 10.1093/aje/kws127; Hung KJ, 2012, OBSTET GYNECOL, V119, P975, DOI 10.1097/AOG.0b013e31824fc9a0; Ioannidis JPA, 2008, J EVAL CLIN PRACT, V14, P951, DOI 10.1111/j.1365-2753.2008.00986.x; Jacoby M, 1999, AM J PREV MED, V16, P318, DOI 10.1016/S0749-3797(99)00029-X; Jewkes R, 2000, REPROD HEALTH MATTER, V8, P93, DOI 10.1016/S0968-8080(00)90010-7; Jewkes R, 2006, INT J EPIDEMIOL, V35, P1461, DOI 10.1093/ije/dyl218; Jewkes R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024256; Jones DL, 2013, AIDS CARE, V25, P702, DOI 10.1080/09540121.2013.772280; Kacanek D, 2013, JAIDS-J ACQ IMM DEF, V64, P400, DOI 10.1097/QAI.0b013e3182a6b0be; Kouyoumdjian FG, 2013, AIDS, V27, P1331, DOI 10.1097/QAD.0b013e32835fd851; McCarraher DR, 2006, J BIOSOC SCI, V38, P169, DOI 10.1017/S0021932005025897; McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074; Miller E, 2007, AMBUL PEDIATR, V7, P360, DOI 10.1016/j.ambp.2007.05.007; Miller E, 2014, CONTRACEPTION, V89, P122, DOI 10.1016/j.contraception.2013.10.011; Miller E, 2010, CONTRACEPTION, V81, P316, DOI 10.1016/j.contraception.2009.12.004; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; Moore AM, 2010, SOC SCI MED, V70, P1737, DOI 10.1016/j.socscimed.2010.02.009; Organization WH, 2013, SUMM RESP INT PARTN; Orsini N., 2006, HETEROGI STATA MODUL; Padian NS, 2007, LANCET, V370, P251, DOI 10.1016/S0140-6736(07)60950-7; Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676; Ramsay J, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005043.pub2; Raneri LG, 2007, PERSPECT SEX REPRO H, V39, P39, DOI 10.1363/3903907; Reeves S, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002213.pub2; Salazar M, 2012, J FAM PLAN REPROD H, V38, P221, DOI 10.1136/jfprhc-2011-000043; Schunemann HJ, 2011, COCHRANE HDB SYSTEMA; Scribano PV, 2013, MATERN CHILD HLTH J, V17, P307, DOI 10.1007/s10995-012-0986-y; Shrier I, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-70; Steichen T., 2001, ECONPAPERS; Stephenson R, 2013, J INTERPERS VIOLENCE, V28, P1020, DOI 10.1177/0886260512459379; Stupp PW, 2007, REPROD MATERNAL CHIL; Teitelman AM, 2008, JOGNN-J OBST GYN NEO, V37, P219, DOI 10.1111/j.1552-6909.2008.00231.x; Thompson SG, 2005, LANCET, V365, P341, DOI 10.1016/S0140-6736(05)17790-3; Van der Wijden C, 2003, COCHRANE DATABASE SY, V4; Van Horne BS, 2009, AM J PUBLIC HEALTH, V99, pS417, DOI 10.2105/AJPH.2007.131870; Weed DL, 2000, INT J EPIDEMIOL, V29, P387, DOI 10.1093/ije/29.3.387; Williams CM, 2008, VIOLENCE AGAINST WOM, V14, P1382, DOI 10.1177/1077801208325187; Wingood GM, 2006, AM J PUBLIC HEALTH, V96, P1085, DOI 10.2105/AJPH.2004.053595; World Health Organization, 2013, GLOB REG EST VIOL WO	75	89	91	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 18	2015	10	2							e0118234	10.1371/journal.pone.0118234	http://dx.doi.org/10.1371/journal.pone.0118234			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CC0WZ	25693056	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000350061500111
J	Kalk, WJ				Kalk, W. John			Guantanamo force feeding trial: the US is wrong to medicalize hunger striking	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Medway Maritime Hosp, Gillingham ME7 5NY, Kent, England	Medway Maritime Hospital	Kalk, WJ (corresponding author), Medway Maritime Hosp, Gillingham ME7 5NY, Kent, England.	wjohnkalk@gmail.com						Annas GJ, 2013, NEW ENGL J MED, V369, P101, DOI 10.1056/NEJMp1306065; [Anonymous], 1991, Lancet, V337, P647; [Anonymous], 2014, GUARDIAN; KALK WJ, 1993, S AFR MED J, V83, P391; KALK WJ, 1991, LANCET, V337, P660, DOI 10.1016/0140-6736(91)92465-E; Keller A, 2014, DOING HARM HLTH PROF; Nicholl DJ, 2007, LANCET, V370, P823, DOI 10.1016/S0140-6736(07)61402-0; Steyn Johan, 2004, INT COMP LAW Q, V53, P1, DOI DOI 10.1093/iclq/53.1.1; World Medical Association, 1975, WORLD MED J, V22, P87; World Medical Association, 2006, WORLD MED ASS DECL M	10	4	4	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 11	2015	350								h669	10.1136/bmj.h669	http://dx.doi.org/10.1136/bmj.h669			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CB0MG	25673236				2023-01-03	WOS:000349319700012
J	Ding, F; Zhang, QR; Ung, COL; Wang, YT; Han, YF; Hu, YJ; Qi, J				Ding, Fan; Zhang, Qianru; Ung, Carolina Oi Lam; Wang, Yitao; Han, Yifan; Hu, Yuanjia; Qi, Jin			An Analysis of Chemical Ingredients Network of Chinese Herbal Formulae for the Treatment of Coronary Heart Disease	PLOS ONE			English	Article							MEDICINE; PHARMACOLOGY; TARGETS	As a complex system, the complicated interactions between chemical ingredients, as well as the potential rules of interactive associations among chemical ingredients of traditional Chinese herbal formulae are not yet fully understood by modern science. On the other hand, network analysis is emerging as a powerful approach focusing on processing complex interactive data. By employing network approach in selected Chinese herbal formulae for the treatment of coronary heart disease (CHD), this article aims to construct and analyze chemical ingredients network of herbal formulae, and provide candidate herbs, chemical constituents, and ingredient groups for further investigation. As a result, chemical ingredients network composed of 1588 ingredients from 36 herbs used in 8 core formulae for the treatment of CHD was produced based on combination associations in herbal formulae. In this network, 9 communities with relative dense internal connections are significantly associated with 14 kinds of chemical structures with P < 0.001. Moreover, chemical structural fingerprints of network communities were detected, while specific centralities of chemical ingredients indicating different levels of importance in the network were also measured. Finally, several distinct herbs, chemical ingredients, and ingredient groups with essential position in the network or high centrality value are recommended for further pharmacology study in the context of new drug development.	[Ding, Fan; Zhang, Qianru; Ung, Carolina Oi Lam; Wang, Yitao; Hu, Yuanjia] Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Taipa 999078, Peoples R China; [Zhang, Qianru] Zunyi Med Univ, Sch Pharm, Zunyi 563003, Peoples R China; [Han, Yifan] Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Kowloon 999077, Hong Kong, Peoples R China; [Qi, Jin] China Pharmaceut Univ, Dept Complex Prescript Tradit Chinese Med, Nanjing 211198, Jiangsu, Peoples R China	University of Macau; Zunyi Medical University; Hong Kong Polytechnic University; China Pharmaceutical University	Hu, YJ (corresponding author), Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Ave Padre Tomas Pereira SJ, Taipa 999078, Peoples R China.	yuanjiahu@umac.mo; yaoyuelingxing@163.com	Hu, Yuanjia/AAW-7721-2021; Ung, Carolina Oi Lam/AAR-2672-2020; Wang, Yitao/O-5184-2016	yuanjia, Hu/0000-0001-5244-8577; Han, Yifan/0000-0002-5833-069X; Ung, Carolina Oi Lam/0000-0003-1915-5099	University of Macau [MYRG119 (Y1-L3)-ICMS12-HYJ, MYRG208 (Y2-L4)-ICMS11-WYT]	University of Macau	The University of Macau provided financial support for this research by the projects MYRG119 (Y1-L3)-ICMS12-HYJ and MYRG208 (Y2-L4)-ICMS11-WYT. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abugessaisa I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104382; Barabasi AL, 2009, SCIENCE, V325, P412, DOI 10.1126/science.1173299; Bi YF, 2013, WORLD SCI TECHNOL MO, V15, P804; Blondel VD, 2008, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2008/10/P10008; Boccaletti S, 2006, PHYS REP, V424, P175, DOI 10.1016/j.physrep.2005.10.009; Cheng KF, 2011, J CANC THER, V2, P91; Chu Y, 2011, J ETHNOPHARMACOL, V137, P1457, DOI 10.1016/j.jep.2011.08.035; Dzubak P, 2006, NAT PROD REP, V23, P394, DOI 10.1039/b515312n; Fortunato S, 2010, PHYS REP, V486, P75, DOI 10.1016/j.physrep.2009.11.002; Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118; Hopkins AL, 2007, NAT BIOTECHNOL, V25, P1110, DOI 10.1038/nbt1007-1110; Hu YJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077247; Janga SC, 2009, MOL BIOSYST, V5, P1536, DOI [10.1039/b908147j, 10.1039/B908147j]; Jiang M, 2011, PLANTA MED, V77, P873, DOI 10.1055/s-0030-1270983; Konkimalla VB, 2008, J ETHNOPHARMACOL, V116, P207, DOI 10.1016/j.jep.2007.12.009; Lancichinetti A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011976; Li S, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-S1-S10; Li S, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-S11-S6; Li S, 2009, CURR BIOINFORM, V4, P188, DOI 10.2174/157489309789071129; Li XX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043918; Li ZJ, 2011, MOD J INTEGR TRADIT, V20, P933; Newman MEJ, 2003, SIAM REV, V45, P167, DOI 10.1137/S003614450342480; Noack A, 2009, PHYS REV E, V79, DOI 10.1103/PhysRevE.79.026102; Owens J, 2006, NAT REV DRUG DISCOV, V5, P1474; Pei LX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057414; Porter M.A., 2009, NOTICES AMS, V56, P1082, DOI DOI 10.1103/PHYSREVE.69.066133; Qin LP, 2008, J ETHNOPHARMACOL, V118, P271, DOI 10.1016/j.jep.2008.04.009; Shi Q, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/697028; Smith Mary Elizabeth, 2012, Semin Oncol Nurs, V28, P64, DOI 10.1016/j.soncn.2011.11.007; Tao WY, 2013, J ETHNOPHARMACOL, V145, P1, DOI 10.1016/j.jep.2012.09.051; van der Greef J, 2011, NATURE, V480, pS87, DOI 10.1038/480S87a; Wang L, 2008, P NATL ACAD SCI USA, V105, P4826, DOI 10.1073/pnas.0712365105; Wang P, 2010, FITOTERAPIA, V81, P793, DOI 10.1016/j.fitote.2010.04.007; Willerson JT, 2004, CIRCULATION, V109, P2, DOI 10.1161/01.CIR.0000129535.04194.38; Yang M, 2012, MOD TRADIT CHIN MED, V14, P1376; Yang M, 2013, COMPUT MATH METHOD M, V2013, DOI 10.1155/2013/971272; Zhang AH, 2012, BMC SYST BIOL, V6, DOI 10.1186/1752-0509-6-20; Zhang AH, 2011, FITOTERAPIA, V82, P1160, DOI 10.1016/j.fitote.2011.07.014; [张兰凤 Zhang Lanfeng], 2005, [中华中医药杂志, China Journal of Traditional Chinese Medicine and Pharmacy], V20, P8; Zhao J, 2010, BRIEF BIOINFORM, V11, P417, DOI 10.1093/bib/bbp063; Zhou XZ, 2009, FIRST INTERNATIONAL WORKSHOP ON DATABASE TECHNOLOGY AND APPLICATIONS, PROCEEDINGS, P188, DOI 10.1109/DBTA.2009.65; Zhu Hui, 2010, Zhongguo Zhong Xi Yi Jie He Za Zhi, V30, P474	42	12	12	1	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2015	10	2							e0116441	10.1371/journal.pone.0116441	http://dx.doi.org/10.1371/journal.pone.0116441			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CB2GK	25658855	Green Submitted, Green Published, gold			2023-01-03	WOS:000349444900039
J	Worku, AG; Tessema, GA; Zeleke, AA				Worku, Abebaw Gebeyehu; Tessema, Gizachew Assefa; Zeleke, Atinkut Alamirrew			Trends of Modern Contraceptive Use among Young Married Women Based on the 2000, 2005, and 2011 Ethiopian Demographic and Health Surveys: A Multivariate Decomposition Analysis	PLOS ONE			English	Article								Introduction Accessing family planning can reduce a significant proportion of maternal, infant, and childhood deaths. In Ethiopia, use of modern contraceptive methods is low but it is increasing. This study aimed to analyze the trends and determinants of changes in modern contraceptive use over time among young married women in Ethiopia. Methods T he study used data from the three Demographic Health Surveys conducted in Ethiopia, in 2000, 2005, and 2011. Young married women age 15-24 years with sample sizes of 2,157 in 2000, 1,904 in 2005, and 2,146 in 2011 were included. Logit-based decomposition analysis technique was used for analysis of factors contributing to the recent changes. STATA 12 was employed for data management and analyses. All calculations presented in this paper were weighted for the sampling probabilities and non-response. Complex sampling procedures were also considered during testing of statistical significance. Results Among young married women, modern contraceptive prevalence increased from 6% in 2000 to 16% in 2005 and to 36% in 2011. The decomposition analysis indicated that 34% of the overall change in modern contraceptive use was due to difference in women's characteristics. Changes in the composition of young women's characteristics according to age, educational status, religion, couple concordance on family size, and fertility preference were the major sources of this increase. Two-thirds of the increase in modern contraceptive use was due to difference in coefficients. Most importantly, the increase was due to change in contraceptive use behavior among the rural population (33%) and among Orthodox Christians (16%) and Protestants (4%). Conclusions Modern contraceptive use among young married women has showed a remarkable increase over the last decade in Ethiopia. Programmatic interventions targeting poor, younger (adolescent), illiterate, and Muslim women would help to maintain the increasing trend in modern contraceptive use.	[Worku, Abebaw Gebeyehu; Tessema, Gizachew Assefa] Univ Gondar, Inst Publ Hlth, Dept Reprod Hlth, Gondar, Ethiopia; [Zeleke, Atinkut Alamirrew] Univ Gondar, Inst Publ Hlth, Dept Hlth Informat, Gondar, Ethiopia	University of Gondar; University of Gondar	Worku, AG (corresponding author), Univ Gondar, Inst Publ Hlth, Dept Reprod Hlth, Gondar, Ethiopia.	abebawgebeyehu@yahoo.com	Zeleke, Atinkut Alamirrew/I-4137-2019; Tessema, Gizachew A/J-9235-2018	Zeleke, Atinkut Alamirrew/0000-0001-7838-9050; Tessema, Gizachew A/0000-0002-4784-8151; Worku, Abebaw Gebeyehu/0000-0002-1146-3399	DHS fellowship program	DHS fellowship program	This study was supported by the 2014 DHS fellowship program. The program covered costs for preparation of the working paper. However, there is no funding support for publication in a journal. The funders had no role in study design, data collection (data extraction in our case) and analysis, decision to publish, or preparation of the manuscript.	Ahmed S, 2012, LANCET, V380, P111, DOI 10.1016/S0140-6736(12)60478-4; Cleland J, 2012, LANCET, V0140-6736, P60609; Cleland J, 2006, REPROD HEALTH MATTER, V14, P17, DOI 10.1016/S0968-8080(06)28250-8; Cleland J, 2006, LANCET, V368, P1810, DOI 10.1016/S0140-6736(06)69480-4; CSA Ethiopia and DHS Macro, 2001, ETH DEM HLTH SURV RE; CSA [Ethiopia] and ICF International, 2012, ETH DEM HLTH SURV RE; CSA Ethiopia and ORC Macro, 2005, ETH DEM HLTH SURV PR; FMOH Ethiopia, 2011, NAT GUID FAM PLANN S; FMOH Ethiopia, 2007, HLTH EXT PROGR ETH; Hogan MC, 2010, LANCET, V375, P1609, DOI 10.1016/S0140-6736(10)60518-1; Lakew Y, 2013, REPROD HEALTH, V10, DOI 10.1186/1742-4755-10-52; Medhanyie A, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-352; Mekonnen W, 2011, REPROD HEALTH, V8, DOI 10.1186/1742-4755-8-37; Mohammed A, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-13; Muhoza DN, 2013, MEASURING SUCCESS FA; Pillai VK, 2011, OPEN ACCESS J CONTRA, V2011; Population Action International, 2013, FAM PLANN SMART INV; RamaRao S, 2003, INT FAM PLAN PERSPEC, V29, P76, DOI 10.2307/3181061; Singh S, 2012, ADD IT COSTS BENEFIT; Transitional Government of Ethiopia, 1993, POP POL TRANS GOV ET; UNEPA, 2012, DEC CHANG CONTR US E; USAID/Africa Bureau, 2011, 3 SUCC SUBS AFR FAM; World Bank, 2007, WORLD DEV REP 2007 D; World Bank, 2021, WORLD DEV IND	24	26	26	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2015	10	1							e0116525	10.1371/journal.pone.0116525	http://dx.doi.org/10.1371/journal.pone.0116525			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC9HX	25635389	Green Published, Green Submitted, gold			2023-01-03	WOS:000350680700042
J	Pearson-Dennett, V; Flavel, SC; Wilcox, RA; Thewlis, D; Vogel, AP; White, JM; Todd, G				Pearson-Dennett, Verity; Flavel, Stanley C.; Wilcox, Robert A.; Thewlis, Dominic; Vogel, Adam P.; White, Jason M.; Todd, Gabrielle			Hand Function is Altered in Individuals with a History of Illicit Stimulant Use	PLOS ONE			English	Article							GRIP FORCE CONTROL; PARKINSONS-DISEASE; CLINICAL-PHARMACOLOGY; COGNITIVE IMPAIRMENT; OBJECT MANIPULATION; ECSTASY; AGE; PERFORMANCE; DISORDERS	Use of illicit stimulant drugs such as methamphetamine, cocaine, and ecstasy are a significant worldwide problem. However, little is known about the effect of these drugs on movement. The aim of the current study was to investigate hand function in adults with a history of illicit stimulant use. We hypothesized that prior use of illicit stimulant drugs is associated with abnormal manipulation of objects. The study involved 22 subjects with a history of illicit stimulant use (aged 29 +/- 8 yrs; time since last use: 1.8 +/- 4.0 yrs) and two control groups comprising 27 non-drug users (aged 25 +/- 8 yrs) and 17 cannabis users with no history of stimulant use (aged 22 +/- 5 yrs). Each subject completed screening tests (neuropsychological assessment, medical history questionnaire, lifetime drug history questionnaire, and urine drug screen) prior to gripping and lifting a light-weight object with the dominant right hand. Horizontal grip force, vertical lift force, acceleration, and first dorsal interosseus electromyographic (EMG) activity were recorded during three trials. In trial one, peak grip force was significantly greater in the stimulant group (12.8 +/- 3.9 N) than in the control groups (non-drug: 10.3 +/- 4.6 N; cannabis: 9.4 +/- 2.9 N, P<0.022). However, peak grip force did not differ between groups in trials two and three. The results suggest that individuals with a history of stimulant use overestimate the grip force required to manipulate a novel object but, are able to adapt grip force in subsequent lifts. The results suggest that movement dysfunction may be an unrecognized consequence of illicit stimulant use.	[Pearson-Dennett, Verity; Flavel, Stanley C.; White, Jason M.; Todd, Gabrielle] Univ S Australia, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia; [Pearson-Dennett, Verity; Flavel, Stanley C.; Thewlis, Dominic; White, Jason M.; Todd, Gabrielle] Univ S Australia, Sansom Inst, Adelaide, SA 5001, Australia; [Wilcox, Robert A.] Flinders Med Ctr, Dept Neurol, Bedford Pk, SA, Australia; [Wilcox, Robert A.] Flinders Univ S Australia, Sch Med, Bedford Pk, SA, Australia; [Thewlis, Dominic] Univ S Australia, Sch Hlth Sci, Adelaide, SA 5001, Australia; [Vogel, Adam P.] Univ Melbourne, Speech Neurosci Unit, Melbourne, Vic 3010, Australia	University of South Australia; University of South Australia; Flinders Medical Centre; Flinders University South Australia; University of South Australia; University of Melbourne	Todd, G (corresponding author), Univ S Australia, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia.	gabrielle.todd@unisa.edu.au	Todd, Gabrielle/K-7122-2012; Thewlis, Dominic/X-1184-2019; White, Jason M/A-2795-2011; Thewlis, Dominic/C-5686-2009; Vogel, Adam/ABD-7685-2020	Todd, Gabrielle/0000-0002-2465-6026; Thewlis, Dominic/0000-0001-6614-8663; White, Jason M/0000-0001-6750-1078; Thewlis, Dominic/0000-0001-6614-8663; Vogel, Adam/0000-0002-3505-2631; Wilcox, Robert/0000-0001-9911-8743; Pearson-Dennett, Verity/0000-0003-0971-2007	Ramaciotti Foundation [ID2974/2010]; National Health and Medical Research Council of Australia [627003]; APV holds an Early Career Research Fellowship [ID 1012302]; Australian Government; University of South Australia	Ramaciotti Foundation; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); APV holds an Early Career Research Fellowship; Australian Government(Australian GovernmentCGIAR); University of South Australia	This work was supported by the Ramaciotti Foundation (GT holds an Establishment Grant; ID2974/2010), National Health and Medical Research Council of Australia (GT holds a Career Development Award: ID 627003; APV holds an Early Career Research Fellowship: ID 1012302), Australian Government (VPD holds an Australian Postgraduate Award), and the University of South Australia (GT holds a Research SA Fellowship and Division of Health Sciences Research Grant, SCF held an Australian Postgraduate Award, and VPD holds a Top-up Scholarship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADAMSON GT, 1965, ERGONOMICS, V8, P237, DOI 10.1080/00140136508930795; AIHW, 2011, AIHW DRUG STAT SER, V22, P1; [Anonymous], 2012, WORLD DRUG REP 2012; Beck A.T., 1996, MANUAL BDI 2, DOI [10.1037/t00742-000, DOI 10.1037/T00742-000]; BENOWITZ NL, 1993, PHARMACOL TOXICOL, V72, P3, DOI 10.1111/j.1600-0773.1993.tb01331.x; Benton AL, 1983, MULTILINGUAL APHASIA; Bousman CA, 2010, J INT NEUROPSYCH SOC, V16, P1047, DOI 10.1017/S1355617710000846; Breen C, 2006, SUBST USE MISUSE, V41, P1095, DOI 10.1080/10826080500411528; Callaghan RC, 2010, MOVEMENT DISORD, V25, P2333, DOI 10.1002/mds.23263; CARDOSO F, 1993, NEUROL CLIN, V11, P625, DOI 10.1016/S0733-8619(18)30143-9; Claudino R, 2013, PERCEPT MOTOR SKILL, V116, P859, DOI 10.2466/10.06.PMS.116.3.859-871; Croft RJ, 2001, PSYCHOPHARMACOLOGY, V153, P373, DOI 10.1007/s002130000591; FEARNLEY JM, 1991, BRAIN, V114, P2283, DOI 10.1093/brain/114.5.2283; Fellows SJ, 2004, MOVEMENT DISORD, V19, P560, DOI 10.1002/mds.10710; Flanagan JR, 2006, CURR OPIN NEUROBIOL, V16, P650, DOI 10.1016/j.conb.2006.10.005; Flanagan JR, 1997, J NEUROSCI, V17, P1519; Flavel SC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052025; Flavel SC, 2012, J APPL PHYSIOL, V113, P1486, DOI 10.1152/japplphysiol.00718.2012; GORDON AM, 1993, J NEUROPHYSIOL, V69, P1789, DOI 10.1152/jn.1993.69.6.1789; Green AR, 2003, PHARMACOL REV, V55, P463, DOI 10.1124/pr.55.3.3; GRIGSBY J, 1995, PERCEPT MOTOR SKILL, V80, P732, DOI 10.2466/pms.1995.80.3.732; Hermsdorfer J, 2003, CLIN NEUROPHYSIOL, V114, P915, DOI 10.1016/S1388-2457(03)00042-7; Johansson RS, 1998, NOVART FDN SYMP, V218, P45; KEARCOLWELL JJ, 1978, J CLIN PSYCHOL, V34, P437, DOI 10.1002/1097-4679(197804)34:2<437::AID-JCLP2270340239>3.0.CO;2-K; King G, 2010, PSYCHOPHARMACOLOGY, V212, P243, DOI 10.1007/s00213-010-1949-x; Melega WP, 2007, NEUROREPORT, V18, P1741, DOI 10.1097/WNR.0b013e3282f0d4f4; Mrazik M, 2010, ARCH CLIN NEUROPSYCH, V25, P236, DOI 10.1093/arclin/acq006; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; STEADWARD RD, 1975, MED SCI SPORT EXER, V7, P309; Thompson G.B., 1992, PSYCHOL ASSESSMENT, V4, P363; Todd G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056438; Todd G, 2010, EUR J NEUROSCI, V32, P1686, DOI 10.1111/j.1460-9568.2010.07444.x; Tombaugh TN, 1999, ARCH CLIN NEUROPSYCH, V14, P167, DOI 10.1016/S0887-6177(97)00095-4; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL; Yamamoto BK, 2010, ANN NY ACAD SCI, V1187, P101, DOI 10.1111/j.1749-6632.2009.05141.x	36	7	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 29	2014	9	12							e115771	10.1371/journal.pone.0115771	http://dx.doi.org/10.1371/journal.pone.0115771			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX7UN	25545892	Green Published, Green Accepted, gold			2023-01-03	WOS:000347120200066
J	Shankaran, S; Laptook, AR; Pappas, A; McDonald, SA; Das, A; Tyson, JE; Poindexter, BB; Schibler, K; Bell, EF; Heyne, RJ; Pedroza, C; Bara, R; Van Meurs, KP; Grisby, C; Huitema, CMP; Garg, M; Ehrenkranz, RA; Shepherd, EG; Chalak, LF; Hamrick, SEG; Khan, AM; Reynolds, AM; Laughon, MM; Truog, WE; Dysart, KC; Carlo, WA; Walsh, MC; Watterberg, KL; Higgins, RD				Shankaran, Seetha; Laptook, Abbot R.; Pappas, Athina; McDonald, Scott. A.; Das, Abhik; Tyson, Jon E.; Poindexter, Brenda B.; Schibler, Kurt; Bell, Edward F.; Heyne, Roy J.; Pedroza, Claudia; Bara, Rebecca; Van Meurs, Krisa P.; Grisby, Cathy; Huitema, Carolyn M. Petrie; Garg, Meena; Ehrenkranz, Richard A.; Shepherd, Edward G.; Chalak, Lina F.; Hamrick, Shannon E. G.; Khan, Amir M.; Reynolds, Anne Marie; Laughon, Matthew M.; Truog, William E.; Dysart, Kevin C.; Carlo, Waldemar A.; Walsh, Michele C.; Watterberg, Kristi L.; Higgins, Rosemary D.		Eunice Kennedy Shriver Natl Inst C	Effect of Depth and Duration of Cooling on Deaths in the NICU Among Neonates With Hypoxic Ischemic Encephalopathy A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WHOLE-BODY HYPOTHERMIA; SYSTEMIC HYPOTHERMIA; OUTCOMES; NEUROPROTECTION; TEMPERATURE; SAFETY; RISK	IMPORTANCE Hypothermia at 33.5 degrees C for 72 hours for neonatal hypoxic ischemic encephalopathy reduces death or disability to 44% to 55%; longer cooling and deeper cooling are neuroprotective in animal models. OBJECTIVE To determine if longer duration cooling (120 hours), deeper cooling (32.0 degrees C), or both are superior to cooling at 33.5 degrees C for 72 hours in neonates who are full-term with moderate or severe hypoxic ischemic encephalopathy. DESIGN, SETTING, AND PARTICIPANTS A randomized, 2 x 2 factorial design clinical trial performed in 18 US centers in the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Neonatal Research Network between October 2010 and November 2013. INTERVENTIONS Neonates were assigned to 4 hypothermia groups; 33.5 degrees C for 72 hours, 32.0 degrees C for 72 hours, 33.5 degrees C for 120 hours, and 32.0 degrees C for 120 hours. MAIN OUTCOMES AND MEASURES The primary outcome of death or disability at 18 to 22 months is ongoing. The independent data and safety monitoring committee paused the trial to evaluate safety (cardiac arrhythmia, persistent acidosis, major vessel thrombosis and bleeding, and death in the neonatal intensive care unit [NICU]) after the first 50 neonates were enrolled, then after every subsequent 25 neonates. The trial was closed for emerging safety profile and futility analysis after the eighth review with 364 neonates enrolled (of 726 planned). This report focuses on safety and NICU deaths by marginal comparisons of 72 hours' vs 120 hours' duration and 33.5 degrees C depth vs 32.0 degrees C depth (predefined secondary outcomes). RESULTS The NICU death rates were 7 of 95 neonates (7%) for the 33.5 degrees C for 72 hours group, 13 of 90 neonates (14%) for the 32.0 degrees C for 72 hours group, 15 of 96 neonates (16%) for the 33.5 degrees C for 120 hours group, and 14 of 83 neonates (17%) for the 32.0 degrees C for 120 hours group. The adjusted risk ratio (RR) for NICU deaths for the 120 hours group vs 72 hours group was 1.37 (95% CI, 0.92-2.04) and for the 32.0 degrees C group vs 33.5 degrees C group was 1.24 (95% CI, 0.69-2.25). Safety outcomes were similar between the 120 hours group vs 72 hours group and the 32.0 degrees C group vs 33.5 degrees C group, except major bleeding occurred among 1% in the 120 hours group vs 3% in the 72 hours group (RR, 0.25 [95% CI, 0.07-0.91]). Futility analysis determined that the probability of detecting a statistically significant benefit for longer cooling, deeper cooling, or both for NICU death was less than 2%. CONCLUSIONS AND RELEVANCE Among neonates who were full-term with moderate or severe hypoxic ischemic encephalopathy, longer cooling, deeper cooling, or both compared with hypothermia at 33.5 degrees C for 72 hours did not reduce NICU death. These results have implications for patient care and design of future trials.	[Shankaran, Seetha; Pappas, Athina; Bara, Rebecca] Wayne State Univ, Dept Pediat, Detroit, MI 48201 USA; [Laptook, Abbot R.] Brown Univ, Women & Infants Hosp, Dept Pediat, Providence, RI 02908 USA; [McDonald, Scott. A.] RTI Int, Social Stat & Environm Sci Unit, Res Triangle Pk, NC USA; [Das, Abhik; Huitema, Carolyn M. Petrie] RTI Int, Social Stat & Environm Sci Unit, Rockville, MD USA; [Tyson, Jon E.; Khan, Amir M.] Univ Texas Houston, Sch Med, Dept Pediat, Houston, TX USA; [Poindexter, Brenda B.] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; [Schibler, Kurt; Pedroza, Claudia; Grisby, Cathy] Cincinnati Childrens Hosp Med Ctr, Perinatal Inst, Cincinnati, OH 45229 USA; [Bell, Edward F.] Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; [Heyne, Roy J.; Chalak, Lina F.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA; [Van Meurs, Krisa P.] Stanford Univ, Sch Med, Div Neonatal & Dev Med, Dept Pediat,Lucile Packard Childrens Hosp, Palo Alto, CA 94304 USA; [Garg, Meena] Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90024 USA; [Ehrenkranz, Richard A.] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA; [Shepherd, Edward G.] Ohio State Univ, Nationwide Childrens Hosp, Dept Pediat, Columbus, OH 43210 USA; [Hamrick, Shannon E. G.] Emory Univ, Sch Med, Dept Pediat, Childrens Healthcare Atlanta, Atlanta, GA USA; [Reynolds, Anne Marie] SUNY Buffalo, Dept Pediat, Buffalo, NY 14260 USA; [Laughon, Matthew M.] Univ N Carolina, Dept Pediat, Div Neonatal Perinatal Med, Chapel Hill, NC USA; [Truog, William E.] Univ Missouri, Childrens Mercy Hosp, Kansas City Sch Med, Dept Pediat, Columbia, MO 65211 USA; [Dysart, Kevin C.] Univ Penn, Childrens Hosp Philadelphia, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Carlo, Waldemar A.] Univ Alabama Birmingham, Div Neonatol, Birmingham, AL USA; [Walsh, Michele C.] Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA; [Watterberg, Kristi L.] Univ New Mexico, Hlth Sci Ctr, Albuquerque, NM 87131 USA; [Higgins, Rosemary D.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Pregnancy & Perinatol Branch, NIH, Bethesda, MD USA	Wayne State University; Brown University; Women & Infants Hospital Rhode Island; Research Triangle Institute; Research Triangle Institute; University of Texas System; University of Texas Health Science Center Houston; Indiana University System; Indiana University Bloomington; Cincinnati Children's Hospital Medical Center; University of Iowa; University of Texas System; University of Texas Southwestern Medical Center Dallas; Lucile Packard Children's Hospital (LPCH); Stanford University; University of California System; University of California Los Angeles; Yale University; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Children's Healthcare of Atlanta (CHOA); Emory University; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of North Carolina; University of North Carolina Chapel Hill; Children's Mercy Hospital; University of Missouri System; University of Missouri Columbia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Alabama System; University of Alabama Birmingham; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; University of New Mexico; University of New Mexico's Health Sciences Center; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Shankaran, S (corresponding author), Wayne State Univ, Childrens Hosp Michigan, Dept Pediat, 3901 Beaubien Blvd, Detroit, MI 48201 USA.	sshankar@med.wayne.edu	Dysart, Kevin/AAQ-6155-2021; Truog, William/R-5576-2019; Shah, Birju A./C-4811-2014; Shepherd, Edward/E-4080-2011; Ambalavanan, Namasivayam/AAI-4088-2020; Das, Abhik/AAF-1883-2020; Keszler, Martin/H-7260-2019	Shah, Birju A./0000-0002-9051-1183; Ambalavanan, Namasivayam/0000-0003-0731-9092; Das, Abhik/0000-0003-2722-0479; Keszler, Martin/0000-0002-9964-664X; Bell, Edward/0000-0002-5568-0889; Shankaran, Seetha/0000-0001-5512-9571; Dysart, Kevin/0000-0003-2715-2293; Lakshminrusimha, Satyan/0000-0001-6098-2155; Boyle, Robert/0000-0002-4913-7580; Pedroza, Claudia/0000-0003-4235-1282; Roghair, Robert/0000-0002-0321-582X; Colaizy, Tarah/0000-0003-2582-1633; Barks, John/0000-0003-1320-905X; Parikh, Nehal/0000-0002-1375-1247; Klein, Jonathan/0000-0002-6693-1823; Gantz, Marie/0000-0001-8528-0184; Nolen, Tracy/0000-0003-2512-343X; Rabe, Glenda/0000-0003-4884-255X; Dagle, John/0000-0002-8238-6159; McDonald, Scott/0000-0002-0054-1099; Segar, Jeffrey/0000-0001-7311-8948; McElroy, Steven/0000-0002-4321-723X; Lindower, Julie/0000-0003-0213-315X	National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Advancing Translational Sciences; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U10HD040492, U10HD036790, U10HD027904, U10HD068270, U10HD040689, UG1HD087229, U10HD027880, U10HD068263, U10HD053089, UG1HD053089, U10HD068284, U10HD053109, UG1HD068270, U10HD021364, U10HD027856, U10HD034216, U10HD068244, U10HD068278, U10HD027853, U10HD027851, U10HD021385, U10HD021373] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000371, UL1TR002529, UL1TR001108, UL1TR000142] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024128] Funding Source: NIH RePORTER	National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	The National Institutes of Health, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and the National Center for Advancing Translational Sciences provided grant support for the Neonatal Research Network's Optimizing Cooling trial through cooperative agreements.	Azzopardi D, 2014, NEW ENGL J MED, V371, P140, DOI 10.1056/NEJMoa1315788; Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; Bennet L, 2007, J PHYSIOL-LONDON, V578, P491, DOI 10.1113/jphysiol.2006.119602; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Cavallaro G, 2011, ARCH DIS CHILD-FETAL, V96, pF374, DOI 10.1136/adc.2009.181826; Compagnoni G, 2008, NEONATOLOGY, V93, P230, DOI 10.1159/000111101; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Guillet R, 2012, PEDIATR RES, V71, P205, DOI 10.1038/pr.2011.30; Hallberg B, 2009, ACTA PAEDIATR, V98, P942, DOI 10.1111/j.1651-2227.2009.01303.x; Iwata O, 2005, ANN NEUROL, V58, P75, DOI 10.1002/ana.20528; Jacobs SE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub3; Jacobs SE, 2011, ARCH PEDIAT ADOL MED, V165, P692, DOI 10.1001/archpediatrics.2011.43; Johnston MV, 2011, LANCET NEUROL, V10, P372, DOI 10.1016/S1474-4422(11)70016-3; Kendall GS, 2012, PEDIATRICS, V130, pE451, DOI 10.1542/peds.2011-3496; Kendall GS, 2010, ARCH DIS CHILD-FETAL, V95, pF408, DOI 10.1136/adc.2010.187211; Laptook A, 2008, PEDIATRICS, V122, P491, DOI 10.1542/peds.2007-1673; Laptook AR, 2013, ANN NEUROL, V73, P520, DOI 10.1002/ana.23843; O'Reilly KM, 2011, ACTA PAEDIATR, V100, P1084, DOI 10.1111/j.1651-2227.2011.02249.x; Palisano R, 1997, DEV MED CHILD NEUROL, V39, P214, DOI 10.1111/j.1469-8749.1997.tb07414.x; Papile LA, 2014, PEDIATRICS, V133, P1146, DOI 10.1542/peds.2014-0899; Perlman JM, 2006, PEDIATRICS, V117, pS28, DOI 10.1542/peds.2005-0620E; POCOCK SJ, 1977, BIOMETRIKA, V64, P191, DOI 10.1093/biomet/64.2.191; Shah SK, 2010, EUR J PEDIATR SURG, V20, P205, DOI 10.1055/s-0029-1241872; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Shankaran S, 2008, PEDIATRICS, V122, pE791, DOI 10.1542/peds.2008-0456; Shankaran S, 2012, NEW ENGL J MED, V366, P2085, DOI 10.1056/NEJMoa1112066; Simbruner G, 2010, PEDIATRICS, V126, pE771, DOI 10.1542/peds.2009-2441; Tagin MA, 2012, ARCH PEDIAT ADOL MED, V166, P558, DOI 10.1001/archpediatrics.2011.1772; THORESEN M, 1995, PEDIATR RES, V37, P667, DOI 10.1203/00006450-199505000-00019; Williams GD, 1997, PEDIATR RES, V42, P700, DOI 10.1203/00006450-199711000-00024; Wyatt JS, 2007, PEDIATRICS, V119, P912, DOI 10.1542/peds.2006-2839	31	150	158	2	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 24	2014	312	24					2629	2639		10.1001/jama.2014.16058	http://dx.doi.org/10.1001/jama.2014.16058			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AX5KW	25536254	Green Published, Green Accepted, Bronze			2023-01-03	WOS:000346966100015
J	Chen, YC; Chiou, C; Lin, MN; Lin, CL				Chen, Yen-Chun; Chiou, Chia; Lin, Ming-Nan; Lin, Chin-Lon			The Prevalence and Risk Factors for Gallstone Disease in Taiwanese Vegetarians	PLOS ONE			English	Article							GALLBLADDER-DISEASE; GENERAL-POPULATION; PHYSICAL-ACTIVITY; UNITED-STATES; CHOLELITHIASIS; PREGNANCY; WOMEN; DIET; CHOLECYSTECTOMY; CHOLESTEROL	Introduction: Gallstone disease (GSD) and its complications are major public health issues globally. Although many community-based studies had addressed the risk factors for GSD, little is known about GSD prevalence and risk factors among Taiwanese vegetarians. Methods: This study included 1721 vegetarians who completed a questionnaire detailing their demographics, medical history, and life-styles. GSD was ascertained by ultrasonography or surgical history of cholecystectomy for GSD. The predictive probability of GSD for male and female vegetarians was estimated from the fitted model. Results: The prevalence of GSD was 8.2% for both male and female vegetarians. The risk of GSD is similar in men and women across all age groups, and increases steadily with increasing age. For male vegetarians, age (OR: 1.04; 95% CI: 1.00-1.08) and serum total bilirubin level (OR: 2.35; 95% CI: 1.31-4.22) predict risk for GSD. For female vegetarians, age (OR: 1.03; 95% CI: 1.01-1.05), BMI (OR: 1.07; 95% CI: 1.01-1.13), and alcohol consumption (OR: 7.85; 95% CI: 1.83-33.73) are associated with GSD. GSD is not associated with type of vegetarian diet, duration of vegetarianism, low education level, physical inactivity, diabetes, coronary artery disease, cerebral vascular accident, chronic renal failure, hepatitis C virus infection, and lipid abnormalities. GSD is also not associated with age at menarche, postmenopausal status, and multiparity in female vegetarians. Conclusions: Risk factors useful for predicting GSD in vegetarians are (1) age and total bilirubin level in men, and (2) age, BMI, and alcohol consumption in women. Many previously identified risk factors for general population does not seem to apply to Taiwanese vegetarians.	[Chen, Yen-Chun] Dalin Tzu Chi Hosp, Dept Internal Med, Buddhist Tzu Chi Med Fdn, Dalin Township, Chiayi County, Taiwan; [Chiou, Chia; Lin, Ming-Nan] Dalin Tzu Chi Hosp, Dept Family Med, Buddhist Tzu Chi Med Fdn, Dalin Township, Chiayi County, Taiwan; [Lin, Ming-Nan] Tzu Chi Univ, Dept Family Med, Coll Med, Hualien, Taiwan; [Lin, Chin-Lon] Tzu Chi Fdn, Hualien, Taiwan; [Lin, Chin-Lon] Buddhist Hualien Tzu Chi Hosp, Dept Internal Med, Hualien, Taiwan; [Lin, Chin-Lon] Tzu Chi Univ, Dept Internal Med, Coll Med, Hualien, Taiwan	Buddhist Tzu Chi General Hospital; Buddhist Tzu Chi General Hospital; Tzu Chi University; Tzu Chi University	Lin, MN (corresponding author), Dalin Tzu Chi Hosp, Dept Family Med, Buddhist Tzu Chi Med Fdn, Dalin Township, Chiayi County, Taiwan.	mingnan.lin@gmail.com						Abu-Eshy S. A., 2007, Eastern Mediterranean Health Journal, V13, P794; ATTILI AF, 1995, HEPATOLOGY, V21, P656, DOI 10.1002/hep.1840210309; BARBARA L, 1995, AM J EPIDEMIOL, V141, P158, DOI 10.1093/oxfordjournals.aje.a117403; BASSO L, 1992, SURG GYNECOL OBSTET, V175, P41; Bini EJ, 2005, HEPATOLOGY, V41, P1029, DOI 10.1002/hep.20647; Chen CH, 2006, J GASTROEN HEPATOL, V21, P1737, DOI 10.1111/j.1440-1746.2006.04381.x; Chen CY, 1998, AGE AGEING, V27, P437, DOI 10.1093/ageing/27.4.437; Chen CY, 1999, HEPATO-GASTROENTEROL, V46, P1607; Chiu TH, PUBLIC HLTH NUTR, V17, P1459; Chiu THT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088547; de Pancorbo CM, 1997, J CLIN EPIDEMIOL, V50, P1347, DOI 10.1016/S0895-4356(97)00198-4; DeSantis A, 1997, HEPATOLOGY, V25, P787, DOI 10.1002/hep.510250401; DWYER JT, 1988, AM J CLIN NUTR, V48, P712, DOI 10.1093/ajcn/48.3.712; Everhart JE, 1999, GASTROENTEROLOGY, V117, P632, DOI 10.1016/S0016-5085(99)70456-7; Festi D, 2008, WORLD J GASTROENTERO, V14, P5282, DOI 10.3748/wjg.14.5282; Gaby AR, 2009, ALTERN MED REV, V14, P258; Halldestam I, 2009, BRIT J SURG, V96, P1315, DOI 10.1002/bjs.6687; HEATON KW, 1991, GUT, V32, P316, DOI 10.1136/gut.32.3.316; Hung SC, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-111; HWANG WS, 1970, GUT, V11, P141, DOI 10.1136/gut.11.2.141; Kothari SN, 2013, J AM COLL SURGEONS, V216, P1057, DOI 10.1016/j.jamcollsurg.2013.02.009; Lee YC, 2014, SCAND J GASTROENTERO, V49, P1001, DOI 10.3109/00365521.2014.920912; Leitzmann MF, 1998, ANN INTERN MED, V128, P417, DOI 10.7326/0003-4819-128-6-199803150-00001; Leitzmann MF, 1999, NEW ENGL J MED, V341, P777, DOI 10.1056/NEJM199909093411101; Liu B, 2009, INT J EPIDEMIOL, V38, P312, DOI 10.1093/ije/dyn174; MARINGHINI A, 1993, ANN INTERN MED, V119, P116, DOI 10.7326/0003-4819-119-2-199307150-00004; MARKS JW, 1984, DIGEST DIS SCI, V29, P1118, DOI 10.1007/BF01317086; Moerman Clara J., 1994, Annals of Epidemiology, V4, P248, DOI 10.1016/1047-2797(94)90104-X; NOMURA H, 1988, AM J EPIDEMIOL, V128, P598, DOI 10.1093/oxfordjournals.aje.a115007; Phillips F, 2005, NUTR BULL, V30, P132, DOI 10.1111/j.1467-3010.2005.00467.x; PIXLEY F, 1985, BRIT MED J, V291, P11, DOI 10.1136/bmj.291.6487.11; Shaffer EA, 2006, BEST PRACT RES CL GA, V20, P981, DOI 10.1016/j.bpg.2006.05.004; SMITH DA, 1979, AM J CLIN NUTR, V32, P1519, DOI 10.1093/ajcn/32.7.1519; Stender S, 2013, HEPATOLOGY, V58, P2133, DOI 10.1002/hep.26563; Stender S, 2013, JAMA INTERN MED, V173, P1222, DOI 10.1001/jamainternmed.2013.6465; Sun H, 2009, WORLD J GASTROENTERO, V15, P1886, DOI 10.3748/wjg.15.1886; THORNTON J, 1983, LANCET, V2, P819; Tonstad S, 2009, DIABETES CARE, V32, P791, DOI 10.2337/dc08-1886; Tsai CJ, 2006, AM J MED, V119, P760, DOI 10.1016/j.amjmed.2006.02.040; VALDIVIESO V, 1993, HEPATOLOGY, V17, P1; Walcher T, 2010, EUR J GASTROEN HEPAT, V22, P1345, DOI 10.1097/MEG.0b013e32833efdb2	41	18	18	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 18	2014	9	12							e115145	10.1371/journal.pone.0115145	http://dx.doi.org/10.1371/journal.pone.0115145			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA4AC	25521621	Green Published, Green Submitted, gold			2023-01-03	WOS:000348845600018
J	Li, JW; Mo, M; Yu, KD; Chen, CM; Hu, Z; Hou, YF; Di, GH; Wu, J; Shen, ZZ; Shao, ZM; Liu, GY				Li, Jian-wei; Mo, Miao; Yu, Ke-da; Chen, Can-ming; Hu, Zhen; Hou, Yi-feng; Di, Gen-hong; Wu, Jiong; Shen, Zhen-zhou; Shao, Zhi-ming; Liu, Guang-yu			ER-Poor and HER2-Positive: A Potential Subtype of Breast Cancer to Avoid Axillary Dissection in Node Positive Patients after Neoadjuvant Chemo-Trastuzumab Therapy	PLOS ONE			English	Article							PATHOLOGICAL COMPLETE REMISSION; OPEN-LABEL; PREOPERATIVE CHEMOTHERAPY; GUIDELINE RECOMMENDATIONS; ADJUVANT BREAST; SENTINEL; BIOPSY; TRIAL; MULTICENTER; PACLITAXEL	Purpose: The study was to estimate the likelihood of axillary downstaging and to identify the factors predicting a pathologically node negative status after neoadjuvant chemotherapy (NAC) with or without trastuzumab in HER2-positive breast cancer. Methods: Patients with HER2-positive, stage IIa-IIIc breast cancer were enrolled. Axillary status was evaluated by palpation and fine needle aspiration (FNA) before NAC. All patients received 4-6 cycles of PCrb (paclitaxel 80 mg/m(2) and carboplatin AUC=2 d1, 8, and 15 of a 28-day cycle, or paclitaxel 175 mg/m(2) and carboplatin AUC=6 every-3-week) and were non-randomly administered trastuzumab (2 mg/kg weekly or 6 mg/kg every-3-week) or not. After NAC, each patient underwent standard axillary lymph node dissection and breast-conserving surgery or mastectomy. And some patients received sentinel lymph node biopsy (SLNB) before axillary dissection. Results: Between November-2007 and June-2013, 255 patients were enrolled. Of them, 157 were confirmed as axillary node positive by FNA (group-A) and 98 as axillary node negative either by FNA or impalpable (group-B). After axillary dissection, the overall pathologically node negative rates (pNNR) were 52.9% in group-A and 69.4% in group-B. The ER-poor/HER2-positive subtype acquired the highest pNNR (79.6% in group-A and 87.9% in group-B, respectively) and the lowest rate of residual with >= 4 nodes involvement (1.9% and 3%, respectively) after PCrb plus trastuzumab. In multivariate analysis, trastuzumab added and ERpoor status were independent factors in predicting a higher pNNR in HER2-positive breast cancer. Forty-six tested patients showed that the ER-poor/HER2-positive subtype acquired a considerable high pNNR and axillary status with SLNB was well macthed with the axillary dissection. Conclusions: ER-poor/HER2-positive subtype of breast cancer is a potential candidate for undergoing sentinel lymph node biopsy instead of regional node dissection for accurate axillary evaluation after effective downstaging by neoadjuvant chemo-trastuzumab therapy.	[Li, Jian-wei; Yu, Ke-da; Chen, Can-ming; Hu, Zhen; Hou, Yi-feng; Di, Gen-hong; Wu, Jiong; Shen, Zhen-zhou; Shao, Zhi-ming; Liu, Guang-yu] Fudan Univ, Inst Canc, Shanghai Canc Ctr, Dept Breast Surg, Shanghai 200433, Peoples R China; [Li, Jian-wei; Mo, Miao; Yu, Ke-da; Chen, Can-ming; Hu, Zhen; Hou, Yi-feng; Di, Gen-hong; Wu, Jiong; Shen, Zhen-zhou; Shao, Zhi-ming; Liu, Guang-yu] Fudan Univ, Coll Med, Dept Oncol, Shanghai 200433, Peoples R China; [Mo, Miao] Fudan Univ, Ctr Canc, Clin Stat Ctr, Shanghai 200433, Peoples R China	Fudan University; Fudan University; Fudan University	Liu, GY (corresponding author), Fudan Univ, Inst Canc, Shanghai Canc Ctr, Dept Breast Surg, Shanghai 200433, Peoples R China.	Liugy123@yahoo.com		Di, Genhong/0000-0003-1171-7907	Shanghai Committee of Science and Technology, China [12DZ2260100]; Shanghai United Developing Technology Project of Municipal Hospitals [SHDC12010116]; Key Clinical Program of the Ministry of Health	Shanghai Committee of Science and Technology, China(Shanghai Science & Technology Committee); Shanghai United Developing Technology Project of Municipal Hospitals; Key Clinical Program of the Ministry of Health	This research is supported by the Shanghai Committee of Science and Technology, China (grant 12DZ2260100), and the Shanghai United Developing Technology Project of Municipal Hospitals (SHDC12010116), the Key Clinical Program of the Ministry of Health (2010-2012). The research funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No other potential confict of interest relevant to this article was reported.	Alvarado R, 2012, ANN SURG ONCOL, V19, P3177, DOI 10.1245/s10434-012-2484-2; Ashikaga T, 2010, J SURG ONCOL, V102, P111, DOI 10.1002/jso.21535; Baselga J, 2012, LANCET, V379, P633, DOI 10.1016/S0140-6736(11)61847-3; Bear HD, 2006, J CLIN ONCOL, V24, P2019, DOI 10.1200/JCO.2005.04.1665; Boughey JC, 2013, JAMA-J AM MED ASSOC, V310, P1455, DOI 10.1001/jama.2013.278932; Buzdar AU, 2005, J CLIN ONCOL, V23, P3676, DOI 10.1200/JCO.2005.07.032; Carlson RW, 2009, J NATL COMPR CANC NE, V7, P122, DOI 10.6004/jnccn.2009.0012; Chen XS, 2010, ANN ONCOL, V21, P961, DOI 10.1093/annonc/mdq041; Classe JM, 2009, J CLIN ONCOL, V27, P726, DOI 10.1200/JCO.2008.18.3228; Fitzal F, 2011, BREAST CANCER RES TR, V127, P121, DOI 10.1007/s10549-010-1164-9; Galimberti V, 2013, LANCET ONCOL, V14, P297, DOI 10.1016/S1470-2045(13)70035-4; Gianni L, 2012, LANCET ONCOL, V13, P25, DOI 10.1016/S1470-2045(11)70336-9; Gianni L, 2010, LANCET, V375, P377, DOI 10.1016/S0140-6736(09)61964-4; Giuliano AE, 2011, JAMA-J AM MED ASSOC, V305, P569, DOI 10.1001/jama.2011.90; Krag DN, 2007, LANCET ONCOL, V8, P881, DOI 10.1016/S1470-2045(07)70278-4; Kuehn T, 2000, BREAST CANCER RES TR, V64, P275, DOI 10.1023/A:1026564723698; Kuehn T, 2013, LANCET ONCOL, V14, P609, DOI 10.1016/S1470-2045(13)70166-9; Lee S, 2007, BREAST CANCER RES TR, V102, P283, DOI 10.1007/s10549-006-9330-9; Lyman GH, 2005, J CLIN ONCOL, V23, P7703, DOI 10.1200/JCO.2005.08.001; Mauri D, 2005, JNCI-J NATL CANCER I, V97, P188, DOI 10.1093/jnci/dji021; Mieog JSD, 2007, BRIT J SURG, V94, P1189, DOI 10.1002/bjs.5894; Newman EA, 2007, ANN SURG ONCOL, V14, P2946, DOI 10.1245/s10434-007-9403-y; Phillips T, 2007, APPL IMMUNOHISTO M M, V15, P325, DOI 10.1097/01.pai.0000213135.16783.bc; Reese DM, 1997, STEM CELLS, V15, P1, DOI 10.1002/stem.150001; Regan MM, 2006, JNCI-J NATL CANCER I, V98, P1571, DOI 10.1093/jnci/djj415; Robidoux A, 2013, LANCET ONCOL, V14, P1183, DOI 10.1016/S1470-2045(13)70411-X; Rouzier R, 2002, J CLIN ONCOL, V20, P1304, DOI 10.1200/JCO.20.5.1304; Shen J, 2007, CANCER-AM CANCER SOC, V109, P1255, DOI 10.1002/cncr.22540; Sobin L, 2009, UICC TNM CLASSIFICAT; Straver ME, 2010, J CLIN ONCOL, V28, P731, DOI 10.1200/JCO.2008.21.7554; Untch M, 2011, J CLIN ONCOL, V29, P3351, DOI 10.1200/JCO.2010.31.4930; Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775; Yu KD, 2013, ONCOLOGIST, V18, P511, DOI 10.1634/theoncologist.2012-0057	33	5	8	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 11	2014	9	12							e114646	10.1371/journal.pone.0114646	http://dx.doi.org/10.1371/journal.pone.0114646			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX8FY	25504233	Green Published, gold, Green Submitted			2023-01-03	WOS:000347146700039
J	Curry, RH				Curry, Raymond H.			Meaningful Roles for Medical Students in the Provision of Longitudinal Patient Care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Curry, RH (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Med, 420 E Super St,Rubloff Bldg 643, Chicago, IL 60611 USA.	rcurry@northwestern.edu	Curry, Raymond H./ABD-2043-2020	Curry, Raymond H./0000-0003-3381-0125				Association of American Medical Colleges, 2014, COR ENTR ACT ENT RES; Gorrindo P, 2014, ACAD MED, V89, P625, DOI 10.1097/ACM.0000000000000164; Grumbach K, 2014, JAMA-J AM MED ASSOC, V311, P1109, DOI 10.1001/jama.2014.705; Lin SY, 2015, J GEN INTERN MED, V30, P150, DOI 10.1007/s11606-014-3018-3; Martinez Jacqueline, 2011, Am J Public Health, V101, pe1, DOI 10.2105/AJPH.2011.300335; Norris TE, 2009, ACAD MED, V84, P902, DOI 10.1097/ACM.0b013e3181a85776; O'Neill SM, 2013, ACAD MED, V88, P1564, DOI 10.1097/ACM.0b013e3182a36bb5; Seiden SC, 2006, QUAL SAF HEALTH CARE, V15, P272, DOI 10.1136/qshc.2006.018044; Smith SE, 2013, MED EDUC, V47, P1184, DOI 10.1111/medu.12217; Vanderbilt University School of Medicine, VAND PROGR INT LEARN	10	21	21	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	2014	312	22					2335	2336		10.1001/jama.2014.16541	http://dx.doi.org/10.1001/jama.2014.16541			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AW5YB	25490320				2023-01-03	WOS:000346345700004
J	Pitts, SR; Morgan, SR; Schrager, JD; Berger, TJ				Pitts, Stephen R.; Morgan, Sofie R.; Schrager, Justin D.; Berger, Todd J.			Emergency Department Resource Use by Supervised Residents vs Attending Physicians Alone	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TEACHING HOSPITALS; CARE; COST; QUALITY; PATIENT	IMPORTANCE Few studies have evaluated the common assumption that graduate medical education is associated with increased resource use. OBJECTIVE To compare resources used in supervised vs attending-only visits in a nationally representative sample of patient visits to US emergency departments (EDs). DESIGN, SETTING, AND PARTICIPANTS Cross-sectional study of the National Hospital Ambulatory Medical Care Survey (2010), a probability sample of US EDs and ED visits. EXPOSURES Supervised visits, defined as visits involving both resident and attending physicians. Three ED teaching types were defined by the proportion of sampled visits that were supervised visits: nonteaching ED, minor teaching ED (half or fewer supervised visits), and major teaching ED (more than half supervised visits). MAIN OUTCOMES AND MEASURES Association of supervised visits with hospital admission, advanced imaging (computed tomography, ultrasound, or magnetic resonance imaging), any blood test, and ED length of stay, adjusted for visit acuity, demographic characteristics, payer type, and geographic region. RESULTS Of 29 182 ED visits to the 336 nonpediatric EDs in the sample, 3374 visits were supervised visits. Compared with the 25 808 attending-only visits, supervised visits were significantly associated with more frequent hospital admission (21% vs 14%; adjusted odds ratio [aOR], 1.42; 95% CI, 1.09-1.85), advanced imaging (28% vs 21%; aOR, 1.27; 95% CI, 1.06-1.51), and a longer median ED stay (226 vs 153 minutes; adjusted geometric mean ratio, 1.32; 95% CI, 1.19-1.45), but not with blood testing (53% vs 45%; aOR, 1.18; 95% CI, 0.96-1.46). Of visits to the sample of 121 minor teaching EDs, a weighted estimate of 9% were supervised visits, compared with 82% of visits to the 34 major teaching EDs. Supervised visits in major teaching EDs compared with attending-only visits were not associated with hospital admission (aOR, 1.15; 95% CI, 0.83-1.58), advanced imaging (aOR, 1.21; 95% CI, 0.96-1.53), or any blood test (aOR, 1.02; 95% CI, 0.79-1.33), but had longer ED stays (adjusted geometric mean ratio, 1.32; 95% CI, 1.14-1.53). CONCLUSIONS AND RELEVANCE In a sample of US EDs, supervised visits were associated with a greater likelihood of hospital admission and use of advanced imaging and with longer ED stays. Whether these associations are different in EDs in which more than half of visits are seen by residents requires further investigation. Copyright 2014 American Medical Association. All rights reserved.	[Pitts, Stephen R.; Morgan, Sofie R.; Schrager, Justin D.] Emory Univ, Sch Med, Dept Emergency Med, Atlanta, GA 30322 USA; [Morgan, Sofie R.] St Vincent Infirm Med Ctr, Emergency Dept, Little Rock, AR USA; [Berger, Todd J.] Univ Texas Southwestern Med Sch, Austin, TX USA	Emory University	Pitts, SR (corresponding author), Emory Univ, Sch Med, Dept Emergency Med, 531 Asbury Circle,Annex Ste N340, Atlanta, GA 30322 USA.	srpitts@emory.edu			Emergency Care Coordination Center of the US Department of Health and Human Services	Emergency Care Coordination Center of the US Department of Health and Human Services	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. For a period during the study's inception, Dr Pitts received partial salary support through a contract with the Emergency Care Coordination Center of the US Department of Health and Human Services. Dr Schrager is currently a resident in the Emory University Emergency Medicine residency. Dr Berger is the program director for the University of Texas Southwestern Medical School Emergency Medicine residency in Austin. No other disclosures were reported.	[Anonymous], EM MED MIL PROJ; [Anonymous], 2010 NHAMCS MICR FIL; [Anonymous], DAT RES BOOK AC YEAR; Ayanian JZ, 2002, MILBANK Q, V80, P569, DOI 10.1111/1468-0009.00023; Brunetti M, 2013, J CLIN EPIDEMIOL, V66, P140, DOI 10.1016/j.jclinepi.2012.04.012; Burt Catharine W, 2004, Vital Health Stat 13, P1; Cooke M, 2010, NEW ENGL J MED, V362, P1253, DOI 10.1056/NEJMp0911502; Farnan JM, 2012, ACAD MED, V87, P428, DOI 10.1097/ACM.0b013e31824822cc; Goodman DC, 2013, HEALTH AFFAIR, V32, P1887, DOI 10.1377/hlthaff.2013.0451; Hackbarth G, 2011, NEW ENGL J MED, V364, P693, DOI 10.1056/NEJMp1012691; Hodges BD, 2012, ACAD MED, V87, P25, DOI 10.1097/ACM.0b013e318238e069; Kocher KE, 2013, MED CARE, V51, P689, DOI 10.1097/MLR.0b013e3182992c7b; Marcotte L, 2014, JAMA-J AM MED ASSOC, V312, P231, DOI 10.1001/jama.2014.6762; MCNAMARA RM, 1992, ANN EMERG MED, V21, P956, DOI 10.1016/S0196-0644(05)82935-X; Morganti KG, RAND RES REPORTS; National Center for Health Statistics CfDCaPC, REL EST; Newhouse JP, 2003, HEALTH AFFAIR, V22, P126, DOI 10.1377/hlthaff.22.6.126; Pitts SR, 2014, ACAD EMERG MED, V21, P497, DOI 10.1111/acem.12375; Pitts SR, 2010, HEALTH AFFAIR, V29, P1620, DOI 10.1377/hlthaff.2009.1026; Raven MC, 2013, JAMA-J AM MED ASSOC, V309, P1145, DOI 10.1001/jama.2013.1948; Scholer SJ, 1996, ARCH PEDIAT ADOL MED, V150, P1154, DOI 10.1001/archpedi.1996.02170360044006; Smith CD, 2012, ANN INTERN MED, V157, P284, DOI 10.7326/0003-4819-157-4-201208210-00496; Zaman O. S., 2010, AM SAFETY NET HOSP H	24	26	26	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	2014	312	22					2394	2400		10.1001/jama.2014.16172	http://dx.doi.org/10.1001/jama.2014.16172			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AW5YB	25490330	Bronze			2023-01-03	WOS:000346345700014
J	Davis, JS; He, V; Anstey, NM; Condon, JR				Davis, Joshua S.; He, Vincent; Anstey, Nicholas M.; Condon, John R.			Long Term Outcomes Following Hospital Admission for Sepsis Using Relative Survival Analysis: A Prospective Cohort Study of 1,092 Patients with 5 Year Follow Up	PLOS ONE			English	Article							INTENSIVE-CARE-UNIT; ENDOTHELIAL DYSFUNCTION; ORGAN DYSFUNCTION; IMMUNOSUPPRESSION; RESUSCITATION; EPIDEMIOLOGY; INFLAMMATION; MULTICENTER; PNEUMONIA; EFFICACY	Background: Sepsis is a leading cause of death in intensive care units and is increasing in incidence. Current trials of novel therapeutic approaches for sepsis focus on 28-day mortality as the primary outcome measure, but excess mortality may extend well beyond this time period. Methods: We used relative survival analysis to examine excess mortality in a cohort of 1,028 patients admitted to a tertiary referral hospital with sepsis during 2007-2008, over the first 5 years of follow up. Expected survival was estimated using the Ederer II method, using Australian life tables as the reference population. Cumulative and interval specific relative survival were estimated by age group, sex, sepsis severity and Indigenous status. Results: Patients were followed for a median of 4.5 years (range 0-5.2). Of the 1028 patients, the mean age was 46.9 years, 52% were male, 228 (22.2%) had severe sepsis and 218 (21%) died during the follow up period. Mortality based on cumulative relative survival exceeded that of the reference population for the first 2 years post admission in the whole cohort and for the first 3 years in the subgroup with severe sepsis. Independent predictors of mortality over the whole follow up period were male sex, Indigenous Australian ethnicity, older age, higher Charlson Comorbidity Index, and sepsis-related organ dysfunction at presentation. Conclusions: The mortality rate of patients hospitalised with sepsis exceeds that of the general population until 2 years post admission. Efforts to improve outcomes from sepsis should examine longer term outcomes than the traditional primary endpoints of 28-day and 90-day mortality.	[Davis, Joshua S.; He, Vincent; Anstey, Nicholas M.; Condon, John R.] Charles Darwin Univ, Menzies Sch Hlth Res, Darwin, NT 0909, Australia; [Davis, Joshua S.; Anstey, Nicholas M.] Royal Darwin Hosp, Dept Infect Dis, Darwin, NT, Australia	Charles Darwin University; Menzies School of Health Research	Davis, JS (corresponding author), Charles Darwin Univ, Menzies Sch Hlth Res, Darwin, NT 0909, Australia.	Joshua.Davis@menzies.edu.au	Condon, John R/N-2281-2013; Davis, Joshua/N-2288-2013	Condon, John R/0000-0003-4952-0990; Davis, Joshua/0000-0001-9864-5699	National Health and Medical Research Council [1013411, 1042072, 496600]; University Postgraduate Research Scholarship from Charles Darwin University	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); University Postgraduate Research Scholarship from Charles Darwin University	The study was supported by the National Health and Medical Research Council: Early Career Fellowship # 1013411 to JSD and Practitioner Fellowship(1042072) and Program Grant (496600) to NMA. VH was supported by University Postgraduate Research Scholarship from Charles Darwin University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABRAHAM E, 1995, JAMA-J AM MED ASSOC, V273, P934, DOI 10.1001/jama.273.12.934; Aird WC, 2003, BLOOD, V101, P3765, DOI 10.1182/blood-2002-06-1887; Alberti C, 2003, AM J RESP CRIT CARE, V168, P77, DOI 10.1164/rccm.200208-785OC; Angus Derek C., 2006, Endocrine Metabolic & Immune Disorders-Drug Targets, V6, P207; Baker C H, 1994, J Fla Med Assoc, V81, P119; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Boomer JS, 2011, JAMA-J AM MED ASSOC, V306, P2594, DOI 10.1001/jama.2011.1829; CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1245, DOI 10.1016/0895-4356(94)90129-5; Davis JS, 2011, MED J AUSTRALIA, V194, P519, DOI 10.5694/j.1326-5377.2011.tb03088.x; Davis JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017260; Davis JS, 2010, CRIT CARE, V14, DOI 10.1186/cc9020; Davis JS, 2009, CRIT CARE, V13, DOI 10.1186/cc8055; Dent OF, 2009, ANN SURG, V249, P402, DOI 10.1097/SLA.0b013e31819a0469; Dick A, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-432; Dickman PW, 2004, STAT MED, V23, P51, DOI 10.1002/sim.1597; Dickman PW, 2009, STATA J; Eerola H, 2001, INT J CANCER, V93, P368, DOI 10.1002/ijc.1341; Esteban A, 2007, CRIT CARE MED, V35, P1284, DOI 10.1097/01.CCM.0000260960.94300.DE; Feigin VL, 2002, CEREBROVASC DIS, V13, P219, DOI 10.1159/000057846; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Ghelani D, 2009, J EVAL CLIN PRACT, V15, P425, DOI 10.1111/j.1365-2753.2008.01030.x; Hack CE, 2001, CRIT CARE MED, V29, pS21, DOI 10.1097/00003246-200107001-00011; Halcox JPJ, 2002, CIRCULATION, V106, P653, DOI 10.1161/01.CIR.0000025404.78001.D8; HOLLENBERG SM, 1994, J CRIT CARE, V9, P262, DOI 10.1016/0883-9441(94)90006-X; Karlsson S, 2009, CRIT CARE MED, V37, P1268, DOI 10.1097/CCM.0b013e31819c13ac; Kellum JA, 2007, ARCH INTERN MED, V167, P1655, DOI 10.1001/archinte.167.15.1655; Lambert PC, 2009, STATA J, V9, P265, DOI 10.1177/1536867X0900900206; Leentjens J, 2013, AM J RESP CRIT CARE, V187, P1287, DOI 10.1164/rccm.201301-0036CP; Lemay AC, 2013, AM J MED SCI; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; Ollendorf DA, 2002, VALUE HEALTH, V5, P79, DOI 10.1046/j.1524-4733.2002.52013.x; Peake SL, 2009, RESUSCITATION, V80, P811, DOI 10.1016/j.resuscitation.2009.03.008; Quartin AA, 1997, JAMA-J AM MED ASSOC, V277, P1058, DOI 10.1001/jama.277.13.1058; Rubulotta F, 2009, CRIT CARE MED, V37, P1329, DOI 10.1097/CCM.0b013e31819d5db1; Scoll BJ, 2009, J UROLOGY, V181, P506, DOI 10.1016/j.juro.2008.10.026; Storgaard M, 2013, SCAND J INFECT DIS; Vincent JL, 2004, CRIT CARE MED, V32, pS209, DOI 10.1097/01.CCM.0000126124.41743.86; Winters BD, 2010, CRIT CARE MED, V38, P1276, DOI 10.1097/CCM.0b013e3181d8cc1d	39	35	35	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 8	2014	9	12							e112224	10.1371/journal.pone.0112224	http://dx.doi.org/10.1371/journal.pone.0112224			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX4MX	25486241	Green Published, gold, Green Submitted			2023-01-03	WOS:000346907600008
J	Richardson, SJ; Brooks, HL; Bramley, G; Coleman, JJ				Richardson, Suzanna J.; Brooks, Hannah L.; Bramley, George; Coleman, Jamie J.			Evaluating the Effectiveness of Self-Administration of Medication (SAM) Schemes in the Hospital Setting: A Systematic Review of the Literature	PLOS ONE			English	Review							PATIENT EDUCATION; TEACHING PROGRAM; DRUG COMPLIANCE; CARE; QUALITY; SATISFACTION; INPATIENTS; MEDICINES; KNOWLEDGE; ERROR	Background: Self-administration of medicines is believed to increase patients' understanding about their medication and to promote their independence and autonomy in the hospital setting. The effect of inpatient self-administration of medication (SAM) schemes on patients, staff and institutions is currently unclear. Objective: To systematically review the literature relating to the effect of SAM schemes on the following outcomes: patient knowledge, patient compliance/medication errors, success in self-administration, patient satisfaction, staff satisfaction, staff workload, and costs. Design: Keyword and text word searches of online databases were performed between January and March 2013. Included articles described and evaluated inpatient SAM schemes. Case studies and anecdotal studies were excluded. Results: 43 papers were included for final analysis. Due to the heterogeneity of results and unclear findings it was not possible to perform a quantitative synthesis of results. Participation in SAM schemes often led to increased knowledge about drugs and drug regimens, but not side effects. However, the effect of SAM schemes on patient compliance/medication errors was inconclusive. Patients and staff were highly satisfied with their involvement in SAM schemes. Conclusions: SAM schemes appear to provide some benefits (e.g. increased patient knowledge), but their effect on other outcomes (e.g. compliance) is unclear. Few studies of high methodological quality using validated outcome measures exist. Inconsistencies in both measuring and reporting outcomes across studies make it challenging to compare results and draw substantive conclusions about the effectiveness of SAM schemes.	[Richardson, Suzanna J.; Brooks, Hannah L.; Coleman, Jamie J.] Univ Hosp Birmingham NHS Fdn Trust, Birmingham B15 2WB, W Midlands, England; [Bramley, George] Univ Birmingham, Sch Hlth & Populat Sci, Birmingham B15 2TT, W Midlands, England; [Coleman, Jamie J.] Univ Birmingham, Coll Med & Dent Sci, Sch Clin & Expt Med, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Birmingham; University of Birmingham	Coleman, JJ (corresponding author), Univ Hosp Birmingham NHS Fdn Trust, Birmingham B15 2WB, W Midlands, England.	j.j.coleman@bham.ac.uk		Bramley, George/0000-0002-3224-1904; Coleman, Jamie/0000-0002-7512-5153	National Institute for Health Research (NIHR) through the Collaborations for Leadership in Applied Health Research and Care for Birmingham and Black Country (CLAHRC-BBC) programme	National Institute for Health Research (NIHR) through the Collaborations for Leadership in Applied Health Research and Care for Birmingham and Black Country (CLAHRC-BBC) programme(National Institute for Health Research (NIHR))	This work was funded by the National Institute for Health Research (NIHR) through the Collaborations for Leadership in Applied Health Research and Care for Birmingham and Black Country (CLAHRC-BBC) programme. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Diabetes Association, 2004, INSULIN ADM DIABETES, V27, ps106; Arpin M, 2007, CAN J HOSP PHARM, V60, P19; Banerjee M, 1999, CAN J STAT, V27, P3, DOI 10.2307/3315487; Barber N, 2002, QUAL SAF HEALTH CARE, V11, P81, DOI 10.1136/qhc.11.1.81; Barry K, 1993, J Nurs Care Qual, V8, P75; BEARDSLEY RS, 1982, CONTEMP PHARM PRACT, V5, P156; Bird C, 1990, Nurs Times, V86, P52; Bream S, 1985, Nurs Times, V81, P32; Buchanan E C, 1972, Am J Hosp Pharm, V29, P928; Buetow S, 2009, ANN FAM MED, V7, P223, DOI 10.1370/afm.941; Burrell G, 1998, J ORTHOPAEDIC NURSIN, V2, P136, DOI DOI 10.1016/S1361-3111(98)80028-9; Carter F, 1999, WORLD IR NURS, V7, P18; COLE P, 1971, AM J HOSP PHARM, V28, P954, DOI 10.1093/ajhp/28.12.954; Coleman JJ, 2013, EVALUATING EFFECTIVE; Collingsworth S, 1997, INT J NURS STUD, V34, P256, DOI 10.1016/S0020-7489(97)00013-8; Deeks PA, 2000, J ADV NURS, V31, P395, DOI 10.1046/j.1365-2648.2000.01286.x; DeProspero T, 1997, PSYCHIATR SERV, V48, P1468; Desborough JAC, 2009, INT J PHARM PRACTICE, pB49; Deshpande Amol, 2009, Open Med, V3, pe69; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Elliott Rohan A, 2009, BMC Geriatr, V9, P27, DOI 10.1186/1471-2318-9-27; Ferner RE, 2006, DRUG SAFETY, V29, P1011, DOI 10.2165/00002018-200629110-00001; Foster M, 1993, AGE AGEING S3, V22, P65; Fuller D, 1995, Prof Nurse, V10, P315; Furlong S, 1996, J ADV NURS, V23, P1254, DOI 10.1046/j.1365-2648.1996.11925.x; Gangopadhyaya KK, 2008, PRACTICAL DIABETES I, V25, P96; George J, 2006, PATIENT EDUC COUNS, V64, P50, DOI 10.1016/j.pec.2005.11.010; Grantham G, 2006, J CLIN NURS, V15, P962, DOI 10.1111/j.1365-2702.2006.01398.x; Hannay D G, 1977, Hosp Adm Can, V19, P36; Hill P, 1992, CARE ELDERLY, V4, P405; Hoffmann R P, 1978, Hosp Pharm, V13, P130; Jensen Louise, 2003, Can J Cardiovasc Nurs, V13, P35; KALLAS KD, 1984, J NURS ADMIN, V14, P38; KLEIN RH, 1974, J NERV MENT DIS, V158, P450, DOI 10.1097/00005053-197406000-00009; Lam P, 2011, J CLIN PHARM THER, V36, P80, DOI 10.1111/j.1365-2710.2009.01157.x; LOWE CJ, 1995, BRIT MED J, V310, P1229, DOI 10.1136/bmj.310.6989.1229; Lugg S, 1997, PSYCHIAT CARE, V4, P225; Macauley C, 1980, Geriatr Nurs, V1, P109; Morton S, 2013, BRIT J SPORTS MED; National Institute for Health and Care Excellence, 2012, SINGL COMP FRAM ALL; National Prescribing Centre, 2008, SERV IMPR GUID SELF; NEWCOMER DR, 1974, DRUG INTEL CLIN PHAR, V8, P374, DOI 10.1177/106002807400800602; Ng T, 1996, CAN J HOSP PHARM, V49, P80; Noy K, 1997, BRIT J NURSING, V6, P368; PARNELL MA, 1959, AM J NURS, V59, P1417, DOI 10.2307/3418020; Pearce M, 1991, NZ PHARM, V11, P18; Pelletier R D, 1983, Hosp Pharm, V18, P86; Pereles L, 1996, J AM GERIATR SOC, V44, P161, DOI 10.1111/j.1532-5415.1996.tb02433.x; Proos M, 1992, J Nurs Care Qual, VSuppl, P18; REIBEL EM, 1969, NURS RES, V18, P65; ROBERTS CJ, 1972, DRUG INTEL CLIN PHAR, V6, P408, DOI 10.1177/106002807200601202; Royal Pharmaceutical Society, 2005, SAF SEC HANDL MED TE; Samoocha D, 2010, J MED INTERNET RES, V12; Stewart D, 2010, INT J PHARM PRACTICE, V18; Tan A., 2006, PHARM PRACTICE, V28, P231; TAYLOR MD, 1984, ARCH PHYS MED REHAB, V65, P612; The Society of Hospital Pharmacists of Australia, 2002, SHPA GUID SELF ADM M; THOMAS SG, 1983, HOSP FORMUL, V18, P871; Traiger GL, 1996, CRITICAL CARE NURSE, V17, P71; Tran T, 2011, ANN PHARMACOTHER, V45, P201, DOI 10.1345/aph.1P473; Trapp M, 1998, Prof Nurse, V14, P199; VANCAMPEN C, 1995, MED CARE RES REV, V52, P109, DOI 10.1177/107755879505200107; WANDLESS I, 1977, BMJ-BRIT MED J, V1, P359, DOI 10.1136/bmj.1.6057.359; Wong FYY, 2011, BMC HEALTH SERV RES, V11, P1; Wood SI, 1992, INT J PHARM PRAC, V1, P240; WOODS JR, 1988, MED CARE, V26, P596, DOI 10.1097/00005650-198806000-00008; Wright J, 2006, PHARM WORLD SCI, V28, P140, DOI 10.1007/s11096-006-9014-x	67	29	31	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2014	9	12							e113912	10.1371/journal.pone.0113912	http://dx.doi.org/10.1371/journal.pone.0113912			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AU8TQ	25463269	gold, Green Published, Green Submitted			2023-01-03	WOS:000345869700068
J	Kurapati, KRV; Samikkannu, T; Atluri, VSR; Kaftanovskaya, E; Yndart, A; Nair, MPN				Kurapati, Kesava Rao Venkata; Samikkannu, Thangavel; Atluri, Venkata Subba Rao; Kaftanovskaya, Elena; Yndart, Adriana; Nair, Madhavan P. N.			beta-Amyloid(1-42), HIV-1(Ba-L) (Clade B) Infection and Drugs of Abuse Induced Degeneration in Human Neuronal Cells and Protective Effects of Ashwagandha (Withania somnifera) and Its Constituent Withanolide A	PLOS ONE			English	Article							AMYLOID BETA-PROTEIN; ALZHEIMERS-DISEASE; IN-VITRO; NEUROCOGNITIVE DISORDERS; MEDICINAL-PLANTS; ROOT EXTRACT; PEPTIDE; NEURODEGENERATION; AGGREGATION; DEPOSITION	Alzheimer's disease (AD) is characterized by progressive dysfunction of memory and higher cognitive functions with abnormal accumulation of extracellular amyloid plaques and intracellular neurofibrillary tangles throughout cortical and limbic brain regions. Withania somnifera (WS) also known as ` ashwagandha' (ASH) is used widely in Ayurvedic medicine as a nerve tonic and memory enhancer. However, there is paucity of data on potential neuroprotective effects of ASH against bAmyloid (1-42) (Ab) induced neuropathogenesis. In the present study, we have tested the neuroprotective effects of Methanol: Chloroform (3: 1) extract of ASH and its constituent Withanolide A (WA) against Ab induced toxicity, HIV-1(Ba-L) (clade B) infection and the effects of drugs of abuse using a human neuronal SK-N-MC cell line. Ab when tested individually, induced cytotoxic effects in SK-N-MC cells as shown by increased trypan blue stained cells. However, when ASH was added to Ab treated cells the toxic effects were neutralized. This observation was supported by cellular localization of Ab, MTT formazan exocytosis, and the levels of acetylcholinesterase activity, confirming the chemopreventive or protective effects of ASH against Ab induced toxicity. Further, the levels of MAP2 were significantly increased in cells infected with HIV-1(Ba-L) (clade B) as well as in cells treated with Cocaine (COC) and Methamphetamine (METH) compared with control cells. In ASH treated cells the MAP2 levels were significantly less compared to controls. Similar results were observed in combination experiments. Also, WA, a purified constituent of ASH, showed same pattern using MTT assay as a parameter. These results suggests that neuroprotective properties of ASH observed in the present study may provide some explanation for the ethnopharmacological uses of ASH in traditional medicine for cognitive and other HIV associated neurodegenerative disorders and further ASH could be a potential novel drug to reduce the brain amyloid burden and/or improve the HIV-1 associated neurocognitive impairments	[Kurapati, Kesava Rao Venkata; Samikkannu, Thangavel; Atluri, Venkata Subba Rao; Yndart, Adriana; Nair, Madhavan P. N.] Florida Int Univ, Herbert Wertheim Coll Med, Inst NeuroImmune Pharmacol, Dept Immunol, Modesto A Maidique Campus, Miami, FL 33199 USA; [Kaftanovskaya, Elena] Florida Int Univ, Herbert Wertheim Coll Med, Miami, FL 33199 USA	State University System of Florida; Florida International University; State University System of Florida; Florida International University	Nair, MPN (corresponding author), Florida Int Univ, Herbert Wertheim Coll Med, Inst NeuroImmune Pharmacol, Dept Immunol, Modesto A Maidique Campus, Miami, FL 33199 USA.	nairm@fiu.edu	Atluri, Venkata/G-3277-2014	Atluri, Venkata/0000-0002-8070-6745	National Institutes Health [1R01MH085259, 1RO37DA025576, 5RO1DA021537, 1RO1DA027049]; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH085259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA025576, R01DA021537, R01DA027049] Funding Source: NIH RePORTER	National Institutes Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	Funding: This study was supported by grants from the National Institutes Health (1R01MH085259, 1RO37DA025576, 5RO1DA021537, and 1RO1DA027049 to Prof. Madhavan Nair). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Achim CL, 2009, J NEUROIMMUNE PHARM, V4, P190, DOI 10.1007/s11481-009-9152-8; Archana R, 1999, J ETHNOPHARMACOL, V64, P91, DOI 10.1016/S0378-8741(98)00107-X; Atluri VSR, 2014, AUSTIN J DRUG ABUSE, V1, P1; Bertram L, 2010, NEURON, V68, P270, DOI 10.1016/j.neuron.2010.10.013; BURDICK D, 1992, J BIOL CHEM, V267, P546; Citron M, 2004, NAT REV NEUROSCI, V5, P677, DOI 10.1038/nrn1495; Citron M, 2010, NAT REV DRUG DISCOV, V9, P387, DOI 10.1038/nrd2896; Eckman EA, 2001, J BIOL CHEM, V276, P24540, DOI 10.1074/jbc.M007579200; Esiri MM, 1998, J NEUROL NEUROSUR PS, V65, P29, DOI 10.1136/jnnp.65.1.29; Gatta LB, 2002, NEUROREPORT, V13, P2031, DOI 10.1097/00001756-200211150-00008; Giunta B, 2011, MOL BRAIN, V4, DOI 10.1186/1756-6606-4-23; Green DA, 2005, AIDS, V19, P407, DOI 10.1097/01.aids.0000161770.06158.5c; Griciuc A, 2013, NEURON, V78, P631, DOI 10.1016/j.neuron.2013.04.014; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Hardy J, 2006, NEURON, V52, P3, DOI 10.1016/j.neuron.2006.09.016; Hu JG, 2001, J BIOL CHEM, V276, P47863, DOI 10.1074/jbc.M104068200; Isobe I, 1999, NEUROSCI LETT, V266, P129, DOI 10.1016/S0304-3940(99)00282-7; IVERSEN LL, 1995, BIOCHEM J, V311, P1; Jain S, 2001, PHYTOTHER RES, V15, P544, DOI 10.1002/ptr.802; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; Kuboyama T, 2005, BRIT J PHARMACOL, V144, P961, DOI 10.1038/sj.bjp.0706122; Kulkarni SK, 2008, PROG NEURO-PSYCHOPH, V32, P1093, DOI 10.1016/j.pnpbp.2007.09.011; Kumar S, 2010, PHYTOTHER RES, V24, P1567, DOI 10.1002/ptr.3261; Kumar V, 2006, PHYTOTHER RES, V20, P1023, DOI 10.1002/ptr.1970; Kurapati KRV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077624; London JA, 1996, P NATL ACAD SCI USA, V93, P4147, DOI 10.1073/pnas.93.9.4147; Melo JB, 2003, NEUROSCI RES, V45, P117, DOI 10.1016/S0168-0102(02)00201-8; Michaelis ML, 2005, J PHARMACOL EXP THER, V312, P659, DOI 10.1124/jpet.104.074450; Mishra L C, 2000, Altern Med Rev, V5, P334; Ohyagi Y, 2005, FASEB J, V19, P255, DOI 10.1096/fj.04-2637fje; Ohyagi Y, 2008, CURR ALZHEIMER RES, V5, P555, DOI 10.2174/156720508786898514; Ohyagi Y, 2006, MINI-REV MED CHEM, V6, P1075, DOI 10.2174/138955706778560175; Patil S, 2007, EUR J NEUROSCI, V26, P2131, DOI 10.1111/j.1460-9568.2007.05797.x; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Prabhulkar S, 2012, J NEUROCHEM, V122, P374, DOI 10.1111/j.1471-4159.2012.07709.x; Rempel HC, 2005, AIDS, V19, P127, DOI 10.1097/00002030-200501280-00004; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Sankar SR, 2007, CELL MOL BIOL LETT, V12, P473, DOI 10.2478/s11658-007-0015-0; Scartezzini P, 2000, J ETHNOPHARMACOL, V71, P23, DOI 10.1016/S0378-8741(00)00213-0; Sehgal N, 2012, P NATL ACAD SCI USA, V109, P3510, DOI 10.1073/pnas.1112209109; SHEARMAN MS, 1994, P NATL ACAD SCI USA, V91, P1470, DOI 10.1073/pnas.91.4.1470; Shirotani K, 2001, J BIOL CHEM, V276, P21895, DOI 10.1074/jbc.M008511200; Soltani MH, 2005, AM J PATHOL, V166, P1841, DOI 10.1016/S0002-9440(10)62493-5; Soontornniyomkij V, 2012, AIDS, V26, P2327, DOI 10.1097/QAD.0b013e32835a117c; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; Tohda C, 2000, NEUROREPORT, V11, P1981, DOI 10.1097/00001756-200006260-00035; Van Nostrand WE, 1999, BIOCHEMISTRY-US, V38, P11570, DOI 10.1021/bi990610f; Vinutha B, 2007, J ETHNOPHARMACOL, V109, P359, DOI 10.1016/j.jep.2006.06.014; Williams P, 2011, NAT PROD REP, V28, P48, DOI 10.1039/c0np00027b; Wogulis M, 2005, J NEUROSCI, V25, P1071, DOI 10.1523/JNEUROSCI.2381-04.2005; Xu JQ, 2009, J NEUROIMMUNE PHARM, V4, P200, DOI 10.1007/s11481-008-9136-0; Yan P, 2006, J BIOL CHEM, V281, P24566, DOI 10.1074/jbc.M602440200; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; Zhang C, 2012, Curr Alzheimer Res; Zhao J, 2002, CHEM PHARM BULL, V50, P760, DOI 10.1248/cpb.50.760	56	24	25	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 21	2014	9	11							e112818	10.1371/journal.pone.0112818	http://dx.doi.org/10.1371/journal.pone.0112818			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX4MM	25415340	Green Published, gold			2023-01-03	WOS:000346906600017
J	Swerdloff, R; Anawalt, BD				Swerdloff, Ronald; Anawalt, Bradley D.			Testosterone-Replacement Therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CARDIOVASCULAR-DISEASE; MEN		[Swerdloff, Ronald] Harbor UCLA Med Ctr, Los Angeles, CA 90502 USA; [Anawalt, Bradley D.] Univ Washington, Med Ctr, Dept Med, Seattle, WA 98195 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Washington; University of Washington Seattle	Swerdloff, R (corresponding author), Harbor UCLA Med Ctr, Los Angeles, CA 90502 USA.		Anawalt, Bradley D./AAW-3316-2020	Anawalt, Bradley D./0000-0003-2652-4032				Bhasin S, 2010, J CLIN ENDOCR METAB, V95, P2536, DOI 10.1210/jc.2009-2354; Finkelstein JS, 2013, NEW ENGL J MED, V369, P1011, DOI 10.1056/NEJMoa1206168; Layton JB, 2014, J CLIN ENDOCR METAB, V99, P835, DOI 10.1210/jc.2013-3570; Fernandez-Balsells MM, 2010, J CLIN ENDOCR METAB, V95, P2560, DOI 10.1210/jc.2009-2575; Page ST, 2014, LANCET DIABETES ENDO, V2, P609, DOI 10.1016/S2213-8587(14)70082-8; Wang C, 2011, DIABETES CARE, V34, P1669, DOI 10.2337/dc10-2339; Wu FCW, 2010, NEW ENGL J MED, V363, P123, DOI 10.1056/NEJMoa0911101	7	14	14	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 20	2014	371	21					2032	2034		10.1056/NEJMclde1406595	http://dx.doi.org/10.1056/NEJMclde1406595			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AT5ST	25409377				2023-01-03	WOS:000345002900016
J	Slovick, A; Durham, SR; Till, SJ				Slovick, Anna; Durham, Stephen R.; Till, Stephen J.			Grass pollen immunotherapy for treatment of allergic rhinitis	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							SUBLINGUAL IMMUNOTHERAPY; EFFICACY; SAFETY; CHILDREN; TABLETS		[Slovick, Anna; Till, Stephen J.] Kings Coll London, Guys Hosp, Sch Med, Div Asthma Allergy & Lung Biol, London SE1 9RT, England; [Durham, Stephen R.] Univ London Imperial Coll Sci Technol & Med, Fac Med, Natl Heart & Lung Inst, Sect Allergy & Clin Immunol, London SW3 6LY, England; [Till, Stephen J.] Guys & St Thomas NHS Fdn Trust, Dept Allergy, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Imperial College London; Guy's & St Thomas' NHS Foundation Trust	Till, SJ (corresponding author), Kings Coll London, Guys Hosp, Sch Med, Div Asthma Allergy & Lung Biol, London SE1 9RT, England.	stephen.till@kcl.ac.uk		Till, Stephen/0000-0003-4518-3093				[Anonymous], 1986, Br Med J (Clin Res Ed), V293, P948; Blaiss M, 2011, J ALLERGY CLIN IMMUN, V127, P64, DOI 10.1016/j.jaci.2010.11.034; Brozek JL, 2010, J ALLERGY CLIN IMMUN, V126, P466, DOI 10.1016/j.jaci.2010.06.047; Calderon MA, 2007, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD001936.PUB2; Cox L, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1016/j.jaci.2010.09.034; Dahl R, 2008, J ALLERGY CLIN IMMUN, V121, P512, DOI 10.1016/j.jaci.2007.10.039; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; de Groot H, 2009, ALLERGY, V64, P963, DOI 10.1111/j.1398-9995.2009.01998.x; Devillier P, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-71; Durham SR, 2007, ALLERGY, V62, P954, DOI 10.1111/j.1398-9995.2007.01402.x; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 2012, J ALLERGY CLIN IMMUN, V129, P717, DOI 10.1016/j.jaci.2011.12.973; Eifan AO, 2007, ALLERGY, V62, P567, DOI 10.1111/j.1398-9995.2006.01301.x; Francis JN, 2008, J ALLERGY CLIN IMMUN, V121, P1120, DOI 10.1016/j.jaci.2008.01.072; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; Javeed N, 1996, CATHETER CARDIO DIAG, V39, P383, DOI 10.1002/(SICI)1097-0304(199612)39:4<383::AID-CCD13>3.3.CO;2-G; Kiel MA, 2013, J ALLERGY CLIN IMMUN, V132, P353, DOI 10.1016/j.jaci.2013.03.013; LANG DM, 1991, ANN INTERN MED, V115, P270, DOI 10.7326/0003-4819-115-4-270; Matricardi PM, 2011, J ALLERGY CLIN IMMUN, V128, P791, DOI 10.1016/j.jaci.2011.03.049; Meadows A, 2013, HEALTH TECHNOL ASSES, V17, P1, DOI 10.3310/hta17270; National Institute for Health and Care Excellence, 2013, GUIDE TO THE METHODS; Nelson HS, 2011, J ALLERGY CLIN IMMUN, V127, P72, DOI 10.1016/j.jaci.2010.11.035; NOON L, 1955, Ann Allergy, V13, P713; Radulovic S, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002893.pub2; REID MJ, 1993, J ALLERGY CLIN IMMUN, V92, P6, DOI 10.1016/0091-6749(93)90030-J; Walker SM, 2011, CLIN EXP ALLERGY, V41, P1177, DOI 10.1111/j.1365-2222.2011.03794.x	26	2	2	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 17	2014	349								g6586	10.1136/bmj.g6586	http://dx.doi.org/10.1136/bmj.g6586			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AU2JX	25403477				2023-01-03	WOS:000345445500002
J	She, TT; Zhao, CK; Feng, JN; Wang, LX; Qu, LK; Fang, K; Cai, SQ; Shou, CC				She, Tiantian; Zhao, Chuanke; Feng, Junnan; Wang, Lixin; Qu, Like; Fang, Ke; Cai, Shaoqing; Shou, Chengchao			Sarsaparilla (Smilax Glabra Rhizome) Extract Inhibits Migration and Invasion of Cancer Cells by Suppressing TGF-beta 1 Pathway	PLOS ONE			English	Article							FOCAL ADHESION KINASE; AQUEOUS EXTRACT; TNF-ALPHA; GROWTH; HYPERSENSITIVITY; ARTHRITIS; TAXIFOLIN; DISTINCT; BETA; ID1	Sarsaparilla, also known as Smilax Glabra Rhizome (SGR), was shown to modulate immunity, protect against liver injury, lower blood glucose and suppress cancer. However, its effects on cancer cell adhesion, migration and invasion were unclear. In the present study, we found that the supernatant of water-soluble extract from SGR (SW) could promote adhesion, inhibit migration and invasion of HepG2, MDA-MB-231 and T24 cells in vitro, as well as suppress metastasis of MDA-MB-231 cells in vivo. Results of F-actin and vinculin dual staining showed the enhanced focal adhesion in SW-treated cells. Microarray analysis indicated a repression of TGF-beta 1 signaling by SW treatment, which was verified by real-time RT-PCR of TGF-beta 1-related genes and immunoblotting of TGFBR1 protein. SW was also shown to antagonize TGF-beta 1-promoted cell migration. Collectively, our study revealed a new antitumor function of Sarsaparilla in counteracting invasiveness of a subset of cancer cells by inhibiting TGF-beta 1 signaling.	[She, Tiantian; Zhao, Chuanke; Feng, Junnan; Wang, Lixin; Qu, Like; Fang, Ke; Shou, Chengchao] Peking Univ, Canc Hosp & Inst, Minist Educ, Key Lab Carcinogenesis & Translat Res, Beijing 100871, Peoples R China; [Cai, Shaoqing] Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing 100871, Peoples R China	Peking University; Peking University	Shou, CC (corresponding author), Peking Univ, Canc Hosp & Inst, Minist Educ, Key Lab Carcinogenesis & Translat Res, Beijing 100871, Peoples R China.	cshou@vip.sina.com			National Basic Research Program of China [2010CB529303, 2013CB910504]	National Basic Research Program of China(National Basic Research Program of China)	Funding was provided by the National Basic Research Program of China (2010CB529303, 2013CB910504), http://www.973.gov.cn/Default_3.aspx. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Bhattacharya R, 2010, J ONCOL, V2010, DOI 10.1155/2010/856105; Cai Y, 2003, J PHARM PHARMACOL, V55, P691, DOI 10.1211/002235703765344612; Casaschi A, 2004, ATHEROSCLEROSIS, V176, P247, DOI 10.1016/j.atherosclerosis.2004.05.020; Chen L, 2007, J PHARMACEUT BIOMED, V43, P1715, DOI 10.1016/j.jpba.2007.01.007; Drumm ML, 2012, ANNU REV PATHOL-MECH, V7, P267, DOI 10.1146/annurev-pathol-011811-120900; Fei MJ, 2005, J ALLERGY CLIN IMMUN, V116, P1350, DOI 10.1016/j.jaci.2005.08.032; Gao YJ, 2011, TOXICOL LETT, V207, P112, DOI 10.1016/j.toxlet.2011.08.024; Gardel ML, 2010, ANNU REV CELL DEV BI, V26, P315, DOI [doi: 10.1146/annu rev. cellbio.011209.122036 PMID: 19575647, DOI 10.1146/ANNU]; Gunn J, 2013, BIOACT FOOD CHRON, P381, DOI 10.1016/B978-0-12-397153-1.00042-1; HASEGAWA K, 1994, J CELL PHYSIOL, V158, P215, DOI 10.1002/jcp.1041580202; Hellemans J, 2004, NAT GENET, V36, P1213, DOI 10.1038/ng1453; Huang JS, 2013, FREE RADICAL BIO MED, V65, P1246, DOI 10.1016/j.freeradbiomed.2013.09.011; Huttenlocher A, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005074; Iddamaldeniya S S, 2006, J Carcinog, V5, P11, DOI 10.1186/1477-3163-5-11; Jia LB, 2012, CHIN J INTEGR MED, V18, P325, DOI 10.1007/s11655-011-0950-5; Jiang JY, 2003, J ETHNOPHARMACOL, V85, P53, DOI 10.1016/S0378-8741(02)00340-9; Jiang JY, 1997, PHARMACOL RES, V36, P309, DOI 10.1006/phrs.1997.0234; Lange K, 2008, CANCER RES, V68, P6942, DOI 10.1158/0008-5472.CAN-08-0347; Leyton J, 2002, EUR J PHARMACOL, V442, P179, DOI 10.1016/S0014-2999(02)01539-X; Liang H.L.M., 2003, CHIN J INTEG TRADIT, V9, P157; Liang YY, 2009, CELL RES, V19, P140, DOI 10.1038/cr.2008.321; Liu GX, 2013, MOLECULES, V18, P5265, DOI [doi: 10.3390/ molecules18055265 PMID: 23698042, DOI 10.3390/M0LECULES18055265]; Ma F, 2010, WORLD J GASTROENTERO, V16, P5629, DOI 10.3748/wjg.v16.i44.5629; Majumdar A, 2012, NAT REV GASTRO HEPAT, V9, P530, DOI 10.1038/nrgastro.2012.114; Meng YG, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-75; O'Connor JW, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0083188, 10.1371/journal.pone.0080504]; Ren XD, 2000, J CELL SCI, V113, P3673; Sa F, 2008, CHEM-BIOL INTERACT, V171, P1, DOI 10.1016/j.cbi.2007.08.012; Sere K, 2012, IMMUNITY, V37, P905, DOI 10.1016/j.immuni.2012.07.019; Shi L, 2013, J ETHNOPHARMACOL, V150, P1038, DOI 10.1016/j.jep.2013.10.023; Tauber S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-200; Tewtrakul S, 2006, J ETHNOPHARMACOL, V105, P312, DOI 10.1016/j.jep.2005.11.021; Theriault A, 2000, J LIPID RES, V41, P1969; Tian HQ, 2010, CHIN J INTEGR MED, V16, P102, DOI 10.1007/s11655-010-0102-3; Tse TW, 2003, CLIN EXP DERMATOL, V28, P469, DOI 10.1046/j.1365-2230.2003.01322.x; Tsuchiya T, 2005, CANCER SCI, V96, P784, DOI 10.1111/j.1349-7006.2005.00113.x; Ulbricht C, 2001, NATURAL STANDARD DAT; Wang J, 2004, J PHARM PHARMACOL, V56, P495, DOI 10.1211/0022357023033; Wang XD, 2007, DIFFERENTIATION, V75, P219, DOI 10.1111/j.1432-0436.2006.00135.x; Wilson T, 2001, BIOL REPROD, V64, P1225, DOI 10.1095/biolreprod64.4.1225; Xu Q, 1999, EUR J PHARMACOL, V377, P93, DOI 10.1016/S0014-2999(99)00401-X; Yi HW, 2008, INT IMMUNOPHARMACOL, V8, P1467, DOI 10.1016/j.intimp.2008.06.006; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zhang GD, 2014, P NATL ACAD SCI USA, V111, P11127, DOI 10.1073/pnas.1410432111; Zheng ZG, 2013, J PHARMACEUT BIOMED, V77, P44, DOI 10.1016/j.jpba.2013.01.003	46	17	19	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 5	2015	10	3							e0118287	10.1371/journal.pone.0118287	http://dx.doi.org/10.1371/journal.pone.0118287			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC9KG	25742000	Green Published, gold, Green Submitted			2023-01-03	WOS:000350688100011
J	Farris, G				Farris, Grace			The library card	LANCET			English	Editorial Material									Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Farris, G (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA.	gfarris@bidmc.harvard.edu							0	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 28	2015	385	9970					766	767		10.1016/S0140-6736(15)60426-3	http://dx.doi.org/10.1016/S0140-6736(15)60426-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CC0UD	25752166				2023-01-03	WOS:000350051700017
J	Kong, SY; Park, MH; Lee, M; Kim, JO; Lee, HR; Han, BW; Svendsen, CN; Sung, SH; Kim, HJ				Kong, Sun-Young; Park, Min-Hye; Lee, Mina; Kim, Jae-Ouk; Lee, Ha-Rim; Han, Byung Woo; Svendsen, Clive N.; Sung, Sang Hyun; Kim, Hyun-Jung			Kuwanon V Inhibits Proliferation, Promotes Cell Survival and Increases Neurogenesis of Neural Stem Cells	PLOS ONE			English	Article							CULTIVATED MULBERRY TREE; CORTEX RADICIS MORACEAE; MORUS-ALBA L.; PROGENITOR CELLS; ROOT BARK; NEURONAL DIFFERENTIATION; PRENYLATED FLAVONOIDS; IN-VITRO; DEATH; PATHWAY	Neural stem cells (NSCs) have the ability to proliferate and differentiate into neurons and glia. Regulation of NSC fate by small molecules is important for the generation of a certain type of cell. The identification of small molecules that can induce new neurons from NSCs could facilitate regenerative medicine and drug development for neurodegenerative diseases. In this study, we screened natural compounds to identify molecules that are effective on NSC cell fate determination. We found that Kuwanon V (KWV), which was isolated from the mulberry tree (Morus bombycis) root, increased neurogenesis in rat NSCs. In addition, during NSC differentiation, KWV increased cell survival and inhibited cell proliferation as shown by 5-bromo-2-deoxyuridine pulse experiments, Ki67 immunostaining and neurosphere forming assays. Interestingly, KWV enhanced neuronal differentiation and decreased NSC proliferation even in the presence of mitogens such as epidermal growth factor and fibroblast growth factor 2. KWV treatment of NSCs reduced the phosphorylation of extracellular signal-regulated kinase 1/2, increased mRNA expression levels of the cyclin-dependent kinase inhibitor p21, down-regulated Notch/Hairy expression levels and up-regulated microRNA miR-9, miR-29a and miR-181a. Taken together, our data suggest that KWV modulates NSC fate to induce neurogenesis, and it may be considered as a new drug candidate that can regenerate or protect neurons in neurodegenerative diseases.	[Kong, Sun-Young; Park, Min-Hye; Lee, Ha-Rim; Kim, Hyun-Jung] Chung Ang Univ, Coll Pharm, Lab Mol & Stem Cell Pharmacol, Seoul 156756, South Korea; [Lee, Mina; Han, Byung Woo; Sung, Sang Hyun] Seoul Natl Univ, Coll Pharm, Seoul, South Korea; [Lee, Mina; Han, Byung Woo; Sung, Sang Hyun] Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul, South Korea; [Lee, Mina] Sunchon Natl Univ, Coll Pharm, Sunchon, Jeollanam Do, South Korea; [Kim, Jae-Ouk] Int Vaccine Inst, Div Sci Lab, Seoul, South Korea; [Svendsen, Clive N.] Cedars Sinai Med Ctr, Board Governors Regenerat Med Inst, Los Angeles, CA 90048 USA	Chung Ang University; Seoul National University (SNU); Seoul National University (SNU); Sunchon National University; International Vaccine Institute; Cedars Sinai Medical Center	Kim, HJ (corresponding author), Chung Ang Univ, Coll Pharm, Lab Mol & Stem Cell Pharmacol, Seoul 156756, South Korea.	hyunjungkim@cau.ac.kr			Chung-Ang University Research Scholarship; National Research Foundation [NRF-2014R1A1A1002607]	Chung-Ang University Research Scholarship; National Research Foundation	This research was supported by the Chung-Ang University Research Scholarship Grants in 2013 and the National Research Foundation (NRF-2014R1A1A1002607). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abematsu Masahiko, 2006, Curr Stem Cell Res Ther, V1, P267, DOI 10.2174/157488806776956887; Anacker C, 2011, MOL PSYCHIATR, V16, P738, DOI 10.1038/mp.2011.26; Boldrini M, 2009, NEUROPSYCHOPHARMACOL, V34, P2376, DOI 10.1038/npp.2009.75; Bonev B, 2012, CELL REPORTS, V2, P10, DOI 10.1016/j.celrep.2012.05.017; Cao XW, 2007, GENE DEV, V21, P531, DOI 10.1101/gad.1519207; Cavanagh JFR, 1997, CEREB CORTEX, V7, P293, DOI 10.1093/cercor/7.4.293; Chadwick W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021660; Chang DJ, 2011, BIOORG MED CHEM LETT, V21, P7050, DOI 10.1016/j.bmcl.2011.09.099; CHEN FJ, 1995, YAKUGAKU ZASSHI, V115, P476, DOI 10.1248/yakushi1947.115.6_476; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Coolen M, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00220; Dat NT, 2009, J NAT PROD, V72, P39, DOI 10.1021/np800491u; Du J, 2003, PHYTOCHEMISTRY, V62, P1235, DOI 10.1016/S0031-9422(02)00753-7; Duan P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097684; Duc MH, 2009, BIOORG MED CHEM LETT, V19, P6759, DOI 10.1016/j.bmcl.2009.09.102; Ebert AD, 2010, NAT REV DRUG DISCOV, V9, P1, DOI 10.1038/nrd3000; El-Beshbishy HA, 2006, LIFE SCI, V78, P2724, DOI 10.1016/j.lfs.2005.10.010; Encinas JM, 2006, P NATL ACAD SCI USA, V103, P8233, DOI 10.1073/pnas.0601992103; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Go HS, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-48; Ham A, 2012, PHYTOTHER RES, V26, P620, DOI 10.1002/ptr.3592; Hao YL, 2004, J NEUROSCI, V24, P6590, DOI 10.1523/JNEUROSCI.5747-03.2004; Hebert SS, 2008, P NATL ACAD SCI USA, V105, P6415, DOI 10.1073/pnas.0710263105; Hitoshi S, 2002, GENE DEV, V16, P846, DOI 10.1101/gad.975202; IKUTA J, 1986, CHEM PHARM BULL, V34, P2471; Jin YS, 2007, PHYTOTHER RES, V21, P605, DOI 10.1002/ptr.2121; Johnson R, 2008, NEUROBIOL DIS, V29, P438, DOI 10.1016/j.nbd.2007.11.001; Jung GA, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-66; Kim HJ, 2007, EXP NEUROL, V203, P394, DOI 10.1016/j.expneurol.2006.08.029; Kim HJ, 2010, ARCH PHARM RES, V33, P1355, DOI 10.1007/s12272-010-0909-7; Kim HJ, 2009, J NEUROCHEM, V110, P1226, DOI 10.1111/j.1471-4159.2009.06212.x; Kim HJ, 2012, KOREAN J PHYSIOL PHA, V16, P1, DOI 10.4196/kjpp.2012.16.1.1; Kim HJ, 2011, BBA-MOL BASIS DIS, V1812, P1, DOI 10.1016/j.bbadis.2010.08.006; Kim HJ, 2009, STEM CELLS, V27, P390, DOI 10.1634/stemcells.2007-1047; Kim SJ, 2008, J BIOL CHEM, V283, P14497, DOI 10.1074/jbc.M708373200; Kim W, 2013, KOREAN J PHYSIOL PHA, V17, P23, DOI 10.4196/kjpp.2013.17.1.23; Laeng P, 2004, J NEUROCHEM, V91, P238, DOI 10.1111/j.1471-4159.2004.02725.x; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lee HJ, 2012, ARCH PHARM RES, V35, P163, DOI 10.1007/s12272-012-0118-7; Lee HJ, 2011, ARCH PHARM RES, V34, P1373, DOI 10.1007/s12272-011-0818-4; Spohr TCLDE, 2010, J NEUROSCI RES, V88, P530, DOI 10.1002/jnr.22218; Liu JW, 2007, J NAT PROD, V70, P1329, DOI 10.1021/np070135j; Longo Frank M., 2006, Current Alzheimer Research, V3, P5, DOI 10.2174/156720506775697089; Louvi A, 2006, NAT REV NEUROSCI, V7, P93, DOI 10.1038/nrn1847; Ma DK, 2009, MOL BRAIN, V2, DOI 10.1186/1756-6606-2-16; Mancini M, 2012, AGING-US, V4, P843, DOI 10.18632/aging.100508; Marcussen AB, 2008, ACTA NEUROL SCAND, V117, P94, DOI 10.1111/j.1600-0404.2007.00910.x; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; NOMURA T, 1978, CHEM PHARM BULL, V26, P1394; Peng ZW, 2012, PROG NEURO-PSYCHOPH, V36, P183, DOI 10.1016/j.pnpbp.2011.08.014; Pieper AA, 2010, CELL, V142, P39, DOI 10.1016/j.cell.2010.06.018; Pouton CW, 2005, ADV DRUG DELIVER REV, V57, P1918, DOI 10.1016/j.addr.2005.08.003; Roshan R, 2014, RNA, V20, P1287, DOI 10.1261/rna.044008.113; Rosser AE, 1997, DEV BRAIN RES, V98, P291, DOI 10.1016/S0165-3806(96)00189-7; Saxe JP, 2007, CHEM BIOL, V14, P1019, DOI 10.1016/j.chembiol.2007.07.016; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Shenoy A, 2014, NAT REV MOL CELL BIO, V15, P565, DOI 10.1038/nrm3854; Shindler KS, 1997, J NEUROSCI, V17, P3112; Singa ANB, 2005, J ETHNOPHARMACOL, V100, P333, DOI 10.1016/j.jep.2005.03.013; Sohn HY, 2004, PHYTOMEDICINE, V11, P666, DOI 10.1016/j.phymed.2003.09.005; Sun AX, 2013, CURR OPIN CELL BIOL, V25, P215, DOI 10.1016/j.ceb.2012.12.007; Svendsen CN, 1998, J NEUROSCI METH, V85, P141, DOI 10.1016/S0165-0270(98)00126-5; Tan SL, 2012, GENES CELLS, V17, P952, DOI 10.1111/gtc.12009; Taupin Philippe, 2010, Recent Pat CNS Drug Discov, V5, P253, DOI 10.2174/157488910793362377; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; Visvanathan J, 2007, GENE DEV, V21, P744, DOI 10.1101/gad.1519107; Wang B, 2009, NEUROSCI LETT, V461, P252, DOI 10.1016/j.neulet.2009.06.020; Wen S, 2009, CELL ADHES MIGR, V3, P107, DOI 10.4161/cam.3.1.7602; Weng MS, 2011, J AGR FOOD CHEM, V59, P1031, DOI 10.1021/jf104263s; Wright LS, 2006, EXP CELL RES, V312, P2107, DOI 10.1016/j.yexcr.2006.03.012; Wurdak H, 2010, P NATL ACAD SCI USA, V107, P16542, DOI 10.1073/pnas.1010300107; Xu C, 2014, STEM CELLS, V32, P2961, DOI 10.1002/stem.1774; Yang WM, 2008, NEUROSCI LETT, V443, P104, DOI 10.1016/j.neulet.2008.07.020; Yoo DY, 2011, PHYTOTHER RES, V25, P809, DOI 10.1002/ptr.3337; Yoon HJ, 2013, BIOORGAN MED CHEM, V21, P7165, DOI 10.1016/j.bmc.2013.08.066; Zheng X, 2008, P NATL ACAD SCI USA, V105, P3368, DOI 10.1073/pnas.0711591105	76	33	34	0	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 23	2015	10	2							e0118188	10.1371/journal.pone.0118188	http://dx.doi.org/10.1371/journal.pone.0118188			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC9BI	25706719	gold, Green Submitted, Green Published			2023-01-03	WOS:000350662100150
J	Kieboom, JK; Verkade, HJ; Burgerhof, JG; Bierens, JJ; van Rheenen, PF; Kneyber, MC; Albers, MJ				Kieboom, J. K.; Verkade, H. J.; Burgerhof, J. G.; Bierens, J. J.; van Rheenen, P. F.; Kneyber, M. C.; Albers, M. J.			Outcome after resuscitation beyond 30 minutes in drowned children with cardiac arrest and hypothermia: Dutch nationwide retrospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACCIDENTAL HYPOTHERMIA; WATER TEMPERATURE; CARDIOPULMONARY BYPASS; SUBMERSION; EPIDEMIOLOGY; GUIDELINES; ASSOCIATION; MANAGEMENT; RESCUE	OBJECTIVES To evaluate the outcome of drowned children with cardiac arrest and hypothermia, and to determine distinct criteria for termination of cardiopulmonary resuscitation in drowned children with hypothermia and absence of spontaneous circulation. DESIGN Nationwide retrospective cohort study. SETTING Emergency departments and paediatric intensive care units of the eight university medical centres in the Netherlands. PARTICIPANTS Children aged up to 16 with cardiac arrest and hypothermia after drowning, who presented at emergency departments and/or were admitted to intensive care. MAIN OUTCOME MEASURE Survival and neurological outcome one year after the drowning incident. Poor outcome was defined as death or survival in a vegetative state or with severe neurological disability (paediatric cerebral performance category (PCPC) >= 4). RESULTS From 1993 to 2012, 160 children presented with cardiac arrest and hypothermia after drowning. In 98 (61%) of these children resuscitation was performed for more than 30 minutes (98/160, median duration 60 minutes), of whom 87 (89%) died (95% confidence interval 83% to 95%; 87/98). Eleven of the 98 children survived (11%, 5% to 17%), but all had a PCPC score >= 4. In the 62 (39%) children who did not require prolonged resuscitation, 17 (27%, 16% to 38%) survived with a PCPC score <= 3 after one year: 10 (6%) had a good neurological outcome (score 1), five (3%) had mild neurological disability (score 2), and two (1%) had moderate neurological disability (score 3). From the original 160 children, only 44 were alive at one year with any outcome. CONCLUSIONS Drowned children in whom return of spontaneous circulation is not achieved within 30 minutes of advanced life support have an extremely poor outcome. Good neurological outcome is more likely when spontaneous circulation returns within 30 minutes of advanced life support, especially when the drowning incident occurs in winter. These findings question the therapeutic value of resuscitation beyond 30 minutes in drowned children with cardiac arrest and hypothermia.	[Kieboom, J. K.; Verkade, H. J.; van Rheenen, P. F.; Kneyber, M. C.] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Dept Paediat, NL-9700 AB Groningen, Netherlands; [Burgerhof, J. G.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, NL-9700 AB Groningen, Netherlands; [Albers, M. J.] St Elizabeth Hosp, Dept Paediat, Tilburg, Netherlands	University of Groningen; University of Groningen; Elisabeth-TweeSteden Ziekenhuis (ETZ)	Kieboom, JK (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Dept Paediat, NL-9700 AB Groningen, Netherlands.	j.k.w.kieboom@umcg.nl	Bierens, Joost/AAW-8332-2020; Kneyber, Martin/AAV-8437-2020; Burgerhof, Johannes G/B-2455-2013	Bierens, Joost/0000-0003-4467-8211; Kneyber, Martin/0000-0002-6008-3376; Burgerhof, Johannes G/0000-0003-3827-9601; Verkade, Henkjan J/0000-0002-7034-2861; /0000-0003-3867-2665				Atkins DL, 2009, CIRCULATION, V119, P1484, DOI 10.1161/CIRCULATIONAHA.108.802678; BIERENS JJLM, 1990, ANN EMERG MED, V19, P1390, DOI 10.1016/S0196-0644(05)82604-6; Bierens Joost J L M, 2002, Curr Opin Crit Care, V8, P578, DOI 10.1097/00075198-200212000-00016; Bierens JJLM, 2013, RESUSCITATION, V84, P1467, DOI 10.1016/j.resuscitation.2013.09.005; BOHN DJ, 1986, CRIT CARE MED, V14, P529, DOI 10.1097/00003246-198606000-00002; Brown DJA, 2012, NEW ENGL J MED, V367, P1930, DOI 10.1056/NEJMra1114208; Brugger H, 2001, RESUSCITATION, V51, P7, DOI 10.1016/S0300-9572(01)00383-5; Corneli HM, 2012, PEDIATR EMERG CARE, V28, P475, DOI 10.1097/PEC.0b013e3182539098; Donoghue AJ, 2005, ANN EMERG MED, V46, P512, DOI 10.1016/j.annemergmed.2005.05.028; Dutch Government, LAWS REG; Dutch Ministry of Infrastructure and the Environment, DAT QUAL DUTCH SURF; Eich C, 2005, RESUSCITATION, V67, P145, DOI 10.1016/j.resuscitation.2005.05.002; Eich C, 2007, RESUSCITATION, V75, P42, DOI 10.1016/j.resuscitation.2007.03.013; Fallat ME, 2014, ANN EMERG MED, V63, P504, DOI 10.1016/j.annemergmed.2014.01.013; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Giesbrecht GG, 2000, AVIAT SPACE ENVIR MD, V71, P733; GRAF WD, 1995, ANN EMERG MED, V26, P312, DOI 10.1016/S0196-0644(95)70079-X; Idris AH, 2003, RESUSCITATION, V59, P45, DOI 10.1016/j.resuscitation.2003.09.003; KUISMA M, 1995, RESUSCITATION, V30, P141, DOI 10.1016/0300-9572(95)00888-Z; KYRIACOU DN, 1994, PEDIATRICS, V94, P137; Laosee Orapin C., 2012, Morbidity and Mortality Weekly Report, V61, P344; Layon AJ, 2009, ANESTHESIOLOGY, V110, P1390, DOI 10.1097/ALN.0b013e3181a4c3b8; Lee LK, 2006, ACAD EMERG MED, V13, P308, DOI 10.1197/j.aem.2005.10.012; Nitta M, 2013, RESUSCITATION, V84, P1568, DOI 10.1016/j.resuscitation.2013.06.017; ORLOWSKI JP, 1979, JACEP-J AM COLL EMER, V8, P176, DOI 10.1016/S0361-1124(79)80121-5; ORLOWSKI JP, 1987, PEDIATR CLIN N AM, V34, P75; ORLOWSKI JP, 1988, JAMA-J AM MED ASSOC, V260, P390, DOI 10.1001/jama.260.3.390; QUAN L, 1992, PEDIATRICS, V90, P909; Quan LD, 2014, RESUSCITATION, V85, P790, DOI 10.1016/j.resuscitation.2014.02.024; Royal Netherlands Meteorological Institute, CLIM SCEN; Ruttmann E, 2007, J THORAC CARDIOV SUR, V134, P594, DOI 10.1016/j.jtcvs.2007.03.049; Salomez F, 2004, RESUSCITATION, V63, P261, DOI 10.1016/j.resuscitation.2004.06.007; Sirbaugh PE, 1999, ANN EMERG MED, V33, P174, DOI 10.1016/S0196-0644(99)70391-4; Soar J, 2010, RESUSCITATION, V81, P1400, DOI 10.1016/j.resuscitation.2010.08.015; Suominen P, 2002, RESUSCITATION, V52, P247, DOI 10.1016/S0300-9572(01)00478-6; Suominen PK, 1997, RESUSCITATION, V35, P111, DOI 10.1016/S0300-9572(97)00036-1; Szpilman D, 2012, NEW ENGL J MED, V366, P2102, DOI 10.1056/NEJMra1013317; Tipton MJ, 2011, RESUSCITATION, V82, P819, DOI 10.1016/j.resuscitation.2011.02.021; Tipton M, 2013, RESUSCITATION, V84, pE31, DOI 10.1016/j.resuscitation.2012.08.339; Topjian AA, 2012, NEUROCRIT CARE, V17, P441, DOI 10.1007/s12028-012-9747-4; Veenhuizen L, 1994, Ned Tijdschr Geneeskd, V138, P906; Venema AM, 2010, RESUSCITATION, V81, P434, DOI 10.1016/j.resuscitation.2010.01.005; Wanscher M, 2012, RESUSCITATION, V83, P1078, DOI 10.1016/j.resuscitation.2012.05.009; World Health Organization, FACTSH DROWN	44	68	76	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 10	2015	350								h418	10.1136/bmj.h418	http://dx.doi.org/10.1136/bmj.h418			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CB0LU	25670715	Green Published, hybrid			2023-01-03	WOS:000349318400017
J	Kong, LW; Wu, JF; Lin, YH; Wang, GF; Wang, J; Liu, JQ; Chen, MX; Du, X; Sun, J; Lin, JP; Dong, JC				Kong, Lingwen; Wu, Jingfeng; Lin, Yanhua; Wang, Genfa; Wang, Jia; Liu, Jiaqi; Chen, Meixia; Du, Xin; Sun, Jing; Lin, Jinpei; Dong, Jingcheng			BuShenYiQi Granule Inhibits Atopic Dermatitis via Improving Central and Skin Hypothalamic -Pituitary -Adrenal Axis Function	PLOS ONE			English	Article							CORTICOTROPIN-RELEASING HORMONE; MAST-CELLS; HPA AXIS; ASTHMATIC-CHILDREN; IMMUNE-SYSTEM; MOUSE MODEL; STRESS; INFLAMMATION; RESPONSES; CRH	Background Dysfunction of central and skin Hypothalamic-Pituitary-Adrenal (HPA) axis play important roles in pathogenesis of atopic dermatitis (AD). Our previous studies showed that several Chinese herbs could improve HPA axis function. In this study, we evaluated the antiinflammatory effects of BuShenYiQi granule (BSYQ), a Chinese herbs formula, in AD mice and explored the effective mechanism from regulation of HPA axis. Methods The ovalbumin (OVA) induced AD mice model were established and treated with BSYQ. We evaluated dermatitis score and histology analysis of dorsal skin lesions, meanwhile, serum corticosterone (CORT), adrenocorticotropic hormone (ACTH), corticotropin-releasing hormone (CRH) and inflammatory cytokines were determined by ELISA. The changes of CRH/proopiomelanocortin(POMC) axis elements, corresponding functional receptors and crucial genes of glucocorticosteroidogenesis in the skin were measured by quantitative real-time PCR and western blot, respectively. Results The symptoms and pathological changes in skin of AD mice were significantly improved and several markers of inflammation and allergy descended obviously after BSYQ treatment. We found that AD mice had insufficient central HPA tone, but these conditions were markedly improved after BSYQ treatment. The AD mice also showed a disturbed expression of skin HPA. In lesion skin of AD mice, the mRNA and protein expressions of CRH decreased significantly, on the contrary, POMC and cytochrome P450 side-chain cleavage enzyme (CYP11A1) increased markedly, meanwhile, NR3C1 (mouse GR), CRHR2 and 11-hydroxylase type 1(CYP11B1) were reduced locally. Most of these tested indexes were improved after BSYQ treatment. Conclusions AD mice displayed the differential expression pattern of central and skin HPA axis and BSYQ treatment significantly alleviated the symptoms of AD mice and presented antiinflammatory and anti-allergic effects via regulating the expression of central and skin HPA axis.	[Kong, Lingwen; Lin, Yanhua; Wang, Genfa; Wang, Jia; Liu, Jiaqi; Chen, Meixia; Du, Xin; Sun, Jing; Lin, Jinpei; Dong, Jingcheng] Fudan Univ, Huashan Hosp, Dept Integrated Tradit Chinese & Western Med, Shanghai 200433, Peoples R China; [Kong, Lingwen; Lin, Yanhua; Wang, Genfa; Wang, Jia; Liu, Jiaqi; Chen, Meixia; Du, Xin; Sun, Jing; Lin, Jinpei; Dong, Jingcheng] Fudan Univ, Inst Integrated Tradit Chinese & Western Med, Shanghai 200433, Peoples R China; [Wu, Jingfeng] Fudan Univ, Huashan Hosp, Dept Dermatol, Shanghai 200433, Peoples R China	Fudan University; Fudan University; Fudan University	Dong, JC (corresponding author), Fudan Univ, Huashan Hosp, Dept Integrated Tradit Chinese & Western Med, Shanghai 200433, Peoples R China.	jcdong2004@126.com		Dong, Jingcheng/0000-0002-5194-367X; Du, Xin/0000-0002-9682-1211	National Basic Science Program of China [2009CB523000]; National Natural Science Foundation of China [81173390/H2902]	National Basic Science Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Basic Science Program of China (no. 2009CB523000) and the National Natural Science Foundation of China (no. 81173390/H2902). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Buske-Kirschbaum A, 2006, PSYCHONEUROENDOCRINO, V31, P439, DOI 10.1016/j.psyneuen.2005.10.006; Buske-Kirschbaum A, 2003, ANN NY ACAD SCI, V992, P231, DOI 10.1111/j.1749-6632.2003.tb03153.x; Buske-Kirschbaum A, 2010, BRAIN BEHAV IMMUN, V24, P1347, DOI 10.1016/j.bbi.2010.06.013; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; ELIAS PM, 1992, SEMIN DERMATOL, V11, P176; Gantz I, 2003, AM J PHYSIOL-ENDOC M, V284, pE468, DOI 10.1152/ajpendo.00434.2002; Gibb J, 2011, BRAIN BEHAV IMMUN, V25, P468, DOI 10.1016/j.bbi.2010.11.008; Gong Zhao-Hua, 2008, Zhongguo Zhong Xi Yi Jie He Za Zhi, V28, P348; Hannen RF, 2011, BIOCHEM BIOPH RES CO, V404, P62, DOI 10.1016/j.bbrc.2010.11.059; Harbuz MS, 2006, ANN NY ACAD SCI, V1069, P51, DOI 10.1196/annals.1351.005; Hendrix S, 2008, J INVEST DERMATOL, V128, P260, DOI 10.1038/sj.jid.5701171; Huang JH, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/938425; Ibarguen-Vargas Y, 2008, PSYCHONEUROENDOCRINO, V33, P1357, DOI 10.1016/j.psyneuen.2008.07.010; Ito N, 2005, FASEB J, V19, P1332, DOI 10.1096/fj.04-1968fje; Jin HL, 2013, INT IMMUNOPHARMACOL, V15, P42, DOI 10.1016/j.intimp.2012.11.009; Karalis K, 1997, J NEUROIMMUNOL, V72, P131, DOI 10.1016/S0165-5728(96)00178-6; Kempuraj D, 2004, ENDOCRINOLOGY, V145, P43, DOI 10.1210/en.2003-0805; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Matsuoka H, 2003, ALLERGY, V58, P139, DOI 10.1034/j.1398-9995.2003.23790.x; MIGLIORATI G, 1994, PHARMACOL RES, V30, P43, DOI 10.1016/1043-6618(94)80086-3; Priftis KN, 2008, TRENDS ENDOCRIN MET, V19, P32, DOI 10.1016/j.tem.2007.10.005; Segerstrom SC, 2004, PSYCHOL BULL, V130, P601, DOI 10.1037/0033-2909.130.4.601; Skobowiat C, 2013, GENE, V530, P1, DOI 10.1016/j.gene.2013.08.035; Slominski A, 2009, BRIT J DERMATOL, V160, P229, DOI 10.1111/j.1365-2133.2008.08958.x; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; Slominski A, 2001, FASEB J, V15, P1678, DOI 10.1096/fj.00-0850rev; SLOMINSKI A, 2013, J STEROID BIOCHEM, V137, P107, DOI [DOI 10.1016/j.jsbmb.2013.02.006, 10.1016/.jsbmb.2013.02.006, DOI 10.1016/J.JSBMB.2013.02.006]; Slominski A, 2007, MOL CELL ENDOCRINOL, V265, P143, DOI 10.1016/j.mce.2006.12.012; Slominski A, 2006, FRONT BIOSCI-LANDMRK, V11, P2230, DOI 10.2741/1966; Slominski AT, 2013, ENDOCR REV, V34, P827, DOI 10.1210/er.2012-1092; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Sprecher E, 2013, J ALLERGY CLIN IMMUN, V132, P1130, DOI 10.1016/j.jaci.2013.09.026; Theoharides TC, 2004, TRENDS PHARMACOL SCI, V25, P563, DOI 10.1016/j.tips.2004.09.007; Theoharides TC, 1998, ENDOCRINOLOGY, V139, P403, DOI 10.1210/en.139.1.403; Theoharides TC, 2006, ANN NY ACAD SCI, V1088, P78, DOI 10.1196/annals.1366.025; Theoharides TC, 2012, BBA-MOL BASIS DIS, V1822, P21, DOI 10.1016/j.bbadis.2010.12.014; Vasiadi M, 2012, J ALLERGY CLIN IMMUN, V129, P1410, DOI 10.1016/j.jaci.2012.01.041; Wang GF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103168; Wang J, 2014, J ETHNOPHARMACOL, V154, P131, DOI 10.1016/j.jep.2014.03.041; Wen MC, 2005, J ALLERGY CLIN IMMUN, V116, P517, DOI 10.1016/j.jaci.2005.05.029; Wu JF, 2011, IMMUNOPHARM IMMUNOT, V33, P49, DOI 10.3109/08923971003725144; Wu JF, 2011, PHARMACOL BIOCHEM BE, V98, P273, DOI 10.1016/j.pbb.2011.01.008; Xu CQ, 2010, EUR J PHARMACOL, V642, P146, DOI 10.1016/j.ejphar.2010.05.012; Zbytek B, 2007, J INVEST DERMATOL, V127, P730, DOI 10.1038/sj.jid.5700607; Zollner EW, 2007, PEDIATR ALLERGY IMMU, V18, P469, DOI 10.1111/j.1399-3038.2007.00539.x	45	6	6	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2015	10	2							e0116427	10.1371/journal.pone.0116427	http://dx.doi.org/10.1371/journal.pone.0116427			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CB2GK	25658752	Green Published, Green Submitted, gold			2023-01-03	WOS:000349444900038
J	Kato, S; Hayashi, S; Kitahara, Y; Nagasawa, K; Aono, H; Shibata, J; Utsumi, D; Amagase, K; Kadowaki, M				Kato, Shinichi; Hayashi, Shusaku; Kitahara, Yumeno; Nagasawa, Koyo; Aono, Hitomi; Shibata, Junichiro; Utsumi, Daichi; Amagase, Kikuko; Kadowaki, Makoto			Saireito (TJ-114), a Japanese Traditional Herbal Medicine, Reduces 5-Fluorouracil-Induced Intestinal Mucositis in Mice by Inhibiting Cytokine-Mediated Apoptosis in Intestinal Crypt Cells	PLOS ONE			English	Article							DAI-KENCHU-TO; RECOMMENDED GUIDELINES; POSTOPERATIVE ILEUS; DAIKENCHUTO TU-100; EPITHELIAL-CELLS; INDUCED DIARRHEA; CHEMOTHERAPY; CANCER; HUMANS; COLON	Clinical chemotherapy frequently causes intestinal mucositis as a side effect, which is accompanied by severe diarrhea. We recently showed that the cytokine-mediated apoptotic pathway might be important for the development of intestinal mucositis induced by 5-fluorouracil (5-FU). Saireito, the traditional Japanese herbal (Kampo) medicine, is widely used to treat diarrhea and various inflammatory diseases in Japan. In the present study, we investigated the effect of saireito on 5-FU-induced intestinal mucositis in mice, especially in relation to apoptosis in the intestinal crypt. Male C57BL/6 mice were given 5-FU (50 mg/kg), i.p. once daily for 6 days. Intestinal mucositis was evaluated histochemically. Saireito (1001000 mg/kg) was administered p.o. twice daily for 6 days. Repeated 5-FU treatment caused severe intestinal mucositis including morphological damage, which was accompanied by body weight loss and diarrhea. Daily administration of saireito reduced the severity of intestinal mucositis in a dose-dependent manner. Body weight loss and diarrhea during 5-FU treatment were also significantly attenuated by saireito administration. The number of apoptotic and caspase-3-activated cells in the intestinal crypt was increased, and was accompanied by up-regulated tumor necrosis factor (TNF)-alpha and interleukin (IL)-1 beta mRNA within 24 h of the first 5-FU injection. However, all of these measures were significantly lower after saireito administration. These results suggest that saireito attenuates 5-FU-induced intestinal mucositis. This action may come from the reduction of apoptosis in the intestinal crypt via suppression of the up-regulation of inflammatory cytokines. Therefore, saireito may be clinically useful for the prevention of intestinal mucositis during cancer chemotherapy.	[Kato, Shinichi; Kitahara, Yumeno; Nagasawa, Koyo; Aono, Hitomi; Shibata, Junichiro; Utsumi, Daichi; Amagase, Kikuko] Kyoto Pharmaceut Univ, Div Pathol Sci, Dept Pharmacol & Expt Therapeut, Yamashina Ku, Kyoto 6078414, Japan; [Hayashi, Shusaku; Kadowaki, Makoto] Toyama Univ, Div Gastrointestinal Pathophysiol, Dept Biosci, Inst Nat Med, Toyama 9300194, Japan	Kyoto Pharmaceutical University; University of Toyama	Kato, S (corresponding author), Kyoto Pharmaceut Univ, Div Pathol Sci, Dept Pharmacol & Expt Therapeut, Yamashina Ku, Kyoto 6078414, Japan.	skato@mb.kyoto-phu.ac.jp	UTSUMI, DAICHI/ABB-8650-2021; UTSUMI, DAICHI/W-6307-2019; Hayashi, Shusaku/AAP-1185-2020	UTSUMI, DAICHI/0000-0001-6602-8426; Hayashi, Shusaku/0000-0002-8304-7255	Institute of Natural Medicine, University of Toyama	Institute of Natural Medicine, University of Toyama	This study was supported by a Grant-in-Aid for the Cooperative Research Project from Institute of Natural Medicine, University of Toyama in 2012 and 2013.	ANILKUMAR TV, 1992, BRIT J CANCER, V65, P552, DOI 10.1038/bjc.1992.113; BEARD DV, 1993, INVEST RADIOL, V28, P732, DOI 10.1097/00004424-199308000-00015; Benson AB, 2004, J CLIN ONCOL, V22, P2918, DOI 10.1200/jco.2004.04.132; Bowen JM, 2005, PATHOLOGY, V37, P56, DOI 10.1080/00313020400023461; Bowen JM, 2006, SUPPORT CARE CANCER, V14, P713, DOI 10.1007/s00520-005-0004-7; Chikakiyo M, 2012, SURG TODAY, V42, P60, DOI 10.1007/s00595-011-0014-7; Daniele B, 2001, J CLIN GASTROENTEROL, V32, P228, DOI 10.1097/00004836-200103000-00010; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Duncan M, 2003, ALIMENT PHARM THER, V18, P853, DOI 10.1046/j.1365-2036.2003.01784.x; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Huang TY, 2009, BIOCHEM BIOPH RES CO, V389, P634, DOI 10.1016/j.bbrc.2009.09.041; Inomata A, 2002, TOXICOL LETT, V133, P231, DOI 10.1016/S0378-4274(02)00204-7; Ito T, 2002, J DERMATOL SCI, V28, P198, DOI 10.1016/S0923-1811(01)00161-X; Itoh T, 2002, J INT MED RES, V30, P428, DOI 10.1177/147323000203000410; Iwasa T, 2012, DIGEST DIS SCI, V57, P2571, DOI 10.1007/s10620-012-2218-0; Kaburaki T, 2013, GRAEF ARCH CLIN EXP, V251, P2733, DOI 10.1007/s00417-013-2473-6; Kaneko A, 2013, GASTROENT RES PRACT, V2013, DOI 10.1155/2013/384057; Keefe DMK, 2000, GUT, V47, P632, DOI 10.1136/gut.47.5.632; Kono T, 2011, J GASTROENTEROL, V46, P1187, DOI 10.1007/s00535-011-0438-2; Kumar S, 2007, CELL DEATH DIFFER, V14, P32, DOI 10.1038/sj.cdd.4402060; Li TS, 2009, CANCER CHEMOTH PHARM, V63, P873, DOI 10.1007/s00280-008-0809-4; Lu CN, 2012, INT IMMUNOPHARMACOL, V14, P121, DOI 10.1016/j.intimp.2012.06.010; Manabe N, 2010, AM J PHYSIOL-GASTR L, V298, pG970, DOI 10.1152/ajpgi.00043.2010; Matsuike T, 1999, PROG MED, V19, P879; Ohno S, 2007, J TRAD MED, V16, P73; Ono T, 2005, NEPHRON EXP NEPHROL, V100, pE132, DOI 10.1159/000085059; Perner A, 2003, GUT, V52, P231, DOI 10.1136/gut.52.2.231; Pritchard DM, 1998, CANCER RES, V58, P5453; Sonis ST, 2004, NAT REV CANCER, V4, P277, DOI 10.1038/nrc1318; Symonds RP, 1998, BRIT J CANCER, V77, P1689, DOI 10.1038/bjc.1998.279; Tokita Y., 2007, Inflammopharmacology, V15, P65, DOI 10.1007/s10787-006-1552-2; Tokita Y, 2007, J PHARMACOL SCI, V104, P303, DOI 10.1254/jphs.FP0070831; Tomita K, 2003, J PHARMACOL SCI, V93, P321, DOI 10.1254/jphs.93.321; Wadler S, 1998, J CLIN ONCOL, V16, P3169, DOI 10.1200/JCO.1998.16.9.3169; Watanabe T, 2010, INT ARCH ALLERGY IMM, V151, P98, DOI 10.1159/000235999; Wu ZQ, 2011, CANCER CHEMOTH PHARM, V68, P87, DOI 10.1007/s00280-010-1451-5; Yasuda M, 2013, BRIT J PHARMACOL, V168, P1388, DOI 10.1111/bph.12019; Yasuda M, 2012, AM J PHYSIOL-GASTR L, V302, pG1133, DOI 10.1152/ajpgi.00535.2011; Yoon SB, 2009, J ETHNOPHARMACOL, V125, P286, DOI 10.1016/j.jep.2009.06.027; Zhu J, 2013, EXP THER MED, V5, P1345, DOI 10.3892/etm.2013.988	40	35	38	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 7	2015	10	1							e0116213	10.1371/journal.pone.0116213	http://dx.doi.org/10.1371/journal.pone.0116213			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AZ4BS	25565296	Green Published, Green Submitted, gold			2023-01-03	WOS:000348167900004
J	Fujita, N; Ono, M; Tomioka, T; Deie, M				Fujita, Naoto; Ono, Miharu; Tomioka, Tomoka; Deie, Masataka			Effects of Hyperbaric Oxygen at 1.25 Atmospheres Absolute with Normal Air on Macrophage Number and Infiltration during Rat Skeletal Muscle Regeneration	PLOS ONE			English	Article							CONTRACTILE FUNCTION; CRUSH INJURY; EXERCISE; THERAPY; HYPOXIA; EXPRESSION; APOPTOSIS; SORENESS; GROWTH; BLOOD	Use of mild hyperbaric oxygen less than 2 atmospheres absolute (2026.54 hPa) with normal air is emerging as a common complementary treatment for severe muscle injury. Although hyperbaric oxygen at over 2 atmospheres absolute with 100% O2 promotes healing of skeletal muscle injury, it is not clear whether mild hyperbaric oxygen is equally effective. The purpose of the present study was to investigate the impact of hyperbaric oxygen at 1.25 atmospheres absolute (1266.59 hPa) with normal air on muscle regeneration. The tibialis anterior muscle of male Wistar rats was injured by injection of bupivacaine hydrochloride, and rats were randomly assigned to a hyperbaric oxygen experimental group or to a nonhyperbaric oxygen control group. Immediately after the injection, rats were exposed to hyperbaric oxygen, and the treatment was continued for 28 days. The cross-sectional area of centrally nucleated muscle fibers was significantly larger in rats exposed to hyperbaric oxygen than in controls 5 and 7 days after injury. The number of CD68- or CD68- and CD206-positive cells was significantly higher in rats exposed to hyperbaric oxygen than in controls 24 h after injury. Additionally, tumor necrosis factor-a and interleukin-10 mRNA expression levels were significantly higher in rats exposed to hyperbaric oxygen than in controls 24 h after injury. The number of Pax7- and MyoD- or MyoD- and myogenin-positive nuclei per mm(2) and the expression levels of these proteins were significantly higher in rats exposed to hyperbaric oxygen than in controls 5 days after injury. These results suggest that mild hyperbaric oxygen promotes skeletal muscle regeneration in the early phase after injury, possibly due to reduced hypoxic conditions leading to accelerated macrophage infiltration and phenotype transition. In conclusion, mild hyperbaric oxygen less than 2 atmospheres absolute with normal air is an appropriate support therapy for severe muscle injuries.	[Fujita, Naoto; Ono, Miharu; Tomioka, Tomoka; Deie, Masataka] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Hiroshima, Hiroshima, Japan; [Fujita, Naoto; Deie, Masataka] Hiroshima Univ, Fac Med, Hiroshima, Hiroshima, Japan	Hiroshima University; Hiroshima University	Fujita, N (corresponding author), Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Hiroshima, Hiroshima, Japan.	fujitan@hiroshima-u.ac.jp		Fujita, Naoto/0000-0001-9416-3502	Japanese Ministry of Education, Culture, Sports, Science, and Technology [25750202]	Japanese Ministry of Education, Culture, Sports, Science, and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This study was supported by Grants-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science, and Technology (no. 25750202 to NF). The URL of the funder's website is http://www.mext.go.jp/english/. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Asano T, 2007, CIRC J, V71, P405, DOI 10.1253/circj.71.405; Babul S, 2003, CLIN J SPORT MED, V13, P138, DOI 10.1097/00042752-200305000-00003; Bajek S, 2011, COLLEGIUM ANTROPOL, V35, P91; Best TM, 1998, AM J SPORT MED, V26, P367, DOI 10.1177/03635465980260030401; Bosco MC, 2004, J IMMUNOL, V172, P1681, DOI 10.4049/jimmunol.172.3.1681; Bozok S, 2012, EUR J MED RES, V17, DOI 10.1186/2047-783X-17-14; Chaillou T, 2014, PFLUG ARCH EUR J PHY, V466, P587, DOI 10.1007/s00424-013-1336-7; Deng B, 2012, J IMMUNOL, V189, P3669, DOI 10.4049/jimmunol.1103180; Escribese MM, 2012, IMMUNOBIOLOGY, V217, P1233, DOI 10.1016/j.imbio.2012.07.002; Germain G, 2003, UNDERSEA HYPERBAR M, V30, P135; Gregorevic P, 2000, J APPL PHYSIOL, V89, P1477, DOI 10.1152/jappl.2000.89.4.1477; Gregorevic P, 2002, MED SCI SPORT EXER, V34, P630, DOI 10.1097/00005768-200204000-00011; Harrison BC, 2001, MED SCI SPORT EXER, V33, P36; Kawada S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072603; Kharraz Y, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/491497; Lewis JS, 1999, J LEUKOCYTE BIOL, V66, P889, DOI 10.1002/jlb.66.6.889; Lu PG, 2013, J NEUROSURG SCI, V57, P253; Malm C, 2000, J PHYSIOL-LONDON, V529, P243, DOI 10.1111/j.1469-7793.2000.00243.x; Mekjavic IB, 2000, MED SCI SPORT EXER, V32, P558, DOI 10.1097/00005768-200003000-00002; Novak ML, 2014, J PATHOL, V232, P344, DOI 10.1002/path.4301; Novak ML, 2013, AM J PATHOL, V183, P1352, DOI 10.1016/j.ajpath.2013.06.034; Otis JS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092363; Rigamonti E, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/560629; Shefer G, 2006, DEV BIOL, V294, P50, DOI 10.1016/j.ydbio.2006.02.022; Takagi R, 2011, J APPL PHYSIOL, V110, P382, DOI 10.1152/japplphysiol.01187.2010; Takeuchi K, 2014, ACTA HISTOCHEM, V116, P327, DOI 10.1016/j.acthis.2013.08.010; Thom SR, 2009, J APPL PHYSIOL, V106, P988, DOI 10.1152/japplphysiol.91004.2008; Tidball JG, 2010, AM J PHYSIOL-REG I, V298, pR1173, DOI 10.1152/ajpregu.00735.2009; Ueng SWN, 2013, J ORTHOP RES, V31, P376, DOI 10.1002/jor.22235; Villalta SA, 2009, HUM MOL GENET, V18, P482, DOI 10.1093/hmg/ddn376; Yu JG, 2002, HISTOCHEM CELL BIOL, V118, P29, DOI 10.1007/s00418-002-0423-1; Yu JG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062056; Zammit PS, 2004, J CELL BIOL, V166, P347, DOI 10.1083/jcb.200312007	33	15	18	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 22	2014	9	12							e115685	10.1371/journal.pone.0115685	http://dx.doi.org/10.1371/journal.pone.0115685			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA3ZY	25531909	Green Submitted, Green Published, gold			2023-01-03	WOS:000348845100094
J	Barrington-Trimis, JL; Samet, JM; McConnell, R				Barrington-Trimis, Jessica L.; Samet, Jonathan M.; McConnell, Rob			Flavorings in Electronic Cigarettes An Unrecognized Respiratory Health Hazard?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Barrington-Trimis, Jessica L.; Samet, Jonathan M.; McConnell, Rob] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA	University of Southern California	Barrington-Trimis, JL (corresponding author), Univ So Calif, Dept Prevent Med, 2001 N Soto St,230-D, Los Angeles, CA 90089 USA.	jtrimis@usc.edu	Barrington-Trimis, Jessica/ABE-7311-2020		NCI NIH HHS [P50CA180905, P50 CA180905] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA180905] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abrams DB, 2014, JAMA-J AM MED ASSOC, V311, P135, DOI 10.1001/jama.2013.285347; [Anonymous], 2012, RESPIRATORY HEALTH A; Bullen C, 2013, LANCET, V382, P1629, DOI 10.1016/S0140-6736(13)61842-5; Farsalinos KE, 2015, NICOTINE TOB RES, V17, P168, DOI 10.1093/ntr/ntu176; Grana R, 2014, CIRCULATION, V129, P1972, DOI 10.1161/CIRCULATIONAHA.114.007667; Hallagan J., 2014, THE SAFETY ASSESSMEN; Kreiss K, 2014, AM J IND MED, V57, P129, DOI 10.1002/ajim.22282; Potera C, 2012, ENVIRON HEALTH PERSP, V120, pA457, DOI 10.1289/ehp.120-a457; Zhu SH, 2014, TOB CONTROL, V23, P3, DOI 10.1136/tobaccocontrol-2014-051670	9	157	159	0	43	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 17	2014	312	23					2493	2494		10.1001/jama.2014.14830	http://dx.doi.org/10.1001/jama.2014.14830			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AW5YN	25383564	Green Accepted			2023-01-03	WOS:000346346900006
J	Keyhani, S; Myers, LJ; Cheng, E; Hebert, P; Williams, LS; Bravata, DM				Keyhani, Salomeh; Myers, Laura J.; Cheng, Eric; Hebert, Paul; Williams, Linda S.; Bravata, Dawn M.			Effect of Clinical and Social Risk Factors on Hospital Profiling for Stroke Readmission A Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							30-DAY READMISSION; HEART-FAILURE; PREDICTION; MORTALITY; IDENTIFY; MODELS; CARE	Background: The Centers for Medicare & Medicaid Services (CMS) and Veterans Health Administration (VA) will report 30-day stroke readmission rates as a measure of hospital quality. A national debate on whether social risk factors should be included in models developed for hospital profiling is ongoing. Objective: To compare a CMS-based model of 30-day readmission with a more comprehensive model that includes measures of social risk (such as homelessness) or clinical factors (such as stroke severity and functional status). Design: Data from a retrospective cohort study were used to develop a CMS-based 30-day readmission model that included age and comorbid conditions based on codes from the International Classification of Diseases, Ninth Revision, Clinical Modification (model 1). This model was then compared with one that included administrative social risk factors (model 2). Finally, the CMS model (model 1) was compared with a model that included social risk and clinical factors from chart review (model 3). These 3 models were used to rank hospitals by 30-day risk-standardized readmission rates and examine facility rankings among the models. Setting: Hospitals in the VA. Participants: Patients hospitalized with stroke in 2007. Measurements: 30-day readmission rates. Results: The 30-day readmission rate was 12.8%. The c-statistics for the 3 models were 0.636, 0.646, and 0.661, respectively. All hospitals were classified as performing "as expected" using all 3 models (that is, performance did not differ from the VA national average); therefore, the addition of detailed clinical information or social risk factors did not alter assessment of facility performance. Limitation: A predominantly male veteran cohort limits the generalizability of these findings. Conclusion: In the VA, more comprehensive models that included social risk and clinical factors did not affect hospital comparisons based on 30-day readmission rates.	[Keyhani, Salomeh] San Francisco VA Med Ctr, San Francisco, CA 94121 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Indiana Univ Sch Med, Vet Hlth Adm Hlth Serv Res & Dev, Stroke Qual Enhancement Res Initiat Program, Indianapolis, IN 46202 USA; Indiana Univ Sch Med, Ctr Excellence Implementing Evidence Based Practi, Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46202 USA; Regenstrief Inst Hlth Care, Indianapolis, IN USA; Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA; Univ Calif Los Angeles, Los Angeles, CA USA; Univ Washington, Seattle, WA 98195 USA; Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; University of California System; University of California San Francisco; Indiana University System; Indiana University Bloomington; US Department of Veterans Affairs; Veterans Health Administration (VHA); Indiana University System; Indiana University Bloomington; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System	Keyhani, S (corresponding author), San Francisco VA Med Ctr, 4150 Clement,111A1, San Francisco, CA 94121 USA.	salomeh.keyhani@va.gov			Veterans Health Administration Office of Quality and Performance; Health Services Research and Development Service Quality Enhancement Research Initiative of the Department of Veterans Affairs [RRP 12-192]; National Heart, Lung, and Blood Institute, U. S. Department of Health and Human Services [1R01HL116522-01A1]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL116522] Funding Source: NIH RePORTER	Veterans Health Administration Office of Quality and Performance; Health Services Research and Development Service Quality Enhancement Research Initiative of the Department of Veterans Affairs; National Heart, Lung, and Blood Institute, U. S. Department of Health and Human Services(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	By the Veterans Health Administration Office of Quality and Performance and Health Services Research and Development Service Quality Enhancement Research Initiative of the Department of Veterans Affairs (RRP 12-192) and the National Heart, Lung, and Blood Institute, U.S. Department of Health and Human Services (1R01HL116522-01A1).	Amarasingham R, 2010, MED CARE, V48, P981, DOI 10.1097/MLR.0b013e3181ef60d9; [Anonymous], 2011, FED REGISTER, V76, P51476; Arbaje AI, 2008, GERONTOLOGIST, V48, P495, DOI 10.1093/geront/48.4.495; Arling G, 2012, CIRC-CARDIOVASC QUAL, V5, P44, DOI 10.1161/CIRCOUTCOMES.111.961474; Austin PC, 2003, MED DECIS MAKING, V23, P526, DOI 10.1177/0272989X03258443; Austin PC, 2002, MED DECIS MAKING, V22, P163, DOI 10.1177/02729890222063044; Bernheim S, 2010, HOSP 30 DAY READMISS; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Go AS, 2013, CIRCULATION, V127, pE6, DOI 10.1161/CIR.0b013e31828124ad; Joynt KE, 2011, JAMA-J AM MED ASSOC, V305, P675, DOI 10.1001/jama.2011.123; Joynt KE, 2011, CIRC-CARDIOVASC QUAL, V4, P53, DOI 10.1161/CIRCOUTCOMES.110.950964; Kansagara D, 2011, JAMA-J AM MED ASSOC, V306, P1688, DOI 10.1001/jama.2011.1515; Keyhani S, 2012, MED CARE, V50, P66, DOI 10.1097/MLR.0b013e3182294092; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Krumholz HM, 1997, ARCH INTERN MED, V157, P99, DOI 10.1001/archinte.157.1.99; Krumholz HM, 2011, RISK ADJUSTMENT MODE; Lichtman JH, 2010, STROKE, V41, P2525, DOI 10.1161/STROKEAHA.110.599159; Morse JM, 2002, AM J INFECT CONTROL, V30, P376, DOI 10.1067/mic.2002.125808; MORSE JM, 1989, SOC SCI MED, V28, P81, DOI 10.1016/0277-9536(89)90309-2; National Quality Forum, 2014, RISK ADJ SOC STAT OT; O'Connell B, 2002, J CLIN NURS, V11, P134, DOI 10.1046/j.1365-2702.2002.00578.x; Reker DM, 2005, J REHABIL RES DEV, V42, P77, DOI 10.1682/JRRD.2003.11.0164; U.S. Department of Health and Human Services, 2011, HOSP COMP; United States Census Bureau, 2014, AM COMM SURV; Williams LS, 2000, STROKE, V31, P858, DOI 10.1161/01.STR.31.4.858; Yale New Haven Health Services Corporation/Center for Outcomes Research and Evaluation, 2012, TEST HOSP LEV AC ISC; Yale New Haven Health Services Corporation/Center for Outcomes Research and Evaluation, 2012, RESP HOSP 30 DAY ISC	27	23	23	1	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 2	2014	161	11					775	U51		10.7326/M14-0361	http://dx.doi.org/10.7326/M14-0361			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AX9UJ	25437405				2023-01-03	WOS:000347247200006
J	Hedman, E; Andersson, G; Lindefors, N; Gustavsson, P; Lekander, M; Ruck, C; Andersson, E; Ljotsson, B				Hedman, Erik; Andersson, Gerhard; Lindefors, Nils; Gustavsson, Petter; Lekander, Mats; Rueck, Christian; Andersson, Erik; Ljotsson, Brjann			Personality Change following Internet-Based Cognitive Behavior Therapy for Severe Health Anxiety	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; III-R HYPOCHONDRIASIS; SELF-REPORT MEASURES; PSYCHOMETRIC EVALUATION; COST-EFFECTIVENESS; SOCIAL ANXIETY; TRAIT CHANGE; DEPRESSION; DISORDERS; TEMPERAMENT	Personality traits have traditionally been viewed as stable, but recent studies suggest that they could be affected through psychological treatment. Internet-based cognitive behavior therapy (ICBT) for severe health anxiety (DSM-IV hypochondriasis) has been shown to be effective in reducing health anxiety, but its effect on measures of personality traits has not been investigated. The main aim of this study was to investigate the impact of ICBT on personality traits in the three broad dimensions -neuroticism, extraversion and aggression. We hypothesized that participants in ICBT would reduce their level of neuroticism compared to controls that did not receive the active treatment. No specific predictions were made regarding extraversion and aggression. Data from a randomized controlled trial were used in which participants were allocated to 12 weeks of ICBT (n=40) or to a basic attention control condition (n=41). Personality traits were assessed with the Swedish Universities Scales of Personality and the primary outcome of health anxiety was the Health Anxiety Inventory. There was a significant interaction effect of group and time on neuroticism-related scales, indicating larger pre-to post-treatment reductions in the Internet-based CBT group compared to the control condition. Analyses at 6-month follow-up showed that changes were stable. Traits relating to extraversion and aggression were largely unchanged. This study is the first to demonstrate that a brief ICBT intervention for severe health anxiety causes long-term changes in measures of personality traits related to neuroticism. The treatment thus has a broader impact than just reducing health anxiety.	[Hedman, Erik; Andersson, Gerhard; Lindefors, Nils; Rueck, Christian; Andersson, Erik; Ljotsson, Brjann] Karolinska Inst, Div Psychiat, Dept Clin Neurosci, Stockholm, Sweden; [Hedman, Erik; Lekander, Mats] Karolinska Inst, Osher Ctr Integrat Med, Dept Clin Neurosci, Stockholm, Sweden; [Hedman, Erik; Gustavsson, Petter; Ljotsson, Brjann] Karolinska Inst, Div Psychol, Dept Clin Neurosci, Stockholm, Sweden; [Andersson, Gerhard] Linkoping Univ, Dept Behav Sci & Learning, Linkoping, Sweden; [Andersson, Gerhard] Linkoping Univ, Swedish Inst Disabil Res, Linkoping, Sweden; [Lekander, Mats] Stockholm Univ, Stress Res Inst, S-10691 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Linkoping University; Linkoping University; Stockholm University	Hedman, E (corresponding author), Karolinska Inst, Div Psychiat, Dept Clin Neurosci, Stockholm, Sweden.	kire.hedman@ki.se	Andersson, Gerhard/J-8529-2012	Andersson, Gerhard/0000-0003-4753-6745; Gustavsson, Petter/0000-0001-9571-9349; Andersson, Erik/0000-0003-0088-8719; Ruck, Christian/0000-0002-8742-0168; Hedman-Lagerlof, Erik/0000-0002-7939-9848	Stockholm County council; Karolinska Institutet	Stockholm County council(Stockholm County Council); Karolinska Institutet(Karolinska Institutet)	The funders of the study were Stockholm County council and Karolinska Institutet, which are both public institutions. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aguera Z, 2012, EUR EAT DISORD REV, V20, P379, DOI 10.1002/erv.2163; American Psychiatric Association, 2000, DIAGN STAT MAN MENT, Vxxxvii; Andersson G, 2014, WORLD PSYCHIATRY, V13, P288, DOI 10.1002/wps.20151; Andersson G, 2009, BEHAV RES THER, V47, P175, DOI 10.1016/j.brat.2009.01.010; BARSKY AJ, 1990, SOC PSYCH PSYCH EPID, V25, P89; Barsky AJ, 1998, ARCH GEN PSYCHIAT, V55, P737, DOI 10.1001/archpsyc.55.8.737; Brandes Mina, 2006, Curr Psychiatry Rep, V8, P263, DOI 10.1007/s11920-006-0061-8; Burger JM, 1993, PERSONALITY; Carlbring P, 2007, COMPUT HUM BEHAV, V23, P1421, DOI 10.1016/j.chb.2005.05.002; Cervenka S, 2010, NEUROIMAGE, V50, P323, DOI 10.1016/j.neuroimage.2009.12.006; Clark DM, 1998, BRIT J PSYCHIAT, V173, P218, DOI 10.1192/bjp.173.3.218; CLONINGER CR, 1993, ARCH GEN PSYCHIAT, V50, P975, DOI 10.1001/archpsyc.1993.01820240059008; Cuijpers P, 2010, ARCH GEN PSYCHIAT, V67, P1086, DOI 10.1001/archgenpsychiatry.2010.130; Eysenck H. J., 1985, PERS INDIVID DIFFER, DOI [DOI 10.1007/978-1-4613-2413-3, 13877]; Eysenck HJ, 1959, BRIT J PSYCHIAT, V105, P61; Farde L, 1997, NATURE, V385, P590, DOI 10.1038/385590a0; Flaskerud Jacquelyn H, 2012, Issues Ment Health Nurs, V33, P631, DOI 10.3109/01612840.2011.647256; FURER P, 2007, TREATING HLTH ANXIET, V15; Furer P, 2005, J CONTEMP PSYCHOTHER, V35, P251, DOI 10.1007/s10879-005-4319-y; Gray J.A., 1991, EXPLORATIONS TEMPERA; Greeven A, 2007, AM J PSYCHIAT, V164, P91, DOI 10.1176/appi.ajp.164.1.91; Gustavsson JP, 2000, ACTA PSYCHIAT SCAND, V102, P217, DOI 10.1034/j.1600-0447.2000.102003217.x; Gustavsson JP, 1997, PERS INDIV DIFFER, V22, P783, DOI 10.1016/S0191-8869(96)00268-1; Hedman E, 2013, PSYCHOL MED, V43, P363, DOI 10.1017/S0033291712001079; Hedman E, 2013, J MED INTERNET RES, V15, P131, DOI 10.2196/jmir.2818; Hedman E, 2012, EXPERT REV PHARM OUT, V12, P745, DOI [10.1586/ERP.12.67, 10.1586/erp.12.67]; Hedman E, 2011, BRIT J PSYCHIAT, V198, P230, DOI 10.1192/bjp.bp.110.086843; Hedman Erik, 2010, Cognitive Behaviour Therapy, V39, P239, DOI 10.1080/16506073.2010.496460; Hedman E, 2010, COMPUT HUM BEHAV, V26, P736, DOI 10.1016/j.chb.2010.01.010; Johansson R, 2013, PEERJ, V1, DOI 10.7717/peerj.39; John O.P., 2008, HDB PERSONALITY THEO; Karsten J, 2012, J PSYCHIATR RES, V46, P644, DOI 10.1016/j.jpsychires.2012.01.024; Lahey BB, 2009, AM PSYCHOL, V64, P241, DOI 10.1037/a0015309; Lovas DA, 2010, J ANXIETY DISORD, V24, P931, DOI 10.1016/j.janxdis.2010.06.019; Ludtke O, 2011, J PERS SOC PSYCHOL, V101, P620, DOI 10.1037/a0023743; Lyoo IK, 2003, ACTA PSYCHIAT SCAND, V107, P298, DOI 10.1034/j.1600-0447.2003.00054.x; McManus F, 2012, J CONSULT CLIN PSYCH; Mortberg E, 2007, PSYCHIAT RES, V152, P81, DOI 10.1016/j.psychres.2006.10.003; NOYES R, 1994, GEN HOSP PSYCHIAT, V16, P78, DOI 10.1016/0163-8343(94)90049-3; NOYES R, 1993, ARCH GEN PSYCHIAT, V50, P961; NOYES R, 1991, COMPR PSYCHIAT, V32, P283, DOI 10.1016/0010-440X(91)90076-O; Posternak MA, 2001, J AFFECT DISORDERS, V66, P139, DOI 10.1016/S0165-0327(00)00304-9; REICH J, 1986, AM J PSYCHIAT, V143, P760; Roberts BW, 2008, CURR DIR PSYCHOL SCI, V17, P31, DOI 10.1111/j.1467-8721.2008.00543.x; Rohde P, 1997, AM J PSYCHIAT, V154, P1593, DOI 10.1176/ajp.154.11.1593; Ruck C, 2006, NORD J PSYCHIAT, V60, P486, DOI 10.1080/08039480601022116; Salkovskis PM, 2002, PSYCHOL MED, V32, P843, DOI 10.1017/S0033291702005822; Seivewright H, 2008, BRIT J PSYCHIAT, V193, P332, DOI 10.1192/bjp.bp.108.052936; Sheehan DV, 1998, J CLIN PSYCHIAT S20, V59, pS22; SPECKENS AEM, 1995, BRIT MED J, V311, P1328, DOI 10.1136/bmj.311.7016.1328; Spinhoven P, 2011, ACTA PSYCHIAT SCAND, V124, P462, DOI 10.1111/j.1600-0447.2011.01753.x; STAATS AW, 1993, BEHAV MODIF, V17, P8, DOI 10.1177/01454455930171003; Svanborg P, 1999, J PERS DISORD, V13, P241, DOI 10.1521/pedi.1999.13.3.241; SVANBORG P, 1994, ACTA PSYCHIAT SCAND, V89, P21, DOI 10.1111/j.1600-0447.1994.tb01480.x; Tang TZ, 2009, ARCH GEN PSYCHIAT, V66, P1322, DOI 10.1001/archgenpsychiatry.2009.166; TAYLOR S, 2004, TREATING HLTH ANXIET, V15; Treanor M, 2011, CLIN PSYCHOL REV, V31, P617, DOI 10.1016/j.cpr.2011.02.003; Wilczek A, 2004, J AM PSYCHOANAL ASS, V52, P1163	58	28	28	1	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 1	2014	9	12							e113871	10.1371/journal.pone.0113871	http://dx.doi.org/10.1371/journal.pone.0113871			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AX7SK	25437150	Green Published, Green Submitted, gold			2023-01-03	WOS:000347114900091
J	Wallock-Richards, D; Doherty, CJ; Doherty, L; Clarke, DJ; Place, M; Govan, JRW; Campopiano, DJ				Wallock-Richards, Daynea; Doherty, Catherine J.; Doherty, Lynsey; Clarke, David J.; Place, Marc; Govan, John R. W.; Campopiano, Dominic J.			Garlic Revisited: Antimicrobial Activity of Allicin-Containing Garlic Extracts against Burkholderia cepacia Complex	PLOS ONE			English	Article							CYSTIC-FIBROSIS; ANTIBACTERIAL PRINCIPLE; INFECTION; EPIDEMIOLOGY; INHIBITION; ALLIINASE; PRODUCTS; AJOENE; GROWTH	The antimicrobial activities of garlic and other plant alliums are primarily based on allicin, a thiosulphinate present in crushed garlic bulbs. We set out to determine if pure allicin and aqueous garlic extracts (AGE) exhibit antimicrobial properties against the Burkholderia cepacia complex (Bcc), the major bacterial phytopathogen for alliums and an intrinsicallymultiresistant and life-threatening human pathogen. We prepared an AGE from commercial garlic bulbs and used HPLC to quantify the amount of allicin therein using an aqueous allicin standard (AAS). Initially we determined the minimum inhibitory concentrations (MICs) of the AGE against 38 Bcc isolates; these MICs ranged from 0.5 to 3% (v/v). The antimicrobial activity of pure allicin (AAS) was confirmed by MIC and minimum bactericidal concentration (MBC) assays against a smaller panel of five Bcc isolates; these included three representative strains of the most clinically important species, B. cenocepacia. Time kill assays, in the presence of ten times MIC, showed that the bactericidal activity of AGE and AAS against B. cenocepacia C6433 correlated with the concentration of allicin. We also used protein mass spectrometry analysis to begin to investigate the possible molecular mechanisms of allicin with a recombinant form of a thiol-dependent peroxiredoxin (BCP, Prx) from B. cenocepacia. This revealed that AAS and AGE modifies an essential BCP catalytic cysteine residue and suggests a role for allicin as a general electrophilic reagent that targets protein thiols. To our knowledge, we report the first evidence that allicin and allicin-containing garlic extracts possess inhibitory and bactericidal activities against the Bcc. Present therapeutic options against these lifethreatening pathogens are limited; thus, allicin-containing compounds merit investigation as adjuncts to existing antibiotics.	[Doherty, Catherine J.; Doherty, Lynsey; Place, Marc; Govan, John R. W.] Univ Edinburgh, Sch Med, Edinburgh, Midlothian, Scotland; [Wallock-Richards, Daynea; Clarke, David J.; Campopiano, Dominic J.] Univ Edinburgh, EastChem Sch Chem, Edinburgh, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Govan, JRW (corresponding author), Univ Edinburgh, Sch Med, Edinburgh, Midlothian, Scotland.	john.r.w.govan@ed.ac.uk; Dominic.Campopiano@ed.ac.uk	Wallock-Richards, Daynea/AAW-2062-2021	Clarke, David/0000-0002-3741-2952; Campopiano, Dominic/0000-0001-8573-6735	University of Edinburgh; Biotechnology and Biological Sciences Research Council (BBSRC) UK [BB/I013687/1]; BBSRC [BB/I013687/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/I013687/1] Funding Source: researchfish	University of Edinburgh; Biotechnology and Biological Sciences Research Council (BBSRC) UK(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	Funding: The authors thank The University of Edinburgh for funding a PhD School of Chemistry Tercentenary studentship (DWR). The authors also thank the Biotechnology and Biological Sciences Research Council (BBSRC) UK for funding (award number BB/I013687/1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ashry NA, 2013, PHARM BIOL, V51, P806, DOI 10.3109/13880209.2013.766895; Balfour-Lynn IM, 2014, J CYST FIBROS, V13, P241, DOI 10.1016/j.jcf.2014.01.003; Banerjee SK, 2002, NUTR J, V1, DOI 10.1186/1475-2891-1-4; Block E., 2010, GARLIC OTHER ALLIUMS; Borlinghaus J, 2014, MOLECULES, V19, P12591, DOI 10.3390/molecules190812591; BURKHOLDER WH, 1950, PHYTOPATHOLOGY, V40, P115; Cavallito CJ, 1944, J AM CHEM SOC, V66, P1950, DOI 10.1021/ja01239a048; CAVALLITO CJ, 1945, J AM CHEM SOC, V67, P1032, DOI 10.1021/ja01222a501; Cavallito CJ, 1944, J AM CHEM SOC, V66, P1952, DOI 10.1021/ja01239a049; Clarke DJ, 2010, BIOCHEMISTRY-US, V49, P1319, DOI 10.1021/bi901703m; Coenye T, 2001, J CLIN MICROBIOL, V39, P3427, DOI 10.1128/JCM.39.10.3427-3436.2001; FELDBERG RS, 1988, ANTIMICROB AGENTS CH, V32, P1763, DOI 10.1128/AAC.32.12.1763; Fischbach MA, 2009, SCIENCE, V325, P1089, DOI 10.1126/science.1176667; FOCKE M, 1990, FEBS LETT, V261, P106, DOI 10.1016/0014-5793(90)80647-2; Fujisawa H, 2008, J AGR FOOD CHEM, V56, P4229, DOI 10.1021/jf8000907; Fujisawa H, 2009, BIOSCI BIOTECH BIOCH, V73, P1948, DOI 10.1271/bbb.90096; Govan JR, 2007, FUTURE MICROBIOL, V2, P153, DOI 10.2217/17460913.2.2.153; Greenberg DE, 2009, CLIN INFECT DIS, V48, P1577, DOI 10.1086/598937; Grimwood K, 2009, J CYST FIBROS, V8, P291, DOI 10.1016/j.jcf.2009.04.002; Holmes A, 1998, EMERG INFECT DIS, V4; Horsley A, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009529.pub2; Horsley A, 2011, FRONT CELL INFECT MI, V1, DOI 10.3389/fcimb.2011.00018; Jakobsen TH, 2012, ANTIMICROB AGENTS CH, V56, P2314, DOI 10.1128/AAC.05919-11; Kyung KH, 2012, CURR OPIN BIOTECH, V23, P142, DOI 10.1016/j.copbio.2011.08.004; Lawson LD, 2001, J AGR FOOD CHEM, V49, P2592, DOI 10.1021/jf001287m; Li JWH, 2009, SCIENCE, V325, P161, DOI 10.1126/science.1168243; LiPuma JJ, 2010, CLIN MICROBIOL REV, V23, P299, DOI 10.1128/CMR.00068-09; Loutet Slade A, 2011, Front Cell Infect Microbiol, V1, P6, DOI [10.3389/fmicb.2011.00159, 10.3389/fcimb.2011.00006]; Mahenthiralingam E, 2000, J CLIN MICROBIOL, V38, P910, DOI 10.1128/JCM.38.2.910-913.2000; Mahenthiralingam E, 2011, CHEM BIOL, V18, P665, DOI 10.1016/j.chembiol.2011.01.020; Mil-Homens D, 2012, FEMS MICROBIOL LETT, V328, P61, DOI 10.1111/j.1574-6968.2011.02476.x; Miron T, 2010, EUR J MED CHEM, V45, P1912, DOI 10.1016/j.ejmech.2010.01.031; Naganawa R, 1996, APPL ENVIRON MICROB, V62, P4238, DOI 10.1128/AEM.62.11.4238-4242.1996; National Committee for Clinical Laboratory Standards, 1997, M27A NAT COMM CLIN L, V17, P1; Nzula S, 2002, J ANTIMICROB CHEMOTH, V50, P265, DOI 10.1093/jac/dkf137; O'Sullivan LA, 2005, LETT APPL MICROBIOL, V41, P8, DOI 10.1111/j.1472-765X.2005.01758.x; Papaleo MC, 2012, BIOTECHNOL ADV, V30, P272, DOI 10.1016/j.biotechadv.2011.06.011; Schwan WR, 2010, ANN CLIN MICROB ANTI, V9, DOI 10.1186/1476-0711-9-4; Shimon LJW, 2007, J MOL BIOL, V366, P611, DOI 10.1016/j.jmb.2006.11.041; SMALL LD, 1947, J AM CHEM SOC, V69, P1710, DOI 10.1021/ja01199a040; Smyth AR, 2010, PEDIATR PULM, V45, P356, DOI 10.1002/ppul.21193; Taylor K, 2007, ANTIMICROB AGENTS CH, V51, P1719, DOI 10.1128/AAC.01531-06; Tullis DE, 2014, J CYST FIBROS, V13, P296, DOI 10.1016/j.jcf.2013.08.011; Waag T, 2010, BIOORG MED CHEM LETT, V20, P5541, DOI 10.1016/j.bmcl.2010.07.062; Waters Valerie, 2006, Expert Rev Anti Infect Ther, V4, P807, DOI 10.1586/14787210.4.5.807; Zhang LL, 2013, FOOD FUNCT, V4, P1229, DOI 10.1039/c3fo60057b	46	60	64	0	52	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 1	2014	9	12							e112726	10.1371/journal.pone.0112726	http://dx.doi.org/10.1371/journal.pone.0112726			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX7SK	25438250	Green Published, gold, Green Submitted			2023-01-03	WOS:000347114900016
J	Aylor, M; Anderson, JM; Vanderford, P; Halsey, M; Lai, S; Braner, DAV				Aylor, Megan; Anderson, JoDee M.; Vanderford, Paula; Halsey, Matthew; Lai, Susanna; Braner, Dana A. V.			Reduction of Pulled Elbow	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							NURSEMAIDS ELBOW		[Aylor, Megan; Anderson, JoDee M.; Vanderford, Paula; Halsey, Matthew; Lai, Susanna; Braner, Dana A. V.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA	Oregon Health & Science University	Braner, DAV (corresponding author), Oregon Hlth & Sci Univ, Dept Pediat, CDRC P, 707 SW Gaines Rd, Portland, OR 97239 USA.	branerd@ohsu.edu	Braner, Dana/Q-4919-2019					Brown D, 2009, ORTHOP NURS, V28, P161, DOI 10.1097/NOR.0b013e3181ada779; Brown M, 2013, ANN EMERG MED, V61, P291, DOI 10.1016/j.annemergmed.2012.10.024; ILLINGWORTH CM, 1975, BRIT MED J, V2, P672, DOI 10.1136/bmj.2.5972.672; Kaplan RE, 2002, PEDIATRICS, V110, P171, DOI 10.1542/peds.110.1.171; Krul M, 2012, COCHRANE DB SYST REV, V1; Macias CG, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e10; McDonald J, 1999, ACAD EMERG MED, V6, P715, DOI 10.1111/j.1553-2712.1999.tb00440.x; Rudloe TF, 2012, PEDIATR EMERG CARE, V28, P771, DOI 10.1097/PEC.0b013e3182624906	8	1	1	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 20	2014	371	21							e32	10.1056/NEJMvcm1211809	http://dx.doi.org/10.1056/NEJMvcm1211809			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AT5ST	25409393				2023-01-03	WOS:000345002900010
J	Fischer, C; Lingsma, HF; Marang-van de Mheen, PJ; Kringos, DS; Klazinga, NS; Steyerberg, EW				Fischer, Claudia; Lingsma, Hester F.; Marang-van de Mheen, Perla J.; Kringos, Dionne S.; Klazinga, Niek S.; Steyerberg, Ewout W.			Is the Readmission Rate a Valid Quality Indicator? A Review of the Evidence	PLOS ONE			English	Article							ACUTE MYOCARDIAL-INFARCTION; RISK-STANDARDIZED MORTALITY; PATIENT SAFETY INDICATORS; LENGTH-OF-STAY; HEART-FAILURE; HOSPITAL READMISSION; PERFORMANCE-MEASURES; CLINICAL-OUTCOMES; DISCHARGE INSTRUCTIONS; EMERGENCY READMISSION	Introduction: Hospital readmission rates are increasingly used for both quality improvement and cost control. However, the validity of readmission rates as a measure of quality of hospital care is not evident. We aimed to give an overview of the different methodological aspects in the definition and measurement of readmission rates that need to be considered when interpreting readmission rates as a reflection of quality of care. Methods: We conducted a systematic literature review, using the bibliographic databases Embase, Medline OvidSP, Web-of-Science, Cochrane central and PubMed for the period of January 2001 to May 2013. Results: The search resulted in 102 included papers. We found that definition of the context in which readmissions are used as a quality indicator is crucial. This context includes the patient group and the specific aspects of care of which the quality is aimed to be assessed. Methodological flaws like unreliable data and insufficient case-mix correction may confound the comparison of readmission rates between hospitals. Another problem occurs when the basic distinction between planned and unplanned readmissions cannot be made. Finally, the multi-faceted nature of quality of care and the correlation between readmissions and other outcomes limit the indicator's validity. Conclusions: Although readmission rates are a promising quality indicator, several methodological concerns identified in this study need to be addressed, especially when the indicator is intended for accountability or pay for performance. We recommend investing resources in accurate data registration, improved indicator description, and bundling outcome measures to provide a more complete picture of hospital care.	[Fischer, Claudia; Lingsma, Hester F.; Steyerberg, Ewout W.] Erasmus MC, Ctr Med Decis Making, Dept Publ Hlth, Rotterdam, Netherlands; [Marang-van de Mheen, Perla J.] Leiden Univ, Med Ctr, Dept Med Decis Making, Leiden, Netherlands; [Kringos, Dionne S.; Klazinga, Niek S.] Amsterdam Med Ctr, Dept Publ Hlth, Amsterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Amsterdam; Academic Medical Center Amsterdam	Fischer, C (corresponding author), Erasmus MC, Ctr Med Decis Making, Dept Publ Hlth, Rotterdam, Netherlands.	c.fischer@erasmusmc.nl	Kringos, Dionne/ABE-2290-2020; de Mheen, Perla J. Marang-van/I-2783-2015	Kringos, Dionne/0000-0003-2711-4713; de Mheen, Perla J. Marang-van/0000-0003-1439-0989; Fischer, Claudia/0000-0001-7574-8097	Dutch Health Care Authority (NZa)	Dutch Health Care Authority (NZa)	This research has been funding by the Dutch Health Care Authority (NZa). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adeyemo D, 2007, ANN ROY COLL SURG, V89, P363, DOI 10.1308/003588407X183409; Ahmed J, 2012, COLORECTAL DIS, V14, P1045, DOI 10.1111/j.1463-1318.2011.02856.x; Almoudaris AM, 2013, GUT, V62, P423, DOI 10.1136/gutjnl-2011-301489; Amin BY, 2012, NEUROSURGERY, V71, pE575, DOI 10.1227/01.neu.0000417785.91373.4d; Auerbach AD, 2010, J AM COLL SURGEONS, V211, P601, DOI 10.1016/j.jamcollsurg.2010.07.006; Auerbach AD, 2009, ANN INTERN MED, V150, P696, DOI 10.7326/0003-4819-150-10-200905190-00007; Axon RN, 2011, JAMA-J AM MED ASSOC, V305, P504, DOI 10.1001/jama.2011.72; Barbieri CE, 2007, J UROLOGY, V178, P1418, DOI 10.1016/j.juro.2007.05.156; Basu A, 2010, INT J HEALTH CARE Q, V23, P436, DOI 10.1108/09526861011037489; Ben-Assuli O, 2013, BMC MED INFORM DECIS, V13, DOI 10.1186/1472-6947-13-49; Benbassat J, 2013, ISR J HEALTH POLICY, V2, DOI 10.1186/2045-4015-2-1; Bernheim SM, 2010, CIRC-CARDIOVASC QUAL, V3, P459, DOI 10.1161/CIRCOUTCOMES.110.957613; Bianco A, 2012, PLOS ONE, V7; Bottle A, 2009, QUAL SAF HEALTH CARE, V18, P303, DOI 10.1136/qshc.2007.026096; Boulding W, 2011, AM J MANAG CARE, V17, P41; Brooke BS, 2012, J VASC SURG, V56, P556, DOI 10.1016/j.jvs.2012.03.260; Burke RE, 2013, J HOSP MED, V8, P102, DOI 10.1002/jhm.1990; Chan FWK, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-186; Chen Judy Y, 2012, J Diabetes Sci Technol, V6, P563; Chung ES, 2008, AM J MED QUAL, V23, P168, DOI 10.1177/1062860608315337; Correll PK, 2007, RESPIROLOGY, V12, P220, DOI 10.1111/j.1440-1843.2006.01039.x; Courtney EDJ, 2003, ANN ROY COLL SURG, V85, P75, DOI 10.1308/003588403321219803; Cram P, 2012, GERIATR ORTHOP SURG, V3, P17, DOI 10.1177/2151458511435723; Dallal RM, 2012, SURG ENDOSC, V26, P754, DOI 10.1007/s00464-011-1947-z; Demir E, 2008, IEEE T INF TECHNOL B, V12, P644, DOI 10.1109/TITB.2007.911311; Demir E, 2012, COMPUT METH PROG BIO, V108, P487, DOI 10.1016/j.cmpb.2011.03.003; Department of Health, 2008, EM READM RAT; Department of Health, 2010, OP FRAM; Desai AS, 2012, CIRCULATION, V126, P501, DOI 10.1161/CIRCULATIONAHA.112.125435; Dobrzanska L, 2006, J CLIN NURS, V15, P599, DOI 10.1111/j.1365-2702.2006.01333.x; Dunlay SM, 2012, ANN INTERN MED, V157, P11, DOI 10.7326/0003-4819-157-1-201207030-00004; Encinosa WE, 2008, HEALTH SERV RES, V43, P2067, DOI 10.1111/j.1475-6773.2008.00882.x; Fischer C, 2012, EUR J PUBLIC HEALTH, V22, P484, DOI 10.1093/eurpub/ckr165; Fonarow GC, 2007, JAMA-J AM MED ASSOC, V297, P61, DOI 10.1001/jama.297.1.61; Forster Alan J, 2012, Open Med, V6, pe75; Gawlas I, 2012, ANN SURG ONCOL, P1; Gheorghiade M, 2013, J AM COLL CARDIOL, V61, P391, DOI 10.1016/j.jacc.2012.09.038; Giamouzis G, 2011, J CARD FAIL, V17, P54, DOI 10.1016/j.cardfail.2010.08.010; Goldfield NI, 2008, HEALTH CARE FINANC R, V30, P75; Grocott MPW, 2010, CURR ANAESTH CRIT CA, V21, P129; Gu Q, 2014, HEALTH SERV RES, V49, P818, DOI 10.1111/1475-6773.12150; Halfon P, 2002, J CLIN EPIDEMIOL, V55, P573, DOI 10.1016/S0895-4356(01)00521-2; Halfon P, 2006, MED CARE, V44, P972, DOI 10.1097/01.mlr.0000228002.43688.c2; Hannan EL, 2011, JACC-CARDIOVASC INTE, V4, P569, DOI 10.1016/j.jcin.2011.01.010; Heggestad T, 2002, HEALTH SERV RES, V37, P647, DOI 10.1111/1475-6773.00042; Hernandez AF, 2010, AM HEART J, V159, P406, DOI 10.1016/j.ahj.2009.12.024; Holt PJE, 2010, EUR J VASC ENDOVASC, V39, P49, DOI 10.1016/j.ejvs.2009.10.003; Horwitz LI, 2012, J HOSP MED, V7, P690, DOI 10.1002/jhm.1965; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Jensen PH, 2009, HEALTH ECON, V18, P1440, DOI 10.1002/hec.1435; Jha AK, 2009, NEW ENGL J MED, V361, P2637, DOI 10.1056/NEJMsa0904859; Jimenez-Puente A, 2004, INT J TECHNOL ASSESS, V20, P385, DOI 10.1017/S0266462304001230; Johnson Tricia, 2012, Qual Manag Health Care, V21, P68, DOI 10.1097/QMH.0b013e31824b9297; Joynt KE, 2011, ANN INTERN MED, V154, P94, DOI 10.7326/0003-4819-154-2-201101180-00008; Judge A, 2006, J PUBLIC HEALTH-UK, V28, P116, DOI 10.1093/pubmed/fdl003; Kaboli PJ, 2012, ANN INTERN MED, V157, P837, DOI 10.7326/0003-4819-157-12-201212180-00003; Kangovi S, 2011, JAMA-J AM MED ASSOC, V306, P1796, DOI 10.1001/jama.2011.1562; Kansagara D, 2011, J GEN INTERN MED, V26, pS125; Kent TS, 2011, J AM COLL SURGEONS, V213, P515, DOI 10.1016/j.jamcollsurg.2011.07.009; Kergoat MJ, 2012, J AM MED DIR ASSOC, V13, P459, DOI 10.1016/j.jamda.2011.11.004; Khawaja FJ, 2012, ARCH INTERN MED, V172, P112, DOI 10.1001/archinternmed.2011.569; Kiran RP, 2004, J AM COLL SURGEONS, V198, P877, DOI 10.1016/j.jamcollsurg.2004.01.036; Kociol RD, 2013, AM HEART J; Kramer AA, 2013, CRIT CARE MED, V41, P24, DOI 10.1097/CCM.0b013e3182657b8a; Krumholz HM, 2013, JAMA-J AM MED ASSOC, V309, P587, DOI 10.1001/jama.2013.333; Krumholz HM, 2009, CIRC-CARDIOVASC QUAL, V2, P407, DOI 10.1161/CIRCOUTCOMES.109.883256; Krumholz HM, 2006, CIRCULATION, V113, P1693, DOI 10.1161/CIRCULATIONAHA.105.611194; Lambrinou E, 2012, INT J NURS STUD, V49, P610, DOI 10.1016/j.ijnurstu.2011.11.002; Lau ACW, 2001, RESP MED, V95, P876, DOI 10.1053/rmed.2001.1180; Lindenauer PK, 2011, J HOSP MED, V6, P142, DOI 10.1002/jhm.890; Luthi JC, 2003, INT J QUAL HEALTH C, V15, P413, DOI 10.1093/intqhc/mzg055; Luthi JC, 2004, QUAL SAF HEALTH CARE, V13, P46, DOI 10.1136/qshc.2003.006999; Maeda JLK, 2010, J CARD FAIL, V16, P411, DOI 10.1016/j.cardfail.2010.01.005; Mansi IA, 2010, J NATL MED ASSOC, V102, P898, DOI 10.1016/S0027-9684(15)30708-2; Marang-van de Mheen PJ, 2010, QUAL SAF HEALTH CARE, V19, DOI 10.1136/qshc.2008.031690; Marcin JP, 2004, CRIT CARE MED, V32, P1477, DOI 10.1097/01.CCM.0000127781.08985.03; Mattke S., 2006, OECD HLTH WORKING PA; Maurer PP, 2004, SWISS MED WKLY, V134, P606; Mayer EK, 2011, BJU INT, V108, pE258, DOI 10.1111/j.1464-410X.2010.10010.x; McConnell KJ, 2013, JAMA INTERN MED, V173, P684, DOI 10.1001/jamainternmed.2013.3577; McCormack R, 2013, J HEALTHC MANAG, V58, P64, DOI 10.1097/00115514-201301000-00011; Mokhtar S. A., 2012, Eastern Mediterranean Health Journal, V18, P474; Morse RB, 2011, JAMA-J AM MED ASSOC, V306, P1454, DOI 10.1001/jama.2011.1385; Nathwani D, 2002, CLIN INFECT DIS, V34, P318, DOI 10.1086/323186; Parker JP, 2003, MED CARE, V41, P407, DOI 10.1097/00005650-200303000-00009; Patterson ME, 2010, MED CARE, V48, P210, DOI 10.1097/MLR.0b013e3181ca3eb4; Polanczyk CA, 2001, J CARD FAIL, V7, P289, DOI 10.1054/jcaf.2001.28931; Ricciardi MJ, 2012, AM J CARDIOL, V110, P1389, DOI 10.1016/j.amjcard.2012.07.002; Roccaforte R, 2005, EUR J HEART FAIL, V7, P1133, DOI 10.1016/j.ejheart.2005.08.005; Rochefort MM, 2012, SURG ONCOL CLIN N AM, V21, P397, DOI 10.1016/j.soc.2012.03.004; Rosen AK, 2013, MED CARE, V51, P37, DOI 10.1097/MLR.0b013e318270c0f7; Rumball-Smith J, 2009, NZ MED J, V122; Rumball-Smith J, 2013, MED CARE, V51, P418, DOI 10.1097/MLR.0b013e31828d1275; Schiotz M, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-347; Schneider EB, 2012, J AM COLL SURGEONS, V214, P390, DOI 10.1016/j.jamcollsurg.2011.12.025; Schopfer DW, 2012, AM HEART J, V164, P80, DOI 10.1016/j.ahj.2012.04.017; Sellers MM, 2013, J AM COLL SURGEONS, V216, P420, DOI 10.1016/j.jamcollsurg.2012.11.013; Shahian DM, 2012, BMJ QUAL SAF, V21, P325, DOI 10.1136/bmjqs-2011-000615; Shepperd S, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000313.pub4; Showalter JW, 2011, J GEN INTERN MED, V26, P718, DOI 10.1007/s11606-011-1712-y; Shulan M, 2013, HEALTH CARE MANAG SC, V16, P167, DOI 10.1007/s10729-013-9220-8; Spector WD, 2012, MED CARE, V50, P863, DOI 10.1097/MLR.0b013e31825f2840; Stefan MS, 2012, J GEN INTERN MED, P1; Stukel TA, 2010, MED CARE, V48, P157, DOI 10.1097/MLR.0b013e3181bd4da7; Tsai TC, 2013, NEW ENGL J MED, V369, P1134, DOI 10.1056/NEJMsa1303118; van Walraven C, 2012, J EVAL CLIN PRACT, V18, P1211, DOI 10.1111/j.1365-2753.2011.01773.x; van Walraven C, 2012, CAN MED ASSOC J, V184, pE810, DOI 10.1503/cmaj.120801; van Walraven C, 2012, J CLIN EPIDEMIOL, V65, P1124, DOI 10.1016/j.jclinepi.2012.04.001; van Walraven C, 2011, CAN MED ASSOC J, V183, pE391, DOI 10.1503/cmaj.101860; VanSuch M, 2006, QUAL SAF HEALTH CARE, V15, P414, DOI 10.1136/qshc.2005.017640; Wallmann R, 2013, INT J CARDIOL, V164, P193, DOI 10.1016/j.ijcard.2011.06.119; Weber RS, 2010, ARCH OTOLARYNGOL, V136, P1212, DOI 10.1001/archoto.2010.215; Wong FKY, 2011, SOC SCI MED, V73, P960, DOI 10.1016/j.socscimed.2011.06.036; Youn YJ, 2012, CIRC J, V76, P1151, DOI 10.1253/circj.CJ-11-1093	114	145	145	0	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 7	2014	9	11							e112282	10.1371/journal.pone.0112282	http://dx.doi.org/10.1371/journal.pone.0112282			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AT3WF	25379675	Green Submitted, Green Published, gold			2023-01-03	WOS:000344863100073
J	Rollig, C; Knop, S; Bornhauser, M				Roellig, Christoph; Knop, Stefan; Bornhaeuser, Martin			Multiple myeloma	LANCET			English	Article							STEM-CELL TRANSPLANTATION; HIGH-DOSE THERAPY; THALIDOMIDE PLUS DEXAMETHASONE; UNDETERMINED SIGNIFICANCE MGUS; SINGLE-AGENT CARFILZOMIB; PHASE-III; INDUCTION THERAPY; MAINTENANCE THERAPY; ELDERLY-PATIENTS; AUTOLOGOUS TRANSPLANTATION	Multiple myeloma is a malignant disease characterised by proliferation of clonal plasma cells in the bone marrow and typically accompanied by the secretion of monoclonal immunoglobulins that are detectable in the serum or urine. Increased understanding of the microenvironmental interactions between malignant plasma cells and the bone marrow niche, and their role in disease progression and acquisition of therapy resistance, has helped the development of novel therapeutic drugs for use in combination with cytostatic therapy. Together with autologous stem cell transplantation and advances in supportive care, the use of novel drugs such as proteasome inhibitors and immunomodulatory drugs has increased response rates and survival substantially in the past several years. Present clinical research focuses on the balance between treatment efficacy and quality of life, the optimum sequencing of treatment options, the question of long-term remission and potential cure by multimodal treatment, the pre-emptive treatment of high-risk smouldering myeloma, and the role of maintenance. Upcoming results of ongoing clinical trials, together with a pipeline of promising new treatments, raise the hope for continuous improvements in the prognosis of patients with myeloma in the future.	[Roellig, Christoph; Bornhaeuser, Martin] Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Med Klin & Poliklin 1, D-01062 Dresden, Germany; [Knop, Stefan] Univ Klinikum Wurzburg, Med Klin & Poliklin 1, Wurzburg, Germany	Technische Universitat Dresden; Carl Gustav Carus University Hospital; University of Wurzburg	Rollig, C (corresponding author), Univ Klinikum Carl Gustav Carus, Med Klin & Poliklin 1, Fetscherstr 74, D-01307 Dresden, Germany.	christoph.roellig@uniklinikum-dresden.de			Amgen; Celgene; Janssen; Novartis; Mundipharma; Onyx; MedA; Genzyme; Gilead; Astellas	Amgen(Amgen); Celgene(Bristol-Myers SquibbCelgene Corporation); Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Novartis(Novartis); Mundipharma; Onyx; MedA; Genzyme(Sanofi-AventisGenzyme Corporation); Gilead(Gilead Sciences); Astellas(Astellas Pharmaceuticals)	CR has received speaker's fees from Amgen, Celgene, Janssen, Novartis, and Amgen. SK has received consultancies, honoraria, and speaker's fees from Celgene, Mundipharma, Janssen, Onyx, and travel or accommodation payments from Celgene. MB has received speaker's fees from Celgene, Novartis, MedA, Genzyme, and Gilead, received a travel grant from Astellas, and has served on an advisory board for Riemser.	Alvares CL, 2006, HAEMATOLOGICA, V91, P141; Attal M, 2003, NEW ENGL J MED, V349, P2495, DOI 10.1056/NEJMoa032290; Attal M, 1996, NEW ENGL J MED, V335, P91, DOI 10.1056/NEJM199607113350204; Attal M, 2012, NEW ENGL J MED, V366, P1782, DOI 10.1056/NEJMoa1114138; Beksac M, 2011, EUR J HAEMATOL, V86, P16, DOI 10.1111/j.1600-0609.2010.01524.x; Berenson JR, 2002, BLOOD, V99, P3163, DOI 10.1182/blood.V99.9.3163; Boccadoro M, 2013, ASCO M, V31, P8509; Casassus P, 2001, BRIT J HAEMATOL, V113, P1020; Cavo M, 2010, LANCET, V376, P2075, DOI 10.1016/S0140-6736(10)61424-9; Chanan-Khan A, 2008, J CLIN ONCOL, V26, P4784, DOI 10.1200/JCO.2007.14.9641; Chanan-Khan AA, 2012, CLIN CANCER RES, V18, P2145, DOI 10.1158/1078-0432.CCR-11-0498; Chanan-Khan AA, 2010, J CLIN ONCOL, V28, P2612, DOI 10.1200/JCO.2009.25.4250; Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837; Dickinson M, 2009, INTERN MED J, V39, P304, DOI 10.1111/j.1445-5994.2008.01824.x; Dimopoulos M, 2009, LEUKEMIA, V23, P1545, DOI 10.1038/leu.2009.89; DIMOPOULOS MA, 1992, J CLIN ONCOL, V10, P587, DOI 10.1200/JCO.1992.10.4.587; Dimopoulos MA, 2012, ASH ANN M, V120, P944; Dispenzieri A, 2009, LEUKEMIA, V23, P215, DOI 10.1038/leu.2008.307; Dispenzieri A, 2012, BLOOD REV, V26, P137, DOI 10.1016/j.blre.2012.03.001; Durie BGM, 2006, LEUKEMIA, V20, P1467, DOI 10.1038/sj.leu.2404284; Durie Brian G M, 2003, Hematol J, V4, P379; Egan JB, 2012, BLOOD, V120, P1060, DOI 10.1182/blood-2012-01-405977; Facon T, 2013, BLOOD, V122, DOI 10.1182/blood.V122.21.2.2; Fermand JP, 1998, BLOOD, V92, P3131, DOI 10.1182/blood.V92.9.3131.421k30_3131_3136; Fritz E, 2000, ANN ONCOL, V11, P1427, DOI 10.1023/A:1026548226770; Garderet L, 2012, J CLIN ONCOL, V30, P2475, DOI 10.1200/JCO.2011.37.4918; Giralt S, 2009, LEUKEMIA, V23, P1904, DOI 10.1038/leu.2009.127; Gorgun GT, 2013, BLOOD, V121, P2975, DOI 10.1182/blood-2012-08-448548; Hahn A., 2011, HAEMATOLOGICA S2, V96, P884; Harousseau JL, 2010, BLOOD, V116, P3743, DOI 10.1182/blood-2010-03-275800; Harousseau JL, 2010, J CLIN ONCOL, V28, P4621, DOI 10.1200/JCO.2009.27.9158; Harousseau JL, 2009, BLOOD, V114, P3139, DOI 10.1182/blood-2009-03-201053; He Y., 2003, COCHRANE DATABASE SY, V2003, DOI [DOI 10.1002/14651858.CD004023, 10.1002/14651858.CD004023]; Hu K, 2000, ONCOLOGY-NY, V14, P101; Lahuerta JJ, 2008, J CLIN ONCOL, V26, P5775, DOI 10.1200/JCO.2008.17.9721; Kapoor P, 2011, LEUKEMIA, V25, P689, DOI 10.1038/leu.2010.313; Kastritis E, 2013, EXPERT OPIN PHARMACO, V14, P1477, DOI 10.1517/14656566.2013.803068; Koreth J, 2007, BIOL BLOOD MARROW TR, V13, P183, DOI 10.1016/j.bbmt.2006.09.010; Kristinsson SY, 2007, J CLIN ONCOL, V25, P1993, DOI 10.1200/JCO.2006.09.0100; Kropff M, 2009, ANN HEMATOL, V88, P1125, DOI 10.1007/s00277-009-0726-6; Kuehl WM, 2012, J CLIN INVEST, V122, P3456, DOI 10.1172/JCI61188; Kumar A, 2011, AM J HEMATOL, V86, P18, DOI 10.1002/ajh.21904; Kumar A, 2011, ACTA HAEMATOL-BASEL, V125, P8, DOI 10.1159/000318880; Kumar A, 2009, J NATL CANCER I, V101, P100, DOI 10.1093/jnci/djn439; Kumar S, 2012, BLOOD, V119, P4375, DOI 10.1182/blood-2011-11-395749; Kumar S, 2011, BLOOD, V118, P1979, DOI 10.1182/blood-2011-02-337329; Kumar SK, 2008, BLOOD, V111, P2516, DOI 10.1182/blood-2007-10-116129; Kumar SK, 2012, CANCER-AM CANCER SOC, V118, P1585, DOI 10.1002/cncr.26422; Kumar SK, 2012, ASH ANN M ABSTR, V120, P3972, DOI DOI 10.1038/LEU.2013.313; Kyle RA, 2010, LEUKEMIA, V24, P1121, DOI 10.1038/leu.2010.60; Kyle RA, 2009, LEUKEMIA, V23, P3, DOI 10.1038/leu.2008.291; Kyle RA, 2007, NEW ENGL J MED, V356, P2582, DOI 10.1056/NEJMoa070389; Lacy MQ, 2006, MAYO CLIN PROC, V81, P1047, DOI 10.4065/81.8.1047; Ladetto M, 2010, J CLIN ONCOL, V28, P2077, DOI 10.1200/JCO.2009.23.7172; Landgren O, 2006, BLOOD, V107, P904, DOI 10.1182/blood-2005-08-3449; Larocca A, 2012, BLOOD, V119, P933, DOI 10.1182/blood-2011-03-344333; Leung N, 2012, ADV CHRONIC KIDNEY D, V19, P297, DOI 10.1053/j.ackd.2012.06.001; Lokhorst HM, 2010, BLOOD, V115, P1113, DOI 10.1182/blood-2009-05-222539; Ludwig H, 2012, ONCOLOGIST, V17, P592, DOI 10.1634/theoncologist.2011-0391; Ludwig H, 2012, BLOOD, V119, P3003, DOI 10.1182/blood-2011-11-374249; Ludwig H, 2009, BLOOD, V113, P3435, DOI 10.1182/blood-2008-07-169565; Matsui W, 2008, CANCER RES, V68, P190, DOI 10.1158/0008-5472.CAN-07-3096; McCarthy PL, 2012, NEW ENGL J MED, V366, P1770, DOI 10.1056/NEJMoa1114083; Mellqvist UH, 2013, BLOOD, V121, P4647, DOI 10.1182/blood-2012-11-464503; Merlini G, 2013, BLOOD, V121, P5124, DOI 10.1182/blood-2013-01-453001; Mhaskar R, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003188.pub3; Mohty B, 2012, LEUKEMIA, V26, P73, DOI 10.1038/leu.2011.310; Moreau P, 2011, BLOOD, V117, P3041, DOI 10.1182/blood-2010-08-300863; Morgan GJ, 2012, HAEMATOL-HEMATOL J, V97, P442, DOI 10.3324/haematol.2011.043372; Morgan GJ, 2012, BLOOD, V119, P7, DOI 10.1182/blood-2011-06-357038; National Cancer Institute, 2013, SURV EP END RES PROG; National Comprehensive Cancer Network, 2013, NCCN GUID DER INF PR; Neben K, 2012, ASH ANN M, V120, P3086; Nooka AK, 2011, ASH ANN M, V118, P1855; Palumbo A, 2008, LEUKEMIA, V22, P414, DOI 10.1038/sj.leu.2405062; Palumbo A, 2009, LEUKEMIA, V23, P1716, DOI 10.1038/leu.2009.122; Palumbo A, 2006, LANCET, V367, P825, DOI 10.1016/S0140-6736(06)68338-4; Palumbo A, 2012, NEW ENGL J MED, V366, P1759, DOI 10.1056/NEJMoa1112704; Palumbo A, 2011, CLIN CANCER RES, V17, P1253, DOI 10.1158/1078-0432.CCR-10-1925; Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442; Palumbo A, 2010, BLOOD, V115, P1873, DOI 10.1182/blood-2009-09-241737; Popat R, 2008, BRIT J HAEMATOL, V141, P512, DOI 10.1111/j.1365-2141.2008.06997.x; Puig N, 2014, LEUKEMIA, V28, P391, DOI 10.1038/leu.2013.217; Rajkumar SV, 2012, AM J HEMATOL, V87, P79, DOI 10.1002/ajh.22237; Rajkumar SV, 2011, AM J HEMATOL, V86, P57, DOI 10.1002/ajh.21913; Rajkumar SV, 2010, LANCET ONCOL, V11, P29, DOI 10.1016/S1470-2045(09)70284-0; Rajkumar SV, 2006, J CLIN ONCOL, V24, P431, DOI 10.1200/JCO.2005.03.0221; Reed V, 2011, CANCER-AM CANCER SOC, V117, P4468, DOI 10.1002/cncr.26031; Reeder CB, 2009, LEUKEMIA, V23, P1337, DOI 10.1038/leu.2009.26; Reeder CB, 2010, BLOOD, V115, P3416, DOI 10.1182/blood-2010-02-271676; RICCARDI A, 1991, EUR J CANCER, V27, P1401, DOI 10.1016/0277-5379(91)90020-E; Richardson PG, 2010, BLOOD, V116, P679, DOI 10.1182/blood-2010-02-268862; Rosinol L, 2012, BLOOD, V120, P1589, DOI 10.1182/blood-2012-02-408922; Miguel JS, 2013, LANCET ONCOL, V14, P1055, DOI 10.1016/S1470-2045(13)70380-2; San Miguel JF, 2013, J CLIN ONCOL, V31, P448, DOI 10.1200/JCO.2012.41.6180; Shustik C, 2007, BRIT J HAEMATOL, V136, P203, DOI 10.1111/j.1365-2141.2006.06405.x; Siegel DS, 2012, BLOOD, V120, P2817, DOI 10.1182/blood-2012-05-425934; Sonneveld P, 2012, J CLIN ONCOL, V30, P2946, DOI 10.1200/JCO.2011.39.6820; Stewart AK, 2009, BLOOD, V114, P5436, DOI 10.1182/blood-2009-07-204651; Terpos E, 2013, J CLIN ONCOL, V31, P2347, DOI 10.1200/JCO.2012.47.7901; van de Velde HJK, 2007, HAEMATOLOGICA, V92, P1399, DOI 10.3324/haematol.11534; Vesole DH, 1999, J CLIN ONCOL, V17, P2173, DOI 10.1200/JCO.1999.17.7.2173; Vickrey E, 2009, CANCER-AM CANCER SOC, V115, P229, DOI 10.1002/cncr.24006; Vij R, 2012, BRIT J HAEMATOL, V158, P739, DOI 10.1111/j.1365-2141.2012.09232.x; Waage A, 2010, BLOOD, V116, P1405, DOI 10.1182/blood-2009-08-237974; Wang M, 2010, BONE MARROW TRANSPL, V45, P498, DOI 10.1038/bmt.2009.176; Wijermans P, 2010, J CLIN ONCOL, V28, P3160, DOI 10.1200/JCO.2009.26.1610; Yeh Y, 2008, BLOOD, V112, P825; Zonder JA, 2010, BLOOD, V116, P5838, DOI 10.1182/blood-2010-08-303487	109	416	447	5	106	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 30	2015	385	9983					2197	2208		10.1016/S0140-6736(14)60493-1	http://dx.doi.org/10.1016/S0140-6736(14)60493-1			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CJ6DG	25540889				2023-01-03	WOS:000355583000030
J	Rowhani-Rahbar, A; Zatzick, D; Wang, J; Mills, BM; Simonetti, JA; Fan, MD; Rivara, FP				Rowhani-Rahbar, Ali; Zatzick, Douglas; Wang, Jin; Mills, Brianna M.; Simonetti, Joseph A.; Fan, Mary D.; Rivara, Frederick P.			Firearm-Related Hospitalization and Risk for Subsequent Violent Injury, Death, or Crime Perpetration A Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; UNITED-STATES; HOMICIDE OFFENDERS; PSYCHIATRIC-DISORDERS; COLLABORATIVE CARE; TRIAL; TRAUMA; BEHAVIORS; MORTALITY; SURVIVORS	Background: Risk for violent victimization or crime perpetration after firearm-related hospitalization (FRH) must be determined to inform the need for future interventions. Objective: To compare the risk for subsequent violent injury, death, or crime perpetration among patients with an FRH, those hospitalized for noninjury reasons, and the general population. Design: Retrospective cohort study. Setting: All hospitals in Washington. Patients: Patients with an FRH and a random sample of those with a non-injury-related hospitalization in 2006 to 2007 (index hospitalization). Measurements: Primary outcomes included subsequent FRH, firearm-related death, and the combined outcome of firearm-or violence-related arrest ascertained through 2011. Results: Among patients with an index FRH (n = 613), rates of subsequent FRH, firearm-related death, and firearm-or violencerelated arrest were 329 (95% CI, 142 to 649), 100 (CI, 21 to 293), and 4221 (CI, 3352 to 5246) per 100 000 person-years, respectively. Compared with the general population, standardized incidence ratios among patients with an index FRH were 30.1 (CI, 14.9 to 61.0) for a subsequent FRH and 7.3 (CI, 2.4 to 22.9) for firearm-related death. In survival analyses that accounted for competing risks, patients with an index FRH were at greater risk for subsequent FRH (subhazard ratio [sHR], 21.2 [CI, 7.0 to 64.0]), firearm-related death (sHR, 4.3 [CI, 1.3 to 14.1]), and firearm- or violence-related arrest (sHR, 2.7 [CI, 2.0 to 3.5]) than those with a non-injury-related index hospitalization. Limitation: Lack of information on whether patients continued to reside in Washington during follow-up may have introduced outcome misclassification. Conclusion: Hospitalization for a firearm-related injury is associated with a heightened risk for subsequent violent victimization or crime perpetration. Further research at the intersection of clinical care, the criminal justice system, and public health to evaluate the effectiveness of interventions delivered to survivors of firearm-related injury is warranted.	Univ Washington, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Rowhani-Rahbar, A (corresponding author), Univ Washington, Dept Epidemiol, Box 357236, Seattle, WA 98195 USA.			Rowhani-Rahbar, Ali/0000-0002-2705-4485; Mills, Brianna/0000-0002-6632-9592	Seattle City Council; University of Washington Royalty Research Fund; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007543] Funding Source: NIH RePORTER	Seattle City Council; University of Washington Royalty Research Fund(University of Washington); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	By the Seattle City Council and the University of Washington Royalty Research Fund.	[Anonymous], NCVS VICT AN TOOL; [Anonymous], 2007, CRIMINOL PUBLIC POL, DOI DOI 10.1111/J.1745-9133.2007.00429.X; [Anonymous], 2014, INJ PREV CONTR DAT S; Broidy LM, 2006, HOMICIDE STUD, V10, P155, DOI 10.1177/1088767906288577; Centers for Disease Control and Prevention, 2014, NAT VIOL DEATH REP S; Cherry D, 1998, ANN EMERG MED, V32, P51, DOI 10.1016/S0196-0644(98)70099-X; Cook PJ, 2005, JAMA-J AM MED ASSOC, V294, P598, DOI 10.1001/jama.294.5.598; Cook PJ, 1999, JAMA-J AM MED ASSOC, V282, P447, DOI 10.1001/jama.282.5.447; Corrigan PW, 2005, PSYCHIAT RES, V136, P153, DOI 10.1016/j.psychres.2005.06.005; Cunningham R, 2009, ANN EMERG MED, V53, P490, DOI 10.1016/j.annemergmed.2008.11.014; DeLisi M, 2006, CRIM JUSTICE BEHAV, V33, P367, DOI 10.1177/0093854806286193; DiScala C, 2004, PEDIATRICS, V113, P1306, DOI 10.1542/peds.113.5.1306; Dowd MD, 1996, AM J PUBLIC HEALTH, V86, P929, DOI 10.2105/AJPH.86.7.929; Elbogen EB, 2009, ARCH GEN PSYCHIAT, V66, P152, DOI 10.1001/archgenpsychiatry.2008.537; Farrington DP, 2012, HOMICIDE STUD, V16, P99, DOI 10.1177/1088767912439398; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Galea S, 2010, AM J PUBLIC HEALTH, V100, P1745, DOI 10.2105/AJPH.2009.179697; Gostin LO, 2011, JAMA-J AM MED ASSOC, V305, P2108, DOI 10.1001/jama.2011.688; Greenspan AI, 2002, J TRAUMA, V53, P709, DOI 10.1097/00005373-200210000-00015; Gubler KD, 1996, J TRAUMA, V41, P952, DOI 10.1097/00005373-199612000-00002; Hawkins JD, 2014, JAMA PEDIATR, V168, P122, DOI 10.1001/jamapediatrics.2013.4009; Howard G, 2000, ANN EPIDEMIOL, V10, P214, DOI 10.1016/S1047-2797(00)00038-7; Kalesan B, 2014, AM J EPIDEMIOL, V179, P303, DOI 10.1093/aje/kwt255; Kellermann AL, 1996, NEW ENGL J MED, V335, P1438, DOI 10.1056/NEJM199611073351906; Lauritsen JL, 2009, CRIMINOLOGY, V47, P361, DOI 10.1111/j.1745-9125.2009.00149.x; Lee J, 2014, SURGERY, V155, P894, DOI 10.1016/j.surg.2014.02.011; Loeber R, 2011, LONG RES SOC BEH SCI, P1, DOI 10.1007/978-1-4419-9949-8; Lustenberger T, 2011, WORLD J SURG, V35, P528, DOI 10.1007/s00268-010-0920-7; Metzl JM, 2011, LANCET, V377, P2172, DOI 10.1016/S0140-6736(11)60950-1; Miller T, 2012, COST FIREARM VIOLENC; Piquero AR, 2003, CRIME JUSTICE, V30, P359, DOI 10.1086/652234; Planty M., 2013, FIREARM VIOLENCE 199; Pulay AJ, 2008, J CLIN PSYCHIAT, V69, P12, DOI 10.4088/JCP.v69n0103; Purtle J, 2013, J TRAUMA ACUTE CARE, V75, P331, DOI 10.1097/TA.0b013e318294f518; RESNICK MD, 2004, J HLTH EC, V0035; RIVARA FP, 1993, JAMA-J AM MED ASSOC, V270, P1962, DOI 10.1001/jama.270.16.1962; Sampson R.J., 2005, RACE CRIME JUSTICE R, P177; Washington State Department of Health, WASH STAT COMPR HOSP; WEISBESKI D, 1989, J TRAUMA, V29, P940, DOI 10.1097/00005373-198907000-00006; Wintemute GJ, 2001, JAMA-J AM MED ASSOC, V285, P1019, DOI 10.1001/jama.285.8.1019; Worrell SS, 2006, J TRAUMA, V60, P379, DOI 10.1097/01.ta.0000203549.15373.7b; Zatzick D, 2004, ARCH GEN PSYCHIAT, V61, P498, DOI 10.1001/archpsyc.61.5.498; Zatzick D, 2014, JAMA PEDIATR, V168, P532, DOI 10.1001/jamapediatrics.2013.4784; Zatzick D, 2013, ANN SURG, V257, P390, DOI 10.1097/SLA.0b013e31826bc313; [No title captured]	45	70	70	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 7	2015	162	7					492	U167		10.7326/M14-2362	http://dx.doi.org/10.7326/M14-2362			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CG4UT	25706337				2023-01-03	WOS:000353283400004
J	Janbaz, KH; Ahsan, MZ; Saqib, F; Imran, I; Zia-Ul-Haq, M; Rashid, MA; Jaafar, HZE; Moga, M				Janbaz, Khalid Hussain; Ahsan, Muhammad Zaeem; Saqib, Fatima; Imran, Imran; Zia-Ul-Haq, Muhammad; Rashid, Muhammad Abid; Jaafar, Hawa Z. E.; Moga, Marius			Scientific Basis for Use of Pyrus pashia Buch.-Ham. ex D. Don. Fruit in Gastrointestinal, Respiratory and Cardiovascular Ailments	PLOS ONE			English	Article							PHENOLIC-COMPOUNDS; MEDICINAL-PLANTS; IN-VITRO; PHARMACOLOGICAL BASIS; ANTIOXIDANT; CALCIUM; BRONCHODILATOR; COMMUNITIES; DISTRICT; EXTRACT	Background Pyrus pashia Buch.-Ham. ex D. Don. has been used conventionally by many communities in the Himalayan region for the management of gastrointestinal, respiratory, and vascular complications. Set against this background, this study was carried out to justify the scientific basis to validate folkloric uses of fruits of Pyrus pashia Buch.-Ham. ex D. Don. (Pp.Cr) in traditional systems of medicine. Methods The crude ethanol extract of fruits of Pyrus pashia Buch.-Ham. ex D. Don. (Pp.Cr) was tested in vitro on isolated rabbit jejunum, tracheal, and aorta preparations. The responses of tissues were recorded using isotonic transducers coupled with a PowerLab data acquisition system. Results The Pp.Cr on application (0.01-5.0 mg/ml) to isolated rabbit jejunum preparation exhibited relaxation through decrease in magnitude and frequency of spontaneous contractions. The Pp.Cr also exerted a relaxant (0.01-5.0 mg/ml) effect on K+(80 mM) induced contractions in isolated rabbit jejunum preparations and caused shifting of the Ca2+ curves (1.0-3.0 mg/ml) toward right in a manner similar to that of verapamil (3 mu M), possibly suggesting presence of Ca2+ channel blocking activity. Subsequently, Pp.Cr in a concentration-dependent fashion (0.01-10.0 mg/ml) caused relaxation of CCh (1 mu M) and K+ (80 mM) induced contractions in isolated rabbit tracheal preparations in a manner comparable to that of dicyclomine, suggesting that the observed relaxant effect is likely to be mediated through antimuscarinic and/or Ca2+ channel blocking activities. Moreover, when evaluated against isolated rabbit aortic preparations, the Pp.Cr in concentrations up to 10 mg/ml exhibited a contractile response that was found to be abolished subsequent to pretreatment of isolated tissue preparation with cyproheptadine (1 mu M), phentolamine (1 mu M), and losartan (1 mu M), suggesting that Pp.Cr may have some alpha-adrenergic, muscarinic, serotonergic, and angiotensin II activities. Conclusions The aqueous ethanolic extract of Pyrus pashia (Pp.Cr) exhibited spasmolytic, bronchodilator, and vaso-constrictive activities possibly through different mechanisms. The spasmolytic and bronchodilator activities are likely to be mediated through blockade of Ca2+ channels, while vasoconstrictive activity may be due to presence of a alpha-adrenergic, muscarinic, serotonergic, and angiotensin II agonistic component.	[Janbaz, Khalid Hussain; Ahsan, Muhammad Zaeem; Saqib, Fatima; Imran, Imran] Bahauddin Zakariya Univ, Fac Pharm, Multan, Pakistan; [Zia-Ul-Haq, Muhammad] Patent Off, Karachi, Pakistan; [Rashid, Muhammad Abid] Univ Agr Faisalabad, Dept Chem & Biochem, Faisalabad, Pakistan; [Jaafar, Hawa Z. E.] Fac Agr, Dept Crop Sci, Selangor, Malaysia; [Moga, Marius] Transilvania Univ Brasov, Dept Med, Brasov, Romania	Bahauddin Zakariya University; University of Agriculture Faisalabad; Universiti Putra Malaysia; Transylvania University of Brasov	Zia-Ul-Haq, M (corresponding author), Patent Off, Karachi, Pakistan.	ahirzia@gmail.com; hawazej@gmail.com	Ahsan, Muhammad Zaeem/GRF-3151-2022; Rashid, Muhammad Abid/G-8109-2015; Janbaz, Khalid Hussain/L-2426-2015; MOGA, MARIUS ALEXANDRU/AHC-2310-2022; Imran, Imran/AAL-5734-2020; Rashid, Muhammad Abid/C-2800-2015; Zia-Ul-Haq, Muhammad/J-1798-2015	Ahsan, Muhammad Zaeem/0000-0002-7367-3818; Imran, Imran/0000-0003-1337-8574; Rashid, Muhammad Abid/0000-0002-3053-2767; saqib, fatima/0000-0001-6242-7147				Abbasi AM, 2013, J ETHNOPHARMACOL, V148, P528, DOI 10.1016/j.jep.2013.04.050; Ahmad Z, 2007, COUNTRY REPORT PLANT; BOLTON TB, 1979, PHYSIOL REV, V59, P606, DOI 10.1152/physrev.1979.59.3.606; BRADING AF, 1980, BRIT J PHARMACOL, V70, P229, DOI 10.1111/j.1476-5381.1980.tb07928.x; CHALLICE JS, 1968, PHYTOCHEMISTRY, V7, P1781, DOI 10.1016/S0031-9422(00)86651-0; CHAMBERS R., 1979, J ETHNOPHARMACOL, V10, P1, DOI DOI 10.1016/0378-8741(79)90013-8; Chaudhary MA, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-166; Farooquee Nehal A., 2004, Journal of Human Ecology, V16, P33; FARRE AJ, 1991, GEN PHARMACOL, V22, P177, DOI 10.1016/0306-3623(91)90331-Y; FLECKENSTEIN A, 1977, ANNU REV PHARMACOL, V17, P149, DOI 10.1146/annurev.pa.17.040177.001053; Gilani AH, 2005, LIFE SCI, V76, P3089, DOI 10.1016/j.lfs.2004.12.021; Gilani SN, 2010, PHYTOTHER RES, V24, P553, DOI 10.1002/ptr.2979; GODFRAIND T, 1986, PHARMACOL REV, V38, P321; Guven K, 2006, PHARM BIOL, V44, P79, DOI 10.1080/13880200600591253; Hussein FTK, 1983, MED PLANTS LIBYA, P7; Janbaz KH, 2013, J PHYSIOL PHARMACOL, V64, P479; Janbaz KH, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-71; Janbaz Khalid Hussain, 2012, Evid Based Complement Alternat Med, V2012, P735653, DOI 10.1155/2012/735653; Jiangsu New Medical College, 1986, DICT CHIN TRAD MED; JOSHI AR, 1990, ECON BOT, V44, P71, DOI 10.1007/BF02861069; Kala CP, 2002, MED PLANTS INDIAN TR; Karaki H, 1997, PHARMACOL REV, V49, P157; KARAKI H, 1988, LIFE SCI, V42, P111, DOI 10.1016/0024-3205(88)90674-1; Khandelwal R, 2008, ORIENT J CHEM, V24, P773; Lama Y C, 2001, MED PLANTS DOLPO AMC; MAGA JA, 1978, CRC CR REV FOOD SCI, V10, P323, DOI 10.1080/10408397809527255; Main A., 2001, PAK J BIOL SCI, V4, P1101, DOI DOI 10.3923/pjbs.2001.1101.1107; MANANDHAR N P, 1990, International Journal of Crude Drug Research, V28, P17; Manandhar Narayan P., 1994, Fitoterapia, V65, P7; MANANDHAR NP, 1995, J ETHNOPHARMACOL, V48, P1, DOI 10.1016/0378-8741(95)01269-J; Meyers KJ, 2003, J AGR FOOD CHEM, V51, P6887, DOI 10.1021/jf034506n; Nakul Chettri, 2005, Lyonia, V8, P89; Nassar MI, 2011, CARBOHYD RES, V346, P64, DOI 10.1016/j.carres.2010.11.007; National Research Council, 1996, GUIDE CARE USE LAB A; Prajapati N.D, 2003, PLANT PHYSL FUNDAMEN; Saklani S, 2012, INT J PHARM SCI RES, V3, P268, DOI 10.13040/IJPSR.0975-8232.3(1).268-72; Sarla Saklani, 2012, Journal of Pharmacy Research, V5, P3030; Shinwari M.I., 1998, HAMDARD MED, V42, P5; Shrestha PM, 2003, J ETHNOPHARMACOL, V86, P81, DOI 10.1016/S0378-8741(03)00051-5; Shui GH, 2002, J CHROMATOGR A, V977, P89, DOI 10.1016/S0021-9673(02)01345-6; SINGH MP, 1979, ECON BOT, V33, P185, DOI 10.1007/BF02858287; Thapa B, 1997, ANIM FEED SCI TECH, V67, P97, DOI 10.1016/S0377-8401(96)01129-7; Tona L, 1998, J ETHNOPHARMACOL, V61, P57, DOI 10.1016/S0378-8741(98)00015-4; Tsering J, 2012, INT J PHARM SCI RES, V3, P2721, DOI 10.13040/IJPSR.0975-8232.3(8).2721-25; VAN ROSSUM J. M., 1963, ARCH INTERNATL PHARMACODYN ET THER, V143, P299; Zia-Ul-Haq M, 2013, OXID COMMUN, V36, P15; Zia-Ul-Haq M, 2014, BIOL RES, V47, DOI 10.1186/0717-6287-47-23; Zia-Ul-Haq M, 2013, ACTA BOT CROAT, V72, P133, DOI 10.2478/v10184-012-0005-9; Zia-Ul-Haq M, 2013, TURK J BIOL, V37, P25, DOI 10.3906/biy-1204-38; Zia-Ul-Haq M, 2013, PAK J PHARM SCI, V26, P185; Zia-Ul-Haq M, 2013, MOLECULES, V18, P2005, DOI 10.3390/molecules18022005	51	27	27	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 18	2015	10	3							e0118605	10.1371/journal.pone.0118605	http://dx.doi.org/10.1371/journal.pone.0118605			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE9BN	25786248	Green Published, Green Submitted, gold			2023-01-03	WOS:000352138500040
J	Yang, C; Li, J; Lin, H; Zhao, KQ; Zheng, CQ				Yang, Chen; Li, Jing; Lin, Hai; Zhao, Keqing; Zheng, Chunquan			Nasal Mucosa Derived-Mesenchymal Stem Cells from Mice Reduce Inflammation via Modulating Immune Responses	PLOS ONE			English	Article							VERSUS-HOST-DISEASE; ALLERGIC RHINITIS	Mesenchymal stem cells (MSCs) have arisen the attention to be a new attractive therapeutic tool treating autoimmune diseases such as allergic rhinitis (AR). AR is a chronic reversible allergic inflammation caused by the excessive activation of T-helper 2 (Th2) cells. Recently, MSCs have been proposed as a new therapy of AR as it can suppress some cytokines to control allogeneic Th2 response and functions. However, how MSCs function to reduce inflammation remains unclear. In this study, we aimed to investigate the role of ectomesenchymal stem cells (ECTO-MSCs) derived from nasal mucosa in eosinophilic inflammation and how it affects some immunoglobulins and cytokines. We used ovalbumin (OVA) as a sensitizer to induce nasal inflammation in mice by both injection and inhalation. In order to obtain deeper insights into the influences of ECTO-MSCs on nasal inflammation, the migration of ECTO-MSCs was assessed, the numbers of eosinophils and sneezing were counted, and several immunoglobulins and cytokines were measured. Here we show the ECTO-MSCs are able to migrate to inflammation site via tail vein injection. Eosinophils and sneezing were suppressed by ECTO-MSCs. Interestingly, IgE, interleukin (IL)-4, IL-5 and IL-10 secreted by Th-2 cells were down-regulated by ECTO-MSCs whereas IgG2 and IFN-gamma were up-regulated. In conclusion, we have observed that ECTO-MSCs are associated with enhanced Th-1 immune response to nasal inflammation and reduced Th-2 immune response. Given the contributions of Th-2 cells to AR, the injection of ECTO-MSCs can be a promising therapy of AR through balancing immune response.	[Yang, Chen; Li, Jing; Lin, Hai; Zhao, Keqing; Zheng, Chunquan] Fudan Univ, Dept Otolaryngol Head & Neck Surg, Eye Ear Nose & Throat Hosp, Shanghai 200433, Peoples R China; [Yang, Chen] Shanghai Jiao Tong Univ, Dept Otolaryngol, Ruijin Hosp, Shanghai 200030, Peoples R China	Fudan University; Shanghai Jiao Tong University	Zheng, CQ (corresponding author), Fudan Univ, Dept Otolaryngol Head & Neck Surg, Eye Ear Nose & Throat Hosp, Shanghai 200433, Peoples R China.	chunquanzheng@163.com			National Natural Science Foundation of China (NSFC) [81470672]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC))	This study is funded by the National Natural Science Foundation of China (NSFC, 81470672). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559; Baksh D, 2004, J CELL MOL MED, V8, P301, DOI 10.1111/j.1582-4934.2004.tb00320.x; Cho KS, 2009, STEM CELLS, V27, P259, DOI 10.1634/stemcells.2008-0283; Ciprandi G, 2005, OTOLARYNG HEAD NECK, V133, P429, DOI 10.1016/j.otohns.2005.05.049; COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169; Delorme B, 2010, STEM CELLS DEV, V19, P853, DOI 10.1089/scd.2009.0267; Ding DC, 2011, CELL TRANSPLANT, V20, P5, DOI 10.3727/096368910X; FRIEDENS.AJ, 1966, J EMBRYOL EXP MORPH, V16, P381; Fu QL, 2012, ALLERGY, V67, P1215, DOI [10.1111/j.1398-9995.2012.02875.x, 10.1111/j.1398-9995.2012.02875.x.]; Huber VC, 2006, CLIN VACCINE IMMUNOL, V13, P981, DOI 10.1128/CVI.00156-06; Kelly JL, 1997, SURGERY, V122, P146, DOI 10.1016/S0039-6060(97)90003-9; Kidd Parris, 2003, Altern Med Rev, V8, P223; Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140-6736(04)16104-7; LeBlanc K, 2008, LANCET, V371, P1579, DOI 10.1016/S0140-6736(08)60690-X; MAGGI E, 1994, ANN NY ACAD SCI, V725, P2, DOI 10.1111/j.1749-6632.1994.tb39784.x; Minguell JJ, 2001, EXP BIOL MED, V226, P507, DOI 10.1177/153537020122600603; Moingeon P, 2006, ALLERGY, V61, P151, DOI 10.1111/j.1398-9995.2006.01002.x; Oreffo ROC, 2005, STEM CELL REV, V1, P169, DOI 10.1385/SCR:1:2:169; Peterson JD, 1998, P NATL ACAD SCI USA, V95, P3071, DOI 10.1073/pnas.95.6.3071; Sun YQ, 2012, STEM CELLS, V30, P2692, DOI 10.1002/stem.1241; Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Wise AF, 2012, NEPHROLOGY, V17, P1, DOI 10.1111/j.1440-1797.2011.01501.x; Yang LY, 1998, J EXP MED, V188, P1739, DOI 10.1084/jem.188.9.1739	24	20	21	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 4	2015	10	3							e0118849	10.1371/journal.pone.0118849	http://dx.doi.org/10.1371/journal.pone.0118849			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC9JM	25739057	Green Published, gold, Green Submitted			2023-01-03	WOS:000350685900081
J	Zhao, WL; Wang, C; Li, ZZ; Chen, L; Li, JB; Cui, WD; Ding, SS; Xi, Q; Wang, F; Jia, F; Xiao, SH; Guo, Y; Zhao, Y				Zhao, Wenli; Wang, Chao; Li, Zhongzheng; Chen, Lei; Li, Jianbo; Cui, Weidong; Ding, Shasha; Xi, Qiang; Wang, Fan; Jia, Fei; Xiao, Shuhua; Guo, Yi; Zhao, Ye			Efficacy and Safety of Transcutaneous Electrical Acupoint Stimulation to Treat Muscle Spasticity following Brain Injury: A Double-Blinded, Multicenter, Randomized Controlled Trial	PLOS ONE			English	Article							NERVE-STIMULATION; MULTIPLE-SCLEROSIS; ACUPUNCTURE POINTS; BOTULINUM TOXIN; DYNORPHIN-A; SPINAL-CORD; POSTSTROKE; STROKE; ELECTROACUPUNCTURE; FREQUENCY	Objective This study was aimed at evaluating the clinical efficacy and safety of transcutaneous electrical acupoint stimulation (TEAS) to treat muscle spasticity after brain injury (Chinese Clinical Trial Registry: ChiCTR-TRC-11001310). Methods A total of 60 patients with muscle spasticity after brain injury were randomized to the following 3 groups: 100, 2, and 0 Hz (sham) TEAS. The acupoints Hegu (LI4)-Yuji (LU10) and Zusanli (ST36)-Chengshan (BL57) on the injured side were stimulated at 0, 2, or 100 Hz, 5 times per week for 4 weeks. The patients were followed up for 1 and 2 months after the treatments. The effects of the treatments on muscle spasticity at the wrist, thumb, the other 4 fingers, elbow, shoulder, knee, and ankle were evaluated by the Modified Ashworth Scale, and the effects on disability were assessed by the Disability Assessment Scale. The walking capability was evaluated by the Holden functional ambulation classification score. The overall performance was assessed by the Global Assessment Scale score and the improved Barthel Index. The safety of the treatments administered was also monitored. Results The wrist spasticity was significantly reduced from baseline at weeks 2, 3, and 4 of treatment and at the 1- and 2-month follow-up visits in the 100 Hz group (P < 0.01). Compared with 2 Hz or sham TEAS, 100 Hz TEAS decreased wrist spasticity at weeks 2, 3, and 4 of treatment and 1 month after treatment (P < 0.001). The other endpoints were not affected by the treatments. No treatment-emergent adverse events were reported during treatments and follow-up visits. Conclusions TEAS appears to be a safe and effective therapy to relieve muscle spasticity after brain injury, although large-scale studies are required to further verify the findings.	[Zhao, Wenli] Tianjin Nankai Hosp, Dept Neurol, Tianjin 300100, Peoples R China; [Wang, Chao; Li, Zhongzheng; Ding, Shasha; Xi, Qiang; Wang, Fan; Jia, Fei; Xiao, Shuhua; Guo, Yi] Tianjin Univ Tradit Chinese Med, Dept Acupuncture & Moxibust, Tianjin 300193, Peoples R China; [Chen, Lei; Li, Jianbo; Cui, Weidong] Tianjin Ninghe Hosp, Dept Acupuncture & Moxibust, Tianjin 301500, Peoples R China; [Zhao, Ye] Tianjin Nankai Hosp, Dept Clin Res, Tianjin 300100, Peoples R China; [Zhao, Ye] Tianjin Acad Integrat Med, Tianjin 300100, Peoples R China	Tianjin University of Traditional Chinese Medicine	Zhao, Y (corresponding author), Tianjin Nankai Hosp, Dept Clin Res, Tianjin 300100, Peoples R China.	zakzy@163.com			Science Foundation on Traditional Chinese Medicine (TCM)/Integrative Medicine of the Tianjin Administration of TCM [11031]	Science Foundation on Traditional Chinese Medicine (TCM)/Integrative Medicine of the Tianjin Administration of TCM	Author: Chao Wang. This work was supported by the Science Foundation on Traditional Chinese Medicine (TCM)/Integrative Medicine of the Tianjin Administration of TCM (grant no. 11031). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arroyo R, 2013, INT J NEUROSCI, V123, P850, DOI 10.3109/00207454.2013.812084; Aydin G, 2005, AM J PHYS MED REHAB, V84, P584, DOI 10.1097/01.phm.0000171173.86312.69; Bhakta BB, 2000, BRIT MED BULL, V56, P476, DOI 10.1258/0007142001903111; Bohannon R. W., 1987, PHYS THER, V67, P206; BROWN P, 1994, J NEUROL NEUROSUR PS, V57, P773, DOI 10.1136/jnnp.57.7.773; Chao AS, 2007, PAIN, V127, P214, DOI 10.1016/j.pain.2006.08.016; Chen CY, 2013, AM J CHINESE MED, V41, P301, DOI 10.1142/S0192415X13500225; De Wolf AC, 2012, J REHABIL MED, V44, P747, DOI 10.2340/16501977-1016; Dong HW, 2005, BRAIN RES BULL, V67, P189, DOI 10.1016/j.brainresbull.2005.06.026; ENDICOTT J, 1976, ARCH GEN PSYCHIAT, V33, P766; FEI H, 1987, KEXUE TONGBAO, V32, P1496; Francis RP, 2011, ACUPUNCTURE ELECTRO, V36, P231, DOI 10.3727/036012911803634139; Francis RP, 2011, CLIN PHYSIOL FUNCT I, V31, P363, DOI 10.1111/j.1475-097X.2011.01025.x; Francisco GE, 2012, STROKE, V43, P3132, DOI 10.1161/STROKEAHA.111.639831; HAN JS, 1991, PAIN, V47, P295, DOI 10.1016/0304-3959(91)90218-M; HAN JS, 1994, CHINESE MED J-PEKING, V107, P6; Kamen L, 2008, CURR MED RES OPIN, V24, P425, DOI [10.1185/030079908X261113, 10.1185/030079908X261113 ]; Kavoussi B, 2007, INTEGR CANCER THER, V6, P251, DOI 10.1177/1534735407305892; Lance J. W., 1980, SPASTICITY DISORDERE; Lv JQ, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-153; Ng SSM, 2010, J NEUROL PHYS THER, V34, P208, DOI 10.1097/NPT.0b013e3181fe0ab0; Omura Y, 2010, ACUPUNCTURE ELECTRO, V35, P147, DOI 10.3727/036012910803860922; Ozcakir S, 2007, CLIN MED RES, V5, P132, DOI 10.3121/cmr.2007.716; SHAH S, 1989, STROKE, V20, P766, DOI 10.1161/01.STR.20.6.766; SHAH S, 1989, J CLIN EPIDEMIOL, V42, P703, DOI 10.1016/0895-4356(89)90065-6; van Kuijk AA, 2007, J REHABIL MED, V39, P33, DOI 10.2340/16501977-0009; Verplancke D, 2005, CLIN REHABIL, V19, P117, DOI 10.1191/0269215505cr827oa; Viosca E, 2005, ARCH PHYS MED REHAB, V86, P1234, DOI 10.1016/j.apmr.2004.11.016; WANG JZ, 1997, CHIN J REHAB THEORY, V3, P111; Ward AB, 2012, EUR J NEUROL, V19, P21, DOI 10.1111/j.1468-1331.2011.03448.x; White P, 2004, ANN INTERN MED, V141, P911, DOI 10.7326/0003-4819-141-12-200412210-00007; Xiang XH, 2014, J NEUROSCI RES, V92, P555, DOI 10.1002/jnr.23351; Yan TB, 2009, J REHABIL MED, V41, P312, DOI 10.2340/16501977-0325; Yu Y, 1993, Zhonghua Yi Xue Za Zhi, V73, P593; Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101	35	16	23	0	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 2	2015	10	2							e0116976	10.1371/journal.pone.0116976	http://dx.doi.org/10.1371/journal.pone.0116976			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA3QK	25643051	Green Published, Green Submitted, gold			2023-01-03	WOS:000348821200029
J	Brown, C				Brown, Craig			PERSONAL VIEW A compassionate complaint about hospital care made a difference	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												cbrown9811@aol.com							0	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 5	2015	350								g7823	10.1136/bmj.g7823	http://dx.doi.org/10.1136/bmj.g7823			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AZ3LU	25569431				2023-01-03	WOS:000348129900004
J	Kessler, TM; Mordasini, L; Weisstanner, C; Juni, P; da Costa, BR; Wiest, R; Thalmann, GN				Kessler, Thomas M.; Mordasini, Livio; Weisstanner, Christian; Jueni, Peter; da Costa, Bruno R.; Wiest, Roland; Thalmann, George N.			Sono-Electro-Magnetic Therapy for Treating Chronic Pelvic Pain Syndrome in Men: A Randomized, Placebo-Controlled, Double-Blind Trial	PLOS ONE			English	Article							SACRAL NEUROMODULATION; NERVE-STIMULATION; MECHANISMS	Objective: To assess the efficacy and safety of sono-electro-magnetic therapy compared to placebo in men with refractory CPPS. Patients and Methods: In a randomized, placebo-controlled, double-blind single center trial, we assessed the effect of sono-electro-magnetic therapy in men with treatment refractory CPPS. Sixty male patients were randomly assigned to treatment with either sono-electro-magnetic (n=30) or placebo therapy (n=30) for 12 weeks. The primary outcome was a change in the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) from baseline to 12 weeks. Results: The 12-week difference between sono-electro-magnetic and placebo therapy in changes of the NIH-CPSI total score was 23.1 points (95% CI -6.8 to 0.6, p=0.11). In secondary comparisons of NIH-CPSI sub-scores, we found differences between groups most pronounced for the quality-of-life sub-score (difference at 12 weeks -1.6, 95% CI -2.8 to -0.4, p=0.015). In stratified analyses, the benefit of sono-electro-magnetic therapy appeared more pronounced among patients who had a symptom duration of 12 months or less (difference in NIH-CPSI total score -8.3, 95% CI -4.5 to 2.6) than in patients with a longer symptom duration (-0.8, 95% CI -4.6 to 3.1; p for interaction=0.023). Conclusions: Sono-electro-magnetic therapy did not result in a significant improvement of symptoms in the overall cohort of treatment refractory CPPS patients compared to placebo treatment. Subgroup analysis indicates, however, that patients with a symptom-duration of 12 months or less may benefit from sono-electro-magnetic therapy, warranting larger randomized controlled trials in this subpopulation.	[Kessler, Thomas M.; Mordasini, Livio; Thalmann, George N.] Univ Bern, Dept Urol, Bern, Switzerland; [Kessler, Thomas M.] Univ Zurich, Balgrist Univ Hosp, Neurourol Spinal Cord Injury Ctr & Res, Zurich, Switzerland; [Weisstanner, Christian; Wiest, Roland] Univ Bern, Inselspital, Univ Inst Diagnost & Intervent Neuroradiol, SCAN, CH-3010 Bern, Switzerland; [Jueni, Peter; da Costa, Bruno R.] Univ Bern, Inst Social & Prevent Med & Clin Trials Unit, CH-3010 Bern, Switzerland	University of Bern; University of Zurich; University of Bern; University Hospital of Bern; University of Bern	Thalmann, GN (corresponding author), Univ Bern, Dept Urol, Bern, Switzerland.	george.thalmann@insel.ch	Juni, Peter/Q-8700-2016	Juni, Peter/0000-0002-5985-0670; Weisstanner, Christian/0000-0003-2830-1000; R. da Costa, Bruno/0000-0002-1786-6332; , Livio/0000-0002-4087-6555	Sonodyn Corporation AG (Solothurn, Switzerland); University Hospital Inselspital (Bern, Switzerland)	Sonodyn Corporation AG (Solothurn, Switzerland); University Hospital Inselspital (Bern, Switzerland)	This research was supported by the Sonodyn Corporation AG (Solothurn, Switzerland) and the University Hospital Inselspital (Bern, Switzerland). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexander RB, 2004, ANN INTERN MED, V141, P581, DOI 10.7326/0003-4819-141-8-200410190-00005; Anothaisintawee T, 2011, JAMA-J AM MED ASSOC, V305, P78, DOI 10.1001/jama.2010.1913; Brookes ST, 2004, J CLIN EPIDEMIOL, V57, P229, DOI 10.1016/j.jclinepi.2003.08.009; Butrick CW, 2009, OBSTET GYN CLIN N AM, V36, P699, DOI 10.1016/j.ogc.2009.08.006; Cohen J., 2013, STAT POWER ANAL BEHA; Duloy Anna M S, 2007, Curr Urol Rep, V8, P336, DOI 10.1007/s11934-007-0081-x; Fall M, 2010, EUR UROL, V57, P35, DOI 10.1016/j.eururo.2009.08.020; Farmer MA, 2011, J UROLOGY, V186, P117, DOI 10.1016/j.juro.2011.03.027; Hassouna MM, 2007, CUAJ-CAN UROL ASSOC, V1, P106; Hrobjartsson A, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003974.pub3; Kessler TM, 2008, EUR UROL SUPPL, V7, P159, DOI 10.1016/S1569-9056(08)60351-6; Kothari S, 2007, ACTA NEUROCHIR SUPPL, V97, P365; Lee SH, 2009, UROLOGY, V73, P1036, DOI 10.1016/j.urology.2008.10.047; Marcelissen T, 2011, J UROLOGY, V186, P387, DOI 10.1016/j.juro.2011.02.2694; McNaughton Collins M, 1998, Curr Opin Urol, V8, P33; Mehnert U, 2010, J UROLOGY, V184, P1011, DOI 10.1016/j.juro.2010.05.035; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; Mordasini L, 2012, J UROLOGY, V188, P2233, DOI 10.1016/j.juro.2012.08.043; Nickel JC, 2008, NEW ENGL J MED, V359, P2663, DOI 10.1056/NEJMoa0803240; Nickel JC, 2004, J UROLOGY, V172, P551, DOI 10.1097/01.ju.0000131592.98562.16; Nnoaham KE, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003222.pub2; Peters KM, 2007, BJU INT, V100, P835, DOI 10.1111/j.1464-410X.2007.07082.x; Peters KM, 2003, INT UROGYNECOL J PEL, V14, P223, DOI 10.1007/s00192-003-1070-3; Propert KJ, 2006, QUAL LIFE RES, V15, P299, DOI 10.1007/s11136-005-1317-1; Schaeffer AT, 2008, INT J ANTIMICROB AG, V31, pS108, DOI 10.1016/j.ijantimicag.2007.08.027; Shoskes Daniel A, 2005, Curr Urol Rep, V6, P296, DOI 10.1007/s11934-005-0027-0; Sluka KA, 2003, J PAIN, V4, P109, DOI 10.1054/jpai.2003.434; Vallejo Ricardo, 2007, Pain Physician, V10, P305; Vickers AJ, 2001, BMJ-BRIT MED J, V323, P1123, DOI 10.1136/bmj.323.7321.1123; Wollner J, 2012, BJU INT, V110, P146, DOI 10.1111/j.1464-410X.2012.10906.x	30	17	21	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 29	2014	9	12							e113368	10.1371/journal.pone.0113368	http://dx.doi.org/10.1371/journal.pone.0113368			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX7UN	25546177	Green Published, Green Accepted, gold			2023-01-03	WOS:000347120200004
J	Delvendahl, I; Gattinger, N; Berger, T; Gleich, B; Siebner, HR; Mall, V				Delvendahl, Igor; Gattinger, Norbert; Berger, Thomas; Gleich, Bernhard; Siebner, Hartwig R.; Mall, Volker			The Role of Pulse Shape in Motor Cortex Transcranial Magnetic Stimulation Using Full-Sine Stimuli	PLOS ONE			English	Article							INPUT-OUTPUT CURVE; CORTICAL EXCITABILITY; CURRENT DIRECTION; WAVE-FORMS; I-WAVES; RTMS; THRESHOLDS; EXCITATION; ACTIVATION; FREQUENCY	A full-sine (biphasic) pulse waveform is most commonly used for repetitive transcranial magnetic stimulation (TMS), but little is known about how variations in duration or amplitude of distinct pulse segments influence the effectiveness of a single TMS pulse to elicit a corticomotor response. Using a novel TMS device, we systematically varied the configuration of full-sine pulses to assess the impact of configuration changes on resting motor threshold (RMT) as measure of stimulation effectiveness with single-pulse TMS of the non-dominant motor hand area (M1). In young healthy volunteers, we (i) compared monophasic, half-sine, and full-sine pulses, (ii) applied two-segment pulses consisting of two identical half-sines, and (iii) manipulated amplitude, duration, and current direction of the first or second full-sine pulse half-segments. RMT was significantly higher using half-sine or monophasic pulses compared with full-sine. Pulses combining two half-sines of identical polarity and duration were also characterized by higher RMT than full-sine stimuli resulting. For full-sine stimuli, decreasing the amplitude of the half-segment inducing posterior-anterior oriented current in M1 resulted in considerably higher RMT, whereas varying the amplitude of the half-segment inducing anterior-posterior current had a smaller effect. These findings provide direct experimental evidence that the pulse segment inducing a posterior-anterior directed current in M1 contributes most to corticospinal pathway excitation. Preferential excitation of neuronal target cells in the posterior-anterior segment or targeting of different neuronal structures by the two half-segments can explain this result. Thus, our findings help understanding the mechanisms of neural stimulation by full-sine TMS.	[Delvendahl, Igor] Univ Leipzig, Carl Ludwig Inst Physiol, D-04109 Leipzig, Germany; [Gattinger, Norbert; Gleich, Bernhard] Tech Univ Munich, IMETUM, Zent Inst Med Tech, Garching, Germany; [Berger, Thomas] Univ Med Ctr Freiburg, Dept Pediat & Adolescent Med, Freiburg, Germany; [Siebner, Hartwig R.] Univ Copenhagen, Hvidovre Hosp, Danish Res Ctr Magnet Resonance, Copenhagen, Denmark; [Siebner, Hartwig R.] Univ Copenhagen, Hvidovre Hosp, Dept Neurol, Copenhagen, Denmark; [Mall, Volker] Tech Univ Munich, Dept Pediat, D-80290 Munich, Germany	Leipzig University; Technical University of Munich; University of Freiburg; University of Copenhagen; University of Copenhagen; Technical University of Munich	Mall, V (corresponding author), Univ Leipzig, Carl Ludwig Inst Physiol, D-04109 Leipzig, Germany.	volker.mall@tum.de	Gleich, Bernhard/D-4803-2009; Delvendahl, Igor/A-7176-2013; Berger, Thomas U/HGA-3594-2022; Siebner, Hartwig R/G-4052-2016	Gleich, Bernhard/0000-0002-0574-7678; Delvendahl, Igor/0000-0002-6151-2363; 	Grant of Excellence "ContAct" from Lundbeckfonden [R59 A5399]; German Research Foundation [DFG MA 3306/4-1]; Lundbeck Foundation [R59-2010-5399] Funding Source: researchfish	Grant of Excellence "ContAct" from Lundbeckfonden; German Research Foundation(German Research Foundation (DFG)); Lundbeck Foundation(Lundbeckfonden)	HRS was supported by a Grant of Excellence "ContAct" from Lundbeckfonden (R59 A5399); VM was supported by a grant from the German Research Foundation (DFG MA 3306/4-1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arai N, 2005, CLIN NEUROPHYSIOL, V116, P605, DOI 10.1016/j.clinph.2004.09.020; Arai N, 2007, CLIN NEUROPHYSIOL, V118, P2227, DOI 10.1016/j.clinph.2007.07.006; Awiszus F, 2003, CLIN NEUROPHYSIOL, P5613; BARKER AT, 1991, J CLIN NEUROPHYSIOL, V8, P26, DOI 10.1097/00004691-199101000-00005; Barker AT, 1991, ELECTROENCEPHALOGR S, P43227; Brockhardt, 2011, TMS MOTOR THRESHOLD; Chen R, 2008, CLIN NEUROPHYSIOL, V119, P504, DOI 10.1016/j.clinph.2007.10.014; CLAUS D, 1990, ELECTROEN CLIN NEURO, V75, P342, DOI 10.1016/0013-4694(90)90112-W; Clay JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045983; COHEN LG, 1990, ELECTROEN CLIN NEURO, V75, P350, DOI 10.1016/0013-4694(90)90113-X; Corthout E, 2001, EXP BRAIN RES, V141, P128, DOI 10.1007/s002210100860; Delvendahl I, 2014, BRAIN STIMUL, V7, P49, DOI 10.1016/j.brs.2013.08.002; Di Lazzaro V, 2001, EXP BRAIN RES, V138, P268; Di Lazzaro V, 2001, EXP BRAIN RES, V141, P121; Di Lazzaro V, 2013, FRONT NEURAL CIRCUIT, V718; Di Lazzaro V, 2008, BRAIN STIMUL, V1, P345, DOI 10.1016/j.brs.2008.07.004; EPSTEIN CM, 1990, NEUROLOGY, V40, P666, DOI 10.1212/WNL.40.4.666; Fitzgerald PB, 2006, CLIN NEUROPHYSIOL, V117, P2584, DOI 10.1016/j.clinph.2006.06.712; Fox PT, 2004, HUM BRAIN MAPP, V22, P1, DOI 10.1002/hbm.20006; Gattinger N, 2012, IEEE T BIO-MED ENG, V59, P1962, DOI 10.1109/TBME.2012.2195180; George MS, 2009, BRAIN STIMUL, V2, P14, DOI 10.1016/j.brs.2008.06.001; Groppa S, 2012, CLIN NEUROPHYSIOL, V123, P858, DOI 10.1016/j.clinph.2012.01.010; Hallett M, 2007, NEURON, V55, P187, DOI 10.1016/j.neuron.2007.06.026; Hamada M, 2013, CEREB CORTEX, V23, P1593, DOI 10.1093/cercor/bhs147; JALINOUS R, 1991, J CLIN NEUROPHYSIOL, V8, P10, DOI 10.1097/00004691-199101000-00004; Jung NH, 2012, BMC NEUROSCI, V13139; Jung NH, 2010, BRAIN STIMUL, V3, P87, DOI 10.1016/j.brs.2009.10.003; Kammer T, 2001, CLIN NEUROPHYSIOL, V112, P2015, DOI 10.1016/S1388-2457(01)00673-3; Kammer T, 2001, CLIN NEUROPHYSIOL, V112, P250, DOI 10.1016/S1388-2457(00)00513-7; Kammer T, 2007, NEUROIMAGE, V36, P313, DOI 10.1016/j.neuroimage.2007.03.001; Kammer T, 2010, CLIN NEUROPHYSIOL, V121, P376, DOI 10.1016/j.clinph.2009.12.002; Laakso I, 2014, PHYS MED BIOL, V59, P203, DOI 10.1088/0031-9155/59/1/203; Maccabee PJ, 1998, J PHYSIOL-LONDON, V513, P571, DOI 10.1111/j.1469-7793.1998.571bb.x; Moller C, 2009, CLIN NEUROPHYSIOL, V120, P1003, DOI 10.1016/j.clinph.2009.03.001; Niehaus L, 2000, CLIN NEUROPHYSIOL, V111, P75, DOI 10.1016/S1388-2457(99)00198-4; Pechmann A, 2012, BRAIN STIMUL, V5, P148, DOI 10.1016/j.brs.2011.02.006; Pell GS, 2011, PROG NEUROBIOL, V93, P59, DOI 10.1016/j.pneurobio.2010.10.003; Peterchev AV, 2008, IEEE T BIO-MED ENG, V55, P257, DOI 10.1109/TBME.2007.900540; Peterchev AV, 2013, CLIN NEUROPHYSIOL, V124, P1364, DOI 10.1016/j.clinph.2013.01.011; Ridding MC, 1997, ELECTROMYOGR MOTOR C, V105, P340, DOI 10.1016/S0924-980X(97)00041-6; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Sakai K, 1997, EXP BRAIN RES, V113, P24, DOI 10.1007/BF02454139; Salvador R, 2011, CLIN NEUROPHYSIOL, V122, P748, DOI 10.1016/j.clinph.2010.09.022; Siebner HR, 2003, EXP BRAIN RES, V148, P1, DOI 10.1007/s00221-002-1234-2; Silbert BI, 2013, CLIN NEUROPHYSIOL, V124, P708, DOI 10.1016/j.clinph.2012.09.018; Sommer M, 2006, CLIN NEUROPHYSIOL, V117, P838, DOI 10.1016/j.clinph.2005.10.029; Sommer M, 2013, BRAIN STIMUL, V6, P363, DOI 10.1016/j.brs.2012.07.003; Tings T, 2005, EXP BRAIN RES, V164, P323, DOI 10.1007/s00221-005-2253-6; Wassermann EM, 2001, CLIN NEUROPHYSIOL, V112, P1367, DOI 10.1016/S1388-2457(01)00585-5; Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8; WASSERMANN EM, 1992, ELECTROEN CLIN NEURO, V85, P1, DOI 10.1016/0168-5597(92)90094-R; Weyh T, 2005, CLIN NEUROPHYSIOL, V116, P1477, DOI 10.1016/j.clinph.2005.02.002; Ziemann U, 2000, J CLIN NEUROPHYSIOL, V17, P397, DOI 10.1097/00004691-200007000-00005; Ziemann U, 2008, BRAIN STIMUL, V1, P164, DOI 10.1016/j.brs.2008.06.006	54	18	18	2	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 16	2014	9	12							e115247	10.1371/journal.pone.0115247	http://dx.doi.org/10.1371/journal.pone.0115247			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA8DI	25514673	Green Submitted, Green Published, gold			2023-01-03	WOS:000349146300045
J	Gray, BM; Vandergrift, JL; Johnston, MM; Reschovsky, JD; Lynn, LA; Holmboe, ES; McCullough, JS; Lipner, RS				Gray, Bradley M.; Vandergrift, Jonathan L.; Johnston, Mary M.; Reschovsky, James D.; Lynn, Lorna A.; Holmboe, Eric S.; McCullough, Jeffrey S.; Lipner, Rebecca S.			Association Between Imposition of a Maintenance of Certification Requirement and Ambulatory Care-Sensitive Hospitalizations and Health Care Costs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-CARE; AMERICAN-BOARD; MEDICAL-SPECIALTIES	IMPORTANCE In 1990, the American Board of Internal Medicine (ABIM) ended lifelong certification by initiating a 10-year Maintenance of Certification (MOC) program that first took effect in 2000. Despite the importance of this change, there has been limited research examining associations between the MOC requirement and patient outcomes. OBJECTIVE To measure associations between the original ABIM MOC requirement and outcomes of care. DESIGN, SETTING, AND PARTICIPANTS Quasi-experimental comparison between outcomes for Medicare beneficiaries treated in 2001 by 2 groups of ABIM-certified internal medicine physicians (general internists). One group (n = 956), initially certified in 1991, was required to fulfill the MOC program in 2001 (MOC-required) and treated 84 215 beneficiaries in the sample; the other group (n = 974), initially certified in 1989, was grandfathered out of the MOC requirement (MOC-grandfathered) and treated 69 830 similar beneficiaries in the sample. We compared differences in outcomes for the beneficiary cohort treated by the MOC-required general internists before (1999-2000) and after (2002-2005) they were required to complete MOC, using the beneficiary cohort treated by the MOC-grandfathered general internists as the control. MAIN OUTCOMES AND MEASURES Quality measures were ambulatory care-sensitive hospitalizations (ACSHs), measured using prevention quality indicators. Ambulatory care-sensitive hospitalizations are hospitalizations triggered by conditions thought to be potentially preventable through better access to and quality of outpatient care. Other outcomes included health care cost measures (adjusted to 2013 dollars). RESULTS Annual incidence of ACSHs (per 1000 beneficiaries) increased from the pre-MOC period (37.9 for MOC-required beneficiaries vs 37.0 for MOC-grandfathered beneficiaries) to the post-MOC period (61.8 for MOC-required beneficiaries vs 61.4 for MOC-grandfathered beneficiaries) for both cohorts, as did annual per-beneficiary health care costs (pre-MOC period, $5157 for MOC-required beneficiaries vs $5133 for MOC-grandfathered beneficiaries; post-MOC period, $7633 for MOC-required beneficiaries vs $7793 for MOC-grandfathered beneficiaries). The MOC requirement was not statistically associated with cohort differences in the growth of the annual ACSH rate (per 1000 beneficiaries, 0.1 [95% CI, -1.7 to 1.9]; P = .92), but was associated with a cohort difference in the annual, per-beneficiary cost growth of -$167 (95% CI, -$270.5 to - $63.5; P = .002; 2.5% of overall mean cost). CONCLUSION AND RELEVANCE Imposition of the MOC requirement was not associated with a difference in the increase in ACSHs but was associated with a small reduction in the growth differences of costs for a cohort of Medicare beneficiaries. Copyright 2014 American Medical Association. All rights reserved.	[Gray, Bradley M.; Vandergrift, Jonathan L.; Lynn, Lorna A.; Lipner, Rebecca S.] Amer Board Internal Med, Philadelphia, PA USA; [Johnston, Mary M.] James Madison Univ, Harrisonburg, VA 22807 USA; [Reschovsky, James D.] Math Policy Res, Washington, DC USA; [Holmboe, Eric S.] Accreditat Council Grad Med Educ, Chicago, IL USA; [McCullough, Jeffrey S.] Univ Minnesota, Minneapolis, MN USA	American Board of Internal Medicine; James Madison University; Mathematica; University of Minnesota System; University of Minnesota Twin Cities	Gray, BM (corresponding author), 510 Walnut St,Ste 1700, Philadelphia, PA 19106 USA.	bradleygraypub2014@gmail.com			American Board of Internal Medicine (ABIM)	American Board of Internal Medicine (ABIM)	Financial and material support was provided by the American Board of Internal Medicine (ABIM).	Agency for Healthcare Research and Quality, QUAL IND US GUID PRE; Alemayehu B, 2004, HEALTH SERV RES, V39, P627, DOI 10.1111/j.1475-6773.2004.00248.x; American Board of Internal Medicine, WHER DOES THE MON GO; American Board of Internal Medicine, WGAT CHANG IN 2014; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480; Austin PC, 2011, PHARM STAT, V10, P150, DOI 10.1002/pst.433; Colla CH, 2012, JAMA-J AM MED ASSOC, V308, P1015, DOI 10.1001/2012.jama.10812; Davies S, 2011, MED CARE, V49, P679, DOI 10.1097/MLR.0b013e3182159e65; Friedberg MW, 2014, JAMA-J AM MED ASSOC, V311, P815, DOI 10.1001/jama.2014.353; Hawkins RE, 2013, J CONTIN EDUC HEALTH, V33, pS7, DOI 10.1002/chp.21201; Holmboe ES, 2008, ARCH INTERN MED, V168, P1396, DOI 10.1001/archinte.168.13.1396; Iglehart JK, 2012, NEW ENGL J MED, V367, P2543, DOI 10.1056/NEJMhpr1211043; Kritek Patricia A, 2010, N Engl J Med, V362, pe54, DOI 10.1056/NEJMclde1003227; Landon BE, 2014, J GEN INTERN MED, V29, P1188, DOI 10.1007/s11606-014-2840-y; Levinson W, 2010, NEW ENGL J MED, V362, P948, DOI 10.1056/NEJMclde0911205; McWilliams JM, 2013, JAMA-J AM MED ASSOC, V310, P829, DOI 10.1001/jama.2013.276302; Medicare Payment Advisory Commission, DAT BOOK HLTH CAR SP; Meerding WJ, 1998, BRIT MED J, V317, P111, DOI 10.1136/bmj.317.7151.111; Miller SH, 2005, J CONTIN EDUC HEALTH, V25, P151, DOI 10.1002/chp.22; Norcini JJ, 2002, MED EDUC, V36, P853, DOI 10.1046/j.1365-2923.2002.01293.x; Norcini J, 2011, MED TEACH, V33, P206, DOI 10.3109/0142159X.2011.551559; Petterson SM, 2012, ANN FAM MED, V10, P503, DOI 10.1370/afm.1431; Pham HH, 2005, JAMA-J AM MED ASSOC, V294, P473, DOI 10.1001/jama.294.4.473; Pham HH, 2009, ARCH INTERN MED, V169, P972, DOI 10.1001/archinternmed.2009.78; Pope GC, 2011, EVALUATION CMS HCC R; Roos LL, 2005, HEALTH SERV RES, V40, P1167, DOI 10.1111/j.1475-6773.2005.00407.x; Sirovich BE, 2014, JAMA INTERN MED, V174, P1640, DOI 10.1001/jamainternmed.2014.3337; Song Z, 2011, NEW ENGL J MED, V365, P909, DOI 10.1056/NEJMsa1101416; STARFIELD B, 1994, JAMA-J AM MED ASSOC, V272, P1903, DOI 10.1001/jama.272.24.1903; StataCorp, STAT STAT SOFTW REL; US Bureau of Labor Statistics, CONS PRIC IND ALL UR; Zhan CL, 2004, HEALTH SERV RES, V39, P345, DOI 10.1111/j.1475-6773.2004.00231.x	32	42	42	1	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	2014	312	22					2348	2357		10.1001/jama.2014.12716	http://dx.doi.org/10.1001/jama.2014.12716			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AW5YB	25490325				2023-01-03	WOS:000346345700009
J	Kakehashi, A; Kato, A; Ishii, N; Wei, M; Morimura, K; Fukushima, S; Wanibuchi, H				Kakehashi, Anna; Kato, Ayumi; Ishii, Naomi; Wei, Min; Morimura, Keiichirou; Fukushima, Shoji; Wanibuchi, Hideki			Valerian Inhibits Rat Hepatocarcinogenesis by Activating GABA(A) Receptor-Mediated Signaling	PLOS ONE			English	Article							LIVER CELL-PROLIFERATION; VALERENIC ACID; FUNCTIONAL REGULATION; OXIDATIVE STRESS; HEPATIC FOCI; STEM; PHARMACOLOGY; EXPRESSION; APOPTOSIS; SUBTYPES	Valerian is widely used as a traditional medicine to improve the quality of sleep due to interaction of several active components with the c-aminobutyric acid (GABA) A receptor (GABA(A)R) system. Recently, activation of GABA signaling in stem cells has been reported to suppress cell cycle progression in vivo. Furthermore, possible inhibitory effects of GABA(A) R agonists on hepatocarcinogenesis have been reported. The present study was performed to investigate modulating effects of Valerian on hepatocarcinogenesis using a medium-term rat liver bioassay. Male F344 rats were treated with one of the most powerful Valerian species (Valeriana sitchensis) at doses of 0, 50, 500 and 5000 ppm in their drinking water after initiation of hepatocarcinogenesis with diethylnitrosamine (DEN). Formation of glutathione S-transferase placental form positive (GST-P+) foci was significantly inhibited by Valerian at all applied doses compared with DEN initiation control rats. Generation of 8-hydroxy-29-deoxyguanosine in the rat liver was significantly suppressed by all doses of Valerian, likely due to suppression of Nrf2, CYP7A1 and induction of catalase expression. Cell proliferation was significantly inhibited, while apoptosis was induced in areas of GST-P+ foci of Valerian groups associated with suppression of c-myc, Mafb, cyclin D1 and induction of p21(Waf1/Cip1), p53 and Bax mRNA expression. Interestingly, expression of the GABA(A) R alpha 1 subunit was observed in GST-P+ foci of DEN control rats, with significant elevation associated with Valerian treatment. These results indicate that Valerian exhibits inhibitory effects on rat hepatocarcinogenesis by inhibiting oxidative DNA damage, suppressing cell proliferation and inducing apoptosis in GST-P+ foci by activating GABA(A) R-mediated signaling.	[Kakehashi, Anna; Kato, Ayumi; Ishii, Naomi; Wei, Min; Morimura, Keiichirou; Fukushima, Shoji; Wanibuchi, Hideki] Osaka City Univ, Dept Mol Pathol, Grad Sch Med, Osaka 558, Japan	Osaka Metropolitan University	Kakehashi, A (corresponding author), Osaka City Univ, Dept Mol Pathol, Grad Sch Med, Osaka 558, Japan.	anna@med.osaka-cu.ac.jp	Kakehashi, Anna/ABF-2986-2020; Wei, Min/GSI-8510-2022	Kakehashi, Anna/0000-0003-1149-1450; 	Ministry of Health, Labor and Welfare of Japan; Grants-in-Aid for Scientific Research [221S0001] Funding Source: KAKEN	Ministry of Health, Labor and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This research was supported by Grant-in-Aid for Scientific Research from the Ministry of Health, Labor and Welfare of Japan. URL: http://www.mhlw.go.jp/english/. No number was supported. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Wadei HAN, 2012, CURR CANCER DRUG TAR, V12, P97; Andang M, 2008, NATURE, V451, P460, DOI 10.1038/nature06488; Beaubrun G, 2000, PSYCHIATR SERV, V51, P1130, DOI 10.1176/appi.ps.51.9.1130; Behar TN, 1998, J NEUROSCI, V18, P6378; Biju Mangatt P, 2002, J Biochem Mol Biol Biophys, V6, P209, DOI 10.1080/10258140290018667; Biju MP, 2002, NEUROCHEM RES, V27, P905, DOI 10.1023/A:1020391514995; Biju MP, 2001, HEPATOL RES, V21, P136, DOI 10.1016/S1386-6346(01)00092-4; Bos R, 1998, PLANTA MED, V64, P143, DOI 10.1055/s-2006-957392; BOUNTHANH C, 1981, PLANTA MED, V41, P21, DOI 10.1055/s-2007-971668; Chen K, 2005, BRAIN RES BULL, V67, P310, DOI 10.1016/j.brainresbull.2005.07.004; Cho HY, 2002, AM J RESP CELL MOL, V26, P175, DOI 10.1165/ajrcmb.26.2.4501; Da Settimo F, 2007, CURR MED CHEM, V14, P2680, DOI 10.2174/092986707782023190; Eadie MJ, 2004, EPILEPSIA, V45, P1338, DOI 10.1111/j.0013-9580.2004.27904.x; FOERSTER W, 1984, PLANTA MED, V50, P7, DOI 10.1055/s-2007-969605; Ganguly K, 2001, CELL, V105, P521, DOI 10.1016/S0092-8674(01)00341-5; GESSNER B, 1984, EEG-EMG-Z ELEK ELEKT, V15, P45; Haydar TF, 2000, J NEUROSCI, V20, P5764, DOI 10.1523/JNEUROSCI.20-15-05764.2000; IMAIDA K, 1989, JPN J CANCER RES, V80, P326, DOI 10.1111/j.1349-7006.1989.tb02314.x; JONES HB, 1993, ARCH TOXICOL, V67, P622, DOI 10.1007/BF01974069; Kakehashi A, 2009, TOXICOL APPL PHARM, V238, P71, DOI 10.1016/j.taap.2009.04.018; Karim N, 2013, AMINO ACIDS, V44, P1139, DOI 10.1007/s00726-012-1456-y; KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849; Khom S, 2007, NEUROPHARMACOLOGY, V53, P178, DOI 10.1016/j.neuropharm.2007.04.018; Kinoshita A, 2003, CARCINOGENESIS, V24, P1389, DOI 10.1093/carcin/bgg079; Kinoshita A, 2002, CARCINOGENESIS, V23, P341, DOI 10.1093/carcin/23.2.341; Kitano M, 1998, CARCINOGENESIS, V19, P1475, DOI 10.1093/carcin/19.8.1475; Leathwood P. D., 1985, PLANTA MED, V2, P144; LU FC, 1988, REGUL TOXICOL PHARM, V8, P45, DOI 10.1016/0273-2300(88)90006-2; Morazzoni P., 1995, Fitoterapia, V66, P99; Mowrey D, 1986, MEANING VALERIAN ROO, P12; Navarrete A, 2006, J AOAC INT, V89, P8; Obrietan K, 1998, J NEUROPHYSIOL, V79, P1360, DOI 10.1152/jn.1998.79.3.1360; Olsen RW, 2009, NEUROPHARMACOLOGY, V56, P141, DOI 10.1016/j.neuropharm.2008.07.045; Pradeep K, 2007, EUR J PHARMACOL, V560, P110, DOI 10.1016/j.ejphar.2006.12.023; Ramharter J, 2009, ORG LETT, V11, P1151, DOI 10.1021/ol9000137; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Sanders S, 1999, CARCINOGENESIS, V20, P41, DOI 10.1093/carcin/20.1.41; Sando R, 2012, CELL, V151, P821, DOI 10.1016/j.cell.2012.09.037; Schuller HM, 2012, CURR CANCER THER REV, V8, P116, DOI 10.2174/157339412800675351; SCHULTZ V, 1998, RATIONAL PHYTOTHERAP; Sieghart W, 2012, BRIT J PHARMACOL, V166, P476, DOI 10.1111/j.1476-5381.2011.01779.x; Tsuda H, 2003, TOXICOL PATHOL, V31, P80, DOI 10.1080/01926230390173879; Weng Y, 2009, ANESTH ANALG, V108, P1538, DOI 10.1213/ane.0b013e31819cd964; Xu WH, 2008, LAB INVEST, V88, P1068, DOI 10.1038/labinvest.2008.75; Young SZ, 2009, PHYSIOLOGY, V24, P171, DOI 10.1152/physiol.00002.2009	45	11	14	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 24	2014	9	11							e113610	10.1371/journal.pone.0113610	http://dx.doi.org/10.1371/journal.pone.0113610			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX2IM	25419570	Green Submitted, Green Published, gold			2023-01-03	WOS:000346766900056
J	Cramer, H; Lauche, R; Azizi, H; Dobos, G; Langhorst, J				Cramer, Holger; Lauche, Romy; Azizi, Hoda; Dobos, Gustav; Langhorst, Jost			Yoga for Multiple Sclerosis: A Systematic Review and Meta-Analysis	PLOS ONE			English	Article							EXERCISE; FATIGUE; PEOPLE; SCHIZOPHRENIA; COMMUNITY; MEDICINE; DISEASE; MOOD; BIAS; MS	While yoga seems to be effective in a number of neuropsychiatric disorders, the evidence of efficacy in multiple sclerosis remains unclear. The aim of this review was to systematically assess and meta-analyze the available data on efficacy and safety of yoga in patients with multiple sclerosis. Medline/PubMed, Scopus, the Cochrane Central Register of Controlled Trials, PsycINFO, CAM-Quest, CAMbase, and IndMED were searched through March 2014. Randomized controlled trials (RCTs) of yoga for patients with multiple sclerosis were included if they assessed health-related quality of life, fatigue, and/or mobility. Mood, cognitive function, and safety were defined as secondary outcome measures. Risk of bias was assessed using the Cochrane tool. Seven RCTs with a total of 670 patients were included. Evidence for short-term effects of yoga compared to usual care were found for fatigue (standardized mean difference [SMD] = -0.52; 95% confidence intervals (CI) = -1.02 to -0.02; p = 0.04; heterogeneity: I-2 = 60%; Chi(2) = 7.43; p = 0.06) and mood (SMD = -0.55; 95% CI = -0.96 to -0.13; p = 0.01; heterogeneity: I-2 = 0%; Chi(2) = 1.25; p = 0.53), but not for health-related quality of life, muscle function, or cognitive function. The effects on fatigue and mood were not robust against bias. No short-term or longer term effects of yoga compared to exercise were found. Yoga was not associated with serious adverse events. In conclusion, since no methodological sound evidence was found, no recommendation can be made regarding yoga as a routine intervention for patients with multiple sclerosis. Yoga might be considered a treatment option for patients who are not adherent to recommended exercise regimens.	[Cramer, Holger; Lauche, Romy; Dobos, Gustav; Langhorst, Jost] Univ Duisburg Essen, Fac Med, Kliniken Essen Mitte, Dept Internal & Integrat Med, Essen, Germany; [Azizi, Hoda] Mashhad Univ Med Sci, Dept Complementary Med, Mashhad, Iran	Kliniken Essen-Mitte; University of Duisburg Essen; Mashhad University Medical Science	Cramer, H (corresponding author), Univ Duisburg Essen, Fac Med, Kliniken Essen Mitte, Dept Internal & Integrat Med, Essen, Germany.	h.cramer@kliniken-essen-mitte.de	Azizi, Hoda/A-6149-2018; Cramer, Holger/AAH-1794-2019; Lauche, Romy/AAQ-7175-2021	Azizi, Hoda/0000-0003-1120-2217; Lauche, Romy/0000-0002-4171-7935; Cramer, Holger/0000-0002-3640-8046	Rut- and Klaus-Bahlsen-Foundation	Rut- and Klaus-Bahlsen-Foundation	This review was supported by a grant from the Rut- and Klaus-Bahlsen-Foundation. The funding source had no influence on the design or conduct of the review; the collection, management, analysis, or interpretation of the data; or in the preparation, review, or approval of the manuscript.	Ahmadi A, 2013, IRAN RED CRESCENT ME, V15, P449, DOI 10.5812/ircmj.3597; Ahmadi A, 2010, J HUM KINET, V23, P71, DOI 10.2478/v10078-010-0009-2; Armijo-Olivo S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096920; Barnes Patricia M, 2004, Adv Data, P1; Barnes Patricia M, 2008, Natl Health Stat Report, P1; Boehm K, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/124703; Cohen J, 1988, STAT POWER ANAL BEHA; Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7; Cramer H, 2015, EUR J PREV CARDIOL, V22, P284, DOI 10.1177/2047487314523132; Cramer H, 2014, INT J CARDIOL, V173, P170, DOI 10.1016/j.ijcard.2014.02.017; Cramer H, 2013, DEPRESS ANXIETY, V30, P1068, DOI 10.1002/da.22166; Cramer H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075515; Cramer H, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-172; Cramer H, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/702914; Cramer H, 2013, CLIN J PAIN, V29, P450, DOI 10.1097/AJP.0b013e31825e1492; Cramer H, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-32; Cramer H, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-412; Cramer H, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/863905; Doulatabad SN, 2013, AFR J TRADIT COMPLEM, V10, P49, DOI 10.4314/ajtcam.v10i1.8; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Egger M, 2003, Health Technol Assess, V7, P1; Feuerstein G, 1998, THE YOGA TRADITION; Garrett M, 2013, MULT SCLER J, V19, P782, DOI 10.1177/1352458512461966; Garrett M, 2013, MULT SCLER J, V19, P790, DOI 10.1177/1352458512461390; Gartlehner G, 2008, Z EVIDENZ FORTBILD Q, V102, P497, DOI 10.1016/j.zefq.2008.08.028; HETHERINGTON J, 1989, PEDIATRICS, V84, P374; Higgins J. P., 2011, COCHRANE HDB SYST RE, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hogan N, 2014, MULT SCLER INT, V2014, DOI 10.1155/2014/109142; Latimer-Cheung AE, 2013, ARCH PHYS MED REHAB, V94, P1829, DOI 10.1016/j.apmr.2013.05.015; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; National Multiple Sclerosis Society, 2008, MAN MS REL FAT; Noseworthy JH, 2000, NEW ENGL J MED, V343, P938, DOI 10.1056/NEJM200009283431307; Oken BS, 2004, NEUROLOGY, V62, P2058, DOI 10.1212/01.WNL.0000129534.88602.5C; Paul L, 2013, 29 C EUR COMM TREATM; Rahnama N, 2011, J ISFAHAN MED SCH, V29, P483; Riazi A, 2003, J NEUROL NEUROSUR PS, V74, P710, DOI 10.1136/jnnp.74.6.710; Sa MJ, 2014, J NEUROL, V261, P1651, DOI 10.1007/s00415-013-7183-9; Schulz KF, 2010, ANN INTERN MED, V152, P726, DOI 10.7326/0003-4819-152-11-201006010-00232; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Senders A, 2012, AUTOIMMUN DIS, V2012, DOI 10.1155/2012/567324; The National Collaborating Centre for Chronic Conditions, 2004, MULT SCLER NAT CLIN; Vancampfort D, 2012, ACTA PSYCHIAT SCAND, V126, P12, DOI 10.1111/j.1600-0447.2012.01865.x; Velikonja O, 2010, CLIN NEUROL NEUROSUR, V112, P597, DOI 10.1016/j.clineuro.2010.03.006; Yadav V, 2014, SUMMARY EVIDENCE BAS; Yadav V, 2014, NEUROLOGY, V82, P1083, DOI 10.1212/WNL.0000000000000250	46	50	51	0	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2014	9	11							e112414	10.1371/journal.pone.0112414	http://dx.doi.org/10.1371/journal.pone.0112414			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA8CP	25390344	Green Submitted, gold, Green Published			2023-01-03	WOS:000349144400079
J	Yoshida, K; Yoshioka, M; Okamura, H; Moriyama, S; Kawazoe, K; Grenier, D; Hinode, D				Yoshida, Kaya; Yoshioka, Masami; Okamura, Hirohiko; Moriyama, Satomi; Kawazoe, Kazuyoshi; Grenier, Daniel; Hinode, Daisuke			Preventive Effect of Daiokanzoto (TJ-84) on 5-Fluorouracil-Induced Human Gingival Cell Death through the Inhibition of Reactive Oxygen Species Production	PLOS ONE			English	Article							NLRP3 INFLAMMASOME; NITRIC-OXIDE; NALP3 INFLAMMASOME; HERBAL MEDICINE; KAMPO MEDICINE; ACTIVATION; EXPRESSION; IL-1-BETA; SECRETION; MUCOSITIS	Daiokanzoto (TJ-84) is a traditional Japanese herbal medicine (Kampo formulation). While many Kampo formulations have been reported to regulate inflammation and immune responses in oral mucosa, there is no evidence to show that TJ-84 has beneficial effects on oral mucositis, a disease resulting from increased cell death induced by chemotherapeutic agents such as 5-fluorouracil (5-FU). In order to develop effective new therapeutic strategies for treating oral mucositis, we investigated (i) the mechanisms by which 5-FU induces the death of human gingival cells and (ii) the effects of TJ-84 on biological events induced by 5-FU. 5-FU-induced lactate dehydrogenase (LDH) release and pore formation in gingival cells (Sa3 cell line) resulted in cell death. Incubating the cells with 5-FU increased the expression of nucleotide-binding domain and leucine-rich repeat containing PYD-3 (NLRP3) and caspase-1. The cleavage of caspase-1 was observed in 5-FU-treated cells, which was followed by an increased secretion of interleukin (IL)-1 beta. The inhibition of the NLRP3 pathway slightly decreased the effects of 5-FU on cell viability and LDH release, suggesting that NLRP3 may be in part involved in 5-FU-induced cell death. TJ-84 decreased 5-FU-induced LDH release and cell death and also significantly inhibited the depolarization of mitochondria and the up-regulation of 5-FU-induced reactive oxygen species (ROS) and nitric oxide (NO) production. The transcriptional factor, nuclear factor-kappa B (NF-kappa B) was not involved in the 5-FU-induced cell death in Sa3 cells. In conclusion, we provide evidence suggesting that the increase of ROS production in mitochondria, rather than NLRP3 activation, was considered to be associated with the cell death induced by 5-FU. The results also suggested that TJ-84 may attenuate 5-FU-induced cell death through the inhibition of mitochondrial ROS production.	[Yoshida, Kaya] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Oral Healthcare Educ, Tokushima 770, Japan; [Yoshioka, Masami] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Oral Hlth Sci & Social Welf, Tokushima 770, Japan; [Okamura, Hirohiko] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Histol & Oral Histol, Tokushima 770, Japan; [Moriyama, Satomi; Hinode, Daisuke] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Hyg & Oral Hlth Sci, Tokushima 770, Japan; [Kawazoe, Kazuyoshi] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Clin Pharm, Tokushima 770, Japan; [Grenier, Daniel] Univ Laval, Fac Dent, Oral Ecol Res Grp, Quebec City, PQ, Canada	Tokushima University; Tokushima University; Tokushima University; Tokushima University; Laval University	Yoshida, K (corresponding author), Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Oral Healthcare Educ, Tokushima 770, Japan.	kaya@tokushima-u.ac.jp	Okamura, Hirohiko/I-5917-2019; Grenier, Daniel/E-5557-2015	Okamura, Hirohiko/0000-0002-3254-5238; Grenier, Daniel/0000-0003-0878-4674; Yoshida, Kaya/0000-0002-3202-0634	Ministry of Education, Culture, Sports, Science & Technology (MEXT) [24390471]	Ministry of Education, Culture, Sports, Science & Technology (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was funded by a Grant-in-Aid for Scientific Research (B), Ministry of Education, Culture, Sports, Science & Technology (MEXT) (DH, 24390471). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ara T, 2008, BIOL PHARM BULL, V31, P1141, DOI 10.1248/bpb.31.1141; Ara T, 2010, BIOL PHARM BULL, V33, P611, DOI 10.1248/bpb.33.611; Arifa RDN, 2014, AM J PATHOL, V184, P2023, DOI 10.1016/j.ajpath.2014.03.012; Belibasakis GN, 2013, INNATE IMMUN-LONDON, V19, P3, DOI 10.1177/1753425912444767; Bostanci N, 2011, CELL IMMUNOL, V270, P88, DOI 10.1016/j.cellimm.2011.04.002; Brown GC, 2002, FREE RADICAL BIO MED, V33, P1440, DOI 10.1016/S0891-5849(02)01112-7; Brown GC, 2010, NITRIC OXIDE-BIOL CH, V23, P153, DOI 10.1016/j.niox.2010.06.001; Bruchard M, 2013, NAT MED, V19, P57, DOI 10.1038/nm.2999; Brune B, 1998, EUR J PHARMACOL, V351, P261, DOI 10.1016/S0014-2999(98)00274-X; Cruz CM, 2007, J BIOL CHEM, V282, P2871, DOI 10.1074/jbc.M608083200; Das S K, 1989, J Assoc Physicians India, V37, P647; Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995; DREIZEN S, 1983, ORAL SURG ORAL MED O, V55, P113, DOI 10.1016/0030-4220(83)90164-0; Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938; Duprez L, 2009, MICROBES INFECT, V11, P1050, DOI 10.1016/j.micinf.2009.08.013; Elting LS, 1997, CLIN INFECT DIS, V25, P247, DOI 10.1086/514550; Fata F, 1999, CANCER-AM CANCER SOC, V86, P1129, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1129::AID-CNCR5>3.0.CO;2-4; Fink SL, 2006, CELL MICROBIOL, V8, P1812, DOI 10.1111/j.1462-5822.2006.00751.x; Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636; Hernandez-Cuellar E, 2012, J IMMUNOL, V189, P5113, DOI 10.4049/jimmunol.1202479; Hiroshima Y, 2010, J PERIODONTAL RES, V45, P79, DOI 10.1111/j.1600-0765.2009.01203.x; Jabaut J, 2013, FREE RADICAL BIO MED, V60, P233, DOI 10.1016/j.freeradbiomed.2013.01.025; Kono Toru, 2010, World J Oncol, V1, P232, DOI 10.4021/wjon263w; Kummer JA, 2007, J HISTOCHEM CYTOCHEM, V55, P443, DOI 10.1369/jhc.6A7101.2006; Lawlor KE, 2014, BBA-GEN SUBJECTS, V1840, P1433, DOI 10.1016/j.bbagen.2013.08.014; Lee BC, 2014, BBA-MOL BASIS DIS, V1842, P446, DOI 10.1016/j.bbadis.2013.05.017; Liao J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/436206; Liao J, 2013, PHARM BIOL, V51, P1538, DOI 10.3109/13880209.2013.801995; MAJNO G, 1995, AM J PATHOL, V146, P3; Masters SL, 2012, IMMUNITY, V37, P1009, DOI 10.1016/j.immuni.2012.08.027; Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980; Okada K, 2007, AM J PHYSIOL-GASTR L, V292, pG1450, DOI 10.1152/ajpgi.00302.2006; Okamoto M, 2010, J BIOL CHEM, V285, P6477, DOI 10.1074/jbc.M109.064907; Okamura H, 2013, FEBS LETT, V587, P48, DOI 10.1016/j.febslet.2012.10.041; Ouyang XS, 2013, BBA-MOL BASIS DIS, V1832, P979, DOI 10.1016/j.bbadis.2013.03.020; Peterson DE, 2011, ANN ONCOL, V22, pvi78, DOI 10.1093/annonc/mdr391; Saadeh CE, 2005, PHARMACOTHERAPY, V25, P540, DOI 10.1592/phco.25.4.540.61035; Schroder K, 2010, SCIENCE, V327, P296, DOI 10.1126/science.1184003; Sonis ST, 2010, ORAL DIS, V16, P597, DOI 10.1111/j.1601-0825.2010.01681.x; Sonis SL, 2002, CRIT REV ORAL BIOL M, V13, P380, DOI 10.1177/154411130201300502; Sonis ST, 2004, NAT REV CANCER, V4, P277, DOI 10.1038/nrc1318; Takuma K, 2001, J BIOL CHEM, V276, P48093, DOI 10.1074/jbc.M108622200; Tang T, 2007, EUR J PHARMACOL, V567, P177, DOI 10.1016/j.ejphar.2007.02.033; Tassi S, 2010, P NATL ACAD SCI USA, V107, P9789, DOI 10.1073/pnas.1000779107; Thomas DD, 2008, FREE RADICAL BIO MED, V45, P18, DOI 10.1016/j.freeradbiomed.2008.03.020; Watanabe K, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/neq067; Wright TH, 2009, CANCER BIOL THER, V8, P923, DOI 10.4161/cbt.8.10.8146; Wu ZQ, 2010, BIOMED PHARMACOTHER, V64, P589, DOI 10.1016/j.biopha.2010.06.006; Yamamoto M, 2000, GASTROENTEROLOGY, V118, P380, DOI 10.1016/S0016-5085(00)70220-4; Yilmaz O, 2010, CELL MICROBIOL, V12, P188, DOI 10.1111/j.1462-5822.2009.01390.x; Yoshino F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082834; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663	52	9	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2014	9	11							e112689	10.1371/journal.pone.0112689	http://dx.doi.org/10.1371/journal.pone.0112689			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA8CP	25389767	Green Published, Green Submitted, gold			2023-01-03	WOS:000349144400119
J	Davaadelger, B; Shen, H; Maki, CG				Davaadelger, Batzaya; Shen, Hong; Maki, Carl G.			Novel Roles for P53 in the Genesis and Targeting of Tetraploid Cancer Cells	PLOS ONE			English	Article							EUKARYOTIC DNA-REPLICATION; CYCLIN-E; EXPRESSION; PROMOTES; GEMININ; ARREST; P21; ENDOREDUPLICATION; SENSITIVITY; INHIBITION	Tetraploid (4N) cells are considered important in cancer because they can display increased tumorigenicity, resistance to conventional therapies, and are believed to be precursors to whole chromosome aneuploidy. It is therefore important to determine how tetraploid cancer cells arise, and how to target them. P53 is a tumor suppressor protein and key regulator of tetraploidy. As part of the "tetraploidy checkpoint", p53 inhibits tetraploid cell proliferation by promoting a G1-arrest in incipient tetraploid cells (referred to as a tetraploid G1 arrest). Nutlin-3a is a preclinical drug that stabilizes p53 by blocking the interaction between p53 and MDM2. In the current study, Nutlin-3a promoted a p53-dependent tetraploid G1 arrest in two diploid clones of the HCT116 colon cancer cell line. Both clones underwent endoreduplication after Nutlin removal, giving rise to stable tetraploid clones that showed increased resistance to ionizing radiation (IR) and cisplatin (CP)-induced apoptosis compared to their diploid precursors. These findings demonstrate that transient p53 activation by Nutlin can promote tetraploid cell formation from diploid precursors, and the resulting tetraploid cells are therapy (IR/CP) resistant. Importantly, the tetraploid clones selected after Nutlin treatment expressed approximately twice as much P53 and MDM2 mRNA as diploid precursors, expressed approximately twice as many p53-MDM2 protein complexes (by co-immunoprecipitation), and were more susceptible to p53-dependent apoptosis and growth arrest induced by Nutlin. Based on these findings, we propose that p53 plays novel roles in both the formation and targeting of tetraploid cells. Specifically, we propose that 1) transient p53 activation can promote a tetraploid-G1 arrest and, as a result, may inadvertently promote formation of therapy-resistant tetraploid cells, and 2) therapy-resistant tetraploid cells, by virtue of having higher P53 gene copy number and expressing twice as many p53-MDM2 complexes, are more sensitive to apoptosis and/or growth arrest by anti-cancer MDM2 antagonists (e.g. Nutlin).	[Davaadelger, Batzaya; Shen, Hong; Maki, Carl G.] Rush Univ, Med Ctr, Dept Anat & Cell Biol, Chicago, IL 60612 USA	Rush University	Maki, CG (corresponding author), Rush Univ, Med Ctr, Dept Anat & Cell Biol, Chicago, IL 60612 USA.	Carl_Maki@rush.edu			National Institutes of Health from the National Cancer Institute (NCI) [1RO1CA137598-01A1]; NATIONAL CANCER INSTITUTE [R01CA137598] Funding Source: NIH RePORTER	National Institutes of Health from the National Cancer Institute (NCI); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by National Institutes of Health Grant 1RO1CA137598-01A1 from the National Cancer Institute (NCI) (to C.G.M.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aylon Y, 2011, MOL ONCOL, V5, P315, DOI 10.1016/j.molonc.2011.07.007; Badie C, 2000, MOL CELL BIOL, V20, P2358, DOI 10.1128/MCB.20.7.2358-2366.2000; Bellanger S, 2007, ONCOGENE, V26, P7175, DOI 10.1038/sj.onc.1210539; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Carvajal LA, 2013, EMBO REP, V14, P414, DOI 10.1038/embor.2013.25; Castedo M, 2006, ANN NY ACAD SCI, V1090, P35, DOI 10.1196/annals.1378.004; Castedo M, 2006, EMBO J, V25, P2584, DOI 10.1038/sj.emboj.7601127; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Davoli T, 2011, ANNU REV CELL DEV BI, V27, P585, DOI 10.1146/annurev-cellbio-092910-154234; de Toledo SM, 1998, CELL GROWTH DIFFER, V9, P887; FAN SJ, 1995, CANCER RES, V55, P1649; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Galipeau PC, 1996, P NATL ACAD SCI USA, V93, P7081, DOI 10.1073/pnas.93.14.7081; Gudkov AV, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001180; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Itzhaki JE, 1997, NAT GENET, V15, P258, DOI 10.1038/ng0397-258; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; Khan SH, 1998, CANCER RES, V58, P396; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Mechali M, 2010, NAT REV MOL CELL BIO, V11, P728, DOI 10.1038/nrm2976; Mihaylov IS, 2002, MOL CELL BIOL, V22, P1868, DOI 10.1128/MCB.22.6.1868-1880.2002; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Pestell KE, 2000, MOL PHARMACOL, V57, P503, DOI 10.1124/mol.57.3.503; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Reid BJ, 2011, CANCER BIOMARK, V9, P307, DOI 10.3233/CBM-2011-0162; Shen H, 2008, CANCER RES, V68, P8260, DOI 10.1158/0008-5472.CAN-08-1901; Shen H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059848; Shen H, 2010, J BIOL CHEM, V285, P23103, DOI 10.1074/jbc.M110.124990; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yoshida K, 2004, ONCOGENE, V23, P3802, DOI 10.1038/sj.onc.1207488	34	9	11	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 7	2014	9	11							e110844	10.1371/journal.pone.0110844	http://dx.doi.org/10.1371/journal.pone.0110844			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT3WF	25380055	Green Published, gold, Green Submitted			2023-01-03	WOS:000344863100015
J	Nordin, N; Salama, SM; Golbabapour, S; Hajrezaie, M; Hassandarvish, P; Kamalidehghan, B; Majid, NA; Hashim, NM; Omar, H; Fadaienasab, M; Karimian, H; Taha, H; Ali, HM; Abdulla, MA				Nordin, Noraziah; Salama, Suzy Munir; Golbabapour, Shahram; Hajrezaie, Maryam; Hassandarvish, Pouya; Kamalidehghan, Behnam; Majid, Nazia Abdul; Hashim, Najihah Mohd; Omar, Hanita; Fadaienasab, Mehran; Karimian, Hamed; Taha, Hairin; Ali, Hapipah Mohd; Abdulla, Mahmood Ameen			Anti-Ulcerogenic Effect of Methanolic Extracts from Enicosanthellum pulchrum (King) Heusden against Ethanol-Induced Acute Gastric Lesion in Animal Models	PLOS ONE			English	Article							PLATELET-ACTIVATING-FACTOR; NITRIC-OXIDE; ANTIOXIDANT PROPERTIES; MUCOSAL DEFENSE; ULCER; PROTEINS; MUCUS; HEAT-SHOCK-PROTEIN-70; PROSTAGLANDINS; LANSOPRAZOLE	A natural source of medicine, Enicosanthellum pulchrum is a tropical plant which belongs to the family Annonaceae. In this study, methanol extract from the leaves and stems of this species was evaluated for its gastroprotective potential against mucosal lesions induced by ethanol in rats. Seven groups of rats were assigned, groups 1 and 2 were given Tween 20 (10% v/v) orally. Group 3 was administered omeprazole 20 mg/kg (10% Tween 20) whilst the remaining groups received the leaf and stem extracts at doses of 150 and 300 mg/kg, respectively. After an additional hour, the rats in groups 2-7 received ethanol (95% v/v; 8 mL/kg) orally while group 1 received Tween 20 (10% v/v) instead. Rats were sacrificed after 1 h and their stomachs subjected to further studies. Macroscopically and histologically, group 2 rats showed extremely severe disruption of the gastric mucosa compared to rats pre-treated with the E. pulchrum extracts based on the ulcer index, where remarkable protection was noticed. Meanwhile, a significant percentage of inhibition was shown with the stem extract at 62% (150 mg/kg) and 65% (300 mg/kg), whilst the percentage with the leaf extract at doses of 150 and 300 mg/kg was 63% and 75%, respectively. An increase in mucus content, nitric oxide, glutathione, prostaglandin E2, superoxide dismutase, protein and catalase, and a decrease in malondialdehyde level compared to group 2 were also obtained. Furthermore, immunohistochemical staining of groups 4-7 exhibited down-regulation of Bax and up-regulation of Hsp70 proteins. The methanol extract from the leaves and the stems showed notable gastroprotective potential against ethanol.	[Nordin, Noraziah; Kamalidehghan, Behnam; Hashim, Najihah Mohd; Karimian, Hamed] Univ Malaya, Fac Med, Dept Pharm, Kuala Lumpur, Malaysia; [Salama, Suzy Munir; Golbabapour, Shahram; Hajrezaie, Maryam; Hassandarvish, Pouya; Abdulla, Mahmood Ameen] Univ Malaya, Fac Med, Dept Biomed Sci, Kuala Lumpur, Malaysia; [Nordin, Noraziah; Omar, Hanita; Fadaienasab, Mehran; Taha, Hairin; Ali, Hapipah Mohd] Univ Malaya, Fac Sci, Dept Chem, Kuala Lumpur, Malaysia; [Golbabapour, Shahram; Hajrezaie, Maryam; Majid, Nazia Abdul] Univ Malaya, Fac Sci, Inst Biol Sci, Kuala Lumpur, Malaysia; [Omar, Hanita] Univ Malaya, Ctr Fdn Studies Sci, Kuala Lumpur, Malaysia	Universiti Malaya; Universiti Malaya; Universiti Malaya; Universiti Malaya; Universiti Malaya	Salama, SM (corresponding author), Univ Malaya, Fac Med, Dept Biomed Sci, Kuala Lumpur, Malaysia.	s.salama999@hotmail.com; ammeen@um.edu.my	MAJID, NAZIA ABDUL/B-9215-2010; Hassandarvish, Pouya/K-8112-2012; Kamalidehghan, Behnam/B-5401-2013; Salama Fanous, Suzy Munir/AAX-6100-2020; Fadaeinasab, Mehran/A-8810-2016; Hashim, Najihah Mohd/J-5508-2015	MAJID, NAZIA ABDUL/0000-0002-6817-8046; Hassandarvish, Pouya/0000-0003-0364-5587; Kamalidehghan, Behnam/0000-0001-8530-8124; Salama Fanous, Suzy Munir/0000-0003-0430-1436; Fadaeinasab, Mehran/0000-0002-2501-894X; Hashim, Najihah Mohd/0000-0003-1133-7998	University of Malaya; Ministry of Higher Education Malaysia under High Impact Research Grant [UM-MOHE UM.C/625/1/HIR/MOHE/SC/09.]	University of Malaya(Universiti Malaya); Ministry of Higher Education Malaysia under High Impact Research Grant	This research has been supported by University of Malaya and Ministry of Higher Education Malaysia under High Impact Research Grant UM-MOHE UM.C/625/1/HIR/MOHE/SC/09. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdelwahab SI, 2013, J ETHNOPHARMACOL, V148, P277, DOI 10.1016/j.jep.2013.04.027; Abdulla MA, 2009, BIOMED RES-INDIA, V20, P35; Al Batran R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064751; Ali T, 2009, GASTROENTEROL CLIN N, V38, P245, DOI 10.1016/j.gtc.2009.03.002; Allen A, 2005, AM J PHYSIOL-CELL PH, V288, pC1, DOI 10.1152/ajpcell.00102.2004; ALLEN A, 1980, GUT, V21, P249, DOI 10.1136/gut.21.3.249; AlRashdi AS, 2012, EVIDENCE BASED COMPL, V2012; Alvarez-Suarez JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025878; [Anonymous], 1950, NATURE; Arafa HMM, 2003, PHARMACOL RES, V48, P285, DOI 10.1016/S1043-6618(03)00154-3; Balamurugan R, 2005, MOL BIOSYST, V1, P36, DOI 10.1039/b503623b; BEHMER O, 1976, MANUAL HISTOLOGIA NO; Biswas K, 2003, J BIOL CHEM, V278, P10993, DOI 10.1074/jbc.M210328200; Blandizzi C, 2000, FUNDAM CLIN PHARM, V14, P89, DOI 10.1111/j.1472-8206.2000.tb00396.x; Blandizzi C, 2005, WORLD J GASTROENTERO, V11, P4052, DOI 10.3748/wjg.v11.i26.4052; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breinbauer R, 2002, ANGEW CHEM INT EDIT, V41, P2879; Brown Lance F., 1999, Comprehensive Therapy, V25, P30, DOI 10.1007/BF02889832; Brucker MC, 1997, J NURSE-MIDWIFERY, V42, P145, DOI 10.1016/S0091-2182(97)00031-1; Brzozowski T, 2005, WORLD J GASTROENTERO, V11, P6450, DOI 10.3748/wjg.v11.i41.6450; Chemicals D., 2005, OECD GUIDELINE TESTI; Chittchang M, 2010, EUR J MED CHEM, V45, P2165, DOI 10.1016/j.ejmech.2010.01.053; CORNE SJ, 1974, J PHYSIOL-LONDON, V242, pP116; Dotevall G, 1971, CLIN VALUE GASTRIC S; Dursun H, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-36; Falcao HD, 2008, MOLECULES, V13, P3198, DOI 10.3390/molecules13123198; Golbabapour S, 2013, BIOMED RES INT, V2013, DOI DOI 10.1155/2013/974185; GORNALL AG, 1949, J BIOL CHEM, V177, P751; Hajrezaie M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051537; HERENDEEN SL, 1979, J BACTERIOL, V139, P185, DOI 10.1128/JB.139.1.185-194.1979; Hirokawa M, 1998, ALCOHOL CLIN EXP RES, V22, p111S, DOI 10.1111/acer.1998.22.s3_part1.111s; Hoogerwerf WA, 2001, GOODMAN GILMANS PHAR, V10th, P1005; Ibrahim IAA, 2012, MOLECULES, V17, P2796, DOI 10.3390/molecules17032796; Ismail IF, 2012, EVIDENCE BASED COMPL, V2012; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Jelski W, 2009, DIGEST DIS SCI, V54, P725, DOI 10.1007/s10620-008-0422-8; Junaidi M, 2013, INT J PHARM RES REV, V1, P380; Ketuly KA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059296; Khazaei M., 2006, IRAN J PHARM THER, V5, P43; Kong DX, 2009, J CHEM INF MODEL, V49, P2376, DOI 10.1021/ci900229c; Konturek PC, 1999, J PHYSIOL PHARMACOL, V50, P211; La Casa C, 2000, J ETHNOPHARMACOL, V71, P45, DOI 10.1016/S0378-8741(99)00174-9; Laine L, 2008, GASTROENTEROLOGY, V135, P41, DOI 10.1053/j.gastro.2008.05.030; LAVAULT M, 1990, PHYTOCHEMISTRY, V29, P3845, DOI 10.1016/0031-9422(90)85344-F; Li CY, 2008, ALCOHOL, V42, P683, DOI 10.1016/j.alcohol.2008.08.009; Li XQ, 2004, DRUG METAB DISPOS, V32, P821, DOI 10.1124/dmd.32.8.821; Mcmanus J, 1964, PAS REACTION STAININ; Miranda KM, 2001, NITRIC OXIDE-BIOL CH, V5, P62, DOI 10.1006/niox.2000.0319; Nassif A, 1996, DIS COLON RECTUM, V39, P217, DOI 10.1007/BF02068079; Nordin N, 2012, PHARM BIOL, V50, P284, DOI 10.3109/13880209.2011.602416; OBERRINGER M, 1995, BIOCHEM BIOPH RES CO, V214, P1009, DOI 10.1006/bbrc.1995.2386; OECD (Organisation for Economic Co-operation and Development), 2002, SER HARM REG OV BIOT, V20, P1; Oh TY, 2005, WORLD J GASTROENTERO, V11, P7450, DOI 10.3748/wjg.v11.i47.7450; Penissi AB, 1999, DIGEST DIS SCI, V44, P708, DOI 10.1023/A:1026601506677; Perry LM, 1980, MED PLANTS E SE ASIA; Peskar BM, 1998, DIGEST DIS SCI, V43, p23S; Repetto MG, 2002, BRAZ J MED BIOL RES, V35, P523, DOI 10.1590/S0100-879X2002000500003; Royer M, 2011, FOOD CHEM TOXICOL, V49, P2180, DOI 10.1016/j.fct.2011.06.003; Salama SM, 2012, EVIDENCE BASED COMPL, V2012; Salama SM, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/157456; Salama SM, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-279; Schneeweiss S, 2006, CLIN PHARMACOL THER, V79, P379, DOI 10.1016/j.clpt.2005.12.304; Sharma RK., 2011, INT J DRUG DEV RES, V3, P351; Shichijo K, 2003, DIGEST DIS SCI, V48, P340, DOI 10.1023/A:1021939829515; Sidahmed H, 2013, EVIDENCE BASED COMPL, V2013; Sidahmed HMA, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-183; Singh J., 2012, INT J PHARM SCI, V4, P412; Stermer E, 2002, ISR MED ASSOC J, V4, P200; SZABO S, 1981, SCIENCE, V214, P200, DOI 10.1126/science.7280691; Araujo DAOV, 2011, REV BRAS FARMACOGN, V21, P721, DOI 10.1590/S0102-695X2011005000117; Rios ERV, 2010, CHEM-BIOL INTERACT, V188, P246, DOI 10.1016/j.cbi.2010.07.020; Wallace JL, 1997, AM J PHYSIOL-GASTR L, V273, pG1246, DOI 10.1152/ajpgi.1997.273.6.G1246; WALLACE JL, 1992, GASTROENTEROL CLIN N, V21, P631; Wallace JL, 2000, GASTROENTEROLOGY, V119, P512, DOI 10.1053/gast.2000.9304; WEI YQ, 1995, CANCER IMMUNOL IMMUN, V40, P73, DOI 10.1007/s002620050146; Yadav DK, 2011, FITOTERAPIA, V82, P666, DOI 10.1016/j.fitote.2011.02.005	76	35	36	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 7	2014	9	11							e111925	10.1371/journal.pone.0111925	http://dx.doi.org/10.1371/journal.pone.0111925			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT3WF	25379712	gold, Green Published, Green Submitted			2023-01-03	WOS:000344863100047
J	Yao, X; Durr, UHN; Gattin, Z; Laukat, Y; Narayanan, RL; Bruckner, AK; Meisinger, C; Lange, A; Becker, S; Zweckstetter, M				Yao, Xuejun; Duerr, Ulrich H. N.; Gattin, Zrinka; Laukat, Yvonne; Narayanan, Rhagavendran L.; Brueckner, Ann-Kathrin; Meisinger, Chris; Lange, Adam; Becker, Stefan; Zweckstetter, Markus			NMR-Based Detection of Hydrogen/Deuterium Exchange in Liposome-Embedded Membrane Proteins	PLOS ONE			English	Article							SOLID-STATE NMR; DEPENDENT ANION CHANNEL; HYDROGEN-DEUTERIUM EXCHANGE; DYNAMIC CHARACTERIZATION; RESONANCE ASSIGNMENT; 2-DIMENSIONAL NMR; MASS-SPECTROMETRY; AMYLOID FIBRILS; APSY-NMR; SPECTROSCOPY	Membrane proteins play key roles in biology. Determination of their structure in a membrane environment, however, is highly challenging. To address this challenge, we developed an approach that couples hydrogen/deuterium exchange of membrane proteins to rapid unfolding and detection by solution-state NMR spectroscopy. We show that the method allows analysis of the solvent protection of single residues in liposome-embedded proteins such as the 349-residue Tom40, the major protein translocation pore in the outer mitochondrial membrane, which has resisted structural analysis for many years.	[Yao, Xuejun; Duerr, Ulrich H. N.; Gattin, Zrinka; Laukat, Yvonne; Narayanan, Rhagavendran L.; Brueckner, Ann-Kathrin; Lange, Adam; Becker, Stefan; Zweckstetter, Markus] Max Planck Inst Biophys Chem, D-37077 Gottingen, Germany; [Meisinger, Chris] Univ Freiburg, Inst Biochem & Molekularbiol, ZBMZ, D-79106 Freiburg, Germany; [Meisinger, Chris] Univ Freiburg, BIOSS Ctr Biol Signalling Studies, D-79106 Freiburg, Germany; [Zweckstetter, Markus] German Ctr Neurodegenerat Dis DZNE, Goottingen, Germany; [Zweckstetter, Markus] Univ Med Ctr, Ctr Nanoscale Microscopy & Mol Physiol Brain CNMP, Gottingen, Germany	Max Planck Society; University of Freiburg; University of Freiburg; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); University of Gottingen	Zweckstetter, M (corresponding author), Max Planck Inst Biophys Chem, D-37077 Gottingen, Germany.	Markus.Zweckstetter@dzne.de	Meisinger, Chris/J-1110-2014	Meisinger, Chris/0000-0002-8326-3548; Lange, Adam/0000-0002-7534-5973; Zweckstetter, Markus/0000-0002-2536-6581	ERC [282008]; Marie Curie fellowship within the 7th EU Framework Programme; DFG collaborative research center [803]; Emmy Noether fellowship	ERC(European Research Council (ERC)European Commission); Marie Curie fellowship within the 7th EU Framework Programme; DFG collaborative research center(German Research Foundation (DFG)); Emmy Noether fellowship(German Research Foundation (DFG))	ERC (grant agreement number 282008) to M Zweckstetter; Marie Curie fellowship within the 7th EU Framework Programme to Z Gattin; DFG collaborative research center 803 and Emmy Noether fellowship to A Lange. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baldus M, 1996, J MAGN RESON SER A, V121, P65, DOI 10.1006/jmra.1996.0137; Bauer AJ, 2011, BIOCHEMISTRY-US, V50, P3408, DOI 10.1021/bi2003247; Bayrhuber M, 2008, P NATL ACAD SCI USA, V105, P15370, DOI 10.1073/pnas.0808115105; Becker L, 2005, J MOL BIOL, V353, P1011, DOI 10.1016/j.jmb.2005.09.019; Bockmann A, 2005, J BIOMOL NMR, V32, P195, DOI 10.1007/s10858-005-8073-y; Catoire LJ, 2010, EUR BIOPHYS J BIOPHY, V39, P623, DOI 10.1007/s00249-009-0513-2; Chill JH, 2007, BBA-BIOMEMBRANES, V1768, P3260, DOI 10.1016/j.bbamem.2007.08.006; Chill JH, 2011, CURR OPIN STRUC BIOL, V21, P627, DOI 10.1016/j.sbi.2011.07.003; Cho MK, 2011, PROTEIN SCI, V20, P387, DOI 10.1002/pro.570; Cross TA, 2011, TRENDS BIOCHEM SCI, V36, P117, DOI 10.1016/j.tibs.2010.07.005; Csizmok V, 2008, J AM CHEM SOC, V130, P16873, DOI 10.1021/ja805510b; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DEMPSEY CE, 1994, J BIOMOL NMR, V4, P879, DOI 10.1007/BF00398417; Eddy MT, 2012, J AM CHEM SOC, V134, P6375, DOI 10.1021/ja300347v; Endo T, 2010, BBA-MOL CELL RES, V1803, P706, DOI 10.1016/j.bbamcr.2009.11.007; Fernandez C, 2004, J MOL BIOL, V336, P1211, DOI 10.1016/j.jmb.2003.09.014; Fiorito F, 2006, J BIOMOL NMR, V35, P27, DOI 10.1007/s10858-006-0030-x; Gopinath T, 2013, PROG NUCL MAG RES SP, V75, P50, DOI 10.1016/j.pnmrs.2013.07.004; GUNTERT P, 1992, J BIOMOL NMR, V2, P619, DOI 10.1007/BF02192850; Hebling CM, 2010, ANAL CHEM, V82, P5415, DOI 10.1021/ac100962c; Hiller S, 2005, P NATL ACAD SCI USA, V102, P10876, DOI 10.1073/pnas.0504818102; Hiller S, 2008, SCIENCE, V321, P1206, DOI 10.1126/science.1161302; Hiller S, 2007, J AM CHEM SOC, V129, P10823, DOI 10.1021/ja072564+; Hong M, 2012, ANNU REV PHYS CHEM, V63, P1, DOI 10.1146/annurev-physchem-032511-143731; Hoshino M, 2002, NAT STRUCT BIOL, V9, P332, DOI 10.1038/nsb792; Ippel JH, 2002, P NATL ACAD SCI USA, V99, P8648, DOI 10.1073/pnas.132098999; Jung YS, 2004, J BIOMOL NMR, V30, P11, DOI 10.1023/B:JNMR.0000042954.99056.ad; Knight MJ, 2012, P NATL ACAD SCI USA, V109, P11095, DOI 10.1073/pnas.1204515109; Krishna MMG, 2004, METHODS, V34, P51, DOI 10.1016/j.ymeth.2004.03.005; Kutik S, 2008, CELL, V132, P1011, DOI 10.1016/j.cell.2008.01.028; Marassi FM, 2011, METHODS, V55, P363, DOI 10.1016/j.ymeth.2011.09.009; Marsh JA, 2006, PROTEIN SCI, V15, P2795, DOI 10.1110/ps.062465306; MOLDAY RS, 1972, BIOCHEMISTRY-US, V11, P150, DOI 10.1021/bi00752a003; Murray DT, 2013, ACCOUNTS CHEM RES, V46, P2172, DOI 10.1021/ar3003442; Narayanan RL, 2010, J AM CHEM SOC, V132, P11906, DOI 10.1021/ja105657f; Neupert W, 2007, ANNU REV BIOCHEM, V76, P723, DOI 10.1146/annurev.biochem.76.052705.163409; Nietlispach D, 2011, CURR OPIN STRUC BIOL, V21, P497, DOI 10.1016/j.sbi.2011.06.009; Novacek J, 2013, J BIOMOL NMR, V56, P291, DOI 10.1007/s10858-013-9761-7; Panchal SC, 2001, J BIOMOL NMR, V20, P135, DOI 10.1023/A:1011239023422; Perry AJ, 2008, PLANT PHYSIOL BIOCH, V46, P265, DOI 10.1016/j.plaphy.2007.12.012; Qureshi T, 2012, TOP CURR CHEM, V326, P123, DOI 10.1007/128_2011_306; Radoicic J, 2014, Q REV BIOPHYS, V47, P249, DOI 10.1017/S0033583514000080; Rey M, 2010, J BIOL CHEM, V285, P34981, DOI 10.1074/jbc.M110.146209; Schanda P, 2007, P NATL ACAD SCI USA, V104, P11257, DOI 10.1073/pnas.0702069104; Schanda P, 2006, J AM CHEM SOC, V128, P9042, DOI 10.1021/ja062025p; Schneider R, 2010, ANGEW CHEM INT EDIT, V49, P1882, DOI 10.1002/anie.200906241; Solyom Z, 2013, J BIOMOL NMR, V55, P311, DOI 10.1007/s10858-013-9715-0; Tian CL, 2003, PROTEIN SCI, V12, P2597, DOI 10.1110/ps.03168503; Tong KI, 2008, J BIOMOL NMR, V42, P59, DOI 10.1007/s10858-008-9264-0; Ujwal R, 2008, P NATL ACAD SCI USA, V105, P17742, DOI 10.1073/pnas.0809634105; Van Melckebeke H, 2011, J MOL BIOL, V405, P765, DOI 10.1016/j.jmb.2010.11.004; Vilar M, 2012, METHODS MOL BIOL, V849, P185, DOI 10.1007/978-1-61779-551-0_13; Villinger S, 2010, P NATL ACAD SCI USA, V107, P22546, DOI 10.1073/pnas.1012310108; Zhang Y, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-40	54	3	3	1	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2014	9	11							e112374	10.1371/journal.pone.0112374	http://dx.doi.org/10.1371/journal.pone.0112374			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AS6XM	25375235	gold, Green Submitted, Green Published			2023-01-03	WOS:000344402600137
J	Meguro, S; Hasumura, T; Hase, T				Meguro, Shinichi; Hasumura, Takahiro; Hase, Tadashi			Body Fat Accumulation in Zebrafish Is Induced by a Diet Rich in Fat and Reduced by Supplementation with Green Tea Extract	PLOS ONE			English	Article							SALMO-SALAR L.; INDUCED OBESITY; SUBCUTANEOUS FAT; LIPID-METABOLISM; RAINBOW-TROUT; BROWN TROUT; ADIPOSITY; GROWTH; SEX; DEPOSITION	Fat-rich diets not only induce obesity in humans but also make animals obese. Therefore, animals that accumulate body fat in response to a high-fat diet (especially rodents) are commonly used in obesity research. The effect of dietary fat on body fat accumulation is not fully understood in zebrafish, an excellent model of vertebrate lipid metabolism. Here, we explored the effects of dietary fat and green tea extract, which has anti-obesity properties, on body fat accumulation in zebrafish. Adult zebrafish were allocated to four diet groups and over 6 weeks were fed a high-fat diet containing basal diet plus two types of fat or a low-fat diet containing basal diet plus carbohydrate or protein. Another group of adult zebrafish was fed a high-fat diet with or without 5% green tea extract supplementation. Zebrafish fed the high-fat diets had nearly twice the body fat (visceral, subcutaneous, and total fat) volume and body fat volume ratio (body fat volume/body weight) of those fed low-fat diets. There were no differences in body fat accumulation between the two high-fat groups, nor were there any differences between the two low-fat groups. Adding green tea extract to the high-fat diet significantly suppressed body weight, body fat volume, and body fat volume ratio compared with the same diet lacking green tea extract. 3-Hydroxyacyl-coenzyme A dehydrogenase and citrate synthase activity in the liver and skeletal muscle were significantly higher in fish fed the diet supplemented with green tea extract than in those fed the unsupplemented diet. Our results suggest that a diet rich in fat, instead of protein or carbohydrate, induced body fat accumulation in zebrafish with mechanisms that might be similar to those in mammals. Consequently, zebrafish might serve as a good animal model for research into obesity induced by high-fat diets.	[Meguro, Shinichi; Hasumura, Takahiro; Hase, Tadashi] Kao Corp, Biol Sci Res, Tokyo, Tochigi, Japan	KAO Corporation	Meguro, S (corresponding author), Kao Corp, Biol Sci Res, Tokyo, Tochigi, Japan.			Meguro, Shinichi/0000-0002-3072-2632				Anderson JL, 2011, METHOD CELL BIOL, V101, P111, DOI 10.1016/B978-0-12-387036-0.00005-0; [Anonymous], 2010, GUIDE CARE USE LAB A; BASS A, 1969, EUR J BIOCHEM, V10, P198, DOI 10.1111/j.1432-1033.1969.tb00674.x; Bertrais S, 1999, INT J OBESITY, V23, P1085, DOI 10.1038/sj.ijo.0801033; BOOZER CN, 1995, AM J PHYSIOL-ENDOC M, V268, pE546; Bose M, 2008, J NUTR, V138, P1677, DOI 10.1093/jn/138.9.1677; BOURGEOIS F, 1983, BRIT J NUTR, V49, P17, DOI 10.1079/BJN19830006; Buettner R, 2007, OBESITY, V15, P798, DOI 10.1038/oby.2007.608; Chu CY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036474; Cnop M, 2002, DIABETES, V51, P1005, DOI 10.2337/diabetes.51.4.1005; Collins S, 2004, PHYSIOL BEHAV, V81, P243, DOI 10.1016/j.physbeh.2004.02.006; Eckel RH, 2005, LANCET, V365, P1415, DOI 10.1016/S0140-6736(05)66378-7; ENZI G, 1986, AM J CLIN NUTR, V44, P739, DOI 10.1093/ajcn/44.6.739; Ghibaudi L, 2002, OBES RES, V10, P956, DOI 10.1038/oby.2002.130; GRAUER WO, 1984, AM J CLIN NUTR, V39, P631, DOI 10.1093/ajcn/39.4.631; Hariri N, 2010, NUTR RES REV, V23, P270, DOI 10.1017/S0954422410000168; Hasumura T, 2012, NUTR METAB, V9, DOI 10.1186/1743-7075-9-73; HILL JO, 1992, INT J OBESITY, V16, P321; Holtta-Vuori M, 2010, BIOCHEM J, V429, P235, DOI 10.1042/BJ20100293; Ikemoto S, 1996, METABOLISM, V45, P1539, DOI 10.1016/S0026-0495(96)90185-7; Jobling M, 1998, AQUAC RES, V29, P601, DOI 10.1111/j.1365-2109.1998.tb01174.x; Jobling M, 2003, AQUAC RES, V34, P311, DOI 10.1046/j.1365-2109.2003.00820.x; Jobling M, 2002, AQUAC RES, V33, P533, DOI 10.1046/j.1365-2109.2002.00738.x; Jobling M, 2002, AQUAC RES, V33, P739, DOI 10.1046/j.1365-2109.2002.00712.x; Kause A, 2007, AQUACULTURE, V271, P162, DOI 10.1016/j.aquaculture.2007.06.005; Kishida K, 2012, ANN MED, V44, P233, DOI 10.3109/07853890.2011.564202; Lieschke GJ, 2007, NAT REV GENET, V8, P353, DOI 10.1038/nrg2091; Lu C, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0034833, 10.1371/journal.pone.0038332]; Matsumoto T, 2010, DIS MODEL MECH, V3, P431, DOI 10.1242/dmm.002311; MATSUZAWA Y, 1995, OBES RES, V3, pS187, DOI 10.1002/j.1550-8528.1995.tb00462.x; Meguro S, 2001, J OLEO SCI, V50, P593, DOI DOI 10.5650/JOS.50.593; Mori T, 2007, J NUTR, V137, P2629, DOI 10.1093/jn/137.12.2629; Murase T, 2006, AM J PHYSIOL-REG I, V290, pR1550, DOI 10.1152/ajpregu.00752.2005; Murase T, 2006, INT J OBESITY, V30, P561, DOI 10.1038/sj.ijo.0803135; Murase T, 2002, INT J OBESITY, V26, P1459, DOI 10.1038/sj.ijo.0802141; Niva T, 1999, ANN ZOOL FENN, V36, P103; Oka Takehiko, 2010, BMC Physiol, V10, P21, DOI 10.1186/1472-6793-10-21; Petro AE, 2004, METABOLISM, V53, P454, DOI 10.1016/j.metabol.2003.11.018; Refstie Stale, 2001, Aquaculture, V193, P91, DOI 10.1016/S0044-8486(00)00473-7; Regost C, 2001, AQUACULTURE, V193, P325, DOI 10.1016/S0044-8486(00)00498-1; Schreiner PJ, 1996, AM J EPIDEMIOL, V144, P335, DOI 10.1093/oxfordjournals.aje.a008934; Shen CL, 2012, NUTR RES, V32, P448, DOI 10.1016/j.nutres.2012.05.001; Shimotoyodome A, 2005, MED SCI SPORT EXER, V37, P1884, DOI 10.1249/01.mss.0000178062.66981.a8; Song Y, 2007, FASEB J, V21, P2042, DOI 10.1096/fj.06-7503com; Srere P.A., 1969, METHODS ENZYMOLOGY, V13, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; Takahashi M, 1999, J NUTR SCI VITAMINOL, V45, P583, DOI 10.3177/jnsv.45.583; Truett AA, 1998, OBES RES, V6, P137, DOI 10.1002/j.1550-8528.1998.tb00328.x; Tschop M, 2001, EXP CLIN ENDOCR DIAB, V109, P307, DOI 10.1055/s-2001-17297; WARWICK ZS, 1992, NEUROSCI BIOBEHAV R, V16, P585, DOI 10.1016/S0149-7634(05)80198-8; Westerbacka J, 2004, DIABETOLOGIA, V47, P1360, DOI 10.1007/s00125-004-1460-1; Westerfield M, 2007, ZEBRAFISH BOOK EDITI; WHO, OB OV; WIEGAND G, 1986, ANNU REV BIOPHYS BIO, V15, P97; Yang SY, 1999, ADV EXP MED BIOL, V466, P133	54	44	46	4	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 18	2015	10	3							e0120142	10.1371/journal.pone.0120142	http://dx.doi.org/10.1371/journal.pone.0120142			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE9BN	25785691	Green Published, gold, Green Submitted			2023-01-03	WOS:000352138500156
J	Silverstein, A				Silverstein, Alex			SPOTLIGHT: PATIENT CENTRED CARE Patient commentary: What I need to self manage my care	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Int Diabet Federat Young Leaders Diabet Program, Manama, Bahrain		Silverstein, A (corresponding author), Int Diabet Federat Young Leaders Diabet Program, Manama, Bahrain.	alexsdiabetes@gmail.com							0	2	2	1	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 10	2015	350								h248	10.1136/bmj.h248	http://dx.doi.org/10.1136/bmj.h248			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CB0LU	25670188				2023-01-03	WOS:000349318400006
J	Shahaduzzaman, M; Nash, K; Hudson, C; Sharif, M; Grimmig, B; Lin, XY; Bai, G; Liu, H; Ugen, KE; Cao, CH; Bickford, PC				Shahaduzzaman, Md; Nash, Kevin; Hudson, Charles; Sharif, Masroor; Grimmig, Bethany; Lin, Xiaoyang; Bai, Ge; Liu, Hui; Ugen, Kenneth E.; Cao, Chuanhai; Bickford, Paula C.			Anti-Human alpha-Synuclein N-Terminal Peptide Antibody Protects against Dopaminergic Cell Death and Ameliorates Behavioral Deficits in an AAV-alpha-Synuclein Rat Model of Parkinson's Disease	PLOS ONE			English	Article							ALZHEIMERS-DISEASE; MEMBRANE-BINDING; IMMUNOTHERAPY; IMMUNIZATION; NEURODEGENERATION; PHOSPHORYLATION; MICROGLIA; STRATEGY	The protein alpha-synuclein (alpha-Syn) has a central role in the pathogenesis of Parkinson's disease (PD) and immunotherapeutic approaches targeting this molecule have shown promising results. In this study, novel antibodies were generated against specific peptides from full length human alpha-Syn and evaluated for effectiveness in ameliorating alpha-Syn-induced cell death and behavioral deficits in an AAV-alpha-Syn expressing rat model of PD. Fisher 344 rats were injected with rAAV vector into the right substantia nigra (SN), while control rats received an AAV vector expressing green fluorescent protein (GFP). Beginning one week after injection of the AAV-alpha-Syn vectors, rats were treated intraperitoneally with either control IgG or antibodies against the N-terminal (AB1), or central region (AB2) of alpha-Syn. An unbiased stereological estimation of TH+, NeuN+, and OX6 (MHC-II) immunostaining revealed that the alpha-Syn peptide antibodies (AB1 and AB2) significantly inhibited alpha-Syn-induced dopaminergic cell (DA) and NeuN+ cell loss (one-way ANOVA (F (3, 30) = 5.8, p = 0.002 and (F (3, 29) = 7.92, p = 0.002 respectively), as well as decreasing the number of activated microglia in the ipsilateral SN (one-way ANOVA F = 14.09; p = 0.0003). Antibody treated animals also had lower levels of alpha-Syn in the ipsilateral SN (one-way ANOVA F (7, 37) = 9.786; p = 0.0001) and demonstrated a partial intermediate improvement of the behavioral deficits. Our data suggest that, in particular, an alpha-Syn peptide antibody against the N-terminal region of the protein can protect against DA neuron loss and, to some extent behavioral deficits. As such, these results may be a potential therapeutic strategy for halting the progression of PD.	[Shahaduzzaman, Md; Sharif, Masroor; Grimmig, Bethany; Bickford, Paula C.] Univ S Florida, Morsani Coll Med, Ctr Excellence Aging & Brain Repair, Dept Neurosurg & Brain Repair, Tampa, FL 33612 USA; [Nash, Kevin; Bickford, Paula C.] Univ S Florida, Morsani Coll Med, Tampa, FL 33612 USA; [Hudson, Charles; Bickford, Paula C.] James A Haley Vet Affairs Hosp, Res Serv, Tampa, FL 33612 USA; [Nash, Kevin; Lin, Xiaoyang; Bai, Ge; Liu, Hui; Cao, Chuanhai] Univ S Florida, USF Hlth Byrd Alzheimers Inst, Tampa, FL 33612 USA; [Ugen, Kenneth E.] Univ S Florida, Morsani Coll Med, Dept Mol Med, Tampa, FL 33612 USA; [Ugen, Kenneth E.] Univ S Florida, Ctr Mol Delivery, Tampa, FL 33612 USA; [Cao, Chuanhai] Univ S Florida, Coll Pharm, Dept Pharmaceut Sci, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Cao, CH (corresponding author), Univ S Florida, USF Hlth Byrd Alzheimers Inst, Tampa, FL 33612 USA.	ccao@health.usf.edu; pbickfor@health.usf.edu	Bickford, Paula C/J-5970-2012; Ugen, Kenneth E/H-6544-2011	Bickford, Paula C/0000-0001-9657-7725; Cao, Chuanhai/0000-0002-5765-6401	VA Medical Research Service grant [1I01BX000231]; Veterans Affairs [I01BX000231] Funding Source: NIH RePORTER	VA Medical Research Service grant; Veterans Affairs(US Department of Veterans Affairs)	Funding provided by VA Medical Research Service grant 1I01BX000231 to PCB. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alerte TNM, 2008, NEUROSCI LETT, V435, P24, DOI 10.1016/j.neulet.2008.02.014; Anderson NL, 2009, MOL CELL PROTEOMICS, V8, P995, DOI 10.1074/mcp.M800446-MCP200; Angela M., 2005, UTILITY OF 6 HYDROXY; Bae EJ, 2012, J NEUROSCI, V32, P13454, DOI 10.1523/JNEUROSCI.1292-12.2012; Bartels T, 2010, BIOPHYS J, V99, P2116, DOI 10.1016/j.bpj.2010.06.035; Boche D, 2008, BRAIN, V131, P3299, DOI 10.1093/brain/awn261; Boche D, 2010, ACTA NEUROPATHOL, V120, P369, DOI 10.1007/s00401-010-0719-5; Brochard V, 2009, J CLIN INVEST, V119, P182, DOI 10.1172/JCI36470; Carty N, 2010, J NEUROSCI METH, V194, P144, DOI 10.1016/j.jneumeth.2010.10.010; Decressac M, 2012, NEUROBIOL DIS, V45, P939, DOI 10.1016/j.nbd.2011.12.013; Fagerqvist T, 2013, J NEUROCHEM, V126, P131, DOI 10.1111/jnc.12175; Foulds PG, 2011, FASEB J, V25, P4127, DOI 10.1096/fj.10-179192; Gardai SJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071634; Ghochikyan A, 2014, NEUROSCI LETT, V560, P86, DOI 10.1016/j.neulet.2013.12.028; Gorbatyuk OS, 2008, P NATL ACAD SCI USA, V105, P763, DOI 10.1073/pnas.0711053105; Gorbatyuk OS, 2010, MOL THER, V18, P1450, DOI 10.1038/mt.2010.115; Guo JL, 2014, NAT MED, V20, P130, DOI 10.1038/nm.3457; Harms AS, 2013, J NEUROSCI, V33, P9592, DOI 10.1523/JNEUROSCI.5610-12.2013; Holmes C, 2008, LANCET, V372, P216, DOI 10.1016/S0140-6736(08)61075-2; Hutter-Saunders JAL, 2011, EXPERT REV NEUROTHER, V11, P1703, DOI [10.1586/ERN.11.163, 10.1586/ern.11.163]; Iancu R, 2005, BEHAV BRAIN RES, V162, P1, DOI 10.1016/j.bbr.2005.02.023; Kim TD, 2002, BIOCHEMISTRY-US, V41, P13782, DOI 10.1021/bi026284c; Kirik D, 2002, P NATL ACAD SCI USA, V99, P4708, DOI 10.1073/pnas.062047599; Koehler NKU, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064649; Kortekaas R, 2005, ANN NEUROL, V57, P176, DOI 10.1002/ana.20369; Kosloski LM, 2010, J NEUROCHEM, V114, P1261, DOI 10.1111/j.1471-4159.2010.06834.x; Kothawala A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043505; Kristen Marciniuk RT, 2013, CLINICAL AND DEVELOP; Lambracht-Washington D, 2013, DISCOV MED, V15, P319; Lannfelt L, 2014, J INTERN MED, V275, P284, DOI 10.1111/joim.12168; Lashuel HA, 2013, NAT REV NEUROSCI, V14, P38, DOI 10.1038/nrn3406; Lemere CA, 2013, MOL NEURODEGENER, V8, DOI 10.1186/1750-1326-8-36; Lemere CA, 2010, NAT REV NEUROL, V6, P108, DOI 10.1038/nrneurol.2009.219; Lindstrom V, 2014, IMMUNOTHERAPY-UK, V6, P141, DOI [10.2217/imt.13.162, 10.2217/IMT.13.162]; Liu L, 2014, DRUG TODAY, V50, P33, DOI 10.1358/dot.2014.50.1.2076506; Madeo J, 2013, AGING DIS, V4, P210; Mandler M, 2014, ACTA NEUROPATHOL; Masliah E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019338; McLean PJ, 2000, J BIOL CHEM, V275, P8812, DOI 10.1074/jbc.275.12.8812; Mosley RL, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a009381; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8; Pabon MM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045256; Peterson LJ, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/401264; Rafii MS, 2013, REV RECENT CLIN TRIA; Sanchez-Guajardo V, 2013, ASN NEURO, V5, P113, DOI 10.1042/AN20120066; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Schneeberger A, 2012, Parkinsonism Relat Disord, V18 Suppl 1, pS11, DOI 10.1016/S1353-8020(11)70006-2; Stefanis L, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a009399; Tran HT, 2014, CELL REP, V7, P2054, DOI 10.1016/j.celrep.2014.05.033; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Valera E, 2013, PHARMACOL THERAPEUT, V138, P311, DOI 10.1016/j.pharmthera.2013.01.013; Vamvaca K, 2009, J MOL BIOL, V389, P413, DOI 10.1016/j.jmb.2009.03.021; Vekrellis K, 2012, EXPERT OPIN THER TAR, V16, P421, DOI 10.1517/14728222.2012.674111; Yu YJ, 2013, NEUROTHERAPEUTICS, V10, P459, DOI 10.1007/s13311-013-0187-4; Zhang Y, 2011, NEUROSCIENTIST, V17, P163, DOI 10.1177/1073858410381532	56	62	67	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2015	10	2							e0116841	10.1371/journal.pone.0116841	http://dx.doi.org/10.1371/journal.pone.0116841			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CB2GK	25658425	Green Published, gold, Green Submitted			2023-01-03	WOS:000349444900072
J	Baum, M				Baum, Michael			Saatchi is right to promote medical innovation but his bill is wrong way to do it	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									UCL, London WC1E 6BT, England	University of London; University College London	Baum, M (corresponding author), UCL, London WC1E 6BT, England.	baum.michael3@gmail.com						ABE O, 1995, NEW ENGL J MED, V333, P1444; Autier P, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c3620; Clarke M, 1998, LANCET, V351, P1451; Dyer C, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h495; Howell A, 2005, LANCET, V365, P60, DOI 10.1016/s0140-6736(04)17666-6; Peedell C, 2014, TIMES; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678	7	3	4	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 4	2015	350								h531	10.1136/bmj.h531	http://dx.doi.org/10.1136/bmj.h531			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CB0IP	25652261				2023-01-03	WOS:000349309500002
J	Singer, AE; Meeker, D; Teno, JM; Lynn, J; Lunney, JR; Lorenz, KA				Singer, Adam E.; Meeker, Daniella; Teno, Joan M.; Lynn, Joanne; Lunney, June R.; Lorenz, Karl A.			Symptom Trends in the Last Year of Life From 1998 to 2010 A Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							ADVANCED CANCER; MULTIPLE IMPUTATION; SUPPORTIVE CARE; PALLIATIVE CARE; OF-LIFE; QUALITY; END; HEALTH; PREVALENCE; DYSPNEA	Background: Calls for improvement in end-of-life care have focused attention on the management of pain and other troubling symptoms at the end of life. Objective: To describe changes in pain intensity and symptom prevalence during the last year of life from 1998 to 2010. Design: Observational study. Setting: The HRS (Health and Retirement Study), a nationally representative longitudinal survey of community-dwelling U. S. residents aged 51 years or older. Participants: 7204 HRS participants who died while enrolled in the study and their family respondents. Measurements: Proxy-reported pain during the last year of life and other symptoms for at least 1 month during the last year of life. Trends in pain intensity and symptom prevalence were analyzed for all decedents and within the categories of sudden death, cancer, congestive heart failure or chronic lung disease, and frailty. Results: Between 1998 and 2010, proxy reports of the prevalence of any pain increased for all decedents from 54.3% (95% CI, 51.6% to 57.1%) to 60.8% (CI, 58.2% to 63.4%), an increase of 11.9% (CI, 3.1% to 21.4%). Reported prevalences of depression and periodic confusion also increased for all decedents by 26.6% (CI, 14.5% to 40.1%) and 31.3% (CI, 18.6% to 45.1%), respectively. Individual symptoms increased in prevalence among specific decedent categories, except in cancer, which showed no significant changes. The prevalence of moderate or severe pain did not change among all decedents or in any specific decedent category. Limitation: Use of proxy reports and limited information about some patient and surrogate variables. Conclusion: Despite national efforts to improve end-of-life care, proxy reports of pain and other alarming symptoms in the last year of life increased from 1998 to 2010.	[Singer, Adam E.] RAND Corp, Pardee RAND Grad Sch, Santa Monica, CA 90407 USA; Univ So Calif, Los Angeles, CA 90089 USA; Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; Brown Univ, Providence, RI 02912 USA; Altarum Inst, Washington, DC USA; [Lunney, June R.] Hosp & Palliat Nurses Assoc, Pittsburgh, PA 15276 USA	RAND Corporation; Pardee RAND Graduate School; University of Southern California; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Brown University	Singer, AE (corresponding author), RAND Corp, Pardee RAND Grad Sch, 1776 Main St,POB 2138, Santa Monica, CA 90407 USA.	asinger@rand.org	Meeker, Daniella/AAV-5953-2020	Meeker, Daniella/0000-0002-1034-7628	National Institute of Nursing Research [R01 NR013372]; Medical Scientist Training Program at the University of California, Los Angeles [T32 GM008042]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR013372] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG024968] Funding Source: NIH RePORTER	National Institute of Nursing Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); Medical Scientist Training Program at the University of California, Los Angeles; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	By the National Institute of Nursing Research (grant R01 NR013372; Dr. Lorenz); Mr. Singer received support from grant T32 GM008042 as a member of the Medical Scientist Training Program at the University of California, Los Angeles.	[Anonymous], 2004, NIH Consens State Sci Statements, V21, P1; [Anonymous], 2011, PRIORITIES NATL QUAL; [Anonymous], 2012, NATL VOLUNTARY CONSE; Barbera L, 2010, CANCER-AM CANCER SOC, V116, P5767, DOI 10.1002/cncr.25681; Ben-Aharon I, 2012, ACTA ONCOL, V51, P996, DOI 10.3109/0284186X.2012.709638; Centers for Medicare & Medicaid Services, 2014, HOSP EXP CAR SURV; Currow DC, 2010, J PAIN SYMPTOM MANAG, V39, P680, DOI 10.1016/j.jpainsymman.2009.09.017; Dy SM, 2012, IMPROVING HLTH CARE; EFRON B, 1987, J AM STAT ASSOC, V82, P171, DOI 10.2307/2289144; Field MJ, 1997, APPROACHING DEATH IM; Fine Robert L, 2007, Proc (Bayl Univ Med Cent), V20, P5; Foley KM, 2001, IMPROVING PALLIATIVE; Hogan C, 2001, HEALTH AFFAIR, V20, P188, DOI 10.1377/hlthaff.20.4.188; Institute of Medicine, 2011, REL PAIN AM BLUEPR T; Juster FT, 1995, J HUM RESOUR, V30, pS7, DOI 10.2307/146277; Langley PC, 2010, VALUE HEALTH, V13, pA395; Lorenz KA, 2001, ANN INTERN MED, V134, P854, DOI 10.7326/0003-4819-134-9_Part_2-200105011-00009; Lorenz KA, 2008, ANN INTERN MED, V148, P147, DOI 10.7326/0003-4819-148-2-200801150-00010; Lunney JR, 2003, JAMA-J AM MED ASSOC, V289, P2387, DOI 10.1001/jama.289.18.2387; Lunney JR, 2002, J AM GERIATR SOC, V50, P1108, DOI 10.1046/j.1532-5415.2002.50268.x; Malin JL, 2011, J PALLIAT MED, V14, P573, DOI 10.1089/jpm.2010.0464; McPherson CJ, 2003, SOC SCI MED, V56, P95, DOI 10.1016/S0277-9536(02)00011-4; Morrison RS, 2011, J PALLIAT MED, V14, P1094, DOI 10.1089/jpm.2011.9634; Morss S, 2011, J PALLIAT MED, V14, P451, DOI 10.1089/jpm.2010.0434; National Hospice and Palliative Care Organization, 2013, NHPCO FACTS FIG HOSP; Reyes-Gibby CC, 2006, J PAIN SYMPTOM MANAG, V32, P118, DOI 10.1016/j.jpainsymman.2006.01.008; Royston P, 2009, STATA J, V9, P466, DOI 10.1177/1536867X0900900308; Rubin DB, 1996, J AM STAT ASSOC, V91, P473, DOI 10.1080/01621459.1996.10476908; Smith AK, 2010, ANN INTERN MED, V153, P563, DOI 10.7326/0003-4819-153-9-201011020-00005; Solano JP, 2006, J PAIN SYMPTOM MANAG, V31, P58, DOI 10.1016/j.jpainsymman.2005.06.007; Steffick DE, 2000, DOCUMENTATION AFFECT; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; Steinhauser KE, 2000, ANN INTERN MED, V132, P825, DOI 10.7326/0003-4819-132-10-200005160-00011; Teno JM, 2013, JAMA-J AM MED ASSOC, V309, P470, DOI 10.1001/jama.2012.207624; Ulmer C, 2010, FUTURE DIRECTIONS NA; University of Michigan, 2008, HLTH RETIREMENT STUD; Walling AM, 2013, JAMA INTERN MED, V173, P2071, DOI 10.1001/jamainternmed.2013.10797; Walling AM, 2012, SUPPORT CARE CANCER, V20, P2189, DOI 10.1007/s00520-012-1462-3; Walling AM, 2010, ARCH INTERN MED, V170, P1057, DOI 10.1001/archinternmed.2010.175	39	84	85	0	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 3	2015	162	3					175	U58		10.7326/M13-1609	http://dx.doi.org/10.7326/M13-1609			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CC1NP	25643305	Green Accepted			2023-01-03	WOS:000350108100003
J	Francis, PA; Regan, MM; Fleming, GF; Lang, I; Ciruelos, E; Bellet, M; Bonnefoi, HR; Climent, MA; Da Prada, GA; Burstein, HJ; Martino, S; Davidson, NE; Geyer, CE; Walley, BA; Coleman, R; Kerbrat, P; Buchholz, S; Ingle, JN; Winer, EP; Rabaglio-Poretti, M; Maibach, R; Ruepp, B; Giobbie-Hurder, A; Price, KN; Colleoni, M; Viale, G; Coates, AS; Goldhirsch, A; Gelber, RD				Francis, Prudence A.; Regan, Meredith M.; Fleming, Gini F.; Lang, Istvan; Ciruelos, Eva; Bellet, Meritxell; Bonnefoi, Herve R.; Climent, Miguel A.; Da Prada, Gian Antonio; Burstein, Harold J.; Martino, Silvana; Davidson, Nancy E.; Geyer, Charles E., Jr.; Walley, Barbara A.; Coleman, Robert; Kerbrat, Pierre; Buchholz, Stefan; Ingle, James N.; Winer, Eric P.; Rabaglio-Poretti, Manuela; Maibach, Rudolf; Ruepp, Barbara; Giobbie-Hurder, Anita; Price, Karen N.; Colleoni, Marco; Viale, Giuseppe; Coates, Alan S.; Goldhirsch, Aron; Gelber, Richard D.		SOFT Investigators; Int Breast Canc Study Grp	Adjuvant Ovarian Suppression in Premenopausal Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							YOUNG-WOMEN; THERAPY; CHEMOTHERAPY; AMENORRHEA	BACKGROUND Suppression of ovarian estrogen production reduces the recurrence of hormone-receptor-positive early breast cancer in premenopausal women, but its value when added to tamoxifen is uncertain. METHODS We randomly assigned 3066 premenopausal women, stratified according to prior receipt or nonreceipt of chemotherapy, to receive 5 years of tamoxifen, tamoxifen plus ovarian suppression, or exemestane plus ovarian suppression. The primary analysis tested the hypothesis that tamoxifen plus ovarian suppression would improve disease-free survival, as compared with tamoxifen alone. In the primary analysis, 46.7% of the patients had not received chemotherapy previously, and 53.3% had received chemotherapy and remained premenopausal. RESULTS After a median follow-up of 67 months, the estimated disease-free survival rate at 5 years was 86.6% in the tamoxifen-ovarian suppression group and 84.7% in the tamoxifen group (hazard ratio for disease recurrence, second invasive cancer, or death, 0.83; 95% confidence interval [CI], 0.66 to 1.04; P=0.10). Multivariable allowance for prognostic factors suggested a greater treatment effect with tamoxifen plus ovarian suppression than with tamoxifen alone (hazard ratio, 0.78; 95% CI, 0.62 to 0.98). Most recurrences occurred in patients who had received prior chemotherapy, among whom the rate of freedom from breast cancer at 5 years was 82.5% in the tamoxifen-ovarian suppression group and 78.0% in the tamoxifen group (hazard ratio for recurrence, 0.78; 95% CI, 0.60 to 1.02). At 5 years, the rate of freedom from breast cancer was 85.7% in the exemestane-ovarian suppression group (hazard ratio for recurrence vs. tamoxifen, 0.65; 95% CI, 0.49 to 0.87). CONCLUSIONS Adding ovarian suppression to tamoxifen did not provide a significant benefit in the overall study population. However, for women who were at sufficient risk for recurrence to warrant adjuvant chemotherapy and who remained premenopausal, the addition of ovarian suppression improved disease outcomes. Further improvement was seen with the use of exemestane plus ovarian suppression.	[Francis, Prudence A.] Univ Melbourne, St Vincents Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Francis, Prudence A.; Coates, Alan S.] Univ Newcastle, Australia & New Zealand Breast Canc Trials Grp, Newcastle, NSW 2300, Australia; [Coates, Alan S.] Univ Sydney, Sydney, NSW 2006, Australia; [Regan, Meredith M.; Giobbie-Hurder, Anita; Gelber, Richard D.] Dana Farber Canc Inst, IBCSG, Ctr Stat, Boston, MA 02115 USA; [Regan, Meredith M.; Gelber, Richard D.] Harvard Univ, Sch Med, Boston, MA USA; [Burstein, Harold J.; Winer, Eric P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Susan F Smith Ctr Womens Canc, Boston, MA 02115 USA; [Burstein, Harold J.; Winer, Eric P.] Alliance Clin Trials Oncol, Boston, MA USA; [Price, Karen N.] Frontier Sci & Technol Res Fdn Inc, IBCSG Stat Ctr, Boston, MA USA; [Gelber, Richard D.] Harvard Univ, Sch Publ Hlth, Frontier Sci & Technol Res Fdn, Boston, MA 02115 USA; [Fleming, Gini F.] Univ Chicago, Med Ctr, Chicago, IL 60637 USA; [Fleming, Gini F.] Alliance Clin Trials Oncol, Chicago, IL USA; [Lang, Istvan] Natl Inst Oncol, Budapest, Hungary; [Lang, Istvan] Int Breast Canc Study Grp, Budapest, Hungary; [Ciruelos, Eva] Univ Hosp 12 Octubre, Madrid, Spain; [Bellet, Meritxell] Vall dHebron Inst Oncol, Barcelona, Spain; [Bellet, Meritxell] Vall dHebron Univ Hosp, Barcelona, Spain; [Ciruelos, Eva; Bellet, Meritxell; Climent, Miguel A.] SOLTI Grp, Barcelona, Spain; [Climent, Miguel A.] Inst Valenciano Oncol, Valencia, Spain; [Bonnefoi, Herve R.] Univ Bordeaux, Inst Bergonie Comprehens Canc Ctr, INSERM, U916, Bordeaux, France; [Kerbrat, Pierre] Univ Rennes, Ctr Eugene Marquis, Rennes, France; [Bonnefoi, Herve R.; Kerbrat, Pierre] European Org Res Treatment Canc, Brussels, Belgium; [Da Prada, Gian Antonio] Salvatore Maugeri Fdn, Pavia, Italy; [Da Prada, Gian Antonio] IBCSG, Pavia, Italy; [Colleoni, Marco; Goldhirsch, Aron] Univ Milan, European Inst Oncol, Milan, Italy; [Colleoni, Marco; Goldhirsch, Aron] Univ Milan, Int Breast Canc Study Grp, Milan, Italy; [Viale, Giuseppe] Univ Milan, European Inst Oncol, IBCSG Cent Pathol Ctr, Milan, Italy; [Martino, Silvana] Angeles Clin, Santa Monica, CA USA; [Martino, Silvana] Res Inst, Santa Monica, CA USA; [Martino, Silvana] SWOG, Santa Monica, CA USA; [Davidson, Nancy E.] Univ Pittsburgh, Med Ctr, Inst Canc, Ctr Canc, Pittsburgh, PA USA; [Davidson, Nancy E.] ECOG ACRIN Canc Res Grp, Pittsburgh, PA USA; [Geyer, Charles E., Jr.] Virginia Commonwealth Univ, Massey Canc Ctr, Sch Med, Richmond, VA 23284 USA; [Geyer, Charles E., Jr.] NRG Oncol, Richmond, VA USA; [Walley, Barbara A.] Tom Baker Canc Clin, Calgary, AB, Canada; [Walley, Barbara A.] Natl Canc Inst Canada, Clin Trials Grp, Calgary, AB, Canada; [Coleman, Robert] Weston Pk Hosp, Sheffield, S Yorkshire, England; [Coleman, Robert] Natl Inst Canc Res, Breast Canc Clin Studies Grp, London, England; [Coleman, Robert] Inst Canc Res, Clin Trials & Stat Unit, London SW3 6JB, England; [Buchholz, Stefan] Univ Med Ctr Regensburg, German Breast Grp, Regensburg, Germany; [Buchholz, Stefan] Univ Med Ctr Regensburg, Dept Obstet & Gynecol, Regensburg, Germany; [Ingle, James N.] Mayo Clin, Rochester, MN USA; [Ingle, James N.] Alliance Clin Trials Oncol, Rochester, MN USA; [Rabaglio-Poretti, Manuela] Univ Bern, Inselspital, Univ Hosp, CH-3010 Bern, Switzerland; [Rabaglio-Poretti, Manuela; Maibach, Rudolf; Ruepp, Barbara] IBCSG Coordinating Ctr, Bern, Switzerland	Peter Maccallum Cancer Center; St Vincent's Hospital Melbourne; University of Melbourne; University of Newcastle; University of Sydney; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Frontier Science Foundation; Frontier Science Foundation; Harvard University; Harvard T.H. Chan School of Public Health; University of Chicago; University of Chicago Medical Center; National Institute of Oncology Hungary; Hospital Universitario 12 de Octubre; Vall d'Hebron Institut d'Oncologia (VHIO); Hospital Universitari Vall d'Hebron; SOLTI Breast Cancer Research Group; Instituto Valenciano De Oncologia; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; UNICANCER; Centre Eugene Marquis; Universite de Rennes; European Organisation for Research & Treatment of Cancer; Istituti Clinici Scientifici Maugeri IRCCS; IRCCS European Institute of Oncology (IEO); University of Milan; University of Milan; IRCCS European Institute of Oncology (IEO); University of Milan; Angeles Clinic & Research Institute; Southwest Oncology Group; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Virginia Commonwealth University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Surgical Adjuvant Breast & Bowel Project; Tom Baker Cancer Clinic; University of Calgary; Queens University - Canada; Canadian Cancer Trials Group; Weston Park Hospital; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; German Breast Group; University of Regensburg; University of Regensburg; Mayo Clinic; University of Bern; University Hospital of Bern	Francis, PA (corresponding author), Peter MacCallum Canc Ctr, Locked Bag 1,ABeckett St, Melbourne, Vic 8006, Australia.	ibcsgcc@ibcsg.org	Francis, Prudence A/J-4003-2012; Coleman, Robert/E-4346-2019; Giobbie-Hurder, Anita/AAU-6193-2021; Viale, Giuseppe/AAE-8921-2019; Geyer, Charles/AGY-0119-2022; Puglisi, Fabio/N-3863-2017; Colleoni, Marco/AAN-8647-2020; Lluch, Ana/R-5493-2019; Perren, Timothy/D-5387-2013	Francis, Prudence A/0000-0002-7207-9286; Geyer, Charles/0000-0002-2379-5702; Puglisi, Fabio/0000-0003-0573-4938; Colleoni, Marco/0000-0002-5743-3013; Lluch, Ana/0000-0003-2766-407X; Ciruelos, Eva/0000-0002-2796-1042; Kroep, Judith/0000-0003-2671-1903; Llombart Cussac, Antonio/0000-0003-4515-8293; Perren, Timothy/0000-0001-8472-8856; Bliss, Judith/0000-0001-7957-7424; Rabaglio, Manuela/0000-0002-6764-1844; Villanova Biazus, Jorge/0000-0002-3821-5264; Haba Rodriguez, Juan Rafael de la/0000-0001-5111-1702	Pfizer; NATIONAL CANCER INSTITUTE [P30CA015083, U10CA180820, U10CA180888, U24CA075362, U10CA180821, UG1CA189867, U10CA180867] Funding Source: NIH RePORTER	Pfizer(Pfizer); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funded by Pfizer and others; SOFT ClinicalTrials.gov number, NCT00066690.	Aebi S, 2000, LANCET, V355, P1869, DOI 10.1016/S0140-6736(00)02292-3; Cancer Therapy Evaluation Program, COMM TERM CRIT ADV E; Castiglione-Gertsch M, 2003, JNCI-J NATL CANCER I, V95, P1833, DOI 10.1093/jnci/djg119; Colleoni M, 2006, J CLIN ONCOL, V24, P1332, DOI 10.1200/JCO.2005.03.0783; Cuzick J, 2007, LANCET, V369, P1711; Davidson NE, 2005, J CLIN ONCOL, V23, P5973, DOI 10.1200/JCO.2005.05.551; Dowsett M, 2010, J CLIN ONCOL, V28, P509, DOI 10.1200/JCO.2009.23.1274; Eifel P, 2001, JNCI-J NATL CANCER I, V93, P979; Goldhirsch A, 2001, J Natl Cancer Inst Monogr, P44; Goldhirsch A, 2001, J CLIN ONCOL, V19, P3817, DOI 10.1200/JCO.2001.19.18.3817; Griggs, 2012, J CLIN ONCOL, V30, P1398, DOI 10.1200/JCO.2012.43.1031; Griggs JJ, 2011, J CLIN ONCOL, V29, P3939, DOI 10.1200/JCO.2011.36.4950; Hackshaw A, 2009, JNCI-J NATL CANCER I, V101, P341, DOI 10.1093/jnci/djn498; Pagani O, 1998, EUR J CANCER, V34, P632, DOI 10.1016/S0959-8049(97)10036-3; Pagani O, 2014, NEW ENGL J MED, V371, P107, DOI 10.1056/NEJMoa1404037; Partridge AH, 2014, BREAST, V23, P209, DOI 10.1016/j.breast.2014.03.011; Regan MM, 2008, ANN ONCOL, V19, P1231, DOI 10.1093/annonc/mdn037; Regan MM, 2013, BREAST, V22, P1094, DOI 10.1016/j.breast.2013.08.009; Swain SM, 2010, NEW ENGL J MED, V363, P2268, DOI 10.1056/NEJMc1009616	19	441	472	0	67	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 29	2015	372	5					436	446		10.1056/NEJMoa1412379	http://dx.doi.org/10.1056/NEJMoa1412379			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CA1CD	25495490	Green Accepted, Green Published			2023-01-03	WOS:000348649700008
J	Beyeler, N; Liu, J; Sieverding, M				Beyeler, Naomi; Liu, Jenny; Sieverding, Maia			A Systematic Review of the Role of Proprietary and Patent Medicine Vendors in Healthcare Provision in Nigeria	PLOS ONE			English	Article							SUB-SAHARAN AFRICA; MALARIA TREATMENT SERVICES; SPECIALIZED DRUG SHOPS; SEEKING BEHAVIOR; COMBINATION THERAPY; ANTIMALARIAL-DRUGS; RETAIL SECTOR; INTERVENTIONS; PROVIDERS; KNOWLEDGE	Background Interventions to reduce the burden of disease and mortality in sub-Saharan Africa increasingly recognize the important role that drug retailers play in delivering basic healthcare services. In Nigeria, owner-operated drug retail outlets, known as patent and proprietary medicine vendors (PPMVs), are a main source of medicines for acute conditions, but their practices are not well understood. Greater understanding of the role of PPMVs and the quality of care they provide is needed in order to inform ongoing national health initiatives that aim to incorporate PPMVs as a delivery mechanism. Objective and Methods This paper reviews and synthesizes the existing published and grey literature on the characteristics, knowledge and practices of PPMVs in Nigeria. We searched published and grey literature using a number of electronic databases, supplemented with website searches of relevant international agencies. We included all studies providing outcome data on PPMVs in Nigeria, including non-experimental studies, and assessed the rigor of each study using the WHO-Johns Hopkins Rigor scale. We used narrative synthesis to evaluate the findings. Results We identified 50 articles for inclusion. These studies provided data on a wide range of PPMV outcomes: training; health knowledge; health practices, including drug stocking and dispensing, client interaction, and referral; compliance with regulatory guidelines; and the effects of interventions targeting PPMVs. In general, PPMVs have low health knowledge and poor health treatment practices. However, the literature focuses largely on services for adult malaria, and little is known about other health areas or services for children. Conclusions This review highlights several concerns with the quality of the private drug retail sector in Nigeria, as well as gaps in the existing evidence base. Future research should adopt a more holistic view of the services provided by PPMV shops, and evaluate intervention strategies that may improve the services provided in this sector.	[Beyeler, Naomi; Liu, Jenny; Sieverding, Maia] Univ Calif San Francisco, Global Hlth Grp, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Beyeler, N (corresponding author), Univ Calif San Francisco, Global Hlth Grp, San Francisco, CA 94143 USA.	Naomi.Beyeler@ucsf.edu			Bill and Melinda Gates Foundation	Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation)	This study was funded by the Bill and Melinda Gates Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdulraheem IS, 2009, EARLY CHILD DEV CARE, V179, P671, DOI 10.1080/03004430701500885; Abuya T, 2009, AM J TROP MED HYG, V80, P905, DOI 10.4269/ajtmh.2009.80.905; Abuya TO, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008937; ACT watch Group SFH/Nigeria and the Independent Evaluation Team, 2012, ENDLINE OUTLET SURVE, DOI [10.1016/j.asjsur.2012.06.010, DOI 10.1016/J.ASJSUR.2012.06.010]; ACTwatch Group SFH/Nigeria and the Independent Evaluation Team, 2009, OUTLET SURVEY REPORT; Adedeji AA, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-230; Africa Health Workforce Observatory [AHWO], 2008, HUMAN RESOURCES FOR; Aguwa EN, 2010, INT J MED MED SCI, V2, P88; Ajayi IO., 2002, INT Q COMMUNITY HEAL, V21, P271, DOI [10.2190/569A-XLPX-YF5C-H9HU, DOI 10.2190/569A-XLPX-YF5C-H9HU]; Akiode A, 2010, EBONYI MED J, V9, P96, DOI DOI 10.4314/EB0MED.V9I2.71688; Akuse RM, 2010, MALAR RES TREAT; Alba S, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-163; Aniebue PN, 2010, NIGERIAN MED J, V51, P30; [Anonymous], 2013, FHI360; [Anonymous], MALARIA J S1, DOI DOI 10.1186/1475-2875-11-S1-P28; Auta A, 2012, N AM J MED SCI, V4, P24, DOI 10.4103/1947-2714.92899; Awodele Olufunsho, 2012, Int J Risk Saf Med, V24, P65, DOI 10.3233/JRS-2012-0562; Awofisayo OS, 2008, TROP J PHARM RES, V7, P1013; Barnes J, 2008, NIGERIA PRIVATE SECT; Berendes S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044775; Brieger WR, 2004, HEALTH POLICY PLANN, V19, P177, DOI 10.1093/heapol/czh021; Brieger WR, 2002, INT Q COMMUNITY HLTH, V21, P19; Chukwuocha UM, 2013, J COMMUN HEALTH, V38, P759, DOI 10.1007/s10900-013-9676-y; Emeka N. C., 2005, Annals of African Medicine, V4, P68; Enato EFO, 2006, SCAND J INFECT DIS, V38, P474, DOI 10.1080/00365540500525153; Enwere OO, 2014, P H MED J, V7, P210; Erhun WO, 2004, J HEALTH POPUL DEV C, V8, P1; Fajola A, 2012, INT Q COMMUNITY HEAL, V32, P195, DOI 10.2190/IQ.32.3.c; Fayemi MM, 2010, J PUBLIC HEALTH POL, V31, P281, DOI 10.1057/jphp.2010.14; Federal Ministry of Health Nigeria, 2013, NATIONAL GUIDELINE F, DOI [10.1016/j.jsps.2013.12.015, DOI 10.1016/J.JSPS.2013.12.015]; Federal Republic of Nigeria, 2005, NATIONAL ANTIMALARIA; Forsberg BC, 2011, HEALTH POLICY PLANN, V26, pi1, DOI 10.1093/heapol/czr050; Goodman C, 2007, AM J TROP MED HYG, V77, P203, DOI 10.4269/ajtmh.2007.77.203; Greer G, 2004, IMPROVING MANAGEMENT; Hebert LE, 2013, J FAM PLAN REPROD H, V39, P29, DOI 10.1136/jfprhc-2011-100244; Higgins JP., 2008, COCHRANE HDB SYSTEMA, DOI [10.1002/14651858.ED000142, DOI 10.1002/14651858.ED000142]; Idowu O A, 2006, Tanzan Health Res Bull, V8, P45; Jimmy EO, 2000, PUBLIC HEALTH, V114, P282, DOI 10.1016/S0033-3506(00)00346-2; Livinus C, 2009, SAHEL MED J, V12; Mangham LJ, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-155; Marek T, 2005, TRENDS AND OPPORTUNI; Marriott A, 2009, OXFAM BRIEFING PAPER; Marsh VM, 2004, TROP MED INT HEALTH, V9, P451, DOI 10.1111/j.1365-3156.2004.01223.x; National Bureau of Statistics UNICEF UNFPA, 2013, NIGERIA MULTIPLE IND, DOI [10.1016/j.jsps.2013.12.015, DOI 10.1016/J.JSPS.2013.12.015]; National Population Commission ICF Macro, 2009, NIGERIA DEMOGRAPHIC; National Population Commission National Malaria Control Programme ICF International, 2012, NIGERIA MALARIA INDI, DOI [10.1016/j.asjsur.2012.06.010, DOI 10.1016/J.ASJSUR.2012.06.010]; National Primary Health Care Development Agency, 2011, DRAFT ESSENTIAL CHIL, DOI [10.1080/17437199.2011.587961, DOI 10.1080/17437199.2011.587961]; Nduka SO, 2013, INT J COLLAB RES INT, V5; Nigerian Federal Ministry of Health, 2010, ESSENTIAL MEDICINE L; Obi I. E., 2010, Journal of College of Medicine, V15, P29; Obitte NC, 2009, SCI RES ESSAYS, V4, P1354; Okeke TA, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-260; Okeke TA, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-97; Okonkwo AD, 2010, AFR HEALTH SCI, V10, P253; Oladepo O, 2011, Afr J Med Med Sci, V40, P345; Oladepo O, 2008, MALARIA TREATMENT IN; Oladepo O, 2007, WORKING PAPER; Onwujekwe O, 2011, INT J EQUITY HEALTH, V10, DOI 10.1186/1475-9276-10-50; Onwujekwe O, 2011, TROP MED INT HEALTH, V16, P1087, DOI 10.1111/j.1365-3156.2011.02821.x; Onwujekwe O, 2011, J PUBLIC HEALTH-UK, V33, P93, DOI 10.1093/pubmed/fdq065; Onwujekwe O, 2010, INT J EQUITY HEALTH, V9, DOI 10.1186/1475-9276-9-22; Onwujekwe O, 2010, HEALTH POLICY, V96, P72, DOI 10.1016/j.healthpol.2009.12.014; Onwujekwe O, 2010, HEALTH POLICY, V94, P144, DOI 10.1016/j.healthpol.2009.09.010; Onwujekwe O, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-22; Onyeneho NG, 2010, J HEALTH POPUL NUTR, V28, P567, DOI 10.3329/jhpn.v28i6.6605; Oyeyemi AS, 2014, TROP J PHARM RES, V13, P163, DOI 10.4314/tjpr.v13i1.23; Palafox B, 2012, ACTWATCH 2009 SUPPLY; Rutta E, 2011, HEALTH RES POLICY SY, V9, DOI 10.1186/1478-4505-9-22; Shah NM, 2011, HEALTH POLICY PLANN, V26, P275, DOI 10.1093/heapol/czq074; Spaid B, 2011, IMPROVED REPRODUCTIV, DOI 10.1016/j.asjsur.2012.06.010; Tekobo AM, 2008, NIGER Q J HOSP MED, V14, P84; Tobin-West CI, 2012, INDIAN J PHARM PRACT, V5, P34; Tobin-West CI, 2011, INT J HEALTH RES, V4, P127; Uguru NP, 2009, BMC INT HEALTH HUM R, V9, DOI 10.1186/1472-698X-9-21; Ujuju C, 2014, J MULTIDISCIP HEALTH, V7, P163, DOI 10.2147/JMDH.S57117; Um L, 2007, BORNO MEDICAL JOURNA, V4, P7; Uzochukwu BSC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091667; Wafula FN, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-223; Wafula FN, 2010, INT J QUAL HEALTH C, V22, P316, DOI 10.1093/intqhc/mzq022; WHO-Johns Hopkins, 2012, 9 POINT RIGOUR SCALE	80	64	64	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 28	2015	10	1							e0117165	10.1371/journal.pone.0117165	http://dx.doi.org/10.1371/journal.pone.0117165			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CA2IM	25629900	Green Published, gold, Green Submitted			2023-01-03	WOS:000348732100071
J	Sisti, DA; Segal, AG; Emanuel, EJ				Sisti, Dominic A.; Segal, Andrea G.; Emanuel, Ezekiel J.			Improving Long-term Psychiatric Care Bring Back the Asylum	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							STATES		[Sisti, Dominic A.; Segal, Andrea G.; Emanuel, Ezekiel J.] Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Sisti, DA (corresponding author), Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, 3401 Market St,Ste 320, Philadelphia, PA 19104 USA.	sistid@upenn.edu		Sisti, Dominic/0000-0002-2282-9253				Baillargeon J, 2009, AM J PSYCHIAT, V166, P103, DOI 10.1176/appi.ajp.2008.08030416; Dlugacz H. A., 2013, ETHICAL ISSUES PRISO, P49; James DJ, 2006, MENTAL HLTH PROBLEMS; Kisely SR, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004408.pub3; MORRISSEY JP, 1986, ANN AM ACAD POLIT SS, V484, P12, DOI 10.1177/0002716286484001002; Scull Andrew, 2011, SAGE HDB MENTAL HLTH, P430; Swanson JW, 2013, AM J PSYCHIAT, V170, P1423, DOI 10.1176/appi.ajp.2013.12091152; Torrey Deberniere J., 2012, JUGYO YOJI; Torrey E. F., 2010, MORE MENTALLY ILL PE	9	83	84	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	2015	313	3					243	244		10.1001/jama.2014.16088	http://dx.doi.org/10.1001/jama.2014.16088			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AZ3RS	25602990				2023-01-03	WOS:000348145000011
J	McCartney, M				McCartney, Margaret			Margaret McCartney: Rectal feeding is torture masquerading as medicine	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												margaret@margaretmccartney.com	mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358				Lifton RJ, 2004, NEW ENGL J MED, V351, P415, DOI 10.1056/NEJMp048065; Rubenstein JD, 2005, JAMA-J AM MED ASSOC, V294, P1544; Senate Select Committee on Intelligence, 2014, COMM STUD CENTR INT; Short AR, 1913, BRIT MED J, V1913, P1361, DOI 10.1136/bmj.1.2739.1361	4	0	0	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 31	2014	349								g7859	10.1136/bmj.g7859	http://dx.doi.org/10.1136/bmj.g7859			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AY4JO	25552464	Bronze, Green Published			2023-01-03	WOS:000347544400006
J	Suzuki, A; Kobayashi, R; Okayasu, S; Kuze, B; Aoki, M; Mizuta, K; Itoh, Y				Suzuki, Akio; Kobayashi, Ryo; Okayasu, Shinji; Kuze, Bunya; Aoki, Mitsuhiro; Mizuta, Keisuke; Itoh, Yoshinori			Pharmacotherapy for Adverse Events Reduces the Length of Hospital Stay in Patients Admitted to Otolaryngology Ward: A Single Arm Intervention Study	PLOS ONE			English	Article							CLINICAL-PRACTICE GUIDELINE; NECK-CANCER; AMERICAN SOCIETY; ORAL MUCOSITIS; DRUG EVENTS; COSTS; CARE; DYSPHAGIA; HEAD; MORTALITY	Background: To determine whether adverse events extend the duration of hospitalization, and to evaluate the effectiveness of medical intervention in ameliorating adverse events and reducing the prolonged hospital stay associated with adverse events. Methods: A single arm intervention study was conducted from October 2012 to March 2014 in the otolaryngology ward of a 614-bed, university-affiliated hospital. Adverse events were monitored daily by physicians, pharmacists and nurses, and recorded in the electronic medical chart for each patient. Appropriate drug management of adverse events was performed by physicians in liaison with pharmacists. The Kaplan-Meier method was used to assess the length of hospitalization of patients who underwent medical intervention for adverse events. Results: Of 571 patients admitted to the otolaryngology ward in a year, 219 patients (38.4%) experienced adverse events of grade >= 2. The duration of hospitalization was affected by the grade of adverse events, with a mean duration of hospital stay of 9.2, 17.2, 28.3 and 47.0 days for grades 0, 1, 2, and 3-4, respectively. Medical intervention lowered the incidence of grade >= 2 adverse events to 14.5%. The length of hospitalization was significantly shorter in patients who showed an improvement of adverse events after medical intervention than those who did not (26.4 days vs. 41.6 days, hazard ratio 1.687, 95% confidence interval: 1.260-2.259, P<0.001). A multivariate Cox proportional hazard analysis indicated that insomnia, constipation, nausea/vomiting, infection, non-cancer pain, oral mucositis, odynophagia and neutropenia were significant risk factors for prolongation of hospital stay. Conclusion: Patients who experienced adverse events are at high risk of prolonged hospitalization. Medical intervention for adverse events was found to be effective in reducing the length of hospital stay associated with adverse events.	[Suzuki, Akio; Kobayashi, Ryo; Okayasu, Shinji; Itoh, Yoshinori] Gifu Univ Hosp, Dept Pharm, Gifu, Japan; [Kuze, Bunya; Aoki, Mitsuhiro; Mizuta, Keisuke] Gifu Univ, Grad Sch Med, Dept Otolaryngol, Gifu, Japan; [Aoki, Mitsuhiro] Gifu Univ Hosp, Dept Med Informat Div, Gifu, Japan	Gifu University; Gifu University; Gifu University	Suzuki, A (corresponding author), Gifu Univ Hosp, Dept Pharm, Gifu, Japan.	akio@gifu-u.ac.jp						Baker GR, 2004, CAN MED ASSOC J, V170, P1678, DOI 10.1503/cmaj.1040498; Basch E, 2011, J CLIN ONCOL, V29, P4189, DOI [10.1200/JCO.2010.34.4614, 10.1200/JOP.2011.000397]; Bates DW, 1997, JAMA-J AM MED ASSOC, V277, P307, DOI 10.1001/jama.277.4.307; Benson AB, 2004, J CLIN ONCOL, V22, P2918, DOI 10.1200/jco.2004.04.132; Bratzler DW, 2013, AM J HEALTH-SYST PH, V70, P540; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; Evans R S, 1992, Proc Annu Symp Comput Appl Med Care, P437; Feng FY, 2007, INT J RADIAT ONCOL, V68, P1289, DOI 10.1016/j.ijrobp.2007.02.049; Forster AJ, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-259; Howard HH, 1989, NEW ENGL J MED, V324, P370; Kaushal R, 2007, CRIT CARE MED, V35, P2479, DOI 10.1097/01.CCM.0000284510.04248.66; Keefe DM, 2007, CANCER-AM CANCER SOC, V109, P820, DOI 10.1002/cncr.22484; Kronenberger Michael B., 1994, Dysphagia, V9, P236, DOI 10.1007/BF00301917; Kulbersh BD, 2006, LARYNGOSCOPE, V116, P883, DOI 10.1097/01.mlg.0000217278.96901.fc; Landrigan CP, 2010, NEW ENGL J MED, V363, P2124, DOI 10.1056/NEJMsa1004404; Manchikanti L, 2012, PAIN PHYSICIAN, V15, pS67; Mercadante S, 2010, INTERN EMERG MED, V5, pS31, DOI 10.1007/s11739-010-0448-8; NCCN, 2022, NCCN CLIN PRACTICE G; Parmentier-Decrucq E, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-10; Schilling MB, 2011, EXP THER MED, V2, P859, DOI 10.3892/etm.2011.312; Shune SE, 2012, HEAD NECK-J SCI SPEC, V34, P776, DOI 10.1002/hed.21819; Smith TJ, 2006, J CLIN ONCOL, V24, P3187, DOI 10.1200/JCO.2006.06.4451; Sonis ST, 2001, J CLIN ONCOL, V19, P2201, DOI 10.1200/JCO.2001.19.8.2201; Vincent C, 2001, BRIT MED J, V322, P517, DOI 10.1136/bmj.322.7285.517; Watanabe T, 2010, INT J CANCER, V127, P1984, DOI 10.1002/ijc.25200; Zimlichman E, 2013, JAMA INTERN MED, V173, P2039, DOI 10.1001/jamainternmed.2013.9763	27	9	9	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 30	2014	9	12							e115879	10.1371/journal.pone.0115879	http://dx.doi.org/10.1371/journal.pone.0115879			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX6YH	25549093	Green Published, Green Submitted, gold			2023-01-03	WOS:000347063500034
J	Adnan, WAHWM; Zaharan, NL; Wong, MH; Lim, SK				Adnan, Wan Ahmad Hafiz Wan Md; Zaharan, Nur Lisa; Wong, Mun Hoe; Lim, Soo Kun			The Effects of Intermittent Fasting during the Month of Ramadan in Chronic Haemodialysis Patients in a Tropical Climate Country	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; ELECTROLYTE BALANCE; LIPID-LEVELS; RECOMMENDATIONS; DIALYSIS; FLUID	Background: Chronic kidney disease is an emerging problem in the majority Muslim countries. Despite the uncertainties of the risks involved, some Muslim patients undergoing chronic haemodialysis choose to observe intermittent fasting during the month of Ramadan. This study aims to investigate the effect of Ramadan fasting in haemodialysis patients residing in a tropical climate country. Methods: This prospective cross sectional study recruited Muslim patients on regular haemodialysis from three haemodialysis centres in Kuala Lumpur from 15th July 2011 to 29th August 2011. Patients who fasted for any number of days were included (n=35, 54% female, age 54 +/- 11 years). 89% of patients fasted for more than 15 days and 49% were diabetics. Dialysis parameters and blood samples were obtained one week prior to Ramadan and during the last week of Ramadan. The differences in dialysis parameters and biochemical values pre- and end-Ramadan were examined using paired t-test. Results: Both pre- and post-dialysis weight were significantly decreased during Ramadan fasting compared to the month prior (p= <0.001). There was a significant decrease in the amount of ultrafiltration (p=0.002). There were no significant differences in dry weight, inter-dialytic weight gain, mean urea reduction ratio or blood pressure measurements comparing pre- and end of Ramadan fasting. There was a significant increase in serum albumin level (p=0.006) and decrease in serum phosphate level (p=0.02) at the end of Ramadan. Conclusion: Ramadan fasting is associated with reduced weight, improved serum albumin and phosphate level in our population of haemodialysis patients. A larger multi-centre study will allow us to understand more about the effects of fasting in this population.	[Adnan, Wan Ahmad Hafiz Wan Md; Wong, Mun Hoe; Lim, Soo Kun] Univ Malaya, Dept Med, Nephrol Unit, Fac Med, Kuala Lumpur 50603, Malaysia; [Zaharan, Nur Lisa] Univ Malaya, Dept Pharmacol, Fac Med, Kuala Lumpur 50603, Malaysia	Universiti Malaya; Universiti Malaya	Adnan, WAHWM (corresponding author), Univ Malaya, Dept Med, Nephrol Unit, Fac Med, Kuala Lumpur 50603, Malaysia.	wahafiz@um.edu.my	Lim, Soo Kun/Q-2012-2019; Zaharan, Nur Lisa/F-8835-2012; LIM, SOO KUN/B-8868-2010; Wan Md Adnan, Wan Ahmad Hafiz/D-9088-2016	Lim, Soo Kun/0000-0001-7589-5150; Zaharan, Nur Lisa/0000-0002-8150-0642; LIM, SOO KUN/0000-0001-7589-5150; Wan Md Adnan, Wan Ahmad Hafiz/0000-0003-0818-5831	Head, Division of Nephrology, Faculty of Medicine, University of Malaya, Kuala Lumpur	Head, Division of Nephrology, Faculty of Medicine, University of Malaya, Kuala Lumpur	We would like to acknowledge the managers and staffs of the participating haemodialysis centres for making it possible for us to conduct this research. Financial assistance was provided by Associate Professor Dr Lim Soo Kun, Head, Division of Nephrology, Faculty of Medicine, University of Malaya, Kuala Lumpur.	Abdalla AH, 1998, AM J NEPHROL, V18, P101, DOI 10.1159/000013316; Aksungar FB, 2005, ANN NUTR METAB, V49, P77, DOI 10.1159/000084739; Al Wakeel J, 2013, PERITON DIALYSIS INT, V33, P86, DOI 10.3747/pdi.2010.00095; Al-Arouj M, 2010, DIABETES CARE, V33, P1895, DOI 10.2337/dc10-0896; ALKHADER AA, 1991, SAUDI MED J, V12, P30; Bernieh B, 2010, SAUDI J KIDNEY DIS T, V21, P898; CHEAH SH, 1990, BRIT J NUTR, V63, P329, DOI 10.1079/BJN19900119; El-Wakil HS, 2007, SAUDI J KIDNEY DIS T, V18, P349; Farag YMK, 2012, NEPHRON CLIN PRACT, V121, pC120, DOI 10.1159/000345149; HALLAK MH, 1988, AM J CLIN NUTR, V48, P1197, DOI 10.1093/ajcn/48.5.1197; HUSAIN R, 1987, BRIT J NUTR, V58, P41, DOI 10.1079/BJN19870067; KENNEDY HJ, 1983, GUT, V24, P702, DOI 10.1136/gut.24.8.702; Khedmat H, 2010, SAUDI J KIDNEY DIS T, V21, P417; Leiper JB, 2003, EUR J CLIN NUTR, V57, pS30, DOI 10.1038/sj.ejcn.1601899; Lim Y N, 2008, Med J Malaysia, V63 Suppl C, P5; MUSTAFA KY, 1978, BRIT J NUTR, V40, P583, DOI 10.1079/BJN19780162; Perk G, 2001, J HUM HYPERTENS, V15, P723, DOI 10.1038/sj.jhh.1001262; Pew Research Center, 2009, MAPPING GLOBAL MUSLI; Prodjosudjadi W, 2009, NEPHROLOGY, V14, P669, DOI 10.1111/j.1440-1797.2009.01137.x; Qurashi S, 2012, EXP CLIN TRANSPLANT, V10, P551, DOI 10.6002/ect.2012.0139; RASHED AH, 1989, LANCET, V1, P1396; RASHED AH, 1992, BRIT MED J, V304, P521, DOI 10.1136/bmj.304.6826.521; Roky R, 2004, ANN NUTR METAB, V48, P296, DOI 10.1159/000081076; Sahin I, 2009, RENAL FAILURE, V31, P920, DOI 10.3109/08860220903219265; Salti I, 2004, DIABETES CARE, V27, P2306, DOI 10.2337/diacare.27.10.2306; Termorshuizen F, 2004, J AM SOC NEPHROL, V15, P1061, DOI 10.1097/01.ASN.0000117976.29592.93	26	11	11	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 29	2014	9	12							e114262	10.1371/journal.pone.0114262	http://dx.doi.org/10.1371/journal.pone.0114262			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX7UN	25546434	Green Submitted, gold, Green Published			2023-01-03	WOS:000347120200008
J	Zaar, M; Fedyk, CG; Pidcoke, HF; Scherer, MR; Ryan, KL; Rickards, CA; Hinojosa-Laborde, C; Convertino, VA; Cap, AP				Zaar, Morten; Fedyk, Chriselda G.; Pidcoke, Heather F.; Scherer, Michael R.; Ryan, Kathy L.; Rickards, Caroline A.; Hinojosa-Laborde, Carmen; Convertino, Victor A.; Cap, Andrew P.			Platelet Activation after Presyncope by Lower Body Negative Pressure in Humans	PLOS ONE			English	Article							BLOOD; VASOPRESSIN; RESPONSES; MECHANISMS; TOLERANCE; STATE	Central hypovolemia elevates hemostatic activity which is essential for preventing exsanguination after trauma, but platelet activation to central hypovolemia has not been described. We hypothesized that central hypovolemia induced by lower body negative pressure (LBNP) activates platelets. Eight healthy subjects were exposed to progressive central hypovolemia by LBNP until presyncope. At baseline and 5 min after presyncope, hemostatic activity of venous blood was evaluated by flow cytometry, thrombelastography, and plasma markers of coagulation and fibrinolysis. Cell counts were also determined. Flow cytometry revealed that LBNP increased mean fluorescence intensity of PAC-1 by 1959 +/- 455 units (P< 0.001) and percent of fluorescence-positive platelets by 27 +/- 18%-points (P=0.013). Thrombelastography demonstrated that coagulation was accelerated (R-time decreased by 0.8 +/- 0.4 min (P=0.001)) and that clot lysis increased (LY60 by 6.0 +/- 5.8%-points (P=0.034)). Plasma coagulation factor VIII and von Willebrand factor ristocetin cofactor activity increased (P=0.011 and P=0.024, respectively), demonstrating increased coagulation activity, while von Willebrand factor antigen was unchanged. Plasma protein C activity and tissue-type plasminogen activator increased (P=0.007 and P=0.017, respectively), and D-dimer increased by 0.03 +/- 0.02 mg l(-1) (P=0.031), demonstrating increased fibrinolytic activity. Plasma prothrombin time and activated partial thromboplastin time were unchanged. Platelet count increased by 15 +/- 13% (P=0.014) and red blood cells by 9 +/- 4% (P=0.002). In humans, LBNP-induced presyncope activates platelets, as evidenced by increased exposure of active glycoprotein IIb/IIIa, accelerates coagulation. LBNP activates fibrinolysis, similar to hemorrhage, but does not alter coagulation screening tests, such as prothrombin time and activated partial thromboplastin time. LBNP results in increased platelet counts, but also in hemoconcentration.	[Zaar, Morten] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA; [Fedyk, Chriselda G.; Pidcoke, Heather F.; Scherer, Michael R.; Ryan, Kathy L.; Hinojosa-Laborde, Carmen; Convertino, Victor A.; Cap, Andrew P.] US Army Inst Surg Res, Ft Sam Houston, TX USA; [Rickards, Caroline A.] Univ N Texas, Hlth Sci Ctr Ft Worth, Ft Worth, TX USA	University of Texas System; University of Texas Health San Antonio; United States Department of Defense; United States Army; University of North Texas System; University of North Texas Health Science Center	Zaar, M (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.	zaar@uthscsa.edu	Pidcoke, Heather/K-7730-2019	Rickards, Caroline/0000-0002-5759-6912; Convertino, Victor/0000-0001-9246-0554	United States Army, Medical Research and Materiel Command	United States Army, Medical Research and Materiel Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC))	This study was funded by the United States Army, Medical Research and Materiel Command. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aleman MM, 2014, THROMB RES, V133, pS38, DOI 10.1016/j.thromres.2014.03.017; Austin AW, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/480648; BOUNAMEAUX H, 1994, THROMB HAEMOSTASIS, V71, P1; Brown NJ, 1999, HEART FAIL REV, V3, P193, DOI [10.1023/A:1009757416302, DOI 10.1023/A:1009757416302]; Cai Y, 2000, J APPL PHYSIOL, V89, P1569, DOI 10.1152/jappl.2000.89.4.1569; Convertino VA, 2000, CLIN PHYSIOL, V20, P177; Cvirn G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042221; Ebert RV, 1941, AM J MED SCI, V201, P655, DOI 10.1097/00000441-194105000-00005; Evans RG, 2001, CLIN EXP PHARMACOL P, V28, P479, DOI 10.1046/j.1440-1681.2001.3473.x; Greenleaf JE, 2000, AM J PHYSIOL-REG I, V279, pR822, DOI 10.1152/ajpregu.2000.279.3.R822; HARIMAN H, 1989, THROMB HAEMOSTASIS, V61, P298; HIRSCH AT, 1993, J APPL PHYSIOL, V75, P1984, DOI 10.1152/jappl.1993.75.5.1984; HJEMDAHL P, 1983, AM J PHYSIOL, V245, pH447, DOI 10.1152/ajpheart.1983.245.3.H447; Jacoby RC, 2001, J TRAUMA, V51, P639, DOI 10.1097/00005373-200110000-00003; Jennings LK, 2009, THROMB HAEMOSTASIS, V102, P248, DOI 10.1160/TH09-03-0192; LIBRE EP, 1968, BLOOD, V31, P358, DOI 10.1182/blood.V31.3.358.358; Masoud M, 2008, HYPERTENSION, V51, P1545, DOI 10.1161/HYPERTENSIONAHA.108.112003; Monroe DM, 2006, ARTERIOSCL THROM VAS, V26, P41, DOI 10.1161/01.ATV.0000193624.28251.83; NORDFANG O, 1993, THROMB HAEMOSTASIS, V70, P448; Nurden AT, 2013, SEMIN THROMB HEMOST, V39, P642, DOI 10.1055/s-0033-1353393; Park MS, 2009, J TRAUMA, V67, P266, DOI 10.1097/TA.0b013e3181ae6f1c; Roberts I, 2011, LANCET, V377, P1096, DOI 10.1016/S0140-6736(11)60278-X; Ruttmann TG, 2003, ANAESTH INTENS CARE, V31, P40, DOI 10.1177/0310057X0303100107; Ryan KL, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00110; Schagatay E, 2001, J APPL PHYSIOL, V90, P1623, DOI 10.1152/jappl.2001.90.4.1623; SHARE L, 1967, ENDOCRINOLOGY, V81, P1140, DOI 10.1210/endo-81-5-1140; Tomasiak M, 2008, BLOOD COAGUL FIBRIN, V19, P615, DOI 10.1097/MBC.0b013e328309905d; Vlot AJ, 1998, THROMB HAEMOSTASIS, V79, P456; von Kanel R, 2000, EUR J HAEMATOL, V65, P357, DOI 10.1034/j.1600-0609.2000.065006357.x; Zaar M, 2009, CLIN PHYSIOL FUNCT I, V29, P427, DOI 10.1111/j.1475-097X.2009.00890.x; Zaar M, 2014, BLOOD COAGUL FIBRIN, V25, P592, DOI 10.1097/MBC.0000000000000114	31	10	10	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 29	2014	9	12							e0116174	10.1371/journal.pone.0116174	http://dx.doi.org/10.1371/journal.pone.0116174			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX7UN	25546432	gold, Green Published, Green Submitted			2023-01-03	WOS:000347120200104
J	Estan, MC; Calvino, E; Calvo, S; Guillen-Guio, B; Boyano-Adanez, MD; de Blas, E; Rial, E; Aller, P				Cristina Estan, Maria; Calvino, Eva; Calvo, Susana; Guillen-Guio, Beatriz; del Carmen Boyano-Adanez, Maria; de Blas, Elena; Rial, Eduardo; Aller, Patricio			Apoptotic Efficacy of Etomoxir in Human Acute Myeloid Leukemia Cells. Cooperation with Arsenic Trioxide and Glycolytic Inhibitors, and Regulation by Oxidative Stress and Protein Kinase Activities	PLOS ONE			English	Article							OXYGEN SPECIES PRODUCTION; FATTY-ACID OXIDATION; ENERGY-METABOLISM; LEVEL; 2-DEOXYGLUCOSE; GLUTATHIONE; ACTIVATION; LONIDAMINE; DEPLETION; GROWTH	Fatty acid synthesis and oxidation are frequently exacerbated in leukemia cells, and may therefore represent a target for therapeutic intervention. In this work we analyzed the apoptotic and chemo-sensitizing action of the fatty acid oxidation inhibitor etomoxir in human acute myeloid leukemia cells. Etomoxir caused negligible lethality at concentrations up to 100 mu M, but efficaciously cooperated to cause apoptosis with the anti-leukemic agent arsenic trioxide (ATO, Trisenox), and with lower efficacy with other anti-tumour drugs (etoposide, cisplatin), in HL60 cells. Etomoxir-ATO cooperation was also observed in NB4 human acute promyelocytic cells, but not in normal (non-tumour) mitogen-stimulated human peripheral blood lymphocytes. Biochemical determinations in HL60 cells indicated that etomoxir (25-200 mu M) dose-dependently inhibited mitochondrial respiration while slightly stimulating glycolysis, and only caused marginal alterations in total ATP content and adenine nucleotide pool distribution. In addition, etomoxir caused oxidative stress (increase in intracellular reactive oxygen species accumulation, decrease in reduced glutathione content), as well as pro-apoptotic LKB-1/AMPK pathway activation, all of which may in part explain the chemo-sensitizing capacity of the drug. Etomoxir also cooperated with glycolytic inhibitors (2-deoxy-D-glucose, lonidamine) to induce apoptosis in HL60 cells, but not in NB4 cells. The combined etomoxir plus 2-deoxy-D-glucose treatment did not increase oxidative stress, caused moderate decrease in net ATP content, increased the AMP/ATP ratio with concomitant drop in energy charge, and caused defensive Akt and ERK kinase activation. Apoptosis generation by etomoxir plus 2-deoxy-D-glucose was further increased by co-incubation with ATO, which is apparently explained by the capacity of ATO to attenuate Akt and ERK activation. In summary, co-treatment with etomoxir may represent an interesting strategy to increase the apoptotic efficacy of ATO and (with some limitations) 2-deoxy-D-glucose which, although clinically important anti-tumour agents, exhibit low efficacy in monotherapy.	[Cristina Estan, Maria; Calvino, Eva; Calvo, Susana; Guillen-Guio, Beatriz; de Blas, Elena; Rial, Eduardo; Aller, Patricio] CSIC, Ctr Invest Biol, Madrid, Spain; [Calvo, Susana; del Carmen Boyano-Adanez, Maria] Univ Alcala, Dept Biol Sistemas, Fac Med & Ciencies Salud, Unidad Bioquim & Biol Mol, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Universidad de Alcala	Rial, E (corresponding author), CSIC, Ctr Invest Biol, Ramiro Maeztu 9, Madrid, Spain.	rial@cib.csic.es; aller@cib.csic.es	Calviño, Eva/H-9219-2015; Rial, Eduardo/A-4242-2008	Rial, Eduardo/0000-0001-8634-8902; Guillen-Guio, Beatriz/0000-0002-3703-1738; Calvino Vanegas, Eva/0000-0003-0316-3035	Spanish Ministerio de Ciencia e Innovacion, Plan Nacional de Investigacion Cientifica, Desarrollo e Innovacion Tecnologica, Direccion General de Investigacion [SAF2010-20256]; Comunidad de Madrid [S2010/BMD-2402]; Consejo Superior de Investigaciones Cientificas	Spanish Ministerio de Ciencia e Innovacion, Plan Nacional de Investigacion Cientifica, Desarrollo e Innovacion Tecnologica, Direccion General de Investigacion; Comunidad de Madrid(Comunidad de Madrid); Consejo Superior de Investigaciones Cientificas	This work was supported by grant SAF2010-20256 (to P.A.) from the Spanish Ministerio de Ciencia e Innovacion, Plan Nacional de Investigacion Cientifica, Desarrollo e Innovacion Tecnologica, Direccion General de Investigacion (http://www.mineco.gob.es/portal/site/mineco/idi), and by Grant S2010/BMD-2402 (to E.R.) from the Comunidad de Madrid (https://www.madrimasd.org). M.C.E. is the recipient of a JAE-Predoc fellowship from the Consejo Superior de Investigaciones Cientificas (http://www.csic.es/web/ guest/programa-jae). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABDELALEEM S, 1994, HORM METAB RES, V26, P88, DOI 10.1055/s-2007-1000779; Abozguia K, 2006, NAT CLIN PRACT CARD, V3, P490, DOI 10.1038/ncpcardio0583; Amadori S, 2005, CURR MED RES OPIN, V21, P403, DOI 10.1185/030079904X20349; Breccia M, 2012, EXPERT OPIN PHARMACO, V13, P1031, DOI 10.1517/14656566.2012.677436; Cabrero A, 2002, J BIOL CHEM, V277, P10100, DOI 10.1074/jbc.M110321200; Calvino E, 2014, J PHARMACOL EXP THER, V348, P324, DOI 10.1124/jpet.113.206714; Calvino E, 2011, BIOCHEM PHARMACOL, V82, P1619, DOI 10.1016/j.bcp.2011.08.017; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; Estan MC, 2012, BIOCHEM PHARMACOL, V84, P1604, DOI 10.1016/j.bcp.2012.09.022; Dai J, 1999, BLOOD, V93, P268, DOI 10.1182/blood.V93.1.268.401a21_268_277; DEKORTE D, 1985, ANAL BIOCHEM, V147, P197, DOI 10.1016/0003-2697(85)90028-4; Di Cosimo S, 2003, DRUGS TODAY, V39, P157, DOI 10.1358/dot.2003.39.3.799451; Diaz Zuanel, 2005, Blood, V105, P1237; Duan WZ, 1999, J NEUROSCI RES, V57, P195, DOI 10.1002/(SICI)1097-4547(19990715)57:2&lt;195::AID-JNR5&gt;3.0.CO;2-P; Dwarakanath BS, 2009, FUTURE ONCOL, V5, P581, DOI [10.2217/fon.09.44, 10.2217/FON.09.44]; Emerling BM, 2009, FREE RADICAL BIO MED, V46, P1386, DOI 10.1016/j.freeradbiomed.2009.02.019; Fantin VR, 2006, ONCOGENE, V25, P4787, DOI 10.1038/sj.onc.1209599; Galan A, 2000, J BIOL CHEM, V275, P11418, DOI 10.1074/jbc.275.15.11418; Hardie DG, 2007, ANNU REV PHARMACOL, V47, P185, DOI 10.1146/annurev.pharmtox.47.120505.105304; Harper ME, 2002, FASEB J, V16, P1550, DOI 10.1096/fj.02-0541com; Hernlund E, 2008, INT J CANCER, V123, P476, DOI 10.1002/ijc.23525; Holubarsch CJF, 2007, CLIN SCI, V113, P205, DOI 10.1042/CS20060307; Hubinger A, 1997, HORM METAB RES, V29, P436, DOI 10.1055/s-2007-979072; Inoguchi T, 2000, DIABETES, V49, P1939, DOI 10.2337/diabetes.49.11.1939; Izyumov DS, 2004, BBA-BIOENERGETICS, V1658, P141, DOI 10.1016/j.bbabio.2004.05.007; Ko YH, 2012, J BIOENERG BIOMEMBR, V44, P163, DOI 10.1007/s10863-012-9417-4; Kritharis A, 2013, ANN HEMATOL, V92, P719, DOI 10.1007/s00277-013-1707-3; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Kuznetsov JN, 2011, MOL CANCER THER, V10, P437, DOI 10.1158/1535-7163.MCT-10-0777; LANOTTE M, 1991, BLOOD, V77, P1080; Li JJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074623; Lieberthal W, 1998, AM J PHYSIOL-RENAL, V274, pF315, DOI 10.1152/ajprenal.1998.274.2.F315; Tirado-Velez JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046484; Merrill CL, 2002, TOXICOL SCI, V68, P93, DOI 10.1093/toxsci/68.1.93; Miller WH, 2002, CANCER RES, V62, P3893; Pike LS, 2011, BBA-BIOENERGETICS, V1807, P726, DOI 10.1016/j.bbabio.2010.10.022; Samudio I, 2010, J CLIN INVEST, V120, P142, DOI 10.1172/JCI38942; Sanchez Y, 2008, INT J CANCER, V123, P1205, DOI 10.1002/ijc.23639; Sanchez Y, 2010, J PHARMACOL EXP THER, V335, P114, DOI 10.1124/jpet.110.168344; Scotland S, 2013, LEUKEMIA, V27, P2129, DOI 10.1038/leu.2013.107; Suganuma K, 2010, LEUKEMIA LYMPHOMA, V51, P2112, DOI 10.3109/10428194.2010.512966; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; Troyano A, 2001, J BIOL CHEM, V276, P47107, DOI 10.1074/jbc.M104516200; Tsunekawa-Imai N, 2013, LEUKEMIA RES, V37, P1132, DOI 10.1016/j.leukres.2013.05.017; Vickers AEM, 2006, TOXICOL IN VITRO, V20, P1173, DOI 10.1016/j.tiv.2006.01.021; Xi HB, 2013, BIOCHEM PHARMACOL, V85, P1463, DOI 10.1016/j.bcp.2013.02.037; Yang CH, 1999, BRIT J CANCER, V81, P796, DOI 10.1038/sj.bjc.6690766; Yi J, 2002, APOPTOSIS, V7, P209, DOI 10.1023/A:1015331229263; Zhao Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.60	50	32	34	2	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 15	2014	9	12							e115250	10.1371/journal.pone.0115250	http://dx.doi.org/10.1371/journal.pone.0115250			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AW9WY	25506699	Green Published, gold, Green Submitted			2023-01-03	WOS:000346607100064
J	Jung, HY; Cho, JH; Jang, HM; Kim, YS; Kang, SW; Yang, CW; Kim, NH; Choi, JY; Park, SH; Kim, CD; Kim, YL				Jung, Hee-Yeon; Cho, Jang-Hee; Jang, Hye Min; Kim, Yon Su; Kang, Shin-Wook; Yang, Chul Woo; Kim, Nam-Ho; Choi, Ji-Young; Park, Sun-Hee; Kim, Chan-Duck; Kim, Yong-Lim		Clinical Res Ctr End Stage Renal	Free Thyroxine Level as an Independent Predictor of Infection-Related Mortality in Patients on Peritoneal Dialysis: A Prospective Multicenter Cohort Study	PLOS ONE			English	Article							THYROID-HORMONE METABOLISM; LOW TRIIODOTHYRONINE; SUBCLINICAL HYPOTHYROIDISM; STAGE; DISEASE; RISK; INFLAMMATION; ASSOCIATION; THYROTROPIN; PREVALENCE	Background: Previous studies have reported the relationship between thyroid hormone levels and mortality in dialysis patients. However, little is known about the association of free thyroxine (fT4) and mortality in patients on peritoneal dialysis (PD). This study investigated the association between basal and annual variation in fT4 level and mortality in PD patients. Methods: Patients on maintenance PD were enrolled from a prospective multicenter cohort study in Korea; their serum triiodothyronine, fT4, and thyroid-stimulating hormone levels were measured 12 months apart. Patients with overt thyroid disease and those receiving thyroid hormone replacement therapy were excluded from the analysis. Patients were divided into two groups based on the median levels of fT4. The differences of all-cause, infection-related, and cardiovascular mortalities were analyzed between the two groups. The association of basal levels and annual variation with mortality was investigated with Kaplan-Meier curves and Cox proportional hazard models. Results: Among 235 PD patients, 31 (13.2%) deaths occurred during the mean follow-up period of 24 months. Infection (38.7%) was the most common cause of death. Lower basal fT4 levels were an independent predictor of all-cause and infection-related death (hazard ratio [HR]=2.74, 95% confidence interval [CI] 1.27-5.90, P=0.01, and HR=6.33, 95% CI 1.16-34.64, P=0.03, respectively). Longitudinally, patients with persistently lower fT4 levels during the 12-month period had significantly higher all-cause mortality than those with persistently higher levels (HR=3.30, 95% CI 1.15-9.41, P=0.03). The area under the receiver operating characteristic curve of fT4 for predicting all-cause and infection-related mortality was 0.60 and 0.68, respectively. Conclusions: fT4 level is an independent predictor of mortality and is especially attributable to infection in PD patients. This predictor was consistent when considering both baseline measurements and annual variation patterns. Close attention to infection in PD patients with relatively lower fT4 levels should be considered.	[Jung, Hee-Yeon; Cho, Jang-Hee; Choi, Ji-Young; Park, Sun-Hee; Kim, Chan-Duck; Kim, Yong-Lim] Kyungpook Natl Univ, Dept Internal Med, Sch Med, Taegu, South Korea; [Jang, Hye Min] Kyungpook Natl Univ, Dept Stat, Taegu, South Korea; [Kim, Yon Su] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 151, South Korea; [Kang, Shin-Wook] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea; [Yang, Chul Woo] Catholic Univ Korea, Coll Med, Dept Internal Med, Seoul, South Korea; [Kim, Nam-Ho] Chonnam Natl Univ, Sch Med, Dept Internal Med, Kwangju, South Korea; [Jung, Hee-Yeon; Cho, Jang-Hee; Jang, Hye Min; Kim, Yon Su; Kang, Shin-Wook; Yang, Chul Woo; Kim, Nam-Ho; Choi, Ji-Young; Park, Sun-Hee; Kim, Chan-Duck; Kim, Yong-Lim] Clin Res Ctr End Stage Renal Dis, Taegu, South Korea; [Kim, Yong-Lim] Kyungpook Natl Univ, Plus KNU Biomed Convergence Program Bk21, Dept Biomed Sci, Taegu, South Korea	Kyungpook National University; Kyungpook National University; Seoul National University (SNU); Yonsei University; Yonsei University Health System; Catholic University of Korea; Chonnam National University; Kyungpook National University	Kim, YL (corresponding author), Kyungpook Natl Univ, Dept Internal Med, Sch Med, Taegu, South Korea.	ylkim@knu.ac.kr	Cho, Jang-hee/ABD-3534-2020; Barretti, Pasqual/K-4156-2012; Jung, Hee-Yeon/AFB-8578-2022	Cho, Jang-hee/0000-0002-7031-5214; Barretti, Pasqual/0000-0003-4979-4836; Jung, Hee-Yeon/0000-0003-0232-7202; Ryu, Dong-Ryeol/0000-0002-5309-7606	Korean Healthcare Technology R&D Project, Ministry for Health and Welfare, Republic of Korea [HI10C2020, A111345]; National Research Foundation - Korea Government (MEST) [20100019392]	Korean Healthcare Technology R&D Project, Ministry for Health and Welfare, Republic of Korea; National Research Foundation - Korea Government (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government)	Funding: This study was supported by a grant from the Korean Healthcare Technology R&D Project, Ministry for Health and Welfare, Republic of Korea (HI10C2020 and A111345), and a National Research Foundation grant funded by the Korea Government (MEST) (No. 20100019392). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bagriacik EU, 2001, CELL IMMUNOL, V212, P92, DOI 10.1006/cimm.2001.1846; BESEDOVSKY H, 1975, P SOC EXP BIOL MED, V150, P466; BESEDOVSKY HO, 1985, INT J CANCER, V36, P209, DOI 10.1002/ijc.2910360213; Brough R, 2006, PEDIATR NEPHROL, V21, P400, DOI 10.1007/s00467-005-2115-2; Cappola AR, 2006, JAMA-J AM MED ASSOC, V295, P1033, DOI 10.1001/jama.295.9.1033; Carrero JJ, 2007, J INTERN MED, V262, P690, DOI 10.1111/j.1365-2796.2007.01865.x; Choi JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084257; CHOPRA IJ, 1983, ANN INTERN MED, V98, P946, DOI 10.7326/0003-4819-98-6-946; Cini G, 2009, BIOMED PHARMACOTHER, V63, P742, DOI 10.1016/j.biopha.2009.08.003; Drechsler C, 2013, AM J KIDNEY DIS; Enia G, 2007, NEPHROL DIAL TRANSPL, V22, P538, DOI 10.1093/ndt/gfl605; Fernandez-Reyes MJ, 2010, CLIN NEPHROL, V73, P238; FUJII T, 1989, ENDOCRINOLOGY, V124, P167, DOI 10.1210/endo-124-1-167; HERSHMAN JM, 1972, J CLIN ENDOCR METAB, V34, P574, DOI 10.1210/jcem-34-3-574; Iervasi G, 2007, ARCH INTERN MED, V167, P1526, DOI 10.1001/archinte.167.14.1526; Kang EW, 2008, AM J NEPHROL, V28, P908, DOI 10.1159/000141933; Kelly G S, 2000, Altern Med Rev, V5, P306; Klein I, 2001, NEW ENGL J MED, V344, P501, DOI 10.1056/NEJM200102153440707; Kruger TE, 1996, ADV NEUROIMMUNOL, V6, P387, DOI 10.1016/S0960-5428(97)00033-2; Lim VS, 2001, AM J KIDNEY DIS, V38, pS80, DOI 10.1053/ajkd.2001.27410; Lo JC, 2005, KIDNEY INT, V67, P1047, DOI 10.1111/j.1523-1755.2005.00169.x; Mariani LH, 2012, J AM SOC NEPHROL, V23, P22, DOI 10.1681/ASN.2010070766; McDonald S, 2012, ANZDATA REGISTRY REP; MCLARTY DG, 1975, LANCET, V2, P275; McQuade C, 2011, THYROID, V21, P837, DOI 10.1089/thy.2010.0298; Meuwese CL, 2012, CLIN J AM SOC NEPHRO, V7, P131, DOI 10.2215/CJN.05250511; Molinaro S, 2012, AM J MED SCI, V343, P65, DOI 10.1097/MAJ.0b013e31822846bd; OZAWA M, 1988, ENDOCRINOLOGY, V123, P1461, DOI 10.1210/endo-123-3-1461; PANG XP, 1989, ENDOCRINOLOGY, V125, P76, DOI 10.1210/endo-125-1-76; Rhee CM, 2013, CLIN J AM SOC NEPHRO, V8, P593, DOI 10.2215/CJN.06920712; ROBEY C, 1989, AM J KIDNEY DIS, V13, P99, DOI 10.1016/S0272-6386(89)80125-8; Perez SR, 2013, PERITON DIALYSIS INT, V33, P697, DOI 10.3747/pdi.2012.00098; SLAG MF, 1981, JAMA-J AM MED ASSOC, V245, P43, DOI 10.1001/jama.245.1.43; Sonawane S, 2006, SEMIN DIALYSIS, V19, P305, DOI 10.1111/j.1525-139X.2006.00177.x; Song SH, 2009, NEPHROL DIAL TRANSPL, V24, P1534, DOI 10.1093/ndt/gfn682; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; Tatar E, 2012, INT UROL NEPHROL, V44, P601, DOI 10.1007/s11255-011-0034-7; Tatar E, 2011, CLIN J AM SOC NEPHRO, V6, P2240, DOI 10.2215/CJN.02540311; US Renal Data System, 2013, USRDS 2013 ANN DAT R; Waring AC, 2012, J CLIN ENDOCR METAB, V97, P862, DOI 10.1210/jc.2011-2684; Wiederkehr MR, 2004, NEPHROL DIAL TRANSPL, V19, P1190, DOI 10.1093/ndt/gfh096; Yilmaz MI, 2011, AM J NEPHROL, V33, P25, DOI 10.1159/000322581; Zoccali C, 2006, KIDNEY INT, V70, P523, DOI 10.1038/sj.ki.5001566; Zoccali C, 2005, J AM SOC NEPHROL, V16, P2789, DOI 10.1681/ASN.2005040356; Zoccali C, 2006, J HYPERTENS, V24, P2039, DOI 10.1097/01.hjh.0000244954.62362.8f	45	6	6	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 1	2014	9	12							e112760	10.1371/journal.pone.0112760	http://dx.doi.org/10.1371/journal.pone.0112760			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX7SK	25436457	gold, Green Published, Green Submitted			2023-01-03	WOS:000347114900017
J	Li, L; Zhang, H; Meng, SQ; Qian, HZ				Li, Li; Zhang, Hong; Meng, Shu-qing; Qian, Hai-zhou			An Updated Meta-Analysis of the Efficacy and Safety of Acupuncture Treatment for Cerebral Infarction	PLOS ONE			English	Article							ISCHEMIC-STROKE; BRAIN; ELECTROACUPUNCTURE; PROLIFERATION; STIMULATION; DEFICITS; INJURY; MODEL	Background: Ischemic stroke is the second most common cause of death and the primary cause of disability throughout the world. Acupuncture is frequently advocated as an adjunct treatment during stroke rehabilitation. The aim of this study was to update the clinical efficacy and safety of acupuncture for cerebral infarction. Methods: Randomized controlled trials (RCT) on acupuncture treating cerebral infarction were searched from the following databases: PubMed, EMBASE, Cochrane Library, CNKI, CMB and VIP from inception to October 2013. The data of RCTs meeting the inclusive criteria were extracted according to Cochrane methods. The meta-analyses were conducted using Rev Man 5.0 software. Results: A total of 25 trials involving 2224 patients were included. The results of this meta-analysis showed that the groups receiving acupuncture (observation group) were superior to the comparison groups (control group), with significant differences in the Clinical Efficacy Rates [OR=4.04, 95% CI (2.93, 5.57), P<0.001], Fugl-Meyer Assessment [MD=11.22, 95% CI (7.62, 14.82), P<0.001], Barthel Index Score [MD=12.84, 95% CI (9.85, 15.82), P<0.001], and Neurological Deficit Score [MD=-22.71, 95% CI (23.84, 21.94), P<0.001]. Three trials reported minor adverse events. Conclusion: Current evidence provisionally demonstrates that acupuncture treatment is superior to either non-acupuncture or conventional therapy for cerebral infarction. Despite this conclusion, given the often low quality of the available trials, further large scale RCTs of better quality are still needed.	[Li, Li; Zhang, Hong; Meng, Shu-qing; Qian, Hai-zhou] Wuhan Univ, Zhongnan Hosp, Dept Neurol, Wuhan 430072, Peoples R China	Wuhan University	Zhang, H (corresponding author), Wuhan Univ, Zhongnan Hosp, Dept Neurol, Wuhan 430072, Peoples R China.	zhangh9@yahoo.com			Scientific Research Foundation from Health Department of Hubei Province in China [JX5A04]	Scientific Research Foundation from Health Department of Hubei Province in China	This work was supported by the Key Projects of Scientific Research Foundation from Health Department of Hubei Province (JX5A04) in China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2002, ACUPUNCTURE REV ANAL, P4; Chen SQ, 1997, CHIN J REHABIL THEOR, V3, P161; Cheng HY, 2008, NEUROSCI LETT, V432, P111, DOI 10.1016/j.neulet.2007.12.009; Cheng X, 2011, WORLD J ACUPUNCT MOX, V21, P15; Feng Lingmei, 2007, J Tradit Chin Med, V27, P100; Furlan AD, 2009, SPINE, V34, P1929, DOI 10.1097/BRS.0b013e3181b1c99f; Guo A, 2012, SHANGHAI J ACUPUNCT, V31, P80; Guo Zhili, 2007, J Tradit Chin Med, V27, P243; Hsing WT, 2012, J ALTERN COMPLEM MED, V18, P341, DOI 10.1089/acm.2011.0131; Huang F, 2008, SHANGHAI J ACUPUNCT, V27, P4; Hui KKS, 2000, HUM BRAIN MAPP, V9, P13, DOI 10.1002/(SICI)1097-0193(2000)9:1<13::AID-HBM2>3.0.CO;2-F; Kong JC, 2010, CAN MED ASSOC J, V182, P1723, DOI 10.1503/cmaj.091113; Lee GJ, 2010, NEUROL RES, V32, pS79, DOI 10.1179/016164109X12537002794200; Lee JD, 2003, NEURORADIOLOGY, V45, P780, DOI 10.1007/s00234-003-1080-3; Li L, 2009, J ACUPUNCT TUINA SCI, V7, P137; LIN R, 2009, J PRACTICAL TRADITIO, V23, P90; Liu QJ, 2001, CHINESE J ORG CHEM, V21, P160; Pei J, 2001, J Tradit Chin Med, V21, P270; Rabinstein AA, 2003, NEUROLOGIST, V9, P137, DOI 10.1097/00127893-200305000-00002; Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518; Rao Ping, 2006, Zhongguo Zhen Jiu, V26, P694; Ren L, 2008, NEUROL RES, V30, P985, DOI 10.1179/174313208X325182; Schuler MS, 2005, J AM GERIATR SOC, V53, P549, DOI 10.1111/j.1532-5415.2005.53178_6.x; Shen PF, 2012, AM J CHINESE MED, V40, P685, DOI 10.1142/S0192415X12500516; Shu XP, 2011, CHINA FOREIGN MED TR, V30, P10; Tao J, 2010, NEUROL RES, V32, P198, DOI 10.1179/174313209X414506; Tong Shuai, 2013, Zhongguo Zhen Jiu, V33, P399; Wang Y, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/480950; Weng ZM, 2013, INT J NURS, V32, P1074; Wu MT, 1999, RADIOLOGY, V212, P133, DOI 10.1148/radiology.212.1.r99jl04133; Wu P, 2010, STROKE, V41, pE171, DOI 10.1161/STROKEAHA.109.573576; Wu X, 2001, WORLD J ACUPUNCT MOX, V11, P24; Wu YC, 2011, J ACUPUNCT TUINA SCI, V9, P315; Xie R, 2004, CHIN J GERIATR CARE, V2, P7; Yang D, 2008, J ACUPUNCT TUINA SCI, V6, P219; Zhang L, 2008, J ACUPUNCT TUINA SCI, V6, P222; Zhang Ning-xia, 2009, Zhen Ci Yan Jiu, V34, P406; Zhang RL, 2005, NEUROSCIENTIST, V11, P408, DOI 10.1177/1073858405278865; Zhang Xin, 2011, Zhongguo Zhong Xi Yi Jie He Za Zhi, V31, P483; Zhao JX, 2011, J TRADIT CHIN MED, V31, P349, DOI 10.1016/S0254-6272(12)60017-X; Zhou F, 2011, J APPL PHYSIOL, V111, P1877, DOI 10.1152/japplphysiol.00313.2011; Zhu S, 2005, WORLD J ACUPUNCT MOX, V15, P8	42	33	37	1	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 1	2014	9	12							e114057	10.1371/journal.pone.0114057	http://dx.doi.org/10.1371/journal.pone.0114057			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX7SK	25438041	Green Published, gold, Green Submitted			2023-01-03	WOS:000347114900115
J	Wolchok, JD; Chan, TA				Wolchok, Jedd D.; Chan, Timothy A.			CANCER Antitumour immunity gets a boost	NATURE			English	Editorial Material							ADVANCED MELANOMA; SAFETY; IMMUNOGENICITY; IPILIMUMAB; ANTI-PD-1; SURVIVAL; ANTIBODY; REVEALS		[Wolchok, Jedd D.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA; [Wolchok, Jedd D.] Mem Sloan Kettering Canc Ctr, Ludwig Ctr, New York, NY 10065 USA; [Chan, Timothy A.] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA; [Chan, Timothy A.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Wolchok, JD (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA.	wolchokj@mskcc.org	Chan, Timothy A/ABD-5850-2021		NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA008748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Brahmer JR, 2010, J CLIN ONCOL, V28, P3167, DOI 10.1200/JCO.2009.26.7609; Coley W. B., 1910, P ROY SOC MED, V3, P1, DOI DOI 10.1177/003591571000301601; Duan F, 2014, J EXP MED, V211, P2231, DOI 10.1084/jem.20141308; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Gubin MM, 2014, NATURE, V515, P577, DOI 10.1038/nature13988; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Koebel CM, 2007, NATURE, V450, P903, DOI 10.1038/nature06309; Matsushita H, 2012, NATURE, V482, P400, DOI 10.1038/nature10755; Page DB, 2014, ANNU REV MED, V65, P185, DOI 10.1146/annurev-med-092012-112807; Powles T, 2014, NATURE, V515, P558, DOI 10.1038/nature13904; Robert C, 2014, LANCET, V384, P1109, DOI 10.1016/S0140-6736(14)60958-2; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Snyder A, 2014, N ENGL J MED; Taube JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003689; Topalian SL, 2014, J CLIN ONCOL, V32, P1020, DOI 10.1200/JCO.2013.53.0105; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Wolchok JD, 2013, ANN ONCOL, V24, P2174, DOI 10.1093/annonc/mdt161; Yadav M, 2014, NATURE, V515, P572, DOI 10.1038/nature14001	21	81	89	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 27	2014	515	7528					496	498		10.1038/515496a	http://dx.doi.org/10.1038/515496a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AW4JP	25428495	Green Accepted			2023-01-03	WOS:000346247600038
J	Kouvonen, A; Koskinen, A; Varje, P; Kokkinen, L; De Vogli, R; Vaananen, A				Kouvonen, Anne; Koskinen, Aki; Varje, Pekka; Kokkinen, Lauri; De Vogli, Roberto; Vaananen, Ari			National Trends in Main Causes of Hospitalization: A Multi-Cohort Register Study of the Finnish Working-Age Population, 1976-2010	PLOS ONE			English	Article							SEX-SPECIFIC TRENDS; DISEASE; HEALTH; RATES; MORTALITY; SCOTLAND; DECLINE; BREAST; BACK; RISK	Background: The health transition theory argues that societal changes produce proportional changes in causes of disability and death. The aim of this study was to identify long-term changes in main causes of hospitalization in working-age population within a nation that has experienced considerable societal change. Methodology: National trends in all-cause hospitalization and hospitalizations for the five main diagnostic categories were investigated in the data obtained from the Finnish Hospital Discharge Register. The seven-cohort sample covered the period from 1976 to 2010 and consisted of 3,769,356 randomly selected Finnish residents, each cohort representing 25% sample of population aged 18 to 64 years. Principal Findings: Over the period of 35 years, the risk of hospitalization for cardiovascular diseases and respiratory diseases decreased. Hospitalization for musculoskeletal diseases increased whereas mental and behavioral hospitalizations slightly decreased. The risk of cancer hospitalization decreased marginally in men, whereas in women an upward trend was observed. Conclusions/Significance: A considerable health transition related to hospitalizations and a shift in the utilization of health care services of working-age men and women took place in Finland between 1976 and 2010.	[Kouvonen, Anne] Univ Helsinki, Dept Social Res, Helsinki, Finland; [Kouvonen, Anne] Univ Social Sci & Humanities, Fac Wroclaw, Wroclaw, Poland; [Kouvonen, Anne] Queens Univ Belfast, UKCRC Ctr Excellence Publ Hlth Northern Ireland, Belfast, Antrim, North Ireland; [Koskinen, Aki; Varje, Pekka; Kokkinen, Lauri; Vaananen, Ari] Finnish Inst Occupat Hlth, Helsinki, Finland; [Koskinen, Aki; Varje, Pekka; Kokkinen, Lauri; Vaananen, Ari] Finnish Inst Occupat Hlth, Tampere, Finland; [Varje, Pekka] Univ Helsinki, Dept Philosophy Hist Culture & Art Studies, Helsinki, Finland; [De Vogli, Roberto] Univ Calif Davis, Sch Med, Dept Publ Hlth Sci, Davis, CA 95616 USA; [De Vogli, Roberto] UCL, Dept Epidemiol & Publ Hlth, London, England	University of Helsinki; SWPS University of Social Sciences & Humanities; Queens University Belfast; Finnish Institute of Occupational Health; Finnish Institute of Occupational Health; University of Helsinki; University of California System; University of California Davis; University of London; University College London	Kouvonen, A (corresponding author), Univ Helsinki, Dept Social Res, Helsinki, Finland.	anne.kouvonen@helsinki.fi	Kokkinen, Lauri PM/O-1295-2018	Kokkinen, Lauri PM/0000-0001-5827-6673; Kokkinen, Lauri/0000-0001-7654-3026; Kouvonen, Anne/0000-0001-6997-8312	Academy of Finland [67172]; Medical Research Council (MRC) [MR/K023241/1]; Economic and Social Research Council (ESRC) [ES/L007509/1, RES-070-27-0034]; Economic and Social Research Council [ES/L007509/1] Funding Source: researchfish; Medical Research Council [MR/K023241/1, MC_CF023241] Funding Source: researchfish; ESRC [ES/L007509/1] Funding Source: UKRI; MRC [MR/K023241/1] Funding Source: UKRI	Academy of Finland(Academy of Finland); Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Economic and Social Research Council (ESRC)(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by the Academy of Finland (grant 67172). A. Kouvonen was supported by the Medical Research Council (MRC) (grant MR/K023241/1) and the Economic and Social Research Council (ESRC) (grant ES/L007509/1). R. De Vogli was supported by the Economic and Social Research Council (ESRC) (grant RES-070-27-0034). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alamgir H, 2006, OCCUP ENVIRON MED, V63, P290, DOI 10.1136/oem.2005.026047; Briffa T, 2011, HEART, V97, P400, DOI 10.1136/hrt.2010.210138; Danaei G, 2011, LANCET, V377, P568, DOI 10.1016/S0140-6736(10)62036-3; Farzadfar F, 2011, LANCET, V377, P578, DOI 10.1016/S0140-6736(10)62038-7; Ford ES, 2007, NEW ENGL J MED, V356, P2388, DOI 10.1056/NEJMsa053935; Freburger JK, 2009, ARCH INTERN MED, V169, P251, DOI 10.1001/archinternmed.2008.543; Frenk J, 1991, Health Transit Rev, V1, P21; Galobardes B, 2006, ANN EPIDEMIOL, V16, P91, DOI 10.1016/j.annepidem.2005.06.053; Getahun D, 2005, J ASTHMA, V42, P373, DOI 10.1081/JAS-200062995; Haldeman GA, 1999, CONGESTIVE HEART FAI; Harper S, 2011, ANNU REV PUBL HEALTH, V32, P39, DOI 10.1146/annurev-publhealth-031210-101234; Hemminki E, 2008, MATURITAS, V61, P299, DOI 10.1016/j.maturitas.2008.09.022; Hjerppe R., 2006, ROAD PROSPERITY EC H; Hoeymans N, 2012, AM J PUBLIC HEALTH, V102, P163, DOI 10.2105/AJPH.2011.300296; Inglis SC, 2012, BRIT J SURG, V99, P680, DOI 10.1002/bjs.8686; Kauppinen T, 2013, ANN OCCUP HYG, V57, P593, DOI 10.1093/annhyg/mes090; Kela [Social Insurance Institution], 2012, STAT YB SOC INS I; Lee JM, 2010, J WOMENS HEALTH, V19, P2033, DOI 10.1089/jwh.2010.2029; Lehto A. M., 2008, TYOOLOJEN KOLME VUOS; Lewsey JD, 2009, CIRC-CARDIOVASC QUAL, V2, P475, DOI 10.1161/CIRCOUTCOMES.108.825968; Lincoln Andrew E, 2002, Work, V18, P99; Lindemann K, 2010, INT J CANCER, V127, P2661, DOI 10.1002/ijc.25267; Liu LJ, 2011, INT J CARDIOL, V149, P39, DOI 10.1016/j.ijcard.2009.11.037; Luepker RV, 2008, CIRCULATION, V117, P592, DOI 10.1161/CIRCULATIONAHA.107.747477; Lykkegaard J, 2012, RESP MED, V106, P549, DOI 10.1016/j.rmed.2011.11.001; Martin BI, 2008, JAMA-J AM MED ASSOC, V299, P656, DOI 10.1001/jama.299.6.656; Mattioli S, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-374; McCallum AK, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-3; Mesle F, 2006, DEMOGRAPHY ANAL SYNT, P247; Moller B, 2005, EUR J CANCER PREV, V14, P117, DOI 10.1097/00008469-200504000-00007; Nedkoff LJ, 2011, CIRC-CARDIOVASC QUAL, V4, P557, DOI 10.1161/CIRCOUTCOMES.110.960005; Nowossadeck E, 2012, DTSCH ARZTEBL INT, V109, P151, DOI 10.3238/arztebl.2012.0151; Nurminen M, 2001, SCAND J WORK ENV HEA, V27, P161, DOI 10.5271/sjweh.605; Pukkala E., 2013, CANC IN FINLAND; Renehan AG, 2010, INT J CANCER, V126, P692, DOI 10.1002/ijc.24803; Schaufelberger M, 2004, EUR HEART J, V25, P300, DOI 10.1016/j.ehj.2003.12.012; Schmidt M, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e356; Schnall P., 2009, UNHEALTHY WORK CAUSE; Straker LM, 2009, ERGONOMICS, V52, P1215, DOI 10.1080/00140130903039101; Sund R, 2012, SCAND J PUBLIC HEALT, V40, P505, DOI 10.1177/1403494812456637; Tan CE, 2012, CIRCULATION, V126, P2177, DOI 10.1161/CIRCULATIONAHA.112.121301; Teppo L, 1999, HLTH IN FINLAND; Thrasher JF, 2009, NICOTINE TOB RES, V11, P591, DOI 10.1093/ntr/ntp039; Towfighi A, 2011, AM J CARDIOL, V108, P1102, DOI 10.1016/j.amjcard.2011.05.046; Tuchsen F, 1996, J CLIN EPIDEMIOL, V49, P791, DOI 10.1016/0895-4356(95)00554-4; Tuchsen F, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001761; Ulmer H, 2007, J INTERN MED, V261, P566, DOI 10.1111/j.1365-2796.2007.01779.x; Vuorenkoski L., 2008, FINLAND HLTH SYSTEM; Wahlbeck K, 2011, BRIT J PSYCHIAT, V199, P453, DOI 10.1192/bjp.bp.110.085100; Wang OJ, 2012, AM J CARDIOL, V109, P1589, DOI 10.1016/j.amjcard.2012.01.381; Wearing SC, 2006, OBES REV, V7, P239, DOI 10.1111/j.1467-789X.2006.00251.x	51	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 7	2014	9	11							e112314	10.1371/journal.pone.0112314	http://dx.doi.org/10.1371/journal.pone.0112314			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AT3WF	25379723	Green Published, Green Submitted, gold			2023-01-03	WOS:000344863100075
J	Gauld, NJ; Kelly, FS; Emmerton, LM; Buetow, SA				Gauld, Natalie J.; Kelly, Fiona S.; Emmerton, Lynne M.; Buetow, Stephen A.			Widening Consumer Access to Medicines: A Comparison of Prescription to Non-Prescription Medicine Switch in Australia and New Zealand	PLOS ONE			English	Article							PHARMACIES; BOARD	Background Despite similarities in health systems and Trans-Tasman Harmonization of medicines scheduling, New Zealand is more active than Australia in 'switching' (reclassifying) medicines from prescription to non-prescription. Objectives To identify and compare enablers and barriers to switch in New Zealand and Australia. Methods We conducted and analyzed 27 in-depth personal interviews with key participants in NZ and Australia and international participants previously located in Australia, and analyzed records of meetings considering switches (2000-2013). Analysis of both sets of data entailed a heuristic qualitative approach that embraced the lead researcher's knowledge and experience. Results The key themes identified were conservatism and political influences in Australia, and an open attitude, proactivity and flexibility in NZ. Pharmacist-only medicine schedules and individuals holding a progressive attitude were proposed to facilitate switch in both countries. A pharmacy retail group drove many switches in NZ ('third-party switch'), unlike Australia. Barriers to switch in both countries included small market sizes, funding of prescription medicines and cost of doctor visits, and lack of market exclusivity. In Australia, advertising limitations for pharmacist-only medicines reportedly discouraged industry from submitting switch applications. Perceptions of pharmacy performance could help or hinder switches. Conclusion Committee and regulator openness to switch, and confidence in pharmacy appear to influence consumer access to medicines. The pharmacist-only medicine schedule in Australasia and the rise of third-party switch and flexibility in switch in NZ could be considered elsewhere to enable switch.	[Gauld, Natalie J.; Buetow, Stephen A.] Univ Auckland, Dept Gen Practice & Primary Hlth Care, Auckland 1, New Zealand; [Kelly, Fiona S.] Univ Auckland, Sch Pharm, Auckland 1, New Zealand; [Kelly, Fiona S.] Griffith Univ, Griffith Hlth Inst, Brisbane, Qld 4111, Australia; [Emmerton, Lynne M.] Curtin Univ, Fac Hlth Sci, Sch Pharm, Perth, WA 6845, Australia	University of Auckland; University of Auckland; Griffith University; Menzies Health Institute Queensland; Curtin University	Gauld, NJ (corresponding author), Univ Auckland, Dept Gen Practice & Primary Hlth Care, Auckland 1, New Zealand.	n.gauld@auckland.ac.nz	Gauld, Natalie/I-6018-2019	Gauld, Natalie/0000-0003-0366-0357; Buetow, Stephen/0000-0002-9771-248X; Kelly, Fiona/0000-0001-7360-4655	University of Auckland	University of Auckland	A travel grant was provided by the University of Auckland for travel to Australia for interviews. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Achanta AS, 2003, CLIN RES REGUL AFF, V20, P1, DOI 10.1081/CRP-120018736; AESGP, 2012, OTC INGR; Alarcon C, 2006, COMPLAINT WEIGHT LOS; [Anonymous], 2006, INT J PHARM PRACT; [Anonymous], 2003, CONSUMER, V425, P6; [Anonymous], 2010, AUSTR MED ASS MIN AI; Armstrong ME, 2006, PLAN B CONTRACEPTIVE; Aronson JK, 2009, BRIT MED BULL, V90, P63, DOI 10.1093/bmb/ldp015; Associate Minister of Health Minister of Health, 2010, ACT MED NZ 2010; Benrimoj SI, 2007, QUAL SAF HEALTH CARE, V16, P354, DOI 10.1136/qshc.2006.019463; Bialy Leisa H., 2007, Journal of Pharmacy Practice and Research, V37, P277; Blenkinsopp A, 2005, COUNTER MEDICATION; Brass EP, 2001, NEW ENGL J MED, V345, P810, DOI 10.1056/NEJMra011080; Brass EP, 2012, J CLIN PHARMACOL, V52, P1277, DOI 10.1177/0091270011412962; Brooker C, 2010, MED OBSERVER    0514; Cohen Joshua, 2003, Am J Ther, V10, P370, DOI 10.1097/00045391-200309000-00010; Davis P, 2009, GLOBAL PUBLIC HLTH; DEMB A, 1992, LONG RANGE PLANN, V25, P9, DOI 10.1016/0024-6301(92)90364-8; Devetak R, 2006, AUST J POLIT SCI, V41, P241, DOI 10.1080/10361140600672451; Duckett S, 2011, AUSTR HLTH CARE SYST, V4th; Endacott R, 2013, J HEALTH SERV RES PO, V18, P13, DOI 10.1258/jhsrp.2012.011154; Gauld N, 2012, SELFCARE, V3, P88; Gauld N, 2012, CLIN THER, V34, P1324, DOI 10.1016/j.clinthera.2012.04.019; Gauld N, 2011, J ANTIMICROB CHEMOTH, V66, P201, DOI 10.1093/jac/dkq409; Gauld NJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107726; Gauld NJ, 2012, J ANTIMICROB CHEMOTH, V67, P2949, DOI 10.1093/jac/dks337; Gauld NJ, 2007, PHARM TODAY     0406; Hardman D., 2009, JUDGMENT DECISION MA; Hillson D, 2008, MANAGING GROUP RISK; Hofstede G., 1980, CULTURES CONSEQUENCE; Kashyap Krishneeta C, 2014, Int J Pharm Pract, V22, P125, DOI 10.1111/ijpp.12052; Kelly FS, 2009, ANN PHARMACOTHER, V43, P1877, DOI 10.1345/aph.1L121; Klein G., 1999, SOURCES POWER; Marris S, 2007, THE AUSTR       0830; Medsafe, 2014, CHANG LEG CLASS MED; Ministry of Health, 2011, BETT SOON MOR CONV H; Morse JM, 1998, QUAL HEALTH RES, V8, P733, DOI 10.1177/104973239800800601; Moustakas C, 1990, HEURISTIC RES; Nelson M., 2003, PHARM EXEC, V23, P66; Nguyen NT, 2006, CLIN THER, V28, P1231, DOI 10.1016/j.clinthera.2006.08.007; Norris PT, 2002, PHARM WORLD SCI, V24, P149, DOI 10.1023/A:1019506120713; Patton M. Q, 2015, QUALITATIVE RES EVAL, V4th; Pharmaceutical Society of New Zealand, 2002, ANN REPORT; Piper D, 2014, PHARM TODAY     1031; Reardon R, 2008, SPINE, V33, pS24, DOI 10.1097/BRS.0b013e3181642f07; ROHRMANN B, 1994, AUST J PSYCHOL, V46, P150, DOI 10.1080/00049539408259490; Schneider CR, 2011, ANN PHARMACOTHER, V45, P402, DOI 10.1345/aph.1P514; Strongman S, 2014, NZ HERALD       0929; United States General Accounting Office, 1995, NONPR DRUGS VAL PHAR; United States Government Accountability Office, 2009, NONPR DRUGS CONS REG; Wallace DM, 2009, SMALL GR RES, V40, P52, DOI 10.1177/1046496408326576; WHO, 2011, NIH PUBL; Yeats J, 2014, PHARM TODAY     1105	53	13	13	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 18	2015	10	3							e0119011	10.1371/journal.pone.0119011	http://dx.doi.org/10.1371/journal.pone.0119011			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CE9BN	25785589	Green Published, gold, Green Submitted			2023-01-03	WOS:000352138500066
J	Kenealy, TW; Parsons, MJG; Rouse, APB; Doughty, RN; Sheridan, NF; Hindmarsh, JKH; Masson, SC; Rea, HH				Kenealy, Timothy W.; Parsons, Matthew J. G.; Rouse, A. Paul B.; Doughty, Robert N.; Sheridan, Nicolette F.; Hindmarsh, Jennifer K. Harre; Masson, Sarah C.; Rea, Harry H.			Telecare for Diabetes, CHF or COPD: Effect on Quality of Life, Hospital Use and Costs. A Randomised Controlled Trial and Qualitative Evaluation	PLOS ONE			English	Article							WHOLE SYSTEMS DEMONSTRATOR; HEART-FAILURE INDEX; SELF-CARE; RESPIRATORY QUESTIONNAIRE; TELEHEALTH QUESTIONNAIRE; HEALTH-CARE; IMPLEMENTATION; SERVICES; OUTCOMES; DISEASE	Objectives To assess the effect of telecare on health related quality of life, self-care, hospital use, costs and the experiences of patients, informal carers and health care professionals. Methods Patients were randomly assigned either to usual care or to additionally entering their data into a commercially-available electronic device that uploaded data once a day to a nurse-led monitoring station. Patients had congestive heart failure (Site A), chronic obstructive pulmonary disease (Site B), or any long-term condition, mostly diabetes (Site C). Site C contributed only intervention patients - they considered a usual care option to be unethical. The study took place in New Zealand between September 2010 and February 2012, and lasted 3 to 6 months for each patient. The primary outcome was health-related quality of life (SF36). Data on experiences were collected by individual and group interviews and by questionnaire. Results There were 171 patients (98 intervention, 73 control). Quality of life, self-efficacy and disease-specific measures did not change significantly, while anxiety and depression both decreased significantly with the intervention. Hospital admissions, days in hospital, emergency department visits, outpatient visits and costs did not differ significantly between the groups. Patients at all sites were universally positive. Many felt safer and more cared-for, and said that they and their family had learned more about managing their condition. Staff could all see potential benefits of telecare, and, after some initial technical problems, many staff felt that telecare enabled them to effectively monitor more patients. Conclusions Strongly positive patient and staff experiences and attitudes complement and contrast with small or non-significant quantitative changes. Telecare led to patients and families taking a more active role in self-management. It is likely that subgroups of patients benefitted in ways that were not measured or visible within the quantitative data, especially feelings of safety and being cared-for.	[Kenealy, Timothy W.] Univ Auckland, Dept Gen Practice & Primary Hlth Care, Auckland 1, New Zealand; [Parsons, Matthew J. G.] Univ Auckland, Fac Med & Hlth Sci, Auckland 1, New Zealand; [Rouse, A. Paul B.] Univ Auckland, Univ Auckland Business Sch, Dept Accounting & Finance, Auckland 1, New Zealand; [Doughty, Robert N.; Rea, Harry H.] Univ Auckland, Dept Med, Auckland 1, New Zealand; [Doughty, Robert N.] Auckland City Hosp, Greenlane Cardiovasc Serv, Auckland, New Zealand; [Sheridan, Nicolette F.; Masson, Sarah C.] Univ Auckland, Fac Med & Hlth Sci, Sch Nursing, Auckland 1, New Zealand; [Hindmarsh, Jennifer K. Harre] Ngati Porou Hauora Charitable Trust, Te Puia Springs, Tairawhiti East, New Zealand	University of Auckland; University of Auckland; University of Auckland; University of Auckland; Auckland City Hospital; University of Auckland	Kenealy, TW (corresponding author), Univ Auckland, Dept Gen Practice & Primary Hlth Care, Auckland 1, New Zealand.	t.kenealy@auckland.ac.nz		Kenealy, Timothy/0000-0001-6002-4766; Parsons, Matthew/0000-0003-2004-1347; Sheridan, Nicolette/0000-0002-8098-2918	New Zealand Ministry of Health and District Health Boards New Zealand: Primary Health Care Strategic Innovations Fund [330530/00]	New Zealand Ministry of Health and District Health Boards New Zealand: Primary Health Care Strategic Innovations Fund	This work was supported by New Zealand Ministry of Health and District Health Boards New Zealand: Primary Health Care Strategic Innovations Fund, Agreement number 330530/00. http://www.dhbsharedservices.health.nz/site/sig/primary-care/innovations-area.aspx Note, this fund ran from 2007-9, see file:///C:/Users/tken008/Downloads/InnovFund %20Information%20for%20website%20Sept09.pdf. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ajwani S., 2003, DECADES DISPARITY ET; Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Benzeval M, 1995, TACKLING INEQUALITIE; Berwick DM, 2008, JAMA-J AM MED ASSOC, V299, P1182, DOI 10.1001/jama.299.10.1182; Boutron I, 2008, ANN INTERN MED, V148, pW60, DOI 10.7326/0003-4819-148-4-200802190-00008-w1; Boutron I, 2008, ANN INTERN MED, V148, P295, DOI 10.7326/0003-4819-148-4-200802190-00008; Cartwright M, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f653; Cooper R., 1991, DESIGN COST MANAGEME; Ekeland AG, 2010, INT J MED INFORM, V79, P736, DOI 10.1016/j.ijmedinf.2010.08.006; Goldberg LR, 2003, AM HEART J, V146, P705, DOI 10.1016/S0002-8703(03)00393-4; Greenhalgh T, 2011, MILBANK Q, V89, P533, DOI 10.1111/j.1468-0009.2011.00642.x; Henderson C, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1035; Hendy J, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-403; Inglis SC, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007228.pub2; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321; Lorig K R, 2001, Eff Clin Pract, V4, P256; McAuley KA, 2003, ASIA PAC J CLIN NUTR, V12, P423; Mcdowell I., 2006, MEASURING HLTH GUIDE, V3, P37, DOI [DOI 10.1093/ACPROF:OSO/9780195165678.001.0001, 10.1093/acprof:oso/9780195165678.001.0001]; McLean S, 2011, COCHRANE DB SYST REV; Meguro M, 2007, CHEST, V132, P456, DOI 10.1378/chest.06-0702; Parsons J, 2012, AGE AGEING, V41, P24, DOI 10.1093/ageing/afr118; Phillips GA, 2006, MED J AUSTRALIA, V184, P602, DOI 10.5694/j.1326-5377.2006.tb00412.x; Riegel B, 2004, J CARD FAIL, V10, P350, DOI 10.1016/j.cardfail.2003.12.001; Riegel B, 2009, J CARDIOVASC NURS, V24, P485, DOI 10.1097/JCN.0b013e3181b4baa0; Roisin R, 2011, GLOBAL STRATEGY INIT; Sandelowski M, 2000, RES NURS HEALTH, V23, P334, DOI 10.1002/1098-240X(200008)23:4<334::AID-NUR9>3.0.CO;2-G; Sandelowski M, 2010, RES NURS HEALTH, V33, P77, DOI 10.1002/nur.20362; Satterfield DW, 2003, DIABETES CARE, V26, P2643, DOI 10.2337/diacare.26.9.2643; Starfield Barbara, 2003, Ann Fam Med, V1, P8, DOI 10.1370/afm.1; Steventon A, 2013, AGE AGEING, V42, P501, DOI 10.1093/ageing/aft008; Tilley N., 1997, REALIST EVALUATION; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Toobert DJ, 2000, DIABETES CARE, V23, P943, DOI 10.2337/diacare.23.7.943; Wagner EH, 1996, MILBANK Q, V74, P511, DOI 10.2307/3350391; Walley J, 2008, LANCET, V372, P1001, DOI 10.1016/S0140-6736(08)61409-9; World Health Organization, 2005, PREP HLTH CAR WORKF; Wyrwich KW, 2005, HEALTH SERV RES, V40, P577, DOI 10.1111/j.1475-6773.2005.0l374.x; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	38	52	54	2	63	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 13	2015	10	3							e0116188	10.1371/journal.pone.0116188	http://dx.doi.org/10.1371/journal.pone.0116188			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CD7NO	25768023	gold, Green Published, Green Submitted			2023-01-03	WOS:000351277500005
J	Zeng, Q; Xiang, YQ; Wu, PH; Lv, X; Qian, CN; Guo, X				Zeng, Qi; Xiang, Yan-Qun; Wu, Pei-Hong; Lv, Xing; Qian, Chao-Nan; Guo, Xiang			A Matched Cohort Study of Standard Chemo-Radiotherapy versus Radiotherapy Alone in Elderly Nasopharyngeal Carcinoma Patients	PLOS ONE			English	Article							RANDOMIZED-TRIAL; CANCER-PATIENTS; NECK-CANCER; CONCURRENT CHEMORADIOTHERAPY; ADJUVANT CHEMOTHERAPY; OLDER PATIENTS; HEAD; TOXICITY; METAANALYSIS; COMORBIDITY	The impact of standard chemo-radiotherapy (CRT) as preferred therapy for elderly patients (age >= 60 years) with nasopharyngeal carcinoma (NPC) remains unclear. Therefore, a strict matched cohort study was conducted to compare the survival and treatment toxicity of standard chemo-radiotherapy in the elderly NPC patients with those of radiotherapy (RT) alone. From 1998 to 2003, total 498 newly diagnosed elderly non-metastatic NPC patients were abstracted and classified into two groups by the treatments they received. For each patient in the CRT group, a matched pair in RT group was identified by matching for gender, age, histological type, T and N classifications, RT dose to primary tumor and neck nodes, and days of radiotherapy. Treatment tolerability and toxicity were clarified, and treatment outcomes were calculated and compared between the two groups. Two groups were well balanced in clinical characteristics because of the strict matching conditions. Totally 87 pairs can be assessed according to the criteria. The 5-year OS, CSS, FFS, and LR-FFS for CRT and RT groups were 62% versus 40% (P= 0.013), 67% versus 47% (P= 0.018), 65% versus 53% (log-rank: P= 0.064, Breslow: P= 0.048), and 88% versus 72%, (P= 0.019), respectively. There was no significant difference in 5-year D-FFS between the two groups (75% vs. 73%, P= 0.456). The CRT group experienced significantly more Grade >= 3 acute mucositis (46.0% vs. 28.7%, P= 0.019). We concluded that standard chemo-radiotherapy can achieve a reasonable local and regional control in elderly NPC patients with acceptable and reversible acute toxicity. However, distant metastasis remains the dominant failure pattern. When the elderly NPC patients are in good performance status following a complete evaluation of overall functional status and comorbidity conditions, standard chemo-radiotherapy is worthy of recommendation.	[Zeng, Qi; Xiang, Yan-Qun; Wu, Pei-Hong; Lv, Xing; Qian, Chao-Nan; Guo, Xiang] Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [Zeng, Qi; Wu, Pei-Hong] Sun Yat Sen Univ, Ctr Canc, Dept Med Imaging & Intervent Radiol, Guangzhou 510275, Guangdong, Peoples R China; [Xiang, Yan-Qun; Lv, Xing; Qian, Chao-Nan; Guo, Xiang] Sun Yat Sen Univ, Ctr Canc, Dept Nasopharyngeal Carcinoma, Guangzhou 510275, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University	Guo, X (corresponding author), Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China.	guoxiang_zlyy@163.com	zeng, qi/AAE-9675-2020	zeng, qi/0000-0002-8700-6661	National Natural Science Foundation of China [81172041, 81472525]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This project has been funded by National Natural Science Foundation of China (No: 81172041; 81472525). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Sarraf M, 1998, J CLIN ONCOL, V16, P1310, DOI 10.1200/JCO.1998.16.4.1310; Ardizzoni A, 2005, J CLIN ONCOL, V23, P569, DOI 10.1200/JCO.2005.11.140; Balducci L, 2000, HEMATOL ONCOL CLIN N, V14, P193, DOI 10.1016/S0889-8588(05)70284-7; Balducci L, 2009, CURR OPIN ONCOL, V21, P310, DOI 10.1097/CCO.0b013e32832b4f25; Baujat B, 2006, INT J RADIAT ONCOL, V64, P47, DOI 10.1016/j.ijrobp.2005.06.037; Bernier J, 2005, NAT CLIN PRACT ONCOL, V2, P305, DOI 10.1038/ncponc0201; BIER H, 1993, EUR ARCH OTO-RHINO-L, V250, P200; Boje CR, 2014, RADIOTHER ONCOL, V110, P91, DOI 10.1016/j.radonc.2013.11.009; Bray F, 2008, CANCER EPIDEM BIOMAR, V17, P2356, DOI 10.1158/1055-9965.EPI-08-0461; Burdette-Radoux S, 2006, ONCOLOGIST, V11, P234, DOI 10.1634/theoncologist.11-3-234; Chan ATC, 2002, ANN ONCOL, V13, P1007, DOI 10.1093/annonc/mdf179; Chang ET, 2006, CANCER EPIDEM BIOMAR, V15, P1765, DOI 10.1158/1055-9965.EPI-06-0353; Chen QY, 2011, JNCI-J NATL CANCER I, V103, P1761, DOI 10.1093/jnci/djr432; Chen Y, 2013, CANCER-AM CANCER SOC, V119, P2230, DOI 10.1002/cncr.28049; COX JD, 1995, INT J RADIAT ONCOL, V31, P1341, DOI 10.1016/0360-3016(95)00060-C; DECKER DA, 1983, CANCER, V52, P602, DOI 10.1002/1097-0142(19830815)52:4<602::AID-CNCR2820520404>3.0.CO;2-6; Derks W, 2005, EUR ARCH OTO-RHINO-L, V262, P21, DOI 10.1007/s00405-004-0744-x; Ho HC, 2008, ACTA OTO-LARYNGOL, V128, P930, DOI 10.1080/00016480701767374; Hong MH, 2000, CANCER, V89, P242, DOI 10.1002/1097-0142(20000715)89:2<242::AID-CNCR6>3.0.CO;2-Z; Hoppe S, 2013, J CLIN ONCOL, V31, P3877, DOI 10.1200/JCO.2012.47.7430; Jia WH, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-178; KENNEDY BJ, 1988, J CLIN ONCOL, V6, P1903, DOI 10.1200/JCO.1988.6.12.1903; Kimmick GG, 1997, DRUG AGING, V10, P34, DOI 10.2165/00002512-199710010-00004; Langendijk JA, 2004, J CLIN ONCOL, V22, P4604, DOI 10.1200/JCO.2004.10.074; Lin JC, 2003, BRIT J CANCER, V88, P187, DOI 10.1038/sj.bjc.6600716; Liu H, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-70; Ma J, 2001, J CLIN ONCOL, V19, P1350, DOI 10.1200/JCO.2001.19.5.1350; Sze HCK, 2012, ORAL ONCOL, V48, P162, DOI 10.1016/j.oraloncology.2011.08.019; Teo PML, 1999, INT J RADIAT ONCOL, V43, P261, DOI 10.1016/S0360-3016(98)00383-6; Tsao S. Y., 1993, Annals Academy of Medicine Singapore, V22, P638; Unger JM, 2006, J CLIN ONCOL, V24, P141, DOI 10.1200/JCO.2005.02.8928; Yancik R, 1996, ANN EPIDEMIOL, V6, P399, DOI 10.1016/S1047-2797(96)00063-4; Zagonel V, 2001, EUR J CANCER, V37, pS229; Zeng Qi, 2008, Ai Zheng, V27, P289; ZHANG L, 2010, BMC BIOINFORMATIC S1, V11, P558, DOI DOI 10.1186/1471-2407-10-558	35	16	17	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 13	2015	10	3							e0119593	10.1371/journal.pone.0119593	http://dx.doi.org/10.1371/journal.pone.0119593			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CD7NO	25768294	gold, Green Published, Green Submitted			2023-01-03	WOS:000351277500087
J	Sakurai, Y; Kolokoltsov, AA; Chen, CC; Tidwell, MW; Bauta, WE; Klugbauer, N; Grimm, C; Wahl-Schott, C; Biel, M; Davey, RA				Sakurai, Yasuteru; Kolokoltsov, Andrey A.; Chen, Cheng-Chang; Tidwell, Michael W.; Bauta, William E.; Klugbauer, Norbert; Grimm, Christian; Wahl-Schott, Christian; Biel, Martin; Davey, Robert A.			Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment	SCIENCE			English	Article							NIEMANN-PICK C1; NAADP; CALCIUM; INFECTION; IDENTIFICATION; TETRANDRINE; MICE	Ebola virus causes sporadic outbreaks of lethal hemorrhagic fever in humans, but there is no currently approved therapy. Cells take up Ebola virus by macropinocytosis, followed by trafficking through endosomal vesicles. However, few factors controlling endosomal virus movement are known. Here we find that Ebola virus entry into host cells requires the endosomal calcium channels called two-pore channels (TPCs). Disrupting TPC function by gene knockout, small interfering RNAs, or small-molecule inhibitors halted virus trafficking and prevented infection. Tetrandrine, the most potent small molecule that we tested, inhibited infection of human macrophages, the primary target of Ebola virus in vivo, and also showed therapeutic efficacy in mice. Therefore, TPC proteins play a key role in Ebola virus infection and may be effective targets for antiviral therapy.	[Sakurai, Yasuteru; Davey, Robert A.] Texas Biomed Res Inst, San Antonio, TX 78227 USA; [Kolokoltsov, Andrey A.] Univ Texas Med Branch, Galveston, TX 77555 USA; [Chen, Cheng-Chang; Grimm, Christian; Wahl-Schott, Christian; Biel, Martin] Univ Munich, Ctr Drug Res, Dept Pharm, CIPSM, Munich, Germany; [Tidwell, Michael W.; Bauta, William E.] SW Res Inst, San Antonio, TX USA; [Klugbauer, Norbert] Univ Freiburg, Inst Expt & Clin Pharmacol & Toxicol, D-79106 Freiburg, Germany	Texas Biomedical Research Institute; University of Texas System; University of Texas Medical Branch Galveston; University of Munich; Southwest Research Institute; University of Freiburg	Davey, RA (corresponding author), Texas Biomed Res Inst, San Antonio, TX 78227 USA.	rdavey@txbiomed.org	Wahl-Schott, Christian A/J-2623-2015; Biel, Martin/G-1175-2014; Grimm, Christian/ABF-9121-2020	Biel, Martin/0000-0002-9974-3052; Grimm, Christian/0000-0002-0177-5559; Davey, Robert/0000-0001-9168-2892; Tidwell, Michael/0000-0002-3760-8752	NIH [R01AI063513]; DOD/DTRA [HDTRA1-12-1-0002, FRBAA09-6H-2-0043]; Ewing Halsell Foundation;  [SFB TRR 152 TP04];  [SFB TRR 152 TP05];  [SFB TRR 152 TP06];  [SFB TRR 152 TP12]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI063513] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD/DTRA(United States Department of DefenseDefense Threat Reduction Agency); Ewing Halsell Foundation; ; ; ; ; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	All BSL4 work was performed at Texas Biomedical Research Institute by Y.S. and veterinary staff. For advice about preparation of NAADP-AM, we thank G. Churchill. For guidance and use of their high-performance liquid chromatography system, we thank A. Hayhurst and L. Sherwood. We thank D. Ren (University of Pennsylvania) for guidance in using the modified patch clamp. A. Reyes and J. Bentz provided technical support. O. Shtanko and M. Anantpadma gave helpful discussions and advice. We also thank all those cited in Materials and Methods for reagents. The data presented in this manuscript are tabulated in the main paper and in the supplementary materials. R.A.D and A.A.K. are inventors on U.S. patent 8,889,743, issued 28 November 2014, entitled "Inhibition of filovirus entry into cells and uses thereof." This work was supported by NIH R01AI063513, DOD/DTRA HDTRA1-12-1-0002, Project FRBAA09-6H-2-0043, the Ewing Halsell Foundation, and SFB TRR 152 TP04, TP05, TP06, and TP12.	Aarhus R, 1995, J BIOL CHEM, V270, P30327, DOI 10.1074/jbc.270.51.30327; Alvarez CP, 2002, J VIROL, V76, P6841, DOI 10.1128/JVI.76.13.6841-6844.2002; Arndt L, 2014, MOL BIOL CELL, V25, P948, DOI 10.1091/mbc.E13-09-0523; Baize S, 2014, NEW ENGL J MED, V371, P1418, DOI 10.1056/NEJMoa1404505; Boguski MS, 2009, SCIENCE, V324, P1394, DOI 10.1126/science.1169920; Brailoiu E, 2010, J BIOL CHEM, V285, P38511, DOI 10.1074/jbc.M110.162073; Bray M, 1999, J INFECT DIS, V179, pS248, DOI 10.1086/514292; Calcraft PJ, 2009, NATURE, V459, P596, DOI 10.1038/nature08030; Cang CL, 2014, NAT CHEM BIOL, V10, P463, DOI 10.1038/nchembio.1522; Cang CL, 2013, CELL, V152, P778, DOI 10.1016/j.cell.2013.01.023; Carette JE, 2011, NATURE, V477, P340, DOI 10.1038/nature10348; Chandran K, 2005, SCIENCE, V308, P1643, DOI 10.1126/science.1110656; Cote M, 2011, NATURE, V477, P344, DOI 10.1038/nature10380; Dai CL, 2007, CANCER CHEMOTH PHARM, V60, P741, DOI 10.1007/s00280-007-0420-0; Dolnik O, 2008, CELL MOL LIFE SCI, V65, P756, DOI 10.1007/s00018-007-7406-2; Feldmann H, 2011, LANCET, V377, P849, DOI 10.1016/S0140-6736(10)60667-8; Friedrich BM, 2012, VIRUSES-BASEL, V4, P1619, DOI 10.3390/v4091619; Galione A, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004036; Gehring G, 2014, J ANTIMICROB CHEMOTH, V69, P2123, DOI 10.1093/jac/dku091; Genazzani AA, 1997, BRIT J PHARMACOL, V121, P1489, DOI 10.1038/sj.bjp.0701295; Grimm C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5699; Kolokoltsov AA, 2009, DRUG DEVELOP RES, V70, P255, DOI 10.1002/ddr.20303; Kondratowicz AS, 2011, P NATL ACAD SCI USA, V108, P8426, DOI 10.1073/pnas.1019030108; Kwan CY, 2002, ACTA PHARMACOL SIN, V23, P1057; Lloyd-Evans E, 2008, NAT MED, V14, P1247, DOI 10.1038/nm.1876; Madrid PB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060579; Martinez O, 2010, CELL MICROBIOL, V12, P148, DOI 10.1111/j.1462-5822.2009.01385.x; Nanbo A, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001121; Naylor E, 2009, NAT CHEM BIOL, V5, P220, DOI 10.1038/nchembio.150; Parkesh R, 2008, CELL CALCIUM, V43, P531, DOI 10.1016/j.ceca.2007.08.006; Ruas M, 2010, CURR BIOL, V20, P703, DOI 10.1016/j.cub.2010.02.049; Saeed MF, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001110; Takada A, 2004, J VIROL, V78, P2943, DOI 10.1128/JVI.78.6.2943-2947.2004; Wang X, 2012, CELL, V151, P372, DOI 10.1016/j.cell.2012.08.036; Zhu MX, 2010, AM J PHYSIOL-CELL PH, V298, pC430, DOI 10.1152/ajpcell.00475.2009	35	354	366	4	142	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 27	2015	347	6225					995	998		10.1126/science.1258758	http://dx.doi.org/10.1126/science.1258758			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CB9NQ	25722412	Green Accepted			2023-01-03	WOS:000349958900039
J	Barnes, T; Winfrow, M; Laboi, P; Wilkie, M				Barnes, Tania; Winfrow, Michael; Laboi, Paul; Wilkie, Martin			Commentary: Supporting patient independence in long term haemodialysis	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Barnes, Tania; Wilkie, Martin] Sheffield Teaching Hosp, Sheffield, S Yorkshire, England; [Laboi, Paul] York Teaching Hosp, York, N Yorkshire, England	University of Sheffield	Wilkie, M (corresponding author), Sheffield Teaching Hosp, Sheffield, S Yorkshire, England.	martin.wilkie@sth.nhs.uk						Cavanaugh KL, 2010, J AM SOC NEPHROL, V21, P1979, DOI 10.1681/ASN.2009111163; Glidewell L, 2013, IMPLEMENT SCI, V8, DOI 10.1186/1748-5908-8-118; Nitsch D, 2011, NEPHROL DIAL TRANSPL, V26, P1670, DOI 10.1093/ndt/gfq561	3	2	2	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 10	2015	350								h252	10.1136/bmj.h252	http://dx.doi.org/10.1136/bmj.h252			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CB0LU	25670189	Bronze			2023-01-03	WOS:000349318400007
J	Altena, R; Fehrmann, RSN; Boer, H; de Vries, EGE; Meijer, C; Gietema, JA				Altena, Renske; Fehrmann, Rudolf S. N.; Boer, Hink; de Vries, Elisabeth G. E.; Meijer, Coby; Gietema, Jourik A.			Growth Differentiation Factor 15 (GDF-15) Plasma Levels Increase during Bleomycin- and Cisplatin-Based Treatment of Testicular Cancer Patients and Relate to Endothelial Damage	PLOS ONE			English	Article							LONG-TERM SURVIVORS; MACROPHAGE INHIBITORY CYTOKINE-1; CARDIOVASCULAR-DISEASE; ACTIVATING TRANSCRIPTION; INDUCED APOPTOSIS; 5-YEAR SURVIVORS; CELL; CHEMOTHERAPY; EXPRESSION; PLATINUM	Introduction Chemotherapy-related endothelial damage contributes to the early development of cardiovascular morbidity in testicular cancer patients. We aimed to identify relevant mechanisms of and search for candidate biomarkers for this endothelial damage. Methods Human micro-vascular endothelial cells (HMEC-1) were exposed to bleomycin or cisplatin with untreated samples as control. 18k cDNA microarrays were used. Gene expression differences were analysed at single gene level and in gene sets clustered in biological pathways and validated by qRT-PCR. Protein levels of a candidate biomarker were measured in testicular cancer patient plasma before, during and after bleomycin-etoposide-cisplatin chemotherapy, and related to endothelial damage biomarkers (von Willebrand Factor (vWF), high-sensitivity C-Reactive Protein (hsCRP)). Results Microarray data identified several genes with highly differential expression; e.g. Growth Differentiation Factor 15 (GDF-15), Activating Transcription Factor 3 (ATF3) and Amphiregulin (AREG). Pathway analysis revealed strong associations with 'p53' and 'Diabetes Mellitus' gene sets. Based on known function, we measured GDF-15 protein levels in 41 testicular patients during clinical follow-up. Pre-chemotherapy GDF-15 levels equalled controls. Throughout chemotherapy GDF-15, vWF and hsCRP levels increased, and were correlated at different time-points. Conclusion An unbiased approach in a preclinical model revealed genes related to chemotherapy-induced endothelial damage, like GDF-15. The increases in plasma GDF-15 levels in testicular cancer patients during chemotherapy and its association with vWF and hsCRP suggest that GDF-15 is a potentially useful biomarker related to endothelial damage.	[Altena, Renske; Fehrmann, Rudolf S. N.; Boer, Hink; de Vries, Elisabeth G. E.; Meijer, Coby; Gietema, Jourik A.] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Groningen, Netherlands; [Fehrmann, Rudolf S. N.] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands	University of Groningen; University of Groningen	Gietema, JA (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Groningen, Netherlands.	j.a.gietema@umcg.nl	Fehrmann, Rudolf/E-2551-2011	Fehrmann, Rudolf/0000-0002-7516-315X; de Vries, Elisabeth/0000-0002-8949-7425; Gietema, Jourik/0000-0003-0629-7354; Altena-Kornalijnslijper, Renske/0000-0001-6944-5209	Dutch Cancer Society [RUG 2009-4365]	Dutch Cancer Society(KWF Kankerbestrijding)	Support was provided by RUG 2009-4365 from the Dutch Cancer Society. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Ago T, 2006, CIRC RES, V98, P294, DOI 10.1161/01.RES.0000207919.83894.9d; ALBERTS DS, 1978, CANCER CHEMOTH PHARM, V1, P177; Breit SN, 2011, GROWTH FACTORS, V29, P187, DOI 10.3109/08977194.2011.607137; Brouwer CAJ, 2013, J CLIN ONCOL, V31, P3906, DOI 10.1200/JCO.2012.46.6086; Brown DA, 2002, LANCET, V359, P2159, DOI 10.1016/S0140-6736(02)09093-1; Cai Y, 2000, BLOOD, V96, P2140, DOI 10.1182/blood.V96.6.2140.h8002140_2140_2148; Chen SC, 2008, ATHEROSCLEROSIS, V201, P281, DOI 10.1016/j.atherosclerosis.2008.02.014; Dirix LY, 1997, ANTI-CANCER DRUG, V8, P859, DOI 10.1097/00001813-199710000-00007; Eckstein N, 2008, J BIOL CHEM, V283, P739, DOI 10.1074/jbc.M706287200; Eggers KM, 2012, SCAND J CLIN LAB INV, V72, P45, DOI 10.3109/00365513.2011.626072; Feldman DR, 2008, JAMA-J AM MED ASSOC, V299, P672, DOI 10.1001/jama.299.6.672; Fossa SD, 2004, BRIT J CANCER, V90, P607, DOI 10.1038/sj.bjc.6601558; Fu MG, 2003, GENE, V315, P33, DOI 10.1016/S0378-1119(03)00730-3; Gietema JA, 2000, LANCET, V355, P1075, DOI 10.1016/S0140-6736(00)02044-4; Hamdi M, 2008, DNA REPAIR, V7, P487, DOI 10.1016/j.dnarep.2007.12.004; Haugnes HS, 2010, J CLIN ONCOL, V28, P4649, DOI 10.1200/JCO.2010.29.9362; Hellemons ME, 2012, DIABETES CARE, V35, P2340, DOI 10.2337/dc12-0180; Herder M, 2013, OBESITY METABOLIS S3, V15, P39; Huang CY, 2007, CLIN CANCER RES, V13, P5825, DOI 10.1158/1078-0432.CCR-07-1037; Huddart RA, 2003, J CLIN ONCOL, V21, P1513, DOI 10.1200/JCO.2003.04.173; Ishii H, 2002, TOXICOL APPL PHARM, V184, P88, DOI 10.1006/taap.2002.9499; Kawauchi J, 2002, J BIOL CHEM, V277, P39025, DOI 10.1074/jbc.M202974200; Kempf T, 2006, CIRC RES, V98, P351, DOI 10.1161/01.RES.0000202805.73038.48; Kempf T, 2012, EUR J ENDOCRINOL, V167, P671, DOI 10.1530/EJE-12-0466; Kool J, 2005, ONCOGENE, V22, P4235, DOI [10.1038/sj.onc.1206611, DOI 10.1038/SJ.0NC.1206611]; L'Azou B, 2005, CELL BIOL TOXICOL, V21, P127, DOI 10.1007/s10565-005-0172-8; Lechner D, 2007, J THROMB HAEMOST, V5, P2445, DOI 10.1111/j.1538-7836.2007.02788.x; Lok DJ, 2013, AM J CARDIOL, V112, P831, DOI 10.1016/j.amjcard.2013.05.013; Mehta RS, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju016; Meinardi MT, 2000, J CLIN ONCOL, V18, P1725, DOI 10.1200/JCO.2000.18.8.1725; Montiel M, 2009, CELL PHYSIOL BIOCHEM, V23, P441, DOI 10.1159/000218191; Nawa T, 2002, ATHEROSCLEROSIS, V161, P281, DOI 10.1016/S0021-9150(01)00639-6; Nobori K, 2002, J MOL CELL CARDIOL, V34, P1387, DOI 10.1006/jmcc.2002.2091; Nuver J, 2005, J CLIN ONCOL, V23, P9130, DOI 10.1200/JCO.2005.01.4092; Nuver J, 2005, EUR J CLIN INVEST, V35, P99, DOI 10.1111/j.1365-2362.2005.01460.x; Nuver J, 2004, EUR J CANCER, V40, P701, DOI 10.1016/j.ejca.2003.12.012; Nuver J, 2010, ONCOL REP, V23, P247, DOI 10.3892/or_00000630; Shi YC, 1998, JPN J CANCER RES, V89, P757, DOI 10.1111/j.1349-7006.1998.tb03281.x; Song HJ, 2012, MOL BIOL REP, V39, P4017, DOI 10.1007/s11033-011-1182-7; Sprauten M, 2012, J CLIN ONCOL, V30, P300, DOI 10.1200/JCO.2011.37.4025; STEFENELLI T, 1988, EUR HEART J, V9, P552, DOI 10.1093/oxfordjournals.eurheartj.a062542; Strumberg D, 2002, ANN ONCOL, V13, P229, DOI 10.1093/annonc/mdf058; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Unsicker K, 2013, CYTOKINE GROWTH F R, V24, P373, DOI 10.1016/j.cytogfr.2013.05.003; Urien S, 2005, CANCER CHEMOTH PHARM, V55, P55, DOI 10.1007/s00280-004-0852-8; van den Belt-Dusebout AW, 2007, J CLIN ONCOL, V25, P4370, DOI 10.1200/JCO.2006.10.5296; van den Belt-Dusebout AW, 2006, J CLIN ONCOL, V24, P467, DOI 10.1200/JCO.2005.02.7193; Vaughn DJ, 2008, CANCER-AM CANCER SOC, V112, P1949, DOI 10.1002/cncr.23389; Weijl NI, 2000, J CLIN ONCOL, V18, P2169, DOI 10.1200/JCO.2000.18.10.2169; Wiklund FE, 2010, AGING CELL, V9, P1057, DOI 10.1111/j.1474-9726.2010.00629.x; Yu MH, 2008, CANCER SCI, V99, P391, DOI 10.1111/j.1349-7006.2008.00696.x	52	31	34	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 15	2015	10	1							e0115372	10.1371/journal.pone.0115372	http://dx.doi.org/10.1371/journal.pone.0115372			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC9HN	25590623	Green Submitted, Green Published, gold			2023-01-03	WOS:000350679400008
J	Pei, LJ; Tan, G; Wang, L; Guo, WJ; Xiao, B; Gao, XL; Wang, L; Li, H; Xu, ZH; Zhang, XH; Zhao, J; Yi, J; Huang, YG				Pei, Lijian; Tan, Gang; Wang, Lei; Guo, Wenjuan; Xiao, Bo; Gao, Xianli; Wang, Li; Li, Hong; Xu, Zhonghuang; Zhang, Xiuhua; Zhao, Jing; Yi, Jie; Huang, Yuguang			Comparison of Combined General-Epidural Anesthesia with General Anesthesia Effects on Survival and Cancer Recurrence: A Meta-Analysis of Retrospective and Prospective Studies	PLOS ONE			English	Article							SPINAL-ANESTHESIA; SURGERY; ANALGESIA; REDUCTION; PAIN; MORTALITY	Objective: Animals underwent combined general-epidural anesthesia (EGA) is reported to have better long-time outcome than general anesthesia (GA). This study aimed to make overall evaluation of the association between these two anesthetic techniques and prognosis of cancer patients undergoing surgery. Methods: Related databases such as PubMed and EMbase were searched for eligible studies that evaluated the influence of EGA and GA on the prognosis of cancer patients undergoing surgery. Selected studies were evaluated according to the inclusion criteria by two reviewers respectively, followed by data extraction and quality assessment. The odds ratio (OR) with their 95% confidence intervals (CIs) were calculated to assess the influence strength of EGA and GA on prognosis of cancer patients. Results: A total of ten studies involving 3254 patients were included. The overall results demonstrated that there was no significant difference between EGA and GA group (OR = 0.88, 95% CI 0.73 to 1.06, P = 0.187) concerning postoperative recurrence and metastasis rate. In regard to the following two factors: cancer category and time of follow-up, subgroup analysis identified significant differences between EGA and GA in the group of patients with prostate cancer and the group with follow-up less than or equal to two years (OR = 0.66, 95% CI 0.46 to 0.95, P = 0.027; OR = 0.70, 95% CI 0.51 to 0.98, P = 0.035; respectively) concerning postoperative recurrence and metastasis rate. However, no significant difference was found in the group of patients with colorectal cancer (OR = 1.06, 95% CI 0.84-1.33, P = 0.62). Conclusions: This meta-analysis showed that EGA might be associated with improvement in prognosis of patients with operable prostate cancer and the cancer patients with follow-up less than or equal to two years. However, no obvious relationship between the improvement in prognosis of colorectal cancer and EGA were detected, comparing to GA. Furthermore, all the results should be interpreted cautiously, as heterogeneous data were used for analyzing.	[Pei, Lijian; Tan, Gang; Wang, Lei; Guo, Wenjuan; Xiao, Bo; Gao, Xianli; Li, Hong; Xu, Zhonghuang; Zhang, Xiuhua; Zhao, Jing; Yi, Jie; Huang, Yuguang] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Anesthesiol, Beijing 100730, Peoples R China; [Wang, Li] Chinese Acad Med Sci, Inst Basic Med Sci, Dept Epidemiol & Biostat, Beijing 100005, Peoples R China; [Wang, Li] Peking Union Med Coll, Sch Basic Med, Beijing 100005, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Huang, YG (corresponding author), Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Anesthesiol, Beijing 100730, Peoples R China.	hyug1999@163.com		lijian, Pei/0000-0001-7174-9105				Bar-Yosef S, 2001, ANESTHESIOLOGY, V94, P1066, DOI 10.1097/00000542-200106000-00022; BEILIN B, 1989, Brain Behavior and Immunity, V3, P129, DOI 10.1016/0889-1591(89)90013-5; Biki B, 2008, ANESTHESIOLOGY, V109, P180, DOI 10.1097/ALN.0b013e31817f5b73; Binczak M, 2013, Ann Fr Anesth Reanim, V32, pe81, DOI 10.1016/j.annfar.2013.02.027; Casati L, 2002, ANESTH ANALG, V94, P1331, DOI 10.1097/00000539-200205000-00053; Christopherson R, 2008, ANESTH ANALG, V107, P325, DOI 10.1213/ane.0b013e3181770f55; Cummings KC, 2012, ANESTHESIOLOGY, V116, P797, DOI 10.1097/ALN.0b013e31824674f6; ERSKINE R, 1992, CAN J ANAESTH, V39, P905, DOI 10.1007/BF03008337; Exadaktylos AK, 2006, ANESTHESIOLOGY, V105, P660, DOI 10.1097/00000542-200610000-00008; Fodale V, 2014, SCI WORLD J, DOI 10.1155/2014/328513; Forget P, 2010, EUR J ANAESTH, V27, P233, DOI 10.1097/EJA.0b013e32832d540e; Gottschalk A, 2010, ANESTHESIOLOGY, V113, P27, DOI 10.1097/ALN.0b013e3181de6d0d; Gupta A, 2011, BRIT J ANAESTH, V107, P164, DOI 10.1093/bja/aer100; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hiller JG, 2014, ACTA ANAESTH SCAND, V58, P281, DOI 10.1111/aas.12255; Hiller JG, 2014, ACTA ANAESTHESIOL SC; Kaneda Kazuhiro, 2006, Masui, V55, P900; Lacassie HJ, 2013, ANESTH ANALG, V117, P653, DOI 10.1213/ANE.0b013e3182a07046; Landoni G, 2012, J CARDIOTHOR VASC AN, V26, P764, DOI 10.1053/j.jvca.2012.04.018; LEWIS J W, 1983, Natural Immunity and Cell Growth Regulation, V3, P43; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Lirk P, 2013, MINERVA ANESTESIOL; MARKOVIC SN, 1993, ANESTHESIOLOGY, V78, P700, DOI 10.1097/00000542-199304000-00013; Merquiol Fanette, 2013, Reg Anesth Pain Med, V38, P398, DOI 10.1097/AAP.0b013e31829cc3fb; Mora S, 2010, CIRCULATION, V121, P1069, DOI 10.1161/CIRCULATIONAHA.109.906479; Myles PS, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1491; Rittner HL, 2008, BRIT J ANAESTH, V101, P40, DOI 10.1093/bja/aen078; Rittner HL, 2002, ANAESTHESIST, V51, P351, DOI 10.1007/s00101-002-0306-9; Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493; Snyder GL, 2010, BRIT J ANAESTH, V105, P106, DOI 10.1093/bja/aeq164; Sotunmbi P, 1999, AFRICAN J MED MED SC, V29, P319; Sotunmbi P T, 2000, Afr J Med Med Sci, V29, P319; Tsui BCH, 2010, CAN J ANAESTH, V57, P107, DOI 10.1007/s12630-009-9214-7; Urwin SC, 2000, BRIT J ANAESTH, V84, P450, DOI 10.1093/oxfordjournals.bja.a013468; Wells GA, 2011, NEWCASTLE OTTAWA SCA; Wijeysundera DN, 2008, LANCET, V372, P562, DOI 10.1016/S0140-6736(08)61121-6; Wuethrich PY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072873; Wuethrich PY, 2010, ANESTHESIOLOGY, V113, P570, DOI 10.1097/ALN.0b013e3181e4f6ec; Zhou D, 2012, WORLD J GASTROENTERO, V18, P3089, DOI 10.3748/wjg.v18.i24.3089	39	45	49	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 30	2014	9	12							e114667	10.1371/journal.pone.0114667	http://dx.doi.org/10.1371/journal.pone.0114667			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX6YH	25548913	Green Published, Green Submitted, gold			2023-01-03	WOS:000347063500008
J	Yang, LZ; Zhang, W; Shi, B; Yang, ZY; Wei, ZD; Gu, F; Zhang, J; Cui, GB; Liu, Y; Zhou, YF; Zhang, XC; Rao, HY				Yang, Li-Zhuang; Zhang, Wei; Shi, Bin; Yang, Zhiyu; Wei, Zhengde; Gu, Feng; Zhang, Jing; Cui, Guanbao; Liu, Ying; Zhou, Yifeng; Zhang, Xiaochu; Rao, Hengyi			Electrical Stimulation over Bilateral Occipito-Temporal Regions Reduces N170 in the Right Hemisphere and the Composite Face Effect	PLOS ONE			English	Article							NONINVASIVE BRAIN-STIMULATION; ACQUIRED PROSOPAGNOSIA; PREFRONTAL CORTEX; INTERHEMISPHERIC CONNECTIVITY; EXTRASTRIATE CORTEX; RECOGNITION ABILITY; VISUAL-CORTEX; MOTOR CORTEX; PERCEPTION; TDCS	Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique that can modulate cortical excitability. Although the clinical value of tDCS has been advocated, the potential of tDCS in cognitive rehabilitation of face processing deficits is less understood. Face processing has been associated with the occipito-temporal cortex (OT). The present study investigated whether face processing in healthy adults can be modulated by applying tDCS over the OT. Experiment 1 investigated whether tDCS can affect N170, a face-sensitive ERP component, with a face orientation judgment task. The N170 in the right hemisphere was reduced in active stimulation conditions compared with the sham stimulation condition for both upright faces and inverted faces. Experiment 2 further demonstrated that tDCS can modulate the composite face effect, a type of holistic processing that reflects the obligatory attention to all parts of a face. The composite face effect was reduced in active stimulation conditions compared with the sham stimulation condition. Additionally, the current polarity did not modulate the effect of tDCS in the two experiments. The present study demonstrates that N170 can be causally manipulated by stimulating the OT with weak currents. Furthermore, our study provides evidence that obligatory attention to all parts of a face can be affected by the commonly used tDCS parameter setting.	[Yang, Li-Zhuang; Zhang, Wei; Yang, Zhiyu; Wei, Zhengde; Gu, Feng; Cui, Guanbao; Zhou, Yifeng; Zhang, Xiaochu] Univ Sci & Technol China, CAS Key Lab Brain Funct & Dis, Hefei, Anhui, Peoples R China; [Yang, Li-Zhuang; Zhang, Wei; Yang, Zhiyu; Wei, Zhengde; Gu, Feng; Cui, Guanbao; Zhou, Yifeng; Zhang, Xiaochu] Univ Sci & Technol China, Sch Life Sci, Hefei, Anhui, Peoples R China; [Shi, Bin; Liu, Ying] Anhui Med Univ, Prov Hosp, Hefei, Anhui, Peoples R China; [Zhang, Jing] Anhui Univ Chinese Med, Affiliated Hosp 1, Hefei, Anhui, Peoples R China; [Zhang, Xiaochu] Chinese Acad Sci, Ctr Med Phys & Technol, Hefei Inst Phys Sci, Hefei, Anhui, Peoples R China; [Zhang, Xiaochu] Univ Sci & Technol China, Sch Humanities & Social Sci, Hefei, Anhui, Peoples R China; [Rao, Hengyi] Univ Penn, Ctr Funct Neuroimaging, Dept Neurol & Radiol, Philadelphia, PA 19104 USA	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Anhui Medical University; Anhui University of Chinese Medicine; Chinese Academy of Sciences; Hefei Institutes of Physical Science, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; University of Pennsylvania; Pennsylvania Medicine	Yang, LZ (corresponding author), Univ Sci & Technol China, CAS Key Lab Brain Funct & Dis, Hefei, Anhui, Peoples R China.	lzyang@ustc.edu.cn; zxcustc@ustc.edu.cn	Zhang, Xiaochu/AAG-8768-2022; Rao, Hengyi/K-5152-2019; Yang, Li-Zhuang/AAJ-3623-2020; Yang, Li-Zhuang/F-3648-2016; Zhang, Xiaochu/AEW-0582-2022; Rao, Hengyi/AAQ-4919-2020; Rao, Hengyi/A-7064-2009; Zhang, Xiaochu/O-9592-2014	Yang, Li-Zhuang/0000-0002-0192-4323; Yang, Li-Zhuang/0000-0002-0192-4323; Rao, Hengyi/0000-0003-2735-2500; Rao, Hengyi/0000-0003-2735-2500; Gu, Feng/0000-0002-5954-5596; Wei, Zhengde/0000-0003-4586-0170; Zhang, Xiaochu/0000-0002-7541-0130	National Natural Science Foundation of China [31230032, 31171083, 31070984, 31471071]; Fundamental Research Funds for the Central Universities of China [WK2070000033]; 100 Talents Programme of The Chinese Academy of Sciences [BJ2070000047]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities of China(Fundamental Research Funds for the Central Universities); 100 Talents Programme of The Chinese Academy of Sciences(Chinese Academy of Sciences)	This work was supported by grants from the National Natural Science Foundation of China (31230032, 31171083, 31070984, 31471071) (http://www.nsfc.gov.cn/publish/portal0/default.htm), and the Fundamental Research Funds for the Central Universities of China (WK2070000033) (http://www.moe.edu.cn/), and 100 Talents Programme of The Chinese Academy of Sciences (BJ2070000047) (http://www.cas.cn/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Avidan G, 2011, NEUROPSYCHOLOGIA, V49, P2541, DOI 10.1016/j.neuropsychologia.2011.05.002; Azabou E, 2013, RESP PHYSIOL NEUROBI, V189, P183, DOI 10.1016/j.resp.2013.07.024; Barton JJS, 2008, J NEUROPSYCHOL, V2, P197, DOI 10.1348/174866407X214172; Barton JJS, 2009, PERCEPTION, V38, P242, DOI 10.1068/p6099; Barton JJS, 2004, PERCEPTION, V33, P939, DOI 10.1068/p5243; Bentin S, 1996, J COGNITIVE NEUROSCI, V8, P551, DOI 10.1162/jocn.1996.8.6.551; Bikson M, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00688; Boggio PS, 2008, DRUG ALCOHOL DEPEN, V92, P55, DOI 10.1016/j.drugalcdep.2007.06.011; Boggio PS, 2008, NEUROSCI LETT, V447, P101, DOI 10.1016/j.neulet.2008.10.009; Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357; Busigny T, 2010, NEUROPSYCHOLOGIA, V48, P4057, DOI 10.1016/j.neuropsychologia.2010.09.017; Busigny T, 2010, CORTEX, V46, P965, DOI 10.1016/j.cortex.2009.07.004; Cecere R, 2013, J NEUROSCI, V33, P6469, DOI 10.1523/JNEUROSCI.3431-12.2013; Dalrymple KA, 2011, NEUROPSYCHOLOGIA, V49, P2553, DOI 10.1016/j.neuropsychologia.2011.05.003; Davies-Thompson J, 2012, J NEUROPHYSIOL, V108, P3087, DOI 10.1152/jn.01171.2011; DeGutis J, 2013, COGNITION, V126, P87, DOI 10.1016/j.cognition.2012.09.004; DERENZI E, 1994, NEUROPSYCHOLOGIA, V32, P893, DOI 10.1016/0028-3932(94)90041-8; DERENZI E, 1986, NEUROPSYCHOLOGIA, V24, P385; Dzhelyova MP, 2011, J COGNITIVE NEUROSCI, V23, P2782, DOI 10.1162/jocn.2011.21604; Eimer M, 2011, BRAIN RES, V1376, P76, DOI 10.1016/j.brainres.2010.12.046; Farah MJ, 1998, PSYCHOL REV, V105, P482, DOI 10.1037/0033-295X.105.3.482; Fecteau S, 2007, J NEUROSCI, V27, P6212, DOI 10.1523/JNEUROSCI.0314-07.2007; Floel A, 2014, NEUROIMAGE, V85, P934, DOI 10.1016/j.neuroimage.2013.05.098; Fregni F, 2008, J CLIN PSYCHIAT, V69, P32, DOI 10.4088/JCP.v69n0105; Gao L, 2009, PSYCHOPHYSIOLOGY, V46, P970, DOI 10.1111/j.1469-8986.2009.00853.x; Gao ZF, 2011, ATTEN PERCEPT PSYCHO, V73, P1477, DOI 10.3758/s13414-011-0109-7; Gauthier I, 2002, J EXP PSYCHOL HUMAN, V28, P431, DOI 10.1037//0096-1523.28.2.431; Gauthier I, 2007, COGNITION, V103, P322, DOI 10.1016/j.cognition.2006.05.003; Haxby JV, 2000, TRENDS COGN SCI, V4, P223, DOI 10.1016/S1364-6613(00)01482-0; HOLE GJ, 1994, PERCEPTION, V23, P65, DOI 10.1068/p230065; Hsiao JH, 2009, PSYCHOL SCI, V20, P455, DOI 10.1111/j.1467-9280.2009.02315.x; Itier RJ, 2011, NEUROIMAGE, V54, P705, DOI 10.1016/j.neuroimage.2010.07.031; Jacobson L, 2012, EXP BRAIN RES, V216, P1, DOI 10.1007/s00221-011-2891-9; Kanwisher N, 1997, J NEUROSCI, V17, P4302; Kongthong N, 2013, NEUROSCI LETT, V544, P141, DOI 10.1016/j.neulet.2013.04.002; Kuo MF, 2014, NEUROIMAGE, V85, P948, DOI 10.1016/j.neuroimage.2013.05.117; Lafontaine MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081721; Le Grand R, 2004, PSYCHOL SCI, V15, P762, DOI 10.1111/j.0956-7976.2004.00753.x; Lindenberg R, 2013, J NEUROSCI, V33, P9176, DOI 10.1523/JNEUROSCI.0055-13.2013; Mattavelli G, 2013, NEUROIMAGE, V76, P24, DOI 10.1016/j.neuroimage.2013.03.020; Maurer D, 2007, NEUROPSYCHOLOGIA, V45, P1438, DOI 10.1016/j.neuropsychologia.2006.11.016; Maurer D, 2002, TRENDS COGN SCI, V6, P255, DOI 10.1016/S1364-6613(02)01903-4; McKone E, 2007, TRENDS COGN SCI, V11, P8, DOI 10.1016/j.tics.2006.11.002; Meinzer M, 2012, J NEUROSCI, V32, P1859, DOI 10.1523/JNEUROSCI.4812-11.2012; Mercure E, 2008, J COGNITIVE NEUROSCI, V20, P2070, DOI 10.1162/jocn.2008.20137; Moos K, 2012, J NEUROSCI, V32, P16360, DOI 10.1523/JNEUROSCI.6233-11.2012; Nasr S, 2009, J VISION, V9, DOI 10.1167/9.5.5; Nguyen V.T., 2013, NEUROIMAGE; Nitsche M A, 2012, Front Psychiatry, V3, P58, DOI 10.3389/fpsyt.2012.00058; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2011, RESTOR NEUROL NEUROS, V29, P463, DOI 10.3233/RNN-2011-0618; Okamoto M, 2004, NEUROIMAGE, V21, P99, DOI 10.1016/j.neuroimage.2003.08.026; Park CH, 2013, NEUROSCI LETT, V539, P7, DOI 10.1016/j.neulet.2013.01.047; Pitcher D, 2007, CURR BIOL, V17, P1568, DOI 10.1016/j.cub.2007.07.063; Pitcher D, 2011, EXP BRAIN RES, V209, P481, DOI 10.1007/s00221-011-2579-1; Pitcher D, 2009, CURR BIOL, V19, P319, DOI 10.1016/j.cub.2009.01.007; Ramon M, 2012, BRAIN COGNITION, V78, P7, DOI 10.1016/j.bandc.2011.10.009; Renzi C, 2013, NEUROIMAGE, V74, P45, DOI 10.1016/j.neuroimage.2013.02.015; Richler JJ, 2008, J EXP PSYCHOL LEARN, V34, P1356, DOI 10.1037/a0013080; Richler JJ, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00553; Richler JJ, 2011, J VISION, V11, DOI 10.1167/11.13.17; Richler JJ, 2011, PSYCHOL SCI, V22, P464, DOI 10.1177/0956797611401753; Richler JJ, 2009, ATTEN PERCEPT PSYCHO, V71, P530, DOI 10.3758/APP.71.3.530; Richler JJ, 2013, VIS COGN, V21; Riddoch MJ, 2008, COGN NEUROPSYCHOL, V25, P3, DOI 10.1080/02643290801920113; Rossion B, 1999, BIOL PSYCHOL, V50, P173, DOI 10.1016/S0301-0511(99)00013-7; Rossion B, 2003, NEUROIMAGE, V20, P1609, DOI 10.1016/j.neuroimage.2003.07.010; Rossion B, 2000, J COGNITIVE NEUROSCI, V12, P793, DOI 10.1162/089892900562606; Rossion B, 2013, VIS COGN, V21, P139, DOI 10.1080/13506285.2013.772929; Rossion B, 2011, VISION RES, V51, P1297, DOI 10.1016/j.visres.2011.04.003; Sadeh B, 2010, NEUROIMAGE, V53, P782, DOI 10.1016/j.neuroimage.2010.06.029; SEMLITSCH HV, 1986, PSYCHOPHYSIOLOGY, V23, P695, DOI 10.1111/j.1469-8986.1986.tb00696.x; Stagg CJ, 2011, NEUROSCIENTIST, V17, P37, DOI 10.1177/1073858410386614; Stanislaw H, 1999, BEHAV RES METH INS C, V31, P137, DOI 10.3758/BF03207704; Tanaka JW, 2006, J COGNITIVE NEUROSCI, V18, P1488, DOI 10.1162/jocn.2006.18.9.1488; TANAKA JW, 1993, Q J EXP PSYCHOL-A, V46, P225, DOI 10.1080/14640749308401045; Towler J, 2012, NEUROPSYCHOLOGIA, V50, P3588, DOI 10.1016/j.neuropsychologia.2012.10.017; Tseng P, 2012, J NEUROSCI, V32, P10554, DOI 10.1523/JNEUROSCI.0362-12.2012; Tso RVY, 2014, PSYCHOL SCI, V25, P1757, DOI 10.1177/0956797614541284; Utz KS, 2010, NEUROPSYCHOLOGIA, V48, P2789, DOI 10.1016/j.neuropsychologia.2010.06.002; Van Belle G, 2011, NEUROPSYCHOLOGIA, V49, P3145, DOI 10.1016/j.neuropsychologia.2011.07.010; Wang RS, 2012, PSYCHOL SCI, V23, P169, DOI 10.1177/0956797611420575; Watanabe S, 2003, NEUROSCIENCE, V116, P879, DOI 10.1016/S0306-4522(02)00752-2; Wong ACN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008405; Wong ACN, 2009, PSYCHOL SCI, V20, P1108, DOI 10.1111/j.1467-9280.2009.02430.x; Young A., 1987, PERCEPTION, V10, P747, DOI DOI 10.1068/P160747; Yovel G, 2008, NEUROPSYCHOLOGIA, V46, P3061, DOI 10.1016/j.neuropsychologia.2008.06.017; Zhou GM, 2012, PSYCHON B REV, V19, P157, DOI 10.3758/s13423-011-0174-x	88	10	10	2	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 22	2014	9	12							e115772	10.1371/journal.pone.0115772	http://dx.doi.org/10.1371/journal.pone.0115772			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA3ZY	25531112	gold, Green Published, Green Submitted			2023-01-03	WOS:000348845100106
J	Pastor-Clerigues, A; Marti-Bonmati, E; Milara, J; Almudever, P; Cortijo, J				Pastor-Clerigues, Alfonso; Marti-Bonmati, Ezequiel; Milara, Javier; Almudever, Patricia; Cortijo, Julio			Anti-Inflammatory and Anti-Fibrotic Profile of Fish Oil Emulsions Used in Parenteral Nutrition-Associated Liver Disease	PLOS ONE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; INTESTINAL FAILURE; FATTY-ACIDS; HEPATIC-FIBROSIS; OMEGA-3-FATTY-ACIDS; CHILDREN; HEPATOCYTES; FIBROBLASTS; RECRUITMENT; ADULT	Home parenteral nutrition (PN) is associated with many complications including severe hepatobiliary dysfunction. Commercial omega-6 fatty acid-soybean based-lipid emulsions in PN may mediate long term PN associate liver disease (PNALD) whereas omega-3-fish oil parenteral emulsions have shown to reverse PNALD in children. However, its clinical effectiveness in adults has been scarcely reported. In this work, we study the role of soybean and fish oil lipid commercial emulsions on inflammatory and profibrotic liver markers in adults with long term PNALD and in in vitro cellular models. Inflammatory and profibrotic markers were measured in serum of ten adults with long term PNALD and in culture supernatants of monocytes. Liver epithelial to mesenchymal transition (EMT) was induced by transforming growth factor beta 1 (TGF beta 1) to evaluate in vitro liver fibrosis. Omegaven (R), a 100% fish oil commercial emulsion, was infused during four months in two patients with severe long term PNALD reversing, at the first month, the inflammatory, profibrotic and clinical parameters of PNALD. The effect was maintained during the treatment course but impaired when conventional lipid emulsions were reintroduced. The other patients under chronic soybean oil-based PN showed elevated inflammatory and profibrotic parameters. In vitro human monocytes stimulated with lipopolysaccharide induced a strong inflammatory response that was suppressed by Omegaven (R), but increased by soybean emulsions. In other experiments, TGFb1 induced EMT that was suppressed by Omegaven (R) and enhanced by soybean oil lipid emulsions. Omegaven (R) improves clinical, anti-inflammatory and anti-fibrotic parameters in adults with long-term home PNALD.	[Pastor-Clerigues, Alfonso; Marti-Bonmati, Ezequiel; Milara, Javier] Univ Gen Hosp Consortium, Hosp Pharm, Clin Nutr Unit, Valencia, Spain; [Milara, Javier; Cortijo, Julio] Univ Gen Hosp Consortium, Clin Res Unit UIC, Valencia, Spain; [Milara, Javier; Cortijo, Julio] Gen Hosp Valencia, Res Fdn, Valencia, Spain; [Almudever, Patricia; Cortijo, Julio] Univ Valencia, Fac Med, Dept Pharmacol, Valencia, Spain; [Milara, Javier; Cortijo, Julio] CIBERES, Hlth Inst Carlos III, Valencia, Spain	University of Valencia; CIBER - Centro de Investigacion Biomedica en Red; CIBERES	Milara, J (corresponding author), Univ Gen Hosp Consortium, Hosp Pharm, Clin Nutr Unit, Valencia, Spain.	xmilara@hotmail.com		MILARA, JAVIER/0000-0001-6033-4211	proyecots de investigacion fundamental no orientada (SAF) [2011-26443]; fondo de investigaciones sanitarias (FIS) [CP11/00293]; centro de investigacion biomedica en red de enfermedades respiratorias (CIBERES) [CB06/06/0027]; Spanish Government [ADE10/00020]; Regional Government Prometeo "Generalitat Valenciana" [II/2013/014]; "centro para el desarrollo tecnologico e industrial (CENIT)'' programme (Spanish Government)	proyecots de investigacion fundamental no orientada (SAF); fondo de investigaciones sanitarias (FIS)(Instituto de Salud Carlos III); centro de investigacion biomedica en red de enfermedades respiratorias (CIBERES); Spanish Government(Spanish GovernmentEuropean Commission); Regional Government Prometeo "Generalitat Valenciana"; "centro para el desarrollo tecnologico e industrial (CENIT)'' programme (Spanish Government)	This work was supported by grants from "proyecots de investigacion fundamental no orientada (SAF) 2011-26443 (JC)'', "fondo de investigaciones sanitarias (FIS) CP11/00293(JM)'', "centro de investigacion biomedica en red de enfermedades respiratorias (CIBERES) CB06/06/0027'', Spanish Government ADE10/00020 (JC), as well as research grants from Regional Government Prometeo II/2013/014 (JC, JM) "Generalitat Valenciana.'' Support from the "centro para el desarrollo tecnologico e industrial (CENIT)'' programme (Spanish Government) was obtained. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282; Bianchini F, 2012, BRIT J NUTR, V108, P2129, DOI 10.1017/S0007114512000359; Braunersreuther V, 2012, WORLD J GASTROENTERO, V18, P727, DOI 10.3748/wjg.v18.i8.727; Burns DL, 2013, JPEN-PARENTER ENTER, V37, P274, DOI 10.1177/0148607112450301; Carter BA, 2007, SEMIN LIVER DIS, V27, P251, DOI 10.1055/s-2007-985070; Cavicchi M, 2000, ANN INTERN MED, V132, P525, DOI 10.7326/0003-4819-132-7-200004040-00003; Chan S, 1999, SURGERY, V126, P28, DOI 10.1067/msy.1999.98925; Chen WJ, 2003, NUTRITION, V19, P275, DOI 10.1016/S0899-9007(02)01009-2; CLAYTON PT, 1993, GASTROENTEROLOGY, V105, P1806, DOI 10.1016/0016-5085(93)91079-W; Dudrick SJ, 2003, JPEN-PARENTER ENTER, V27, P291, DOI 10.1177/0148607103027004291; Fermino ML, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026004; Galbois A, 2009, HEPATOLOGY, V49, P175, DOI 10.1002/hep.22582; Goulet O, 2009, CURR OPIN ORGAN TRAN, V14, P256, DOI 10.1097/MOT.0b013e32832ac06f; Hasegawa T, 2001, ALIMENT PHARM THERAP, V15, P1667, DOI 10.1046/j.1365-2036.2001.01083.x; Hellerbrand C, 1999, J HEPATOL, V30, P77, DOI 10.1016/S0168-8278(99)80010-5; Karlmark KR, 2009, HEPATOLOGY, V50, P261, DOI 10.1002/hep.22950; Kelly DA, 1998, NUTRITION, V14, P153, DOI 10.1016/S0899-9007(97)00232-3; Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Le HD, 2010, JPEN-PARENTER ENTER, V34, P477, DOI 10.1177/0148607110371806; Leber B, 2009, WIEN KLIN WOCHENSCHR, V121, P732, DOI 10.1007/s00508-009-1288-2; Lee S, 2007, HEPATOLOGY, V45, P841, DOI 10.1002/hep.21645; Mercer DF, 2013, J PEDIATR GASTR NUTR, V56, P364, DOI 10.1097/MPG.0b013e31827e208c; Milara J, 2013, THORAX, V68, P410, DOI 10.1136/thoraxjnl-2012-201761; Mukhopadhyay P, 2014, HEPATOLOGY, V59, P1998, DOI 10.1002/hep.26763; Pellicoro A, 2014, NAT REV IMMUNOL, V14, P181, DOI 10.1038/nri3623; Puiggros C, 2009, JPEN-PARENTER ENTER, V33, P501, DOI 10.1177/0148607109333001; Raptis DA, 2014, J HEPATOL, V60, P625, DOI 10.1016/j.jhep.2013.11.006; Sala-Vila A, 2007, CURR OPIN CLIN NUTR, V10, P165, DOI 10.1097/MCO.0b013e32802bf787; Segovia-Silvestre T, 2011, FIBROGENESIS TISSUE, V4, DOI 10.1186/1755-1536-4-19; Sitia G, 2004, J CLIN INVEST, V113, P1158, DOI 10.1172/JCI200421087; Soden JS, 2010, J PEDIATR-US, V156, P327, DOI 10.1016/j.jpeds.2009.08.033; Strandberg K, 2010, PULM PHARMACOL THER, V23, P316, DOI 10.1016/j.pupt.2010.03.004; Suri S, 2008, BIOCHEM PHARMACOL, V76, P645, DOI 10.1016/j.bcp.2008.06.010; Valdes F, 2002, MOL CANCER RES, V1, P68; Vanek VW, 2012, NUTR CLIN PRACT, V27, P150, DOI 10.1177/0884533612439896; Venecourt-Jackson E, 2013, NUTRITION, V29, P356, DOI 10.1016/j.nut.2012.07.009; Wall R, 2010, NUTR REV, V68, P280, DOI 10.1111/j.1753-4887.2010.00287.x; Wanten GJA, 2007, AM J CLIN NUTR, V85, P1171; Xu ZW, 2012, CLIN NUTR, V31, P217, DOI 10.1016/j.clnu.2011.10.001; Xue ZF, 2013, WORLD J GASTROENTERO, V19, P1380, DOI 10.3748/wjg.v19.i9.1380; Zeisberg M, 2007, J BIOL CHEM, V282, P23337, DOI 10.1074/jbc.M700194200	42	29	29	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2014	9	12							e115404	10.1371/journal.pone.0115404	http://dx.doi.org/10.1371/journal.pone.0115404			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AW6JI	25502575	Green Published, gold, Green Submitted			2023-01-03	WOS:000346375400093
J	Zhang, XB; Jiang, XT; Du, YP; Yuan, YT; Chen, B				Zhang, Xiao-Bin; Jiang, Xing-Tang; Du, Yan-Ping; Yuan, Ya-Ting; Chen, Bo			Efficacy of Continuous Positive Airway Pressure on Testosterone in Men with Obstructive Sleep Apnea: A Meta-Analysis	PLOS ONE			English	Article							ERECTILE DYSFUNCTION; SEXUAL FUNCTION; OBESE MEN; HYPOGONADISM; SECRETION; QUALITY	Objective: To evaluate the efficacy of continuous positive airway pressure (CPAP) on serum testosterone in men with obstructive sleep apnea (OSA). Methods: Two reviewers independently searched PubMed, Cochrane library, Embase and Web of Science before June 2014. Information on characteristics of subjects, study design, pre- and post-CPAP treatment of serum total testosterone, free testosterone and sexual hormone blinding protein (SHBG) was extracted for analysis. Results: A total of 7 studies with 9 cohorts that included 232 men were pooled into meta-analysis. There was no change of total testosterone levels before and after CPAP treatment in OSA men (standardized mean difference (SMD)= -0.14, 95% CI: -0.63 to 0.34, z = 0.59, p = 0.558), even subdivided by CPAP therapeutic duration (>3 months). Meanwhile, no significant differences in free testosterone and SHBG were detected after CPAP treatment (SMD = 0.16, 95% CI: -0.09 to 0.40, z = 1.25, p = 0.211 and SMD = -0.58, 95% CI: -1.30 to 0.14, z = 1.59, p = 0.112, respectively). Conclusion: CPAP has no influence on testosterone levels in men with OSA, further large-scale, well-design interventional investigation is needed.	[Zhang, Xiao-Bin; Jiang, Xing-Tang; Du, Yan-Ping; Yuan, Ya-Ting; Chen, Bo] Xiamen Univ, Zhongshan Hosp, Dept Resp Med, Xiamen, Peoples R China	Xiamen University	Zhang, XB (corresponding author), Xiamen Univ, Zhongshan Hosp, Dept Resp Med, Xiamen, Peoples R China.	zhangxiaobincn@126.com			Fujian Provincial Health Bureau [2013-2-88]	Fujian Provincial Health Bureau	This work was supported by grant 2013-2-88 for Youth Research Fund from Fujian Provincial Health Bureau. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bahammam SA, 2011, RESP MED, V105, P1755, DOI 10.1016/j.rmed.2011.07.007; Bercea RM, 2015, CLIN RESPIR J, V9, P342, DOI 10.1111/crj.12150; Bratel T, 1999, RESP MED, V93, P1, DOI 10.1016/S0954-6111(99)90068-9; CAMARGO CA, 1983, NEW ENGL J MED, V309, P314; Canguven Onder, 2010, Arch Ital Urol Androl, V82, P143; Celec P, 2014, J ENDOCRINOL INVEST, V37, P9, DOI 10.1007/s40618-013-0003-3; CISTULLI PA, 1994, AM J RESP CRIT CARE, V149, P530, DOI 10.1164/ajrccm.149.2.8306057; Gambineri A, 2003, J ENDOCRINOL INVEST, V26, P493, DOI 10.1007/BF03345209; Giltay EJ, 2010, J SEX MED, V7, P2572, DOI 10.1111/j.1743-6109.2010.01859.x; Goncalves MA, 2005, SLEEP MED, V6, P333, DOI 10.1016/j.sleep.2005.03.001; GRUNSTEIN RR, 1989, J CLIN ENDOCR METAB, V68, P352, DOI 10.1210/jcem-68-2-352; Hoekema A, 2007, J SEX MED, V4, P1153, DOI 10.1111/j.1743-6109.2006.00341.x; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Karacan I, 1995, J SEX MARITAL THER, V21, P239, DOI 10.1080/00926239508414643; Knapp A, 2014, CLIN ENDOCRINOL, V81, P254, DOI 10.1111/cen.12401; Liao M, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0039234, 10.1371/journal.pone.0034085]; Liu P, 2011, J SLEEP RES, V20, P5; Liu PY, 2003, J CLIN ENDOCR METAB, V88, P3605, DOI 10.1210/jc.2003-030236; Luboshitzky R, 2005, OBES RES, V13, P780, DOI 10.1038/oby.2005.88; Luboshitzky R, 2003, NEUROENDOCRINOL LETT, V24, P463; Luboshitzky R, 2002, J CLIN ENDOCR METAB, V87, P3394, DOI 10.1210/jc.87.7.3394; Macrea MM, 2010, SLEEP BREATH, V14, P253, DOI 10.1007/s11325-010-0373-0; Meston N, 2003, J INTERN MED, V254, P447, DOI 10.1046/j.1365-2796.2003.01212.x; SANDBLOM RE, 1983, NEW ENGL J MED, V308, P508, DOI 10.1056/NEJM198303033080908; Suehiro M, 2014, ENDOCR PRACT, V20, p37A; Takeuchi S, 2015, SLEEP BREATH, V19, P85, DOI 10.1007/s11325-014-0966-0; Vgontzas AN, 2007, J CLIN ENDOCR METAB, V92, P4199, DOI 10.1210/jc.2007-0774; Vlkova B, 2014, ANDROLOGIA, V46, P386, DOI 10.1111/and.12092; White DP, 2005, AM J RESP CRIT CARE, V172, P1363, DOI 10.1164/rccm.200412-1631SO; Wittert G, 2012, ENDOCR REV, P33; Yassin DJ, 2014, J SEX MED, V11, P1567, DOI 10.1111/jsm.12523; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; Zhuravlev VN, 2009, ANDROLOGIA, V41, P193, DOI 10.1111/j.1439-0272.2008.00914.x	33	14	14	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 11	2014	9	12							e115033	10.1371/journal.pone.0115033	http://dx.doi.org/10.1371/journal.pone.0115033			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX8FY	25503098	gold, Green Published, Green Submitted			2023-01-03	WOS:000347146700086
J	Hua, X; Tan, SN; Bandara, HMHN; Fu, YJ; Liu, SG; Smyth, HDC				Hua, Xin; Tan, Shengnan; Bandara, H. M. H. N.; Fu, Yujie; Liu, Siguo; Smyth, Hugh D. C.			Externally Controlled Triggered-Release of Drug from PLGA Micro and Nanoparticles	PLOS ONE			English	Article							IRON-OXIDE NANOPARTICLES; PSEUDOMONAS-AERUGINOSA; POLYVINYL-ALCOHOL; IN-VITRO; CANDIDA-ALBICANS; NANOSPHERES; FIELD; CIPROFLOXACIN; MICROSPHERES; DELIVERY	Biofilm infections are extremely hard to eradicate and controlled, triggered and controlled drug release properties may prolong drug release time. In this study, the ability to externally control drug release from micro and nanoparticles was investigated. We prepared micro/nanoparticles containing ciprofloxacin (CIP) and magnetic nanoparticles encapsulated in poly (lactic-co-glycolic acid) PLGA. Both micro/nanoparticles were observed to have narrow size distributions. We investigated and compared their passive and externally triggered drug release properties based on their different encapsulation structures for the nano and micro systems. In passive release studies, CIP demonstrated a fast rate of release in first 2 days which then slowed and sustained release for approximately 4 weeks. Significantly, magnetic nanoparticles containing systems all showed ability to have triggered drug release when exposed to an external oscillating magnetic field (OMF). An experiment where the OMF was turned on and off also confirmed the ability to control the drug release in a pulsatile manner. The magnetically triggered release resulted in a 2-fold drug release increase compared with normal passive release. To confirm drug integrity following release, the antibacterial activity of released drug was evaluated in Pseudomonas aeruginosa biofilms in vitro. CIP maintained its antimicrobial activity after encapsulation and triggered release.	[Hua, Xin; Liu, Siguo] Chinese Acad Agr Sci, State Key Lab Vet Biotechnol, Harbin Vet Res Inst, Harbin 150001, Peoples R China; [Tan, Shengnan; Fu, Yujie] Northeast Forestry Univ, State Engn Lab Bioresource Ecoutilizat, Harbin, Peoples R China; [Bandara, H. M. H. N.; Smyth, Hugh D. C.] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA	Chinese Academy of Agricultural Sciences; Harbin Veterinary Research Institute, CAAS; Northeast Forestry University - China; University of Texas System; University of Texas Austin	Liu, SG (corresponding author), Chinese Acad Agr Sci, State Key Lab Vet Biotechnol, Harbin Vet Res Inst, Harbin 150001, Peoples R China.	siguo_liu@yahoo.com.cn; hugh.smyth@austin.utexas.edu	Bandara, Nihal/O-7287-2014	Bandara, Nihal/0000-0001-7652-2030; Smyth, Hugh/0000-0002-6582-5869	National Heart, Lung, and Blood Institute of the National Institutes of Health [R33HL092812-03]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R33HL092812] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The National Heart, Lung, and Blood Institute of the National Institutes of Health under R33HL092812-03 provided funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexiou C, 2002, J MAGN MAGN MATER, V252, P363, DOI 10.1016/S0304-8853(02)00605-4; Araujo J, 2009, COLLOID SURFACE B, V72, P48, DOI 10.1016/j.colsurfb.2009.03.028; Arnold MM, 2007, J CONTROL RELEASE, V121, P100, DOI 10.1016/j.jconrel.2007.05.039; Bandara HMHN, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-125; Banin E, 2005, P NATL ACAD SCI USA, V102, P11076, DOI 10.1073/pnas.0504266102; Blum JS, 2008, J CONTROL RELEASE, V129, P66, DOI 10.1016/j.jconrel.2008.04.002; Chiang WL, 2012, SMALL, V8, P3584, DOI 10.1002/smll.201201743; Cirpanli Y, 2005, J MICROENCAPSUL, V22, P877, DOI 10.1080/02652040500273878; Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318; Driscoll JA, 2007, DRUGS, V67, P351, DOI 10.2165/00003495-200767030-00003; Fernandez-Pacheco R, 2007, J MAGN MAGN MATER, V311, P318, DOI 10.1016/j.jmmm.2006.11.192; Gorner T, 1999, J CONTROL RELEASE, V57, P259, DOI 10.1016/S0168-3659(98)00121-7; Hans ML, 2002, CURR OPIN SOLID ST M, V6, P319, DOI 10.1016/S1359-0286(02)00117-1; Hergt R, 2006, J PHYS-CONDENS MAT, V18, pS2919, DOI 10.1088/0953-8984/18/38/S26; Hickey AJ, 2007, J PHARM SCI-US, V96, P1282, DOI 10.1002/jps.20916; Hilger I, 2002, ACAD RADIOL, V9, P198, DOI 10.1016/S1076-6332(03)80171-X; Hu SH, 2011, CHEM COMMUN, V47, P1776, DOI 10.1039/c0cc03998e; Jain RA, 2000, BIOMATERIALS, V21, P2475, DOI 10.1016/S0142-9612(00)00115-0; Jin Y, 2004, ARCH ORAL BIOL, V49, P789, DOI 10.1016/j.archoralbio.2004.04.011; Kini S, 2011, IEEE T MAGN, V47, P2882, DOI 10.1109/TMAG.2011.2158403; Lee SC, 1999, J CONTROL RELEASE, V59, P123, DOI 10.1016/S0168-3659(98)00185-0; Mahmoudi M, 2009, J PHYS CHEM C, V113, P9573, DOI 10.1021/jp9001516; Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377; Mao ZW, 2005, J CONTROL RELEASE, V104, P193, DOI 10.1016/j.jconrel.2005.02.005; McCarthy JR, 2007, NANOMEDICINE-UK, V2, P153, DOI 10.2217/17435889.2.2.153; McGill SL, 2009, IEEE T NANOBIOSCI, V8, P33, DOI 10.1109/TNB.2009.2017292; Meers P, 2008, J ANTIMICROB CHEMOTH, V61, P859, DOI 10.1093/jac/dkn059; Page-Clisson ME, 1998, J CONTROL RELEASE, V56, P23, DOI 10.1016/S0168-3659(98)00065-0; PARK TG, 1995, BIOMATERIALS, V16, P1123, DOI 10.1016/0142-9612(95)93575-X; Peng XH, 2008, INT J NANOMED, V3, P311; Petri-Fink A, 2005, BIOMATERIALS, V26, P2685, DOI 10.1016/j.biomaterials.2004.07.023; Pierce GE, 2005, J IND MICROBIOL BIOT, V32, P309, DOI 10.1007/s10295-005-0225-2; Pradhan P, 2010, J CONTROL RELEASE, V142, P108, DOI 10.1016/j.jconrel.2009.10.002; Ramchandani M, 1998, J CONTROL RELEASE, V54, P167, DOI 10.1016/S0168-3659(97)00113-2; RITGER P L, 1987, Journal of Controlled Release, V5, P37, DOI 10.1016/0168-3659(87)90035-6; Roca AG, 2012, IEEE T MAGN, V48, P4054, DOI 10.1109/TMAG.2012.2201459; Sahoo SK, 2002, J CONTROL RELEASE, V82, P105, DOI 10.1016/S0168-3659(02)00127-X; Shen JM, 2013, ACS APPL MATER INTER, V5, P7014, DOI 10.1021/am401277s; Soppimath KS, 2001, J CONTROL RELEASE, V70, P1, DOI 10.1016/S0168-3659(00)00339-4; Subramani K, 2009, CURR NANOSCI, V5, P135, DOI 10.2174/157341309788185406; Vert M, 1998, J CONTROL RELEASE, V53, P85, DOI 10.1016/S0168-3659(97)00240-X; WOOD DM, 2006, COCHRANE DB SYST REV, V1; Xu CJ, 2009, J AM CHEM SOC, V131, P15346, DOI 10.1021/ja905938a; Yin JH, 2006, INT J PHARMACEUT, V314, P46, DOI 10.1016/j.ijpharm.2006.01.047; Young JI, 2003, INT J PHARM, V259, P79, DOI 10.1016/S0378-5173(03)00207-2	45	33	33	1	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 5	2014	9	12							e114271	10.1371/journal.pone.0114271	http://dx.doi.org/10.1371/journal.pone.0114271			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX4MS	25479357	Green Submitted, Green Published, gold			2023-01-03	WOS:000346907200061
J	Koblizek, V; Pecen, L; Zatloukal, J; Kocianova, J; Plutinsky, M; Kolek, V; Novotna, B; Kocova, E; Pracharova, S; Tichopad, A				Koblizek, Vladimir; Pecen, Ladislav; Zatloukal, Jaromir; Kocianova, Jana; Plutinsky, Marek; Kolek, Vitezslav; Novotna, Barbora; Kocova, Eva; Pracharova, Sarka; Tichopad, Ales			Real-Life GOLD 2011 Implementation: The Management of COPD Lacks Correct Classification and Adequate Treatment	PLOS ONE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; GUIDELINE DEVELOPMENT.; COORDINATING EFFORTS; THORACIC-SOCIETY; PHYSICIANS; RECOMMENDATIONS; PREVALENCE; DIAGNOSIS	Chronic obstructive pulmonary disease (COPD) is a serious, yet preventable and treatable, disease. The success of its treatment relies largely on the proper implementation of recommendations, such as the recently released Global Strategy for Diagnosis, Management, and Prevention of COPD (GOLD 2011, of late December 2011). The primary objective of this study was to examine the extent to which GOLD 2011 is being used correctly among Czech respiratory specialists, in particular with regard to the correct classification of patients. The secondary objective was to explore what effect an erroneous classification has on inadequate use of inhaled corticosteroids (ICS). In order to achieve these goals, a multicenter, cross-sectional study was conducted, consisting of a general questionnaire and patient-specific forms. A subjective classification into the GOLD 2011 categories was examined, and then compared with the objectively computed one. Based on 1,355 patient forms, a discrepancy between the subjective and objective classifications was found in 32.8% of cases. The most common reason for incorrect classification was an error in the assessment of symptoms, which resulted in underestimation in 23.9% of cases, and overestimation in 8.9% of the patients' records examined. The specialists seeing more than 120 patients per month were most likely to misclassify their condition, and were found to have done so in 36.7% of all patients seen. While examining the subjectively driven ICS prescription, it was found that 19.5% of patients received ICS not according to guideline recommendations, while in 12.2% of cases the ICS were omitted, contrary to guideline recommendations. Furthermore, with consideration to the objectively-computed classification, it was discovered that 15.4% of patients received ICS unnecessarily, whereas in 15.8% of cases, ICS were erroneously omitted. It was therefore concluded that Czech specialists tend either to under-prescribe or overuse inhaled corticosteroids.	[Koblizek, Vladimir; Novotna, Barbora; Kocova, Eva; Pracharova, Sarka] Charles Univ Prague, Fac Med Hradec Kralove, Dept Pulm, Hradec Kralove, Czech Republic; [Koblizek, Vladimir; Novotna, Barbora; Kocova, Eva; Pracharova, Sarka] Univ Hosp Hradec Kralove, Hradec Kralove, Czech Republic; [Pecen, Ladislav; Tichopad, Ales] CEEOR Inst, Prague, Czech Republic; [Zatloukal, Jaromir; Kolek, Vitezslav] Palacky Univ Olomouc, Fac Med & Dent, Dept Resp Med & TB, Ostrava, Czech Republic; [Zatloukal, Jaromir; Kolek, Vitezslav] Univ Hosp Olomouc, Ostrava, Czech Republic; [Kocianova, Jana] Chest Clin, Ostrava, Czech Republic; [Plutinsky, Marek] Masaryk Univ, Fac Med, Dept Resp Med & TB, Brno, Czech Republic; [Plutinsky, Marek] Univ Hosp Brno, Brno, Czech Republic	Charles University Prague; University Hospital Hradec Kralove; University Hospital Hradec Kralove; Palacky University Olomouc; University Hospital Olomouc; Masaryk University Brno; University Hospital Brno	Tichopad, A (corresponding author), CEEOR Inst, Prague, Czech Republic.	tichopad@ceeor.com	Koblizek, Vladimir/AAC-5374-2019; Kocova, Eva/N-1702-2017; Pecen, Ladislav/G-7057-2014; Plutinsky, Marek/ABF-2366-2020	Kocova, Eva/0000-0002-1185-7697; Plutinsky, Marek/0000-0003-1723-3794; Koblizek, Vladimir/0000-0002-2446-2790	Boehringer Ingelheim; Czech Ministry of Health [00179906]	Boehringer Ingelheim(Boehringer Ingelheim); Czech Ministry of Health(Ministry of Health, Czech Republic)	The study was funded by Boehringer Ingelheim. The study was awarded the Czech Ministry of Health grant, number of reference: DRO(UHHK, 00179906). Boehringer Ingelheim has contributed to the study design by providing the outline for data input requested, conceiving the preliminary version of the doctors' questionnaire and supervising the study conduct throughout its course. The Czech Ministry of Health did not intervene in the study design or its conduct, except for its compliance assessment and registration. The funders had a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bellamy David, 2006, Prim Care Respir J, V15, P48, DOI 10.1016/j.pcrj.2005.11.003; Bridevaux PO, 2010, EUR RESPIR J, V36, P1259, DOI 10.1183/09031936.00004110; Buist AS, 2008, INT J TUBERC LUNG D, V12, P703; Burgers Jako S, 2012, Proc Am Thorac Soc, V9, P304, DOI 10.1513/pats.201208-067ST; Caballero A, 2008, CHEST, V133, P343, DOI 10.1378/chest.07-1361; Decramer M, 2013, ACTA CLIN BELG, V68, P325, DOI 10.2143/ACB.3403; Desalu OO, 2013, PRIM CARE RESP J, V22, P79, DOI 10.4104/pcrj.2013.00014; Dong Y. H., 2014, CHEST; Ford ES, 2014, COPD; Glaab T, 2006, INT J CHRONIC OBSTR, V3, P141; Glaab T, 2012, INT J CHRONIC OBSTR, V7, P101, DOI 10.2147/COPD.S27887; Global initiative for chronic obstructive lung disease (GOLD), 2016, GLOBAL STRATEGY DIAG; Grimshaw Jeremy M, 2012, Proc Am Thorac Soc, V9, P298, DOI 10.1513/pats.201208-066ST; Gupta Dheeraj, 2013, Lung India, V30, P228, DOI 10.4103/0970-2113.116248; Hoonhorst SJM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087443; Kew KM, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010844.pub2; Kew KM, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010115.pub2; Koblizek V, 2013, BIOMED PAP, V157, P189, DOI 10.5507/bp.2013.039; Lee H, 2013, AM FAM PHYSICIAN, V88, P655; Lucas AEM, 2008, FAM PRACT, V25, P86, DOI 10.1093/fampra/cmn006; Maio S, 2014, CURR MED RES OPIN; Maly M., 2013, Studia Pneumologica et Phthiseologica, V73, P128; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; Miravitlles M, 2014, ARCH BRONCONEUMOL, V50, P1, DOI 10.1016/S0300-2896(14)70070-5; Miravitlles M, 2009, RESP MED, V103, P714, DOI 10.1016/j.rmed.2008.11.019; Montanari Ugo, 2013, Recenti Progressi in Medicina, V104, P23, DOI 10.1701/1226.13591; National Institute of Health and Care Excellence, CHRON OBSTR PULM DIS; O'Donnell DE, 2007, CAN RESPIR J, V14, p5B, DOI 10.1155/2007/830570; Parker DR, 2013, BMC FAM PRACT, V14, DOI 10.1186/1471-2296-14-56; Poznanska Anna, 2011, Przegl Epidemiol, V65, P483; Qaseem A, 2011, ANN INTERN MED, V155, P179, DOI 10.7326/0003-4819-155-3-201108020-00008; Roche N, 2014, BMC PULM MED, V14, DOI 10.1186/1471-2466-14-56; Sarc I, 2011, J EVAL CLIN PRACT, V17, P737, DOI 10.1111/j.1365-2753.2010.01617.x; Schunemann Holger J, 2012, Proc Am Thorac Soc, V9, P215, DOI 10.1513/pats.201208-053ST; Smidth M, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-385; Valipour A, 2014, PHENOTYPES COPD CENT; Vestbo J, 2014, RESP MED, V108, P729, DOI 10.1016/j.rmed.2014.03.002; White P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075221; WHO, WHO EUR DET MORT DAT; Wilt Timothy J, 2012, Proc Am Thorac Soc, V9, P243, DOI 10.1513/pats.201208-058ST; World Health Organisation, BURD COPD; Yawn Barbara P, 2012, Proc Am Thorac Soc, V9, P219, DOI 10.1513/pats.201208-054ST	42	13	13	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 7	2014	9	11							e111078	10.1371/journal.pone.0111078	http://dx.doi.org/10.1371/journal.pone.0111078			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT3WF	25380287	Green Published, gold, Green Submitted			2023-01-03	WOS:000344863100018
J	van Rennings, L; von Munchhausen, C; Ottilie, H; Hartmann, M; Merle, R; Honscha, W; Kasbohrer, A; Kreienbrock, L				van Rennings, Lisa; von Muenchhausen, Christiane; Ottilie, Henry; Hartmann, Maria; Merle, Roswitha; Honscha, Walther; Kaesbohrer, Annemarie; Kreienbrock, Lothar			Cross-Sectional Study on Antibiotic Usage in Pigs in Germany	PLOS ONE			English	Article							ANTIMICROBIAL DRUG-USE; SWINE FARMS; VETERINARY-MEDICINE; CONSUMPTION; ONTARIO	To be able to analyze the relationship between the level of resistance and the use of antimicrobials, it is necessary to collect detailed data on antimicrobial usage. For this reason, data on antimicrobial use on 495 pig farms from entire Germany were collected and analyzed. In Germany, each application and dispensing of medicines to food-producing animals is documented in detail obligatorily by the veterinarian. This information was collected retrospectively for the year 2011. The analyses undertook separate examinations on the age groups sow, piglet, weaner and fattening pig; both the route of administration and indication per active ingredient, and active ingredient class, were evaluated. In total, 20,374 kg of antimicrobial substances were used in the study population. Tetracyclines were used in highest amounts, followed by beta-lactams, trimethoprim-sulfonamides and macrolides. Concerning the frequency of using an active substance per animal, polypeptides were most commonly administered. In all age groups, respiratory infections were the main indication for using antimicrobials, followed by intestinal diseases in piglets, weaners and fattening pigs and diseases of reproductive organs in sows. Over a period of 100 days, the median number of treatment days with one antimicrobial substance for piglets was 15 days, for weaners about 6 days, for fattening pigs about 4 days and for sows about 1 day. A multifactorial ANOVA was conducted to investigate which factors are associated with the treatment frequency. The factors "veterinarian" and "age group" were related to the treatment frequency, just as the interaction between "veterinarian" and "farm size" as well as the interaction between "veterinarian" and "age group".	[van Rennings, Lisa; von Muenchhausen, Christiane; Hartmann, Maria; Merle, Roswitha; Kreienbrock, Lothar] Univ Vet Med Hannover, WHO Collaborating Ctr Res & Training Vet Publ Hlt, Dept Biometry Epidemiol & Informat Proc, Hannover, Germany; [Ottilie, Henry; Honscha, Walther] Univ Leipzig, Fac Vet, Inst Pharmacol Pharm & Toxicol, D-04109 Leipzig, Germany; [Kaesbohrer, Annemarie] Fed Inst Risk Assessment, Berlin, Germany	University of Veterinary Medicine Hannover, Foundation; Leipzig University; Federal Institute for Risk Assessment	van Rennings, L (corresponding author), Univ Vet Med Hannover, WHO Collaborating Ctr Res & Training Vet Publ Hlt, Dept Biometry Epidemiol & Informat Proc, Hannover, Germany.	lisa.van.rennings@tiho-hannover.de		Merle, Roswitha/0000-0002-8688-2926	Federal Institute for Risk Assessment, Berlin [FK 1329-441, FK 1329-482]	Federal Institute for Risk Assessment, Berlin	This study was supported by research grants from the Federal Institute for Risk Assessment, Diedersdorfer Weg 1, D-12277 Berlin (Grant No.: FK 1329-441 and FK 1329-482). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aarestrup FM, 2010, AM J VET RES, V71, P726, DOI 10.2460/ajvr.71.7.726; Arnold S, 2004, PHARMACOEPIDEM DR S, V13, P323, DOI 10.1002/pds.874; AURES, 2013, RES OST AURES 2012 A; Bondt N, 2013, PREV VET MED, V108, P10, DOI 10.1016/j.prevetmed.2012.07.009; Bos MEH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077525; BTK ArgeVET, 2000, DTSCH TIERARZTEBLATT, V48; Bundesamt Statistisches, 2012, LAND UND FORSTW FISC; Callens B, 2012, PREV VET MED, V106, P53, DOI 10.1016/j.prevetmed.2012.03.001; Casal J, 2007, VET RES, V38, P481, DOI 10.1051/vetres:2007010; Chauvin C, 2002, PREV VET MED, V55, P109, DOI 10.1016/S0167-5877(02)00091-0; Chavin C, 2001, VET RES, V32, P533, DOI 10.1051/vetres:2001145; DANMAP,, 2021, US ANT AG OCC ANT RE; DART, 2011, DART DTSCH ANT RES; Dunlop RH, 1998, CAN VET J, V39, P87; Dunlop RH, 1998, PREV VET MED, V34, P247, DOI 10.1016/S0167-5877(97)00093-7; EMA, 2013, EMA2864162012REV1; European commission, 2003, OFFICIAL J, VL268, P29; European Medicines Agency (EMA), 2013, SAL VET ANT AG 25 EU; Hajek P, 2009, J VET PHARMACOL THER, V32, P60; Jensen VF, 2012, J VET PHARMACOL THER, V35, P33, DOI 10.1111/j.1365-2885.2011.01291.x; Jensen VF, 2004, PREV VET MED, V64, P201, DOI 10.1016/j.prevetmed.2004.04.001; Jordan D, 2009, AUST VET J, V87, P222, DOI 10.1111/j.1751-0813.2009.00430.x; KTBL, 2012, BETR LANDW 2012 13 K; LAVES, 2011, BER ANT LANDW NUTZT; MARAN, 2013, MARAN 2012 MON ANT R; Merle R, 2014, BMC VET RES, V10, DOI 10.1186/1746-6148-10-7; Merle R, 2013, BERL MUNCH TIERARZTL, V126, P326, DOI 10.2376/0005-9366-126-326; Merle R, 2012, PREV VET MED, V104, P34, DOI 10.1016/j.prevetmed.2011.10.013; Merle R, 2012, BERL MUNCH TIERARZTL, V125, P52, DOI 10.2376/0005-9366-125-52; Mollenhauer Y., 2010, THESIS TIERARZTLICHE; Moreno MA, 2012, VET REC, V171, DOI 10.1136/vr.100818; Morley PS, 2005, J VET INTERN MED, V19, P617, DOI 10.1892/0891-6640(2005)19[617:ADUIVM]2.0.CO;2; Rajic A, 2006, CAN VET J, V47, P446; Robanus M, 2011, THESIS U LEIPZIG; Sanchez-Vazquez MJ, 2012, PREV VET MED, V104, P65, DOI 10.1016/j.prevetmed.2011.11.003; SVARM, 2013, SVARM 2012 SWED VET; Timmerman T, 2006, PREV VET MED, V74, P251, DOI 10.1016/j.prevetmed.2005.10.003; Ungemach FR, 2006, INT J MED MICROBIOL, V296, P33, DOI 10.1016/j.ijmm.2006.01.059; van der Fels-Klerx HJ, 2011, J ANIM SCI, V89, P1922, DOI 10.2527/jas.2010-3046; van Rennings L, 2014, BERL MUNCH TIERARZTL, V127, P10; van Rennings L, 2013, BERL MUNCH TIERARZTL, V126, P297, DOI 10.2376/0005-9366-126-297; Vieira AR, 2011, EPIDEMIOL INFECT, V139, P1601, DOI 10.1017/S0950268810002724; Wallmann J, 2013, DT TIERARZTEBL, V9, P1230; Wassenaar TM, 2005, CRIT REV MICROBIOL, V31, P155, DOI 10.1080/10408410591005110; WHO, 2009, ATC DDD IND 2013; WHO, 2011, WHO CRIT IMP ANT HUM	46	87	89	0	39	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 18	2015	10	3							e0119114	10.1371/journal.pone.0119114	http://dx.doi.org/10.1371/journal.pone.0119114			28	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE9BN	25785688	gold, Green Submitted, Green Published			2023-01-03	WOS:000352138500075
J	Thomas, KH; Martin, RM; Knipe, DW; Higgins, JPT; Gunnell, D				Thomas, Kyla H.; Martin, Richard M.; Knipe, Duleeka W.; Higgins, Julian P. T.; Gunnell, David			Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RECEPTOR PARTIAL AGONIST; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND PLACEBO; SUSTAINED-RELEASE BUPROPION; SMOKING-CESSATION; SMOKELESS TOBACCO; BIPOLAR DISORDER; CLINICAL-TRIAL; EFFICACY; SAFETY	Objective To determine the risk of neuropsychiatric adverse events associated with use of varenicline compared with placebo in randomised controlled trials. Design Systematic review and meta-analysis comparing study effects using two summary estimates in fixed effects models, risk differences, and Peto odds ratios. Data sources Medline, Embase, PsycINFO, the Cochrane Central Register of Controlled Trials (CENTRAL), and clinicaltrials.gov. Eligibility criteria for selecting studies Randomised controlled trials with a placebo comparison group that reported on neuropsychiatric adverse events (depression, suicidal ideation, suicide attempt, suicide, insomnia, sleep disorders, abnormal dreams, somnolence, fatigue, anxiety) and death. Studies that did not involve human participants, did not use the maximum recommended dose of varenicline (1 mg twice daily), and were cross over trials were excluded. Results In the 39 randomised controlled trials (10 761 participants), there was no evidence of an increased risk of suicide or attempted suicide (odds ratio 1.67, 95% confidence interval 0.33 to 8.57), suicidal ideation (0.58, 0.28 to 1.20), depression (0.96, 0.75 to 1.22), irritability (0.98, 0.81 to 1.17), aggression (0.91, 0.52 to 1.59), or death (1.05, 0.47 to 2.38) in the varenicline users compared with placebo users. Varenicline was associated with an increased risk of sleep disorders (1.63, 1.29 to 2.07), insomnia (1.56, 1.36 to 1.78), abnormal dreams (2.38, 2.05 to 2.77), and fatigue (1.28, 1.06 to 1.55) but a reduced risk of anxiety (0.75, 0.61 to 0.93). Similar findings were observed when risk differences were reported. There was no evidence for a variation in depression and suicidal ideation by age group, sex, ethnicity, smoking status, presence or absence of psychiatric illness, and type of study sponsor (that is, pharmaceutical industry or other). Conclusions This meta-analysis found no evidence of an increased risk of suicide or attempted suicide, suicidal ideation, depression, or death with varenicline. These findings provide some reassurance for users and prescribers regarding the neuropsychiatric safety of varenicline. There was evidence that varenicline was associated with a higher risk of sleep problems such as insomnia and abnormal dreams. These side effects, however, are already well recognised. Systematic review registration PROSPERO 2014: CRD42014009224.	[Thomas, Kyla H.; Martin, Richard M.; Knipe, Duleeka W.; Higgins, Julian P. T.; Gunnell, David] Univ Bristol, Sch Social & Community Med, Bristol BS8 2PS, Avon, England	University of Bristol	Thomas, KH (corresponding author), Univ Bristol, Sch Social & Community Med, Bristol BS8 2PS, Avon, England.	Thomaskyla.thomas@bristol.ac.uk	Gunnell, David/ABE-6653-2020; Higgins, Julian PT/H-4008-2011	Gunnell, David/0000-0002-0829-6470; Higgins, Julian PT/0000-0002-8323-2514; Knipe, Duleeka/0000-0002-1040-7635; Thomas, Kyla/0000-0001-5418-4034; Martin, Richard/0000-0002-7992-7719	National Institute for Health Research; National Institute for Health Research [DRF-2010-03-138]; Wellcome Trust [WT099874MA]; Academy of Medical Sciences (AMS) [AMS-SGCL12-Thomas] Funding Source: researchfish; National Institute for Health Research [NF-SI-0512-10068, CL-2013-25-003] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR)); National Institute for Health Research(National Institute for Health Research (NIHR)); Wellcome Trust(Wellcome Trust); Academy of Medical Sciences (AMS)(Academy of Medical Sciences (AMS)); National Institute for Health Research(National Institute for Health Research (NIHR))	KHT is currently funded by a clinical lectureship from the National Institute for Health Research. Part of this work was undertaken while KHT was on a National Institute for Health Research doctoral research fellowship (DRF-2010-03-138). DWK is funded by a Wellcome Trust four year studentship (WT099874MA). DG is an NIHR senior investigator. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research, or the Department of Health.	Allender S, 2009, TOB CONTROL, V18, P262, DOI 10.1136/tc.2008.026294; [Anonymous], 2008, SMOK CESS SERV PRIM; Anthenelli RM, 2013, ANN INTERN MED, V159, P390, DOI 10.7326/0003-4819-159-6-201309170-00005; Bolliger CT, 2011, CLIN THER, V33, P465, DOI 10.1016/j.clinthera.2011.04.013; Bradburn MJ, 2007, STAT MED, V26, P53, DOI 10.1002/sim.2528; Brandon TH, 2011, PSYCHOPHARMACOLOGY, V218, P391, DOI 10.1007/s00213-011-2327-z; Burstein AH, 2006, J CLIN PHARMACOL, V46, P1234, DOI 10.1177/0091270006291837; Cahill K, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD009329.pub2, 10.1002/14651858.CD006103.pub6]; Chengappa KNR, 2014, J CLIN PSYCHIAT, V75, P765, DOI 10.4088/JCP.13m08756; Cinciripini PM, 2013, JAMA PSYCHIAT, V70, P522, DOI 10.1001/jamapsychiatry.2013.678; Ebbert JO, 2011, NICOTINE TOB RES, V13, P820, DOI 10.1093/ntr/ntr078; Etter JF, 2007, ADDICTION, V102, P815, DOI 10.1111/j.1360-0443.2007.01822.x; Evins AE, 2014, JAMA-J AM MED ASSOC, V311, P145, DOI 10.1001/jama.2013.285113; Faessel H, 2009, CLIN THER, V31, P177, DOI 10.1016/j.clinthera.2009.01.003; Fagerstrom K, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c6549; Fatemi SH, 2013, SCHIZOPHR RES, V146, P376, DOI 10.1016/j.schres.2013.02.015; Garza D, 2011, BIOL PSYCHIAT, V69, P1075, DOI 10.1016/j.biopsych.2010.12.005; Gibbons RD, 2013, AM J PSYCHIAT, V170, P1460, DOI 10.1176/appi.ajp.2013.12121599; Gonzales D, 2014, CLIN PHARMACOL THER, V96, P390, DOI 10.1038/clpt.2014.124; Gonzales D, 2006, JAMA-J AM MED ASSOC, V296, P47, DOI 10.1001/jama.296.1.47; Gunnell D, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b3805; Harbord RM, 2009, STATA J, V9, P197, DOI 10.1177/1536867X0900900202; Harris RJ, 2008, STATA J, V8, P3, DOI 10.1177/1536867X0800800102; Higgins J. P., 2011, COCHRANE HDB SYST RE, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hong LE, 2011, ARCH GEN PSYCHIAT, V68, P1195, DOI 10.1001/archgenpsychiatry.2011.83; Huang YB, 2012, J PUBLIC HEALTH-HEID, V20, P355, DOI 10.1007/s10389-011-0476-5; Hughes JR, 2011, NICOTINE TOB RES, V13, P955, DOI 10.1093/ntr/ntr103; Jha P, 2014, NEW ENGL J MED, V370, P60, DOI 10.1056/NEJMra1308383; Jorenby DE, 2006, JAMA-J AM MED ASSOC, V296, P56, DOI 10.1001/jama.296.1.56; Kishi T, 2014, EUR ARCH PSYCHIAT CL; Litten RZ, 2013, J ADDICT MED, V7, P277, DOI 10.1097/ADM.0b013e31829623f4; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; McClure EA, 2013, NICOTINE TOB RES, V15, P139, DOI 10.1093/ntr/nts101; McKee SA, 2009, BIOL PSYCHIAT, V66, P185, DOI 10.1016/j.biopsych.2009.01.029; Medicines and Healthcare Products Regulatory Agency, 2008, DRUG SAFETY UPDATE, V2, P2; Meszaros ZS, 2013, J CLIN PSYCHOPHARM, V33, P243, DOI 10.1097/JCP.0b013e3182870551; Meyer TE, 2013, ADDICTION, V108, P203, DOI 10.1111/j.1360-0443.2012.04024.x; Miller M, 2000, AM J PUBLIC HEALTH, V90, P768, DOI 10.2105/AJPH.90.5.768; Miller M, 2000, AM J EPIDEMIOL, V151, P1060, DOI 10.1093/oxfordjournals.aje.a010148; Mitchell JM, 2012, PSYCHOPHARMACOLOGY, V223, P299, DOI 10.1007/s00213-012-2717-x; Mocking RJT, 2013, NEUROPSYCHOPHARMACOL, V38, P476, DOI 10.1038/npp.2012.205; Nakamura M, 2007, CLIN THER, V29, P1040, DOI 10.1016/j.clinthera.2007.06.012; Niaura R, 2008, CURR MED RES OPIN, V24, P1931, DOI [10.1185/03007990802177523, 10.1185/03007990802177523 ]; Nides M, 2006, ARCH INTERN MED, V166, P1561, DOI 10.1001/archinte.166.15.1561; Oncken C, 2006, ARCH INTERN MED, V166, P1571, DOI 10.1001/archinte.166.15.1571; Peto R, 2000, BRIT MED J, V321, P323, DOI 10.1136/bmj.321.7257.323; Plebani JG, 2013, DRUG ALCOHOL DEPEN, V133, P754, DOI 10.1016/j.drugalcdep.2013.06.019; Plebani JG, 2012, DRUG ALCOHOL DEPEN, V121, P163, DOI 10.1016/j.drugalcdep.2011.08.025; Poling J, 2010, AM J ADDICTION, V19, P401, DOI 10.1111/j.1521-0391.2010.00066.x; Prescribing and Primary Care team Health and Social Care Information Centre, 2013, PRESCR COST AN ENGL; Prochaska JJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e2856; Rennard S, 2012, NICOTINE TOB RES, V14, P343, DOI 10.1093/ntr/ntr220; Rigotti NA, 2010, CIRCULATION, V121, P221, DOI 10.1161/CIRCULATIONAHA.109.869008; Shim JC, 2012, NEUROPSYCHOPHARMACOL, V37, P660, DOI 10.1038/npp.2011.238; Singh S, 2011, CAN MED ASSOC J, V183, P1359, DOI 10.1503/cmaj.110218; Stein MD, 2013, DRUG ALCOHOL DEPEN, V133, P486, DOI 10.1016/j.drugalcdep.2013.07.005; Steinberg MB, 2011, ADDICT BEHAV, V36, P1127, DOI 10.1016/j.addbeh.2011.07.002; Sterne JAC, 2004, STATA J, V4, P127, DOI 10.1177/1536867X0400400204; Tashkin DP, 2011, CHEST, V139, P591, DOI 10.1378/chest.10-0865; Taylor G, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1151; Thomas KH, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5704; Tonnesen P, 2013, NICOTINE TOB RES, V15, P419, DOI 10.1093/ntr/nts146; Tonstad S, 2006, JAMA-J AM MED ASSOC, V296, P64, DOI 10.1001/jama.296.1.64; Tsai ST, 2007, CLIN THER, V29, P1027, DOI 10.1016/j.clinthera.2007.06.011; US Food and Drug Administration, 2009, FDA DRUG SAF NEWSL; Walker AM, 1996, EPIDEMIOLOGY, V7, P335; Wang C, 2009, RESPIROLOGY, V14, P384, DOI 10.1111/j.1440-1843.2008.01476.x; Weiner E, 2011, SCHIZOPHR RES, V129, P94, DOI 10.1016/j.schres.2011.02.003; Williams JM, 2012, J CLIN PSYCHIAT, V73, P654, DOI 10.4088/JCP.11m07522; Williams KE, 2007, CURR MED RES OPIN, V23, P793, DOI 10.1185/030079907X182185; Wong J, 2012, ANESTHESIOLOGY, V117, P755, DOI 10.1097/ALN.0b013e3182698b42; Zesiewicz TA, 2012, NEUROLOGY, V78, P545, DOI 10.1212/WNL.0b013e318247cc7a; Zhao QY, 2011, J CLIN PHARMACOL, V51, P492, DOI 10.1177/0091270010370461	74	93	96	0	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 12	2015	350								h1109	10.1136/bmj.h1109	http://dx.doi.org/10.1136/bmj.h1109			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CD6EQ	25767129	hybrid, Green Published			2023-01-03	WOS:000351182700001
J	Gasparetto, JC; Peccinini, RG; de Francisco, TMG; Cerqueira, LB; Campos, FR; Pontarolo, R				Gasparetto, Joao Cleverson; Peccinini, Rosangela Goncalves; Guimaraes de Francisco, Thais Martins; Cerqueira, Letcia Bonancio; Campos, Francinete Ramos; Pontarolo, Roberto			A Kinetic Study of the Main Guaco Metabolites Using Syrup Formulation and the Identification of an Alternative Route of Coumarin Metabolism in Humans	PLOS ONE			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; BIP. EX BAKER; KAURENOIC ACID; MIKANIA-GLOMERATA; BRONCHODILATOR ACTIVITY; HUMAN SERUM; LAEVIGATA; 7-HYDROXYCOUMARIN; PLASMA; PHARMACOKINETICS	For decades guaco species have been empirically used for the treatment of respiratory diseases. However, studies have shown that the toxic and therapeutic effects of the main guaco metabolites are dose-dependent, and none clinical study was done to evaluate the behavior of these substances in humans. In this work, a pilot study measuring the kinetic profile of the main guaco metabolites was performed leading to the knowledge of an alternative route of coumarin metabolism in humans. Initial screenings demonstrated that the administration of 60 mL of guaco syrup (single dose) did not provide sufficient levels of coumarin (COU), 7-hydroxycoumarin (7-HCOU), o-coumaric acid (OCA) and kaurenoic acid (KAU). The pharmacokinetic parameters were calculated by orally administering 60 mL of guaco syrup spiked with 1500 mg of COU. The kinetic study demonstrated that the plasmatic levels of 7-HCOU (considered the main metabolite of COU) were 10 times lower than the levels of COU, and the kinetic profile of 7-HCOU suggests sequential metabolism in the liver with low access of 7-HCOU to the systemic circulation. The study also demonstrated that OCA is one of the main bioavailable metabolites of COU. Therefore, the hydrolysis of the lactone ring forming a carboxylated compound is one of the possible routes of COU metabolism in humans. The half-lives of COU, 7-HCOU and OCA were approximately 4.0, 1.0 and 3.0 h, respectively and there was evidence that the recommended dosage of guaco syrup did not provide sufficient levels of COU, 7-HCOU or OCA to obtain a bronchodilation effect. Clinical studies are necessary to prove the efficacy and safety of products based on guaco.	[Gasparetto, Joao Cleverson; Guimaraes de Francisco, Thais Martins; Cerqueira, Letcia Bonancio; Campos, Francinete Ramos; Pontarolo, Roberto] Univ Fed Parana, Dept Pharm, Curitiba, PR, Brazil; [Peccinini, Rosangela Goncalves] Univ Estadual Paulista, Dept Nat Act Principles & Toxicol, Araraquara, SP, Brazil	Universidade Federal do Parana; Universidade Estadual Paulista	Pontarolo, R (corresponding author), Univ Fed Parana, Dept Pharm, Curitiba, PR, Brazil.	pontarolo@ufpr.br	CERQUEIRA, LETICIA/H-5121-2016; Campos, Francinete/AAU-1346-2020; Peccinini, Rosangela/G-6068-2015; Pontarolo, Roberto/G-6948-2014	Peccinini, Rosangela/0000-0002-2692-8101; Pontarolo, Roberto/0000-0002-7049-4363; CAMPOS, FRANCINETE/0000-0002-9688-2030	Fundacao Araucaria; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior	Fundacao Araucaria(Fundacao Araucaria de Apoio ao Desenvolvimento Cientifico e Tecnologico do Estado do Parana FAFundacao de Amparo a Pesquisa e Inovacoo Estado de Santa Catarina (FAPESC)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	JCG received scholarship from Fundacao Araucaria and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Billeclke S, 2000, DRUG METAB DISPOS, V28, P1335; Bogan DP, 1996, J CHROMATOGR B, V686, P267, DOI 10.1016/S0378-4347(96)00234-4; BOOTH AN, 1959, J BIOL CHEM, V234, P946; Born SL, 2000, DRUG METAB DISPOS, V28, P218; Cavalcanti BC, 2010, MUTAT RES-GEN TOX EN, V701, P153, DOI 10.1016/j.mrgentox.2010.06.010; Cavalcanti BC, 2006, FOOD CHEM TOXICOL, V44, P388, DOI 10.1016/j.fct.2005.08.011; Choi RJ, 2011, PHYTOMEDICINE, V18, P677, DOI 10.1016/j.phymed.2010.11.010; Costa-Lotufo LV, 2002, TOXICON, V40, P1231, DOI 10.1016/S0041-0101(02)00128-9; de Moura RS, 2002, J PHARM PHARMACOL, V54, P249, DOI 10.1211/0022357021778277; dos Santos SC, 2006, PLANTA MED, V72, P679, DOI 10.1055/s-2006-931577; EGAN DA, 1992, J CHROMATOGR-BIOMED, V582, P137, DOI 10.1016/0378-4347(92)80312-E; Fierro IM, 1999, J ETHNOPHARMACOL, V66, P19, DOI 10.1016/S0378-8741(98)00151-2; Food and D. Administration, 2001, BIOAN METH VAL GUID; Ford RA, 2001, FOOD CHEM TOXICOL, V39, P153, DOI 10.1016/S0278-6915(00)00123-X; Gasparetto JC, 2011, PHARM ANAL ACTA, V2, P1; Gasparetto JC, 2011, J SEP SCI, V34, P740, DOI 10.1002/jssc.201000792; Gasparetto JC, 2010, REV BRAS FARMACOGN, V20, P627, DOI 10.1590/S0102-695X2010000400025; Gasparetto JC, 2012, TOXICITY AND DRUG TESTING, P297; Graca C, 2007, J ETHNOPHARMACOL, V112, P430, DOI 10.1016/j.jep.2007.03.026; Hoult JRS, 1996, GEN PHARMACOL-VASC S, V27, P713, DOI 10.1016/0306-3623(95)02112-4; Houston JB, 1982, PHARMACOL THERAPEUT, V15, P521; Labaune JP, 1993, FARMACOCINETICA, DOI [10.7399/FH.2013.37.6.742, DOI 10.7399/FH.2013.37.6.742]; Lacy A, 2004, CURR PHARM DESIGN, V10, P3797, DOI 10.2174/1381612043382693; Lake BG, 1999, FOOD CHEM TOXICOL, V37, P423, DOI 10.1016/S0278-6915(99)00010-1; LAKE BG, 1989, TOXICOL APPL PHARM, V97, P311, DOI 10.1016/0041-008X(89)90336-0; Napimoga MH, 2010, J PHARM PHARMACOL, V62, P809, DOI 10.1211/jpp.62.07.0001; NTP, 1993, NAT TOX PROGR TECH R, V422, P1; Ramanitrahasimbola D, 2005, J ETHNOPHARMACOL, V102, P400, DOI 10.1016/j.jep.2005.06.037; RITSCHEL WA, 1981, J CLIN PHARMACOL, V21, P294, DOI 10.1002/j.1552-4604.1981.tb01770.x; RITSCHEL WA, 1977, EUR J CLIN PHARMACOL, V12, P457, DOI 10.1007/BF00561066; RITSCHEL WA, 1984, METHOD FIND EXP CLIN, V6, P363; ROVEI V, 1982, BRIT J CLIN PHARMACO, V14, P769, DOI 10.1111/j.1365-2125.1982.tb02035.x; SHILLING WH, 1969, NATURE, V221, P664, DOI 10.1038/221664b0; Silva RZ, 2000, THESIS U FEDERAL SAN; Suyenaga ES, 2002, PHYTOTHER RES, V16, P519, DOI 10.1002/ptr.908; Teske M., 1997, HERBARIUM COMPENDIO; THORNES RD, 1994, J CANCER RES CLIN, V120, pS32, DOI 10.1007/BF01377122; THORNES RD, 1982, LANCET, V2, P328; Tirapelli CR, 2004, EUR J PHARMACOL, V492, P233, DOI 10.1016/j.ejphar.2004.04.003; Tirapelli CR, 2002, FITOTERAPIA, V73, P56, DOI 10.1016/S0367-326X(01)00365-3; Toutain PL, 2004, J VET PHARMACOL THER, V27, P427, DOI 10.1111/j.1365-2885.2004.00600.x; Vasconcelos JF, 2009, EUR J PHARMACOL, V609, P126, DOI 10.1016/j.ejphar.2009.03.027; West GB, 2005, J EXP BIOL, V208, P1575, DOI 10.1242/jeb.01589; White CR, 2005, J EXP BIOL, V208, P1611, DOI 10.1242/jeb.01501	44	11	11	0	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 10	2015	10	3							e0118922	10.1371/journal.pone.0118922	http://dx.doi.org/10.1371/journal.pone.0118922			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CD7MX	25757073	Green Published, Green Submitted, gold			2023-01-03	WOS:000351275700032
J	Horwitz, LI; Lin, ZQ; Herrin, J; Bernheim, S; Drye, EE; Krumholz, HM; Ross, JS				Horwitz, Leora I.; Lin, Zhenqiu; Herrin, Jeph; Bernheim, Susannah; Drye, Elizabeth E.; Krumholz, Harlan M.; Ross, Joseph S.			Association of hospital volume with readmission rates: a retrospective cross-sectional study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BARIATRIC SURGERY; MORTALITY; CARE; QUALITY; OUTCOMES; PROGRAM	OBJECTIVE To examine the association of hospital volume (a marker of quality of care) with hospital readmission rates. DESIGN Retrospective cross-sectional study. SETTING 4651US acute care hospitals. STUDY DATA 6 916 644 adult discharges, excluding patients receiving psychiatric or medical cancer treatment. MAIN OUTCOME MEASURES We used Medicare fee-for-service data from 1 July 2011 to 30 June 2012 to calculate observed-to-expected, unplanned, 30 day, standardized readmission rates for hospitals and for specialty cohorts medicine, surgery/gynecology, cardiorespiratory, cardiovascular, and neurology. We assessed the association of hospital volume by quintiles with 30 day, standardized readmission rates, with and without adjustment for hospital characteristics (safety net status, teaching status, geographic region, urban/rural status, nurse to bed ratio, ownership, and cardiac procedure capability. We also examined associations with the composite outcome of 30 day, standardized readmission or mortality rates. RESULTS Mean 30 day, standardized readmission rate among the fifth of hospitals with the lowest volume was 14.7 (standard deviation 5.3) compared with 15.9 (1.7) among the fifth of hospitals with the highest volume (P < 0.001). We observed the same pattern of lower readmission rates in the lowest versus highest volume hospitals in the specialty cohorts for medicine (16.6 v 17.4, P < 0.001), cardiorespiratory (18.5 v 20.5, P < 0.001), and neurology (13.2 v 14.0, p = 0.01) cohorts; the cardiovascular cohort, however, had an inverse association (14.6 v 13.7, P < 0.001). These associations remained after adjustment for hospital characteristics except in the cardiovascular cohort, which became non-significant, and the surgery/gynecology cohort, in which the lowest volume fifth of hospitals had significantly higher standardized readmission rates than the highest volume fifth (difference 0.63 percentage points (95% confidence interval 0.10 to 1.17), P = 0.02). Mean 30 day, standardized mortality or readmission rate was not significantly different between highest and lowest volume fifths (20.4 v 20.2, P = 0.19) and was highest in the middle fifth of hospitals (range 20.6-20.8). CONCLUSIONS Standardized readmission rates are lowest in the lowest volume hospitals-opposite from the typical association of greater hospital volume with better outcomes. This association was independent of hospital characteristics and was only partially attenuated by examining mortality and readmission together. Our findings suggest that readmissions are associated with different aspects of care than mortality or complications.	[Horwitz, Leora I.] NYU, Div Healthcare Delivery Sci, Dept Populat Hlth, Langone Med Ctr, New York, NY 10012 USA; [Horwitz, Leora I.] NYU, Sch Med, Ctr Healthcare Innovat & Delivery Sci, New York, NY USA; [Lin, Zhenqiu; Bernheim, Susannah; Drye, Elizabeth E.; Krumholz, Harlan M.; Ross, Joseph S.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA; [Herrin, Jeph; Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Med, Sect Cardiovasc Med, New Haven, CT 06510 USA; [Herrin, Jeph] Hlth Res & Educ Trust, Chicago, IL USA; [Bernheim, Susannah; Ross, Joseph S.] Yale Univ, Sch Med, Dept Med, Sect Gen Internal Med, New Haven, CT 06510 USA; [Drye, Elizabeth E.] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA; [Krumholz, Harlan M.; Ross, Joseph S.] Yale Univ, Sect Hlth Policy & Adm, Sch Epidemiol & Publ Hlth, New Haven, CT USA	New York University; NYU Langone Medical Center; New York University; Yale University; Yale University; Yale University; Yale University; Yale University	Horwitz, LI (corresponding author), NYU, Div Healthcare Delivery Sci, Dept Populat Hlth, Langone Med Ctr, New York, NY 10012 USA.	leora.horwitz@nyumc.org	Horwitz, Leora/ABD-1292-2020; , Harlan/AAI-2875-2020; Horwitz, Leora/A-6959-2009	Ross, Joseph/0000-0002-9218-3320; Horwitz, Leora/0000-0003-1800-6040	Center for Medicare & Medicaid Services, an agency of the US Department of Health and Human Services [HHSM-500-2013-13018I, HHSM-500-T0001]; Agency for Healthcare Research and Quality [R01 HS022882]; National Institute on Aging [K08 AG038336, K08 AG032886]; American Federation for Aging Research; National Heart, Lung, and Blood Institute [U01 HL105270-03]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS022882] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL105270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG038336, K08AG032886] Funding Source: NIH RePORTER	Center for Medicare & Medicaid Services, an agency of the US Department of Health and Human Services; Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); American Federation for Aging Research; National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was performed under contract HHSM-500-2013-13018I, Task Order HHSM-500-T0001, funded by the Center for Medicare & Medicaid Services, an agency of the US Department of Health and Human Services. This work was also supported by the Agency for Healthcare Research and Quality (R01 HS022882). LIH and JSR are supported by the National Institute on Aging (K08 AG038336 and K08 AG032886, respectively) and by the American Federation for Aging Research through the Paul B Beeson Career Development Award Program. HMK is supported by grant U01 HL105270-03 (Center for Cardiovascular Outcomes Research at Yale University) from the National Heart, Lung, and Blood Institute. No funding source had any role in the study design; in the collection, analysis, and interpretation of data; or in the writing of the report. The Center for Medicare & Medicaid Services reviewed and approved the use of its data for this work and approved submission of the manuscript.	Agency for Healthcare Research and Quality, 2013, INP QUAL IND TECHN S; Agency for Healthcare Research and Quality, 2013, PED QUAL IND TECHN S; Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337; Borenstein SH, 2005, J PEDIATR SURG, V40, P75, DOI 10.1016/j.jpedsurg.2004.09.002; Burns EM, 2011, BRIT J SURG, V98, P408, DOI 10.1002/bjs.7312; Coleman EA, 2006, ARCH INTERN MED, V166, P1822, DOI 10.1001/archinte.166.17.1822; Conover M., 2012, HOSP WIDE ALL CAUSE; Demetriades D, 2005, ANN SURG, V242, P512, DOI 10.1097/01.sla.0000184169.73614.09; Dudley RA, 2000, JAMA-J AM MED ASSOC, V283, P1159, DOI 10.1001/jama.283.9.1159; Fischer JP, 2013, PLAST RECONSTR SURG, V132, P666, DOI 10.1097/PRS.0b013e31829acc8c; Ghaferi AA, 2009, NEW ENGL J MED, V361, P1368, DOI 10.1056/NEJMsa0903048; Goodney PP, 2003, ANN SURG, V238, P161, DOI 10.1097/01.SLA.0000081094.66659.c3; Gooiker GA, 2011, BRIT J SURG, V98, P485, DOI 10.1002/bjs.7413; Gooiker G A, 2010, Eur J Surg Oncol, V36 Suppl 1, pS27, DOI 10.1016/j.ejso.2010.06.024; Hernandez AF, 2010, JAMA-J AM MED ASSOC, V303, P1716, DOI 10.1001/jama.2010.533; Holt PJE, 2007, BRIT J SURG, V94, P395, DOI 10.1002/bjs.5710; Horwitz LI, 2014, ANN INTERN MED, V161, pS66, DOI 10.7326/M13-3000; Horwitz LI, 2013, CTR MEDICARE MED SER; Jack BW, 2009, ANN INTERN MED, V150, P178, DOI 10.7326/0003-4819-150-3-200902030-00007; Joynt KE, 2011, ANN INTERN MED, V154, P94, DOI 10.7326/0003-4819-154-2-201101180-00008; Joynt KE, 2011, CIRC-CARDIOVASC QUAL, V4, P53, DOI 10.1161/CIRCOUTCOMES.110.950964; Krumholz HM, 2013, NEW ENGL J MED, V368, P100, DOI 10.1056/NEJMp1212324; Magid DJ, 2000, JAMA-J AM MED ASSOC, V284, P3131, DOI 10.1001/jama.284.24.3131; Mayer EK, 2011, BJU INT, V108, pE258, DOI 10.1111/j.1464-410X.2010.10010.x; National Center for Health Statistics, 2006, NCHS URB RUR CLASS S; Nguyen NT, 2004, ANN SURG, V240, P586, DOI 10.1097/01.sla.0000140752.74893.24; Normand SLT, 2007, STAT SCI, V22, P206, DOI 10.1214/088342307000000096; PHIBBS CS, 1996, JAMA-J AM MED ASSOC, V276, P1054; Pose PN, 2010, EUR HEART J, V31, P1985, DOI 10.1093/eurheartj/ehq151; Reames BN, 2014, ANN SURG, V260, P244, DOI 10.1097/SLA.0000000000000375; Ross JS, 2007, HEALTH AFFAIR, V26, P238, DOI 10.1377/hlthaff.26.1.238; Ross JS, 2010, NEW ENGL J MED, V362, P1110, DOI 10.1056/NEJMsa0907130; Roy CL, 2009, J GEN INTERN MED, V24, P374, DOI 10.1007/s11606-008-0848-x; The Leapfrog Group, 2008, EV BAS HOSP REF FACT; Tsai TC, 2013, NEW ENGL J MED, V369, P1134, DOI 10.1056/NEJMsa1303118; Urbach DR, 2004, BRIT MED J, V328, P737, DOI 10.1136/bmj.38030.642963.AE; Weller WE, 2007, J AM COLL SURGEONS, V204, P383, DOI 10.1016/j.jamcollsurg.2006.12.031; Wouters MWJM, 2012, CANCER-AM CANCER SOC, V118, P1754, DOI 10.1002/cncr.26383; Zevin B, 2012, ANN SURG, V256, P60, DOI 10.1097/SLA.0b013e3182554c62	39	41	41	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 9	2015	350								h447	10.1136/BMJ.h447	http://dx.doi.org/10.1136/BMJ.h447			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CB0LA	25665806	Green Published, hybrid			2023-01-03	WOS:000349316200001
J	Ding, YH; Zou, XJ; Jiang, X; Wu, JY; Zhang, YR; Chen, D; Liang, B				Ding, YiHong; Zou, XiaoJu; Jiang, Xue; Wu, JieYu; Zhang, YuRu; Chen, Dan; Liang, Bin			Pu-Erh Tea Down-Regulates Sterol Regulatory Element-Binding Protein and Stearyol-CoA Desaturase to Reduce Fat Storage in Caenorhaditis elegans	PLOS ONE			English	Article							GALLIC ACID; CAENORHABDITIS-ELEGANS; OXIDATIVE DAMAGE; LIPID-METABOLISM; BODY-FAT; EXTRACT; BLACK; MICE; DIET; CHOLESTEROL	Consumption of Pu-erh has been reported to result in numerous health benefits, but the mechanisms underlying purported weight-loss and lowering of lipid are poorly understood. Here, we used the nematode Caenorhaditis elegans to explore the water extract of Pu-erh tea (PTE) functions to reduce fat storage. We found that PTE down-regulates the expression of the master fat regulator SBP-1, a homologue of sterol regulatory element binding protein (SREBP) and its target stearoyl-CoA desaturase (SCD), a key enzyme in fat biosynthesis, leading to an increased ratio of stearic acid (C18:0) to oleic acid (C18:1n-9), and subsequently decreased fat storage. We also found that both the pharyngeal pumping rate and food uptake of Caenorhaditis elegans decreased with exposure to PTE. Collectively, these results provide an experimental basis for explaining the ability of Pu-erh tea in promoting inhibition of food uptake and the biosynthesis of fat via SBP-1 and SCD, thereby reducing fat storage.	[Ding, YiHong; Jiang, Xue; Wu, JieYu; Zhang, YuRu; Liang, Bin] Chinese Acad Sci, Kunming Inst Zool, Chinese Acad Sci & Yunnan Prov, Key Lab Anim Models & Human Dis Mech, Kunming 650223, Peoples R China; [Zou, XiaoJu; Chen, Dan] Kunming Univ, Dept Life Sci & Technol, Key Lab Special Biol Resource Dev & Utilizat Univ, Kunming 650214, Peoples R China	Chinese Academy of Sciences; Kunming Institute of Zoology; Kunming University	Zou, XJ (corresponding author), Kunming Univ, Dept Life Sci & Technol, Key Lab Special Biol Resource Dev & Utilizat Univ, Kunming 650214, Peoples R China.	xiaojuzou@163.com; liangb@mail.kiz.ac.cn			National Natural Science Foundation of China (NSFC) [31160216, 31171134]; Yunnan Natural Science Foundation [2011FZ179]; Kunming University Science Project [YJL11018]; Yunnan Provincial Science and Technology Department [2014HB022]; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [P40OD010440] Funding Source: NIH RePORTER	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Yunnan Natural Science Foundation(Natural Science Foundation of Yunnan Province); Kunming University Science Project; Yunnan Provincial Science and Technology Department; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by National Natural Science Foundation of China (NSFC) 31160216 to XJ Zou and 31171134 to B Liang; Yunnan Natural Science Foundation 2011FZ179 and Kunming University Science Project YJL11018 to XJ Zou; and Yunnan Provincial Science and Technology Department 2014HB022. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Avery Leon, 2012, WormBook, P1, DOI 10.1895/wormbook.1.150.1; Bak EJ, 2013, SCAND J CLIN LAB INV, V73, P607, DOI 10.3109/00365513.2013.831470; Bene H, 2001, BIOCHEM BIOPH RES CO, V284, P1194, DOI 10.1006/bbrc.2001.5102; Brock TJ, 2007, GENETICS, V176, P865, DOI 10.1534/genetics.107.071860; Brock TJ, 2006, PLOS GENET, V2, P997, DOI 10.1371/journal.pgen.0020108; Brooks KK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007545; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Cao ZH, 2011, PHYTOTHER RES, V25, P234, DOI 10.1002/ptr.3247; Chen HX, 2013, J FOOD SCI, V78, pC1665, DOI 10.1111/1750-3841.12288; Chiang CT, 2006, ONCOL RES, V16, P119, DOI 10.3727/000000006783981143; Duh PD, 2004, J AGR FOOD CHEM, V52, P8169, DOI 10.1021/jf0490551; Finucane MM, 2011, LANCET, V377, P557, DOI 10.1016/S0140-6736(10)62037-5; Fujita H, 2008, PHYTOTHER RES, V22, P1275, DOI 10.1002/ptr.2477; Fujita H, 2008, NUTR RES, V28, P450, DOI 10.1016/j.nutres.2008.04.005; Gong JS, 2010, J FOOD SCI, V75, pH182, DOI 10.1111/j.1750-3841.2010.01675.x; Gong JiaShun, 2009, Asian Journal of Agricultural Sciences, V1, P48; Hodson L, 2013, PROG LIPID RES, V52, P15, DOI 10.1016/j.plipres.2012.08.002; Hou Y, 2009, EXP GERONTOL, V44, P434, DOI 10.1016/j.exger.2009.03.007; Huang HC, 2011, FOOD FUNCT; Huang QF, 2013, FOOD CHEM TOXICOL, V53, P75, DOI 10.1016/j.fct.2012.11.039; Jeon TI, 2012, TRENDS ENDOCRIN MET, V23, P65, DOI 10.1016/j.tem.2011.10.004; Jie GL, 2006, J AGR FOOD CHEM, V54, P8058, DOI 10.1021/jf061663o; Jones KT, 2009, DIS MODEL MECH, V2, P224, DOI 10.1242/dmm.001933; Kade IJ, 2013, J BASIC CLIN PHYSL P, P1; Kniazeva M, 2004, PLOS BIOL, V2, P1446, DOI 10.1371/journal.pbio.0020257; Koch B, 2001, J MICROBIOL METH, V45, P187, DOI 10.1016/S0167-7012(01)00246-9; Ku KM, 2010, J AGR FOOD CHEM, V58, P345, DOI 10.1021/jf902818c; Kuo KL, 2005, J AGR FOOD CHEM, V53, P480, DOI 10.1021/jf049375k; Liang B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009869; Ma X, 2013, J MED FOOD, V16, P259, DOI 10.1089/jmf.2012.2520; McKay RM, 2003, DEV CELL, V4, P131, DOI 10.1016/S1534-5807(02)00411-2; Mullaney BC, 2009, BBA-MOL CELL BIOL L, V1791, P474, DOI 10.1016/j.bbalip.2008.12.013; Ntambi JM, 2004, PROG LIPID RES, V43, P91, DOI 10.1016/S0163-7827(03)00039-0; NTAMBI JM, 1995, PROG LIPID RES, V34, P139, DOI 10.1016/0163-7827(94)00010-J; Ntambi JM, 2002, P NATL ACAD SCI USA, V99, P11482, DOI 10.1073/pnas.132384699; Oi Y, 2012, PHYTOTHER RES, V26, P475, DOI 10.1002/ptr.3602; Patel SS, 2011, PHARMACOGN RES, V3, P239, DOI 10.4103/0974-8490.89743; Perez CL, 2008, CELL METAB, V8, P266, DOI 10.1016/j.cmet.2008.08.007; Prince PSM, 2011, J BIOCHEM MOL TOXIC, V25, P101, DOI 10.1002/jbt.20365; Punithavathi VR, 2011, J BIOCHEM MOL TOXIC, V25, P68, DOI 10.1002/jbt.20360; Punithavathi VR, 2011, EUR J PHARMACOL, V650, P465, DOI 10.1016/j.ejphar.2010.08.059; SANO M, 1986, CHEM PHARM BULL, V34, P221; Shi X, 2013, J LIPID RES, V54, P2504, DOI 10.1194/jlr.M039669; Shimamura Y, 2013, BIOSCI BIOTECH BIOCH, V77, P1455, DOI 10.1271/bbb.130097; Van Gilst MR, 2005, PLOS BIOL, V3, P301, DOI 10.1371/journal.pbio.0030053; Walker AK, 2011, CELL, V147, P840, DOI 10.1016/j.cell.2011.09.045; Watts JL, 2009, TRENDS ENDOCRIN MET, V20, P58, DOI 10.1016/j.tem.2008.11.002; Watts JL, 2006, DEV BIOL, V292, P381, DOI 10.1016/j.ydbio.2006.01.013; Watts JL, 2002, P NATL ACAD SCI USA, V99, P5854, DOI 10.1073/pnas.092064799; Watts JL, 2000, BIOCHEM BIOPH RES CO, V272, P263, DOI 10.1006/bbrc.2000.2772; Way TD, 2009, J AGR FOOD CHEM, V57, P5257, DOI 10.1021/jf900730e; Yamashita Y, 2012, J AGR FOOD CHEM, V60, P11366, DOI 10.1021/jf303597c; Yang FJ, 2006, NATURE, V442, P700, DOI 10.1038/nature04942; Yang TTC, 1997, PHARMACOL RES, V35, P505, DOI 10.1006/phrs.1997.0176; Yuan H, 2009, ACTA NUTR SIN, V31, P176; Yuan HuaBing, 2009, Acta Nutrimenta Sinica, V31, P167; Zhang L, 2011, J AGR FOOD CHEM, V59, P8754, DOI 10.1021/jf2015733; Zhang P, 2012, MOL CELL PROTEOMICS, V11, P317, DOI 10.1074/mcp.M111.016345; Zhang SBO, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-96; Zhang YR, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-164; Zhao LJ, 2011, INT J MOL SCI, V12, P7581, DOI 10.3390/ijms12117581; Zheng J, 2011, INT J OBES LOND	62	20	23	6	52	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2015	10	2							e0113815	10.1371/journal.pone.0113815	http://dx.doi.org/10.1371/journal.pone.0113815			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CB2GK	25659129	gold, Green Submitted, Green Published			2023-01-03	WOS:000349444900006
J	Zirpoli, H; Abdillahi, M; Quadri, N; Ananthakrishnan, R; Wang, LJ; Rosario, R; Zhu, ZB; Deckelbaum, RJ; Ramasamy, R				Zirpoli, Hylde; Abdillahi, Mariane; Quadri, Nosirudeen; Ananthakrishnan, Radha; Wang, Lingjie; Rosario, Rosa; Zhu, Zhengbin; Deckelbaum, Richard J.; Ramasamy, Ravichandran			Acute Administration of n-3 Rich Triglyceride Emulsions Provides Cardioprotection in Murine Models after Ischemia-Reperfusion	PLOS ONE			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; ACTIVATED RECEPTOR-GAMMA; FATTY-ACIDS; MYOCARDIAL-ISCHEMIA; FISH-OIL; INJURY; OMEGA-3-FATTY-ACIDS; EXPRESSION; AKT; MECHANISMS	Dietary n-3 fatty acids (FAs) may reduce cardiovascular disease risk. We questioned whether acute administration of n-3 rich triglyceride (TG) emulsions could preserve cardiac function and decrease injury after ischemia/reperfusion (I/R) insult. We used two different experimental models: in vivo, C57BL/6 mice were exposed to acute occlusion of the left anterior descending coronary artery (LAD), and ex-vivo, C57BL/6 murine hearts were perfused using Langendorff technique (LT). In the LAD model, mice treated with n-3 TG emulsion (1.5g/kg body weight), immediately after ischemia and 1h later during reperfusion, significantly reduced infarct size and maintained cardiac function (p<0.05). In the LT model, administration of n-3 TG emulsion (300mgTG/100ml) during reperfusion significantly improved functional recovery (p<0.05). In both models, lactate dehydrogenase (LDH) levels, as a marker of injury, were significantly reduced by n-3 TG emulsion. To investigate the mechanisms by which n-3 FAs protects hearts from I/R injury, we investigated changes in key pathways linked to cardioprotection. In the ex-vivo model, we showed that n-3 FAs increased phosphorylation of AKT and GSK3a proteins (p<0.05). Acute n-3 TG emulsion treatment also increased Bcl-2 protein level and reduced an autophagy marker, Beclin-1 (p<0.05). Additionally, cardioprotection by n-3 TG emulsion was linked to changes in PPAR. protein expression (p<0.05). Rosiglitazone and p-AKT inhibitor counteracted the positive effect of n-3 TG; GSK3 beta inhibitor plus n-3 TG significantly inhibited LDH release. We conclude that acute n-3 TG injection during reperfusion provides cardioprotection. This may prove to be a novel acute adjunctive reperfusion therapy after treating patients with myocardial infarction.	[Zirpoli, Hylde; Abdillahi, Mariane; Deckelbaum, Richard J.] Columbia Univ, Inst Human Nutr, Coll Phys & Surg, New York, NY 10032 USA; [Zirpoli, Hylde; Deckelbaum, Richard J.] Columbia Univ, Dept Pediat, Coll Phys & Surg, New York, NY 10027 USA; [Abdillahi, Mariane; Quadri, Nosirudeen; Ananthakrishnan, Radha; Wang, Lingjie; Rosario, Rosa; Zhu, Zhengbin; Ramasamy, Ravichandran] NYU, Sch Med, Dept Med, New York, NY USA	Columbia University; Columbia University; New York University	Deckelbaum, RJ (corresponding author), Columbia Univ, Inst Human Nutr, Coll Phys & Surg, New York, NY 10032 USA.	ramasr02@nyumc.org; rjd20@columbia.edu		Ramasamy, Ravichandran/0000-0002-3666-3346	NIH [AG026467, HL61783]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061783, P01HL060901] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG026467] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Funding provided by NIH AG026467 and NIH HL61783. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdelrahman M, 2005, CARDIOVASC RES, V65, P772, DOI 10.1016/j.cardiores.2004.12.008; Abdillahi M, 2012, AM J PHYSIOL-HEART C, V303, pH297, DOI 10.1152/ajpheart.00999.2011; Akbar M, 2005, P NATL ACAD SCI USA, V102, P10858, DOI 10.1073/pnas.0502903102; Aleshin A, 2008, AM J PHYSIOL-HEART C, V294, pH1823, DOI 10.1152/ajpheart.01210.2007; Barandon L, 2005, CIRC RES, V96, P1299, DOI 10.1161/01.RES.0000171895.06914.2c; Barros KV, 2013, CLIN NUTR, V32, P993, DOI 10.1016/j.clnu.2013.02.010; Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09; Birnbaum Y, 2011, BASIC RES CARDIOL, V106, P431, DOI 10.1007/s00395-011-0162-3; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Buja LM, 2005, CARDIOVASC PATHOL, V14, P170, DOI 10.1016/j.carpath.2005.03.006; Caputo M, 2011, J CELL PHYSIOL, V226, P187, DOI 10.1002/jcp.22323; CASTILLO RL, 2013, CELL BIOCHEMISTRY AN, V32, P274, DOI DOI 10.1002/CBF.3012PMID:24166314; Chang CL, 2013, CURR OPIN LIPIDOL, V24, P345, DOI 10.1097/MOL.0b013e3283616364; Chanoit G, 2008, AM J PHYSIOL-HEART C, V295, pH1227, DOI 10.1152/ajpheart.00610.2008; Chen ZY, 2001, AM J PHYSIOL-HEART C, V280, pH2313, DOI 10.1152/ajpheart.2001.280.5.H2313; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Delgado-Lista J, 2012, BRIT J NUTR, V107, pS201, DOI 10.1017/S0007114512001596; Densupsoontorn N, 2007, LIPIDS, V42, P885, DOI 10.1007/s11745-007-3093-x; Duan SZ, 2005, CIRC RES, V97, P372, DOI 10.1161/01.RES.0000179226.34112.6d; Filion KB, 2010, BMC CARDIOVASC DISOR, V10, DOI 10.1186/1471-2261-10-24; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; GAO JY, 2011, CIRC J, V75, P843; Griendling KK, 2003, CIRCULATION, V108, P1912, DOI 10.1161/01.CIR.0000093660.86242.BB; Hwang YYC, 2004, FASEB J, V18, P1192, DOI 10.1096/fj.03-1400com; Imahashi K, 2004, CIRC RES, V95, P734, DOI 10.1161/01.RES.0000143898.67182.4c; Juhaszova M, 2009, CIRC RES, V104, P1240, DOI 10.1161/CIRCRESAHA.109.197996; Jung UJ, 2008, AM J CLIN NUTR, V87, p2003S, DOI 10.1093/ajcn/87.6.2003S; Jung UJ, 2012, ARTERIOSCL THROM VAS, V32, P2929, DOI 10.1161/ATVBAHA.112.300188; Kilter H, 2009, DIABETES OBES METAB, V11, P1060, DOI 10.1111/j.1463-1326.2009.01097.x; Li JY, 2012, ANESTHESIOLOGY, V117, P836, DOI 10.1097/ALN.0b013e3182655e73; Lichtenstein AH, 2006, CIRCULATION, V114, P82, DOI 10.1161/CIRCULATIONAHA.106.176158; Lopaschuk GD, 2010, PHYSIOL REV, V90, P207, DOI 10.1152/physrev.00015.2009; Lou PH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087205; Marczin N, 2003, ARCH BIOCHEM BIOPHYS, V420, P222, DOI 10.1016/j.abb.2003.08.037; McKenney JM, 2007, PHARMACOTHERAPY, V27, P715, DOI 10.1592/phco.27.5.715; Morrison A, 2011, AM J PHYSIOL-HEART C, V301, pH895, DOI 10.1152/ajpheart.00137.2011; Mullonkal CJ, 2007, J INVEST SURG, V20, P195, DOI 10.1080/08941930701366471; Murphy E, 2005, EXPERT OPIN THER TAR, V9, P447, DOI 10.1517/14728222.9.3.447; Murphy E, 2004, J CLIN INVEST, V113, P1526, DOI 10.1172/JCI200421986; Murphy E, 2008, PHYSIOL REV, V88, P581, DOI 10.1152/physrev.00024.2007; Murphy E, 2007, ANNU REV PHYSIOL, V69, P51, DOI 10.1146/annurev.physiol.69.031905.163645; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Qi KM, 2002, BIOCHEMISTRY-US, V41, P3119, DOI 10.1021/bi015770h; Rahman S, 2011, ANESTHESIOLOGY, V115, P242, DOI 10.1097/ALN.0b013e318223b8b9; Rauch B, 2010, CIRCULATION, V122, P2152, DOI 10.1161/CIRCULATIONAHA.110.948562; Rodrigo R, 2013, CLIN SCI, V124, P1, DOI 10.1042/CS20110663; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046; Simoens CM, 2008, AM J CLIN NUTR, V88, P282, DOI 10.1093/ajcn/88.2.282; Skulas-Ray AC, 2011, AM J CLIN NUTR, V93, P243, DOI 10.3945/ajcn.110.003871; Son NH, 2007, J CLIN INVEST, V117, P2791, DOI 10.1172/JCI30335; Son NHP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046549; Sugden M C, 2012, Curr Mol Pharmacol, V5, P224; Vacek TP, 2012, CELL BIOCHEM BIOPHYS, V62, P1, DOI 10.1007/s12013-011-9281-6; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; Wang G, 2005, METABOLISM, V54, P590, DOI 10.1016/j.metabol.2004.11.017; Williams JJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056233; Xu TD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102292; Xu ZL, 2014, J MOL CELL CARDIOL, V66, P12, DOI 10.1016/j.yjmcc.2013.10.016; Xue BZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045990; Zhu Y, 2013, CELL PHYSIOL BIOCHEM, V32, P663, DOI 10.1159/000354470	60	13	18	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 5	2015	10	1							e0116274	10.1371/journal.pone.0116274	http://dx.doi.org/10.1371/journal.pone.0116274			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AZ3BG	25559887	Green Published, Green Submitted, gold			2023-01-03	WOS:000348102200014
J	Hazewindus, M; Haenen, GRMM; Weseler, AR; Bast, A				Hazewindus, Merel; Haenen, Guido R. M. M.; Weseler, Antje R.; Bast, Aalt			Protection against Chemotaxis in the Anti-Inflammatory Effect of Bioactives from Tomato Ketchup	PLOS ONE			English	Article							NF-KAPPA-B; OXIDATIVE STRESS; ALPHA-TOCOPHEROL; GENE-EXPRESSION; MEDITERRANEAN DIET; ENDOTHELIAL-CELLS; VITAMIN-C; LYCOPENE; PREVENTION; ATHEROSCLEROSIS	The consumption of tomato products has been associated with a decreased risk for chronic inflammatory diseases. In this study, the anti-inflammatory potential of tomato ketchup was evaluated by studying the effect of tomato ketchup extracts and bioactives from tomato ketchup on human monocytes and vascular endothelial cells (HUVEC). HUVEC were pre-treated for 1 h with either individual bioactives (7.5 mu M lycopene, 1.4 mu M alpha-tocopherol or 55 mu M ascorbic acid) or a combination of these three compounds, or with the hydrophilic or lipophilic tomato ketchup extracts or with the two extracts combined. After the pretreatment, the cells were washed and challenged with TNF-alpha (10 ng/ml) for 6 h. The medium was used for the determination of the release of cytokines and the chemotaxis of monocytes. Inflammatory protein expression and production were assayed with real-time RT-PCR and ELISA. It was found that tomato ketchup extracts significantly reduced gene expression and release of the pro-inflammatory cytokines TNF-alpha and IL-8 in HUVEC after the inflammatory challenge, whereas the release of the anti-inflammatory cytokine IL-10 was increased. Chemotaxis was effectively impeded as demonstrated by a reduced monocyte migration. This effect correlated with the reduction of IL-8 production in the presence of the test compounds and extracts. The results consistently emphasize the contribution of lycopene to the anti-inflammatory effect of tomato ketchup. Other compounds in tomato ketchup such as a-tocopherol and ascorbic acid appeared to strengthen the anti-inflammatory effect of lycopene. The tomato ketchup extracts subtly interfered with several inflammatory phases that inhibit chemotaxis. Such a pleotropic mode of action exemplifies its potential mitigation of diseases characterized by prolonged low grade inflammation.	[Hazewindus, Merel; Haenen, Guido R. M. M.; Weseler, Antje R.; Bast, Aalt] Maastricht Univ, Dept Toxicol, Fac Hlth Med & Life Sci, Maastricht, Netherlands	Maastricht University	Haenen, GRMM (corresponding author), Maastricht Univ, Dept Toxicol, Fac Hlth Med & Life Sci, Maastricht, Netherlands.	g.haenen@maastrichtuniversity.nl	Bast, Aalt/I-7809-2013	Haenen, Guido/0000-0001-6986-290X; Bast, Aalt/0000-0002-5383-2789	Maastricht University	Maastricht University	The funding of the study was primarily from Maastricht University. All people that contributed to the study were employed directly by Maastricht University. H.J. Heinz Company also had no role in the study design, the data collection and analysis, decision to publish, or preparation of the manuscript. The funding of H.J. Heinz Company was used to pay the salary of Merel Hazewindus and as bench fee for chemicals and equipment. In addition, H.J. Heinz Company provided the tomato ketchup.	Agarwal Anita, 2001, J Med Food, V4, P9, DOI 10.1089/10966200152053668; Bast A, 2013, TRENDS PHARMACOL SCI, V34, P430, DOI 10.1016/j.tips.2013.05.010; Blackwell TS, 1997, AM J RESP CELL MOL, V17, P3, DOI 10.1165/ajrcmb.17.1.f132; Blum A, 2007, CLIN INVEST MED, V30, pE70; Bose KSC, 2007, ANN NUTR METAB, V51, P477, DOI 10.1159/000111170; Canene-Adams K, 2005, J NUTR, V135, P1226, DOI 10.1093/jn/135.5.1226; Carcamo JM, 2002, BIOCHEMISTRY-US, V41, P12995, DOI 10.1021/bi0263210; Cascio G, 2012, CURR DIABETES REV, V8, P2, DOI 10.2174/157339912798829241; Christman JW, 2000, BRAIN PATHOL, V10, P153; Denton CP, 1998, CLIN EXP IMMUNOL, V114, P293; Di Tomo P, 2012, MOL NUTR FOOD RES, V56, P217, DOI 10.1002/mnfr.201100500; Djuric Z, 2001, INT J FOOD SCI NUTR, V52, P143, DOI 10.1080/713671775; Ellinger S, 2009, AKTUEL UROL, V40, P37, DOI 10.1055/s-2008-1077031; Engelmann NJ, 2011, ADV NUTR, V2, P51, DOI 10.3945/an.110.000075; Erl W, 1997, AM J PHYSIOL, P634; Esfahani A, 2011, J AM COLL NUTR, V30, P285, DOI 10.1080/07315724.2011.10719971; Feng D, 2010, INFLAMM RES, V59, P115, DOI 10.1007/s00011-009-0077-8; Frusciante L, 2007, MOL NUTR FOOD RES, V51, P609, DOI 10.1002/mnfr.200600158; Galkina E, 2007, ARTERIOSCL THROM VAS, V27, P2292, DOI 10.1161/ATVBAHA.107.149179; Galkina E, 2009, ANNU REV IMMUNOL, V27, P165, DOI 10.1146/annurev.immunol.021908.132620; Geraets L, 2007, EUR J PHARMACOL, V573, P241, DOI 10.1016/j.ejphar.2007.07.013; Gil A, 2011, PUBLIC HEALTH NUTR, V14, P2316, DOI 10.1017/S1368980011002576; Hayden MS, 2006, ONCOGENE, V25, P6758, DOI 10.1038/sj.onc.1209943; Hazewindus M, 2012, FOOD CHEM, V132, P954, DOI 10.1016/j.foodchem.2011.11.075; Hung CF, 2008, EUR J PHARMACOL, V586, P275, DOI 10.1016/j.ejphar.2008.03.001; Jacob K, 2008, BRIT J NUTR, V99, P137, DOI 10.1017/S0007114507791894; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lucier G, 2000, FACTORS AFFECTING TO, P282; Mackinnon ES, 2009, J MED FOOD, V12, P829, DOI 10.1089/jmf.2008.0118; Markovits N, 2009, ISR MED ASSOC J, V11, P598; Martin J, 2007, CURR PHARM DESIGN, V13, P1751, DOI 10.2174/138161207780831248; Minorsky PV, 2002, PLANT PHYSIOL, V130, P1077, DOI 10.1104/pp.900054; NIKI E, 1987, ANN NY ACAD SCI, V498, P186, DOI 10.1111/j.1749-6632.1987.tb23761.x; Niki E, 1987, FREE RADIC BIOL MED; Palozza P, 2011, CURR MED CHEM, V18, P1846, DOI 10.2174/092986711795496845; Palozza P, 2010, CURR MED CHEM, V17, P2547, DOI 10.2174/092986710791556041; Palozza P, 2011, J NUTR BIOCHEM, V22, P259, DOI 10.1016/j.jnutbio.2010.02.003; Palozza P, 2010, ARCH BIOCHEM BIOPHYS, V504, P26, DOI 10.1016/j.abb.2010.06.031; PEREZ P, 1995, MOL CELL BIOL, V15, P3523; Rao AV, 2002, EXP BIOL MED, V227, P908, DOI 10.1177/153537020222701011; Rao P, 2010, NATURE, V466, P1115, DOI 10.1038/nature09283; Re R, 2003, EUR J CLIN NUTR, V57, P1545, DOI 10.1038/sj.ejcn.1601723; Riccardi G, 2004, CLIN NUTR, V23, P447, DOI 10.1016/j.clnu.2004.02.006; Riso P, 2006, J AGR FOOD CHEM, V54, P2563, DOI 10.1021/jf053033c; Roberts LJ, 2007, FREE RADICAL BIO MED, V43, P1388, DOI 10.1016/j.freeradbiomed.2007.06.019; Sanchez-Moreno C, 2006, J NUTR BIOCHEM, V17, P183, DOI 10.1016/j.jnutbio.2005.07.001; Simone RE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019652; Singh U, 2004, ANN NY ACAD SCI, V1031, P195, DOI 10.1196/annals.1331.019; Soehnlein O, 2009, BLOOD, V114, P4613, DOI 10.1182/blood-2009-06-221630; van Haaften RIM, 2001, BIOCHEM BIOPH RES CO, V280, P631, DOI 10.1006/bbrc.2000.4174; Wang Y, 2011, DEV GROWTH DIFFER, V53, P495, DOI 10.1111/j.1440-169X.2011.01265.x; Weber C, 2011, NAT MED, V17, P1410, DOI 10.1038/nm.2538; Weisburger JH, 1999, FOOD CHEM TOXICOL, V37, P943, DOI 10.1016/S0278-6915(99)00086-1; Yang YY, 2004, ATHEROSCLEROSIS, V174, P207, DOI 10.1016/j.atherosclerosis.2004.01.024	54	18	18	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2014	9	12							e114387	10.1371/journal.pone.0114387	http://dx.doi.org/10.1371/journal.pone.0114387			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX7UC	25551565	gold, Green Published, Green Submitted			2023-01-03	WOS:000347119100011
J	Lukovic, JA; Miletic, V; Pekmezovic, T; Trajkovic, G; Ratkovic, N; Aleksic, D; Grgurevic, A				Lukovic, Jasminka Adzic; Miletic, Vladimir; Pekmezovic, Tatjana; Trajkovic, Goran; Ratkovic, Nevena; Aleksic, Danijela; Grgurevic, Anita			Self-Medication Practices and Risk Factors for Self-Medication among Medical Students in Belgrade, Serbia	PLOS ONE			English	Article							UNIVERSITY-STUDENTS; HEALTH-CARE; DRUG-USE; ALCOHOL; SEEKING; ANTIBIOTICS; ADOLESCENTS; ATTITUDES; BEHAVIOR	Introduction: Self-medication among future health care professionals can represent a serious threat to professionalism in medicine and it has potential to put at risk public trust into this profession. The aim of this research was to investigate prevalence and risk factors for self-medication among population of medical students, because it was previously shown that their attitudes towards pharmacotherapy could affect the way they could prescribe medication in the future. Material and Methods: Research was performed as a cross-sectional study and it included 1296 (84.1%) 1st, 3rd and 6th year students of School of Medicine, University of Belgrade. Students filled out a demographic and self-medication questionnaire created for the purpose of this research and the Physical Health Questionnaire - 9 (PHQ-9). Questions about self-medication were related to the period of the previous year. Results: Self-medication was reported by 79.9% students. The most frequently self-prescribed medications were analgesics (55.4%). Independent risk factors for self-medication were possession of home-pharmacies (OR=5.3, CI 95% 3.89-7.23), lower level of father's education (OR=1.6, CI 95% 1.18-2.25), consumption of alcoholic beverages (OR=1.5, CI 95% 1.13-2.08), less than 1 hour spent in physical activity per week (OR=1.4, CI 95% 1.00-2.02), female gender (OR=1.4, CI 95% 1.02-1.89), older age (OR=1.1, CI 95% 1.07-1.21) and higher PHQ-9 score (OR=1.09, CI 95% 1.05-1.12). Conclusions: Self-medication is an important issue among population of medical students. Prevalence of self-medication could be controlled through regulatory authorities and further education.	[Lukovic, Jasminka Adzic; Pekmezovic, Tatjana; Grgurevic, Anita] Univ Belgrade, Sch Med, Inst Epidemiol, Belgrade, Serbia; [Miletic, Vladimir] Assoc Mental Hlth Promot, Belgrade, Serbia; [Trajkovic, Goran] Univ Belgrade, Sch Med, Inst Med Stat & Informat, Belgrade, Serbia; [Ratkovic, Nevena; Aleksic, Danijela] Clin Ctr Serbia, Belgrade, Serbia	University of Belgrade; University of Belgrade; Clinical Centre of Serbia	Grgurevic, A (corresponding author), Univ Belgrade, Sch Med, Inst Epidemiol, Belgrade, Serbia.	anita.grgurevic@gmail.com						Abay SM, 2010, J YOUNG PHARM, V2, P306, DOI 10.4103/0975-1483.66798; Badiger S, 2012, AUSTRALAS MED J, V5, P217, DOI 10.4066/AMJ.2012.1007; Bertoldi AD, 2010, CAD SAUDE PUBLICA, V26, P1945, DOI 10.1590/S0102-311X2010001000011; Bertoldi AD, 2014, J ADOLESCENT HEALTH, V55, P175, DOI 10.1016/j.jadohealth.2014.02.010; Betancourt J, 2013, P R HEALTH SCI J, V32, P89; Brimstone R, 2007, MED EDUC, V41, P74, DOI 10.1111/j.1365-2929.2006.02649.x; Cheaito L, 2014, INT J PUBLIC HEALTH, V59, P319, DOI 10.1007/s00038-013-0493-y; Chew-Graham CA, 2003, MED EDUC, V37, P873, DOI 10.1046/j.1365-2923.2003.01627.x; da Silva MGC, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-339; Demissie Z, 2014, MATERN CHIL IN PRESS; Donkor ES, 2012, INT J ENV RES PUB HE, V9, P3519, DOI 10.3390/ijerph9103519; El Ezz N F A, 2011, J Prev Med Hyg, V52, P196; EPSTEIN AM, 1984, AM J MED, V77, P313, DOI 10.1016/0002-9343(84)90709-5; Eticha T, 2014, PLOS ONE, V12; Fayyazi Bordbar MR, 2014, SUBST USE M IN PRESS; Gardiner Paula, 2007, BMC Complement Altern Med, V7, P39, DOI 10.1186/1472-6882-7-39; Gazibara T, 2013, GERIATR NURS, V34, P486, DOI 10.1016/j.gerinurse.2013.08.002; Hofmeister EH, 2010, J VET MED EDUC, V37, P403, DOI 10.3138/jvme.37.4.403; James H, 2006, MED PRIN PRACT, V15, P270, DOI 10.1159/000092989; Kauffman SE, 1997, SOC WORK, V42, P231, DOI 10.1093/sw/42.3.231; Keel PK, 2007, J ABNORM PSYCHOL, V116, P422, DOI 10.1037/0021-843X.116.2.422; Kisic-Tepavcevic D, 2013, AM J DRUG ALCOHOL AB, V39, P130, DOI 10.3109/00952990.2012.746348; Klemenc-Ketis Z, 2010, INT J CLIN PHARM TH, V48, P705; Klemenc-Ketis Z, 2010, MED PRIN PRACT, V19, P395, DOI 10.1159/000316380; Kroenke K, 2002, PSYCHIAT ANN, V32, P509, DOI 10.3928/0048-5713-20020901-06; Kumar N, 2013, PLOS ONE, V28; Lazareck S, 2012, J CLIN PSYCHIAT, V73, pE588, DOI 10.4088/JCP.11m07345; Montgomery AJ, 2011, OCCUP MED-OXFORD, V61, P490, DOI 10.1093/occmed/kqr098; Pan H, 2012, PLOS ONE, V27; Pekmezovic T, 2011, QUAL LIFE RES, V20, P391, DOI 10.1007/s11136-010-9754-x; Roberts LW, 2000, ACAD MED, V75, P272, DOI 10.1097/00001888-200003000-00019; Roberts LW, 2001, COMPR PSYCHIAT, V42, P1, DOI 10.1053/comp.2001.19747; Sawalha AF, 2008, RES SOC ADMIN PHARM, V4, P164, DOI 10.1016/j.sapharm.2007.04.004; Ullah H, 2013, ACTA POL PHARM, V70, P919; Van der Veer T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028038; WHO, 2011, WHO GLOB REP NONC DI WHO GLOB REP NONC DI; World Health Organization, 2000, REG GUID TEL PROD; Zafar Syed Nabeel, 2008, J Pak Med Assoc, V58, P214	38	67	68	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 11	2014	9	12							e114644	10.1371/journal.pone.0114644	http://dx.doi.org/10.1371/journal.pone.0114644			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AX8FY	25503967	Green Submitted, Green Published, gold			2023-01-03	WOS:000347146700038
J	Bouquie, R; Wainstein, L; Pilet, P; Mussini, JM; Deslandes, G; Clouet, J; Dailly, E; Jolliet, P; Victorri-Vigneau, C				Bouquie, Regis; Wainstein, Laura; Pilet, Paul; Mussini, Jean-Marie; Deslandes, Guillaume; Clouet, Johann; Dailly, Eric; Jolliet, Pascale; Victorri-Vigneau, Caroline			Crushed and Injected Buprenorphine Tablets: Characteristics of Princeps and Generic Solutions	PLOS ONE			English	Article							DERMATITIS NICOLAUS-SYNDROME; PARTICULATE MATTER; INFUSION PHLEBITIS; LIVEDO; FILTRATION; AUSTRALIA; DIVERSION	Self-injection of high-dose buprenorphine is responsible for well-described complications. In 2011, we have been alerted by unusual but serious cutaneous complication among injection buprenorphine users. A prospective data collection identified 30 cases of necrotic cutaneous lesions after injection of filtered buprenorphine solution, among which 25 cases occurred following injection of buprenorphine generics. The main goal of our study was to put forward particularities that could explain the cutaneous complications, by qualitatively and quantitatively confronting particles present in Subutex and generics solutions. We used the same protocol that injected-buprenorphine users: generic or subutex tablets were crushed in sterile water and filtered through 2 filters commonly used (cotton-pad and sterifilt). Solutions were analyzed by laser granulometry, flow cytometry and scanning electron microscopy. We have highlighted the wide variation of the quantity and the size of the particles present in solution between the two drugs after cotton-pad filtration. The proportion of particles <10 mu m is systematically higher in the generic solutions than with Subutex. All of the insoluble particles found in generic solutions contain silica, whereas non-organic element was to be identified in the insoluble particles of Subutex. One skin biopsy obtained from one patient who developed a necrotic lesion after intravenous injection of filtrated solution of buprenorphine generic, shows non-organic elements. Identification of particles in situ enables us to confirm the presence of silica in the biopsy. Actually the monitoring of patient receiving generic of buprenorphine must be strengthened.	[Bouquie, Regis; Wainstein, Laura; Deslandes, Guillaume] CHU Nantes, Serv Pharmacol Clin, F-44035 Nantes 01, France; [Bouquie, Regis; Jolliet, Pascale; Victorri-Vigneau, Caroline] Univ Nantes, EA Biostat Pharmacoepidemiol & Mesures Subject Sa, Nantes, France; [Pilet, Paul] Univ Nantes, INSERM, UMR 791, Lab Ingn Osteoarticulaire & Dent LIOAD, Nantes, France; [Pilet, Paul] CHU Nantes, Pole Hosp Univ 4, F-44035 Nantes 01, France; [Mussini, Jean-Marie] CHU Nantes, Anat Pathol Lab, F-44035 Nantes 01, France; [Clouet, Johann] Univ Nantes, INSERM, Unite Mixte Rech Sante UMRS 791, Lab Ingen Osteoarticulaire & Dent LIOAD, Nantes, France; [Clouet, Johann] CHU Nantes, Pole Hosp Univ 7, Pharm Cent, F-44035 Nantes 01, France; [Dailly, Eric; Jolliet, Pascale] CHU Nantes, Serv Pharmacol Clin, F-44035 Nantes 01, France; [Dailly, Eric] Univ Nantes, EA Therapeut Clin & Expt Infect 3826, Nantes, France; [Victorri-Vigneau, Caroline] CHU Nantes, Serv Pharmacol Clin, F-44035 Nantes 01, France	Nantes Universite; CHU de Nantes; Nantes Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes; Nantes Universite; Nantes Universite; CHU de Nantes	Bouquie, R (corresponding author), CHU Nantes, Serv Pharmacol Clin, F-44035 Nantes 01, France.	regis.bouquie@chu-nantes.fr	Paul, Pilet/A-3755-2015; Clouet, Johann/P-1358-2014; Jolliet, pascale/L-9026-2015; Victorri Vigneau, Caroline/L-9030-2015	Victorri-Vigneau, Caroline/0000-0002-3745-2532; Dailly, Eric/0000-0002-5400-335X; Pascale, JOLLIET/0000-0003-0191-9249				ABRAHAM JL, 1980, ENVIRON RES, V21, P94, DOI 10.1016/0013-9351(80)90011-0; *AC NAT PHARM, 2011, SEANC THEM MAT PREM; Bellot B, 2014, ARCH PEDIATRIE, V21, P377, DOI 10.1016/j.arcped.2014.01.016; BOLLINGER RO, 1978, AM J HOSP PHARM, V35, P312, DOI 10.1093/ajhp/35.3.312; Brecheteau F, 2013, J SEX MED, V10, P2866, DOI 10.1111/jsm.12282; BREWSTER D, 1981, J PHARM PHARMACOL, V33, P500, DOI 10.1111/j.2042-7158.1981.tb13848.x; Cherasse A, 2003, JOINT BONE SPINE, V70, P390, DOI 10.1016/S1297-319X(03)00137-4; Corazza M, 2001, J EUR ACAD DERMATOL, V15, P585, DOI 10.1046/j.1468-3083.2001.00320.x; DAVIS NM, 1970, AM J HOSP PHARM, V27, P822, DOI 10.1093/ajhp/27.10.822; DELUCA PP, 1975, AM J HOSP PHARM, V32, P1001, DOI 10.1093/ajhp/32.10.1001; DRESSLER FA, 1989, AM J CARDIOL, V64, P909, DOI 10.1016/0002-9149(89)90841-2; EVANS WE, 1976, AM J HOSP PHARM, V33, P1160, DOI 10.1093/ajhp/33.11.1160; Gaudez C, 2003, REV NEUROL-FRANCE, V159, P571; Gayken J, 2006, J BURN CARE RES, V27, P541, DOI 10.1097/01.BCR.0000225917.09339.03; Glaizal M, 2011, THERAPIE, V66, P545, DOI 10.2515/therapie/2011069; Grau D, 2010, NOUV REV FR, P188; Guarneri C, 2010, AM J CLIN DERMATOL, V11, P51, DOI 10.2165/1153426-S0-000000000-00000; GUYTON AC, 1997, HUM PHYSIOL MECH DIS; HAHN HH, 1969, ARCH INTERN MED, V123, P656, DOI 10.1001/archinte.123.6.656; Hornez E, 2010, ANN CHIR PLAST ESTH, V55, P159, DOI 10.1016/j.anplas.2008.12.004; Jenkinson RA, 2005, ADDICTION, V100, P197, DOI 10.1111/j.1360-0443.2004.00958.x; Just PA, 2007, AM J DERMATOPATH, V29, P72, DOI 10.1097/01.dad.0000211508.67736.d4; Kienast AK, 2008, CLIN EXP DERMATOL, V33, P555, DOI 10.1111/j.1365-2230.2008.02861.x; Kim SK, 2012, ARCH PLAST SURG-APS, V39, P249, DOI 10.5999/aps.2012.39.3.249; Marangi GF, 2010, J DERMATOL, V37, P488, DOI 10.1111/j.1346-8138.2010.00864.x; Modzelewska I, 1980, Wiad Lek, V33, P231; Nayci Sillan, 2013, Indian Dermatol Online J, V4, P152, DOI 10.4103/2229-5178.110642; Perli Daniel, 2012, BMJ Case Rep, V2012, DOI 10.1136/bcr-2012-007785; Potier A, 2007, ANN DERMATOL VENER, V134, P148, DOI 10.1016/S0151-9638(07)91607-5; Rahimi-Movaghar A, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007775.pub2; Roux P, 2011, DRUG ALCOHOL REV, V30, P287, DOI 10.1111/j.1465-3362.2011.00285.x; Ruffieux P, 1996, DERMATOLOGY, V193, P368, DOI 10.1159/000246298; Schneider P, 2010, ARCH DERMATOL, V146, P208, DOI 10.1001/archdermatol.2009.372; SCHROEDER HG, 1976, AM J HOSP PHARM, V33, P543, DOI 10.1093/ajhp/33.6.543; Scott J, 2005, J SUBST USE, V10, P293, DOI DOI 10.1080/14659890412331319425; STANDRING S, 2008, GRAYS ANATOMY ANATOM, P127; *TIPH CAN, RAPP 2010 DONN REC R; Wainstein L, 2015, BRIT J DERMATOL, V172, P1412, DOI 10.1111/bjd.13503; Winstock AR, 2008, INT J DRUG POLICY, V19, P450, DOI 10.1016/j.drugpo.2007.03.002; Zaragoza J, 2013, ANN DERMATOL VENER, V140, P713, DOI 10.1016/j.annder.2013.07.009	40	14	14	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 4	2014	9	12							e113991	10.1371/journal.pone.0113991	http://dx.doi.org/10.1371/journal.pone.0113991			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AW6MB	25474108	Green Published, Green Submitted, gold			2023-01-03	WOS:000346382500101
J	Van Huffel, L; Tomson, CRV; Ruige, J; Nistor, I; Van Biesen, W; Bolignano, D				Van Huffel, Liesbeth; Tomson, Charles R. V.; Ruige, Johannes; Nistor, Ionut; Van Biesen, Wim; Bolignano, Davide			Dietary Restriction and Exercise for Diabetic Patients with Chronic Kidney Disease: A Systematic Review	PLOS ONE			English	Article							BODY-MASS INDEX; OBESITY PARADOX; WEIGHT-LOSS; CARDIORESPIRATORY FITNESS; CARDIOVASCULAR RISK; SEVERE HYPOGLYCEMIA; GLYCEMIC CONTROL; HOSPITAL STAY; MUSCLE MASS; ALL-CAUSE	Background: Obesity and sedentary lifestyle are major health problems and key features to develop cardiovascular disease. Data on the effects of lifestyle interventions in diabetics with chronic kidney disease (CKD) have been conflicting. Study Design: Systematic review. Population: Diabetes patients with CKD stage 3 to 5. Search Strategy and Sources: Medline, Embase and Central were searched to identify papers. Intervention: Effect of a negative energy balance on hard outcomes in diabetics with CKD. Outcomes: Death, cardiovascular events, glycaemic control, kidney function, metabolic parameters and body composition. Results: We retained 11 studies. There are insufficient data to evaluate the effect on mortality to promote negative energy balance. None of the studies reported a difference in incidence of Major Adverse Cardiovascular Events. Reduction of energy intake does not alter creatinine clearance but significantly reduces proteinuria (mean difference from -0.66 to -1.77 g/24 h). Interventions with combined exercise and diet resulted in a slower decline of eGFR (-9.2 vs. -20.7 mL/min over two year observation; p<0.001). Aerobic and resistance exercise reduced HbA1c (-0.51 (-0.87 to -0.14); p=0.007 and -0.38 (-0.72 to -0.22); p=0.038, respectively). Exercise interventions improve the overall functional status and quality of life in this subgroup. Aerobic exercise reduces BMI (-0.74% (-1.29 to -0.18); p=0.009) and body weight (-2.2 kg (-3.9 to -0.6); p=0.008). Resistance exercise reduces trunk fat mass (-0,7+/-0,1 vs. +0,8 kg +/-0,1 kg; p=0,001-0,005). In none of the studies did the intervention cause an increase in adverse events. Limitations: All studies used a different intervention type and mixed patient groups. Conclusions: There is insufficient evidence to evaluate the effect of negative energy balance interventions on mortality in diabetic patients with advanced CKD. Overall, these interventions have beneficial effects on glycaemic control, BMI and body composition, functional status and quality of life, and no harmful effects were observed.	[Van Huffel, Liesbeth; Ruige, Johannes] Ghent Univ Hosp, Dept Endocrinol, Ghent, Belgium; [Van Huffel, Liesbeth; Nistor, Ionut; Van Biesen, Wim; Bolignano, Davide] Ghent Univ Hosp, ERBP, Ghent, Belgium; [Tomson, Charles R. V.] Southmead Hosp, Richard Bright Kidney Unit, Bristol, Avon, England; [Nistor, Ionut] Univ Med & Pharm Gr T Popa, Dr CI Parhon Univ Hosp, Iasi, Romania; [Van Biesen, Wim] Ghent Univ Hosp, Div Renal, Ghent, Belgium; [Bolignano, Davide] CNR Inst Clin Physiol, Reggio Di Calabria, Italy	Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital; Southmead Hospital; Grigore T Popa University of Medicine & Pharmacy; Ghent University; Ghent University Hospital; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR)	Van Biesen, W (corresponding author), Ghent Univ Hosp, ERBP, Ghent, Belgium.	guidelines@era-edta.org	Biguzzi, Felipe A/E-4724-2015; Bolignano, Davide/AAB-3232-2019	Bolignano, Davide/0000-0003-3032-245X; Tomson, Charles/0000-0002-0224-8726				Abbott KC, 2004, KIDNEY INT, V65, P597, DOI 10.1111/j.1523-1755.2004.00385.x; Abdulla J, 2008, EUR HEART J, V29, P594, DOI 10.1093/eurheartj/ehn010; Afshinnia F, 2010, NEPHROL DIAL TRANSPL, V25, P1173, DOI 10.1093/ndt/gfp640; Balducci S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049297; Bolignano D, 2013, NEPHROL DIAL TRANSPL, V28, P82, DOI 10.1093/ndt/gft302; Bonds DE, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.b4909; Brodovicz KG, 2013, CURR MED RES OPIN, V29, P101, DOI 10.1185/03007995.2012.754744; Cappy C S, 1999, J Ren Nutr, V9, P63; Castaneda C, 2002, DIABETES CARE, V25, P2335, DOI 10.2337/diacare.25.12.2335; Centers for Disease Control and Prevention (CDC), 2014, NAT CHRON KIDN DIS F; Chen PY, 2010, J NURS RES, V18, P98, DOI 10.1097/JNR.0b013e3181dda726; Fleischmann E, 1999, KIDNEY INT, V55, P1560, DOI 10.1046/j.1523-1755.1999.00389.x; Fox CS, 2006, CIRCULATION, V113, P2914, DOI 10.1161/CIRCULATIONAHA.106.613828; Goel K, 2011, AM HEART J, V161, P590, DOI 10.1016/j.ahj.2010.12.012; Heiwe S, 2011, COCHRANE DB SYST REV, V5; Hsu PF, 2013, DIABETES CARE, V36, P894, DOI 10.2337/dc12-0916; Huang CX, 2010, KIDNEY INT, V77, P624, DOI 10.1038/ki.2009.524; International Diabetes Federation, 2013, IDF DIABETES ATLAS, Vsixth; Kalantar-Zadeh K, 2005, AM J KIDNEY DIS, V46, P489, DOI 10.1053/j.ajkd.2005.05.020; Kalantar-Zadeh K, 2004, J AM COLL CARDIOL, V43, P1439, DOI 10.1016/j.jacc.2003.11.039; Kalantar-Zadeh K, 2010, MAYO CLIN PROC, V85, P991, DOI 10.4065/mcp.2010.0336; Leavey SF, 1998, AM J KIDNEY DIS, V31, P997, DOI 10.1053/ajkd.1998.v31.pm9631845; Leehey DJ, 2009, CARDIOVASC DIABETOL, V8, DOI 10.1186/1475-2840-8-62; MacLaughlin HL, 2010, AM J KIDNEY DIS, V55, P69, DOI 10.1053/j.ajkd.2009.09.011; MARCKMANN P, 1989, J INTERN MED, V226, P429, DOI 10.1111/j.1365-2796.1989.tb01419.x; Matsuoka Kempei, 1991, Journal of Diabetic Complications, V5, P98, DOI 10.1016/0891-6632(91)90032-K; McAuley PA, 2012, MAYO CLIN PROC, V87, P443, DOI 10.1016/j.mayocp.2012.01.013; McCoy RG, 2013, ENDOCR PRACT, V19, P792, DOI 10.4158/EP12382.OR; Morales E, 2003, AM J KIDNEY DIS, V41, P319, DOI 10.1053/ajkd.2003.50039; Noori N, 2010, AM J CLIN NUTR, V92, P1060, DOI 10.3945/ajcn.2010.29188; Norris SL, 2005, COCHRANE DB SYST REV, V3; Park J, 2014, PROG CARDIOVASC DIS, V56, P415, DOI 10.1016/j.pcad.2013.10.005; Port FK, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1341061; Postorino M, 2009, J AM COLL CARDIOL, V53, P1265, DOI 10.1016/j.jacc.2008.12.040; Ramkumar N, 2005, PERITON DIALYSIS INT, V25, P461; Saiki A, 2005, INT J OBESITY, V29, P1115, DOI 10.1038/sj.ijo.0803009; Sigal RJ, 2007, ANN INTERN MED, V147, P357, DOI 10.7326/0003-4819-147-6-200709180-00005; SOLERTE SB, 1989, INT J OBESITY, V13, P203; Stenvinkel P, 2008, CLIN J AM SOC NEPHRO, V3, P505, DOI 10.2215/CJN.03670807; Tawney KW, 2000, AM J KIDNEY DIS, V36, P581, DOI 10.1053/ajkd.2000.16197; Thomas DR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002968.pub2; Wang JL, 2012, NEPHRON CLIN PRACT, V121, pC102, DOI 10.1159/000345159; Wing R, 2013, NEW ENGL J MED, V369, P145, DOI 10.1056/NEJMoa1212914; Yu TM, 2014, NEUROLOGY, V83, P686, DOI 10.1212/WNL.0000000000000711; Zhao YN, 2012, DIABETES CARE, V35, P1126, DOI 10.2337/dc11-2048; Zoungas S, 2010, NEW ENGL J MED, V363, P1410, DOI 10.1056/NEJMoa1003795	46	26	26	0	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 25	2014	9	11							e113667	10.1371/journal.pone.0113667	http://dx.doi.org/10.1371/journal.pone.0113667			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AU9GL	25423489	Green Published, Green Submitted, gold			2023-01-03	WOS:000345899700050
J	Sato, K; Choyke, PL; Kobayashi, H				Sato, Kazuhide; Choyke, Peter L.; Kobayashi, Hisataka			Photoimmunotherapy of Gastric Cancer Peritoneal Carcinomatosis in a Mouse Model	PLOS ONE			English	Article							CYTOSINE-ANALOG CS-682; ORTHOTOPIC MODEL; FLUORESCENT; EFFICACY; SURVIVAL; GROWTH; TUMORS	Photoimmunotherapy (PIT) is a new cancer treatment that combines the specificity of antibodies for targeting tumors with the toxicity induced by photosensitizers after exposure to near infrared (NIR) light. We performed PIT in a model of disseminated gastric cancer peritoneal carcinomatosis and monitored efficacy with in vivo GFP fluorescence imaging. In vitro and in vivo experiments were conducted with a HER2-expressing, GFP-expressing, gastric cancer cell line (N87-GFP). A conjugate comprised of a photosensitizer, IR-700, conjugated to trastuzumab (tra-IR700), followed by NIR light was used for PIT. In vitro PIT was evaluated by measuring cytotoxicity with dead staining and a decrease in GFP fluorescence. In vivo PIT was evaluated in a disseminated peritoneal carcinomatosis model and a flank xenograft using tumor volume measurements and GFP fluorescence intensity. In vivo anti-tumor effects of PIT were confirmed by significant reductions in tumor volume (at day 15, p<0.0001 vs. control) and GFP fluorescence intensity (flank model: at day 3, PIT treated vs. control p<0.01 and peritoneal disseminated model: at day 3 PIT treated vs. control, p<0.05). Cytotoxic effects in vitro were shown to be dependent on the light dose and caused necrotic cell rupture leading to GFP release and a decrease in fluorescence intensity in vitro. Thus, loss of GFP fluorescence served as a useful biomarker of cell necrosis after PIT.	[Sato, Kazuhide; Choyke, Peter L.; Kobayashi, Hisataka] NCI, Mol Imaging Program, Ctr Canc Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kobayashi, H (corresponding author), NCI, Mol Imaging Program, Ctr Canc Res, Bethesda, MD 20892 USA.	Kobayash@mail.nih.gov		Sato, Kazuhide/0000-0003-3025-088X	NIH Intramural program; JSPS; NATIONAL CANCER INSTITUTE [ZIABC011513] Funding Source: NIH RePORTER	NIH Intramural program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the NIH Intramural program and JSPS Research Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Caysa H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047927; de Martel C, 2013, GASTROENTEROL CLIN N, V42, P219, DOI 10.1016/j.gtc.2013.01.003; Ferro A, 2014, EUR J CANCER, V50, P1330, DOI 10.1016/j.ejca.2014.01.029; Gretschel S, 2006, BRIT J SURG, V93, P1530, DOI 10.1002/bjs.5513; Hoffman RM, 2005, NAT REV CANCER, V5, P796, DOI 10.1038/nrc1717; Hoffman RM, 2002, LANCET ONCOL, V3, P546, DOI 10.1016/S1470-2045(02)00848-3; Katz MH, 2004, CANCER RES, V64, P1828, DOI 10.1158/0008-5472.CAN-03-3350; Katz MH, 2003, CANCER RES, V63, P5521; Kimura H, 2010, J CELL BIOCHEM, V110, P1439, DOI 10.1002/jcb.22693; MEW D, 1983, J IMMUNOL, V130, P1473; Mitsunaga M, 2012, BIOCONJUGATE CHEM, V23, P604, DOI 10.1021/bc200648m; Mitsunaga M, 2011, NAT MED, V17, P1685, DOI 10.1038/nm.2554; Nakajima T, 2013, THERANOSTICS, V3, P357, DOI 10.7150/thno.5908; Nakajima T, 2012, CANCER RES, V72, P4622, DOI 10.1158/0008-5472.CAN-12-1298; Sano K, 2013, ACS NANO, V7, P717, DOI 10.1021/nn305011p; Sato K, 2014, MOL ONCOL, V8, P620, DOI 10.1016/j.molonc.2014.01.006; Sato K, 2011, MOL BIOL CELL, V22, P3103, DOI 10.1091/mbc.E11-03-0274; Shirasu N., 2014, INT J CANCER, P1; Spring BQ, 2014, P NATL ACAD SCI USA, V111, pE933, DOI 10.1073/pnas.1319493111; Sugarbaker PH, 2000, ONCOLOGY-BASEL, V58, P96, DOI 10.1159/000012086; Thomassen I, 2014, INT J CANCER, V134, P622, DOI 10.1002/ijc.28373; Vermes I, 2000, J IMMUNOL METHODS, V243, P167, DOI 10.1016/S0022-1759(00)00233-7; Walsh GM, 1998, J IMMUNOL METHODS, V217, P153, DOI 10.1016/S0022-1759(98)00103-3; Yamashita-Kashima Y, 2014, GASTRIC CANCER, V17, P638, DOI 10.1007/s10120-013-0329-8; Yang M, 2000, P NATL ACAD SCI USA, V97, P1206, DOI 10.1073/pnas.97.3.1206	25	58	66	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 17	2014	9	11							e113276	10.1371/journal.pone.0113276	http://dx.doi.org/10.1371/journal.pone.0113276			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT8BL	25401794	Green Published, Green Submitted, gold			2023-01-03	WOS:000345158700128
J	Montag, C; Haase, L; Seidel, D; Bayerl, M; Gallinat, J; Herrmann, U; Dannecker, K				Montag, Christiane; Haase, Laura; Seidel, Dorothea; Bayerl, Martin; Gallinat, Juergen; Herrmann, Uwe; Dannecker, Karin			A Pilot RCT of Psychodynamic Group Art Therapy for Patients in Acute Psychotic Episodes: Feasibility, Impact on Symptoms and Mentalising Capacity	PLOS ONE			English	Article							EMOTIONAL AWARENESS SCALE; GERMAN VERSION; SCHIZOPHRENIA; MIND; DEFICITS; PSYCHOPATHOLOGY; MENTALIZATION; PSYCHOTHERAPY; ALEXITHYMIA; DEPRESSION	This pilot study aimed to evaluate the feasibility of an assessor-blind, randomised controlled trial of psychodynamic art therapy for the treatment of patients with schizophrenia, and to generate preliminary data on the efficacy of this intervention during acute psychotic episodes. Fifty-eight inpatients with DSM-diagnoses of schizophrenia were randomised to either 12 twice-weekly sessions of psychodynamic group art therapy plus treatment as usual or to standard treatment alone. Primary outcome criteria were positive and negative psychotic and depressive symptoms as well as global assessment of functioning. Secondary outcomes were mentalising function, estimated with the Reading the mind in the eyes test and the Levels of emotional awareness scale, self-efficacy, locus of control, quality of life and satisfaction with care. Assessments were made at baseline, at post-treatment and at 12 weeks' follow-up. At 12 weeks, 55% of patients randomised to art therapy, and 66% of patients receiving treatment as usual were examined. In the per-protocol sample, art therapy was associated with a significantly greater mean reduction of positive symptoms and improved psychosocial functioning at post-treatment and follow-up, and with a greater mean reduction of negative symptoms at follow-up compared to standard treatment. The significant reduction of positive symptoms at post-treatment was maintained in an attempted intention-to-treat analysis. There were no group differences regarding depressive symptoms. Of secondary outcome parameters, patients in the art therapy group showed a significant improvement in levels of emotional awareness, and particularly in their ability to reflect about others' emotional mental states. This is one of the first randomised controlled trials on psychodynamic group art therapy for patients with acute psychotic episodes receiving hospital treatment. Results prove the feasibility of trials on art therapy during acute psychotic episodes and justify further research to substantiate preliminary positive results regarding symptom reduction and the recovery of mentalising function.	[Montag, Christiane; Haase, Laura; Seidel, Dorothea; Bayerl, Martin; Gallinat, Juergen] Charite, Dept Psychiat & Psychotherapy, D-13353 Berlin, Germany; [Seidel, Dorothea; Herrmann, Uwe; Dannecker, Karin] Weissensee Sch Art Kunsthochschule Berlin Weissen, Art Therapy Dept, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Montag, C (corresponding author), Charite, Dept Psychiat & Psychotherapy, Campus Mitte, D-13353 Berlin, Germany.	christiane.montag@charite.de		Montag, Christiane/0000-0002-3307-276X	Weissensee School of Art	Weissensee School of Art	The study was financially supported by the Weissensee School of Art. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andreasen N., 1984, SCALE ASSESSMENT POS; Andreasen NC, 1983, SCALE ASSESSMENT NEG; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1111/1469-7610.00715; Baslet G, 2009, J NERV MENT DIS, V197, P655, DOI 10.1097/NMD.0b013e3181b3b20f; Boelte S, 2009, READING MIND EYES TE; Bora E, 2009, ACTA PSYCHIAT SCAND, V120, P253, DOI 10.1111/j.1600-0447.2009.01414.x; Brent B, 2009, J CLIN PSYCHOL, V65, P803, DOI 10.1002/jclp.20615; Brooker J., 2007, USE ART WORK ART PSY; Brune M, 2007, SCHIZOPHR RES, V92, P151, DOI 10.1016/J.SCHRES.2007.01.006; Brune M, 2005, SCHIZOPHRENIA BULL, V31, P21, DOI 10.1093/schbul/sbi002; Crawford MJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e846; Crawford MJ, 2007, EVID-BASED MENT HEAL, V10, P69, DOI 10.1136/ebmh.10.3.69; Dannecker K, 2010, PSYCHE ASTHETIK TRAN; Fergusson D, 2002, BMJ-BRIT MED J, V325, P652, DOI 10.1136/bmj.325.7365.652; First M, 2016, STRUCTURED CLIN INTE; Fonagy P., 2002, AFFEKTREGULIERUNG ME; Franklin M., 1992, ART THERAPY J AM ART, V9, P78, DOI [10.1080/07421656.1992.10758941, DOI 10.1080/07421656.1992.10758941]; Franks M, 2007, INT J ART THERAPY FO, V12, P3, DOI DOI 10.1080/17454830701265188; Gold C, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004025.pub2; GREEN BL, 1987, HOSP COMMUNITY PSYCH, V38, P988; Greenwood H, 2012, WHAT ASPEKTS ART THE; Guhne U, 2012, NERVENARZT, V83, P855, DOI 10.1007/s00115-011-3472-7; Harrow M, 2009, PSYCHIAT RES, V168, P186, DOI 10.1016/j.psychres.2008.06.002; Heenan D, 2006, DISABIL SOC, V21, P179, DOI 10.1080/09687590500498143; HELMCHEN H, 1995, NERVENARZT, V66, P231; Heubrock D, 1992, Z DIFFER DIAGNOSTISC, V13, P161; Karterud S., 2004, THER COMMUNITIES, V25, P43, DOI DOI 10.1080/08039480410006304; Kidd DC, 2013, SCIENCE, V342, P377, DOI 10.1126/science.1239918; Kircher TTJ, 2007, NEUROIMAGE, V34, P281, DOI 10.1016/j.neuroimage.2006.08.044; Korver-Nieberg N, 2014, PSYCHOL PSYCHOTHER-T, V87, P127, DOI 10.1111/papt.12010; Krampen G., 1991, FRAGEBOGEN KOMPETENZ; LANE RD, 1990, J PERS ASSESS, V55, P124, DOI 10.1207/s15327752jpa5501&2_12; LANE RD, 1987, AM J PSYCHIAT, V144, P133; Leech N.L., 2005, SPSS INTERMEDIATE ST, V2nd ed.; LEHRL S, 1995, ACTA NEUROL SCAND, V91, P335, DOI 10.1111/j.1600-0404.1995.tb07018.x; Leon AC, 2011, J PSYCHIATR RES, V45, P626, DOI 10.1016/j.jpsychires.2010.10.008; Levenson H., 1981, RES LOCUS CONTROL CO, P1, DOI DOI 10.1016/B978-0-12-443201-7.50006-3; Little RJ, 2012, STAT MED, V31, P3433, DOI 10.1002/sim.5519; Lysaker PH, 2011, PSYCHOL PSYCHOTHER-T, V84, P58, DOI 10.1348/147608310X520436; MacBeth A, 2011, PSYCHOL PSYCHOTHER-T, V84, P42, DOI 10.1348/147608310X530246; Mahony J., 1992, ART THERAPY HDB, P173; Mo SL, 2008, PSYCHIAT RES, V157, P21, DOI 10.1016/j.psychres.2006.04.002; Montag C, 2011, PSYCHIAT RES, V186, P203, DOI 10.1016/j.psychres.2010.09.006; Moritz S, 2007, CURR OPIN PSYCHIATR, V20, P619, DOI 10.1097/YCO.0b013e3282f0b8ed; MUESER KT, 1990, PSYCHOL MED, V20, P253, DOI 10.1017/S003329170001758X; Muller MJ, 1999, J PSYCHIATR RES, V33, P433, DOI 10.1016/S0022-3956(99)00018-7; National Research Council Panel on Handling Missing Data in Clinical Trials Committee on National Statistics Division of Behavioral and Social Sciences and Education, 2010, PREVENTION TREATMENT; Navratil L, 1965, SCHIZOPHRENIE KUNST; Or MB, 2010, ART PSYCHOTHER, V37, P319, DOI 10.1016/j.aip.2010.05.007; Patterson S., 2011, INT J ART THER, V16, P70, DOI [https://doi.org/10.1080/17454832.2011.604038, DOI 10.1080/17454832.2011.604038]; Patterson S, 2011, J MENT HEALTH, V20, P328, DOI 10.3109/09638237.2011.556163; Persons RW, 2009, INT J OFFENDER THER, V53, P433, DOI 10.1177/0306624X08320208; Prinzhorn H., 1922, BILDNEREI GEISTESKRA; Pukrop R, 1999, NERVENARZT, V70, P41, DOI 10.1007/s001150050399; Richardson P., 2007, J MENT HEALTH, V16, P483, DOI [DOI 10.1080/09638230701483111, https://doi.org/10.1080/09638230701483111]; Riedel-Heller SG, 2012, PSYCHOTHER PSYCH MED, V62, P425, DOI 10.1055/s-0032-1327676; Rohricht F, 2006, PSYCHOL MED, V36, P669, DOI 10.1017/S0033291706007161; Ruddy R, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003728.pub2; Sarra N, 1998, ART PSYCHOTHERAPY GR; Sass H, 2003, MANUAL PSYCHISCHER S; Schaverien Joy, 1997, ART PSYCHOTHERAPY PS; SCHMIDT J, 1989, PSYCHOTHER PSYCH MED, V39, P248; Spaniol S, 2001, ART PSYCHOTHER, V28, P221, DOI 10.1016/S0197-4556(01)00108-3; Springham N., 2012, INT J ART THERAPY, V17, P115, DOI [10.1080/17454832.2012.734835, DOI 10.1080/17454832.2012.734835]; Sprong M, 2007, BRIT J PSYCHIAT, V191, P5, DOI 10.1192/bjp.bp.107.035899; Subic-Wrana C, 2005, PSYCHOSOM MED, V67, P483, DOI 10.1097/01.psy.0000160461.19239.13; Subic-Wrana C, 2001, PSYCHOTHERAPEUT, V46, P176, DOI 10.1007/s002780100157; Subic-Wrana C, 2011, INT J PSYCHOANAL, V92, P289, DOI 10.1111/j.1745-8315.2011.00392.x; Subic-Wrana C, 2010, PSYCHOSOM MED, V72, P404, DOI 10.1097/PSY.0b013e3181d35e83; Teglbjaerg HS, 2011, PSYCHOPATHOLOGY, V44, P314, DOI 10.1159/000325025; Ulrich G, 2007, ACTA PSYCHIAT SCAND, V116, P362, DOI 10.1111/j.1600-0447.2007.01073.x; van Ginkel J. R, 2014, SPSS SYNTAX APPLYING; van Ginkel JR, 2014, MULTIVAR BEHAV RES, V49, P78, DOI 10.1080/00273171.2013.855890; van 't Wout M, 2007, COMPR PSYCHIAT, V48, P27, DOI 10.1016/j.comppsych.2006.07.003; Vauth R, 2004, PSYCHIAT RES, V128, P155, DOI 10.1016/j.psychres.2004.05.018; Wright CC, 2003, J CLIN EPIDEMIOL, V56, P833, DOI 10.1016/S0895-4356(03)00155-0; [郑日昌 Zheng Richang], 2005, [心理学报, Acta Psychologica Sinica], V37, P403	77	45	45	0	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2014	9	11							e112348	10.1371/journal.pone.0112348	http://dx.doi.org/10.1371/journal.pone.0112348			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AY6YT	25393414	Green Submitted, Green Published, gold			2023-01-03	WOS:000347709300053
J	Fujii, S; Matsumoto, S; Nojima, S; Morii, E; Kikuchi, A				Fujii, S.; Matsumoto, S.; Nojima, S.; Morii, E.; Kikuchi, A.			Arl4c expression in colorectal and lung cancers promotes tumorigenesis and may represent a novel therapeutic target	ONCOGENE			English	Article							GASTRIC-CANCER; SIGNALING PATHWAYS; EXCHANGE FACTORS; TUMOR-CELLS; WNT; BINDING; ACTIVATION; INVASION; FAMILY; GROWTH	We recently demonstrated that expression of ADP-ribosylation factor (ARF)-like 4c (Arl4c) induced by a combination of Wnt/beta-catenin and epidermal growth factor/Ras signaling in normal epithelial cells grown in three-dimensional culture promotes cellular migration and proliferation, resulting in formation of tube-like structures, suggesting the involvement of Arl4c in epithelial morphogenesis. It is conceivable that there could be a common mechanism between epithelial morphogenesis and carcinogenesis. Therefore the current study was conducted to investigate whether Arl4c might be involved in tumorigenesis. Immunohistochemical analyses of tissue specimens obtained from colorectal and lung cancer patients revealed that Arl4c was not observed in non-tumor regions but was strongly expressed at high frequencies in tumor lesions. Inhibition of Wnt/beta-catenin or Ras/mitogen-activated protein kinase signaling reduced Arl4c mRNA levels in HCT116 colorectal cancer cells and A549 lung cancer cells. Knockdown of Arl4c inhibited Rac activity and also prevented nuclear localization of yes-associated protein (YAP)/transcriptional co-activator with PDZ-binding motif (TAZ) in these cancer cells. Arl4c-depleted cancer cells consistently showed decreased migration, invasion and proliferation capabilities both in vitro and in vivo. Furthermore, direct injection of Arl4c small interfering RNA (siRNA) into HCT116 cell-derived tumors (in vivo treatment with siRNA) inhibited tumor growth in immunodeficient mice. These results suggest that Arl4c is involved in tumorigenesis and might represent a novel therapeutic target for suppressing proliferation and invasion of colorectal and lung cancer cells.	[Fujii, S.; Matsumoto, S.; Kikuchi, A.] Osaka Univ, Dept Mol Biol & Biochem, Grad Sch Med, Suita, Osaka 5650871, Japan; [Fujii, S.] Osaka Univ, IPBS, Inst Acad Initiat, Suita, Osaka 5650871, Japan; [Nojima, S.; Morii, E.] Osaka Univ, Dept Pathol, Grad Sch Med, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University	Kikuchi, A (corresponding author), Osaka Univ, Dept Mol Biol & Biochem, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	akikuchi@molbiobc.med.osaka-u.ac.jp			Ministry of Education, Science and Culture of Japan [25250018, 26861547, 25860211, 23112004]; Uehara Memorial Foundation	Ministry of Education, Science and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Uehara Memorial Foundation(Uehara Memorial Foundation)	We thank Dr Y Shintani and Dr K Shojima for valuable discussions regarding Arl4c expression and their technical assistance. We also thank Dr T Kobayashi, Dr W Yasui and Dr K Matsumoto for donating cells. This work was supported by Grants-in-Aid for Scientific Research to AK (2013-2014) (No. 25250018), SF (2014) (No. 26861547) and SM (2013-2014) (No. 25860211) and for Scientific Research on Innovative Areas to AK (2011-2014) (No. 23112004) from the Ministry of Education, Science and Culture of Japan and by grants from the Uehara Memorial Foundation.	Barry ER, 2013, NATURE, V493, P106, DOI 10.1038/nature11693; Burd CG, 2004, TRENDS CELL BIOL, V14, P687, DOI 10.1016/j.tcb.2004.10.004; Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; Dorsett Y, 2004, NAT REV DRUG DISCOV, V3, P318, DOI 10.1038/nrd1345; Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101; Engel T, 2004, FEBS LETT, V566, P241, DOI 10.1016/j.febslet.2004.04.048; Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919; Gayet J, 2001, ONCOGENE, V20, P5025, DOI 10.1038/sj.onc.1204611; Gon H, 2013, MOL BIOL CELL, V24, P3764, DOI 10.1091/mbc.E13-07-0357; Hanaki H, 2012, MOL CANCER THER, V11, P298, DOI 10.1158/1535-7163.MCT-11-0682; Hashimoto S, 2004, P NATL ACAD SCI USA, V101, P6647, DOI 10.1073/pnas.0401753101; Hofmann I, 2007, CURR BIOL, V17, P711, DOI 10.1016/j.cub.2007.03.007; Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356; Ikeda JI, 2009, CANCER SCI, V100, P429, DOI 10.1111/j.1349-7006.2008.01066.x; Jacobs S, 1999, FEBS LETT, V456, P384, DOI 10.1016/S0014-5793(99)00759-0; Ji H, 2010, NATURE, V467, P338, DOI 10.1038/nature09367; Jiao S, 2014, CANCER CELL, V25, P166, DOI 10.1016/j.ccr.2014.01.010; Kagawa Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083629; Kikuchi A, 2011, INT REV CEL MOL BIO, V291, P21, DOI 10.1016/B978-0-12-386035-4.00002-1; Krypuy M, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-295; Kurayoshi M, 2006, CANCER RES, V66, P10439, DOI 10.1158/0008-5472.CAN-06-2359; Li CC, 2007, MOL BIOL CELL, V18, P4420, DOI 10.1091/mbc.E07-02-0149; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Matsumoto S, 2014, EMBO J, V33, P702, DOI 10.1002/embj.201386942; Matsumoto S, 2010, EMBO J, V29, P1192, DOI 10.1038/emboj.2010.26; McCormick F, 1999, TRENDS BIOCHEM SCI, V24, pM53, DOI 10.1016/S0968-0004(99)01480-2; Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016; Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998; Mori M, 2001, MODERN PATHOL, V14, P72, DOI 10.1038/modpathol.3880259; Nieto MA, 2013, SCIENCE, V342; O'Brien LE, 2002, NAT REV MOL CELL BIO, V3, P531, DOI 10.1038/nrm859; Pasqualato S, 2002, EMBO REP, V3, P1035, DOI 10.1093/embo-reports/kvf221; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Salhia B, 2005, CANCER RES, V65, P8792, DOI 10.1158/0008-5472.CAN-05-0160; Sato A, 2010, EMBO J, V29, P41, DOI 10.1038/emboj.2009.322; Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202; She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023; Shitashige M, 2010, CANCER RES, V70, P5024, DOI 10.1158/0008-5472.CAN-10-0306; Sunaga N, 2011, MOL CANCER THER, V10, P336, DOI 10.1158/1535-7163.MCT-10-0750; Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029; Wang LJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065539; Wei SM, 2009, BIOCHEM BIOPH RES CO, V384, P352, DOI 10.1016/j.bbrc.2009.04.125; Yamamoto H, 2009, GASTROENTEROLOGY, V137, P242, DOI 10.1053/j.gastro.2009.02.003; Yang J, 2006, J BIOL CHEM, V281, P17751, DOI 10.1074/jbc.M600831200	46	45	47	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2015	34	37					4834	4844		10.1038/onc.2014.402	http://dx.doi.org/10.1038/onc.2014.402			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR0YP	25486429				2023-01-03	WOS:000361050000004
J	Yoshihara, K; Wang, Q; Torres-Garcia, W; Zheng, S; Vegesna, R; Kim, H; Verhaak, RGW				Yoshihara, K.; Wang, Q.; Torres-Garcia, W.; Zheng, S.; Vegesna, R.; Kim, H.; Verhaak, R. G. W.			The landscape and therapeutic relevance of cancer-associated transcript fusions	ONCOGENE			English	Article							GENE FUSIONS; TYROSINE KINASE; BREAST-CANCER; IDENTIFICATION; GENOME; REARRANGEMENTS; ABERRATIONS; INHIBITION; RESOURCE; PATTERNS	Transcript fusions as a result of chromosomal rearrangements have been a focus of attention in cancer as they provide attractive therapeutic targets. To identify novel fusion transcripts with the potential to be exploited therapeutically, we analyzed RNA sequencing, DNA copy number and gene mutation data from 4366 primary tumor samples. To avoid false positives, we implemented stringent quality criteria that included filtering of fusions detected in RNAseq data from 364 normal tissue samples. Our analysis identified 7887 high confidence fusion transcripts across 13 tumor types. Our fusion prediction was validated by evidence of a genomic rearrangement for 78 of 79 fusions in 48 glioma samples where whole-genome sequencing data were available. Cancers with higher levels of genomic instability showed a corresponding increase in fusion transcript frequency, whereas tumor samples harboring fusions contained statistically significantly fewer driver gene mutations, suggesting an important role for tumorigenesis. We identified at least one in-frame protein kinase fusion in 324 of 4366 samples (7.4%). Potentially druggable kinase fusions involving ALK, ROS, RET, NTRK and FGFR gene families were detected in bladder carcinoma (3.3%), glioblastoma (4.4%), head and neck cancer (1.0%), low-grade glioma (1.5%), lung adenocarcinoma (1.6%), lung squamous cell carcinoma (2.3%) and thyroid carcinoma (8.7%), suggesting a potential for application of kinase inhibitors across tumor types. Inframe fusion transcripts involving histone methyltransferase or histone demethylase genes were detected in 111 samples (2.5%) and may additionally be considered as therapeutic targets. In summary, we described the landscape of transcript fusions detected across a large number of tumor samples and revealed fusion events with clinical relevance that have not been previously recognized. Our results support the concept of basket clinical trials where patients are matched with experimental therapies based on their genomic profile rather than the tissue where the tumor originated.	[Yoshihara, K.; Wang, Q.; Torres-Garcia, W.; Zheng, S.; Vegesna, R.; Kim, H.; Verhaak, R. G. W.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Yoshihara, K.] Niigata Univ, Grad Sch Med & Dent Sci, Dept Obstet & Gynecol, Niigata, Japan; [Verhaak, R. G. W.] Univ Texas MD Anderson Canc Ctr, Dept Genome Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Niigata University; University of Texas System; UTMD Anderson Cancer Center	Verhaak, RGW (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Dept Bioinformat & Computat Biol, 1400 Pressler St,Unit 1410, Houston, TX 77030 USA.	rverhaak@mdanderson.org	Kim, Hoon/AAL-9283-2020; Yoshihara, Kosuke/AAU-9874-2020; Verhaak, Roel/ABE-7058-2020; Torres-Garcia, Wandaliz/L-6347-2017	Kim, Hoon/0000-0003-4244-6126; Yoshihara, Kosuke/0000-0002-2254-3378; 	Mary K Chapman Foundation; Michael & Susan Dell Foundation; US National Cancer Institute (MD Anderson TCGA Genome Data Analysis Center) [CA143883, CA083639]; MD Anderson Cancer Center [P30 CA016672]; NATIONAL CANCER INSTITUTE [U24CA143883, P50CA083639, P30CA016672] Funding Source: NIH RePORTER	Mary K Chapman Foundation; Michael & Susan Dell Foundation; US National Cancer Institute (MD Anderson TCGA Genome Data Analysis Center); MD Anderson Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The results published here are in whole or part based upon data generated by The Cancer Genome Atlas project established by the NCI and NHGRI. Information about TCGA and the investigators and institutions who constitute the TCGA research network can be found at 'http://cancergenome.nih.gov'. This work was supported in part by the Mary K Chapman Foundation, the Michael & Susan Dell Foundation (honoring Lorraine Dell), US National Cancer Institute (MD Anderson TCGA Genome Data Analysis Center) grant numbers CA143883 and CA083639, and MD Anderson Cancer Center Support Grant P30 CA016672 (the Bioinformatics Shared Resource).	Arrowsmith CH, 2012, NAT REV DRUG DISCOV, V11, P384, DOI 10.1038/nrd3674; Asmann YW, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr362; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Cadot B, 2009, CANCER RES, V69, P6074, DOI 10.1158/0008-5472.CAN-08-2796; Chen K, 2009, NAT METHODS, V6, P677, DOI [10.1038/NMETH.1363, 10.1038/nmeth.1363]; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Daigle SR, 2011, CANCER CELL, V20, P53, DOI 10.1016/j.ccr.2011.06.009; Edgren H, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-1-r6; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Gough SM, 2014, CANCER DISCOV, V4, P564, DOI 10.1158/2159-8290.CD-13-0419; Guo GW, 2013, NAT GENET, V45, P1459, DOI 10.1038/ng.2798; Hallberg B, 2013, NAT REV CANCER, V13, P685, DOI 10.1038/nrc3580; Hojfeldt JW, 2013, NAT REV DRUG DISCOV, V12, P917, DOI 10.1038/nrd4154; Honeyman JN, 2014, SCIENCE, V343, P1010, DOI 10.1126/science.1249484; Kalyana-Sundaram S, 2012, NEOPLASIA, V14, P702, DOI 10.1593/neo.12914; Kantarjian H, 2006, CANCER-AM CANCER SOC, V106, P1794, DOI 10.1002/cncr.21792; Kantarjian H, 2010, NEW ENGL J MED, V362, P2260, DOI 10.1056/NEJMoa1002315; Kim P, 2010, NUCLEIC ACIDS RES, V38, pD81, DOI 10.1093/nar/gkp982; Lam ET, 2010, J CLIN ONCOL, V28, P2323, DOI 10.1200/JCO.2009.25.0068; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Li J, 2013, NAT METHODS, V10, P1046, DOI [10.1038/nmeth.2650, 10.1038/NMETH.2650]; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41; Meyerson M, 2010, NAT REV GENET, V11, P685, DOI 10.1038/nrg2841; Mitelman F, 2004, NAT GENET, V36, P331, DOI 10.1038/ng1335; Mitelman F, 2007, NAT REV CANCER, V7, P233, DOI 10.1038/nrc2091; NOWELL PC, 1960, SCIENCE, V132, P1497; Olsen EA, 2007, J CLIN ONCOL, V25, P3109, DOI 10.1200/JCO.2006.10.2434; Parker M, 2014, NATURE, V506, P451, DOI 10.1038/nature13109; R Core Team, 2021, R LANG ENV STAT COMP; Seo JS, 2012, GENOME RES, V22, P2109, DOI 10.1101/gr.145144.112; Shah N, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-818; Shaw AT, 2013, NAT REV CANCER, V13, P772, DOI 10.1038/nrc3612; Shaw AT, 2013, NEW ENGL J MED, V368, P2385, DOI 10.1056/NEJMoa1214886; Shern JF, 2014, CANCER DISCOV, V4, P216, DOI 10.1158/2159-8290.CD-13-0639; Singh D, 2012, SCIENCE, V337, P1231, DOI 10.1126/science.1220834; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Teng YC, 2013, CANCER RES, V73, P4711, DOI 10.1158/0008-5472.CAN-12-3165; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Torres-Garcia W, 2014, BIOINFORMATICS, V30, P2224, DOI 10.1093/bioinformatics/btu169; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vaishnavi A, 2013, NAT MED, V19, P1469, DOI 10.1038/nm.3352; Watson IR, 2013, NAT REV GENET, V14, P703, DOI 10.1038/nrg3539; Wells SA, 2010, J CLIN ONCOL, V28, P767, DOI 10.1200/JCO.2009.23.6604; Wu CX, 2012, J PATHOL, V227, P53, DOI 10.1002/path.3987; Wu YM, 2013, CANCER DISCOV, V3, P636, DOI 10.1158/2159-8290.CD-13-0050; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760; Zhao M, 2013, NUCLEIC ACIDS RES, V41, pD970, DOI 10.1093/nar/gks937; Zheng SY, 2013, GENE DEV, V27, P1462, DOI 10.1101/gad.213686.113	53	296	300	2	40	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2015	34	37					4845	4854		10.1038/onc.2014.406	http://dx.doi.org/10.1038/onc.2014.406			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR0YP	25500544	Green Accepted			2023-01-03	WOS:000361050000005
J	Del Mastro, L; De Placido, S; Bruzzi, P; De Laurentiis, M; Boni, C; Cavazzini, G; Durando, A; Turletti, A; Nistico, C; Valle, E; Garrone, O; Puglisi, F; Montemurro, F; Barni, S; Ardizzoni, A; Gamucci, T; Colantuoni, G; Giuliano, M; Gravina, A; Papaldo, P; Bighin, C; Bisagni, G; Forestieri, V; Cognetti, F				Del Mastro, Lucia y; De Placido, Sabino; Bruzzi, Paolo; De Laurentiis, Michele; Boni, Corrado; Cavazzini, Giovanna; Durando, Antonio; Turletti, Anna; Nistico, Cecilia; Valle, Enrichetta; Garrone, Ornella; Puglisi, Fabio; Montemurro, Filippo; Barni, Sandro; Ardizzoni, Andrea; Gamucci, Teresa; Colantuoni, Giuseppe; Giuliano, Mario; Gravina, Adriano; Papaldo, Paola; Bighin, Claudia; Bisagni, Giancarlo; Forestieri, Valeria; Cognetti, Francesco		Grp Italiano Mammella GIM Investig	Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 x 2 factorial, randomised phase 3 trial	LANCET			English	Article							CLINICAL-TRIALS; METAANALYSIS; PACLITAXEL; REGIMENS; LEUKEMIA; OUTCOMES; WOMEN	Background Whether addition of fluorouracil to epirubicin, cyclophosphamide, and paclitaxel (EC-P) is favourable in adjuvant treatment of patients with node-positive breast cancer is controversial, as is the benefit of increased density of dosing. We aimed to address these questions in terms of improvements in disease-free survival. Methods In this 2 x 2 factorial, open-label, phase 3 trial, we enrolled patients aged 18-70 years with operable, node positive, early-stage breast cancer from 81 Italian centres. Eligible patients were randomly allocated in a 1: 1: 1: 1 ratio with a centralised, interactive online system to receive either dose-dense chemotherapy (administered intravenously every 2 weeks with pegfilgrastim support) with fluorouracil plus EC-P (FEC-P) or EC-P or to receive standard-interval chemotherapy (administered intravenously every 3 weeks) with FEC-P or EC-P. The primary study endpoint was disease-free survival, assessed with the Kaplan-Meier method in the intention-to-treat population. Our primary comparisons were between dose schedule (every 2 weeks vs every 3 weeks) and dose type (FEC-P vs EC-P). This study is registered with ClinicalTrials.gov, number NCT00433420. Findings Between April 24, 2003, and July 3, 2006, we recruited 2091 patients. 88 patients were enrolled in centres that only provided standard-intensity dosing. After a median follow-up of 7.0 years (interquartile range [IQR] 4.5-6.3), 140 (26%) of 545 patients given EC-P every 3 weeks, 157 (29%) of 544 patients given FEC-P every 3 weeks, 111 (22%) of 502 patients given EC-P every 2 weeks, and 113 (23%) of 500 patients given FEC-P every 2 weeks had a disease-free survival event. For the dose-density comparison, disease-free survival at 5 years was 81% (95% CI 79-84) in patients treated every 2 weeks and 76% (74-79) in patients treated every 3 weeks (HR 0.77, 95% CI 0.65-0.92; p=0.004); overall survival rates at 5 years were 94% (93-96) and 89% (87-91; HR 0.65, 0.51-0.84; p=0.001) and for the chemotherapy-type comparison, disease-free survival at 5 years was 78% (75-81) in the FEC-P groups and 79% (76-82) in the EC-P groups (HR 1.06, 0.89-1.25; p=0.561); overall survival rates at 5 years were 91% (89-93) and 92% (90-94; 1.16, 0.91-1.46; p=0.234). Compared with 3 week dosing, chemotherapy every 2 weeks was associated with increased rate of grade 3-4 of anaemia (14 [1.4%] of 988 patients vs two [0.2%] of 984 patients; p=0.002); transaminitis (19 [1.9%] vs four [0.4%]; p=0.001), and myalgias (31 [3.1%] vs 16 [1.6%]; p=0.019), and decreased rates of grade 3-4 neutropenia (147 [14.9%] vs 433 [44.0%]; p<0.0001). Addition of fluorouracil led to increased rates of grade 3-4 neutropenia (354 [34.5%] of 1025 patients on FEC-P vs 250 [24.2%] of 1032 patients on EC-P; p<0.0001), fever (nine [0.9%] vs two [0.2%]), nausea (47 [4.6%] vs 28 [2.7%]), and vomiting (32 [3.1%] vs 15 [1.4%]). Interpretation In patients with node-positive early breast cancer, dose-dense adjuvant chemotherapy improved disease-free survival compared with standard interval chemotherapy. Addition of fluorouracil to a sequential EC-P regimen was not associated with an improved disease-free survival outcome.	[Del Mastro, Lucia y; Bighin, Claudia] Ist Nazl Ric Canc, IRCCS AOU San Martino IST, Dept Med Oncol, I-16132 Genoa, Italy; [Bruzzi, Paolo] Ist Nazl Ric Canc, IRCCS AOU San Martino IST, Epidemiol Unit, I-16132 Genoa, Italy; [De Placido, Sabino; Giuliano, Mario; Forestieri, Valeria] Azienda Osped Univ Federico II, Med Oncol, Naples, Italy; [De Laurentiis, Michele; Gravina, Adriano] Ist Nazl Tumori IRCCS Fdn Pascale, Med Oncol, Naples, Italy; [Boni, Corrado; Bisagni, Giancarlo] IRCCS Arcispedale S Maria Nuova, Med Oncol, Reggio Emilia, Italy; [Cavazzini, Giovanna] Azienda Osped Carlo Poma, Med Oncol, Mantua, Italy; [Durando, Antonio] Azienda Osped Univ Citta Saute & Sci, Breast Unit, Turin, Italy; [Turletti, Anna] ASLTO1, Med Oncol, Turin, Italy; [Nistico, Cecilia; Papaldo, Paola; Cognetti, Francesco] Ist Regina Elena Studio & Cura Tumori, Dept Med Oncol, Rome, Italy; [Valle, Enrichetta] ASL8 Osped Oncol, Med Oncol, Cagliari, Italy; [Garrone, Ornella] Osped Insegnamento S Croce & Carle, Dept Med Oncol, Cuneo, Italy; [Puglisi, Fabio] Azienda Osped Udine, Dept Oncol, Udine, Italy; [Montemurro, Filippo] Fdn Piemonte Oncol Candiolo Canc Ctr IRCCS, Investigat Clin Oncol, Turin, Italy; [Barni, Sandro] Azienda Osped, Med Oncol, Bergamo, Italy; [Ardizzoni, Andrea] Azienda Osped Univ, Med Oncol, Parma, Italy; [Gamucci, Teresa] Osped SS, ASL Frosinone, Med Oncol, Sora, Frosinone, Italy; [Colantuoni, Giuseppe] Azienda Osped S Giuseppe Moscati, Med Oncol, Avellino, Italy	University of Genoa; IRCCS AOU San Martino IST; University of Genoa; IRCCS AOU San Martino IST; IRCCS Fondazione Pascale; IRCCS Arcispedale S. Maria Nuova; Hospital Carlo Poma; A.O.U. Citta della Salute e della Scienza di Torino; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Fondazione del Piemonte per l'Oncologia; University of Parma; University Hospital of Parma; San Giuseppe Moscati Hospital	Del Mastro, L (corresponding author), Ist Nazl Ric Canc, IRCCS AOU San Martino IST, Dept Oncol, I-16132 Genoa, Italy.	lucia.delmastro@hsanmartino.it	Morano, Federica/B-7910-2018; Garrone, Ornella/HHS-9402-2022; Bisagni, Giancarlo/AAC-2735-2020; ardizzoni, andrea/AAC-4337-2021; Puglisi, Fabio/N-3863-2017; De Laurentiis, Michelino/AAC-6321-2022; Montemurro, Filippo/AAC-1957-2019; Cognetti, Francesco/AAC-2637-2019; Garrone, Ornella/AAC-5978-2022; Bruzzi, Paolo/AAU-3363-2021; Del Mastro, Lucia/J-6163-2016; Ferro, Antonella/AAA-8241-2020	Morano, Federica/0000-0002-5306-3596; Bisagni, Giancarlo/0000-0003-1042-3771; ardizzoni, andrea/0000-0003-2678-0714; Puglisi, Fabio/0000-0003-0573-4938; De Laurentiis, Michelino/0000-0001-9009-1572; Garrone, Ornella/0000-0001-7359-5410; Del Mastro, Lucia/0000-0002-9546-5841; Ferro, Antonella/0000-0003-4109-6769; Nistico, Cecilia/0000-0002-2379-5550; DE PLACIDO, Sabino/0000-0001-5077-6286; Bruzzi, Paolo/0000-0002-7874-2077; COGNETTI, FRANCESCO/0000-0003-2022-9446; Nuzzo, Annamaria/0000-0001-7328-5877; BIGHIN, Claudia/0000-0001-9956-0216; Montemurro, Filippo/0000-0003-4231-2291	Bristol-Myers Squibb; Pharmacia; Dompe Biotec	Bristol-Myers Squibb(Bristol-Myers Squibb); Pharmacia; Dompe Biotec	Bristol-Myers Squibb, Pharmacia, and Dompe Biotec.; We thank Marco Venturini, leader of the Gruppo Italiano Mammella (GIM) group, who left all of us too early. We thank patients, physicians, nurses, and trial coordinators who participated in the GIM2 trial. We acknowledge Giovanni Cucchiara and Carlo Panzano of Clinical Research Technology, Salerno, Italy, for clinical record online management. Simona Pastorino provided all the technical assistance and computer work for statistical analyses. The GIM group received financial support for trial conduct from Bristol-Myers Squibb and Pharmacia. Bristol-Myers Squibb provided paclitaxel and Dompe Biotech, Italy provided filgrastim.	Albain K, 2012, LANCET, V379, P432, DOI 10.1016/S0140-6736(11)61625-5; Berry DA, 2006, JAMA-J AM MED ASSOC, V295, P1658, DOI 10.1001/jama.295.14.1658; Bonilla L, 2010, JNCI-J NATL CANCER I, V102, P1845, DOI 10.1093/jnci/djq409; Budd GT, 2015, J CLIN ONCOL, V33, P58, DOI 10.1200/JCO.2014.56.3296; Cameron D, 2012, CANC RES S, V72; Citron ML, 2003, J CLIN ONCOL, V21, P1431, DOI 10.1200/JCO.2003.09.081; De Laurentiis M, 2008, J CLIN ONCOL, V26, P44, DOI 10.1200/JCO.2007.11.3787; Henderson IC, 2003, J CLIN ONCOL, V21, P976, DOI 10.1200/JCO.2003.02.063; Hillner BE, 2012, J CLIN ONCOL, V30, P772, DOI 10.1200/JCO.2011.40.2537; Hudis CA, 2007, J CLIN ONCOL, V25, P2127, DOI 10.1200/JCO.2006.10.3523; Kummel S, 2006, BRIT J CANCER, V94, P1237, DOI 10.1038/sj.bjc.6603085; Lambertini M, 2014, J CLIN ONCOL S, V32, p15s; Linden HM, 2007, J CLIN ONCOL, V25, P656, DOI 10.1200/JCO.2006.07.0847; Loibl S, 2011, SUPPORT CARE CANCER, V19, P1789, DOI 10.1007/s00520-010-1020-9; Lyman GH, 2010, J CLIN ONCOL, V28, P2914, DOI 10.1200/JCO.2009.25.8723; Moebus V, 2010, J CLIN ONCOL, V28, P2874, DOI 10.1200/JCO.2009.24.7643; *NAT CANC I, COMM TOX CRIT VERS 2; Proschan MA, 2000, CONTROL CLIN TRIALS, V21, P527, DOI 10.1016/S0197-2456(00)00106-9; Smith TJ, 2006, J CLIN ONCOL, V24, P3187, DOI 10.1200/JCO.2006.06.4451; Sparano JA, 2008, NEW ENGL J MED, V358, P1663, DOI 10.1056/NEJMoa0707056; Swain SM, 2013, J CLIN ONCOL, V31, P3197, DOI 10.1200/JCO.2012.48.1275; Venturini M, 2005, JNCI-J NATL CANCER I, V97, P1724, DOI 10.1093/jnci/dji398	22	117	117	1	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 9	2015	385	9980					1863	1872		10.1016/S0140-6736(14)62048-1	http://dx.doi.org/10.1016/S0140-6736(14)62048-1			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CH6ZE	25740286				2023-01-03	WOS:000354184500030
J	Frost, SHL; Frayo, SL; Miller, BW; Orozco, JJ; Booth, GC; Hylarides, MD; Lin, YK; Green, DJ; Gopal, AK; Pagel, JM; Back, TA; Fisher, DR; Press, OW				Frost, Sofia H. L.; Frayo, Shani L.; Miller, Brian W.; Orozco, Johnnie J.; Booth, Garrett C.; Hylarides, Mark D.; Lin, Yukang; Green, Damian J.; Gopal, Ajay K.; Pagel, John M.; Back, Tom A.; Fisher, Darrell R.; Press, Oliver W.			Comparative Efficacy of Lu-177 and Y-90 for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft Models	PLOS ONE			English	Article							B-CELL LYMPHOMAS; STREPTAVIDIN FUSION PROTEIN; NON-HODGKIN-LYMPHOMA; MONOCLONAL-ANTIBODY; PHASE I/II; INTRAPERITONEAL RADIOIMMUNOTHERAPY; OVARIAN-CANCER; MOUSE MODEL; THERAPY; TUMORS	Purpose Pretargeted radioimmunotherapy (PRIT) is a multi-step method of selectively delivering high doses of radiotherapy to tumor cells while minimizing exposure to surrounding tissues. Yttrium-90 (Y-90) and lutetium-177 (Lu-177) are two of the most promising beta-particle emitting radionuclides used for radioimmunotherapy, which despite having similar chemistries differ distinctly in terms of radiophysical features. These differences may have important consequences for the absorbed dose to tumors and normal organs. Whereas Y-90 has been successfully applied in a number of preclinical and clinical radioimmunotherapy settings, there have been few published pretargeting studies with Lu-177. We therefore compared the therapeutic potential of targeting either Y-90 or Lu-177 to human B-cell lymphoma xenografts in mice. Methods Parallel experiments evaluating the biodistribution, imaging, dosimetry, therapeutic efficacy, and toxicity were performed in female athymic nude mice bearing either Ramos (Burkitt lymphoma) or Granta (mantle cell lymphoma) xenografts, utilizing an anti-CD20 antibody-streptavidin conjugate (1F5-SA) and an Y-90- or Lu-177-labeled 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid (DOTA)-biotin second step reagent. Results The two radionuclides displayed comparable biodistributions in tumors and normal organs; however, the absorbed radiation dose delivered to tumor was more than twice as high for Y-90 (1.3 Gy/MBq) as for Lu-177 (0.6 Gy/MBq). More importantly, therapy with Y-90-DOTA-biotin was dramatically more effective than with Lu-177-DOTA-biotin, with 100% of Ramos xenograft-bearing mice cured with 37 MBq Y-90, whereas 0% were cured using identical amounts of Lu-177-DOTA-biotin. Similar results were observed in mice bearing Granta xenografts, with 80% of the mice cured with Y-90-PRIT and 0% cured with 177Lu-PRIT. Toxicities were comparable with both isotopes. Conclusion Y-90 was therapeutically superior to 177Lu for streptavidin-biotin PRIT approaches in these human lymphoma xenograft models.	[Frost, Sofia H. L.; Frayo, Shani L.; Orozco, Johnnie J.; Booth, Garrett C.; Hylarides, Mark D.; Lin, Yukang; Green, Damian J.; Gopal, Ajay K.; Pagel, John M.; Press, Oliver W.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA; [Miller, Brian W.] Pacific Northwest Natl Lab, Richland, WA USA; [Miller, Brian W.] Univ Arizona, Coll Opt Sci, Tucson, AZ USA; [Green, Damian J.; Gopal, Ajay K.; Pagel, John M.; Press, Oliver W.] Univ Washington, Dept Med, Seattle, WA USA; [Green, Damian J.; Gopal, Ajay K.; Pagel, John M.; Press, Oliver W.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA; [Back, Tom A.] Univ Gothenburg, Sahlgrenska Acad, Gothenburg, Sweden; [Fisher, Darrell R.] Dade Moeller Hlth Grp, Richland, WA USA	Fred Hutchinson Cancer Center; United States Department of Energy (DOE); Pacific Northwest National Laboratory; University of Arizona; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Gothenburg	Frost, SHL (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA.	sfrost@fredhutch.org		Back, Tom/0000-0002-3375-9473; Gopal, Ajay/0000-0003-3023-6834; Press, Oliver/0000-0002-3147-8037	Walker Immunotherapy Research Fellowship from Doug and Maggie Walker; David & Patricia Giuliani Family Foundation; Geoffrey Sally White; Wyner-Stokes Foundation; Frederick Kullman Memorial Fund; National Cancer Institute [P01CA044991, R01CA076287, R01CA138720, R01CA172582, R01CA136639, R01CA154897, R01CA109663, K08CA151682]; Dade Moeller Health Group; NATIONAL CANCER INSTITUTE [R01CA154897, R01CA076287, R01CA109663, R01CA136639, P01CA044991, R01CA138720, K08CA151682] Funding Source: NIH RePORTER	Walker Immunotherapy Research Fellowship from Doug and Maggie Walker; David & Patricia Giuliani Family Foundation; Geoffrey Sally White; Wyner-Stokes Foundation; Frederick Kullman Memorial Fund; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Dade Moeller Health Group; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Research reported in this manuscript was supported by a Walker Immunotherapy Research Fellowship from Doug and Maggie Walker (SHLF); by the David & Patricia Giuliani Family Foundation (OWP); by Geoffrey & Sally White (OWP); by the Wyner-Stokes Foundation (OWP); by the Frederick Kullman Memorial Fund (JMP); and by the National Cancer Institute under award numbers P01CA044991 (OWP, MDH, YL, AKG, JMP, DRF), R01CA076287 (OWP, SLF, GCB, MDH, YL, JMP), R01CA138720 (JMP, JJO), R01CA172582 (JMP), R01CA136639 (OWP, YL), R01CA154897 (OWP, DJG), R01CA109663 (OWP, SLF, GCB, MDH, YL, JMP), and K08CA151682 (DJG). Dade Moeller Health Group provided support in the form of salary for author DRF, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the 'author contributions' section.	Alvarez RD, 1997, GYNECOL ONCOL, V65, P94, DOI 10.1006/gyno.1996.4577; Axworthy DB, 2000, P NATL ACAD SCI USA, V97, P1802, DOI 10.1073/pnas.97.4.1802; Axworthy DB, 1999, US patent, Patent No. [5 955 605, 5955605]; Bernhardt P, 2001, ACTA ONCOL, V40, P602; Buchsbaum DJ, 2005, CLIN CANCER RES, V11, P8180, DOI 10.1158/1078-0432.CCR-05-0607; Donnou Sabrina, 2012, Adv Hematol, V2012, P701704, DOI 10.1155/2012/701704; Ferlay J, 2013, GLOBOCAN 2012 V1 0 C; Forrer F, 2005, J NUCL MED, V46, P1310; Forrer F, 2013, J NUCL MED, V54, P1045, DOI 10.2967/jnumed.112.115170; Goldenberg DM, 2006, J CLIN ONCOL, V24, P823, DOI 10.1200/JCO.2005.03.8471; Gopal AK, 2003, BLOOD, V102, P2351, DOI 10.1182/blood-2003-02-0622; HUI TE, 1994, CANCER, V73, P951; HUMM JL, 1990, J NUCL MED, V31, P75; Jadayel DM, 1997, LEUKEMIA, V11, P64, DOI 10.1038/sj.leu.2400555; Kaminski MS, 2000, BLOOD, V96, P1259, DOI 10.1182/blood.V96.4.1259.h8001259_1259_1266; KLEIN G, 1975, INTERVIROLOGY, V5, P319, DOI 10.1159/000149930; Lewis MR, 2004, NUCL MED BIOL, V31, P213, DOI 10.1016/j.nucmedbio.2003.08.004; Meredith RF, 1996, J NUCL MED, V37, P1491; Miller BW, 2014, NUCL INSTRUMENTS M A; Miller WH, 2005, CANCER BIOTHER RADIO, V20, P436, DOI 10.1089/cbr.2005.20.436; Mohsin H, 2011, BIOCONJUGATE CHEM, V22, P2444, DOI 10.1021/bc200258x; Mulligan T, 1995, CLIN CANCER RES, V1, P1447; NCRP, 1985, HDB RAD MEAS PROC, Vxvi; Paganelli G, 1999, EUR J NUCL MED, V26, P348, DOI 10.1007/s002590050397; Pagel JM, 2003, BLOOD, V101, P2340, DOI 10.1182/blood-2002-03-0874; Pagel JM, 2006, BLOOD, V108, P328, DOI 10.1182/blood-2005-11-4327; Pagel JM, 2009, BLOOD, V113, P4903, DOI 10.1182/blood-2008-11-187401; Persson M, 2007, CANCER RES, V67, P326, DOI 10.1158/0008-5472.CAN-06-2363; PRESS OW, 1993, NEW ENGL J MED, V329, P1219, DOI 10.1056/NEJM199310213291702; Press OW, 2000, BLOOD, V96, P2934; Press OW, 2001, BLOOD, V98, P2535, DOI 10.1182/blood.V98.8.2535; SCHLOM J, 1991, CANCER RES, V51, P2889; Schoffelen R, 2010, J NUCL MED, V51, P1780, DOI 10.2967/jnumed.110.079376; Seidl C, 2011, EUR J NUCL MED MOL I, V38, P312, DOI 10.1007/s00259-010-1639-2; Sharkey RM, 2003, CANCER RES, V63, P354; Stein R, 2001, J NUCL MED, V42, P967; Subbiah K, 2003, J NUCL MED, V44, P437; Uusijarvi H, 2006, J NUCL MED, V47, P807; Walter RB, 2010, CANCER BIOTHER RADIO, V25, P125, DOI 10.1089/cbr.2010.0759; Witzig TE, 2002, J CLIN ONCOL, V20, P2453, DOI 10.1200/JCO.2002.11.076	40	14	14	2	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 18	2015	10	3							e0120561	10.1371/journal.pone.0120561	http://dx.doi.org/10.1371/journal.pone.0120561			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE9BN	25785845	gold, Green Submitted, Green Published			2023-01-03	WOS:000352138500181
J	Dunlop, A; Welsh, L; McQuaid, D; Dean, J; Gulliford, S; Hansen, V; Bhide, S; Nutting, C; Harrington, K; Newbold, K				Dunlop, Alex; Welsh, Liam; McQuaid, Dualta; Dean, Jamie; Gulliford, Sarah; Hansen, Vibeke; Bhide, Shreerang; Nutting, Chris; Harrington, Kevin; Newbold, Kate			Brain-Sparing Methods for IMRT of Head and Neck Cancer	PLOS ONE			English	Article							NASOPHARYNGEAL CARCINOMA; COGNITIVE DECLINE; RADIATION-THERAPY; RADIOTHERAPY; CISPLATIN; TUMORS	Purpose Radical radiotherapy for head and neck cancer (HNC) may deliver significant doses to brain structures. There is evidence that this may cause a decline in neurocognitive function (NCF). Radiation dose to the medial temporal lobes, and particularly to the hippocampi, seems to be critical in determining NCF outcomes. We evaluated the feasibility of two alternative intensity-modulated radiotherapy (IMRT) techniques to generate hippocampus-and brain-sparing HNC treatment plans to preserve NCF. Methods and Materials A planning study was undertaken for ten patients with HNC whose planning target volume (PTV) included the nasopharynx. Patients had been previously treated using standard (chemo)-IMRT techniques. Bilateral hippocampi were delineated according to the RTOG atlas, on T1w MRI co-registered to the RT planning CT. Hippocampus-sparing plans (HSRT), and whole-brain/hippocampus-sparing fixed-field non-coplanar IMRT (BSRT) plans, were generated. DVHs and dose difference maps were used to compare plans. NTCP calculations for NCF impairment, based on hippocampal dosimetry, were performed for all plans. Results Significant reductions in hippocampal doses relative to standard plans were achieved in eight of ten cases for both HSRT and BSRT. EQD2 D40% to bilateral hippocampi was significantly reduced from a mean of 23.5 Gy (range 14.5-35.0) in the standard plans to a mean of 8.6 Gy (4.2-24.7) for HSRT (p = 0.001) and a mean of 9.0 Gy (4.3-17.3) for BSRT (p < 0.001). Both HSRT and BSRT resulted in a significant reduction in doses to the whole brain, brain stem, and cerebellum. Conclusion We demonstrate that IMRT plans for HNC involving the nasopharynx can be successfully optimised to significantly reduce dose to the bilateral hippocampi and whole brain. The magnitude of the achievable dose reductions results in significant reductions in the probability of radiation-induced NCF decline. These results could readily be translated into a future clinical trial.	[Dunlop, Alex; McQuaid, Dualta; Gulliford, Sarah; Hansen, Vibeke] Inst Canc Res, Joint Dept Phys, London SW3 6JB, England; [Dunlop, Alex; McQuaid, Dualta; Gulliford, Sarah; Hansen, Vibeke] Royal Marsden NHS Fdn Trust, London, England; [Welsh, Liam; Bhide, Shreerang; Nutting, Chris; Harrington, Kevin; Newbold, Kate] Royal Marsden Hosp, London SW3 6JJ, England; [Welsh, Liam; Dean, Jamie; Bhide, Shreerang; Harrington, Kevin] Inst Canc Res, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Dunlop, A (corresponding author), Inst Canc Res, Joint Dept Phys, London SW3 6JB, England.	Alex.Dunlop@rmh.nhs.uk	Newbold, Kate/AAA-9176-2022; Dean, Jamie/H-4618-2019	Dean, Jamie/0000-0002-5434-8032; Gulliford, Sarah/0000-0002-1768-2904; Harrington, Kevin/0000-0002-6014-348X	NHS Executive; Cancer Research UK [C46/A10588, C7224/A13407]; National Institute for Health Research Royal Marsden; Institute of Cancer Research Biomedical Research Centre; Cancer Research UK [13407] Funding Source: researchfish; Engineering and Physical Sciences Research Council [1240077] Funding Source: researchfish	NHS Executive; Cancer Research UK(Cancer Research UK); National Institute for Health Research Royal Marsden; Institute of Cancer Research Biomedical Research Centre; Cancer Research UK(Cancer Research UK); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	This work was undertaken in The Royal Marsden NHS Foundation Trust which received a proportion of its funding from the NHS Executive; the views expressed in this publication are those of the authors and not necessarily those of the NHS Executive. This work was supported by Cancer Research UK Programme Grants C46/A10588 and C7224/A13407. The authors also acknowledge the support of the National Institute for Health Research Royal Marsden and Institute of Cancer Research Biomedical Research Centre. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abayomi OK, 2002, ACTA ONCOL, V41, P346, DOI 10.1080/028418602760169389; Bhide SA, 2008, BRIT J CANCER, V99, P57, DOI 10.1038/sj.bjc.6604444; Bhide SA, 2012, BRIT J RADIOL, V85, P487, DOI 10.1259/bjr/85942136; Cao Y, 2009, CLIN CANCER RES, V15, P1747, DOI 10.1158/1078-0432.CCR-08-1420; Chapman CH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057768; Cheung MC, 2000, ARCH NEUROL-CHICAGO, V57, P1347, DOI 10.1001/archneur.57.9.1347; Corvo R, 2007, RADIOTHER ONCOL, V85, P156, DOI 10.1016/j.radonc.2007.04.002; Dirix P, 2010, LANCET ONCOL, V11, P85, DOI 10.1016/S1470-2045(09)70231-1; Gan HK, 2011, INT J RADIAT ONCOL, V81, P126, DOI 10.1016/j.ijrobp.2010.05.004; Gondi V, 2013, INT J RADIAT ONCOL, V87, P1186, DOI DOI 10.1016/J.IJR0BP.2013.10.005; Gondi V, 2013, INT J RADIAT ONCOL, V85, P348, DOI 10.1016/j.ijrobp.2012.11.031; Gondi V, 2010, RADIOTHER ONCOL, V97, P370, DOI 10.1016/j.radonc.2010.09.013; Gondi V, 2010, INT J RADIAT ONCOL, V78, P1244, DOI 10.1016/j.ijrobp.2010.01.039; Greene-Schloesser D, 2012, FRONT ONCOL, V2, P1, DOI 10.3389/fonc.2012.00073; Gulliford SL, 2012, RADIOTHER ONCOL, V104, P205, DOI 10.1016/j.radonc.2012.07.005; Holliday EB, 2014, INT J RADIAT ONCOL, V89, P292, DOI 10.1016/j.ijrobp.2014.02.029; Hsiao KY, 2010, INT J RADIAT ONCOL, V77, P722, DOI 10.1016/j.ijrobp.2009.06.080; International Commission on Radiation Units and Measurements, 2010, J ICRU, V10, P1; LEE PWH, 1989, J NEUROL NEUROSUR PS, V52, P488, DOI 10.1136/jnnp.52.4.488; Li YQ, 2003, CANCER RES, V63, P5950; Miah AB, 2012, INT J RADIAT ONCOL, V82, P539, DOI 10.1016/j.ijrobp.2010.09.055; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Namikawa K, 2000, BIOL TRACE ELEM RES, V74, P223, DOI 10.1385/BTER:74:3:223; Nutting CM, 2011, LANCET ONCOL, V12, P127, DOI 10.1016/S1470-2045(10)70290-4; Paddick I, 2000, J NEUROSURG, V93, P219, DOI 10.3171/jns.2000.93.supplement_3.0219; Peiffer AM, 2013, NEUROLOGY, V80, P747, DOI 10.1212/WNL.0b013e318283bb0a; Powell C., 2013, RADIOTHER ONCOL; Troy L, 2000, PSYCHO-ONCOL, V9, P29, DOI 10.1002/(SICI)1099-1611(200001/02)9:1<29::AID-PON428>3.0.CO;2-Z; Welsh L, 2014, CLIN ONCOLOGY	29	13	14	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 17	2015	10	3							e0120141	10.1371/journal.pone.0120141	http://dx.doi.org/10.1371/journal.pone.0120141			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CD7QC	25781636	Green Submitted, Green Published, gold			2023-01-03	WOS:000351284600131
J	Hunter, DJ				Hunter, David J.			Viscosupplementation for Osteoarthritis of the Knee	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRAARTICULAR HYALURONIC-ACID; RANDOMIZED CONTROLLED-TRIALS; CLINICAL-PRACTICE GUIDELINES; MOLECULAR-WEIGHT; SYSTEMATIC ANALYSIS; GLOBAL BURDEN; UNITED-STATES; METAANALYSIS; MANAGEMENT; INJECTION	A 67-year-old woman with right-knee osteoarthritis is referred by her primary care physician for treatment of her knee pain. The patient weighs 83 kg and is 161 cm tall, and her body-mass index (the weight in kilograms divided by the square of the height in meters) is 32. She has had pain intermittently for 9 years, which has been relieved with infrequent use of naproxen. She has recently become more sedentary and is finding it increasingly difficult to play golf. A recent radiograph of her right knee reveals moderate joint-space narrowing and osteophytes, affecting primarily the medial tibiofemoral compartment and lateral patellofemoral compartment. A friend at her golf club received a hyaluronate injection and had sustained relief of her knee pain for 6 months. The patient inquires about whether this form of therapy may be appropriate for her. The specialist recommends weight loss and exercise and counsels the patient about the appropriate use of viscosupplements.	[Hunter, David J.] Royal N Shore Hosp, Dept Rheumatol, St Leonards, NSW 2065, Australia; [Hunter, David J.] Univ Sydney, Kolling Inst, Sydney, NSW 2006, Australia	Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research	Hunter, DJ (corresponding author), Royal N Shore Hosp, Dept Rheumatol, St Leonards, NSW 2065, Australia.	david.hunter@sydney.edu.au			Abbott; Flexion; Merck Serono	Abbott(Abbott Laboratories); Flexion; Merck Serono(Merck & Company)	Dr. Hunter reports receiving fees for serving on advisory boards from Abbott, Flexion, and Merck Serono and receiving royalties from DJO Global from a license agreement related to a patellofemoral sleeve. No other potential conflict of interest relevant to this article was reported.	Access Economics, 2007, ACC EC PAINF REAL EC; Albert C, 2006, JOINT BONE SPINE, V73, P205, DOI 10.1016/j.jbspin.2005.03.005; Arrich J, 2005, CAN MED ASSOC J, V172, DOI 10.1503/cmaj.1041203; BALAZS EA, 1993, J RHEUMATOL, V20, P3; BALAZS EA, 1967, ARTHRITIS RHEUM, V10, P357, DOI 10.1002/art.1780100407; Bannuru RR, 2011, OSTEOARTHR CARTILAGE, V19, P611, DOI 10.1016/j.joca.2010.09.014; Bannuru RR, 2009, ARTHRIT RHEUM-ARTHR, V61, P1704, DOI 10.1002/art.24925; BELLAMY N, 2005, COCHRANE DB SYST REV, V2; Bennell KL, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4934; Berenbaum F, 2012, ANN RHEUM DIS, V71, P1454, DOI 10.1136/annrheumdis-2011-200972; Calmbach WL, 2003, AM FAM PHYSICIAN, V68, P917; Campbell J, 2007, OSTEOARTHR CARTILAGE, V15, P1424, DOI 10.1016/j.joca.2007.01.022; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P345; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P120; Chevalier X, 2010, ANN RHEUM DIS, V69, P113, DOI 10.1136/ard.2008.094623; Conrozier T, 2008, EXPERT OPIN PHARMACO, V9, P1797, DOI [10.1517/14656566.9.10.1797, 10.1517/14656566.9.10.1797 ]; Dehaan MN, 2007, J RHEUMATOL, V34, P2099; Dunlop DD, 2001, ARTHRITIS RHEUM-US, V44, P212, DOI 10.1002/1529-0131(200101)44:1<212::AID-ANR28>3.0.CO;2-Q; Eisenberg Center at Oregon Health and Science University, 2009, 3 TREATM OST KNEE EV; Ghosh P, 2002, SEMIN ARTHRITIS RHEU, V32, P10, DOI 10.1053/sarh.2002.33720; Glazier RH, 1998, CAN MED ASSOC J, V158, P1037; GUCCIONE AA, 1994, AM J PUBLIC HEALTH, V84, P351, DOI 10.2105/AJPH.84.3.351; Helmick CG, 2008, ARTHRITIS RHEUM-US, V58, P15, DOI 10.1002/art.23177; Henley B, 2008, J BONE JOINT SURG AM, V90A, P2781, DOI 10.2106/JBJS.H.00374; Hochberg MC, 2012, ARTHRIT CARE RES, V64, P465, DOI 10.1002/acr.21596; Hunter David J, 2007, Ann Intern Med, V147, pITC8; Hunter DJ, 2011, BEST PRACT RES CL RH, V25, P801, DOI 10.1016/j.berh.2011.11.008; Hunter DJ, 2011, BRIT J SPORT MED, V45, P283, DOI 10.1136/bjsm.2010.081117; Hunter DJ, 2011, ARTHRIT CARE RES, V63, P31, DOI 10.1002/acr.20278; Jackson DW, 2002, J BONE JOINT SURG AM, V84A, P1522, DOI 10.2106/00004623-200209000-00003; Jawad Ali S M, 2005, Am J Ther, V12, P98, DOI 10.1097/00045391-200501000-00013; Jevsevar DS, 2013, J AM ACAD ORTHOP SUR, V21, P571, DOI 10.5435/JAAOS-21-09-571; Jubb RW, 2003, INT J CLIN PRACT, V57, P467; Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V; Lo GH, 2003, JAMA-J AM MED ASSOC, V290, P3115, DOI 10.1001/jama.290.23.3115; Losina E, 2013, ARTHRIT CARE RES, V65, P703, DOI 10.1002/acr.21898; Losina E, 2011, ANN INTERN MED, V154, P217, DOI 10.7326/0003-4819-154-4-201102150-00001; Maheu E, 2011, CLIN EXP RHEUMATOL, V29, P527; McAlindon TE, 2014, OSTEOARTHR CARTILAGE, V22, P363, DOI 10.1016/j.joca.2014.01.003; McAlindon TE, 2012, NAT REV RHEUMATOL, V8, P635, DOI 10.1038/nrrheum.2012.152; Medina JM, 2006, J FAM PRACTICE, V55, P669; Miller LE, 2013, CLIN MED INSIGHTS-AR, V6, P57, DOI 10.4137/CMAMD.S12743; Modawal A, 2005, J FAM PRACTICE, V54, P758; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; Navarro-Sarabia F, 2011, ANN RHEUM DIS, V70, P1957, DOI 10.1136/ard.2011.152017; Neogi T, 2013, RHEUM DIS CLIN N AM, V39, P1, DOI 10.1016/j.rdc.2012.10.004; Pencharz JN, 2002, ARTHRITIS RES, V4, P36, DOI 10.1186/ar381; Reichenbach S, 2007, ARTHRIT RHEUM-ARTHR, V57, P1410, DOI 10.1002/art.23103; Richmond J, 2009, J AM ACAD ORTHOP SUR, V17, P591, DOI 10.5435/00124635-200909000-00006; Rutjes AWS, 2012, ANN INTERN MED, V157, P180, DOI 10.7326/0003-4819-157-3-201208070-00473; Strand V, 2012, OSTEOARTHR CARTILAGE, V20, P350, DOI 10.1016/j.joca.2012.01.013; Strauss EJ, 2009, AM J SPORT MED, V37, P1636, DOI 10.1177/0363546508326984; Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2; Wang CT, 2004, J BONE JOINT SURG AM, V86A, P538, DOI 10.2106/00004623-200403000-00012; Wang YY, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-195; Wind WM, 2004, J ARTHROPLASTY, V19, P858, DOI 10.1016/j.arth.2004.02.042; Zhang W, 2008, ANN RHEUM DIS, V67, P1716, DOI 10.1136/ard.2008.092015; Zhang W, 2010, OSTEOARTHR CARTILAGE, V18, P476, DOI 10.1016/j.joca.2010.01.013	58	81	86	0	36	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 12	2015	372	11					1040	1047		10.1056/NEJMct1215534	http://dx.doi.org/10.1056/NEJMct1215534			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CD0XK	25760356				2023-01-03	WOS:000350797300008
J	Vase, L; Baram, S; Takakura, N; Takayama, M; Yajima, H; Kawase, A; Schuster, L; Kaptchuk, TJ; Schou, S; Jensen, TS; Zachariae, R; Svensson, P				Vase, Lene; Baram, Sara; Takakura, Nobuari; Takayama, Miho; Yajima, Hiroyoshi; Kawase, Akiko; Schuster, Lars; Kaptchuk, Ted J.; Schou, Soren; Jensen, Troels Staehelin; Zachariae, Robert; Svensson, Peter			Can Acupuncture Treatment Be Double-Blinded? An Evaluation of Double-Blind Acupuncture Treatment of Postoperative Pain	PLOS ONE			English	Article							PLACEBO NEEDLE; CONTROLLED-TRIAL; VISUAL ANALOG; EFFICACY; EXPECTATIONS; MULTICENTER; COMPONENTS; SUCCESS	Blinding protects against bias but the success of blinding is seldom assessed and reported in clinical trials including studies of acupuncture where blinding represents a major challenge. Recently, needles with the potential for double-blinding were developed, so we tested if acupuncture can be double-blinded in a randomized study of sixty-seven patients with acute pain >= 3 (0-10 scale following third molar removal) who received active acupuncture with a penetrating needle or placebo acupuncture with a non-penetrating needle. To test if acupuncture was administered double-blind, patients and acupuncturists were asked about perceived treatment allocation at the end of the study. To test if there were clues which led to identification of the treatment, deep dull pain associated with needle application and rotation (termed "de qi" in East Asian medicine), and patients' pain levels were assessed. Perceived treatment allocation depended on actual group allocation (p < 0.015) for both patients and acupuncturists, indicating that the needles were not successful in doubleblinding. Up to 68% of patients and 83% of acupuncturists correctly identified the treatment, but for patients the distribution was not far from 50/50. Also, there was a significant interaction between actual or perceived treatment and the experience of de qi (p = 0.027), suggesting that the experience of de qi and possible non-verbal clues contributed to correct identification of the treatment. Yet, of the patients who perceived the treatment as active or placebo, 50% and 23%, respectively, reported de qi. Patients' acute pain levels did not influence the perceived treatment. In conclusion, acupuncture treatment was not fully double-blinded which is similar to observations in pharmacological studies. Still, the nonpenetrating needle is the only needle that allows some degree of practitioner blinding. The study raises questions about alternatives to double-blind randomized clinical trials in the assessment of acupuncture treatment.	[Vase, Lene; Zachariae, Robert] Aarhus Univ, Dept Psychol & Behav Sci, Aarhus, Denmark; [Vase, Lene; Jensen, Troels Staehelin] Aarhus Univ Hosp, Danish Pain Res Ctr, DK-8000 Aarhus, Denmark; [Baram, Sara; Schou, Soren; Svensson, Peter] Aarhus Univ, Dept Dent, Sect Clin Oral Physiol, Aarhus, Denmark; [Baram, Sara] Aarhus Univ, Dept Dent, Sect Oral & Maxillofacial Surg & Oral Pathol, Aarhus, Denmark; [Takakura, Nobuari; Takayama, Miho; Yajima, Hiroyoshi; Kawase, Akiko] Tokyo Ariake Univ Med & Hlth Sci, Dept Acupuncture & Moxibust, Tokyo, Japan; [Schuster, Lars] Acupuncture Acad, Copenhagen, Denmark; [Schuster, Lars] Acupuncture Acad, Aarhus, Denmark; [Kaptchuk, Ted J.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA; [Zachariae, Robert] Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus, Denmark	Aarhus University; Aarhus University; Aarhus University; Aarhus University; Japanese Foundation for Cancer Research; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Aarhus University	Vase, L (corresponding author), Aarhus Univ, Dept Psychol & Behav Sci, Aarhus, Denmark.	lenevase@psy.au.dk	Svensson, Peter/H-6735-2012; Takakura, Nobuari/AFS-7564-2022; Jensen, Troels Staehelin/A-3418-2009	Jensen, Troels Staehelin/0000-0002-3487-6380; Zachariae, Robert/0000-0001-9076-3068; Vase, Lene/0000-0002-0379-2256; Baram, Sara/0000-0003-0525-4125	Innovative Medicines Initiative Joint Undertaking [115007]; European Union's Seventh Framework Programme (FP7)	Innovative Medicines Initiative Joint Undertaking; European Union's Seventh Framework Programme (FP7)	Lene Vase is part of the Europain Collaboration, which has received support from the Innovative Medicines Initiative Joint Undertaking, under grant agreement no. 115007, the resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' kind contribution, www.imi.europa.eu. The funding source had the possibility to comment on the design and the reporting of the study, but had no role in the collection, analysis, and interpretation of the data and the decision to submit for publication.	Bausell RB, 2005, EVAL HEALTH PROF, V28, P9, DOI 10.1177/0163278704273081; Berman BM, 2004, ANN INTERN MED, V141, P901, DOI 10.7326/0003-4819-141-12-200412210-00006; Boutron I, 2004, J CLIN EPIDEMIOL, V57, P543, DOI 10.1016/j.jclinepi.2003.12.010; BYINGTON RP, 1985, JAMA-J AM MED ASSOC, V253, P1733, DOI 10.1001/jama.253.12.1733; Cardenas DD, 2002, PAIN, V96, P365, DOI 10.1016/S0304-3959(01)00483-3; Collins SL, 1997, PAIN, V72, P95, DOI 10.1016/S0304-3959(97)00005-5; Diener HC, 2006, LANCET NEUROL, V5, P310, DOI 10.1016/S1474-4422(06)70382-9; Fergusson D, 2004, BRIT MED J, V328, P432, DOI 10.1136/bmj.37952.631667.EE; Good P., 1994, PERMUTATIONS TEST PR; GRACELY RH, 1985, LANCET, V1, P43; Haake M, 2007, ARCH INTERN MED, V167, P1892, DOI 10.1001/archinte.167.17.1892; Hrobjartsson A, 2007, INT J EPIDEMIOL, V36, P654, DOI 10.1093/ije/dym020; Kaptchuk TJ, 2008, BMJ-BRIT MED J, V336, P999, DOI 10.1136/bmj.39524.439618.25; Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010; Kelley JM, 2009, PSYCHOSOM MED, V71, P789, DOI 10.1097/PSY.0b013e3181acee12; Kobayashi A, 2010, EVID-BASED COMPL ALT, V7, P359, DOI 10.1093/ecam/nem155; Kong J, 2007, J ALTERN COMPLEM MED, V13, P1059, DOI 10.1089/acm.2007.0524; Lewith GT, 2010, CLIN RES COMPLEMENTA; MARGRAF J, 1991, J CONSULT CLIN PSYCH, V59, P184, DOI 10.1037/0022-006X.59.1.184; OWENS WD, 1978, ANESTHESIOLOGY, V49, P239, DOI 10.1097/00000542-197810000-00003; Park Jongbae, 2002, Acupunct Med, V20, P168; Pomeranz B., 1998, SCI BASIS ACUPUNCTUR, P6, DOI 10.1007/978-3-642-18988-3_2; PRICE DD, 1994, PAIN, V56, P217, DOI 10.1016/0304-3959(94)90097-3; Price DD, 2008, ANNU REV PSYCHOL, V59, P565, DOI 10.1146/annurev.psych.59.113006.095941; Price DD, 2013, PLACEBO AND PAIN: FROM BENCH TO BEDSIDE, P215, DOI 10.1016/B978-0-12-397928-5.00021-0; RABKIN JG, 1986, PSYCHIAT RES, V19, P75, DOI 10.1016/0165-1781(86)90094-6; Schulz KF, 2011, INT J SURG, V9, P672, DOI 10.1016/j.ijsu.2011.09.004; Streitberger K, 1998, LANCET, V352, P364, DOI 10.1016/S0140-6736(97)10471-8; Takakura N, 2009, OPEN MED, V3, P54; Takakura N, 2011, ACUPUNCT MED, V29, P203, DOI 10.1136/aim.2010.002857; Takakura N, 2010, ACUPUNCT MED, V28, P144, DOI 10.1136/aim.2009.001230; Takakura N, 2008, ACUPUNCT MED, V26, P224, DOI 10.1136/aim.26.4.224; Takakura Nobuari, 2007, BMC Complement Altern Med, V7, P31, DOI 10.1186/1472-6882-7-31; Teig Silje, 2006, Acupunct Med, V24, P80; Turner JA, 2002, PAIN, V99, P91, DOI 10.1016/S0304-3959(02)00060-X; Vase L, 2003, PAIN, V105, P17, DOI 10.1016/S0304-3959(03)00073-3; Vase L, 2013, PAIN, V154, P1659, DOI 10.1016/j.pain.2013.05.008; Wiseman N., 1998, PRACTICAL DICT CHINE; World Health Organization. (WHO) Regional Office for the Western Pacific, 2008, WHO STAND AC POINT L	39	35	36	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 6	2015	10	3							e0119612	10.1371/journal.pone.0119612	http://dx.doi.org/10.1371/journal.pone.0119612			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC9KQ	25747157	Green Published, gold, Green Submitted			2023-01-03	WOS:000350689400081
J	Rottenkolber, M; Voogd, E; van Dijk, L; Primatesta, P; Becker, C; Schlienger, R; de Groot, MCH; Alvarez, Y; Durand, J; Slattery, J; Afonso, A; Requena, G; Gil, M; Alvarez, A; Hesse, U; Gerlach, R; Hasford, J; Fischer, R; Klungel, OH; Schmiedl, S				Rottenkolber, Marietta; Voogd, Eef; van Dijk, Liset; Primatesta, Paola; Becker, Claudia; Schlienger, Raymond; de Groot, Mark C. H.; Alvarez, Yolanda; Durand, Julie; Slattery, Jim; Afonso, Ana; Requena, Gema; Gil, Miguel; Alvarez, Arturo; Hesse, Ulrik; Gerlach, Roman; Hasford, Joerg; Fischer, Rainald; Klungel, Olaf H.; Schmiedl, Sven			Time Trends of Period Prevalence Rates of Patients with Inhaled Long-Acting Beta-2-Agonists-Containing Prescriptions: A European Comparative Database Study	PLOS ONE			English	Article							OVERLAP SYNDROME; GENERAL-PRACTICE; ASTHMA; SALMETEROL; PERSISTENCE; MEDICATION; DISEASE	Background Inhaled, long-acting beta-2-adrenoceptor agonists (LABA) have well-established roles in asthma and/or COPD treatment. Drug utilisation patterns for LABA have been described, but few studies have directly compared LABA use in different countries. We aimed to compare the prevalence of LABA-containing prescriptions in five European countries using a standardised methodology. Methods A common study protocol was applied to seven European healthcare record databases (Denmark, Germany, Spain, the Netherlands (2), and the UK (2)) to calculate crude and age-and sex-standardised annual period prevalence rates (PPRs) of LABA-containing prescriptions from 2002-2009. Annual PPRs were stratified by sex, age, and indication (asthma, COPD, asthma and COPD). Results From 2002-2009, age-and sex-standardised PPRs of patients with LABA-containing medications increased in all databases (58.2%-185.1%). Highest PPRs were found in men >= 80 years old and women 70-79 years old. Regarding the three indications, the highest age-and sex-standardised PPRs in all databases were found in patients with "asthma and COPD" but with large inter-country variation. In those with asthma or COPD, lower PPRs and smaller inter-country variations were found. For all three indications, PPRs for LABA-containing prescriptions increased with age. Conclusions Using a standardised protocol that allowed direct inter-country comparisons, we found highest rates of LABA-containing prescriptions in elderly patients and distinct differences in the increased utilisation of LABA-containing prescriptions within the study period throughout the five European countries.	[Rottenkolber, Marietta; Hasford, Joerg] Univ Munich, Inst Med Informat Sci Biometry & Epidemiol, Munich, Germany; [Voogd, Eef; van Dijk, Liset; de Groot, Mark C. H.; Afonso, Ana; Klungel, Olaf H.] Univ Utrecht, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht Inst Pharmaceut Sci, Utrecht, Netherlands; [Voogd, Eef; van Dijk, Liset] Netherlands Inst Hlth Serv Res, Utrecht, Netherlands; [Primatesta, Paola] Novartis Pharma AG, Basel, Switzerland; [Becker, Claudia] Univ Basel, Div Clin Pharm & Epidemiol, Basel, Switzerland; [Alvarez, Yolanda; Durand, Julie; Slattery, Jim] European Med Agcy, London, England; [Requena, Gema] Univ Alcala, Sch Med & Hlth Sci, Dept Biomed Sci 2, Pharmacol Unit, Madrid, Spain; [Gil, Miguel; Alvarez, Arturo] Spanish Agcy Med & Med Devices, Div Pharmacoepidemiol & Pharmacovigilance, BIFAP Unit, Madrid, Spain; [Hesse, Ulrik] Danish Med Agcy Laegemiddelstyrelsen, Med Control Div, Copenhagen, Denmark; [Gerlach, Roman] Natl Assoc Statutory Hlth Insurance Phys Bavaria, Munich, Germany; [Fischer, Rainald] Univ Munich, Univ Hosp, Med Klin & Poliklin 5, Munich, Germany; [Schmiedl, Sven] Univ Witten Herdecke, Fac Hlth, Sch Med, Dept Clin Pharmacol, Witten, Germany; [Schmiedl, Sven] HELIOS Clin Wuppertal, Clin Pharmacol, Philipp Klee Inst, Wuppertal, Germany	University of Munich; Utrecht University; Netherlands Institute for Health Services Research; Novartis; University of Basel; Universidad de Alcala; University of Munich; Witten Herdecke University	Rottenkolber, M (corresponding author), Univ Munich, Inst Med Informat Sci Biometry & Epidemiol, Munich, Germany.	rottenk@ibe.med.uni-muenchen.de	de Groot, Mark CH/A-9891-2012; Alvarez, Yolanda/I-4672-2019	de Groot, Mark CH/0000-0002-5764-5788; 	Innovative Medicine Initiative Joint Undertaking [115004]; European Union's Seventh Framework Programme (FP7); Pfizer; AstraZeneca	Innovative Medicine Initiative Joint Undertaking; European Union's Seventh Framework Programme (FP7); Pfizer(Pfizer); AstraZeneca(AstraZeneca)	The PROTECT project has received support from the Innovative Medicine Initiative Joint Undertaking (www.imi.europa.eu) under Grant Agreement no 115004, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/20072013) and EFPIA companies' in-kind contribution. In addition, as a special form of the IMI JU grant, Utrecht University and University of Alcala received a direct financial contribution from Pfizer and AstraZeneca, respectively. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Co-authors Paola Primatesta and Raymond Schlienger are employed by Novartis Pharma AG. Novartis Pharma AG provided support in the form of salaries for authors PP and RS, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbing-Karahagopian V, 2014, CURR CLIN PHARMACOL, V9, P130, DOI 10.2174/1574884708666131111211802; Agresti A, 1998, AM STAT, V52, P119, DOI 10.2307/2685469; Baiardi P, 2010, ACTA PAEDIATR, V99, P544, DOI 10.1111/j.1651-2227.2009.01668.x; Bianchi M, 2010, EUR J CLIN PHARMACOL, V66, P929, DOI 10.1007/s00228-010-0845-y; Buffels Johan, 2009, Prim Care Respir J, V18, P34, DOI 10.3132/pcrj.2008.00047; Cai B, 2012, PHARMACOEPIDEM DR S, V21, P770, DOI 10.1002/pds.3277; Cates CJ, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006924.pub3; Cates CJ, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006922.pub3; Chong J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009157.pub2; DiSantostefano RL, 2011, DRUG SAFETY, V34, P511, DOI 10.2165/11587370-000000000-00000; Furu K, 2007, EUR J CLIN PHARMACOL, V63, P693, DOI 10.1007/s00228-007-0301-9; Gibson PG, 2009, THORAX, V64, P728, DOI 10.1136/thx.2008.108027; Global Initiative for Asthma (GINA), 2014, GLOB STRAT ASTHM MAN; GOLD, 2011, GLOB STRAT DIAGN MAN; Hansen S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036328; Hasford J, 2010, ALLERGY, V65, P347, DOI 10.1111/j.1398-9995.2009.02161.x; Haupt D, 2008, PHARM WORLD SCI, V30, P509, DOI 10.1007/s11096-008-9197-4; Higashi A, 2011, J GEN INTERN MED, V26, P1465, DOI 10.1007/s11606-011-1796-4; Klein RJ, 2001, HLTH PEOPLE 2010 STA, V20, P1; Lurie P, 2005, LANCET, V366, P1261, DOI 10.1016/S0140-6736(05)67518-6; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; Papaiwannou A, 2014, J THORAC DIS, V6, pS146, DOI 10.3978/j.issn.2072-1439.2014.03.04; ROBERTS SJ, 1994, THORAX, V49, P1090, DOI 10.1136/thx.49.11.1090; Schmiedl S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105110; Sen EF, 2011, EUR J PEDIATR, V170, P81, DOI 10.1007/s00431-010-1275-7; Spiegelman M, 1968, INTRO DEMOGRAPHY; Stirbu-Wagner I, 2010, LANDELIJK INFOMATIEN; To T, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-204	29	9	9	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 23	2015	10	2							e0117628	10.1371/journal.pone.0117628	http://dx.doi.org/10.1371/journal.pone.0117628			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC9BI	25706152	Green Published, gold, Green Submitted			2023-01-03	WOS:000350662100106
J	Pizzo, PA; Walker, DM				Pizzo, Philip A.; Walker, David M.			Should We Practice What We Profess? Care near the End of Life	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Pizzo, Philip A.] Stanford Univ, Sch Med, Stanford, CA 94305 USA	Stanford University								Gallo JJ, 2003, J AM GERIATR SOC, V51, P961, DOI 10.1046/j.1365-2389.2003.51309.x; Kellehear, 2014, INNER LIFE DYING PER; Periyakoil VS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098246; Smith TJ, 2012, J CLIN ONCOL, V30, P880, DOI 10.1200/JCO.2011.38.5161; Teno JM, 2013, JAMA-J AM MED ASSOC, V309, P470, DOI 10.1001/jama.2012.207624	5	14	14	1	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 12	2015	372	7					595	598		10.1056/NEJMp1413167	http://dx.doi.org/10.1056/NEJMp1413167			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CA8CK	25671250				2023-01-03	WOS:000349143900002
J	Halpern, SD; Emanuel, EJ				Halpern, Scott D.; Emanuel, Ezekiel J.			Can the United States Buy Better Advance Care Planning?	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							OF-LIFE CARE; PALLIATIVE CARE; END; TRANSITIONS; IMPACT		Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Halpern, SD (corresponding author), Univ Penn, 719 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.	shalpern@exchange.upenn.edu						American Hospital Association, 2014, AM HOSP ASS ANN HOSP; Back AL, 2007, ARCH INTERN MED, V167, P453, DOI 10.1001/archinte.167.5.453; Halpern SD, 2013, HEALTH AFFAIR, V32, P408, DOI 10.1377/hlthaff.2012.0895; Kwok AC, 2011, LANCET, V378, P1408, DOI 10.1016/S0140-6736(11)61268-3; May P, 2014, J PALLIAT MED, V17, P1054, DOI 10.1089/jpm.2013.0594; Quest T, 2010, J PAIN SYMPTOM MANAG, V39, P334, DOI 10.1016/j.jpainsymman.2009.11.247; Riley GF, 2010, HEALTH SERV RES, V45, P565, DOI 10.1111/j.1475-6773.2010.01082.x; Teno JM, 2013, JAMA-J AM MED ASSOC, V309, P470, DOI 10.1001/jama.2012.207624	8	14	14	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 3	2015	162	3					224	U133		10.7326/M14-2476	http://dx.doi.org/10.7326/M14-2476			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CC1NP	25486099				2023-01-03	WOS:000350108100008
J	Liu, TY; Gong, W; Tan, ZJ; Lu, W; Wu, XS; Weng, H; Ding, Q; Shu, YJ; Bao, RF; Cao, Y; Wang, XA; Zhang, F; Li, HF; Xiang, SS; Jiang, L; Hu, YP; Mu, JS; Li, ML; Wu, WG; Shen, BY; Jiang, LX; Liu, YB				Liu, Tian-Yu; Gong, Wei; Tan, Zhu-Jun; Lu, Wei; Wu, Xiang-Song; Weng, Hao; Ding, Qian; Shu, Yi-Jun; Bao, Run-Fa; Cao, Yang; Wang, Xu-An; Zhang, Fei; Li, Huai-Feng; Xiang, Shan-Shan; Jiang, Lin; Hu, Yun-ping; Mu, Jia-Sheng; Li, Mao-Lan; Wu, Wen-Guang; Shen, Bai-Yong; Jiang, Li-Xin; Liu, Ying-Bin			Baicalein Inhibits Progression of Gallbladder Cancer Cells by Downregulating ZFX	PLOS ONE			English	Article							SELF-RENEWAL; CARCINOMA METASTASIS; PROTEOMIC ANALYSIS; IN-VIVO; PROLIFERATION; GROWTH; SCUTELLARIA; EXPRESSION; KNOCKDOWN; APOPTOSIS	Baicalein, a widely used Chinese herbal medicine, has multiple pharmacological activities. However, the precise mechanisms of the anti-proliferation and anti-metastatic effects of baicalein on gallbladder cancer (GBC) remain poorly understood. Therefore, the aim of this study was to assess the anti-proliferation and anti-metastatic effects of baicalein and the related mechanism(s) on GBC. In the present study, we found that treatment with baicalein induced a significant inhibitory effect on proliferation and promoted apoptosis in GBC-SD and SGC996 cells, two widely used gallbladder cancer cell lines. Additionally, treatment with baicalein inhibited the metastasis of GBC cells. Moreover, we demonstrated for the first time that baicalein inhibited GBC cell growth and metastasis via down-regulation of the expression level of Zinc finger protein X-linked (ZFX). In conclusion, our studies suggest that baicalein may be a potential phytochemical flavonoid for therapeutics of GBC and ZFX may serve as a molecular marker or predictive target for GBC.	[Liu, Tian-Yu; Gong, Wei; Tan, Zhu-Jun; Lu, Wei; Jiang, Lin; Hu, Yun-ping; Liu, Ying-Bin] Shanghai Jiao Tong Univ, Sch Med, Inst Biliary Tract Dis, Shanghai 200030, Peoples R China; [Liu, Tian-Yu; Gong, Wei; Tan, Zhu-Jun; Lu, Wei; Jiang, Lin; Hu, Yun-ping; Liu, Ying-Bin] Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Lab Gen Surg, Shanghai 200030, Peoples R China; [Liu, Tian-Yu; Gong, Wei; Tan, Zhu-Jun; Lu, Wei; Wu, Xiang-Song; Weng, Hao; Ding, Qian; Shu, Yi-Jun; Bao, Run-Fa; Cao, Yang; Wang, Xu-An; Zhang, Fei; Li, Huai-Feng; Xiang, Shan-Shan; Jiang, Lin; Hu, Yun-ping; Mu, Jia-Sheng; Li, Mao-Lan; Wu, Wen-Guang; Liu, Ying-Bin] Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Dept Gen Surg, Shanghai 200092, Peoples R China; [Shen, Bai-Yong] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Gen Surg, Shanghai 200025, Peoples R China; [Jiang, Li-Xin] Jiangyin Hosp Tradit Chinese Med, Dept Gen Surg, Jiangyin, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Jiang, LX (corresponding author), Jiangyin Hosp Tradit Chinese Med, Dept Gen Surg, Jiangyin, Peoples R China.	15961665000@163.com; liuybphd@126.com	wang, xuan/GXF-3679-2022; Liu, Yingbin/AAI-1919-2020; LIU, YING/GZL-7252-2022	Liu, Yingbin/0000-0001-6110-0185; 	National Natural Science Foundation of China [81172026, 81272402, 81301816, 81172029]; National High Technology Research and Development Program (863 Program) [2012AA022606]; Foundation for Interdisciplinary research of Shanghai Jiao Tong University [YG2011ZD07]; Shanghai science and technology commission inter-governmental international cooperation project [12410705900]; Shanghai science and technology commission medical-guiding project [12401905800]; Natural Science Research Foundation of Shanghai Jiao Tong University School of Medicine [13XJ10037]; Sailing program of Shanghai science and technology commission [14YF1403000]; Specialized Research Foundation for Ph.D Program of Higher Education-Priority Development Field [20130073130014]; Program for Changjiang Scholars; Leading Talent program of Shanghai	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National High Technology Research and Development Program (863 Program)(National High Technology Research and Development Program of China); Foundation for Interdisciplinary research of Shanghai Jiao Tong University; Shanghai science and technology commission inter-governmental international cooperation project; Shanghai science and technology commission medical-guiding project; Natural Science Research Foundation of Shanghai Jiao Tong University School of Medicine; Sailing program of Shanghai science and technology commission; Specialized Research Foundation for Ph.D Program of Higher Education-Priority Development Field; Program for Changjiang Scholars(Program for Changjiang Scholars & Innovative Research Team in University (PCSIRT)); Leading Talent program of Shanghai	This study was supported by National Natural Science Foundation of China (No. 81172026, 81272402, 81301816 and 81172029), National High Technology Research and Development Program (863 Program) (No. 2012AA022606), Foundation for Interdisciplinary research of Shanghai Jiao Tong University (No. YG2011ZD07), Shanghai science and technology commission inter-governmental international cooperation project (No. 12410705900), Shanghai science and technology commission medical-guiding project (No. 12401905800), Program for Changjiang Scholars, Natural Science Research Foundation of Shanghai Jiao Tong University School of Medicine (No. 13XJ10037), Leading Talent program of Shanghai, Sailing program of Shanghai science and technology commission (14YF1403000) and Specialized Research Foundation for Ph.D Program of Higher Education-Priority Development Field (No. 20130073130014). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdollahi A, 1999, ONCOGENE, V18, P6477, DOI 10.1038/sj.onc.1203067; Akiyoshi S, 2012, BRIT J CANCER, V107, P1345, DOI 10.1038/bjc.2012.326; Buttar NS, 2006, CURR OPIN GASTROEN, V22, P505, DOI 10.1097/01.mog.0000239864.73962.db; Cellot S, 2007, CELL, V129, P239, DOI 10.1016/j.cell.2007.04.002; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Chen JC, 2013, INT J MOL SCI, V14, P6012, DOI 10.3390/ijms14036012; Cheng YH, 2012, TOXICOL APPL PHARM, V263, P360, DOI 10.1016/j.taap.2012.07.010; Dong P, 2011, CHINESE MED J-PEKING, V124, P4236, DOI 10.3760/cma.j.issn.0366-6999.2011.24.021; Galan-Caridad JM, 2007, CELL, V129, P345, DOI 10.1016/j.cell.2007.03.014; Harel S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042302; Hu G, 2009, GENE DEV, V23, P837, DOI 10.1101/gad.1769609; Huang WS, 2012, PROTEOMICS, V12, P810, DOI 10.1002/pmic.201100270; KIMURA Y, 1981, CHEM PHARM BULL, V29, P2308; Li K, 2013, INT J CLIN EXP PATHO, V6, P2460; Li ML, 2013, TUMOR BIOL, V34, P3995, DOI 10.1007/s13277-013-0988-4; Li ML, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0587-7; Li-Weber M, 2009, CANCER TREAT REV, V35, P57, DOI 10.1016/j.ctrv.2008.09.005; Lin CC, 1996, AM J CHINESE MED, V24, P31, DOI 10.1142/S0192415X96000050; Liu TY, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-64; Ma GZ, 2013, INFLAMMATION, V36, P457, DOI 10.1007/s10753-012-9566-y; Miller G, 2008, EJSO-EUR J SURG ONC, V34, P306, DOI 10.1016/j.ejso.2007.07.206; Naveenkumar C, 2013, BASIC CLIN PHARMACOL, V112, P270, DOI 10.1111/bcpt.12025; Ohashi K, 2000, CANCER-AM CANCER SOC, V88, P2201, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2201::AID-CNCR2>3.3.CO;2-E; Orrenius S, 2004, TOXICOL LETT, V149, P19, DOI 10.1016/j.toxlet.2003.12.017; Quan ZW, 2010, CANCER LETT, V295, P252, DOI 10.1016/j.canlet.2010.03.008; SHIMA I, 1992, CANCER, V70, P2747, DOI 10.1002/1097-0142(19921215)70:12<2747::AID-CNCR2820701204>3.0.CO;2-5; Shimada K, 2011, BRIT J SURG, V98, P117, DOI 10.1002/bjs.7262; Tan ZJ, 2013, GENE, V528, P261, DOI 10.1016/j.gene.2013.06.064; Tan ZJ, 2012, MOL CELL BIOCHEM, V369, P27, DOI 10.1007/s11010-012-1365-0; Wang JD, 2011, MED ONCOL, V28, pS295, DOI 10.1007/s12032-010-9758-y; Wang JW, 2009, CANCER LETT, V281, P71, DOI 10.1016/j.canlet.2009.02.020; Wu S, 2013, CANCER LETT, V337, P293, DOI 10.1016/j.canlet.2013.04.003; Yu SY, 2011, BLOOD, V117, P2166, DOI 10.1182/blood-2010-09-306563; Zha WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074175; Zhang ZP, 2012, PHYTOTHER RES, V26, P932, DOI 10.1002/ptr.3657	35	140	147	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2015	10	1							e0114851	10.1371/journal.pone.0114851	http://dx.doi.org/10.1371/journal.pone.0114851			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC4PT	25617627	Green Submitted, Green Published, gold			2023-01-03	WOS:000350336000003
J	Kanno, H; Kawakami, Z; Mizoguchi, K; Ikarashi, Y; Kase, Y				Kanno, Hitomi; Kawakami, Zenji; Mizoguchi, Kazushige; Ikarashi, Yasushi; Kase, Yoshio			Yokukansan, a Kampo Medicine, Protects PC12 Cells from Glutamate-Induced Death by Augmenting Gene Expression of Cystine/Glutamate Antiporter System Xc(-)	PLOS ONE			English	Article							TRADITIONAL JAPANESE MEDICINE; THIAMINE-DEFICIENT RATS; PSYCHOLOGICAL SYMPTOMS; CORTICAL-NEURONS; OXIDATIVE STRESS; NERVOUS-SYSTEM; CYSTINE UPTAKE; DEMENTIA; NEUROTOXICITY; X(C)(-)	Effects of the kampo medicine yokukansan on gene expression of the cystine/glutamate antiporter system Xc(-), which protects against glutamate-induced cytotoxicity, were examined in Pheochromocytoma cells (PC12 cells). Yokukansan inhibited glutamate-induced PC12 cell death. Similar cytoprotective effects were found in Uncaria hook. Experiments to clarify the active compounds revealed that geissoschizine methyl ether, hirsuteine, hirsutine, and procyanidin B1 in Uncaria hook, had cytoprotective effects. These components enhanced gene expressions of system Xc(-) subunits xCT and 4F2hc, and also ameliorated the glutamate-induced decrease in glutathione levels. These results suggest that the cytoprotective effect of yokukansan may be attributed to geissoschizine methyl ether, hirsuteine, hirsutine, and procyanidin B1 in Uncaria hook.	[Kanno, Hitomi; Kawakami, Zenji; Mizoguchi, Kazushige; Ikarashi, Yasushi; Kase, Yoshio] Tsumura & Co, Kampo Sci Strategies Div, Tsumura Res Labs, Inashiki, Ibaraki, Japan	Tsumura & Company	Kanno, H (corresponding author), Tsumura & Co, Kampo Sci Strategies Div, Tsumura Res Labs, Inashiki, Ibaraki, Japan.	kanno_hitomi@mail.tsumura.co.jp			Tsumura Co.	Tsumura Co.(Tsumura & Company)	This study was funded by Tsumura & Co. The funder provided support in the form of salaries for all authors, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; Behrens PF, 2002, BRAIN, V125, P1908, DOI 10.1093/brain/awf180; Bridges RJ, 2012, BRIT J PHARMACOL, V165, P20, DOI 10.1111/j.1476-5381.2011.01480.x; Chen JY, 2012, MOL CELL, V45, P196, DOI 10.1016/j.molcel.2011.11.023; Cheung NS, 1998, NEUROPHARMACOLOGY, V37, P1419, DOI 10.1016/S0028-3908(98)00123-3; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; Chung WJ, 2005, J NEUROSCI, V25, P7101, DOI 10.1523/JNEUROSCI.5258-04.2005; Conrad M, 2012, AMINO ACIDS, V42, P231, DOI 10.1007/s00726-011-0867-5; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Edwards MA, 2007, NEUROTOXICOLOGY, V28, P876, DOI 10.1016/j.neuro.2007.04.006; EYER P, 1986, ANAL BIOCHEM, V153, P57, DOI 10.1016/0003-2697(86)90061-8; FROISSARD P, 1994, NEUROCHEM INT, V24, P485, DOI 10.1016/0197-0186(94)90096-5; Han F, 2008, NEUROSCI LETT, V430, P275, DOI 10.1016/j.neulet.2007.11.021; Harkany T, 2000, EUR J NEUROSCI, V12, P2735, DOI 10.1046/j.1460-9568.2000.00164.x; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; Iizuka S, 2010, NEUROPATHOLOGY, V30, P524, DOI 10.1111/j.1440-1789.2010.01101.x; Ikarashi Y, 2009, BIOL PHARM BULL, V32, P1701, DOI 10.1248/bpb.32.1701; Imamura S, 2011, CELL MOL NEUROBIOL, V31, P787, DOI 10.1007/s10571-011-9676-3; Iwasaki K, 2005, J CLIN PSYCHIAT, V66, P248, DOI 10.4088/JCP.v66n0214; Iwasaki K, 2012, PSYCHOGERIATRICS, V12, P235, DOI 10.1111/j.1479-8301.2012.00413.x; Kanno H, 2013, J ETHNOPHARMACOL, V149, P360, DOI 10.1016/j.jep.2013.06.052; Kawakami Z, 2009, NEUROSCIENCE, V159, P1397, DOI 10.1016/j.neuroscience.2009.02.004; Kawakami Z, 2011, CELL MOL NEUROBIOL, V31, P1203, DOI 10.1007/s10571-011-9722-1; Kawakami Z, 2011, J ETHNOPHARMACOL, V134, P74, DOI 10.1016/j.jep.2010.11.063; Kawakami Z, 2010, EUR J PHARMACOL, V626, P154, DOI 10.1016/j.ejphar.2009.09.046; Kubota K., 2013, Journal of Traditional Medicines, V30, P102; Lewerenz J, 2013, ANTIOXID REDOX SIGN, V18, P522, DOI 10.1089/ars.2011.4391; Lewerenz J, 2012, AMINO ACIDS, V42, P171, DOI 10.1007/s00726-011-0862-x; Lo M, 2008, J CELL PHYSIOL, V215, P593, DOI 10.1002/jcp.21366; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Matsuda Y, 2013, HUM PSYCHOPHARM CLIN, V28, P80, DOI 10.1002/hup.2286; MICHAELS RL, 1990, J NEUROSCI, V10, P283; Mizukami K, 2009, INT J NEUROPSYCHOPH, V12, P191, DOI 10.1017/S146114570800970X; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MURPHY TH, 1990, FASEB J, V4, P1624, DOI 10.1096/fasebj.4.6.2180770; Nagata K, 2012, PHYTOMEDICINE, V19, P524, DOI 10.1016/j.phymed.2012.02.008; Penugonda S, 2005, BRAIN RES, V1056, P132, DOI 10.1016/j.brainres.2005.07.032; Pereira CF, 2000, NEUROSCI RES, V37, P227, DOI 10.1016/S0168-0102(00)00124-3; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; SAKAI M, 1994, J BIOL CHEM, V269, P31430; Todd KG, 2001, METHODS, V23, P55, DOI 10.1006/meth.2000.1105; Tsuji M, 2001, J BIOL CHEM, V276, P32779, DOI 10.1074/jbc.M101403200; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Vazhappilly R, 2010, NEUROCHEM INT, V56, P569, DOI 10.1016/j.neuint.2009.12.020	45	16	17	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2014	9	12							e116275	10.1371/journal.pone.0116275	http://dx.doi.org/10.1371/journal.pone.0116275			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX7UC	25551766	Green Published, Green Submitted, gold			2023-01-03	WOS:000347119100118
J	Sakaguchi, Y; Fujii, N; Shoji, T; Hayashi, T; Rakugi, H; Iseki, K; Tsubakihara, Y; Isaka, Y				Sakaguchi, Yusuke; Fujii, Naohiko; Shoji, Tatsuya; Hayashi, Terumasa; Rakugi, Hiromi; Iseki, Kunitoshi; Tsubakihara, Yoshiharu; Isaka, Yoshitaka		Japanese Soc Dialysis Therapy	Magnesium Modifies the Cardiovascular Mortality Risk Associated with Hyperphosphatemia in Patients Undergoing Hemodialysis: A Cohort Study	PLOS ONE			English	Article							REGULAR DIALYSIS TREATMENT; KIDNEY-DISEASE; MINERAL METABOLISM; DIETARY MAGNESIUM; SERUM MAGNESIUM; CALCIUM; CALCIFICATION; PHOSPHORUS; HYPOMAGNESEMIA; METAANALYSIS	Background: In vitro studies have shown inhibitory effects of magnesium (Mg) on phosphate-induced calcification of vascular smooth muscle cells, raising the possibility that maintaining a high Mg level may be useful for reducing cardiovascular risks of patients with hyperphosphatemia. We examined how serum Mg levels affect the association between serum phosphate levels and the risk of cardiovascular mortality in patients undergoing hemodialysis. Methods: A nationwide register-based cohort study was conducted using database of the Renal Data Registry of the Japanese Society for Dialysis Therapy in 2009. We identified 142,069 patients receiving in-center hemodialysis whose baseline serum Mg and phosphate levels were available. Study outcomes were one-year cardiovascular and all-cause mortality. Serum Mg levels were categorized into three groups (lower, <2.7 mg/dL; intermediate, >= 2.7, <3.1 mg/dL; and higher, >= 3.1 mg/dL). Results: During follow-up, 11,401 deaths occurred, out of which 4,751 (41.7%) were ascribed to cardiovascular disease. In multivariable analyses, an increase in serum phosphate levels elevated the risk of cardiovascular mortality in the lowerand intermediate-Mg groups, whereas no significant risk increment was observed in the higher-Mg group. Moreover, among patients with serum phosphate levels of >= 6.0 mg/dL, the cardiovascular mortality risk significantly decreased with increasing serum Mg levels (adjusted odds ratios [95% confidence intervals] of the lower-, intermediate-, and higher-Mg groups were 1.00 (reference), 0.81 [0.66- 0.99], and 0.74 [0.56-0.97], respectively.). An interaction between Mg and phosphate on the risk of cardiovascular mortality was statistically significant (P=0.03). Conclusion: Serum Mg levels significantly modified the mortality risk associated with hyperphosphatemia in patients undergoing hemodialysis.	[Sakaguchi, Yusuke; Rakugi, Hiromi; Isaka, Yoshitaka] Osaka Univ, Grad Sch Med, Suita, Osaka 5650871, Japan; [Fujii, Naohiko; Iseki, Kunitoshi; Tsubakihara, Yoshiharu] Japanese Soc Dialysis Therapy, Comm Renal Data Registry, Tokyo, Japan; [Shoji, Tatsuya; Hayashi, Terumasa] Osaka Gen Med Ctr, Dept Kidney Dis & Hypertens, Osaka 5588558, Japan	Osaka University	Isaka, Y (corresponding author), Osaka Univ, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	isaka@kid.med.osaka-u.ac.jp	Fujii, Naohiko/ABG-8766-2021	Fujii, Naohiko/0000-0002-6411-8599; Rakugi, Hiromi/0000-0001-6508-4338				[Anonymous], 2009, ANN DAT REP ATL CHRO; Ayus JC, 2007, KIDNEY INT, V71, P336, DOI 10.1038/sj.ki.5002044; Ayus JC, 2005, J AM SOC NEPHROL, V16, P2778, DOI 10.1681/ASN.2005040392; Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2; Bowler M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093625; Covic A, 2013, NEPHROL DIAL TRANSPL, V28, P2383, DOI 10.1093/ndt/gft203; D'Haese PC, 1999, CLIN CHEM, V45, P1548; de Jager DJ, 2009, JAMA-J AM MED ASSOC, V302, P1782, DOI 10.1001/jama.2009.1488; Del Gobbo LC, 2013, AM J CLIN NUTR, V98, P160, DOI 10.3945/ajcn.112.053132; Foley RN, 1998, AM J KIDNEY DIS, V32, pS112, DOI 10.1053/ajkd.1998.v32.pm9820470; Hruby A, 2014, JACC-CARDIOVASC IMAG, V7, P59, DOI 10.1016/j.jcmg.2013.10.006; Ishimura E, 2007, CLIN NEPHROL, V68, P222; Kanbay M, 2012, AM J NEPHROL, V36, P228, DOI 10.1159/000341868; Kircelli F, 2012, NEPHROL DIAL TRANSPL, V27, P514, DOI 10.1093/ndt/gfr321; KROLL MH, 1985, CLIN CHEM, V31, P244; Larsson SC, 2012, AM J CLIN NUTR, V95, P362, DOI 10.3945/ajcn.111.022376; Louvet L, 2013, NEPHROL DIAL TRANSPL, V28, P869, DOI 10.1093/ndt/gfs520; Maier JAM, 2012, CLIN SCI, V122, P397, DOI 10.1042/CS20110506; Massy ZA, 2012, CLIN KIDNEY J, V5, P52, DOI 10.1093/ndtplus/sfr167; Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414; Montezano AC, 2010, HYPERTENSION, V56, P453, DOI 10.1161/HYPERTENSIONAHA.110.152058; Nakai S, 2012, THER APHER DIAL, V16, P483, DOI 10.1111/j.1744-9987.2012.01143.x; Nakai S, 2012, THER APHER DIAL, V16, P11, DOI 10.1111/j.1744-9987.2011.01050.x; Naves-Diaz M, 2011, NEPHROL DIAL TRANSPL, V26, P1938, DOI 10.1093/ndt/gfq304; Qu XH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057720; Sakaguchi Y, 2014, KIDNEY INT, V85, P174, DOI 10.1038/ki.2013.327; Stenvinkel P, 2008, CLIN J AM SOC NEPHRO, V3, P505, DOI 10.2215/CJN.03670807; Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020; Tzanakis I, 1997, NEPHROL DIAL TRANSPL, V12, P2036, DOI 10.1093/ndt/12.9.2036; Van Laecke S, 2012, NEPHROL DIAL TRANSPL, V27, P4003, DOI 10.1093/ndt/gfs126; Wyskida K, 2012, J RENAL NUTR, V22, P19, DOI 10.1053/j.jrn.2011.03.001	31	46	47	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 29	2014	9	12							e0116273	10.1371/journal.pone.0116273	http://dx.doi.org/10.1371/journal.pone.0116273			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX7UN	25545498	Green Published, gold, Green Submitted			2023-01-03	WOS:000347120200109
J	Arsenault, BJ; Barter, P; DeMicco, DA; Bao, WH; Preston, GM; LaRosa, JC; Grundy, SM; Deedwania, P; Greten, H; Wenger, NK; Shepherd, J; Waters, DD; Kastelein, JJP				Arsenault, Benoit J.; Barter, Philip; DeMicco, David A.; Bao, Weihang; Preston, Gregory M.; LaRosa, John C.; Grundy, Scott M.; Deedwania, Prakash; Greten, Heiner; Wenger, Nanette K.; Shepherd, James; Waters, David D.; Kastelein, John J. P.		Treating New Targets Tnt Investig	Prediction of Cardiovascular Events in Statin-Treated Stable Coronary Patients of the Treating to New Targets Randomized Controlled Trial by Lipid and Non-Lipid Biomarkers	PLOS ONE			English	Article							C-REACTIVE PROTEIN; HEART-DISEASE; NATRIURETIC PEPTIDE; RISK PREDICTION; ATORVASTATIN; ATHEROSCLEROSIS; INFLAMMATION; THERAPY; MEN; PROGRESSION	Several plasma non-lipid biomarkers have been shown to predict major cardiovascular events (MCVEs) in population studies. Our objective was to investigate the relationship between lipid and non-lipid biomarkers levels achieved during statin therapy and the incidence of MCVEs in patients with stable coronary heart disease (CHD). We conducted a substudy of the TNT (Treating to New Targets) study, which was a randomized trial that compared the efficacy of high (80 mg) versus low (10 mg) dose atorvastatin for the secondary prevention of CHD. Fasting plasma levels of standard lipids and of 18 non-lipid biomarkers were obtained after an 8-week run-in period on atorvastatin 10 mg in 157 patients who experienced MCVEs during the 4.9 years of study follow-up and in 1349 controls. MCVE was defined as CHD death, nonfatal, non-procedure-related myocardial infarction, resuscitated cardiac arrest, and fatal or nonfatal stroke. After adjusting for age, sex and treatment arm, plasma levels of high-density lipoprotein (HDL) cholesterol, triglycerides, high-sensitivity C-reactive protein (hsCRP), insulin, neopterin, N-terminal pro-brain natriuretic peptide (BNP), lipoprotein(a) [Lp(a)], and the soluble receptor for advanced glycation end products (sRAGE) were predictive of recurrent MCVEs (P <= 0.02 for each doubling of plasma concentration). However, no significant association was observed between the risk of recurrent MCVEs and plasma levels of low-density lipoprotein cholesterol, adiponectin, cystatin C, lipoprotein-associated phospholipase A2, monocyte chemotactic protein-1, matrix metalloproteinase-9, myeloperoxidase, osteopontin, soluble CD40 ligand, soluble intercellular adhesion molecule-1, or soluble vascular cell adhesion molecule-1. After further adjustment for diabetes, hypertension, smoking, and BMI, the relationship between hsCRP, insulin and MCVE were no longer significant, while the relationship between Lp(a), neopterin, NT-proBNP and sRAGE and MCVE remained statistically significant. In conclusion, in patients with CHD treated with atorvastatin, plasma levels of Lp(a), neopterin, NT-proBNP, and sRAGE are associated with the risk of recurrent MCVEs.	[Arsenault, Benoit J.; Kastelein, John J. P.] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands; [Barter, Philip] Heart Res Inst, Sydney, NSW, Australia; [DeMicco, David A.; Bao, Weihang; Preston, Gregory M.] Pfizer Inc, New York, NY USA; [LaRosa, John C.] SUNY Hlth Sci Ctr, Brooklyn, NY USA; [Grundy, Scott M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Deedwania, Prakash] Vet Affairs Cent Calif Hlth Care Syst, San Francisco, CA USA; [Deedwania, Prakash] Univ Calif San Francisco, Sch Med, San Francisco, CA USA; [Greten, Heiner] Univ Klinikum, Eppendorf, Germany; [Wenger, Nanette K.] Emory Univ, Sch Med, Atlanta, GA USA; [Shepherd, James] Univ Glasgow, Glasgow, Lanark, Scotland; [Waters, David D.] San Francisco Gen Hosp, San Francisco, CA 94110 USA	University of Amsterdam; Academic Medical Center Amsterdam; University of Sydney; Heart Research Institute; Pfizer; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Francisco; Emory University; University of Glasgow; San Francisco General Hospital Medical Center	Kastelein, JJP (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	j.j.kastelein@amc.uva.nl	Kastelein, John/AAF-7950-2020		Pfizer Inc.; Fonds de la recherche en sante du Quebec; Fondation de l'Institut universitaire de cardiologie et de pneumologie de Quebec; Pfizer	Pfizer Inc.(Pfizer); Fonds de la recherche en sante du Quebec(Fonds de la Recherche en Sante du Quebec); Fondation de l'Institut universitaire de cardiologie et de pneumologie de Quebec; Pfizer(Pfizer)	This study was funded by Pfizer Inc. Benoit J. Arsenault is supported by a post-doctoral fellowship from the Fonds de la recherche en sante du Quebec and the Fondation de l'Institut universitaire de cardiologie et de pneumologie de Quebec. Two authors are Pfizer employees and may hold stock in the company. As sponsor, Pfizer in cooperation with the steering committee had a role in all aspects of the study. The secondary biomarker analysis was funded by Pfizer. However, the decision to publish and preparation of the manuscript was driven solely by the authors.	[Anonymous], 2013, J AM COLL CARDIOL, V61, P1750; Arsenault Benoit J, 2011, J Am Coll Cardiol, V57, P63, DOI 10.1016/j.jacc.2010.06.052; Boekholdt SM, 2006, ATHEROSCLEROSIS, V187, P415, DOI 10.1016/j.atherosclerosis.2005.09.023; Bonnet J, 2008, CLIN THER, V30, P2298, DOI 10.1016/j.clinthera.2008.12.023; Clarke R, 2009, NEW ENGL J MED, V361, P2518, DOI 10.1056/NEJMoa0902604; Colhoun HM, 2011, DIABETES, V60, P2379, DOI 10.2337/db11-0291; Danesh J, 2004, NEW ENGL J MED, V350, P1387, DOI 10.1056/NEJMoa032804; Deshmukh HA, 2012, J LIPID RES, V53, P1000, DOI 10.1194/jlr.P021113; Di Angelantonio E, 2009, CIRCULATION, V120, P2177, DOI 10.1161/CIRCULATIONAHA.109.884866; Emberson JR, 2007, J AM COLL CARDIOL, V49, P311; Helfand M, 2009, ANN INTERN MED, V151, P496, DOI 10.7326/0003-4819-151-7-200910060-00010; Hopewell JC, 2013, EUR HEART J, V34, P982, DOI 10.1093/eurheartj/ehs344; Kamstrup PR, 2009, JAMA-J AM MED ASSOC, V301, P2331, DOI 10.1001/jama.2009.801; Koh KK, 2010, J AM COLL CARDIOL, V55, P1209, DOI 10.1016/j.jacc.2009.10.053; LaRosa JC, 2005, NEW ENGL J MED, V352, P1425, DOI 10.1056/NEJMoa050461; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Meuwese MC, 2008, ATHEROSCLEROSIS, V197, P916, DOI 10.1016/j.atherosclerosis.2007.08.011; Morrow DA, 2006, CIRCULATION, V114, P281, DOI 10.1161/CIRCULATIONAHA.106.628909; Nissen SE, 2004, JAMA-J AM MED ASSOC, V291, P1071, DOI 10.1001/jama.291.9.1071; Packard RRS, 2008, CLIN CHEM, V54, P24, DOI 10.1373/clinchem.2007.097360; Ray KK, 2007, CIRCULATION, V115, P3071, DOI 10.1161/CIRCULATIONAHA.106.666511; Ridker PM, 2008, NEW ENGL J MED, V359, P2195, DOI 10.1056/NEJMoa0807646; Ridker PM, 2009, LANCET, V373, P1175, DOI 10.1016/S0140-6736(09)60447-5; Ridker PM, 2008, CIRCULATION, V118, P2243, DOI 10.1161/CIRCULATIONAHA.108.814251; Ridker PM, 2005, NEW ENGL J MED, V352, P20, DOI 10.1056/NEJMoa042378; Sarwar N, 2007, EUR HEART J, V28, P2491, DOI 10.1093/eurheartj/ehm115; Scirica BM, 2009, CLIN CHEM, V55, P265, DOI 10.1373/clinchem.2008.117192; Singh U, 2008, AM J CARDIOL, V102, P321, DOI 10.1016/j.amjcard.2008.03.057; West MJ, 2008, EUR HEART J, V29, P923, DOI 10.1093/eurheartj/ehn007	29	36	36	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 22	2014	9	12							e114519	10.1371/journal.pone.0114519	http://dx.doi.org/10.1371/journal.pone.0114519			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA3ZY	25531109	Green Published, gold			2023-01-03	WOS:000348845100016
J	Walker, N; Howe, C; Glover, M; McRobbie, H; Barnes, J; Nosa, V; Parag, V; Bassett, B; Bullen, C				Walker, Natalie; Howe, Colin; Glover, Marewa; McRobbie, Hayden; Barnes, Joanne; Nosa, Vili; Parag, Varsha; Bassett, Bruce; Bullen, Christopher			Cytisine versus Nicotine for Smoking Cessation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REPLACEMENT THERAPY; FAGERSTROM TEST; NEW-ZEALAND; TRIAL; VARENICLINE; EFFICACY	BACKGROUND Placebo-controlled trials indicate that cytisine, a partial agonist that binds the nicotinic acetylcholine receptor and is used for smoking cessation, almost doubles the chances of quitting at 6 months. We investigated whether cytisine was at least as effective as nicotine-replacement therapy in helping smokers to quit. METHODS We conducted a pragmatic, open-label, noninferiority trial in New Zealand in which 1310 adult daily smokers who were motivated to quit and called the national quitline were randomly assigned in a 1: 1 ratio to receive cytisine for 25 days or nicotine-replacement therapy for 8 weeks. Cytisine was provided by mail, free of charge, and nicotine-replacement therapy was provided through vouchers for low-cost patches along with gum or lozenges. Low-intensity, telephone-delivered behavioral support was provided to both groups through the quitline. The primary outcome was self-reported continuous abstinence at 1 month. RESULTS At 1 month, continuous abstinence from smoking was reported for 40% of participants receiving cytisine (264 of 655) and 31% of participants receiving nicotine-replacement therapy (203 of 655), for a difference of 9.3 percentage points (95% confidence interval, 4.2 to 14.5). The effectiveness of cytisine for continuous abstinence was superior to that of nicotine-replacement therapy at 1 week, 2 months, and 6 months. In a prespecified subgroup analysis of the primary outcome, cytisine was superior to nicotine-replacement therapy among women and noninferior among men. Self-reported adverse events over 6 months occurred more frequently in the cytisine group (288 events among 204 participants) than in the group receiving nicotine-replacement therapy (174 events among 134 participants); adverse events were primarily nausea and vomiting and sleep disorders. CONCLUSIONS When combined with brief behavioral support, cytisine was found to be superior to nicotine-replacement therapy in helping smokers quit smoking, but it was associated with a higher frequency of self-reported adverse events.	[Walker, Natalie; Howe, Colin; Parag, Varsha; Bullen, Christopher] Univ Auckland, Natl Inst Hlth Innovat, Auckland 1142, New Zealand; [Glover, Marewa] Univ Auckland, Ctr Tobacco Control Res, Dept Social & Community Hlth, Auckland 1142, New Zealand; [Nosa, Vili] Univ Auckland, Dept Pacific Hlth, Auckland 1142, New Zealand; [Barnes, Joanne] Univ Auckland, Sch Populat Hlth, Auckland 1142, New Zealand; [Barnes, Joanne] Univ Auckland, Sch Pharm, Auckland 1142, New Zealand; [Bassett, Bruce] Quit Grp, Wellington, New Zealand; [McRobbie, Hayden] Queen Mary Univ London, Wolfson Inst Prevent Med, London, England; [McRobbie, Hayden] Barts & London Queen Marys Sch Med & Dent, UK Ctr Tobacco & Alcohol Studies, London, England	University of Auckland; University of Auckland; University of Auckland; University of Auckland; University of Auckland; University of London; Queen Mary University London; University of London; Queen Mary University London	Walker, N (corresponding author), Univ Auckland, Natl Inst Hlth Innovat, Sch Populat Hlth, Private Bag 92019, Auckland 1142, New Zealand.	n.walker@auckland.ac.nz	Bullen, Chris/E-4594-2017; Nosa, Vili/AAJ-4476-2020; McRobbie, Hayden/B-4552-2018	Bullen, Chris/0000-0001-6807-2930; McRobbie, Hayden/0000-0002-7777-1845; Barnes, Joanne/0000-0002-1522-8433; Glover, Marewa/0000-0002-1572-3784	Health Research Council of New Zealand; Australian New Zealand Clinical Trials Registry [ACTRN12610000590066]	Health Research Council of New Zealand(Health Research Council of New Zealand); Australian New Zealand Clinical Trials Registry	Funded by the Health Research Council of New Zealand; Australian New Zealand Clinical Trials Registry number, ACTRN12610000590066.	[Anonymous], 2010, TOB US NZ KEY FIND 2; Aubin HJ, 2008, THORAX, V63, P717, DOI 10.1136/thx.2007.090647; Aveyard P, 2013, THORAX, V68, P989, DOI 10.1136/thoraxjnl-2013-203246; Borland R, 2001, ADDICTION, V96, P881, DOI 10.1046/j.1360-0443.2001.9668819.x; Bullen C., 2008, COCHRANE DB SYST REV, V3; Bullen C, 2008, J SMOK CESS, V3, P30, DOI 10.1375/jsc.3.1.30; Bullen C, 2010, ADDICTION, V105, P1474, DOI 10.1111/j.1360-0443.2010.02989.x; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; Cahill K, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006103.pub2; Cappelleri JC, 2007, ADDICT BEHAV, V32, P912, DOI 10.1016/j.addbeh.2006.06.028; Cepeda-Benito A, 2004, J CONSULT CLIN PSYCH, V72, P712, DOI 10.1037/0022-006X.72.4.712; Coe JW, 2005, J MED CHEM, V48, P3474, DOI 10.1021/jm050069n; Etter JF, 2006, ARCH INTERN MED, V166, P1553, DOI 10.1001/archinte.166.15.1553; Fagerstrom K, 2012, NICOTINE TOB RES, V14, P75, DOI 10.1093/ntr/ntr137; Feigen, 2006, RAPID REV NONNHS TRE; Godley E, 2006, INTRO KOWHAI STYX RE; Hajek P, 2013, THORAX, V68, P1037, DOI 10.1136/thoraxjnl-2012-203035; HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119; LI J, 2007, QUITLINE CALLERS COM; Li Judy, 2007, N Z Med J, V120, pU2584; Ministry of Health, 2007, NZ SMOK CESS GUID; Perkins KA, 2008, NICOTINE TOB RES, V10, P1245, DOI 10.1080/14622200802097506; Prochaska JJ, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5198; Stapleton JA, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5736; Stapleton JA, 2012, NICOTINE TOB RES, V14, P463, DOI 10.1093/ntr/ntr236; Tindle M, 2014, DRUG TEST ANAL; Tutka P, 2006, PHARMACOL REP, V58, P777; Walker N, 2012, ADDICTION, V107, P1857, DOI 10.1111/j.1360-0443.2012.03906.x; Walker N, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-880; Walker N, 2011, ADDICTION, V106, P1176, DOI 10.1111/j.1360-0443.2011.03419.x; WEBB CJ, 1980, NEW ZEAL J BOT, V18, P463, DOI 10.1080/0028825X.1980.10425167; West R, 2005, ADDICTION, V100, P299, DOI 10.1111/j.1360-0443.2004.00995.x; West R, 2004, PSYCHOPHARMACOLOGY, V177, P195, DOI 10.1007/s00213-004-1923-6; West R, 2011, NEW ENGL J MED, V365, P1193, DOI 10.1056/NEJMoa1102035	34	111	115	0	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 18	2014	371	25					2353	2362		10.1056/NEJMoa1407764	http://dx.doi.org/10.1056/NEJMoa1407764			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AW7DX	25517706	Bronze			2023-01-03	WOS:000346425800004
J	Spackman, E; Richmond, S; Sculpher, M; Bland, M; Brealey, S; Gabe, R; Hopton, A; Keding, A; Lansdown, H; Perren, S; Torgerson, D; Watt, I; MacPherson, H				Spackman, Eldon; Richmond, Stewart; Sculpher, Mark; Bland, Martin; Brealey, Stephen; Gabe, Rhian; Hopton, Ann; Keding, Ada; Lansdown, Harriet; Perren, Sara; Torgerson, David; Watt, Ian; MacPherson, Hugh			Cost-Effectiveness Analysis of Acupuncture, Counselling and Usual Care in Treating Patients with Depression: The Results of the ACUDep Trial	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL	Background: New evidence on the clinical effectiveness of acupuncture plus usual care (acupuncture) and counselling plus usual care (counselling) for patients with depression suggests the need to investigate the health-related quality of life and costs of these treatments to understand whether they should be considered a good use of limited health resources. Methods and Findings: The cost-effectiveness analyses are based on the Acupuncture, Counselling or Usual care for Depression (ACUDep) trial results. Statistical analyses demonstrate a difference in mean quality adjusted life years (QALYs) and suggest differences in mean costs which are mainly due to the price of the interventions. Probabilistic sensitivity analysis is used to express decision uncertainty. Acupuncture and counselling are found to have higher mean QALYs and costs than usual care. In the base case analysis acupuncture has an incremental cost-effectiveness ratio (ICER) of 4,560 pound per additional QALY and is cost-effective with a probability of 0.62 at a cost-effectiveness threshold of 20,000 pound per QALY. Counselling compared with acupuncture is more effective and more costly with an ICER of 71,757 pound and a probability of being cost-effective of 0.36. A scenario analysis of counselling versus usual care, excluding acupuncture as a comparator, results in an ICER of 7,935 pound and a probability of 0.91. Conclusions: Acupuncture is cost-effective compared with counselling or usual care alone, although the ranking of counselling and acupuncture depends on the relative cost of delivering these interventions. For patients in whom acupuncture is unavailable or perhaps inappropriate, counselling has an ICER less than most cost-effectiveness thresholds. However, further research is needed to determine the most cost-effective treatment pathways for depressed patients when the full range of available interventions is considered.	[Spackman, Eldon; Sculpher, Mark] Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England; [Richmond, Stewart; Bland, Martin; Brealey, Stephen; Gabe, Rhian; Hopton, Ann; Keding, Ada; Lansdown, Harriet; Perren, Sara; Torgerson, David; MacPherson, Hugh] Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England; [Watt, Ian] Univ York, Hull York Med Sch, York YO10 5DD, N Yorkshire, England	University of York - UK; University of York - UK; University of Hull; University of York - UK	Spackman, E (corresponding author), Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England.	eldon.spackman@york.ac.uk	Torgerson, David/L-4566-2019	Torgerson, David/0000-0002-1667-4275; Spackman, David Eldon/0000-0001-8558-5973; Gabe, Rhian/0000-0002-0273-3094; Keding, Ada/0000-0002-1182-887X; brealey, stephen/0000-0001-9749-7014; Sculpher, Mark/0000-0003-3746-9913	National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme [RP-PG-0707-10186]	National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme(National Institute for Health Research (NIHR))	This article presents independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme (RP-PG-0707-10186). The views expressed are those of the author(s) and not necessarily those of the National Health Service, the NIHR or the Department of Health. The funders, and the University of York in its role as sponsor for the study, had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barth J, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001454; Bower P, 2000, BMJ-BRIT MED J, V321, P1389, DOI 10.1136/bmj.321.7273.1389; Churchill R, 2001, HTA, V5, P183; Claxton K, 1999, J HEALTH ECON, V18, P341, DOI 10.1016/S0167-6296(98)00039-3; Claxton K, 2013, METHODS ESTIMATION N; Curtis L., 2012, UNIT COSTS HLTH SOCI; DOLAN P, 1995, HEALTH ECON, V4, P289, DOI 10.1002/hec.4730040405; Fava M, 2003, BIOL PSYCHIAT, V53, P649, DOI 10.1016/S0006-3223(03)00231-2; Gilbody S, 2002, IMPROVING RECOGNITIO; Hopton AK, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000456; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; MacPherson H, 2012, BMC GASTROENTEROLOGY, V12; MacPherson H, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001518; MacPherson H, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-209; Manca A, 2005, HEALTH ECON, V14, P487, DOI 10.1002/hec.944; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; Mellor-Clark J, 2001, OCCAS PAP R COLL GEN, Vvi-7; National Institute for Health and Care Excellence (NICE), 2013, GUID METH TECHN APPR; NHS Choices, 2014, AC; NICE, 2010, DEPR TREATM MAN DEPR, P707; Seggar L, 2002, BEHAV THER, V33, P17; Smith CA, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004046.pub3; Thomas CM, 2003, BRIT J PSYCHIAT, V183, P514, DOI 10.1192/bjp.183.6.514; Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654; Whiting M, 2008, COMPLEMENT THER MED, V16, P87, DOI 10.1016/j.ctim.2007.07.005; Willan AR, 2005, STAT MED, V24, P131, DOI 10.1002/sim.1794	27	11	11	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 26	2014	9	11							e113726	10.1371/journal.pone.0113726	http://dx.doi.org/10.1371/journal.pone.0113726			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CA8CZ	25426637	Green Published, Green Submitted, gold			2023-01-03	WOS:000349145400082
J	Pereira, RC; Juppner, H; Gales, B; Salusky, IB; Wesseling-Perry, K				Pereira, Renata C.; Jueppner, Harald; Gales, Barbara; Salusky, Isidro B.; Wesseling-Perry, Katherine			Osteocytic Protein Expression Response to Doxercalciferol Therapy in Pediatric Dialysis Patients	PLOS ONE			English	Article							GROWTH-FACTOR 23; DENTIN MATRIX PROTEIN-1; CHRONIC KIDNEY-DISEASE; C-TERMINAL FRAGMENT; PARATHYROID-HORMONE; SECONDARY HYPERPARATHYROIDISM; PHOSPHATE HOMEOSTASIS; RENAL OSTEODYSTROPHY; BREAST-CARCINOMA; GENE-EXPRESSION	Background Osteocytic protein expression is dysregulated in CKD and is affected by changes in mineral metabolism; however the effects of active vitamin D sterol therapy on osteocyte protein expression in advanced CKD is unknown. Methods Eleven pediatric patients with end stage kidney disease underwent bone biopsy, were treated for 8 months with doxercalciferol, and then underwent a second bone biopsy. Bone expression of fibroblast growth factor 23 (FGF23), dentin matrix protein 1 (DMP1), and sclerostin were determined by immunohistochemistry and quantified by Ariol Scanning. Western blot analysis and qRT-PCR was performed on bone abstracts of a subset of study subjects to determine the nature (i.e. size) of FGF23 and DMP1 in bone before and after therapy. Results As assessed by immunohistochemistry, bone FGF23, DMP1 and sclerostin protein all increased with therapy. In the case of FGF23, this increase was due to an increase in the full-length molecule without the appearance of FGF23 fragments. DMP1 was present primarily in its full-length formin healthy controls while 57kDa and 37kDa fragments of DMP1 were apparent in bone of dialysis patients at baseline and the 57 kDa appeared to decrease with therapy. Conclusion Marked changes in osteocytic protein expression accompany doxercalciferol therapy, potentially impacting bone mineralization and the skeletal response to PTH. The effects of these bone changes on long-term outcomes remain to be determined.	[Pereira, Renata C.; Gales, Barbara; Salusky, Isidro B.; Wesseling-Perry, Katherine] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA; [Jueppner, Harald] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; [Jueppner, Harald] Massachusetts Gen Hosp, Pediat Nephrol Unit, Boston, MA 02114 USA; [Jueppner, Harald] Harvard Univ, Sch Med, Boston, MA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Wesseling-Perry, K (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA.	kwesseling@mednet.ucla.edu			USPHS [DK-67563, DK-35423, DK-080984, PO-1DK11794]; CTSI [UL1 TR-000124]; Casey Lee Ball Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000124] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK011794, R01DK035423, K23DK080984, R01DK067563] Funding Source: NIH RePORTER	USPHS(United States Department of Health & Human ServicesUnited States Public Health Service); CTSI; Casey Lee Ball Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported in part by USPHS grants DK-67563, DK-35423, DK-080984, PO-1DK11794, and CTSI grant UL1 TR-000124 and funds from the Casey Lee Ball Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bacchetta J, 2013, CLIN J AM SOC NEPHRO, V8, P824, DOI 10.2215/CJN.00330112; Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005-0239; Bhattacharyya N, 2012, TRENDS ENDOCRIN MET, V23, P610, DOI 10.1016/j.tem.2012.07.002; Bhattacharyya N, 2012, J BONE MINER RES, V27, P1132, DOI 10.1002/jbmr.1546; Cejka D, 2011, CLIN J AM SOC NEPHRO, V6, P877, DOI 10.2215/CJN.06550810; Chaussain C, 2009, EUR CELLS MATER, V18, P84, DOI 10.22203/eCM.v018a08; Faul C, 2011, J CLIN INVEST, V121, P4393, DOI 10.1172/JCI46122; Gokhale S, 2007, APPL IMMUNOHISTO M M, V15, P451, DOI 10.1097/PAI.0b013e31802ee998; Gomes SA, 2008, J BONE MINER METAB, V26, P110, DOI 10.1007/s00774-007-0788-2; GOODMAN WG, 1994, KIDNEY INT, V46, P1160, DOI 10.1038/ki.1994.380; Gutierrez OM, 2008, NEW ENGL J MED, V359, P584, DOI 10.1056/NEJMoa0706130; Hollis BW, 1996, CLIN CHEM, V42, P586; Huang BZ, 2008, CALCIFIED TISSUE INT, V82, P401, DOI 10.1007/s00223-008-9140-7; Isakova T, 2011, KIDNEY INT, V79, P1370, DOI 10.1038/ki.2011.47; Jiang Z, 2004, HISTOPATHOLOGY, V45, P218, DOI 10.1111/j.1365-2559.2004.01930.x; Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188; Larsson T, 2004, ENDOCRINOLOGY, V145, P3087, DOI 10.1210/en.2003-1768; Lavi-Moshayoff V, 2010, AM J PHYSIOL-RENAL, V299, pF882, DOI 10.1152/ajprenal.00360.2010; Leys CM, 2007, SURGERY, V141, P41, DOI 10.1016/j.surg.2006.05.009; Liu SG, 2008, AM J PHYSIOL-ENDOC M, V295, pE254, DOI 10.1152/ajpendo.90201.2008; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lorenz-Depiereux B, 2006, NAT GENET, V38, P1248, DOI 10.1038/ng1868; Lu YB, 2011, J BONE MINER RES, V26, P331, DOI 10.1002/jbmr.226; Martin A, 2012, MOL ENDOCRINOL, V26, P1883, DOI 10.1210/me.2012-1062; Meir T, 2014, KIDNEY INT, V86, P1106, DOI 10.1038/ki.2014.215; Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414; Nociti FH, 2014, J DENT RES, V93, P148, DOI 10.1177/0022034513516344; Pereira RC, 2009, BONE, V45, P1161, DOI 10.1016/j.bone.2009.08.008; Rhee Y, 2011, BONE, V49, P636, DOI 10.1016/j.bone.2011.06.025; Sabbagh Y, 2012, J BONE MINER RES, V27, P1757, DOI 10.1002/jbmr.1630; Sanchez CP, 1998, KIDNEY INT, V53, P1358, DOI 10.1046/j.1523-1755.1998.00866.x; Shimada T, 2010, J CLIN ENDOCR METAB, V95, P578, DOI 10.1210/jc.2009-1603; Smith ER, 2012, J CLIN ENDOCR METAB, V97, P3357, DOI 10.1210/jc.2012-1811; Turbin DA, 2008, BREAST CANCER RES TR, V110, P417, DOI 10.1007/s10549-007-9736-z; von Marschall Z, 2008, J BIOL CHEM, V283, P32730, DOI 10.1074/jbc.M804283200; Wesseling-Perry K, 2012, CLIN J AM SOC NEPHRO, V7, P146, DOI 10.2215/CJN.05940611; Wesseling-Perry K, 2011, KIDNEY INT, V79, P112, DOI 10.1038/ki.2010.352	37	18	18	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 16	2015	10	3							e0120856	10.1371/journal.pone.0120856	http://dx.doi.org/10.1371/journal.pone.0120856			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CD6EY	25774916	Green Published, Green Submitted, gold			2023-01-03	WOS:000351183500195
J	Jun, E; Kim, S; Kim, JH; Cha, K; So, IS; Son, HN; Lee, BH; Kim, K; Kwon, IC; Kim, SY; Kim, IS				Jun, Eunsung; Kim, Soyoun; Kim, Jong-Ho; Cha, Kiweon; So, In-Seop; Son, Hye-Nam; Lee, Byung-Heon; Kim, Kwangmeyung; Kwon, Ick Chan; Kim, Sang Yoon; Kim, In-San			Design of a Multicomponent Peptide-Woven Nanocomplex for Delivery of siRNA	PLOS ONE			English	Article							DE-NOVO PEPTIDE; STRUCTURE PREDICTION; INTRACELLULAR DELIVERY; MOLECULAR-DYNAMICS; ENDOSOMAL ESCAPE; INTERFERING RNA; CELLULAR UPTAKE; CANCER-THERAPY; PEP-FOLD; GENE	We developed and tested a multicomponent peptide-woven siRNA nanocomplex (PwSN) comprising different peptides designed for efficient cellular targeting, endosomal escape, and release of siRNA. To enhance tumor-specific cellular uptake, we connected an interleukin-4 receptor-targeting peptide (I4R) to a nine-arginine peptide (9r), yielding I4R-9r. To facilitate endosomal escape, we blended endosomolytic peptides into the I4R-9r to form a multicomponent nanocomplex. Lastly, we modified 9r peptides by varying the number and positions of positive charges to obtain efficient release of siRNA from the nanocomplex in the cytosol. Using this step-wise approach for overcoming the biological challenges of siRNA delivery, we obtained an optimized PwSN with significant biological activity in vitro and in vivo. Interestingly, surface plasmon resonance analyses and three-dimensional peptide models demonstrated that our designed peptide adopted a unique structure that was correlated with faster complex disassembly and a better gene-silencing effect. These studies further elucidate the siRNA nanocomplex delivery pathway and demonstrate the applicability of our stepwise strategy to the design of siRNA carriers capable of overcoming multiple challenges and achieving efficient delivery.	[Jun, Eunsung; Kim, Soyoun; So, In-Seop; Son, Hye-Nam; Lee, Byung-Heon] Kyungpook Natl Univ, Sch Med, Cell & Matrix Res Inst, Dept Biochem & Cell Biol, Daegu, South Korea; [Kim, Jong-Ho] Kyung Hee Univ, Coll Pharm, Dept Pharmaceut Sci, Seoul, South Korea; [Cha, Kiweon] Korea Ctr Dis Control & Prevent KCDC, Korea Natl Inst Hlth, Div High Risk Pathogen Res, Osong, Chungbuk, South Korea; [Jun, Eunsung; Kim, Kwangmeyung; Kwon, Ick Chan; Kim, Sang Yoon; Kim, In-San] Korea Inst Sci & Technol, Ctr Theragnosis, Biomed Res Inst, Seoul, South Korea; [Kim, Sang Yoon] Univ Ulsan, Coll Med, Dept Otolaryngol, Seoul, South Korea	Kyungpook National University; Kyung Hee University; Korea Centers for Disease Control & Prevention (KCDC); Korea National Institute of Health (KNIH); Korea CDC Center for Infectious Disease; Korea Institute of Science & Technology (KIST); University of Ulsan	Kim, IS (corresponding author), Korea Inst Sci & Technol, Ctr Theragnosis, Biomed Res Inst, Seoul, South Korea.	iskim14@kist.re.kr	김, 인산/I-8988-2014; Kim, In-San/D-3956-2017; Kim, Soyoun/Y-1276-2018; Kim, Kwangmeyung/ABB-2882-2021; KWON, ICK CHAN/AAS-4776-2020	KWON, ICK CHAN/0000-0003-1272-7074	National Research Foundation of Korea(NRF) - Korea government(MEST) [2010-0029206]; National Research Foundation of Korea( NRF) - Korea government [2014R1A5A2009242]; KIST Institutional Program [2E25000]	National Research Foundation of Korea(NRF) - Korea government(MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaNational Research Foundation of KoreaKorean Government); National Research Foundation of Korea( NRF) - Korea government; KIST Institutional Program(Korea Institute of Science & Technology (KIST))	This work was supported by the National Research Foundation of Korea(NRF) grant funded by the Korea government(MEST) (2010-0029206); by the National Research Foundation of Korea( NRF) grant funded by the Korea government (2014R1A5A2009242); by the KIST Institutional Program (Project No. 2E25000). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aliabadi HM, 2012, BIOMATERIALS, V33, P2546, DOI 10.1016/j.biomaterials.2011.11.079; Beloor J, 2012, BIOMATERIALS, V33, P1640, DOI 10.1016/j.biomaterials.2011.11.008; Bruno K, 2011, ADV DRUG DELIVER REV, V63, P1210, DOI 10.1016/j.addr.2011.09.003; Choi KM, 2011, ACS NANO, V5, P8690, DOI 10.1021/nn202597c; Ding Y, 2012, BIOMATERIALS, V33, P8893, DOI 10.1016/j.biomaterials.2012.08.057; Dominska M, 2010, J CELL SCI, V123, P1183, DOI 10.1242/jcs.066399; Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200; Han L, 2012, ACS NANO, V6, P7340, DOI 10.1021/nn3024688; Nguyen J, 2012, ACCOUNTS CHEM RES, V45, P1153, DOI 10.1021/ar3000162; Jung HJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040010; Kanasty R, 2013, NAT MATER, V12, P967, DOI [10.1038/NMAT3765, 10.1038/nmat3765]; Kaur H, 2007, PROTEIN PEPTIDE LETT, V14, P626; Kim JH, 2012, J CONTROL RELEASE, V157, P493, DOI 10.1016/j.jconrel.2011.09.070; Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901; Kwok A, 2011, NANOMED-NANOTECHNOL, V7, P210, DOI 10.1016/j.nano.2010.07.005; Kwon EJ, 2008, BIOCONJUGATE CHEM, V19, P920, DOI 10.1021/bc700448h; Kwon EJ, 2010, MOL PHARMACEUT, V7, P1260, DOI 10.1021/mp1000668; Kwon YJ, 2012, ACCOUNTS CHEM RES, V45, P1077, DOI 10.1021/ar200241v; Lee MY, 2011, ACS NANO, V5, P6138, DOI 10.1021/nn2017793; Lee SY, 2010, J CONTROL RELEASE, V141, P339, DOI 10.1016/j.jconrel.2009.10.007; Li X, 2013, BIOMATERIALS, V34, P1391, DOI 10.1016/j.biomaterials.2012.10.072; Lobovkina T, 2011, ACS NANO, V5, P9977, DOI 10.1021/nn203745n; Lundberg P, 2007, FASEB J, V21, P2664, DOI 10.1096/fj.06-6502com; Maupetit J, 2010, J COMPUT CHEM, V31, P726, DOI 10.1002/jcc.21365; Maupetit J, 2009, NUCLEIC ACIDS RES, V37, pW498, DOI 10.1093/nar/gkp323; Nam JO, 2012, MOL CANCER RES, V10, P1010, DOI 10.1158/1541-7786.MCR-11-0600; Ouyang DF, 2010, J PHYS CHEM B, V114, P9220, DOI 10.1021/jp911906e; Ouyang DF, 2010, J PHYS CHEM B, V114, P9231, DOI 10.1021/jp911913c; Paredes-Gamero EJ, 2012, MOL PHARMACEUT, V9, P2686, DOI 10.1021/mp300251j; Petros RA, 2010, NAT REV DRUG DISCOV, V9, P615, DOI 10.1038/nrd2591; Pulford B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011085; Ren Y, 2012, ACS NANO, V6, P8620, DOI 10.1021/nn301975s; SAHLIN S, 1983, J IMMUNOL METHODS, V60, P115, DOI 10.1016/0022-1759(83)90340-X; Sakurai Y, 2011, BIOMATERIALS, V32, P5733, DOI 10.1016/j.biomaterials.2011.04.047; Sethi D, 2012, BIOCONJUGATE CHEM, V23, P158, DOI 10.1021/bc2004507; Sonawane ND, 2003, J BIOL CHEM, V278, P44826, DOI 10.1074/jbc.M308643200; Strumberg D, 2012, INT J CLIN PHARM TH, V50, P76, DOI 10.5414/CPP50076; Thevenet P, 2012, NUCLEIC ACIDS RES, V40, pW288, DOI 10.1093/nar/gks419; van Asbeck AH, 2013, ACS NANO, V7, P3797, DOI 10.1021/nn305754c; Vasumathi V, 2013, SOFT MATTER, V9, P1372, DOI 10.1039/c2sm26804c; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996; Wang YH, 2006, BIOCHEM BIOPH RES CO, V346, P758, DOI 10.1016/j.bbrc.2006.05.205; Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742; Wu XL, 2010, BIOCONJUGATE CHEM, V21, P208, DOI 10.1021/bc9005283; Ye SF, 2012, NANOMED-NANOTECHNOL, V8, P833, DOI 10.1016/j.nano.2011.10.003	45	6	7	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 23	2015	10	2							e0118310	10.1371/journal.pone.0118310	http://dx.doi.org/10.1371/journal.pone.0118310			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC9BI	25705892	Green Published, gold, Green Submitted			2023-01-03	WOS:000350662100165
J	Park, JI; Kim, M; Kim, H; An, JN; Lee, J; Yang, SH; Cho, JH; Kim, YL; Park, KS; Oh, YK; Lim, CS; Kim, DK; Kim, YS; Lee, JP				Park, Ji In; Kim, Myounghee; Kim, Ho; An, Jung Nam; Lee, Jeonghwan; Yang, Seung Hee; Cho, Jang-Hee; Kim, Yong-Lim; Park, Ki-Soo; Oh, Yun Kyu; Lim, Chun Soo; Kim, Dong Ki; Kim, Yon Su; Lee, Jung Pyo			Not Early Referral but Planned Dialysis Improves Quality of Life and Depression in Newly Diagnosed End Stage Renal Disease Patients: A Prospective Cohort Study in Korea	PLOS ONE			English	Article							SUBOPTIMAL INITIATION; PRACTICE PATTERNS; MENTAL-HEALTH; ASSOCIATION; MORTALITY; OUTCOMES; NEPHROLOGIST; IMPACT	Background Health-related quality of life (HRQOL) has recently become an important issue. It reportedly affects morbidity and mortality in patients with end-stage renal disease (ESRD). In this study, we investigated whether early referral and planned dialysis improve the HRQOL and depression of patients with ESRD. Methods We prospectively enrolled newly diagnosed patients with ESRD, from 31 hospitals in Korea, who completed questionnaires at 3 months after dialysis. We also got follow-up survey at 1 year after dialysis. To measure HRQOL and depression, Kidney Disease Quality of Life Short Form 36 (KDQOL-36) and Beck's Depression Inventory (BDI) were utilized. Results A total of 643 patients were analyzed. Referral type did not affect either KDQOL-36 or BDI scores. However, the planned dialysis group showed significantly better scores in 4 of 5 KDQOL-36 domains than did the unplanned group at 3 months after dialysis and partly, the effect was sustained for 1 year after dialysis. The benefit of planned dialysis was significant after adjusting for age, sex, type of dialysis, marital status, educational attainment, occupation, modified Charlson comorbidity index, albumin, and hemoglobin levels. BDI scores were also lower which indicate less depressive mood in planned dialysis group than those in unplanned group both at 3 months and 1 year after dialysis. Conclusions Not early referral but planned dialysis improved both the short-and long-term HRQOL and depression of patients with ESRD. Nephrologists should try to help patients to initiate dialysis in a planned manner.				nephrolee@gmail.com	Lee, Jeonghwan/C-5214-2011; Cho, Jang-hee/ABD-3534-2020; Oh, Yun Kyu/J-5542-2012; Kim, Dong Ki/J-5389-2012; Kim, Ho/AAS-2402-2021	Lee, Jeonghwan/0000-0003-3199-635X; Cho, Jang-hee/0000-0002-7031-5214; Kim, Dong Ki/0000-0002-5195-7852; Kim, Ho/0000-0001-7472-3752; Park, Ji In/0000-0003-4662-3759	Korea Healthcare technology R&D Project, Ministry of Health and Welfare, Republic of Korea [HI10C2020]	Korea Healthcare technology R&D Project, Ministry of Health and Welfare, Republic of Korea	This study was supported by a grant of the Korea Healthcare technology R&D Project, Ministry of Health and Welfare, Republic of Korea. (HI10C2020). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Buck J, 2007, NEPHROL DIAL TRANSPL, V22, P3240, DOI 10.1093/ndt/gfm387; Caskey FJ, 2003, NEPHROL DIAL TRANSPL, V18, P1330, DOI 10.1093/ndt/gfg156; Chilcot J, 2011, NEPHROL DIAL TRANSPL, V26, P1628, DOI 10.1093/ndt/gfq611; Choi JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084257; Cukor D, 2006, NAT CLIN PRACT NEPHR, V2, P678, DOI 10.1038/ncpneph0359; Farrokhi F, 2014, AM J KIDNEY DIS, V63, P623, DOI 10.1053/j.ajkd.2013.08.024; Finkelstein FO, 2000, NEPHROL DIAL TRANSPL, V15, P1911, DOI 10.1093/ndt/15.12.1911; Hughes SA, 2013, NEPHROL DIAL TRANSPL, V28, P392, DOI 10.1093/ndt/gfs431; Kim DH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055323; Kim JY, 2013, QUAL LIFE RES, V22, P753, DOI 10.1007/s11136-012-0203-x; Kimmel PL, 2000, KIDNEY INT, V57, P2093, DOI 10.1046/j.1523-1755.2000.00059.x; Knight EL, 2003, KIDNEY INT, V63, P1843, DOI 10.1046/j.1523-1755.2003.00931.x; Lee J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099460; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Levin A, 2013, KIDNEY INT, V83, P1001, DOI 10.1038/ki.2013.91; Loos C, 2003, J AM GERIATR SOC, V51, P229, DOI 10.1046/j.1532-5415.2003.51062.x; Mapes DL, 2003, KIDNEY INT, V64, P339, DOI 10.1046/j.1523-1755.2003.00072.x; Marron B, 2006, NEPHROL DIAL TRANSPL, V21, pii51; Mendelssohn DC, 2011, NEPHROL DIAL TRANSPL, V26, P2959, DOI 10.1093/ndt/gfq843; Mendelssohn DC, 2009, BMC NEPHROL, V10, DOI 10.1186/1471-2369-10-22; Rayner HC, 2014, AM J KIDNEY DIS; Sesso R, 1997, NEPHROL DIAL TRANSPL, V12, P2111, DOI 10.1093/ndt/12.10.2111; Smart NA, 2011, AM J MED, V124, P1073, DOI 10.1016/j.amjmed.2011.04.026; Yokoyama Y, 2009, NEPHRON CLIN PRACT, V113, pC191, DOI 10.1159/000232601	25	23	23	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 23	2015	10	2							e0117582	10.1371/journal.pone.0117582	http://dx.doi.org/10.1371/journal.pone.0117582			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC9BI	25706954	Green Published, Green Submitted, gold			2023-01-03	WOS:000350662100103
J	Young, LJ; Barrett, CE				Young, Larry J.; Barrett, Catherine E.			Can oxytocin treat autism?	SCIENCE			English	Editorial Material							SPECTRUM DISORDERS; CHILDREN; OXTR		[Young, Larry J.; Barrett, Catherine E.] Emory Univ, Silvio O Conte Ctr Oxytocin & Social Cognit, Dept Psychiat, Yerkes Natl Primate Res Ctr, Atlanta, GA 30329 USA	Emory University	Young, LJ (corresponding author), Emory Univ, Silvio O Conte Ctr Oxytocin & Social Cognit, Dept Psychiat, Yerkes Natl Primate Res Ctr, Atlanta, GA 30329 USA.	lyoun03@emory.edu	Young, Larry/HGE-5031-2022	Barrett, Catherine/0000-0002-2692-4194	NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH096983, P50MH100023] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS096050] Funding Source: NIH RePORTER; NCRR NIH HHS [P51 RR000165] Funding Source: Medline; NIMH NIH HHS [P50 MH100023, R01 MH096983] Funding Source: Medline; NINDS NIH HHS [T32 NS096050] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anagnostou E, 2014, BRAIN RES, V1580, P188, DOI 10.1016/j.brainres.2014.01.049; Aoki Y, 2014, BRAIN, V137, P3073, DOI 10.1093/brain/awu231; Barrett CE, 2014, NEUROPHARMACOLOGY, V85, P357, DOI 10.1016/j.neuropharm.2014.05.041; Freeman SM, 2014, PSYCHONEUROENDOCRINO, V45, P128, DOI 10.1016/j.psyneuen.2014.03.023; Gordon I, 2013, P NATL ACAD SCI USA, V110, P20953, DOI 10.1073/pnas.1312857110; Guastella AJ, 2015, J CHILD PSYCHOL PSYC, V56, P444, DOI 10.1111/jcpp.12305; Huang HP, 2014, NEUROPSYCHOPHARMACOL, V39, P1102, DOI 10.1038/npp.2013.310; LoParo D, 2015, MOL PSYCHIATR, V20, P640, DOI 10.1038/mp.2014.77; Modi ME, 2015, NEUROPSYCHOPHARMACOL, V40, P1856, DOI 10.1038/npp.2015.35; Owen SF, 2013, NATURE, V500, P458, DOI 10.1038/nature12330; Parker KJ, 2014, P NATL ACAD SCI USA, V111, P12258, DOI 10.1073/pnas.1402236111; Penagarikano O, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010257; Skuse DH, 2014, P NATL ACAD SCI USA, V111, P1987, DOI 10.1073/pnas.1302985111; Teng BL, 2013, NEUROPHARMACOLOGY, V72, P187, DOI 10.1016/j.neuropharm.2013.04.038; Tyzio R, 2014, SCIENCE, V343, P675, DOI 10.1126/science.1247190	15	140	142	3	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 20	2015	347	6224					825	826		10.1126/science.aaa8120	http://dx.doi.org/10.1126/science.aaa8120			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CB6UB	25700501	Green Accepted			2023-01-03	WOS:000349761100021
J	Kiss, B; Laszlo, JF; Szalai, A; Porszasz, R				Kiss, Balazs; Laszlo, Janos F.; Szalai, Andrea; Porszasz, Robert			Analysis of the Effect of Locally Applied Inhomogeneous Static Magnetic Field-Exposure on Mouse Ear Edema - A Double Blind Study	PLOS ONE			English	Article							PAIN; RESPONSES; CHANNELS	The effect static magnetic field (SMF)-exposure may exert on edema development has been investigated. A 6 h long whole-body (WBSMF) or local (LSMF), continuous, inhomogeneous SMF-exposure was applied on anesthetized mice in an in vivo model of mustard oil (MO)-induced ear edema. LSMF was applied below the treated ear, below the lumbar spine, or below the mandible. Ear thickness (v) was checked 8 times during the exposure period (at 0, 0.25, 1, 2, 3, 4, 5, and 6 h). The effect size of the applied treatment (eta) on ear thickness was calculated by the formula eta = 100% x (1-v(j)/v(i)), where group i is the control group and j is the treated group. Results showed that MO treatment in itself induced a significant ear edema with an effect of 9% (p< 0.001). WBSMF or LSMF on the spine in combination with MO treatment increased ear thickness even further resulting in an effect eta> 11% in both cases compared to SMF-exposure alone (p< 0.001). In these cases SMF-exposure alone without MO treatment reduced ear thickness significantly (p< 0.05), but within estimated experimental error. In cases of LSMF-exposure on the head, a significant SMF-exposure induced ear thickness reduction was found (eta = 5%, p< 0.05). LSMF-exposure on the spine affected ear thickness with and without MO treatment almost identically, which provides evidence that the place of local SMF action may be in the lower spinal region.	[Kiss, Balazs] Semmelweis Univ, Dept Biophys & Radiat Biol, H-1085 Budapest, Hungary; [Kiss, Balazs] Semmelweis Univ, MTA SE Mol Biophys Res Grp, H-1085 Budapest, Hungary; [Laszlo, Janos F.] Univ Debrecen, Dept Comp Sci, Debrecen, Hungary; [Laszlo, Janos F.] E Comers LLC, Budapest, Hungary; [Szalai, Andrea; Porszasz, Robert] Univ Debrecen, Med & Hlth Sci Ctr, Dept Pharmacol & Pharmacotherapy, Debrecen, Hungary	Semmelweis University; Semmelweis University; University of Debrecen; University of Debrecen	Kiss, B (corresponding author), Semmelweis Univ, Dept Biophys & Radiat Biol, H-1085 Budapest, Hungary.	balazs.kiss@eok.sote.hu	Kiss, Balazs/J-8371-2017; Porszasz, Robert/HGD-4008-2022	Kiss, Balazs/0000-0002-2347-5928; Porszasz, Robert/0000-0001-7910-9145				AlChaer ED, 1997, NEUROREPORT, V8, P3267, DOI 10.1097/00001756-199710200-00016; Alves LA, 2013, MOLECULES, V18, P10953, DOI 10.3390/molecules180910953; Bautista DM, 2006, CELL, V124, P1269, DOI 10.1016/j.cell.2006.02.023; Gabor Miklos, 2003, Methods Mol Biol, V225, P129; Gyires K, 2008, BIOELECTROMAGNETICS, V29, P456, DOI 10.1002/bem.20413; He YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054376; Holcomb RR, 1994, USA Patents, Patent No. [US 5312321 A, 5312321]; Jokela K, 2011, HEALTH PHYS, V100, P641, DOI 10.1097/HP.0b013e318202ec7e; Kiss B, 2013, BIOELECTROMAGNETICS, V34, P385, DOI 10.1002/bem.21781; Laszlo J, 2011, HORIZONS NEUROSCIENC, P106; Laszlo J, 2007, BIOELECTROMAGNETICS, V28, P615, DOI 10.1002/bem.20341; Laszlo J, 2009, LIFE SCI, V84, P12, DOI 10.1016/j.lfs.2008.10.009; Laszlo JF, 2012, INT J RADIAT BIOL, V88, P430, DOI 10.3109/09553002.2012.661916; LASZLO JF, 2010, PROGR ELECTROMAGNETI, V6, P307, DOI DOI 10.2529/PIERS091005062944; Li ZY, 2007, IN VIVO, V21, P61; Moran MM, 2004, CURR OPIN NEUROBIOL, V14, P362, DOI 10.1016/j.conb.2004.05.003; Morris C, 2005, BIOELECTROMAGNETICS, V26, P1, DOI 10.1002/bem.20047; Morris CE, 2008, AM J PHYSIOL-HEART C, V294, pH50, DOI 10.1152/ajpheart.00529.2007; Morris CE, 2007, J APPL PHYSIOL, V103, P629, DOI 10.1152/japplphysiol.01133.2006; Ohkubo C, 1997, IN VIVO, V11, P221; Okano H, 1999, BIOELECTROMAGNETICS, V20, P161, DOI 10.1002/(SICI)1521-186X(1999)20:3<161::AID-BEM2>3.0.CO;2-O; Okano H, 2005, BIOELECTROMAGNETICS, V26, P611, DOI 10.1002/bem.20144; Okano H, 2001, BIOELECTROMAGNETICS, V22, P408, DOI 10.1002/bem.68; Pereda J, 2006, BRIT J PHARMACOL, V149, P450, DOI 10.1038/sj.bjp.0706871; Rosen AD, 2003, BIOELECTROMAGNETICS, V24, P517, DOI 10.1002/bem.10124; Sandor K, 2007, LIFE SCI, V81, P97, DOI 10.1016/j.lfs.2007.04.029; Sprenger C, 2012, CURR BIOL, V22, P1019, DOI 10.1016/j.cub.2012.04.006; Valet M, 2004, PAIN, V109, P399, DOI 10.1016/j.pain.2004.02.033; Vergallo C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072374; Waltham MA, 2012, COMP ANATOMY HISTOLO	30	3	3	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2015	10	2							e0118089	10.1371/journal.pone.0118089	http://dx.doi.org/10.1371/journal.pone.0118089			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC0XE	25695832	Green Published, gold, Green Submitted			2023-01-03	WOS:000350062300040
J	Gao, Y; Zong, CJ; Liu, F; Fang, L; Cai, RL; Shi, Y; Chen, X; Qi, Y				Gao, Yuan; Zong, Chuanjie; Liu, Fen; Fang, Lei; Cai, Runlan; Shi, Yue; Chen, Xi; Qi, Yun			Evaluation of the Intestinal Transport of a Phenylethanoid Glycoside-Rich Extract from Cistanche deserticola across the Caco-2 Cell Monolayer Model	PLOS ONE			English	Article							PERMEABILITY; ABSORPTION; PREDICTION; SYSTEM	Phenylethanoid glycosides (PhGs), a class of polyphenolic compounds, are considered one of major bioactive constituents of Cistanche deserticola Y.C. Ma (CD), whose extract is orally used in traditional Chinese medicine. Although previous pharmacological studies have reported that PhGs exert many activities, their intestinal transport profiles have not been clarified. In this study, we investigated the intestinal permeability of a PhG-rich extract (PRE) from CD as an integrated system in the Caco-2 cell monolayer model using a bioassay system. The results showed that PRE is primarily transported via poorly absorbed passive diffusion down a concentration gradient without efflux, which provides the pharma-cokinetic basis for the clinical application of PhGs in CD. We also determined the intestinal permeability of three major PhGs [acteoside (AC), isoacteoside (IS) and echinacoside (EC)] by HLPC. Furthermore, we developed a novel HPLC-fluorescence detection method to accurately determine the flux amount of AC and IS. As expected, the transport characteristics of the three PhGs are consistent with those of PRE, indicating that the present bioassay system is appropriate and reliable for the evaluation of the transport characteristics of active ingredient groups (AIG) in PRE. Moreover, this system may also be suitable for other plant extracts given appropriate bioactivity.	[Gao, Yuan; Liu, Fen; Fang, Lei; Cai, Runlan; Shi, Yue; Chen, Xi; Qi, Yun] Chinese Acad Med Sci, Inst Med Plant Dev, Dept Res Ctr Pharmacol & Toxicol, Beijing 100730, Peoples R China; [Gao, Yuan; Liu, Fen; Fang, Lei; Cai, Runlan; Shi, Yue; Chen, Xi; Qi, Yun] Peking Union Med Coll, Beijing 100730, Peoples R China; [Zong, Chuanjie] Heilongjiang Univ Chinese Med, Harbin, Heilongjiang, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Medicinal Plant Development - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Heilongjiang University of Chinese Medicine	Chen, X (corresponding author), Chinese Acad Med Sci, Inst Med Plant Dev, Dept Res Ctr Pharmacol & Toxicol, Beijing 100730, Peoples R China.	chenxi@implad.ac.cn; yqi@implad.ac.cn	Fang, Lei/HHN-8887-2022	Fang, Lei/0000-0001-9980-8285	National Natural Science Foundation of China [81173645, 81274163]; Ministry of Science and Technology of the People's Republic of China [2012ZX09301-002-001, 2014ZX09201022-006]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of the People's Republic of China(Ministry of Science and Technology, China)	This work was supported by the National Natural Science Foundation of China (Nos. 81173645 and 81274163) and National S&T Major Project and Scientific Researchers Aiding Enterprise Item (Nos. 2012ZX09301-002-001 and 2014ZX09201022-006) from the Ministry of Science and Technology of the People's Republic of China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ARTURSSON P, 1991, BIOCHEM BIOPH RES CO, V175, P880, DOI 10.1016/0006-291X(91)91647-U; Artursson P, 2001, ADV DRUG DELIVER REV, V46, P27, DOI 10.1016/S0169-409X(00)00128-9; Cai RL, 2010, PHYTOTHER RES, V24, P313, DOI 10.1002/ptr.2927; [蔡润兰 CAI Run-lan], 2008, [中国药学杂志, Chinese Pharmaceutical Journal], V43, P1871; Center for Drug Evaluation and Research, 2004, GUID IND BOT DRUG PR, P5; Center for Drug Evaluation and Research, 2012, GUID IND DRUG INT ST, P64, DOI [10.1177/0091270007312153, DOI 10.1177/0091270007312153]; Dong Q, 2007, CARBOHYD RES, V342, P1343, DOI 10.1016/j.carres.2007.03.017; Eguchi A, 2005, FREE RADICAL RES, V39, P1367, DOI 10.1080/10715760500045624; Fu G, 2008, CURR MED CHEM, V15, P2592, DOI 10.2174/092986708785908996; Jiang Y, 2009, J CHROMATOGR A, V1216, P1970, DOI 10.1016/j.chroma.2008.07.031; Jung SJ, 2006, J PHARMACEUT BIOMED, V41, P469, DOI 10.1016/j.jpba.2005.12.020; Li N, 2012, PLANTA MED, V78, P692, DOI 10.1055/s-0031-1298368; MURAI M, 1995, PLANTA MED, V61, P479, DOI 10.1055/s-2006-958143; RANALDI G, 1992, ANTIMICROB AGENTS CH, V36, P1374, DOI 10.1128/AAC.36.7.1374; Sandri G, 2007, EUR J PHARM BIOPHARM, V65, P68, DOI 10.1016/j.ejpb.2006.07.016; The State Commission of Chinese Pharmacopoeia, 2010, PHARM PEOPL 2 REP 1, P126, DOI [10.1016/j.ijpddr.2014.09.001, DOI 10.1016/J.IJPDDR.2014.09.001]; Wang LN, 2008, XI BEI YAO XUE ZA ZH, V23, P67; Wang M, 2008, AM J CHINESE MED, V36, P1199, DOI 10.1142/S0192415X08006521; Wang T, 2012, AM J CHINESE MED, V40, P1123, DOI 10.1142/S0192415X12500838; Xiong Q, 2000, EUR J PHARMACOL, V400, P137, DOI 10.1016/S0014-2999(00)00354-X; Xiong QB, 1996, BIOL PHARM BULL, V19, P1580, DOI 10.1248/bpb.19.1580; Xiong QB, 1998, PLANTA MED, V64, P120, DOI 10.1055/s-2006-957387; Yamashita S, 2000, EUR J PHARM SCI, V10, P195, DOI 10.1016/S0928-0987(00)00076-2; Yang DZ, 2013, J CHROMATOGR SCI, V51, P716, DOI 10.1093/chromsci/bmt057; Yang XW, 2010, PLANTA MED, V76, P1587, DOI 10.1055/s-0030-1249810; Yee SY, 1997, PHARMACEUT RES, V14, P763, DOI 10.1023/A:1012102522787; Zhao B, 2011, PLANTA MED, V77, P1531, DOI 10.1055/s-0030-1270741	27	17	19	0	43	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2015	10	2							e0116490	10.1371/journal.pone.0116490	http://dx.doi.org/10.1371/journal.pone.0116490			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA3QZ	25646971	gold, Green Submitted, Green Published			2023-01-03	WOS:000348822600026
J	Holcomb, JB; Tilley, BC; Baraniuk, S; Fox, EE; Wade, CE; Podbielski, JM; del Junco, DJ; Brasel, KJ; Bulger, EM; Callcut, RA; Cohen, MJ; Cotton, BA; Fabian, TC; Inaba, K; Kerby, JD; Muskat, P; O'Keeffe, T; Rizoli, S; Robinson, BRH; Scalea, TM; Schreiber, MA; Stein, DM; Weinberg, JA; Callum, JL; Hess, JR; Matijevic, N; Miller, CN; Pittet, JF; Hoyt, DB; Pearson, GD; Leroux, B; van Belle, G				Holcomb, John B.; Tilley, Barbara C.; Baraniuk, Sarah; Fox, Erin E.; Wade, Charles E.; Podbielski, Jeanette M.; del Junco, Deborah J.; Brasel, Karen J.; Bulger, Eileen M.; Callcut, Rachael A.; Cohen, Mitchell Jay; Cotton, Bryan A.; Fabian, Timothy C.; Inaba, Kenji; Kerby, Jeffrey D.; Muskat, Peter; O'Keeffe, Terence; Rizoli, Sandro; Robinson, Bryce R. H.; Scalea, Thomas M.; Schreiber, Martin A.; Stein, Deborah M.; Weinberg, Jordan A.; Callum, Jeannie L.; Hess, John R.; Matijevic, Nena; Miller, Christopher N.; Pittet, Jean-Francois; Hoyt, David B.; Pearson, Gail D.; Leroux, Brian; van Belle, Gerald		PROPPR Study Grp	Transfusion of Plasma, Platelets, and Red Blood Cells in a 1:1:1 vs a 1:1:2 Ratio and Mortality in Patients With Severe Trauma The PROPPR Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DAMAGE CONTROL RESUSCITATION; MULTIPLE-ORGAN FAILURE; FRESH-FROZEN PLASMA; MASSIVE TRANSFUSION; MAJOR TRAUMA; PRODUCTS; MULTICENTER; SURVIVAL; RISK; COAGULOPATHY	IMPORTANCE Severely injured patients experiencing hemorrhagic shock often require massive transfusion. Earlier transfusion with higher blood product ratios (plasma, platelets, and red blood cells), defined as damage control resuscitation, has been associated with improved outcomes; however, there have been no large multicenter clinical trials. OBJECTIVE To determine the effectiveness and safety of transfusing patients with severe trauma and major bleeding using plasma, platelets, and red blood cells in a 1:1:1 ratio compared with a 1:1:2 ratio. DESIGN, SETTING, AND PARTICIPANTS Pragmatic, phase 3, multisite, randomized clinical trial of 680 severely injured patients who arrived at 1 of 12 level I trauma centers in North America directly from the scene and were predicted to require massive transfusion between August 2012 and December 2013. INTERVENTIONS Blood product ratios of 1:1:1 (338 patients) vs 1:1:2 (342 patients) during active resuscitation in addition to all local standard-of-care interventions (uncontrolled). MAIN OUTCOMES AND MEASURES Primary outcomes were 24-hour and 30-day all-cause mortality. Prespecified ancillary outcomes included time to hemostasis, blood product volumes transfused, complications, incidence of surgical procedures, and functional status. RESULTS No significant differences were detected in mortality at 24 hours (12.7% in 1:1:1 group vs 17.0% in 1:1:2 group; difference, -4.2%[95% CI, -9.6% to 1.1%]; P=.12) or at 30 days (22.4% vs 26.1%, respectively; difference, -3.7%[95% CI, -10.2% to 2.7%]; P=.26). Exsanguination, which was the predominant cause of death within the first 24 hours, was significantly decreased in the 1:1:1 group (9.2% vs 14.6% in 1:1:2 group; difference, -5.4%[95% CI, -10.4% to -0.5%]; P=.03). More patients in the 1:1:1 group achieved hemostasis than in the 1:1:2 group (86% vs 78%, respectively; P=.006). Despite the 1:1:1 group receiving more plasma (median of 7Uvs5U, P<.001) and platelets (12 U vs 6 U, P<.001) and similar amounts of red blood cells (9 U) over the first 24 hours, no differences between the 2 groups were found for the 23 prespecified complications, including acute respiratory distress syndrome, multiple organ failure, venous thromboembolism, sepsis, and transfusion-related complications. CONCLUSIONS AND RELEVANCE Among patients with severe trauma and major bleeding, early administration of plasma, platelets, and red blood cells in a 1:1:1 ratio compared with a 1:1:2 ratio did not result in significant differences in mortality at 24 hours or at 30 days. However, more patients in the 1:1:1 group achieved hemostasis and fewer experienced death due to exsanguination by 24 hours. Even though there was an increased use of plasma and platelets transfused in the 1:1:1 group, no other safety differenceswere identified between the 2 groups.	[Holcomb, John B.; Fox, Erin E.; Wade, Charles E.; Podbielski, Jeanette M.; del Junco, Deborah J.; Cotton, Bryan A.; Matijevic, Nena] Univ Texas Hlth Sci Ctr Houston, Ctr Translat Injury Res, Div Acute Care Surg, Sch Med,Dept Surg, Houston, TX 77030 USA; [Tilley, Barbara C.; Baraniuk, Sarah] Univ Texas Hlth Sci Ctr Houston, Div Biostat, Sch Publ Hlth, Houston, TX 77030 USA; [Brasel, Karen J.] Med Coll Wisconsin, Div Trauma & Crit Care, Dept Surg, Milwaukee, WI 53226 USA; [Bulger, Eileen M.] Univ Washington, Sch Med, Dept Surg, Div Trauma & Crit Care, Seattle, WA 98195 USA; [Callcut, Rachael A.; Cohen, Mitchell Jay] Univ Calif San Francisco, Sch Med, Dept Surg, Div Gen Surg, San Francisco, CA 94143 USA; [Fabian, Timothy C.; Weinberg, Jordan A.] Univ Tennessee, Ctr Hlth Sci, Coll Med, Div Trauma & Surg Crit Care,Dept Surg, Memphis, TN 38163 USA; [Inaba, Kenji] Univ So Calif, Div Trauma & Crit Care, Los Angeles, CA USA; [Kerby, Jeffrey D.] Univ Alabama Birmingham, Sch Med, Dept Surg, Div Trauma Burns & Surg Crit Care, Birmingham, AL USA; [Muskat, Peter; Robinson, Bryce R. H.] Univ Cincinnati, Coll Med, Dept Surg, Div Trauma Crit Care, Cincinnati, OH USA; [O'Keeffe, Terence] Univ Arizona, Dept Surg, Div Trauma Crit Care & Emergency Surg, Tucson, AZ USA; [Rizoli, Sandro] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada; [Scalea, Thomas M.; Stein, Deborah M.] Univ Maryland, Sch Med, Program Trauma, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA; [Schreiber, Martin A.] Oregon Hlth & Sci Univ, Sch Med, Div Trauma Crit Care & Acute Care Surg, Portland, OR 97201 USA; [Callum, Jeannie L.] Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Dept Clin Pathol, Toronto, ON M4N 3M5, Canada; [Hess, John R.] Univ Washington, Sch Med, Dept Lab Med, Seattle, WA 98195 USA; [Miller, Christopher N.] Univ Cincinnati, Coll Med, Dept Emergency Med, Cincinnati, OH USA; [Pittet, Jean-Francois] Univ Alabama Birmingham, Sch Med, Dept Anesthesiol, Div Crit Care & Perioperat Med, Birmingham, AL USA; [Hoyt, David B.] Amer Coll Surg, Chicago, IL USA; [Pearson, Gail D.] NHLBI, Div Cardiovasc Sci, NIH, Bethesda, MD 20892 USA; [Leroux, Brian; van Belle, Gerald] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA; [van Belle, Gerald] Univ Washington, Sch Publ Hlth, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; Medical College of Wisconsin; University of Washington; University of Washington Seattle; University of California System; University of California San Francisco; University of Tennessee System; University of Tennessee Health Science Center; University of Southern California; University of Alabama System; University of Alabama Birmingham; University System of Ohio; University of Cincinnati; University of Arizona; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University System of Maryland; University of Maryland Baltimore; Oregon Health & Science University; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Washington; University of Washington Seattle; University System of Ohio; University of Cincinnati; University of Alabama System; University of Alabama Birmingham; American College of Surgeons; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Holcomb, JB (corresponding author), Univ Texas Hlth Sci Ctr Houston, Ctr Translat Injury Res, 6410 Fannin St, Houston, TX 77030 USA.	john.holcomb@uth.tmc.edu	Leroux, Brian G/H-2254-2015; Callcut, Rachael/ABE-1484-2021; Wong, Monica D/D-9016-2017	Wong, Monica D/0000-0001-7041-9518; Stein, Deborah/0000-0003-3683-3963; Galvagno, Samuel/0000-0001-5563-4092; holcomb, john/0000-0001-8312-9157	US National Heart, Lung, and Blood Institute [U01HL077863]; US Department of Defense; Defence Research and Development Canada; Canadian Institutes of Health Research-Institute of Circulatory and Respiratory Health [CRR-120612]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001425, UL1TR000077] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL077863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM074902] Funding Source: NIH RePORTER	US National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); US Department of Defense(United States Department of Defense); Defence Research and Development Canada; Canadian Institutes of Health Research-Institute of Circulatory and Respiratory Health(Canadian Institutes of Health Research (CIHR)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported with grant U01HL077863 from the US National Heart, Lung, and Blood Institute and funding from the US Department of Defense, the Defence Research and Development Canada in partnership with the Canadian Institutes of Health Research-Institute of Circulatory and Respiratory Health (grant CRR-120612).	Amer Soc Anesthesiologists Task Fo, 2006, ANESTHESIOLOGY, V105, P198; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Baraniuk S, 2014, INJURY, V45, P1287, DOI 10.1016/j.injury.2014.06.001; Borgman MA, 2007, J TRAUMA, V63, P805, DOI 10.1097/TA.0b013e3181271ba3; Bulger EM, 2011, ANN SURG, V253, P431, DOI 10.1097/SLA.0b013e3181fcdb22; Cotton BA, 2011, ANN SURG, V254, P598, DOI 10.1097/SLA.0b013e318230089e; del Junco DJ, 2013, J TRAUMA ACUTE CARE, V75, pS24, DOI 10.1097/TA.0b013e31828fa3b9; del Junco DJ, 2013, J TRAUMA ACUTE CARE, V75, pS97, DOI 10.1097/TA.0b013e318298b0a4; Duchesne JC, 2008, J TRAUMA, V65, P272, DOI 10.1097/TA.0b013e31817e5166; Dutton R, 2009, CLIN TRIALS, V6, P467, DOI 10.1177/1740774509344102; Dzik WH, 2011, CRIT CARE, V15, DOI 10.1186/cc10498; FARRINGTON CP, 1990, STAT MED, V9, P1447, DOI 10.1002/sim.4780091208; Hauser CJ, 2010, J TRAUMA, V69, P489, DOI 10.1097/TA.0b013e3181edf36e; Ho AMH, 2005, AM J SURG, V190, P479, DOI 10.1016/j.amjsurg.2005.03.034; Ho AMH, 2012, ANESTHESIOLOGY, V116, P716, DOI 10.1097/ALN.0b013e318245c47b; Holcomb JB, 2008, ANN SURG, V248, P447, DOI 10.1097/SLA.0b013e318185a9ad; Holcomb JB, 2007, J TRAUMA, V62, P307, DOI 10.1097/TA.0b013e3180324124; Holcomb JB, 2013, HEMATOL-AM SOC HEMAT, P656, DOI 10.1182/asheducation-2013.1.656; Holcomb JB, 2013, JAMA SURG, V148, P127, DOI 10.1001/2013.jamasurg.387; Holcomb JB, 2011, J TRAUMA, V71, pS318, DOI 10.1097/TA.0b013e318227edbb; Holcomb JB, 2011, SHOCK, V35, P107, DOI 10.1097/SHK.0b013e3181f7fd01; Hollis S, 2002, STAT MED, V21, P3823, DOI 10.1002/sim.1276; HOYT DB, 1994, J TRAUMA, V37, P426, DOI 10.1097/00005373-199409000-00016; Huber-Wagner S, 2007, VOX SANG, V92, P69, DOI 10.1111/j.1423-0410.2006.00858.x; Johansson PI, 2009, VOX SANG, V96, P111, DOI 10.1111/j.1423-0410.2008.01130.x; Johansson PI, 2013, TRANSFUSION, V53, P3088, DOI 10.1111/trf.12214; Johansson PI, 2014, BLOOD, V124, P3052, DOI 10.1182/blood-2014-05-575340; Johnson JL, 2010, ARCH SURG-CHICAGO, V145, P973, DOI 10.1001/archsurg.2010.216; Kautza BC, 2012, J TRAUMA ACUTE CARE, V72, P106, DOI 10.1097/TA.0b013e3182410a3c; Kelly JM, 2013, EXPERT REV HEMATOL, V6, P631, DOI 10.1586/17474086.2013.859520; Klein JP, 2003, SURVIVAL ANALYSIS TE; Langan NR, 2014, JAMA SURG, V149, P904, DOI 10.1001/jamasurg.2014.940; Moore EE, 2009, J AM COLL SURGEONS, V208, P1, DOI 10.1016/j.jamcollsurg.2008.09.023; Nascimento B, 2013, CMAJ, V185, P583; Nunez TC, 2009, J TRAUMA, V66, P346, DOI 10.1097/TA.0b013e3181961c35; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; OBRIEN PC, 1983, BIOMETRICS, V39, P787, DOI 10.2307/2531110; Park PK, 2013, J TRAUMA ACUTE CARE, V75, pS238, DOI 10.1097/TA.0b013e31829a8c71; Perkins JG, 2009, J TRAUMA, V66, pS77, DOI 10.1097/TA.0b013e31819d8936; Pieracci FM, 2012, TRAUMA, P216; Radwan ZA, 2013, JAMA SURG, V148, P170, DOI 10.1001/jamasurgery.2013.414; Rhee P, 2014, ANN SURG, V260, P13, DOI 10.1097/SLA.0000000000000600; Roback JD, 2010, TRANSFUSION, V50, P1227, DOI 10.1111/j.1537-2995.2010.02632.x; Robinson BRH, 2013, J TRAUMA ACUTE CARE, V75, pS61, DOI 10.1097/TA.0b013e31828fa408; Sarode R, 2013, CIRCULATION, V128, P1234, DOI 10.1161/CIRCULATIONAHA.113.002283; Sauaia A, 2014, J TRAUMA ACUTE CARE, V76, P582, DOI 10.1097/TA.0000000000000147; Savage SA, 2013, J TRAUMA ACUTE CARE, V74, P396, DOI 10.1097/TA.0b013e31827a3639; Scalea TM, 2008, ANN SURG, V248, P578, DOI 10.1097/SLA.0b013e31818990ed; Shaz BH, 2010, TRANSFUSION, V50, P493, DOI 10.1111/j.1537-2995.2009.02414.x; Silverman T, 2005, TRANSFUSION, V45, p14S, DOI 10.1111/j.0041-1132.2005.00157.x; Snyder CW, 2009, J TRAUMA, V66, P358, DOI 10.1097/TA.0b013e318196c3ac; Spahn DR, 2013, CRIT CARE, V17, DOI 10.1186/cc12685; Sperry JL, 2008, J TRAUMA, V65, P986, DOI 10.1097/TA.0b013e3181878028; Tisherman SA., 2014, ANN SURG, DOI [10.1097/SLA.0b013e3181df0401, DOI 10.1097/SLA.0B013E3181DF0401]; US Army Institute of Surgical Research, 2014, JOINT THEATER TRAUMA; US Centers for Disease Control and Prevention, 2012, INJURY PREVENTION AN; US Department of Health and Human Services; US Food and Drug Administration, 2013, GUIDANCE FOR INSTITU; US Food and Drug Administration, 2010, PRODUCT DEVELOPMENT; VANELTEREN P, 1960, B INT STATIST INST, V37, P351; Watson GA, 2009, J TRAUMA, V67, P221, DOI 10.1097/TA.0b013e3181ad5957	60	1245	1281	6	83	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	2015	313	5					471	482		10.1001/jama.2015.12	http://dx.doi.org/10.1001/jama.2015.12			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CA7AV	25647203	Green Accepted			2023-01-03	WOS:000349070300011
J	Zhang, YS; Li, YQ; Deng, JH; Ji, ZG; Yu, HY; Li, HZ				Zhang, Yushi; Li, Yongqiang; Deng, Jianhua; Ji, Zhigang; Yu, Hongyan; Li, Hanzhong			Sorafenib Neoadjuvant Therapy in the Treatment of High Risk Renal Cell Carcinoma	PLOS ONE			English	Article							GUIDELINES; EFFICACY; ADJUVANT	Objective To evaluate the clinical efficacy of sorafenib as preoperative neoadjuvant therapy in patients with high risk renal cell carcinoma (RCC). Materials and Methods Clinical data of 18 patients with high risk RCC who received surgery done successfully after preoperative neoadjuvant therapy with sorafenib in Peking Union Medical College Hospital (PUMCH) from April 2007 to October 2013 have been reviewed and analyzed in this study. Results Among the 18 patients there were 13 male and 5 female, with a median age of 54.6 years. The objective response rate (ORR) of the operation on the selected patients is very high (94.4%), including 4 cases (22.2%) of partial response (PR) and 13 cases (72.2%) of stable disease (SD). After preoperative sorafenib treatment, the average tumor size of the 18 patients decreased from 7.8 cm (ranging from 3.6 to 19.2 cm) to 6.2 cm (ranging from 2.4 to 16.8 cm), and the median value of average tumor CT value decreased from 61HU to 52 HU. Among the 5 patients who had IVC tumor thrombi, the grades of tumor thrombi in 2 patients who were grade II before sorafenib treatment became grade I and grade 0 respectively, 2 patients of grade III both became grade II. Conclusion Preoperative neoadjuvant therapy with sorafenib for high risk RCC patients can significantly decrease primary tumor volume as well as tumor thrombus, which could help the nephron-sparing surgery (NSS) or radical nephrectomy to be done successfully.	[Zhang, Yushi; Li, Yongqiang; Deng, Jianhua; Ji, Zhigang; Yu, Hongyan; Li, Hanzhong] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Urol, Beijing 100730, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital	Li, HZ (corresponding author), Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Urol, Beijing 100730, Peoples R China.	lihanzhongpro@126.com	Yu, Houyong/R-1592-2016	Yu, Houyong/0000-0002-6543-5924				Baccala A, 2007, INT J UROL, V14, P1095, DOI 10.1111/j.1442-2042.2007.01902.x; Choueiri M, 2011, CURR CLIN PHARMACOL, V6, P144, DOI 10.2174/157488411797189415; Chow WH, 2013, CANCER-AM CANCER SOC, V119, P388, DOI 10.1002/cncr.27690; Di Silverio F, 2008, UROL INT, V80, P451, DOI 10.1159/000132708; Dutcher JP, 2013, THER ADV UROL, V5, P338, DOI 10.1177/1756287213505672; Escudier B, 2012, ANN ONCOL, V23, P65, DOI 10.1093/annonc/mds227; Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655; King SC, 2014, J UROLOGY, V191, P1665, DOI 10.1016/j.juro.2013.12.046; LAW TM, 1995, CANCER-AM CANCER SOC, V76, P824, DOI 10.1002/1097-0142(19950901)76:5<824::AID-CNCR2820760517>3.0.CO;2-N; Miles KA, 2012, EUR RADIOL, V22, P1430, DOI 10.1007/s00330-012-2379-4; Porta C, 2009, ANTI-CANCER DRUG, V20, P409, DOI 10.1097/CAD.0b013e32831fb500; Rini BI, 2009, LANCET, V373, P1119, DOI 10.1016/S0140-6736(09)60229-4; Schrader AJ, 2012, INT J UROL, V19, P903, DOI 10.1111/j.1442-2042.2012.03065.x; Strumberg D, 2012, EXPERT OPIN PHARMACO, V13, P407, DOI 10.1517/14656566.2012.654776; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Tobert CM, 2013, UROL ONCOL-SEMIN ORI, V31, P1316, DOI 10.1016/j.urolonc.2011.12.014; Weikert S, 2010, WORLD J UROL, V28, P247, DOI 10.1007/s00345-010-0555-1; Yang L, 2012, ONCOL LETT, V3, P935, DOI 10.3892/ol.2012.585; Ye DW, 2014, ONCOTARGETS THER, V7, P925, DOI 10.2147/OTT.S41828; Zhang HL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-249	20	23	23	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2015	10	2							e0115896	10.1371/journal.pone.0115896	http://dx.doi.org/10.1371/journal.pone.0115896			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA3QZ	25647522	Green Published, Green Submitted, gold			2023-01-03	WOS:000348822600016
J	Carels, N; Tilli, T; Tuszynski, JA				Carels, Nicolas; Tilli, Tatiana; Tuszynski, Jack A.			A Computational Strategy to Select Optimized Protein Targets for Drug Development toward the Control of Cancer Diseases	PLOS ONE			English	Article							INVASIVE BREAST-CANCER; GROWTH-FACTOR; DOWN-REGULATION; MESENCHYMAL TRANSITION; CELL-PROLIFERATION; PANCREATIC-CANCER; INHIBITION; KINASE; NUCLEOPHOSMIN; COMPLEXITY	In this report, we describe a strategy for the optimized selection of protein targets suitable for drug development against neoplastic diseases taking the particular case of breast cancer as an example. We combined human interactome and transcriptome data from malignant and control cell lines because highly connected proteins that are up-regulated in malignant cell lines are expected to be suitable protein targets for chemotherapy with a lower rate of undesirable side effects. We normalized transcriptome data and applied a statistic treatment to objectively extract the sub-networks of down-and up-regulated genes whose proteins effectively interact. We chose the most connected ones that act as protein hubs, most being in the signaling network. We show that the protein targets effectively identified by the combination of protein connectivity and differential expression are known as suitable targets for the successful chemotherapy of breast cancer. Interestingly, we found additional proteins, not generally targeted by drug treatments, which might justify the extension of existing formulation by addition of inhibitors designed against these proteins with the consequence of improving therapeutic outcomes. The molecular alterations observed in breast cancer cell lines represent either driver events and/or driver pathways that are necessary for breast cancer development or progression. However, it is clear that signaling mechanisms of the luminal A, B and triple negative subtypes are different. Furthermore, the up- and down-regulated networks predicted subtype-specific drug targets and possible compensation circuits between up-and down-regulated genes. We believe these results may have significant clinical implications in the personalized treatment of cancer patients allowing an objective approach to the recycling of the arsenal of available drugs to the specific case of each breast cancer given their distinct qualitative and quantitative molecular traits.	[Carels, Nicolas; Tilli, Tatiana] Fundacao Oswaldo Cruz, Ctr Desenvolvimento Tecnol Saude, CNPq,Lab Modelagem Sistemas Biol, INCT IDN,Natl Inst Sci & Technol Innovat Neglecte, Rio De Janeiro, Brazil; [Tuszynski, Jack A.] Univ Alberta, Fac Med & Dent, Dept Oncol, Edmonton, AB T6G 1Z2, Canada; [Tuszynski, Jack A.] Univ Alberta, Dept Phys, Edmonton, AB T6G 2E1, Canada	Center for Technological Development in Health (CDTS); Fundacao Oswaldo Cruz; University of Alberta; University of Alberta	Tuszynski, JA (corresponding author), Univ Alberta, Fac Med & Dent, Dept Oncol, Edmonton, AB T6G 1Z2, Canada.	jack.tuszynski@gmail.com	Tuszynski, Jack/AAA-2073-2020; Carels, Nicolas/L-4687-2016; Tilli, T M/L-3057-2016; Tilli, Tatiana M/F-8166-2012	Tuszynski, Jack/0000-0001-9976-0429; Carels, Nicolas/0000-0003-4547-7155; Tilli, T M/0000-0003-3699-1494; Tilli, Tatiana M/0000-0002-1111-018X				Alegre MM, 2012, J ONCOL, V2012, DOI 10.1155/2012/575647; Alevy YG, 2012, J CLIN INVEST, V122, P4555, DOI 10.1172/JCI64896; Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; Atkinson DM, 2008, HEAD NECK-J SCI SPEC, V30, P790, DOI 10.1002/hed.20770; Barcellos-Hoff MH, 2013, NAT REV CANCER, V13, P511, DOI 10.1038/nrc3536; Bockmayr M, 2013, BMC SYST BIOL, V7, DOI 10.1186/1752-0509-7-78; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Boyer-Guittaut M, 2014, AUTOPHAGY, V10, P986, DOI 10.4161/auto.28390; Braun Michael, 2009, Cancer Genomics & Proteomics, V6, P31; Bredel M, 2011, NEW ENGL J MED, V364, P627, DOI 10.1056/NEJMoa1006312; Breitkreutz D, 2014, BIOMAT INT S MATH CO, P250; Breitkreutz D, 2012, P NATL ACAD SCI USA, V109, P9209, DOI 10.1073/pnas.1201416109; Bretones G, 2015, BBA-GENE REGUL MECH, V1849, P506, DOI 10.1016/j.bbagrm.2014.03.013; Cao WD, 2010, APOPTOSIS, V15, P230, DOI 10.1007/s10495-009-0437-4; Carels N, 2013, BIOINFORM BIOL INSIG, V7, P35, DOI 10.4137/BBI.S10053; Chong R, 2009, CELL HOST MICROBE, V6, P268, DOI 10.1016/j.chom.2009.08.006; Conesa A, 2005, BIOINFORMATICS, V21, P3674, DOI 10.1093/bioinformatics/bti610; Corazzari M, 2007, BRIT J CANCER, V96, P1062, DOI 10.1038/sj.bjc.6603672; Costanzo A, 2014, FEBS LETT, V588, P2590, DOI 10.1016/j.febslet.2014.06.047; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; de Magalhaes JP, 2013, NAT REV CANCER, V13, P357, DOI 10.1038/nrc3497; Deshiere A, 2011, MOL CELL BIOCHEM, V356, P11, DOI 10.1007/s11010-011-0942-y; Didelot C, 2008, CELL DEATH DIFFER, V15, P859, DOI 10.1038/sj.cdd.4402320; Dong S, 2008, LEUKEMIA, V22, P572, DOI 10.1038/sj.leu.2405064; Faust K, 2010, BIOINFORMATICS, V26, P1211, DOI 10.1093/bioinformatics/btq105; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Ganapathy-Kanniappan S, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-152; Garlaschelli D, 2010, SYMMETRY-BASEL, V2, P1683, DOI 10.3390/sym2031683; Gay B, 1999, INT J CANCER, V83, P235, DOI 10.1002/(SICI)1097-0215(19991008)83:2<235::AID-IJC15>3.0.CO;2-B; Ghosh A, 2013, ONCOL REP, V29, P1161, DOI 10.3892/or.2012.2186; Giubellino A, 2007, CANCER RES, V67, P6012, DOI 10.1158/0008-5472.CAN-07-0022; Goodarzi AA, 2011, NAT STRUCT MOL BIOL, V18, P831, DOI 10.1038/nsmb.2077; Grisendi S, 2006, NAT REV CANCER, V6, P493, DOI 10.1038/nrc1885; Guo CM, 2013, FUTURE ONCOL, V9, P1773, DOI [10.2217/FON.13.114, 10.2217/fon.13.114]; Haines E, 2014, J BIOL CHEM, V289, P5687, DOI 10.1074/jbc.M113.516047; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Handa Y, 2010, J MOL BIOL, V404, P260, DOI 10.1016/j.jmb.2010.09.033; HE T, 2013, PLOS ONE, V8, P59345, DOI DOI 10.1371/JOURNAL.PONE.0059345; HINOW P, 2014, ALGEBRAIC TOPOLOGICA, P42331; Howe AK, 2004, BBA-MOL CELL RES, V1692, P159, DOI 10.1016/j.bbamcr.2004.03.005; Huang L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.256; Huang TH, 2013, CANCER CELL, V23, P796, DOI 10.1016/j.ccr.2013.04.027; Ishigaki Y, 2013, EXP BIOL MED, V238, P889, DOI 10.1177/1535370213494646; Jiang N, 2012, CHEMOTHER RES PRACT, V2012, DOI DOI 10.1155/2012/817304; Kendrick H, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-591; Kim HC, 2010, CELL MOL LIFE SCI, V67, P3499, DOI 10.1007/s00018-010-0388-5; Klebig C, 2005, CANCER RES, V65, P394; Korsching E, 2005, J PATHOL, V206, P451, DOI 10.1002/path.1797; Krynetskaia NF, 2009, MOL CANCER THER, V8, P864, DOI 10.1158/1535-7163.MCT-08-0695; Lahat G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010105; Li B, 2013, CLIN CANCER RES, V19, P5835, DOI 10.1158/1078-0432.CCR-12-3629; Li ZW, 2012, BBA-REV CANCER, V1826, P13, DOI 10.1016/j.bbcan.2012.02.001; Lim DHK, 2010, OBSTET GYNAECOL, V12, P37, DOI 10.1576/toag.12.1.037.27556; Ling SHM, 2009, BIOSCIENCE REP, V29, P339, DOI 10.1042/BSR20090034; Lo SJ, 2013, HEPATOLOGY, V57, P1893, DOI 10.1002/hep.26209; Luo Y, 2014, MOL MED REP, V9, P387, DOI 10.3892/mmr.2013.1831; Marquardt JU, 2012, BBA-MOL BASIS DIS, V1822, P942, DOI 10.1016/j.bbadis.2012.02.012; Mathur S, 1998, CANCER, V82, P816, DOI 10.1002/(SICI)1097-0142(19980301)82:5<816::AID-CNCR3>3.0.CO;2-H; Mendelsohn J, 2002, J CLIN ONCOL, V20, p1S, DOI 10.1200/JCO.2002.07.121; Miwa D, 2013, ANGIOGENESIS, V16, P675, DOI 10.1007/s10456-013-9345-x; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Nihira K, 2014, J PATHOL, V234, P277, DOI 10.1002/path.4354; Oltean S, 2012, BIOCHEM SOC T, V40, P831, DOI 10.1042/BST20120051; Ougolkov AV, 2006, CLIN CANCER RES, V12, P5074, DOI 10.1158/1078-0432.CCR-06-0196; Pallares J, 2009, AM J PATHOL, V174, P287, DOI 10.2353/ajpath.2009.080552; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Perez-Nadales E, 2004, BREAST CANCER RES, V6, P137, DOI 10.1186/bcr792; Qi W, 2008, ONCOGENE, V27, P4210, DOI 10.1038/onc.2008.54; Rachidi SM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057911; Ren HN, 2009, MOL CANCER THER, V8, P1106, DOI 10.1158/1535-7163.MCT-08-0779; Rickelt S, 2012, CELL TISSUE RES, V348, P281, DOI 10.1007/s00441-011-1314-3; Roma-Rodrigues C, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/179486; Sagot Y, 2000, BRIT J PHARMACOL, V131, P721, DOI 10.1038/sj.bjp.0703633; Schneble EJ, 2014, IMMUNOTHERAPY-UK, V6, P519, DOI [10.2217/IMT.14.22, 10.2217/imt.14.22]; Shepelev V, 2006, BRIEF BIOINFORM, V7, P178, DOI 10.1093/bib/bbl003; Shi YK, 2010, CANCER GENE THER, V17, P694, DOI 10.1038/cgt.2010.25; Sillibourne JE, 2007, MOL BIOL CELL, V18, P3667, DOI 10.1091/mbc.E06-07-0604; Taniuchi K, 2005, CANCER RES, V65, P3092, DOI 10.1158/0008.5472.CAN-04-3646; Usuki F, 2013, P NATL ACAD SCI USA, V110, P15037, DOI 10.1073/pnas.1300654110; Vita M, 2006, SEMIN CANCER BIOL, V16, P318, DOI 10.1016/j.semcancer.2006.07.015; Wang J, 2009, J CELL MOL MED, V13, P3888, DOI 10.1111/j.1582-4934.2009.00873.x; Wang PP, 2014, MOL CELL, V54, P378, DOI 10.1016/j.molcel.2014.03.007; Warren K, 2012, P NATL ACAD SCI USA, V109, P9587, DOI 10.1073/pnas.1204673109; Wilker E, 2004, J MOL CELL CARDIOL, V37, P633, DOI 10.1016/j.yjmcc.2004.04.015; Wu YH, 2012, DERMATOL SIN, V30, P1, DOI 10.1016/j.dsi.2012.02.004; Ye Diana Zi, 2012, Cell Logist, V2, P105; Yu HY, 2011, NAT METHODS, V8, P478, DOI [10.1038/NMETH.1597, 10.1038/nmeth.1597]; Zaman N, 2013, CELL REP, V5, P216, DOI 10.1016/j.celrep.2013.08.028; Zeng Q, 2000, J CELL SCI, V113, P471; Zhang Y, 2008, CANCER LETT, V265, P298, DOI 10.1016/j.canlet.2008.02.024; Zheng L, 2004, CELL RES, V14, P497, DOI 10.1038/sj.cr.7290253	92	17	17	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2015	10	1							e0115054	10.1371/journal.pone.0115054	http://dx.doi.org/10.1371/journal.pone.0115054			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA3QM	25625699	Green Published, gold			2023-01-03	WOS:000348821400005
J	Rosenbaum, L				Rosenbaum, Lisa			Beyond Belief - How People Feel about Taking Medications for Heart Disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MYOCARDIAL-INFARCTION; ADHERENCE; ASSOCIATION; RISK								Robert Wood Johnson Clinical Scholars Program	Robert Wood Johnson Clinical Scholars Program(Robert Wood Johnson Foundation (RWJF))	Supported by the Robert Wood Johnson Clinical Scholars Program.	Akincigil A, 2008, J GEN INTERN MED, V23, P115, DOI 10.1007/s11606-007-0351-9; Antman EM, 2008, CIRCULATION, V117, P296, DOI 10.1161/CIRCULATIONAHA.107.188209; Balady GJ, 2011, CIRCULATION, V124, P2951, DOI 10.1161/CIR.0b013e31823b21e2; Choudhry NK, 2011, NEW ENGL J MED, V365, P2088, DOI 10.1056/NEJMsa1107913; Finucane ML, 2000, J BEHAV DECIS MAKING, V13, P1, DOI 10.1002/(SICI)1099-0771(200001/03)13:1<1::AID-BDM333>3.0.CO;2-S; Ho PM, 2009, CIRCULATION, V119, P3028, DOI 10.1161/CIRCULATIONAHA.108.768986; Loewenstein GF, 2001, PSYCHOL BULL, V127, P267, DOI 10.1037//0033-2909.127.2.267; Lown B, PERSONAL BLOG; McAfee T, 2013, LANCET, V382, P2003, DOI 10.1016/S0140-6736(13)61686-4; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Slovic P, 2007, DRUG INF J, V41, P81, DOI 10.1177/009286150704100110; Tilson HH, 2004, ANN PHARMACOTHER, V38, P161, DOI 10.1345/aph.1D207	12	27	28	1	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 8	2015	372	2					183	187		10.1056/NEJMms1409015	http://dx.doi.org/10.1056/NEJMms1409015			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AY2UA	25564902				2023-01-03	WOS:000347443300016
J	Dieltjens, T; Moonens, I; Van Praet, K; De Buck, E; Vandekerckhove, P				Dieltjens, Tessa; Moonens, Inge; Van Praet, Koen; De Buck, Emmy; Vandekerckhove, Philippe			A Systematic Literature Search on Psychological First Aid: Lack of Evidence to Develop Guidelines	PLOS ONE			English	Article							PSYCHOSOCIAL INTERVENTIONS; MENTAL-HEALTH; SUPPORT	Background: Providing psychological first aid (PFA) is generally considered to be an important element in preliminary care of disaster victims. Using the best available scientific basis for courses and educational materials, the Belgian Red Cross-Flanders wants to ensure that its volunteers are trained in the best way possible. Objective: To identify effective PFA practices, by systematically reviewing the evidence in existing guidelines, systematic reviews and individual studies. Methods: Systematic literature searches in five bibliographic databases (MEDLINE, PsycINFO, The Cochrane Library, PILOTS and G-I-N) were conducted from inception to July 2013. Results: Five practice guidelines were included which were found to vary in the development process (AGREE II score 20-53%) and evidence base used. None of them provides solid evidence concerning the effectiveness of PFA practices. Additionally, two systematic reviews of PFA were found, both noting a lack of studies on PFA. A complementary search for individual studies, using a more sensitive search strategy, identified 11 237 references of which 102 were included for further full-text examination, none of which ultimately provides solid evidence concerning the effectiveness of PFA practices. Conclusion: The scientific literature on psychological first aid available to date, does not provide any evidence about the effectiveness of PFA interventions. Currently it is impossible to make evidence-based guidelines about which practices in psychosocial support are most effective to help disaster and trauma victims.	[Dieltjens, Tessa; De Buck, Emmy; Vandekerckhove, Philippe] Belgian Red Cross Flanders, Ctr Evidence Based Practice, Mechelen, Belgium; [Moonens, Inge; Van Praet, Koen] Belgian Red Cross Flanders, Psychosocial Intervent Serv, Mechelen, Belgium; [Vandekerckhove, Philippe] Cathollic Univ Leuven, Fac Med, Dept Publ Hlth & Primary Care, Leuven, Belgium; [Vandekerckhove, Philippe] Univ Ghent, Fac Med, B-9000 Ghent, Belgium	Ghent University	Dieltjens, T (corresponding author), Belgian Red Cross Flanders, Ctr Evidence Based Practice, Mechelen, Belgium.	Tessa.dieltjens@rodekruis.be						American Psychiatric Association, 1980, DIAGN STAT MAN MANT; [Anonymous], 2007, PSYCHIATRY, V70, P283, DOI 10.1521/psyc.2007.70.4.283; Bisson JI., 2009, SYSTEMATIC REV PSYCH; Bisson JI, 2010, BRIT J PSYCHIAT, V196, P69, DOI 10.1192/bjp.bp.109.066266; Blanchet K., 2013, EVIDENCE REV RES HLT; BRACE S, 2010, J PARAMEDIC PRACTICE, V2, P502; Brake HT, 2009, NURS HEALTH SCI, V11, P336, DOI 10.1111/j.1442-2018.2009.00491.x; Brouwers MC, 2010, CAN MED ASSOC J, V182, pE839, DOI 10.1503/cmaj.090449; Brymer M., 2012, PSYCHOL 1 AID SCH FI; Cassan P, 2011, INT 1 AID RESUSCITAI; Chandra A, 2014, DISASTER MED PUBLIC, V8, P95, DOI 10.1017/dmp.2013.112; De Buck E, 2014, INT J EVID-BASED HEA, V12, P39, DOI 10.1097/01.XEB.0000444637.88465.a3; Declercq F, 2007, J CLIN PSYCHOL, V63, P1239, DOI 10.1002/jclp.20426; Everly George S Jr, 2006, Int J Emerg Ment Health, V8, P93; Evidence Aid Priority Setting Group, 2013, PLOS CURR, V5; Falzon L, 2010, PROF PSYCHOL-RES PR, V41, P550, DOI 10.1037/a0021352; Fox JH, 2012, DISASTER MED PUBLIC, V6, P247, DOI 10.1001/dmp.2012.39; Gerdin M, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001632; Gibbons SW, 2013, PSYCHOL SERV; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Hollon SD, 2014, ANNU REV CLIN PSYCHO, V10, P213, DOI 10.1146/annurev-clinpsy-050212-185529; Hunt Matthew R, 2012, Am J Disaster Med, V7, P211; Inter-Agency Standing Committee, 2007, IASC GUID MENT HLTH; International Federation Reference Centre for Psychosocial Support, 2009, PSYCH INT HDB; JACOBS GA, 1995, PROF PSYCHOL-RES PR, V26, P543, DOI 10.1037/0735-7028.26.6.543; Jacobs GA, 2007, AM PSYCHOL, V62, P932, DOI 10.1037/0003-066X.62.8.932; Juen B, 2013, ANN ENPS FOR 2013 PS; Kelly CM, 2010, BMC PSYCHIATRY, V10, DOI 10.1186/1471-244X-10-49; Knudsen L., 1997, PSYCHOL 1 AID HUMAN; Lilienfeld SO, 2013, CLIN PSYCHOL REV, V33, P883, DOI 10.1016/j.cpr.2012.09.008; Moher David, 2009, Open Med, V3, pe123; O'Mathuna Donal P, 2010, J Evid Based Med, V3, P65, DOI 10.1111/j.1756-5391.2010.01076.x; OPSIC: Operationalising psychosocial support in crisis, 2014, EUR UN 7 FRAM PROJ; Pagoto SL, 2007, J CLIN PSYCHOL, V63, P695, DOI 10.1002/jclp.20376; Pekevski Jordan, 2013, J Emerg Manag, V11, P39; Reyes G, 2004, PSYCHOTHERAPY, V41, P399, DOI 10.1037/0033-3204.41.4.399; Rose S. C., 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000560; Ruzek J.I., 2007, J MENTAL HLTH COUNS, V29, P17, DOI [DOI 10.17744/MEHC.29.1.5RACQXJUEAFABGWP, https://doi.org/10.17744/mehc.29.1.5racqxjueafabgwp]; Salmon TW, 1917, CARE TREATMENT MENT; Shultz James M, 2013, Disaster Health, V1, P1, DOI [10.4161/dish.26006, 10.4161/dish.24414]; SPAITE DW, 1995, ANN EMERG MED, V26, P146, DOI 10.1016/S0196-0644(95)70144-3; Summey JR, 2001, ANN AM PSYCHOTHERAPY, V4, P18; Tol WA, 2011, LANCET, V378, P1581, DOI 10.1016/S0140-6736(11)61094-5; Tol WA, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001096; van Ommeren M., 2011, PSYCHOL 1 AID GUIDE; Vandekerckhove P, 2013, DISASTER MED PUBLIC, V7, P593, DOI 10.1017/dmp.2013.109; Verschuur M, 2007, SOC SCI MED, V65, P1430, DOI 10.1016/j.socscimed.2007.05.014; Vymetal S, 2011, PREHOSP DISASTER MED, V26, P234, DOI 10.1017/S1049023X11006303; World Health Organization, 2012, WHO HDB GUID DEV	49	75	77	4	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2014	9	12							e114714	10.1371/journal.pone.0114714	http://dx.doi.org/10.1371/journal.pone.0114714			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AW6JI	25503520	Green Submitted, Green Published, gold			2023-01-03	WOS:000346375400047
J	Klein, PMC; Zaal, IJ; Spitoni, C; Ong, DSY; van der Kooi, AW; Bonten, MJM; Slooter, AJC; Cremer, OL				Klein, Peter M. C.; Zaal, Irene J.; Spitoni, Cristian; Ong, David S. Y.; van der Kooi, Arendina W.; Bonten, Marc J. M.; Slooter, Arjen J. C.; Cremer, Olaf L.			The attributable mortality of delirium in critically ill patients: prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INTENSIVE-CARE-UNIT; MECHANICALLY VENTILATED PATIENTS; RANDOMIZED CONTROLLED-TRIAL; MARGINAL STRUCTURAL MODELS; RISK-FACTORS; OLDER PATIENTS; ICU PATIENTS; OBSERVATIONAL COHORT; HOSPITAL MORTALITY; TERM MORTALITY	Objective To determine the attributable mortality caused by delirium in critically ill patients. Design Prospective cohort study. Setting 32 mixed bed intensive care unit in the Netherlands, January 2011 to July 2013. Participants 1112 consecutive adults admitted to an intensive care unit for a minimum of 24 hours. Exposures Trained observers evaluated delirium daily using a validated protocol. Logistic regression and competing risks survival analyses were used to adjust for baseline variables and a marginal structural model analysis to adjust for confounding by evolution of disease severity before the onset of delirium. Main outcome measure Mortality during admission to an intensive care unit. Results Among 1112 evaluated patients, 558 (50.2%) developed at least one episode of delirium, with a median duration of 3 days (interquartile range 2-7 days). Crude mortality was 94/558 (17%) in patients with delirium compared with 40/554 (7%) in patients without delirium (P<0.001). Delirium was significantly associated with mortality in the multivariable logistic regression analysis (odds ratio 1.77, 95% confidence interval 1.15 to 2.72) and survival analysis (subdistribution hazard ratio 2.08, 95% confidence interval 1.40 to 3.09). However, the association disappeared after adjustment for time varying confounders in the marginal structural model (subdistribution hazard ratio 1.19, 95% confidence interval 0.75 to 1.89). Using this approach, only 7.2% (95% confidence interval -7.5% to 19.5%) of deaths in the intensive care unit were attributable to delirium, with an absolute mortality excess in patients with delirium of 0.9% (95% confidence interval -0.9% to 2.3%) by day 30. In post hoc analyses, however, delirium that persisted for two days or more remained associated with a 2.0% (95% confidence interval 1.2% to 2.8%) absolute mortality increase. Furthermore, competing risk analysis showed that delirium of any duration was associated with a significantly reduced rate of discharge from the intensive care unit (cause specific hazard ratio 0.65, 95% confidence interval 0.55 to 0.76). Conclusions Overall, delirium prolongs admission in the intensive care unit but does not cause death in critically ill patients. Future studies should focus on episodes of persistent delirium and its long term sequelae rather than on acute mortality.	[Klein, Peter M. C.; Zaal, Irene J.; Ong, David S. Y.; van der Kooi, Arendina W.; Slooter, Arjen J. C.; Cremer, Olaf L.] Univ Med Ctr Utrecht, Dept Intens Care Med, NL-3508 GA Utrecht, Netherlands; [Spitoni, Cristian] Univ Utrecht, Dept Math, Utrecht, Netherlands; [Bonten, Marc J. M.] Univ Med Ctr Utrecht, Dept Med Microbiol, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University; Utrecht University Medical Center	Klein, PMC (corresponding author), Univ Med Ctr Utrecht, Dept Intens Care Med, NL-3508 GA Utrecht, Netherlands.	p.m.c.kleinklouwenberg@umcutrecht.nl	Cremer, Olaf L/G-3855-2016	Cremer, Olaf L/0000-0003-4264-1108; Ong, David/0000-0001-5688-6443; van Diem-Zaal, Irene/0000-0002-8946-7920	Centre for Translational Molecular Medicine [04I-201]; Netherlands Organization of Scientific Research (NWO) [Vici 918.76.611]	Centre for Translational Molecular Medicine; Netherlands Organization of Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO))	This work was supported by the Centre for Translational Molecular Medicine (http://www.ctmm.nl), project MARS (grant 04I-201). MB has received research funding from the Netherlands Organization of Scientific Research (NWO Vici 918.76.611). The study sponsors did not have a role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.	Agarwal V, 2010, J BURN CARE RES, V31, P706, DOI 10.1097/BCR.0b013e3181eebee9; Al-Qadheeb NS, 2014, CRIT CARE MED, V42, P1442, DOI 10.1097/CCM.0000000000000224; Aldemir M, 2001, CRIT CARE, V5, P265, DOI 10.1186/cc1044; Axell AIRG, 2002, ACTA ANAESTH SCAND, V46, P726, DOI 10.1034/j.1399-6576.2002.460616.x; Balas MC, 2007, J NURS SCHOLARSHIP, V39, P147, DOI 10.1111/j.1547-5069.2007.00160.x; Bekaert M, 2011, AM J RESP CRIT CARE, V184, P1133, DOI 10.1164/rccm.201105-0867OC; Bekaert M, 2010, LIFETIME DATA ANAL, V16, P45, DOI 10.1007/s10985-009-9130-8; Breitbart W, 2002, PSYCHOSOMATICS, V43, P183, DOI 10.1176/appi.psy.43.3.183; Chang YL, 2008, AM J CRIT CARE, V17, P567; Dubois MJ, 2001, INTENS CARE MED, V27, P1297, DOI 10.1007/s001340101017; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Ely EW, 2013, MODIFYING IMPACT ICU; Engels JM, 2003, J CLIN EPIDEMIOL, V56, P968, DOI 10.1016/S0895-4356(03)00170-7; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Freedman DA, 2006, AM STAT, V60, P299, DOI 10.1198/000313006X152207; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Gofton TE, 2012, NAT REV NEUROL, V8, P557, DOI 10.1038/nrneurol.2012.183; Greenland S, 2003, EPIDEMIOLOGY, V14, P300, DOI 10.1097/00001648-200305000-00009; Hernan MA, 2000, EPIDEMIOLOGY, V11, P561, DOI 10.1097/00001648-200009000-00012; Hshieh TT, 2008, J GERONTOL A-BIOL, V63, P764, DOI 10.1093/gerona/63.7.764; Hughes CG, 2011, ANESTH ANALG, V112, P1212, DOI 10.1213/ANE.0b013e318215366d; Jaber S, 2005, CHEST, V128, P2749, DOI 10.1378/chest.128.4.2749; KISHI Y, 1995, GEN HOSP PSYCHIAT, V17, P371, DOI 10.1016/0163-8343(95)00056-W; Klouwenberg PMCK, 2013, CRIT CARE MED, V41, P2373, DOI 10.1097/CCM.0b013e3182923712; Kurth T, 2006, AM J EPIDEMIOL, V163, P262, DOI 10.1093/aje/kwj047; Lin SM, 2008, J CRIT CARE, V23, P372, DOI 10.1016/j.jcrc.2006.09.001; Lin SM, 2004, CRIT CARE MED, V32, P2254, DOI 10.1097/01.CCM.0000145587.16421.BB; MacLullich AMJ, 2008, J PSYCHOSOM RES, V65, P229, DOI 10.1016/j.jpsychores.2008.05.019; Martin BJ, 2010, CRIT CARE, V14, DOI 10.1186/cc9273; McNicoll L, 2003, J AM GERIATR SOC, V51, P591, DOI 10.1034/j.1600-0579.2003.00201.x; Ouimet S, 2007, INTENS CARE MED, V33, P66, DOI 10.1007/s00134-006-0399-8; Pandharipande P, 2006, ANESTHESIOLOGY, V104, P21, DOI 10.1097/00000542-200601000-00005; Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372; Pandharipande P, 2008, J TRAUMA, V65, P34, DOI 10.1097/TA.0b013e31814b2c4d; Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644; Patel SB, 2014, AM J RESP CRIT CARE, V189, P658, DOI 10.1164/rccm.201310-1815OC; Pisani MA, 2007, ARCH INTERN MED, V167, P1629, DOI 10.1001/archinte.167.15.1629; Pisani MA, 2010, J CRIT CARE, V25, DOI 10.1016/j.jcrc.2010.02.009; Pisani MA, 2009, AM J RESP CRIT CARE, V180, P1092, DOI 10.1164/rccm.200904-0537OC; Pisani MA, 2009, CRIT CARE MED, V37, P177, DOI 10.1097/CCM.0b013e318192fcf9; Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56; Robins JM, 2000, EPIDEMIOLOGY, V11, P550, DOI 10.1097/00001648-200009000-00011; Salluh JI, 2010, CRIT CARE, V14, DOI 10.1186/cc9333; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Seaman JS, 2006, PSYCHOSOMATICS, V47, P56, DOI 10.1176/appi.psy.47.1.56; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Shehabi Y, 2013, INTENS CARE MED, V39, P910, DOI 10.1007/s00134-013-2830-2; Shi CM, 2010, CHINESE MED J-PEKING, V123, P993, DOI 10.3760/cma.j.issn.0366-6999.2010.08.004; Shintani AK, 2009, CRIT CARE MED, V37, P2939, DOI 10.1097/CCM.0b013e3181b7fbbb; Steiner LA, 2011, EUR J ANAESTH, V28, P628, DOI 10.1097/EJA.0b013e328349b7f5; Strijbos MJ, 2013, BMC GERIATR, V13, DOI 10.1186/1471-2318-13-78; Svenningsen H, 2013, ACTA ANAESTH SCAND, V57, P288, DOI 10.1111/aas.12048; Thomason JWW, 2005, CRIT CARE, V9, pR375, DOI 10.1186/cc3729; Tomasi CD, 2012, J CRIT CARE, V27, P212, DOI 10.1016/j.jcrc.2011.05.015; Trzepacz P T, 2000, Semin Clin Neuropsychiatry, V5, P132; Trzepacz PT, 1999, DEMENT GERIATR COGN, V10, P330, DOI 10.1159/000017164; van den Boogaard M, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e420; van den Boogaard M, 2012, INT J NURS STUD, V49, P775, DOI 10.1016/j.ijnurstu.2011.11.016; van den Boogaard M, 2010, CRIT CARE, V14, DOI 10.1186/cc9214; van der Wal WM, 2011, J STAT SOFTW, V43, P1; van Eijk M M J, 2008, Ned Tijdschr Geneeskd, V152, P2768; van Gool WA, 2010, LANCET, V375, P773, DOI 10.1016/S0140-6736(09)61158-2; van Rompaey B, 2009, CRIT CARE, V13, DOI 10.1186/cc7892; Wolkewitz M, 2008, CRIT CARE, V12, DOI 10.1186/cc6852; Wolkewitz M, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5060; Woods JC, 2004, INTENS CARE MED, V30, P1066, DOI 10.1007/s00134-004-2193-9; Zaal IJ, 2015, J CRIT CARE, V30, P375, DOI 10.1016/j.jcrc.2014.10.031; Zaal IJ, 2013, INTENS CARE MED, V39, P481, DOI 10.1007/s00134-012-2726-6; Zaal IJ, 2012, DRUGS, V72, P1457, DOI 10.2165/11635520-000000000-00000; Zhang ZG, 2013, GEN HOSP PSYCHIAT, V35, P105, DOI 10.1016/j.genhosppsych.2012.11.003; Zimmerman JE, 2006, CRIT CARE MED, V34, P1297, DOI 10.1097/01.CCM.0000215112.84523.F0	71	115	120	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 24	2014	349								g6652	10.1136/bmj.g6652	http://dx.doi.org/10.1136/bmj.g6652			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AW2KC	25422275	Green Published, hybrid			2023-01-03	WOS:000346115400002
J	Majrooh, MA; Hasnain, S; Akram, J; Siddiqui, A; Memon, ZA				Majrooh, Muhammad Ashraf; Hasnain, Seema; Akram, Javaid; Siddiqui, Arif; Memon, Zahid Ali			Coverage and Quality of Antenatal Care Provided at Primary Health Care Facilities in the 'Punjab' Province of 'Pakistan'	PLOS ONE			English	Article							PATIENT SATISFACTION; DETERMINANTS; INDIA	Background: Antenatal care is a very important component of maternal health services. It provides the opportunity to learn about risks associated with pregnancy and guides to plan the place of deliveries thereby preventing maternal and infant morbidity and mortality. In 'Pakistan' antenatal services to rural population are being provided through a network of primary health care facilities designated as Basic Health Units and Rural Health Centers. Pakistan is a developing country, consisting of four provinces and federally administered areas. Each province is administratively subdivided in to 'Divisions' and 'Districts'. By population 'Punjab' is the largest province of Pakistan having 36 districts. This study was conducted to assess the coverage and quality antenatal care in the primary health care facilities in 'Punjab' province of 'Pakistan'. Methods: Quantitative and Qualitative methods were used to collect data. Using multistage sampling technique nine out of thirty six districts were selected and 19 primary health care facilities of public sector (seventeen Basic Health Units and two Rural Health Centers were randomly selected from each district. Focus group discussions and in-depth interviews were conducted with clients, providers and health managers. Results: The overall enrollment for antenatal checkup was 55.9% and drop out was 32.9% in subsequent visits. The quality of services regarding assessment, treatment and counseling was extremely poor. The reasons for low coverage and quality were the distant location of facilities, deficiency of facility resources, indifferent attitude and non availability of the staff. Moreover, lack of client awareness about importance of antenatal care and self empowerment for decision making to seek care were also responsible for low coverage. Conclusion: The coverage and quality of the antenatal care services in 'Punjab' are extremely compromised. Only half of the expected pregnancies are enrolled and out of those 1/3 drop out in follow-up visits.	[Majrooh, Muhammad Ashraf; Hasnain, Seema; Akram, Javaid; Siddiqui, Arif] Allama Iqbal Med Coll, Lahore, Pakistan; [Memon, Zahid Ali] Populat Surv Int Greenstar, Karachi, Pakistan		Majrooh, MA (corresponding author), Allama Iqbal Med Coll, Lahore, Pakistan.	majrooh58@yahoo.com	Memon, Zahid Ali/GRE-8118-2022	Memon, Zahid Ali/0000-0002-5321-8885	Maternal and Newborn Health Programme - Research and Advocacy Fund (RAF)	Maternal and Newborn Health Programme - Research and Advocacy Fund (RAF)	This manuscript is an output from a research funded by Maternal and Newborn Health Programme - Research and Advocacy Fund (RAF) and conducted by Research Society Allama Iqbal Medical College Lahore, Pakistan. The views expressed and the information contained is not necessarily endorsed by funding agencies DFID/AusAID. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abou-Zahr CL, 2003, ANTENATAL CARE DEV C; Ali AAA, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-67; Andaleeb SS, 2001, SOC SCI MED, V52, P1359, DOI 10.1016/S0277-9536(00)00235-5; [Anonymous], MULT IND CLUST SURV; [Anonymous], 2007, PAK STAT YB; [Anonymous], DISTR HLTH INF SYST; [Anonymous], DISTR BAS MULT IND C, P12; Barua A, 2003, REPROD HEALTH MATTER, V11, P140, DOI 10.1016/S0968-8080(03)02162-1; Ghobashi Mohammed, 2008, Sultan Qaboos Univ Med J, V8, P325; Gupta R S, 2006, J Commun Dis, V38, P79; Hudak PL, 2000, SPINE, V25, P3167, DOI 10.1097/00007632-200012150-00012; Jafari F, 2010, HEALTH CARE WOMEN IN, V31, P571, DOI 10.1080/07399331003646323; Luyben AG, 2005, MIDWIFERY, V21, P212, DOI 10.1016/j.midw.2004.11.001; MCCARTHY J, 1992, STUD FAMILY PLANN, V23, P23, DOI 10.2307/1966825; Musarrat Jabeen, 2005, Journal of Postgraduate Medical Institute, V19, P377; National Institute of Population Studies (NIPS) and Macro International, 2006, PAKISTAN DEMOGRAPHIC; Nisar N, 2003, JPMA, V53, P1; Nisar Nighat, 2007, J Ayub Med Coll Abbottabad, V19, P11; Raisa BG, 2009, J PROFESSIONAL NURSI, V25, P240; Rani M, 2008, INT J QUAL HEALTH C, V20, P62, DOI 10.1093/intqhc/mzm052; Tarekegn SM, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-161; United Nations Decade of Education for Sustainable Develop- ment, 2005, IMPR MAT HLTH, P1; World Health Organization, 2008, MAT MORT 2005 EST DE, P48; Zeidan Z. A., 2011, KHARTOUM MED J, V4, P590; Ziaul Hasan, 2007, Journal of Postgraduate Medical Institute, V21, P29	25	45	49	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 19	2014	9	11							e113390	10.1371/journal.pone.0113390	http://dx.doi.org/10.1371/journal.pone.0113390			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AU3SG	25409502	Green Published, Green Submitted, gold			2023-01-03	WOS:000345533200107
J	Ahmed, B; Nanji, K; Mujeeb, R; Patel, MJ				Ahmed, Bilal; Nanji, Kashmira; Mujeeb, Rakshinda; Patel, Muhammad Junaid			Effects of Polypharmacy on Adverse Drug Reactions among Geriatric Outpatients at a Tertiary Care Hospital in Karachi: A Prospective Cohort Study	PLOS ONE			English	Article							ELDERLY-PATIENTS; EVENTS	Background: Adverse drug reactions (ADRs) present a challenging and expensive public health problem. Polypharmacy is defined according to the WHO criteria as the, "concurrent use of five or more different prescription medication''. Elderly are more prone to adverse reactions due to comorbid conditions, longer lists of medications and sensitivity to drug effects. The aim of the study is to estimate the incidence and strength of association of ADRs due to polypharmacy among the geriatric cohort attending outpatient clinics at a tertiary care center. Methods: A hospital based prospective cohort study was conducted at ambulatory care clinics of Aga Khan University Hospital April 2012 to March 2013. One thousand geriatrics patients (age >= 65 years) visiting ambulatory clinics were identified. They were divided on the basis of exposure (polypharmacy vs. no polypharmacy). We followed them from the time of their enrollment (day zero) to six weeks, checking up on them once a week. Incidence was calculated and Cox Proportional Hazard Model estimates were used. Results: The final analysis was performed on 1000 elderly patients. The occurrence of polypharmacy was 70% and the incidence of ADRs was 10.5% among the study cohort. The majority (30%) of patients were unable to read or write. The use of herbal medicine was reported by 3.2% of the patients and homeopathic by 3%. Our Cox adjusted model shows that polypharmacy was 2.3 times more associated with ADRs, con-current complementary and alternative medicine (CAM) was 7.4 times and those who cannot read and write were 1.5 times more associated with ADRs. Conclusion: The incidence of ADRs due to poly pharmacy is alarmingly high. The factors associated with ADRs are modifiable. Policies are needed to design and strengthen the prescription pattern.	[Ahmed, Bilal; Mujeeb, Rakshinda; Patel, Muhammad Junaid] Aga Khan Univ, Dept Med, Karachi, Pakistan; [Nanji, Kashmira] Aga Khan Univ, Dept Family Med, Karachi, Pakistan	Aga Khan University; Aga Khan University	Patel, MJ (corresponding author), Aga Khan Univ, Dept Med, Karachi, Pakistan.	junaiddrpatel@gmail.com			University Research Council, Aga Khan University URC [102013MED]	University Research Council, Aga Khan University URC	This work was supported by the University Research Council, Aga Khan University URC ID 102013MED. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Budnitz DS, 2007, ANN INTERN MED, V147, P755, DOI 10.7326/0003-4819-147-11-200712040-00006; Chumney Elinor C., 2006, Pharmacy Pract (Granada), V4, P103, DOI 10.4321/s1885-642x2006000300001; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; Edwards IR, 2000, LANCET, V356, P1255, DOI 10.1016/S0140-6736(00)02799-9; Ernst E, 2000, BMJ-BRIT MED J, V321, P1133, DOI 10.1136/bmj.321.7269.1133; Field TS, 2004, J AM GERIATR SOC, V52, P1349, DOI 10.1111/j.1532-5415.2004.52367.x; Gandhi TK, 2003, NEW ENGL J MED, V348, P1556, DOI 10.1056/NEJMsa020703; Haider SI, 2007, INT J CLIN PHARM TH, V45, P643; Hajjar Emily R, 2003, Am J Geriatr Pharmacother, V1, P82; Herman Patricia M, 2005, BMC Complement Altern Med, V5, P11, DOI 10.1186/1472-6882-5-11; Hilmer SN, 2008, AUST PRESCR, V31, P2, DOI 10.18773/austprescr.2008.001; Hohl CM, 2001, ANN EMERG MED, V38, P666, DOI 10.1067/mem.2001.119456; Lam DPY, 2010, J AM GERIATR SOC, V58, P203, DOI 10.1111/j.1532-5415.2009.02656.x; Najjar MF, 2010, HEALTHMED, V4; Nguyen Julia K, 2006, Am J Geriatr Pharmacother, V4, P36, DOI 10.1016/j.amjopharm.2006.03.002; Nobili A, 2011, EUR J CLIN PHARMACOL, V67, P507, DOI 10.1007/s00228-010-0977-0; Population Division Department of Economic and Social Affairs United Nations, 2013, WORLD POP AG 2013; Sabzwari SR, 2013, J PAK MED ASSOC, V63, P624; Steinman MA, 2006, J AM GERIATR SOC, V54, P1516, DOI 10.1111/j.1532-5415.2006.00889.x; Thomsen LA, 2007, ANN PHARMACOTHER, V41, P1411, DOI 10.1345/aph.1H658; Trumic Edisa, 2012, Mater Sociomed, V24, P68, DOI 10.5455/msm.2012.24.68-72; Viktil KK, 2007, BRIT J CLIN PHARMACO, V63, P187, DOI 10.1111/j.1365-2125.2006.02744.x; WORLD HEALTH ORGANIZATION, 2009, DENGUE: GUIDELINES FOR DIAGNOSIS, TREATMENT, PREVENTION AND CONTROL, P3	23	58	61	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 17	2014	9	11							e112133	10.1371/journal.pone.0112133	http://dx.doi.org/10.1371/journal.pone.0112133			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT8BL	25402452	Green Submitted, Green Published, gold			2023-01-03	WOS:000345158700029
J	Hou, YY; Cheng, BF; Zhou, MG; Fang, RP; Jiang, M; Hou, WB; Bai, G				Hou, Yuanyuan; Cheng, Binfeng; Zhou, Mengge; Fang, Runping; Jiang, Min; Hou, Wenbin; Bai, Gang			Searching for Synergistic Bronchodilators and Novel Therapeutic Regimens for Chronic Lung Diseases from a Traditional Chinese Medicine, Qingfei Xiaoyan Wan	PLOS ONE			English	Article							FLIGHT MASS-SPECTROMETRY; KAPPA-B INHIBITORS; OBSTRUCTIVE PULMONARY-DISEASE; BIOACTIVE COMPOUNDS; ALKALOIDAL EXTRACT; IDENTIFICATION; ARCTIGENIN; MECHANISMS; AGONISTS; ARCTIIN	Classical Chinese pharmacopeias describe numerous excellent herbal formulations, and each prescription is an outstanding pool of effective compounds for drug discovery. Clarifying the bioactivity of the combined mechanisms of the ingredients in complex traditional Chinese medicine formulas is challenging. A classical formula known as Qingfei Xiaoyan Wan, used clinically as a treatment for prevalent chronic lung disease, was investigated in this work. A mutually enhanced bioactivity-guided ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC/Q-TOF-MS) characterization system was proposed, coupled with a dual-luciferase reporter assay for beta(2)AR-agonist cofactor screening. Arctiin, arctigenin, descurainoside and descurainolide B, four lignin compounds that showed synergistic bronchodilation effects with ephedrine, were revealed. The synergistic mechanism of arctigenin with the beta(2)ARagonist involved with the reduction of free Ca2+ was clarified by a dual-luciferase reporter assay for intracellular calcium and the Ca2+ indicator fluo-4/AM to monitor changes in the fluorescence. The relaxant and contractile responses of airway smooth muscle are regulated by crosstalk between the intracellular cAMP and calcium signaling pathways. Our data indicated the non-selective beta AR agonist ephedrine as the principal bronchodilator of the formula, whereas the lignin ingredients served as adjuvant ingredients. A greater understanding of the mechanisms governing the control of these pathways, based on conventional wisdom, could lead to the identification of novel therapeutic targets or new agents for the treatment of asthma and COPD.	[Hou, Yuanyuan; Cheng, Binfeng; Zhou, Mengge; Fang, Runping; Jiang, Min; Bai, Gang] Nankai Univ, State Key Lab Med Chem Biol, Tianjin 300071, Peoples R China; [Hou, Yuanyuan; Cheng, Binfeng; Zhou, Mengge; Fang, Runping; Jiang, Min; Bai, Gang] Nankai Univ, Coll Pharm, Tianjin Key Lab Mol Drug Res, Tianjin 300071, Peoples R China; [Hou, Wenbin] Tianjin Inst Pharmaceut Res, Tianjin Engn Lab Qual Control Techn TCM, Tianjin, Peoples R China	Nankai University; Nankai University	Bai, G (corresponding author), Nankai Univ, State Key Lab Med Chem Biol, Tianjin 300071, Peoples R China.	gangbai@nankai.edu.cn	Jiang, Min/HGT-8781-2022; Fang, Runping/AAF-6835-2020		National Natural Science Foundation of China [81173638, 81373506]; Specialized Research Fund for the Doctor Program of Higher Education of China [20120031110042]; Key Program of Natural Science of Foundation of Tianjin, China [13JCZDJC31400]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Specialized Research Fund for the Doctor Program of Higher Education of China(Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); Key Program of Natural Science of Foundation of Tianjin, China	This work was supported by a Grant from the National Natural Science Foundation of China (grant no: 81173638 and 81373506), the Specialized Research Fund for the Doctor Program of Higher Education of China (grant no: 20120031110042) and the Key Program of Natural Science of Foundation of Tianjin, China (grant no: 13JCZDJC31400). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	An XD, 2012, J ALTERN COMPLEM MED, V18, P731, DOI 10.1089/acm.2011.0389; Awale S, 2006, CANCER RES, V66, P1751, DOI 10.1158/0008-5472.CAN-05-3143; Azmir J, 2013, J FOOD ENG, V117, P426, DOI 10.1016/j.jfoodeng.2013.01.014; Bai G, 2008, ACTA PHARMACOL SIN, V29, P1187, DOI 10.1111/j.1745-7254.2008.00859.x; Bai G, 2014, CHIN HERB MED, V6, P85, DOI 10.1016/S1674-6384(14)60013-7; Billington CK, 2012, BRIT J PHARMACOL, V166, P401, DOI 10.1111/j.1476-5381.2011.01719.x; Brusotti G, 2014, J PHARMACEUT BIOMED, V87, P218, DOI 10.1016/j.jpba.2013.03.007; Butler L, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/739716; Carolan BJ, 2013, J ALLERGY CLIN IMMUN, V131, P627, DOI 10.1016/j.jaci.2013.01.010; Chan Yuk-Shing, 2011, Inflammopharmacology, V19, P245, DOI 10.1007/s10787-010-0062-4; Cheng BF, 2012, ANAL BIOANAL CHEM, V404, P2445, DOI 10.1007/s00216-012-6332-9; Gu Y, 2012, BIOCHEM PHARMACOL, V84, P468, DOI 10.1016/j.bcp.2012.06.002; Hall IP, 2000, EUR RESPIR J, V15, P1120, DOI 10.1034/j.1399-3003.2000.01523.x; He F, 2012, PLANTA MED, V78, P800, DOI 10.1055/s-0031-1298433; Holzinger F, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1155/2011/382789; Hong F, 2011, ARCH BIOCHEM BIOPHYS, V510, P135, DOI 10.1016/j.abb.2011.04.018; Hou YY, 2012, J CHROMATOGR B, V908, P98, DOI 10.1016/j.jchromb.2012.10.004; Hou YY, 2012, J CHROMATOGR A, V1227, P203, DOI 10.1016/j.chroma.2012.01.008; Huang XD, 2004, J CHROMATOGR B, V812, P71, DOI 10.1016/j.jchromb.2004.06.046; Jiang M, 2013, J ETHNOPHARMACOL, V147, P426, DOI 10.1016/j.jep.2013.03.032; Lee S, 2011, J INFLAMM-LOND, V8, DOI 10.1186/1476-9255-8-16; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; Mohamed NH, 2009, REC NAT PROD, V3, P58; Morphy R, 2009, CURR PHARM DESIGN, V15, P587, DOI 10.2174/138161209787315594; Patwardhan B, 2004, CURR SCI INDIA, V86, P789; Preissner S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051020; Pujol A, 2010, TRENDS PHARMACOL SCI, V31, P115, DOI 10.1016/j.tips.2009.11.006; Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO; Radhakrishnan ML, 2008, J CHEM INF MODEL, V48, P1055, DOI 10.1021/ci700452r; Ritchie MF, 2011, CELL CALCIUM, V49, P314, DOI 10.1016/j.ceca.2010.10.001; Shi Q, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044921; Sun K, 2004, CHEM PHARM BULL, V52, P1483, DOI 10.1248/cpb.52.1483; Wang L, 2008, P NATL ACAD SCI USA, V105, P4826, DOI 10.1073/pnas.0712365105; Wu L, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/705315; Wu RH, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/323715; Xu SY, 2001, METHODOLOGY PHARM EX; Yuan R, 2000, PHARMACOL THERAPEUT, V86, P191, DOI 10.1016/S0163-7258(00)00039-5; Zhang HW, 2012, J ADV NURS, V68, P1679, DOI 10.1111/j.1365-2648.2011.05925.x; Zhao ZY, 2013, BIOL TRACE ELEM RES, V156, P181, DOI 10.1007/s12011-013-9839-9	39	13	14	1	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 14	2014	9	11							e113104	10.1371/journal.pone.0113104	http://dx.doi.org/10.1371/journal.pone.0113104			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AU4DF	25397687	gold, Green Published, Green Submitted			2023-01-03	WOS:000345558500133
J	Hou, CL; Liu, H; Zhang, J; Zhang, SH; Yang, FJ; Zeng, XF; Thacker, PA; Zhang, GL; Qiao, SY				Hou, Chengli; Liu, Hong; Zhang, Jiang; Zhang, Shihai; Yang, Fengjuan; Zeng, Xiangfang; Thacker, Philip A.; Zhang, Guolong; Qiao, Shiyan			Intestinal Microbiota Succession and Immunomodulatory Consequences after Introduction of Lactobacillus reuteri I5007 in Neonatal Piglets	PLOS ONE			English	Article							GRADIENT GEL-ELECTROPHORESIS; GUT MICROBIOTA; GASTROINTESTINAL-TRACT; IMMUNE-SYSTEM; HYGIENE HYPOTHESIS; FERMENTUM I5007; MUCOSAL DEFENSE; HOST; BACTERIA; COMPLEX	Seventy-two, suckling piglets, obtained from 9 litters standardized to 8 piglets, were assigned to 1 of 3 treatments (n = 24) to compare short-term, early administration with intermittent, longer-term administration of Lactobacillus reuteri I5007. The treatments were a control (given a placebo of 0.1% peptone water from day 1 to 5) or treatments in which 1.7 x 10 (10) CFU Lactobacillus reuteri was administrated either daily for 4 days starting on day 1 or every 4th day from day 1 to 17. Five piglets per treatment were killed at 3 time points (day 7, 14 and 21). Denaturing Gradient Electrophoresis of ileal digesta revealed an increase in the presence of Lactobacillus reuteri I5007 and Clostridium lentocellum (on day 14 and 21) in the every 4th-day treatment and Actinobacillus porcinus (on day 7 and 14) in both Lactobacillus reuteri treatments, while reducing the abundance of E. coli on day 21 in the every 4th-day treatment. Real-time qPCR of ileal digesta showed an increase in Bifidobacterium spp. on day 14 for both Lactobacillus reuteri I5007 treatments. An increase in the concentration of lactic acid and a lower pH was observed in the first 4-day treatment on day 7 and the every 4th day treatment on day 14. The relative abundance of mRNA for TGF-beta was increased while that for IFN-gamma was decreased in the mesenteric lymph nodes of piglets treated with Lactobacillus reuteri every 4th day. In conclusion, early intervention with Lactobacillus reuteri increases the presence of beneficial bacteria and decreases the presence of undesirable microbes in the lower gastrointestinal tract. The changes appear to be mediated by altering the intestinal pH through lactic acid production resulting in favorable bacterial species colonization. A prolonged duration of treatment (i.e. every 4th day) would appear to be superior to treatment only during the first 4 days.	[Hou, Chengli; Liu, Hong; Zhang, Jiang; Zhang, Shihai; Yang, Fengjuan; Zeng, Xiangfang; Qiao, Shiyan] China Agr Univ, State Key Lab Anim Nutr, Beijing 100193, Peoples R China; [Thacker, Philip A.] Univ Saskatchewan, Dept Anim & Poultry Sci, Saskatoon, SK S7N 0W0, Canada; [Zhang, Guolong] Oklahoma State Univ, Dept Anim Sci, Stillwater, OK 74078 USA	China Agricultural University; University of Saskatchewan; Oklahoma State University System; Oklahoma State University - Stillwater	Qiao, SY (corresponding author), China Agr Univ, State Key Lab Anim Nutr, 2 Yuanmingyuan West Rd, Beijing 100193, Peoples R China.	qiaoshy@mafic.ac.cn	Zhang, Guolong/HCI-5587-2022; Hou, Chengli/AGY-1396-2022; chengli, Hou/AGZ-4530-2022; Zhang, Guolong/AAU-8197-2020	chengli, Hou/0000-0002-5617-8655; Zhang, Guolong/0000-0003-4781-5816	National Natural Science Foundation of China [31420103908]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This research was financially supported by the National Natural Science Foundation of China (Grant Number 31420103908). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aranda PS, 2012, ELECTROPHORESIS, V33, P366, DOI 10.1002/elps.201100335; Ashida H, 2012, NAT CHEM BIOL, V8, P36, DOI 10.1038/nchembio.741; Bailey M, 2005, P NUTR SOC, V64, P451, DOI 10.1079/PNS2005452; Bauer Eva, 2006, Current Issues in Intestinal Microbiology, V7, P35; Bezkorovainy A, 2001, AM J CLIN NUTR, V73, p399S, DOI 10.1093/ajcn/73.2.399s; Bjorksten B, 2006, CLIN EXP ALLERGY, V36, P1215, DOI 10.1111/j.1365-2222.2006.02579.x; Bjorksten B, 2009, NESTLE NUTR WORKS SE, V64, P11, DOI 10.1159/000235780; Boyle RJ, 2006, AM J CLIN NUTR, V83, P1256, DOI 10.1093/ajcn/83.6.1256; Brandt K, 2012, CLINICS, V67, P113, DOI 10.6061/clinics/2012(02)05; Bron PA, 2012, NAT REV MICROBIOL, V10, P66, DOI 10.1038/nrmicro2690; Claud EC, 2011, ANAEROBE, V17, P180, DOI 10.1016/j.anaerobe.2011.02.004; Collado-Romero M, 2010, VET RES, V41, DOI 10.1051/vetres/2009072; Delzenne NM, 2011, ANNU REV NUTR, V31, P15, DOI 10.1146/annurev-nutr-072610-145146; dos Santos VM, 2010, CURR OPIN BIOTECH, V21, P539, DOI 10.1016/j.copbio.2010.08.003; Dowd SE, 2008, BMC MICROBIOL, V8, DOI [10.1186/1471-2180-8-125, 10.1186/1471-2180-8-43]; Duncker SC, 2006, VET IMMUNOL IMMUNOP, V111, P239, DOI 10.1016/j.vetimm.2006.01.017; Forchielli ML, 2005, BRIT J NUTR, V93, pS41, DOI 10.1079/BJN20041356; Franklin MA, 2002, J ANIM SCI, V80, P2904; Gaskins HR, 2008, CLIN INFECT DIS, V46, pS80, DOI 10.1086/523336; Hansen CHF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034043; Hou CL, 2014, J BIOTECHNOL, V179, P63, DOI 10.1016/j.jbiotec.2014.03.019; Isolauri E., 2004, CURR PAEDIAT, V14, P104, DOI DOI 10.1016/J.CUPE.2003.11.002; Kelly D, 2007, MUTAT RES-FUND MOL M, V622, P58, DOI 10.1016/j.mrfmmm.2007.03.011; Kok RG, 1996, APPL ENVIRON MICROB, V62, P3668, DOI 10.1128/AEM.62.10.3668-3672.1996; Konstantinov SR, 2004, APPL ENVIRON MICROB, V70, P3821, DOI 10.1128/AEM.70.7.3821-3830.2004; Leser TD, 2002, APPL ENVIRON MICROB, V68, P673, DOI 10.1128/AEM.68.2.673-690.2002; Levast B, 2010, VET IMMUNOL IMMUNOP, V137, P261, DOI 10.1016/j.vetimm.2010.06.004; Li XJ, 2008, J APPL MICROBIOL, V104, P1082, DOI 10.1111/j.1365-2672.2007.03636.x; Liu H, 2014, J AGR FOOD CHEM, V62, P860, DOI 10.1021/jf403288r; Livingston M, 2010, IMMUNOL CELL BIOL, V88, P99, DOI 10.1038/icb.2009.71; Mackie RI, 1999, AM J CLIN NUTR, V69, p1035S, DOI 10.1093/ajcn/69.5.1035s; Marzotto M, 2006, RES MICROBIOL, V157, P857, DOI 10.1016/j.resmic.2006.06.007; Mazmanian SK, 2005, CELL, V122, P107, DOI 10.1016/j.cell.2005.05.007; Moue M, 2008, BBA-GEN SUBJECTS, V1780, P134, DOI 10.1016/j.bbagen.2007.11.006; Musso G, 2010, DIABETES CARE, V33, P2277, DOI 10.2337/dc10-0556; Muyzer G, 1998, ANTON LEEUW INT J G, V73, P127, DOI 10.1023/A:1000669317571; Nadkarni MA, 2002, MICROBIOL-SGM, V148, P257, DOI 10.1099/00221287-148-1-257; Nubel U, 1996, J BACTERIOL, V178, P5636; Paulin SM, 2007, INFECT IMMUN, V75, P3950, DOI 10.1128/IAI.00366-07; Rakoff-Nahoum S, 2008, MUCOSAL IMMUNOL, V1, pS10, DOI 10.1038/mi.2008.49; Rauch M, 2010, GUT MICROBES, V1, P335, DOI 10.4161/gmic.1.5.13169; Round JL, 2009, NAT REV IMMUNOL, V9, P313, DOI 10.1038/nri2515; Schmidt B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028284; SWORDS WE, 1993, BIOL NEONATE, V63, P191, DOI 10.1159/000243931; Walter J, 2001, APPL ENVIRON MICROB, V67, P2578, DOI 10.1128/AEM.67.6.2578-2585.2001; Walter J, 2011, P NATL ACAD SCI USA, V108, P4645, DOI 10.1073/pnas.1000099107; Wang XQ, 2012, J NUTR, V142, P7, DOI 10.3945/jn.111.147074; Ye LL, 2008, DEV COMP IMMUNOL, V32, P966, DOI 10.1016/j.dci.2008.01.008; Yi JQ, 2013, ASIAN AUSTRAL J ANIM, V26, P1181, DOI 10.5713/ajas.2013.13129; Zoetendal EG, 1998, APPL ENVIRON MICROB, V64, P3854	51	27	31	1	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 16	2015	10	3							e0119505	10.1371/journal.pone.0119505	http://dx.doi.org/10.1371/journal.pone.0119505			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CD6EY	25775260	Green Published, Green Submitted, gold			2023-01-03	WOS:000351183500099
J	Debnath, T; Ghosh, S; Potlapuvu, US; Kona, L; Kamaraju, SR; Sarkar, S; Gaddam, S; Chelluri, LK				Debnath, Tanya; Ghosh, Sutapa; Potlapuvu, Usha Shalini; Kona, Lakshmi; Kamaraju, Suguna Ratnakar; Sarkar, Suprabhat; Gaddam, Sumanlatha; Chelluri, Lakshmi Kiran			Proliferation and Differentiation Potential of Human Adipose-Derived Stem Cells Grown on Chitosan Hydrogel	PLOS ONE			English	Article							BONE-MARROW; TISSUE; BIOMATERIALS; SCAFFOLD	Applied tissue engineering in regenerative medicine warrants our enhanced understanding of the biomaterials and its function. The aim of this study was to evaluate the proliferation and differentiation potential of human adipose-derived stem cells (hADSCs) grown on chitosan hydrogel. The stability of this hydrogel is pH-dependent and its swelling property is pivotal in providing a favorable matrix for cell growth. The study utilized an economical method of cross linking the chitosan with 0.5% glutaraldehyde. Following the isolation of hADSCs from omentum tissue, these cells were cultured and characterized on chitosan hydrogel. Subsequent assays that were performed included JC-1 staining for the mitochondrial integrity as a surrogate marker for viability, cell proliferation and growth kinetics by MTT assay, lineage specific differentiation under two-dimensional culture conditions. Confocal imaging, scanning electron microscopy (SEM), and flow cytometry were used to evaluate these assays. The study revealed that chitosan hydrogel promotes cell proliferation coupled with > 90% cell viability. Cytotoxicity assays demonstrated safety profile. Furthermore, glutaraldehyde cross linked chitosan showed < 5% cytotoxicity, thus serving as a scaffold and facilitating the expansion and differentiation of hADSCs across endoderm, ectoderm and mesoderm lineages. Additional functionalities can be added to this hydrogel, particularly those that regulate stem cell fate.	[Debnath, Tanya; Potlapuvu, Usha Shalini; Kamaraju, Suguna Ratnakar; Chelluri, Lakshmi Kiran] Global Hosp, Transplant Immunol & Stem Cell Lab, Hyderabad, Andhra Pradesh, India; [Ghosh, Sutapa; Sarkar, Suprabhat] Indian Inst Chem Technol, I&PC Div, Nanomat Lab, Hyderabad 500007, Andhra Pradesh, India; [Kona, Lakshmi] Global Hosp, Dept Bariatr Surg, Hyderabad, Andhra Pradesh, India; [Gaddam, Sumanlatha] Osmania Univ, Dept Genet, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Technology (IICT); Osmania University	Ghosh, S (corresponding author), Indian Inst Chem Technol, I&PC Div, Nanomat Lab, Hyderabad 500007, Andhra Pradesh, India.	sutapa69arun@gmail.com; lkiran@globalhospitalsindia.com						Beahm EK, 2003, CLIN PLAST SURG, V30, P547, DOI 10.1016/S0094-1298(03)00072-5; Berger J, 2004, EUR J PHARM BIOPHARM, V57, P19, DOI 10.1016/s0939-6411(03)00161-9; Bissell M J, 1987, Prog Clin Biol Res, V249, P251; Cheburu CN, 2011, MED-SURG J, V115, P864; Cheng YH, 2010, TISSUE ENG PT A, V16, P695, DOI [10.1089/ten.tea.2009.0229, 10.1089/ten.TEA.2009.0229]; Daley WP, 2008, J CELL SCI, V121, P255, DOI 10.1242/jcs.006064; Dhanasekaran M, 2012, CYTOTECHNOLOGY, V64, P497, DOI 10.1007/s10616-012-9427-4; Diekman BO, 2010, TISSUE ENG PT A, V16, P523, DOI 10.1089/ten.TEA.2009.0398; Distantina S, 2013, ENG J-THAIL, V17, P57, DOI 10.4186/ej.2013.17.3.57; Gomathysankar S, 2014, ARCH PLAST SURG-APS, V41, P452, DOI 10.5999/aps.2014.41.5.452; Gonçalves Vanessa L., 2005, Polímeros, V15, P6, DOI 10.1590/S0104-14282005000100005; Gunatillake Pathiraja A., 2003, European Cells & Materials, V5, P1; Hassan W, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt182; Hoemann CD, 2005, OSTEOARTHR CARTILAGE, V13, P318, DOI 10.1016/j.joca.2004.12.001; Ikeda T, 2014, BIOMED RES INT, V2014, P8; Jurgens WJFM, 2008, CELL TISSUE RES, V332, P415, DOI 10.1007/s00441-007-0555-7; Kang YM, 2010, INT J MOL SCI, V11, P4140, DOI 10.3390/ijms11104140; Kern S, 2006, STEM CELLS, V24, P1294, DOI 10.1634/stemcells.2005-0342; Kim KS, 2009, TISSUE ENG PT A, V15, P3201, DOI [10.1089/ten.tea.2008.0704, 10.1089/ten.TEA.2008.0704]; Koppula PR, 2009, CELL IMMUNOL, V259, P61, DOI 10.1016/j.cellimm.2009.05.014; Lakshmi KC, 2012, STEM CELLS EXTRACELL; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; Li B, 2013, MAR DRUGS, V11, P1534, DOI 10.3390/md11051534; Lutolf MP, 2005, NAT BIOTECHNOL, V23, P47, DOI 10.1038/nbt1055; Monteiro OAC, 1999, INT J BIOL MACROMOL, V26, P119, DOI 10.1016/S0141-8130(99)00068-9; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Naderi-Meshkin H, 2014, CELL BIOL INT, V38, P72, DOI 10.1002/cbin.10181; Neuss S, 2008, BIOMATERIALS, V29, P302, DOI 10.1016/j.biomaterials.2007.09.022; Patel PN, 2005, J BIOMED MATER RES A, V73A, P313, DOI 10.1002/jbm.a.30291; Patrick CW, 2001, ANAT RECORD, V263, P361, DOI 10.1002/ar.1113; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Pountos I, 2007, INJURY, V38, pS23, DOI 10.1016/S0020-1383(08)70006-8; ROSSMURPHY SB, 1994, POLYM GELS NETW, V2, P229, DOI 10.1016/0966-7822(94)90007-8; Rosso F, 2005, J CELL PHYSIOL, V203, P465, DOI 10.1002/jcp.20270; Salamon A, 2014, MATERIALS, V7, P1342, DOI 10.3390/ma7021342; Song KD, 2010, J MATER SCI-MATER M, V21, P2835, DOI 10.1007/s10856-010-4131-4; Tibbitt MW, 2009, BIOTECHNOL BIOENG, V103, P655, DOI 10.1002/bit.22361; Wagers AJ, 2004, CELL, V116, P639, DOI 10.1016/S0092-8674(04)00208-9; Wang LY, 2006, COLLOID SURFACE B, V50, P126, DOI 10.1016/j.colsurfb.2006.05.006; Wu XM, 2007, J BIOMED MATER RES A, V81A, P59, DOI 10.1002/jbm.a.31003; Zamora DO, 2012, JOVE-J VIS EXP, DOI 10.3791/3624; Zhang SG, 2003, NAT BIOTECHNOL, V21, P1171, DOI 10.1038/nbt874; Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02-02-0105	43	41	42	1	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 6	2015	10	3							e0120803	10.1371/journal.pone.0120803	http://dx.doi.org/10.1371/journal.pone.0120803			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC9KQ	25746846	gold, Green Published, Green Submitted			2023-01-03	WOS:000350689400099
J	Falzarano, D; Feldmann, H				Falzarano, Darryl; Feldmann, Heinz			Delineating Ebola entry	SCIENCE			English	Editorial Material							NIEMANN-PICK C1; VIRUS INFECTION		[Falzarano, Darryl] Univ Saskatchewan, Int Vaccine Ctr, Vaccine & Infect Dis Org, Saskatoon, SK, Canada; [Feldmann, Heinz] NIAID, Lab Virol, Div Intramural Res, NIH, Hamilton, MT USA	University of Saskatchewan; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Falzarano, D (corresponding author), Univ Saskatchewan, Int Vaccine Ctr, Vaccine & Infect Dis Org, Saskatoon, SK, Canada.	feldmannh@niaid.nih.gov			Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Division Of Integrative Organismal Systems [1522491] Funding Source: National Science Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001089] Funding Source: NIH RePORTER	Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Division Of Integrative Organismal Systems(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health.	Carette JE, 2011, NATURE, V477, P340, DOI 10.1038/nature10348; Chandran K, 2005, SCIENCE, V308, P1643, DOI 10.1126/science.1110656; Cote M, 2011, NATURE, V477, P344, DOI 10.1038/nature10380; Hunt CL, 2012, VIRUSES-BASEL, V4, P258, DOI 10.3390/v4020258; Kolokoltsov AA, 2009, DRUG DEVELOP RES, V70, P255, DOI 10.1002/ddr.20303; Nanbo A, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001121; Picazo E, 2015, DRUG DISCOV TODAY, V20, P277, DOI 10.1016/j.drudis.2014.12.010; Qiu XG, 2014, NATURE, V514, P47, DOI 10.1038/nature13777; Saeed MF, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001110; Sakurai Y, 2015, SCIENCE, V347, P995, DOI 10.1126/science.1258758	10	8	9	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 27	2015	347	6225					947	948		10.1126/science.aaa8121	http://dx.doi.org/10.1126/science.aaa8121			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CB9NQ	25722396				2023-01-03	WOS:000349958900017
J	Souza, GV; Simas, AS; Bastos-Pereira, AL; Frois, GRA; Ribas, JLC; Verdan, MH; Kassuya, CAL; Stefanello, ME; Zampronio, AR				Souza, Georgea V.; Simas, Alex S.; Bastos-Pereira, Amanda L.; Frois, Gisele R. A.; Ribas, Joao L. C.; Verdan, Maria H.; Kassuya, Candida A. L.; Stefanello, Maria E.; Zampronio, Aleksander R.			Antinociceptive Activity of the Ethanolic Extract, Fractions, and Aggregatin D Isolated from Sinningia aggregata Tubers	PLOS ONE			English	Article							PROTEIN-KINASE-C; NITRIC-OXIDE; INFLAMMATORY HYPERNOCICEPTION; MECHANICAL HYPERALGESIA; COLORIMETRIC ASSAY; DIRECT ANTAGONISM; BRADYKININ; CYTOKINES; ALPHA; SENSITIZATION	The present study investigated the effects of the ethanolic extract (ESa), fractions, and compounds isolated from Sinningia aggregata in male Swiss mice on carrageenan-induced paw edema, neutrophil migration, mechanical hyperalgesia, formalin-induced nociception, and lipopolysaccharide-induced fever. The ESa did not alter edema, neutrophil migration, or fever at any of the doses tested. However, the ESa reduced phase II of formalin-induced nociception and carrageenan-induced mechanical hyperalgesia. The petroleum ether (PE) and ethyl acetate (EA) fractions and aggregatin D (AgD; isolated from the EA fraction) reduced formalin-induced nociception. Anthraquinones from the PE fraction were ineffective. AgD also inhibited carrageenan-induced mechanical hyperalgesia. Neither the ESa nor AgD altered thermal nociception or motor performance. Local administration of AgD also reduced hyperalgesia induced by carrageenan, bradykinin, tumor necrosis factor-alpha, interleukin-1 beta, cytokine-induced neutrophil chemoattractant, prostaglandin E-2, and dopamine but not hyperalgesia induced by forskolin or dibutyryl cyclic adenosine monophosphate. The positive control dipyrone reduced the response induced by all of the stimuli. Additionally, glibenclamide abolished the analgesic effect of dipyrone but not the one induced by AgD. AgD did not change lipopolysaccharide-induced nitric oxide production by macrophages or the nociception induced by capsaicin, cinnamaldehyde, acidified saline, or menthol. These results suggest that the ESa has important antinociceptive activity, and this activity results at least partially from the presence of AgD. AgD reduced mechanical hyperalgesia induced by several inflammatory mediators through mechanisms that are different from classic analgesic drugs.	[Souza, Georgea V.; Simas, Alex S.; Bastos-Pereira, Amanda L.; Frois, Gisele R. A.; Ribas, Joao L. C.; Kassuya, Candida A. L.; Zampronio, Aleksander R.] Univ Fed Parana, Dept Pharmacol, Ctr Politecn, BR-81531980 Curitiba, Parana, Brazil; [Verdan, Maria H.; Stefanello, Maria E.] Univ Fed Parana, Dept Chem, Ctr Politecn, BR-81530900 Curitiba, Parana, Brazil	Universidade Federal do Parana; Universidade Federal do Parana	Zampronio, AR (corresponding author), Univ Fed Parana, Dept Pharmacol, Ctr Politecn, POB 19031, BR-81531980 Curitiba, Parana, Brazil.	aleksander@ufpr.br	Zampronio, Aleksander R/B-3915-2013; Kassuya, Candida A. L./G-8329-2011; VERDAN, MARIA H/E-2013-2016; Bastos-Pereira, Amanda/AAQ-1375-2020	VERDAN, MARIA H/0000-0002-2460-0372; Bastos-Pereira, Amanda/0000-0001-9416-1208; Kassuya, Candida/0000-0002-8998-9219; Ribas, Joao/0000-0003-0545-5920; Zampronio, Aleksander/0000-0002-8354-7081	Araucaria Foundation of the State of Parana, Brazil [413/09-15118]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, CNPq, Brazil	Araucaria Foundation of the State of Parana, Brazil; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, CNPq, Brazil(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	Araucaria Foundation of the State of Parana, Brazil # 413/09-15118 and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, CNPq, Brazil for the scholarships for GVS, ASS, ALBP, and JLCR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahn KY, 2005, BIOCHEM BIOPH RES CO, V336, P93, DOI 10.1016/j.bbrc.2005.08.059; al-Swayeh OA, 2000, BRIT J PHARMACOL, V130, P1453, DOI 10.1038/sj.bjp.0703509; Alves DP, 2002, EUR J PHARMACOL, V444, P47, DOI 10.1016/S0014-2999(02)01412-7; Amir Mohammad, 2007, Acta Pharmaceutica (Zagreb), V57, P31, DOI 10.2478/v10007-007-0003-y; Andrade EL, 2008, NEUROSCIENCE, V152, P511, DOI 10.1016/j.neuroscience.2007.12.039; Aoganghua A, 2011, INT J MOL MED, V28, P937, DOI 10.3892/ijmm.2011.773; Baggio CH, 2012, INT J BIOL MACROMOL, V50, P872, DOI 10.1016/j.ijbiomac.2011.10.023; Barber LA, 1996, J NEUROCHEM, V67, P72; Barbosa FL, 2013, BASIC CLIN PHARM TOX; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chautems A, 2010, CANDOLLEA, V65, P241, DOI 10.15553/c2010v652a6; CODERRE TJ, 1984, PAIN, V18, P13, DOI 10.1016/0304-3959(84)90122-2; COELHO MM, 1992, AM J PHYSIOL, V263, pR423, DOI 10.1152/ajpregu.1992.263.2.R423; CUNHA FQ, 1992, BRIT J PHARMACOL, V107, P660, DOI 10.1111/j.1476-5381.1992.tb14503.x; Cunha TM, 2007, EUR J PHARMACOL, V573, P221, DOI 10.1016/j.ejphar.2007.07.007; Cunha TM, 2004, BRAZ J MED BIOL RES, V37, P401, DOI 10.1590/S0100-879X2004000300018; Cunha TM, 2005, P NATL ACAD SCI USA, V102, P1755, DOI 10.1073/pnas.0409225102; de Souza GEP, 2002, INFLAMM RES, V51, P24, DOI 10.1007/PL00000278; Decarie A, 1996, PEPTIDES, V17, P1009; Denadai-Souza A, 2009, EUR J PAIN, V13, P812, DOI 10.1016/j.ejpain.2008.09.012; DEYOUNG LM, 1989, AGENTS ACTIONS, V26, P335; Dina OA, 2005, PAIN, V115, P191, DOI 10.1016/j.pain.2005.02.028; DIXON WJ, 1980, ANNU REV PHARMACOL, V20, P441, DOI 10.1146/annurev.pa.20.040180.002301; DRAY A, 1988, NEUROSCI LETT, V91, P301, DOI 10.1016/0304-3940(88)90697-0; DUARTE IDG, 1988, BRAZ J MED BIOL RES, V21, P341; DUARTE IDG, 1992, EUR J PHARMACOL, V217, P225, DOI 10.1016/0014-2999(92)90881-4; Ferreira S H, 1993, Drugs, V46 Suppl 1, P1; FERREIRA SH, 1972, NATURE-NEW BIOL, V240, P200, DOI 10.1038/newbio240200a0; Ferreira SH, 1997, BRIT J PHARMACOL, V121, P883, DOI 10.1038/sj.bjp.0701211; Fine PG, 2009, PAIN MED, V10, pS79, DOI 10.1111/j.1526-4637.2009.00666.x; Gao Y, 2011, BRAIN RES BULL, V84, P406, DOI 10.1016/j.brainresbull.2011.01.017; GASIC GP, 1992, ANNU REV PHYSIOL, V54, P507, DOI 10.1146/annurev.physiol.54.1.507; GILLIGAN JP, 1994, INFLAMMATION, V18, P285, DOI 10.1007/BF01534269; Fusaro MCGD, 2010, EUR J PHARMACOL, V649, P177, DOI 10.1016/j.ejphar.2010.09.037; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HUNSKAAR S, 1987, PAIN, V30, P103, DOI 10.1016/0304-3959(87)90088-1; Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019; Kanashiro A, 2009, AM J PHYSIOL-REG I, V296, pR1631, DOI 10.1152/ajpregu.90527.2008; Khasar SG, 1998, EUR J NEUROSCI, V10, P435, DOI 10.1046/j.1460-9568.1998.00030.x; Kassuya CAL, 2009, J ETHNOPHARMACOL, V124, P369, DOI 10.1016/j.jep.2009.06.003; Levine JD, 2007, BBA-MOL BASIS DIS, V1772, P989, DOI 10.1016/j.bbadis.2007.01.008; LORENZETTI BB, 1985, EUR J PHARMACOL, V114, P375, DOI 10.1016/0014-2999(85)90383-8; Lu Y, 2011, BIOCHEM PHARMACOL, V82, P1700, DOI 10.1016/j.bcp.2011.08.022; Luo P, 2010, J PHARMACOL EXP THER, V335, P735, DOI 10.1124/jpet.110.170852; Mazzon E, 2008, CLIN EXP IMMUNOL, V153, P136, DOI 10.1111/j.1365-2249.2008.03669.x; MEMO M, 1986, J NEURAL TRANSM, P19; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; Moretao MP, 2004, IMMUNOL LETT, V93, P189, DOI 10.1016/j.imlet.2004.03.021; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Narumiya S, 2009, J MOL MED, V87, P1015, DOI 10.1007/s00109-009-0500-1; Otuki MF, 2005, J PHARMACOL EXP THER, V313, P310, DOI 10.1124/jpet.104.071779; PERRETTI M, 1994, PHARMACOL RES, V30, P53, DOI 10.1016/1043-6618(94)80087-1; Petho G, 2012, PHYSIOL REV, V92, P1699, DOI 10.1152/physrev.00048.2010; Quintao NLM, 2005, ANESTH ANALG, V101, P1763, DOI 10.1213/01.ane.0000184182.03203.61; Riva D, 2012, QUIM NOVA, V35, P974, DOI 10.1590/S0100-40422012000500020; Rudaya AY, 2005, AM J PHYSIOL-REG I, V289, pR1244, DOI 10.1152/ajpregu.00370.2005; Song SH, 2009, INT IMMUNOPHARMACOL, V9, P298, DOI 10.1016/j.intimp.2008.12.003; Southall MD, 2001, J BIOL CHEM, V276, P16083, DOI 10.1074/jbc.M011408200; Stefanello M.E.A., 2005, Rev. bras. farmacogn., V15, P331, DOI 10.1590/S0102-695X2005000400013; Swinny EE, 2000, MAGN RESON CHEM, V38, P1031, DOI 10.1002/1097-458X(200012)38:12<1031::AID-MRC780>3.0.CO;2-3; TADA H, 1986, J IMMUNOL METHODS, V93, P157, DOI 10.1016/0022-1759(86)90183-3; TAIWO YO, 1988, BRAIN RES, V458, P402, DOI 10.1016/0006-8993(88)90487-8; THOMAS G, 1980, PROSTAGLANDINS, V19, P39, DOI 10.1016/0090-6980(80)90152-5; Verdan MH, 2010, J NAT PROD, V73, P1434, DOI 10.1021/np1002466; Verdan MH, 2009, BIOCHEM SYST ECOL, V37, P40, DOI 10.1016/j.bse.2008.11.009; Verri WA, 2006, PHARMACOL THERAPEUT, V112, P116, DOI 10.1016/j.pharmthera.2006.04.001; Villarreal CF, 2013, PHARMACOL BIOCHEM BE, V103, P678, DOI 10.1016/j.pbb.2012.11.006; Villasenor IM, 2002, PHYTOTHER RES, V16, P417, DOI 10.1002/ptr.910; Vranken Jan H., 2009, Central Nervous System Agents in Medicinal Chemistry, V9, P71; WERNER U, 1992, AGENTS ACTIONS, pC101; Zakrzewska JM, 2010, EXPERT OPIN PHARMACO, V11, P1239, DOI 10.1517/14656561003767449	72	12	13	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 26	2015	10	2							e0117501	10.1371/journal.pone.0117501	http://dx.doi.org/10.1371/journal.pone.0117501			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC2ZH	25719394	Green Published, gold, Green Submitted			2023-01-03	WOS:000350213200026
J	Xu, QL; Liu, JX; Wang, ZL; Guo, XH; Zhou, GB; Liu, YA; Huang, QB; Su, L				Xu, Qiulin; Liu, Jingxian; Wang, Zhenglian; Guo, Xiaohua; Zhou, Gengbiao; Liu, Yanan; Huang, Qiaobing; Su, Lei			Heat Stress-Induced Disruption of Endothelial Barrier Function Is via PAR1 Signaling and Suppressed by Xuebijing Injection	PLOS ONE			English	Article							GLYCATION END-PRODUCTS; EZRIN/RADIXIN/MOESIN PROTEINS; MOESIN PHOSPHORYLATION; CELLS; PERMEABILITY; MICE; STROKE; INCREASES; INJURY	Increased vascular permeability leading to acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) is central to the pathogenesis of heatstroke. Protease-activated receptor 1 (PAR1), the receptor for thrombin, plays a key role in disruption of endothelial barrier function in response to extracellular stimuli. However, the role of PAR1 in heat stress-induced endothelial hyper-permeability is unknown. In this study, we measured PAR1 protein expression in heat-stressed human umbilical venous endothelial cells (HUVECs), investigated the influences of PAR1 on endothelial permeability, F-actin rearrangement, and moesin phosphorylation by inhibiting PAR1 with its siRNA, neutralizing antibody (anti-PAR1), specific inhibitor(RWJ56110), and Xuebijing injection (XBJ), a traditional Chinese medicine used for sepsis treatment, and evaluated the role of PAR1 in heatstroke- related ALI/ARDS in mice by suppressing PAR1 with RWJ56110, anti-PAR1and XBJ. We found that heat stress induced PAR1 protein expression 2h after heat stress in endothelial cells, caused the release of endothelial matrix metalloprotease 1, an activator of PAR1, after 60 or 120 min of heat stimulation, as well as promoted endothelial hyper-permeability and F-actin rearrangement, which were inhibited by suppressing PAR1 with RWJ56110, anti-PAR1 and siRNA. PAR1 mediated moesin phosphorylation, which caused F-actin rearrangement and disruption of endothelial barrier function. To corroborate findings from in vitro experiments, we found that RWJ56110 and the anti-PAR1 significantly decreased lung edema, pulmonary microvascular permeability, protein exudation, and leukocytes infiltrations in heatstroke mice. Additionally, XBJ was found to suppress PAR1-moesin signal pathway and confer protective effects on maintaining endothelial barrier function both in vitro and in vivo heat-stressed model, similar to those observed above with the inhibition of PAR1. These results suggest that PAR1 is a potential therapeutic target in heatstroke.	[Xu, Qiulin; Su, Lei] Guangzhou Mil Command, Gen Hosp, Dept ICU, Key Lab Trop Zone Trauma Care & Tissue Repair PLA, Guangzhou, Guangdong, Peoples R China; [Xu, Qiulin] Huabo Biopharmaceut Res Inst, Postdoctoral Workstn, Guangzhou, Guangdong, Peoples R China; [Liu, Jingxian; Liu, Yanan] Southern Med Univ, Guangzhou, Guangdong, Peoples R China; [Wang, Zhenglian; Zhou, Gengbiao] Guangzhou Univ Chinese Med, Guangzhou, Guangdong, Peoples R China; [Guo, Xiaohua; Huang, Qiaobing] Southern Med Univ, Dept Pathophysiol, Guangzhou, Guangdong, Peoples R China	Southern Theater Command General Hospital; Southern Medical University - China; Guangzhou University of Chinese Medicine; Southern Medical University - China	Huang, QB (corresponding author), Southern Med Univ, Dept Pathophysiol, Guangzhou, Guangdong, Peoples R China.	bing@smu.edu.cn; slei_icu@163.com			Natural Science Foundation of Guangdong Province, China [S2013040015661]; China Postdoctoral Science Foundation [2014M552180]; National Natural Science Foundation of China [31300950]; Project of Medical Research of People's Liberation Army [BWS12J108]	Natural Science Foundation of Guangdong Province, China(National Natural Science Foundation of Guangdong Province); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Project of Medical Research of People's Liberation Army	This work was supported by the PhD Start-up Fund of Natural Science Foundation of Guangdong Province, China (S2013040015661, http://pro.gdstc.gov.cn/egrantweb/), China Postdoctoral Science Foundation(2014M552180, http://jj.chinapostdoctor.org.cn/V1/Program1/Default.aspx), National Natural Science Foundation of China (31300950, http://www.nsfc.gov.cn/), and Project of Medical Research of People's Liberation Army (BWS12J108). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adyshev DM, 2013, AM J PHYSIOL-LUNG C, V305, P1240, DOI 10.1152/ajplung.00355.2012; Asehnoune K, 2013, CRIT CARE, V17, DOI 10.1186/cc12502; Austin KM, 2013, BLOOD, V121, P431, DOI 10.1182/blood-2012-09-355958; Broquet A, 2014, CRIT CARE MED, V42, pE441, DOI 10.1097/CCM.0000000000000311; Chen Y, 2013, J TRADIT CHIN MED, V33, P243, DOI 10.1016/S0254-6272(13)60133-8; Chui A., 2014, PLACENTA; Dematte JE, 1998, ANN INTERN MED, V129, P173, DOI 10.7326/0003-4819-129-3-199808010-00001; Guo XH, 2009, AM J PHYSIOL-HEART C, V297, pH238, DOI 10.1152/ajpheart.00196.2009; Helwig BG, 2011, PHYSIOL GENOMICS, V43, P1096, DOI 10.1152/physiolgenomics.00076.2011; Hirano Katsuya, 2003, J Atheroscler Thromb, V10, P211; Jeon S, 2010, NEUROCHEM INT, V56, P810, DOI 10.1016/j.neuint.2010.03.005; Ji J, 2014, EXP THER MED, V7, P1745, DOI 10.3892/etm.2014.1639; Juncker-Jensen A, 2013, CANCER RES, V73, P4196, DOI 10.1158/0008-5472.CAN-12-4495; Kim HS, 2010, J NEUROCHEM, V113, P1565, DOI 10.1111/j.1471-4159.2010.06713.x; Koss M, 2006, J IMMUNOL, V176, P1218, DOI 10.4049/jimmunol.176.2.1218; Li QQ, 2011, BRAIN RES, V1373, P1, DOI 10.1016/j.brainres.2010.12.032; Ng KY, 2004, J PHARM SCI-US, V93, P896, DOI 10.1002/jps.20015; Pirot N, 2014, AM J PHYSIOL-LUNG C, V306, pL775, DOI 10.1152/ajplung.00200.2013; SHARMA HS, 1990, ACT NEUR S, V51, P383; Tressel SL, 2011, EMBO MOL MED, V3, P370, DOI 10.1002/emmm.201100145; Varghese GM, 2005, EMERG MED J, V22, P185, DOI 10.1136/emj.2003.009365; Wang JP, 2012, CARDIOVASC DIABETOL, V11, DOI 10.1186/1475-2840-11-7; Wang LJ, 2012, ACTA DIABETOL, V49, P47, DOI 10.1007/s00592-011-0267-z; Wang LQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090472; WIJSMAN JA, 1993, ACTA NEUROPATHOL, V86, P49, DOI 10.1007/BF00454898; Zhang YL, 2013, J MOL MED, V91, P117, DOI 10.1007/s00109-012-0940-x	26	9	15	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 18	2015	10	2							e0118057	10.1371/journal.pone.0118057	http://dx.doi.org/10.1371/journal.pone.0118057			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC0WZ	25693178	Green Published, Green Submitted, gold			2023-01-03	WOS:000350061500092
J	Schneiderman, H				Schneiderman, Henry			Efficacy at the Bedside	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							TEAM		[Schneiderman, Henry] St Francis Hosp & Med Ctr, Sect Palliat Med, Hartford, CT 06105 USA; [Schneiderman, Henry] Univ Connecticut, Sch Med, Farmington, CT USA; [Schneiderman, Henry] Yale Univ, Sch Nursing, New Haven, CT 06536 USA	Saint Francis Hospital & Medical Center; University of Connecticut; Yale University	Schneiderman, H (corresponding author), St Francis Hosp & Med Ctr, Sect Palliat Med, Hartford, CT 06105 USA.	heschnei@stfranciscare.org						Butler K., 2014, KNOCKING ON HEAVENS, P269; Dentzer S., 2013, HEALTH AFFAIR, V32, P6; Elder A, 2013, JAMA-J AM MED ASSOC, V310, P799, DOI 10.1001/jama.2013.227195; Golden A, 2013, ANN INTERN MED, V159, P642, DOI 10.7326/0003-4819-159-9-201311050-00714; Grey Margaret, 2013, Conn Med, V77, P113; Reisman A, 2013, ANN INTERN MED, V159, P640, DOI 10.7326/0003-4819-159-9-201311050-00713; Resnick B, 2013, J AM GERIATR SOC, V61, P1019, DOI 10.1111/jgs.12272; Schneiderman H., 1994, CONSULTANT, V34, P1041; Schneiderman H., 2009, CONSULTANT, V49, P361; Schneiderman H., 2009, CONSULTANT, V49, P270; Verghese A, 2008, NEW ENGL J MED, V359, P2748, DOI 10.1056/NEJMp0807461	11	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	2015	313	6					569	570		10.1001/jama.2014.13720	http://dx.doi.org/10.1001/jama.2014.13720			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CA7AZ	25668258				2023-01-03	WOS:000349070700013
J	Sackley, CM; Walker, MF; Burton, CR; Watkins, CL; Mant, J; Roalfe, AK; Wheatley, K; Sheehan, B; Sharp, L; Stant, KE; Fletcher-Smith, J; Steel, K; Wilde, K; Irvine, L; Peryer, G				Sackley, Catherine M.; Walker, Marion F.; Burton, Christopher R.; Watkins, Caroline L.; Mant, Jonathan; Roalfe, Andrea K.; Wheatley, Keith; Sheehan, Bart; Sharp, Leslie; Stant, Katie E.; Fletcher-Smith, Joanna; Steel, Kerry; Wilde, Kate; Irvine, Lisa; Peryer, Guy		OTCH Trial Investigators	An occupational therapy intervention for residents with stroke related disabilities in UK care homes (OTCH): cluster randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FALLS; REHABILITATION; DEPRESSION; FACILITIES; RISK	OBJECTIVE To evaluate the clinical efficacy of an established programme of occupational therapy in maintaining functional activity and reducing further health risks from inactivity in care home residents living with stroke sequelae. DESIGN Pragmatic, parallel group, cluster randomised controlled trial. SETTING 228 care homes (> 10 beds each), both with and without the provision of nursing care, local to 11 trial administrative centres across the United Kingdom. PARTICIPANTS 1042 care home residents with a history of stroke or transient ischaemic attack, including those with language and cognitive impairments, not receiving end of life care. 114 homes (n = 568 residents, 64% from homes providing nursing care) were allocated to the intervention arm and 114 homes (n = 474 residents, 65% from homes providing nursing care) to standard care (control arm). Participating care homes were randomised between May 2010 and March 2012. INTERVENTION Targeted three month programme of occupational therapy, delivered by qualified occupational therapists and assistants, involving patient centred goal setting, education of care home staff, and adaptations to the environment. MAIN OUTCOME MEASURES Primary outcome at the participant level: scores on the Barthel index of activities of daily living at three months post-randomisation. Secondary outcome measures at the participant level: Barthel index scores at six and 12 months post-randomisation, and scores on the Rivermead mobility index, geriatric depression scale-15, and EuroQol EQ-5D-3L questionnaire, at all time points. RESULTS 64% of the participants were women and 93% were white, with a mean age of 82.9 years. Baseline characteristics were similar between groups for all measures, personal characteristics, and diagnostic tests. Overall, 2538 occupational therapy visits were made to 498 participants in the intervention arm (mean 5.1 visits per participant). No adverse events attributable to the intervention were recorded. 162 (11%) died before the primary outcome time point, and 313 (30%) died over the 12 months of the trial. The primary outcome measure did not differ significantly between the treatment arms. The adjusted mean difference in Barthel index score at three months was 0.19 points higher in the intervention arm (95% confidence interval -0.33 to 0.70, P = 0.48). Secondary outcome measures also showed no significant differences at all time points. CONCLUSIONS This large phase III study provided no evidence of benefit for the provision of a routine occupational therapy service, including staff training, for care home residents living with stroke related disabilities. The established three month individualised course of occupational therapy targeting stroke related disabilities did not have an impact on measures of functional activity, mobility, mood, or health related quality of life, at all observational time points. Providing and targeting ameliorative care in this clinically complex population strategies.	[Sackley, Catherine M.] Kings Coll London, Dept Physiotherapy, London WC2R 2LS, England; [Walker, Marion F.; Fletcher-Smith, Joanna] Univ Nottingham, Div Rehabil & Ageing, Fac Med & Hlth Sci, Nottingham NG7 2RD, England; [Burton, Christopher R.] Bangor Univ, Sch Healthcare Sci, Bangor, Gwynedd, Wales; [Watkins, Caroline L.] UCLan, Sch Hlth, Preston, Lancs, England; [Mant, Jonathan] Dept Publ Hlth & Primary Care, Primary Care Unit, Cambridge, England; [Roalfe, Andrea K.; Stant, Katie E.] Univ Birmingham, Birmingham, W Midlands, England; [Wheatley, Keith] Univ Birmingham, Canc Res UK Clin Trials Unit, Birmingham, W Midlands, England; [Sheehan, Bart] John Radcliffe Hosp, Directorate Acute Med & Rehabil, Oxford OX3 9DU, England; [Sharp, Leslie; Wilde, Kate; Irvine, Lisa; Peryer, Guy] Univ E Anglia, Fac Med & Hlth Sci, Norwich NR4 7TJ, Norfolk, England; [Steel, Kerry] Queen Elizabeth Hosp Birmingham, Birmingham, W Midlands, England	University of London; King's College London; University of Nottingham; Bangor University; University of Central Lancashire; University of Birmingham; Cancer Research UK; University of Birmingham; University of Oxford; University of East Anglia; University of Birmingham	Peryer, G (corresponding author), Univ E Anglia, Fac Med & Hlth Sci, Norwich Res Pk, Norwich NR4 7TJ, Norfolk, England.	g.peryer@uea.ac.uk	Irvine, Lisa/ABH-5953-2020	Burton, Christopher/0000-0003-1159-1494; Logan, Philippa/0000-0002-6657-2381; Peryer, Guy/0000-0003-0425-6911; Walker, Marion/0000-0002-3534-591X; Irvine, Lisa/0000-0003-1936-3584; sackley, catherine/0000-0002-8580-6622; Dawes, Helen/0000-0002-2933-5213	UK National Institute for Health Research [08/14/30]; National Institute for Health Research [NF-SI-0510-10024, 08/14/30, NF-SI-0508-10243, NF-SI-0512-10092] Funding Source: researchfish	UK National Institute for Health Research(National Institute for Health Research (NIHR)); National Institute for Health Research(National Institute for Health Research (NIHR))	The OTCH study was funded by the UK National Institute for Health Research Health Technology Assessment programme (08/14/30). The results will be published in full in Health Technology Assessment. All researchers acted independently to the funding body. The funding body had no role in designing the study, data collection, analysing and interpreting the data, or writing the report. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the funding body, the NHS, or the Department of Health. The research team acknowledge the support of the NIHR, through the Comprehensive Clinical Research Network, in particular, Jacqueline Briggs and Rhian Hughes. The corresponding author (GP) confirms full access to all the data in the study and had final responsibility for the decision to submit for publication.	Barodawala S, 2001, CLIN REHABIL, V15, P607, DOI 10.1191/0269215501cr454oa; Bray H, 2008, POPULATION TRENDS, V131, P8; Care Quality Commission, 2012, HLTH CAR CAR HOM SPE; Centre for Policy and Aging, 2012, PROF RES BUP CAR HOM; Collen F M, 1991, Int Disabil Stud, V13, P50; Collin C, 1988, Int Disabil Stud, V10, P61; Crocker T, 2013, AGE AGEING, V42, P682, DOI 10.1093/ageing/aft133; Damian J, 2013, BMC GERIATR, V13, DOI 10.1186/1471-2318-13-6; Department of Health, 2006, OPD NEW AMB OLD AG N; Dworzynski K, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f3615; Fletcher-Smith JC, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010116.pub2; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Folstein MF, 2001, MINI MENTAL STATE EX; Gage H, 2012, BMC GERIATR, V12, DOI 10.1186/1471-2318-12-71; Gompertz P., 1994, CLIN REHABIL, V8, P233, DOI [DOI 10.1177/026921559400800308, 10.1177/026921559400800308]; Hankey GJ, 2013, LANCET GLOB HEALTH, V1, pE239, DOI 10.1016/S2214-109X(13)70095-0; Harwood RH, 2004, AGE AGEING, V33, P529, DOI 10.1093/ageing/afh191; Hsieh YW, 2007, NEUROREHAB NEURAL RE, V21, P233, DOI 10.1177/1545968306294729; Kerse N, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1445; Legg L, 2007, BMJ-BRIT MED J, V335, P922, DOI 10.1136/bmj.39343.466863.55; Lievesley N, 2011, CHANGING ROLE CARE H; Macdonald A, 2007, AGE AGEING, V36, P16, DOI 10.1093/ageing/afl126; MAHONEY F I, 1965, Md State Med J, V14, P61; Masterson-Algar P, 2014, J EVAL CLIN PRACT, V20, P445, DOI 10.1111/jep.12174; National Institute for Health and Care Excellence, 2013, STROK REH LONG TERM; Paterson M, 2006, BRIT J OCCUPATIONAL, V69, P115, DOI DOI 10.1177/030802260606900304; Puffer S, 2003, BMJ-BRIT MED J, V327, P785, DOI 10.1136/bmj.327.7418.785; Rapp K, 2012, J AM MED DIR ASSOC, V13, DOI 10.1016/j.jamda.2011.06.011; Sackley C, 2009, BMJ-BRIT MED J, V339, P670; Sackley C, 2006, INT J THER REHABIL, V13, P370, DOI 10.12968/ijtr.2006.13.8.370; Sackley CM, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-52; Sackley C, 2006, STROKE, V37, P2336, DOI 10.1161/01.STR.0000237124.20596.92; Sackley C, 2008, STROKE, V39, P3329, DOI 10.1161/STROKEAHA.108.518563; Sackley CM, 2008, CLIN REHABIL, V22, P714, DOI 10.1177/0269215508089058; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165; Syder D, 1993, SHEFFIELD SCREENING; Underwood M, 2013, LANCET, V382, P41, DOI 10.1016/S0140-6736(13)60649-2; van den Berg Maayken, 2006, Nurs Times, V102, P32; van Wijk I, 2006, J NEUROL NEUROSUR PS, V77, P1238, DOI 10.1136/jnnp.2006.089391; Walker MF, 2004, STROKE, V35, P2226, DOI 10.1161/01.STR.0000137766.17092.fb; Whitney J, 2012, J AM MED DIR ASSOC, V13, P535, DOI 10.1016/j.jamda.2012.03.009; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; World Health Organization, 2001, INT CLASS FUNCT DIS	43	26	26	3	37	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 5	2015	350								h468	10.1136/bmj.h468	http://dx.doi.org/10.1136/bmj.h468			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CB0JX	25657106	hybrid, Green Published, Green Accepted			2023-01-03	WOS:000349313100005
J	Boakye, MK; Pietersen, DW; Kotze, A; Dalton, DL; Jansen, R				Boakye, Maxwell Kwame; Pietersen, Darren William; Kotze, Antoinette; Dalton, Desire-Lee; Jansen, Raymond			Knowledge and Uses of African Pangolins as a Source of Traditional Medicine in Ghana	PLOS ONE			English	Article							PLANTS; CONSENSUS; REMEDIES; HEALERS; STATE	Traditional medicine has been practised in Ghana for centuries with the majority of Ghanaians still patronising the services of traditional healers. Throughout Africa a large number of people use pangolins as a source of traditional medicine, however, there is a dearth of information on the use of animals in folk medicine in Ghana, in particular the use of pangolins. The aim of this study was to determine the prevalent use of pangolins and the level of knowledge of pangolin use among traditional healers in Ghana for the treatment of human ailments. Data was gathered from 48 traditional healers using semi-structured interviews on the traditional medicinal use of pangolin body parts in the Kumasi metropolis of Ghana. The cultural importance index, relative frequency of citation, informant agreement ratio and use agreement values were calculated to ascertain the most culturally important pangolin body part as well as the level of knowledge dissemination among traditional healers with regards pangolin body parts. Our study revealed that 13 body parts of pangolins are used to treat various medicinal ailments. Pangolin scales and bones were the most prevalent prescribed body parts and indicated the highest cultural significance among traditional healing practices primarily for the treatment of spiritual protection, rheumatism, financial rituals and convulsions. Despite being classified under Schedule 1 of Ghana's Wildlife Conservation Act of 1971 (LI 685), that prohibits anyone from hunting or being in possession of a pangolin, our results indicated that the use of pangolins for traditional medicinal purposes is widespread among traditional healers in Ghana. A study on the population status and ecology of the three species of African pangolins occurring in Ghana is urgently required in order to determine the impact this harvest for traditional medical purposes has on their respective populations as current levels appear to be unmonitored and unsustainable.	[Boakye, Maxwell Kwame; Jansen, Raymond] Tshwane Univ Technol, Dept Environm Water & Earth Sci, Pretoria, South Africa; [Kotze, Antoinette; Dalton, Desire-Lee] Natl Zool Gardens South Africa, Pretoria, South Africa; [Kotze, Antoinette] Univ Free State, Dept Genet, Bloemfontein, South Africa; [Pietersen, Darren William; Kotze, Antoinette; Jansen, Raymond] African Pangolin Working Grp, Pretoria, South Africa	Tshwane University of Technology; National Research Foundation - South Africa; National Zoological Gardens of South Africa; University of the Free State	Boakye, MK (corresponding author), Tshwane Univ Technol, Dept Environm Water & Earth Sci, Pretoria, South Africa.	maxwell_boakye@yahoo.com	Boakye, Maxwell Kwame/Q-9301-2019	Boakye, Maxwell Kwame/0000-0002-5796-4121; Jansen, Raymond/0000-0003-4741-3307; Dalton, Desire Lee/0000-0001-5975-6425	Tshwane University of Technology; National Zoological Gardens of South Africa; Rufford Foundation [13600-1]	Tshwane University of Technology; National Zoological Gardens of South Africa(National Research Foundation - South Africa); Rufford Foundation	The authors are grateful to the Tshwane University of Technology (www.tut.ac.za), National Zoological Gardens of South Africa (www.nzg.ac.za) and the Rufford Foundation (www.rufford.org) (RSG reference: 13600-1) for funding this project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abel C, 2005, ALTERN MED REV, V10, P112; Akpona HA, 2008, MAMMALIA, V72, P198, DOI 10.1515/MAMM.2008.046; Almeida CDCBR, 2006, J ETHNOBIOL ETHNOMED, V2, DOI 10.1186/1746-4269-2-15; Alves RRN, 2007, BIOSCIENCE, V57, P949, DOI 10.1641/B571107; Alves RRN, 2006, J ETHNOPHARMACOL, V107, P259, DOI 10.1016/j.jep.2006.03.007; Alves RRN, 2008, J ETHNOBIOL ETHNOMED, V4, DOI 10.1186/1746-4269-4-3; Alves RRN, 2008, BMC COMPLEM ALTERN M, V8, DOI 10.1186/1472-6882-8-44; Alves RRN, 2005, J ETHNOBIOL ETHNOMED, V1, DOI [10.1186/1746-4269-1-10, 10.1186/1746-4269-1-5]; Asante E., 2013, J SOCIOL RES, V4, P256, DOI DOI 10.5296/JSR.V4I2.4224; Ayodele, 2012, GLOBAL J MED RES, V12, P6; Babbie E., 2010, PRACTICE SOCIAL RES, V10th; Boakye MK, 2014, J ETHNOBIOL ETHNOMED, V10, DOI 10.1186/1746-4269-10-76; Brautigam Amie, 1994, Traffic Bulletin, V15, P15; Chakkaravarthy QA, 2012, P 3 SEM SMALL MAMM I, P50; Challender D, 2014, ASIAN GEOGRAPHIC, V103, P86; CHALLENDER D. W. S., 2012, TRAFFIC B, V24, P53; Challender DWS, 2014, SCALING PANGOLIN CON; Costa-Neto EM, 2004, SUSTAIN DEV, V12, P161, DOI 10.1002/sd.234; de Graft Aikins A, 2012, Ghana Med J, V46, P59; Department for International Development (DFID), 2011, MAL COUNTR PROF VERS; Dove N, 2010, J BLACK STUD, V40, P823, DOI 10.1177/0021934708320001; Gaski AL, 1994, PRESCRIPTION EXTINCT; Gaudin TJ, 2009, J MAMM EVOL, V16, P235, DOI 10.1007/s10914-009-9119-9; Ghana Districts, 2006, REP ALL DISTR REP GH; Ghana Health Service, 2010, ANN REPORT; Ghana Statistical Service, 2012, POP REG DISTR AG GRO; Heinrich M, 1998, SOC SCI MED, V47, P1859, DOI 10.1016/S0277-9536(98)00181-6; Heinrich M, 2009, J ETHNOPHARMACOL, V124, P1, DOI 10.1016/j.jep.2009.03.043; Insoll Timothy, 2011, Anthropol Med, V18, P181, DOI 10.1080/13648470.2011.591196; Kang S, 2003, QUESTION ATTITUDE S; Kaspal P, 2012, P 3 SEM SMALL MAMM I, P37; Kumasi Metropolitan Assembly, 2006, THIS METR; Marshall NT, 1998, SEARCHING CURE CONSE; Ministry of Health, 2005, POL GUID TRAD MED DE; Moerman DE, 2007, J ETHNOPHARMACOL, V112, P451, DOI 10.1016/j.jep.2007.04.001; Ntiamoa-Baidu Y., 1997, WILDLIFE FOOD SECURI; Omolewa M, 2007, INT REV EDUC, V53, P593, DOI 10.1007/s11159-007-9060-1; Pietersen DW, 2014, S AFR J WILDL RES, V44, P167, DOI 10.3957/056.044.0209; President's Malaria Initiative, 2012, MAL OP PLAN FY2012 Y; Gazzaneo LRS, 2005, J ETHNOBIOL ETHNOMED, V1, DOI 10.1186/1746-4269-1-9; Sato A, 2012, THESIS LONDON SCH EC; Sodeinde O.A., 1999, Traffic Bulletin, V18, P35; Sodeinde Olufemi A., 1994, Oryx, V28, P43; Soewu DA, 2011, J ETHNOBIOL ETHNOMED, V7, DOI 10.1186/1746-4269-7-25; Soewu DA, 2009, J ETHNOBIOL ETHNOMED, V5, DOI 10.1186/1746-4269-5-39; Tabi MM, 2006, INT NURS REV, V53, P52, DOI 10.1111/j.1466-7657.2006.00444.x; Tabong PTN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054429; Tardio J, 2008, ECON BOT, V62, P24, DOI 10.1007/s12231-007-9004-5; Thomas E, 2009, J ETHNOPHARMACOL, V122, P60, DOI 10.1016/j.jep.2008.11.021; Trotter RT., 1986, PLANTS INDIGENOUS ME, P91, DOI [10.4324/9781315060385-6, DOI 10.4324/9781315060385-6]; Twumasi PA, 1979, J OPINION, V9, P29, DOI [10.2307/1166260, DOI 10.2307/1166260]; WHO, 2002, WHO TRADITIONAL MED	52	44	48	2	55	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 20	2015	10	1							e0117199	10.1371/journal.pone.0117199	http://dx.doi.org/10.1371/journal.pone.0117199			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AZ4OZ	25602281	Green Submitted, gold, Green Published			2023-01-03	WOS:000348203500045
J	Lewis, JD; Wilton, M; Mott, GA; Lu, WW; Hassan, JA; Guttman, DS; Desveaux, D				Lewis, Jennifer D.; Wilton, Mike; Mott, G. Adam; Lu, Wenwan; Hassan, Jana A.; Guttman, David S.; Desveaux, Darrell			Immunomodulation by the Pseudomonas syringae HopZ Type III Effector Family in Arabidopsis	PLOS ONE			English	Article							DISEASE RESISTANCE GENE; YOPJ SUPERFAMILY; ACETYLATION; PATTERN; PROTEIN; SPECIFICITY; PERCEPTION; ACTIVATION; SECRETION; FLAGELLIN	Pseudomonas syringae employs a type III secretion system to inject 20-30 different type III effector (T3SE) proteins into plant host cells. A major role of T3SEs is to suppress plant immune responses and promote bacterial infection. The YopJ/HopZ acetyltransferases are a superfamily of T3SEs found in both plant and animal pathogenic bacteria. In P. syringae, this superfamily includes the evolutionarily diverse HopZ1, HopZ2 and HopZ3 alleles. To investigate the roles of the HopZ family in immunomodulation, we generated dexamethasone-inducible T3SE transgenic lines of Arabidopsis for HopZ family members and characterized them for immune suppression phenotypes. We show that all of the HopZ family members can actively suppress various facets of Arabidopsis immunity in a catalytic residuedependent manner. HopZ family members can differentially suppress the activation of mitogen-activated protein (MAP) kinase cascades or the production of reactive oxygen species, whereas all members can promote the growth of non-virulent P. syringae. Localization studies show that four of the HopZ family members containing predicted myristoylation sites are localized to the vicinity of the plasma membrane while HopZ3 which lacks the myristoylation site is at least partially nuclear localized, suggesting diversification of immunosuppressive mechanisms. Overall, we demonstrate that despite significant evolutionary diversification, all HopZ family members can suppress immunity in Arabidopsis.	[Lewis, Jennifer D.; Wilton, Mike; Mott, G. Adam; Lu, Wenwan; Guttman, David S.; Desveaux, Darrell] Univ Toronto, Dept Cell & Syst Biol, Toronto, ON, Canada; [Lewis, Jennifer D.] USDA, Ctr Plant Gene Express, Albany, CA USA; [Lewis, Jennifer D.; Hassan, Jana A.] Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; [Guttman, David S.; Desveaux, Darrell] Univ Toronto, Ctr Anal Genome Evolut & Funct, Toronto, ON, Canada	University of Toronto; United States Department of Agriculture (USDA); University of California System; University of California Berkeley; University of Toronto	Lewis, JD (corresponding author), Univ Toronto, Dept Cell & Syst Biol, Toronto, ON, Canada.	jdlewis@berkeley.edu	Guttman, David S/A-7839-2011	Guttman, David S/0000-0001-8479-3869; Mott, Adam/0000-0001-9803-103X	Natural Sciences and Engineering Research Council of Canada; Canada Research Chair in Plant-Microbe Systems Biology or Comparative Genomics; Centre for the Analysis of Genome Evolution and Function; United States Department of Agriculture Agricultural Research Service [5335-21000- 040-00D]	Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Canada Research Chair in Plant-Microbe Systems Biology or Comparative Genomics; Centre for the Analysis of Genome Evolution and Function; United States Department of Agriculture Agricultural Research Service(United States Department of Agriculture (USDA)USDA Agricultural Research Service)	This work was supported by Natural Sciences and Engineering Research Council of Canada awards to DSG and DD; a Canada Research Chair in Plant-Microbe Systems Biology (DD) or Comparative Genomics (DSG); the Centre for the Analysis of Genome Evolution and Function (DD and DSG); United States Department of Agriculture Agricultural Research Service 5335-21000- 040-00D (JDL). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Asai T, 2002, NATURE, V415, P977, DOI 10.1038/415977a; BISGROVE SR, 1994, PLANT CELL, V6, P927, DOI 10.1105/tpc.6.7.927; Boller T, 2009, ANNU REV PLANT BIOL, V60, P379, DOI 10.1146/annurev.arplant.57.032905.105346; Deslandes L, 2012, TRENDS PLANT SCI, V17, P644, DOI 10.1016/j.tplants.2012.06.011; Elowitz M, 2010, NATURE, V468, P889, DOI 10.1038/468889a; Felix G, 1999, PLANT J, V18, P265, DOI 10.1046/j.1365-313X.1999.00265.x; Feng F, 2012, CURR OPIN PLANT BIOL, V15, P469, DOI 10.1016/j.pbi.2012.03.004; Gomez-Gomez L, 1999, PLANT J, V18, P277, DOI 10.1046/j.1365-313X.1999.00451.x; Guo M, 2009, MOL PLANT MICROBE IN, V22, P1069, DOI 10.1094/MPMI-22-9-1069; INNES RW, 1993, PLANT J, V4, P813, DOI 10.1046/j.1365-313X.1993.04050813.x; Jiang SS, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003715; Jones JDG, 2006, NATURE, V444, P323, DOI 10.1038/nature05286; Katagiri Fumiaki, 2002, Arabidopsis Book, V1, pe0039, DOI 10.1199/tab.0039; Lee AHY, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002523; Lee J, 2012, PLANT PHYSIOL, V158, P1803, DOI 10.1104/pp.111.190686; Lewis JD, 2008, J BACTERIOL, V190, P2880, DOI 10.1128/JB.01702-07; Lewis JD, 2014, PLANT SIGNAL BEHAV, V9, DOI 10.4161/psb.27563; Lewis JD, 2013, P NATL ACAD SCI USA, V110, P18722, DOI 10.1073/pnas.1315520110; Lewis JD, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-8; Lewis JD, 2011, MOL PLANT PATHOL, V12, P928, DOI [10.1111/J.1364-3703.2011.00719.X, 10.1111/j.1364-3703.2011.00719.x]; Lewis JD, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000894; Lewis JD, 2009, SEMIN CELL DEV BIOL, V20, P1055, DOI 10.1016/j.semcdb.2009.06.003; Lindeberg M, 2012, TRENDS MICROBIOL, V20, P199, DOI 10.1016/j.tim.2012.01.003; Ma WB, 2006, PLOS GENET, V2, P2131, DOI 10.1371/journal.pgen.0020209; Macho AP, 2014, SCIENCE, V343, P1509, DOI 10.1126/science.1248849; Macho AP, 2010, NEW PHYTOL, V187, P1018, DOI 10.1111/j.1469-8137.2010.03381.x; Mittal R, 2006, P NATL ACAD SCI USA, V103, P18574, DOI 10.1073/pnas.0608995103; Mudgett MB, 1999, MOL MICROBIOL, V32, P927, DOI 10.1046/j.1365-2958.1999.01403.x; Mukherjee S, 2007, TRENDS BIOCHEM SCI, V32, P210, DOI 10.1016/j.tibs.2007.03.007; Mukherjee S, 2006, SCIENCE, V312, P1211, DOI 10.1126/science.1126867; Paquette N, 2012, P NATL ACAD SCI USA, V109, P12710, DOI 10.1073/pnas.1008203109; Pitzschke A, 2009, CURR OPIN PLANT BIOL, V12, P421, DOI 10.1016/j.pbi.2009.06.008; Roine E, 1997, P NATL ACAD SCI USA, V94, P3459, DOI 10.1073/pnas.94.7.3459; SIMONICH MT, 1995, MOL PLANT MICROBE IN, V8, P637, DOI 10.1094/MPMI-8-0637; Thomma BPHJ, 2011, PLANT CELL, V23, P4, DOI 10.1105/tpc.110.082602; Ustun S, 2014, MOL PLANT MICROBE IN, V27, P611, DOI 10.1094/MPMI-12-13-0363-R; Vinatzer BA, 2006, MOL MICROBIOL, V62, P26, DOI 10.1111/j.1365-2958.2006.05350.x; Wilton M, 2010, PLANT SIGNAL BEHAV, V5, P746, DOI 10.1073/pnas.0904739107; Wilton M, 2010, P NATL ACAD SCI USA, V107, P2349, DOI 10.1073/pnas.0904739107; Zhou HB, 2011, CELL HOST MICROBE, V9, P177, DOI 10.1016/j.chom.2011.02.007; Zhou HB, 2009, MOL PLANT MICROBE IN, V22, P176, DOI 10.1094/MPMI-22-2-0176; Zipfel C, 2004, NATURE, V428, P764, DOI 10.1038/nature02485	42	27	28	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 29	2014	9	12							e0116152	10.1371/journal.pone.0116152	http://dx.doi.org/10.1371/journal.pone.0116152			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX7UN	25546415	Green Published, gold			2023-01-03	WOS:000347120200102
J	Dorj, G; Sunderland, B; Hendrie, D; Parsons, R				Dorj, Gereltuya; Sunderland, Bruce; Hendrie, Delia; Parsons, Richard			Parenteral Medication Prescriptions, Dispensing and Administration Habits in Mongolia	PLOS ONE			English	Article							HEPATITIS-C VIRUS; INJECTION PRACTICES; UNSAFE INJECTIONS; RAPID ASSESSMENT; CARE; INFECTION; COMMUNITY; TRANSMISSION; POPULATION; SETTINGS	High levels of injection prescribing were reported in Mongolia. Understanding the factors influencing the injection prescribing is essential to reduce their inappropriate use. The study evaluated the views, experiences and attitudes of community members associated with the prescribing of injections in Mongolia. A structured questionnaire focusing on respondents' characteristics, experiences and views about injections was developed and administered face-to-face to community members in Ulaanbaatar, Mongolia. Standard descriptive statistics were used to summarize demographic data and responses to the questionnaires. Dependant variables were compared using Kruskal-Wallis Tests for independence. Statistical analyses were performed using SPSS Version 21.0. Six hundred participants were approached and the response rate was 79% (n=474). Almost half of the respondents were aged between 31 and 50 (n=228, 48.1%) and 40.9% of respondents were male (n=194). Most respondents were from Ulaanbaatar city (n=407, 85.7%). All respondents had received injections in the past and 268 (56.5%) had received injection in the past year. The most common reason for having an injection in the past year was reported as treatment of a disease (n=163, 60.8%), or for administration of vitamins (n=70, 26.1%). Injections were prescribed by a doctor (n=353, 74.9%), dispensed by a pharmacist (n=283, 59.7%) and administered by a nurse (n=277, 54.9%). Only 16% of all respondents had the expectation of receiving injections when they visited a doctor (n=77). An important perception regarding injections was that they hastened the recovery process (n=269, 56.8%). When asked their opinion about therapeutic injections, 40% of all respondents agreed that injections were a better medicine (n=190) than oral medications, with older respondents strongly agreeing (p<0.001). Based on this total sample, approximately 1891 injections per 1000 patients were administered.The excessive injection use seems to be promoted by inappropriate prescribing, dispensing and administration of medication by doctors and others.	[Dorj, Gereltuya; Sunderland, Bruce; Parsons, Richard] Curtin Univ, Sch Pharm, Perth, WA 6845, Australia; [Hendrie, Delia] Curtin Univ, Sch Publ Hlth, Perth, WA 6845, Australia	Curtin University; Curtin University	Dorj, G (corresponding author), Curtin Univ, Sch Pharm, Perth, WA 6845, Australia.	gereltuya.dorj@postgrad.curtin.edu.au	Dorj, Gereltuya/K-4714-2019; Dorj, Gereltuya/AAE-6796-2019; Dorj, Gereltuya/AAH-6080-2020	Dorj, Gereltuya/0000-0001-9489-6829; Hendrie, Delia/0000-0001-5022-5281				Altaf A, 2001, PILOT TESTING WHO TO, P42; Altaf Arshad, 2004, J Ayub Med Coll Abbottabad, V16, P35; Ariuntuya S, 2011, HLTH INDICATORS MONG; Berild D, 2002, INT J ANTIMICROB AG, V20, P333, DOI 10.1016/S0924-8579(02)00203-0; Bolormaa TS, 2007, MONG HLTH SYST REV H; Cheraghali A. M., 2006, Journal of Pharmacology and Toxicology, V1, P33; Chowdhury A, 2003, HEPATOLOGY, V37, P802, DOI 10.1053/jhep.2003.50157; Chowdhury AKA, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-779; Cobey M, 2011, KNOWLEDGE ATTITUDES; Dashdelger A, 1998, WHO COLLABORAT UNPUB; Davaasuren D, 2006, REPORT ASSESSMENT IN, P20; Dorj G, 2014, EVALUATION PRESCRIBI, P318; DUA V, 1994, SOC SCI MED, V38, P717, DOI 10.1016/0277-9536(94)90462-6; Frank C, 2000, LANCET, V355, P887, DOI 10.1016/S0140-6736(99)06527-7; Gumodoka B, 1996, TROP MED INT HEALTH, V1, P874; Hadiyono JEP, 1996, SOC SCI MED, V42, P1177, DOI 10.1016/0277-9536(95)00391-6; HARKNESS JA, 1998, ZUMA NACHRICHTEN SPE, V0003; Hauri AM, 2004, INT J STD AIDS, V15, P7, DOI 10.1258/095646204322637182; Hutin YJF, 2003, BMJ-BRIT MED J, V327, P1075, DOI 10.1136/bmj.327.7423.1075; Hutin YVF, 2001, PILOT TESTING WHO TO, P10; Janjua NZ, 2005, INT J QUAL HEALTH C, V17, P401, DOI 10.1093/intqhc/mzi048; Jiang Q, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-324; Kermode M, 2004, HEALTH PROMOT INT, V19, P95, DOI 10.1093/heapro/dah110; Khan AJ, 2000, B WORLD HEALTH ORGAN, V78, P956; Lakshman M, 2000, SOC SCI MED, V51, P11, DOI 10.1016/S0277-9536(99)00426-8; Langsten RL, 2005, J HEALTH POPUL NUTR, V23, P282; Logez S, 2004, AM J INFECT CONTROL, V32, P31, DOI 10.1016/j.ajic.2003.06.006; Marx MA, 2003, AM J TROP MED HYG, V68, P258, DOI 10.4269/ajtmh.2003.68.258; Ministry of Health Mongolia, 2009, 6 ESS DRUG LIST MONG; Ministry of Health Mongolia, 2010, GUID AMB CAR; Raglow GJ, 2001, TROP MED INT HEALTH, V6, P69, DOI 10.1046/j.1365-3156.2001.00653.x; Rajasekaran M, 2003, PUBLIC HEALTH, V117, P208, DOI 10.1016/S0033-3506(03)00065-9; Reeler AV, 2000, B WORLD HEALTH ORGAN, V78, P135; REELER AV, 1990, SOC SCI MED, V31, P1119, DOI 10.1016/0277-9536(90)90233-I; Simonsen L, 1999, B WORLD HEALTH ORGAN, V77, P789; Singh S, 2000, SCAND J INFECT DIS, V32, P3, DOI 10.1080/00365540050164137; SURVIVAL II C. H. I. L. D., 2002, INJ PRACT RAP ASS RE; Talaat M, 2003, TROP MED INT HEALTH, V8, P234, DOI 10.1046/j.1365-3156.2003.01015.x; van Staa A, 1996, DAP RES SERIES, P127; Vong S, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-56; World Health Organization and The SIGN alliance, 2001, INJ SAF; Xia GL, 1996, INT HEPATOL COMMUN, V5, P62, DOI 10.1016/S0928-4346(96)82012-3	42	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 22	2014	9	12							e115384	10.1371/journal.pone.0115384	http://dx.doi.org/10.1371/journal.pone.0115384			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CA3ZY	25531766	gold, Green Published, Green Submitted, Green Accepted			2023-01-03	WOS:000348845100062
J	Cho, I; Park, H; Choi, YJ; Hwang, MH; Bates, DW				Cho, Insook; Park, Hyeok; Choi, Youn Jeong; Hwang, Mi Heui; Bates, David W.			Understanding the Nature of Medication Errors in an ICU with a Computerized Physician Order Entry System	PLOS ONE			English	Article							INTENSIVE-CARE-UNIT; ADVERSE DRUG EVENTS; ADMINISTRATION ERRORS; FACILITIES; SAFETY; IMPACT; RECORD	Objectives: We investigated incidence rates to understand the nature of medication errors potentially introduced by utilizing a computerized physician order entry (CPOE) system in the three clinical phases of the medication process: prescription, administration, and documentation. Methods: Overt observations and chart reviews were employed at two surgical intensive care units of a 950-bed tertiary teaching hospital. Ten categories of high-risk drugs prescribed over a four-month period were noted and reviewed. Error definition and classifications were adapted from previous studies for use in the present research. Incidences of medication errors in the three phases of the medication process were analyzed. In addition, nurses' responses to prescription errors were also assessed. Results: Of the 534 prescriptions issued, 286 (53.6%) included at least one error. The proportion of errors was 19.0% (58) of the 306 drug administrations, of which two-thirds were verbal orders classified as errors due to incorrectly entered prescriptions. Documentation errors occurred in 205 (82.7%) of 248 correctly performed administrations. When tracking incorrectly entered prescriptions, 93% of the errors were intercepted by nurses, but two-thirds of them were recorded as prescribed rather than administered. Conclusion: The number of errors occurring at each phase of the medication process was relatively high, despite long experience with a CPOE system. The main causes of administration errors and documentation errors were prescription errors and verbal order processes. To reduce these errors, hospital-level and unit-level efforts toward a better system are needed.	[Cho, Insook; Choi, Youn Jeong; Hwang, Mi Heui] Inha Univ, Dept Nursing, Inchon, South Korea; [Cho, Insook; Bates, David W.] Harvard Univ, Sch Med, Boston, MA USA; [Cho, Insook; Bates, David W.] Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA; [Park, Hyeok; Choi, Youn Jeong; Hwang, Mi Heui] Inha Univ Hosp, Dept Nursing, Inchon, South Korea; [Bates, David W.] Partners Healthcare Syst Inc, Wellesley, MA USA	Inha University; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Inha University; Inha University Hospital; Partners Healthcare System	Cho, I (corresponding author), Inha Univ, Dept Nursing, Inchon, South Korea.	Insook.cho@inha.ac.kr	Bates, David/AAE-7283-2019	Cho, Insook/0000-0002-5152-9567	Korea Research Foundation Grant - Korean Government (MOEHRD) [331-2007-1-E00273, KRF-2013R1A1A2006387]; Centers for Education and Research on Therapeutics (CERT) [U19HS021094]; Agency for Healthcare Research and Quality, Rockville, MD, USA; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U19HS021094] Funding Source: NIH RePORTER	Korea Research Foundation Grant - Korean Government (MOEHRD)(Ministry of Education & Human Resources Development (MOEHRD), Republic of KoreaNational Research Foundation of KoreaKorean Government); Centers for Education and Research on Therapeutics (CERT); Agency for Healthcare Research and Quality, Rockville, MD, USA(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	This study was supported by the Korea Research Foundation Grant funded by the Korean Government (MOEHRD, 331-2007-1-E00273). D.W.B was sponsored by the Centers for Education and Research on Therapeutics (CERT Grant # U19HS021094), Agency for Healthcare Research and Quality, Rockville, MD, USA. I.C. was also supported by a Korea Research Foundation Grant, which was funded by the Korean Government (MOEHRD, No. KRF-2013R1A1A2006387). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali J, 2010, ANAESTHESIA, V65, P119, DOI 10.1111/j.1365-2044.2009.06134.x; Aspden P., 2006, I MED, P26; Barker KN, 2002, ARCH INTERN MED, V162, P1897, DOI 10.1001/archinte.162.16.1897; Bradley Victoria M, 2006, J Healthc Inf Manag, V20, P46; Calabrese AD, 2001, INTENS CARE MED, V27, P1592, DOI 10.1007/s001340101065; Cho I, 2009, STUD HEALTH TECHNOL, V146, P445, DOI 10.3233/978-1-60750-024-7-445; Colpaert K, 2006, CRIT CARE, V10, DOI 10.1186/cc3983; DeYoung JL, 2009, AM J HEALTH-SYST PH, V66, P1110, DOI 10.2146/ajhp080355; Flynn EA, 2002, AM J HEALTH-SYST PH, V59, P436, DOI 10.1093/ajhp/59.5.436; Heo JH, 2013, INT J MED INFORM, V82, P987, DOI 10.1016/j.ijmedinf.2013.07.001; Institute for Safe Medication Practices, 2008, I SAF MED PRACT HIGH; Koppel R, 2005, JAMA-J AM MED ASSOC, V293, P1197, DOI 10.1001/jama.293.10.1197; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; Lee KO, 2000, J KOREAN ACAD NURS, V30, P1243; Magrabi F, 2010, J AM MED INFORM ASSN, V17, P575, DOI 10.1136/jamia.2009.001719; Metzger J, 2010, HEALTH AFFAIR, V29, P655, DOI 10.1377/hlthaff.2010.0160; Middleton B, 2013, J AM MED INFORM ASSN, V20, pE2, DOI 10.1136/amiajnl-2012-001458; Moreland PJ, 2012, CIN-COMPUT INFORM NU, V30, P97, DOI 10.1097/NCN.0b013e318224b54e; Nanji KC, 2011, J AM MED INFORM ASSN, V18, P767, DOI 10.1136/amiajnl-2011-000205; Page A., 2004, KEEPING PATIENTS SAF; Tissot E, 1999, INTENS CARE MED, V25, P353, DOI 10.1007/s001340050857; van den Bemt PMLA, 2002, CRIT CARE MED, V30, P846, DOI 10.1097/00003246-200204000-00022; Walsh KE, 2006, PEDIATRICS, V118, P1872, DOI 10.1542/peds.2006-0810; Warrick C, 2011, INTENS CARE MED, V37, P691, DOI 10.1007/s00134-010-2126-8; Wilmer A, 2010, QUAL SAF HEALTH CARE, V19, DOI 10.1136/qshc.2008.030783	25	9	9	0	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 19	2014	9	12							e114243	10.1371/journal.pone.0114243	http://dx.doi.org/10.1371/journal.pone.0114243			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AX8WK	25526059	Green Published, Green Submitted, gold			2023-01-03	WOS:000347186200001
J	Schulman, KA				Schulman, Kevin A.			Review: In adult outpatients, nurse-managed protocols improve hemoglobin A(1c) levels and blood pressure Commentary	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Duke Univ, Duke Clin Res Inst, Durham, NC 27708 USA	Duke University	Schulman, KA (corresponding author), Duke Univ, Duke Clin Res Inst, Durham, NC 27708 USA.							Vaughn BT, 2010, HEALTH AFFAIR, V29, P933, DOI 10.1377/hlthaff.2009.0675	1	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 16	2014	161	12							JC6	10.7326/0003-4819-161-12-201412160-02006	http://dx.doi.org/10.7326/0003-4819-161-12-201412160-02006			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AX9UW	25506878				2023-01-03	WOS:000347248400012
J	Jiang, G; Li, RH; Sun, C; Liu, YQ; Zheng, JN				Jiang, Guan; Li, Rong-Hua; Sun, Chao; Liu, Yan-Qun; Zheng, Jun-Nian			Dacarbazine Combined Targeted Therapy versus Dacarbazine Alone in Patients with Malignant Melanoma: A Meta-Analysis	PLOS ONE			English	Article							METASTATIC MELANOMA; DOUBLE-BLIND; PHASE-II; PLUS DACARBAZINE; CANCER STATISTICS; TEMOZOLOMIDE; TRIAL	Background: Malignant melanoma is the most aggressive and deadly form of skin cancer. Dacarbazine (DTIC) has been the approved first-line treatment for metastatic melanoma in routine clinical practice. However, response rates with single-agent DTIC are low. The objective of this study was to compare the efficacy and safety of DTIC with or without placebo and DTIC-based combination therapies in patients with advanced metastatic melanoma. Methods: We searched from electronic databases such as The Cochrane Library, MEDLINE, EBSCO, EMBASE, Ovid, CNKI, and CBMDisc from 2003 to 2013. The primary outcome measures were overall response and 1-year survival, and the secondary outcome measurements were adverse events. Results: Nine randomized controlled trials (RCTs) involving 2,481 patients were included in the meta-analysis. DTIC-based combination therapies was superior to DTIC alone in overall response (combined risk ratio [RR] = 1.60, 95% confidence interval [CI]: 1.27-2.01) and 1-year survival (combined RR=1.26, 95% CI: 1.14-1.39). Patients with DTIC-based combination therapies had higher incidence of adverse events including nausea (combined RR=1.23, 95% CI: 1.10-1.36), vomiting (combined RR=1.73, 95% CI: 1.41-2.12) and neutropenia (combined RR=1.75, 95% CI: 1.42-2.16) compared to the group for DTIC alone. Conclusion: These data suggested that DTIC-based combination therapies could moderately improve the overall response and the 1-year survival but increased the incidence of adverse events. Further large-scale, high-quality, placebo-controlled, double-blind trials are needed to confirm this conclusion.	[Jiang, Guan; Li, Rong-Hua; Sun, Chao; Liu, Yan-Qun] Xuzhou Med Coll, Affiliated Hosp, Dept Dermatol, Xuzhou 221002, Peoples R China; [Jiang, Guan; Zheng, Jun-Nian] Xuzhou Med Coll, Jiangsu Key Lab Biol Canc Therapy, Xuzhou 221002, Peoples R China; [Jiang, Guan] Ctr Dis Control & Prevent Xuzhou City, Xuzhou 221002, Peoples R China	Xuzhou Medical University; Xuzhou Medical University	Zheng, JN (corresponding author), Xuzhou Med Coll, Jiangsu Key Lab Biol Canc Therapy, Xuzhou 221002, Peoples R China.	dr.guanjiang@gmail.com	Li, Ronghua/AAP-8236-2021		National Natural Science Foundation of China [81372916]; Xuzhou Medical Young Talents Project	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Xuzhou Medical Young Talents Project	This project is supported by Grants from the National Natural Science Foundation of China (No. 81372916) and Xuzhou Medical Young Talents Project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2008, REV MAN REV MAN COMP; Bedikian AY, 2006, J CLIN ONCOL, V24, P4738, DOI 10.1200/JCO.2006.06.0483; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Crosby T, 2000, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD001215; Cui CL, 2013, MOL THER, V21, P1456, DOI 10.1038/mt.2013.79; Eggermont AMM, 2004, EUR J CANCER, V40, P1825, DOI 10.1016/j.ejca.2004.04.030; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Huncharek M, 2001, MELANOMA RES, V11, P75, DOI 10.1097/00008390-200102000-00009; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Jiang G, 2011, BIOCHEM BIOPH RES CO, V406, P311, DOI 10.1016/j.bbrc.2011.02.042; Kefford RF, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-69; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; McDermott DF, 2008, J CLIN ONCOL, V26, P2178, DOI 10.1200/JCO.2007.14.8288; Middleton MR, 2000, J CLIN ONCOL, V18, P158, DOI 10.1200/JCO.2000.18.1.158; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Murrell J, 2013, CANCER TREAT REV, V39, P833, DOI 10.1016/j.ctrv.2013.06.004; O'Day S, 2011, BRIT J CANCER, V105, P346, DOI 10.1038/bjc.2011.183; Plummer ER, 2011, CLIN CANCER RES, V11, P3402; Querfeld C, 2011, CLIN CANCER RES, V17, P5748, DOI 10.1158/1078-0432.CCR-11-0556; Quirin C, 2007, INT J CANCER, V121, P2801, DOI 10.1002/ijc.23052; Rigel DS, 2010, CA-CANCER J CLIN, V60, P301, DOI 10.3322/caac.20074; Robert C, 2013, LANCET ONCOL, V14, P733, DOI 10.1016/S1470-2045(13)70237-7; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Rubin Krista M, 2013, Semin Oncol Nurs, V29, P195, DOI 10.1016/j.soncn.2013.06.005; Sasse AD, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005413.pub2; Sherrill B, 2013, BRIT J CANCER, V109, P8, DOI 10.1038/bjc.2013.298; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Yin ZQ, 2012, J DERMATOL TREAT, V23, P449, DOI 10.3109/09546634.2011.579082	30	30	31	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 11	2014	9	12							e111920	10.1371/journal.pone.0111920	http://dx.doi.org/10.1371/journal.pone.0111920			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX8FY	25502446	Green Published, Green Submitted			2023-01-03	WOS:000347146700003
J	Burlakova, LE; Tulumello, BL; Karatayev, AY; Krebs, RA; Schloesser, DW; Paterson, WL; Griffith, TA; Scott, MW; Crail, T; Zanatta, DT				Burlakova, Lyubov E.; Tulumello, Brianne L.; Karatayev, Alexander Y.; Krebs, Robert A.; Schloesser, Donald W.; Paterson, Wendy L.; Griffith, Traci A.; Scott, Mariah W.; Crail, Todd; Zanatta, David T.			Competitive Replacement of Invasive Congeners May Relax Impact on Native Species: Interactions among Zebra, Quagga, and Native Unionid Mussels	PLOS ONE			English	Article							FRESH-WATER MUSSELS; LAKE ST-CLAIR; DREISSENA-POLYMORPHA PALLAS; GREAT-LAKES; COASTAL WETLAND; NORTH-AMERICA; LAWRENCE-RIVER; BIOCHEMICAL-COMPOSITION; BIVALVES UNIONIDAE; AMBLEMA PLICATA	Determining when and where the ecological impacts of invasive species will be most detrimental and whether the effects of multiple invaders will be superadditive, or subadditive, is critical for developing global management priorities to protect native species in advance of future invasions. Over the past century, the decline of freshwater bivalves of the family Unionidae has been greatly accelerated by the invasion of Dreissena. The purpose of this study was to evaluate the current infestation rates of unionids by zebra (Dreissena polymorpha) and quagga (D. rostriformis bugensis) mussels in the lower Great Lakes region 25 years after they nearly extirpated native unionids. In 2011-2012, we collected infestation data for over 4000 unionids from 26 species at 198 nearshore sites in lakes Erie, Ontario, and St. Clair, the Detroit River, and inland Michigan lakes and compared those results to studies from the early 1990s. We found that the frequency of unionid infestation by Dreissena recently declined, and the number of dreissenids attached to unionids in the lower Great Lakes has fallen almost ten-fold since the early 1990s. We also found that the rate of infestation depends on the dominant Dreissena species in the lake: zebra mussels infested unionids much more often and in greater numbers. Consequently, the proportion of infested unionids, as well as the number and weight of attached dreissenids were lower in waterbodies dominated by quagga mussels. This is the first large-scale systematic study that revealed how minor differences between two taxonomically and functionally related invaders may have large consequences for native communities they invade.	[Burlakova, Lyubov E.; Tulumello, Brianne L.; Karatayev, Alexander Y.; Paterson, Wendy L.] SUNY Buffalo, Great Lakes Ctr, Buffalo, NY 14260 USA; [Burlakova, Lyubov E.] SUNY Buffalo, Res Fdn, Off Sponsored Programs, Buffalo, NY USA; [Krebs, Robert A.] Cleveland State Univ, Dept Biol Geol & Environm Sci, Cleveland, OH 44115 USA; [Schloesser, Donald W.] US Geol Survey, Great Lakes Sci Ctr, Ann Arbor, MI USA; [Paterson, Wendy L.; Griffith, Traci A.; Scott, Mariah W.; Zanatta, David T.] Cent Michigan Univ, Inst Great Lakes Res, Dept Biol, Mt Pleasant, MI 48859 USA; [Crail, Todd] Univ Toledo, Lake Erie Ctr, Dept Environm Sci, Toledo, OH 43606 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University System of Ohio; Cleveland State University; United States Department of the Interior; United States Geological Survey; Central Michigan University; University System of Ohio; University of Toledo	Burlakova, LE (corresponding author), SUNY Buffalo, Great Lakes Ctr, Buffalo, NY 14260 USA.	burlakle@buffalostate.edu	Zanatta, David/AAR-6797-2020	Zanatta, David/0000-0002-3174-071X; Krebs, Robert/0000-0003-3384-5870; Burlakova, Lyubov/0000-0002-2995-919X	U.S. Fish and Wildlife Service (US FWS) via the Great Lakes Fish and Wildlife Restoration Act (GLFWRA) [30191-A-G152]; NSF URM award [0731582]; Research Foundation of SUNY	U.S. Fish and Wildlife Service (US FWS) via the Great Lakes Fish and Wildlife Restoration Act (GLFWRA); NSF URM award; Research Foundation of SUNY	Funding support came from the U.S. Fish and Wildlife Service (US FWS) via the Great Lakes Fish and Wildlife Restoration Act (GLFWRA, project #30191-A-G152). Support for B. Tulumello was also provided by an NSF URM award #0731582 to C. M. Pennuto (SUNY Buffalo State), and L. Burlakova was supported in part by Research Foundation of SUNY. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Any opinions, findings, conclusions, or recommendations expressed in the publication are those of the author(s) and do not necessarily reflect the view of GLFWRA, NSF, USGS, or SUNY RF.	Allen DC, 2009, J N AM BENTHOL SOC, V28, P93, DOI 10.1899/07-170.1; ARTER HE, 1989, AQUAT SCI, V51, P87, DOI 10.1007/BF00879296; Baker SM, 2008, AM MIDL NAT, V160, P20, DOI 10.1674/0003-0031(2008)160[20:ZMDPAT]2.0.CO;2; Baker SM, 1997, CAN J FISH AQUAT SCI, V54, P512, DOI 10.1139/cjfas-54-3-512; Baker SM, 2000, AM MIDL NAT, V143, P443, DOI 10.1674/0003-0031(2000)143[0443:PSABCO]2.0.CO;2; Baldwin BS, 2002, CAN J FISH AQUAT SCI, V59, P680, DOI 10.1139/F02-043; bij de Vaate A G Van der Velde R S E W Leuven K C M Heiler, 2014, QUAGGA ZEBRA MUSSELS, V2, P83, DOI [10.1201/b15437-11, DOI 10.1201/B15437-11]; Bodis E, 2014, BIOL INVASIONS, V16, P1373, DOI 10.1007/s10530-013-0575-z; BOGAN AE, 1993, AM ZOOL, V33, P599; Bogan AE, 2008, HYDROBIOLOGIA, V595, P139, DOI 10.1007/s10750-007-9011-7; Bowers R, 2005, HYDROBIOLOGIA, V545, P93, DOI 10.1007/s10750-005-2212-z; Bowers R, 2004, AM MIDL NAT, V151, P286, DOI 10.1674/0003-0031(2004)151[0286:EOHOUU]2.0.CO;2; Bowers RW, 2007, WETLANDS, V27, P203, DOI 10.1672/0277-5212(2007)27[203:FPOZMA]2.0.CO;2; Burlakova LE, 2000, INT REV HYDROBIOL, V85, P529, DOI 10.1002/1522-2632(200011)85:5/6<529::AID-IROH529>3.3.CO;2-F; Carlton JT, 2008, J GREAT LAKES RES, V34, P770, DOI 10.3394/0380-1330-34.4.770; Casper AF, 2010, J GREAT LAKES RES, V36, P184, DOI 10.1016/j.jglr.2009.10.001; Clarke K.R., 2006, PRIMER V6 USER MANUA; CLARKE KR, 1993, AUST J ECOL, V18, P117, DOI 10.1111/j.1442-9993.1993.tb00438.x; Claxton WT, 1998, CAN J ZOOL, V76, P1269, DOI 10.1139/cjz-76-7-1269; Conn DB, 1993, 3RD P INT ZEBR MUSS, P223; Crail TD, 2011, J GREAT LAKES RES, V37, P199, DOI 10.1016/j.jglr.2010.12.006; Cummings KS, 1992, INHS MANUAL, V5; Diggins TP, 2004, BIOL INVASIONS, V6, P83, DOI 10.1023/B:BINV.0000010124.00582.d3; Dussart GBJ, 1966, LIMNOLOGIE; Flynn DFB, 2011, ECOLOGY, V92, P1573, DOI 10.1890/10-1245.1; Fuller P, 2014, NONINDIGENOUS AQUATI; GILLIS PL, 1994, CAN J ZOOL, V72, P1260; Goodrich C, 1932, OCCAS PAP MUS ZOOL U, V238, P8; Graf Daniel L., 2002, Occasional Papers on Mollusks Museum of Comparative Zoology Harvard University, V6, P175; GRIFFITHS RW, 1991, CAN J FISH AQUAT SCI, V48, P1381, DOI 10.1139/f91-165; Haag WR, 2012, NORTH AMERICAN FRESHWATER MUSSELS: NATURAL HISTORY, ECOLOGY, AND CONSERVATION, P1, DOI 10.1017/CBO9781139048217; HAAG WR, 1993, CAN J FISH AQUAT SCI, V50, P13, DOI 10.1139/f93-002; Hayes Keith R., 2003, P382; HEBERT PDN, 1989, CAN J FISH AQUAT SCI, V46, P1587, DOI 10.1139/f89-202; HEBERT PDN, 1991, CAN J ZOOL, V69, P405, DOI 10.1139/z91-063; Higgins SN, 2010, ECOL MONOGR, V80, P179, DOI 10.1890/09-1249.1; Hollandsworth D, 2011, AM MIDL NAT, V166, P369, DOI 10.1674/0003-0031-166.2.369; HUNTER RD, 1992, NAUTILUS, V106, P60; Karatayev A.Y., 2013, QUAGGA ZEBRA MUSSELS, V2nd ed., P695; Karatayev AY, 2014, J GREAT LAKES RES, V40, P550, DOI 10.1016/j.jglr.2014.04.010; Karatayev AY, 2011, J SHELLFISH RES, V30, P923, DOI 10.2983/035.030.0334; Karatayev AY, 2010, J SHELLFISH RES, V29, P975, DOI 10.2983/035.029.0432; Karatayev AY, 2002, INVASIVE AQUATIC SPECIES OF EUROPE: DISTRIBUTION, IMPACTS AND MANAGEMENT, P433; Karatayev AY, 1998, J SHELLFISH RES, V17, P1219; Karatayev AY, 1997, J SHELLFISH RES, V16, P187; Karatayev VA, 2013, J GREAT LAKES RES, V39, P622, DOI 10.1016/j.jglr.2013.09.007; Keller RP, 2007, CONSERV BIOL, V21, P191, DOI 10.1111/j.1523-1739.2006.00563.x; Koehl MAR, 1996, ANNU REV ECOL SYST, V27, P501, DOI 10.1146/annurev.ecolsys.27.1.501; Lavorel S, 2002, FUNCT ECOL, V16, P545, DOI 10.1046/j.1365-2435.2002.00664.x; LEWANDOWSKI K, 1976, Polskie Archiwum Hydrobiologii, V23, P409; Lozano SJ, 2011, STATUS MACROINVERTEB, P1; Lucy F.E., 2014, QUAGGA ZEBRA MUSSELS, V2nd ed., P623; Lydeard C, 2004, BIOSCIENCE, V54, P321, DOI 10.1641/0006-3568(2004)054[0321:TGDONM]2.0.CO;2; MACKIE GL, 1991, HYDROBIOLOGIA, V219, P251, DOI 10.1007/BF00024759; McGill BJ, 2006, TRENDS ECOL EVOL, V21, P178, DOI 10.1016/j.tree.2006.02.002; McGoldrick DJ, 2009, J GREAT LAKES RES, V35, P137, DOI 10.1016/j.jglr.2008.11.007; Metcalfe-Smith JL, 1998, J GREAT LAKES RES, V24, P845, DOI 10.1016/S0380-1330(98)70866-4; Mills EL, 2003, CAN J FISH AQUAT SCI, V60, P471, DOI [10.1139/f03-033, 10.1139/F03-033]; MILLS EL, 1993, J GREAT LAKES RES, V19, P1, DOI 10.1016/S0380-1330(93)71197-1; Nalepa TF, 1996, J GREAT LAKES RES, V22, P354, DOI 10.1016/S0380-1330(96)70961-9; NALEPA TF, 1991, J GREAT LAKES RES, V17, P214, DOI 10.1016/S0380-1330(91)71358-0; NALEPA TF, 1994, CAN J FISH AQUAT SCI, V51, P2227, DOI 10.1139/f94-225; Nichols S. Jerrine, 1997, Journal of Shellfish Research, V16, P346; Nichols SJ, 1999, CAN J ZOOL, V77, P423, DOI 10.1139/cjz-77-3-423; Nichols SJ, 1997, NATURE, V389, P921, DOI 10.1038/40039; Patterson MWR, 2005, J GREAT LAKES RES, V31, P223, DOI 10.1016/S0380-1330(05)70316-6; Pennuto CM, 2012, J GREAT LAKES RES, V38, P161, DOI 10.1016/j.jglr.2012.04.002; Peyer SM, 2010, J EXP BIOL, V213, P2602, DOI 10.1242/jeb.042549; Peyer SM, 2009, J EXP BIOL, V212, P2026, DOI 10.1242/jeb.028688; Protasov Alexander A., 1994, Archiwum Rybactwa Polskiego, V2, P257; Rauschert ESJ, 2012, ECOL APPL, V22, P1413, DOI 10.1890/11-2107.1; RICCIARDI A, 1995, CAN J FISH AQUAT SCI, V52, P1449, DOI 10.1139/f95-140; Ricciardi A, 1996, CAN J FISH AQUAT SCI, V53, P1434, DOI 10.1139/f96-068; Ricciardi A, 1995, CAN J FISH AQUAT SCI, V52, P2695, DOI 10.1139/f95-858; SCHLOESSER D W, 1991, Journal of Shellfish Research, V10, P355; Schloesser Don W., 1999, Northeastern Naturalist, V6, P341, DOI 10.2307/3858274; Schloesser DW, 2006, AM MIDL NAT, V155, P307, DOI 10.1674/0003-0031(2006)155[307:EOFMBU]2.0.CO;2; Schloesser DW, 1996, AM ZOOL, V36, P300; SCHLOESSER DW, 1994, CAN J FISH AQUAT SCI, V51, P2234, DOI 10.1139/f94-226; Schloesser DW, 1998, AM MIDL NAT, V140, P299, DOI 10.1674/0003-0031(1998)140[0299:IOZAQM]2.0.CO;2; SEBESTYEN O, 1938, VERH INT VER LIMNOL, V8, P169; Sherman JJ, 2013, J GREAT LAKES RES, V39, P201, DOI 10.1016/j.jglr.2013.03.001; Silayeva A. A., 2005, VESTNIK TYUMENSKOGO, V5, P112; Simberloff D, 2006, ECOL LETT, V9, P912, DOI 10.1111/j.1461-0248.2006.00939.x; Simberloff Daniel, 1999, Biological Invasions, V1, P21, DOI 10.1023/A:1010086329619; Sousa R, 2011, FRESHWATER BIOL, V56, P867, DOI 10.1111/j.1365-2427.2010.02532.x; Spoo A, 2008, PEARLY MUSSELS PENNS; Strayer D. L., 2014, QUAGGA ZEBRA MUSSELS, P71; Strayer DL, 2007, J N AM BENTHOL SOC, V26, P111, DOI 10.1899/0887-3593(2007)26[111:EOZMDP]2.0.CO;2; Strayer DL, 2004, BIOSCIENCE, V54, P429, DOI 10.1641/0006-3568(2004)054[0429:CPOPMN]2.0.CO;2; Strayer DL, 1996, FRESHWATER BIOL, V36, P771; Strayer DL, 1999, J N AM BENTHOL SOC, V18, P74, DOI 10.2307/1468010; Strayer DL, 1997, NY STATE MUS MEM, V26; TUCKER JK, 1994, J FRESHWATER ECOL, V9, P129, DOI 10.1080/02705060.1994.9664439; Ward JM, 2007, DIVERS DISTRIB, V13, P155, DOI 10.1111/j.1472-4642.2007.00336.x; Warton DI, 2011, ECOLOGY, V92, P3, DOI 10.1890/10-0340.1; Watkins JM, 2007, J GREAT LAKES RES, V33, P642, DOI 10.3394/0380-1330(2007)33[642:EFREOD]2.0.CO;2; Watters G.T., 2009, FRESHWATER MUSSELS O; Yang SA, 2011, AM NAT, V177, P110, DOI 10.1086/657433; Zanatta DT, 2002, J GREAT LAKES RES, V28, P479, DOI 10.1016/S0380-1330(02)70599-6; Zanatta DT, NE NAT IN PRESS; Zar J. H., 2010, BIOSTAT ANAL, V5th	102	28	31	0	99	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2014	9	12							e114926	10.1371/journal.pone.0114926	http://dx.doi.org/10.1371/journal.pone.0114926			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AY3YM	25490103	Green Published, Green Submitted, gold			2023-01-03	WOS:000347515300096
J	Poole, D; Chieregato, A; Langer, M; Viaggi, B; Cingolani, E; Malacarne, P; Mengoli, F; Nardi, G; Nascimben, E; Riccioni, L; Turriziani, I; Volpi, A; Coniglio, C; Gordini, G				Poole, Daniele; Chieregato, Arturo; Langer, Martin; Viaggi, Bruno; Cingolani, Emiliano; Malacarne, Paolo; Mengoli, Francesca; Nardi, Giuseppe; Nascimben, Ennio; Riccioni, Luigi; Turriziani, Ilaria; Volpi, Annalisa; Coniglio, Carlo; Gordini, Giovanni		Trauma Update Working Grp	Systematic Review of the Literature and Evidence-Based Recommendations for Antibiotic Prophylaxis in Trauma: Results from an Italian Consensus of Experts	PLOS ONE			English	Article							PENETRATING ABDOMINAL-TRAUMA; INFECTIOUS-DISEASES SOCIETY; STAPHYLOCOCCUS-AUREUS MRSA; BASILAR SKULL FRACTURES; EARLY-ONSET PNEUMONIA; ANTIMICROBIAL RESISTANCE; KLEBSIELLA-AEROGENES; COMATOSE PATIENTS; GUIDELINES; GRADE	Background: Antibiotic prophylaxis is frequently administered in severe trauma. However, the risk of selecting resistant bacteria, a major issue especially in critical care environments, has not been sufficiently investigated. The aim of the present study was to provide guidelines for antibiotic prophylaxis for four different trauma-related clinical conditions, taking into account the risks of antibiotic-resistant bacteria selection, thus innovating previous guidelines in the field. Methods: The MEDLINE database was searched for studies comparing antibiotic prophylaxis to controls (placebo or no antibiotic administration) in four clinical traumatic conditions that were selected on the basis of the traumatic event frequency and/or infection severity. The selected studies focused on the prevention of early ventilator associated pneumonia (VAP) in comatose patients with traumatic brain injury, of meningitis in severe basilar skull fractures, of wound infections in long-bone open fractures. Since no placebo-controlled study was available for deep surgical site-infections prevention in abdominal trauma with enteric contamination, we compared 24-hour and 5-day antibiotic prophylaxis policies. A separate specific research focused on the question of antibiotic-resistant bacteria selection caused by antibiotic prophylaxis, an issue not adequately investigated by the selected studies. Randomised trials, reviews, meta-analyses, observational studies were included. Data extraction was carried out by one author according to a predefined protocol, using an electronic form. The strength of evidence was stratified and recommendations were given according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria. Results: Uncertain evidence deserving further studies was found for two-dose antibiotic prophylaxis for early VAP prevention in comatose patients. In the other cases the risk of resistant-bacteria selection caused by antibiotic administration for 48 hours or more, outweighed potential benefits. Conclusions: When accounting for antibiotic-resistant bacteria selection we found no evidence in favour of antibiotic prophylaxis lasting two or more days in the studied clinical conditions.	[Poole, Daniele] Osped San Martino Genova, UO Anestesia & Rianimaz, Belluno, Italy; [Chieregato, Arturo; Viaggi, Bruno] AOU Careggi, SOD Anestesia & Area Intens CTO, Florence, Italy; [Langer, Martin] Fdn IRCCS Ist Nazl Tumori, Dipartimento Anestesia & Rianimaz, Milan, Italy; [Langer, Martin] Univ Milan, Milan, Italy; [Cingolani, Emiliano; Nardi, Giuseppe; Riccioni, Luigi] AO San Camillo Forlanini, UOC Shock & Trauma, Rome, Italy; [Malacarne, Paolo] Azienda Osped Univ Pisana, UO Anestesia & Rianimaz PS, Pisa, Italy; [Mengoli, Francesca; Turriziani, Ilaria; Coniglio, Carlo; Gordini, Giovanni] Osped Maggiore Bologna, UO Rianimaz 118, Bologna, Italy; [Nascimben, Ennio] Neurorianimaz Osped S Maria Ca Foncello, Treviso, Italy; [Volpi, Annalisa] Azienda Osped Univ Parma, I-43100 Parma, Italy	ULSS 1 Dolomiti; Ospedale di Belluno; University of Genoa; IRCCS AOU San Martino IST; University of Florence; Azienda Ospedaliero Universitaria Careggi; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Milan; Azienda Ospedaliera San Camillo-Forlanini; University of Pisa; Azienda Ospedaliero Universitaria Pisana; AUSL di Bologna; ULSS 2 Marca TV; Ospedale Ca' Foncello Treviso; University of Parma; University Hospital of Parma	Poole, D (corresponding author), Osped San Martino Genova, UO Anestesia & Rianimaz, Belluno, Italy.	daniele.poole@alice.it	Gordini, Giovanni/AAB-8170-2022; Volpi, Annalisa/AHH-5394-2022; Viaggi, Bruno/X-5074-2018; Coniglio, Carlo/AAB-7128-2022; Poole, Daniele/X-7210-2019	Gordini, Giovanni/0000-0003-4518-0204; Volpi, Annalisa/0000-0001-5337-9155; Viaggi, Bruno/0000-0001-5710-2479; Coniglio, Carlo/0000-0002-8207-0525; Poole, Daniele/0000-0001-5279-9844				Acquarolo A, 2005, INTENS CARE MED, V31, P510, DOI 10.1007/s00134-005-2585-5; ALTMAN DG, 1995, BRIT MED J, V311, P485, DOI 10.1136/bmj.311.7003.485; Andrews J, 2013, J CLIN EPIDEMIOL, V66, P719, DOI 10.1016/j.jclinepi.2012.03.013; Andrews JC, 2013, J CLIN EPIDEMIOL, V66, P726, DOI 10.1016/j.jclinepi.2013.02.003; Assmann SF, 2000, LANCET, V355, P1064, DOI 10.1016/S0140-6736(00)02039-0; Atkins D, 2004, BMC HEALTH SERV RES, V4, DOI 10.1186/1472-6963-4-38; Babyak MA, 2004, PSYCHOSOM MED, V66, P411, DOI 10.1097/01.psy.0000127692.23278.a9; Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015; BERGMAN BR, 1982, ACTA ORTHOP SCAND, V53, P57, DOI 10.3109/17453678208992179; Bonten MJM, 1998, ARCH INTERN MED, V158, P1127, DOI 10.1001/archinte.158.10.1127; Bozorgzadeh A, 1999, AM J SURG, V177, P125, DOI 10.1016/S0002-9610(98)00317-1; Brand M, 2013, COCHRANE DB SYST REV, V11; Brand M, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007370.pub2; Bratzler DW, 2004, CLIN INFECT DIS, V38, P1706, DOI 10.1086/421095; Braun R, 1987, J Orthop Trauma, V1, P12, DOI 10.1097/00005131-198701010-00002; Brodie HA, 1997, ARCH OTOLARYNGOL, V123, P749; Cornwell EE, 1999, J GASTROINTEST SURG, V3, P648, DOI 10.1016/S1091-255X(99)80088-2; Dagi T F, 1983, Am J Emerg Med, V1, P295, DOI 10.1016/0735-6757(83)90109-2; de Kraker MEA, 2011, J ANTIMICROB CHEMOTH, V66, P398, DOI 10.1093/jac/dkq412; de Kraker MEA, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001104; de Kraker MEA, 2011, ANTIMICROB AGENTS CH, V55, P1598, DOI 10.1128/AAC.01157-10; DEMETRIADES D, 1992, INJURY, V23, P377, DOI 10.1016/0020-1383(92)90011-G; Dickey R L, 1989, J Orthop Trauma, V3, P6, DOI 10.1097/00005131-198903010-00002; Eftekhar B, 2004, J NEUROSURG, V101, P757, DOI 10.3171/jns.2004.101.5.0757; FABIAN TC, 1992, SURGERY, V112, P788; FEINSTEIN AR, 1995, J CLIN EPIDEMIOL, V48, P71, DOI 10.1016/0895-4356(94)00110-C; Filius PMG, 2005, ANTIMICROB AGENTS CH, V49, P2879, DOI 10.1128/AAC.49.7.2879-2886.2005; FRAZEE RC, 1988, POSTGRAD MED, V83, P267, DOI 10.1080/00325481.1988.11700238; Gosselin R A, 2004, Cochrane Database Syst Rev, pCD003764, DOI 10.1002/14651858.CD003764.pub2; Gould IM, 1999, J ANTIMICROB CHEMOTH, V43, P459, DOI 10.1093/jac/43.4.459; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.06.004, 10.1016/j.jclinepi.2011.03.017]; Harbarth S, 2000, CIRCULATION, V101, P2916, DOI 10.1161/01.CIR.101.25.2916; Hauser Carl J, 2006, Surg Infect (Larchmt), V7, P379; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; HOFF JT, 1976, J NEUROSURG, V44, P649; Hoff WS, 2011, J TRAUMA, V70, P751, DOI 10.1097/TA.0b013e31820930e5; Hospenthal DR, 2011, J TRAUMA, V71, pS210, DOI 10.1097/TA.0b013e318227ac4b; Hurwitz B, 1999, BRIT MED J, V318, P661, DOI 10.1136/bmj.318.7184.661; IGNELZI RJ, 1975, J NEUROSURG, V43, P721, DOI 10.3171/jns.1975.43.6.0721; Ioannidis JPA, 2007, CAN MED ASSOC J, V176, P1091, DOI 10.1503/cmaj.060410; KERNODLE DS, 1988, ANTIMICROB AGENTS CH, V32, P202, DOI 10.1128/AAC.32.2.202; Kirton OC, 2000, J TRAUMA, V49, P822, DOI 10.1097/00005373-200011000-00006; Klastersky J, 1976, Surg Neurol, V6, P111; Levy SB, 2002, J ANTIMICROB CHEMOTH, V49, P25, DOI 10.1093/jac/49.1.25; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Lipsitch M, 2002, EMERG INFECT DIS, V8, P347, DOI 10.3201/eid0804.010312; Luchette FA, 2000, E PRACT MAN GUID WOR; Moher D, 2001, BMC Med Res Methodol, V1, P2, DOI 10.1186/1471-2288-1-2; Naimi TS, 2003, JAMA-J AM MED ASSOC, V290, P2976, DOI 10.1001/jama.290.22.2976; PATZAKIS MJ, 1983, CLIN ORTHOP RELAT R, P31; PATZAKIS MJ, 1974, J BONE JOINT SURG AM, VA 56, P532, DOI 10.2106/00004623-197456030-00010; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; PRICE D, 1970, J CLIN PATHOL, V23, P378, DOI 10.1136/jcp.23.4.378-c; PRICE DJE, 1972, J NEUROL NEUROSUR PS, V35, P903, DOI 10.1136/jnnp.35.6.903; PRICE DJE, 1970, LANCET, V2, P1213; Rahal JJ, 1998, JAMA-J AM MED ASSOC, V280, P1233, DOI 10.1001/jama.280.14.1233; Ratilal BO, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD004884, 10.1002/14651858.CD004884.pub3]; Rojczyk M, 1983, Hefte Unfallheilkd, V162, P33; Schentag JJ, 1998, CLIN INFECT DIS, V26, P1204, DOI 10.1086/520287; Sirvent JM, 1997, AM J RESP CRIT CARE, V155, P1729, DOI 10.1164/ajrccm.155.5.9154884; Sjolund M, 2003, ANN INTERN MED, V139, P483, DOI 10.7326/0003-4819-139-6-200309160-00011; Solomkin JS, 2010, CLIN INFECT DIS, V50, P133, DOI 10.1086/649554; Tacconelli E, 2008, J ANTIMICROB CHEMOTH, V61, P26, DOI 10.1093/jac/dkm416; Tacconelli Evelina, 2009, Antimicrob Agents Chemother, V53, P4264, DOI 10.1128/AAC.00431-09; Tacconelli E, 2009, CURR OPIN INFECT DIS, V22, P352, DOI 10.1097/QCO.0b013e32832d52e0; Valles J, 2013, CHEST, V143, P1219, DOI 10.1378/chest.12-1361; Valverde A, 2008, J CLIN MICROBIOL, V46, P2796, DOI 10.1128/JCM.01008-08; Villalobos T, 1998, CLIN INFECT DIS, V27, P364, DOI 10.1086/514666; Zrebeet H A, 1986, Del Med J, V58, P741	70	17	20	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 20	2014	9	11							e113676	10.1371/journal.pone.0113676	http://dx.doi.org/10.1371/journal.pone.0113676			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT9ND	25412442	Green Published, Green Submitted, gold			2023-01-03	WOS:000345253000071
J	Liu, YL; Zhang, R; Huang, J; Zhao, X; Liu, DL; Sun, WT; Mai, YF; Zhang, P; Wang, YJ; Cao, H; Yang, KH				Liu, Yali; Zhang, Rui; Huang, Jiao; Zhao, Xu; Liu, Danlu; Sun, Wanting; Mai, Yuefen; Zhang, Peng; Wang, Yajun; Cao, Hua; Yang, Ke Hu			Reporting Quality of Systematic Reviews/Meta-Analyses of Acupuncture	PLOS ONE			English	Article							METAANALYSES; TRIALS	Background: The QUOROM and PRISMA statements were published in 1999 and 2009, respectively, to improve the consistency of reporting systematic reviews (SRs)/meta-analyses (MAs) of clinical trials. However, not all SRs/MAs adhere completely to these important standards. In particular, it is not clear how well SRs/MAs of acupuncture studies adhere to reporting standards and which reporting criteria are generally ignored in these analyses. Objectives: To evaluate reporting quality in SRs/MAs of acupuncture studies. Methods: We performed a literature search for studies published prior to 2014 using the following public archives: PubMed, EMBASE, Web of Science, the Cochrane Database of Systematic Reviews (CDSR), the Chinese Biomedical Literature Database (CBM), the Traditional Chinese Medicine (TCM) database, the Chinese Journal Full-text Database (CJFD), the Chinese Scientific Journal Full-text Database (CSJD), and the Wanfang database. Data were extracted into pre-prepared Excel data-extraction forms. Reporting quality was assessed based on the PRISMA checklist (27 items). Results: Of 476 appropriate SRs/MAs identified in our search, 203, 227, and 46 were published in Chinese journals, international journals, and the Cochrane Database, respectively. In 476 SRs/MAs, only 3 reported the information completely. By contrast, approximately 4.93% (1/203), 8.81% (2/227) and 0.00% (0/46) SRs/Mas reported less than 10 items in Chinese journals, international journals and CDSR, respectively. In general, the least frequently reported items (reported <= 50%) in SRs/MAs were "protocol and registration'', "risk of bias across studies'', and "additional analyses'' in both methods and results sections. Conclusions: SRs/MAs of acupuncture studies have not comprehensively reported information recommended in the PRISMA statement. Our study underscores that, in addition to focusing on careful study design and performance, attention should be paid to comprehensive reporting standards in SRs/MAs on acupuncture studies.	[Liu, Yali; Zhang, Rui; Huang, Jiao; Zhao, Xu; Liu, Danlu; Sun, Wanting; Mai, Yuefen; Zhang, Peng; Yang, Ke Hu] Lanzhou Univ, Sch Basic Med Sci, Evidence Based Med Ctr, Lanzhou 730000, Peoples R China; [Liu, Yali; Liu, Danlu; Yang, Ke Hu] Key Lab Clin Translat Res & Evidence Based Med Ga, Lanzhou, Peoples R China; [Zhang, Rui; Huang, Jiao; Liu, Danlu; Yang, Ke Hu] Lanzhou Univ, Clin Med Coll 1, Lanzhou 730000, Peoples R China; [Zhao, Xu; Sun, Wanting; Mai, Yuefen] Lanzhou Univ, Clin Med Coll 2, Lanzhou 730000, Peoples R China; [Zhang, Peng] Shandong Univ, Qilu Hosp, Dept Cardiol, Jinan 250100, Shandong, Peoples R China; [Wang, Yajun] Gansu Univ Tradit Chinese Med, Acupuncture & Massage Coll, Lanzhou, Peoples R China; [Cao, Hua] Gansu Prov Hosp Tradit Chinese Med, Dept Neurol, Lanzhou, Peoples R China	Lanzhou University; Lanzhou University; Lanzhou University; Shandong University; Gansu University of Chinese Medicine	Yang, KH (corresponding author), Lanzhou Univ, Sch Basic Med Sci, Evidence Based Med Ctr, Lanzhou 730000, Peoples R China.	kehuyangebm2006@126.com		Liu, Yali/0000-0003-0037-6326	National Natural Science Foundation of China [81373882]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Project supported by the National Natural Science Foundation of China (Grant No. 81373882) http://www.nsfc.gov.cn/Portal0/default152.htm The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Delaney A, 2005, CRIT CARE, V9, pR575, DOI 10.1186/cc3803; Fleming PS, 2013, ANGLE ORTHOD, V83, P158, DOI 10.2319/032612-251.1; Gagnier Joel J, 2013, J Bone Joint Surg Am, V95, pe771, DOI 10.2106/JBJS.L.00597; Kelly KD, 2001, ANN EMERG MED, V38, P518, DOI 10.1067/mem.2001.115881; Kiriakou J, 2013, J DENT, V41, P1181, DOI 10.1016/j.jdent.2013.09.006; Liu YL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028130; Lui S, 2010, ACUPUNCT MED, V28, P149, DOI 10.1136/aim.2010.002444; Ma B, 2012, J ALTERN COMPLEM MED, V18, P813, DOI 10.1089/acm.2011.0274; Ma B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020185; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Moher D, 2011, 19 COCHR C; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Moher D, 2007, PLOS MED, V4, P447, DOI 10.1371/journal.pmed.0040078; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; Padula RS, 2012, BRAZ J PHYS THER, V16, P281; Richards Derek, 2004, Evid Based Dent, V5, P17, DOI 10.1038/sj.ebd.6400242; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; Sood A, 2005, J ALTERN COMPLEM MED, V11, P719, DOI 10.1089/acm.2005.11.719; Swingler GH, 2003, BRIT MED J, V327, P1083, DOI 10.1136/bmj.327.7423.1083; Tao KM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027611; Willis BH, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-163; Wu TX, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-46	22	2	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 14	2014	9	11							e113172	10.1371/journal.pone.0113172	http://dx.doi.org/10.1371/journal.pone.0113172			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AU4DF	25397774	Green Published, Green Submitted, gold			2023-01-03	WOS:000345558500140
J	Coresh, J; Jafar, TH				Coresh, Josef; Jafar, Tazeen H.			Disparities in worldwide treatment of kidney failure	LANCET			English	Editorial Material							DIALYSIS; CARE		[Coresh, Josef] George W Comstock Ctr Publ Hlth Res & Prevent, Baltimore, MD 21287 USA; [Coresh, Josef] Johns Hopkins Univ, Baltimore, MD 21218 USA; [Jafar, Tazeen H.] Duke NUS Grad Med Sch, Singapore, Singapore	Johns Hopkins University; National University of Singapore	Coresh, J (corresponding author), George W Comstock Ctr Publ Hlth Res & Prevent, Baltimore, MD 21287 USA.	coresh@jhu.edu						Archdeacon P, 2013, CLIN J AM SOC NEPHRO, V8, P1609, DOI 10.2215/CJN.01140113; Bamgboye EL, 2003, KIDNEY INT, V63, P93, DOI 10.1046/j.1523-1755.63.s83.19.x; Dirks JH, 2006, KIDNEY INT, V70, P982, DOI 10.1038/sj.ki.5001798; Gansevoort RT, 2013, LANCET, V382, P339, DOI 10.1016/S0140-6736(13)60595-4; Hoerger TJ, 2010, AM J KIDNEY DIS, V55, P463, DOI 10.1053/j.ajkd.2009.11.017; Levey AS, 2012, LANCET, V379, P165, DOI 10.1016/S0140-6736(11)60178-5; Liyanage T, 2015, LANCET; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Morad Z, 2015, AM J KIDNEY DIS, V65, P799, DOI 10.1053/j.ajkd.2014.09.031; Pecoits R, 2009, PERITON DIALYSIS INT, V29, pS222; Ramachandran R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067812; Wagstaff A, 2014, WHO BENEFITS GOVT HL; Williams ME, 2012, SEMIN DIALYSIS, V25, P633, DOI 10.1111/sdi.12018	13	31	31	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 16	2015	385	9981					1926	1928		10.1016/S0140-6736(14)61890-0	http://dx.doi.org/10.1016/S0140-6736(14)61890-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CI1YR	25777668				2023-01-03	WOS:000354541700008
J	Greene, JA; Riggs, KR				Greene, Jeremy A.; Riggs, Kevin R.			Why Is There No Generic Insulin? Historical Origins of a Modern Problem	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							LONG-ACTING INSULIN; PATENTS		[Greene, Jeremy A.; Riggs, Kevin R.] Johns Hopkins Univ, Sch Med, Div Gen Internal Med, Baltimore, MD 21218 USA; [Greene, Jeremy A.] Johns Hopkins Univ, Sch Med, Dept Hist Med, Baltimore, MD USA; [Riggs, Kevin R.] Johns Hopkins Univ, Sch Med, Berman Inst Bioeth, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Greene, JA (corresponding author), Johns Hopkins Univ, Sch Med, Div Gen Internal Med, Baltimore, MD 21218 USA.			Riggs, Kevin/0000-0002-0015-5809	NATIONAL LIBRARY OF MEDICINE [G13LM010890] Funding Source: NIH RePORTER; NLM NIH HHS [G13 LM010890] Funding Source: Medline	NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Bliss Michael, 1982, DISCOVERY INSULIN; BRANGE J, 1988, NATURE, V333, P679, DOI 10.1038/333679a0; Cassier M, 2008, HIST TECHNOL, V24, P153, DOI 10.1080/07341510701810948; DiMasi J., 2012, TUFTS CTR STUDY DRUG, P21, DOI DOI 10.1093/OXFORDHB/9780199742998.013.0002; Dusetzina SB, 2014, J CLIN ONCOL, V32, P306, DOI 10.1200/JCO.2013.52.9123; Engelberg AB, 2010, NEW ENGL J MED, V362, P664; FELIG P, 1984, JAMA-J AM MED ASSOC, V251, P393, DOI 10.1001/jama.251.3.393; Feudtner C., 2003, BITTERSWEET DIABETES; Frank RG, 2007, NEW ENGL J MED, V357, P1993, DOI 10.1056/NEJMp078193; Gabriel Joseph M., 2014, MED MONOPOLY INTELLE; GOEDDEL DV, 1979, P NATL ACAD SCI USA, V76, P106, DOI 10.1073/pnas.76.1.106; Grabowski H, 1996, PHARMACOECONOMICS, V10, P110, DOI 10.2165/00019053-199600102-00017; Greene JA, 2014, GENERIC UNBRANDING M; Haas JS, 2005, ANN INTERN MED, V142, P891, DOI 10.7326/0003-4819-142-11-200506070-00006; HAGEDORS H. C., 1936, Journal of the American Medical Association, V106, P177; Heinemann L, 2000, DIABETES CARE, V23, P644, DOI 10.2337/diacare.23.5.644; Heinemann L, 2012, DIABETES TECHNOL THE, V14, P986, DOI 10.1089/dia.2012.0247; Hirsch IB, 2005, NEW ENGL J MED, V352, P174, DOI 10.1056/NEJMra040832; Hitchings AW, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e7941; Horvath K, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005613.pub3; LAWRENCE RD, 1953, BRIT MED J, V1, P242, DOI 10.1136/bmj.1.4804.242; Light DW, 2011, BIOSOCIETIES, V6, P34, DOI 10.1057/biosoc.2010.40; LOGIE AW, 1976, BRIT MED J, V1, P879, DOI 10.1136/bmj.1.6014.879-a; Louet S, 2003, NAT BIOTECHNOL, V21, P956, DOI 10.1038/nbt0903-956; Owens DR, 2012, DIABETES TECHNOL THE, V14, P989, DOI 10.1089/dia.2012.0105; Piette JD, 2004, DIABETES CARE, V27, P384, DOI 10.2337/diacare.27.2.384; Richter B, 2002, ENDOCRIN METAB CLIN, V31, P723, DOI 10.1016/S0889-8529(02)00020-8; Selvin E, 2014, ANN INTERN MED, V160, P517, DOI 10.7326/M13-2411; SLAYTON RE, 1955, NEW ENGL J MED, V253, P722, DOI 10.1056/NEJM195510272531704; Tamblyn R, 2001, JAMA-J AM MED ASSOC, V285, P421, DOI 10.1001/jama.285.4.421	30	52	53	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 19	2015	372	12					1171	1175		10.1056/NEJMms1411398	http://dx.doi.org/10.1056/NEJMms1411398			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CD6EZ	25785977				2023-01-03	WOS:000351183600016
J	Wu, WS; Zhang, CY; Lin, WJ; Chen, Q; Guo, XD; Qian, Y; Zhang, LJ				Wu, Wensheng; Zhang, Canyang; Lin, Wenjing; Chen, Quan; Guo, Xindong; Qian, Yu; Zhang, Lijuan			Quantitative Structure-Property Relationship (QSPR) Modeling of Drug-Loaded Polymeric Micelles via Genetic Function Approximation	PLOS ONE			English	Article							BLOCK-COPOLYMER MICELLES; PH-SENSITIVE MICELLES; TRIBLOCK COPOLYMERS; EXTERNAL VALIDATION; DELIVERY; METHACRYLATE); PREDICTION; RELEASE; LENGTH	Self-assembled nano-micelles of amphiphilic polymers represent a novel anticancer drug delivery system. However, their full clinical utilization remains challenging because the quantitative structure-property relationship (QSPR) between the polymer structure and the efficacy of micelles as a drug carrier is poorly understood. Here, we developed a series of QSPR models to account for the drug loading capacity of polymeric micelles using the genetic function approximation (GFA) algorithm. These models were further evaluated by internal and external validation and a Y-randomization test in terms of stability and generalization, yielding an optimization model that is applicable to an expanded materials regime. As confirmed by experimental data, the relationship between microstructure and drug loading capacity can be well-simulated, suggesting that our models are readily applicable to the quantitative evaluation of the drug-loading capacity of polymeric micelles. Our work may offer a pathway to the design of formulation experiments.	[Wu, Wensheng; Zhang, Canyang; Lin, Wenjing; Chen, Quan; Guo, Xindong; Qian, Yu; Zhang, Lijuan] S China Univ Technol, Sch Chem & Chem Engn, Guangzhou 510641, Guangdong, Peoples R China; [Wu, Wensheng] Zhaoqing Univ, Sch Chem & Chem Engn, Zhaoqing, Peoples R China	South China University of Technology; Zhaoqing University	Zhang, LJ (corresponding author), S China Univ Technol, Sch Chem & Chem Engn, Guangzhou 510641, Guangdong, Peoples R China.	celjzh@scut.edu.cn	Zhang, Can Yang/G-7104-2015; ZHANG, Can Yang/AAK-2267-2021; ZHANG, CANYANG/O-8171-2016	ZHANG, CANYANG/0000-0002-6975-5781; Zhang, Lijuan/0000-0002-9765-1875	National Natural Science Foundation of China [21176090]; Team Project of Natural Science Foundation of Guangdong Province, China [S2011030001366]; Specialized Research Fund for the Doctoral Program of Higher Education of China [20130172110009]; Fundamental Research Funds for the Central Universities, China [2013ZP0010, 2013ZZ0059, 2014ZP0020]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Team Project of Natural Science Foundation of Guangdong Province, China(National Natural Science Foundation of China (NSFC)); Specialized Research Fund for the Doctoral Program of Higher Education of China(Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); Fundamental Research Funds for the Central Universities, China(Fundamental Research Funds for the Central Universities)	This work was financially supported by National Natural Science Foundation of China (No. 21176090), Team Project of Natural Science Foundation of Guangdong Province, China (No. S2011030001366), Specialized Research Fund for the Doctoral Program of Higher Education of China (No. 20130172110009), and Fundamental Research Funds for the Central Universities, China (No. 2013ZP0010, 2013ZZ0059, 2014ZP0020). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Atkinson A.C., 1985, PLOTS TRANSFORMATION; Babel MS, 2007, WATER RESOUR MANAG, V21, P573, DOI 10.1007/s11269-006-9030-6; Bahl J, 2012, J CHEMOMETR, V26, P85, DOI 10.1002/cem.2415; Bauhuber S, 2012, J CONTROL RELEASE, V162, P446, DOI 10.1016/j.jconrel.2012.07.017; Bouton F, 2010, LANGMUIR, V26, P7962, DOI 10.1021/la904836m; Dearden JC, 2009, SAR QSAR ENVIRON RES, V20, P241, DOI 10.1080/10629360902949567; Fagerberg T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065590; Feng C, 2013, LANGMUIR, V29, P10922, DOI 10.1021/la402335d; Feng ST, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100732; Friedman J, 1990, 102 LAB COMP STAT; FRIEDMAN JH, 1991, ANN STAT, V19, P1, DOI 10.1214/aos/1176347963; Gharagheizi F, 2012, CHEM ENG SCI, V76, P99, DOI 10.1016/j.ces.2012.03.033; Golbraikh A, 2002, J MOL GRAPH MODEL, V20, P269, DOI 10.1016/S1093-3263(01)00123-1; Gramatica P, 2004, EVALUATION DIFFERENT, P177; Gramatica P, 2007, QSAR COMB SCI, V26, P694, DOI 10.1002/qsar.200610151; Guo XD, 2012, IND ENG CHEM RES, V51, P4719, DOI 10.1021/ie2014668; Hira SK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094309; Holland J.H, 1992, CONTROL ARTIFICIAL I; Kataoka K, 2001, ADV DRUG DELIVER REV, V47, P113, DOI 10.1016/S0169-409X(00)00124-1; Kim SW, 2011, J CONTROL RELEASE, V155, P116, DOI 10.1016/j.jconrel.2011.03.023; Kim S, 2008, J CONTROL RELEASE, V132, P222, DOI 10.1016/j.jconrel.2008.07.004; Lavasanifar A, 2002, ADV DRUG DELIVER REV, V54, P169, DOI 10.1016/S0169-409X(02)00015-7; Lei BL, 2009, ANAL CHIM ACTA, V644, P17, DOI 10.1016/j.aca.2009.04.019; Lin WJ, 2014, J MATER CHEM B, V2, P4008, DOI 10.1039/c3tb21694b; Lin WJ, 2014, NANOSCALE RES LETT, V9, DOI 10.1186/1556-276X-9-243; Luo YL, 2013, IND ENG CHEM RES, V52, P1571, DOI 10.1021/ie3024164; Luo ZL, 2012, J CONTROL RELEASE, V162, P185, DOI 10.1016/j.jconrel.2012.06.027; Mehra R, 2013, MED CHEM RES, V22, P2303, DOI 10.1007/s00044-012-0225-5; Mhlanga P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053367; Oerlemans C, 2010, PHARM RES-DORDR, V27, P2569, DOI 10.1007/s11095-010-0233-4; Poon Z, 2011, NANOMED-NANOTECHNOL, V7, P201, DOI 10.1016/j.nano.2010.07.008; ROGERS D, 1994, J CHEM INF COMP SCI, V34, P854, DOI 10.1021/ci00020a020; Roy K, 2013, CHEM ENG SCI, V87, P141, DOI 10.1016/j.ces.2012.10.002; Roy K, 2012, CHEM ENG SCI, V73, P86, DOI 10.1016/j.ces.2012.01.005; Roy K, 2012, J CHEM INF MODEL, V52, P396, DOI 10.1021/ci200520g; Schuurmann G, 2008, J CHEM INF MODEL, V48, P2140, DOI 10.1021/ci800253u; Shahlaei M, 2013, CHEM REV, V113, P8093, DOI 10.1021/cr3004339; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Siepmann J, 2004, J CONTROL RELEASE, V96, P123, DOI 10.1016/j.jconrel.2004.01.011; Tatiya PD, 2013, IND ENG CHEM RES, V52, P1562, DOI 10.1021/ie301813a; Torchilin VP, 2004, CELL MOL LIFE SCI, V61, P2549, DOI 10.1007/s00018-004-4153-5; Tyrrell ZL, 2010, PROG POLYM SCI, V35, P1128, DOI 10.1016/j.progpolymsci.2010.06.003; Xiong XB, 2011, J CONTROL RELEASE, V155, P248, DOI 10.1016/j.jconrel.2011.04.028; Xu Y, 2014, IND ENG CHEM RES, V53, P4718, DOI 10.1021/ie4043196; Yang XL, 2014, PHARM RES-DORDR, V31, P291, DOI 10.1007/s11095-013-1160-y; Yang YQ, 2013, ACTA BIOMATER, V9, P7679, DOI 10.1016/j.actbio.2013.05.006; Yang YQ, 2012, LANGMUIR, V28, P8251, DOI 10.1021/la301099q; Zhang CY, 2014, J CONTROL RELEASE, V180, P42, DOI 10.1016/j.jconrel.2014.02.015; Zhang CY, 2012, BIOMATERIALS, V33, P6273, DOI 10.1016/j.biomaterials.2012.05.025; Zhang YH, 2010, NANOSCALE RES LETT, V5, P917, DOI 10.1007/s11671-010-9583-4; Zheng LS, 2011, J COLLOID INTERF SCI, V363, P114, DOI 10.1016/j.jcis.2011.07.040	51	36	38	1	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 17	2015	10	3							e0119575	10.1371/journal.pone.0119575	http://dx.doi.org/10.1371/journal.pone.0119575			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CD7QC	25780923	Green Published, Green Submitted, gold			2023-01-03	WOS:000351284600076
J	Han, JH; Han, JS; Kim, EJ; Doh, FM; Koo, HM; Kim, CH; Lee, MJ; Oh, HJ; Park, JT; Han, SH; Ryu, DR; Yoo, TH; Kang, SW				Han, Jae Hyun; Han, Ji Suk; Kim, Eun Jin; Doh, Fa Mee; Koo, Hyang Mo; Kim, Chan Ho; Lee, Mi Jung; Oh, Hyung Jung; Park, Jung Tak; Han, Seung Hyeok; Ryu, Dong-Ryeol; Yoo, Tae-Hyun; Kang, Shin-Wook			Diastolic Dysfunction Is an Independent Predictor of Cardiovascular Events in Incident Dialysis Patients with Preserved Systolic Function	PLOS ONE			English	Article							LEFT ATRIAL VOLUME; LEFT-VENTRICULAR HYPERTROPHY; STAGE RENAL-DISEASE; HEART-FAILURE; EJECTION FRACTION; EUROPEAN-SOCIETY; PROGNOSTIC VALUE; RAPID DECLINE; FOLLOW-UP; MORTALITY	Background Diastolic heart failure (HF), the prevalence of which is gradually increasing, is associated with cardiovascular (CV) morbidity and mortality in the general population and, more specifically, in patients with end-stage renal disease (ESRD). However, the impact of diastolic dysfunction on CV outcomes has not been studied in incident dialysis patients with preserved systolic function. Methods This prospective observational cohort study investigates the clinical consequence of diastolic dysfunction and the predictive power of diastolic echocardiographic parameters for CV events in 194 incident ESRD patients with normal or near normal systolic function, who started dialysis between July 2008 and August 2012. Results During a mean follow-up duration of 27.2 months, 57 patients (29.4%) experienced CV events. Compared to the CV event-free group, patients with CV events had a significantly higher left ventricular (LV) mass index, ratio of early mitral flow velocity (E) to early mitral annulus velocity (E') (E/E'), LA volume index (LAVI), deceleration time, and right ventricular systolic pressure, and a significantly lower LV ejection fraction and E'. In multivariate Cox proportional hazard analysis, E/E'>15 and LAVI>32 mL/m(2) significantly predicted CV events (E/E'>15: hazard ratio [HR] = 5.40, 95% confidence interval [CI] = 2.73-10.70, P<.001; LAVI>32 mL/m(2): HR = 5.56, 95% CI = 2.28-13.59, P<.001]. Kaplan-Meier analysis revealed that patients with both E/E'>15 and LAVI>32mL/m(2) had the worst CV outcomes. Conclusion An increase in E/E' or LAVI is a significant risk factor for CV events in incident dialysis patients with preserved LV systolic function.	[Han, Jae Hyun; Han, Ji Suk; Kim, Eun Jin; Doh, Fa Mee; Koo, Hyang Mo; Kim, Chan Ho; Lee, Mi Jung; Oh, Hyung Jung; Park, Jung Tak; Han, Seung Hyeok; Yoo, Tae-Hyun; Kang, Shin-Wook] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea; [Ryu, Dong-Ryeol] Ewha Womans Univ, Sch Med, Dept Internal Med, Seoul, South Korea; [Kang, Shin-Wook] Yonsei Univ, Coll Med, Severance Biomed Sci Inst, Brain Korea PLUS Project Med Sci 21, Seoul, South Korea	Yonsei University; Yonsei University Health System; Ewha Womans University; Yonsei University; Yonsei University Health System	Kang, SW (corresponding author), Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea.	kswkidney@yuhs.ac	; Han, Seung Hyeok/K-4559-2018	Yoo, Tae-Hyun/0000-0002-9183-4507; Park, Jung Tak/0000-0002-2325-8982; doh, fa mee/0000-0002-4780-6728; Kang, Shin-Wook/0000-0002-5677-4756; Ryu, Dong-Ryeol/0000-0002-5309-7606; Lee, Mi Jung/0000-0001-8888-029X; Han, Seung Hyeok/0000-0001-7923-5635	Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine; Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea [HI10C2020]	Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine; Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea	This work was supported by the Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, and a grant of the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (HI10C2020). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Astorri E, 1997, CARDIOLOGY, V88, P152, DOI 10.1159/000177322; Bella JN, 2002, CIRCULATION, V105, P1928, DOI 10.1161/01.CIR.0000015076.37047.D9; Bhatia RS, 2006, NEW ENGL J MED, V355, P260, DOI 10.1056/NEJMoa051530; Bolton K, 2005, AM J KIDNEY DIS, V45, pS7, DOI 10.1053/j.ajkd.2005.01.016; DEVEREUX RB, 1986, AM J CARDIOL, V57, P450, DOI 10.1016/0002-9149(86)90771-X; Dickstein K, 2008, EUR J HEART FAIL, V10, P933, DOI 10.1016/j.ejheart.2008.08.005; FOLEY RN, 1995, KIDNEY INT, V47, P186, DOI 10.1038/ki.1995.22; Glassock RJ, 2009, CLIN J AM SOC NEPHRO, V4, pS79, DOI 10.2215/CJN.04860709; GREAVES SC, 1994, AM J KIDNEY DIS, V24, P768, DOI 10.1016/S0272-6386(12)80670-6; Halley CM, 2011, ARCH INTERN MED, V171, P1082, DOI 10.1001/archinternmed.2011.244; Kim JK, 2012, J AM SOC ECHOCARDIOG, V25, P411, DOI 10.1016/j.echo.2011.11.026; Kim SJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035534; Kim SJ, 2012, J AM SOC ECHOCARDIOG, V25, P421, DOI 10.1016/j.echo.2011.12.005; Kim SJ, 2011, NEPHROL DIAL TRANSPL, V26, P3732, DOI 10.1093/ndt/gfr118; Koo HM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087231; London GM, 2002, NEPHROL DIAL TRANSPL, V17, P29, DOI 10.1093/ndt/17.suppl_1.29; London GM, 2001, J AM SOC NEPHROL, V12, P2759, DOI 10.1681/ASN.V12122759; Lopez B, 2008, KIDNEY INT, V74, pS19, DOI 10.1038/ki.2008.512; Moller JE, 2003, CIRCULATION, V107, P2207, DOI 10.1161/01.CIR.0000066318.21784.43; Nagueh SF, 2009, EUR J ECHOCARDIOGR, V10, P165, DOI 10.1093/ejechocard/jep007; O'Connor CM, 2000, AM J CARDIOL, V86, P863, DOI 10.1016/S0002-9149(00)01107-3; Oh JK, 1997, J AM SOC ECHOCARDIOG, V10, P246, DOI 10.1016/S0894-7317(97)70062-2; Ommen SR, 2000, CIRCULATION, V102, P1788; Owan TE, 2006, NEW ENGL J MED, V355, P251, DOI 10.1056/NEJMoa052256; Paulus WJ, 2007, EUR HEART J, V28, P2539, DOI 10.1093/eurheartj/ehm037; Paulus WJ, 1998, EUR HEART J, V19, P990; Perseghin G, 2005, J AM COLL CARDIOL, V46, P1085, DOI 10.1016/j.jacc.2005.05.075; Pritchett AM, 2005, J AM COLL CARDIOL, V45, P87, DOI 10.1016/j.jacc.2004.09.054; Redfield MM, 2003, JAMA-J AM MED ASSOC, V289, P194, DOI 10.1001/jama.289.2.194; Rudski LG, 2010, J AM SOC ECHOCARDIOG, V23, P685, DOI 10.1016/j.echo.2010.05.010; Sharma R, 2006, J AM SOC ECHOCARDIOG, V19, P266, DOI 10.1016/j.echo.2005.10.006; Simek C L, 1995, J Am Soc Echocardiogr, V8, P37, DOI 10.1016/S0894-7317(05)80356-6; Sweitzer NK, 2008, AM J CARDIOL, V101, P1151, DOI 10.1016/j.amjcard.2007.12.014; Tripepi G, 2007, J AM SOC NEPHROL, V18, P1316, DOI 10.1681/ASN.2006080881; Wang AYM, 2011, AM J KIDNEY DIS, V57, P308, DOI 10.1053/j.ajkd.2010.07.019; Wang AYM, 2004, J AM SOC NEPHROL, V15, P2186, DOI 10.1097/01.ASN.0000135053.98172.D6; Yamada S, 2010, CLIN J AM SOC NEPHRO, V5, P1793, DOI 10.2215/CJN.00050110; Yancy CW, 2006, J AM COLL CARDIOL, V47, P76, DOI 10.1016/j.jacc.2005.09.022; Zoccali C, 2004, J AM SOC NEPHROL, V15, P1029, DOI 10.1097/01.ASN.0000117977.14912.91; Zoccali C, 2004, KIDNEY INT, V65, P1492, DOI 10.1111/j.1523-1755.2004.00530.x	40	33	35	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 4	2015	10	3							e0118694	10.1371/journal.pone.0118694	http://dx.doi.org/10.1371/journal.pone.0118694			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC9JM	25739020	Green Published, Green Submitted, gold			2023-01-03	WOS:000350685900062
J	O'Loughlin, A; Dinneen, SF				O'Loughlin, Aonghus; Dinneen, Sean F.			The Ipswich Touch Test at home had 78% sensitivity and 94% specificity for detecting loss of foot sensation	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							DIABETIC FOOT		[O'Loughlin, Aonghus] Galway Univ Hosp, Galway, Ireland; NUI Galway, Galway, Ireland	Ollscoil na Gaillimhe-University of Galway	O'Loughlin, A (corresponding author), Galway Univ Hosp, Galway, Ireland.			Dinneen, Sean/0000-0002-6636-0493				Arad Y, 2011, DIABETES CARE, V34, P1041, DOI 10.2337/dc10-1666; Boulton AJM, 2008, DIABETES CARE, V31, P1679, DOI 10.2337/dc08-9021; Dorresteijn JAN, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001488.pub3; Monteiro-Soares M, 2012, DIABETES-METAB RES, V28, P574, DOI 10.1002/dmrr.2319	4	1	1	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 17	2015	162	4							JC10	10.7326/ACPJC-2015-162-4-010	http://dx.doi.org/10.7326/ACPJC-2015-162-4-010			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CC3FU	25686185				2023-01-03	WOS:000350232500001
J	Gabizon, A; Bradbury, M; Prabhakar, U; Zamboni, W; Libutti, S; Grodzinski, P				Gabizon, Alberto; Bradbury, Michelle; Prabhakar, Uma; Zamboni, William; Libutti, Steven; Grodzinski, Piotr			Cancer nanomedicines: closing the translational gap	LANCET			English	Editorial Material							PERSONALIZED MEDICINE; NANOPARTICLES		[Gabizon, Alberto] Shaare Zedek Med Ctr, Jerusalem, Israel; [Gabizon, Alberto] Hebrew Univ Jerusalem, Sch Med, IL-91010 Jerusalem, Israel; [Bradbury, Michelle] Cornell Univ, Sloan Kettering Inst Canc Res, New York, NY 10021 USA; [Bradbury, Michelle] Cornell Univ, Weill Med Coll, New York, NY 10021 USA; [Prabhakar, Uma; Grodzinski, Piotr] NCI, Alliance Nanotechnol Canc, Bethesda, MD 20892 USA; [Zamboni, William] Univ N Carolina, UNC Lineberger Comprehens Canc Ctr, UNC Eshelman Sch Pharm, Chapel Hill, NC USA; [Libutti, Steven] Albert Einstein Coll Med, New York, NY USA	Hebrew University of Jerusalem; Shaare Zedek Medical Center; Hebrew University of Jerusalem; Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of North Carolina; University of North Carolina Chapel Hill; Yeshiva University	Grodzinski, P (corresponding author), NCI, Alliance Nanotechnol Canc, Bethesda, MD 20892 USA.	grodzinp@mail.nih.gov	Gabizon, Alberto/C-6171-2009		NCI NIH HHS [R01 CA161280] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 2014, WORLD CANC REP 2014; Davis ME, 2008, NAT REV DRUG DISCOV, V7, P771, DOI 10.1038/nrd2614; Duncan R, 2011, MOL PHARMACEUT, V8, P2101, DOI 10.1021/mp200394t; Etheridge ML, 2013, NANOMED-NANOTECHNOL, V9, P1, DOI 10.1016/j.nano.2012.05.013; Jain KK, 2011, MED PRIN PRACT, V20, P1, DOI 10.1159/000319928; Kamaly N, 2012, CHEM SOC REV, V41, P2971, DOI 10.1039/c2cs15344k; Karathanasis E, 2009, RADIOLOGY, V250, P398, DOI 10.1148/radiol.2502080801; Moon JJ, 2012, ADV MATER, V24, P3724, DOI 10.1002/adma.201200446; Petersen AL, 2012, ADV DRUG DELIVER REV, V64, P1417, DOI 10.1016/j.addr.2012.09.003; Phillips E, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009524; Prabhakar U, 2013, CANCER RES, V73, P2412, DOI 10.1158/0008-5472.CAN-12-4561; Xing Y, 2014, THERANOSTICS, V4, P290, DOI 10.7150/thno.7341	12	53	55	1	44	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 20	2014	384	9961					2175	2176		10.1016/S0140-6736(14)61457-4	http://dx.doi.org/10.1016/S0140-6736(14)61457-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AX0QC	25625382	Green Accepted			2023-01-03	WOS:000346655700006
J	Wild, K; Scholz, M; Ropohl, A; Brauer, L; Paulsen, F; Burger, PHM				Wild, Katharina; Scholz, Michael; Ropohl, Axel; Braeuer, Lars; Paulsen, Friedrich; Burger, Pascal H. M.			Strategies against Burnout and Anxiety in Medical Education - Implementation and Evaluation of a New Course on Relaxation Techniques (Relacs) for Medical Students	PLOS ONE			English	Article							HEALTH; DEPRESSION; PREVALENCE	Burnout and stress-related mental disorders (depression, anxiety) occur in medical students and physicians with a significantly higher prevalence than in the general population. At the same time, the learning of coping mechanisms against stress is still not an integral part of medical education. In this pilot study we developed an elective course for learning relaxation techniques and examined the condition of the students before and after the course. 42 students participated in the semester courses in 2012 and 2013 as well as in a survey at the start and end of each course. The students were instructed in autogenic training (AT) and progressive muscle relaxation according to Jacobsen (PMR) with the goal of independent and regular exercising. At the beginning and the end of the semester/course the students were interviewed using standardized, validated questionnaires on burnout (BOSS-II) and anxiety (STAI-G), depression (BDI), quality of life (SF-12) and sense of coherence (SOC-L9). We compared the results of our students participating in Relacs with results from eight semester medical students (n=88), assessed with the same questionnaires at similar points of time within their semester. Participating students showed a significant decline in cognitive and emotional burnout stress and in trait anxiety. Furthermore, they showed a reduction in state anxiety and a conspicuous decrease in mean depression. The sense of coherence increased at the same time. A comparative cohort of medical students of 8th semester students, showed lower values for the specified measurement parameters at the beginning, but showed no progressive changes. Our course introducing AT and PMR led to a significant reduction of burnout and anxiety within the participating group of medical students. Even the course attendance for just one semester resulted in significant improvements in the evaluated parameters in contrast to those students who did not attend the course.	[Wild, Katharina; Scholz, Michael; Braeuer, Lars; Paulsen, Friedrich] Univ Erlangen Nurnberg, Dept Anat 2, D-91054 Erlangen, Germany; [Ropohl, Axel; Burger, Pascal H. M.] Psychiat & Psychotherapeut Specialist Hosp Women, Hosp Meissenberg, Zug, Switzerland	University of Erlangen Nuremberg	Scholz, M (corresponding author), Univ Erlangen Nurnberg, Dept Anat 2, D-91054 Erlangen, Germany.	michael.scholz@fau.de		Paulsen, Friedrich/0000-0002-0527-0953; Scholz, Michael/0000-0001-8440-6785				Arigoni F, 2010, SWISS MED WKLY, V140, DOI 10.4414/smw.2010.13070; Arigoni F, 2009, SUPPORT CARE CANCER, V17, P75, DOI 10.1007/s00520-008-0465-6; Bailer J, 2008, PSYCHOTHER PSYCH MED, V58, P423, DOI 10.1055/s-2007-986293; Beck AT, 2009, BDI 2 BECK DEPRESSIO; BLANCHARD EB, 1991, J CONSULT CLIN PSYCH, V59, P467, DOI 10.1037/0022-006X.59.3.467; Buddeberg-Fischer B, 2009, Z PSYCHOSOM MED PSYC, V55, P37, DOI 10.13109/zptm.2009.55.1.37; Burger PHM, 2014, PSYCHOTHER IN PRESS; Busch MA, 2013, BUNDESGESUNDHEITSBLA, V56, P733, DOI 10.1007/s00103-013-1688-3; Dahlin Marie E, 2007, BMC Med Educ, V7, P6, DOI 10.1186/1472-6920-7-6; Dehghan-nayeri N, 2011, COMPLEMENT THER MED, V19, P194, DOI 10.1016/j.ctim.2011.06.002; Dyrbye LN, 2009, MED EDUC, V43, P274, DOI 10.1111/j.1365-2923.2008.03282.x; Dyrbye LN, 2005, MAYO CLIN PROC, V80, P1613, DOI 10.4065/80.12.1613; Hagemann W, 2009, BOSS BURNOUT SCREENI; Hyman SA, 2011, ANESTHESIOLOGY, V114, P194, DOI 10.1097/ALN.0b013e318201ce9a; Ishak W, 2013, CLIN TEACH, V10, P242, DOI 10.1111/tct.12014; Ishak Waguih William, 2009, J Grad Med Educ, V1, P236, DOI 10.4300/JGME-D-09-00054.1; Jurkat HB, 2011, NERVENARZT, V82, P646, DOI 10.1007/s00115-010-3039-z; Laux L, 1970, STATE TRAIT ANGST IN; Park CL, 2003, HEALTH PSYCHOL, V22, P627, DOI 10.1037/0278-6133.22.6.627; Prinz P., 2012, GMS Z MED AUSBILD, V29; Raskin, 2007, NERVENARZT S2, V78, P162; Saarschmidt UF, 2008, AVEM ARBEITSBEZOGENE, P31; Scholz M, 2014, PSYCHOTHER PSYCHOSOM; Shanafelt TD, 2002, ANN INTERN MED, V136, P358, DOI 10.7326/0003-4819-136-5-200203050-00008; Singer S., 2007, SENSE COHERENCE SCAL; Song QH, 2013, INT J CLIN EXP MED, V6, P979; Stetter F, 2002, APPL PSYCHOPHYS BIOF, V27, P45, DOI 10.1023/A:1014576505223; Thomas K., 2006, PRAXIS AUTOGENEN TRA; Thomas NK, 2004, JAMA-J AM MED ASSOC, V292, P2880, DOI 10.1001/jama.292.23.2880; Voltmer E, 2010, MED TEACH, V32, pE422, DOI 10.3109/0142159X.2010.496008; Warnecke E, 2011, MED EDUC, V45, P381, DOI 10.1111/j.1365-2923.2010.03877.x; Whitehouse WG, 1996, PSYCHOSOM MED, V58, P249, DOI 10.1097/00006842-199605000-00009	32	49	49	1	41	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 17	2014	9	12							e114967	10.1371/journal.pone.0114967	http://dx.doi.org/10.1371/journal.pone.0114967			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AX9IA	25517399	Green Submitted, Green Published, gold			2023-01-03	WOS:000347215600033
J	Wayne, PM; Gow, BJ; Costa, MD; Peng, CK; Lipsitz, LA; Hausdorff, JM; Davis, RB; Walsh, JN; Lough, M; Novak, V; Yeh, GY; Ahn, AC; Macklin, EA; Manor, B				Wayne, Peter M.; Gow, Brian J.; Costa, Madalena D.; Peng, C. -K.; Lipsitz, Lewis A.; Hausdorff, Jeffrey M.; Davis, Roger B.; Walsh, Jacquelyn N.; Lough, Matthew; Novak, Vera; Yeh, Gloria Y.; Ahn, Andrew C.; Macklin, Eric A.; Manor, Brad			Complexity-Based Measures Inform Effects of Tai Chi Training on Standing Postural Control: Cross-Sectional and Randomized Trial Studies	PLOS ONE			English	Article							OLDER-ADULTS; BALANCE CONTROL; PHYSIOLOGICAL COMPLEXITY; CHALLENGES INHERENT; MULTISCALE ENTROPY; STABILITY LIMITS; OPEN-LOOP; FALLS; COMMUNITY; DYNAMICS	Background: Diminished control of standing balance, traditionally indicated by greater postural sway magnitude and speed, is associated with falls in older adults. Tai Chi (TC) is a multisystem intervention that reduces fall risk, yet its impact on sway measures vary considerably. We hypothesized that TC improves the integrated function of multiple control systems influencing balance, quantifiable by the multi-scale "complexity'' of postural sway fluctuations. Objectives: To evaluate both traditional and complexity-based measures of sway to characterize the short- and potential long-term effects of TC training on postural control and the relationships between sway measures and physical function in healthy older adults. Methods: A cross-sectional comparison of standing postural sway in healthy TC-nalve and TC-expert (24.5 +/- 12 yrs experience) adults. TC-nalve participants then completed a 6-month, two-arm, wait-list randomized clinical trial of TC training.Postural sway was assessed before and after the training during standing on a force-plate with eyes-open (EO) and eyes-closed (EC). Anterior-posterior (AP) and medio-lateral (ML) sway speed, magnitude, and complexity (quantified by multiscale entropy) were calculated. Single- legged standing time and Timed-Up-and- Go tests characterized physical function. Results: At baseline, compared to TC-nalve adults (n=60, age 64.5 +/- 7.5 yrs), TC-experts (n=27, age 62.8 +/- 7.5 yrs) exhibited greater complexity of sway in the AP EC (P=0.023), ML EO (P, 0.001), and ML EC (P, 0.001) conditions. Traditional measures of sway speed and magnitude were not significantly lower among TC-experts. Intention-to-treat analyses indicated no significant effects of short-term TC training; however, increases in AP EC and ML EC complexity amongst those randomized to TC were positively correlated with practice hours (P=0.044, P=0.018). Long- and short-term TC training were positively associated with physical function. Conclusion: Multiscale entropy offers a complementary approach to traditional COP measures for characterizing sway during quiet standing, and may be more sensitive to the effects of TC in healthy adults.	[Wayne, Peter M.; Gow, Brian J.; Walsh, Jacquelyn N.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Osher Ctr Integrat Med, Boston, MA 02115 USA; [Costa, Madalena D.; Peng, C. -K.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Interdisciplinary Med & Biotechnol, Boston, MA 02115 USA; [Costa, Madalena D.; Peng, C. -K.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Margret & HA Rey Inst Nonlinear Dynam Med, Boston, MA 02115 USA; [Peng, C. -K.] Natl Cent Univ, Ctr Dynam Biomarkers & Translat Med, Chungli 32054, Taiwan; [Lipsitz, Lewis A.; Novak, Vera; Manor, Brad] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Gerontol, Boston, MA 02115 USA; [Lipsitz, Lewis A.; Lough, Matthew] Hebrew SeniorLife, Inst Aging Res, Roslindale, MA USA; [Hausdorff, Jeffrey M.] Tel Aviv Med Ctr & Sch Med, Dept Neurol, Movement Disorders Unit, Tel Aviv, Israel; [Hausdorff, Jeffrey M.] Tel Aviv Univ, Dept Phys Therapy, IL-69978 Tel Aviv, Israel; [Hausdorff, Jeffrey M.] Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel; [Davis, Roger B.; Yeh, Gloria Y.; Ahn, Andrew C.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Gen Med & Primary Care, Boston, MA 02115 USA; [Novak, Vera] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Neurol, Boston, MA 02115 USA; [Ahn, Andrew C.] Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Boston, MA 02114 USA; [Macklin, Eric A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Biostat, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; National Central University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Hebrew SeniorLife; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Tel Aviv University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Wayne, PM (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Osher Ctr Integrat Med, Boston, MA 02115 USA.	pwayne@partners.org	Peng, Chung-Kang/N-1308-2019; Macklin, Eric A/E-2955-2013	Peng, Chung-Kang/0000-0003-3666-9833; Macklin, Eric A/0000-0003-1618-3502; Gow, Brian/0000-0002-7682-1943	National Center for Complementary and Alternative Medicine (NCCAM) at the National Institutes of Health (NIH) [R21 AT005501-01A1]; Harvard Clinical and Translational Science Center, from the National Center for Research Resourses (NCRR) [UL1 RR025758]; National Institute on Aging (NIA) [R37-AG25037]; NIH-National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [5R21-DK-084463-02]; National Institutes of Health (NIH)-National Institute on Aging (NIA) [1R01-AG-0287601-A2]; Harvard Catalyst \ The Harvard Clinical and Translational Science Center (National Center for Research Resources); Harvard Catalyst \ The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences); Harvard Catalyst \ The Harvard Clinical and Translational Science Center (National Institutes of Health Award) [8UL1TR000170-05]; Harvard Catalyst \ The Harvard Clinical and Translational Science Center (Harvard University); Irving and Edyth S. Usen and Family Chair in Geriatric Medicine at Hebrew SeniorLife; NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE [R21AT005501] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG041785, R00AG030677, R01AG025037] Funding Source: NIH RePORTER	National Center for Complementary and Alternative Medicine (NCCAM) at the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); Harvard Clinical and Translational Science Center, from the National Center for Research Resourses (NCRR); National Institute on Aging (NIA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIH-National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Institutes of Health (NIH)-National Institute on Aging (NIA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Harvard Catalyst \ The Harvard Clinical and Translational Science Center (National Center for Research Resources); Harvard Catalyst \ The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences); Harvard Catalyst \ The Harvard Clinical and Translational Science Center (National Institutes of Health Award)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harvard Catalyst \ The Harvard Clinical and Translational Science Center (Harvard University); Irving and Edyth S. Usen and Family Chair in Geriatric Medicine at Hebrew SeniorLife; NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This publication was made possible by grant number R21 AT005501-01A1 from the National Center for Complementary and Alternative Medicine (NCCAM: http://nccam.nih.gov/) at the National Institutes of Health (NIH: http://www.nih.gov/), and from grant number UL1 RR025758 supporting the Harvard Clinical and Translational Science Center, from the National Center for Research Resourses (NCRR: http://www.nih.gov/about/almanac/organization/NCRR.htm). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NCCAM, NCRR, or the NIH. Dr. Lipsitz was supported by grant R37-AG25037 from the National Institute on Aging (NIA: http://www.nia. nih.gov/) and the Irving and Edyth S. Usen and Family Chair in Geriatric Medicine at Hebrew SeniorLife. Dr. Novak has received grants from the NIH-National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK: http://www.niddk.nih. gov/) (5R21-DK-084463-02) and the National Institutes of Health (NIH)-National Institute on Aging (NIA: http://www.nia.nih.gov/) (1R01-AG-0287601-A2) unrelated to this study. The work in the SAFE lab was conducted with support from Harvard Catalyst (http://catalyst.harvard.edu/) vertical bar The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health Award 8UL1TR000170-05 and financial contributions from Harvard University and its affiliated academic health care centers). The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic health care centers, or the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baumgartner T., 2006, MEASUREMENT EVALUATI, V8th ed.; Burgener SC, 2008, AM J ALZHEIMERS DIS, V23, P382, DOI 10.1177/1533317508317527; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Chen YS, 2011, ARCH PHYS MED REHAB, V92, P886, DOI 10.1016/j.apmr.2010.12.043; COLLINS JJ, 1995, EXP BRAIN RES, V104, P480, DOI 10.1007/BF00231982; COLLINS JJ, 1993, EXP BRAIN RES, V95, P308, DOI 10.1007/BF00229788; Costa M, 2007, EPL-EUROPHYS LETT, V77, DOI 10.1209/0295-5075/77/68008; Costa M, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.021906; Costa M, 2002, COMPUT CARDIOL, V29, P137, DOI 10.1109/CIC.2002.1166726; Costa M, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.068102; Duarte M, 2008, EXP BRAIN RES, V191, P265, DOI 10.1007/s00221-008-1521-7; Fischer M, 2014, USE PRAGMAT IN PRESS, V21; Gatts Strawberry, 2008, V52, P87, DOI 10.1159/000134289; Gillespie L. D., 2012, COCHRANE DB SYST REV, V9, DOI DOI 10.1002/14651858.CD007146; Guan HW, 2011, AM J CHINESE MED, V39, P251, DOI 10.1142/S0192415X11008798; Gyllensten AL, 2010, ARCH PHYS MED REHAB, V91, P215, DOI 10.1016/j.apmr.2009.10.009; Hakim RM, 2010, PHYS OCCUP THER GERI, V28, P63, DOI 10.3109/02703181003605861; Harmer PeterA., 2008, V52, P124, DOI 10.1159/000134293; Hausdorff JM, 2007, HUM MOVEMENT SCI, V26, P555, DOI 10.1016/j.humov.2007.05.003; Hausdorff JM, 2009, CHAOS, V19, DOI 10.1063/1.3147408; HEIL DP, 1995, MED SCI SPORT EXER, V27, P599; Hong YL, 2000, BRIT J SPORT MED, V34, P29, DOI 10.1136/bjsm.34.1.29; JACKSON AS, 1995, MED SCI SPORT EXER, V27, P113; Jacobson BH, 1997, PERCEPT MOTOR SKILL, V84, P27, DOI 10.2466/pms.1997.84.1.27; JUDGE JO, 1993, PHYS THER, V73, P254, DOI 10.1093/ptj/73.4.254; Kang HG, 2009, J GERONTOL A-BIOL, V64, P1304, DOI 10.1093/gerona/glp113; Kuh D, 2005, J GERONTOL A-BIOL, V60, P224, DOI 10.1093/gerona/60.2.224; Lan C, 1998, MED SCI SPORT EXER, V30, P345, DOI 10.1097/00005768-199803000-00003; Li FZ, 2012, NEW ENGL J MED, V366, P511, DOI 10.1056/NEJMoa1107911; Li L, 2010, AM J CHINESE MED, V38, P113, DOI 10.1142/S0192415X10007701; Lima BN, 2014, J SPORT SCI MED, V13, P564; Lin MR, 2004, J AM GERIATR SOC, V52, P1343, DOI 10.1111/j.1532-5415.2004.52366.x; Lipsitz LA, 2002, J GERONTOL A-BIOL, V57, pB115, DOI 10.1093/gerona/57.3.B115; Liu H, 2010, J GERIATR PHYS THER, V33, P103, DOI 10.1097/JPT.0b013e3181eda1c4; Lundebjerg N, 2001, J AM GERIATR SOC, V49, P664, DOI 10.1046/j.1532-5415.2001.49115.x; MAKI BE, 1994, J GERONTOL, V49, pM72, DOI 10.1093/geronj/49.2.M72; Manor B, 2014, J AM GERIAT IN PRESS; Manor B, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-87; Manor B, 2010, J APPL PHYSIOL, V109, P1786, DOI 10.1152/japplphysiol.00390.2010; Manson J, 2013, BMC GERIATR, V13, DOI 10.1186/1471-2318-13-114; Melzer I, 2004, AGE AGEING, V33, P602, DOI 10.1093/ageing/afh218; Pajala S, 2008, J GERONTOL A-BIOL, V63, P171, DOI 10.1093/gerona/63.2.171; Peng CK, 2009, ADV DATA SCI ADAPT, V1, P61, DOI 10.1142/S1793536909000035; Pluchino A, 2012, ARCH PHYS MED REHAB, V93, P1138, DOI 10.1016/j.apmr.2012.01.023; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; Prieto TE, 1996, IEEE T BIO-MED ENG, V43, P956, DOI 10.1109/10.532130; Rigoldi C, 2013, RES DEV DISABIL, V34, P840, DOI 10.1016/j.ridd.2012.11.007; Robertson DGE, 2003, J ELECTROMYOGR KINES, V13, P569, DOI 10.1016/S1050-6411(03)00080-4; Rubenstein LZ, 2002, CLIN GERIATR MED, V18, P141, DOI 10.1016/S0749-0690(02)00002-2; Rubenstein LZ, 2001, ANN INTERN MED, V135, P686, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00007; Sattin RW, 2005, J AM GERIATR SOC, V53, P1168, DOI 10.1111/j.1532-5415.2005.53375.x; Schneider Ellen Caylor, 2010, N C Med J, V71, P547; Shumway-Cook A, 2000, PHYS THER, V80, P896, DOI 10.1093/ptj/80.9.896; Shumway-Cook A, 2006, MOTOR CONTROL TRANSL, V3; Stevens JA, 2006, INJURY PREV, V12, P290, DOI 10.1136/ip.2005.011015; Taylor-Piliae RE, 2014, ARCH PHYS MED REHAB, V95, P816, DOI 10.1016/j.apmr.2014.01.001; Thurner S, 2002, AUDIOL NEURO-OTOL, V7, P240, DOI 10.1159/000063740; Tousignant M, 2013, DISABIL REHABIL, V35, P1429, DOI 10.3109/09638288.2012.737084; Tsang WW, 2004, ARCH PHYS MED REHAB, V85, P129, DOI 10.1016/j.apmr.2003.02.002; Tsang WWN, 2004, MED SCI SPORT EXER, V36, P648, DOI 10.1249/01.MSS.0000121941.57669.BF; Tsang WWN, 2003, MED SCI SPORT EXER, V35, P1962, DOI 10.1249/01.MSS.0000099110.17311.A2; Vereeck L, 2008, INT J AUDIOL, V47, P67, DOI 10.1080/14992020701689688; Wayne PM, 2008, J ALTERN COMPLEM MED, V14, P191, DOI 10.1089/acm.2007.7170B; Wayne PM, 2008, J ALTERN COMPLEM MED, V14, P95, DOI 10.1089/acm.2007.7170A; Wayne PM, 2013, CONTEMP CLIN TRIALS, V34, P21, DOI 10.1016/j.cct.2012.09.006; Wei Q, 2012, ENTROPY-SWITZ, V14, P2157, DOI 10.3390/e14112157; Wolf SL, 1997, PHYS THER, V77, P371, DOI 10.1093/ptj/77.4.371; Wolf SL, 1996, J AM GERIATR SOC, V44, P489, DOI 10.1111/j.1532-5415.1996.tb01432.x; Wu G, 2002, ARCH PHYS MED REHAB, V83, P1364, DOI 10.1053/apmr.2002.34596; Wu G, 2010, ARCH PHYS MED REHAB, V91, P849, DOI 10.1016/j.apmr.2010.01.024; Wu ZH, 2009, ADV DATA SCI ADAPT, V1, P1, DOI 10.1142/S1793536909000047	72	43	43	0	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 10	2014	9	12							e114731	10.1371/journal.pone.0114731	http://dx.doi.org/10.1371/journal.pone.0114731			28	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AW9YP	25494333	gold, Green Submitted, Green Published			2023-01-03	WOS:000346611400072
J	Tazoe, T; Endoh, T; Kitamura, T; Ogata, T				Tazoe, Toshiki; Endoh, Takashi; Kitamura, Taku; Ogata, Toru			Polarity Specific Effects of Transcranial Direct Current Stimulation on Interhemispheric Inhibition	PLOS ONE			English	Article							HUMAN MOTOR CORTEX; LATENCY AFFERENT INHIBITION; THETA-BURST-STIMULATION; TRANSCALLOSAL INHIBITION; INTRACORTICAL CIRCUITS; BRAIN-STIMULATION; EXCITABILITY; HEMISPHERE; PATHWAYS; RECOVERY	Transcranial direct current stimulation (tDCS) has been used as a useful interventional brain stimulation technique to improve unilateral upper-limb motor function in healthy humans, as well as in stroke patients. Although tDCS applications are supposed to modify the interhemispheric balance between the motor cortices, the tDCS after-effects on interhemispheric interactions are still poorly understood. To address this issue, we investigated the tDCS after-effects on interhemispheric inhibition (IHI) between the primary motor cortices (M1) in healthy humans. Three types of tDCS electrode montage were tested on separate days; anodal tDCS over the right M1, cathodal tDCS over the left M1, bilateral tDCS with anode over the right M1 and cathode over the left M1. Single-pulse and paired-pulse transcranial magnetic stimulations were given to the left M1 and right M1 before and after tDCS to assess the bilateral corticospinal excitabilities and mutual direction of IHI. Regardless of the electrode montages, corticospinal excitability was increased on the same side of anodal stimulation and decreased on the same side of cathodal stimulation. However, neither unilateral tDCS changed the corticospinal excitability at the unstimulated side. Unilateral anodal tDCS increased IHI from the facilitated side M1 to the unchanged side M1, but it did not change IHI in the other direction. Unilateral cathodal tDCS suppressed IHI both from the inhibited side M1 to the unchanged side M1 and from the unchanged side M1 to the inhibited side M1. Bilateral tDCS increased IHI from the facilitated side M1 to the inhibited side M1 and attenuated IHI in the opposite direction. Sham-tDCS affected neither corticospinal excitability nor IHI. These findings indicate that tDCS produced polarity-specific after-effects on the interhemispheric interactions between M1 and that those after-effects on interhemispheric interactions were mainly dependent on whether tDCS resulted in the facilitation or inhibition of the M1 sending interhemispheric volleys.	[Tazoe, Toshiki; Endoh, Takashi; Kitamura, Taku; Ogata, Toru] Natl Rehabil Ctr Persons Disabil, Dept Rehabil Movement Funct, Res Inst, Tokorozawa, Saitama, Japan; [Tazoe, Toshiki] Japan Soc Promot Sci, Tokyo, Japan; [Endoh, Takashi] Uekusa Gakuen Univ, Fac Child Dev & Educ, Chiba, Japan; [Kitamura, Taku] Shibaura Inst Technol, Div Funct Control Syst, Grad Sch Engn & Sci, Saitama, Japan	Japan Society for the Promotion of Science; Shibaura Institute of Technology	Tazoe, T (corresponding author), Natl Rehabil Ctr Persons Disabil, Dept Rehabil Movement Funct, Res Inst, Tokorozawa, Saitama, Japan.	Tot12@pitt.edu	Ogata, Toru/ADC-3560-2022	Ogata, Toru/0000-0001-9011-8640	 [23.10759];  [24700612]	; 	This research was supported by Grants-in-Aid for Research Fellow of the Japan Society for the Promotion of Science to TT (#23.10759) and by Grants-in-Aids for Young Scientist B to TE (#24700612). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Avanzino L, 2007, J PHYSIOL-LONDON, V583, P99, DOI 10.1113/jphysiol.2007.134510; Baumer T, 2007, EXP BRAIN RES, V180, P195, DOI 10.1007/s00221-007-0866-7; Batsikadze G, 2013, J PHYSIOL-LONDON, V591, P1987, DOI 10.1113/jphysiol.2012.249730; Boggio PS, 2007, RESTOR NEUROL NEUROS, V25, P123; Boggio PS, 2006, NEUROSCI LETT, V404, P232, DOI 10.1016/j.neulet.2006.05.051; Bradnam LV, 2012, CEREB CORTEX, V22, P2662, DOI 10.1093/cercor/bhr344; Bradnam LV, 2011, J NEUROPHYSIOL, V105, P2582, DOI 10.1152/jn.01084.2010; CATSMANBERREVOETS CE, 1980, EXP BRAIN RES, V39, P433; Chen R, 2003, J NEUROPHYSIOL, V89, P1256, DOI 10.1152/jn.00950.2002; Daskalakis ZJ, 2002, J PHYSIOL-LONDON, V543, P317, DOI 10.1113/jphysiol.2002.017673; Di Lazzaro V, 2008, J PHYSIOL-LONDON, V586, P3871, DOI 10.1113/jphysiol.2008.152736; Di Lazzaro V, 1999, EXP BRAIN RES, V124, P520, DOI 10.1007/s002210050648; Di Lazzaro V, 2012, J NEURAL TRANSM, V119, P1499, DOI 10.1007/s00702-012-0845-4; Duque J, 2007, J COGNITIVE NEUROSCI, V19, P204, DOI 10.1162/jocn.2007.19.2.204; FERBERT A, 1992, J PHYSIOL-LONDON, V453, P525, DOI 10.1113/jphysiol.1992.sp019243; Fregni F, 2005, NEUROREPORT, V16, P1551, DOI 10.1097/01.wnr.0000177010.44602.5e; Gerloff C, 1998, J PHYSIOL-LONDON, V510, P249, DOI 10.1111/j.1469-7793.1998.249bz.x; Gilio F, 2003, J PHYSIOL-LONDON, V551, P563, DOI 10.1113/jphysiol.2003.044313; Hinder MR, 2010, EXP BRAIN RES, V205, P423, DOI 10.1007/s00221-010-2379-z; Hummel F, 2005, BRAIN, V128, P490, DOI 10.1093/brain/awh369; Hummel FC, 2006, LANCET NEUROL, V5, P708, DOI 10.1016/S1474-4422(06)70525-7; Kang Eun Kyoung, 2011, Exp Transl Stroke Med, V3, P4, DOI 10.1186/2040-7378-3-4; Kidgell DJ, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-64; Kim DY, 2010, AM J PHYS MED REHAB, V89, P879, DOI 10.1097/PHM.0b013e3181f70aa7; Kobayashi M, 2009, EUR J NEUROSCI, V29, P833, DOI 10.1111/j.1460-9568.2009.06628.x; Kukaswadia S, 2005, J PHYSIOL-LONDON, V563, P915, DOI 10.1113/jphysiol.2004.080010; Lang N, 2004, EXP BRAIN RES, V156, P439, DOI 10.1007/s00221-003-1800-2; Lee H, 2007, J PHYSIOL-LONDON, V580, P1021, DOI 10.1113/jphysiol.2006.126011; Li JY, 2013, J NEUROPHYSIOL, V109, P659, DOI 10.1152/jn.01044.2011; Lindenberg R, 2013, J NEUROSCI, V33, P9176, DOI 10.1523/JNEUROSCI.0055-13.2013; Mahmoudi H, 2011, DISABIL REHABIL, V33, P1383, DOI 10.3109/09638288.2010.532283; Mordillo-Mateos L, 2012, BRAIN STIMUL, V5, P214, DOI 10.1016/j.brs.2011.05.001; Nelson AJ, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-31; NETZ J, 1995, EXP BRAIN RES, V104, P527; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2003, CLIN NEUROPHYSIOL, V114, P600, DOI 10.1016/S1388-2457(02)00412-1; Nitsche MA, 2005, J PHYSIOL-LONDON, V568, P291, DOI 10.1113/jphysiol.2005.092429; Nowak DA, 2009, NEUROREHAB NEURAL RE, V23, P641, DOI 10.1177/1545968309336661; O'Shea J, 2014, NEUROIMAGE, V85, P924, DOI 10.1016/j.neuroimage.2013.05.096; Pal PK, 2005, J NEUROPHYSIOL, V94, P1668, DOI 10.1152/jn.01306.2004; Perez MA, 2008, J NEUROSCI, V28, P5631, DOI 10.1523/JNEUROSCI.0093-08.2008; Rehme AK, 2011, CEREB CORTEX, V21, P756, DOI 10.1093/cercor/bhq140; Roche N, 2012, CLIN NEUROPHYSIOL, V123, P1027, DOI 10.1016/j.clinph.2011.09.011; Roche N, 2009, J PHYSIOL-LONDON, V587, P5653, DOI 10.1113/jphysiol.2009.177550; Scelzo E, 2011, NEUROSCI LETT, V498, P167, DOI 10.1016/j.neulet.2011.05.007; Sehm B, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00183; Shin HW, 2011, NEUROREPORT, V22, P166, DOI 10.1097/WNR.0b013e3283439511; Suppa A, 2008, J PHYSIOL-LONDON, V586, P4489, DOI 10.1113/jphysiol.2008.156596; Tazoe T, 2014, J NEUROSCI, V34, P13924, DOI 10.1523/JNEUROSCI.1648-14.2014; Tazoe T, 2013, J NEUROSCI, V33, P16178, DOI 10.1523/JNEUROSCI.2638-13.2013; Tazoe T, 2013, EUR J NEUROSCI, V37, P96, DOI 10.1111/ejn.12026; Tremblay S, 2013, NEUROREPORT, V24, P46, DOI 10.1097/WNR.0b013e32835c36b8; Trompetto C, 2003, CLIN NEUROPHYSIOL, V114, P2181, DOI 10.1016/S1388-2457(03)00213-X; Tsutsumi R, 2014, J NEUROPHYSIOL, V111, P26, DOI 10.1152/jn.00515.2013; Tsutsumi R, 2012, J NEUROPHYSIOL, V108, P1130, DOI 10.1152/jn.00300.2012; Vines BW, 2008, EUR J NEUROSCI, V28, P1667, DOI 10.1111/j.1460-9568.2008.06459.x; Vines BW, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-103; Vines BW, 2006, NEUROREPORT, V17, P671, DOI 10.1097/00001756-200604240-00023; Waters-Metenier S, 2014, J NEUROSCI, V34, P1037, DOI 10.1523/JNEUROSCI.2282-13.2014; Williams JA, 2010, PHYS THER, V90, P398, DOI 10.2522/ptj.20090075; Zimerman M, 2012, STROKE, V43, P2185, DOI 10.1161/STROKEAHA.111.645382	62	55	61	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 5	2014	9	12							e114244	10.1371/journal.pone.0114244	http://dx.doi.org/10.1371/journal.pone.0114244			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX4MS	25478912	Green Submitted, Green Published, gold			2023-01-03	WOS:000346907200053
J	Zhu, HH; Huang, XJ				Zhu, Hong-Hu; Huang, Xiao-Jun			Oral Arsenic and Retinoic Acid for Non-High-Risk Acute Promyelocytic Leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							TRIOXIDE		[Zhu, Hong-Hu; Huang, Xiao-Jun] Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China	Peking University	Zhu, HH (corresponding author), Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China.	xjhrm@medmail.com.cn	Huang, Xiao-Jun/HIK-3759-2022	Huang, Xiao-Jun/0000-0002-2145-6643				Lo-Coco F, 2013, NEW ENGL J MED, V369, P111, DOI 10.1056/NEJMoa1300874; O'Donnell MR, 2013, J NATL COMPR CANC NE, V11, P1047, DOI 10.6004/jnccn.2013.0127; Zhu HH, 2014, NEW ENGL J MED, V370, P1864, DOI 10.1056/NEJMc1316382; Zhu HH, 2013, J CLIN ONCOL, V31, P4215, DOI 10.1200/JCO.2013.48.8312	4	65	79	1	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 4	2014	371	23					2239	2241		10.1056/NEJMc1412035	http://dx.doi.org/10.1056/NEJMc1412035			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AW0IY	25470713	Bronze			2023-01-03	WOS:000345976700029
J	Bagcchi, S				Bagcchi, Sanjeet			BLOOD DONATION More blood for India	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												drsanjitbagchi@gmail.com						Aggarwal S, 2012, ANN TROP MED PUBLIC, V5, P50; [Anonymous], 2014, DNA; Bhaumik S, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5623; Indian Red Cross Society, 2013, NAT VOL BLOOD DON DA; Sharman G., 2012, WEEK            0901; World Health Organization, BLOOD SAF AV	6	3	3	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 28	2014	349								g7166	10.1136/bmj.g7166	http://dx.doi.org/10.1136/bmj.g7166			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AW2KH	25432665				2023-01-03	WOS:000346115900002
J	Volpe, D; Giantin, MG; Fasano, A				Volpe, Daniele; Giantin, Maria Giulia; Fasano, Alfonso			A Wearable Proprioceptive Stabilizer (Equistasi (R)) for Rehabilitation of Postural Instability in Parkinson's Disease: A Phase II Randomized Double-Blind, Double-Dummy, Controlled Study	PLOS ONE			English	Article							TENDON VIBRATION; MUSCLE VIBRATION; CONTROLLED-TRIAL; GROUP IA; PEOPLE; RESPONSES; BALANCE; FALLS; EXERCISE; STANCE	Background: Muscle spindles endings are extremely sensitive to externally applied vibrations, and under such circumstances they convey proprioceptive inflows to the central nervous system that modulate the spinal reflexes excitability or the muscle responses elicited by postural perturbations. The aim of this pilot study is to test the feasibility and effectiveness of a balance training program in association with a wearable proprioceptive stabilizer (Equistasi) that emits focal mechanical vibrations in patients with PD. Methods: Forty patients with PD were randomly divided in two groups wearing an active or inactive device. All the patients received a 2-month intensive program of balance training. Assessments were performed at baseline, after the rehabilitation period (T1), and two more months after (T2). Posturographic measures were used as primary endpoint; secondary measures of outcome included the number of falls and several clinical scales for balance and quality of life. Results: Both groups improved at the end of the rehabilitation period and we did not find significant between-group differences in any of the principal posturographic measures with the exception of higher sway area and limit of stability on the instrumental functional reach test during visual deprivation at T1 in the Equistasi group. As for the secondary outcome, we found an overall better outcome in patients enrolled in the Equistasi group: 1) significant improvement at T1 on Berg Balance Scale (+45.0%, p = .026), Activities-specific Balance Confidence (+83.7, p = .004), Falls Efficacy Scale (-33.3%, p = .026) and PDQ-39 (-48.8%, p = .004); 2) sustained improvement at T2 in terms of UPDRS-III, Berg Balance Scales, Time Up and Go and PDQ-39; 3) significant and sustained reduction of the falls rate. Conclusions: This pilot trial shows that a physiotherapy program for training balance in association with focal mechanical vibration exerted by a wearable proprioceptive stabilizer might be superior than rehabilitation alone in improving patients' balance.	[Volpe, Daniele; Giantin, Maria Giulia] S Raffaele Arcangelo Fatebenefratelli Hosp, Dept Phys Med & Rehabil, Venice, Italy; [Fasano, Alfonso] Toronto Western Hosp, Morton & Gloria Shulman Movement Disorders Clin, Toronto, ON M5T 2S8, Canada; [Fasano, Alfonso] Toronto Western Hosp, Edmond J Safra Program Parkinsons Dis, Toronto, ON M5T 2S8, Canada; [Fasano, Alfonso] Univ Toronto, Div Neurol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Volpe, D (corresponding author), S Raffaele Arcangelo Fatebenefratelli Hosp, Dept Phys Med & Rehabil, Venice, Italy.	dott.dvolpe@libero.it	Fasano, Alfonso/K-2558-2018	Fasano, Alfonso/0000-0001-5346-0180				Abdo WF, 2006, J NEUROL NEUROSUR PS, V77, P1367, DOI 10.1136/jnnp.2006.091322; Allen NE, 2011, MOVEMENT DISORD, V26, P1605, DOI 10.1002/mds.23790; Ashburn A, 2007, J NEUROL NEUROSUR PS, V78, P678, DOI 10.1136/jnnp.2006.099333; BECKLEY DJ, 1993, ELECTROEN CLIN NEURO, V89, P22, DOI 10.1016/0168-5597(93)90080-9; Benatru I, 2008, NEUROPHYSIOL CLIN, V38, P459, DOI 10.1016/j.neucli.2008.07.006; Berardelli A, 2013, EUR J NEUROL, V20, P16, DOI 10.1111/ene.12022; BERG K, 1995, SCAND J REHABIL MED, V27, P27; Bosco C, 1999, CLIN PHYSIOL, V19, P183; Bove M, 2003, J PHYSIOL-LONDON, V550, P617, DOI 10.1113/jphysiol.2003.043331; BURKE D, 1976, J PHYSIOL-LONDON, V261, P695, DOI 10.1113/jphysiol.1976.sp011581; Conte A, 2013, NAT REV NEUROL, V9, P687, DOI 10.1038/nrneurol.2013.224; CORDO P, 1995, J NEUROPHYSIOL, V74, P1675, DOI 10.1152/jn.1995.74.4.1675; Courtine G, 2007, J NEUROPHYSIOL, V97, P772, DOI 10.1152/jn.00764.2006; De Nunzio AM, 2010, CLIN NEUROPHYSIOL, V121, P240, DOI 10.1016/j.clinph.2009.10.018; De Nunzio AM, 2008, MOVEMENT DISORD, V23, P2186, DOI 10.1002/mds.22201; Demirci M, 1997, ANN NEUROL, V41, P781, DOI 10.1002/ana.410410614; DESMEDT JE, 1978, J PHYSIOL-LONDON, V285, P197, DOI 10.1113/jphysiol.1978.sp012567; DUNCAN PW, 1990, J GERONTOL, V45, pM192, DOI 10.1093/geronj/45.6.M192; EKLUND G, 1972, UPSALA J MED SCI, V77, P112, DOI 10.1517/03009734000000016; Fahn S, 1987, RECENT DEV PARKINSON, V2, P153; Fasano A, 2012, NEUROL SCI, V33, P1215, DOI 10.1007/s10072-012-1126-6; Fiorio M, 2007, NEUROSCI LETT, V417, P312, DOI 10.1016/j.neulet.2007.02.050; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Goodwin VA, 2011, J NEUROL NEUROSUR PS, V82, P1232, DOI 10.1136/jnnp-2011-300919; Hirsch MA, 2003, ARCH PHYS MED REHAB, V84, P1109, DOI 10.1016/S0003-9993(03)00046-7; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; HORAK FB, 1992, J NEUROL SCI, V111, P46, DOI 10.1016/0022-510X(92)90111-W; Ivanenko YP, 2000, J NEUROPHYSIOL, V84, P1737, DOI 10.1152/jn.2000.84.4.1737; Jacobs JV, 2006, NEUROSCIENCE, V141, P999, DOI 10.1016/j.neuroscience.2006.04.014; Kerr GK, 2010, NEUROLOGY, V75, P116, DOI 10.1212/WNL.0b013e3181e7b688; Kording KP, 2006, TRENDS COGN SCI, V10, P319, DOI 10.1016/j.tics.2006.05.003; LACKNER JR, 1979, AVIAT SPACE ENVIR MD, V50, P346; Lamont RM, 2012, PARKINSONS DIS-US, V2012, DOI 10.1155/2012/856237; Latt MD, 2009, MOVEMENT DISORD, V24, P1280, DOI 10.1002/mds.22561; Li FZ, 2012, NEW ENGL J MED, V366, P511, DOI 10.1056/NEJMoa1107911; MARSDEN CD, 1969, BRAIN, V92, P647, DOI 10.1093/brain/92.3.647; Menant JC, 2011, MOVEMENT DISORD, V26, P637, DOI 10.1002/mds.23547; Mohapatra S, 2012, EXP BRAIN RES, V217, P197, DOI 10.1007/s00221-011-2986-3; Morris ME, 2006, PHYS THER, V86, P1426, DOI 10.2522/ptj.20050277; Morris ME, 2010, PHYS THER, V90, P280, DOI 10.2522/ptj.20090091; Morris ME, 2009, MOVEMENT DISORD, V24, P64, DOI 10.1002/mds.22295; Munneke M, 2010, LANCET NEUROL, V9, P46, DOI 10.1016/S1474-4422(09)70327-8; Nanhoe-Mahabier W, 2012, PARKINSONISM RELAT D, V18, P1017, DOI 10.1016/j.parkreldis.2012.05.018; Nardone A, 2005, CLIN NEUROPHYSIOL, V116, P1370, DOI 10.1016/j.clinph.2005.01.015; Nardone A, 2006, MOVEMENT DISORD, V21, P1515, DOI 10.1002/mds.21015; Necking LE, 1996, J HAND SURG-BRIT EUR, V21B, P753, DOI 10.1016/S0266-7681(96)80180-X; Nieuwboer A, 2009, PARKINSONISM RELAT D, V15, pS53, DOI 10.1016/S1353-8020(09)70781-3; Nonnekes J, 2013, EXPERT REV NEUROTHER, V13, P1303, DOI 10.1586/14737175.2013.839231; Paul SS, 2012, GAIT POSTURE, V36, P639, DOI 10.1016/j.gaitpost.2012.04.013; Peterka RJ, 2002, J NEUROPHYSIOL, V88, P1097, DOI 10.1152/jn.2002.88.3.1097; PETO V, 1995, QUAL LIFE RES, V4, P241, DOI 10.1007/BF02260863; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; POWELL LE, 1995, J GERONTOL A-BIOL, V50, pM28, DOI 10.1093/gerona/50A.1.M28; Rocchi L, 2006, NEUROSCI LETT, V406, P128, DOI 10.1016/j.neulet.2006.07.027; Rochester L, 2010, MOVEMENT DISORD, V25, P906, DOI 10.1002/mds.22978; ROLL JP, 1982, EXP BRAIN RES, V47, P177; SCHIEPPATI M, 1991, BRAIN, V114, P1227, DOI 10.1093/brain/114.3.1227; SCHIEPPATI M, 1984, EXP BRAIN RES, V56, P448; SCHIEPPATI M, 1994, ELECTROEN CLIN NEURO, V93, P286, DOI 10.1016/0168-5597(94)90031-0; Scoppa F, 2013, GAIT POSTURE, V37, P290, DOI 10.1016/j.gaitpost.2012.07.009; Slijper H, 2004, BRAIN RES, V1015, P57, DOI 10.1016/j.brainres.2004.04.054; Smiley-Oyen AL, 2002, GAIT POSTURE, V16, P188, DOI 10.1016/S0966-6362(02)00005-X; Soh SE, 2011, PARKINSONISM RELAT D, V17, P1, DOI 10.1016/j.parkreldis.2010.08.012; Tan D, 2012, PARKINSONISM RELAT D, V18, P117, DOI 10.1016/j.parkreldis.2011.07.014; Thompson Mary, 2007, J Geriatr Phys Ther, V30, P43; TINETTI ME, 1990, J GERONTOL, V45, pP239, DOI 10.1093/geronj/45.6.P239; Tomlinson CL, 2010, MOVEMENT DISORD, V25, P2649, DOI 10.1002/mds.23429; Valkovic P, 2006, MOVEMENT DISORD, V21, P59, DOI 10.1002/mds.20679; Valkovic P, 2006, NEUROSCI LETT, V401, P92, DOI 10.1016/j.neulet.2006.02.073	69	22	24	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 17	2014	9	11							e112065	10.1371/journal.pone.0112065	http://dx.doi.org/10.1371/journal.pone.0112065			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT8BL	25401967	Green Published, gold, Green Submitted			2023-01-03	WOS:000345158700026
J	Muck, A; Adams, BD				Muck, Andrew; Adams, Bruce D.			Early goal-directed therapy did not reduce mortality more than usual care in early septic shock	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							SEVERE SEPSIS		[Muck, Andrew] Univ Hosp, Dept Emergency Med, San Antonio, TX 78229 USA; UT Sch Med San Antonio, San Antonio, TX USA		Muck, A (corresponding author), Univ Hosp, Dept Emergency Med, San Antonio, TX 78229 USA.							Gaieski DF, 2010, CRIT CARE MED, V38, P1045, DOI 10.1097/CCM.0b013e3181cc4824; Lagu T, 2012, CRIT CARE MED, V40, P754, DOI 10.1097/CCM.0b013e318232db65; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Yealy DM, 2014, NEW ENGL J MED, V370, P1683, DOI 10.1056/NEJMoa1401602	4	2	2	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 17	2015	162	6							JC4	10.7326/ACPJC-2015-162-6-004	http://dx.doi.org/10.7326/ACPJC-2015-162-6-004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CD7OH	25775347				2023-01-03	WOS:000351279600003
J	Bashar, K; Zafar, A; Elsheikh, S; Healy, DA; Clarke-Moloney, M; Casserly, L; Burke, PE; Kavanagh, EG; Walsh, SR				Bashar, Khalid; Zafar, Adeel; Elsheikh, Sawsan; Healy, Donagh A.; Clarke-Moloney, Mary; Casserly, Liam; Burke, Paul E.; Kavanagh, Eamon G.; Walsh, Stewart R.			Predictive Parameters of Arteriovenous Fistula Functional Maturation in a Population of Patients with End-Stage Renal Disease	PLOS ONE			English	Article							VASCULAR ACCESS; SURVIVAL; OUTCOMES; STENOSIS	Introduction With increasing numbers of patients diagnosed with ESRD, arteriovenous fistula (AVF) maturation has become a major factor in improving both dialysis related outcomes and quality of life of those patients. Compared to other types of access it has been established that a functional AVF access is the least likely to be associated with thrombosis, infection, hospital admissions, secondary interventions to maintain patency and death. Aim Study of demographic factors implicated in the functional maturation of arteriovenous fistulas. Also, to explore any possible association between preoperative haematological investigations and functional maturation. Methods We performed a retrospective chart review of all patients with ESRD who were referred to the vascular service in the University Hospital of Limerick for creation of vascular access for HD. We included patients with primary AVFs; and excluded those who underwent secondary procedures. Results Overall AVF functional maturation rate in our study was 53.7%(52/97). Female gender showed significant association with nonmaturation (P = 0.004) and was the only predictor for non-maturation in a logistic regression model (P = 0.011). Patients who had history of renal transplant (P = 0.036), had relatively lower haemoglobin levels (P = 0.01) and were on calcium channel blockers (P = 0.001) showed better functional maturation rates. Conclusion Female gender was found to be associated with functional non-maturation, while a history kidney transplant, calcium channel-blocker agents and low haemoglobin levels were all associated with successful functional maturation. In view of the conflicting evidence in the literature, large prospective multi-centre registry-based studies with well-defined outcomes are needed.	[Bashar, Khalid; Zafar, Adeel; Healy, Donagh A.; Clarke-Moloney, Mary; Burke, Paul E.; Kavanagh, Eamon G.] Univ Hosp Limerick, Dept Vasc Surg, Limerick, Ireland; [Elsheikh, Sawsan] James Connolly Mem Hosp, Dept Acute Med, Dublin, Ireland; [Casserly, Liam] Univ Hosp Limerick, Dept Nephrol, Limerick, Ireland; [Walsh, Stewart R.] Natl Univ Ireland, Dept Surg, Galway, Ireland	University of Limerick; University of Limerick; Ollscoil na Gaillimhe-University of Galway	Bashar, K (corresponding author), Univ Hosp Limerick, Dept Vasc Surg, Limerick, Ireland.	khalid@live.ie	Walsh, Stewart R/AAC-1229-2021	Walsh, Stewart/0000-0002-1006-9541				Allon M, 2002, KIDNEY INT, V62, P1109, DOI 10.1111/j.1523-1755.2002.kid551.x; Allon M, 2001, KIDNEY INT, V60, P2013, DOI 10.1046/j.1523-1755.2001.00031.x; Allon M, 2007, CLIN J AM SOC NEPHRO, V2, P786, DOI 10.2215/CJN.00860207; Allon M, 2011, AM J KIDNEY DIS, V58, P437, DOI 10.1053/j.ajkd.2011.04.018; Amorim Pedro, 2013, Rev Port Cir Cardiotorac Vasc, V20, P211; Bashar K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104931; Bhalodia R, 2011, SEMIN DIALYSIS, V24, P355, DOI 10.1111/j.1525-139X.2010.00760.x; Centre Ecotox Centre Suisse d'ecotoxicologie appliquee (Eawag/EPFL), 2012, SURV QUAL SED SUISS, P34; Chand DH, 2009, PEDIATR NEPHROL, V24, P1121, DOI 10.1007/s00467-008-0812-3; Conte MS, 2011, J VASC SURG, V54, P1383, DOI 10.1016/j.jvs.2011.05.005; Corp I, 2013, IBM SPSS STAT WIND V; COX JL, 1991, PROG CARDIOVASC DIS, V34, P45, DOI 10.1016/0033-0620(91)90019-I; DAVIES MG, 1994, BRIT J SURG, V81, P1254, DOI 10.1002/bjs.1800810904; Dixon BS, 2002, AM J KIDNEY DIS, V39, P92, DOI 10.1053/ajkd.2002.29886; Feldman HI, 2003, AM J KIDNEY DIS, V42, P1000, DOI 10.1016/j.ajkd.2003.07.003; Frankel A, 2006, EUR J VASC ENDOVASC, V31, P417, DOI 10.1016/j.ejvs.2005.10.003; Jemcov TK, 2013, J VASC ACCESS, V14, P356, DOI 10.5301/jva.5000163; KDOQI NKF-, 2006, UPD CLIN PRACT GUID; Lee T, 2011, CLIN J AM SOC NEPHRO, V6, P575, DOI 10.2215/CJN.06630810; LEVENE H, 1949, ANN MATH STAT, V20, P91, DOI 10.1214/aoms/1177730093; Lok CE, 2005, KIDNEY INT, V67, P2462, DOI 10.1111/j.1523-1755.2005.00355.x; MILLER VM, 1992, AM J PHYSIOL, V263, pH103, DOI 10.1152/ajpheart.1992.263.1.H103; Newby AC, 2000, J PATHOL, V190, P300, DOI 10.1002/(SICI)1096-9896(200002)190:3<300::AID-PATH596>3.0.CO;2-I; Ocak G, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-79; Oliver MJ, 2001, KIDNEY INT, V60, P1532, DOI 10.1046/j.1523-1755.2001.00956.x; Peterson WJ, 2008, CLIN J AM SOC NEPHRO, V3, P437, DOI 10.2215/CJN.03480807; Pisoni RL, 2002, KIDNEY INT, V61, P305, DOI 10.1046/j.1523-1755.2002.00117.x; Polkinghorne KR, 2004, J AM SOC NEPHROL, V15, P477, DOI 10.1097/01.ASN.0000109668.05157.05; Rayner HC, 2004, AM J KIDNEY DIS, V44, pS22, DOI 10.1053/j.ajkd.2004.08.007; Rayner HC, 2003, KIDNEY INT, V63, P323, DOI 10.1046/j.1523-1755.2003.00724.x; Renaud CJ, 2012, J VASC SURG, V56, P433, DOI 10.1016/j.jvs.2012.01.063; Rodriguez JA, 2000, NEPHROL DIAL TRANSPL, V15, P402, DOI 10.1093/ndt/15.3.402; Salmela B, 2013, CLIN J AM SOC NEPHRO, V8, P962, DOI 10.2215/CJN.03860412; Santoro A, 2006, J NEPHROL, V19, P259; Sedlacek M, 2001, AM J KIDNEY DIS, V38, P560, DOI 10.1053/ajkd.2001.26873; Stoumpos S, 2014, AM J NEPHROL, V39, P491, DOI 10.1159/000362744; Yilmaz H, 2014, RENAL FAILURE, V36, P1390, DOI 10.3109/0886022X.2014.945183; Zadeh MK, 2008, J VASC ACCESS, V9, P133, DOI 10.1177/112972980800900210; Zadeh MK, 2012, INT J NEPHROL, V2012, DOI 10.1155/2012/942950	39	38	39	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 13	2015	10	3							e0119958	10.1371/journal.pone.0119958	http://dx.doi.org/10.1371/journal.pone.0119958			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CD7NO	25768440	gold, Green Published, Green Submitted			2023-01-03	WOS:000351277500104
J	Nyondo, AL; Choko, AT; Chimwaza, AF; Muula, AS				Nyondo, Alinane Linda; Choko, Augustine Talumba; Chimwaza, Angela Faith; Muula, Adamson Sinjani			Invitation Cards during Pregnancy Enhance Male Partner Involvement in Prevention of Mother to Child Transmission (PMTCT) of Human Immunodeficiency Virus (HIV) in Blantyre, Malawi: A Randomized Controlled Open Label Trial	PLOS ONE			English	Article							SUB-SAHARAN AFRICA; REPRODUCTIVE HEALTH; MATERNAL HEALTH; ANTENATAL ATTENDANCE; EASTERN UGANDA; SERVICES; WOMEN; OPPORTUNITIES; INFECTION; BARRIERS	Introduction Male involvement (MI) is vital for the uptake of Prevention of Mother to Child Transmission (PMTCT) of Human Immunodeficiency Virus (HIV) interventions. Partner notification (PN) is among the strategies identified for MI in PMTCT services. The purpose of this randomized controlled trial was to evaluate the efficacy of an invitation card to the male partners as a strategy for MI in PMTCT services by comparing the proportion of pregnant women that were accompanied by their partners between the intervention and the non-intervention study groups. Methods Pregnant women attending antenatal care without a male partner at South Lunzu and Mpemba health centres in Blantyre, Malawi, were enrolled in the study from June to December 2013. In an intention-to-treat analysis, we compared all participants that were randomized in the invitation card group with the standard of care (SoC) group. Risk ratios (RR) with 95% confidence intervals (CI) were computed to assess the efficacy of the invitation card. Results Of the 462 randomized women, 65/230 (28.26%) of the women in the invitation card group reported to the antenatal care clinic with their partners compared to 44/232 (18.97%) women in the SoC group. In an unadjusted intention-to-treat analysis women in the invitation card group were 50% more likely to be accompanied by their male partners than those in the SoC group RR: 1.49 (95% CI: 1.06-2.09); p = 0.02. Our random effects analysis showed that there was no clustering by site of recruitment with an inter cluster correlation coefficient (ICC) of 1.98 x 10(-3), (95% CI: 1.78 x 10(-7) - 0.96 x 10(-1)); p = 0.403. Conclusion An invitation card significantly increased the proportion of women who were accompanied by their male partners for the PMTCT services. An invitation card is a feasible strategy for MI in PMTCT.	[Nyondo, Alinane Linda; Muula, Adamson Sinjani] Univ Malawi, Coll Med, Sch Publ Hlth & Family Med, Blantyre, Malawi; [Choko, Augustine Talumba] Malawi Liverpool Wellcome Trust Clin Res Programm, Blantyre, Malawi; [Chimwaza, Angela Faith] Univ Malawi, Kamuzu Coll Nursing, Blantyre, Malawi	University of Malawi; University of Malawi; University of Malawi	Nyondo, AL (corresponding author), Univ Malawi, Coll Med, Sch Publ Hlth & Family Med, Blantyre, Malawi.	lindaalinane@gmail.com	Muula, Adamson/AAF-1153-2020; Nyondo, Alinane/AFN-8844-2022	Nyondo, Alinane/0000-0002-3572-3810	Consortium for Advanced Research Training in Africa (CARTA); Wellcome Trust (UK) [087547/Z/08/Z]; Department for International Development (DfID) under the Development Partnerships in Higher Education (DelPHE); Carnegie Corporation of New York [B 8606]; Ford Foundation [1100-0399]; Google.org [191994]; Sida [54100029]; Bill and Melinda Gates Foundation [51228]; Malawi Health Research Capacity Strengthening Initiative; DFID; Wellcome Trust [HRCSI/PhD/12/09]	Consortium for Advanced Research Training in Africa (CARTA); Wellcome Trust (UK)(Wellcome Trust); Department for International Development (DfID) under the Development Partnerships in Higher Education (DelPHE); Carnegie Corporation of New York; Ford Foundation; Google.org; Sida; Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); Malawi Health Research Capacity Strengthening Initiative; DFID; Wellcome Trust(Wellcome TrustEuropean Commission)	This research was partially funded by a Fellowship award provided by the Consortium for Advanced Research Training in Africa (CARTA). CARTA has been funded by the Wellcome Trust (UK) (Grant No: 087547/Z/08/Z), the Department for International Development (DfID) under the Development Partnerships in Higher Education (DelPHE), the Carnegie Corporation of New York (Grant No: B 8606), the Ford Foundation (Grant No: 1100-0399), Google.org (Grant No: 191994), Sida (Grant No: 54100029), and the Bill and Melinda Gates Foundation (Grant No: 51228). This study was also funded by the Malawi Health Research Capacity Strengthening Initiative, a DFID and Wellcome Trust funded programme grant number HRCSI/PhD/12/09. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alio AP, 2010, MATERN CHILD HLTH J, V14, P931, DOI 10.1007/s10995-009-0531-9; Aluisio A, 2011, JAIDS-J ACQ IMM DEF, V56, P76, DOI 10.1097/QAI.0b013e3181fdb4c4; Angotti N, 2011, HEALTH POLICY PLANN, V26, P307, DOI 10.1093/heapol/czq066; Betancourt TS., 2010, J INT AIDS SOC, V13; Blantyre DHO, 2012, BLANT STAT; Brown LB, 2011, JAIDS-J ACQ IMM DEF, V56, P437, DOI 10.1097/QAI.0b013e318202bf7d; Byamugisha R, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-43; Byamugisha R, 2010, REPROD HEALTH, V7, DOI 10.1186/1742-4755-7-12; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Dudgeon MR, 2004, SOC SCI MED, V59, P1379, DOI 10.1016/j.socscimed.2003.11.035; EGPAF, 2011, MAL INV PMTCT REACH; Farquhar C, 2004, JAIDS-J ACQ IMM DEF, V37, P1620, DOI 10.1097/00126334-200412150-00016; Ferguson L, 2012, TROP MED INT HEALTH, V17, P564, DOI 10.1111/j.1365-3156.2012.02958.x; Gourlay A, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.1.18588; [Government of Malawi MoH Ministry of Health], 2014, MAL INT HIV PROGR RE; Homsy J, 2007, JAIDS-J ACQ IMM DEF, V44, P366, DOI 10.1097/QAI.0b013e31802f1303; Kalembo FW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066517; Katz DA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007602; Kululanga LI, 2011, REPROD HEALTH, V8, DOI 10.1186/1742-4755-8-36; Low N, 2006, LANCET, V368, P2001, DOI 10.1016/S0140-6736(06)69482-8; Maman S, 2011, J MIDWIFERY WOM HEAL, V56, P325, DOI 10.1111/j.1542-2011.2011.00029.x; Martin LT, 2007, MATERN CHILD HLTH J, V11, P595, DOI 10.1007/s10995-007-0209-0; Mathews C, 2007, COCHRANE DATABASE SY; Mbuyi B, 2004, INVOLVING MALE PARTN; Mlay R, 2008, AIDS CARE, V20, P356, DOI 10.1080/09540120701561304; Mohlala BKF, 2011, AIDS, V25, P1535, DOI 10.1097/QAD.0b013e328348fb85; Morfaw F, 2013, SYST REV, V2, DOI 10.1186/2046-4053-2-5; Moth I A, 2005, SAHARA J, V2, P244; Msuya SE, 2008, AIDS CARE, V20, P700, DOI 10.1080/09540120701687059; Mullany BC, 2006, SOC SCI MED, V62, P2798, DOI 10.1016/j.socscimed.2005.11.013; Mullany BC, 2007, HEALTH EDUC RES, V22, P166, DOI 10.1093/her/cyl060; NSO, 2008, POP HOUS CENS RES, P1; Nyondo AL, 2013, GLOBAL HEALTH ACTION, V6, P1, DOI 10.3402/gha.v6i0.22780; Nyondo AL, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-691; Rosen S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001056; Semrau K, 2005, AIDS, V19, P603, DOI 10.1097/01.aids.0000163937.07026.a0; Sternberg P, 2004, HEALTH PROMOT INT, V19, P389, DOI 10.1093/heapro/dah312; Theuring S, 2009, AIDS BEHAV, V13, pS92, DOI 10.1007/s10461-009-9543-0; UNAIDS, 2013, UNAIDS GLOB REP AIDS; Wettstein C, 2012, AIDS, V26, P2361, DOI 10.1097/QAD.0b013e328359ab0c; WHO, 2012, US ANT DRUGS TREAT P; WHO, 2010, PMTCT STRAT VIS 2010, DOI [10.1016/S0140-6736(14)60844-8, DOI 10.1016/S0140-6736(14)60844-8]; Wringe A, 2008, TROP MED INT HEALTH, V13, P319, DOI 10.1111/j.1365-3156.2008.02005.x	43	45	45	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2015	10	3							e0119273	10.1371/journal.pone.0119273	http://dx.doi.org/10.1371/journal.pone.0119273			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CC4HV	25734485	Green Published, Green Submitted, gold			2023-01-03	WOS:000350314700062
J	Cotton, D				Cotton, Deborah			Celebrating the ACP Centennial: From the Annals Archive	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																		Committee on Approaching Death: Addressing Key End of Life Issues, 2014, DYING AM IMPR QUAL H; Halpern SD, 2015, ANN INTERN MED, V162, P224, DOI 10.7326/M14-2476; MARSHALL JR, 1969, ANN INTERN MED, V70, P615, DOI 10.7326/0003-4819-70-3-615; Ness DL, 2015, ANN INTERN MED, V162, P226, DOI 10.7326/M14-2537; Pizzo PA, 2015, ANN INTERN MED, V162, P228, DOI 10.7326/M14-2399; Rao JK, 2015, ANN INTERN MED, V162, P230, DOI 10.7326/M14-2479; Singer AE, 2015, ANN INTERN MED, V162, P175, DOI 10.7326/M13-1609	7	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 3	2015	162	3					232	232		10.7326/M14-2865	http://dx.doi.org/10.7326/M14-2865			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CC1NP	25643307				2023-01-03	WOS:000350108100012
J	Tsuruya, K; Fukuma, S; Wakita, T; Ninomiya, T; Nagata, M; Yoshida, H; Fujimi, S; Kiyohara, Y; Kitazono, T; Uchida, K; Shirota, T; Akizawa, T; Akiba, T; Saito, A; Fukuhara, S				Tsuruya, Kazuhiko; Fukuma, Shingo; Wakita, Takafumi; Ninomiya, Toshiharu; Nagata, Masaharu; Yoshida, Hisako; Fujimi, Satoru; Kiyohara, Yutaka; Kitazono, Takanari; Uchida, Kazuhiro; Shirota, Tomoko; Akizawa, Tadao; Akiba, Takashi; Saito, Akira; Fukuhara, Shunichi			Dietary Patterns and Clinical Outcomes in Hemodialysis Patients in Japan: A Cohort Study	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; CARDIOVASCULAR-DISEASE; COLORECTAL-CANCER; DIALYSIS PATIENTS; HISTORY QUESTIONNAIRES; CLUSTER-ANALYSIS; MORTALITY; HISAYAMA; METAANALYSIS; GUIDELINES	Background & Objectives Little is known about actual dietary patterns and their associations with clinical outcomes in hemodialysis patients. We identified dietary patterns in hemodialysis patients in Japan and examined associations between dietary patterns and clinical outcomes. Design, setting, participants, measurements We used data from 3,080 general-population participants in the Hisayama study (year 2007), and data from 1,355 hemodialysis patients in the Japan Dialysis Outcomes and Practice Patterns Study (JDOPPS: years 2005-2007). Food intake was measured using a brief self-administered diet-history questionnaire (BDHQ). To identify food groups with the Hisayama population data, we used principal components analysis with Promax rotation. We adjusted the resulting food groups for total daily energy intake, and then we used those adjusted food-group scores to identify dietary patterns in the JDOPPS patients by cluster analysis (Ward's method). We then used Cox regression to examine the association between dietary patterns and a composite of adverse clinical outcomes: hospitalization due to cardiovascular disease or death due to any cause. Results We identified three food groups: meat, fish, and vegetables. Using those groups we then identified three dietary patterns: well-balanced, unbalanced, and other. After adjusting for potential confounders, we found an association between an unbalanced diet and important clinical events (hazard ratio 1.90, 95% C.I. 1.19-3.04). Conclusions Hemodialysis patients whose diet was unbalanced were more likely to have adverse clinical outcomes. Thus hemodialysis patients might benefit not only from portion control, but also from a diet that is well-balanced diet with regard to the food groups identified here as meat, fish, and vegetables.	[Tsuruya, Kazuhiko; Yoshida, Hisako] Kyushu Univ, Grad Sch Med Sci, Dept Integrated Therapy Chron Kidney Dis, Fukuoka 812, Japan; [Fukuma, Shingo; Fukuhara, Shunichi] Kyoto Univ, Grad Sch Med & Publ Hlth, Dept Healthcare Epidemiol, Kyoto, Japan; [Fukuma, Shingo] Inst Hlth Outcomes & Proc Evaluat Res iHope Int, Tokyo, Japan; [Wakita, Takafumi] Kansai Univ, Fac Sociol, Osaka, Japan; [Ninomiya, Toshiharu; Kitazono, Takanari] Kyushu Univ, Grad Sch Med Sci, Dept Med & Clin Sci, Fukuoka 812, Japan; [Nagata, Masaharu] Kyushu Univ, Grad Sch Med Sci, Commun Med Educ Unit, Fukuoka 812, Japan; [Fujimi, Satoru] Fukuoka Renal Clin, Fukuoka, Japan; [Kiyohara, Yutaka] Kyushu Univ, Grad Sch Med Sci, Dept Environm Med, Fukuoka 812, Japan; [Uchida, Kazuhiro; Shirota, Tomoko] Nakamura Gakuen Univ, Sch Hlth & Nutr Sci, Dept Hlth Promot, Fukuoka, Japan; [Akizawa, Tadao] Showa Univ, Sch Med, Dept Med, Div Nephrol, Tokyo 142, Japan; [Akiba, Takashi] Tokyo Womens Med Univ, Kidney Ctr, Dept Blood Purificat & Internal Med, Tokyo, Japan; [Saito, Akira] Shonantobu Gen Hosp, Div Nephrol, Kanagawa, Japan; [Saito, Akira] Shonantobu Gen Hosp, Dialysis Ctr, Kanagawa, Japan; [Fukuhara, Shunichi] Fukushima Med Univ, Ctr Innovat Res Commun & Clin Excellence, Fukushima, Japan	Kyushu University; Kyoto University; Kansai University; Kyushu University; Kyushu University; Kyushu University; Showa University; Tokyo Women's Medical University; Fukushima Medical University	Fukuhara, S (corresponding author), Kyoto Univ, Grad Sch Med & Publ Hlth, Dept Healthcare Epidemiol, Kyoto, Japan.	fukuhara.shunichi.6m@kyoto-u.ac.jp		Wakita, Takafumi/0000-0003-2293-5918; Fukuma, Shingo/0000-0002-8379-8761	scientific research grants from Kyowa Hakko Kirin (Japan)	scientific research grants from Kyowa Hakko Kirin (Japan)	This study is supported by scientific research grants from Kyowa Hakko Kirin (Japan). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	CATTELL RB, 1965, BIOMETRICS, V21, P405, DOI 10.2307/2528100; Combe C, 2004, AM J KIDNEY DIS, V44, pS39, DOI 10.1053/j.ajkd.2004.08.010; Everitt B.S., 2001, CLUSTER ANAL; Flood A, 2008, AM J CLIN NUTR, V88, P176, DOI 10.1093/ajcn/88.1.176; Fukuhara M, 2012, J HYPERTENS, V30, P893, DOI 10.1097/HJH.0b013e328351d380; Hata J, 2013, CIRCULATION, V128, P1198, DOI 10.1161/CIRCULATIONAHA.113.002424; Heerspink HL, 2009, LANCET, V373, P1009, DOI 10.1016/S0140-6736(09)60212-9; Kalantar-Zadeh K, 2009, CIRCULATION, V119, P671, DOI 10.1161/CIRCULATIONAHA.108.807362; Katsuki S, 1966, Prog Brain Res, V21, P64; Kobayashi S, 2012, J EPIDEMIOL, V22, P151, DOI 10.2188/jea.JE20110075; Kobayashi S, 2011, PUBLIC HEALTH NUTR, V14, P1200, DOI 10.1017/S1368980011000504; Kopple JD, 2001, AM J KIDNEY DIS, V37, pS66, DOI 10.1053/ajkd.2001.20748; Krishnamurthy VMR, 2012, KIDNEY INT, V81, P300, DOI 10.1038/ki.2011.355; Kubo M, 2003, STROKE, V34, P2349, DOI 10.1161/01.STR.0000090348.52943.A2; Kuriyama S, 2008, CLIN EXP NEPHROL, V12, P165, DOI 10.1007/s10157-007-0020-7; Kutner NG, 2002, AM J KIDNEY DIS, V39, P1018, DOI 10.1053/ajkd.2002.32775; Mahabir S, 2006, EUR J CLIN NUTR, V60, P561, DOI 10.1038/sj.ejcn.1602359; Mailloux LU, 2000, SEMIN DIALYSIS, V13, P150, DOI 10.1046/j.1525-139x.2000.00040.x; Noori N, 2010, CLIN J AM SOC NEPHRO, V5, P683, DOI 10.2215/CJN.08601209; Okubo H, 2006, AM J CLIN NUTR, V83, P1185, DOI 10.1093/ajcn/83.5.1185; Palmer SC, 2011, JAMA-J AM MED ASSOC, V305, P1119, DOI 10.1001/jama.2011.308; Pisoni RL, 2004, AM J KIDNEY DIS, V44, pS7, DOI 10.1053/j.ajkd.2004.08.005; Port FK, 2004, AM J KIDNEY DIS, V44, pS1, DOI 10.1053/j.ajkd.2004.08.004; Reedy J, 2010, AM J EPIDEMIOL, V171, P479, DOI 10.1093/aje/kwp393; Sanghavi S, 2013, SEMIN DIALYSIS, V26, P597, DOI 10.1111/sdi.12123; Sasaki S, 2000, J NUTR SCI VITAMINOL, V46, P285, DOI 10.3177/jnsv.46.285; Sasaki S, 1998, J Epidemiol, V8, P203; Sherman RA, 2009, AM J KIDNEY DIS, V54, P18, DOI 10.1053/j.ajkd.2009.01.269; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; Wirfalt E, 2009, EUR J CLIN NUTR, V63, P707, DOI 10.1038/ejcn.2008.40	30	14	14	3	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 21	2015	10	1							e0116677	10.1371/journal.pone.0116677	http://dx.doi.org/10.1371/journal.pone.0116677			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AZ4PR	25607947	Green Submitted, Green Published, gold			2023-01-03	WOS:000348205300031
J	Abushufa, AM; Eldehni, MT; Odudu, A; Evans, PD; O'Sullivan, SE; McIntyre, CW				Abushufa, Adil M.; Eldehni, Mohamed T.; Odudu, Aghogho; Evans, Philip D.; O'Sullivan, Saoirse E.; McIntyre, Chris W.			Defining Uremic Arterial Functional Abnormalities in Patients Recently Started on Haemodialysis: Combined In Vivo and Ex Vivo Assessment	PLOS ONE			English	Article							ENDOTHELIUM-DEPENDENT VASODILATATION; STAGE RENAL-DISEASE; VASCULAR CALCIFICATION; RESISTANCE ARTERIES; FAILURE; DYSFUNCTION; STIFFNESS; OUTCOMES; VESSELS; RATS	Endothelial dysfunction is a key initiating event in vascular disease in chronic kidney disease (CKD) patients and haemodialysis (HD) patients exhibit significant vascular abnormalities. To understand this further, we examined how ex vivo intrinsic function in isolated arteries correlates with in vivo assessments of cardiovascular status in HD patients. Abdominal fat biopsies were obtained from 11 HD patients and 26 non-uremic controls. Subcutaneous arteries were dissected and mounted on a wire myograph, and cumulative concentration-response curves to noradrenalin, endothelin-1, a thromboxane A(2) agonist (U46619), angiotensin II, vasopressin, bradykinin (BK), acetylcholine (ACh) and sodium nitroprusside (SNP) were constructed. Pulse wave velocity and blood pressure were measured in HD patients. Enhanced (P<0.05-0.0001) maximal contractile responses (R-max) to all spasmogens (particularly vasopressin) were observed in arteries from HD patients compared to controls, and this effect was more pronounced in arteries with an internal diameter. 600 mm. The potency (pEC(50)) of U46619 (P<0.01) and vasopressin (P<0.001) was also increased in arteries >600 mu m of HD patients. The maximal relaxant response to the endothelium-dependent dilators ACh and BK were lower in HD patients (P<0.01-P<0.0001) (worse for ACh than BK); however the endothelium-independent dilator SNP was similar in both groups. PWV was significantly correlated with the vasoconstrictor response to vasopressin (P=0.042) in HD patients. HD patients are primed for hypertension and end organ demand ischaemia by a highly sensitised pressor response. The failure of arterial relaxation is mediated by endothelial dysfunction. Intrinsic vascular abnormalities may be important in sensitising HD patients to recurrent cumulative ischaemic end organ injury.	[Abushufa, Adil M.; Eldehni, Mohamed T.; Odudu, Aghogho; Evans, Philip D.; O'Sullivan, Saoirse E.; McIntyre, Chris W.] Univ Nottingham, Sch Med, Div Med Sci & Grad Entry Med, Nottingham, England; [Eldehni, Mohamed T.; Odudu, Aghogho; Evans, Philip D.; McIntyre, Chris W.] Royal Derby Hosp, Dept Renal Med, Derby, England	University of Nottingham; University of Nottingham	O'Sullivan, SE (corresponding author), Univ Nottingham, Sch Med, Div Med Sci & Grad Entry Med, Nottingham, England.	Saoirse.osullivan@nottingham.ac.uk	McIntyre, Christopher W/O-8927-2014; Odudu, Aghogho/K-9048-2014	Odudu, Aghogho/0000-0002-4863-1560; Eldehni, Mohamed/0000-0003-1681-9048; O'Sullivan, Saoirse Elizabeth/0000-0002-1672-6610				AALKJAER C, 1986, CLIN SCI, V71, P657, DOI 10.1042/cs0710657; Annuk M, 2001, NEPHROL DIAL TRANSPL, V16, P302, DOI 10.1093/ndt/16.2.302; Baylis C, 2008, AM J PHYSIOL-RENAL, V294, pF1, DOI 10.1152/ajprenal.00424.2007; Blacher J, 1999, CIRCULATION, V99, P2434, DOI 10.1161/01.CIR.99.18.2434; Bostom AG, 1999, J AM SOC NEPHROL; Burton JO, 2009, CLIN J AM SOC NEPHRO, V4, P914, DOI 10.2215/CJN.03900808; Eldehni MT, 2012, SEMIN DIALYSIS, V25, P253, DOI 10.1111/j.1525-139X.2012.01057.x; Ferraro B, 2003, KIDNEY INT, V63, P2207, DOI 10.1046/j.1523-1755.2003.00008.x; Hand MF, 1998, KIDNEY INT, V53, P1068, DOI 10.1046/j.1523-1755.1998.00851.x; Hasdan G, 2002, KIDNEY INT, V61, P586, DOI 10.1046/j.1523-1755.2002.00166.x; Kielstein JT, 2002, J AM SOC NEPHROL, V13, P170, DOI 10.1681/ASN.V131170; Luksha L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036056; Luksha R, 2011, CLIN SCI, V120, P525, DOI 10.1042/CS20100277; Mallamaci F, 2002, KIDNEY INT, V61, P609, DOI 10.1046/j.1523-1755.2002.00144.x; McIntyre CA, 1998, BRIT J PHARMACOL, V123, P1555, DOI 10.1038/sj.bjp.0701768; McIntyre CW, 2010, SEMIN DIALYSIS, V23, P449, DOI 10.1111/j.1525-139X.2010.00782.x; Morris STW, 2001, KIDNEY INT, V60, P1077, DOI 10.1046/j.1523-1755.2001.0600031077.x; Morris STW, 2000, NEPHROL DIAL TRANSPL, V15, P1194, DOI 10.1093/ndt/15.8.1194; MULVANY MJ, 1977, CIRC RES, V41, P19, DOI 10.1161/01.RES.41.1.19; Oflaz H, 2003, CLIN TRANSPLANT, V17, P528, DOI 10.1046/j.1399-0012.2003.00100.x; Pucci G, 2012, J HYPERTENS; Raggi P, 2007, ADV CHRONIC KIDNEY D, V14, P37, DOI 10.1053/j.ackd.2006.10.006; Shinohara K, 2004, KIDNEY INT, V65, P936, DOI 10.1111/j.1523-1755.2004.00468.x; Sigrist MK, 2008, NEPHRON CLIN PRACT, V108, pC121, DOI 10.1159/000114202; VALLANCE P, 1992, LANCET, V339, P572; Van Biesen W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017148; Wabel P, 2008, NEPHROL DIAL TRANSPL, V23, P2965, DOI 10.1093/ndt/gfn228	27	0	0	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 29	2014	9	12							e113462	10.1371/journal.pone.0113462	http://dx.doi.org/10.1371/journal.pone.0113462			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX7UN	25546407	Green Published, gold, Green Submitted			2023-01-03	WOS:000347120200006
J	Bower, KJ; McGinley, JL; Miller, KJ; Clark, RA				Bower, Kelly J.; McGinley, Jennifer L.; Miller, Kimberly J.; Clark, Ross A.			Instrumented Static and Dynamic Balance Assessment after Stroke Using Wii Balance Boards: Reliability and Association with Clinical Tests	PLOS ONE			English	Article							SIT-TO-STAND; POSTURAL CONTROL; PRESSURE MEASURES; INDIVIDUALS; POSTSTROKE; VALIDITY; PERFORMANCE; SYSTEM; GAIT	Background and Objectives: The Wii Balance Board (WBB) is a globally accessible device that shows promise as a clinically useful balance assessment tool. Although the WBB has been found to be comparable to a laboratory-grade force platform for obtaining centre of pressure data, it has not been comprehensively studied in clinical populations. The aim of this study was to investigate the measurement properties of tests utilising the WBB in people after stroke. Methods: Thirty individuals who were more than three months post-stroke and able to stand unsupported were recruited from a single outpatient rehabilitation facility. Participants performed standardised assessments incorporating the WBB and customised software (static stance with eyes open and closed, static weight-bearing asymmetry, dynamic mediolateral weight shifting and dynamic sit-to-stand) in addition to commonly employed clinical tests (10 Metre Walk Test, Timed Up and Go, Step Test and Functional Reach) on two testing occasions one week apart. Test-retest reliability and construct validity of the WBB tests were investigated. Results: All WBB-based outcomes were found to be highly reliable between testing occasions (ICC =0.82 to 0.98). Correlations were poor to moderate between WBB variables and clinical tests, with the strongest associations observed between task-related activities, such as WBB mediolateral weight shifting and the Step Test. Conclusions: The WBB, used with customised software, is a reliable and potentially useful tool for the assessment of balance and weight-bearing asymmetry following stroke. Future research is recommended to further investigate validity and responsiveness.	[Bower, Kelly J.; McGinley, Jennifer L.] Univ Melbourne, Dept Physiotherapy, Melbourne, Vic, Australia; [Bower, Kelly J.] Royal Melbourne Hosp, Dept Physiotherapy, Melbourne, Vic, Australia; [Miller, Kimberly J.] Univ British Columbia, Dept Phys Therapy, Vancouver, BC V5Z 1M9, Canada; [Bower, Kelly J.; Clark, Ross A.] Australian Catholic Univ, Sch Exercise Sci, Melbourne, Vic, Australia	University of Melbourne; Royal Melbourne Hospital; University of British Columbia; Australian Catholic University	Bower, KJ (corresponding author), Univ Melbourne, Dept Physiotherapy, Melbourne, Vic, Australia.	kelly.bower@mh.org.au	Clark, Ross A/R-5664-2018; Clark, Ross/K-7613-2019	Clark, Ross A/0000-0002-7291-8553; Clark, Ross/0000-0002-7291-8553; McGinley, Jennifer/0000-0003-3775-9267; Miller, Kimberly/0000-0002-9826-7269	National Health and Medical Research Council	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	Funding: This study was funded in part by a National Health and Medical Research Council postgraduate scholarship (https://www.nhmrc.gov.au/) awarded to author KB. The authors received no additional specific funding for this work.	Barra J, 2009, NEUROLOGY, V72, P1582, DOI 10.1212/WNL.0b013e3181a4123a; Batchelor FA, 2012, INT J STROKE, V7, P482, DOI 10.1111/j.1747-4949.2012.00796.x; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Bower KJ, 2014, CLIN REHABIL, V28, P912, DOI 10.1177/0269215514527597; Chang JO, 2013, CLIN J SPORT MED; Cheng PT, 1998, ARCH PHYS MED REHAB, V79, P1043, DOI 10.1016/S0003-9993(98)90168-X; Chien CW, 2007, ARCH PHYS MED REHAB, V88, P374, DOI 10.1016/j.apmr.2006.11.019; Chou SW, 2003, AM J PHYS MED REHAB, V82, P42, DOI 10.1097/01.PHM.0000043769.93584.4D; Clark RA, 2010, GAIT POSTURE, V31, P307, DOI 10.1016/j.gaitpost.2009.11.012; Clark RA, 2011, GAIT POSTURE, V34, P288, DOI 10.1016/j.gaitpost.2011.04.010; de Haart M, 2005, ARCH PHYS MED REHAB, V86, P755, DOI 10.1016/j.apmr.2004.10.010; de Oliveira CB, 2008, J REHABIL RES DEV, V45, P1215, DOI 10.1682/JRRD.2007.09.0150; DUNCAN PW, 1990, J GERONTOL, V45, pM192, DOI 10.1093/geronj/45.6.M192; Eng JJ, 2002, ARCH PHYS MED REHAB, V83, P1138, DOI 10.1053/apmr.2002.33644; Fleiss JL, 1986, DESIGN ANAL CLIN EXP; Frykberg GE, 2007, J REHABIL MED, V39, P448, DOI 10.2340/16501977-0071; Geurts ACH, 2005, GAIT POSTURE, V22, P267, DOI 10.1016/j.gaitpost.2004.10.002; Gray VL, 2014, GAIT POSTURE, V40, P198, DOI 10.1016/j.gaitpost.2014.03.191; Hill KD., 1996, PHYSIOTHER CAN, V48, P257, DOI DOI 10.3138/PTC.48.4.257; Holmes JD, 2013, CLIN REHABIL, V27, P361, DOI 10.1177/0269215512458684; Huurnink A, 2013, J BIOMECH, V46, P1392, DOI 10.1016/j.jbiomech.2013.02.018; Hyndman D, 2009, NEUROREHAB NEURAL RE, V23, P847, DOI 10.1177/1545968309338192; Kamper SJ, 2009, J MAN MANIP THER, V17, P163, DOI 10.1179/jmt.2009.17.3.163; Kamphuis JF, 2013, STROKE RES TREAT, V2013, DOI 10.1155/2013/692137; Karlsson A, 2000, CLIN BIOMECH, V15, P365, DOI 10.1016/S0268-0033(99)00096-0; Leroux A, 2006, AM J PHYS MED REHAB, V85, P820, DOI 10.1097/01.phm.0000233179.64769.8c; Liston RAL, 1996, ARCH PHYS MED REHAB, V77, P425, DOI 10.1016/S0003-9993(96)90028-3; Lomaglio MJ, 2005, GAIT POSTURE, V22, P126, DOI 10.1016/j.gaitpost.2004.08.002; Mokkink LB, 2010, J CLIN EPIDEMIOL, V63, P737, DOI 10.1016/j.jclinepi.2010.02.006; Nardone A, 2009, GAIT POSTURE, V30, P5, DOI 10.1016/j.gaitpost.2009.02.006; Niam S, 1999, ARCH PHYS MED REHAB, V80, P1227, DOI 10.1016/S0003-9993(99)90020-5; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; Portney LG., 2000, FDN CLIN RES APPL PR, V2, DOI DOI 10.1016/S0039-6257(02)00362-4; Ruhe A, 2010, GAIT POSTURE, V32, P436, DOI 10.1016/j.gaitpost.2010.09.012; Sawacha Z, 2013, J NEUROENG REHABIL, V10, DOI 10.1186/1743-0003-10-95; Scaglioni-Solano P, 2014, INT J REHABIL RES, V37, P138, DOI 10.1097/MRR.0000000000000046; Sullivan JE, 2013, PHYS THER, V93, P1383, DOI 10.2522/ptj.20120492; van Bloemendaal M, 2012, DISABIL REHABIL, V34, P2207, DOI 10.3109/09638288.2012.680649; Visser JE, 2008, CLIN NEUROPHYSIOL, V119, P2424, DOI 10.1016/j.clinph.2008.07.220	40	31	32	0	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 26	2014	9	12							e115282	10.1371/journal.pone.0115282	http://dx.doi.org/10.1371/journal.pone.0115282			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX9RO	25541939	Green Published, gold, Green Submitted			2023-01-03	WOS:000347239900032
J	Margalida, A; Bogliani, G; Bowden, CGR; Donazar, JA; Genero, F; Gilbert, M; Karesh, WB; Kock, R; Lubroth, J; Manteca, X; Naidoo, V; Neimanis, A; Sanchez-Zapata, JA; Taggart, MA; Vaarten, J; Yon, L; Kuiken, T; Green, RE				Margalida, A.; Bogliani, G.; Bowden, C. G. R.; Donazar, J. A.; Genero, F.; Gilbert, M.; Karesh, W. B.; Kock, R.; Lubroth, J.; Manteca, X.; Naidoo, V.; Neimanis, A.; Sanchez-Zapata, J. A.; Taggart, M. A.; Vaarten, J.; Yon, L.; Kuiken, T.; Green, R. E.			One Health approach to use of veterinary pharmaceuticals	SCIENCE			English	Editorial Material							PROMOTING HUMAN HEALTH; TO-CRADLE STEWARDSHIP; ENVIRONMENTAL DISPOSITION; SOUTH-ASIA; DICLOFENAC; MEDICINES; DRUGS; DISPOSAL; VULTURES					t.kuiken@erasmusmc.nl	Margalida, Antoni/AAG-5337-2020; Yon, Lisa K/G-4453-2011; Karesh, William/AAU-9084-2020; Margalida, Antoni/A-2723-2011; Naidoo, Vinny/A-1508-2008; Sanchez-Zapata, Jose Antonio/H-1413-2015; Margalida, Antoni/A-2723-2011; Neimanis, Aleksija/E-4168-2016	Yon, Lisa K/0000-0002-9765-3192; Karesh, William/0000-0001-6042-2860; Margalida, Antoni/0000-0002-0576-3993; Naidoo, Vinny/0000-0003-2740-5983; Sanchez-Zapata, Jose Antonio/0000-0001-8230-4953; Taggart, Mark/0000-0002-0649-8490; Kock, Richard/0000-0002-6561-3209; Gilbert, Martin/0000-0002-9930-4383; Donazar, Jose Antonio/0000-0002-9433-9755; Margalida, Antoni/0000-0002-3904-6212; Bogliani, Giuseppe/0000-0001-9066-6540; Kuiken, Thijs/0000-0001-5501-9049; Margalida, Antoni/0000-0002-7383-671X; Neimanis, Aleksija/0000-0001-7747-2290				Aarestrup FM, 2008, EXPERT REV ANTI-INFE, V6, P733, DOI 10.1586/14787210.6.5.733; Agerstrand M, 2009, ENVIRON INT, V35, P778, DOI 10.1016/j.envint.2008.12.001; Alexandratos N., 2012, WORLD AGR 2030 2050, DOI DOI 10.22004/AG.ECON.288998; Baron M, 2012, WASTE BIOMASS VALORI, V3, P395, DOI 10.1007/s12649-012-9146-2; Beynon SA, 2012, VET PARASITOL, V189, P125, DOI 10.1016/j.vetpar.2012.03.041; Boxall ABA, 2010, HANDB EXP PHARMACOL, V199, P291, DOI 10.1007/978-3-642-10324-7_12; Chaudhry MJI, 2012, BIRD CONSERV INT, V22, P389, DOI 10.1017/S0959270912000445; Committee for Medicinal Products for Veterinary Use, 2008, EMEACVMP4182822005RE; Daughton CG, 2003, ENVIRON HEALTH PERSP, V111, P757, DOI 10.1289/ehp.5947; Daughton CG, 2003, ENVIRON HEALTH PERSP, V111, P775, DOI 10.1289/ehp.5948; Del Hoyo J., 1994, HDB BIRDS WORLD, V2; Friton GM, 2005, VET REC, V156, P809, DOI 10.1136/vr.156.25.809; Green RE, 2004, J APPL ECOL, V41, P793, DOI 10.1111/j.0021-8901.2004.00954.x; Kools SAE, 2008, REGUL TOXICOL PHARM, V50, P59, DOI 10.1016/j.yrtph.2007.06.003; Kools Stefan A. E., 2008, Integrated Environmental Assessment and Management, V4, P399, DOI 10.1897/IEAM_2008-002.1; Margalida A, 2012, SCI REP-UK, V2, DOI 10.1038/srep00753; Naidoo V, 2010, BIOL LETTERS, V6, P339, DOI 10.1098/rsbl.2009.0818; National Office of Animal Health, FACTS FIG UK AN MED; Pain DJ, 2008, BIRD CONSERV INT, V18, pS30, DOI 10.1017/S0959270908000324; Prakash V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049118; Sanchez-Zapata JA, 2010, BIRD STUDY, V57, P352, DOI 10.1080/00063651003674946; Sharma AK, 2014, BIRD CONSERV INT, V24, P282, DOI 10.1017/S0959270913000609; Tong AYC, 2011, ENVIRON INT, V37, P292, DOI 10.1016/j.envint.2010.10.002; Zorrilla I., 2014, CONSERV BIOL, DOI 10.1111/cobi.12417	24	59	60	2	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 12	2014	346	6215					1296	1298		10.1126/science.1260260	http://dx.doi.org/10.1126/science.1260260			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AW3MA	25477214	Green Submitted			2023-01-03	WOS:000346189600025
J	Lv, MM; Zhu, XY; Wang, H; Wang, F; Guan, WX				Lv, Mengmeng; Zhu, Xingya; Wang, Hao; Wang, Feng; Guan, Wenxian			Roles of Caloric Restriction, Ketogenic Diet and Intermittent Fasting during Initiation, Progression and Metastasis of Cancer in Animal Models: A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							RANDOMIZED CONTROLLED-TRIAL; GROWTH-FACTOR-I; FACTOR-BINDING PROTEIN-3; DISEASE RISK MARKERS; SKIN TUMOR PROMOTION; C-REACTIVE PROTEIN; PROSTATE-CANCER; ENERGY RESTRICTION; WEIGHT-LOSS; MAMMARY CARCINOGENESIS	Background: The role of dietary restriction regimens such as caloric restriction, ketogenic diet and intermittent fasting in development of cancers has been detected via abundant preclinical experiments. However, the conclusions are controversial. We aim to review the relevant animal studies systematically and provide assistance for further clinical studies. Methods: Literatures on associations between dietary restriction and cancer published in PubMed in recent twenty years were comprehensively searched. Animal model, tumor type, feeding regimen, study length, sample size, major outcome, conclusion, quality assessment score and the interferential step of cancer were extracted from each eligible study. We analyzed the tumor incidence rates from 21 studies about caloric restriction. Results: Fifty-nine studies were involved in our system review. The involved studies explored roles of dietary restriction during initiation, progression and metastasis of cancer. About 90.9% of the relevant studies showed that caloric restriction plays an anti-cancer role, with the pooled OR (95% CI) of 0.20 (0.12, 0.34) relative to controls. Ketogenic diet was also positively associated with cancer, which was indicated by eight of the nine studies. However, 37.5% of the related studies obtained a negative conclusion that intermittent fasting was not significantly preventive against cancer. Conclusions: Caloric restriction and ketogenic diet are effective against cancer in animal experiments while the role of intermittent fasting is doubtful and still needs exploration. More clinical experiments are needed and more suitable patterns for humans should be investigated.	[Lv, Mengmeng] Nanjing Med Univ, Affiliated Canc Hosp, Canc Inst Jiangsu Prov, Dept Gen Surg, Nanjing, Jiangsu, Peoples R China; [Lv, Mengmeng] Nanjing Med Univ, Clin Sch 1, Nanjing, Jiangsu, Peoples R China; [Zhu, Xingya] Nanjing Med Univ, Gulou Clin Med Coll, Nanjing, Jiangsu, Peoples R China; [Zhu, Xingya; Wang, Hao; Wang, Feng; Guan, Wenxian] Nanjing Univ, Nanjing Gulou Hosp, Coll Med, Dept Gastrointestinal Surg, Nanjing 210008, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing University	Guan, WX (corresponding author), Nanjing Univ, Nanjing Gulou Hosp, Coll Med, Dept Gastrointestinal Surg, Nanjing 210008, Jiangsu, Peoples R China.	guanwx810@126.com						Abdelwahab MG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036197; Berrigan D, 2002, CARCINOGENESIS, V23, P817, DOI 10.1093/carcin/23.5.817; Birt DF, 1997, CARCINOGENESIS, V18, P2107, DOI 10.1093/carcin/18.11.2107; Blando J, 2011, CANCER PREV RES, V4, P2002, DOI 10.1158/1940-6207.CAPR-11-0182; Boileau TWM, 2003, JNCI-J NATL CANCER I, V95, P1578, DOI 10.1093/jnci/djg081; Bonorden MJL, 2009, NUTR CANCER, V61, P265, DOI 10.1080/01635580802419798; Buschemeyer WC, 2010, PROSTATE, V70, P1037, DOI 10.1002/pros.21136; Carver DK, 2011, CANCER PREV RES, V4, P562, DOI 10.1158/1940-6207.CAPR-10-0294; Cava E, 2013, AGING-US, V5, P507, DOI 10.18632/aging.100581; Cleary MP, 2007, EXP BIOL MED, V232, P70; Cleary Margot P, 2011, J Carcinog, V10, P21, DOI 10.4103/1477-3163.85181; Coffer PJ, 2009, CELL RES, V19, P797, DOI 10.1038/cr.2009.81; De Lorenzo MS, 2011, CARCINOGENESIS, V32, P1381, DOI 10.1093/carcin/bgr107; Dirx MJM, 2003, INT J CANCER, V106, P766, DOI 10.1002/ijc.11277; Dogan S, 2010, ONCOL LETT, V1, P167, DOI 10.3892/ol_00000031; Dunlap SM, 2012, CANCER PREV RES, V5, P930, DOI 10.1158/1940-6207.CAPR-12-0034; Dunn SE, 1997, CANCER RES, V57, P4667; ENGELMAN RW, 1994, CANCER RES, V54, P5724; Eslami S, 2012, BIOIMPACTS, V2, P213, DOI 10.5681/bi.2012.028; Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128; Freedland SJ, 2008, PROSTATE, V68, P11, DOI 10.1002/pros.20683; Galet C, 2013, INT J MOL SCI, V14, P13782, DOI 10.3390/ijms140713782; Gillette CA, 1997, CARCINOGENESIS, V18, P1183, DOI 10.1093/carcin/18.6.1183; Golan T, 2011, ONCOLOGY-NY, V25, P518; Harvey AE, 2013, MOL CARCINOGEN, V52, P997, DOI 10.1002/mc.21940; Harvie MN, 2011, INT J OBESITY, V35, P714, DOI 10.1038/ijo.2010.171; Harvie M, 2013, BRIT J NUTR, V110, P1534, DOI 10.1017/S0007114513000792; Heikkila K, 2009, CANCER CAUSE CONTROL, V20, P15, DOI 10.1007/s10552-008-9212-z; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Ho VW, 2011, CANCER RES, V71, P4484, DOI 10.1158/0008-5472.CAN-10-3973; Hursting SD, 1997, CANCER RES, V57, P2843; Hursting SD, 2010, CARCINOGENESIS, V31, P83, DOI 10.1093/carcin/bgp280; Imayama I, 2012, CANCER RES, V72, P2314, DOI 10.1158/0008-5472.CAN-11-3092; JAMES SJ, 1994, CANCER RES, V54, P5508; Jiang WQ, 2008, CANCER RES, V68, P5492, DOI 10.1158/0008-5472.CAN-07-6721; Jiang YS, 2013, J NEURO-ONCOL, V114, P25, DOI 10.1007/s11060-013-1154-y; Kandori H, 2005, CANCER SCI, V96, P221, DOI 10.1111/j.1349-7006.2005.00041.x; Lanza-Jacoby S, 2013, EXP BIOL MED, V238, P787, DOI 10.1177/1535370213493727; Lashinger LM, 2011, CANCER PREV RES, V4, P1041, DOI 10.1158/1940-6207.CAPR-11-0023; Lashinger LM, 2011, CANCER PREV RES, V4, P1030, DOI 10.1158/1940-6207.CAPR-11-0027; Lee C, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003293; Liu B, 2007, ONCOGENE, V26, P1811, DOI 10.1038/sj.onc.1209977; Longo VD, 2010, TRENDS PHARMACOL SCI, V31, P89, DOI 10.1016/j.tips.2009.11.004; Mai V, 2003, CANCER RES, V63, P1752; Maroon J, 2013, J CHILD NEUROL, V28, P1002, DOI 10.1177/0883073813488670; Marsh J, 2008, CLIN CANCER RES, V14, P7751, DOI 10.1158/1078-0432.CCR-08-0213; Martin-Montalvo A, 2011, ONCOGENE, V30, P505, DOI 10.1038/onc.2010.492; Mason C, 2013, CANCER EPIDEM BIOMAR, V22, P1457, DOI 10.1158/1055-9965.EPI-13-0337; Mavropoulos JC, 2009, CANCER PREV RES, V2, P557, DOI 10.1158/1940-6207.CAPR-08-0188; McCormick DL, 2007, NUTR CANCER, V57, P194, DOI 10.1080/01635580701277494; Mizuno NK, 2013, CANCER PREV RES, V6, P540, DOI 10.1158/1940-6207.CAPR-13-0033; Moore T, 2012, CANCER PREV RES, V5, P1236, DOI 10.1158/1940-6207.CAPR-12-0234; Mulrooney TJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018085; NEBELING LC, 1995, J AM COLL NUTR, V14, P202; Nogueira LM, 2012, ENDOCR-RELAT CANCER, V19, P57, DOI 10.1530/ERC-11-0213; Ong KR, 2009, CANCER PREV RES, V2, P720, DOI 10.1158/1940-6207.CAPR-09-0008; Otto C, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-122; Pape-Ansorge KA, 2002, NUTR CANCER, V44, P161, DOI 10.1207/S15327914NC4402_07; Phoenix KN, 2010, BREAST CANCER RES TR, V123, P333, DOI 10.1007/s10549-009-0647-z; Poff AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065522; Rocha NS, 2002, TERATOGEN CARCIN MUT, V22, P129, DOI 10.1002/tcm.10005; Rogozina OP, 2013, BREAST CANCER RES TR, V138, P395, DOI 10.1007/s10549-013-2464-7; Rowlands MA, 2012, CANCER RES, V72, P503, DOI 10.1158/0008-5472.CAN-11-1601; Safdie FM, 2009, AGING-US, V1, P988, DOI 10.18632/aging.100114; Saleh AD, 2013, CELL CYCLE, V12, P1955, DOI 10.4161/cc.25016; Scaglia N, 2008, INT J ONCOL, V33, P839, DOI 10.3892/ijo_00000072; Seyfried BTN, 2009, J CANCER RES THER, V5, P7, DOI 10.4103/0973-1482.55134; Seyfried TN, 2003, BRIT J CANCER, V89, P1375, DOI 10.1038/sj.bjc.6601269; Shelton LM, 2010, ASN NEURO, V2, DOI 10.1042/AN20100002; Siemes C, 2006, J CLIN ONCOL, V24, P5216, DOI 10.1200/JCO.2006.07.1381; Simone BA, 2013, FUTURE ONCOL, V9, P959, DOI [10.2217/fon.13.31, 10.2217/FON.13.31]; Stafford P, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-74; Stewart JW, 2005, CARCINOGENESIS, V26, P1077, DOI 10.1093/carcin/bgi051; Suttie AW, 2005, TOXICOL PATHOL, V33, P386, DOI 10.1080/01926230590930272; Tagliaferro AR, 1996, J NUTR, V126, P1398, DOI 10.1093/jn/126.5.1398; Thomas JA, 2010, PROSTATE CANCER P D, V13, P350, DOI 10.1038/pcan.2010.24; Thompson HJ, 2004, CANCER RES, V64, P5643, DOI 10.1158/0008-5472.CAN-04-0787; Tomasi C, 1999, CARCINOGENESIS, V20, P1979, DOI 10.1093/carcin/20.10.1979; Tomita Mariko, 2012, J Carcinog, V11, P10, DOI 10.4103/1477-3163.99176; Tsao JL, 2002, CARCINOGENESIS, V23, P1807, DOI 10.1093/carcin/23.11.1807; van Ginhoven TM, 2010, J SURG ONCOL, V102, P348, DOI 10.1002/jso.21649; VonTungeln LS, 1996, CANCER LETT, V104, P133, DOI 10.1016/0304-3835(96)04232-2; Wang T, 2011, CANCER EPIDEM BIOMAR, V20, P971, DOI 10.1158/1055-9965.EPI-10-1222; Wheatley KE, 2008, NUTR CANCER, V60, P61, DOI 10.1080/01635580701510150; Wright JL, 2013, PROSTATE, V73, P1345, DOI 10.1002/pros.22682; Yamaza H, 2010, AGING CELL, V9, P372, DOI 10.1111/j.1474-9726.2010.00563.x; Zhou WH, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-5; Zhu ZJ, 2005, MOL CARCINOGEN, V42, P170, DOI 10.1002/mc.20071	88	122	123	2	56	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 11	2014	9	12							e115147	10.1371/journal.pone.0115147	http://dx.doi.org/10.1371/journal.pone.0115147			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX8FY	25502434	gold, Green Published, Green Submitted			2023-01-03	WOS:000347146700093
J	Jin, CN; Liu, M; Sun, JP; Fang, F; Wen, YN; Yu, CM; Lee, APW				Jin, Chun-Na; Liu, Ming; Sun, Jing-Ping; Fang, Fang; Wen, Yong-Na; Yu, Cheuk-Man; Lee, Alex Pui-Wai			The Prevalence and Prognosis of Resistant Hypertension in Patients with Heart Failure	PLOS ONE			English	Article							PRESERVED EJECTION FRACTION; SYSTOLIC BLOOD-PRESSURE; LEFT-VENTRICULAR HYPERTROPHY; LEVELS PREDICT SURVIVAL; UNITED-STATES; ATRIAL-FIBRILLATION; CLINICAL-FEATURES; HIGH-RISK; MORTALITY; OUTCOMES	Background: Resistant hypertension is associated with adverse clinical outcome in hypertensive patients. However, the prognostic significance of resistant hypertension in patients with heart failure remains uncertain. Methods and Results: The 1 year survival and heart failure re-hospitalization rate of 1288 consecutive patients admitted to a university hospital for either newly diagnosed heart failure or an exacerbation of prior chronic heart failure was analyzed. Resistant hypertension was defined as uncontrolled blood pressure (>140/90 mmHg) despite being compliant with an antihypertensive regimen that includes 3 or more drugs (including a diuretic). A total of 176 (13.7%) heart failure patients had resistant hypertension. There was no difference in all cause mortality, cardiovascular mortality, and heart failure related re-hospitalization between patients with versus without resistant hypertension. Diabetes [hazard ratio=1.62, 95% confidence interval=1.13-2.34; P=0.010] and serum sodium >139 mmol/L (hazard ratio=1.54, 95% confidence interval=1.06-2.23; P=0.024) were independently associated with resistant hypertension. Patients with resistant hypertension had a relatively higher survival rate (86.9% vs. 83.8%), although the difference was not significant (log-rank x(2)=1.00, P=0.317). In patients with reduced ejection fraction, heart failure related re-hospitalization was significantly lower in patients with resistant hypertension (45.8% vs. 59.1%, P=0.050). Conclusions: Resistant hypertension appears to be not associated with adverse clinical outcome in patients with heart failure, in fact may be a protective factor for reduced heart failure related re-hospitalization in patients with reduced ejection fraction.	[Jin, Chun-Na; Liu, Ming; Sun, Jing-Ping; Fang, Fang; Wen, Yong-Na; Yu, Cheuk-Man; Lee, Alex Pui-Wai] Chinese Univ Hong Kong, Prince Wales Hosp, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,Div Cardiol, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital	Lee, APW (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,Div Cardiol, Hong Kong, Hong Kong, Peoples R China.	alexpwlee@cuhk.edu.hk	Lee, Alex Pui-Wai/E-9217-2013; Yu, Cheuk-man/P-3747-2015; Fang, Fang/B-9912-2017	Lee, Alex Pui-Wai/0000-0002-4120-155X; Fang, Fang/0000-0002-4023-2928				Abraham WT, 2008, J AM COLL CARDIOL, V52, P347, DOI 10.1016/j.jacc.2008.04.028; Anand IS, 2007, J AM COLL CARDIOL, V49, P32, DOI 10.1016/j.jacc.2006.04.109; Anker SD, 1997, LANCET, V349, P1050, DOI 10.1016/S0140-6736(96)07015-8; Badheka AO, 2011, AM J CARDIOL, V108, P1283, DOI 10.1016/j.amjcard.2011.06.045; Bhatia RS, 2006, NEW ENGL J MED, V355, P260, DOI 10.1056/NEJMoa051530; Bisognano JD, 2009, J CARD FAIL, V15, pS63, DOI 10.1016/j.cardfail.2009.06.191; Brophy JM, 2004, AM J MED, V116, P300, DOI 10.1016/j.amjmed.2003.09.035; Buiciuc O, 2011, J CARD FAIL, V17, P907, DOI 10.1016/j.cardfail.2011.08.002; CHOBANIAN AV, 2003, HYPERTENSION, V42, P1206, DOI [DOI 10.1161/01.HYP.0000107251.49515.c2, DOI 10.1161/01.HYP.0000107251.49515.C2]; Cygankiewicz I, 2009, AM J CARDIOL, V103, P1003, DOI 10.1016/j.amjcard.2008.11.061; Daugherty SL, 2012, CIRCULATION, V125, P1635, DOI 10.1161/CIRCULATIONAHA.111.068064; Davies JE, 2013, INT J CARDIOL, V162, P189, DOI 10.1016/j.ijcard.2012.09.019; De Blois J, 2010, J CARD FAIL, V16, P225, DOI 10.1016/j.cardfail.2009.12.002; de la Sierra A, 2011, HYPERTENSION, V57, P898, DOI 10.1161/HYPERTENSIONAHA.110.168948; Egan BM, 2011, CIRCULATION, V124, P1046, DOI 10.1161/CIRCULATIONAHA.111.030189; Fagard RH, 2009, HYPERTENSION, V54, P1084, DOI 10.1161/HYPERTENSIONAHA.109.136655; Fonarow GC, 2008, ARCH INTERN MED, V168, P847, DOI 10.1001/archinte.168.8.847; Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2981; Goldberg RJ, 2007, ARCH INTERN MED, V167, P490, DOI 10.1001/archinte.167.5.490; Grigorian-Shamagian L, 2008, J CARD FAIL, V14, P561, DOI 10.1016/j.cardfail.2008.03.006; Gupta AK, 2011, J HYPERTENS, V29, P2004, DOI 10.1097/HJH.0b013e32834a8a42; Harjola VP, 2010, EUR J HEART FAIL, V12, P239, DOI 10.1093/eurjhf/hfq002; Hawkins NM, 2007, HEART, V93, P59, DOI 10.1136/hrt.2005.083949; Horwich TB, 2008, AM HEART J, V155, P883, DOI 10.1016/j.ahj.2007.11.043; Jonsson A, 2010, EUR J HEART FAIL, V12, P25, DOI 10.1093/eurjhf/hfp175; Kostis JB, 1997, JAMA-J AM MED ASSOC, V278, P212; Kwon BJ, 2010, EUR J HEART FAIL, V12, P1339, DOI 10.1093/eurjhf/hfq157; Lee DS, 2003, JAMA-J AM MED ASSOC, V290, P2581, DOI 10.1001/jama.290.19.2581; Lee TT, 2006, AM HEART J, V151, P76, DOI 10.1016/j.ahj.2005.03.009; Linssen GCM, 2011, EUR J HEART FAIL, V13, P1111, DOI 10.1093/eurjhf/hfr066; Liu M, 2012, EUR J HEART FAIL, V14, P39, DOI 10.1093/eurjhf/hfr154; McAdam-Marx C, 2009, CLIN THER, V31, P1116, DOI 10.1016/j.clinthera.2009.05.007; MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601; Moser M, 1996, J AM COLL CARDIOL, V27, P1214, DOI 10.1016/0735-1097(95)00606-0; Nunez J, 2010, EUR J HEART FAIL, V12, P38, DOI 10.1093/eurjhf/hfp176; Persell SD, 2011, HYPERTENSION, V57, P1076, DOI 10.1161/HYPERTENSIONAHA.111.170308; Persson H, 2007, J AM COLL CARDIOL, V49, P687, DOI 10.1016/j.jacc.2006.08.062; Pocock SJ, 2006, EUR HEART J, V27, P65, DOI 10.1093/eurheartj/ehi555; Pulignano G, 2002, AM HEART J, V143, P45, DOI 10.1067/mhj.2002.119608; Raphael CE, 2009, HEART, V95, P56, DOI 10.1136/hrt.2007.134973; Sarafidis PA, 2008, J AM COLL CARDIOL, V52, P1749, DOI 10.1016/j.jacc.2008.08.036; Sarafidis PA, 2013, NAT REV NEPHROL, V9, P51, DOI 10.1038/nrneph.2012.260; Wolf-Maier K, 2003, JAMA-J AM MED ASSOC, V289, P2363, DOI 10.1001/jama.289.18.2363; Writing Group M, 2012, CIRCULATION, V125, pe2	44	12	12	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2014	9	12							e114958	10.1371/journal.pone.0114958	http://dx.doi.org/10.1371/journal.pone.0114958			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AY3YM	25490405	Green Published, Green Submitted, gold			2023-01-03	WOS:000347515300098
J	Angus, SD; Piotrowska, MJ				Angus, Simon D.; Piotrowska, Monika Joanna			A Matter of Timing: Identifying Significant Multi-Dose Radiotherapy Improvements by Numerical Simulation and Genetic Algorithm Search	PLOS ONE			English	Article							CELLULAR-AUTOMATON MODEL; STRAND BREAK REPAIR; ACCELERATED RADIOTHERAPY; RADIATION RESPONSE; MULTICELLULAR SPHEROIDS; INCOMPLETE-REPAIR; NORMAL TISSUE; LUNG-CANCER; SOLID TUMOR; CELLS	Multi-dose radiotherapy protocols (fraction dose and timing) currently used in the clinic are the product of human selection based on habit, received wisdom, physician experience and intra-day patient timetabling. However, due to combinatorial considerations, the potential treatment protocol space for a given total dose or treatment length is enormous, even for relatively coarse search; well beyond the capacity of traditional in-vitro methods. In constrast, high fidelity numerical simulation of tumor development is well suited to the challenge. Building on our previous single-dose numerical simulation model of EMT6/Ro spheroids, a multi-dose irradiation response module is added and calibrated to the effective dose arising from 18 independent multi-dose treatment programs available in the experimental literature. With the developed model a constrained, non-linear, search for better performing cadidate protocols is conducted within the vicinity of two benchmarks by genetic algorithm (GA) techniques. After evaluating less than 0.01% of the potential benchmark protocol space, candidate protocols were identified by the GA which conferred an average of 9.4% (max benefit 16.5%) and 7.1% (13.3%) improvement (reduction) on tumour cell count compared to the two benchmarks, respectively. Noticing that a convergent phenomenon of the top performing protocols was their temporal synchronicity, a further series of numerical experiments was conducted with periodic time-gap protocols (10 h to 23 h), leading to the discovery that the performance of the GA search candidates could be replicated by 17-18 h periodic candidates. Further dynamic irradiation-response cell-phase analysis revealed that such periodicity cohered with latent EMT6/Ro cell-phase temporal patterning. Taken together, this study provides powerful evidence towards the hypothesis that even simple inter-fraction timing variations for a given fractional dose program may present a facile, and highly cost-effecitive means of significantly improving clinical efficacy.	[Angus, Simon D.] Monash Univ, Dept Econ, Melbourne, Vic 3004, Australia; [Piotrowska, Monika Joanna] Univ Warsaw, Inst Appl Math & Mech, Fac Math Informat & Mech, Warsaw, Mazowieckie, Poland	Monash University; University of Warsaw	Angus, SD (corresponding author), Monash Univ, Dept Econ, Melbourne, Vic 3004, Australia.	simon.angus@monash.edu	Angus, Simon D/AAR-1871-2021	Angus, Simon D/0000-0001-7095-5054; Piotrowska, Monika/0000-0003-0156-8290	Polish Ministry of Science and Higher Education [IP2011041971]	Polish Ministry of Science and Higher Education(Ministry of Science and Higher Education, Poland)	This work was financed in part by the Polish Ministry of Science and Higher Education within the Iuventus Plus Grant: "Mathematical modelling of neoplastic processes" (grant No. IP2011041971) from the budget for science in years the 2012-2014. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmad SU, 2010, BIOMED SIGNAL PROCES, V5, P189, DOI 10.1016/j.bspc.2010.03.001; Angus SD, 2010, APPL MATH WARSAW, V37, P69; Angus SD, 2013, J THEOR BIOL, V320, P23, DOI 10.1016/j.jtbi.2012.11.035; Bertuzzi A, 2010, B MATH BIOL, V72, P1069, DOI 10.1007/s11538-009-9482-y; Bevilacqua V, 2007, IMAGE VISION COMPUT, V25, P196, DOI 10.1016/j.imavis.2006.01.027; Bhide SA, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-25; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; Board of the Faculty of Clinical Oncology, 2006, RAD DOS FRACT; Bortfeld T, 1999, SEMIN RADIAT ONCOL, V9, P20, DOI 10.1016/S1053-4296(99)80052-6; Bourhis J, 2006, LANCET, V368, P843, DOI 10.1016/S0140-6736(06)69121-6; Byrne H, 2009, J MATH BIOL, V58, P657, DOI 10.1007/s00285-008-0212-0; Calzolari D, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000249; Carabe-Fernandez A, 2011, BRIT J RADIOL, V84, P546, DOI 10.1259/bjr/19934996; CASCIARI JJ, 1992, J CELL PHYSIOL, V151, P386, DOI 10.1002/jcp.1041510220; Cotrutz C, 2003, PHYS MED BIOL, V48, P2987, DOI 10.1088/0031-9155/48/18/303; Crone C., 1984, HDB PHYSL CARDIOVASC, P411; DAIRKEE SH, 1995, CANCER RES, V55, P2516; Duchting W, 1996, APPL MATH COMPUT, V74, P191, DOI 10.1016/0096-3003(95)00092-5; DURAND RE, 1984, BRIT J CANCER, V49, P203; DURAND RE, 1980, RADIAT RES, V81, P85, DOI 10.2307/3575364; EMAMI B, 1991, INT J RADIAT ONCOL, V21, P109, DOI 10.1016/0360-3016(91)90171-Y; Engelhart M, 2011, MATH BIOSCI, V229, P123, DOI 10.1016/j.mbs.2010.11.007; Ezzell GA, 1996, MED PHYS, V23, P293, DOI 10.1118/1.597660; Fowler J F, 1992, BJR Suppl, V24, P187; Fowler JF, 2002, RADIAT RES, V158, P141, DOI 10.1667/0033-7587(2002)158[0141:RBDFAS]2.0.CO;2; Fowler JF, 1999, RADIAT RES, V152, P124, DOI 10.2307/3580085; FREYER JP, 1980, CANCER RES, V40, P3956; FREYER JP, 1986, CANCER RES, V46, P3513; FREYER JP, 1986, CANCER RES, V46, P3504; FREYER JP, 1985, J CELL PHYSIOL, V124, P516, DOI 10.1002/jcp.1041240323; Gao N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062156; Haas OCL, 2006, STUD MULTIDISCIP, V3, P447; Haasbeek CJA, 2009, LUNG CANCER, V64, P1, DOI 10.1016/j.lungcan.2008.07.008; HAHN GM, 1974, CANCER RES, V34, P351; HAHN GM, 1973, RADIAT RES, V55, P280, DOI 10.2307/3573683; Hendry J H, 1996, Clin Oncol (R Coll Radiol), V8, P297, DOI 10.1016/S0936-6555(05)80715-0; Holland J.H, 1992, CONTROL ARTIFICIAL I; Holland JH, 2012, SCHOLARPEDIA, V7, P1482, DOI [DOI 10.4249/SCHOLARPEDIA.1482, DOI 10.4249/SCH0LARPEDIA.1482]; Jiang Y, 2005, BIOPHYS J, V89, P3884, DOI 10.1529/biophysj.105.060640; KAL HB, 1976, CANCER RES, V36, P1923; Kehwar T S, 2005, J Cancer Res Ther, V1, P168; KELLEY SD, 1981, CELL TISSUE KINET, V14, P611, DOI 10.1111/j.1365-2184.1981.tb00846.x; Kempf H, 2010, EUR PHYS J D, V60, P177, DOI 10.1140/epjd/e2010-00178-4; Kempf H, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003295; Kim JJ, 2005, NAT REV CANCER, V5, P516, DOI 10.1038/nrc1650; Lei J, 2009, COMPUTER METHODS PRO, V93; Li ZP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083739; Longo JA, 1997, RADIAT RES, V147, P35, DOI 10.2307/3579440; Alfonso JCL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089380; LUK CK, 1986, BRIT J CANCER, V54, P25, DOI 10.1038/bjc.1986.148; LUK CK, 1987, INT J RADIAT ONCOL, V13, P885, DOI 10.1016/0360-3016(87)90104-0; Mak IWY, 2014, AM J TRANSL RES, V6, P114; Mangar SA, 2005, EUR J CANCER, V41, P908, DOI 10.1016/j.ejca.2004.12.028; Mortensen HR, 2012, RADIOTHER ONCOL, V103, P69, DOI 10.1016/j.radonc.2012.01.002; MUSTAFIN AT, 1982, BIOSYSTEMS, V15, P111, DOI 10.1016/0303-2647(82)90025-9; O'Rourke SFC, 2009, J MATH BIOL, V58, P799, DOI 10.1007/s00285-008-0222-y; Otsuka S, 2011, INT J RADIAT ONCOL, V81, P1538, DOI 10.1016/j.ijrobp.2011.05.034; Patel AA, 2001, J THEOR BIOL, V213, P315, DOI 10.1006/jtbi.2001.2385; Petrovic D, 2011, EXPERT SYST APPL, V38, P6994, DOI 10.1016/j.eswa.2010.12.015; Petrovic S, 2011, EXPERT SYST APPL, V38, P10759, DOI 10.1016/j.eswa.2011.01.109; Piotrowska MJ, 2009, J THEOR BIOL, V258, P165, DOI 10.1016/j.jtbi.2009.02.008; Powathil GG, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003120; Powathil GG, 2012, J THEOR BIOL, V308, P1, DOI 10.1016/j.jtbi.2012.05.015; ROCKWELL S, 1980, BRIT J CANCER, V41, P118; Rosenstein BS, 2004, INT J RADIAT ONCOL, V60, P1393, DOI 10.1016/j.ijrobp.2004.05.072; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; Saunders M, 1997, LANCET, V350, P161, DOI 10.1016/S0140-6736(97)06305-8; Sugie C, 2006, INT J RADIAT ONCOL, V64, P619, DOI 10.1016/j.ijrobp.2005.03.032; THAMES HD, 1985, INT J RADIAT BIOL, V47, P319, DOI 10.1080/09553008514550461; UK CR, 2010, RAD BRIEFSH; Venkatasubramanian R, 2006, J THEOR BIOL, V242, P440, DOI 10.1016/j.jtbi.2006.03.011; Wein LM, 2000, INT J RADIAT ONCOL, V47, P1073, DOI 10.1016/S0360-3016(00)00534-4; Wilson GD, 2004, CANCER METAST REV, V23, P209, DOI 10.1023/B:CANC.0000031762.91306.b4; Yu Y, 1997, MED PHYS, V24, P1742, DOI 10.1118/1.597951; Zacharaki EI, 2004, COMPUT METH PROG BIO, V76, P193, DOI 10.1016/j.cmpb.2004.07.003	75	7	7	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2014	9	12							e114098	10.1371/journal.pone.0114098	http://dx.doi.org/10.1371/journal.pone.0114098			28	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AU8TQ	25460164	Green Published, gold, Green Submitted			2023-01-03	WOS:000345869700097
J	Gubin, MM; Zhang, XL; Schuster, H; Caron, E; Ward, JP; Noguchi, T; Ivanova, Y; Hundal, J; Arthur, CD; Krebber, WJ; Mulder, GE; Toebes, M; Vesely, MD; Lam, SSK; Korman, AJ; Allison, JP; Freeman, GJ; Sharpe, AH; Pearce, EL; Schumacher, TN; Aebersold, R; Rammensee, HG; Melief, CJM; Mardis, ER; Gillanders, WE; Artyomov, MN; Schreiber, RD				Gubin, Matthew M.; Zhang, Xiuli; Schuster, Heiko; Caron, Etienne; Ward, Jeffrey P.; Noguchi, Takuro; Ivanova, Yulia; Hundal, Jasreet; Arthur, Cora D.; Krebber, Willem-Jan; Mulder, Gwenn E.; Toebes, Mireille; Vesely, Matthew D.; Lam, Samuel S. K.; Korman, Alan J.; Allison, James P.; Freeman, Gordon J.; Sharpe, Arlene H.; Pearce, Erika L.; Schumacher, Ton N.; Aebersold, Ruedi; Rammensee, Hans-Georg; Melief, Cornelis J. M.; Mardis, Elaine R.; Gillanders, William E.; Artyomov, Maxim N.; Schreiber, Robert D.			Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens	NATURE			English	Article							EXOME ANALYSIS REVEALS; QUANTITATIVE PROTEOMICS; T-CELLS; PD-1; INFLAMMATION; RESPONSES; EQUILIBRIUM; PREDICTIONS; IPILIMUMAB; TOLERANCE	The immune system influences the fate of developing cancers by not only functioning as a tumour promoter that facilitates cellular transformation, promotes tumour growth and sculpts tumour cell immunogenicity(1-6), but also as an extrinsic tumour suppressor that either destroys developing tumours or restrains their expansion(1,2,7). Yet, clinically apparent cancers still arise in immunocompetent individuals in part as a consequence of cancer-induced immunosuppression. In many individuals, immunosuppression is mediated by cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and programmed death-1 (PD -1), two immunomodulatory receptors expressed on T cells(8,9). Monoclonal-antibody-based therapies targeting CTLA-4 and/or PD-1 (checkpoint blockade) have yielded significant clinical benefits including durable responses to patients with different malignancies(10-13). However, little is known about the identity of the tumour antigens that function as the targets of T cells activated by checkpoint blockade immunotherapy and whether these antigens can be used to generate vaccines that are highly tumour-specific. Here we use genomics and bioinformatics approaches to identify tumour-specific mutant proteins as a major class of T-cell rejection antigens following anti-PD-1 and/or anti-CTLA-4 therapy of mice bearing progressively growing sarcomas, and we show that therapeutic synthetic long-peptide vaccines incorporating these mutant epitopes induce tumour rejection comparably to checkpoint blockade immunotherapy. Although mutant tumour-antigen-specific T cells are present in progressively growing tumours, they are reactivated following treatment with anti-PD-1 and/or anti-CTLA-4 and display some overlapping but mostly treatment-specific transcriptional profiles, rendering them capable of mediating tumour rejection. These results reveal that tumour-specific mutant antigens are not only important targets of checkpoint blockade therapy, but they can also be used to develop personalized cancer-specific vaccines and to probe the mechanistic	[Gubin, Matthew M.; Ward, Jeffrey P.; Noguchi, Takuro; Ivanova, Yulia; Arthur, Cora D.; Vesely, Matthew D.; Lam, Samuel S. K.; Pearce, Erika L.; Artyomov, Maxim N.; Schreiber, Robert D.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; [Zhang, Xiuli; Gillanders, William E.] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; [Schuster, Heiko; Rammensee, Hans-Georg] German Canc Res Ctr, Dept Immunol, Inst Cell Biol, D-72076 Tubingen, Germany; [Schuster, Heiko; Rammensee, Hans-Georg] German Canc Res Ctr, German Canc Consortium DKTK, D-72076 Tubingen, Germany; [Caron, Etienne; Aebersold, Ruedi] ETH, Dept Biol, Inst Mol Syst Biol, CH-8093 Zurich, Switzerland; [Ward, Jeffrey P.] Washington Univ, Sch Med, Dept Med, Div Oncol, St Louis, MO 63110 USA; [Hundal, Jasreet; Mardis, Elaine R.] Washington Univ, Sch Med, Genome Inst, St Louis, MO 63108 USA; [Krebber, Willem-Jan; Mulder, Gwenn E.; Melief, Cornelis J. M.] ISA Therapeut BV, NL-2333 CH Leiden, Netherlands; [Toebes, Mireille; Schumacher, Ton N.] Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands; [Korman, Alan J.] Bristol Myers Squibb Co, Redwood City, CA 94063 USA; [Allison, James P.] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; [Freeman, Gordon J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Sharpe, Arlene H.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA 02115 USA; [Aebersold, Ruedi] Univ Zurich, Fac Sci, CH-8093 Zurich, Switzerland; [Melief, Cornelis J. M.] Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, NL-2333 ZA Leiden, Netherlands; [Mardis, Elaine R.] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Eberhard Karls University of Tubingen; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Swiss Federal Institutes of Technology Domain; ETH Zurich; Washington University (WUSTL); Washington University (WUSTL); Netherlands Cancer Institute; Bristol-Myers Squibb; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; University of Zurich; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Washington University (WUSTL)	Schreiber, RD (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, 660 South Euclid Ave, St Louis, MO 63110 USA.	schreiber@immunology.wustl.edu	Noguchi, Takuro/AAW-9101-2020; Schumacher, Ton/Y-2432-2019; Vesely, Matthew/AFM-2324-2022; Freeman, Gordon/AAC-5380-2019; Mardis, Elaine/W-2202-2019; Vesely, Matthew/AAM-6813-2020; Schreiber, Robert/Q-7550-2019	Schumacher, Ton/0000-0003-0517-8804; Vesely, Matthew/0000-0001-9363-945X; Freeman, Gordon/0000-0002-7210-5616; Schreiber, Robert/0000-0003-1590-2341; Lam, Siu Kit/0000-0003-1671-3999; Ward, Jeffrey/0000-0002-9707-895X; Allison, James/0000-0001-8980-5697; Gubin, Matthew/0000-0001-7443-2752	National Cancer Institute [R01 CA043059, U01 CA141541, T32 CA00954729]; Cancer Research Institute; WWWW Foundation; Siteman Cancer Center/Barnes-Jewish Hospital (Cancer Frontier Fund); Susan G. Komen for the Cure (Promise grant); National Human Genome Research Institute; National Institute of Health [P50 CA101942, P01 A1054456]; Dutch Cancer Society (Queen Wilhelmina Research Award); Marie Curie Intra-European Fellowship within the Seventh Framework Programme of the European Community for Research; postdoctoral training grant(Irvington Postdoctoral Fellowship)from the Cancer Research Institute; NATIONAL CANCER INSTITUTE [P30CA091842, P30CA016672, R01CA043059, R01CA190700, P50CA101942, U01CA141541, T32CA009547, R37CA043059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI091965, P01AI054456] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR048335] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Research Institute; WWWW Foundation; Siteman Cancer Center/Barnes-Jewish Hospital (Cancer Frontier Fund); Susan G. Komen for the Cure (Promise grant); National Human Genome Research Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dutch Cancer Society (Queen Wilhelmina Research Award); Marie Curie Intra-European Fellowship within the Seventh Framework Programme of the European Community for Research; postdoctoral training grant(Irvington Postdoctoral Fellowship)from the Cancer Research Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We are grateful to K. Murphy for the Batf3<SUP>-/-</SUP> mice, T. Hansen for providing MHC class I antibodies and the H-2K<SUP>b</SUP> construct, D. Fremont for the human beta 2m construct, and the National Institutes of Health (NIH) Tetramer Core Facility for producing MHC class I tetramers. We also thank R. Ahmed and M. Hashimoto for the multiplex staining strategy used to define functional and dysfunctional T cells. We thank A. Bensimon, O. Schubert and P. Kouvonen for instrument maintenance and for technical support with the mass spectrometry measurements and R. Vanganipuram, M. Selby and J. Valle for generating and supplying anti-PD-1 and anti-CTLA-4 in endotoxin-free sterile form. We also thank K. Sheehan, P. Allen, G. Dunn and R. Chan for constructive criticisms and comments, all members of the Schreiber laboratory for discussions, and the many members of The Genome Institute at Washington University School of Medicine. We would also like to thank W. Song for his assistance with the bioinformatics approaches, P. Kvistborg for assistance with tetramer combinatorial coding, and Christopher Nelson for advice with peptide-MHC monomer purification. This work was supported by grants to R.D.S. from the National Cancer Institute (R01 CA043059, U01 CA141541), the Cancer Research Institute and the WWWW Foundation; to R.D.S. and W.E.G. from The Siteman Cancer Center/Barnes-Jewish Hospital (Cancer Frontier Fund); to W.E.G. from Susan G. Komen for the Cure (Promise grant); to E.R.M. from the National Human Genome Research Institute; to G.J.F. from the National Institute of Health (P50 CA101942, P01 A1054456, P50 CA101942); to A.H.S. from the National Institute of Health (P50 CA101942); and to T.N.S. from the Dutch Cancer Society (Queen Wilhelmina Research Award). E.C. is supported by a Marie Curie Intra-European Fellowship within the Seventh Framework Programme of the European Community for Research. M.M.G. was supported by a postdoctoral training grant (T32 CA00954729) from the National Cancer Institute and is currently supported by a postdoctoral training grant(Irvington Postdoctoral Fellowship)from the Cancer Research Institute. Aspects of studies at Washington University were performed with assistance by the Immunomonitoring Laboratory of the Center for Human Immunology and Immunotherapy Programs and the Siteman Comprehensive Cancer Center.	Andersen RS, 2012, NAT PROTOC, V7, P891, DOI 10.1038/nprot.2012.037; Brunner MC, 1999, J IMMUNOL, V162, P5813; Castle JC, 2012, CANCER RES, V72, P1081, DOI 10.1158/0008-5472.CAN-11-3722; Corbiere V, 2011, CANCER RES, V71, P1253, DOI 10.1158/0008-5472.CAN-10-2693; Coussens LM, 2013, SCIENCE, V339, P286, DOI 10.1126/science.1232227; Curran MA, 2010, P NATL ACAD SCI USA, V107, P4275, DOI 10.1073/pnas.0915174107; Domon B, 2010, NAT BIOTECHNOL, V28, P710, DOI 10.1038/nbt.1661; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Duraiswamy J, 2013, CANCER RES, V73, P3591, DOI 10.1158/0008-5472.CAN-12-4100; Escher C, 2012, PROTEOMICS, V12, P1111, DOI 10.1002/pmic.201100463; ESQUIVEL F, 1992, J EXP MED, V175, P163, DOI 10.1084/jem.175.1.163; Fritsch EF, 2014, CANCER IMMUNOL RES, V2, P522, DOI 10.1158/2326-6066.CIR-13-0227; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Hildner K, 2008, SCIENCE, V322, P1097, DOI 10.1126/science.1164206; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hoof I, 2009, IMMUNOGENETICS, V61, P1, DOI 10.1007/s00251-008-0341-z; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Koebel CM, 2007, NATURE, V450, P903, DOI 10.1038/nature06309; Kowalewski Daniel J, 2013, Methods Mol Biol, V960, P145, DOI 10.1007/978-1-62703-218-6_12; Kvistborg P, 2012, ONCOIMMUNOLOGY, V1, DOI 10.4161/onci.18851; Lange V, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.61; Lundegaard C, 2008, NUCLEIC ACIDS RES, V36, pW509, DOI 10.1093/nar/gkn202; MacLean B, 2010, BIOINFORMATICS, V26, P966, DOI 10.1093/bioinformatics/btq054; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Matsushita H, 2012, NATURE, V482, P400, DOI 10.1038/nature10755; Nielsen M, 2005, IMMUNOGENETICS, V57, P33, DOI 10.1007/s00251-005-0781-7; Okazaki T, 2013, NAT IMMUNOL, V14, P1212, DOI 10.1038/ni.2762; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Paul S, 2013, J IMMUNOL, V191, P5831, DOI 10.4049/jimmunol.1302101; Peters B, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-132; Quezada SA, 2011, IMMUNOL REV, V241, P104, DOI 10.1111/j.1600-065X.2011.01007.x; Robbins PF, 2013, NAT MED, V19, P747, DOI 10.1038/nm.3161; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Spiotto MT, 2004, NAT MED, V10, P294, DOI 10.1038/nm999; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thommen DS, 2012, J IMMUNOL, V188, P5283, DOI 10.4049/jimmunol.1101506; Toebes M, 2006, NAT MED, V12, P246, DOI 10.1038/nm1360; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tran E, 2014, SCIENCE, V344, P641, DOI 10.1126/science.1251102; Trinchieri G, 2012, ANNU REV IMMUNOL, V30, P677, DOI 10.1146/annurev-immunol-020711-075008; van Rooij N, 2013, J CLIN ONCOL, V31, pE439, DOI 10.1200/JCO.2012.47.7521; West EE, 2011, IMMUNITY, V35, P285, DOI 10.1016/j.immuni.2011.05.017; Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035; Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369; Wolkers MC, 2004, SCIENCE, V304, P1314, DOI 10.1126/science.1096268	46	1354	1435	13	569	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 27	2014	515	7528					577	+		10.1038/nature13988	http://dx.doi.org/10.1038/nature13988			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AW4JP	25428507	Green Accepted, Green Submitted			2023-01-03	WOS:000346247600056
J	Gorczynski, RM; Chen, ZQ; Erin, N; Khatri, I; Podnos, A				Gorczynski, Reginald M.; Chen, Zhiqi; Erin, Nuray; Khatri, Ismat; Podnos, Anna			Comparison of Immunity in Mice Cured of Primary/Metastatic Growth of EMT6 or 4THM Breast Cancer by Chemotherapy or Immunotherapy	PLOS ONE			English	Article							REGULATORY T-CELLS; TUMOR-CELLS; PULMONARY METASTASIS; THERAPEUTIC TARGET; CD200 EXPRESSION; PROMOTES; INFLAMMATION; CD4(+)	Purpose: We have compared cure from local/metastatic tumor growth in BALB/c mice receiving EMT6 or the poorly immunogenic, highly metastatic 4THM, breast cancer cells following manipulation of immunosuppressive CD200:CD200R interactions or conventional chemotherapy. Methods: We reported previously that EMT6 tumors are cured in CD200R1KO mice following surgical resection and immunization with irradiated EMT6 cells and CpG oligodeoxynucleotide (CpG), while wild-type (WT) animals developed pulmonary and liver metastases within 30 days of surgery. We report growth and metastasis of both EMT6 and a highly metastatic 4THM tumor in WT mice receiving iv infusions of Fab anti-CD200R1 along with CpG/tumor cell immunization. Metastasis was followed both macroscopically (lung/liver nodules) and microscopically by cloning tumor cells at limiting dilution in vitro from draining lymph nodes (DLN) harvested at surgery. We compared these results with local/metastatic tumor growth in mice receiving 4 courses of combination treatment with anti-VEGF and paclitaxel. Results: In WT mice receiving Fab anti-CD200R, no tumor cells are detectable following immunotherapy, and CD4+ cells produced increased TNF alpha/IL-2/IFN gamma on stimulation with EMT6 in vitro. No long-term cure was seen following surgery/immunotherapy of 4THM, with both microscopic (tumors in DLN at limiting dilution) and macroscopic metastases present within 14 d of surgery. Chemotherapy attenuated growth/metastases in 4THM tumor-bearers and produced a decline in lung/liver metastases, with no detectable DLN metastases in EMT6 tumor-bearing mice-these latter mice nevertheless showed no significantly increased cytokine production after restimulation with EMT6 in vitro. EMT6 mice receiving immunotherapy were resistant to subsequent re-challenge with EMT6 tumor cells, but not those receiving curative chemotherapy. Anti-CD4 treatment caused tumor recurrence after immunotherapy, but produced no apparent effect in either EMT6 or 4THM tumor bearers after chemotherapy treatment. Conclusion: Immunotherapy, but not chemotherapy, enhances CD4+ immunity and affords long-term control of breast cancer growth and resistance to new tumor foci.	[Gorczynski, Reginald M.; Chen, Zhiqi; Khatri, Ismat; Podnos, Anna] Univ Hlth Network, Toronto Gen Hosp, Toronto, ON, Canada; [Gorczynski, Reginald M.] Univ Toronto, Fac Med, Dept Immunol, Toronto, ON, Canada; [Gorczynski, Reginald M.] Univ Toronto, Inst Med Sci, Toronto, ON, Canada; [Erin, Nuray] Akdeniz Univ, Sch Med, Dept Med Pharmacol, TR-07058 Antalya, Turkey	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University of Toronto; Akdeniz University	Gorczynski, RM (corresponding author), Univ Hlth Network, Toronto Gen Hosp, Toronto, ON, Canada.	rgorczynski@uhnres.utoronto.ca	Gorczynski, Reginald/AAA-1435-2019; Erin, Nuray/B-8616-2012	Erin, Nuray/0000-0002-6116-1970	Canadian Cancer Society [RG-11]	Canadian Cancer Society(Canadian Cancer Society (CCS))	Supported by a grant (RG-11) to RMG from the Canadian Cancer Society (www.cancer.ca). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abadi YM, 2013, J IMMUNOL, V190, P3806, DOI 10.4049/jimmunol.1202439; Anderson KS, 2009, CANCER INVEST, V27, P361, DOI 10.1080/07357900802574421; Assudani DP, 2007, CANCER IMMUNOL IMMUN, V56, P70, DOI 10.1007/s00262-006-0154-6; Baxevanis CN, 2006, CANCER IMMUNOL IMMUN, V55, P85, DOI 10.1007/s00262-005-0692-3; Beyer M, 2009, CANCER RES, V69, P4346, DOI 10.1158/0008-5472.CAN-08-3796; Calogero RA, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1745; Campoli Michael, 2004, Breast Dis, V20, P105; Chaudhuri S, 2000, P NATL ACAD SCI USA, V97, P11451, DOI 10.1073/pnas.97.21.11451; DeNardo DG, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1746; DISIS ML, 1994, CANCER RES, V54, P16; Duraiswamy J, 2013, CANCER RES, V73, P3591, DOI 10.1158/0008-5472.CAN-12-4100; Einav U, 2005, ONCOGENE, V24, P6367, DOI 10.1038/sj.onc.1208797; Erin N, 2014, ONCOGENE IN PRESS; Erin N, 2006, BREAST CANCER RES TR, V99, P351, DOI 10.1007/s10549-006-9219-7; Gorczynski RM, 2013, BREAST CANCER RES TR, V142, P271, DOI 10.1007/s10549-013-2735-3; Gorczynski RM, 2011, BREAST CANCER RES TR, V130, P49, DOI 10.1007/s10549-010-1259-3; Gorczynski RM, 2010, BREAST CANCER RES TR, V123, P405, DOI 10.1007/s10549-009-0667-8; HAMILTON G, 1988, J CANCER RES CLIN, V114, P191, DOI 10.1007/BF00417836; Huang B, 2006, CANCER RES, V66, P1123, DOI 10.1158/0008-5472.CAN-05-1299; Jarnicki AG, 2006, J IMMUNOL, V177, P896, DOI 10.4049/jimmunol.177.2.896; JEROME KR, 1993, J IMMUNOL, V151, P1654; Liang ZX, 2005, CANCER RES, V65, P967; Lu X, 2009, J BIOL CHEM, V284, P29087, DOI 10.1074/jbc.M109.035899; Ma XR, 2009, MOL CANCER THER, V8, P490, DOI 10.1158/1535-7163.MCT-08-0485; Marincola F M, 2000, Adv Immunol, V74, P181, DOI 10.1016/S0065-2776(08)60911-6; McWhirter JR, 2006, P NATL ACAD SCI USA, V103, P1041, DOI 10.1073/pnas.0510081103; Menard S, 1997, CLIN CANCER RES, V3, P817; Moreaux J, 2008, BIOCHEM BIOPH RES CO, V366, P117, DOI 10.1016/j.bbrc.2007.11.103; Olkhanud PB, 2009, CANCER RES, V69, P5996, DOI 10.1158/0008-5472.CAN-08-4619; Pakala SB, 2013, CANCER RES, V73, P3761, DOI 10.1158/0008-5472.CAN-12-3998; Pandit TS, 2009, INT J ONCOL, V35, P297, DOI 10.3892/ijo_00000340; Petermann KB, 2007, J CLIN INVEST, V117, P3922, DOI 10.1172/JCI32163; Pfeffer U, 2009, CLIN EXP METASTAS, V26, P547, DOI 10.1007/s10585-009-9254-y; Podnos A, 2012, BREAST CANCER RES TR, V136, P117, DOI 10.1007/s10549-012-2258-3; Pollard JW, 2008, J LEUKOCYTE BIOL, V84, P623, DOI 10.1189/jlb.1107762; Qin FXF, 2009, CELL MOL IMMUNOL, V6, P3, DOI 10.1038/cmi.2009.2; Ramsey-Goldman R, 1998, J INVEST MED, V46, P217; Siva A, 2008, CANCER IMMUNOL IMMUN, V57, P987, DOI 10.1007/s00262-007-0429-6; Standish Leanna J, 2008, J Soc Integr Oncol, V6, P158; Takahashi M, 2009, CLIN EXP METASTAS, V26, P817, DOI 10.1007/s10585-009-9281-8; Tan TT, 2007, CURR OPIN IMMUNOL, V19, P209, DOI 10.1016/j.coi.2007.01.001; TICHATSCHEK E, 1988, CANCER IMMUNOL IMMUN, V27, P278; Tonks A, 2007, LEUKEMIA, V21, P566, DOI 10.1038/sj.leu.2404559; Tsavaris N, 2002, BRIT J CANCER, V87, P21, DOI 10.1038/sj.bjc.6600347; Yang L, 2004, CANCER CELL, V6, P409, DOI 10.1016/j.ccr.2004.08.031; Yang L, 2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004; Zhou G, 2006, BLOOD, V107, P628, DOI 10.1182/blood-2005-07-2737	47	12	12	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 19	2014	9	11							e113597	10.1371/journal.pone.0113597	http://dx.doi.org/10.1371/journal.pone.0113597			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AU3SG	25409195	gold, Green Submitted, Green Published			2023-01-03	WOS:000345533200139
J	Sadler, E; Hales, B; Henry, B; Xiong, W; Myers, J; Wynnychuk, L; Taggar, R; Heyland, D; Fowler, R				Sadler, Erin; Hales, Brigette; Henry, Blair; Xiong, Wei; Myers, Jeff; Wynnychuk, Lesia; Taggar, Ru; Heyland, Daren; Fowler, Robert			Factors Affecting Family Satisfaction with Inpatient End-of-Life Care	PLOS ONE			English	Article							QUALITY; HEALTH	Background: Little data exists addressing satisfaction with end-of-life care among hospitalized patients, as they and their family members are systematically excluded from routine satisfaction surveys. It is imperative that we closely examine patient and institution factors associated with quality end-of-life care and determine high-priority target areas for quality improvement. Methods: Between September 1, 2010 and January 1, 2012 the Canadian Health care Evaluation Project (CANHELP) Bereavement Questionnaire was mailed to the next-of-kin of recently deceased inpatients to seek factors associated with satisfaction with end-of-life care. The primary outcome was the global rating of satisfaction. Secondary outcomes included rates of actual versus preferred location of death, associations between demographic factors and global satisfaction, and identification of targets for quality improvement. Results: Response rate was 33% among 275 valid addresses. Overall, 67.4% of respondents were very or completely satisfied with the overall quality of care their relative received. However, 71.4% of respondents who thought their relative did not die in their preferred location favoured an out-of-hospital location of death. A common location of death was the intensive care unit (45.7%); however, this was not the preferred location of death for 47.6% of such patients. Multivariate Poisson regression analysis showed respondents who believed their relative died in their preferred location were 1.7 times more likely to be satisfied with the end-of-life care that was provided (p = 0.001). Items identified as high-priority targets for improvement included: relationships with, and characteristics of health care professionals; illness management; communication; and end-of-life decision-making. Interpretation: Nearly three-quarters of recently deceased inpatients would have preferred an out-of-hospital death. Intensive care units were a common, but not preferred, location of in-hospital deaths. Family satisfaction with end-of-life care was strongly associated with their relative dying in their preferred location. Improved communication regarding end-of-life care preferences should be a high-priority quality improvement target.	[Sadler, Erin] Univ Toronto, Dept Gen Surg, Toronto, ON, Canada; [Hales, Brigette; Henry, Blair; Myers, Jeff; Wynnychuk, Lesia; Taggar, Ru] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; [Xiong, Wei] Sunnybrook Hlth Sci Ctr, Trauma Emergency & Crit Care Program, Toronto, ON M4N 3M5, Canada; [Heyland, Daren] Queens Univ, Dept Crit Care Med, Kingston, ON, Canada; [Fowler, Robert] Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, Toronto, ON M4N 3M5, Canada; [Fowler, Robert] Univ Toronto, Dept Med, Toronto, ON, Canada	University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Queens University - Canada; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Fowler, R (corresponding author), Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, Toronto, ON M4N 3M5, Canada.	Rob.fowler@sunnybrook.ca		Henry, Blair/0000-0002-1073-9592	Heart and Stroke Foundation of Ontario; University of Toronto Department of Medicine Integrating Challenge Grant; Technology Evaluation in the Elderly Network Center of Excellence	Heart and Stroke Foundation of Ontario(Heart & Stroke Foundation of Ontario); University of Toronto Department of Medicine Integrating Challenge Grant; Technology Evaluation in the Elderly Network Center of Excellence	The Heart and Stroke Foundation of Ontario, the University of Toronto Department of Medicine Integrating Challenge Grant, and the Technology Evaluation in the Elderly Network Center of Excellence have supported this body of work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Burns KEA, 2008, CAN MED ASSOC J, V179, P245, DOI 10.1503/cmaj.080372; Canadian Institute for Health Information, 2007, HLTH CAR US END LIF; Dodek PM, 2004, CRIT CARE MED, V32, P1922, DOI 10.1097/01.CCM.0000139920.53790.61; Frost DW, 2011, CRIT CARE MED, V39, P1174, DOI 10.1097/CCM.0b013e31820eacf2; Heyland DK, 2013, JAMA INTERN MED, V173, P778, DOI 10.1001/jamainternmed.2013.180; Heyland DK, 2010, PALLIATIVE MED, V24, P682, DOI 10.1177/0269216310373168; Heyland DK, 2000, J PALLIATIVE CARE, V16, pS10, DOI 10.1177/082585970001601S04; Johnson TP, 2012, JAMA-J AM MED ASSOC, V307, P1805, DOI 10.1001/jama.2012.3532; McPherson CJ, 2003, SOC SCI MED, V56, P95, DOI 10.1016/S0277-9536(02)00011-4; Morss S, 2008, J AM GERIATR SOC, V56, P124, DOI 10.1111/j.1532-5415.2007.01507.x; Singer PA, 2002, BMJ-BRIT MED J, V324, P1291, DOI 10.1136/bmj.324.7349.1291; Skrobik Y., 2010, CMAJ CANADIAN MED AS, V182, P747, DOI [10.1503/cmaj.l00131, DOI 10.1503/CMAJ.L00131]; Soberman L R, 1997, Qual Manag Health Care, V5, P63; Standing Senate Committee on Social Affairs Science and Technology, 2000, QUAL END OF LIF CAR; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	16	36	36	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 17	2014	9	11							e110860	10.1371/journal.pone.0110860	http://dx.doi.org/10.1371/journal.pone.0110860			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT8BL	25401710	Green Published, gold, Green Submitted			2023-01-03	WOS:000345158700009
J	Correia, M; Thiagarajan, V; Coutinho, I; Gajula, GP; Petersen, SB; Neves-Petersen, MT				Correia, Manuel; Thiagarajan, Viruthachalam; Coutinho, Isabel; Gajula, Gnana Prakash; Petersen, Steffen B.; Neves-Petersen, Maria Teresa			Modulating the Structure of EGFR with UV Light: New Possibilities in Cancer Therapy	PLOS ONE			English	Article							EPIDERMAL-GROWTH-FACTOR; EXCITED-STATE CHEMISTRY; AROMATIC-AMINO-ACIDS; RECEPTOR EXTRACELLULAR DOMAIN; VITAMIN-D; ULTRAVIOLET-IRRADIATION; SIGNAL-TRANSDUCTION; OXIDATION-PRODUCTS; CRYSTAL-STRUCTURE; DECAY KINETICS	The epidermal growth factor receptor (EGFR) is a member of the ErbB family of receptor tyrosine kinases. EGFR is activated upon binding to e. g. epidermal growth factor (EGF), leading to cell survival, proliferation and migration. EGFR overactivation is associated with tumor progression. We have previously shown that low dose UVB illumination of cancer cells overexpressing EGFR prior to adding EGF halted the EGFR signaling pathway. We here show that UVB illumination of the extracellular domain of EGFR (sEGFR) induces protein conformational changes, disulphide bridge breakage and formation of tryptophan and tyrosine photoproducts such as dityrosine, N-formylkynurenine and kynurenine. Fluorescence spectroscopy, circular dichroism and thermal studies confirm the occurrence of conformational changes. An immunoassay has confirmed that UVB light induces structural changes in the EGF binding site. A monoclonal antibody which competes with EGF for binding sEGFR was used. We report clear evidence that UVB light induces structural changes in EGFR that impairs the correct binding of an EGFR specific antibody that competes with EGF for binding EGFR, confirming that the 3D structure of the EGFR binding domain suffered conformational changes upon UV illumination. The irradiance used is in the same order of magnitude as the integrated intensity in the solar UVB range. The new photonic technology disables a key receptor and is most likely applicable to the treatment of various types of cancer, alone or in combination with other therapies.	[Correia, Manuel] Aalborg Univ, Dept Phys & Nanotechnol, Aalborg, Denmark; [Thiagarajan, Viruthachalam; Coutinho, Isabel; Gajula, Gnana Prakash; Neves-Petersen, Maria Teresa] Int Iberian Nanotechnol Lab INL, Dept Nanomed, BioPhoton Grp, Braga, Portugal; [Thiagarajan, Viruthachalam] Bharathidasan Univ, Sch Chem, Tiruchirappalli, Tamil Nadu, India; [Petersen, Steffen B.] Aalborg Univ, Dept Hlth Sci & Technol, Aalborg, Denmark; [Petersen, Steffen B.] SUNY Buffalo, Inst Lasers Photon & Biophoton, Buffalo, NY 14260 USA	Aalborg University; International Iberian Nanotechnology Laboratory; Bharathidasan University; Aalborg University; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Neves-Petersen, MT (corresponding author), Int Iberian Nanotechnol Lab INL, Dept Nanomed, BioPhoton Grp, Braga, Portugal.	nevespetersen@gmail.com	Petersen, Steffen b/E-8727-2015; Coutinho, Isabel/J-4165-2016; INL, Citations/K-3436-2015; Viruthachalam, Thiagarajan/I-2503-2013	Petersen, Steffen b/0000-0002-0739-2751; INL, Citations/0000-0002-3745-5100; Correia, Manuel/0000-0001-7619-2780; Thiagarajan, Viruthachalam/0000-0003-4197-2255	"Fundaco para a Ciencia e Tecnologia" (FCT) [SFRH/BD/61012/2009]; "Programa Operacional Potencial Humano" (POPH); European Social Fund ("Fundo Social Europeu", FSE)	"Fundaco para a Ciencia e Tecnologia" (FCT); "Programa Operacional Potencial Humano" (POPH); European Social Fund ("Fundo Social Europeu", FSE)(European Social Fund (ESF))	MC acknowledges the support from "Fundaco para a Ciencia e Tecnologia" (FCT) for the PhD grant (SFRH/BD/61012/2009) supported by "Programa Operacional Potencial Humano" (POPH) in the framework of "Quadro de Referencia Estrategica Nacional" (QREN) and co-financed by the European Social Fund ("Fundo Social Europeu", FSE). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adachi S, 2011, J BIOL CHEM, V286, P26178, DOI 10.1074/jbc.M111.240630; Banwell CM, 2003, RECENT RESULTS CANC, V164, P83; BENT DV, 1975, J AM CHEM SOC, V97, P2599, DOI 10.1021/ja00843a002; BENT DV, 1975, J AM CHEM SOC, V97, P2606, DOI 10.1021/ja00843a003; BENT DV, 1975, J AM CHEM SOC, V97, P2612, DOI 10.1021/ja00843a004; Budiyanto A, 2003, J INVEST DERMATOL, V121, P1088, DOI 10.1046/j.1523-1747.2003.12529.x; Cao C, 2008, CELL SIGNAL, V20, P1830, DOI 10.1016/j.cellsig.2008.06.010; Casanova ML, 2002, CANCER RES, V62, P3402; Correia M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050733; Correia M, 2012, J FLUORESC, V22, P323, DOI 10.1007/s10895-011-0963-7; CREED D, 1984, PHOTOCHEM PHOTOBIOL, V39, P537; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; Finley EL, 1997, PHOTOCHEM PHOTOBIOL, V66, P635, DOI 10.1111/j.1751-1097.1997.tb03200.x; Finley EL, 1998, PROTEIN SCI, V7, P2391, DOI 10.1002/pro.5560071116; FUKUNAGA Y, 1982, J BIOCHEM-TOKYO, V92, P129, DOI 10.1093/oxfordjournals.jbchem.a133909; Garland CF, 2006, AM J PUBLIC HEALTH, V96, P252, DOI 10.2105/AJPH.2004.045260; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; Gasteiger E., 2005, PROTEOMICS PROTOCOLS, P571, DOI [10.1385/1-59259-890-0:571, DOI 10.1385/1-59259-890-0:571]; Giulivi C, 2003, AMINO ACIDS, V25, P227, DOI 10.1007/s00726-003-0013-0; Gorham ED, 2005, J STEROID BIOCHEM, V97, P179, DOI 10.1016/j.jsbmb.2005.06.018; Grant WB, 2002, CANCER-AM CANCER SOC, V94, P1867, DOI 10.1002/cncr.10427; Greenfield NJ, 2006, NAT PROTOC, V1, P2876, DOI 10.1038/nprot.2006.202; Han W, 2012, CANCER LETT, V318, P124, DOI 10.1016/j.canlet.2012.01.011; HOFFMAN MZ, 1972, J AM CHEM SOC, V94, P7950, DOI 10.1021/ja00778a002; Huang RP, 1996, J CELL BIOL, V133, P211, DOI 10.1083/jcb.133.1.211; Jacob JS, 1996, J BIOL CHEM, V271, P19950, DOI 10.1074/jbc.271.33.19950; JONES CA, 1987, RADIAT RES, V110, P244, DOI 10.2307/3576902; Kaskel P, 2001, BRIT J DERMATOL, V145, P602, DOI 10.1046/j.1365-2133.2001.04432.x; Kawaguchi J, 2012, ONCOL REP, V27, P935, DOI 10.3892/or.2011.1612; KAWAMOTO T, 1992, IN VITRO CELL DEV-AN, V28A, P782; Kerwin BA, 2007, J PHARM SCI-US, V96, P1468, DOI 10.1002/jps.20815; Kiguchi K, 1998, MOL CARCINOGEN, V22, P73, DOI 10.1002/(SICI)1098-2744(199806)22:2<73::AID-MC2>3.0.CO;2-L; Kim YN, 2002, EXP CELL RES, V280, P134, DOI 10.1006/excr.2002.5623; LI Z, 1989, BIOPHYS J, V56, P361, DOI 10.1016/S0006-3495(89)82682-7; Liu P, 2012, P NATL ACAD SCI USA, V109, P10861, DOI 10.1073/pnas.1201114109; Macdonald J, 2006, BBA-MOL CELL RES, V1763, P870, DOI 10.1016/j.bbamcr.2006.05.002; Malencik DA, 2003, AMINO ACIDS, V25, P233, DOI 10.1007/s00726-003-0014-z; MALENCIK DA, 1987, BIOCHEMISTRY-US, V26, P695, DOI 10.1021/bi00377a006; Moan J., 2001, RAD HOME OUTDOORS WO, P69; Neves-Petersen MT, 2009, BIOPHYS J, V97, P211, DOI 10.1016/j.bpj.2009.01.065; Neves-Petersen MT, 2006, PROTEIN SCI, V15, P343, DOI 10.1110/ps.051885306; Neves-Petersen MT, 2002, PROTEIN SCI, V11, P588, DOI 10.1110/ps.06002; Newton-Bishop JA, 2011, EUR J CANCER, V47, P732, DOI 10.1016/j.ejca.2010.10.008; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; Nilsen LTN, 2011, PHOTOCH PHOTOBIO SCI, V10, P1129, DOI 10.1039/c1pp05029j; Noonberg SB, 2000, DRUGS, V59, P753, DOI 10.2165/00003495-200059040-00003; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Olsen BB, 2007, INT J ONCOL, V30, P181; Petersen MTN, 1999, PROTEIN ENG, V12, P535, DOI 10.1093/protein/12.7.535; PIRIE A, 1971, BIOCHEM J, V125, P203, DOI 10.1042/bj1250203; Pukkala E, 2009, ACTA ONCOL, V48, P646, DOI 10.1080/02841860902913546; Riener CK, 2002, ANAL BIOANAL CHEM, V373, P266, DOI 10.1007/s00216-002-1347-2; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Segrelles C, 2002, ONCOGENE, V21, P53, DOI 10.1038/sj.onc.1205032; Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X; Suzuki S, 2005, CANCER-AM CANCER SOC, V103, P1265, DOI 10.1002/cncr.20909; Tao RH, 2008, J CELL SCI, V121, P3207, DOI 10.1242/jcs.033399; Teresa M., 2012, MOL PHOTOCHEM VAR AS, V37947, P1, DOI [10.5772/37947, DOI 10.5772/37947]; Wan YS, 2001, INT J ONCOL, V18, P461; Webb AR, 2006, PHOTOCHEM PHOTOBIOL, V82, P1697, DOI 10.1562/2006-09-01-RA-670; Xu YR, 2006, AM J PATHOL, V169, P823, DOI 10.2353/ajpath.2006.050449; Yarden Y, 2001, EUR J CANCER, V37, pS3; Zhang YG, 2001, DNA CELL BIOL, V20, P769, DOI 10.1089/104454901753438589	63	15	15	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2014	9	11							e111617	10.1371/journal.pone.0111617	http://dx.doi.org/10.1371/journal.pone.0111617			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT9MC	25386651	Green Published, Green Submitted, gold			2023-01-03	WOS:000345250400023
J	Krens, LL; Simkens, LHJ; Baas, JM; Koomen, ER; Gelderblom, H; Punt, CJA; Guchelaar, HJ				Krens, Lisanne L.; Simkens, Lieke H. J.; Baas, Jara M.; Koomen, Els R.; Gelderblom, Hans; Punt, Cornelis J. A.; Guchelaar, Henk-Jan			Statin Use Is Not Associated with Improved Progression Free Survival in Cetuximab Treated KRAS Mutant Metastatic Colorectal Cancer Patients: Results from the CAIRO2 Study	PLOS ONE			English	Article							RECTAL-CANCER; NEOADJUVANT CHEMORADIATION; PATHOLOGICAL RESPONSE; THERAPY; BEVACIZUMAB; RECURRENCE	Statins may inhibit the expression of the mutant KRAS phenotype by preventing the prenylation and thus the activation of the KRAS protein. This study was aimed at retrospectively evaluating the effect of statin use on outcome in KRAS mutant metastatic colorectal cancer patients (mCRC) treated with cetuximab. Treatment data were obtained from patients who were treated with capecitabine, oxaliplatin bevacizumab +/- cetuximab in the phase III CAIRO2 study. A total of 529 patients were included in this study, of whom 78 patients were on statin therapy. In patients with a KRAS wild type tumor (n = 321) the median PFS was 10.3 vs. 11.4 months for non-users compared to statin users and in patients with a KRAS mutant tumor (n = 208) this was 7.6 vs. 6.2 months, respectively. The hazard ratio (HR) for PFS for statin users was 1.12 (95% confidence interval 0.78-1.61) and was not influenced by treatment arm, KRAS mutation status or the KRAS*statin interaction. Statin use adjusted for covariates was not associated with increased PFS (HR = 1.01, 95% confidence interval 0.71-1.54). In patients with a KRAS wild type tumor the median OS for non-users compared to statin users was 22.4 vs. 19.8 months and in the KRAS mutant tumor group the OS was 18.1 vs. 14.5 months. OS was significantly shorter in statin users versus non-users (HR = 1.54; 95% confidence interval 1.06-2.22). However, statin use, adjusted for covariates was not associated with increased OS (HR = 1.41, 95% confidence interval 0.95-2.10). In conclusion, the use of statins at time of diagnosis was not associated with an improved PFS in KRAS mutant mCRC patients treated with chemotherapy and bevacizumab plus cetuximab.	[Krens, Lisanne L.; Koomen, Els R.; Guchelaar, Henk-Jan] Leiden Univ, Med Ctr, Dept Clin Pharm & Toxicol, Leiden, Netherlands; [Simkens, Lieke H. J.; Punt, Cornelis J. A.] Univ Amsterdam, Acad Med Ctr, Dept Med Oncol, NL-1105 AZ Amsterdam, Netherlands; [Baas, Jara M.; Gelderblom, Hans] Leiden Univ, Med Ctr, Dept Clin Oncol, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Guchelaar, HJ (corresponding author), Leiden Univ, Med Ctr, Dept Clin Pharm & Toxicol, Leiden, Netherlands.	H.J.Guchelaar@lumc.nl	guchelaar, henk-jan/AAP-1381-2021	Gelderblom, Hans/0000-0001-9270-8636; Guchelaar, Henk-Jan/0000-0002-7085-1383				Chan KKW, 2003, CLIN CANCER RES, V9, P10; Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275; Eisenberg Daniel A., 1998, American Journal of Medicine, V104, p2S, DOI 10.1016/S0002-9343(98)00038-2; Gonyeau MJ, 2014, CURR ATHEROSCLER REP, V16, DOI 10.1007/s11883-013-0383-z; Graaf MR, 2004, CANCER TREAT REV, V30, P609, DOI 10.1016/j.ctrv.2004.06.010; Graaf MR, 2004, J CLIN ONCOL, V22, P2388, DOI 10.1200/JCO.2004.02.027; Katz MS, 2005, INT J RADIAT ONCOL, V62, P1363, DOI 10.1016/j.ijrobp.2004.12.033; Konstantinopoulos PA, 2007, NAT REV DRUG DISCOV, V6, P540, DOI 10.1038/nrd2221; Krens LL, 2010, DRUG DISCOV TODAY, V15, P502, DOI 10.1016/j.drudis.2010.05.012; Lee J, 2009, CANCER CHEMOTH PHARM, V64, P657, DOI 10.1007/s00280-008-0913-5; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; Liu Y, 2013, CANC CAUSES CONTROL; Mace AG, 2013, DIS COLON RECTUM, V56, P1217, DOI 10.1097/DCR.0b013e3182a4b236; Maciejak A, 2013, BMC BIOTECHNOL, V13, DOI 10.1186/1472-6750-13-68; Ng K, 2011, JNCI-J NATL CANCER I, V103, P1540, DOI 10.1093/jnci/djr307; Nielsen SF, 2012, NEW ENGL J MED, V367, P1792, DOI 10.1056/NEJMoa1201735; Scartozzi M, 2009, ANN ONCOL, V20, P227, DOI 10.1093/annonc/mdn637; Siddiqui AA, 2009, DIGEST DIS SCI, V54, P1307, DOI 10.1007/s10620-009-0790-8; Theodoropoulos G, 2002, DIS COLON RECTUM, V45, P895, DOI 10.1007/s10350-004-6325-7; Tol J, 2010, CLIN THER, V32, P437, DOI 10.1016/j.clinthera.2010.03.012; Tol J, 2009, NEW ENGL J MED, V360, P563, DOI 10.1056/NEJMoa0808268	21	26	27	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2014	9	11							e112201	10.1371/journal.pone.0112201	http://dx.doi.org/10.1371/journal.pone.0112201			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AS6XM	25375154	Green Published, gold, Green Submitted			2023-01-03	WOS:000344402600117
J	Gapstur, SM; Patel, AV; Banks, E; Dal Maso, L; Talamini, R; Chetrit, A; Hirsh-Yechezkel, G; Lubin, F; Sadetzki, S; Beral, V; Bull, D; Cairns, B; Crossley, B; Gaitskell, K; Goodill, A; Green, J; Hermon, C; Key, T; Moser, K; Reeves, G; Sitas, F; Collins, R; Peto, R; Gonzalez, CA; Lee, N; Marchbanks, P; Ory, HW; Peterson, HB; Wingo, PA; Martin, N; Silpisornkosol, S; Theetranont, C; Boosiri, B; Chutivongse, S; Jimakorn, P; Virutamasen, P; Wongsrichanalai, C; Goodman, MT; Lidegaard, O; Kjaer, SK; Morch, LS; Tjonneland, A; Byers, T; Rohan, T; Mosgaard, B; Vessey, M; Yeates, D; Freudenheim, JL; Titus, LJ; Chang-Claude, J; Kaaks, R; Anderson, KE; Lazovich, D; Robien, K; Hampton, J; Newcomb, PA; Rossing, MA; Thomas, DB; Weiss, NS; Lokkegaard, E; Riboli, E; Clavel-Chapelon, F; Cramer, D; Hankinson, SE; Tamimi, RM; Tworoger, SS; Franceschi, S; La Vecchia, C; Negri, E; Adami, HO; Magnusson, C; Riman, T; Weiderpass, E; Wolk, A; Schouten, LJ; van den Brandt, PA; Chantarakul, N; Koetsawang, S; Rachawat, D; Palli, D; Black, A; Brinton, LA; Freedman, DM; Hartge, P; Hsing, AW; Jnr, JVL; Lissowska, J; Hoover, RN; Schairer, C; Babb, C; Urban, M; Graff-Iversen, S; Selmer, R; Bain, CJ; Green, AC; Purdie, DM; Siskind, V; Webb, PM; Moysich, K; McCann, SE; Hannaford, P; Kay, C; Binns, CW; Lee, AH; Zhang, M; Ness, RB; Nasca, P; Coogan, PF; Palmer, JR; Rosenberg, L; Whittemore, A; Katsouyanni, K; Trichopoulou, A; Trichopoulos, D; Tzonou, A; Dabancens, A; Martinez, L; Molina, R; Salas, O; Lurie, G; Carney, ME; Wilkens, LR; Hartman, L; Manjer, J; Olsson, H; Kumle, M; Grisso, JA; Morgan, M; Wheeler, JE; Edwards, RP; Kelley, JL; Modugno, F; Onland-Moret, NC; Peeters, PHM; Casagrande, J; Pike, MC; Wu, AH; Canfell, K; Miller, AB; Gram, IT; Lund, E; McGowan, L; Shu, XO; Zheng, W; Farley, TMM; Holck, S; Meirik, O; Risch, HA				Gapstur, S. M.; Patel, A. V.; Banks, E.; Dal Maso, L.; Talamini, R.; Chetrit, A.; Hirsh-Yechezkel, G.; Lubin, F.; Sadetzki, S.; Beral, V.; Bull, D.; Cairns, B.; Crossley, B.; Gaitskell, K.; Goodill, A.; Green, J.; Hermon, C.; Key, T.; Moser, K.; Reeves, G.; Sitas, F.; Collins, R.; Peto, R.; Gonzalez, C. A.; Lee, N.; Marchbanks, P.; Ory, H. W.; Peterson, H. B.; Wingo, P. A.; Martin, N.; Silpisornkosol, S.; Theetranont, C.; Boosiri, B.; Chutivongse, S.; Jimakorn, P.; Virutamasen, P.; Wongsrichanalai, C.; Goodman, M. T.; Lidegaard, O.; Kjaer, S. K.; Morch, L. S.; Tjonneland, A.; Byers, T.; Rohan, T.; Mosgaard, B.; Vessey, M.; Yeates, D.; Freudenheim, J. L.; Titus, L. J.; Chang-Claude, J.; Kaaks, R.; Anderson, K. E.; Lazovich, D.; Robien, K.; Hampton, J.; Newcomb, P. A.; Rossing, M. A.; Thomas, D. B.; Weiss, N. S.; Lokkegaard, E.; Riboli, E.; Clavel-Chapelon, F.; Cramer, D.; Hankinson, S. E.; Tamimi, R. M.; Tworoger, S. S.; Franceschi, S.; La Vecchia, C.; Negri, E.; Adami, H. O.; Magnusson, C.; Riman, T.; Weiderpass, E.; Wolk, A.; Schouten, L. J.; van den Brandt, P. A.; Chantarakul, N.; Koetsawang, S.; Rachawat, D.; Palli, D.; Black, A.; Brinton, L. A.; Freedman, D. M.; Hartge, P.; Hsing, A. W.; Jnr, J. V. Lacey; Lissowska, J.; Hoover, R. N.; Schairer, C.; Babb, C.; Urban, M.; Graff-Iversen, S.; Selmer, R.; Bain, C. J.; Green, A. C.; Purdie, D. M.; Siskind, V.; Webb, P. M.; Moysich, K.; McCann, S. E.; Hannaford, P.; Kay, C.; Binns, C. W.; Lee, A. H.; Zhang, M.; Ness, R. B.; Nasca, P.; Coogan, P. F.; Palmer, J. R.; Rosenberg, L.; Whittemore, A.; Katsouyanni, K.; Trichopoulou, A.; Trichopoulos, D.; Tzonou, A.; Dabancens, A.; Martinez, L.; Molina, R.; Salas, O.; Lurie, G.; Carney, M. E.; Wilkens, L. R.; Hartman, L.; Manjer, J.; Olsson, H.; Kumle, M.; Grisso, J. A.; Morgan, M.; Wheeler, J. E.; Edwards, R. P.; Kelley, J. L.; Modugno, F.; Onland-Moret, N. C.; Peeters, P. H. M.; Casagrande, J.; Pike, M. C.; Wu, A. H.; Canfell, K.; Miller, A. B.; Gram, I. T.; Lund, E.; McGowan, L.; Shu, X. O.; Zheng, W.; Farley, T. M. M.; Holck, S.; Meirik, O.; Risch, H. A.		Collaborative Grp Epidemiological	Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies	LANCET			English	Article							THERAPY	Background Half the epidemiological studies with information about menopausal hormone therapy and ovarian cancer risk remain unpublished, and some retrospective studies could have been biased by selective participation or recall. We aimed to assess with minimal bias the effects of hormone therapy on ovarian cancer risk. Methods Individual participant datasets from 52 epidemiological studies were analysed centrally. The principal analyses involved the prospective studies (with last hormone therapy use extrapolated forwards for up to 4 years). Sensitivity analyses included the retrospective studies. Adjusted Poisson regressions yielded relative risks (RRs) versus never-use. Findings During prospective follow-up, 12 110 postmenopausal women, 55% (6601) of whom had used hormone therapy, developed ovarian cancer. Among women last recorded as current users, risk was increased even with <5 years of use (RR 1.43, 95% CI 1.31-1.56; p<0.0001). Combining current-or-recent use (any duration, but stopped <5 years before diagnosis) resulted in an RR of 1.37 (95% CI 1.29-1.46; p<0.0001); this risk was similar in European and American prospective studies and for oestrogen-only and oestrogen-progestagen preparations, but differed across the four main tumour types (heterogeneity p<0.0001), being definitely increased only for the two most common types, serous (RR 1.53, 95% CI 1.40-1.66; p<0.0001) and endometrioid (1.42, 1.20-1.67; p<0.0001). Risk declined the longer ago use had ceased, although about 10 years after stopping long-duration hormone therapy use there was still an excess of serous or endometrioid tumours (RR 1.25, 95% CI 1.07-1.46, p=0.005). Interpretation The increased risk may well be largely or wholly causal; if it is, women who use hormone therapy for 5 years from around age 50 years have about one extra ovarian cancer per 1000 users and, if its prognosis is typical, about one extra ovarian cancer death per 1700 users.	[Gapstur, S. M.; Patel, A. V.] Amer Canc Soc, Atlanta, GA 30329 USA; [Banks, E.] Australian Natl Univ, Caberra, ACT, Australia; [Dal Maso, L.; Talamini, R.] Aviano Canc Ctr, I-33081 Aviano, Italy; [Chetrit, A.; Hirsh-Yechezkel, G.; Lubin, F.; Sadetzki, S.] Gertner Inst, Tel Hashomer, Israel; [Beral, V.; Bull, D.; Cairns, B.; Crossley, B.; Gaitskell, K.; Goodill, A.; Green, J.; Hermon, C.; Key, T.; Moser, K.; Reeves, G.] Canc Epidemiol Unit, Oxford, England; [Sitas, F.] NSW Canc Council, Woolloomooloo, NSW, Australia; [Collins, R.; Peto, R.] Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England; [Collins, R.; Peto, R.] Epidemiol Studies Unit CTSU, Oxford, England; [Gonzalez, C. A.] Catalan Inst Oncol, Barcelona, Spain; [Lee, N.; Marchbanks, P.; Ory, H. W.; Peterson, H. B.; Wingo, P. A.] Ctr Dis Control & Prevent, Atlanta, GA USA; [Martin, N.; Silpisornkosol, S.; Theetranont, C.] Chiang Mai Univ, Chiang Mai, Thailand; [Boosiri, B.; Chutivongse, S.; Jimakorn, P.; Virutamasen, P.; Wongsrichanalai, C.] Chulalongkorn Univ, Bangkok, Thailand; [Goodman, M. T.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; [Lidegaard, O.; Kjaer, S. K.; Morch, L. S.] Copenhagen Univ Hosp, Copenhagen, Denmark; [Kjaer, S. K.; Tjonneland, A.] Danish Canc Soc Res Ctr, Copenhagen, Denmark; [Byers, T.] Colorado Sch Publ Hlth, Denver, CO USA; [Rohan, T.] Albert Einstein Coll Med, Bronx, NY 10467 USA; [Mosgaard, B.] Herlev Univ Hosp, Copenhagen, Denmark; [Vessey, M.; Yeates, D.] Dept Publ Hlth, Oxford, England; [Freudenheim, J. L.] SUNY Buffalo, Dept Social & Prevent Med, Buffalo, NY 14260 USA; [Titus, L. J.] Geisel Sch Med Dartmouth, Hanover, NH USA; [Chang-Claude, J.; Kaaks, R.] German Canc Res Ctr, Heidelberg, Germany; [Anderson, K. E.; Lazovich, D.; Robien, K.] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA; [Hampton, J.; Newcomb, P. A.; Rossing, M. A.; Thomas, D. B.; Weiss, N. S.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA; [Lokkegaard, E.] Univ Copenhagen, Hillerod Hosp, DK-1168 Copenhagen, Denmark; [Riboli, E.] Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England; [Clavel-Chapelon, F.] INSERM, U1018, Villejuif, France; [Clavel-Chapelon, F.] Paris South Univ, Inst Gustave Roussy, Villejuif, France; [Cramer, D.; Hankinson, S. E.; Tamimi, R. M.; Tworoger, S. S.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA; [Franceschi, S.] Int Agcy Res Canc, F-69372 Lyon, France; [La Vecchia, C.; Negri, E.] Univ Milan, Ist Ric Farmacol Mario Negri, I-20122 Milan, Italy; [Adami, H. O.; Magnusson, C.; Riman, T.; Weiderpass, E.; Wolk, A.] Karolinska Inst, Stockholm, Sweden; [Schouten, L. J.; van den Brandt, P. A.] Maastricht Univ, NL-6200 MD Maastricht, Netherlands; [Chantarakul, N.; Koetsawang, S.; Rachawat, D.] Mahidol Univ, Bangkok 10700, Thailand; [Palli, D.] Canc Res & Prevent Inst, Florence, Italy; [Black, A.; Brinton, L. A.; Freedman, D. M.; Hartge, P.; Hsing, A. W.; Jnr, J. V. Lacey; Lissowska, J.; Hoover, R. N.; Schairer, C.] NCI, Bethesda, MD 20892 USA; [Babb, C.; Urban, M.] MRC, Canc Epidemiol Res Grp, Natl Hlth Lab Serv, Johannesburg, South Africa; [Graff-Iversen, S.; Selmer, R.] Norwegian Inst Publ Hlth, Oslo, Norway; [Bain, C. J.; Green, A. C.; Purdie, D. M.; Siskind, V.; Webb, P. M.] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia; [Bain, C. J.; Green, A. C.; Purdie, D. M.; Siskind, V.; Webb, P. M.] Univ Queensland, Brisbane, Qld, Australia; [Moysich, K.; McCann, S. E.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA; [Hannaford, P.; Kay, C.] Royal Coll Gen Practitioners Oral Contracept Stud, London, England; [Binns, C. W.; Lee, A. H.; Zhang, M.] Curtin Univ, Sch Publ Hlth, Perth, WA 6845, Australia; [Ness, R. B.] Univ Texas Houston, Sch Publ Hlth, Houston, TX USA; [Nasca, P.] Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Boston, MA 02125 USA; [Coogan, P. F.; Palmer, J. R.; Rosenberg, L.] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA; [Whittemore, A.] Stanford Univ, Stanford, CA 94305 USA; [Katsouyanni, K.; Trichopoulou, A.; Trichopoulos, D.; Tzonou, A.] Univ Athens, Sch Med, GR-11527 Athens, Greece; [Dabancens, A.; Martinez, L.; Molina, R.; Salas, O.] Univ Chile, Santiago, Chile; [Lurie, G.; Carney, M. E.; Wilkens, L. R.] Univ Hawaii, Honolulu, HI 96822 USA; [Hartman, L.; Manjer, J.; Olsson, H.] Univ Lund Hosp, S-22185 Lund, Sweden; [Kumle, M.] Univ Hosp North Norway, Tromso, Norway; [Grisso, J. A.; Morgan, M.; Wheeler, J. E.] Univ Penn, Philadelphia, PA 19104 USA; [Edwards, R. P.; Kelley, J. L.; Modugno, F.] Univ Pittsburgh, Pittsburgh, PA 15260 USA; [Onland-Moret, N. C.; Peeters, P. H. M.] Univ Med Ctr, Utrecht, Netherlands; [Casagrande, J.; Pike, M. C.; Wu, A. H.] Univ So Calif, Los Angeles, CA USA; [Canfell, K.] Univ New S Wales, Sydney, NSW 2052, Australia; [Miller, A. B.] Univ Toronto, Toronto, ON M5S 1A1, Canada; [Gram, I. T.; Lund, E.] Arctic Univ Tromso, Tromso, Norway; [McGowan, L.] George Washington Univ, Washington, DC USA; [Shu, X. O.; Zheng, W.] Vanderbilt Univ, Nashville, TN 37235 USA; [Farley, T. M. M.; Holck, S.; Meirik, O.] WHO, CH-1211 Geneva, Switzerland; [Risch, H. A.] Yale Univ, Sch Publ Hlth, New Haven, CT 06520 USA	American Cancer Society; Australian National University; University of Oxford; Cancer Council New South Wales; Radcliffe Infirmary; University of Oxford; University of Oxford; Catalan Institute of Oncology; Centers for Disease Control & Prevention - USA; Chiang Mai University; Chulalongkorn University; Cedars Sinai Medical Center; University of Copenhagen; Danish Cancer Society; Colorado School of Public Health; Yeshiva University; Albert Einstein College of Medicine; University of Copenhagen; Herlev & Gentofte Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Dartmouth College; Helmholtz Association; German Cancer Research Center (DKFZ); University of Minnesota System; University of Minnesota Twin Cities; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Copenhagen; Imperial College London; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Harvard University; World Health Organization; International Agency for Research on Cancer (IARC); Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Milan; Karolinska Institutet; Maastricht University; Mahidol University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Health Laboratory Service; Norwegian Institute of Public Health (NIPH); QIMR Berghofer Medical Research Institute; University of Queensland; Roswell Park Cancer Institute; Curtin University; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Massachusetts System; University of Massachusetts Boston; Boston University; Stanford University; Athens Medical School; National & Kapodistrian University of Athens; Universidad de Chile; University of Hawaii System; Lund University; Skane University Hospital; UiT The Arctic University of Tromso; University Hospital of North Norway; University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Utrecht University; Utrecht University Medical Center; University of Southern California; University of New South Wales Sydney; University of Toronto; UiT The Arctic University of Tromso; George Washington University; Vanderbilt University; World Health Organization; Yale University	Gapstur, SM (corresponding author), NDPH, Canc Epidemiol Unit, Richard Doll Bldg, Oxford OX3 7LF, England.	collaborations@ceu.ox.ac.uk	Green, Adele C/P-2736-2014; Weiderpass, Elisabete/M-4029-2016; Schouten, Leo J/AAB-2275-2019; Green, Adele C/B-5324-2011; Negri, Eva Vanna Lorenza/AAC-5698-2019; dal maso, luigino/J-3616-2018; de Villiers, Chantal Babb/AAL-3787-2021; franceschi, silvia/M-2452-2014; Webb, Penelope/D-5736-2013; Brinton, Louise A/G-7486-2015; Weiderpass, Elisabete/AAP-2747-2021; Katsouyanni, Klea/D-4856-2014; Lissowska, Jolanta/AAH-3252-2020; Onland-Moret, N. Charlotte/G-9185-2011	Green, Adele C/0000-0002-2753-4841; Weiderpass, Elisabete/0000-0003-2237-0128; Schouten, Leo J/0000-0003-3361-7560; Negri, Eva Vanna Lorenza/0000-0001-9712-8526; dal maso, luigino/0000-0001-6163-200X; de Villiers, Chantal Babb/0000-0003-1334-1819; franceschi, silvia/0000-0003-4181-8071; Webb, Penelope/0000-0003-0733-5930; Brinton, Louise A/0000-0003-3853-8562; Weiderpass, Elisabete/0000-0003-2237-0128; Katsouyanni, Klea/0000-0002-0132-9575; Lissowska, Jolanta/0000-0003-2695-5799; Onland-Moret, N. Charlotte/0000-0002-2360-913X; van den Brandt, Piet/0000-0001-8781-8099; Kjaer, Susanne/0000-0002-8347-1398; La Vecchia, Carlo/0000-0003-1441-897X; Magnusson, Cecilia/0000-0002-8567-6725; Goodman, Marc/0000-0002-4839-3021; Morch, Lina/0000-0001-6506-2569; Lokkegaard, Ellen/0000-0003-4149-5663; Olsson, Hakan/0000-0002-8794-9635; Riboli, Elio/0000-0001-6795-6080	Medical Research Council, Cancer Research UK; Cancer Research UK; UK Medical Research Council; MRC [MC_U137686850] Funding Source: UKRI; Cancer Research UK [16896, 16491] Funding Source: researchfish; Medical Research Council [MC_U137686850] Funding Source: researchfish; Novo Nordisk Fonden [NNF14OC0011645] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [UM1CA182910, P30CA071789] Funding Source: NIH RePORTER	Medical Research Council, Cancer Research UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)Cancer Research UK); Cancer Research UK(Cancer Research UK); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Novo Nordisk Fonden(Novo Nordisk Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Medical Research Council, Cancer Research UK.r The chief acknowledgment is to the participants and to the investigators in these studies. Data checking and analysis in the Oxford Cancer Epidemiology Unit was supported by Cancer Research UK and the UK Medical Research Council. Adrian Goodill drew the graphs.	Beral V, 2008, LANCET, V371, P303, DOI 10.1016/S0140-6736(08)60167-1; Beral V, 2012, LANCET ONCOL, V13, P1141, DOI 10.1016/S1470-2045(12)70425-4; Beral V, 2012, LANCET ONCOL, V13, P946, DOI [10.1016/S1470-2045(12)70365-0, 10.1016/S1470-2045(12)70322-4]; Beral V, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001200; Beral V, 2007, LANCET, V369, P1703, DOI 10.1016/S0140-6736(07)60534-0; de Villiers TJ, 2013, CLIMACTERIC, V16, P316, DOI 10.3109/13697137.2013.795683; European Medicines Agency, GUID CLIN INV MED PR; Fritz A., 2000, INT CLASSIFICATION D; International Agency for Research on Cancer, 2007, INT AG RES CANC MON, V91; Kurman RJ, 2011, HUM PATHOL, V42, P918, DOI 10.1016/j.humpath.2011.03.003; Medicines and Healthcare products Regulatory Agency (MHRA), HORM REPL THER SAF U; Morch LS, 2009, JAMA-J AM MED ASSOC, V302, P289; Plummer M, 2004, STAT MED, V23, P93, DOI 10.1002/sim.1485; Rodriguez C, 2001, JAMA-J AM MED ASSOC, V285, P1460, DOI 10.1001/jama.285.11.1460; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; US Food and Drug Administration, ESTR ESTR PROG THER	16	230	242	3	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 9	2015	385	9980					1835	1842		10.1016/S0140-6736(14)61687-1	http://dx.doi.org/10.1016/S0140-6736(14)61687-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CH6ZE	25684585	Green Published, hybrid			2023-01-03	WOS:000354184500027
J	Ogata, Y; Matono, K; Tsuda, H; Ushijima, M; Uchida, S; Akagi, Y; Shirouzu, K				Ogata, Yutaka; Matono, Keiko; Tsuda, Hideaki; Ushijima, Masataka; Uchida, Shinji; Akagi, Yoshito; Shirouzu, Kazuo			Randomized Phase II Study of 5-Fluorouracil Hepatic Arterial Infusion with or without Antineoplastons as an Adjuvant Therapy after Hepatectomy for Liver Metastases from Colorectal Cancer	PLOS ONE			English	Article							HISTONE DEACETYLASE INHIBITORS; CELLS-IN-VITRO; HEPATOCELLULAR-CARCINOMA; COLON-CANCER; RESECTION; DIFFERENTIATION; PHENYLBUTYRATE; PHENYLACETATE; SURVIVAL; GROWTH	Background Antineoplastons are naturally occurring peptides and amino acid derivatives found in human blood and urine. Antineoplaston A10 and AS2-1 reportedly control neoplastic growth and do not significantly inhibit normal cell growth. Antineoplastons contain 3-phenylacetyla-mino-2, 6-piperidinedione (A10), phenylacetylglutamine plus phenylacetylisoglutamine (A10-I), and phenylacetylglutamine plus phenylacetate (AS2-1). This open label, non-blinded randomized phase II study compared the efficacy of hepatic arterial infusion (HAI) with 5-fluorouracil, with or without antineoplastons as a postoperative therapy for colorectal metastasis to the liver. Methods Sixty-five patients with histologically confirmed metastatic colon adenocarcinoma in liver, who had undergone hepatectomy, and/or thermal ablation for liver metastases were enrolled between 1998-2004 in Kurume University Hospital. Patients were randomly assigned to receive systemic antineoplastons (A10-I infusion followed by per-oral AS2-1) plus HAI (AN arm) or HAI alone (control arm) based on the number of metastases and presence/absence of extra-hepatic metastasis at the time of surgery. Primary endpoint was cancer-specific survival (CSS); secondary endpoints were relapse-free survival (RFS), status and extent of recurrence, salvage surgery (rate) and toxicity. Findings Overall survival was not statistically improved (p=0.105) in the AN arm (n=32). RFS was not significant (p=0.343). Nevertheless, the CSS rate was significantly higher in the AN arm versus the control arm (n=33) with a median survival time 67 months (95% CI 43-not calculated) versus 39 months (95% CI 28-47) (p=0.037) and 5 year CSS rate 60% versus 32% respectively. Cancer recurred more often in a single organ than in multiple organs in the AN arm versus the control arm. The limited extent of recurrent tumours in the AN arm meant more patients remained eligible for salvage surgery. Major adverse effects of antineoplastons were fullness of the stomach and phlebitis. No serious toxicity, including bone marrow suppression, liver or renal dysfunction, were found in the AN arm. Interpretation Antineoplastons (A10 Injection and AS2-1) might be useful as adjunctive therapy in addition to HAI after hepatectomy in colorectal metastases to the liver.	[Ogata, Yutaka; Uchida, Shinji] Kurume Univ, Med Ctr, Dept Surg, Kurume, Fukuoka 830, Japan; [Matono, Keiko; Ushijima, Masataka; Akagi, Yoshito; Shirouzu, Kazuo] Kurume Univ, Sch Med, Dept Surg, Kurume, Fukuoka 830, Japan; [Tsuda, Hideaki] Kurume Daiichi Social Insurance Hosp, Kurume, Fukuoka, Japan	Kurume University; Kurume University	Ogata, Y (corresponding author), Kurume Univ, Med Ctr, Dept Surg, Kurume, Fukuoka 830, Japan.	yogata@med.kurume-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [13671364, 14770672]	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by a Grant-in-Aid for Scientific Research (C) (No. 13671364) and a Grant-in-Aid for Young Scientist (B) (No. 14770672) from the Ministry of Education, Culture, Sports, Science and Technology of Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Buckner JC, MAYO CLIN P; BURZYNSKI SR, 1976, PHYSIOL CHEM PHYS M, V8, P275; ENSMINGER WD, 1978, CANCER RES, V38, P3784; Fong Y, 1999, ANN SURG, V230, P309, DOI 10.1097/00000658-199909000-00004; Harrison LE, 1998, SURGERY, V124, P541, DOI 10.1067/msy.1998.90180; Iannitti T, 2011, DRUGS R&D, V11, P227, DOI 10.2165/11591280-000000000-00000; Kanas Gena P, 2012, Clin Epidemiol, V4, P283, DOI 10.2147/CLEP.S34285; Kanat O, 2012, J GASTROINTEST ONCOL, V3, P130, DOI 10.3978/j.issn.2078-6891.2011.025; Kemeny N, 1999, NEW ENGL J MED, V341, P2039, DOI 10.1056/NEJM199912303412702; Kemeny NE, 2005, NEW ENGL J MED, V352, P734, DOI 10.1056/NEJM200502173520723; LIAU M C, 1989, International Journal of Experimental and Clinical Chemotherapy, V2, P187; LIU L, 1994, J INVEST DERMATOL, V103, P335, DOI 10.1111/1523-1747.ep12394874; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Matono K, 2005, ONCOL REP, V13, P389; Melchior SW, 1999, INT J ONCOL, V14, P501; Mitry E, 2008, J CLIN ONCOL, V26, P4906, DOI 10.1200/JCO.2008.17.3781; Mocellin S, 2007, J CLIN ONCOL, V25, P5649, DOI 10.1200/JCO.2007.12.1764; Nelson R, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003770.pub3; Nishida H, 1991, J JPN SOC CANC THER, V26, P595; Nordlinger B, 2008, LANCET, V371, P1007, DOI 10.1016/S0140-6736(08)60455-9; Ogata Y, 2010, ANN ONCOL, V21, P221; Portier G, 2006, J CLIN ONCOL, V24, P4976, DOI 10.1200/JCO.2006.06.8353; Qiu TZ, 2013, FUTURE ONCOL, V9, P255, DOI [10.2217/FON.12.173, 10.2217/fon.12.173]; Rees M, 2008, ANN SURG, V247, P125, DOI 10.1097/SLA.0b013e31815aa2c2; SAMID D, 1993, J CLIN INVEST, V91, P2288, DOI 10.1172/JCI116457; Sung MW, 2007, ANTICANCER RES, V27, P995; Tomlinson JS, 2007, J CLIN ONCOL, V25, P4575, DOI 10.1200/JCO.2007.11.0833; TSUDA H, 1992, JPN J CANCER RES, V83, P527, DOI 10.1111/j.1349-7006.1992.tb01960.x; Tsuda Hideaki, 1995, Kurume Medical Journal, V42, P241; Tsuda Hideaki, 1996, Kurume Medical Journal, V43, P137; Ushijima M, 2014, ONCOL REP, V31, P19, DOI 10.3892/or.2013.2839; Wagner JM, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0012-4; Weber SM, 2000, ANN SURG ONCOL, V7, P643, DOI 10.1007/s10434-000-0643-3; Yeo W, 2012, J CLIN ONCOL, V30, P3361, DOI 10.1200/JCO.2011.41.2395	34	2	3	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2015	10	3							e0120064	10.1371/journal.pone.0120064	http://dx.doi.org/10.1371/journal.pone.0120064			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CD9NQ	25790229	Green Published, Green Submitted, gold			2023-01-03	WOS:000351425400126
J	Perry, RJ; Zhang, DY; Zhang, XM; Boyer, JL; Shulman, GI				Perry, Rachel J.; Zhang, Dongyan; Zhang, Xian-Man; Boyer, James L.; Shulman, Gerald I.			Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats	SCIENCE			English	Article							INSULIN-RESISTANCE	Nonalcoholic fatty liver disease (NAFLD) is a major factor in the pathogenesis of type 2 diabetes (T2D) and nonalcoholic steatohepatitis (NASH). The mitochondrial protonophore 2,4 dinitrophenol (DNP) has beneficial effects on NAFLD, insulin resistance, and obesity in preclinical models but is too toxic for clinical use. We developed a controlled-release oral formulation of DNP, called CRMP (controlled-release mitochondrial protonophore), that produces mild hepatic mitochondrial uncoupling. In rat models, CRMP reduced hypertriglyceridemia, insulin resistance, hepatic steatosis, and diabetes. It also normalized plasma transaminase concentrations, ameliorated liver fibrosis, and improved hepatic protein synthetic function in a methionine/choline-deficient rat model of NASH. Chronic treatment with CRMP was not associated with any systemic toxicity. These data offer proof of concept that mild hepatic mitochondrial uncoupling may be a safe and effective therapy for the related epidemics of metabolic syndrome, T2D, and NASH.	[Perry, Rachel J.; Zhang, Dongyan; Shulman, Gerald I.] Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; [Perry, Rachel J.; Zhang, Xian-Man; Boyer, James L.; Shulman, Gerald I.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; [Perry, Rachel J.; Shulman, Gerald I.] Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA; [Boyer, James L.] Yale Univ, Sch Med, Yale Liver Ctr, New Haven, CT USA	Howard Hughes Medical Institute; Yale University; Yale University; Yale University; Yale University	Shulman, GI (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA.	gerald.shulman@yale.edu	Shulman, Gerald I./P-7176-2019	Shulman, Gerald I./0000-0003-1529-5668; Perry, Rachel/0000-0003-0748-8064	United States National Institutes of Health [R01 DK-40936, R24 DK-085638, U24 DK-059635, T32 DK-101019, P30 DK-45735, P30 DK-34989, UL1 TR-000142]; Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000142] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U24DK059635, P30DK045735, R24DK085638, T32DK101019, R01DK040936, P30DK034989] Funding Source: NIH RePORTER	United States National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank J. Dong, C. Soroka, J. P. Camporez, M. Jurczak, J. Stack, M. Kahn, C. Borders, Y. Kosover, A. Nasiri, G. Butrico, M. Batsu, and W. Zhu for their invaluable technical assistance; C. Frassetto and A. Barkley for their work to formulate the CRMP; B. Ehrlich for assistance with the thermal algesia studies; M. Kashgarian for expert analysis of renal histology; and A. Ray and C. Tay for toxicology advice. Yale University has applied for a patent (provisional patent application 61/919, 003) related to the use of CRMP and similar protonophores for the treatment of metabolic diseases, including NAFLD/NASH and T2D. This research was funded by grants from the United States National Institutes of Health (R01 DK-40936, R24 DK-085638, U24 DK-059635, T32 DK-101019, P30 DK-45735, P30 DK-34989, and UL1 TR-000142) and the Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.	Ip E, 2004, HEPATOLOGY, V39, P1286, DOI 10.1002/hep.20170; Leclercq IA, 2000, J CLIN INVEST, V105, P1067, DOI 10.1172/JCI8814; Perry RJ, 2014, NAT MED, V20, P759, DOI 10.1038/nm.3579; Perry RJ, 2013, CELL METAB, V18, P740, DOI 10.1016/j.cmet.2013.10.004; Petersen KF, 1999, AM J PHYSIOL-ENDOC M, V276, pE529, DOI 10.1152/ajpendo.1999.276.3.E529; Ratziu V, 2010, J HEPATOL, V53, P372, DOI 10.1016/j.jhep.2010.04.008; Samuel VT, 2004, J BIOL CHEM, V279, P32345, DOI 10.1074/jbc.M313478200	7	190	196	2	117	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 13	2015	347	6227					1253	1256		10.1126/science.aaa0672	http://dx.doi.org/10.1126/science.aaa0672			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CD1GZ	25721504	Green Accepted			2023-01-03	WOS:000350824300039
J	Robak, T; Huang, HQ; Jin, J; Zhu, J; Liu, T; Samoilova, O; Pylypenko, H; Verhoef, G; Siritanaratkul, N; Osmanov, E; Alexeeva, J; Pereira, J; Drach, J; Mayer, J; Hong, XN; Okamoto, R; Pei, LX; Rooney, B; van de Velde, H; Cavalli, F				Robak, Tadeusz; Huang, Huiqiang; Jin, Jie; Zhu, Jun; Liu, Ting; Samoilova, Olga; Pylypenko, Halyna; Verhoef, Gregor; Siritanaratkul, Noppadol; Osmanov, Evgenii; Alexeeva, Julia; Pereira, Juliana; Drach, Johannes; Mayer, Jiri; Hong, Xiaonan; Okamoto, Rumiko; Pei, Lixia; Rooney, Brendan; van de Velde, Helgi; Cavalli, Franco		LYM-3002 Investigators	Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RELAPSED MULTIPLE-MYELOMA; EUROPEAN-MCL-NETWORK; PERIPHERAL NEUROPATHY; RANDOMIZED-TRIALS; PHASE-2 PINNACLE; PROGNOSTIC INDEX; FREE SURVIVAL; RITUXIMAB; VINCRISTINE; CYCLOPHOSPHAMIDE	BACKGROUND The proteasome inhibitor bortezomib was initially approved for the treatment of relapsed mantle-cell lymphoma. We investigated whether substituting bortezomib for vincristine in frontline therapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) could improve outcomes in patients with newly diagnosed mantle-cell lymphoma. METHODS In this phase 3 trial, we randomly assigned 487 adults with newly diagnosed mantle-cell lymphoma who were ineligible or not considered for stem-cell transplantation to receive six to eight 21-day cycles of R-CHOP intravenously on day 1 (with prednisone administered orally on days 1 to 5) or VR-CAP (R-CHOP regimen, but replacing vincristine with bortezomib at a dose of 1.3 mg per square meter of body-surface area on days 1, 4, 8, and 11). The primary end point was progression-free survival. RESULTS After a median follow-up of 40 months, median progression-free survival (according to independent radiologic review) was 14.4 months in the R-CHOP group versus 24.7 months in the VR-CAP group (hazard ratio favoring the VR-CAP group, 0.63; P<0.001), a relative improvement of 59%. On the basis of investigator assessment, the median durations of progression-free survival were 16.1 months and 30.7 months, respectively (hazard ratio, 0.51; P<0.001), a relative improvement of 96%. Secondary end points were consistently improved in the VR-CAP group, including the complete response rate (42% vs. 53%), the median duration of complete response (18.0 months vs. 42.1 months), the median treatment-free interval (20.5 months vs. 40.6 months), and the 4-year overall survival rate (54% vs. 64%). Rates of neutropenia and thrombocytopenia were higher in the VR-CAP group. CONCLUSIONS VR-CAP was more effective than R-CHOP in patients with newly diagnosed mantle-cell lymphoma but at the cost of increased hematologic toxicity. (Funded by Janssen Research and Development and Millennium Pharmaceuticals; LYM-3002 ClinicalTrials.gov number, NCT00722137.)	[Robak, Tadeusz] Med Univ Lodz, Dept Hematol, Copernicus Mem Hosp, Lodz, Poland; [Huang, Huiqiang] Sun Yat Sen Univ, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China; [Jin, Jie] Zhejiang Univ, Coll Med, Dept Hematol, Affiliated Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China; [Zhu, Jun] Beijing Canc Hosp, Dept Lymphat Oncol, Beijing, Peoples R China; [Liu, Ting] Sichuan Univ, Dept Hematol, West China Hosp, Chengdu 610064, Peoples R China; [Hong, Xiaonan] Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai 200433, Peoples R China; [Samoilova, Olga] Nizhny Novgorod Region Clin Hosp, Nizhnii Novgorod, Russia; [Osmanov, Evgenii] Russian Acad Med Sci, Canc Res Ctr, NN Blokhin Acad Med Sci, Moscow, Russia; [Alexeeva, Julia] Fed Ctr Heart Blood & Endocrinol, St Petersburg, Russia; [Pylypenko, Halyna] Cherkassy Reg Oncol Ctr, Dept Hematol, Cherkassy, Ukraine; [Verhoef, Gregor] Univ Hosp Leuven, Dept Hematol, Leuven, Belgium; [van de Velde, Helgi] Janssen Res & Dev, Beerse, Belgium; [Siritanaratkul, Noppadol] Mahidol Univ, Fac Sci, Siriraj Hosp, Dept Med, Bangkok 10400, Thailand; [Pereira, Juliana] Univ Sao Paulo, Fac Med, Hosp Clin, BR-09500900 Sao Paulo, Brazil; [Drach, Johannes] Med Univ Vienna, Vienna Gen Hosp, Div Oncol, Dept Internal Med 1, Vienna, Austria; [Mayer, Jiri] Fac Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic; [Okamoto, Rumiko] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Chemotherapy, Tokyo, Japan; [Pei, Lixia] Janssen Res & Dev, Raritan, NJ USA; [Rooney, Brendan] Janssen Cilag, Janssen Res & Dev, High Wycombe, Bucks, England; [Cavalli, Franco] Osped San Giovanni Bellinzona, Oncol Inst Southern Switzerland, CH-6500 Bellinzona, Switzerland	Medical University Lodz; Sun Yat Sen University; Zhejiang University; Peking University; Sichuan University; Fudan University; Russian Academy of Medical Sciences; KU Leuven; University Hospital Leuven; Johnson & Johnson; Janssen Pharmaceuticals; Mahidol University; Universidade de Sao Paulo; Medical University of Vienna; University Hospital Brno; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Johnson & Johnson; Janssen Pharmaceuticals; Johnson & Johnson; Institute of Oncology Research (IOR); Regional Hospital of Bellinzona & Valleys, San Giovanni	Cavalli, F (corresponding author), Osped San Giovanni Bellinzona, Oncol Inst Southern Switzerland, CH-6500 Bellinzona, Switzerland.	franco.cavalli@eoc.ch	Robak, Tadeusz/AAW-7365-2021; Greil, Richard F/C-7673-2017; Remy, GRESSIN/G-7303-2014; PEREIRA, JULIANA/C-2742-2014; Zachee, Pierre/B-5391-2018; Belada, David/P-9728-2017; le gouill, steven/L-1650-2015	Robak, Tadeusz/0000-0002-3411-6357; Greil, Richard F/0000-0002-4462-3694; Remy, GRESSIN/0000-0002-9188-3501; PEREIRA, JULIANA/0000-0002-0655-2821; Zachee, Pierre/0000-0002-2275-5143; Belada, David/0000-0002-4981-6188; le gouill, steven/0000-0001-9840-2128; GONZALEZ BARCA, EVA/0000-0002-1323-1508; Osmanov, Evgenii/0000-0002-3067-1601; Ojeda-Uribe, Mario/0000-0001-6881-6055; Alekseeva, Julia/0000-0003-4453-5616	Research and Development and Millennium Pharmaceuticals	Research and Development and Millennium Pharmaceuticals	Funded by Janssen Research and Development and Millennium Pharmaceuticals; LYM-3002 ClinicalTrials.gov number, NCT00722137.	[Anonymous], 2014, VELC BORT INJ SUB IN; Barbee MS, 2013, ANN PHARMACOTHER, V47, P1136, DOI 10.1177/1060028013503122; Broyl A, 2010, LANCET ONCOL, V11, P1057, DOI 10.1016/S1470-2045(10)70206-0; Cavaletti G, 2010, LEUKEMIA LYMPHOMA, V51, P1178, DOI 10.3109/10428194.2010.483303; Cheson BD, 2007, J CLIN ONCOL, V25, P579, DOI 10.1200/JCO.2006.09.2403; Determann O, 2008, BLOOD, V111, P2385, DOI 10.1182/blood-2007-10-117010; Dreyling M, 2014, ANN ONCOL, V25, P83, DOI 10.1093/annonc/mdu264; Fisher RI, 2006, J CLIN ONCOL, V24, P4867, DOI 10.1200/JCO.2006.07.9665; Flinn IW, 2014, BLOOD, V123, P2944, DOI 10.1182/blood-2013-11-531327; Furman RR, 2010, CANCER-AM CANCER SOC, V116, P5432, DOI 10.1002/cncr.25509; Garcia M, 2009, CANCER-AM CANCER SOC, V115, P1041, DOI 10.1002/cncr.24141; Goy A, 2009, ANN ONCOL, V20, P520, DOI 10.1093/annonc/mdn656; Goy A, 2010, LEUKEMIA LYMPHOMA, V51, P1269, DOI 10.3109/10428194.2010.483302; Herrmann A, 2009, J CLIN ONCOL, V27, P511, DOI 10.1200/JCO.2008.16.8435; Hoster E, 2008, BLOOD, V111, P558, DOI 10.1182/blood-2007-06-095331; Hoster E, 2014, J CLIN ONCOL, V32, P1338, DOI 10.1200/JCO.2013.52.2466; Howard OM, 2002, J CLIN ONCOL, V20, P1288, DOI 10.1200/JCO.20.5.1288; Kane RC, 2007, CLIN CANCER RES, V13, P5291, DOI 10.1158/1078-0432.CCR-07-0871; Kluin-Nelemans HC, 2012, NEW ENGL J MED, V367, P520, DOI 10.1056/NEJMoa1200920; Lenz G, 2005, J CLIN ONCOL, V23, P1984, DOI 10.1200/JCO.2005.08.133; Lonial S, 2005, BLOOD, V106, P3777, DOI 10.1182/blood-2005-03-1173; Lonial S, 2008, BRIT J HAEMATOL, V143, P222, DOI 10.1111/j.1365-2141.2008.07321.x; McKay P, 2012, BRIT J HAEMATOL, V159, P405, DOI 10.1111/bjh.12046; Moreau P, 2011, LANCET ONCOL, V12, P431, DOI 10.1016/S1470-2045(11)70081-X; Mounier N, 2008, ANN ONCOL S4, V19; Murai K, 2014, EUR J HAEMATOL, V93, P290, DOI 10.1111/ejh.12342; National Cancer Institute National Institutes of Health, COMM TERM CRIT ADV E; NCCN, 2020, ANT; O'Connor OA, 2009, BRIT J HAEMATOL, V145, P34, DOI 10.1111/j.1365-2141.2008.07466.x; Ribrag V, 2009, CANCER-AM CANCER SOC, V115, P4540, DOI 10.1002/cncr.24518; Ruan J, 2011, J CLIN ONCOL, V29, P690, DOI 10.1200/JCO.2010.31.1142; Rummel MJ, 2013, LANCET, V381, P1184; Shi DS, 2014, J CLIN INVEST, V124, P3757, DOI 10.1172/JCI75247; Tiemann M, 2005, BRIT J HAEMATOL, V131, P29, DOI 10.1111/j.1365-2141.2005.05716.x; Vose Julie M, 2013, Am J Hematol, V88, P1082, DOI 10.1002/ajh.23615; Williams ME, 2013, HEMATOL-AM SOC HEMAT, P568, DOI 10.1182/asheducation-2013.1.568	36	268	281	0	67	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 5	2015	372	10					944	953		10.1056/NEJMoa1412096	http://dx.doi.org/10.1056/NEJMoa1412096			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CC4EU	25738670	Green Published, Green Submitted			2023-01-03	WOS:000350304500010
J	Lee, JS; Shukla, S; Kim, JA; Kim, M				Lee, Jong Suk; Shukla, Shruti; Kim, Jung-Ae; Kim, Myunghee			Anti-Angiogenic Effect of Nelumbo nucifera Leaf Extracts in Human Umbilical Vein Endothelial Cells with Antioxidant Potential	PLOS ONE			English	Article							OXIDATIVE STRESS; NITRIC-OXIDE; CONSTITUENTS; INHIBITION; LEAVES; DAMAGE	Nelumbo nucifera Gaertn (Nymphaeaceae) has long been used as a traditional herb in Chinese, Japanese, Indian, and Korean medicinal practices since prehistoric times and flourishes today as the primary form of medicine. This study reports for the first time the potent ability of N. nucifera leaf extracts to inhibit vascular endothelial growth factor (VEGF)-induced angiogenesis in vitro and in vivo, as well as their antioxidant efficacy in various scavenging models and an analysis of their chemical composition. In vivo anti-angiogenic activity was evaluated in a chick chorioallantoic membrane (CAM) model using fertilized chicken eggs, in human umbilical vein endothelial cells (HUVECs) by using cell viability, cell proliferation and tube formation assays, and by determining intracellular reactive oxygen species (ROS) in vitro. The antioxidant efficacy of N. nucifera leaf extracts was determined in various scavenging models, including total phenolic and flavonoid content. The chemical composition of N. nucifera leaf extracts was determined by GC-MS analysis, which revealed the presence of different phytochemicals. The IC50 values for the DPPH radical scavenging activities of water and methanol extracts were found to be 1699.47 and 514.36 mu g ml(-1), and their total phenolic and flavonoid contents were 85.01 +/- 2.32 and 147.63 +/- 2.23 mg GAE g dry mass(-1) and 35.38 +/- 1.32 and 41.86 +/- 1.07 mg QA g dry mass(-1), respectively. N. nucifera leaf extracts (10-100 mu g ml(-1)) exhibited significant dose-dependent inhibition of VEGF-induced angiogenesis, as well as VEGF-induced proliferation and tube formation in HUVECs. In this study, N. nucifera leaf extracts displayed potent antioxidant and inhibitory effects on VEGF-induced angiogenesis. N. nucifera exerted an inhibitory effect on VEGF-induced proliferation and tube formation, as well as CAM angiogenesis in vivo. Moreover, N. nucifera leaf extracts significantly blocked VEGF-induced ROS production in HUVECs, confirming their possible anti-angiogenic mechanism.	[Lee, Jong Suk; Shukla, Shruti; Kim, Myunghee] Yeungnam Univ, Dept Food Sci & Technol, Kyongsan 712749, Gyeongbuk, South Korea; [Kim, Jung-Ae] Yeungnam Univ, Coll Pharm, Kyongsan 712749, Gyeongbuk, South Korea	Yeungnam University; Yeungnam University	Kim, M (corresponding author), Yeungnam Univ, Dept Food Sci & Technol, Kyongsan 712749, Gyeongbuk, South Korea.	foodtech@ynu.ac.kr	Kim, Myunghee/AAP-8425-2020; Kim, Myunghee/AAO-6713-2021; shukla, shruti/M-7538-2016	Kim, Myunghee/0000-0002-1340-435X; Kim, Myunghee/0000-0002-1340-435X; 	Basic Science Research Program of the National Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future Planning [2012R1A1A3011096]; Yeungnam University Research Grant	Basic Science Research Program of the National Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future Planning; Yeungnam University Research Grant	This research was supported by the Basic Science Research Program of the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (2012R1A1A3011096) and supported by the Yeungnam University Research Grant in 2012. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abul Hasnat M, 2014, J FOOD BIOCHEM, V38, P6, DOI 10.1111/jfbc.12019; Ahn JH, 2013, BIOORG MED CHEM LETT, V23, P3604, DOI 10.1016/j.bmcl.2013.04.013; Banerjee D, 2014, LETT APPL MICROBIOL, V58, P25, DOI 10.1111/lam.12151; Barbosa-Pereira L, 2013, FOOD RES INT, V51, P663, DOI 10.1016/j.foodres.2013.01.042; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BLOIS MS, 1958, NATURE, V181, P1199, DOI 10.1038/1811199a0; Bursal E, 2011, FOOD RES INT, V44, P2217, DOI 10.1016/j.foodres.2010.11.001; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chung YC, 2005, FOOD CHEM, V91, P419, DOI 10.1016/j.foodchem.2004.06.022; Colavitti R, 2002, J BIOL CHEM, V277, P3101, DOI 10.1074/jbc.M107711200; Davis JM, 2009, AM J PHYSIOL-REG I, V296, pR1071, DOI 10.1152/ajpregu.90925.2008; Fukuda S, 2006, CELL BIOCHEM BIOPHYS, V44, P43, DOI 10.1385/CBB:44:1:043; Hurst RD, 2010, MOL NUTR FOOD RES, V54, P353, DOI 10.1002/mnfr.200900094; Jaafar H. Z. E., 2013, Australian Journal of Crop Science, V7, P276; Karki R, 2012, EVID-BASED COMPL ALT, V2012, P1; Kitawat BS, 2013, NEW J CHEM, V37, P2541, DOI 10.1039/c3nj00308f; Lee JS, 2012, EUR J PHARMACOL, V677, P22, DOI 10.1016/j.ejphar.2011.12.012; Lee JS, 2008, J MED FOOD, V11, P643, DOI 10.1089/jmf.2007.0629; Lin MC, 2009, J AGR FOOD CHEM, V57, P5925, DOI 10.1021/jf901058a; Ling ZQ, 2005, J AGR FOOD CHEM, V53, P2441, DOI 10.1021/jf040325p; Liu CP, 2004, LIFE SCI, V75, P699, DOI 10.1016/j.lfs.2004.01.019; Manian R, 2008, FOOD CHEM, V107, P1000, DOI 10.1016/j.foodchem.2007.09.008; MARCOCCI L, 1994, BIOCHEM BIOPH RES CO, V201, P748, DOI 10.1006/bbrc.1994.1764; Melnikov MM, 1971, CHEM PESTICIDE, P100; Min JK, 2004, CANCER RES, V64, P644, DOI 10.1158/0008-5472.CAN-03-3250; Mousa AS, 2005, NUTR CANCER, V53, P104, DOI 10.1207/s15327914nc5301_12; Mukherjee PK, 2009, J PHARM PHARMACOL, V61, P407, DOI 10.1211/jpp/61.04.0001; Muslim NS, 2010, INT J PHARMACOL, V6, P591, DOI 10.3923/ijp.2010.591.599; Narasimhan S, 2006, J ETHNOPHARMACOL, V104, P423, DOI 10.1016/j.jep.2005.09.029; Ohkoshi E, 2007, PLANTA MED, V73, P1255, DOI 10.1055/s-2007-990223; Park BC, 2009, J PHARMACOL SCI, V111, P1, DOI 10.1254/jphs.08305FP; Rashid R. B., 2003, Saudi Pharmaceutical Journal, V11, P52; Razali N, 2008, FOOD CHEM, V111, P38, DOI 10.1016/j.foodchem.2008.03.024; Sakanaka S, 2005, FOOD CHEM, V89, P569, DOI 10.1016/j.foodchem.2004.03.013; Selvamangai G., 2012, Asian Pacific Journal of Tropical Biomedicine, V2, pS1329; Singleton VL, 1999, METHOD ENZYMOL, V299, P152; Slaughter JC, 1999, BIOL REV, V74, P259, DOI 10.1017/S0006323199005332; Weber V, 2002, BIOORGAN MED CHEM, V10, P1647, DOI 10.1016/S0968-0896(02)00053-6; Xu X, 2011, MOLECULES, V16, P2551, DOI 10.3390/molecules16032551; Yang ZD, 2012, NAT PROD RES, V26, P387, DOI 10.1080/14786419.2010.487188; Zurbonsen K, 1991, GEN PHARMACOL, V32, P135	41	37	38	0	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2015	10	2							e0118552	10.1371/journal.pone.0118552	http://dx.doi.org/10.1371/journal.pone.0118552			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC2IM	25714482	gold, Green Published, Green Submitted			2023-01-03	WOS:000350168700083
J	Knudsen, S; Hother, C; Gronbaek, K; Jensen, T; Hansen, A; Mazin, W; Dahlgaard, J; Moller, MB; Ralfkiaer, E; Brown, PD				Knudsen, Steen; Hother, Christoffer; Gronbaek, Kirsten; Jensen, Thomas; Hansen, Anker; Mazin, Wiktor; Dahlgaard, Jesper; Moller, Michael Boe; Ralfkiaer, Elizabeth; Brown, Peter de Nully			Development and Blind Clinical Validation of a MicroRNA Based Predictor of Response to Treatment with R-CHO(E)P in DLBCL	PLOS ONE			English	Article							CELL; EXPRESSION; CANCER; SURVIVAL; MODEL	MicroRNAs (miRNA) are a group of short noncoding RNAs that regulate gene expression at the posttranscriptional level. It has been shown that microRNAs are independent predictors of outcome in patients with diffuse large B-cell lymphoma (DLBCL) treated with the drug combination R-CHOP. Based on the measured growth inhibition of 60 human cancer cell lines (NCI60) in the presence of doxorubicine, cyclophosphamide, vincristine and etoposide as well as the baseline microRNA expression of the 60 cell lines, a microRNA based response predictor to CHOP was developed. The response predictor consisting of 20 microRNAs was blindly validated in a cohort of 116 de novo DLBCL patients treated with R-CHOP or R-CHOEP as first line treatment. The predicted sensitivity based on diagnostic FFPE samples matched the clinical response, with decreasing sensitivity in poor responders (P = 0.03). When the International Prognostic Index (IPI) was included in the prediction analysis, the separation between responders and non-responders improved (P = 0.001). Thirteen patients developed relapse, and five patients predicted sensitive to their second and third line treatment survived a median 1194 days, while eight patients predicted not sensitive to their second and third line treatment survived a median 187 days (90% CI: 485 days versus 227 days). Among the latter group it was predicted that four would have been sensitive to another second line treatment than the one they received. The predictions were almost the same when diagnostic biopsies were used as when relapse biopsies were used. These preliminary findings warrant testing in a larger cohort of relapse patients to confirm whether the miRNA based predictor can select the optimal second line treatment and increase survival.	[Knudsen, Steen; Jensen, Thomas; Hansen, Anker; Mazin, Wiktor; Dahlgaard, Jesper] Med Prognosis Inst, Horsholm, Denmark; [Hother, Christoffer; Gronbaek, Kirsten; Brown, Peter de Nully] Rigshosp, Dept Hematol, DK-2100 Copenhagen, Denmark; [Ralfkiaer, Elizabeth] Rigshosp, Dept Pathol, DK-2100 Copenhagen, Denmark; [Moller, Michael Boe] Odense Univ Hosp, Dept Pathol, DK-5000 Odense, Denmark	Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; University of Southern Denmark; Odense University Hospital	Knudsen, S (corresponding author), Med Prognosis Inst, Horsholm, Denmark.	steen@medical-prognosis.com	Møller, Michael Boe/AAD-2113-2019; Møller, Michael B/G-8340-2016	Møller, Michael Boe/0000-0003-2041-3630; Møller, Michael B/0000-0003-2041-3630; Dahlgaard, Jesper/0000-0002-1798-6799; Gronbaek, Kirsten/0000-0002-1535-9601	Danish Council for Strategic Research; MPI; Novo Nordisk Fonden [NNF13OC0003435] Funding Source: researchfish	Danish Council for Strategic Research(Danske Strategiske Forskningsrad (DSF)); MPI; Novo Nordisk Fonden(Novo Nordisk Foundation)	MPI acknowledges support from the Danish Council for Strategic Research (http://ufm.dk/forskning-og-innovation/rad-og-udvalg/detstrategiske-forskningsrad). ER acknowledges support from MPI. MPI had a role in study design, data collection and analysis, decision to publish, and preparation of the manuscript.	Alencar AJ, 2011, CLIN CANCER RES, V17, P4125, DOI 10.1158/1078-0432.CCR-11-0224; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Chen JJ, 2012, MOL CANCER THER, V11, P34, DOI 10.1158/1535-7163.MCT-11-0620; Cheson BD, 1999, J CLIN ONCOL, V17, P1244, DOI 10.1200/JCO.1999.17.4.1244; Glinsmann-Gibson BJ, 2010, BLOOD, V116, P1282; Han S, 2003, BREAST CANCER RES TR, V82, P11, DOI 10.1023/B:BREA.0000003843.53726.63; Ivanovska I, 2008, MOL CELL BIOL, V28, P2167, DOI 10.1128/MCB.01977-07; Knudsen S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087415; Lenz G, 2008, NEW ENGL J MED, V359, P2313, DOI 10.1056/NEJMoa0802885; Li C, 2009, BLOOD, V113, P6681, DOI 10.1182/blood-2009-01-202028; Li Y, 2009, CANCER SCI, V100, P1234, DOI 10.1111/j.1349-7006.2009.01164.x; Montes-Moreno S, 2011, BLOOD, V118, P1034, DOI 10.1182/blood-2010-11-321554; Patnaik SK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049918; Poliseno L, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000594; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; Volinia S, 2010, GENOME RES, V20, P589, DOI 10.1101/gr.098046.109; Wang WT, 2013, JNCI-J NATL CANCER I, V105, P1284, DOI 10.1093/jnci/djt202; Wright G, 2003, P NATL ACAD SCI USA, V100, P9991, DOI 10.1073/pnas.1732008100	20	16	17	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 18	2015	10	2							e0115538	10.1371/journal.pone.0115538	http://dx.doi.org/10.1371/journal.pone.0115538			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC0WZ	25692889	Green Submitted, Green Published, gold			2023-01-03	WOS:000350061500009
J	Ma, YS; Olendzki, BC; Wang, JS; Persuitte, GM; Li, WJ; Fang, H; Merriam, PA; Wedick, NM; Ockene, IS; Culver, AL; Schneider, KL; Olendzki, GF; Carmody, J; Ge, TJ; Zhang, ZY; Pagoto, SL				Ma, Yunsheng; Olendzki, Barbara C.; Wang, Jinsong; Persuitte, Gioia M.; Li, Wenjun; Fang, Hua; Merriam, Philip A.; Wedick, Nicole M.; Ockene, Ira S.; Culver, Annie L.; Schneider, Kristin L.; Olendzki, Gin-Fei; Carmody, James; Ge, Tingjian; Zhang, Zhiying; Pagoto, Sherry L.			Single-Component Versus Multicomponent Dietary Goals for the Metabolic Syndrome A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							SEASONAL-VARIATION; PHYSICAL-ACTIVITY; BEHAVIOR CHANGES; NATIONAL-HEALTH; FIBER; ASSOCIATION; RISK; INTERVENTION; PREVENTION; MANAGEMENT	Background: Few studies have compared diets to determine whether a program focused on 1 dietary change results in collateral effects on other untargeted healthy diet components. Objective: To evaluate a diet focused on increased fiber consumption versus the multicomponent American Heart Association (AHA) dietary guidelines. Design: Randomized, controlled trial from June 2009 to January 2014. (ClinicalTrials.gov: NCT00911885) Setting: Worcester, Massachusetts. Participants: 240 adults with the metabolic syndrome. Intervention: Participants engaged in individual and group sessions. Measurements: Primary outcome was weight change at 12 months. Results: At 12 months, mean change in weight was -2.1 kg (95% CI, -2.9 to -1.3 kg) in the high-fiber diet group versus -2.7 kg (CI, -3.5 to -2.0 kg) in the AHA diet group. The mean between-group difference was 0.6 kg (CI, -0.5 to 1.7 kg). During the trial, 12 (9.9%) and 15 (12.6%) participants dropped out of the high-fiber and AHA diet groups, respectively (P = 0.55). Eight participants developed diabetes (hemoglobin A(1c) level >= 6.5%) during the trial: 7 in the high-fiber diet group and 1 in the AHA diet group (P = 0.066). Limitations: Generalizability is unknown. Maintenance of weight loss after cessation of group sessions at 12 months was not assessed. Definitive conclusions cannot be made about dietary equivalence because the study was powered for superiority. Conclusion: The more complex AHA diet may result in up to 1.7 kg more weight loss; however, a simplified approach to weight reduction emphasizing only increased fiber intake may be a reasonable alternative for persons with difficulty adhering to more complicated diet regimens.	[Ma, Yunsheng; Olendzki, Barbara C.; Persuitte, Gioia M.; Li, Wenjun; Merriam, Philip A.; Wedick, Nicole M.; Culver, Annie L.; Olendzki, Gin-Fei; Carmody, James; Zhang, Zhiying; Pagoto, Sherry L.] Univ Massachusetts, Sch Med, Dept Med, Div Prevent & Behav Med, Worcester, MA 01655 USA; [Wang, Jinsong] Yangzhou Univ, Coll Med, Dept Prevent Med, Yangzhou 225001, Jiangsu, Peoples R China; [Fang, Hua] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Div Biostat, Worcester, MA 01655 USA; [Fang, Hua] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Hlth Serv Res, Worcester, MA 01655 USA; [Ockene, Ira S.] Univ Massachusetts, Sch Med, Div Cardiovasc Med, Dept Med, Worcester, MA 01655 USA; [Schneider, Kristin L.] Univ Med & Sci, Dept Psychol, N Chicago, IL 60064 USA; [Ge, Tingjian] Univ Massachusetts, Dept Comp Sci, Lowell, MA 01854 USA	University of Massachusetts System; University of Massachusetts Worcester; Yangzhou University; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Lowell	Ma, YS (corresponding author), Univ Massachusetts, Sch Med, Dept Med, Div Prevent & Behav Med, 55 Lake Ave North, Worcester, MA 01655 USA.	Yunsheng.Ma@umassmed.edu	Olendzki, Barbara/K-1067-2019; Olendzki, Barbara/AAQ-9077-2020; Li, Wenjun/F-5634-2015; Ma, Yunsheng/D-9665-2016	Olendzki, Barbara/0000-0003-4307-5187; Li, Wenjun/0000-0001-5335-7386; Ma, Yunsheng/0000-0003-2317-3716	National Heart, Lung, and Blood Institute; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K24HL124366, R01HL094575] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	National Heart, Lung, and Blood Institute.	Ajani UA, 2004, J NUTR, V134, P1181, DOI 10.1093/jn/134.5.1181; Grundy Scott M, 2005, Crit Pathw Cardiol, V4, P198; [Anonymous], 2012, DIABETES CARE, V35, pS11, DOI [10.2337/dc35-S011, 10.2337/dc12-s004, 10.2337/dc12-s011]; BLOCK G, 1992, J AM DIET ASSOC, V92, P969; Carpenter JR, 2013, J BIOPHARM STAT, V23, P1352, DOI 10.1080/10543406.2013.834911; Chuwa EWL, 2006, BRIT J SURG, V93, P3, DOI 10.1002/bjs.5249; Feldeisen SE, 2007, APPL PHYSIOL NUTR ME, V32, P46, DOI 10.1139/h06-101; Feng CY, 2013, STAT MED, V32, P230, DOI 10.1002/sim.5486; FRISON L, 1992, STAT MED, V11, P1685, DOI 10.1002/sim.4780111304; Go AS, 2013, CIRCULATION, V127, pE6, DOI 10.1161/CIR.0b013e31828124ad; Grundy SM, 2004, CIRCULATION, V109, P433, DOI 10.1161/01.CIR.0000111245.75752.C6; King DE, 2003, AM J CARDIOL, V92, P1335, DOI 10.1016/j.amjcard.2003.08.020; Lappalainen R, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-310; Lichtenstein A, 2006, CIRCULATION, V114, pE629, DOI 10.1161/CIRCULATIONAHA.106.180281; Ma Y, 2006, EUR J CLIN NUTR, V60, P519, DOI 10.1038/sj.ejcn.1602346; Ma YS, 2006, AM J CLIN NUTR, V83, P760, DOI 10.1093/ajcn/83.4.760; Ma YS, 2008, NUTRITION, V24, P941, DOI 10.1016/j.nut.2008.04.005; Marlett JA, 2002, J AM DIET ASSOC, V102, P993, DOI 10.1016/S0002-8223(02)90228-2; Matthews CE, 2000, MED SCI SPORT EXER, V32, P976; Matthews CE, 2001, AM J EPIDEMIOL, V153, P172, DOI 10.1093/aje/153.2.172; Matthews CE, 2001, AM J EPIDEMIOL, V153, P987, DOI 10.1093/aje/153.10.987; McCullough ML, 2006, PUBLIC HEALTH NUTR, V9, P152, DOI 10.1079/PHN2005938; McCullough ML, 2002, AM J CLIN NUTR, V76, P1261, DOI 10.1093/ajcn/76.6.1261; Merriam PA, 1999, J BIOL RHYTHM, V14, P330, DOI 10.1177/074873099129000669; Merriam PA, 2012, J ACAD NUTR DIET, V112, P621, DOI 10.1016/j.jand.2012.01.024; Ockene IS, 2012, AM J PUBLIC HEALTH, V102, P336, DOI 10.2105/AJPH.2011.300357; Ockene IS, 2002, J AM COLL CARDIOL, V40, P630, DOI 10.1016/S0735-1097(02)02078-8; Pagoto S, 2007, HLTH PSYCHOL S1, V27, pS91; Pagoto SL, 2013, JAMA-J AM MED ASSOC, V310, P687, DOI 10.1001/jama.2013.8601; Park Y, 2005, JAMA-J AM MED ASSOC, V294, P2849, DOI 10.1001/jama.294.22.2849; Pearson TA, 2013, CIRCULATION, V127, P1730, DOI 10.1161/CIR.0b013e31828f8a94; Roger JH, 2014, SAS CODE SENSITIVITY; Ryan P., 1999, STATA TECHNICAL B, V50, P36; Spring B, 2012, ARCH INTERN MED, V172, P789, DOI 10.1001/archinternmed.2012.1044; Yang QH, 2014, JAMA INTERN MED, V174, P516, DOI 10.1001/jamainternmed.2013.13563; Zivkovic AM, 2007, AM J CLIN NUTR, V86, P285, DOI 10.1093/ajcn/86.2.285	36	28	30	1	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 17	2015	162	4					248	+		10.7326/M14-0611	http://dx.doi.org/10.7326/M14-0611			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CC3FU	25686165	Green Accepted			2023-01-03	WOS:000350232500014
J	Chen, Y; Feng, J; Gilbert, C; Yin, H; Liang, JH; Li, XX				Chen, Yi; Feng, Jing; Gilbert, Clare; Yin, Hong; Liang, Jianhong; Li, Xiaoxin			Time at Treatment of Severe Retinopathy of Prematurity in China: Recommendations for Guidelines in More Mature Infants	PLOS ONE			English	Article							THRESHOLD RETINOPATHY; OUTCOMES	Purpose To investigate the postmenstrual (PMA) age at treatment of severe retinopathy of prematurity (i.e. Type 1 prethreshold or threshold) in infants in a tertiary referral center in China. Principal Findings 76.6% (359/469) of infants were treated for threshold disease. 67.5% (317/469) of infants had a birth weight (BW) of 1250g or above and almost 30% (126) had a gestational age (GA) of 32 weeks or above. There was little difference in the characteristics of infants treated for Type 1 prethreshold or threshold ROP. After controlling for GA, PMA age at treatment was highest in infants with BW >= 2000g (mean PMA 40.3 +/- 4.4 weeks, p<0.001); after controlling for BW, higher GA was associated with higher PMA at treatment (mean PMA 41.5 weeks for gestational age >34 weeks, p<0.001). For every three weeks increase in GA there was a two-week increase in PMA at treatment (R2 = 0.20, p<0.001). The time at treatment of Type 1 prethreshold disease was similar to that for threshold disease i.e. chronological age 5.6-7.4 weeks, or PMA 34.1-40.2 weeks but the lower end of the 95% confidence interval for chronological age for Type 1 prethreshold disease among infants with BW >= 2000g was 3.7 weeks (i.e. before the recommended interval of 4-6 weeks after birth). Significance The Chinese guidelines regarding timing of the first examination are appropriate for infants with BW <2000g, but more mature infants should be examined a little earlier, at 3 weeks after birth, in order to detect Type 1 prethreshold disease which has a better prognosis than threshold.	[Chen, Yi; Feng, Jing; Yin, Hong; Liang, Jianhong; Li, Xiaoxin] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100871, Peoples R China; [Chen, Yi; Feng, Jing; Yin, Hong; Liang, Jianhong; Li, Xiaoxin] Minist Educ, Key Lab Vis Loss & Restorat, Beijing, Peoples R China; [Gilbert, Clare] London Sch Hyg & Trop Med, Dept Clin Res, Int Ctr Eye Hlth, London WC1, England	Peking University; University of London; London School of Hygiene & Tropical Medicine	Li, XX (corresponding author), Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100871, Peoples R China.	drli_xiao_xin@163.com		Feng, Jing/0000-0002-7658-9865				Asano Matthew K, 2014, Int Ophthalmol Clin, V54, P225, DOI 10.1097/IIO.0000000000000012; Blencowe H, 2013, PEDIATR RES, V74, P35, DOI 10.1038/pr.2013.205; Carden SM, 2008, CLIN EXP OPHTHALMOL, V36, P159, DOI 10.1111/j.1442-9071.2008.01682.x; Chen Y, 2006, BRIT J OPHTHALMOL, V90, P268, DOI 10.1136/bjo.2005.078063; Chinese Medical Association, 2005, ZHONGHUA YAN KE ZA Z, V41, P375; Coats DK, 2000, J AAPOS, V4, P183, DOI 10.1016/S1091-8531(00)70011-5; Coordination Group for the Survey of Present Status of Oxygen Use in Premature Infants in NICUs and Prevention and Treatment of ROP, 2012, Zhonghua Er Ke Za Zhi, V50, P167; Fierson WM, 2013, PEDIATRICS, V131, P189, DOI 10.1542/peds.2012-2996; Gilbert C, 2005, PEDIATRICS, V115, pE518, DOI 10.1542/peds.2004-1180; Gilbert C, 1997, LANCET, V350, P12, DOI 10.1016/S0140-6736(97)01107-0; Gole GA, 2005, ARCH OPHTHALMOL-CHIC, V123, P991, DOI 10.1001/archopht.123.7.991; Good WV, 2010, ARCH OPHTHALMOL-CHIC, V128, P663, DOI 10.1001/archophthalmol.2010.72; Good WV, 2003, ARCH OPHTHALMOL-CHIC, V121, P1684; Good WV, 2005, PEDIATRICS, V116, P15, DOI 10.1542/peds.2004-1413; Houston SK, 2013, LASER MED SCI, V28, P683, DOI 10.1007/s10103-011-1021-z; Hutchinson AK, 1998, ARCH OPHTHALMOL-CHIC, V116, P608, DOI 10.1001/archopht.116.5.608; Limburg H, 2012, OPHTHALMOLOGY, V119, P355, DOI 10.1016/j.ophtha.2011.07.037; Nguyen TH, 2000, OBSTET GYNECOL, V95, P867, DOI 10.1016/S0029-7844(99)00639-0; Nicoara SD, 2014, J PEDIAT OPHTH STRAB, V51, P39, DOI 10.3928/01913913-20131112-02; Palmer EA, 2005, ARCH OPHTHALMOL-CHIC, V123, P311; Palmer EA, 2002, ARCH OPHTHALMOL-CHIC, V120, P595; Palmer EA, 2006, J AAPOS, V10, P500, DOI 10.1016/j.jaapos.2006.09.005; Repka MX, 2011, ARCH OPHTHALMOL-CHIC, V129, P1175, DOI 10.1001/archophthalmol.2011.229; Sinha Renu, 2014, J Anaesthesiol Clin Pharmacol, V30, P258, DOI 10.4103/0970-9185.130050; Wei KL., 2005, CHIN J NAT MED, V7, P25; Weller A, 1998, J PSYCHOSOM OBST GYN, V19, P111, DOI 10.3109/01674829809048504; Wilkinson AR, 2009, EYE, V23, P2137, DOI 10.1038/eye.2008.128; Yang CY, 2011, PEDIATR NEONATOL, V52, P321, DOI 10.1016/j.pedneo.2011.08.004; 黎晓新, 2004, [中华眼底病杂志, Chinese Journal of Ocular Fundus Diseases], V20, P384	29	22	22	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 9	2015	10	2							e0116669	10.1371/journal.pone.0116669	http://dx.doi.org/10.1371/journal.pone.0116669			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA7UO	25664992	Green Submitted, Green Accepted, Green Published, gold			2023-01-03	WOS:000349123100011
J	Kaufman, RM; Djulbegovic, B; Gernsheimer, T; Kleinman, S; Tinmouth, AT; Capocelli, KE; Cipolle, MD; Cohn, CS; Fung, MK; Grossman, BJ; Mintz, PD; O'Malley, BA; Sesok-Pizzini, DA; Shander, A; Stack, GE; Webert, KE; Weinstein, R; Welch, BG; Whitman, GJ; Wong, EC; Tobian, AAR				Kaufman, Richard M.; Djulbegovic, Benjamin; Gernsheimer, Terry; Kleinman, Steven; Tinmouth, Alan T.; Capocelli, Kelley E.; Cipolle, Mark D.; Cohn, Claudia S.; Fung, Mark K.; Grossman, Brenda J.; Mintz, Paul D.; O'Malley, Barbara A.; Sesok-Pizzini, Deborah A.; Shander, Aryeh; Stack, Gary E.; Webert, Kathryn E.; Weinstein, Robert; Welch, Babu G.; Whitman, Glenn J.; Wong, Edward C.; Tobian, Aaron A. R.			Platelet Transfusion: A Clinical Practice Guideline From the AABB	ANNALS OF INTERNAL MEDICINE			English	Article							RANDOMIZED CONTROLLED-TRIAL; TRAUMATIC INTRACRANIAL HEMORRHAGE; PROGENITOR-CELL TRANSPLANT; VENOUS CATHETER PLACEMENT; BRAIN-INJURY PATIENTS; ACUTE LUNG INJURY; ACUTE-LEUKEMIA; LUMBAR PUNCTURE; ANTIPLATELET THERAPY; BLEEDING DIATHESES	Background: The AABB (formerly, the American Association of Blood Banks) developed this guideline on appropriate use of platelet transfusion in adult patients. Methods: These guidelines are based on a systematic review of randomized, clinical trials and observational studies (1900 to September 2014) that reported clinical outcomes on patients receiving prophylactic or therapeutic platelet transfusions. An expert panel reviewed the data and developed recommendations using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. Recommendation 1: The AABB recommends that platelets should be transfused prophylactically to reduce the risk for spontaneous bleeding in hospitalized adult patients with therapyinduced hypoproliferative thrombocytopenia. The AABB recommends transfusing hospitalized adult patients with a platelet count of 10 x 10(9) cells/L or less to reduce the risk for spontaneous bleeding. The AABB recommends transfusing up to a single apheresis unit or equivalent. Greater doses are not more effective, and lower doses equal to one half of a standard apheresis unit are equally effective. (Grade: strong recommendation; moderate-quality evidence) Recommendation 2: The AABB suggests prophylactic platelet transfusion for patients having elective central venous catheter placement with a platelet count less than 20 x 10(9) cells/L. (Grade: weak recommendation; low-quality evidence) Recommendation 3: The AABB suggests prophylactic platelet transfusion for patients having elective diagnostic lumbar puncture with a platelet count less than 50 x 10(9) cells/L. (Grade: weak recommendation; very-low-quality evidence) Recommendation 4: The AABB suggests prophylactic platelet transfusion for patients having major elective nonneuraxial surgery with a platelet count less than 50 x 10(9) cells/L. (Grade: weak recommendation; very-low-quality evidence) Recommendation 5: The AABB recommends against routine prophylactic platelet transfusion for patients who are nonthrombocytopenic and have cardiac surgery with cardiopulmonary bypass. The AABB suggests platelet transfusion for patients having bypass who exhibit perioperative bleeding with thrombocytopenia and/or evidence of platelet dysfunction. (Grade: weak recommendation; very-low-quality evidence) Recommendation 6: The AABB cannot recommend for or against platelet transfusion for patients receiving antiplatelet therapy who have intracranial hemorrhage (traumatic or spontaneous). (Grade: uncertain recommendation; very-low-quality evidence)	Brigham & Womens Hosp, Boston, MA 02115 USA; [Djulbegovic, Benjamin] Univ S Florida, Tampa, FL 33612 USA; [Gernsheimer, Terry] Univ Washington, Seattle, WA 98195 USA; [Kleinman, Steven] Univ British Columbia, Victoria, BC V9A 4W4, Canada; Ottawa Hosp Res Inst, Ottawa, ON, Canada; Childrens Hosp Colorado, Aurora, CO 80045 USA; Christiana Care Hlth Syst, Wilmington, DE USA; Univ Minnesota, Minneapolis, MN USA; Univ Vermont, Burlington, VT USA; Washington Univ, Sch Med, St Louis, MO USA; US FDA, Silver Spring, MD USA; Wayne State Univ, Detroit, MI USA; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Englewood Hosp & Med Ctr, Englewood, NJ USA; Yale Univ, Sch Med, West Haven, CT 06516 USA; McMaster Univ, Hamilton, ON, Canada; [Weinstein, Robert] Univ Massachusetts, Sch Med, Worcester, MA 01655 USA; [Welch, Babu G.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; Johns Hopkins Univ, Baltimore, MD USA; Childrens Natl Med Ctr, Washington, DC 20010 USA	Harvard University; Brigham & Women's Hospital; State University System of Florida; University of South Florida; University of Washington; University of Washington Seattle; University of British Columbia; University of Ottawa; Ottawa Hospital Research Institute; Children's Hospital Colorado; Christiana Care Health System; University of Minnesota System; University of Minnesota Twin Cities; University of Vermont; Washington University (WUSTL); US Food & Drug Administration (FDA); Wayne State University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Englewood Hospital & Medical Center; Yale University; McMaster University; University of Massachusetts System; University of Massachusetts Worcester; University of Texas System; University of Texas Southwestern Medical Center Dallas; Johns Hopkins University; Children's National Health System	Kaufman, RM (corresponding author), Brigham & Womens Hosp, Dept Pathol, Blood Bank, Amory 260,75 Francis St, Boston, MA 02115 USA.	rmkaufman@partners.org	Kaufman, Richard M/E-8890-2018; Stack, Gary/E-9646-2014; Djulbegovic, Benjamin/I-3661-2012	Kaufman, Richard M/0000-0003-1520-4535; Stack, Gary/0000-0002-6501-7255; Djulbegovic, Benjamin/0000-0003-0671-1447; Fung, Mark/0000-0001-6081-4151; Grossman, Brenda/0000-0002-1500-8211				Anglin CO, 2013, J NEUROSURG, V118, P676, DOI 10.3171/2012.11.JNS12622; Barrera R, 1996, CANCER, V78, P2025, DOI 10.1002/(SICI)1097-0142(19961101)78:9<2025::AID-CNCR26>3.3.CO;2-T; BISHOP JF, 1987, AM J HEMATOL, V26, P147, DOI 10.1002/ajh.2830260205; BREUER AC, 1982, CANCER-AM CANCER SOC, V49, P2168, DOI 10.1002/1097-0142(19820515)49:10<2168::AID-CNCR2820491031>3.0.CO;2-O; Choi S, 2009, ANESTH ANALG, V109, P648, DOI 10.1213/ane.0b013e3181ac13d1; Creutzfeldt CJ, 2009, J STROKE CEREBROVASC, V18, P221, DOI 10.1016/j.jstrokecerebrovasdis.2008.10.007; Diedrich B, 2005, TRANSFUSION, V45, P1064, DOI 10.1111/j.1537-2995.2005.04157.x; Doerfler ME, 1996, CHEST, V110, P185, DOI 10.1378/chest.110.1.185; Downey DM, 2009, AM SURGEON, V75, P1100; Duffy SM, 2013, J CLIN APHERESIS, V28, P356, DOI 10.1002/jca.21279; Eder AF, 2013, TRANSFUSION, V53, P1442, DOI 10.1111/j.1537-2995.2012.03935.x; Estcourt L, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004269.pub3; Ferraris VA, 2011, ANN THORAC SURG, V91, P944, DOI 10.1016/j.athoracsur.2010.11.078; Feusner J, 2004, PEDIATR BLOOD CANCER, V43, P793, DOI 10.1002/pbc.20201; Fisher NC, 1999, INTENS CARE MED, V25, P481, DOI 10.1007/s001340050884; FRITZ RD, 1959, NEW ENGL J MED, V261, P59, DOI 10.1056/NEJM195907092610202; Fuller AK, 2011, TRANSFUSION, V51, P1469, DOI 10.1111/j.1537-2995.2010.03039.x; Greeno E, 2007, TRANSFUSION, V47, P201, DOI 10.1111/j.1537-2995.2007.01089.x; Guyatt GH, 2008, BMJ-BRIT MED J, V336, P1049, DOI 10.1136/bmj.39493.646875.AE; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Haas B, 2010, J VASC INTERV RADIOL, V21, P212, DOI 10.1016/j.jvir.2009.10.032; Haas FJ, 2011, BLOOD TRANSFUSION GU; HAN T, 1966, CANCER, V19, P1937, DOI 10.1002/1097-0142(196612)19:12<1937::AID-CNCR2820191221>3.0.CO;2-G; Heckman KD, 1997, J CLIN ONCOL, V15, P1143, DOI 10.1200/JCO.1997.15.3.1143; Heddle NM, 2009, BLOOD, V113, P1564, DOI 10.1182/blood-2008-09-178236; Heddle NM, 2002, TRANSFUSION, V42, P556, DOI 10.1046/j.1537-2995.2002.00094.x; Heddle NM, 1999, TRANSFUSION, V39, P231, DOI 10.1046/j.1537-2995.1999.39399219278.x; Howard SC, 2000, JAMA-J AM MED ASSOC, V284, P2222, DOI 10.1001/jama.284.17.2222; Ivascu FA, 2008, J TRAUMA, V65, P785, DOI 10.1097/TA.0b013e3181848caa; JPAC - Joint United Kingdom (UK) Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee, 2013, TRANSF HDB TRANSF SU; Kelsey P, 2003, BRIT J HAEMATOL, V122, P10; Kitanovski L, 2008, ZDR VESTN, V77, pI111; Kumar A, 2015, TRANSFUSION, V55, P1116, DOI 10.1111/trf.12943; Lozano M, 2014, VOX SANG, V106, P330, DOI 10.1111/vox.12110; Malloy PC, 2009, J VASC INTERV RADIOL, V20, pS240, DOI 10.1016/j.jvir.2008.11.027; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; Mumtaz H, 2000, AM J SURG, V180, P503, DOI 10.1016/S0002-9610(00)00552-3; MURPHY S, 1982, AM J HEMATOL, V12, P347, DOI 10.1002/ajh.2830120406; Nishijima DK, 2012, J TRAUMA ACUTE CARE, V72, P1658, DOI 10.1097/TA.0b013e318256dfc5; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; Patel IJ, 2012, J VASC INTERV RADIOL, V23, P727, DOI 10.1016/j.jvir.2012.02.012; Qureshi HY, 2008, ANAL BIOCHEM, V382, P138, DOI 10.1016/j.ab.2008.07.027; Ray CE, 1997, RADIOLOGY, V204, P97, DOI 10.1148/radiology.204.1.9205228; Rebulla P, 1997, NEW ENGL J MED, V337, P1870, DOI 10.1056/NEJM199712253372602; Riley W, 2012, TRANSFUSION, V52, P1957, DOI 10.1111/j.1537-2995.2011.03539.x; ROY AJ, 1973, TRANSFUSION, V13, P283, DOI 10.1111/j.1537-2995.1973.tb05490.x; Ruell J, 2007, BRIT J HAEMATOL, V136, P347, DOI 10.1111/j.1365-2141.2006.06433.x; Samama CM, 2006, MINERVA ANESTESIOL, V72, P447; Samama CM, 2005, CAN J ANAESTH, V52, P30, DOI 10.1007/BF03018577; Schiffer CA, 2001, J CLIN ONCOL, V19, P1519, DOI 10.1200/JCO.2001.19.5.1519; Segal HC, 2005, BRIT J HAEMATOL, V128, P520, DOI 10.1111/j.1365-2141.2004.05352.x; Sensebe L, 2005, BLOOD, V105, P862, DOI 10.1182/blood-2004-05-1841; Slichter SJ, 2010, NEW ENGL J MED, V362, P600, DOI 10.1056/NEJMoa0904084; SLICHTER SJ, 1978, CLIN HAEMATOL, V7, P523; SOLOMON J, 1978, LANCET, V1, P267; Spiess BD, 2004, TRANSFUSION, V44, P1143, DOI 10.1111/j.1537-2995.2004.03322.x; Stanworth SJ, 2014, TRANSFUSION, V54, P2385, DOI 10.1111/trf.12646; Stanworth SJ, 2013, NEW ENGL J MED, V368, P1771, DOI 10.1056/NEJMoa1212772; Stramer SL, 2007, ARCH PATHOL LAB MED, V131, P702; Tinmouth A, 2004, TRANSFUSION, V44, P1711, DOI 10.1111/j.0041-1132.2004.04118.x; Tosetto A, 2009, THROMB RES, V124, pE13, DOI 10.1016/j.thromres.2009.06.009; Toy P, 2012, BLOOD, V119, P1757, DOI 10.1182/blood-2011-08-370932; van Veen JJ, 2004, BRIT J HAEMATOL, V127, P233, DOI 10.1111/j.1365-2141.2004.05178.x; van Veen JJ, 2010, BRIT J HAEMATOL, V148, P15, DOI 10.1111/j.1365-2141.2009.07899.x; Vavricka SR, 2003, ANN HEMATOL, V82, P570, DOI 10.1007/s00277-003-0707-0; Wandt H, 2012, LANCET, V380, P1309, DOI 10.1016/S0140-6736(12)60689-8; Washington CW, 2011, J TRAUMA, V71, P358, DOI 10.1097/TA.0b013e318220ad7e; Whitaker BI, 2013, 2011 NATL BLOOD COLL; Whitlock R, 2005, CRIT CARE CLIN, V21, P589, DOI 10.1016/j.ccc.2005.04.003; Wong DK, 2008, J TRAUMA, V65, P1303, DOI 10.1097/TA.0b013e318185e234; Zeidler K, 2011, TRANSFUSION, V51, P2269, DOI 10.1111/j.1537-2995.2011.03147.x; Zumberg MS, 2002, BIOL BLOOD MARROW TR, V8, P569, DOI 10.1053/bbmt.2002.v8.pm12434952	72	475	501	2	40	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 3	2015	162	3					205	U118		10.7326/M14-1589	http://dx.doi.org/10.7326/M14-1589			17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CC1NP	25383671				2023-01-03	WOS:000350108100006
J	Noto, MJ; Domenico, HJ; Byrne, DW; Talbot, T; Rice, TW; Bernard, GR; Wheeler, AP				Noto, Michael J.; Domenico, Henry J.; Byrne, Daniel W.; Talbot, Tom; Rice, Todd W.; Bernard, Gordon R.; Wheeler, Arthur P.			Chlorhexidine Bathing and Health Care-Associated Infections A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; BLOOD-STREAM INFECTIONS; TRANSMISSION; PREVENTION; ORGANISMS; GLUCONATE; IMPACT; COSTS	IMPORTANCE Daily bathing of critically ill patients with the broad-spectrum, topical antimicrobial agent chlorhexidine is widely performed and may reduce health care-associated infections. OBJECTIVE To determine if daily bathing of critically ill patients with chlorhexidine decreases the incidence of health care-associated infections. DESIGN, SETTING, AND PARTICIPANTS A pragmatic cluster randomized, crossover study of 9340 patients admitted to 5 adult intensive care units of a tertiary medical center in Nashville, Tennessee, from July 2012 through July 2013. INTERVENTIONS Units performed once-daily bathing of all patients with disposable cloths impregnated with 2% chlorhexidine or nonantimicrobial cloths as a control. Bathing treatments were performed for a 10-week period followed by a 2-week washout period during which patients were bathed with nonantimicrobial disposable cloths, before crossover to the alternate bathing treatment for 10 weeks. Each unit crossed over between bathing assignments 3 times during the study. MAIN OUTCOMES AND MEASURES The primary prespecified outcome was a composite of central line-associated bloodstream infections (CLABSIs), catheter-associated urinary tract infections (CAUTIs), ventilator-associated pneumonia (VAP), and Clostridium difficile infections. Secondary outcomes included rates of clinical cultures that tested positive for multidrug-resistant organisms, blood culture contamination, health care-associated bloodstream infections, and rates of the primary outcome by ICU. RESULTS During the chlorhexidine bathing period, 55 infections occurred: 4 CLABSI, 21 CAUTI, 17 VAP, and 13 C difficile. During the control bathing period, 60 infections occurred: 4 CLABSI, 32 CAUTI, 8 VAP, and 16 C difficile. The primary outcome rate was 2.86 per 1000 patient-days during the chlorhexidine and 2.90 per 1000 patient-days during the control bathing periods (rate difference, -0.04; 95% CI, -1.10 to 1.01; P = .95). After adjusting for baseline variables, no difference between groups in the rate of the primary outcome was detected. Chlorhexidine bathing did not change rates of infection-related secondary outcomes including hospital-acquired bloodstream infections, blood culture contamination, or clinical cultures yielding multidrug-resistant organisms. In a prespecified subgroup analysis, no difference in the primary outcome was detected in any individual intensive care unit. CONCLUSION AND RELEVANCE In this pragmatic trial, daily bathing with chlorhexidine did not reduce the incidence of health care-associated infections including CLABSIs, CAUTIs, VAP, or C difficile. These findings do not support daily bathing of critically ill patients with chlorhexidine.	[Noto, Michael J.; Talbot, Tom; Rice, Todd W.; Bernard, Gordon R.; Wheeler, Arthur P.] Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA; [Domenico, Henry J.; Byrne, Daniel W.] Vanderbilt Univ, Dept Biostat, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Noto, MJ (corresponding author), Vanderbilt Univ, Med Ctr, MCN, 1161 21st Ave S,T-1223, Nashville, TN 37232 USA.	michael.j.noto@vanderbilt.edu	Byrne, Daniel/GRE-6302-2022; Rice, Todd/X-7853-2019; 卢, 悄佳/Z-5223-2019	Rice, Todd/0000-0002-7136-5408; Talbot, Thomas/0000-0002-6139-212X	National Institutes of Health and through the Vanderbilt Institute for Clinical and Translational Research [UL1 TR000445, 2T32HL087738-06]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000445] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL087738] Funding Source: NIH RePORTER	National Institutes of Health and through the Vanderbilt Institute for Clinical and Translational Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Research reported in this publication was supported by grants UL1 TR000445 and 2T32HL087738-06 from the National Institutes of Health and through the Vanderbilt Institute for Clinical and Translational Research. The chlorhexidine impregnated and nonantimicrobial cloths were purchased from Sage Products.	Calfee DP, 2014, INFECT CONT HOSP EP, V35, P772, DOI [10.1086/676534, 10.1017/S0899823X00193882]; Centers for Disease Control and Prevention, CDC NHSN SURV DEF SP; Climo MW, 2013, NEW ENGL J MED, V368, P533, DOI 10.1056/NEJMoa1113849; Climo MW, 2009, CRIT CARE MED, V37, P1858, DOI 10.1097/CCM.0b013e31819ffe6d; Huang SS, 2013, NEW ENGL J MED, V368, P2255, DOI 10.1056/NEJMoa1207290; Karki S, 2012, J HOSP INFECT, V82, P71, DOI 10.1016/j.jhin.2012.07.005; Kassakian SZ, 2011, INFECT CONT HOSP EP, V32, P238, DOI 10.1086/658334; Kaye KS, 2014, J AM GERIATR SOC, V62, P306, DOI 10.1111/jgs.12634; O'Grady NP, 2011, CLIN INFECT DIS, V52, pE162, DOI 10.1093/cid/cir257; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Roberts RR, 2010, MED CARE, V48, P1026, DOI 10.1097/MLR.0b013e3181ef60a2; Rupp ME, 2012, INFECT CONT HOSP EP, V33, P1094, DOI 10.1086/668024; Siegel JD, 2007, AM J INFECT CONTROL, V35, pS65, DOI 10.1016/j.ajic.2007.10.007; Suwantarat N, 2014, INFECT CONT HOSP EP, V35, P1183, DOI 10.1086/677628; University HealthSystem Consortium, AB UHC; Vernon MO, 2006, ARCH INTERN MED, V166, P306, DOI 10.1001/archinte.166.3.306; Viray MA, 2014, INFECT CONT HOSP EP, V35, P243, DOI 10.1086/675292; Wang JT, 2008, J ANTIMICROB CHEMOTH, V62, P514, DOI 10.1093/jac/dkn208; Warren DK, 2006, CRIT CARE MED, V34, P2084, DOI 10.1097/01.CCM.0000227648.15804.2D	19	124	131	0	57	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 27	2015	313	4					369	378		10.1001/jama.2014.18400	http://dx.doi.org/10.1001/jama.2014.18400			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CA7BS	25602496	Bronze, Green Accepted			2023-01-03	WOS:000349072600019
J	Baeumler, PI; Fleckenstein, J; Takayama, S; Simang, M; Seki, T; Irnich, D				Baeumler, Petra I.; Fleckenstein, Johannes; Takayama, Shin; Simang, Michael; Seki, Takashi; Irnich, Dominik			Effects of Acupuncture on Sensory Perception: A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							COLD-PRESSOR PAIN; ELECTRICAL NERVE-STIMULATION; MYOFASCIAL TRIGGER POINTS; TENSION-TYPE HEADACHE; THERMAL PAIN; CHRONIC NECK; MANUAL ACUPUNCTURE; SHAM ACUPUNCTURE; CONTROLLED-TRIAL; DOUBLE-BLIND	Background: The effect of acupuncture on sensory perception has never been systematically reviewed; although, studies on acupuncture mechanisms are frequently based on the idea that changes in sensory thresholds reflect its effect on the nervous system. Methods: Pubmed, EMBASE and Scopus were screened for studies investigating the effect of acupuncture on thermal or mechanical detection or pain thresholds in humans published in English or German. A meta-analysis of high quality studies was performed. Results: Out of 3007 identified articles 85 were included. Sixty five studies showed that acupuncture affects at least one sensory threshold. Most studies assessed the pressure pain threshold of which 80% reported an increase after acupuncture. Significant short-and long-term effects on the pressure pain threshold in pain patients were revealed by two meta-analyses including four and two high quality studies, respectively. In over 60% of studies, acupuncture reduced sensitivity to noxious thermal stimuli, but measuring methods might influence results. Few but consistent data indicate that acupuncture reduces pin-prick like pain but not mechanical detection. Results on thermal detection are heterogeneous. Sensory threshold changes were equally frequent reported after manual acupuncture as after electroacupuncture. Among 48 sham-controlled studies, 25 showed stronger effects on sensory thresholds through verum than through sham acupuncture, but in 9 studies significant threshold changes were also observed after sham acupuncture. Overall, there is a lack of high quality acupuncture studies applying comprehensive assessments of sensory perception. Conclusions: Our findings indicate that acupuncture affects sensory perception. Results are most compelling for the pressure pain threshold, especially in pain conditions associated with tenderness. Sham acupuncture can also cause such effects. Future studies should incorporate comprehensive, standardized assessments of sensory profiles in order to fully characterize its effect on sensory perception and to explore the predictive value of sensory profiles for the effectiveness of acupuncture.	[Baeumler, Petra I.; Fleckenstein, Johannes; Simang, Michael; Irnich, Dominik] Univ Munich LMU, Dept Anaesthesiol, Ctr Multidisciplinary Pain, Munich, Germany; [Takayama, Shin; Seki, Takashi] Tohoku Univ, Dept Tradit Asian Med, Sendai, Miyagi 980, Japan; [Simang, Michael] Univ Munich LMU, Inst Med Informat Sci Biometry & Epidemiol, Munich, Germany	University of Munich; Tohoku University; University of Munich	Baeumler, PI (corresponding author), Univ Munich LMU, Dept Anaesthesiol, Ctr Multidisciplinary Pain, Munich, Germany.	Petra.Baeumler@med.uni-muenchen.de	Fleckenstein, Johannes/AAL-1315-2021; Takayama, Shin/AAP-7007-2021; Takayama, Shin/GSN-7228-2022	Takayama, Shin/0000-0002-6388-4566; Fleckenstein, Johannes/0000-0003-3442-0380	University of Munich & Tohoku University	University of Munich & Tohoku University	University of Munich & Tohoku University provided support in the form of salaries for all authors as depicted in the corresponding affiliations, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Abuaisha BB, 1998, DIABETES RES CLIN PR, V39, P115, DOI 10.1016/S0168-8227(97)00123-X; Agostinho CMS, 2009, EUR J PAIN, V13, P779, DOI 10.1016/j.ejpain.2008.10.002; Ahn Andrew C, 2007, Acupunct Med, V25, P11; Amand M, 2011, ACUPUNCT MED, V29, P47, DOI 10.1136/aim.2010.002485; ANDERSON DG, 1974, CAN J PSYCHOL, V28, P239, DOI 10.1037/h0081990; Arendt-Nielsen L, 2009, J PAIN, V10, P556, DOI 10.1016/j.jpain.2009.02.002; ASHTON H, 1984, J PSYCHOSOM RES, V28, P301, DOI 10.1016/0022-3999(84)90052-7; Barlas P, 2000, CLIN PHYSIOL, V20, P449, DOI 10.1046/j.1365-2281.2000.00280.x; Barlas P, 2006, PAIN, V122, P81, DOI 10.1016/j.pain.2006.01.012; Barnes Patricia M., 2008, NATL HLTH STAT REPOR, V12, P1, DOI DOI 10.1037/E623942009-001; Benoliel R, 2011, J OROFAC PAIN, V25, P32; BERLIN FS, 1975, ANESTHESIOLOGY, V42, P527, DOI 10.1097/00000542-197505000-00002; BROCKHAUS A, 1990, PAIN, V43, P181, DOI 10.1016/0304-3959(90)91071-P; Carlsson Christer, 2002, Acupunct Med, V20, P82; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chae Y, 2006, J PHYSIOL SCI, V56, P425, DOI 10.2170/physiolsci.RP010206; Chou LW, 2011, AM J PHYS MED REHAB, V90, P1036, DOI 10.1097/PHM.0b013e3182328875; CLARK WC, 1974, SCIENCE, V184, P1096, DOI 10.1126/science.184.4141.1096; CROZE S, 1976, BRAIN RES, V104, P335, DOI 10.1016/0006-8993(76)90628-4; Cruccu G, 2010, EUR J NEUROL, V17, P1010, DOI 10.1111/j.1468-1331.2010.02969.x; DARIANSMITH I, 1973, J NEUROPHYSIOL, V36, P325, DOI 10.1152/jn.1973.36.2.325; DAY RL, 1975, ANESTHESIOLOGY, V43, P507, DOI 10.1097/00000542-197511000-00005; DELUZE C, 1992, BRIT MED J, V305, P1249, DOI 10.1136/bmj.305.6864.1249; Downs NM, 2005, ARCH PHYS MED REHAB, V86, P1252, DOI 10.1016/j.apmr.2004.10.037; DYCK PJ, 1993, NEUROLOGY, V43, P1500, DOI 10.1212/WNL.43.8.1500; DYCK PJ, 1993, NEUROLOGY, V43, P1508, DOI 10.1212/WNL.43.8.1508; Eardley S, 2012, FORSCH KOMPLEMENTMED, V19, P18, DOI 10.1159/000342708; Edwards Janet, 2003, Acupunct Med, V21, P80; Farber PL, 1997, ACUPUNCTURE ELECTRO, V22, P109, DOI 10.3727/036012997816356725; Fernandez-Carnero J, 2010, J OROFAC PAIN, V24, P106; Finniss DG, 2010, LANCET, V375, P686, DOI 10.1016/S0140-6736(09)61706-2; FISCHER AA, 1987, PAIN, V30, P115, DOI 10.1016/0304-3959(87)90089-3; Fu ZH, 2007, J ALTERN COMPLEM MED, V13, P47, DOI 10.1089/acm.2006.6125; Galloon S, 1977, DTSCH ARZTEBLATT, V74, P879; Garell PC, 1996, J NEUROPHYSIOL, V75, P1177, DOI 10.1152/jn.1996.75.3.1177; GARNSWORTHY RK, 1988, J NEUROPHYSIOL, V59, P1083, DOI 10.1152/jn.1988.59.4.1083; Goddard G, 2002, J OROFAC PAIN, V16, P71; Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562; Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019; Harris RE, 2008, ARTHRITIS RHEUM, V58, P903, DOI 10.1002/art.23223; Harris RE, 2006, J PAIN, V7, P521, DOI 10.1016/j.jpain.2006.01.455; He D, 2004, PAIN, V109, P299, DOI 10.1016/j.pain.2004.01.018; Huang WJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032960; Hubscher M, 2008, J ALTERN COMPLEM MED, V14, P1011, DOI 10.1089/acm.2008.0173; Ilbuldu E, 2004, PHOTOMED LASER SURG, V22, P306; Irnich D, 2003, PHYS MED REHAB KUROR, V13, P215; Irnich D, 2002, SCHMERZ, V16, P93, DOI 10.1007/s004820100094; Irnich D, 2001, BMJ-BRIT MED J, V322, P1574, DOI 10.1136/bmj.322.7302.1574; Irnich D, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/neq009; Itoh K, 2011, CHIN MED-UK, V6, DOI 10.1186/1749-8546-6-24; Jensen TS, 2003, PAIN, V102, P1, DOI 10.1016/S0304-3959(03)00006-X; Jones L, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009234.pub2; Karst M, 2000, PAIN, V88, P199, DOI 10.1016/S0304-3959(00)00315-8; KITADE T, 1981, AM J CHINESE MED, V9, P243, DOI 10.1142/S0192415X81000329; KITADE T, 1988, ACUPUNCTURE ELECTRO, V13, P87, DOI 10.3727/036012988816358705; KITADE T, 1979, AM J CHINESE MED, V7, P241, DOI 10.1142/S0192415X79000209; KNOX VJ, 1977, PAIN, V4, P49, DOI 10.1016/0304-3959(77)90086-0; KNOX VJ, 1981, J ABNORM PSYCHOL, V90, P28, DOI 10.1037/0021-843X.90.1.28; KNOX VJ, 1979, PSYCHOSOM MED, V41, P477; KNOX VJ, 1977, J ABNORM PSYCHOL, V86, P639; Kong J, 2005, J PAIN, V6, P55, DOI 10.1016/j.jpain.2004.10.005; Kong J, 2009, NEUROIMAGE, V45, P940, DOI 10.1016/j.neuroimage.2008.12.025; Konopka KH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043526; Kotani N, 2001, REGION ANESTH PAIN M, V26, P532, DOI 10.1053/rapm.2001.25897; Kumnerddee Wipoo, 2009, J Med Assoc Thai, V92 Suppl 1, pS117; LAMOTTE RH, 1978, J NEUROPHYSIOL, V41, P509, DOI 10.1152/jn.1978.41.2.509; Lang PM, 2010, ANESTH ANALG, V110, P1448, DOI 10.1213/ANE.0b013e3181d3e7ef; Langhorst J, 2010, RHEUMATOLOGY, V49, P778, DOI 10.1093/rheumatology/kep439; Le Bars D, 2002, BRAIN RES REV, V40, P29, DOI 10.1016/S0165-0173(02)00186-8; Lee JH, 2013, CLIN J PAIN, V29, P172, DOI 10.1097/AJP.0b013e31824909f9; Leung A, 2005, J ALTERN COMPLEM MED, V11, P653, DOI 10.1089/acm.2005.11.653; Leung AY, 2008, BMC COMPLEM ALTERN M, V8, DOI 10.1186/1472-6882-8-18; LI SC, 1983, ACUPUNCTURE ELECTRO, V8, P105, DOI 10.3727/036012983816714984; Li WH, 2008, COMPLEMENT THER MED, V16, P278, DOI 10.1016/j.ctim.2008.02.011; LIM TW, 1977, MED J AUSTRALIA, V1, P440, DOI 10.5694/j.1326-5377.1977.tb130796.x; Lin JG, 2008, AM J CHINESE MED, V36, P635, DOI 10.1142/S0192415X08006107; LIN MT, 1981, AM J CHINESE MED, V9, P305, DOI 10.1142/S0192415X81000408; Linde K, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-75; Linde K, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007587; List Thomas, 1993, Journal of Orofacial Pain, V7, P275; LLOYD MA, 1976, ANESTHESIOLOGY, V44, P147, DOI 10.1097/00000542-197602000-00011; LUNDEBERG T, 1989, AM J CHINESE MED, V17, P99, DOI 10.1142/S0192415X89000176; Lundeberg T, 1988, EAR NOSE THROAT J, V67; LYNN B, 1977, PAIN, V3, P339, DOI 10.1016/0304-3959(77)90064-1; Ma C, 2010, CLIN J PAIN, V26, P251, DOI 10.1097/AJP.0b013e3181b8cdc8; Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3; MacPherson Hugh, 2010, J Evid Based Med, V3, P140, DOI 10.1111/j.1756-5391.2010.01086.x; MacPherson H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077438; Maier C, 2010, PAIN, V150, P439, DOI 10.1016/j.pain.2010.05.002; Manheimer E, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001977.pub2; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; MORET V, 1991, PAIN, V45, P135, DOI 10.1016/0304-3959(91)90178-Z; Nabeta T, 2002, COMPLEMENT THER MED, V10, P217, DOI 10.1016/S0965-2299(02)00082-1; OCHOA J, 1983, J PHYSIOL-LONDON, V342, P633, DOI 10.1113/jphysiol.1983.sp014873; PAUSER G, 1975, WIEN KLIN WOCHENSCHR, V87, P25; Perez-Palomares S, 2010, J MUSCULOSKELET PAIN, V18, P23, DOI 10.3109/10582450903496047; Petersen GL, 2012, PAIN, V153, P1292, DOI 10.1016/j.pain.2012.03.011; Pfau DB, 2012, CURR PAIN HEADACHE R, V16, P199, DOI 10.1007/s11916-012-0261-3; Pfau DB, 2009, PAIN, V147, P72, DOI 10.1016/j.pain.2009.08.010; Pittler MH, 2008, CLIN J PAIN, V24, P731, DOI 10.1097/AJP.0b013e3181759231; PRICE DD, 1984, PAIN, V19, P27, DOI 10.1016/0304-3959(84)90062-9; Rolke R, 2006, PAIN, V123, P231, DOI 10.1016/j.pain.2006.01.041; Sandkuhler J, 1997, J NEUROSCI, V17, P6483; Schliessbach J, 2012, EVID-BASED COMPL ALT, V2012, P1, DOI 10.1155/2012/785613; Schliessbach J, 2011, PAIN MED, V12, P268, DOI 10.1111/j.1526-4637.2010.01051.x; Schmelz M, 2010, NEUROSCI LETT, V470, P158, DOI 10.1016/j.neulet.2009.05.064; SEIDEL U, 2002, DTSCH Z AKUPUNKTUR, V45, P258; Shen Yoshi F, 2007, Pain Pract, V7, P256; Shen YF, 2009, J OROFAC PAIN, V23, P353; Shukla S, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-45; Singh BB, 2006, ALTERN THER HEALTH M, V12, P34; Smith CA, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007854.pub2; Sprenger C, 2011, PAIN, V152, P428, DOI 10.1016/j.pain.2010.11.018; Sprott H, 2000, WIEN KLIN WOCHENSCHR, V112, P580; Srbely JZ, 2010, J REHABIL MED, V42, P463, DOI 10.2340/16501977-0535; Staud R, 2001, PAIN, V91, P165, DOI 10.1016/S0304-3959(00)00432-2; Stern J A, 1977, Ann N Y Acad Sci, V296, P175, DOI 10.1111/j.1749-6632.1977.tb38171.x; STEWART D, 1977, BRIT MED J, V1, P67, DOI 10.1136/bmj.1.6053.67; Takeda W, 1994, Arthritis Care Res, V7, P118, DOI 10.1002/art.1790070304; TALBOT JD, 1987, PAIN, V30, P221, DOI 10.1016/0304-3959(87)91078-5; Tampin B, 2012, PAIN; Targino RA, 2008, J REHABIL MED, V40, P582, DOI 10.2340/16501977-0216; Tobbackx Y, 2013, EUR J PAIN, V17, P279, DOI 10.1002/j.1532-2149.2012.00215.x; Tong YQ, 2010, J ACUPUNCT MERIDIAN, V3, P95, DOI 10.1016/S2005-2901(10)60018-0; Treede RD, 2002, PAIN, V98, P235, DOI 10.1016/S0304-3959(02)00203-8; ULETT GA, 1978, ACUPUNCTURE ELECTRO, V3, P191, DOI 10.3727/036012978817553131; UMINO M, 1984, Bulletin of Tokyo Medical and Dental University, V31, P93; VERDUGO R, 1992, BRAIN, V115, P893, DOI 10.1093/brain/115.3.893; Vicente-Barrero M, 2012, MED ORAL PATOL ORAL; Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654; WAND-TETLEY J I, 1956, Ann Phys Med, V3, P90; Wang SM, 2009, ANESTH ANALG, V109, P932, DOI 10.1213/ane.0b013e3181ad9292; Westermann A, 2011, CLIN J PAIN, V27, P782, DOI 10.1097/AJP.0b013e31821d8fce; WIESENFELDHALLIN Z, 1984, BRAIN RES, V311, P375, DOI 10.1016/0006-8993(84)90104-5; World Health Organisation, 1993, STAND AC NOM; Wylde V, 2012, RHEUMATOLOGY, V51, P535, DOI 10.1093/rheumatology/ker343; Xue CCL, 2004, HEADACHE, V44, P333, DOI 10.1111/j.1526-4610.2004.04077.x; YARNITSKY D, 1991, BRAIN, V114, P1819, DOI 10.1093/brain/114.4.1819; YOON SH, 1986, AM J CHINESE MED, V14, P179, DOI 10.1142/S0192415X86000296; Zaslawski CJ, 2003, COMPLEMENT THER MED, V11, P11, DOI 10.1016/S0965-2299(02)00116-4; Zhang SP, 2009, EVID BASED COMPLEMEN; Zhang WT, 2003, NEUROREPORT, V14, P1591, DOI 10.1097/00001756-200308260-00010; Zhang Y, 2012, BRIT J ANAESTH, V109, P245, DOI 10.1093/bja/aes136; Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004; Zhu XM, 2002, AM J CHINESE MED, V30, P13, DOI 10.1142/S0192415X02000028	146	28	29	0	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2014	9	12							e113731	10.1371/journal.pone.0113731	http://dx.doi.org/10.1371/journal.pone.0113731			40	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AW6JI	25502787	gold, Green Published			2023-01-03	WOS:000346375400014
J	Iunes, DH; Rocha, CBJ; Borges, NCS; Marcon, CO; Pereira, VM; Carvalho, LC				Iunes, Denise H.; Rocha, Carmelia B. J.; Borges, Nathalia C. S.; Marcon, Caroline O.; Pereira, Valeria M.; Carvalho, Leonardo C.			Self-Care Associated with Home Exercises in Patients with Type 2 Diabetes Mellitus	PLOS ONE			English	Article							FOOT; PREVENTION; MANAGEMENT; KINEMATICS; PATTERNS; GAIT	The objective of this study was to verify self-care guidelines together with lower limb home exercises alter ankle and foot plantar pressure and alignment in patient with Type 2 Diabetes Mellitus (DM) measuring health and sociodemographic factors. The health factors analyzed were sensitivity and circulation aspects, risk rating, and neuropathy symptom score, ankle and foot alignment (photogrammetry), plantar pressures, and postural stability (baropodometry) before and after administering these guidelines and home exercises in 97 patients type 2 DM during 10 months. The self-care guidelines and exercises changed the forefoot alignment (Right Foot - Initial vs Final, p=0.04; Left Foot, P<0.01), the center of the force displacement in the mediolateral (Right Foot - Initial versus Final, p=0.02; Left Foot, P<0.01), and the anterior-posterior (Right foot - Initial versus Final, p=0.01) direction, and body balance (Initial versus Final, p=0.02). There was no change in the remaining assessed parameters. Self-care associated with the guidelines for home exercises for the lower limbs in patients with type 2 DM are effective in maintaining and improving the alignment of the feet, mediolateral stability and prevention of complications.	[Iunes, Denise H.; Rocha, Carmelia B. J.; Borges, Nathalia C. S.; Marcon, Caroline O.; Carvalho, Leonardo C.] Univ Fed Alfenas, Alfenas, Brazil; [Pereira, Valeria M.] Hlth Municipal State Alfenas, Alfenas, Brazil	Universidade Federal de Alfenas	Iunes, DH (corresponding author), Univ Fed Alfenas, Alfenas, Brazil.	deniseiunes@unifal-mg.edu.br	Iunes, Denise Hollanda/AAF-6014-2019; carvalho, Leonardo LCC/E-4759-2015; Iunes, Denise H/K-6099-2017	Iunes, Denise Hollanda/0000-0003-1396-9980; carvalho, Leonardo LCC/0000-0001-8170-5819; Iunes, Denise H/0000-0003-1396-9980; Carvalho, Leonardo/0000-0001-6511-8315	Research Support Foundation of Minas Gerais [APQ - 01538-10, APQ 02794-11]	Research Support Foundation of Minas Gerais	This project was supported by a grant from the Research Support Foundation of Minas Gerais (APQ - 01538-10 and APQ 02794-11). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Am Diabetes Assoc, 2006, DIABETES CARE, V29, pS4; Bakker K, 2012, DIABETES-METAB RES, V28, P225, DOI 10.1002/dmrr.2253; Bargellini I, 2013, J VASC SURG, V57, P1204, DOI 10.1016/j.jvs.2012.10.104; Bonnet C, 2009, J MOTOR BEHAV, V41, P172, DOI 10.3200/JMBR.41.2.172-192; Chand G., 2012, CLINL QUERIES NEPHRO, V2, P144, DOI DOI 10.1016/S2211-9477(12)70009-2; Chao Y, 2013, COLLEGIAN IN PRESS; Chellan Gopi, 2012, Foot (Edinb), V22, P298, DOI 10.1016/j.foot.2012.08.007; Gurney JK, 2013, GAIT POSTURE, V37, P135, DOI 10.1016/j.gaitpost.2012.06.007; Hamill J., 2008, BIOMECHANICAL BASIS; International Diabetes Federation, 2005, GLOB GUID TYP 2 DIAB; Kapandji AI, 2010, PHYSL JOINTS LOWER L; Kimball Z, 2013, BURNS, V39, P279, DOI 10.1016/j.burns.2012.06.006; Kivlan Benjamin R, 2011, Foot (Edinb), V21, P84, DOI 10.1016/j.foot.2011.04.004; Lavery LA, 2007, DIABETES CARE, V30, P14, DOI 10.2337/dc06-1600; Medical Research Council, 1981, 45 MED RES COUNC; Moreira Rodrigo O., 2005, Arq Bras Endocrinol Metab, V49, P944, DOI 10.1590/S0004-27302005000600014; Nagase T, 2011, J PLAST RECONSTR AES, V64, P860, DOI 10.1016/j.bjps.2010.12.003; Pollock RD, 2004, DIABETES RES CLIN PR, V64, P117, DOI 10.1016/j.diabres.2003.10.014; Rocha RM, 2009, ACTA PAUL ENFERM, V22, P17, DOI 10.1590/S0103-21002009000100003; Rosenbaum D., 1994, GAIT POSTURE, V2, P191, DOI DOI 10.1016/0966-6362(94)90007-8); Sacco ICN, 2009, CLIN BIOMECH, V24, P687, DOI 10.1016/j.clinbiomech.2009.05.003; Sawacha Z, 2012, GAIT POSTURE, V36, P20, DOI 10.1016/j.gaitpost.2011.12.007; Sawacha Z, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-37; Sawacha Z, 2009, CLIN BIOMECH, V24, P722, DOI 10.1016/j.clinbiomech.2009.07.007; STAHELI LT, 1987, J BONE JOINT SURG AM, V69A, P426; Trombini-Souza Francis, 2009, Fisioter. Pesqui., V16, P205; Van Schie CHM, 2004, DIABETES CARE, V27, P1668, DOI 10.2337/diacare.27.7.1668; Vatankhah N, 2009, PRIM CARE DIABETES, V3, P73, DOI 10.1016/j.pcd.2009.05.003; YOUNG MJ, 1993, DIABETOLOGIA, V36, P150, DOI 10.1007/BF00400697	29	22	23	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 5	2014	9	12							e114151	10.1371/journal.pone.0114151	http://dx.doi.org/10.1371/journal.pone.0114151			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX4MS	25479542	Green Submitted, Green Published, gold			2023-01-03	WOS:000346907200046
J	Horwitz, LI; Partovian, C; Lin, ZQ; Grady, JN; Herrin, J; Conover, M; Montague, J; Dillaway, C; Bartczak, K; Suter, LG; Ross, JS; Bernheim, SM; Krumholz, HM; Drye, EE				Horwitz, Leora I.; Partovian, Chohreh; Lin, Zhenqiu; Grady, Jacqueline N.; Herrin, Jeph; Conover, Mitchell; Montague, Julia; Dillaway, Chloe; Bartczak, Kathleen; Suter, Lisa G.; Ross, Joseph S.; Bernheim, Susannah M.; Krumholz, Harlan M.; Drye, Elizabeth E.			Development and Use of an Administrative Claims Measure for Profiling Hospital-wide Performance on 30-Day Unplanned Readmission	ANNALS OF INTERNAL MEDICINE			English	Article							QUALITY-OF-CARE; STATISTICAL-METHODS; RATES; RISK; ADJUSTMENT; OUTCOMES; MODEL	Background: Existing publicly reported readmission measures are condition-specific, representing less than 20% of adult hospitalizations. An all-condition measure may better measure quality and promote innovation. Objective: To develop an all-condition, hospital-wide readmission measure. Design: Measure development study. Setting: 4821 U.S. hospitals. Patients: Medicare fee-for-service beneficiaries aged 65 years or older. Measurements: Hospital-level, risk-standardized unplanned readmissions within 30 days of discharge. The measure uses Medicare fee-for-service claims and is a composite of 5 specialty-based, risk-standardized rates for medicine, surgery/gynecology, cardiorespiratory, cardiovascular, and neurology cohorts. The 2007-2008 admissions were randomly split for development and validation. Models were adjusted for age, principal diagnosis, and comorbid conditions. Calibration in Medicare and all-payer data was examined, and hospital rankings in the development and validation samples were compared. Results: The development data set contained 8 018 949 admissions associated with 1 276 165 unplanned readmissions (15.9%). The median hospital risk-standardized unplanned readmission rate was 15.8 (range, 11.6 to 21.9). The 5 specialty cohort models accurately predicted readmission risk in both Medicare and all-payer data sets for average-risk patients but slightly overestimated readmission risk at the extremes. Overall hospital risk-standardized readmission rates did not differ statistically in the split samples (P = 0.71 for difference in rank), and 76% of hospitals' validation-set rankings were within 2 deciles of the development rank (24% were more than 2 deciles). Of hospitals ranking in the top or bottom deciles, 90% remained within 2 deciles (10% were more than 2 deciles) and 82% remained within 1 decile (18% were more than 1 decile). Limitation: Risk adjustment was limited to that available in claims data. Conclusion: A claims-based, hospital-wide unplanned readmission measure for profiling hospitals produced reasonably consistent results in different data sets and was similarly calibrated in both Medicare and all-payer data.	[Ross, Joseph S.] Yale Univ, Sch Med, Dept Internal Med, Gen Internal Med Sect, New Haven, CT 06520 USA; [Partovian, Chohreh; Lin, Zhenqiu; Grady, Jacqueline N.; Montague, Julia; Suter, Lisa G.; Bernheim, Susannah M.; Krumholz, Harlan M.; Drye, Elizabeth E.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06510 USA; Hlth Res & Educ Trust, Chicago, IL USA	Yale University; Yale University	Horwitz, LI (corresponding author), NYU, Sch Med, Dept Populat Hlth, 550 First Ave,TRB Room 607, New York, NY 10016 USA.	leora.horwitz@nyumc.org	, Harlan/AAI-2875-2020; Horwitz, Leora/ABD-1292-2020; Horwitz, Leora/A-6959-2009	Horwitz, Leora/0000-0003-1800-6040; Ross, Joseph/0000-0002-9218-3320; Conover, Mitchell/0000-0001-5682-3688	Centers for Medicare & Medicaid Services; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL105270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG032886, P30AG021342, K08AG038336] Funding Source: NIH RePORTER	Centers for Medicare & Medicaid Services; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Centers for Medicare & Medicaid Services.	Amarasingham R, 2010, MED CARE, V48, P981, DOI 10.1097/MLR.0b013e3181ef60d9; Anderson GM, 2014, HOSP ESCORECARD REPO; Appleby J, 2010, KAISER HLTH NEW 0707; Ash AS, 2012, STAT ISSUES ASSESSIN; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Bradley EH, 2012, J AM COLL CARDIOL, V60, P607, DOI 10.1016/j.jacc.2012.03.067; Canadian Broadcasting Corporation, 2013, RAT MY HOSP; Centers for Medicare & Medicaid Services, 2014, HOSP WID READM VERB; CHAMBERS M, 1990, BRIT MED J, V301, P1134, DOI 10.1136/bmj.301.6761.1134; Coleman EA, 2006, ARCH INTERN MED, V166, P1822, DOI 10.1001/archinte.166.17.1822; DESHARNAIS S, 1991, EVAL HEALTH PROF, V14, P228, DOI 10.1177/016327879101400206; DESHARNAIS S, 1991, HEALTH SERV RES, V26, P425; FLEMING PJ, 1986, COMMUN ACM, V29, P218, DOI 10.1145/5666.5673; Food and Drug Administration, 2012, FED REGISTER, V77, P2012; Goldfield NI, 2008, HEALTH CARE FINANC R, V30, P75; Grosso LM, 2014, HOSP LEVEL 30 DAY AL; Halfon P, 2006, MED CARE, V44, P972, DOI 10.1097/01.mlr.0000228002.43688.c2; Harrell Frank E., 2001, REGRESSION MODELING; He YL, 2014, STAT MED, V33, P1081, DOI 10.1002/sim.6012; Healthcare Cost and Utilization Project (HCUP), 2006, HCUP CLIN CLASS SOFT; Horwitz L., HOSP WIDE ALL CAUSE; Horwitz LI, 2013, JAMA INTERN MED, V173, P1715, DOI 10.1001/jamainternmed.2013.9318; Horwitz LI, 2013, J HOSP MED, V8, P436, DOI 10.1002/jhm.2021; Jack BW, 2009, ANN INTERN MED, V150, P178, DOI 10.7326/0003-4819-150-3-200902030-00007; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Keenan PS, 2008, CIRC-CARDIOVASC QUAL, V1, P29, DOI 10.1161/CIRCOUTCOMES.108.802686; Krumholz H, 2014, HOSP 30 DAY HEART FA; Krumholz H, 2014, HOSP 30 DAY PNEUMONI; Krumholz HM, 2013, NEW ENGL J MED, V368, P100, DOI 10.1056/NEJMp1212324; Krumholz HM, 2011, CIRC-CARDIOVASC QUAL, V4, P243, DOI 10.1161/CIRCOUTCOMES.110.957498; Krumholz HM, 2006, CIRCULATION, V113, P456, DOI 10.1161/CIRCULATIONAHA.105.170769; Krumholz HM., HOSP 30 DAY AMI READ; Lindenauer PK, 2011, J HOSP MED, V6, P142, DOI 10.1002/jhm.890; Mukamel DB, 1998, MED CARE, V36, P945, DOI 10.1097/00005650-199807000-00002; National Committee for Quality Assurance, 2013, PLAN ALL CAUS READM; National Quality Forum, NAT VOL CONS STAND P; National Quality Forum, MEAS EV CRIT; Naylor MD, 1999, JAMA-J AM MED ASSOC, V281, P613, DOI 10.1001/jama.281.7.613; Normand SLT, 2007, HEALTH SERV OUTCOME, V7, P79, DOI 10.1007/s10742-006-0018-8; Normand SLT, 1997, J AM STAT ASSOC, V92, P803, DOI 10.2307/2965545; Pope GC, 2004, HEALTH CARE FINANC R, V25, P119; UnitedHealthcare, 2013, RISK ADJ 30 DAY ALL; van Walraven C, 2012, J EVAL CLIN PRACT, V18, P1211, DOI 10.1111/j.1365-2753.2011.01773.x; Wal-Mart, 2010, KAISER HLTH NEW 1012; Wennberg JE, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f549; WILCOXON F, 1946, J ECON ENTOMOL, V39, P269, DOI 10.1093/jee/39.2.269; Wray NP, 1997, MED CARE, V35, P768, DOI 10.1097/00005650-199708000-00003; Ziaeian B, 2012, J GEN INTERN MED, V27, P1513, DOI 10.1007/s11606-012-2168-4	48	64	67	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 18	2014	161	10		S			S66	S75		10.7326/M13-3000	http://dx.doi.org/10.7326/M13-3000			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CW3RR	25402406	Green Accepted			2023-01-03	WOS:000364909900010
J	Casagrande, JC; Macorini, LFB; Antunes, KA; dos Santos, UP; Campos, JF; Dias, JM; Sangalli, A; Cardoso, CAL; Vieira, MD; Rabelo, LA; Paredes-Gamero, EJ; dos Santos, EL; Souza, KD				Casagrande, Junior Cesar; Benitez Macorini, Luis Fernando; Antunes, Katia Avila; dos Santos, Uilson Pereira; Campos, Jaqueline Ferreira; Dias-Junior, Nelson Miguel; Sangalli, Andreia; Lima Cardoso, Claudia Andrea; Vieira, Maria do Carmo; Rabelo, Luiza Antas; Paredes-Gamero, Edgar Julian; dos Santos, Edson Lucas; Souza, Kely de Picoli			Antioxidant and Cytotoxic Activity of Hydroethanolic Extract from Jacaranda decurrens Leaves	PLOS ONE			English	Article							OXIDATIVE DAMAGE; CELL-DEATH; LIPID-PEROXIDATION; URSOLIC ACID; FLAVONOIDS; MEMBRANE; PROPOLIS; TUMOR	Background and Purpose: Leaves of Jacaranda decurrens are used in traditional Brazilian medicine to treat metabolic diseases related to increased reactive oxygen species. The present study evaluated the antioxidant and cytotoxic potential of hydroethanolic extract from the leaves of Jacaranda decurrens subsp. symmetrifoliolata. Experimental Approach: Phenolic compounds, flavonoids and saponins were evaluated in an ethanol: water (80: 20, v/v) extract from the leaves of Jacaranda decurrens subsp. symmetrifoliolata (E-Jds). The antioxidant activity of E-Jds was investigated by assessing the following: 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical scavenging activity; protection against 2,2'-azobis (2-amidinopropane) dihydrochloride (AAPH)-induced hemolysis of erythrocytes; in vitro and in vivo malondialdehyde dosage; and the ability to activate antioxidant enzymes. K562 leukemia cells were used for the cytotoxic evaluation of E-Jds and for the assessment of the cell death profile through flow cytometry. Key Results: Phenolic and flavonoid compounds were quantified as 14.38% and 2.15%, respectively, of E-Jds. These phenolic and flavonoid compounds proved to be able to scavenge DPPH free radicals with an IC50 of 9.3 +/- 3.3 mu g/mL, to protect up to 50% of erythrocytes against AAPH-induced hemolysis and to reduce in vitro and in vivo malondialdehyde levels up to 84% and 22%, respectively. E-Jds also increased glutathione peroxidase enzyme activity, with a concomitant decrease in superoxide dismutase and catalase activity, and exhibited dose-dependent cytotoxic activity on K562 erythroleukemia cells with cell death occurring via both late apoptosis and necrosis. Conclusions: E-Jds exhibits in vitro and in vivo antioxidant potential, which may be the mechanism mediating the metabolic activities reported in folk medicine. Furthermore, the cytotoxic activity identified in this study contributes with the knowledge of antiproliferative activities that have been described in the literature for the genus Jacaranda.	[Casagrande, Junior Cesar; Benitez Macorini, Luis Fernando; Antunes, Katia Avila; dos Santos, Uilson Pereira; Campos, Jaqueline Ferreira; Sangalli, Andreia; Vieira, Maria do Carmo; dos Santos, Edson Lucas; Souza, Kely de Picoli] Fed Univ Grande Dourados, Dourados, MS, Brazil; [Lima Cardoso, Claudia Andrea] Univ Estadual Mato Grosso do Sul, Dourados, MS, Brazil; [Dias-Junior, Nelson Miguel; Rabelo, Luiza Antas] Univ Fed Alagoas, Maceio, Alagoas, Brazil; [Paredes-Gamero, Edgar Julian] Univ Fed Sao Paulo, Sao Paulo, Brazil	Universidade Federal da Grande Dourados; Universidade Estadual de Mato Grosso do Sul; Universidade Federal de Alagoas; Universidade Federal de Sao Paulo (UNIFESP)	Souza, KD (corresponding author), Fed Univ Grande Dourados, Dourados, MS, Brazil.	kelypicoli@gmail.com	Santos, Edson/C-6820-2014; dos Santos, Edson Lucas/AAU-5857-2020; Cardoso, Claudia Andrea Lima/AAK-5578-2020; de Picoli Souza, Kely/I-1248-2015; Dias-Júnior, Nelson Miguel/AAG-9506-2021; Paredes-Gamero, Edgar J/C-4791-2012; Vieira, Maria do Carmo MCV/D-4860-2016; de Picoli Souza, Kely/AAU-5978-2020; Rabêlo, Luiza A./S-4050-2019	Santos, Edson/0000-0002-6557-7914; dos Santos, Edson Lucas/0000-0002-6557-7914; Cardoso, Claudia Andrea Lima/0000-0002-4907-0056; de Picoli Souza, Kely/0000-0001-5764-2125; Paredes-Gamero, Edgar J/0000-0003-3686-8402; de Picoli Souza, Kely/0000-0001-5764-2125; Ferreira Campos, Jaqueline/0000-0002-4981-238X	Fundacao de Apoio ao Desenvolvimento do Ensino; Ciencia e Tecnologia do Mato Grosso do Sul (FUNDECT); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (Capes)	Fundacao de Apoio ao Desenvolvimento do Ensino; Ciencia e Tecnologia do Mato Grosso do Sul (FUNDECT); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (Capes)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	This work was supported by grants of the Fundacao de Apoio ao Desenvolvimento do Ensino, Ciencia e Tecnologia do Mato Grosso do Sul (FUNDECT), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (Capes). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. ELS, CALC and MCV are CNPq research productivity fellows.	Abdollahzad H, 2009, INT J VITAM NUTR RES, V79, P281, DOI 10.1024/0300-9831.79.56.281; Ashokkumar P, 2008, BIOMED PHARMACOTHER, V62, P590, DOI 10.1016/j.biopha.2008.06.031; de Almeida MRA, 2013, PAK J PHARM SCI, V26, P881; Blatt CTT, 1998, PLANT SYST EVOL, V210, P289, DOI 10.1007/BF00985673; Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615; Campos JF, 2014, FOOD CHEM TOXICOL, V65, P374, DOI 10.1016/j.fct.2014.01.008; Chaabane F, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-153; Chiste RC, 2014, LIFE SCI, V99, P52, DOI 10.1016/j.lfs.2014.01.059; Bieski IGC, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/272749; Croft KD, 1998, ANN NY ACAD SCI, V854, P435, DOI 10.1111/j.1749-6632.1998.tb09922.x; Day BJ, 2009, BIOCHEM PHARMACOL, V77, P285, DOI 10.1016/j.bcp.2008.09.029; de Carvalho CA, 2009, REV BRAS FARMACOGN, V19, P592, DOI 10.1590/S0102-695X2009000400015; De Martino L, 2012, INT J MOL SCI, V13, P5406, DOI 10.3390/ijms13055406; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Gasmi J, 2013, PHYTOMEDICINE, V20, P734, DOI 10.1016/j.phymed.2013.01.012; Ginsburg I, 2011, ARCH BIOCHEM BIOPHYS, V506, P12, DOI 10.1016/j.abb.2010.11.009; Gu Y, 2012, BIOCHEM PHARMACOL, V84, P468, DOI 10.1016/j.bcp.2012.06.002; Gupta D, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-13; Haider L, 2011, BRAIN, V134, P1914, DOI 10.1093/brain/awr128; Halliwell B, 2004, BRIT J PHARMACOL, V142, P231, DOI 10.1038/sj.bjp.0705776; Iqbal Jamshed, 2012, ISRN Pharmacol, V2012, P563267, DOI 10.5402/2012/563267; Jo Y, 2005, ARCH PHARM RES, V28, P885, DOI 10.1007/BF02973871; Johansen JS, 2005, CARDIOVASC DIABETOL, V4, DOI 10.1186/1475-2840-4-5; Katiyar SK, 2001, CARCINOGENESIS, V22, P287, DOI 10.1093/carcin/22.2.287; Kazi A, 2003, INT J MOL MED, V12, P879; Kuliaviene I, 2013, WORLD J GASTROENTERO, V19, P5678, DOI 10.3748/wjg.v19.i34.5678; Lee WL, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/925804; Liberio SA, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-108; Lu J, 2007, BIOCHEM PHARMACOL, V74, P1078, DOI 10.1016/j.bcp.2007.07.007; Mailloux RJ, 2014, REDOX BIOL, V2, P123, DOI 10.1016/j.redox.2013.12.011; Massaoka MH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038698; Meda A, 2005, FOOD CHEM, V91, P571, DOI 10.1016/j.foodchem.2004.10.006; Moraes VWR, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.190; Nyska A, 2002, TOXICOL PATHOL, V30, P620, DOI 10.1080/01926230290166724; OGURA M, 1977, LLOYDIA, V40, P157; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; Paredes-Gamero EJ, 2012, BBA-GEN SUBJECTS, V1820, P1062, DOI 10.1016/j.bbagen.2012.02.015; Pietta PG, 2000, J NAT PROD, V63, P1035, DOI 10.1021/np9904509; Martucci MEP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093149; Rana A, 2013, NAT PROD RES, V27, P1167, DOI 10.1080/14786419.2012.717290; Rao CV, 2012, CURR DRUG TARGETS, V13, P1820; Sharif T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032526; Valente MJ, 2011, FOOD CHEM TOXICOL, V49, P86, DOI 10.1016/j.fct.2010.10.001; VARANDA EM, 1992, J NAT PROD, V55, P800, DOI 10.1021/np50084a015; Wang Y, 2013, NUTRIENTS, V5, P2969, DOI 10.3390/nu5082969; Xu P, 2008, HYPERTENSION, V51, P574, DOI 10.1161/HYPERTENSIONAHA.107.102764; Yamasaki M, 2013, J OLEO SCI, V62, P925, DOI 10.5650/jos.62.925; Yin MC, 2007, J AGR FOOD CHEM, V55, P7177, DOI 10.1021/jf071242m	49	14	14	0	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 17	2014	9	11							e112748	10.1371/journal.pone.0112748	http://dx.doi.org/10.1371/journal.pone.0112748			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT8BL	25402205	gold, Green Published, Green Submitted			2023-01-03	WOS:000345158700067
J	Knaul, FM; Farmer, PE; Bhadelia, A; Berman, P; Horton, R				Knaul, Felicia M.; Farmer, Paul E.; Bhadelia, Afsan; Berman, Philippa; Horton, Richard			Closing the divide: the Harvard Global Equity Initiative-Lancet Commission on global access to pain control and palliative care	LANCET			English	Editorial Material									[Knaul, Felicia M.; Bhadelia, Afsan] Harvard Global Equ Initiat, Boston, MA 02115 USA; [Farmer, Paul E.] Harvard Univ, Sch Med, Boston, MA USA; [Berman, Philippa; Horton, Richard] The Lancet, London, England	Harvard University; Harvard Medical School	Knaul, FM (corresponding author), Harvard Global Equ Initiat, Boston, MA 02115 USA.	felicia_knaul@harvard.edu		Knaul, Felicia/0000-0002-0512-4788				Beaglehole R, 2011, LANCET, V377, P1438, DOI 10.1016/S0140-6736(11)60393-0; Callahan D., 2002, THICAL DIMENSIONS HL, P3; Cohen J., 2012, APPLYING PUBLIC HLTH, P3, DOI [10.1093/acprof:oso/9780199599400.003.0010, DOI 10.1093/ACPROF:OSO/9780199599400.003.0010]; de Lima L., LEY NACL CUIDADOS PA; European Association of Palliative Care, 2014, ALB PASS 1 PALL CAR; Gawande A., 2014, MED WHAT MATTERS END; Harvard Global Equity Initiative, HGEI LANC COMM GLOB; Human Rights Watch, 2009, PLEAS DO NOT MAK US; International Association for Hospice and Palliative Care, VIS AND MISS; Jamison DT, 2013, LANCET, V382, P1898, DOI 10.1016/S0140-6736(13)62105-4; Kmietowicz Z., 2014, BMJ-BRIT MED J, V348, pg1744; Knaul FM, 2012, CLOSING CANC DIVIDE, P96; Knaul FM., 2012, CLOSING CANC DIVIDE, P29; Krakauer EL, 2007, ETHNOG STUD SUBJ, V7, P381; Krakauer EL, 2008, J PAIN SYMPTOM MANAG, V36, P505, DOI 10.1016/j.jpainsymman.2007.11.015; Liberman J, 2010, LANCET, V376, P856, DOI 10.1016/S0140-6736(10)60880-X; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Knaul FM, 2012, LANCET, V380, P1259, DOI 10.1016/S0140-6736(12)61068-X; Merriman Anne, 2010, Philos Ethics Humanit Med, V5, P10, DOI 10.1186/1747-5341-5-10; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; Ntizimira C., 2014, INTEGRATION PALLIATI; Pastrana T, 2014, PALLIATIVE MED, V28, P1; Paudel BD, 2015, J PAIN SYMPTOM MANAG, V49, P111, DOI 10.1016/j.jpainsymman.2014.02.011; Powell RA, 2015, LANCET ONCOL, V16, P131, DOI 10.1016/S1470-2045(15)70002-1; Secretaria de gobernacio: Diario Oficial De La Federacion, DIARIO OFICIAL FEDER; Sepulveda J, 2006, LANCET, V368, P2017, DOI 10.1016/S0140-6736(06)69569-X; Steedman MR, 2014, HEALTH AFFAIR, V33, P1612, DOI 10.1377/hlthaff.2014.0379; Worldwide Palliative Care Alliance World Health Organization, 2014, GLOB ATL PALL CAR EN	28	39	40	2	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 22	2015	386	9995					722	724		10.1016/S0140-6736(15)60289-6	http://dx.doi.org/10.1016/S0140-6736(15)60289-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CQ0LR	25762055	Bronze			2023-01-03	WOS:000360287900008
J	Casasnovas, O; Coiffier, B				Casasnovas, Olivier; Coiffier, Bertrand			Hodgkin's lymphoma: better outcomes with fewer drugs?	LANCET			English	Editorial Material							TRIAL; ABVD		[Casasnovas, Olivier] CHU Dijon, Hematol Clin, Dijon, France; [Coiffier, Bertrand] Ctr Hosp Lyon Sud, Hosp Civils Lyon, Hematol Clin, F-69310 Pierre Benite, France	CHU Dijon Bourgogne; CHU Lyon	Coiffier, B (corresponding author), Ctr Hosp Lyon Sud, Hosp Civils Lyon, Hematol Clin, F-69310 Pierre Benite, France.	bertrand.coiffier@univ-lyon1.fr		Casasnovas, Rene-Olivier/0000-0002-1156-8983				Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087; Behringer K, 2015, LANCET, V385, P1418, DOI 10.1016/S0140-6736(14)61469-0; BONADONNA G, 1975, CANCER, V36, P252, DOI 10.1002/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7; Eghbali H, 2005, BLOOD, V106, p240A; Engert A, 2010, NEW ENGL J MED, V363, P640, DOI 10.1056/NEJMoa1000067; Federico M, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.8507; Meyer RM, 2012, NEW ENGL J MED, V366, P399, DOI 10.1056/NEJMoa1111961; Radford J, 2012, BLOOD, V120, P547, DOI 10.1182/blood.V120.21.547.547; Raemaekers JMM, 2014, J CLIN ONCOL, V32, P1188, DOI 10.1200/JCO.2013.51.9298; Viviani S, 2011, NEW ENGL J MED, V365, P203, DOI 10.1056/NEJMoa1100340; von Tresckow B, 2012, J CLIN ONCOL, V30, P907, DOI 10.1200/JCO.2011.38.5807	11	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 11	2015	385	9976					1371	+		10.1016/S0140-6736(14)61701-3	http://dx.doi.org/10.1016/S0140-6736(14)61701-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CF7EU	25539731				2023-01-03	WOS:000352719800007
J	Pauwels, K; Simoens, S; Casteels, M; Huys, I				Pauwels, Kim; Simoens, Steven; Casteels, Minne; Huys, Isabelle			Insights into European Drug Shortages: A Survey of Hospital Pharmacists	PLOS ONE			English	Article							NATIONAL-SURVEY; UNITED-STATES; PHARMACEUTICALS; STRATEGIES; IMPACT; CARE	Drug shortages are a complex and global phenomenon. When a drug cannot be delivered at the moment of patient demand, every stakeholder in the health care system is affected. The aim of this study was to investigate the characteristics, clinical impact, financial impact and management of drug shortages in European hospital pharmacies and identify opportunities for prevention and mitigation of drug shortages in Europe. An online survey was designed based on a review of the literature and interviews and was sent to subscribers of Hospital Pharmacy Europe between June and September 2013. Forty-five percent of respondents (n = 161) indicated that life sustaining or life preserving drugs such as oncology drugs were affected by drug shortages. More than 30% of respondents indicated that drug shortages in Europe were always or often associated with increased costs for hospitals, increased personnel costs and more expensive alternative drugs (n = 161). On the question when information about a drug shortage was obtained, 42% of respondents answered that information from the pharmaceutical company was obtained at the time of no delivery, 50% indicated that information from the wholesaler was obtained at the time of no delivery, while 40% of respondents indicated that information was never or rarely received from the government (n = 161). Fifty seven percent of respondents strongly agreed that an obligation to the producer to notify further shortages could help to solve the problem (n = 161). These results showed that pharmaceutical companies and wholesalers are already involved in the management of drug shortages, while a role is still reserved for the government. Mandatory notification in advance and centralized information can help to reduce workload for hospital pharmacists, will allow early anticipation of drug shortages and will facilitate mitigation of the clinical impact on patients.	[Pauwels, Kim; Simoens, Steven; Casteels, Minne; Huys, Isabelle] Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, B-3000 Leuven, Belgium	KU Leuven	Pauwels, K (corresponding author), Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, B-3000 Leuven, Belgium.	Kim.Pauwels@pharm.kuleuven.be	Huys, Isabelle/M-8673-2016	Simoens, Steven/0000-0002-9512-2005	Agency for Innovation by Science and Technology; Research Foundation Flanders; TEVA	Agency for Innovation by Science and Technology; Research Foundation Flanders(FWO); TEVA(Teva Pharmaceutical Industries)	KP is funded by the Agency for Innovation by Science and Technology (http://www.iwt.be/english/welcome). The study is included in a project supported by Research Foundation Flanders (http://www.fwo.be/en/). The study is included in a project supported by TEVA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alspach JG, 2012, CRIT CARE NURSE, V32, P11, DOI 10.4037/ccn2012818; American Hospital Association, 2011, AHA SURV DRUG SHORT; [Anonymous], 2013, COMP MACR GEOGR CONT; Bart TN, 2008, VALUE HEALTH, V11, P996, DOI 10.1111/j.1524-4733.2008.00339.x; Birgli ag, 2013, EV MED SHORT EUR MOR; Capstick TGD, 2011, INT J TUBERC LUNG D, V15, P754, DOI 10.5588/ijtld.10.0568; Chabner BA, 2011, NEW ENGL J MED, V365, P2147, DOI 10.1056/NEJMp1112633; Cherici C, 2013, NAVIGATING DRUG SHOR; Dal MF, 2013, PREV MED, V57, P146; Dylst P, 2011, HEALTH POLICY, V101, P146, DOI 10.1016/j.healthpol.2011.03.004; European Association of Hospital Pharmacists, 2013, MED SHORT EUR HOSP; European Association of Pharmaceutical Full-line Wholesalers, 2012, MED SHORT EUR THEIR; European Generic medicines Association (EGA), 2013, EGA POS PAP TEND UNS; Gatesman ML, 2011, NEW ENGL J MED, V365, P1653, DOI 10.1056/NEJMp1109772; Generics and Biosimilarrs Initiative, 2012, UK DRUG SHORT AR FAR; Generics and Biosimilarrs Initiative, 2012, APPG REP DRUG SHORT; Generics and Biosimilarrs Initiative, 2011, BIOS CANC DRUG SHORT; Generics and Biosimilarrs Initiative, 2012, DRUG SHORT WOES CONT; Gray A, 2012, B WORLD HEALTH ORGAN, V154-154A; Hall R, 2013, CAN J ANESTH, V60, P539, DOI 10.1007/s12630-013-9920-z; IHS Healthcare and Pharma Blog, 2013, DRUG SHORT RES PRIC; IHS Healthcare and Pharma Blog, 2012, PAR EXP LEAD DRUG SH; IHS Healthcare and Pharma Blog, 2012, COST CONT POL IMP DR; IMS institute, 2011, DRUG SHORT CLOS LOOK; Institute for Safe Medication Practices, 2010, DRUG SHORT NAT SURV; ISPE, 2013, REP ISPE DRUG SHORT; Kaakeh R, 2011, AM J HEALTH-SYST PH, V68, P1811, DOI 10.2146/ajhp110210; Mayer DK, 2012, CLIN J ONCOL NURS, V16, P107, DOI 10.1188/12.CJON.107-108; McBride A, 2013, AM J HEALTH-SYST PH, V70, P609, DOI 10.2146/ajhp120563; Morrissey John, 2012, Hosp Health Netw, V86, P46; Pharmaceutical Service Negotiating Committee (PSNC), 2013, BRAND MED SHORT; Rider Anne Elise, 2013, J Pharm Pract, V26, P183, DOI 10.1177/0897190013482332; Tirelli U, 2012, EUR REV MED PHARMACO, V16, P138; Ventola C Lee, 2011, P T, V36, P740; Woodcock J, 2013, CLIN PHARMACOL THER, V93, P170, DOI 10.1038/clpt.2012.220	35	58	61	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 16	2015	10	3							e0119322	10.1371/journal.pone.0119322	http://dx.doi.org/10.1371/journal.pone.0119322			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CD6EY	25775406	Green Accepted, Green Published, Green Submitted, gold			2023-01-03	WOS:000351183500082
J	Czarniak, P; Bint, L; Favie, L; Parsons, R; Hughes, J; Sunderland, B				Czarniak, Petra; Bint, Lewis; Favie, Laurent; Parsons, Richard; Hughes, Jeff; Sunderland, Bruce			Clinical Setting Influences Off-Label and Unlicensed Prescribing in a Paediatric Teaching Hospital	PLOS ONE			English	Article							INTENSIVE-CARE UNIT; DRUG-USE; MEDICATION USE; CHILDREN; MEDICINES; WARDS; FINLAND	Purpose To estimate the prevalence of off-label and unlicensed prescribing during 2008 at a major paediatric teaching hospital in Western Australia. Methods A 12-month retrospective study was conducted at Princess Margaret Hospital using medication chart records randomly selected from 145,550 patient encounters from the Emergency Department, Inpatient Wards and Outpatient Clinics. Patient and prescribing data were collected. Drugs were classified as off-label or unlicensed based on Australian registration data. A hierarchical system of age, indication, route of administration and dosage was used. Drugs were classified according to the Anatomical Therapeutic Chemical Code. Results A total of 1,037 paediatric patients were selected where 2,654 prescriptions for 330 different drugs were prescribed to 699 patients (67.4%). Most off-label drugs (n = 295; 43.3%) were from the nervous system; a majority of unlicensed drugs were systemic hormonal preparations excluding sex hormones (n = 22, 32.4%). Inpatients were prescribed more off-label drugs than outpatients or Emergency Department patients (p < 0.0001). Most off-label prescribing occurred in infants and children (31.7% and 35.9% respectively) and the highest percentage of unlicensed prescribing (7.2%) occurred in infants (p < 0.0001). There were 25.7% of off-label and 2.6% of unlicensed medications prescribed across all three settings. Common reasons for off-label prescribing were dosage (47.4%) and age (43.2%). Conclusion This study confirmed off-label and unlicensed use of drugs remains common. Further, that prevalence of both is influenced by the clinical setting, which has implications in regards to medication misadventure, and the need to have systems in place to minimise medication errors. Further, there remains a need for changes in the regulatory system in Australia to ensure that manufacturers incorporate, as it becomes available, evidence regarding efficacy and safety of their drugs in children in the official product information.	[Czarniak, Petra; Parsons, Richard; Hughes, Jeff; Sunderland, Bruce] Curtin Univ, Bentley, WA, Australia; [Bint, Lewis] Princess Margaret Hosp, Subiaco, WA, Australia; [Favie, Laurent] Univ Utrecht, Dept Pharmaceut Sci, NL-3508 TC Utrecht, Netherlands	Curtin University; Utrecht University	Czarniak, P (corresponding author), Curtin Univ, Bentley, WA, Australia.	P.Czarniak@curtin.edu.au						AMH Children's Dosing Companion, 2013, AMH CHILDR DOS COMP; [Anonymous], 2008, THER GOODS ADM PROD; Avenel S, 2000, ARCH PEDIATRIE, V7, P143, DOI 10.1016/S0929-693X(00)88083-5; Bajcetic M, 2005, EUR J CLIN PHARMACOL, V61, P775, DOI 10.1007/s00228-005-0981-y; Ballard CDJ, 2013, J PAEDIATR CHILD H, V49, P38, DOI 10.1111/jpc.12065; Barr J, 2002, AM J PERINAT, V19, P67, DOI 10.1055/s-2002-23557; Conroy S, 2003, ANN ONCOL, V14, P42, DOI 10.1093/annonc/mdg031; Conroy S, 1999, ARCH DIS CHILD-FETAL, V80, pF142, DOI 10.1136/fn.80.2.F142; Conroy S, 2001, PAEDIATR ANAESTH, V11, P431, DOI 10.1046/j.1460-9592.2001.00697.x; Conroy S, 2000, BRIT MED J, V320, P79, DOI 10.1136/bmj.320.7227.79; Craig J S, 2001, Ir Med J, V94, P237; Di Paolo Ermindo R, 2006, Swiss Med Wkly, V136, P218; European Medicines Agency, 2001, ICH TOP E11 CLIN INV; Gavrilov V, 2000, ISRAEL MED ASSOC J, V2, P595; Hsien L, 2008, PHARM WORLD SCI, V30, P497, DOI 10.1007/s11096-008-9193-8; LEE JHW, 2013, J HYDRO ENVIRON RES, V0007; Lindell-Osuagwu L, 2014, J CLIN PHARM THER, V39, P144, DOI 10.1111/jcpt.12119; Lindell-Osuagwu L, 2009, J CLIN PHARM THER, V34, P277, DOI 10.1111/j.1365-2710.2008.01005.x; McKinzie JP, 1997, AM J EMERG MED, V15, P118, DOI 10.1016/S0735-6757(97)90079-6; MIMS Australia, 2008, MONTHL IND MED SPEC; Neubert A, 2004, DRUG SAFETY, V27, P1059, DOI 10.2165/00002018-200427130-00006; O'Donnell CPF, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.5.e52; Palcevski G, 2012, EUR J CLIN PHARMACOL, V68, P1073, DOI 10.1007/s00228-012-1221-x; Ribeiro M, 2012, I CONF SENS TECHNOL, P1, DOI 10.1109/ICSensT.2012.6461670; Santos DB, 2008, EUR J CLIN PHARMACOL, V64, P1111, DOI 10.1007/s00228-008-0543-1; Sinha Y, 2007, J PAEDIATR CHILD H, V43, P107, DOI 10.1111/j.1440-1754.2007.00970.x; 't Jong GW, 2002, EUR J CLIN PHARMACOL, V58, P293, DOI 10.1007/s00228-002-0479-9; 't Jong GW, 2001, PEDIATRICS, V108, P1089, DOI 10.1542/peds.108.5.1089; Turner S, 1996, LANCET, V347, P549, DOI 10.1016/S0140-6736(96)91182-4; Turner Sean, 1999, Australian Journal of Hospital Pharmacy, V29, P265; Zanon D, 2012, EUROPEAN J PEDIAT, P1	31	21	21	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 10	2015	10	3							e0120630	10.1371/journal.pone.0120630	http://dx.doi.org/10.1371/journal.pone.0120630			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CD7MX	25756896	Green Published, gold			2023-01-03	WOS:000351275700070
J	Sutherland, JJ; Daly, TM; Liu, X; Goldstein, K; Johnston, JA; Ryan, TP				Sutherland, Jeffrey J.; Daly, Thomas M.; Liu, Xiong; Goldstein, Keith; Johnston, Joseph A.; Ryan, Timothy P.			Co-Prescription Trends in a Large Cohort of Subjects Predict Substantial Drug-Drug Interactions	PLOS ONE			English	Article							GENERAL-PRACTICE; ANTIDEPRESSANTS; INHIBITOR; EVENTS; ALERTS; ENZYME; CARE	Pharmaceutical prescribing and drug-drug interaction data underlie recommendations on drug combinations that should be avoided or closely monitored by prescribers. Because the number of patients taking multiple medications is increasing, a comprehensive view of prescribing patterns in patients is important to better assess real world pharmaceutical response and evaluate the potential for multi-drug interactions. We obtained self-reported prescription data from NHANES surveys between 1999 and 2010, and confirm the previously reported finding of increasing drug use in the elderly. We studied co-prescription drug trends by focusing on the 2009-2010 survey, which contains prescription data on 690 drugs used by 10,537 subjects. We found that medication profiles were unique for individuals aged 65 years or more, with >= 98 unique drug regimens encountered per 100 subjects taking 3 or more medications. When drugs were viewed by therapeutic class, it was found that the most commonly prescribed drugs were not the most commonly co-prescribed drugs for any of the 16 drug classes investigated. We cross-referenced these medication lists with drug interaction data from Drugs.com to evaluate the potential for drug interactions. The number of drug alerts rose proportionally with the number of co-prescribed medications, rising from 3.3 alerts for individuals prescribed 5 medications to 11.7 alerts for individuals prescribed 10 medications. We found 22% of elderly subjects taking both a substrate and inhibitor of a given cytochrome P450 enzyme, and 4% taking multiple inhibitors of the same enzyme simultaneously. By examining drug pairs prescribed in 0.1% of the population or more, we found low agreement between co-prescription rate and co-discussion in the literature. These data show that prescribing trends in treatment could drive a large extent of individual variability in drug response, and that current pairwise approaches to assessing drug-drug interactions may be inadequate for predicting real world outcomes.	[Sutherland, Jeffrey J.; Liu, Xiong] Eli Lilly & Co, Lilly Res Labs IT, Indianapolis, IN 46285 USA; [Daly, Thomas M.] Cleveland Clin, Pathol & Lab Med Inst, Cleveland, OH 44106 USA; [Goldstein, Keith] Eli Lilly & Co, Drug Disposit & Toxicol, Indianapolis, IN 46285 USA; [Johnston, Joseph A.] Eli Lilly & Co, Global Patient Outcomes & Real World Evidence, Indianapolis, IN 46285 USA; [Ryan, Timothy P.] Sano Informed Prescribing, Brentwood, TN USA	Eli Lilly; Cleveland Clinic Foundation; Eli Lilly; Eli Lilly	Sutherland, JJ (corresponding author), Eli Lilly & Co, Lilly Res Labs IT, Indianapolis, IN 46285 USA.	sutherlandje@lilly.com; tim@thinksano.com	Liu, Xiong/O-3480-2019	Liu, Xiong/0000-0003-4522-7228; Johnston, Joseph/0000-0003-3913-9256	Eli Lilly; Sano	Eli Lilly(Eli Lilly); Sano	Eli Lilly and Sano Informed Prescribing provided support in the form of salaries and benefits for authors Jeffrey J. Sutherland, Xiong Liu, Keith Goldstein, Joseph A. Johnston, and Timothy P. Ryan, but did not have any additional role in the study design, decision to publish, data collection and analysis, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section	Bowlin SJ, 2013, MAYO CLIN PROC, V88, P139, DOI 10.1016/j.mayocp.2012.10.020; Duke JD, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002614; ElDesoky Ehab S, 2007, Am J Ther, V14, P488, DOI 10.1097/01.mjt.0000183719.84390.4d; Flockhart DA., 2007, DRUG INTERACTIONS CY; Gokula M, 2012, CLIN GERIATR MED, V28, P323, DOI 10.1016/j.cger.2012.01.011; Gu Qiuping, 2010, NCHS Data Brief, P1; Harpaz R, 2012, CLIN PHARMACOL THER, V91, P1010, DOI 10.1038/clpt.2012.50; Kent DM, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-85; Kerr KP, 2014, J CLIN PHARM THER, V39, P383, DOI 10.1111/jcpt.12163; Kootstra-Ros JE, 2006, J CLIN PHARMACOL, V46, P1320, DOI 10.1177/0091270006293754; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; Moura C, 2009, J PHARM PHARM SCI, V12, P266, DOI 10.18433/J35C7Z; Muscatello MR, 2012, HUM PSYCHOPHARM CLIN, V27, P239, DOI 10.1002/hup.2217; Paterno MD, 2009, J AM MED INFORM ASSN, V16, P40, DOI 10.1197/jamia.M2808; Preskorn Sheldon H, 2007, J Psychiatr Pract, V13, P5, DOI 10.1097/00131746-200701000-00002; Raschetti R, 1999, EUR J CLIN PHARMACOL, V54, P959, DOI 10.1007/s002280050582; Schoen C, 2011, HEALTH AFFAIR, V30, P2437, DOI 10.1377/hlthaff.2011.0923; Shah NR, 2006, J AM MED INFORM ASSN, V13, P5, DOI 10.1197/jamia.M1868; Tamblyn RM, 1996, CAN MED ASSOC J, V154, P1177; Tatonetti NP, 2011, CLIN PHARMACOL THER, V90, P133, DOI 10.1038/clpt.2011.83; Tragni E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078827; van Baal PH, 2011, POPUL HEALTH METR, V9, DOI 10.1186/1478-7954-9-51; Verger P, 2008, CAN J PSYCHIAT, V53, P94, DOI 10.1177/070674370805300204; Zhao S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006548	24	27	28	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 4	2015	10	3							e0118991	10.1371/journal.pone.0118991	http://dx.doi.org/10.1371/journal.pone.0118991			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC9JM	25739022	Green Published, gold, Green Submitted			2023-01-03	WOS:000350685900089
J	Kaatabi, H; Bamosa, AO; Badar, A; Al-Elq, A; Abou-Hozaifa, B; Lebda, F; Al-Khadra, A; Al-Almaie, S				Kaatabi, Huda; Bamosa, Abdullah Omar; Badar, Ahmed; Al-Elq, Abdulmohsen; Abou-Hozaifa, Bodour; Lebda, Fatma; Al-Khadra, Akram; Al-Almaie, Sameeh			Nigella sativa Improves Glycemic Control and Ameliorates Oxidative Stress in Patients with Type 2 Diabetes Mellitus: Placebo Controlled Participant Blinded Clinical Trial	PLOS ONE			English	Article							ANTIOXIDANT DEFENSE SYSTEM; PANCREATIC BETA-CELLS; LIPID-PEROXIDATION; INSULIN-RESISTANCE; THYMOQUINONE; DAMAGE; OIL; HYPERGLYCEMIA; EXPRESSION; EXTRACT	Background and Objective Oxidative stress plays an important role in pathogenesis of diabetes mellitus and its complications. Our previous study has shown glucose lowering effect produced by 3 months supplementation of Nigella sativa (NS) in combination with oral hypoglycemic drugs among type 2 diabetics. This study explored the long term glucose lowering effect (over one year) of NS in patients with type 2 diabetes mellitus on oral hypoglycemic drugs and to study its effect on redox status of such patients. Methods 114 type 2 diabetic patients on standard oral hypoglycemic drugs were assigned into 2 groups by convenience. The control group (n = 57) received activated charcoal as placebo and NS group (n = 57) received 2g NS, daily, for one year in addition to their standard medications. Fasting blood glucose (FBG), glycosylated hemoglobin (HbA(1c)), C-peptide, total antioxidant capacity (TAC), superoxide dismutase (SOD), catalase (CAT), glutathione and thiobarbituric acid reactive substances (TBARS) at the baseline, and every 3 months thereafter were determined. Insulin resistance and beta-cell activity were calculated using HOMA 2 calculator. Results Comparison between the two groups showed a significant drop in FBG (from 180 +/- 5.75 to 180 +/- 5.59 in control Vs from 195 +/- 6.57 to 172 +/- 5.83 in NS group), HbA1c (from 8.2 +/- 0.12 to 8.5 +/- 0.14 in control VS from 8.6 +/- 0.13 to 8.2 +/- 0.14 in NS group), and TBARS (from 48.3 +/- 6.89 to 52.9 +/- 5.82 in control VS from 54.1 +/- 4.64 to 41.9 +/- 3.16 in NS group), in addition to a significant elevation in TAC, SOD and glutathione in NS patients compared to controls. In NS group, insulin resistance was significantly lower, while beta-cell activity was significantly higher than the baseline values during the whole treatment period. Conclusion Long term supplementation with Nigella sativa improves glucose homeostasis and enhances antioxidant defense system in type 2 diabetic patients treated with oral hypoglycemic drugs.	[Kaatabi, Huda; Bamosa, Abdullah Omar; Badar, Ahmed; Abou-Hozaifa, Bodour; Lebda, Fatma] Univ Dammam, Coll Med, Dept Physiol, Dammam, Saudi Arabia; [Al-Elq, Abdulmohsen; Al-Khadra, Akram] Univ Dammam, Coll Med, Dept Med, Dammam, Saudi Arabia; [Al-Almaie, Sameeh] Univ Dammam, Coll Med, Dept Family Med, Dammam, Saudi Arabia	Imam Abdulrahman Bin Faisal University; Imam Abdulrahman Bin Faisal University; Imam Abdulrahman Bin Faisal University	Bamosa, AO (corresponding author), Univ Dammam, Coll Med, Dept Physiol, Dammam, Saudi Arabia.	aosbamosa@gmail.com	Bamosa, Abdullah/AAD-5564-2019; Badar, Ahmed/A-2650-2009; Elq, Abdulmohsen Al/AAP-2276-2021; alkhadra, Akram/D-4199-2017	Badar, Ahmed/0000-0001-5183-7570; Elq, Abdulmohsen Al/0000-0002-3906-0188; bamosa, Abdullah/0000-0001-5941-4353; alkhadra, Akram/0000-0001-6302-9378	University of Dammam	University of Dammam	This study was supported by University of Dammam, from its own budget. There is no external source of funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al Wafai RJ, 2013, PANCREAS, V42, P841, DOI 10.1097/MPA.0b013e318279ac1c; Al-Logmani A, 2011, J DIAB MELL, V1; Alimohammadi S, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-137; Aronson D, 2008, ADV CARDIOL, V45, P1, DOI 10.1159/000115118; ASAYAMA K, 1993, FREE RADICAL BIO MED, V15, P597, DOI 10.1016/0891-5849(93)90162-N; Badary OA, 2003, DRUG CHEM TOXICOL, V26, P87, DOI 10.1081/DCT-120020404; Bamosa Abdullah O, 2010, Indian J Physiol Pharmacol, V54, P344; Benhaddou-Andaloussi A, 2008, PHARM BIOL, V46, P96, DOI 10.1080/13880200701734810; Benhaddou-Andaloussi A, 2011, EVID-BASED COMPL ALT, V2011, DOI 10.1155/2011/538671; El-Gharieb Mahmood A., 2010, Toxicological and Environmental Chemistry, V92, P395, DOI 10.1080/02772240902955719; Fararh KM, 2004, RES VET SCI, V77, P123, DOI 10.1016/j.rvsc.2004.03.002; Fiorentino TV, 2013, CURR PHARM DESIGN, V19, P5695, DOI 10.2174/1381612811319320005; Hamdy NM, 2009, PHARMACOLOGY, V84, P127, DOI 10.1159/000234466; Ismail M, 2010, FREE RADICAL BIO MED, V48, P664, DOI 10.1016/j.freeradbiomed.2009.12.002; Kanter M, 2004, ANAT REC PART A, V279A, P685, DOI 10.1002/ar.a.20056; Khanam M, 2008, BANGL J PHARMACOL, V4, P17; Levy JC, 1998, DIABETES CARE, V21, P2191, DOI 10.2337/diacare.21.12.2191; Meral I, 2001, J VET MED A, V48, P593, DOI 10.1046/j.1439-0442.2001.00393.x; Najmi A, 2008, INT J DIABETES DEV C, V28, P11, DOI 10.4103/0973-3930.41980; Pari L, 2009, LIFE SCI, V85, P830, DOI 10.1016/j.lfs.2009.10.021; Pitocco D, 2013, INT J MOL SCI, V14, P21525, DOI 10.3390/ijms141121525; Pourghassem-Gargari B, 2009, J MED PLANTS RES, V3, P815; Shi Y, 2009, J DIABETES, V1, P151, DOI 10.1111/j.1753-0407.2009.00030.x; Song FF, 2007, CLIN SCI, V112, P599, DOI 10.1042/CS20060323; Soskic SS, 2011, OPEN CARDIOVASC MED, V5, P153, DOI 10.2174/1874192401105010153; Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405; Tahraoui A, 2007, J ETHNOPHARMACOL, V110, P105, DOI 10.1016/j.jep.2006.09.011; Tanaka Y, 2002, P NATL ACAD SCI USA, V99, P12363, DOI 10.1073/pnas.192445199; Tiedge M, 1997, DIABETES, V46, P1733, DOI 10.2337/diabetes.46.11.1733; Tiganis T, 2011, TRENDS PHARMACOL SCI, V32, P82, DOI 10.1016/j.tips.2010.11.006; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6	31	64	65	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 23	2015	10	2							e0113486	10.1371/journal.pone.0113486	http://dx.doi.org/10.1371/journal.pone.0113486			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC9BI	25706772	Green Published, Green Submitted, gold			2023-01-03	WOS:000350662100001
J	Lopez, EMJ; Ghetmiri, E; Gettle, LM; Reed, MF; McAllister, BP				Lopez, Eric Mark J.; Ghetmiri, Ehsan; Gettle, Lori M.; Reed, Michael F.; McAllister, Brian P.			Encephalopathy and high anion gap metabolic acidosis: an unusual herald of buried bumper syndrome	LANCET			English	Editorial Material									[Lopez, Eric Mark J.; Ghetmiri, Ehsan; McAllister, Brian P.] Penn State Coll Med, Penn State Milton S Hershey Med Ctr, Dept Med, Hershey, PA 17033 USA; [Gettle, Lori M.] Penn State Coll Med, Penn State Milton S Hershey Med Ctr, Dept Radiol, Hershey, PA 17033 USA; [Reed, Michael F.] Penn State Coll Med, Penn State Milton S Hershey Med Ctr, Dept Surg, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	McAllister, BP (corresponding author), Penn State Coll Med, Milton S Hershey Med Ctr, 500 Univ Dr,POB 850, Hershey, PA 17033 USA.	bmcallister@hmc.psu.edu		Reed, Michael/0000-0001-8478-8605				Bertolini R, 2014, WORLD J GASTROENTERO, V20, P11439, DOI 10.3748/wjg.v20.i32.11439; Biswas Saptarshi, 2014, Case Rep Crit Care, V2014, P634953, DOI 10.1155/2014/634953; Kang Kyung Pyo, 2006, Electrolyte Blood Press, V4, P53, DOI 10.5049/EBP.2006.4.1.53; NGHIEM CH, 1988, WESTERN J MED, V148, P332; Rahnemai-Azar AA, 2014, WORLD J GASTROENTERO, V20, P7739, DOI 10.3748/wjg.v20.i24.7739	5	0	0	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 21	2015	385	9969					744	744		10.1016/S0140-6736(15)60030-7	http://dx.doi.org/10.1016/S0140-6736(15)60030-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CB7ED	25706220				2023-01-03	WOS:000349788300031
J	Kabir, AUI; Bin Samad, M; Ahmed, A; Jahan, MR; Akhter, F; Tasnim, J; Hasan, SMN; Sayfe, SS; Hannan, JMA				Kabir, Ashraf U. I.; Bin Samad, Mehdi; Ahmed, Arif; Jahan, Mohammad Rajib; Akhter, Farjana; Tasnim, Jinat; Hasan, S. M. Nageeb; Sayfe, Sania Sarker; Hannan, J. M. A.			Aqueous Fraction of Beta vulgaris Ameliorates Hyperglycemia in Diabetic Mice due to Enhanced Glucose Stimulated Insulin Secretion, Mediated by Acetylcholine and GLP-1, and Elevated Glucose Uptake via Increased Membrane Bound GLUT4 Transporters	PLOS ONE			English	Article							MEDICAL NUTRITION THERAPY; VAR. CICLA EXTRACT; SKELETAL-MUSCLE; GLYCEMIC CONTROL; IN-VIVO; B-CELLS; GLUCAGON; RESISTANCE; RELEASE; PATHOGENESIS	Background The study was designed to investigate the probable mechanisms of anti-hyperglycemic activity of B. Vulgaris. Methodology/Principal Findings Aqueous fraction of B. Vulgaris extract was the only active fraction (50mg/kg). Plasma insulin level was found to be the highest at 30 mins after B. Vulgaris administration at a dose of 200mg/kg.B. Vulgaris treated mice were also assayed for plasma Acetylcholine, Glucagon Like Peptide-1 (GLP-1), Gastric Inhibitory Peptide (GIP), Vasoactive Intestinal Peptide, Pituitary Adenylate Cyclase-Activating Peptide (PACAP), Insulin Like Growth Factor-1 (IGF-1), Pancreatic Polypeptides (PP), and Somatostatin, along with the corresponding insulin levels. Plasma Acetylcholine and GLP-1 significantly increased in B. Vulgaris treated animals and were further studied. Pharmacological enhancers, inhibitors, and antagonists of Acetylcholine and GLP-1 were also administered to the test animals, and corresponding insulin levels were measured. These studies confirmed the role of acetylcholine and GLP-1 in enhanced insulin secretion (p<0.05). Principal signaling molecules were quantified in isolated mice islets for the respective pathways to elucidate their activities. Elevated concentrations of Acetylcholine and GLP-1 in B. Vulgaris treated mice were found to be sufficient to activate the respective pathways for insulin secretion (p<0.05). The amount of membrane bound GLUT1 and GLUT4 transporters were quantified and the subsequent glucose uptake and glycogen synthesis were assayed. We showed that levels of membrane bound GLUT4 transporters, glucose-6-phosphate in skeletal myocytes, activity of glycogen synthase, and level of glycogen deposited in the skeletal muscles all increased (p<0.05). Conclusion Findings of the present study clearly prove the role of Acetylcholine and GLP-1 in the Insulin secreting activity of B. Vulgaris. Increased glucose uptake in the skeletal muscles and subsequent glycogen synthesis may also play a part in the anti-hyperglycemic activity of B. Vulgaris.	[Kabir, Ashraf U. I.; Bin Samad, Mehdi; Ahmed, Arif; Jahan, Mohammad Rajib; Akhter, Farjana; Tasnim, Jinat; Hasan, S. M. Nageeb; Hannan, J. M. A.] North South Univ, Dept Pharmaceut Sci, Dhaka, Bangladesh; [Sayfe, Sania Sarker] Khulna Univ, Sch Life Sci, Pharm Discipline, Khulna, Bangladesh	North South University (NSU); Khulna University	Kabir, AUI (corresponding author), North South Univ, Dept Pharmaceut Sci, Dhaka, Bangladesh.	ashraful_kabir@ymail.com	KABIR, ASHRAF UL/AAR-9200-2020	KABIR, ASHRAF UL/0000-0002-9449-8238; Jahan, Mohammad Rajib/0000-0002-1289-2435; Samad, Mehdi Bin/0000-0002-1774-7069; Akhter, Farjana/0000-0003-3258-6854				Amer Diabet Associat, 2008, DIABETES CARE, V31, pS61, DOI 10.2337/dc08-S061; Andrikopoulos S, 2008, AM J PHYSIOL-ENDOC M, V295, pE1323, DOI 10.1152/ajpendo.90617.2008; [Anonymous], 1996, PHYSIOLOGIST; Baggio LL, 2007, GASTROENTEROLOGY, V132, P2131, DOI 10.1053/j.gastro.2007.03.054; Baron AD, 1995, J CLIN INVEST, V96, P2792, DOI 10.1172/JCI118349; BARON AD, 1988, AM J PHYSIOL, V255, pE769, DOI 10.1152/ajpendo.1988.255.6.E769; Bolen S, 2007, ANN INTERN MED, V147, P386, DOI 10.7326/0003-4819-147-6-200709180-00178; Bolkent S, 2000, J ETHNOPHARMACOL, V73, P251, DOI 10.1016/S0378-8741(00)00328-7; Boulton AJM, 1998, MED CLIN N AM, V82, P909, DOI 10.1016/S0025-7125(05)70029-8; DANFORTH WH, 1965, J BIOL CHEM, V240, P588; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; Duttaroy A, 2004, DIABETES, V53, P1714, DOI 10.2337/diabetes.53.7.1714; Escribano J, 1998, PHYTOCHEM ANALYSIS, V9, P124, DOI 10.1002/(SICI)1099-1565(199805/06)9:3&lt;124::AID-PCA401&gt;3.0.CO;2-0; EVANS DJ, 1984, J CLIN INVEST, V74, P1515, DOI 10.1172/JCI111565; FEHMANN HC, 1989, SIGNAL TRANSMISSION, P28669; FRANZ MJ, 1995, J AM DIET ASSOC, V95, P1009, DOI 10.1016/S0002-8223(95)00276-6; Gerich JE, 2003, ARCH INTERN MED, V163, P1306, DOI 10.1001/archinte.163.11.1306; Hannan JMA, 2012, BRIT J NUTR, V107, P1316, DOI 10.1017/S0007114511004284; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; HONEY RN, 1980, ENDOCRINOLOGY, V107, P1065, DOI 10.1210/endo-107-4-1065; Ilkova H, 1997, DIABETES CARE, V20, P1353, DOI 10.2337/diacare.20.9.1353; KLEIN R, 1995, DIABETES CARE, V18, P258, DOI 10.2337/diacare.18.2.258; KLEIN R, 1994, ARCH INTERN MED, V154, P2169, DOI 10.1001/archinte.154.19.2169; KLIP A, 1987, FEBS LETT, V224, P224, DOI 10.1016/0014-5793(87)80452-0; KORANYI LI, 1991, DIABETOLOGIA, V34, P763, DOI 10.1007/BF00401526; KRAEGEN EW, 1993, BIOCHEM J, V295, P287, DOI 10.1042/bj2950287; Li DS, 2009, NAT PROTOC, V4, P1649, DOI 10.1038/nprot.2009.150; LOUBATIE.MM, 1973, DIABETOLOGIA, V9, P439, DOI 10.1007/BF00461685; MALAISSE WJ, 1979, METABOLISM, V28, P373, DOI 10.1016/0026-0495(79)90111-2; MOJSOV S, 1987, J CLIN INVEST, V79, P616, DOI 10.1172/JCI112855; Monnier L, 2006, JAMA-J AM MED ASSOC, V295, P1681, DOI 10.1001/jama.295.14.1681; MORGAN HE, 1961, J BIOL CHEM, V236, P253; NAUCK MA, 1993, DIABETOLOGIA, V36, P741, DOI 10.1007/BF00401145; Parks M, 2010, NEW ENGL J MED, V362, P774, DOI 10.1056/NEJMp1001578; Pastors JG, 2002, DIABETES CARE, V25, P608, DOI 10.2337/diacare.25.3.608; PORTE D, 1967, J CLIN INVEST, V46, P86, DOI 10.1172/JCI105514; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; Prentki M, 2013, CELL METAB, V18, P162, DOI 10.1016/j.cmet.2013.05.018; RASMUSSEN H, 1990, DIABETES CARE, V13, P655, DOI 10.2337/diacare.13.6.655; Ravid M, 1998, ARCH INTERN MED, V158, P998, DOI 10.1001/archinte.158.9.998; RUBIN RJ, 1994, J CLIN ENDOCR METAB, V78, pA809, DOI 10.1210/jcem.78.4.8157701; Sener G., 2002, Journal of Medicinal Food, V5, P37, DOI 10.1089/109662002753723205; SOWERS JR, 1993, AM J HYPERTENS, V6, pS260, DOI 10.1093/ajh/6.7.260S; Szkudelski T, 2001, PHYSIOL RES, V50, P537; Trinder P, 1969, ANN CLIN BIOCH INT J, V6, P24; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Umpierrez GE, 2002, J CLIN ENDOCR METAB, V87, P978, DOI 10.1210/jc.87.3.978; VillarPalasi C, 1997, FASEB J, V11, P544, DOI 10.1096/fasebj.11.7.9212078; Vilsboll T, 2007, DIABETES CARE, V30, P1608, DOI 10.2337/dc06-2593; Wang Q, 2004, DIABETOLOGIA, V47, P478, DOI 10.1007/s00125-004-1327-5; YANARDA GR, 1998, PHARM PHARM COMMUNIC, V4, P309; Yanardag R, 2002, PHYTOTHER RES, V16, P758, DOI 10.1002/ptr.1041; Yarat Aysen, 1998, Pharmacy and Pharmacology Communications, V4, P271; Zisman A, 2000, NAT MED, V6, P924, DOI 10.1038/78693	54	13	13	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2015	10	2							e0116546	10.1371/journal.pone.0116546	http://dx.doi.org/10.1371/journal.pone.0116546			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA3QZ	25647228	Green Submitted, Green Published, gold			2023-01-03	WOS:000348822600028
J	Hung, PY; Ho, BC; Lee, SY; Chang, SY; Kao, CL; Lee, SS; Lee, CN				Hung, Pei-Yun; Ho, Bing-Ching; Lee, Szu-Yuan; Chang, Sui-Yuan; Kao, Chuan-Liang; Lee, Shoei-Sheng; Lee, Chun-Nan			Houttuynia cordata Targets the Beginning Stage of Herpes Simplex Virus Infection	PLOS ONE			English	Article							NF-KAPPA-B; ANTI-HSV ACTIVITY; INFLUENZA-VIRUS; GLYCOPROTEIN-D; TYPE-1; CELLS; PROTEIN; ENTRY; TRANSCRIPTION; RESISTANCE	Herpes simplex virus (HSV), a common latent virus in humans, causes certain severe diseases. Extensive use of acyclovir (ACV) results in the development of drug-resistant HSV strains, hence, there is an urgent need to develop new drugs to treat HSV infection. Houttuynia cordata (H. cordata), a natural herbal medicine, has been reported to exhibit anti-HSV effects which is partly NF-kappa B-dependent. However, the molecular mechanisms by which H. cordata inhibits HSV infection are not elucidated thoroughly. Here, we report that H. cordata water extracts (HCWEs) inhibit the infection of HSV-1, HSV-2, and acyclovir-resistant HSV-1 mainly via blocking viral binding and penetration in the beginning of infection. HCWEs also suppress HSV replication. Furthermore, HCWEs attenuate the first-wave of NF-kappa B activation, which is essential for viral gene expressions. Further analysis of six compounds in HCWEs revealed that quercetin and isoquercitrin inhibit NF-kappa B activation and additionally, quercetin also has an inhibitory effect on viral entry. These results indicate that HCWEs can inhibit HSV infection through multiple mechanisms and could be a potential lead for development of new drugs for treating HSV.	[Hung, Pei-Yun; Ho, Bing-Ching; Lee, Szu-Yuan; Chang, Sui-Yuan; Kao, Chuan-Liang; Lee, Chun-Nan] Natl Taiwan Univ, Coll Med, Dept Clin Lab Sci & Med Biotechnol, Taipei 100, Taiwan; [Ho, Bing-Ching] Natl Taiwan Univ, Coll Med, Ctr Genom Med, Taipei 100, Taiwan; [Chang, Sui-Yuan; Kao, Chuan-Liang; Lee, Chun-Nan] Natl Taiwan Univ Hosp, Dept Lab Med, Taipei 100, Taiwan; [Lee, Shoei-Sheng] Natl Taiwan Univ, Coll Med, Sch Pharm, Taipei 100, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Lee, CN (corresponding author), Natl Taiwan Univ, Coll Med, Dept Clin Lab Sci & Med Biotechnol, Taipei 100, Taiwan.	cnalee@ntu.edu.tw		CHANG, SUI-YUAN/0000-0002-6009-6724; KAO, CHUAN-LIANG/0000-0002-1020-2605; HO, BING-CHING/0000-0003-4356-3279; LEE, SHOEI-SHENG/0000-0002-6628-2448	National Research Program for Genomic Medicine of Taiwan [CCMP97-RD-208]	National Research Program for Genomic Medicine of Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported by National Research Program for Genomic Medicine of Taiwan (CCMP97-RD-208). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABOUKARAM M, 1992, J NAT PROD, V55, P1525, DOI 10.1021/np50088a022; Amici C, 2006, J BIOL CHEM, V281, P7110, DOI 10.1074/jbc.M512366200; BALFOUR HH, 1983, ANN INTERN MED, V98, P404, DOI 10.7326/0003-4819-98-3-404; BARINGER JR, 1974, NEW ENGL J MED, V291, P828, DOI 10.1056/NEJM197410172911606; BEVILACQUA F, 1991, J ACQ IMMUN DEF SYND, V4, P967; Brasier AR, 2006, CARDIOVASC TOXICOL, V6, P111, DOI 10.1385/CT:6:2:111; Chen SH, 2008, J CLIN INVEST, V118, P3470, DOI 10.1172/JCI35114; Chen XQ, 2011, ANTIVIR RES, V92, P341, DOI 10.1016/j.antiviral.2011.09.005; Chen YY, 2003, J NUTR SCI VITAMINOL, V49, P327, DOI 10.3177/jnsv.49.327; Chiang LC, 2003, AM J CHINESE MED, V31, P355, DOI 10.1142/S0192415X03001090; Choi HJ, 2009, EUR J PHARM SCI, V37, P329, DOI 10.1016/j.ejps.2009.03.002; EPSTEIN JB, 1991, ORAL SURG ORAL MED O, V72, P47, DOI 10.1016/0030-4220(91)90188-I; ERLICH KS, 1989, NEW ENGL J MED, V320, P293, DOI 10.1056/NEJM198902023200506; EVERETT RD, 1984, EMBO J, V3, P3135, DOI 10.1002/j.1460-2075.1984.tb02270.x; Faith SA, 2006, ANTIVIR RES, V72, P242, DOI 10.1016/j.antiviral.2006.06.011; Farah A, 2008, J NUTR, V138, P2309, DOI 10.3945/jn.108.095554; Farooq AV, 2012, SURV OPHTHALMOL, V57, P448, DOI 10.1016/j.survophthal.2012.01.005; FULLER AO, 1992, J VIROL, V66, P5002, DOI 10.1128/JVI.66.8.5002-5012.1992; GELMAN IH, 1985, P NATL ACAD SCI USA, V82, P5265, DOI 10.1073/pnas.82.16.5265; HAYASHI K, 1995, PLANTA MED, V61, P237, DOI 10.1055/s-2006-958063; HEROLD BC, 1991, J VIROL, V65, P1090, DOI 10.1128/JVI.65.3.1090-1098.1991; Jo HY, 2008, J VET SCI, V9, P267, DOI 10.4142/jvs.2008.9.3.267; JOHNSON DC, 1988, J VIROL, V62, P4605, DOI 10.1128/JVI.62.12.4605-4612.1988; JOHNSON DC, 1990, J VIROL, V64, P2569, DOI 10.1128/JVI.64.6.2569-2576.1990; JONES KA, 1985, NATURE, V317, P179, DOI 10.1038/317179a0; Kavouras JH, 2007, J NEUROVIROL, V13, P416, DOI 10.1080/13550280701460573; Kim JC, 2008, MOL BIOL+, V42, P413, DOI 10.1134/S0026893308030096; Knopf CW, 2000, ACTA VIROL, V44, P289; Kupila L, 2006, NEUROLOGY, V66, P75, DOI 10.1212/01.wnl.0000191407.81333.00; Lau KM, 2008, J ETHNOPHARMACOL, V118, P79, DOI 10.1016/j.jep.2008.03.018; LEE WC, 1993, J VIROL, V67, P5088, DOI 10.1128/JVI.67.9.5088-5097.1993; Liu Zhao-Mei, 2006, Zhongguo Zhong Yao Za Zhi, V31, P1753; Lu HM, 2006, J ETHNOPHARMACOL, V104, P245, DOI 10.1016/j.jep.2005.09.012; Lyu SY, 2005, ARCH PHARM RES, V28, P1293, DOI 10.1007/BF02978215; Marcelletti JF, 2002, ANTIVIR RES, V56, P153, DOI 10.1016/S0166-3542(02)00105-5; MCLAREN C, 1985, ANTIMICROB AGENTS CH, V28, P740, DOI 10.1128/AAC.28.6.740; Melancon JM, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-120; Meng J, 2005, CHEM PHARM BULL, V53, P1604, DOI 10.1248/cpb.53.1604; Meng Jiang, 2006, Zhongguo Zhong Yao Za Zhi, V31, P1335; Moerdyk-Schauwecker M, 2009, ANTIVIR RES, V84, P131, DOI 10.1016/j.antiviral.2009.07.020; Mommeja-Marin H, 2003, CLIN INFECT DIS, V37, P1527, DOI 10.1086/379520; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; Newman DJ, 2003, J NAT PROD, V66, P1022, DOI 10.1021/np030096l; Ng LT, 2007, AM J CHINESE MED, V35, P465, DOI 10.1142/S0192415X07004989; Ottosen S, 2006, VIROLOGY, V345, P468, DOI 10.1016/j.virol.2005.10.011; Piret J, 2011, ANTIMICROB AGENTS CH, V55, P459, DOI 10.1128/AAC.00615-10; SACKS WR, 1987, J VIROL, V61, P829, DOI 10.1128/JVI.61.3.829-839.1987; Sato M, 1997, J RHEUMATOL, V24, P1680; Savov VM, 2006, EXP TOXICOL PATHOL, V58, P59, DOI 10.1016/j.etp.2006.05.002; Shih CM, 2004, EUR J PHARMACOL, V496, P41, DOI 10.1016/j.ejphar.2004.06.016; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Spear PG, 2004, CELL MICROBIOL, V6, P401, DOI 10.1111/j.1462-5822.2004.00389.x; Su CT, 2008, ANTIVIR RES, V79, P62, DOI 10.1016/j.antiviral.2008.01.156; Taddeo B, 2003, P NATL ACAD SCI USA, V100, P12408, DOI 10.1073/pnas.2034952100; Tao J, 2007, ANTIVIR RES, V75, P227, DOI 10.1016/j.antiviral.2007.03.008; Tatti S, 2010, BRIT J DERMATOL, V162, P176, DOI 10.1111/j.1365-2133.2009.09375.x; Thi THN, 2012, BIOTECHNOL LETT, V34, P831, DOI 10.1007/s10529-011-0845-8; TUTUPALLI LV, 1975, LLOYDIA, V38, P92; Warner MS, 1998, VIROLOGY, V246, P179, DOI 10.1006/viro.1998.9218; Wutzler P, 1997, INTERVIROLOGY, V40, P343, DOI 10.1159/000150567; Xu FJ, 2006, JAMA-J AM MED ASSOC, V296, P964, DOI 10.1001/jama.296.8.964; Xu GH, 2009, ARCH PHARM RES, V32, P275, DOI 10.1007/s12272-009-1233-y; Yasin B, 2004, J VIROL, V78, P5147, DOI 10.1128/JVI.78.10.5147-5156.2004	63	46	52	1	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 2	2015	10	2							e0115475	10.1371/journal.pone.0115475	http://dx.doi.org/10.1371/journal.pone.0115475			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA3QK	25643242	Green Submitted, Green Published, gold			2023-01-03	WOS:000348821200010
J	Zhou, T; Zeng, SX; Ye, DW; Wei, Q; Zhang, X; Huang, YR; Ye, ZQ; Yang, Y; Zhang, W; Tian, Y; Zhou, FJ; Jie, J; Chen, SP; Sun, Y; Xie, LP; Yao, X; Na, YQ; Sun, YH				Zhou, Tie; Zeng, Shu-xiong; Ye, Ding-wei; Wei, Qiang; Zhang, Xu; Huang, Yi-ran; Ye, Zhang-qun; Yang, Yong; Zhang, Wei; Tian, Ye; Zhou, Fang-jian; Jie, Jin; Chen, Shi-ping; Sun, Yan; Xie, Li-ping; Yao, Xing; Na, Yan-qun; Sun, Ying-hao			A Multicenter, Randomized Clinical Trial Comparing the Three-Weekly Docetaxel Regimen plus Prednisone versus Mitoxantone plus Prednisone for Chinese Patients with Metastatic Castration Refractory Prostate Cancer	PLOS ONE			English	Article							CHANGING THERAPEUTIC LANDSCAPE; PHASE-II; DOUBLE-BLIND; EFFICACY; ANTIGEN; RECOMMENDATIONS; GUIDELINES; SURVIVAL; PLACEBO; MEN	Purpose To explore the feasibility and efficacy of docetaxel plus prednisone for Chinese population with metastatic castration refractory prostate cancer (mCRPC). Patients and methods A total of 228 patients recruited from 15 centers were randomized to receive 10 cycles of D3P arm (docetaxel: 75 mg/m(2), intravenous infusion, every three weeks; Prednisone 10mg orally given daily) or M3P arm (mitoxantrone: 12 mg/m(2), intravenous infusion, every three weeks; Prednisone 10mg orally given daily). Primary end point was overall survival, and secondary end points were events progression-free survival (PFS), response rate, response duration. Quality of life (QoL) was also assessed in both treatment groups. Results The median overall survival was 21.88 months in D3P arm and 13.67 months in M3P arm (P = 0.0011, hazard ratio = 0.63, 95% confidence interval, 0.46-0.86). Subgroup analysis was consistent with the results of overall analysis. Events progression-free survival (pain, PSA, tumor and disease) were significantly improved in D3P arm compared with M3P arm. PSA response rate was 35.11% for patients treated by D3P arm and 19.39% for M3P arm (P = 0.0155). Pain response rate was higher in D3P arm (61.11%, P = 0.0011) than in M3P (23.08%) arm. No statistical differences were found between D3P arm and M3P arm for QoL, tumor response rate and response duration of PSA and pain. The tolerability and overall safety of D3P arm were generally comparable to that of M3P arm. Conclusions Compared with M3P arm, D3P arm significantly prolonged overall survival for the Chinese patients with mCRPC and improved the response rate for PSA and pain.	[Zhou, Tie; Zeng, Shu-xiong; Sun, Ying-hao] Second Mil Med Univ, Changhai Hosp, Dept Urol, Shanghai 200433, Peoples R China; [Ye, Ding-wei] Fudan Univ, Dept Urol, Shanghai Canc Ctr, Shanghai 200433, Peoples R China; [Wei, Qiang] Sichuan Univ, Dept Urol, West China Hosp, West China Sch Med, Chengdu 610064, Peoples R China; [Zhang, Xu] Chinese PLA, Sch Med, Chinese PLA Gen Hosp, Dept Urol, Beijing, Peoples R China; [Huang, Yi-ran] Shanghai Jiao Tong Univ, Sch Med, Dept Urol, Renji Hosp, Shanghai 200030, Peoples R China; [Ye, Zhang-qun] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Urol, Wuhan 430074, Peoples R China; [Yang, Yong] Peking Univ, Beijing Canc Hosp, Dept Urol, Beijing 100871, Peoples R China; [Zhang, Wei] Nanjing Med Univ, Jiangsu Prov Hosp, Dept Urol, Nanjing, Jiangsu, Peoples R China; [Tian, Ye] Capital Med Univ, Beijing Friendship Hosp, Dept Urol, Beijing, Peoples R China; [Zhou, Fang-jian] Sun Yat Sen Univ, Canc Hosp, Dept Urol, Guangzhou 510275, Guangdong, Peoples R China; [Jie, Jin] Peking Univ, Hosp 1, Dept Urol, Beijing 100871, Peoples R China; [Chen, Shi-ping] Fujian Union Hosp, Dept Urol, Fuzhou, Peoples R China; [Sun, Yan] Chinese Acad Med Sci, Canc Hosp, Dept Urol, Beijing 100730, Peoples R China; [Xie, Li-ping] Zhejiang Univ, Affiliated Hosp 1, Dept Urol, Hangzhou 310003, Zhejiang, Peoples R China; [Yao, Xing] Tianjin Med Univ, Tianjin Canc Hosp, Dept Urol, Tianjin, Peoples R China; [Na, Yan-qun] Peking Univ, Dept Urol, Shougang Hosp, Beijing 100871, Peoples R China	Naval Medical University; Fudan University; Sichuan University; Chinese People's Liberation Army General Hospital; Shanghai Jiao Tong University; Huazhong University of Science & Technology; Peking University; Nanjing Medical University; Capital Medical University; Sun Yat Sen University; Peking University; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Zhejiang University; Tianjin Medical University; Peking University	Sun, YH (corresponding author), Second Mil Med Univ, Changhai Hosp, Dept Urol, 168 Changhai Rd, Shanghai 200433, Peoples R China.	nayanqun@cuan.com; yinghao.sun@yahoo.com	Xie, li/HGE-6052-2022	Zeng, Shuxiong/0000-0001-7656-9437	Sanofi-Aventis company; Changhai hospital GCP platform [2012ZX09303011-002]	Sanofi-Aventis company(Sanofi-Aventis); Changhai hospital GCP platform	This study was sponsored by Sanofi-Aventis company. The study protocol was designed by Sanofi-Aventis personnel, and reviewed and approved by all the study co-authors. All the centers involved in this study received grants from Sanofi-Aventis for recruiting patients and conducting this clinical trial. The data were collected and maintained by Sanofi-Aventis. The statistical analysis was undertaken by an independent statistical department receiving fees from Sanofi-Aventis, but these results were not seen by Aventis, or the study co-authors, or any other investigators until the study closed. Tie Zhou and Shu-xiong Zeng drafted the manuscript and it was reviewed and approved by the all the coauthors. Sanofi-Aventis also reviewed the manuscript, but its final content was entirely determined by the co-authors. We also appreciate the supports from Changhai hospital GCP platform (2012ZX09303011-002).	Berthold DR, 2008, CLIN CANCER RES, V14, P2763, DOI 10.1158/1078-0432.CCR-07-0944; Berthold DR, 2008, J CLIN ONCOL, V26, P242, DOI 10.1200/JCO.2007.12.4008; Bubley GJ, 1999, J CLIN ONCOL, V17, P3461, DOI 10.1200/JCO.1999.17.11.3461; Chi KN, 2010, J CLIN ONCOL, V28, P4247, DOI 10.1200/JCO.2009.26.8771; El Halim Mohamed Abu Hamar Abd, 2010, Hematol Oncol Stem Cell Ther, V3, P121; Ernst DS, 2003, J CLIN ONCOL, V21, P3335, DOI 10.1200/JCO.2003.03.042; Fujiwara K, 1999, ANTICANCER RES, V19, P639; Heidenreich A, 2014, EUR UROL, V65, P467, DOI 10.1016/j.eururo.2013.11.002; Howard Diana N, 2008, J Oncol Pharm Pract, V14, P45, DOI 10.1177/1078155207085387; Kantoff PW, 1999, J CLIN ONCOL, V17, P2506, DOI 10.1200/JCO.1999.17.8.2506; Kelly WK, 2012, J CLIN ONCOL, V30, P1534, DOI 10.1200/JCO.2011.39.4767; Kirby M, 2011, INT J CLIN PRACT, V65, P1180, DOI 10.1111/j.1742-1241.2011.02799.x; Lee KH, 2013, CANCER CHEMOTH PHARM, V71, P843, DOI 10.1007/s00280-013-2075-3; Naito S, 2008, JPN J CLIN ONCOL, V38, P365, DOI 10.1093/jjco/hyn029; Olbert PJ, 2006, ANTI-CANCER DRUG, V17, P993, DOI 10.1097/01.cad.0000231468.69535.97; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Polite BN, 2012, CANCER-AM CANCER SOC, V118, P1083, DOI 10.1002/cncr.26394; Scher HI, 2008, J CLIN ONCOL, V26, P1148, DOI 10.1200/JCO.2007.12.4487; Seal BS, 2013, VALUE HEALTH, V16, P872, DOI 10.1016/j.jval.2013.03.1628; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Thatai LC, 2004, UROLOGY, V64, P738, DOI 10.1016/j.urology.2004.05.024; Yap TA, 2011, NAT REV CLIN ONCOL, V8, P597, DOI 10.1038/nrclinonc.2011.117; [叶定伟 YE Dingwei], 2007, [中国癌症杂志, China Oncology], V17, P177; Zhang HL, 2007, UROL INT, V79, P307, DOI 10.1159/000109714	25	19	22	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2015	10	1							e0117002	10.1371/journal.pone.0117002	http://dx.doi.org/10.1371/journal.pone.0117002			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA3QM	25625938	Green Published, Green Submitted, gold			2023-01-03	WOS:000348821400026
J	Fekete, T				Fekete, Thomas			In critical illness, high-protein enteral nutrition with immune-modulating nutrients did not reduce infections	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Temple Univ, Sch Med, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Fekete, T (corresponding author), Temple Univ, Sch Med, Philadelphia, PA 19122 USA.		van Zanten, Arthur R.H./ABB-1169-2021; Fekete, Thomas/AFI-5367-2022	van Zanten, Arthur R.H./0000-0001-6276-7192; 				Heyland D, 2013, NEW ENGL J MED, V368, P1489, DOI 10.1056/NEJMoa1212722; McClave SA, 2009, JPEN-PARENTER ENTER, V33, P277, DOI 10.1177/0148607109335234	2	0	1	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 20	2015	162	2							JC9	10.7326/ACPJC-2015-162-2-009	http://dx.doi.org/10.7326/ACPJC-2015-162-2-009			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CC1NB	25599369				2023-01-03	WOS:000350106600008
J	Yu, HY; Ahn, JH; Park, SW; Jung, YS				Yu, Hye Yon; Ahn, Ji Hun; Park, Se Won; Jung, Yi-Sook			Preventive Effect of Yuzu and Hesperidin on Left Ventricular Remodeling and Dysfunction in Rat Permanent Left Anterior Descending Coronary Artery Occlusion Model	PLOS ONE			English	Article							HEART-FAILURE; MYOCARDIAL-INFARCTION; OXIDATIVE STRESS; ACTIVATION; INJURY; MOUSE; DEATH; (-)-EPICATECHIN; INHIBITION; DISEASE	Left ventricular (LV) remodeling, which includes ventricular dilatation and increased interstitial fibrosis after myocardial infarction (MI), is the critical process underlying the progression to heart failure. Therefore, a novel approach for preventing LV remodeling after MI is highly desirable. Yuzu is a citrus plant originating in East Asia, and has a number of cardioprotective properties such as hesperidin. However, no study has proved whether yuzu can prevent LV remodeling. The aim of this study was to determine the effects of yuzu on heart failure (HF) and its potential impact on the LV remodeling process after MI. Our in vivo study using the permanent left anterior descending coronary artery (LAD) occlusion model demonstrate that one week pre-treatment with yuzu or its major metabolite hesperidin before LAD occlusion significantly attenuated cardiac dysfunction, myocyte apoptosis and inflammation. Not only yuzu but also hesperidin inhibited caspase-3 activity, myeloperoxidase expression, a-smooth muscle actin expression, and matrix metalloproteinase2 activity in a permanent LAD occlusion rat model. To our knowledge, our findings provide the first evidence that yuzu and hesperidin prevent MI-induced ventricular dysfunction and structural remodeling of myocardium.	[Yu, Hye Yon] Ajou Univ, Sch Med, Dept Physiol, Suwon 441749, South Korea; [Yu, Hye Yon; Jung, Yi-Sook] Ajou Univ, Coll Pharm, Suwon 441749, South Korea; [Ahn, Ji Hun] Soon Chun Hyang Univ, Gumi Hosp, Dept Cardiol, Gumi, South Korea; [Park, Se Won] Konkuk Univ, Coll Life & Environm Sci, Seoul, South Korea; [Jung, Yi-Sook] Ajou Univ, Res Inst Pharmaceut Sci & Technol, Suwon 441749, South Korea	Ajou University; Ajou University; Soonchunhyang University; Konkuk University; Ajou University	Jung, YS (corresponding author), Ajou Univ, Coll Pharm, Suwon 441749, South Korea.	yisjung@ajou.ac.kr			Bio-industry Technology Development Program [111093-3]; Ministry for Food, Agriculture, Forestry and Fisheries, Republic of Korea; Next-Generation BioGreen 21 Program [PJ009074]; Rural Development Administration, Republic of Korea	Bio-industry Technology Development Program; Ministry for Food, Agriculture, Forestry and Fisheries, Republic of Korea; Next-Generation BioGreen 21 Program(Rural Development Administration (RDA), Republic of Korea); Rural Development Administration, Republic of Korea(Rural Development Administration (RDA), Republic of Korea)	This research was supported by Bio-industry Technology Development Program (111093-3), Ministry for Food, Agriculture, Forestry and Fisheries, Republic of Korea. This research was also supported by a grant from the Next-Generation BioGreen 21 Program (No. PJ009074), Rural Development Administration, Republic of Korea. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akhlaghi M, 2010, PLANT FOOD HUM NUTR, V65, P193, DOI 10.1007/s11130-010-0182-4; Anatoliotakis N, 2013, CURR TOP MED CHEM, V13, P115, DOI 10.2174/1568026611313020004; Campian ME, 2010, EUR J HEART FAIL, V12, P653, DOI 10.1093/eurjhf/hfq066; Creemers EEJM, 2001, CIRC RES, V89, P201, DOI 10.1161/hh1501.094396; Diwan A, 2003, CURR MOL MED, V3, P161, DOI 10.2174/1566524033361537; Dorn GW, 2009, CARDIOVASC RES, V81, P465, DOI 10.1093/cvr/cvn243; Eapen Z, 2009, CURR OPIN CARDIOL, V24, P223, DOI 10.1097/HCO.0b013e32832a11ff; Gao E, 2010, CIRC RES, V107, P1445, DOI 10.1161/CIRCRESAHA.110.223925; Gonzalez A, 2011, J AM COLL CARDIOL, V58, P1833, DOI 10.1016/j.jacc.2011.06.058; Jessup M, 2003, NEW ENGL J MED, V348, P2007, DOI 10.1056/NEJMra021498; Jitkova Y, 2012, CIRCULATION, V125, P3159; Kandasamy AD, 2010, CARDIOVASC RES, V85, P413, DOI 10.1093/cvr/cvp268; Kido M, 2005, J AM COLL CARDIOL, V46, P2116, DOI 10.1016/j.jacc.2005.08.045; Kim MY, 2010, CARDIOVASC RES, V87, P119, DOI 10.1093/cvr/cvq048; Kim SJ, 2014, ARCH PHARM RES, V37, P1079, DOI 10.1007/s12272-013-0309-x; Konstam MA, 2011, JACC-CARDIOVASC IMAG, V4, P98, DOI 10.1016/j.jcmg.2010.10.008; Konstantinidis K, 2012, ARTERIOSCL THROM VAS, V32, P1552, DOI 10.1161/ATVBAHA.111.224915; Lal H, 2012, CIRCULATION, V125, P65, DOI 10.1161/CIRCULATIONAHA.111.050666; Paulus W J, 2000, Heart Fail Monit, V1, P50; Pchejetski D, 2012, EUR HEART J, V33, P2360, DOI 10.1093/eurheartj/ehr389; Samsamshariat SA, 2005, CARDIOVASC REVASCULA, V6, P70, DOI 10.1016/j.carrev.2005.07.002; Shin JW, 2014, BIOMOL THER, V22, P17, DOI 10.4062/biomolther.2013.102; Strauer BE, 2010, EUR J HEART FAIL, V12, P721, DOI 10.1093/eurjhf/hfq095; Sutton MGS, 2000, CIRCULATION, V101, P2981, DOI 10.1161/01.CIR.101.25.2981; Tang W H Wilson, 2011, Congest Heart Fail, V17, P105, DOI 10.1111/j.1751-7133.2011.00221.x; van den Borne SWM, 2010, NAT REV CARDIOL, V7, P30, DOI 10.1038/nrcardio.2009.199; van Wijk B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044692; Yamazaki KG, 2008, AM J PHYSIOL-HEART C, V295, pH761, DOI 10.1152/ajpheart.00413.2008; Yamazaki KG, 2010, J AM COLL CARDIOL, V55, P2869, DOI 10.1016/j.jacc.2010.01.055; Yang B, 2013, EXPERT OPIN THER TAR, V17, P255, DOI 10.1517/14728222.2013.745513; Yang HI, 2013, BIOMOL THER, V21, P84, DOI 10.4062/biomolther.2012.101; Yi W, 2012, CIRCULATION, V125, P3159, DOI 10.1161/CIRCULATIONAHA.112.099937; Yu HY, 2011, FOOD CHEM TOXICOL, V49, P3018, DOI 10.1016/j.fct.2011.09.038	33	46	46	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 5	2015	10	1							e110596	10.1371/journal.pone.0110596	http://dx.doi.org/10.1371/journal.pone.0110596			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AZ3BG	25559243	Green Submitted, Green Published, gold			2023-01-03	WOS:000348102200002
J	Linnemann, C; van Buuren, MM; Bies, L; Verdegaal, EME; Schotte, R; Calis, JJA; Behjati, S; Velds, A; Hilkmann, H; el Atmioui, D; Visser, M; Stratton, MR; Haanen, JBAG; Spits, H; van der Burg, SH; Schumacher, TNM				Linnemann, Carsten; van Buuren, Marit M.; Bies, Laura; Verdegaal, Els M. E.; Schotte, Remko; Calis, Jorg J. A.; Behjati, Sam; Velds, Arno; Hilkmann, Henk; el Atmioui, Dris; Visser, Marten; Stratton, Michael R.; Haanen, John B. A. G.; Spits, Hergen; van der Burg, Sjoerd H.; Schumacher, Ton N. M.			High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4(+) T cells in human melanoma	NATURE MEDICINE			English	Article							CD4+T CELLS; B-CELLS; TUMOR; PATIENT; IDENTIFICATION; REACTIVITY; GENES	Tumor-specific neo-antigens that arise as a consequence of mutations(1,2) are thought to be important for the therapeutic efficacy of cancer immunotherapies(3-5). Accumulating evidence suggests that neo-antigens may be commonly recognized by intratumoral CD8(+) T cells(3-7), but it is unclear whether neoantigen-specific CD4(+) T cells also frequently reside within human tumors. In view of the accepted role of tumor-specific CD4(+) T-cell responses in tumor control(8-10), we addressed whether neo-antigen-specific CD4(+) T-cell reactivity is a common property in human melanoma.	[Linnemann, Carsten; van Buuren, Marit M.; Bies, Laura; Calis, Jorg J. A.; Haanen, John B. A. G.; Schumacher, Ton N. M.] Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands; [Verdegaal, Els M. E.; Visser, Marten; van der Burg, Sjoerd H.] Leiden Univ, Med Ctr, Dept Clin Oncol, Leiden, Netherlands; [Schotte, Remko; Spits, Hergen] AIMM Therapeut BV, Amsterdam, Netherlands; [Behjati, Sam; Stratton, Michael R.] Wellcome Trust Res Labs, Wellcome Trust Sanger Inst, Canc Genome Project, Hinxton, England; [Velds, Arno] Netherlands Canc Inst, Cent Genom Facil, Amsterdam, Netherlands; [Hilkmann, Henk; el Atmioui, Dris] Netherlands Canc Inst, Peptide Synth Facil, Amsterdam, Netherlands; [Haanen, John B. A. G.] Netherlands Canc Inst, Div Med Oncol, Amsterdam, Netherlands	Netherlands Cancer Institute; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Wellcome Trust Sanger Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute	Schumacher, TNM (corresponding author), Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands.	c.linnemann@nki.nl; t.schumacher@nki.nl	van der Burg, Sjoerd H/T-1875-2017; Spits, Hergen/N-2581-2019; Schumacher, Ton/Y-2432-2019; Haanen, John/AAD-8578-2022; Verdegaal, Elizabeth/Y-2597-2018; Haanen, John/AAD-8534-2022	van der Burg, Sjoerd H/0000-0002-6556-0354; Spits, Hergen/0000-0003-3269-8338; Schumacher, Ton/0000-0003-0517-8804; Verdegaal, Elizabeth/0000-0002-4449-8707; Haanen, John/0000-0001-5884-7704; Velds, Arno/0000-0003-4333-8872	Worldwide Cancer Research [14-0321]; PhD Fellowship Program of Boehringer Ingelheim Fonds-Foundation; Dutch Cancer Society [UVA 2010-4822, NKI 2012-5463, UL 2012-5544]; Wellcome Trust Research Training Fellowship for Clinicians; Wellcome Trust [WT098051]; Anticancer Fund; K.G. Jebsen Foundation; EU; Stand Up To Cancer-Cancer Research Institute Cancer Immunology Translational Cancer Research Grant	Worldwide Cancer Research; PhD Fellowship Program of Boehringer Ingelheim Fonds-Foundation(Boehringer Ingelheim); Dutch Cancer Society(KWF Kankerbestrijding); Wellcome Trust Research Training Fellowship for Clinicians; Wellcome Trust(Wellcome TrustEuropean Commission); Anticancer Fund; K.G. Jebsen Foundation; EU(European Commission); Stand Up To Cancer-Cancer Research Institute Cancer Immunology Translational Cancer Research Grant	We are grateful to A. Pfauth, F. van Diepen and C. Bachas for flow cytometric support; W van de Kasteele and T. de Jong for technical assistance; N. van Root) and B. Heemskerk for handling of patient material; and R. Kluin, M. Nieuwland and R. van Kerkhoven for support with next generation sequencing. We thank G. Bendle and P. Kvistborg for critical reading of the manuscript, and members from the Schumacher and Haanen laboratories for useful discussions. This work was supported by Worldwide Cancer Research grant 14-0321 (to C.L. and T.N.M.S.), the PhD Fellowship Program of Boehringer Ingelheim Fonds-Foundation for Basic Research in Biomedicine (to C.L.), Dutch Cancer Society grants: UVA 2010-4822 (to H.S.), NKI 2012-5463 (to J.B.A.G.H., S.H.v.d.B. and T.N.M.S.) and UL 2012-5544 (to E.M.E.V.), The Wellcome Trust Research Training Fellowship for Clinicians (to S.B.), The Wellcome Trust Grant WT098051 (to MRS.), the Anticancer Fund (to E.M.E.V., M.V.) the K.G. Jebsen Foundation (to T.N.M.S.), EU FP7 SUPERSIST, and the Stand Up To Cancer-Cancer Research Institute Cancer Immunology Translational Cancer Research Grant (to T.N.M.S.). SU2C is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research.	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Britten CM, 2013, NAT BIOTECHNOL, V31, P880, DOI 10.1038/nbt.2708; Champiat S, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.27817; Deffrennes V, 2001, J IMMUNOL, V167, P98, DOI 10.4049/jimmunol.167.1.98; Friedman KM, 2012, J IMMUNOTHER, V35, P400, DOI 10.1097/CJI.0b013e31825898c5; Hunder NN, 2008, NEW ENGL J MED, V358, P2698, DOI 10.1056/NEJMoa0800251; Jandus C, 2009, CANCER RES, V69, P8085, DOI 10.1158/0008-5472.CAN-09-2226; Kenter GG, 2009, NEW ENGL J MED, V361, P1838, DOI 10.1056/NEJMoa0810097; Kitano S, 2013, CANCER IMMUNOL RES, V1, P235, DOI 10.1158/2326-6066.CIR-13-0068; Kvistborg P, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008918; Kvistborg P, 2012, ONCOIMMUNOLOGY, V1, DOI 10.4161/onci.18851; Kwakkenbos MJ, 2014, METHODS, V65, P38, DOI 10.1016/j.ymeth.2013.07.002; Kwakkenbos MJ, 2010, NAT MED, V16, P123, DOI 10.1038/nm.2071; Lu YC, 2014, CLIN CANCER RES, V20, P3401, DOI 10.1158/1078-0432.CCR-14-0433; Lu YC, 2013, J IMMUNOL, V190, P6034, DOI 10.4049/jimmunol.1202830; Mason D, 1998, IMMUNOL TODAY, V19, P395, DOI 10.1016/S0167-5699(98)01299-7; Mautner J, 2005, INT J CANCER, V115, P752, DOI 10.1002/ijc.20927; Ossendorp F, 1998, J EXP MED, V187, P693, DOI 10.1084/jem.187.5.693; Overwijk WW, 2013, J IMMUNOTHER CANCER, V1, DOI 10.1186/2051-1426-1-11; Quezada SA, 2010, J EXP MED, V207, P637, DOI 10.1084/jem.20091918; Rajasagi M, 2014, BLOOD, V124, P453, DOI 10.1182/blood-2014-04-567933; Robbins PF, 2013, NAT MED, V19, P747, DOI 10.1038/nm.3161; Tran E, 2014, SCIENCE, V344, P641, DOI 10.1126/science.1251102; van Rooij N, 2013, J CLIN ONCOL, V31, pE439, DOI 10.1200/JCO.2012.47.7521; Verdegaal EME, 2011, CANCER IMMUNOL IMMUN, V60, P953, DOI 10.1007/s00262-011-1004-8; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wang RF, 1999, SCIENCE, V284, P1351, DOI 10.1126/science.284.5418.1351; Wick DA, 2014, CLIN CANCER RES, V20, P1125, DOI 10.1158/1078-0432.CCR-13-2147	28	473	501	5	91	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2015	21	1					81	85		10.1038/nm.3773	http://dx.doi.org/10.1038/nm.3773			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	AZ7OM	25531942				2023-01-03	WOS:000348408000017
J	Somagoni, J; Boakye, CHA; Godugu, C; Patel, AR; Faria, HAM; Zucolotto, V; Singh, M				Somagoni, Jaganmohan; Boakye, Cedar H. A.; Godugu, Chandraiah; Patel, Apurva R.; Mendonca Faria, Henrique Antonio; Zucolotto, Valtencir; Singh, Mandip			Nanomiemgel - A Novel Drug Delivery System for Topical Application - In Vitro and In Vivo Evaluation	PLOS ONE			English	Article							LIPID NANOPARTICLES; SKIN INFLAMMATION; MODEL; COMBINATION; FORMULATION; INHIBITION; CAPSAICIN; RELEASE; PATHWAY; NSAIDS	Aim: The objective of this study was to formulate and evaluate a unique matrix mixture (nanomiemgel) of nanomicelle and nanoemulsion containing aceclofenac and capsaicin using in vitro and in vivo analyses and to compare it to a marketed formulation (Aceproxyvon). Methods: Nanomicelles were prepared using Vitamin E TPGS by solvent evaporation method and nanoemulsion was prepared by high-pressure homogenization method. In vitro drug release and human skin permeation studies were performed and analyzed using HPLC. The efficiency of nanomiemgel as a delivery system was investigated using an imiquimod-induced psoriatic like plaque model developed in C57BL/6 mice. Results: Atomic Force Microscopy images of the samples exhibited a globular morphology with an average diameter of 200, 250 and 220 nm for NMI, NEM and NMG, respectively. Nanomiemgel demonstrated a controlled release drug pattern and induced 2.02 and 1.97-fold more permeation of aceclofenac and capsaicin, respectively than Aceproxyvon through dermatomed human skin. Nanomiemgel also showed 2.94 and 2.09-fold greater Cmax of aceclofenac and capsaicin, respectively than Aceproxyvon in skin microdialysis study in rats. The PASI score, ear thickness and spleen weight of the imiquimod-induced psoriatic-like plaque model were significantly (p<0.05) reduced in NMG treated mice compared to free drug, NEM, NMI & Aceproxyvon. Conclusion: Using a new combination of two different drug delivery systems (NEM+ NMI), the absorption of the combined system (NMG) was found to be better than either of the individual drug delivery systems due to the utilization of the maximum possible paths of absorption available for that particular drug. of of	[Somagoni, Jaganmohan; Boakye, Cedar H. A.; Godugu, Chandraiah; Patel, Apurva R.; Singh, Mandip] Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Tallahassee, FL 32307 USA; [Mendonca Faria, Henrique Antonio; Zucolotto, Valtencir] Univ Sao Paulo, Nanomed & Nanotoxicol Grp, Phys Inst Sao Carlos, BR-13566590 Sao Carlos, SP, Brazil	State University System of Florida; Florida A&M University; Universidade de Sao Paulo	Singh, M (corresponding author), Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Tallahassee, FL 32307 USA.	mandip.sachdeva@famu.edu	Faria, Henrique Antonio Mendonça/M-5774-2013; Zucolotto, Valtencir/B-9103-2012; Faria, Henrique A. M./K-2782-2019; Godugu, Chandraiah/F-4741-2018	Faria, Henrique Antonio Mendonça/0000-0001-6976-6897; Faria, Henrique A. M./0000-0001-6976-6897; Godugu, Chandraiah/0000-0001-5904-3134; HYDERABAD, NIPER/0000-0001-7521-1150; Zucolotto, Valtencir/0000-0003-4307-3077; Sachdeva, Mandip/0000-0001-9192-8143	NCRR NIH HHS [G12RR 03020] Funding Source: Medline; NIMHD NIH HHS [P20 MD006738, G12 MD007582] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003020] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [G12MD007582] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIMHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))		Alvarez-Soria MA, 2006, ANN RHEUM DIS, V65, P998, DOI 10.1136/ard.2005.046920; Bhattacharyya S, 2014, BIOMATERIALS, V35, P509, DOI 10.1016/j.biomaterials.2013.09.073; Byamba D, 2014, EXP DERMATOL, V13, P12448; Chooluck K, 2013, PHARMAZIE, V68, P135, DOI 10.1691/ph.2013.2116; Chougule M, 2011, LUNG CANCER, V71, P271, DOI 10.1016/j.lungcan.2010.06.002; Chougule MB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017733; Dasgupta S, 2013, CURR DRUG DELIV, V10, P656, DOI 10.2174/156720181006131125150023; Desai PR, 2013, J CONTROL RELEASE, V170, P51, DOI 10.1016/j.jconrel.2013.04.021; Desai PR, 2012, PHARM RES-DORDR, V29, P2587, DOI 10.1007/s11095-012-0789-2; Ercan N, 2013, INFLAMMOPHARMACOLOGY, V21, P413, DOI 10.1007/s10787-013-0175-7; Flutter B, 2013, EUR J IMMUNOL, V43, P3138, DOI 10.1002/eji.201343801; Gomes MJ, 2014, INT J NANOMED, V9, P1231, DOI 10.2147/IJN.S45561; Kakumanu S, 2011, NANOMED-NANOTECHNOL, V7, P277, DOI 10.1016/j.nano.2010.12.002; Lapeyre-Mestre M, 2013, FUND CLIN PHARMACOL, V27, P223, DOI 10.1111/j.1472-8206.2011.00991.x; Laporte JR, 2004, DRUG SAFETY, V27, P411, DOI 10.2165/00002018-200427060-00005; Lau WM, 2008, CURR PHARM DESIGN, V14, P794, DOI 10.2174/138161208784007653; Lee SE, 2013, EXP DERMATOL, V22, P59, DOI 10.1111/exd.12055; Manjanna KM, 2010, CRIT REV THER DRUG, V27, P509, DOI 10.1615/CritRevTherDrugCarrierSyst.v27.i6.20; Martin-Martinez J, 2014, 2014 POW SYST COMP C, P1, DOI 10.1109/VARI.2014. 6957088; Mizoguchi H, 2014, PEPTIDES, V51, P15, DOI 10.1016/j.peptides.2013.10.012; Mozsik G, 2014, PROG DRUG RES, V68, P209, DOI 10.1007/978-3-0348-0828-6_9; Nasr M, 2008, J MICROENCAPSUL, V25, P499, DOI [10.1080/02652040802055411, 10.1080/02652040802055411 ]; Oshima S, 2012, BIOL PHARM BULL, V35, P203, DOI 10.1248/bpb.35.203; Pande V, 2014, ADV PHARM BULL, V4, P121, DOI 10.5681/apb.2014.019; Puglia C, 2013, CURR MED CHEM, V20, P1847; Raza K, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/406731; Sahoo S, 2014, DRUG DELIV, V20, P1; Shah PP, 2012, J CONTROL RELEASE, V161, P735, DOI 10.1016/j.jconrel.2012.05.011; Shah PP, 2012, BIOMATERIALS, V33, P1607, DOI 10.1016/j.biomaterials.2011.11.011; Singh TP, 2011, AM J PATHOL, V178, P699, DOI 10.1016/j.ajpath.2010.10.008; Tausend W, 2014, J CUTAN MED SURG, V18, P156, DOI 10.2310/7750.2013.13125; Tavano L, 2011, COLLOID SURFACE B, V87, P333, DOI 10.1016/j.colsurfb.2011.05.041; van der Fits L, 2009, J IMMUNOL, V182, P5836, DOI 10.4049/jimmunol.0802999; Wavikar P, 2013, AAPS PHARMSCITECH, V14, P222, DOI 10.1208/s12249-012-9908-y; Yu M, 2014, EUR J PHARM BIOPHARM, V2	35	43	45	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 29	2014	9	12							e115952	10.1371/journal.pone.0115952	http://dx.doi.org/10.1371/journal.pone.0115952			30	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX7UN	25546392	Green Published, Green Submitted, gold			2023-01-03	WOS:000347120200085
J	Song, LW; Yang, MC; Knoff, JN; Wu, TC; Hung, CF				Song, Liwen; Yang, Ming-Chieh; Knoff, Jayne; Wu, T. -C.; Hung, Chien-Fu			Cancer Immunotherapy Employing an Innovative Strategy to Enhance CD4+T Cell Help in the Tumor Microenvironment	PLOS ONE			English	Article							CROSS-PRESENTATION; ANTIGENIC PEPTIDE; IMMUNE-RESPONSES; VACCINE POTENCY; CPG DNA; ADJUVANT; RADIOTHERAPY; COMBINATION; DELIVERY	Chemotherapy and/or radiation therapy are widely used as cancer treatments, but the antitumor effects they produce can be enhanced when combined with immunotherapies. Chemotherapy kills tumor cells, but it also releases tumor antigen and allows the cross-presentation of the tumor antigen to trigger antigen-specific cell-mediated immune responses. Promoting CD4+ T helper cell immune responses can be used to enhance the cross-presentation of the tumor antigen following chemotherapy. The pan HLA-DR binding epitope (PADRE peptide) is capable of generating antigen-specific CD4+ T cells that bind various MHC class II molecules with high affinity and has been widely used in conjunction with vaccines to improve their potency by enhancing CD4+ T cell responses. Here, we investigated whether intratumoral injection of PADRE and the adjuvant CpG into HPV16 E7-expressing TC-1 tumors following cisplatin chemotherapy could lead to potent antitumor effects and antigen-specific cell-mediated immune responses. We observed that treatment with all three agents produced the most potent antitumor effects compared to pairwise combinations. Moreover, treatment with cisplatin, CpG and PADRE was able to control tumors at a distant site, indicating that our approach is able to induce cross-presentation of the tumor antigen. Treatment with cisplatin, CpG and PADRE also enhanced the generation of PADRE-specific CD4+ T cells and E7-specific CD8+ T cells and decreased the number of MDSCs in tumor loci. The treatment regimen presented here represents a universal approach to cancer control.	[Song, Liwen] Tongji Univ, Shanghai Peoples Hosp 10, Dept Obstet & Gynecol, Shanghai 200092, Peoples R China; [Song, Liwen] Fudan Univ, Sch Pharm, Shanghai 200433, Peoples R China; [Song, Liwen] Shanghai Inst Planned Parenthood Res, Dept Pharmacol & Toxicol, Shanghai, Peoples R China; [Song, Liwen; Knoff, Jayne; Wu, T. -C.; Hung, Chien-Fu] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; [Wu, T. -C.] Johns Hopkins Med Inst, Dept Obstet & Gynecol, Baltimore, MD 21205 USA; [Wu, T. -C.] Johns Hopkins Med Inst, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; [Wu, T. -C.; Hung, Chien-Fu] Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA; [Yang, Ming-Chieh] Kaohsiung Vet Gen Hosp, Kaohsiung, Taiwan	Tongji University; Fudan University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Kaohsiung Veterans General Hospital	Hung, CF (corresponding author), Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA.	chung2@jhmi.edu		Bissonette, Jayne/0000-0001-8376-9242	National Institutes of Health/National Cancer Institute Cervical Cancer [SPORE P50CA098252, 2R01CA114425-06]; NATIONAL CANCER INSTITUTE [P50CA098252, R01CA114425] Funding Source: NIH RePORTER	National Institutes of Health/National Cancer Institute Cervical Cancer; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Institutes of Health/National Cancer Institute Cervical Cancer SPORE P50CA098252 and 2R01CA114425-06 grants. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALEXANDER J, 1994, IMMUNITY, V1, P751, DOI 10.1016/S1074-7613(94)80017-0; Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498; Carpentier AF, 1999, CANCER RES, V59, P5429; Chuang TH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108808; Ellerby HM, 1999, NAT MED, V5, P1032, DOI 10.1038/12469; Gray RC, 2007, J LEUKOCYTE BIOL, V81, P1075, DOI 10.1189/jlb.1006606; Hung CF, 2007, MOL THER, V15, P1211, DOI 10.1038/sj.mt.6300121; Kang TH, 2013, CELL BIOSCI, V3, DOI 10.1186/2045-3701-3-48; Kang TH, 2013, CANCER RES, V73, P2493, DOI 10.1158/0008-5472.CAN-12-4241; Kang TH, 2013, MOL THER, V21, P542, DOI 10.1038/mt.2012.233; Kim D, 2008, GENE THER, V15, P677, DOI 10.1038/sj.gt.3303102; Kuchtey J, 2005, J IMMUNOL, V175, P2244, DOI 10.4049/jimmunol.175.4.2244; La Rosa C, 2012, J INFECT DIS, V205, P1294, DOI 10.1093/infdis/jis107; Lee S, 2010, CANCER IMMUNOL IMMUN, V59, P1073, DOI 10.1007/s00262-010-0834-0; Lin KY, 1996, CANCER RES, V56, P21; Link BK, 2006, J IMMUNOTHER, V29, P558, DOI 10.1097/01.cji.0000211304.60126.8f; Meng YX, 2005, INT J CANCER, V116, P992, DOI 10.1002/ijc.21131; Peng SW, 2013, CANCER IMMUNOL IMMUN, V62, P171, DOI 10.1007/s00262-012-1322-5; Shirota H, 2014, EXPERT REV VACCINES, V13, P299, DOI 10.1586/14760584.2014.863715; Sinha P, 2011, BLOOD, V117, P5381, DOI 10.1182/blood-2010-11-321752; Wierecky J, 2006, CANCER RES, V66, P5910, DOI 10.1158/0008-5472.CAN-05-3905; Wu A, 2011, GENE THER, V18, P304, DOI 10.1038/gt.2010.151; Wu CY, 2014, CLIN CANCER RES, V20, P644, DOI 10.1158/1078-0432.CCR-13-1334; Wu CY, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-88; Zoglmeier C, 2011, CLIN CANCER RES, V17, P1765, DOI 10.1158/1078-0432.CCR-10-2672	26	12	12	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 22	2014	9	12							e115711	10.1371/journal.pone.0115711	http://dx.doi.org/10.1371/journal.pone.0115711			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA3ZY	25531529	gold, Green Submitted, Green Published			2023-01-03	WOS:000348845100100
J	Hou, Q; He, WJ; Hao, HJ; Han, QW; Chen, L; Dong, L; Liu, JJ; Li, X; Zhang, YJ; Ma, YZ; Han, WD; Fu, XB				Hou, Qian; He, Wen-Jun; Hao, Hao-Jie; Han, Qing-Wang; Chen, Li; Dong, Liang; Liu, Jie-Jie; Li, Xiang; Zhang, Ya-Jing; Ma, Ying-Zhi; Han, Wei-Dong; Fu, Xiao-Bing			The Four-Herb Chinese Medicine ANBP Enhances Wound Healing and Inhibits Scar Formation via Bidirectional Regulation of Transformation Growth Factor Pathway	PLOS ONE			English	Article							RABBIT EAR; RAT SKIN; REPAIR; FIBROSIS; MECHANISMS; REGENERATION; INFLAMMATION; FIBROBLASTS; EXPRESSION; CELLS	The four-herb Chinese medicine ANBP is a pulverized mixture of four herbs including Agrimonia Eupatoria (A), Nelumbo Nucifera Gaertn (N), Boswellia Carteri (B) and Pollen Typhae Angustifoliae (P). The combination of the four herbs was first described in Chinese canonical medicine about 2000 years ago for treatment of various trauma disorders, such as hemostasis, antiinflammatory, analgesia, and wound healing, etc. However, the precise mechanisms of ANBP are still unclear. In our study, using rabbit ear hypertrophic scar models of full-thickness skin defect, we showed that local ANBP treatment not only significantly enhanced wound healing by relieving inflammation, increasing formation of granulation tissue and accelerating re-epithelialization, but also reduced scar formation by decreasing collagen production, protuberant height and volume of scars, and increasing collagen maturity. We demonstrated that these effects of ANBP are associated with transforming growth factor (TGF)-beta 1-mediated signalling pathways through Smad-dependent pathways. ANBP treatment significantly increased expression of TGF-beta 1 and Smad2/3 mRNA at the early stage of wound healing, and led to markedly decrease expression of TGF-beta 1 and Smad2/3 compared with the control group after 14 days post-wounding. Taken together, our results defined a bidirectional regulation role of ANBP for TGF-beta 1/Smad pathway in promoting wound healing and alleviating scar formation, which may be an effective therapy for human wounds at the earliest stage.	[Hou, Qian; He, Wen-Jun; Hao, Hao-Jie; Han, Qing-Wang; Chen, Li; Dong, Liang; Liu, Jie-Jie; Li, Xiang; Zhang, Ya-Jing; Ma, Ying-Zhi; Han, Wei-Dong; Fu, Xiao-Bing] Chinese Peoples Liberat Army Gen Hosp, Inst Basic Med, Beijing, Peoples R China; [Hou, Qian] Chinese PLA 148th Hosp, Dept Internal Med, Zibo, Peoples R China; [Fu, Xiao-Bing] Chinese Peoples Liberat Army Gen Hosp, Affiliated Hosp 1, Wound Healing & Cell Biol Lab, Beijing, Peoples R China	Chinese People's Liberation Army General Hospital; Chinese People's Liberation Army General Hospital	Han, WD (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Inst Basic Med, Beijing, Peoples R China.	hanwdrsw69@yahoo.com; fuxiaobing@vip.sina.com	Hao, Haojie/D-6982-2013		National Basic Science and Development Program (973 Programme) [2012CB518103, 2012CB518105]; 863 Projects of Ministry of Science and Technology of China [2013AA020105, 2012AA020502]; National Natural Science Foundation of China [81121004, 81230041, 31100705, 30901564, 81101883]; China Postdoctoral Science Foundation [2013M542517]; Beijing Novel Program [2008B53, 2009A038]; Science and Technology Project of Hunan Provincial Science and Technology Department [2012FJ3012]; Scientific Research Project of Traditional Chinese Medicine in Hunan Province [2012111]	National Basic Science and Development Program (973 Programme)(National Basic Research Program of China); 863 Projects of Ministry of Science and Technology of China(National High Technology Research and Development Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Beijing Novel Program(Beijing Municipal Science & Technology Commission); Science and Technology Project of Hunan Provincial Science and Technology Department; Scientific Research Project of Traditional Chinese Medicine in Hunan Province	This research was supported in part by the National Basic Science and Development Program (973 Programme, 2012CB518103 and 2012CB518105), the 863 Projects of Ministry of Science and Technology of China (2013AA020105 and 2012AA020502), the National Natural Science Foundation of China (81121004, 81230041, 31100705, 30901564, and 81101883), the China Postdoctoral Science Foundation (2013M542517), the Beijing Novel Program (2008B53, 2009A038), the Science and Technology Project of Hunan Provincial Science and Technology Department (2012FJ3012) and the Scientific Research Project of Traditional Chinese Medicine in Hunan Province (2012111). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AMENTO EP, 1991, CIBA F SYMP, V157, P115; Colwell AS, 2005, PLAST RECONSTR SURG, V116, P1387, DOI 10.1097/01.prs.0000182343.99694.28; Colwell AS, 2005, ADV BIOCHEM ENG BIOT, V93, P83, DOI 10.1007/b99972; Colwell AS, 2003, FRONT BIOSCI-LANDMRK, V8, pS1240, DOI 10.2741/1183; Cuttle L, 2005, WOUND REPAIR REGEN, V13, P198, DOI 10.1111/j.1067-1927.2005.130211.x; Falanga V, 2005, LANCET, V366, P1736, DOI 10.1016/S0140-6736(05)67700-8; Gurtner GC, 2008, NATURE, V453, P314, DOI 10.1038/nature07039; Hou Q, 2011, CANCER SCI, V102, P1287, DOI 10.1111/j.1349-7006.2011.01933.x; Ihn H, 2008, J DERMATOL SCI, V49, P103, DOI 10.1016/j.jdermsci.2007.05.014; Kapoor M, 2008, J CLIN INVEST, V118, P3279, DOI 10.1172/JCI35381; Kim JJ, 2012, J ETHNOPHARMACOL, V140, P213, DOI 10.1016/j.jep.2011.12.035; Lam W, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001270; Li P, 2011, J PATHOL, V223, P659, DOI 10.1002/path.2831; LIN RY, 1995, ANN SURG, V222, P146, DOI 10.1097/00000658-199508000-00006; Liu X, 2005, J TRAUMA, V59, P682, DOI 10.1097/01.ta.0000177674.55388.40; Martin P, 2005, TRENDS CELL BIOL, V15, P599, DOI 10.1016/j.tcb.2005.09.002; Meng FW, 2008, J CELL SCI, V121, P2904, DOI 10.1242/jcs.032417; Mori R, 2008, J EXP MED, V205, P43, DOI 10.1084/jem.20071412; Mutsaers SE, 1997, INT J BIOCHEM CELL B, V29, P5, DOI 10.1016/S1357-2725(96)00115-X; Ohkura N, 2012, BLOOD COAGUL FIBRIN, V23, P254, DOI 10.1097/MBC.0b013e3283504148; Pugazhenthi K, 2008, J PINEAL RES, V44, P387, DOI 10.1111/j.1600-079X.2007.00541.x; Roberts AB, 2006, CYTOKINE GROWTH F R, V17, P19, DOI 10.1016/j.cytogfr.2005.09.008; SHAH M, 1995, J CELL SCI, V108, P985; Shi HX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059966; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Tilton Robert, 2010, Chin Med, V5, P30, DOI 10.1186/1749-8546-5-30; Wolcott R D, 2008, J Wound Care, V17, P333; Wolfram D, 2009, DERMATOL SURG, V35, P171, DOI 10.1111/j.1524-4725.2008.34406.x; Xie JL, 2008, WOUND REPAIR REGEN, V16, P576, DOI 10.1111/j.1524-475X.2008.00405.x; Ye M, 2007, RAPID COMMUN MASS SP, V21, P3593, DOI 10.1002/rcm.2832	30	24	28	2	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2014	9	12							e112274	10.1371/journal.pone.0112274	http://dx.doi.org/10.1371/journal.pone.0112274			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AY3YM	25489732	Green Published, gold, Green Submitted			2023-01-03	WOS:000347515300002
J	Bansal, M; Yang, JC; Karan, C; Menden, MP; Costello, JC; Tang, H; Xiao, GH; Li, YJ; Allen, J; Zhong, R; Chen, BB; Kim, MS; Wang, T; Heiser, LM; Realubit, R; Mattioli, M; Alvarez, MJ; Shen, Y; Gallahan, D; Singer, D; Saez-Rodriguez, J; Xie, Y; Stolovitzky, G; Califano, A; Abbuehl, JP; Altman, RB; Balcome, S; Bell, A; Bender, A; Berger, B; Bernard, J; Bieberich, AA; Borboudakis, G; Chan, C; Chen, TH; Choi, J; Coelho, LP; Creighton, CJ; Dampier, W; Davisson, VJ; Deshpande, R; Diao, LX; Di Camillo, B; Dundar, M; Ertel, A; Goswami, CP; Gottlieb, A; Gould, MN; Goya, J; Grau, M; Gray, JW; Hejase, HA; Hoffmann, MF; Homicsko, K; Homilius, M; Hwang, W; Ijzerman, AP; Kallioniemi, O; Karacali, B; Kaski, S; Kim, J; Krishnan, A; Lee, J; Lee, YS; Lenselink, EB; Lenz, P; Li, L; Li, J; Liang, H; Mpindi, JP; Myers, CL; Newton, MA; Overington, JP; Parkkinen, J; Prill, RJ; Peng, J; Pestell, R; Qiu, P; Rajwa, B; Sadanandam, A; Sambo, F; Sridhar, A; Sun, W; Toffolo, GM; Tozeren, A; Troyanskaya, OG; Tsamardinos, I; van Vlijmen, HWT; Wang, W; Wegner, JK; Wennerberg, K; van Westen, GJP; Xia, T; Yang, Y; Yao, V; Yuan, Y; Zeng, HY; Zhang, SH; Zhao, JF; Zhou, J				Bansal, Mukesh; Yang, Jichen; Karan, Charles; Menden, Michael P.; Costello, James C.; Tang, Hao; Xiao, Guanghua; Li, Yajuan; Allen, Jeffrey; Zhong, Rui; Chen, Beibei; Kim, Minsoo; Wang, Tao; Heiser, Laura M.; Realubit, Ronald; Mattioli, Michela; Alvarez, Mariano J.; Shen, Yao; Gallahan, Daniel; Singer, Dinah; Saez-Rodriguez, Julio; Xie, Yang; Stolovitzky, Gustavo; Califano, Andrea; Abbuehl, Jean-Paul; Altman, Russ B.; Balcome, Shawn; Bell, Ana; Bender, Andreas; Berger, Bonnie; Bernard, Jonathan; Bieberich, Andrew A.; Borboudakis, Giorgos; Chan, Christina; Chen, Ting-Huei; Choi, Jaejoon; Coelho, Luis Pedro; Creighton, Chad J.; Dampier, Will; Davisson, V. Jo; Deshpande, Raamesh; Diao, Lixia; Di Camillo, Barbara; Dundar, Murat; Ertel, Adam; Goswami, Chirayu P.; Gottlieb, Assaf; Gould, Michael N.; Goya, Jonathan; Grau, Michael; Gray, Joe W.; Hejase, Hussein A.; Hoffmann, Michael F.; Homicsko, Krisztian; Homilius, Max; Hwang, Woochang; Ijzerman, Adriaan P.; Kallioniemi, Olli; Karacali, Bilge; Kaski, Samuel; Kim, Junho; Krishnan, Arjun; Lee, Junehawk; Lee, Young-Suk; Lenselink, Eelke B.; Lenz, Peter; Li, Lang; Li, Jun; Liang, Han; Mpindi, John-Patrick; Myers, Chad L.; Newton, Michael A.; Overington, John P.; Parkkinen, Juuso; Prill, Robert J.; Peng, Jian; Pestell, Richard; Qiu, Peng; Rajwa, Bartek; Sadanandam, Anguraj; Sambo, Francesco; Sridhar, Arvind; Sun, Wei; Toffolo, Gianna M.; Tozeren, Aydin; Troyanskaya, Olga G.; Tsamardinos, Ioannis; van Vlijmen, Herman W. T.; Wang, Wen; Wegner, Joerg K.; Wennerberg, Krister; van Westen, Gerard J. P.; Xia, Tian; Yang, Yang; Yao, Victoria; Yuan, Yuan; Zeng, Haoyang; Zhang, Shihua; Zhao, Junfei; Zhou, Jian		Cellworks Group; NCI-DREAM Community	A community computational challenge to predict the activity of pairs of compounds	NATURE BIOTECHNOLOGY			English	Article							DRUG-COMBINATIONS; SYSTEMS BIOLOGY; CANCER; THERAPY; NETWORK; CHEMOTHERAPY; MODELS; INHIBITION; EXPRESSION; RESISTANCE	Recent therapeutic successes have renewed interest in drug combinations, but experimental screening approaches are costly and often identify only small numbers of synergistic combinations. The DREAM consortium launched an open challenge to foster the development of in silico methods to computationally rank 91 compound pairs, from the most synergistic to the most antagonistic, based on gene-expression profiles of human B cells treated with individual compounds at multiple time points and concentrations. Using scoring metrics based on experimental dose-response curves, we assessed 32 methods (31 community-generated approaches and SynGen), four of which performed significantly better than random guessing. We highlight similarities between the methods. Although the accuracy of predictions was not optimal, we find that computational prediction of compound-pair activity is possible, and that community challenges can be useful to advance the field of in silico compound-synergy prediction.	[Bansal, Mukesh; Alvarez, Mariano J.; Shen, Yao; Califano, Andrea] Columbia Univ, Dept Syst Biol, New York, NY USA; [Bansal, Mukesh; Alvarez, Mariano J.; Shen, Yao; Califano, Andrea] Columbia Univ, Ctr Computat Biol & Bioinformat, New York, NY USA; [Yang, Jichen; Tang, Hao; Xiao, Guanghua; Allen, Jeffrey; Zhong, Rui; Chen, Beibei; Kim, Minsoo; Wang, Tao; Xie, Yang] Univ Texas SW Med Ctr Dallas, Quantitat Biomed Res Ctr, Dept Clin Sci, Dallas, TX 75390 USA; [Karan, Charles; Realubit, Ronald] Columbia Univ, Columbia Genome Ctr, High Throughput Screening Facil, New York, NY USA; [Menden, Michael P.; Saez-Rodriguez, Julio] European Bioinformat Inst, European Mol Biol Lab, Cambridge, England; [Costello, James C.] Boston Univ, Dept Biomed Engn, Howard Hughes Med Inst, Boston, MA 02215 USA; [Costello, James C.] Boston Univ, Howard Hughes Med Inst, Ctr Synthet Biol, Boston, MA 02215 USA; [Li, Yajuan] Univ Texas SW Med Ctr Dallas, Dept Immunol, Dallas, TX 75390 USA; [Kim, Minsoo; Xie, Yang] Univ Texas SW Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dallas, TX USA; [Heiser, Laura M.] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97201 USA; [Mattioli, Michela] Fdn Ist Italiano Tecnol IIT, Ctr Genom Sci IIT SEMM, Milan, Italy; [Gallahan, Daniel; Singer, Dinah] NCI, Div Canc Biol, Bethesda, MD 20892 USA; [Stolovitzky, Gustavo] IBM Corp, Thomas J Watson Res Ctr, IBM Computat Biol Ctr, Yorktown Hts, NY 10598 USA; [Califano, Andrea] Columbia Univ, Dept Biomed Informat, New York, NY USA; [Califano, Andrea] Columbia Univ, Dept Biochem & Mol Biophys, New York, NY USA; [Califano, Andrea] Columbia Univ, Inst Canc Genet, New York, NY USA; [Califano, Andrea] Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY USA; [Abbuehl, Jean-Paul; Bernard, Jonathan] Swiss Fed Inst Technol Lausanne EPFL, Swiss Inst Expt Canc Res ISREC, Lausanne, Switzerland; [Altman, Russ B.; Gottlieb, Assaf] Stanford Univ, Dept Genet, Stanford, CA 94305 USA; [Balcome, Shawn; Deshpande, Raamesh; Myers, Chad L.; Wang, Wen; Xia, Tian] Univ Minnesota, Minneapolis, MN USA; [Bell, Ana; Homilius, Max; Lee, Young-Suk; Troyanskaya, Olga G.; Yao, Victoria] Princeton Univ, Dept Comp Sci, Princeton, NJ 08544 USA; [Bell, Ana; Goya, Jonathan; Homilius, Max; Krishnan, Arjun; Lee, Young-Suk; Troyanskaya, Olga G.; Yao, Victoria; Zhou, Jian] Princeton Univ, Lewis Sigler Inst Integrat Genom, Princeton, NJ 08544 USA; [Bender, Andreas] Univ Cambridge, Unilever Ctr, Cambridge, England; [Berger, Bonnie; Peng, Jian; Zeng, Haoyang] MIT, Comp Sci & Artificial Intelligence Lab, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Bieberich, Andrew A.; Davisson, V. Jo] Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA; [Borboudakis, Giorgos; Tsamardinos, Ioannis] Univ Crete, Dept Comp Sci, Iraklion, NE, Greece; [Borboudakis, Giorgos; Tsamardinos, Ioannis] FORTH, Inst Comp Sci, Iraklion, NE, Greece; [Chan, Christina; Hejase, Hussein A.] Michigan State Univ, Dept Comp Sci & Engn, E Lansing, MI 48824 USA; [Chan, Christina] Michigan State Univ, Dept Chem Engn & Mat Sci, E Lansing, MI 48824 USA; [Chan, Christina] Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA; [Chen, Ting-Huei; Sun, Wei] Univ N Carolina, Dept Biostat, Chapel Hill, NC 27515 USA; [Choi, Jaejoon; Hwang, Woochang; Kim, Junho; Lee, Junehawk] Korea Adv Inst Sci & Technol, Daejeon, South Korea; [Coelho, Luis Pedro] Univ Lisbon, Inst Med Mol, Fac Med, Lisbon, Portugal; [Creighton, Chad J.] Baylor Coll Med, Dept Med, Dan L Duncan Ctr Div Biostat, Houston, TX 77030 USA; [Dampier, Will; Tozeren, Aydin] Drexel Univ, Ctr Integrated Bioinformat, Philadelphia, PA 19104 USA; [Diao, Lixia; Li, Jun; Liang, Han; Qiu, Peng; Yang, Yang; Yuan, Yuan] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Di Camillo, Barbara; Sambo, Francesco; Toffolo, Gianna M.] Univ Padua, Dept Informat Engn, Padua, Italy; [Dundar, Murat] IUPUI, Dept Comp & Informat Sci, Indianapolis, IN USA; [Ertel, Adam; Pestell, Richard] Jefferson Kimmel Canc Ctr, Philadelphia, PA USA; [Cellworks Group] Cellworks Grp Inc, San Jose, CA USA; [Goswami, Chirayu P.; Li, Lang] IU Sch Med, Ctr Computat Biol & Bioinformat, Indianapolis, IN USA; [Gould, Michael N.; Hoffmann, Michael F.] Univ Wisconsin, Dept Oncol & Carbone Canc Ctr, Madison, WI USA; [Grau, Michael; Lenz, Peter] Univ Marburg, Dept Phys, Marburg, Germany; [Ijzerman, Adriaan P.; Lenselink, Eelke B.] Leiden Univ, Leiden Acad Ctr Drug Res, Leiden, Netherlands; [Kallioniemi, Olli; Mpindi, John-Patrick; Wennerberg, Krister] Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki, Finland; [Karacali, Bilge] Izmir Inst Technol, Izmir, Turkey; [Kaski, Samuel; Parkkinen, Juuso] Aalto Univ, Helsinki Inst Informat Technol, Dept Informat & Comp Sci, Espoo, Finland; [Kaski, Samuel] Univ Helsinki, Inst Informat Technol HIIT, Dept Comp Sci, Helsinki, Finland; [Lee, Junehawk] Korea Inst Sci & Technol Informat, Daejeon, South Korea; [Li, Jun] Chinese Acad Sci, Shanghai Inst Biol Sci, CAS MPG Partner Inst Computat Biol, Key Lab Computat Biol, Shanghai, Peoples R China; [Liang, Han; Yuan, Yuan] Baylor Coll Med, Grad Program Struct & Computat Biol & Mol Biophys, Houston, TX 77030 USA; [Newton, Michael A.] Univ Wisconsin, Dept Stat, Madison, WI USA; [Newton, Michael A.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA; [Overington, John P.; van Westen, Gerard J. P.] Wellcome Trust Genome Campus, European Bioinformat Inst EMBL EBI, Cambridge, England; [Prill, Robert J.] IBM Almaden Res Ctr, San Jose, CA USA; [Rajwa, Bartek] Purdue Univ, Bindley Biosci Ctr, W Lafayette, IN 47907 USA; [Sridhar, Arvind] Swiss Fed Inst Technol Lausanne EPFL, Inst Elect Engn, Embedded Syst Lab ESL, Lausanne, Switzerland; [Sun, Wei] Univ N Carolina, Dept Genet, Chapel Hill, NC USA; [van Vlijmen, Herman W. T.; Wegner, Joerg K.] Janssen Pharmaceut, Beerse, Belgium; [Yang, Yang] Univ Texas Hlth Sci Ctr, Sch Publ Hlth, Div Biostat, Houston, TX USA; [Zhang, Shihua; Zhao, Junfei] Chinese Acad Sci, Acad Math & Syst Sci, Natl Ctr Math & Interdisciplinary Sci, Beijing, Peoples R China; [Qiu, Peng] Univ Colorado, Sch Med, Dept Pharmacol, Anschutz Med Campus, Aurora, CO USA; [Qiu, Peng] Georgia Inst Technol, Dept Biomed Engn, Atlanta, GA USA; [Qiu, Peng] Emory Univ, Atlanta, GA 30322 USA	Columbia University; Columbia University; University of Texas System; University of Texas Southwestern Medical Center Dallas; Columbia University; European Molecular Biology Laboratory (EMBL); Boston University; Howard Hughes Medical Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Oregon Health & Science University; Istituto Italiano di Tecnologia - IIT; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); International Business Machines (IBM); Columbia University; Columbia University; Columbia University; Columbia University; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Institute Experimental Cancer Research; Stanford University; University of Minnesota System; University of Minnesota Twin Cities; Princeton University; Princeton University; University of Cambridge; Massachusetts Institute of Technology (MIT); Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Crete; Foundation for Research & Technology - Hellas (FORTH); Michigan State University; Michigan State University; Michigan State University; University of North Carolina; University of North Carolina Chapel Hill; Korea Advanced Institute of Science & Technology (KAIST); Universidade de Lisboa; Baylor College of Medicine; Drexel University; University of Texas System; UTMD Anderson Cancer Center; University of Padua; Indiana University System; Indiana University-Purdue University Indianapolis; Jefferson University; Indiana University System; Indiana University Bloomington; University of Wisconsin System; University of Wisconsin Madison; Philipps University Marburg; Leiden University; Leiden University - Excl LUMC; University of Helsinki; Izmir Institute of Technology; Aalto University; University of Helsinki; University of Helsinki; Korea Institute of Science & Technology Information (KISTI); Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Max Planck Society; Baylor College of Medicine; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; European Molecular Biology Laboratory (EMBL); Wellcome Trust Sanger Institute; International Business Machines (IBM); Purdue University System; Purdue University; Purdue University West Lafayette Campus; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of North Carolina; University of North Carolina Chapel Hill; Johnson & Johnson; Janssen Pharmaceuticals; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; Chinese Academy of Sciences; Academy of Mathematics & System Sciences, CAS; University of Colorado System; University of Colorado Anschutz Medical Campus; University System of Georgia; Georgia Institute of Technology; Emory University	Stolovitzky, G (corresponding author), IBM Corp, Thomas J Watson Res Ctr, IBM Computat Biol Ctr, Yorktown Hts, NY 10598 USA.	Yang.Xie@UTSouthwestern.edu; gustavo@us.ibm.com; califano@c2b2.columbia.edu	Wang, Tao/K-3518-2016; Li, Jun/AAE-4393-2022; Di Camillo, Barbara/L-3202-2013; Yao, Vicky/AAC-6183-2020; yang, jichen/HDL-9203-2022; Yuan, Yuan/H-4007-2013; Kallioniemi, Olli P/H-5111-2011; Mattioli, Michela/K-3951-2013; Hwang, Woochang/AAU-8398-2020; Wennerberg, Krister/AAH-2919-2022; Coelho, Luis Pedro/D-1260-2009; Zhao, Junfei/J-1425-2018; Overington, John P/G-8607-2015; Wang, Wen/E-6320-2012; Bender, Andreas/C-6942-2009; Gray, Joe/AAX-9549-2020; van Westen, Gerard/HHZ-3762-2022; Dundar, M. Murat/C-3846-2011; IJzerman, Ad/ABG-1353-2020; Wennerberg, Krister/AFM-0539-2022; van Westen, Gerard JP/D-7432-2011; He, Liye/C-8843-2015; Saez-Rodriguez, Julio/H-7114-2019; Dundar, Murat/U-1837-2019; Rajwa, Bartek/B-3169-2009; Homilius, Max/AAW-1251-2021; Kaski, Samuel/B-6684-2008	Li, Jun/0000-0002-1171-7141; Di Camillo, Barbara/0000-0001-8415-4688; Yao, Vicky/0000-0002-3201-9983; Yuan, Yuan/0000-0003-4706-7897; Kallioniemi, Olli P/0000-0002-3231-0332; Mattioli, Michela/0000-0002-1692-9178; Hwang, Woochang/0000-0003-0876-7305; Wennerberg, Krister/0000-0002-1352-4220; Coelho, Luis Pedro/0000-0002-9280-7885; Overington, John P/0000-0002-5859-1064; Wang, Wen/0000-0002-5812-6744; Bender, Andreas/0000-0002-6683-7546; IJzerman, Ad/0000-0002-1182-2259; Wennerberg, Krister/0000-0002-1352-4220; van Westen, Gerard JP/0000-0003-0717-1817; He, Liye/0000-0002-6632-2112; Saez-Rodriguez, Julio/0000-0002-8552-8976; Rajwa, Bartek/0000-0001-7540-8236; Homilius, Max/0000-0001-7240-0028; Kaski, Samuel/0000-0003-1925-9154; Abbuehl, Jean-Paul/0000-0003-3135-6969; Wegner, Jorg Kurt/0000-0002-1852-9434; Sadanandam, Anguraj/0000-0001-8485-5150; Costello, James/0000-0003-3158-9682; Troyanskaya, Olga/0000-0002-5676-5737; Califano, Andrea/0000-0003-4742-3679; Borboudakis, Giorgos/0000-0001-7355-8871; Lee, Junehawk/0000-0001-8908-0884; Peng, Jian/0000-0002-1736-2978; Altman, Russ/0000-0003-3859-2905; Lenz, Peter/0000-0001-7705-3950; Zeng, Haoyang/0000-0003-1057-2865; Dundar, Murat/0000-0001-5752-468X; Grau, Michael/0000-0003-1909-0133; Homicsko, Krisztian/0000-0003-0912-6198; Bansal, Mukesh/0000-0003-1481-6767	Multiscale Analysis of Genomic and Cellular Networks (MAGNet) [5U54CA121852-08]; Library of Integrated Network-based Cellular Signatures Program (LINCS) [1U01CA164184-02, 3U01HL111566-02]; National Institutes of Health (NIH) [5R01CA152301]; Cancer Prevention and Research Institute of Texas (CPRIT) [RP101251]; NIH, NCI [U54 CA112970]; Direct For Computer & Info Scie & Enginr [1252648] Funding Source: National Science Foundation; NATIONAL CANCER INSTITUTE [P50CA098258, R01CA152301, U54CA121852, P50CA058207, U01CA164184, U01CA168426, P30CA016672, U54CA112970] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL111566] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [T32HG003284] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM081871, R01GM071966] Funding Source: NIH RePORTER	Multiscale Analysis of Genomic and Cellular Networks (MAGNet); Library of Integrated Network-based Cellular Signatures Program (LINCS); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention and Research Institute of Texas (CPRIT); NIH, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Direct For Computer & Info Scie & Enginr(National Science Foundation (NSF)NSF - Directorate for Computer & Information Science & Engineering (CISE)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The data for this challenge were kindly provided prepublication by A. Califano's laboratory. The general idea of the challenge was conceived in a workshop co-organized by National Cancer Institute (NCI) and Dialogue for Reverse Engineering Assessments and Methods (DREAM) on April 23, 2012. We acknowledge the contributions of all the participants in that summit, whose list of attendees can be accessed by the following link http://tinyurl.com/n3zp443. We would like to thank L. Pasqualucci and A. Holmes for processing the genetic profile of the OCI-LY3 cell line; W.K. Lim for normalizing GEPs; S. Dhindaw for proofreading the manuscript; F.M. Giorgi for helping with the figures of the manuscript; H. Li for tissue culture; P. Guarnieri, A. Ambesi, S. Anand, P. Subramaniam and S. Irshad for their valuable comments and feedback during the preparation of this manuscript. GeneTitan hybridizations were run at Rutgers University facility (Bionomics Research and Technology Center -BRTC). This work is supported in part by the Multiscale Analysis of Genomic and Cellular Networks (MAGNet) grant (5U54CA121852-08) and Library of Integrated Network-based Cellular Signatures Program (LINCS) grants (1U01CA164184-02 and 3U01HL111566-02) to A.C.; National Institutes of Health (NIH) grant (5R01CA152301) and Cancer Prevention and Research Institute of Texas (CPRIT) grant (RP101251) to Y.X. and NIH, NCI grant (U54 CA112970) to J.W.G.	Al-Lazikani B, 2012, NAT BIOTECHNOL, V30, P679, DOI 10.1038/nbt.2284; Alexe G, 2005, 2005 IEEE Computational Systems Bioinformatics Conference, Proceedings, P322, DOI 10.1109/CSB.2005.7; Araujo RP, 2005, BIOSYSTEMS, V80, P57, DOI 10.1016/j.biosystems.2004.10.002; Aytes A, 2014, CANCER CELL, V25, P638, DOI 10.1016/j.ccr.2014.03.017; Bokemeyer C, 2009, J CLIN ONCOL, V27, P663, DOI 10.1200/JCO.2008.20.8397; Borisy AA, 2003, P NATL ACAD SCI USA, V100, P7977, DOI 10.1073/pnas.1337088100; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Chen J. C., CELL IN PRESS; Chudnovsky Y, 2014, CELL REP, V6, P313, DOI 10.1016/j.celrep.2013.12.032; Cokol M, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.71; Di Camillo B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032391; FERNANDES DJ, 1980, P NATL ACAD SCI-BIOL, V77, P5663, DOI 10.1073/pnas.77.10.5663; Fitzgerald JB, 2006, NAT CHEM BIOL, V2, P458, DOI 10.1038/nchembio817; Gottlieb A, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.26; Green MR, 2010, BLOOD, V116, P3268, DOI 10.1182/blood-2010-05-282780; Guyon I, 2002, MACH LEARN, V46, P389, DOI 10.1023/A:1012487302797; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Helguera AM, 2013, EUR J MED CHEM, V59, P75, DOI 10.1016/j.ejmech.2012.10.035; Hoshida Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015543; Ibrahim YH, 2012, CANCER DISCOV, V2, P1036, DOI 10.1158/2159-8290.CD-11-0348; Jia J, 2009, NAT REV DRUG DISCOV, V8, P111, DOI 10.1038/nrd2683; Jin GX, 2011, BIOINFORMATICS, V27, pI310, DOI 10.1093/bioinformatics/btr202; Keith CT, 2005, NAT REV DRUG DISCOV, V4, P71, DOI 10.1038/nrd1609; Lefebvre C, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.31; Lehar J, 2009, NAT BIOTECHNOL, V27, P659, DOI 10.1038/nbt.1549; Marbach D, 2012, NAT METHODS, V9, P796, DOI [10.1038/NMETH.2016, 10.1038/nmeth.2016]; Margolin AA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006112; Nelson HS, 2001, J ALLERGY CLIN IMMUN, V107, P397, DOI 10.1067/mai.2001.112939; Norel R, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.70; Olshen AB, 2004, BIOSTATISTICS, V5, P557, DOI 10.1093/biostatistics/kxh008; Pedregosa F, 2011, J MACH LEARN RES, V12, P2825; Piovan E, 2013, CANCER CELL, V24, P766, DOI 10.1016/j.ccr.2013.10.022; Prill RJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009202; Puri Neelu, 2008, J Carcinog, V7, P9; Rajendran P, 2011, CLIN CANCER RES, V17, P1425, DOI 10.1158/1078-0432.CCR-10-1123; Rawlinson R, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-483; Recht A, 1996, NEW ENGL J MED, V334, P1356, DOI 10.1056/NEJM199605233342102; Schlessinger A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004433; Shah MA, 2001, CLIN CANCER RES, V7, P2168; STEIN GE, 1984, CLIN PHARMACY, V3, P591; van Westen GJP, 2013, NAT METHODS, V10, P116, DOI 10.1038/nmeth.2339; Vermorken JB, 2008, NEW ENGL J MED, V359, P1116, DOI 10.1056/NEJMoa0802656; Vilar S, 2012, J AM MED INFORM ASSN, V19, P1066, DOI 10.1136/amiajnl-2012-000935; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Yonesaka K, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002442; Zhang J, 2013, P NATL ACAD SCI USA, V110, P1398, DOI 10.1073/pnas.1205299110; Zhao S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006548; Zhao XM, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002323	49	175	177	3	37	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2014	32	12					1213	+		10.1038/nbt.3052	http://dx.doi.org/10.1038/nbt.3052			12	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	AW3AD	25419740	Green Published, Green Accepted, hybrid			2023-01-03	WOS:000346156800023
J	Gadoud, A; Kane, E; Macleod, U; Ansell, P; Oliver, S; Johnson, M				Gadoud, Amy; Kane, Eleanor; Macleod, Una; Ansell, Pat; Oliver, Steven; Johnson, Miriam			Palliative Care among Heart Failure Patients in Primary Care: A Comparison to Cancer Patients Using English Family Practice Data	PLOS ONE			English	Article							LIFE; END; HOSPITALIZATION; SOCIETY	Introduction: Patients with heart failure have a significant symptom burden and other palliative care needs often over a longer period than patients with cancer. It is acknowledged that this need may be unmet but by how much has not been quantified in primary care data at the population level. Methods: This was the first use of Clinical Practice Research Datalink, the world's largest primary care database to explore recognition of the need for palliative care. Heart failure and cancer patients who had died in 2009 aged 18 or over and had at least one year of primary care records were identified. A palliative approach to care among patients with heart failure was compared to that among patients with cancer using entry onto a palliative care register as a marker for a palliative approach to care. Results: Among patients with heart failure, 7% (234/3 122) were entered on the palliative care register compared to 48% (3 669/7 608) of cancer patients. Of heart failure patients on the palliative care register, 29% (69/234) were entered onto the register within a week of their death. Conclusions: This confirms that the stark inequity in recognition of palliative care needs for people with heart failure in a large primary care dataset. We recommend a move away from prognosis based criteria for palliative care towards a patient centred approach, with assessment of and attention to palliative needs including advance care planning throughout the disease trajectory.	[Gadoud, Amy; Macleod, Una; Johnson, Miriam] Univ Hull, Hull York Med Sch, Kingston Upon Hull, East Yorkshire, England; [Kane, Eleanor; Ansell, Pat; Oliver, Steven] Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England; [Oliver, Steven] Univ York, Hull York Med Sch, York YO10 5DD, N Yorkshire, England	University of Hull; University of York - UK; University of York - UK; University of Hull; University of York - UK	Gadoud, A (corresponding author), Univ Hull, Hull York Med Sch, Kingston Upon Hull, East Yorkshire, England.	amy.gadoud@hyms.ac.uk	Gadoud, Amy/E-8420-2014	Gadoud, Amy/0000-0001-6351-1535; Johnson, Miriam/0000-0001-6204-9158; Kane, Eleanor/0000-0002-7438-9982	Hull York Medical School; Academy of Medical Sciences (AMS) [AMS-SGCL11-Gadoud] Funding Source: researchfish; National Institute for Health Research [CL-2013-03-002] Funding Source: researchfish	Hull York Medical School; Academy of Medical Sciences (AMS)(Academy of Medical Sciences (AMS)); National Institute for Health Research(National Institute for Health Research (NIHR))	CPRD data were obtained free of charge under a Medical Research Council (MRC) initiative. AG salary funded by Hull York Medical School. The funders had no role in study design, data collection, decision to publish or preparation of the manuscript.	Allen LA, 2012, CIRCULATION, V125, P1928, DOI 10.1161/CIR.0b013e31824f2173; Barclay S, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X549018; Bhattarai N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029776; BMA & NHS Employers, 2009, QUALITY OUTCOMES FRA; Boyd KJ, 2009, PALLIATIVE MED, V23, P767, DOI 10.1177/0269216309346541; Campbell S, 2010, QUALITY OUTCOMES FRA; Department of Health, 2008, END LIF CAR STRAT PR; Haga K, 2012, HEART, V98, P579, DOI 10.1136/heartjnl-2011-301021; Harrison N, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X641465; Health and Social Care Information Centre, 2010, QUAL OUTC FRAM 2009; Hogg KJ, 2012, HEART, V98, P523, DOI 10.1136/heartjnl-2012-301753; Howlett J, 2010, CAN J CARDIOL, V26, P135, DOI 10.1016/S0828-282X(10)70351-2; Husted MG, 2014, BMJ SUPPORT PALLIAT, V4, P146, DOI 10.1136/bmjspcare-2013-000601; Jaarsma T, 2009, EUR J HEART FAIL, V11, P433, DOI 10.1093/eurjhf/hfp041; Jhund PS, 2009, CIRCULATION, V119, P515, DOI 10.1161/CIRCULATIONAHA.108.812172; Khan NF, 2010, BRIT J GEN PRACT, V60, DOI 10.3399/bjgp10X483562; Khan NF, 2010, ANN FAM MED, V8, P418, DOI 10.1370/afm.1162; Ko DT, 2008, AM HEART J, V155, P324, DOI 10.1016/j.ahj.2007.08.036; Lloyd-Jones DM, 1998, ANN INTERN MED, V129, P1020, DOI 10.7326/0003-4819-129-12-199812150-00005; Mehta PA, 2009, HEART, V95, P1851, DOI 10.1136/hrt.2008.156034; National Institute for Health and Care Excellence (NICE), 2013, QUAL OUTC FRAM QOF; National Survey of Patient Activity Data for Specialist Palliative Care Services, 2013, MIN DAT SET FULL REP; Office for National Statistics, 2010, POP EST UK ENGL WAL; Omega, 2009, END LIF CAR PRIM CAR; Primary Care Commissioning, 2009, DEC 2009 QOF BUS RUL; Shamini G, 2006, USERS GUIDE DATA COL; Smith TJ, 2012, J CLIN ONCOL, V30, P880, DOI 10.1200/JCO.2011.38.5161; Stewart S, 2002, BRIT MED J, V325, P915, DOI 10.1136/bmj.325.7370.915; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Teno J M, 2001, J Palliat Med, V4, P457, DOI 10.1089/109662101753381593; Warmenhoven F, 2012, ANN FAM MED, V10, P330, DOI 10.1370/afm.1373; Whellan DJ, 2014, J CARD FAIL, V20, P121, DOI 10.1016/j.cardfail.2013.12.003; You JJ, 2013, CANADIAN MED ASS J	33	64	65	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 25	2014	9	11							e113188	10.1371/journal.pone.0113188	http://dx.doi.org/10.1371/journal.pone.0113188			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AU9GL	25423169	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000345899700023
J	Li, S; An, YZ; Ren, JY; Zhu, FX; Chen, H				Li, Shu; An, You-zhong; Ren, Jing-yi; Zhu, Feng-xue; Chen, Hong			Myocardial Injury after Surgery Is a Risk Factor for Weaning Failure from Mechanical Ventilation in Critical Patients Undergoing Major Abdominal Surgery	PLOS ONE			English	Article							NONINVASIVE VENTILATION; PNEUMONIA; DISEASE; IMPACT; CARE	Background: Myocardial injury after noncardiac surgery (MINS) is a newly proposed concept that is common among adults undergoing noncardiac surgery and associated with substantial mortality. We analyzed whether MINS was a risk factor for weaning failure in critical patients who underwent major abdominal surgery. Methods: This retrospective study was conducted in the Department of Critical Care Medicine of Peking University People's Hospital. The subjects were all critically ill patients who underwent major abdominal surgery between January 2011 and December 2013. Clinical and laboratory parameters during the perioperative period were investigated. Backward stepwise regression analysis was performed to evaluate MINS relative to the rate of weaning failure. Age, hypertension, chronic renal disease, left ventricular ejection fraction before surgery, Acute Physiologic and Chronic Health Evaluation II score, pleural effusion, pneumonia, acute kidney injury, duration of mechanical ventilation before weaning and the level of albumin after surgery were treated as independent variables. Results: This study included 381 patients, of whom 274 were successfully weaned. MINS was observed in 42.0% of the patients. The MINS incidence was significantly higher in patients who failed to be weaned compared to patients who were successfully weaned (56.1% versus 36.5%; P < 0.001). Independent predictive factors of weaning failure were MINS, age, lower left ventricular ejection fraction before surgery and lower serum albumin level after surgery. The MINS odds ratio was 4.098 (95% confidence interval, 1.07 to 15.6; P = 0.04). The patients who were successfully weaned had shorter hospital stay lengths and a higher survival rate than those who failed to be weaned. Conclusion: MINS is a risk factor for weaning failure from mechanical ventilation in critical patients who have undergone major abdominal surgery, independent of age, lower left ventricular ejection fraction before surgery and lower serum albumin levels after surgery.	[Li, Shu; An, You-zhong; Zhu, Feng-xue] Peking Univ, Peoples Hosp, Dept Crit Care Med, Beijing 100871, Peoples R China; [Ren, Jing-yi; Chen, Hong] Peking Univ, Peoples Hosp, Dept Cardiol, Beijing 100871, Peoples R China	Peking University; Peking University	Chen, H (corresponding author), Peking Univ, Peoples Hosp, Dept Crit Care Med, Beijing 100871, Peoples R China.	chenhong0418@aliyun.com						Ali ZA, 2008, EUR J VASC ENDOVASC, V35, P413, DOI 10.1016/j.ejvs.2007.10.007; Boles JM, 2007, EUR RESPIR J, V29, P1033, DOI 10.1183/09031936.00010206; Botto F, 2014, ANESTHESIOLOGY, V120, P564, DOI 10.1097/ALN.0000000000000113; Carroll K, 2003, J PUBLIC HEALTH MED, V25, P29, DOI 10.1093/pubmed/fdg007; Dunning J, 2003, EUR J CARDIO-THORAC, V24, P270, DOI 10.1016/S1010-7940(03)00269-0; Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8; Epstein SK, 2009, RESP CARE, V54, P198; Glossop AJ, 2012, BRIT J ANAESTH, V109, P305, DOI 10.1093/bja/aes270; Gupta Barkha, 2010, J Clin Med Res, V2, P68, DOI 10.4021/jocmr2010.03.261e; Hadda V, 2014, LUNG INDIA, V31, P4, DOI 10.4103/0970-2113.125886; Mehta RH, 2008, CIRCULATION, V117, P876, DOI 10.1161/CIRCULATIONAHA.107.728147; Monnet X, 2007, CURR OPIN CRIT CARE, V13, P6, DOI 10.1097/MCC.0b013e328013c865; Naughton C, 2007, INT J CLIN PRACT, V61, P768, DOI 10.1111/j.1742-1241.2007.01304.x; Nozawa E, 2005, INT HEART J, V46, P819, DOI 10.1536/ihj.46.819; Pinsky MR, 2000, INTENS CARE MED, V26, P1164, DOI 10.1007/s001340000619; Porhomayon J, 2012, CRIT CARE RES PRACT, V2012, DOI 10.1155/2012/173527; Shi ZD, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008367.pub2; Siddiqui MMA, 2012, CARDIOVASC DIAGN THE, V2, P192, DOI 10.3978/j.issn.2223-3652.2012.06.05; Teboul JL, 2010, CRIT CARE, V14, DOI 10.1186/cc8852; Thille AW, 2013, AM J RESP CRIT CARE, V187, P1294, DOI 10.1164/rccm.201208-1523CI; TORRES A, 1995, AM J RESP CRIT CARE, V152, P137, DOI 10.1164/ajrccm.152.1.7599812; Zhu F, 2013, CHINESE MED J-PEKING, V126, P1337, DOI 10.3760/cma.j.issn.0366-6999.20121744	22	8	10	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 19	2014	9	11							e113410	10.1371/journal.pone.0113410	http://dx.doi.org/10.1371/journal.pone.0113410			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AU3SG	25409182	Green Published, gold, Green Submitted			2023-01-03	WOS:000345533200114
J	Shahab, L; Beard, E; Brown, J; West, R				Shahab, Lion; Beard, Emma; Brown, Jamie; West, Robert			Prevalence of NRT Use and Associated Nicotine Intake in Smokers, Recent Ex-Smokers and Longer-Term Ex-Smokers	PLOS ONE			English	Article							REPLACEMENT THERAPY; SMOKING-CESSATION; TOBACCO DEPENDENCE; CIGARETTE; COTININE; DURATION; IMPACT; AID; GUM	Background: Nicotine replacement therapy (NRT) is used by smokers wanting to reduce their smoking and to quit. However, there are very little data on nicotine intake associated with NRT use in representative population samples. This study aimed to provide estimates for NRT use and associated nicotine exposure among smokers, recent and longer-term exsmokers in England, a country with a permissive regulatory regime for nicotine substitution. Methods: In the Smoking Toolkit Study, a monthly series of representative household surveys of adults aged 16+ in England, current and recent ex-smokers who agreed to be re-contacted were followed up 6 months later and standard socio-demographic and smoking characteristics assessed (N = 5,467, response rate 25.1%). A random sub-sample (N = 1,614; 29.5%) also provided saliva, analysed for cotinine. Results: The sample followed up was broadly representative of the original sample. At follow-up, 11.8% (95% CI 10.9-12.8, N = 565) of current smokers, 34.8% (95% CI 28.9-41.3, N = 77) of recent (<= 3 months) ex-smokers, and 7.8% (95% CI 5.6-10.6, N = 36) of longer-term (>3 months) ex-smokers reported using NRT. Smokers who used NRT had similar saliva cotinine concentrations to smokers who did not use NRT (mean +/- sd = 356.0 +/- 198.6 ng/ml vs. 313.1 +/- 178.4 ng/ml). Recent exsmokers who used NRT had levels that were somewhat lower, but not significantly so, than current smokers (216.7 +/- 179.3 ng/ml). Longer-term ex-smokers using NRT had still lower levels (157.3 +/- 227.1 ng/ml), which differed significantly from smokers using NRT (p = 0.024). Conclusions: Concurrent use of nicotine replacement therapy while smoking is relatively uncommon and is not associated with higher levels of nicotine intake. Among ex-smokers, NRT use is common in the short but not longer-term and among longer-term users is associated with lower nicotine intake than in smokers.	[Shahab, Lion; Beard, Emma; Brown, Jamie; West, Robert] UCL, Dept Epidemiol & Publ Hlth, London, England; [Brown, Jamie] UCL, Dept Clin Educ & Hlth Psychol, London, England	University of London; University College London; University of London; University College London	Shahab, L (corresponding author), UCL, Dept Epidemiol & Publ Hlth, London, England.	lion.shahab@ucl.ac.uk	Brown, Jamie/F-4413-2011; Shahab, Lion/B-5835-2009; West, Robert/B-5414-2009	Brown, Jamie/0000-0002-2797-5428; Shahab, Lion/0000-0003-4033-442X; West, Robert/0000-0001-6398-0921	Department of Health, Cancer Research UK; Pfizer; GlaxoSmithKline; Johnson and Johnson; Cancer Research UK [14135] Funding Source: researchfish; Economic and Social Research Council [ES/G007489/1] Funding Source: researchfish; Medical Research Council [MR/K023195/1B, MR/K023195/1] Funding Source: researchfish	Department of Health, Cancer Research UK(Cancer Research UK); Pfizer(Pfizer); GlaxoSmithKline(GlaxoSmithKline); Johnson and Johnson(Johnson & JohnsonJohnson & Johnson USA); Cancer Research UK(Cancer Research UK); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This study was funded by the Department of Health, Cancer Research UK, Pfizer, GlaxoSmithKline and Johnson and Johnson. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beard E, 2013, TOB CONTROL, V22, P118, DOI 10.1136/tobaccocontrol-2011-050007; Beard E, 2011, PSYCHOPHARMACOLOGY, V218, P609, DOI 10.1007/s00213-011-2359-4; BENOWITZ NL, 1982, J PHARMACOL EXP THER, V221, P368; Benowitz NL, 1997, J AM COLL CARDIOL, V29, P1422, DOI 10.1016/S0735-1097(97)00079-X; Black A, 2012, ADDICTION, V107, P2037, DOI 10.1111/j.1360-0443.2012.03955.x; Eliasson B, 1996, CIRCULATION, V94, P878, DOI 10.1161/01.CIR.94.5.878; Etter JF, 2009, ADDICT BEHAV, V34, P246, DOI 10.1016/j.addbeh.2008.10.018; Fagerstrom Karl Olov, 2002, Nicotine Tob Res, V4 Suppl 2, pS73; FEYERABEND C, 1990, J PHARM PHARMACOL, V42, P450, DOI 10.1111/j.2042-7158.1990.tb06592.x; Fidler JA, 2011, PSYCHOPHARMACOLOGY, V217, P587, DOI 10.1007/s00213-011-2317-1; Fidler JA, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-479; Fidler JA, 2011, ADDICTION, V106, P631, DOI 10.1111/j.1360-0443.2010.03226.x; FOULDS J, 1994, AM J PUBLIC HEALTH, V84, P1182, DOI 10.2105/AJPH.84.7.1182; Fucito LM, 2014, NICOTINE TOB RES, V16, P909, DOI 10.1093/ntr/ntu087; Hajek P, 2007, PREV MED, V44, P230, DOI 10.1016/j.ypmed.2006.10.005; HEATHERTON TF, 1989, BRIT J ADDICT, V84, P791; Hubbard R, 2005, TOB CONTROL, V14, P416, DOI 10.1136/tc.2005.011387; Joseph AM, 2011, ARCH INTERN MED, V171, P1894, DOI 10.1001/archinternmed.2011.500; Kotz D, 2013, DRUG ALCOHOL DEPEN, V128, P15, DOI 10.1016/j.drugalcdep.2012.07.012; Le Houezec J, 2011, DRUG ALCOHOL REV, V30, P119, DOI 10.1111/j.1465-3362.2010.00264.x; Le Strat Y, 2011, TOB CONTROL, V20, P338, DOI 10.1136/tc.2010.038703; MHRA, 2009, MHRA PUBL ASS REP US; NICE, 2013, TOB HARM RED; Schnoll RA, 2010, ANN INTERN MED, V152, P144, DOI 10.7326/0003-4819-152-3-201002020-00005; Shahab L, 2013, CNS DRUGS, V27, P1007, DOI 10.1007/s40263-013-0116-4; Shahab L, 2009, ADDICTION, V104, P1420, DOI 10.1111/j.1360-0443.2009.02641.x; Shiffman S, 2008, HEALTH POLICY, V86, P17, DOI 10.1016/j.healthpol.2007.08.006; Silla K, 2014, NICOTINE TOB RES, V16, P1050, DOI 10.1093/ntr/ntu019; Sims TH, 2002, CNS DRUGS, V16, P653, DOI 10.2165/00023210-200216100-00001; Stratton S, 2001, CLEARING SMOKE ADDRE; Tonnesen P, 1999, EUR RESPIR J, V13, P238, DOI 10.1034/j.1399-3003.1999.13b04.x; Wang D, 2008, HEALTH TECHNOL ASSES, V12, piii, DOI DOI 10.3310/HTA12020; Wennike P, 2003, ADDICTION, V98, P1395, DOI 10.1046/j.1360-0443.2003.00489.x; West R, 2005, TOB CONTROL, V14, P166, DOI 10.1136/tc.2004.008649	34	6	6	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2014	9	11							e113045	10.1371/journal.pone.0113045	http://dx.doi.org/10.1371/journal.pone.0113045			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AX7UZ	25405343	Green Published, gold			2023-01-03	WOS:000347121300073
J	Mouncey, PR; Osborn, TM; Power, GS; Harrison, DA; Sadique, MZ; Grieve, RD; Jahan, R; Harvey, SE; Bell, D; Bion, JF; Coats, TJ; Singer, M; Young, JD; Rowan, KM				Mouncey, Paul R.; Osborn, Tiffany M.; Power, G. Sarah; Harrison, David A.; Sadique, M. Zia; Grieve, Richard D.; Jahan, Rahi; Harvey, Sheila E.; Bell, Derek; Bion, Julian F.; Coats, Timothy J.; Singer, Mervyn; Young, J. Duncan; Rowan, Kathryn M.		ProMISe Trial Investigators	Trial of Early, Goal-Directed Resuscitation for Septic Shock	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SURVIVING SEPSIS CAMPAIGN; ORGAN FAILURE; CRITICAL-CARE; GUIDELINES; MANAGEMENT; THERAPY; SCORE; UNITS	BACKGROUND Early, goal-directed therapy (EGDT) is recommended in international guidelines for the resuscitation of patients presenting with early septic shock. However, adoption has been limited, and uncertainty about its effectiveness remains. METHODS We conducted a pragmatic randomized trial with an integrated cost-effectiveness analysis in 56 hospitals in England. Patients were randomly assigned to receive either EGDT (a 6-hour resuscitation protocol) or usual care. The primary clinical outcome was all-cause mortality at 90 days. RESULTS We enrolled 1260 patients, with 630 assigned to EGDT and 630 to usual care. By 90 days, 184 of 623 patients (29.5%) in the EGDT group and 181 of 620 patients (29.2%) in the usual-care group had died (relative risk in the EGDT group, 1.01; 95% confidence interval [CI], 0.85 to 1.20; P = 0.90), for an absolute risk reduction in the EGDT group of -0.3 percentage points (95% CI, -5.4 to 4.7). Increased treatment intensity in the EGDT group was indicated by increased use of intravenous fluids, vasoactive drugs, and red-cell transfusions and reflected by significantly worse organ-failure scores, more days receiving advanced cardiovascular support, and longer stays in the intensive care unit. There were no significant differences in any other secondary outcomes, including health-related quality of life, or in rates of serious adverse events. On average, EGDT increased costs, and the probability that it was cost-effective was below 20%. CONCLUSIONS In patients with septic shock who were identified early and received intravenous antibiotics and adequate fluid resuscitation, hemodynamic management according to a strict EGDT protocol did not lead to an improvement in outcome.	[Mouncey, Paul R.; Power, G. Sarah; Harrison, David A.; Jahan, Rahi; Harvey, Sheila E.; Rowan, Kathryn M.] Intens Care Natl Audit & Res Ctr, Clin Trials Unit, London WC1V 6AZ, England; [Sadique, M. Zia; Grieve, Richard D.] London Sch Hyg & Trop Med, Dept Hlth Serv Res & Policy, London WC1, England; [Bell, Derek] Univ London Imperial Coll Sci Technol & Med, Fac Med, London, England; [Bell, Derek] Chelsea & Westminster Hosp NHS Fdn Trust, Dept Acute Med, London, England; [Singer, Mervyn] UCL, Bloomsbury Inst Intens Care Med, London, England; [Bion, Julian F.] Univ Birmingham, Dept Intens Care Med, Birmingham, W Midlands, England; [Coats, Timothy J.] Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England; [Young, J. Duncan] Univ Oxford, Nuffield Div Anaesthet, Oxford, England; [Osborn, Tiffany M.] Washington Univ, Dept Surg, St Louis, MO 63130 USA; [Osborn, Tiffany M.] Washington Univ, Dept Emergency Med, St Louis, MO 63130 USA	Intensive Care National Audit & Research Centre; University of London; London School of Hygiene & Tropical Medicine; Imperial College London; Imperial College London; University of London; University College London; University of Birmingham; University of Leicester; University of Oxford; Washington University (WUSTL); Washington University (WUSTL)	Rowan, KM (corresponding author), Intens Care Natl Audit & Res Ctr, Napier House,24 High Holborn, London WC1V 6AZ, England.	kathy.rowan@icnarc.org	Osborn, Tiffany/AAT-2281-2020; Harrison, David A/O-4355-2018; Skene, Imogen/D-6153-2018; Coats, Timothy/AAW-1254-2021; Young, John D/M-9756-2016; Singer, Mervyn/Q-6142-2019	Harrison, David A/0000-0002-9002-9098; Skene, Imogen/0000-0001-5215-2899; Coats, Timothy/0000-0003-2736-2784; Singer, Mervyn/0000-0002-1042-6350; Sadique, Zia/0000-0001-5814-0258; Brealey, David/0000-0002-1982-3379; Young, John Duncan/0000-0002-6838-4835; Mouncey, Paul/0000-0002-8510-8517; Bion, Julian/0000-0003-0344-5403; Rowan, Kathryn/0000-0001-8217-5602; Harvey, Sheila/0000-0001-7604-8607; Harvey, Daniel/0000-0002-5165-3277; Weldring, Theresa/0000-0001-6955-6822; Grieve, Richard/0000-0001-8899-1301	United Kingdom National Institute for Health Research Health Technology Assessment Programme; National Institute for Health Research [SRF-2013-06-016, 07/37/47] Funding Source: researchfish	United Kingdom National Institute for Health Research Health Technology Assessment Programme; National Institute for Health Research(National Institute for Health Research (NIHR))	Funded by the United Kingdom National Institute for Health Research Health Technology Assessment Programme; ProMISe Current Controlled Trials number, ISRCTN36307479.	[Anonymous], 2014, NEW ENGL J MED, DOI DOI 10.1056/NEJMoa1401602; [Anonymous], 2013, GUID METH TECHN APPR; [Anonymous], 2005, MENTAL CAPACITY ACT; Ara R, 2010, VALUE HEALTH, V13, P509, DOI 10.1111/j.1524-4733.2010.00700.x; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Chapman M, 2005, CRIT CARE, V9, P307, DOI 10.1186/cc3726; Cuthbertson BH, 2013, CRIT CARE, V17, DOI 10.1186/cc12616; Dellinger R. P., 2013, INTENS CARE MED, V41, P580, DOI [DOI 10.1007/s00134-012-2769-8, 10.1007/s00134-012-2769-8]; Dellinger RP, 2008, CRIT CARE MED, V36, P296, DOI 10.1097/01.CCM.0000298158.12101.41; Dellinger RP, 2004, CRIT CARE MED, V32, P1448; Harrison DA, 2004, CRIT CARE, V8, pR99, DOI 10.1186/cc2834; Harvey SE, 2006, INTENS CARE MED, V32, P2020, DOI 10.1007/s00134-006-0358-4; Ho BCH, 2006, CRIT CARE, V10, DOI 10.1186/cc4918; Huang DT, 2013, INTENS CARE MED, V39, P1760, DOI 10.1007/s00134-013-3024-7; Jawad Issrah, 2012, J Glob Health, V2, P010404, DOI 10.7189/jogh.02.010404; Kaukonen KM, 2014, JAMA-J AM MED ASSOC, V311, P1308, DOI 10.1001/jama.2014.2637; Levy MM, 2015, CRIT CARE MED, V43, P3, DOI [10.1097/CCM.0000000000000723, 10.1007/s00134-014-3496-0]; Levy MM, 2012, LANCET INFECT DIS, V12, P919, DOI 10.1016/S1473-3099(12)70239-6; Peake SL, 2014, NEW ENGL J MED, V371, P1496, DOI 10.1056/NEJMoa1404380; Power GS, 2013, CRIT CARE RESUSC, V15, P311; Reade MC, 2010, INTENS CARE MED, V36, P11, DOI 10.1007/s00134-009-1650-x; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Shapiro NI, 2003, CRIT CARE MED, V31, P670, DOI 10.1097/01.CCM.0000054867.01688.D1; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; [No title captured]	25	943	1033	1	109	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 2	2015	372	14					1301	1311		10.1056/NEJMoa1500896	http://dx.doi.org/10.1056/NEJMoa1500896			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CE7NL	25776532	Green Published, Green Submitted, Green Accepted			2023-01-03	WOS:000352028500005
J	Rutsche, B; Hauser, TU; Jancke, L; Grabner, RH				Ruetsche, Bruno; Hauser, Tobias U.; Jaencke, Lutz; Grabner, Roland H.			When Problem Size Matters: Differential Effects of Brain Stimulation on Arithmetic Problem Solving and Neural Oscillations	PLOS ONE			English	Article							TRANSCRANIAL DC STIMULATION; HUMAN MOTOR CORTEX; ELECTRICAL-STIMULATION; THETA OSCILLATIONS; PREFRONTAL CORTEX; NEURONAL-ACTIVITY; MENTAL ADDITION; UPPER ALPHA; EEG; RETRIEVAL	The problem size effect is a well-established finding in arithmetic problem solving and is characterized by worse performance in problems with larger compared to smaller operand size. Solving small and large arithmetic problems has also been shown to involve different cognitive processes and distinct electroencephalography (EEG) oscillations over the left posterior parietal cortex (LPPC). In this study, we aimed to provide further evidence for these dissociations by using transcranial direct current stimulation (tDCS). Participants underwent anodal (30min, 1.5 mA, LPPC) and sham tDCS. After the stimulation, we recorded their neural activity using EEG while the participants solved small and large arithmetic problems. We found that the tDCS effects on performance and oscillatory activity critically depended on the problem size. While anodal tDCS improved response latencies in large arithmetic problems, it decreased solution rates in small arithmetic problems. Likewise, the lower-alpha desynchronization in large problems increased, whereas the theta synchronization in small problems decreased. These findings reveal that the LPPC is differentially involved in solving small and large arithmetic problems and demonstrate that the effects of brain stimulation strikingly differ depending on the involved neuro-cognitive processes.	[Ruetsche, Bruno] Swiss Fed Inst Technol, Inst Behav Sci, Res Learning & Instruct, Zurich, Switzerland; [Ruetsche, Bruno; Hauser, Tobias U.] Univ Zurich, Neurosci Ctr Zurich ZNZ, Zurich, Switzerland; [Ruetsche, Bruno; Hauser, Tobias U.] Swiss Fed Inst Technol, Zurich, Switzerland; [Hauser, Tobias U.] UCL, Wellcome Trust Ctr Neuroimaging, Inst Neurol, London, England; [Hauser, Tobias U.] Univ Zurich, Univ Clin Child & Adolescent Psychiat, Zurich, Switzerland; [Jaencke, Lutz] Univ Zurich, Div Neuropsychol, Inst Psychol, Zurich, Switzerland; [Jaencke, Lutz] Univ Zurich, Int Normal Aging & Plast Imaging Ctr, Zurich, Switzerland; [Jaencke, Lutz] Univ Zurich, Ctr Integrat Human Physiol ZIHP, Zurich, Switzerland; [Jaencke, Lutz] Univ Zurich, Univ Res Prior Program, Dynam Healthy Aging, Zurich, Switzerland; [Jaencke, Lutz] King Abdulaziz Univ, Dept Special Educ, Jeddah 21413, Saudi Arabia; [Grabner, Roland H.] Graz Univ, Sect Educ Neurosci, Dept Psychol, Graz, Austria; [Grabner, Roland H.] Univ Gottingen, Inst Psychol, Dept Educ Psychol, D-37073 Gottingen, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of London; University College London; University of Zurich; University of Zurich; University of Zurich; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP); University of Zurich; King Abdulaziz University; University of Graz; University of Gottingen	Rutsche, B (corresponding author), Swiss Fed Inst Technol, Inst Behav Sci, Res Learning & Instruct, Zurich, Switzerland.	bruno.ruetsche@ifv.gess.ethz.ch	Grabner, Roland/AAE-7272-2020	Grabner, Roland/0000-0003-0385-8910; Rutsche, Bruno/0000-0002-5432-2721; Hauser, Tobias U./0000-0002-7997-8137	Swiss National Science Foundation [100014_140515 / 1]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	This study was funded by a grant awarded to TUH and RHG by the Swiss National Science Foundation (100014_140515 / 1; http://www.snf.ch). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANNETT M, 1970, BRIT J PSYCHOL, V61, P303, DOI 10.1111/j.2044-8295.1970.tb01248.x; Ansari D, 2008, NAT REV NEUROSCI, V9, P278, DOI 10.1038/nrn2334; Ashcraft M. H., 1987, FORMAL METHODS DEV P, P302, DOI DOI 10.1007/978-1-4612-4694-7_9; Ashcraft MH, 2009, PSYCHOL LEARN MOTIV, V51, P121, DOI 10.1016/S0079-7421(09)51004-3; ASHCRAFT MH, 1981, MEM COGNITION, V9, P185, DOI 10.3758/BF03202334; Balconi M, 2012, NEUROSCI LETT, V517, P25, DOI 10.1016/j.neulet.2012.04.010; Bastiaansen M, 2006, PROG BRAIN RES, V159, P179, DOI 10.1016/S0079-6123(06)59012-0; Bastiaansen MCM, 2005, J COGNITIVE NEUROSCI, V17, P530, DOI 10.1162/0898929053279469; BINDMAN LJ, 1964, J PHYSIOL-LONDON, V172, P369, DOI 10.1113/jphysiol.1964.sp007425; Bolognini N, 2010, BRAIN RES, V1349, P76, DOI 10.1016/j.brainres.2010.06.053; Campbell J.I.D., 1995, MATH COGN, V1, P121, DOI DOI 10.3758/BF03197037; Campbell JID, 2001, J EXP PSYCHOL GEN, V130, P299, DOI 10.1037//0096-3445.130.2.299; CAMPBELL JID, 1987, J EXP PSYCHOL LEARN, V13, P109, DOI 10.1037/0278-7393.13.1.109; Chi RP, 2010, BRAIN RES, V1353, P168, DOI 10.1016/j.brainres.2010.07.062; Cohen J., 2013, STAT POWER ANAL BEHA; De Smedt B, 2009, EXP BRAIN RES, V195, P635, DOI 10.1007/s00221-009-1839-9; de Vries MH, 2010, J COGNITIVE NEUROSCI, V22, P2427, DOI 10.1162/jocn.2009.21385; Dehaene S, 2003, COGN NEUROPSYCHOL, V20, P487, DOI 10.1080/02643290244000239; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Elmer S, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-29; Filmer HL, 2014, TRENDS NEUROSCI, V37, P742, DOI 10.1016/j.tins.2014.08.003; Fiori V, 2011, J COGNITIVE NEUROSCI, V23, P2309, DOI 10.1162/jocn.2010.21579; Fregni F, 2005, EXP BRAIN RES, V166, P23, DOI 10.1007/s00221-005-2334-6; Gandiga PC, 2006, CLIN NEUROPHYSIOL, V117, P845, DOI 10.1016/j.clinph.2005.12.003; Grabner RH, 2007, NEUROIMAGE, V38, P346, DOI 10.1016/j.neuroimage.2007.07.041; Grabner RH, 2007, BRAIN RES BULL, V72, P57, DOI 10.1016/j.brainresbull.2007.01.001; Grabner RH, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00428; Grabner RH, 2011, BIOL PSYCHOL, V87, P128, DOI 10.1016/j.biopsycho.2011.02.019; Grabner RH, 2009, NEUROPSYCHOLOGIA, V47, P604, DOI 10.1016/j.neuropsychologia.2008.10.013; Hauser TU, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00244; Herwig U, 2003, BRAIN TOPOGR, V16, P95, DOI 10.1023/B:BRAT.0000006333.93597.9d; HOMAN RW, 1987, ELECTROEN CLIN NEURO, V66, P376, DOI 10.1016/0013-4694(87)90206-9; Iuculano T, 2013, J NEUROSCI, V33, P4482, DOI 10.1523/JNEUROSCI.4927-12.2013; Iyer MB, 2005, NEUROLOGY, V64, P872, DOI 10.1212/01.WNL.0000152986.07469.E9; Jacobs J, 2006, NEUROIMAGE, V32, P978, DOI 10.1016/j.neuroimage.2006.02.018; Jacobson L, 2012, BRAIN RES, V1439, P66, DOI 10.1016/j.brainres.2011.12.036; Jacobson L, 2012, EXP BRAIN RES, V216, P1, DOI 10.1007/s00221-011-2891-9; Jensen O, 2002, EUR J NEUROSCI, V15, P1395, DOI 10.1046/j.1460-9568.2002.01975.x; Kadosh RC, 2013, TRENDS NEUROSCI EDUC, V2, P85, DOI 10.1016/j.tine.2013.04.001; Kadosh RC, 2010, CURR BIOL, V20, P2016, DOI 10.1016/j.cub.2010.10.007; Kasashima Y, 2012, EXP BRAIN RES, V221, P263, DOI 10.1007/s00221-012-3166-9; Keeser D, 2011, NEUROIMAGE, V55, P644, DOI 10.1016/j.neuroimage.2010.12.004; Kirk EP, 2001, J EXP PSYCHOL LEARN, V27, P157, DOI 10.1037/0278-7393.27.1.157; Klimesch W, 1996, INT J PSYCHOPHYSIOL, V24, P61, DOI 10.1016/S0167-8760(96)00057-8; Klimesch W, 2005, EXP PSYCHOL, V52, P99, DOI 10.1027/1618-3169.52.2.99; Klimesch W, 1998, NEUROSCI LETT, V244, P73, DOI 10.1016/S0304-3940(98)00122-0; Klimesch W., 1993, Brain Topography, V5, P241, DOI 10.1007/BF01128991; Klimesch W, 1997, NEUROSCI LETT, V238, P9, DOI 10.1016/S0304-3940(97)00771-4; Klimesch W, 1999, BRAIN RES REV, V29, P169, DOI 10.1016/S0165-0173(98)00056-3; Klimesch W., 1992, J PSYCHOPHYSIOL, V6, P185; Koessler L, 2009, NEUROIMAGE, V46, P64, DOI 10.1016/j.neuroimage.2009.02.006; Kong H, 2005, COGNITIVE BRAIN RES, V22, P397, DOI 10.1016/j.cogbrainres.2004.09.011; Krause B, 2013, DEV COGN NEUROSCI; Lang N, 2005, EUR J NEUROSCI, V22, P495, DOI 10.1111/j.1460-9568.2005.04233.x; Laufs H, 2003, NEUROIMAGE, V19, P1463, DOI 10.1016/S1053-8119(03)00286-6; LeFevre J, 1996, J EXP PSYCHOL LEARN, V22, P216, DOI 10.1037/0278-7393.22.1.216; Maeoka H, 2012, NEUROSCI LETT, V512, P12, DOI 10.1016/j.neulet.2012.01.037; Marshall L, 2004, J NEUROSCI, V24, P9985, DOI 10.1523/JNEUROSCI.2725-04.2004; Matsumoto J, 2010, J NEUROENG REHABIL, V7, DOI 10.1186/1743-0003-7-27; Miniussi C, 2012, CLIN EEG NEUROSCI, V43, P184, DOI 10.1177/1550059412444976; Miranda PC, 2006, CLIN NEUROPHYSIOL, V117, P1623, DOI 10.1016/j.clinph.2006.04.009; Mognon A, 2011, PSYCHOPHYSIOLOGY, V48, P229, DOI 10.1111/j.1469-8986.2010.01061.x; Monte-Silva K, 2013, BRAIN STIMUL, V6, P424, DOI 10.1016/j.brs.2012.04.011; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2009, EXP NEUROL, V219, P14, DOI 10.1016/j.expneurol.2009.03.038; Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004; Nyhus E, 2010, NEUROSCI BIOBEHAV R, V34, P1023, DOI 10.1016/j.neubiorev.2009.12.014; Ohn SH, 2008, NEUROREPORT, V19, P43, DOI 10.1097/WNR.0b013e3282f2adfd; Osipova D, 2006, J NEUROSCI, V26, P7523, DOI 10.1523/JNEUROSCI.1948-06.2006; PARKMAN JM, 1971, J EXP PSYCHOL, V89, P335, DOI 10.1037/h0031198; Parsons S., 2005, DOES NUMERACY MATTER; PFURTSCHELLER G, 1970, Z GES EXP MED, V152, P284, DOI 10.1007/BF02044912; Pfurtscheller G, 2005, ELECTROENCEPHALOGRAP, P1004; Pisoni A, 2012, NEUROSCIENCE, V223, P56, DOI 10.1016/j.neuroscience.2012.07.046; Polania R, 2011, NEUROIMAGE, V54, P2287, DOI 10.1016/j.neuroimage.2010.09.085; PURPURA DP, 1965, J NEUROPHYSIOL, V28, P166, DOI 10.1152/jn.1965.28.1.166; R Development Core Team, 2012, R LANG ENV STAT COMP, DOI [10.1002/jcc.22917, DOI 10.1002/JCC.22917]; Royer JM, 1999, CONTEMP EDUC PSYCHOL, V24, P181, DOI 10.1006/ceps.1999.1004; Sarkar A, 2014, J NEUROSCI, V34, P16605, DOI 10.1523/JNEUROSCI.3129-14.2014; Schlaug G, 2011, NEUROPSYCHOL REV, V21, P288, DOI 10.1007/s11065-011-9181-y; Sparing R, 2009, BRAIN, V132, P3011, DOI 10.1093/brain/awp154; Sparing R, 2008, NEUROPSYCHOLOGIA, V46, P261, DOI 10.1016/j.neuropsychologia.2007.07.009; Stagg CJ, 2011, NEUROPSYCHOLOGIA, V49, P800, DOI 10.1016/j.neuropsychologia.2011.02.009; Stanescu-Cosson R, 2000, BRAIN, V123, P2240, DOI 10.1093/brain/123.11.2240; Stone DB, 2009, NEUROREPORT, V20, P1115, DOI 10.1097/WNR.0b013e32832e9aa2; Utz KS, 2010, NEUROPSYCHOLOGIA, V48, P2789, DOI 10.1016/j.neuropsychologia.2010.06.002; Varela F, 2001, NAT REV NEUROSCI, V2, P229, DOI 10.1038/35067550; Verguts T, 2005, MEM COGNITION, V33, P1, DOI 10.3758/BF03195293; Vines BW, 2006, NEUROREPORT, V17, P1047, DOI 10.1097/01.wnr.0000223396.05070.a2; Zago L, 2001, NEUROIMAGE, V13, P314, DOI 10.1006/nimg.2000.0697; Zbrodoff W., 2005, HDB MATH COGNITION, P331; Zhou XL, 2007, NEUROIMAGE, V35, P871, DOI 10.1016/j.neuroimage.2006.12.017; Zion-Golumbic E, 2010, J COGNITIVE NEUROSCI, V22, P263, DOI 10.1162/jocn.2009.21251	93	17	17	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2015	10	3							e0120665	10.1371/journal.pone.0120665	http://dx.doi.org/10.1371/journal.pone.0120665			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CD9NQ	25789486	Green Accepted, Green Published, gold, Green Submitted			2023-01-03	WOS:000351425400170
J	Ng, SSS; Chan, TO; To, KW; Chan, KKP; Ngai, J; Tung, A; Ko, FWS; Hui, DSC				Ng, Susanna S. S.; Chan, Tat-On; To, Kin-Wang; Chan, Ken K. P.; Ngai, Jenny; Tung, Alvin; Ko, Fanny W. S.; Hui, David S. C.			Prevalence of Obstructive Sleep Apnea Syndrome and CPAP Adherence in the Elderly Chinese Population	PLOS ONE			English	Article							POSITIVE AIRWAY PRESSURE; COMMERCIAL BUS DRIVERS; QUALITY-OF-LIFE; APNOEA/HYPOPNOEA SYNDROME; HONG-KONG; OXIDATIVE STRESS; HEART HEALTH; ADULTS; COMMUNITY; SCALE	Background This study assessed the prevalence of obstructive sleep apnea syndrome (OSAS) and CPAP adherence in the elderly Chinese in Hong Kong. Methods We conducted a sleep questionnaire survey among the elders aged >= 60 years in the community centres followed by level 3 home sleep study (Embletta). Subjects with an apnea hypopnea index (AHI) >= 15/hr alone and those with AHI >= 5/hr plus either cardiovascular risk factors or Epworth Sleepiness Score (ESS) >= 10 were offered CPAP treatment. Results Altogether 819 subjects were interviewed with mean (SD) age of 73.9 (7.5) years, BMI 24.2 (3.6) kg/m(2), neck circumference 34.9 (3.4) cm and ESS 6.6 (5.2). Daytime sleepiness was reported by 72.4%, snoring loudly 5.1% and witnessed apnea 4%. Among 234 subjects who underwent home sleep study, 156 (66.7%), 102 (43.6%), 70 (29.9%) and 45 (19.2%) had AHI >= 5, >= 10, >= 15 and >= 20/hr respectively, with the prevalence increasing with age and BMI. In the sample, 149 subjects (63.7%) were classified as having OSAS, as defined by an AHI >= 5/hr with associated symptoms, involving 81 men (74.3%) and 68 women (54.4%). Neck circumference and snoring frequency were the only positive independent factors associated with the AHI and the diagnosis of OSAS. Among 141 subjects who were offered CPAP treatment, 30 accepted CPAP prescription with improvement of ESS and cognitive function over 12 months with CPAP usage of 4.2 (2.2) h/night. Conclusion This study showed a high prevalence of OSAS among the community elders in Hong Kong. Home CPAP acceptance was low but there was significant improvement of subjective sleepiness and cognitive function among those on CPAP treatment.	[Ng, Susanna S. S.; Chan, Tat-On; To, Kin-Wang; Chan, Ken K. P.; Ngai, Jenny; Tung, Alvin; Ko, Fanny W. S.; Hui, David S. C.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Div Resp Med, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital	Hui, DSC (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Div Resp Med, Shatin, Hong Kong, Peoples R China.	dschui@cuhk.edu.hk	Hui, David Shu-Cheong/O-2754-2015; Ng, Susanna SS/G-7431-2017; Ko, Fanny W. S./B-8958-2016; Ng, Susanna/ABI-4965-2020	Hui, David Shu-Cheong/0000-0003-4382-2445; Ng, Susanna SS/0000-0002-4554-7312; Ko, Fanny W. S./0000-0001-8454-0087; 				Allen RP, 2005, ARCH INTERN MED, V165, P1286, DOI 10.1001/archinte.165.11.1286; Aloia M S, 2001, Sleep Breath, V5, P13, DOI 10.1007/s11325-001-0013-9; American Academy of Sleep Medicine, 2005, INT CLASS SLEEP DIS, V2nd; ANCOLIISRAEL S, 1991, SLEEP, V14, P486, DOI 10.1093/sleep/14.6.486; BEARPARK H, 1995, AM J RESP CRIT CARE, V151, P1459, DOI 10.1164/ajrccm.151.5.7735600; Chung KF, 2000, J PSYCHOSOM RES, V49, P367, DOI 10.1016/S0022-3999(00)00186-0; Damjanovic D, 2009, EUR RESPIR J, V33, P804, DOI 10.1183/09031936.00023408; Dingli K, 2003, EUR RESPIR J, V21, P253, DOI 10.1183/09031936.03.00298103; Engleman HM, 2004, THORAX, V59, P618, DOI 10.1136/thx.2003.015867; ENGLEMAN HM, 1994, LANCET, V343, P572, DOI 10.1016/S0140-6736(94)91522-9; Epstein LJ, 2009, J CLIN SLEEP MED, V5, P263; Flemons WW, 1998, AM J RESP CRIT CARE, V158, P494; FOLEY DJ, 1995, SLEEP, V18, P425, DOI 10.1093/sleep/18.6.425; Gami AS, 2005, NEW ENGL J MED, V352, P1206, DOI 10.1056/NEJMoa041832; Gozal D, 2008, AM J RESP CRIT CARE, V177, P369, DOI 10.1164/rccm.200608-1190PP; Hui DSC, 2006, RESPIROLOGY, V11, P723, DOI 10.1111/j.1440-1843.2006.00932.x; Hui DSC, 2000, CHEST, V117, P1410, DOI 10.1378/chest.117.5.1410; Hui DSC, 2002, INTERN MED J, V32, P149, DOI 10.1046/j.1444-0903.2001.00196.x; Hui DSC, 2001, CHEST, V120, P170, DOI 10.1378/chest.120.1.170; Ip MSM, 2001, CHEST, V119, P62, DOI 10.1378/chest.119.1.62; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Johns MW, 2000, J SLEEP RES, V9, P5, DOI 10.1046/j.1365-2869.2000.00177.x; KUMP K, 1994, AM J RESP CRIT CARE, V150, P735, DOI 10.1164/ajrccm.150.3.8087345; Lavie L, 2009, PROG CARDIOVASC DIS, V51, P303, DOI 10.1016/j.pcad.2008.08.003; Malhotra A, 2009, PROG CARDIOVASC DIS, V51, P279, DOI 10.1016/j.pcad.2008.10.004; Marin JM, 2005, LANCET, V365, P1046, DOI 10.1016/S0140-6736(05)71141-7; Martinez-Garcia MA, 2012, AM J RESP CRITICAL C; Masa JF, 2000, AM J RESP CRIT CARE, V162, P1407, DOI 10.1164/ajrccm.162.4.9907019; Ng SS, RESPIROLOGY CARLTON, V15, P336, DOI [10.1111/j.1440-1843.2009.01697, DOI 10.1111/J.1440-1843.2009.01697.X]; O'Connor GT, 2003, SLEEP, V26, P74; Parish JM, 2000, SLEEP MED, V1, P209, DOI 10.1016/S1389-9457(00)00011-3; Sforza E, EUR RESP J; Weaver TE, 2007, SLEEP MED REV, V11, P99, DOI 10.1016/j.smrv.2006.08.001; Young T, 2002, AM J RESP CRIT CARE, V165, P1217, DOI 10.1164/rccm.2109080; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; Young T, 2002, ARCH INTERN MED, V162, P893, DOI 10.1001/archinte.162.8.893	36	15	23	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 16	2015	10	3							e0119829	10.1371/journal.pone.0119829	http://dx.doi.org/10.1371/journal.pone.0119829			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CD6EY	25774657	Green Published, Green Submitted, gold			2023-01-03	WOS:000351183500130
J	Kahn, MW				Kahn, Michael W.			On Taking Notice - Learning Mindfulness from (Boston) Brahmins	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Kahn, Michael W.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Kahn, Michael W.] Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Kahn, MW (corresponding author), Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.							Kabat-Zinn J, 2009, LIBR J	1	2	2	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 5	2015	372	10					901	903		10.1056/NEJMp1410397	http://dx.doi.org/10.1056/NEJMp1410397			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CC4EU	25738665				2023-01-03	WOS:000350304500005
J	Joshi, M; Rice, SJ; Liu, X; Miller, B; Belani, CP				Joshi, Monika; Rice, Shawn J.; Liu, Xin; Miller, Bruce; Belani, Chandra P.			Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer	PLOS ONE			English	Article							MEK INHIBITION; RESISTANCE; MUTATIONS; MELANOMA; PATHWAY; MCL-1; ACTIVATION; PACLITAXEL; DEPENDENCE; GEFITINIB	V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) mutated lung cancer is relatively aggressive and is resistant to currently available therapies. In a recent phase II study for patients with BRAF-V600E non-small cell lung cancer (NSCLC), BRAF V600E inhibitor demonstrated evidence of activity, but 30% of this selected group progressed while on treatment, suggesting a need for developing alternative strategies. We tested two different options to enhance the efficacy of vemurafenib (BRAF V600E inhibitor) in BRAF mutated NSCLC. The first option was the addition of erlotinib to vemurafenib to see whether the combination provided synergy. The second was to induce MEK inhibition (downstream of RAF) with trametinib (MEK inhibitor). We found that the combination of vemurafenib and erlotinib was not synergistic to the inhibition of p-ERK signaling in BRAF-V600E cells. Vemurafenib caused significant apoptosis, G1 arrest and upregulation of BIM in BRAF-V600 cells. Trametinib was effective as a single agent in BRAF mutated cells, either V600E or non-V600E. Finally, the combination of vemurafenib and trametinib caused a small but significant increase in apoptosis as well as a significant upregulation of BIM when compared to either single agent. Thus, hinting at the possibility of utilizing a combinational approach for the management of this group of patients. Importantly, trametinib alone caused upregulation of p-AKT in BRAF non-V600 mutated cells, while this effect was nullified with the combination. This finding suggests that, the combination of a MEK inhibitor with a BRAF inhibitor will be more efficacious in the clinical setting for patients with BRAF mutated NSCLC.	[Joshi, Monika; Rice, Shawn J.; Liu, Xin; Miller, Bruce; Belani, Chandra P.] Penn State Hershey Canc Inst, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Belani, CP (corresponding author), Penn State Hershey Canc Inst, Hershey, PA 17033 USA.	cbelani@psu.edu	Joshi, Monika/N-8286-2019	Joshi, Monika/0000-0003-4286-8492				Akiyama T, 2009, MOL CANCER THER, V8, P3173, DOI 10.1158/1535-7163.MCT-09-0685; Borisy AA, 2003, P NATL ACAD SCI USA, V100, P7977, DOI 10.1073/pnas.1337088100; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Ebi H, 2011, J CLIN INVEST, V121, P4311, DOI 10.1172/JCI57909; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Foster JS, 2003, J BIOL CHEM, V278, P41355, DOI 10.1074/jbc.M302830200; Haferkamp S, 2013, J INVEST DERMATOL, V133, P1601, DOI 10.1038/jid.2013.6; Infante JR, 2012, LANCET ONCOL, V13, P773, DOI 10.1016/S1470-2045(12)70270-X; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Joseph EW, 2010, P NATL ACAD SCI USA, V107, P14903, DOI 10.1073/pnas.1008990107; Li R, 2005, CELL DEATH DIFFER, V12, P292, DOI 10.1038/sj.cdd.4401554; Lin LP, 2014, P NATL ACAD SCI USA, V111, pE748, DOI 10.1073/pnas.1320956111; Marchetti A, 2011, J CLIN ONCOL, V29, P3574, DOI 10.1200/JCO.2011.35.9638; Memmott RM, 2010, CLIN CANCER RES, V16, P4, DOI 10.1158/1078-0432.CCR-09-0234; Meng JR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013026; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Moulding DA, 2000, BLOOD, V96, P1756, DOI 10.1182/blood.V96.5.1756.h8001756_1756_1763; Moulding DA, 1998, BLOOD, V92, P2495, DOI 10.1182/blood.V92.7.2495.2495_2495_2502; Naoki K, 2002, CANCER RES, V62, P7001; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Paik PK, 2011, J CLIN ONCOL, V29, P2046, DOI 10.1200/JCO.2010.33.1280; Planchard D, 2013, ASCO M, V31, P8009; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Pratilas CA, 2008, CANCER RES, V68, P9375, DOI 10.1158/0008-5472.CAN-08-2223; Rosell R, 2009, NEW ENGL J MED, V361, P958, DOI 10.1056/NEJMoa0904554; Sarris EG, 2012, PHARMACEUTICALS-BASE, V5, P1236, DOI 10.3390/ph5111236; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Song LX, 2005, CANCER BIOL THER, V4, P267, DOI 10.4161/cbt.4.3.1496; Su ZL, 2011, J MOL DIAGN, V13, P74, DOI 10.1016/j.jmoldx.2010.11.010; Troiani T, 2012, BRIT J CANCER, V106, P1648, DOI 10.1038/bjc.2012.129; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Zhou CC, 2011, LANCET ONCOL, V12, P735, DOI 10.1016/S1470-2045(11)70184-X	35	46	48	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 23	2015	10	2							e0118210	10.1371/journal.pone.0118210	http://dx.doi.org/10.1371/journal.pone.0118210			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC9BI	25706985	gold, Green Submitted, Green Published			2023-01-03	WOS:000350662100153
J	Nishino, Y; Gilmour, S; Shibuya, K				Nishino, Yoshitaka; Gilmour, Stuart; Shibuya, Kenji			Inequality in Diabetes-Related Hospital Admissions in England by Socioeconomic Deprivation and Ethnicity: Facility-Based Cross-Sectional Analysis	PLOS ONE			English	Article							PRIMARY-CARE; INTERMEDIATE OUTCOMES; SOUTH ASIANS; PREVALENCE; QUALITY; 21ST-CENTURY; PREVENTION; FRAMEWORK; DATABASE; OBESITY	Objective To investigate the effect of social deprivation and ethnicity on inpatient admissions due to diabetes in England. Design Facility-based cross-sectional analysis. Setting National Health Service (NHS) trusts in England reporting inpatient admissions with better than 80% data reporting quality from 2010-2011 (355 facilities). Participants Non-obstetric patients over 16 years old in all NHS facilities in England. The sample size after exclusions was 5,147,859 all-cause admissions. Main Outcome Measures The relative risk of inpatient admissions and readmissions due to diabetes adjusted for confounders. Results There were 445,504 diabetes-related hospital admissions in England in 2010, giving a directly (age-sex) standardized rate of 1049.0 per 100,000 population (95% confidence interval (CI): 1046.0-1052.1). The relative risk of inpatient admission in the most deprived quintile was 2.08 times higher than that of the least deprived quintile (95% CI: 2.02-2.14), and the effect of deprivation varied across ethnicities. About 30.1% of patients admitted due to diabetes were readmitted at least once due to diabetes. South Asians showed 2.62 times (95% CI: 2.51 - 2.74) higher admission risk. Readmission risk increased with IMD among white British but not other ethnicities. South Asians showed slightly lower risk of readmission than white British (0.86, 95% CI: 0.80 - 0.94). Conclusions More deprived areas had higher rates of inpatient admissions and readmissions due to diabetes. South Asian British showed higher admission risk and lower readmission risk than white British. However, there was almost no difference by ethnicity in readmission due to diabetes. Higher rates of admission among deprived people may not necessarily reflect higher prevalence, but higher admission rates in south Asian British may be explained by their higher prevalence because their lower readmission risk suggests no inequality in primary care to prevent readmission. Better interventions in poorer areas, are needed to reduce these inequalities.	[Nishino, Yoshitaka; Gilmour, Stuart; Shibuya, Kenji] Univ Tokyo, Grad Sch Med, Dept Global Hlth Policy, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Nishino, Y (corresponding author), Univ Tokyo, Grad Sch Med, Dept Global Hlth Policy, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	ny28tom@cameo.plala.or.jp		Shibuya, Kenji/0000-0003-2528-7530	Ministry of Health, Labour and Welfare, Japan [H24-25-007]	Ministry of Health, Labour and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan)	This study was in part supported by a Grant-in-Aid for Scientific Research from the Ministry of Health, Labour and Welfare, Japan (Grant No. H24-25-007) (http://www.mhlw.go.jp/english/policy/other/research-projects/index.html). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.	Agyemang C, 2011, EPIDEMIOLOGY, V22, P563, DOI 10.1097/EDE.0b013e31821d1096; Appleby J, 2011, BMJ, V342; Ashworth M, 2007, BRIT J GEN PRACT, V57, P441; Blackledge HM, 2003, HEART, V89, P615, DOI 10.1136/heart.89.6.615; BRADDON FFM, 1986, BMJ-BRIT MED J, V293, P299, DOI 10.1136/bmj.293.6542.299; Chiu M, 2011, DIABETES CARE, V34, P1741, DOI 10.2337/dc10-2300; Correa-De-Araujo R, 2006, WOMEN HEALTH ISS, V16, P56, DOI 10.1016/j.whi.2005.08.003; Dalton ARH, 2011, DIABETIC MED, V28, P525, DOI 10.1111/j.1464-5491.2011.03251.x; Department for Communities and Local Government, 2011, ENGL IND DEPR 2010 T; Dixon A, 2012, EUR J PUBLIC HEALTH, V22, P9, DOI 10.1093/eurpub/ckq177; Engelgau MM, 2003, J AM SOC NEPHROL, V14, pS88, DOI 10.1097/01.ASN.0000070143.71933.B0; Farmer A, 2012, DIABETIC MED; Fischbacher CM, 2009, J PUBLIC HEALTH-UK, V31, P239, DOI 10.1093/pubmed/fdp003; Forouhi NG, 2006, DIABETIC MED, V23, P189, DOI 10.1111/j.1464-5491.2005.01787.x; Gray A, 2002, BRIT MED J, V325, P860, DOI 10.1136/bmj.325.7369.860; Gulliford MC, 2007, DIABETIC MED, V24, P505, DOI 10.1111/j.1464-5491.2007.02090.x; Guthrie B, 2009, DIABETIC MED, V26, P1269, DOI 10.1111/j.1464-5491.2009.02837.x; Hex N, 2012, DIABETIC MED, V29, P855, DOI 10.1111/j.1464-5491.2012.03698.x; Imkampe AK, 2011, EUR J PUBLIC HEALTH, V21, P484, DOI 10.1093/eurpub/ckq106; James GD, 2012, J ROY SOC MED, V105, P300, DOI 10.1258/jrsm.2012.110289; Majeed A, 2000, BRIT MED J, V321, P1057, DOI 10.1136/bmj.321.7268.1057; MCKEIGUE PM, 1991, LANCET, V337, P382, DOI 10.1016/0140-6736(91)91164-P; Morris S, 2005, SOC SCI MED, V60, P1251, DOI 10.1016/j.socscimed.2004.07.016; National Institute for Health and Care Excellence, 2013, ASS BOD MASS IND WAI; NHS England, 2013, NHS ENGL BOARD AGR I; Office for National Statistics, 2012, 2011 CENS ENGL WAL P; Office for National Statistics Neighbourhood Statistics, LOW SUP OUTP AR POP; Office of National Statistics, 2012, EX SUMM 2010 BAS NPP; Reid FDA, 1999, BRIT MED J, V319, P98, DOI 10.1136/bmj.319.7202.98; Ricci-Cabello I, 2010, HEALTH SOC CARE COMM, V18, P572, DOI 10.1111/j.1365-2524.2010.00960.x; Riste L, 2001, DIABETES CARE, V24, P1377, DOI 10.2337/diacare.24.8.1377; Sheikh A, 2011, BMJ-BRIT MED J, V343, P343, DOI DOI 10.1136/BMJ.D6054; Smith JA, 2012, BMJ, V344; The Health and Social Care Information Centre, 2010, HES DAT DICT; Thompson R, 2012, DIABETIC MED; Waller J, 2009, BRIT J CANCER, V101, pS24, DOI 10.1038/sj.bjc.6605387	36	26	27	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 23	2015	10	2							e0116689	10.1371/journal.pone.0116689	http://dx.doi.org/10.1371/journal.pone.0116689			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CC9BI	25705895	Green Published, Green Submitted, gold			2023-01-03	WOS:000350662100045
J	Lund, S; Richardson, A; May, C				Lund, Susi; Richardson, Alison; May, Carl			Barriers to Advance Care Planning at the End of Life: An Explanatory Systematic Review of Implementation Studies	PLOS ONE			English	Article							CLINICAL-PRACTICE; FAILURE; PATIENT; WORK; UK	Context Advance Care Plans (ACPs) enable patients to discuss and negotiate their preferences for the future including treatment options at the end of life. Their implementation poses significant challenges. Objective To investigate barriers and facilitators to the implementation of ACPs, focusing on their workability and integration in clinical practice. Design An explanatory systematic review of qualitative implementation studies. Data sources Empirical studies that reported interventions designed to support ACP in healthcare. Web of Knowledge, Ovid MEDLINE, CINAHL, PsycINFO, British Nursing Index and PubMed databases were searched. Methods Direct content analysis, using Normalization Process Theory, to identify and characterise relevant components of implementation processes. Results 13 papers identified from 166 abstracts were included in the review. Key factors facilitating implementation were: specially prepared staff utilizing a structured approach to interactions around ACPs. Barriers to implementation were competing demands of other work, the emotional and interactional nature of patient-professional interactions around ACPs, problems in sharing decisions and preferences within and between healthcare organizations. Conclusions This review demonstrates that doing more of the things that facilitate delivery of ACPs will not reduce the effects of those things that undermine them. Structured tools are only likely to be partially effective and the creation of a specialist cadre of ACP facilitators is unlikely to be a sustainable solution. The findings underscore both the challenge and need to find ways to routinely incorporate ACPs in clinical settings where multiple and competing demands impact on practice. Interventions most likely to meet with success are those that make elements of Advance Care Planning workable within complex and time pressured clinical workflows.	[Lund, Susi; Richardson, Alison; May, Carl] Univ Southampton, Fac Hlth Sci, Southampton, Hants, England; [Lund, Susi] Royal Berkshire NHS Fdn Trust, Reading, Berks, England; [Richardson, Alison; May, Carl] Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England; [Richardson, Alison; May, Carl] Natl Inst Hlth Res Collaborat Leadership Appl Res, Southampton, Hants, England	University of Southampton; Royal Berkshire Hospital; University of Southampton; University Hospital Southampton NHS Foundation Trust	Lund, S (corresponding author), Univ Southampton, Fac Hlth Sci, Southampton, Hants, England.	s.lund@soton.ac.uk		May, Carl/0000-0002-0451-2690	former South Central Strategic Health Authority; National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care (NIHR CLAHRC) Wessex	former South Central Strategic Health Authority; National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care (NIHR CLAHRC) Wessex	SL is a Post Doctoral Research Fellow supported by the former South Central Strategic Health Authority. AR and CRM's contribution to this work was partly supported by the National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care (NIHR CLAHRC) Wessex which is a partnership between Wessex NHS organizations and partners and the University of Southampton. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baker A, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X625175; Blakeman T, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X636056; Bond CJ, 2011, AGE AGEING, V40, P450, DOI 10.1093/ageing/afr025; Boyd K, 2010, BRIT J GEN PRACT, V60, DOI 10.3399/bjgp10X544032; Bravo G, 2012, BMC MED ETHICS, V13, DOI 10.1186/1472-6939-13-1; Conroy S, 2009, CLIN MED, V9, P76, DOI 10.7861/clinmedicine.9-1-76; De Vleminck A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084905; Department of Health, 2008, END LIF CAR STRAT PR; Detering KM, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1345; DoH, 2013, MOR CAR LESS PATHW R; Elwyn G., 2008, IMPLEMENTATION SCI, V3; Elwyn G, 2013, PATIENT EDUC COUNS, V90, P207, DOI 10.1016/j.pec.2012.06.036; Fagerlin A, 2004, HASTINGS CENT REP, V34, P30, DOI 10.2307/3527683; Gallacher K, 2011, ANN FAM MED, V9, P235, DOI 10.1370/afm.1249; Glaser BG, 1965, AWARENESS DYING; Hockley J, 2010, PALLIATIVE MED, V24, P828, DOI 10.1177/0269216310373162; Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687; Jeong SYS, 2007, CONTEMP NURSE, V26, P184, DOI 10.5172/conu.2007.26.2.184; Jeong SYS, 2010, J CLIN NURS, V19, P389, DOI 10.1111/j.1365-2702.2009.03001.x; Lloyd A, 2013, IMPLEMENT SCI, V8, DOI 10.1186/1748-5908-8-102; Love A, 2014, PALLIATIVE MED, V28, P1026, DOI 10.1177/0269216314531313; Lynn J, 2003, ANN INTERN MED, V138, P812, DOI 10.7326/0003-4819-138-10-200305200-00009; Mair FS, 2012, B WORLD HEALTH ORGAN, V90, P357, DOI 10.2471/BLT.11.099424; Matlock DD, 2011, HLTH EXPECTATIONS, V17, P49, DOI [10.1111/j.1369-7625.2011,00732.x, DOI 10.1111/J.1369-7625.2011,00732.X]; May C, 2014, INT J NURS STUD, V51, P289, DOI 10.1016/j.ijnurstu.2013.06.019; May C, 2013, IMPLEMENT SCI, V8, DOI 10.1186/1748-5908-8-18; May C, 2009, SOCIOLOGY, V43, P535, DOI 10.1177/0038038509103208; McEvoy R, 2014, IMPLEMENT SCI, V9, DOI 10.1186/1748-5908-9-2; Moher D, 2011, J CLIN EPIDEMIOL, V64, P718, DOI 10.1016/j.jclinepi.2010.09.013; National Confidential Enquiry into Patient Outcome and Death, 2012, TIM TO INT; Norlander L, 2000, Home Healthc Nurse, V18, P532, DOI 10.1097/00004045-200009000-00012; Obolensky L, 2010, J MED ETHICS, V36, P518, DOI 10.1136/jme.2009.033977; Pettit SJ, 2012, BMJ SUPPORT PALLIAT, V2, P94, DOI 10.1136/bmjspcare-2011-000176; Rhee JJ, 2011, AUST HEALTH REV, V35, P197, DOI 10.1071/AH10883; Sabatino CP, 2010, MILBANK Q, V88, P211, DOI 10.1111/j.1468-0009.2010.00596.x; Sampson EL, 2011, PALLIATIVE MED, V25, P197, DOI 10.1177/0269216310391691; Schickedanz AD, 2009, J AM GERIATR SOC, V57, P31, DOI 10.1111/j.1532-5415.2008.02093.x; Schiff R, 2009, AGE AGEING, V38, P81, DOI 10.1093/ageing/afn235; Seymour J, 2010, BMC PALLIATIVE CARE, V9; Seymour J, 2013, INT J PALLIAT NURS, V19, P369, DOI 10.12968/ijpn.2013.19.8.369; Shanley C, 2009, AUSTRALAS J AGEING, V28, P211, DOI 10.1111/j.1741-6612.2009.00383.x; Simon J, 2008, J PALLIAT CARE, V24, P256, DOI 10.1177/082585970802400405; Stein GL, 2013, BRIT J SOC WORK, V43, P233, DOI 10.1093/bjsw/bct013; Storey Les, 2013, Nurs Older People, V25, P14; Watson R, 2011, CHILD CARE HLTH DEV, V37, P780, DOI 10.1111/j.1365-2214.2011.01293.x	45	175	175	0	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2015	10	2							e0116629	10.1371/journal.pone.0116629	http://dx.doi.org/10.1371/journal.pone.0116629			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CC9IO	25679395	Green Published, Green Submitted, gold, Green Accepted			2023-01-03	WOS:000350682600029
J	Cheng, CJ; Bahal, R; Babar, IA; Pincus, Z; Barrera, F; Liu, C; Svoronos, A; Braddock, DT; Glazer, PM; Engelman, DM; Saltzman, WM; Slack, FJ				Cheng, Christopher J.; Bahal, Raman; Babar, Imran A.; Pincus, Zachary; Barrera, Francisco; Liu, Connie; Svoronos, Alexander; Braddock, Demetrios T.; Glazer, Peter M.; Engelman, Donald M.; Saltzman, W. Mark; Slack, Frank J.			MicroRNA silencing for cancer therapy targeted to the tumour microenvironment	NATURE			English	Article							PEPTIDE-NUCLEIC-ACIDS; IN-VIVO; CELL PROLIFERATION; ONCOMIR ADDICTION; TRANSLOCATION; TRANSCRIPTOME; MOLECULES; BARRIERS; DELIVERY; MODEL	MicroRNAs are short non-codingRNAs expressed in different tissue and cell types that suppress the expression of target genes. As such, microRNAs are critical cogs innumerous biological processes(1,2), and dysregulated microRNA expression is correlated with many human diseases. Certain microRNAs, called oncomiRs, play a causal role in the onset and maintenance of cancer when overexpressed. Tumours that depend on these microRNAs are said to display oncomiR addiction(3-5). Some of the most effective anticancer therapies target oncogenes such as EGFR and HER2; similarly, inhibition of oncomiRs using antisense oligomers (that is, antimiRs) is an evolving therapeutic strategy(6,7). However, the in vivo efficacy of current antimiR technologies is hindered by physiological and cellular barriers to delivery into targeted cells(8). Here we introduce a novel antimiR delivery platform that targets the acidic tumour microenvironment, evades systemic clearance by the liver, and facilitates cell entry via a non-endocytic pathway. We find that the attachment of peptide nucleic acid antimiRs to a peptide with a low pH-induced transmembrane structure (pHLIP) produces a novel construct that could target the tumour microenvironment, transport antimiRs across plasma membranes under acidic conditions such as those found in solid tumours (pH approximately 6), and effectively inhibit the miR-155 oncomiR in a mouse model of lymphoma. This study introduces a new model for using antimiRs as anti-cancer drugs, which can have broad impacts on the field of targeted drug delivery.	[Cheng, Christopher J.; Babar, Imran A.; Pincus, Zachary; Liu, Connie; Slack, Frank J.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06511 USA; [Cheng, Christopher J.; Saltzman, W. Mark] Yale Univ, Dept Biomed Engn, New Haven, CT 06511 USA; [Cheng, Christopher J.; Barrera, Francisco; Svoronos, Alexander; Engelman, Donald M.] Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06511 USA; [Bahal, Raman; Glazer, Peter M.] Yale Univ, Dept Therapeut Radiol, New Haven, CT 06511 USA; [Braddock, Demetrios T.] Yale Univ, Dept Pathol, New Haven, CT 06511 USA	Yale University; Yale University; Yale University; Yale University; Yale University	Slack, FJ (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave, Boston, MA 02215 USA.	fslack@bidmc.harvard.edu	Glazer, Peter/S-7651-2019	Pincus, Zachary/0000-0001-9785-5977; Slack, Frank/0000-0001-8263-0409; Glazer, Peter/0000-0003-4525-5560; Barrera, Francisco N./0000-0002-5200-7891; Bahal, Raman/0000-0002-4514-8004	Ruth L. Kirschstein Postdoctoral Fellowship from the National Cancer Institute/National Institutes of Health (NCI/NIH) [F32CA174247]; NCI/NIH [R01CA131301, R01CA148996]; National Heart, Lung, and Blood Institute (NHLBI)/NIH [R01HL085416]; National Institute of General Medical Sciences (NIGMS)/NIH [R01GM073857]; National Institute of Environmental Health Sciences (NIEHS)/NIH [R01ES005775]; National Institute of Biomedical Imaging and Bioengineering (NIBIB)/NIH [R01EB000487]; NHLBI/NIH [2T32HL007974]; Yale Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE [P30CA016359, F32CA174247, R01CA149128, R01CA131301, R01CA148996] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000142] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007974, R01HL085416] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000487] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005775] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM073857, T32GM007205] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R00AG042487] Funding Source: NIH RePORTER	Ruth L. Kirschstein Postdoctoral Fellowship from the National Cancer Institute/National Institutes of Health (NCI/NIH); NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Heart, Lung, and Blood Institute (NHLBI)/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of General Medical Sciences (NIGMS)/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Institute of Environmental Health Sciences (NIEHS)/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Institute of Biomedical Imaging and Bioengineering (NIBIB)/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NHLBI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Yale Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank M. Bosenberg, Y. Dang, A. Karabadzhak, and J. Zhou for discussions and suggestions; R. Ardito, M. Bonk, K. Card, D. Caruso, D. Jenci, D. Laliberte, W. Nazzaro, N. Santiago, and S. Wilson for rodent services; A. Brooks for tissue pathology services; Antech Diagnostics for complete blood count analysis; E. Aronesty, B. Cooper, and E. Norris at Expression Analysis for RNA-seq services; and J. Deacon, A. Kasinski, J. Sawyer, and C. Stahlhut for reading the manuscript. C. J. C. is the recipient of a Ruth L. Kirschstein Postdoctoral Fellowship from the National Cancer Institute/National Institutes of Health (NCI/NIH) (F32CA174247). Our work has been supported by grants from the NCI/NIH (R01CA131301), the National Heart, Lung, and Blood Institute (NHLBI)/NIH (R01HL085416), the National Institute of General Medical Sciences (NIGMS)/NIH (R01GM073857), the National Institute of Environmental Health Sciences (NIEHS)/NIH (R01ES005775), the NCI/NIH (R01CA148996), the National Institute of Biomedical Imaging and Bioengineering (NIBIB)/NIH (R01EB000487), the NHLBI/NIH (2T32HL007974), and pilot grants from the Yale Comprehensive Cancer Center.	Babar IA, 2012, P NATL ACAD SCI USA, V109, pE1695, DOI 10.1073/pnas.1201516109; Brognara E, 2014, J NEURO-ONCOL, V118, P19, DOI 10.1007/s11060-014-1405-6; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Cheng CJ, 2013, CURR MED CHEM, V20, P3582; Cheng CJ, 2012, CANCER J, V18, P232, DOI 10.1097/PPO.0b013e318258b75b; Christensen L, 1995, J Pept Sci, V1, P175; Costinean S, 2006, P NATL ACAD SCI USA, V103, P7024, DOI 10.1073/pnas.0602266103; Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002; Eifel PJ., 2011, DEVITA HELLMAN ROSEN; Elmen J, 2008, NATURE, V452, P896, DOI 10.1038/nature06783; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fabani MM, 2010, NUCLEIC ACIDS RES, V38, P4466, DOI 10.1093/nar/gkq160; Fabbri E, 2011, EPIGENOMICS-UK, V3, P733, DOI [10.2217/EPI.11.90, 10.2217/epi.11.90]; Gottwein E, 2007, NATURE, V450, P1096, DOI 10.1038/nature05992; He L., 2004, NAT REV GENET, V5, P522; Kasinski AL, 2011, NAT REV CANCER, V11, P849, DOI 10.1038/nrc3166; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Li SC, 2012, MOL MED REP, V5, P949, DOI 10.3892/mmr.2012.779; Loeb GB, 2012, MOL CELL, V48, P760, DOI 10.1016/j.molcel.2012.10.002; Medina PP, 2010, NATURE, V467, P86, DOI 10.1038/nature09284; NIELSEN PE, 1994, BIOCONJUGATE CHEM, V5, P3, DOI 10.1021/bc00025a001; Obad S, 2011, NAT GENET, V43, P371, DOI 10.1038/ng.786; Ostergaard H, 2004, J CELL BIOL, V166, P337, DOI 10.1083/jcb.200402120; Rai D, 2008, CANCER GENET CYTOGEN, V181, P8, DOI 10.1016/j.cancergencyto.2007.10.008; Rather MI, 2013, J BIOL CHEM, V288, P608, DOI 10.1074/jbc.M112.425736; Reshetnyak YK, 2011, MOL IMAGING BIOL, V13, P1146, DOI 10.1007/s11307-010-0457-z; Reshetnyak YK, 2006, P NATL ACAD SCI USA, V103, P6460, DOI 10.1073/pnas.0601463103; Sahu B, 2011, J ORG CHEM, V76, P5614, DOI 10.1021/jo200482d; Sandhu Sukhinder K, 2011, Adv Hematol, V2011, P347137, DOI 10.1155/2011/347137; Shiraishi Takehiko, 2011, Artif DNA PNA XNA, V2, P90; Stenvang Jan, 2012, Silence, V3, P1, DOI 10.1186/1758-907X-3-1; Thevenin D, 2009, CHEM BIOL, V16, P754, DOI 10.1016/j.chembiol.2009.06.006; VAUPEL P, 1989, CANCER RES, V49, P6449; Wang YZ, 2014, CLIN EXP IMMUNOL, V176, P207, DOI 10.1111/cei.12265; White PJ, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001021; Xu GR, 2010, RNA, V16, P1610, DOI 10.1261/rna.2194910; Zhang Y, 2012, BLOOD, V120, P1678, DOI 10.1182/blood-2012-02-410647	37	580	607	17	78	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 5	2015	518	7537					107	+		10.1038/nature13905	http://dx.doi.org/10.1038/nature13905			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA7LE	25409146	Green Accepted			2023-01-03	WOS:000349098000041
J	Dimick, JB; Ghaferi, AA				Dimick, Justin B.; Ghaferi, Amir A.			Hospital Readmission as a Quality Measure in Surgery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							COMPLICATIONS; CARE	IMPORTANCE Readmissions after surgery are costly and may reflect quality of care in the index hospitalization. OBJECTIVES To determine the timing of postoperative complications with respect to hospital discharge and the frequency of readmission stratified by predischarge and postdischarge occurrence of complications. DESIGN, SETTING, AND PARTICIPANTS This is a retrospective cohort study of national Veterans Affairs Surgical Quality Improvement Program preoperative risk and outcome data on the Surgical Care Improvement Project cohort for operations performed from January 2005 to August 2009, including colorectal, arthroplasty, vascular, and gynecologic procedures. The association between timing of complication with respect to index hospitalization and 30-day readmission was modeled using generalized estimating equations. MAIN OUTCOME AND MEASURE All-cause readmission within 30 days of the index surgical hospitalization discharge. RESULTS Our study of 59 273 surgical procedures performed at 112 Department of Veterans Affairs (VA) hospitals found an overall complication rate of 22.6%(predischarge complications, 71.9%; postdischarge complications, 28.1%). The proportion of postdischarge complications varied significantly, from 8.7% for respiratory complications to 55.7% for surgical site infection (P<.001). The overall 30-day readmission rate was 11.9%, of which only 56.0% of readmissions were associated with a currently assessed complication. Readmission was predicted by patient comorbid conditions, procedure factors, and the occurrence of postoperative complications. Multivariable generalized estimating equation models of readmission adjusting for patient and procedure characteristics, hospital, and index length of stay found that the occurrence of postdischarge complications had the highest odds of readmission (odds ratio, 7.4-20.8) compared with predischarge complications (odds ratio, 0.9-1.48). CONCLUSIONS AND RELEVANCE More than one-quarter of assessed complications are diagnosed after hospital discharge and strongly predict readmission. Hospital discharge is an insufficient end point for quality assessment. Although readmission is associated with complications, almost half of readmissions are not associated with a complication currently assessed by the Veterans Affairs Surgical Quality Improvement Program.	[Dimick, Justin B.; Ghaferi, Amir A.] Univ Michigan, Dept Surg, Ctr Healthcare Outcomes & Policy, 2800 Plymouth Rd,Bldg 16,Off 136E, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Dimick, JB (corresponding author), Univ Michigan, Dept Surg, Ctr Healthcare Outcomes & Policy, 2800 Plymouth Rd,Bldg 16,Off 136E, Ann Arbor, MI 48109 USA.	jdimick@umich.edu						Girotti ME, 2014, JAMA SURG, V149, P757, DOI 10.1001/jamasurg.2014.163; Glance LG, 2014, JAMA SURG, V149, P439, DOI 10.1001/jamasurg.2014.4; Jha AK, 2014, JAMA-J AM MED ASSOC, V312, P225, DOI 10.1001/jama.2014.7204; Joynt KE, 2013, JAMA-J AM MED ASSOC, V309, P342, DOI 10.1001/jama.2012.94856; Morris MS, 2014, JAMA SURG, V149, P348, DOI 10.1001/jamasurg.2013.4064; Shih T, 2015, ANN SURG, V261, P1027, DOI 10.1097/SLA.0000000000000778; Tsai TC, 2013, NEW ENGL J MED, V369, P1134, DOI 10.1056/NEJMsa1303118	7	34	34	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	2015	313	5					512	+		10.1001/jama.2014.14179	http://dx.doi.org/10.1001/jama.2014.14179			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CA7AV	25647207				2023-01-03	WOS:000349070300015
J	Pizzo, PA				Pizzo, Philip A.			The Doctor: For Life and at the End of Life	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							PALLIATIVE CARE; CANCER		Stanford Univ, Sch Med, Stanford, CA 94305 USA	Stanford University	Pizzo, PA (corresponding author), Stanford Univ, Sch Med, Lorry Lokey Res Bldg,265 Campus Dr G1078, Stanford, CA 94305 USA.	ppizzo@stanford.edu						Committee on Approaching Death: Addressing Key End of Life Issues, 2014, DYING AM IMPR QUAL H; Committee on Improving the Quality of Cancer Care: Addressing the Challenges of an Aging Population Board on Health Care Services Institute of Medicine, 2013, DEL HIGH QUAL CANC C; Smith TJ, 2012, J CLIN ONCOL, V30, P880, DOI 10.1200/JCO.2011.38.5161; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Weeks JC, 2012, NEW ENGL J MED, V367, P1616, DOI 10.1056/NEJMoa1204410	5	5	5	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 3	2015	162	3					228	U139		10.7326/M14-2399	http://dx.doi.org/10.7326/M14-2399			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CC1NP	25486216				2023-01-03	WOS:000350108100010
J	Curley, MAQ; Wypij, D; Watson, RS; Grant, MJC; Asaro, LA; Cheifetz, IM; Dodson, BL; Franck, LS; Gedeit, RG; Angus, DC; Matthay, MA				Curley, Martha A. Q.; Wypij, David; Watson, R. Scott; Grant, Mary Jo C.; Asaro, Lisa A.; Cheifetz, Ira M.; Dodson, Brenda L.; Franck, Linda S.; Gedeit, Rainer G.; Angus, Derek C.; Matthay, Michael A.		Network	Protocolized Sedation vs Usual Care in Pediatric Patients Mechanically Ventilated for Acute Respiratory Failure A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CRITICALLY-ILL PATIENTS; CHILDREN; DELIRIUM; UNIT; INFANTS; WITHDRAWAL; EFFICACY; OUTCOMES; INTERRUPTION; INSTRUMENT	IMPORTANCE Protocolized sedation improves clinical outcomes in critically ill adults, but its effect in children is unknown. OBJECTIVE To determine whether critically ill children managed with a nurse-implemented, goal-directed sedation protocol experience fewer days of mechanical ventilation than patients receiving usual care. DESIGN, SETTING, AND PARTICIPANTS Cluster randomized trial conducted in 31 US pediatric intensive care units (PICUs). A total of 2449 children (mean age, 4.7 years; range, 2 weeks to 17 years) mechanically ventilated for acute respiratory failure were enrolled in 2009-2013 and followed up until 72 hours after opioids were discontinued, 28 days, or hospital discharge. INTERVENTION Intervention PICUs (17 sites; n = 1225 patients) used a protocol that included targeted sedation, arousal assessments, extubation readiness testing, sedation adjustment every 8 hours, and sedation weaning. Control PICUs (14 sites; n = 1224 patients) managed sedation per usual care. MAIN OUTCOMES AND MEASURES The primary outcome was duration of mechanical ventilation. Secondary outcomes included time to recovery from acute respiratory failure, duration of weaning from mechanical ventilation, neurological testing, PICU and hospital lengths of stay, in-hospital mortality, sedation-related adverse events, measures of sedative exposure (wakefulness, pain, and agitation), and occurrence of iatrogenic withdrawal. RESULTS Duration of mechanical ventilation was not different between the 2 groups (intervention: median, 6.5 [IQR, 4.1-11.2] days; control: median, 6.5 [IQR, 3.7-12.1] days). Sedation-related adverse events including inadequate pain and sedation management, clinically significant iatrogenic withdrawal, and unplanned endotracheal tube/invasive line removal were not significantly different between the 2 groups. Intervention patients experienced more postextubation stridor (7% vs 4%; P = .03) and fewer stage 2 or worse immobility-related pressure ulcers (<1% vs 2%; P = .001). In exploratory analyses, intervention patients had fewer days of opioid administration (median, 9 [IQR, 5-15] days vs 10 [IQR, 4-21] days; P = .01), were exposed to fewer sedative classes (median, 2 [IQR, 2-3] classes vs 3 [IQR, 2-4] classes; P < .001), andwere more often awake and calm while intubated (median, 86%[IQR, 67%-100%] of days vs 75%[IQR, 50%-100%] of days; P = .004) than control patients, respectively; however, intervention patients had more days with any report of a pain score >= 4 (median, 50%[IQR, 27%-67%] of days vs 23%[IQR, 0%-46%] of days; P < .001) and any report of agitation (median, 60%[IQR, 33%-80%] vs40%[IQR, 13%-67%]; P = .003), respectively. CONCLUSIONS AND RELEVANCE Among children undergoing mechanical ventilation for acute respiratory failure, the use of a sedation protocol compared with usual care did not reduce the duration of mechanical ventilation. Exploratory analyses of secondary outcomes suggest a complex relationship among wakefulness, pain, and agitation.	[Curley, Martha A. Q.] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA; [Curley, Martha A. Q.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Curley, Martha A. Q.] Boston Childrens Hosp, Crit Care & Cardiovasc Program, Boston, MA USA; [Wypij, David] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Wypij, David] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Wypij, David; Asaro, Lisa A.] Boston Childrens Hosp, Dept Cardiol, Boston, MA USA; [Watson, R. Scott] Seattle Childrens Res Inst, Ctr Child Hlth Behav & Dev, Seattle, WA USA; [Watson, R. Scott; Angus, Derek C.] Clin Res Invest & Syst Modeling Acute Illness Ctr, Pittsburgh, PA USA; [Grant, Mary Jo C.] Primary Childrens Med Ctr, Salt Lake City, UT USA; [Cheifetz, Ira M.] Duke Univ, Med Ctr, Durham, NC USA; [Dodson, Brenda L.] Boston Childrens Hosp, Dept Pharm, Boston, MA USA; [Franck, Linda S.] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Harvard University; Boston Children's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Seattle Children's Hospital; Duke University; Harvard University; Boston Children's Hospital; University of California System; University of California San Francisco	Curley, MAQ (corresponding author), Univ Penn, Claire M Fagin Hall,418 Curie Blvd 425, Philadelphia, PA 19104 USA.	curley@nursing.upenn.edu	Curley, Martha A/F-3579-2016; Angus, Derek C/E-9671-2012; Cheifetz, Ira/I-8692-2019	Curley, Martha A/0000-0001-5228-6694; Cheifetz, Ira/0000-0002-1174-1571; Franck, Linda/0000-0003-4291-9181; Wypij, David/0000-0001-8367-8711; Watson, R. Scott/0000-0002-2581-7186; Gedeit, Rainer/0000-0003-2420-9493; Asaro, Lisa/0000-0001-5736-0304; Faustino, Edward Vincent S./0000-0001-6155-2691	National Heart, Lung, and Blood Institute; National Institute of Nursing Research, National Institutes of Health [U01 HL086622, U01 HL086649]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL086622, U01HL086649] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Nursing Research, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was supported by grants from the National Heart, Lung, and Blood Institute and the National Institute of Nursing Research, National Institutes of Health (grant U01 HL086622 to Dr Curley and grant U01 HL086649 to Dr Wypij).	Anand KJS, 2010, PEDIATRICS, V125, pE1208, DOI 10.1542/peds.2009-0489; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Batt J, 2013, AM J RESP CRIT CARE, V187, P238, DOI 10.1164/rccm.201205-0954SO; Brook AD, 1999, CRIT CARE MED, V27, P2609, DOI 10.1097/00003246-199912000-00001; Campbell MK, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5661; Colville G, 2008, AM J RESP CRIT CARE, V177, P976, DOI 10.1164/rccm.200706-857OC; Creten C, 2011, MINERVA ANESTESIOL, V77, P1099; Curley MAQ, 2006, J CRIT CARE, V21, P23, DOI 10.1016/j.jcrc.2005.12.004; Curley MAQ, 2005, JAMA-J AM MED ASSOC, V294, P229, DOI 10.1001/jama.294.2.229; CURLEY MAQ, 2003, PEDIATR CRIT CARE ME, V4, pA158; Curley MAQ, 2006, PEDIATR CRIT CARE ME, V7, P107, DOI 10.1097/01.PCC.0000200955.40962.38; Donner A, 2010, DESIGN ANAL CLUSTER; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Franck LS, 2008, PEDIATR CRIT CARE ME, V9, P573, DOI 10.1097/PCC.0b013e31818c8328; Gangnon RE, 2004, BIOMETRIKA, V91, P263, DOI 10.1093/biomet/91.2.263; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Grant MJC, 2012, CRIT CARE MED, V40, P1317, DOI 10.1097/CCM.0b013e31823c8ae3; Hartman ME, 2009, PEDIATR CRIT CARE ME, V10, P246, DOI 10.1097/PCC.0b013e31819a3bb9; Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802; Jackson JC, 2010, AM J RESP CRIT CARE, V182, P183, DOI 10.1164/rccm.200903-0442OC; Jenkins IA, 2007, PEDIATR ANESTH, V17, P675, DOI 10.1111/j.1460-9592.2006.02180.x; Jouvet P, 2015, PEDIATR CRIT CARE ME, V16, P428, DOI 10.1097/PCC.0000000000000350; Kearns GL, 2003, NEW ENGL J MED, V349, P1157, DOI 10.1056/NEJMra035092; Khemani RG, 2014, AM J RESP CRIT CARE, V189; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Kress JP, 2003, AM J RESP CRIT CARE, V168, P1457, DOI 10.1164/rccm.200303-455OC; Kudchadkar SR, 2014, CRIT CARE MED, V42, P1592, DOI 10.1097/CCM.0000000000000326; Kudchadkar SR, 2014, SLEEP MED REV, V18, P103, DOI 10.1016/j.smrv.2013.02.002; LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085; Merkel S I, 1997, Pediatr Nurs, V23, P293; Mesotten D, 2012, JAMA-J AM MED ASSOC, V308, P1641, DOI 10.1001/jama.2012.12424; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372; Pollack MM, 1996, CRIT CARE MED, V24, P743, DOI 10.1097/00003246-199605000-00004; Randolph AG, 2002, JAMA-J AM MED ASSOC, V288, P2561, DOI 10.1001/jama.288.20.2561; Reade MC, 2014, NEW ENGL J MED, V370, P444, DOI 10.1056/NEJMra1208705; Schoenfeld DA, 2002, CRIT CARE MED, V30, P1772, DOI 10.1097/00003246-200208000-00016; Smith HAB, 2011, CRIT CARE MED, V39, P150, DOI 10.1097/CCM.0b013e3181feb489; Solodiuk Jean, 2003, J Pediatr Nurs, V18, P295, DOI 10.1016/S0882-5963(03)00090-3; Strom T, 2010, LANCET, V375, P475, DOI 10.1016/S0140-6736(09)62072-9; Tobias JD, 2000, CRIT CARE MED, V28, P2122, DOI 10.1097/00003246-200006000-00079; Traube C, 2014, CRIT CARE MED, V42, P656, DOI 10.1097/CCM.0b013e3182a66b76; Twite Mark D, 2004, Pediatr Crit Care Med, V5, P521, DOI 10.1097/01.PCC.0000144710.13710.2E; van Zellem L, 2014, PEDIATR CRIT CARE ME, V15, P189, DOI 10.1097/PCC.0000000000000044; Wong D L, 1988, Pediatr Nurs, V14, P9; Xie TL, 2003, STAT MED, V22, P2835, DOI 10.1002/sim.1536	48	248	249	4	56	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 27	2015	313	4					379	389		10.1001/jama.2014.18399	http://dx.doi.org/10.1001/jama.2014.18399			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CA7BS	25602358	Green Accepted, Bronze			2023-01-03	WOS:000349072600020
J	Lim, MSC; Zhang, XD; Kennedy, E; Li, Y; Yang, Y; Li, L; Li, YX; Temmerman, M; Luchters, S				Lim, Megan S. C.; Zhang, Xu-Dong; Kennedy, Elissa; Li, Yan; Yang, Yin; Li, Lin; Li, Yun-Xia; Temmerman, Marleen; Luchters, Stanley			Sexual and Reproductive Health Knowledge, Contraception Uptake, and Factors Associated with Unmet Need for Modern Contraception among Adolescent Female Sex Workers in China	PLOS ONE			English	Article							TRANSMITTED INFECTIONS; BEHAVIOR; VIOLENCE; WOMEN; HIV; DRINKING; ALCOHOL; RISK	Objective In China, policy and social taboo prevent unmarried adolescents from accessing sexual and reproductive health (SRH) services. Research is needed to determine the SRH needs of highly disadvantaged groups, such as adolescent female sex workers (FSWs). This study describes SRH knowledge, contraception use, pregnancy, and factors associated with unmet need for modern contraception among adolescent FSWs in Kunming, China. Methods A cross-sectional study using a one-stage cluster sampling method was employed to recruit adolescents aged 15 to 20 years, and who self-reported having received money or gifts in exchange for sex in the past 6 months. A semi-structured questionnaire was administered by trained peer educators or health workers. Multivariable logistic regression was conducted to determine correlates of low knowledge and unmet need for modern contraception. Results SRH knowledge was poor among the 310 adolescents surveyed; only 39% had heard of any long-acting reversible contraception (implant, injection or IUD). Despite 98% reporting not wanting to get pregnant, just 43% reported consistent condom use and 28% currently used another form of modern contraception. Unmet need for modern contraception was found in 35% of adolescents, and was associated with having a current non-paying partner, regular alcohol use, and having poorer SRH knowledge. Past abortion was common (136, 44%). In the past year, 76% had reported a contraception consultation but only 27% reported ever receiving SRH information from a health service. Conclusions This study demonstrated a low level of SRH knowledge, a high unmet need for modern contraception and a high prevalence of unintended pregnancy among adolescent FSWs in Kunming. Most girls relied on condoms, emergency contraception, or traditional methods, putting them at risk of unwanted pregnancy. This study identifies an urgent need for Chinese adolescent FSWs to be able to access quality SRH information and effective modern contraception.	[Lim, Megan S. C.] Burnet Inst, Ctr Populat Hlth, Melbourne, Vic, Australia; [Zhang, Xu-Dong; Temmerman, Marleen; Luchters, Stanley] Univ Ghent, Int Ctr Reprod Hlth, Dept Obstet & Gynaecol, B-9000 Ghent, Belgium; [Kennedy, Elissa; Luchters, Stanley] Burnet Inst, Ctr Int Hlth, Melbourne, Vic, Australia; [Lim, Megan S. C.; Kennedy, Elissa; Luchters, Stanley] Monash Univ, Sch Publ Hlth & Prevent Med, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia; [Li, Yan] Kunming Med Univ, Sch Publ Hlth, Kunming, Peoples R China; [Yang, Yin] Kunming Third Peoples Hosp, Dept AIDS Management, Kunming, Peoples R China; [Li, Lin] Kunming Maternal & Child Hlth Care Ctr, Dept Primary Hlth Care, Kunming, Peoples R China; [Li, Yun-Xia] Kunming Maternal & Child Hlth Care Ctr, Dept AIDS Prevent, Kunming, Peoples R China	Burnet Institute; Ghent University; Burnet Institute; Monash University; Kunming Medical University	Zhang, XD (corresponding author), Univ Ghent, Int Ctr Reprod Hlth, Dept Obstet & Gynaecol, B-9000 Ghent, Belgium.	Xudong.Zhang@UGent.be		Luchters, Stanley/0000-0001-5235-5629	FSW research from the AIDS department of Kunming Public Health Bureau [KM2012AIDS]; Kunming Xishan District Center for Disease Prevention and Control [XSCDC-FSW-2012-06]	FSW research from the AIDS department of Kunming Public Health Bureau; Kunming Xishan District Center for Disease Prevention and Control	This study was supported by grants on FSW research from the AIDS department of Kunming Public Health Bureau (KM2012AIDS), the Kunming Xishan District Center for Disease Prevention and Control (XSCDC-FSW-2012-06). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	*AS PAC NETW SEX W, 2012, HIV SEX WORK COLL IN, P42331; Bearinger LH, 2007, LANCET, V369, P1220, DOI 10.1016/S0140-6736(07)60367-5; Bruce J, 2007, GIRLS LEFT REDIRECTI; Bruce J., 2006, NOTE SOCIAL EC DEV R; Chandra-Mouli V, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-1; Cheng Y, 2004, INT J GYNECOL OBSTET, V87, P199, DOI 10.1016/j.ijgo.2004.06.010; Chersich MF, 2007, INT J STD AIDS, V18, P764, DOI 10.1258/095646207782212342; Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group, 2012, OBSTET GYNECOL, V120, P983, DOI DOI 10.1097/AOG.0B013E3182723B7D; *DEP MAT NEWB CHIL, 2011, GUID PREV EARL PREGN, P42331; Ditmore MH., 2013, SEX WORK DRUG USE OV; Fang Xiaoyi, 2007, World Health Popul, V9, P46; Hong Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062290; Hu Y., 2010, J INT REPROD HLTH FA, V29.6, P392; *INT WOM HLTH COAL, 2008, TRIPL JEOP FEM AD SE, P42331; Kavanaugh ML, 2011, OBSTET GYNECOL, V117, P1349, DOI 10.1097/AOG.0b013e31821c47c9; KENDAL M, 2010, SEX WORK HIV, P42331; Li JK, 2013, EUR J CONTRACEP REPR, V18, P148, DOI 10.3109/13625187.2013.776673; Li L, 2009, DERMATOL VENEREOL, V31, P1; Luchters S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068855; Luchters S, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-384; Luchters S, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-143; Mao Z-Y, 2011, NW POPUL, V32, P95, DOI DOI 10.15884/J.CNKI.ISSN.1007-0672.2011.05.016; MIDDLETONLEE S, 2011, HIV SRHR INTEGRATION, P42331; Moraros J, 2012, J HIV-AIDS SOC SERV, V11, P125, DOI 10.1080/15381501.2012.678117; *NAT BUR STAT CHIN, 2011, NAT POP CENS 2010, P42331; Neal S, 2012, ACTA OBSTET GYN SCAN, V91, P1114, DOI 10.1111/j.1600-0412.2012.01467.x; Okal J, 2011, AIDS CARE, V23, P612, DOI 10.1080/09540121.2010.525605; *PATH, 2013, PHIL INT FAM PLANN H, P42331; Poon AN, 2011, AIDS CARE, V23, P5, DOI 10.1080/09540121.2011.554519; *POP COUNC, 2001, REPR TRACT INF INTR, P42331; QIAN X, 2004, BMC HEALTH SERV RES, V4, pE1; Sawyer SM, 2012, LANCET, V379, P1630, DOI 10.1016/S0140-6736(12)60072-5; Silverman JG, 2011, ARCH DIS CHILD, V96, P478, DOI 10.1136/adc.2009.178715; Tang J, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-917; TAYLOR C, 2007, SERVICES YOUNG PEOPL, P42331; TEAL SB, 2013, J ADOLESCENT HEALTH, V52, P35, DOI DOI 10.1016/J.JADOHEALTH.2012.07.016; Tu XW, 2004, B WORLD HEALTH ORGAN, V82, P274; Tucker JD, 2005, AIDS, V19, P539, DOI 10.1097/01.aids.0000163929.84154.87; *UNFPA, 2013, STAT WORLD POP MOTH, P42331; UNICEF, 2019, TANZ MOST VULN AD BE; United Nations Population Fund (UNFPA), 2013, AD PREGN REV EV; Wechsberg WM, 2006, AIDS BEHAV, V10, P131, DOI 10.1007/s10461-005-9036-8; WHO, 2011, SEX REPR HLTH YOUNG; *WHO DEP REPR HLTH, 2004, SEL PRACT REC CONTR, P42331; Williamson Lisa M, 2009, Reprod Health, V6, P3, DOI 10.1186/1742-4755-6-3; World Health Organization, 2013, IMPL COMPR HIV STI P; ZHANG C, 2014, JOURNAL, P42331; Zhang C, 2013, PSYCHOL HEALTH MED, V18, P330, DOI 10.1080/13548506.2012.712705; Zhang XD, 2014, EUR J CONTRACEP REPR, V19, P368, DOI 10.3109/13625187.2014.927421; Zhang XD, 2013, SEX TRANSM INFECT, V89, P237, DOI 10.1136/sextrans-2012-050690; Zheng X., 2010, POPUL DEV, V16, P2; Zhou YY, 2013, BMC MED IMAGING, V13, DOI 10.1186/1471-2342-13-13	52	21	21	2	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2015	10	1							e0115435	10.1371/journal.pone.0115435	http://dx.doi.org/10.1371/journal.pone.0115435			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CA3QM	25625194	Green Published, gold			2023-01-03	WOS:000348821400008
J	Li, TF; Fan, H; Wang, YX				Li, Teng-Fei; Fan, Hui; Wang, Yong-Xiang			Epidural Sustained Release Ropivacaine Prolongs Anti-Allodynia and Anti-Hyperalgesia in Developing and Established Neuropathic Pain	PLOS ONE			English	Article							C-FOS; LOCAL-ANESTHETICS; OIL SUSPENSIONS; SODIUM-CHANNELS; NERVE INJURY; BUPIVACAINE; LIDOCAINE; RAT; SURGERY; MODEL	Ropivacaine is a local anesthetic widely used for regional anesthesia and epidural analgesia, but its relatively short duration limits its clinical use. A novel sustained release lipid formulation of ropivacaine has been recently developed to prolong its duration. We examined the epidural anti-hypersensitivity and preemptive effects of ropivacaine in mesylate injection and sustained release suspension forms in a rat model of neuropathy produced by peripheral nerve injury. Epidural administration of ropivacaine mesylate injection specifically blocked mechanical allodynia and thermal hyperalgesia by approximately 50% with a biological half-effective duration of approximately 3 hrs. The equivalent dose of ropivacaine free-base in sustained release suspension significantly prolonged the duration of anti-allodynia and anti-hyperalgesia by approximately 2 times. Multiple daily epidural injections of ropivacaine in both the mesylate injection and sustained-release suspension forms did not induce tolerance or potentiation to anti-allodynia or anti-hyperalgesia. Moreover, the single or multiple daily administration of ropivacaine mesylate injection before surgery in particular, markedly blocked the initiation and development of neuropathic pain, increasing the biological half-effective duration from less than 4 hrs up to 1 or 2 days. The single and multiple daily epidural injection of ropivacaine sustained release suspension further delayed the biological half-lives to 2 and 3 days, respectively. Our results indicate that the epidural administration of ropivacaine effectively blocks neuropathic pain without the induction of analgesic tolerance, and significantly delays the development of neuropathy produced by peripheral nerve injury. Epidural ropivacaine sustained release suspension produces much longer blockade effects of mechanical allodynia and heat hyperalgesia, and more significantly delays the development of neuropathic pain.	[Li, Teng-Fei; Fan, Hui; Wang, Yong-Xiang] Shanghai Jiao Tong Univ, Sch Pharm, Kings Lab, Shanghai 200030, Peoples R China	Shanghai Jiao Tong University	Wang, YX (corresponding author), Shanghai Jiao Tong Univ, Sch Pharm, Kings Lab, Shanghai 200030, Peoples R China.	yxwang@sjtu.edu.cn			Xi'an Libang Pharmaceutical Co. (Xi'an, China)	Xi'an Libang Pharmaceutical Co. (Xi'an, China)	This research was financially supported by Xi'an Libang Pharmaceutical Co. (Xi'an, China). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abram SE, 1996, REGION ANESTH, V21, P117; AKERMAN B, 1988, ACTA ANAESTH SCAND, V32, P571, DOI 10.1111/j.1399-6576.1988.tb02788.x; Albi-Feldzer A, 2013, ANESTHESIOLOGY, V118, P318, DOI 10.1097/ALN.0b013e31827d88d8; Amir R, 2006, J PAIN, V7, pS1, DOI 10.1016/j.jpain.2006.01.444; ARNER S, 1990, PAIN, V43, P287, DOI 10.1016/0304-3959(90)90026-A; Avelino A, 1998, J UROLOGY, V159, P567, DOI 10.1016/S0022-5347(01)63985-5; Batoz H, 2009, ANESTH ANALG, V109, P240, DOI 10.1213/ane.0b013e3181a4928d; CHAPLAN SR, 1995, ANESTHESIOLOGY, V83, P775, DOI 10.1097/00000542-199510000-00017; Charlet A, 2011, J PAIN, V12, P246, DOI 10.1016/j.jpain.2010.07.005; Crosby E, 1998, CAN J ANAESTH, V45, P1066, DOI 10.1007/BF03012393; DEVOR M, 1992, PAIN, V48, P261, DOI 10.1016/0304-3959(92)90067-L; DURANT PAC, 1986, ANESTHESIOLOGY, V64, P43, DOI 10.1097/00000542-198601000-00008; Dworkin RH, 2007, PAIN, V132, P237, DOI 10.1016/j.pain.2007.08.033; England JD, 1996, NEUROLOGY, V47, P272, DOI 10.1212/WNL.47.1.272; Gong N, 2014, J NEUROSCI, V34, P5322, DOI 10.1523/JNEUROSCI.4703-13.2014; Harris JA, 1998, BRAIN RES BULL, V45, P1, DOI 10.1016/S0361-9230(97)00277-3; Herbland A, 2006, REGION ANESTH PAIN M, V31, P34, DOI 10.1016/j.rapm.2005.10.008; Hogan QH, 1997, ANESTHESIOLOGY, V86, P216, DOI 10.1097/00000542-199701000-00026; Huang JL, 2012, AMINO ACIDS, V43, P1905, DOI 10.1007/s00726-012-1390-z; Ji Ru-Rong, 2004, Sci STKE, V2004, preE14; Kanai Y, 1999, REGION ANESTH PAIN M, V24, P444, DOI 10.1016/S1098-7339(99)90012-3; Kemp MI, 2010, PROGR MED CHEM, V49, P81, DOI 10.1016/S0079-6468(10)49003-7; KIM SH, 1992, PAIN, V50, P355, DOI 10.1016/0304-3959(92)90041-9; KOLTZENBURG M, 1994, BRAIN, V117, P579, DOI 10.1093/brain/117.3.579; LANGERMAN L, 1991, ANESTH ANALG, V72, P635; Larsen SW, 2008, EUR J PHARM SCI, V34, P37, DOI 10.1016/j.ejps.2008.02.005; LEUNG JM, 1995, ANESTHESIOLOGY, V83, P1132, DOI 10.1097/00000542-199511000-00034; Lierz P, 2004, EUR J ANAESTH, V21, P32, DOI 10.1017/S0265021504001061; Lin CT, 2012, ANESTHESIOL RES PRAC, V2012, DOI 10.1155/2012/921405; LIU S, 1995, ANESTHESIOLOGY, V82, P1474, DOI 10.1097/00000542-199506000-00019; Lu WD, 2013, Patent, Patent No. [103142458A, 103142458]; McClure JH, 1996, BRIT J ANAESTH, V76, P300, DOI 10.1093/bja/76.2.300; Mitchell VA, 1999, ANESTH ANALG, V89, P989, DOI 10.1097/00000539-199910000-00031; Oda A, 2000, ANESTH ANALG, V91, P1213, DOI 10.1097/00000539-200011000-00031; Pedersen BT, 2008, DRUG DELIV, V15, P23, DOI 10.1080/10717540701828657 ; Ratajczak-Enselme M, 2009, EUR J PHARM BIOPHARM, V72, P54, DOI 10.1016/j.ejpb.2008.11.003; Rose FX, 2007, ANESTH ANALG, V105, P859, DOI 10.1213/01.ane.0000278129.37099.fa; ROY ML, 1992, J NEUROSCI, V12, P2104; Shin JW, 2008, ANESTH ANALG, V107, P1587, DOI 10.1213/ane.0b013e31818200aa; Shum P, 2001, ADV DRUG DELIVER REV, V53, P273, DOI 10.1016/S0169-409X(01)00232-0; Smith LJ, 2002, PAIN, V97, P267, DOI 10.1016/S0304-3959(02)00028-3; Stenberg C, 2005, BASIC CLIN PHARMACOL, V96, P381, DOI 10.1111/j.1742-7843.2005.pto_07.x; Sun XH, 2004, ANESTH ANALG, V98, P1093, DOI 10.1213/01.ANE.0000104580.89717.A2; Terpstra AHM, 2001, J NUTR, V131, P2067, DOI 10.1093/jn/131.7.2067; Toda S, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-2; Wei H, 2007, BRAIN RES, V1148, P105, DOI 10.1016/j.brainres.2007.02.040; Zimmermann M, 2001, EUR J PHARMACOL, V429, P23, DOI 10.1016/S0014-2999(01)01303-6; Zink W, 2008, CURR OPIN ANESTHESIO, V21, P645, DOI 10.1097/ACO.0b013e32830c214c	48	8	9	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2015	10	1							e0117321	10.1371/journal.pone.0117321	http://dx.doi.org/10.1371/journal.pone.0117321			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC4PT	25617901	Green Published, Green Submitted, gold			2023-01-03	WOS:000350336000042
J	Behbahani, M				Behbahani, Mandana			Evaluation of In Vitro Anticancer Activity of Ocimum Basilicum, Alhagi Maurorum, Calendula Officinalis and Their Parasite Cuscuta Campestris	PLOS ONE			English	Article							CELLS; ANTIOXIDANT; EXPRESSION; APOPTOSIS; LUTEIN; BCL-2; VIVO; P53	The present investigation was carried out to study the relationship between presence of cytotoxic compounds in Ocimum basilicum, Alhagi maurorum, Calendula officinalis and their parasite Cuscuta campestris. The cytotoxic activity of the pure compounds was performed by MTT assay against breast cancer cell lines (MCF-7 and MDA-MB-231) and normal breast cell line (MCF 10A). The induction of apoptosis was measured by the expression levels of p53, bcl-2, bax and caspase-3 genes using quantitative Real Time PCR. Three active fractions were detected by nuclear magnetic resonance as lutein, lupeol and eugenol, respectively, in C. officinalis, A. maurorum and O. basilicum. These compounds and their epoxidized forms were also detected in their parasite C. campestris. The cytotoxic activity of lutein epoxide, lupeol epoxide and eugenol epoxide was significantly more than lutein, lupeol and eugenol. The mRNA expression level of p53, caspase-3 and bax genes were increased in both cancer cells treated with all pure compounds. However, bcl-2 gene expression decreased in treated breast cancer cells. In conclusion, all the data indicated that the epoxide forms of lupeol, lutein and eugenol are potential drug candidates for inducing apoptosis in human breast cancer cells.	Univ Isfahan, Fac Adv Sci & Technol, Dept Biotechnol, Esfahan 8174673441, Iran	University of Isfahan	Behbahani, M (corresponding author), Univ Isfahan, Fac Adv Sci & Technol, Dept Biotechnol, Esfahan 8174673441, Iran.	Ma_behbahani@yahoo.com			University of Isfahan, Isfahan, Iran	University of Isfahan, Isfahan, Iran	This study was financially supported by the University of Isfahan, Isfahan, Iran. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agha AM, 1996, PHYTOTHER RES, V10, P117, DOI 10.1002/(SICI)1099-1573(199603)10:2&lt;117::AID-PTR782&gt;3.0.CO;2-X; Behbahani M, 2013, ANTIVIR RES, V97, P376, DOI 10.1016/j.antiviral.2013.01.001; Borole S. P., 2011, Research Journal of Pharmaceutical, Biological and Chemical Sciences, V2, P657; Dawson Jean H., 1994, Reviews of Weed Science, V6, P265; Deans S. G., 1995, Flavour and Fragrance Journal, V10, P323, DOI 10.1002/ffj.2730100507; Edelenbos M, 2001, J AGR FOOD CHEM, V49, P4768, DOI 10.1021/jf010569z; Fido Roger J., 1995, V49, P423; Finnegan NM, 2001, BRIT J CANCER, V85, P115, DOI 10.1054/bjoc.2001.1850; Ghule R.S., 2011, J ADV PHARM ED RES, V1, P45; Gilani Anwar-Ul Hassan, 1992, International Journal of Pharmacognosy, V30, P296; Humphries JM, 2003, J AGR FOOD CHEM, V51, P1322, DOI 10.1021/jf026073e; Jadhav RB, 2005, J PLANT INTERACT, V1, P171, DOI 10.1080/17429140600986161; Jimenez-Medina E, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-119; Kobayashi S, 1997, BREAST CANCER RES TR, V42, P173, DOI 10.1023/A:1005760013810; Laghari AH, 2012, NAT PROD RES, V26, P173, DOI 10.1080/14786419.2010.538846; Lakshminarayana R, 2013, CHEM-BIOL INTERACT, V203, P448, DOI 10.1016/j.cbi.2013.03.006; Matsuda T, 2013, JPN J CLIN ONCOL, V43, P449, DOI 10.1093/jjco/hyt045; MIYASHITA T, 1995, CELL, V80, P293; Ni IBP, 2006, TROP BIOMED, V23, P53; Qamar KA, 2010, LETT DRUG DES DISCOV, V7, P726; Rates SMK, 2001, TOXICON, V39, P603, DOI 10.1016/S0041-0101(00)00154-9; Saeed MA, 2002, FITOTERAPIA, V73, P417, DOI 10.1016/S0367-326X(02)00127-2; Saleem M, 2008, CLIN CANCER RES, V14, P2119, DOI 10.1158/1078-0432.CCR-07-4413; Shai LJ, 2008, J ETHNOPHARMACOL, V119, P238, DOI 10.1016/j.jep.2008.06.036; Siddique HR, 2011, LIFE SCI, V88, P285, DOI 10.1016/j.lfs.2010.11.020; Suzuki K, 1999, JPN J CLIN ONCOL, V29, P323, DOI 10.1093/jjco/29.7.323	26	33	37	1	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 30	2014	9	12							e116049	10.1371/journal.pone.0116049	http://dx.doi.org/10.1371/journal.pone.0116049			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX6YH	25548920	Green Published, gold, Green Submitted			2023-01-03	WOS:000347063500048
J	Bailey, KM; Cornnell, HH; Ibrahim-Hashim, A; Wojtkowiak, JW; Hart, CP; Zhang, XM; Leos, R; Martinez, GV; Baker, AF; Gillies, RJ				Bailey, Kate M.; Cornnell, Heather H.; Ibrahim-Hashim, Arig; Wojtkowiak, Jonathan W.; Hart, Charles P.; Zhang, Xiaomeng; Leos, Rafael; Martinez, Gary V.; Baker, Amanda F.; Gillies, Robert J.			Evaluation of the "Steal" Phenomenon on the Efficacy of Hypoxia Activated Prodrug TH-302 in Pancreatic Cancer	PLOS ONE			English	Article							SQUAMOUS-CELL CARCINOMA; TUMOR OXYGENATION; IN-VIVO; TIRAPAZAMINE; METABOLISM; CISPLATIN; HYDRALAZINE; METASTASES; RADIATION; DEFECTS	Pancreatic ductal adenocarcinomas are desmoplastic and hypoxic, both of which are associated with poor prognosis. Hypoxia-activated prodrugs (HAPs) are specifically activated in hypoxic environments to release cytotoxic or cytostatic effectors. TH-302 is a HAP that is currently being evaluated in a Phase III clinical trial in pancreatic cancer. Using animal models, we show that tumor hypoxia can be exacerbated using a vasodilator, hydralazine, improving TH-302 efficacy. Hydralazine reduces tumor blood flow through the "steal" phenomenon, in which atonal immature tumor vasculature fails to dilate in coordination with normal vasculature. We show that MIA PaCa-2 tumors exhibit a "steal" effect in response to hydralazine, resulting in decreased tumor blood flow and subsequent tumor pH reduction. The effect is not observed in SU.86.86 tumors with mature tumor vasculature, as measured by CD31 and smooth muscle actin (SMA) immunohistochemistry staining. Combination therapy of hydralazine and TH-302 resulted in a reduction in MIA PaCa-2 tumor volume growth after 18 days of treatment. These studies support a combination mechanism of action for TH-302 with a vasodilator that transiently increases tumor hypoxia.	[Bailey, Kate M.; Cornnell, Heather H.; Ibrahim-Hashim, Arig; Wojtkowiak, Jonathan W.; Zhang, Xiaomeng; Martinez, Gary V.; Gillies, Robert J.] H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Imaging & Metab, Tampa, FL 33612 USA; [Bailey, Kate M.; Cornnell, Heather H.; Ibrahim-Hashim, Arig; Wojtkowiak, Jonathan W.; Zhang, Xiaomeng; Martinez, Gary V.; Gillies, Robert J.] Res Inst, Tampa, FL 33612 USA; [Gillies, Robert J.] H Lee Moffitt Canc Ctr & Res Inst, Dept Radiol, Tampa, FL 33612 USA; [Leos, Rafael; Baker, Amanda F.] Univ Arizona, Coll Med, Arizona Canc Ctr, Hematol Oncol Sect, Tucson, AZ 85724 USA; [Hart, Charles P.] Threshold Pharmaceut, San Francisco, CA 94080 USA; [Bailey, Kate M.] Univ S Florida, Canc Biol PhD Program, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute; Arizona Center Cancer Care; University of Arizona; State University System of Florida; University of South Florida	Gillies, RJ (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Imaging & Metab, Tampa, FL 33612 USA.	Robert.Gillies@Moffitt.org	Martinez, Gary/HJA-3440-2022	Hart, Charles/0000-0003-4440-726X	 [R01CA125627-02];  [R01CA077575-10];  [P30CA076292-16];  [P30CA023074-35]; NATIONAL CANCER INSTITUTE [R01CA125627, P30CA023074, R01CA077575, P30CA076292] Funding Source: NIH RePORTER	; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by grants R01CA125627-02; R01CA077575-10; P30CA076292-16 (Robert J. Gillies) and P30CA023074-35 (Amanda F. Baker). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adachi E, 1999, ONCOL RES, V11, P179; Bhujwalla Z M, 1990, NMR Biomed, V3, P178, DOI 10.1002/nbm.1940030406; BHUJWALLA ZM, 1990, RADIOTHER ONCOL, V19, P281, DOI 10.1016/0167-8140(90)90155-P; Bhujwalla ZM, 1996, MAGN RESON MED, V36, P204, DOI 10.1002/mrm.1910360206; Borad MJ, 2012, P 103 ANN M AM ASS C, pLB; Brizel DM, 1996, CANCER RES, V56, P941; Cairns RA, 2007, P NATL ACAD SCI USA, V104, P9445, DOI 10.1073/pnas.0611662104; Cardenas-Rodriguez J, 2012, MAGN RESON IMAGING, V30, P1002, DOI 10.1016/j.mri.2012.02.015; Chu GC, 2007, J CELL BIOCHEM, V101, P887, DOI 10.1002/jcb.21209; Dorie MJ, 1997, CANCER CHEMOTH PHARM, V39, P361, DOI 10.1007/s002800050584; Duan JX, 2008, J MED CHEM, V51, P2412, DOI 10.1021/jm701028q; Erkan MM, 2009, NEOPLASIA, V11, P497, DOI 10.1593/neo.81618; GATENBY RA, 1988, INT J RADIAT ONCOL, V14, P831, DOI 10.1016/0360-3016(88)90002-8; Gatzemeier U, 1998, BRIT J CANCER, V77, P15, DOI 10.1038/bjc.1998.431; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hicks KO, 2010, CLIN CANCER RES, V16, P4946, DOI 10.1158/1078-0432.CCR-10-1439; Hicks KO, 1998, INT J RADIAT ONCOL, V42, P641, DOI 10.1016/S0360-3016(98)00268-5; HORSMAN MR, 1995, BRIT J CANCER, V72, P1474, DOI 10.1038/bjc.1995.532; Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626; Kyle AH, 1999, CANCER CHEMOTH PHARM, V43, P213, DOI 10.1007/s002800050886; Le QTX, 2009, J CLIN ONCOL, V27, P3014, DOI 10.1200/JCO.2008.21.3868; Liu Q, 2012, CANCER CHEMOTH PHARM, V69, P1487, DOI 10.1007/s00280-012-1852-8; Mahadevan D, 2007, MOL CANCER THER, V6, P1186, DOI 10.1158/1535-7163.MCT-06-0686; Matsumoto S, 2014, ANTIOXIDANTS REDOX S; Meng FY, 2012, MOL CANCER THER, V11, P740, DOI 10.1158/1535-7163.MCT-11-0634; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Reddy SB, 2009, EXPERT OPIN INV DRUG, V18, P77, DOI [10.1517/13543780802567250, 10.1517/13543780802567250 ]; Rischin D, 2010, J CLIN ONCOL, V28, P2989, DOI 10.1200/JCO.2009.27.4449; Saito K, 2012, MAGN RESON MED, V67, P801, DOI 10.1002/mrm.23065; SECOMB TW, 1995, ACTA ONCOL, V34, P313, DOI 10.3109/02841869509093981; Society AC, 2014, CANC FACTS FIG 2014; Sun JD, 2012, CLIN CANCER RES, V18, P758, DOI 10.1158/1078-0432.CCR-11-1980; Takakusagi Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107995; TEICHER BA, 1994, CANCER METAST REV, V13, P139, DOI 10.1007/BF00689633; TROTTER MJ, 1989, INT J RADIAT ONCOL, V17, P785, DOI 10.1016/0360-3016(89)90067-9; Van der Heijden MS, 2004, AM J PATHOL, V165, P651, DOI 10.1016/S0002-9440(10)63329-9; Weinmann M, 2004, FASEB J, V18, P1906, DOI 10.1096/fj.04-1918fje; Wojtkowiak JW, 2014, CANC METABO IN PRESS; Zhang XM, 2010, J NUCL MED, V51, P1167, DOI 10.2967/jnumed.109.068981	40	17	17	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 22	2014	9	12							e113586	10.1371/journal.pone.0113586	http://dx.doi.org/10.1371/journal.pone.0113586			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA3ZY	25532146	Green Published, gold, Green Submitted			2023-01-03	WOS:000348845100005
J	Mullan, PC; Kessler, DO; Cheng, A				Mullan, Paul C.; Kessler, David O.; Cheng, Adam			Educational Opportunities With Postevent Debriefing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SIMULATION		[Mullan, Paul C.] George Washington Univ, Sch Med & Hlth Sci, Div Emergency Med, Childrens Natl Med Ctr, Falls Church, VA 22041 USA; [Kessler, David O.] New York Presbyterian Morgan Stanley Childrens Ho, New York, NY USA; [Kessler, David O.] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; [Cheng, Adam] Alberta Childrens Prov Gen Hosp, Sect Emergency Med, Calgary, AB T2T 5C7, Canada; [Cheng, Adam] Univ Calgary, Calgary, AB, Canada	George Washington University; NewYork-Presbyterian Hospital; Morgan Stanley Children's Hospital; Columbia University; Alberta Childrens Hospital; University of Calgary; University of Calgary	Mullan, PC (corresponding author), George Washington Univ, Sch Med & Hlth Sci, Div Emergency Med, Childrens Natl Med Ctr, 3381 Ardley Ct, Falls Church, VA 22041 USA.	pmullan@childrensnational.org	Cheng, Adam/L-9496-2017; Mullan, Paul/ABG-6659-2020	Cheng, Adam/0000-0002-1039-7502; Mullan, Paul/0000-0001-5153-1299				Bandari J, 2012, JT COMM J QUAL PATIE, V38, P154, DOI 10.1016/S1553-7250(12)38020-3; Boet S, 2013, ANN SURG, V258, P53, DOI 10.1097/SLA.0b013e31829659e4; Cheng A, 2014, MED EDUC, V48, P657, DOI 10.1111/medu.12432; Cheng A, 2013, JAMA PEDIATR, V167, P528, DOI 10.1001/jamapediatrics.2013.1389; Hatala R, 2014, ADV HEALTH SCI EDUC, V19, P251, DOI 10.1007/s10459-013-9462-8; HOYT DB, 1988, J TRAUMA, V28, P435, DOI 10.1097/00005373-198804000-00003; Mullan PC, 2013, RESUSCITATION, V84, P946, DOI 10.1016/j.resuscitation.2012.12.005; Sandhu N, 2013, CJEM, V15, P1; Weiner E, 2014, AM J OBSTET GYNECOL, V210, DOI 10.1016/j.ajog.2014.01.007; Wolfe H, 2014, CRIT CARE MED, V42, P1688, DOI 10.1097/CCM.0000000000000327	10	51	51	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	2014	312	22					2333	2334		10.1001/jama.2014.15741	http://dx.doi.org/10.1001/jama.2014.15741			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AW5YB	25490319				2023-01-03	WOS:000346345700003
J	Montagner, IM; Merlo, A; Zuccolotto, G; Renier, D; Campisi, M; Pasut, G; Zanovello, P; Rosato, A				Montagner, Isabella Monia; Merlo, Anna; Zuccolotto, Gaia; Renier, Davide; Campisi, Monica; Pasut, Gianfranco; Zanovello, Paola; Rosato, Antonio			Peritoneal Tumor Carcinomatosis: Pharmacological Targeting with Hyaluronan-Based Bioconjugates Overcomes Therapeutic Indications of Current Drugs	PLOS ONE			English	Article							CYTOREDUCTIVE SURGERY; GASTRIC-CANCER; FUTURE-DIRECTIONS; HYDROSOLUBLE BIOCONJUGATE; LOCOREGIONAL TREATMENT; PACLITAXEL; DELIVERY; ACID; IDENTIFICATION; RECEPTOR	Peritoneal carcinomatosis still lacks reliable therapeutic options. We aimed at testing a drug delivery strategy allowing a controlled release of cytotoxic molecules and selective targeting of tumor cells. We comparatively assessed the efficacy of a loco-regional intraperitoneal treatment in immunocompromised mice with bioconjugates formed by chemical linking of paclitaxel or SN-38 to hyaluronan, against three models of peritoneal carcinomatosis derived from human colorectal, gastric and esophageal tumor cell xenografts. In vitro, bioconjugates were selectively internalized through mechanisms largely dependent on interaction with the CD44 receptor and caveolin-mediated endocytosis, which led to accumulation of compounds into lysosomes of tumor cells. Moreover, they inhibited tumor growth comparably to free drugs. In vivo, efficacy of bioconjugates or free drugs against luciferase-transduced tumor cells was assessed by bioluminescence optical imaging, and by recording mice survival. The intraperitoneal administration of bioconjugates in tumor-bearing mice exerted overlapping or improved therapeutic efficacy compared with unconjugated drugs. Overall, drug conjugation to hyaluronan significantly improved the profiles of in vivo tolerability and widened the field of application of existing drugs, over their formal approval or current use. Therefore, this approach can be envisaged as a promising therapeutic strategy for locoregional treatment of peritoneal carcinomatosis.	[Montagner, Isabella Monia; Merlo, Anna; Zanovello, Paola; Rosato, Antonio] Veneto Inst Oncol IOV IRCCS, Padua, Italy; [Zuccolotto, Gaia] Univ Padua, Dept Med, Padua, Italy; [Renier, Davide; Campisi, Monica] Fidia Farmaceutici SpA, Abano Terme, Italy; [Pasut, Gianfranco] Univ Padua, Dept Pharmaceut & Pharmacol Sci, Padua, Italy; [Zanovello, Paola; Rosato, Antonio] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy	IRCCS Istituto Oncologico Veneto (IOV); University of Padua; University of Padua; University of Padua	Rosato, A (corresponding author), Veneto Inst Oncol IOV IRCCS, Padua, Italy.	antonio.rosato@unipd.it	Rosato, Antonio/E-8626-2010; Montagner, Isabella Monia/AAI-2317-2019; Pasut, Gianfranco/I-5944-2012; montagner, isabella monia/K-1653-2016; ZUCCOLOTTO, GAIA/K-1654-2016; Merlo, Anna/FCK-4327-2022	Rosato, Antonio/0000-0002-5263-8386; Montagner, Isabella Monia/0000-0002-5778-2221; Pasut, Gianfranco/0000-0002-8754-0899; montagner, isabella monia/0000-0002-5778-2221; ZUCCOLOTTO, GAIA/0000-0002-2002-8807; Merlo, Anna/0000-0002-2741-9624; Zanovello, Paola/0000-0002-9996-2669	Italian Association for Cancer Research (AIRC) [IG-13121, 10016]	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro)	This work was supported by Italian Association for Cancer Research (AIRC, IG-13121; and Special Program Molecular Clinical Oncology 5 per mille ID 10016 to AR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	al-Shammaa HAH, 2008, WORLD J GASTROENTERO, V14, P1159, DOI 10.3748/wjg.14.1159; Aoyagi Keishiro, 2013, World J Crit Care Med, V2, P48, DOI 10.5492/wjccm.v2.i4.48; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Authier N, 2001, NEUROTOX RES, V3, P301, DOI 10.1007/BF03033269; Banzato A, 2008, CLIN CANCER RES, V14, P3598, DOI 10.1158/1078-0432.CCR-07-2019; Bassi PF, 2011, J UROLOGY, V185, P445, DOI 10.1016/j.juro.2010.09.073; Bozzetti F, 2008, J SURG ONCOL, V98, P273, DOI 10.1002/jso.21052; Brucher BLDM, 2012, CANCER INVEST, V30, P209, DOI 10.3109/07357907.2012.654871; Clementi C, 2011, MOL PHARMACEUT, V8, P1063, DOI 10.1021/mp2001445; Coccolini F, 2013, WORLD J GASTROENTERO, V19, P6979, DOI 10.3748/wjg.v19.i41.6979; Contreras-Ruiz L, 2011, MOL VIS, V17, P279; Correa P, 2013, GASTROENTEROL CLIN N, V42, P211, DOI 10.1016/j.gtc.2013.01.002; CROUCH SPM, 1993, J IMMUNOL METHODS, V160, P81, DOI 10.1016/0022-1759(93)90011-U; De Smet L, 2013, SCI WORLD J, DOI 10.1155/2013/720858; Dodds HM, 1998, J PHARMACOL EXP THER, V286, P578; Dong ZK, 2013, J APPL POLYM SCI, V130, P927, DOI 10.1002/app.39247; Duncan R, 2013, ADV DRUG DELIVER REV, V65, P60, DOI 10.1016/j.addr.2012.08.012; Elias D, 2012, SURG ONCOL CLIN N AM, V21, P611, DOI 10.1016/j.soc.2012.07.014; Elias D, 2010, J CLIN ONCOL, V28, P63, DOI 10.1200/JCO.2009.23.9285; Entwistle J, 1996, J CELL BIOCHEM, V61, P569, DOI 10.1002/(SICI)1097-4644(19960616)61:4<569::AID-JCB10>3.0.CO;2-B; Faryammanesh R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093173; Gelderblom H, 2001, EUR J CANCER, V37, P1590, DOI 10.1016/S0959-8049(01)00171-X; Gill RS, 2011, J SURG ONCOL, V104, P692, DOI 10.1002/jso.22017; Glockzin G, 2012, SURG ONCOL CLIN N AM, V21, P625, DOI 10.1016/j.soc.2012.07.002; Glockzin G, 2009, WORLD J SURG ONCOL, V7, DOI 10.1186/1477-7819-7-5; Gros SJ, 2010, ANTICANCER RES, V30, P3933; Isacke CM, 2002, INT J BIOCHEM CELL B, V34, P718, DOI 10.1016/S1357-2725(01)00166-2; Jaganathan SK, 2013, WORLD J GASTROENTERO, V19, P7726, DOI 10.3748/wjg.v19.i43.7726; Jain JP, 2008, EXPERT OPIN DRUG DEL, V5, P889, DOI [10.1517/17425247.5.8.889, 10.1517/17425247.5.8.889 ]; Keyaerts M, 2008, EUR J NUCL MED MOL I, V35, P999, DOI 10.1007/s00259-007-0664-2; Konigsrainer I, 2012, WORLD J GASTROENTERO, V18, P5317, DOI 10.3748/wjg.v18.i38.5317; Kumar Shalini Sree, 2014, Gastrointest Cancer Res, V7, P23; Larson N, 2013, INT J PHARMACEUT, V454, P435, DOI 10.1016/j.ijpharm.2013.06.046; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Liao YH, 2005, DRUG DELIV, V12, P327, DOI 10.1080/10717540590952555; Lu Z, 2010, FUTURE ONCOL, V6, P1625, DOI 10.2217/FON.10.100; Montagner IM, 2013, UROL ONCOL-SEMIN ORI, V31, P1261, DOI 10.1016/j.urolonc.2012.01.005; Nakamura H, 2014, J CONTROL RELEASE, V174, P81, DOI 10.1016/j.jconrel.2013.11.011; Northfelt DW, 2012, AM J CLIN ONCOL; Oommen OP, 2013, MACROMOL BIOSCI; Passot G, 2013, EUR J SURG ONCOL; Patnaik A, 2013, CANCER CHEMOTH PHARM, V71, P1499, DOI 10.1007/s00280-013-2149-2; Pucciarelli S, 2003, BRIT J SURG, V90, P66, DOI 10.1002/bjs.4006; Rosato A, 2006, UROL ONCOL-SEMIN ORI, V24, P207, DOI 10.1016/j.urolonc.2005.08.020; Schweigert M, 2013, NAT REV GASTRO HEPAT, V10, P230, DOI 10.1038/nrgastro.2012.236; Serafino A, 2011, CURR CANCER DRUG TAR, V11, P572, DOI 10.2174/156800911795655976; Smit JK, 2013, RADIOTHER ONCOL, V107, P434, DOI 10.1016/j.radonc.2013.03.027; Sorbi C, 2009, CARBOHYD RES, V344, P91, DOI 10.1016/j.carres.2008.09.021; Sugahara S, 2007, J CONTROL RELEASE, V117, P40, DOI 10.1016/j.jconrel.2006.10.009; Takaishi S, 2009, STEM CELLS, V27, P1006, DOI 10.1002/stem.30; Varshosaz J, 2012, EXPERT OPIN DRUG DEL, V9, P509, DOI 10.1517/17425247.2012.673580; Walker AS, 2014, J CANCER, V5, P44, DOI 10.7150/jca.7809; Yuan Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031802; Zhao JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021419; Zhou B, 2003, GLYCOBIOLOGY, V13, P339, DOI 10.1093/glycob/cwg029	55	10	10	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 10	2014	9	11							e112240	10.1371/journal.pone.0112240	http://dx.doi.org/10.1371/journal.pone.0112240			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT3DP	25383653	Green Submitted, Green Published, gold			2023-01-03	WOS:000344816700043
J	Ganasegeran, K; Rajendran, AK; Al-Dubai, SAR				Ganasegeran, Kurubaran; Rajendran, Anantha Kumar; Al-Dubai, Sami Abdo Radman			Psycho-Socioeconomic Factors Affecting Complementary and Alternative Medicine Use among Selected Rural Communities in Malaysia: A Cross-Sectional Study	PLOS ONE			English	Article							ATTITUDES; ADULTS	Introduction: The use of complementary and alternative medicine (CAM) as a source of cure has gained much spectrum worldwide, despite skeptics and advocates of evidence-based practice conceptualized such therapies as human nostrum. Objective: This study aimed to explore the factors affecting CAM use among rural communities in Malaysia. Methods: A cross-sectional study was carried out on 288 occupants across four rural villages within the District of Selama, Perak, Malaysia. A survey that consisted of socio-economic characteristics, history of CAM use and the validated Holistic Complementary and Alternative Medicine Questionnaire (HCAMQ) were used. Results: The prevalence of self-reported CAM use over the past one year was 53.1%. Multiple logistic regression analyses yielded three significant predictors of CAM use: monthly household income of less than MYR 2500, higher education level, and positive attitude towards CAM. Conclusion: Psycho-socioeconomic factors were significantly associated with CAM use among rural communities in Malaysia.	[Ganasegeran, Kurubaran] HTAR, Dept Med, Klang, Selangor, Malaysia; [Ganasegeran, Kurubaran; Rajendran, Anantha Kumar] MSU, Int Med Sch, Off Persiaran Olahraga, Sect 13, Shah Alam, Selangor, Malaysia; [Al-Dubai, Sami Abdo Radman] Int Med Univ, Dept Community Med, Kuala Lumpur 57000, Malaysia	Management Science University; International Medical University Malaysia	Ganasegeran, K (corresponding author), HTAR, Dept Med, Jalan Langat, Klang, Selangor, Malaysia.	medkuru@yahoo.com	AL-DUBAI, SAMI ABDO/AAA-1731-2022; AL-DUBAI, SAMI ABDO/M-4129-2019; AL-DUBAI, SAMI Abdo Radman/J-6120-2013; Ganasegeran, Kurubaran/E-4931-2013	AL-DUBAI, SAMI ABDO/0000-0002-1989-5452; AL-DUBAI, SAMI ABDO/0000-0002-1989-5452; AL-DUBAI, SAMI Abdo Radman/0000-0002-1989-5452; Ganasegeran, Kurubaran/0000-0002-9480-1815				Abuduli M., 2011, MALAYS J PUBLIC HLTH, V11, P1; Adams J, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-85; Akyol AD, 2011, J CLIN NURS, V20, P1035, DOI 10.1111/j.1365-2702.2010.03498.x; Alshagga MA, 2011, ANN THORAC MED, V6, P115, DOI 10.4103/1817-1737.82438; [Anonymous], 2013, MALAYSIAN NO DEV COR; Arcury TA, 2006, J GERONTOL B-PSYCHOL, V61, P62; Arcury TA, 2006, ETHNIC DIS, V16, P723; Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; Bishop FL, 2007, J HEALTH PSYCHOL, V12, P851, DOI 10.1177/1359105307082447; Bulck JV, 2009, EUR J PUBLIC HEALTH, V20, P227; Chan Y. H., 2004, SMJ Singapore Medical Journal, V45, P149; Chiappelli F, 2005, EVID-BASED COMPL ALT, V2, P453, DOI 10.1093/ecam/neh106; Ernst E, 2000, B WORLD HEALTH ORGAN, V78, P252; Farooqui M, 2013, ALTERN INTEG MED, V1; Frass M, 2012, OCHSNER J, V12, P45; Hu H, 2013, ISRN PUBLIC HLTH, V2013, P7; Hyland ME, 2003, COMPLEMENT THER MED, V11, P33, DOI 10.1016/S0965-2299(02)00113-9; Kuunibe N., 2012, International Journal of Humanities and Social Science, V2, P288; Limsatchapanich S., 2013, HLTH SCI J, V7, P436; McFadden KL, 2010, EXPLORE-NY, V6, P380, DOI 10.1016/j.explore.2010.08.004; McLaughlin D, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-34; Mollaoglu M, 2013, ACTA CLIN CROAT, V52, P181; Nguyen D, 2014, RURAL REMOTE HEALTH, V14; Shreffler-Grant J, 2005, PUBLIC HEALTH NURS, V22, P323, DOI 10.1111/j.0737-1209.2005.220407.x; Testerman J, 2004, COMPLEMENT HLTH PRAC, V9, P81, DOI [10.1177/1076167503261254, DOI 10.1177/1076167503261254]; Thomas K, 2004, J PUBLIC HEALTH, V26, P152, DOI 10.1093/pubmed/fdh139; Yekta Z, 2007, J RES HEALTH SCI, V7, P24; Zollman C, 1999, BRIT MED J, V319, P693, DOI 10.1136/bmj.319.7211.693	28	15	15	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2014	9	11							e112124	10.1371/journal.pone.0112124	http://dx.doi.org/10.1371/journal.pone.0112124			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AS6XM	25375256	Green Published, Green Submitted, gold			2023-01-03	WOS:000344402600109
J	Rathe, J; Andersen, M; Jarbol, DE; Christensen, RD; Hallas, J; Sondergaard, J				Rathe, Jette; Andersen, Morten; Jarbol, Dorte Ejg; Christensen, Rene dePont; Hallas, Jesper; Sondergaard, Jens			Generic Switching and Non-Persistence among Medicine Users: A Combined Population-Based Questionnaire and Register Study	PLOS ONE			English	Article							MEDICATION ADHERENCE; ANTIEPILEPTIC DRUGS; SUBSTITUTION; BELIEFS; PATIENT	Background Generic substitution means that one medicinal product is replaced by another product containing the same active substance. It is strictly regulated with respect to its bioequivalence, and all products must have undergone appropriate studies. Although generic substitution is widely implemented, it still remains to be answered how generic switch influences persistence to long-term treatment, and if it is modified by patients' concerns about medicine and views on generic medicine. This study focuses on users of antidepressants and antiepileptics, and their experience of generic switching. Methods The study was an observational cohort study. By use of a prescription database, we identified patients who had redeemed prescriptions on generically substitutable drugs, and a questionnaire was mailed to them. We analyzed predictors of discontinuation in relation to generic switch and patients' attitudes towards generic medicines and concerns about their medicine. Results Patients who experience their first-time switch of a specific drug were at higher risk of non-persistence, Hazard Ratio 2.98, 95% CI (1.81; 4.89) versus those who have never switched, and 35.7% became non-persistent during the first year of follow-up. Generic switching did not influence persistence considerably in those having previous experience with generic switching of the specific drug. Stratified analyses on users of antidepressants and antiepileptics underpin the results, showing higher risk of non-persistence for first-time switchers for both drug categories. Conclusion In conclusion, patients who are first-time switchers of a specific drug were at higher risk of non-persistence compared to never switchers and those having experienced previous generic switching.	[Rathe, Jette; Jarbol, Dorte Ejg; Christensen, Rene dePont; Sondergaard, Jens] Univ Southern Denmark, Inst Publ Hlth, Res Unit Gen Practice, Odense, Denmark; [Andersen, Morten] Karolinska Inst, Dept Med Solna, Ctr Pharmacoepidemiol, Stockholm, Sweden; [Hallas, Jesper] Univ Southern Denmark, Inst Publ Hlth, Res Unit Clin Pharmacol, Odense, Denmark	University of Southern Denmark; Karolinska Institutet; University of Southern Denmark	Rathe, J (corresponding author), Univ Southern Denmark, Inst Publ Hlth, Res Unit Gen Practice, Odense, Denmark.	jrathe@health.sdu.dk	Andersen, Morten/H-3555-2011; Søndergaard, Jens js/F-3031-2013; Jarbøl, Dorte E/P-8791-2015	Andersen, Morten/0000-0001-7029-2860; Søndergaard, Jens js/0000-0002-1629-1864; Jarbøl, Dorte E/0000-0002-3241-4190	Danish Ministry of Health [2007/S145-180398]; Region of Southern Denmark Research PhD Foundation [11/28042]; Region of Southern Denmark Research Foundation [12/21277]	Danish Ministry of Health; Region of Southern Denmark Research PhD Foundation; Region of Southern Denmark Research Foundation	The study was partly funded through a contract with the Danish Ministry of Health, tender number 2007/S145-180398, the Region of Southern Denmark Research PhD Foundation (j.nr: 11/28042) and the Region of Southern Denmark Research Foundation (j.nr: 12/21277). The funder (The Danish Ministry of Health) initiated this study, but the authors designed the study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alhewiti Abdullah, 2014, Int J Family Med, V2014, P479596, DOI 10.1155/2014/479596; Andersen M, 2009, GENERIC SUBSTITUTION; Andrade SE, 2006, PHARMACOEPIDEM DR S, V15, P565, DOI 10.1002/pds.1230; Barron TI, 2010, VALUE HEALTH, V13, P796, DOI 10.1111/j.1524-4733.2010.00741.x; Beaton DE, 2000, SPINE, V25, P3186, DOI 10.1097/00007632-200012150-00014; Berg MJ, 2008, EPILEPSY BEHAV, V13, P693, DOI 10.1016/j.yebeh.2008.06.001; Briesacher BA, 2009, AM J MANAG CARE, V15, P450; Dylst P, 2013, EXPERT REV PHARM OUT, V13, P59, DOI [10.1586/ERP.12.83, 10.1586/erp.12.83]; Frank L, 2000, SCIENCE, V287, P2398, DOI 10.1126/science.287.5462.2398; Gaist D, 1997, DAN MED BULL, V44, P445; Hamann J, 2013, EUR NEUROPSYCHOPHARM, V23, P686, DOI 10.1016/j.euroneuro.2012.08.007; Horne R, 1999, PSYCHOL HEALTH, V14, P1, DOI 10.1080/08870449908407311; Horne R, 2000, HDB DRUG RES METHODO; Horne R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080633; Howland RH, 2010, J PSYCHOSOC NURS MEN, V48, P13, DOI 10.3928/02793695-20101105-01; Hunot Vivien M, 2007, Prim Care Companion J Clin Psychiatry, V9, P91; Johnston A, 2011, BRIT J CLIN PHARMACO, V72, P727, DOI 10.1111/j.1365-2125.2011.03987.x; Kesselheim AS, 2013, JAMA INTERN MED, V173, P202, DOI 10.1001/2013.jamainternmed.997; Larsen J, 2002, BRIT J CLIN PHARMACO, V53, P375, DOI 10.1046/j.1365-2125.2002.01563.x; Mardby AC, 2007, PATIENT EDUC COUNS, V69, P158, DOI 10.1016/j.pec.2007.08.011; Moller Pedersen K, 2003, Eur J Health Econ, V4, P60; Nakhutina L, 2011, EPILEPSY BEHAV, V22, P584, DOI 10.1016/j.yebeh.2011.08.007; Olesen C, 2013, PHARMACOEPIDEM DR S, V22, P1093, DOI 10.1002/pds.3497; Ostergaard K, 2012, EUR J CLIN PHARMACOL, V68, P1631, DOI 10.1007/s00228-012-1293-7; Pechlivanoglou P, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-89; Peterson AM, 2007, VALUE HEALTH, V10, P3, DOI 10.1111/j.1524-4733.2006.00139.x; Rathe J, 2014, PHARMACOEPIDEM DR S, V23, P965, DOI 10.1002/pds.3671; Rathe J, 2013, EUR J CLIN PHARMACOL, V69, P1827, DOI 10.1007/s00228-013-1539-z; Sander JW, 2010, EXPERT REV NEUROTHER, V10, P1887, DOI 10.1586/ERN.10.163; Shrank WH, 2011, AM J MED, V124, P309, DOI 10.1016/j.amjmed.2010.11.020; Shrank WH, 2009, MED CARE, V47, P319, DOI 10.1097/MLR.0b013e31818af850; Strom O, 2012, OSTEOPOROSIS INT, V23, P2201, DOI 10.1007/s00198-011-1850-4; The Association of Danish Pharmacies, DRUGS IN DENM; Ude M, 2011, J HYPERTENS, V29, P1837, DOI 10.1097/HJH.0b013e32834942be; Van Wijk BLG, 2006, J CLIN EPIDEMIOL, V59, P11, DOI 10.1016/j.jclinepi.2005.05.005; Van Wijk BLG, 2006, ANN PHARMACOTHER, V40, P15, DOI 10.1345/aph.1G163; Verbeeck RK, 2012, J PHARM PHARM SCI, V15, P376, DOI 10.18433/J3VC8J; Vermeire E, 2001, J CLIN PHARM THER, V26, P331, DOI 10.1046/j.1365-2710.2001.00363.x	38	15	15	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 16	2015	10	3							e0119688	10.1371/journal.pone.0119688	http://dx.doi.org/10.1371/journal.pone.0119688			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CD6EY	25775472	Green Submitted, Green Published, gold			2023-01-03	WOS:000351183500110
J	Chen, L; Yu, B; Zhang, YF; Gao, X; Zhu, L; Ma, TH; Yang, H				Chen, Lei; Yu, Bo; Zhang, Yaofang; Gao, Xin; Zhu, Liang; Ma, Tonghui; Yang, Hong			Bioactivity-Guided Fractionation of an Antidiarrheal Chinese Herb Rhodiola kirilowii (Regel) Maxim Reveals (-)-Epicatechin-3-Gallate and (-)-Epigallocatechin-3-Gallate as Inhibitors of Cystic Fibrosis Transmembrane Conductance Regulator	PLOS ONE			English	Article							NATURAL-PRODUCTS; CFTR INHIBITORS; MOLECULAR-BASIS; CHOLERA-TOXIN; CHANNEL; THERAPY; DISCOVERY; EGCG; ACTIVATORS; RESOURCES	Cystic fibrosis transmembrane conductance regulator (CFTR) is the principal apical route for transepithelial fluid transport induced by enterotoxin. Inhibition of CFTR has been confirmed as a pharmaceutical approach for the treatment of secretory diarrhea. Many traditional Chinese herbal medicines, like Rhodiola kirilowii (Regel) Maxim, have long been used for the treatment of secretory diarrhea. However, the active ingredients responsible for their therapeutic effectiveness remain unknown. The purpose of this study is to identify CFTR inhibitors from Rhodiola kirilowii (Regel) Maxim via bioactivity-directed isolation strategy. We first identified fractions of Rhodiola kirilowii (Regel) Maxim that inhibited CFTR Cl- channel activity. Further bioactivity-directed fractionation led to the identification of (-)-epigallocatechin-3-gallate (EGCG) as CFTR Cl- channel inhibitor. Analysis of 5 commercially available EGCG analogs including (+)-catechins (C), (-)-epicatechin (EC), (-)-epigallocatechin (EGC), (-)-epicatechin-3-gallate (ECG) and EGCG revealed that ECG also had CFTR inhibitory activity. EGCG dose-dependently and reversibly inhibited CFTR Cl- channel activity in transfected FRT cells with an IC50 value around 100 mu M. In ex vivo studies, EGCG and ECG inhibited CFTR-mediated short-circuit currents in isolated rat colonic mucosa in a dose-dependent manner. In an intestinal closed-loop model in mice, intraluminal application of EGCG (10 mu g) and ECG (10 mu g) significantly reduced cholera toxin-induced intestinal fluid secretion. CFTR Cl-channel is a molecular target of natural compounds EGCG and ECG. CFTR inhibition may account, at least in part, for the antidiarrheal activity of Rhodiola kirilowii (Regel) Maxim. EGCG and ECG could be new lead compounds for development of CFTR-related diseases such as secretory diarrhea.	[Chen, Lei; Yu, Bo; Ma, Tonghui; Yang, Hong] Liaoning Normal Univ, Sch Life Sci, Liaoning Prov Key Lab Biotechnol & Drug Discovery, Dalian 116029, Peoples R China; [Zhang, Yaofang; Zhu, Liang; Ma, Tonghui] Dalian Med Univ, Coll Basic Med Sci, Dalian 116044, Peoples R China; [Gao, Xin] Yanbian Univ, Sch Med, Yanji 133002, Peoples R China	Liaoning Normal University; Dalian Medical University; Yanbian University	Yang, H (corresponding author), Liaoning Normal Univ, Sch Life Sci, Liaoning Prov Key Lab Biotechnol & Drug Discovery, Dalian 116029, Peoples R China.	hyanglnnu@gmail.com		Ma, Tonghui/0000-0001-9338-1030	National Natural Science Foundation of China [81473265, 31471099, 81173109, 30973577]; Specialized Research Fund for the Doctoral Program of Higher Education [20112136110002]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Specialized Research Fund for the Doctoral Program of Higher Education(Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP))	This work was supported by National Natural Science Foundation of China (No. 81473265; 31471099; 81173109; 30973577), Specialized Research Fund for the Doctoral Program of Higher Education (20112136110002). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barrett KE, 2000, ANNU REV PHYSIOL, V62, P535, DOI 10.1146/annurev.physiol.62.1.535; CHAO AC, 1994, EMBO J, V13, P1065, DOI 10.1002/j.1460-2075.1994.tb06355.x; Chen D, 2011, ADV CLIN CHEM, V53, P155, DOI 10.1016/S0065-2423(11)53007-0; Cragg GM, 2013, BBA-GEN SUBJECTS, V1830, P3670, DOI 10.1016/j.bbagen.2013.02.008; Frizzell RA, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a009563; GABRIEL SE, 1994, SCIENCE, V266, P107, DOI 10.1126/science.7524148; Galietta LVJ, 2001, AM J PHYSIOL-CELL PH, V281, pC1734, DOI 10.1152/ajpcell.2001.281.5.C1734; Greger R, 2000, ANNU REV PHYSIOL, V62, P467, DOI 10.1146/annurev.physiol.62.1.467; He CY, 2004, CHEM RES CHINESE U, V20, P334; Hsiao WLW, 2010, PLANTA MED, V76, P1118, DOI 10.1055/s-0030-1250186; Huang ZJ, 2011, MINI-REV MED CHEM, V11, P1122, DOI 10.2174/138955711797655362; Jiang MA, 2010, PLANTA MED, V76, P2048, DOI 10.1055/s-0030-1250456; Li T, 2013, ANTIVIR RES, V97, P1, DOI 10.1016/j.antiviral.2012.10.006; Li XM, 2011, MT SINAI J MED, V78, P697, DOI 10.1002/msj.20294; Luzhetskyy A, 2007, CURR OPIN INVEST DR, V8, P608; Ma TH, 2002, J CLIN INVEST, V110, P1651, DOI 10.1172/JCI200216112; Ma TH, 2002, J BIOL CHEM, V277, P37235, DOI 10.1074/jbc.M205932200; May BH, 2012, J ALTERN COMPLEM MED, V18, P1101, DOI 10.1089/acm.2011.0587; Moran O, 2008, J CYST FIBROS, V7, P483, DOI 10.1016/j.jcf.2008.05.003; Muanprasat C, 2004, J GEN PHYSIOL, V124, P125, DOI 10.1085/jgp.200409059; Muanprasat C, 2007, BIOL PHARM BULL, V30, P502, DOI 10.1248/bpb.30.502; Muanprasat C, 2012, J PHARMACOL SCI, V118, P82, DOI 10.1254/jphs.11153FP; Namkung W, 2010, FASEB J, V24, P4178, DOI 10.1096/fj.10-160648; Reygaert W, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00162; Riordan JR, 2008, ANNU REV BIOCHEM, V77, P701, DOI 10.1146/annurev.biochem.75.103004.142532; Singh BN, 2011, BIOCHEM PHARMACOL, V82, P1807, DOI 10.1016/j.bcp.2011.07.093; Smith AJ, 2013, MOL PHARMACEUT, V10, P2948, DOI 10.1021/mp4000794; Thiagarajah JR, 2012, CLIN PHARMACOL THER, V92, P287, DOI 10.1038/clpt.2012.114; Thiagarajah JR, 2013, CURR OPIN PHARMACOL, V13, P888, DOI 10.1016/j.coph.2013.08.005; Thiagarajah JR, 2005, TRENDS PHARMACOL SCI, V26, P172, DOI 10.1016/j.tips.2005.02.003; Thiagarajah JR, 2003, CURR OPIN PHARMACOL, V3, P594, DOI 10.1016/j.coph.2003.06.012; TODA M, 1992, MICROBIOL IMMUNOL, V36, P999, DOI 10.1111/j.1348-0421.1992.tb02103.x; Velazquez C, 2009, J ETHNOPHARMACOL, V126, P455, DOI 10.1016/j.jep.2009.09.016; Venkatasubramanian J, 2010, CURR OPIN GASTROEN, V26, P123, DOI 10.1097/MOG.0b013e3283358a45; Verkman AS, 2006, CURR PHARM DESIGN, V12, P2235, DOI 10.2174/138161206777585148; Verkman AS, 2013, CURR PHARM DESIGN, V19, P3529, DOI 10.2174/13816128113199990321; Verkman AS, 2009, NAT REV DRUG DISCOV, V8, P153, DOI 10.1038/nrd2780; Wang XF, 2004, EXP PHYSIOL, V89, P417, DOI 10.1113/expphysiol.2003.027003; Yang H, 2003, J BIOL CHEM, V278, P35079, DOI 10.1074/jbc.M303098200; Yang SP, 2012, ACTA PHARMACOL SIN, V33, P1147, DOI 10.1038/aps.2012.105; Zegarra-Moran O, 2002, BRIT J PHARMACOL, V137, P504, DOI 10.1038/sj.bjp.0704882; Zhang YF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094302	42	21	24	1	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 6	2015	10	3							e0119122	10.1371/journal.pone.0119122	http://dx.doi.org/10.1371/journal.pone.0119122			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC9KQ	25747701	gold, Green Published, Green Submitted			2023-01-03	WOS:000350689400045
J	Marini, JJ; Vincent, JL; Annane, D				Marini, John J.; Vincent, Jean-Louis; Annane, Djillali			Critical Care Evidence-New Directions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MORTALITY		[Marini, John J.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; [Vincent, Jean-Louis] Univ Libre Bruxelles, Dept Intens Care Med, Brussels, Belgium; [Annane, Djillali] Univ Versailles SQY, Hop Raymond Poincare, AP HP, Dept Med, Garches, France	University of Minnesota System; University of Minnesota Twin Cities; Universite Libre de Bruxelles; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; UDICE-French Research Universities; Universite Paris Saclay	Marini, JJ (corresponding author), Reg Hosp, Dept Pulm & Crit Care Med, 640 Jackson St,MS11203B, St Paul, MN 55101 USA.	marin002@umn.edu	Annane, Djillali/R-7947-2019	Vincent, Jean-Louis/0000-0001-6011-6951				HAYES MA, 1994, NEW ENGL J MED, V330, P1717, DOI 10.1056/NEJM199406163302404; Iwashyna TJ, 2010, JAMA-J AM MED ASSOC, V304, P1787, DOI 10.1001/jama.2010.1553; Kaukonen KM, 2014, JAMA-J AM MED ASSOC, V311, P1308, DOI 10.1001/jama.2014.2637; Shehabi Y, 2012, AM J RESP CRIT CARE, V186, P724, DOI 10.1164/rccm.201203-0522OC; Tonelli AR, 2014, INTENS CARE MED, V40, P769, DOI 10.1007/s00134-014-3272-1; Wang LW, 2011, NEW ENGL J MED, V364, P1144, DOI 10.1056/NEJMra1010600	6	27	27	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	2015	313	9					893	894		10.1001/jama.2014.18484	http://dx.doi.org/10.1001/jama.2014.18484			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CC3FN	25602680				2023-01-03	WOS:000350231800008
J	Awh, E; Vogel, EK				Awh, Edward; Vogel, Edward K.			Attention: feedback focuses a wandering mind	NATURE NEUROSCIENCE			English	Editorial Material							WORKING-MEMORY CAPACITY; FLUID INTELLIGENCE; IMPROVEMENT		[Awh, Edward; Vogel, Edward K.] Univ Oregon, Dept Psychol, Eugene, OR 97403 USA; [Awh, Edward; Vogel, Edward K.] Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA	University of Oregon; University of Oregon	Awh, E (corresponding author), Univ Oregon, Dept Psychol, Eugene, OR 97403 USA.	awh@uoregon.edu; vogel@uoregon.edu	Vogel, Edward K/AAW-9466-2021	Awh, Edward/0000-0002-5211-5278	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH087214] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH087214] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Caroll J.B, 1993, HUMAN COGNITIVE ABIL; Debettencourt MT, 2015, NAT NEUROSCI, V18, P470, DOI 10.1038/nn.3940; Jaeggi SM, 2008, P NATL ACAD SCI USA, V105, P6829, DOI 10.1073/pnas.0801268105; Kane MJ, 2007, PSYCHOL SCI, V18, P614, DOI 10.1111/j.1467-9280.2007.01948.x; Kane MJ, 2002, PSYCHON B REV, V9, P637, DOI 10.3758/BF03196323; Klingberg T, 2002, J CLIN EXP NEUROPSYC, V24, P781, DOI 10.1076/jcen.24.6.781.8395; Morrison AB, 2011, PSYCHON B REV, V18, P46, DOI 10.3758/s13423-010-0034-0; Mrazek MD, 2013, PSYCHOL SCI, V24, P776, DOI 10.1177/0956797612459659; Mrazek MD, 2012, J EXP PSYCHOL GEN, V141, P788, DOI 10.1037/a0027968; Redick TS, 2013, J EXP PSYCHOL GEN, V142, P359, DOI 10.1037/a0029082; Schooler JW, 2011, TRENDS COGN SCI, V15, P319, DOI 10.1016/j.tics.2011.05.006; Thorndike EL, 1901, PSYCHOL REV, V8, P247, DOI 10.1037/h0071363; TURNER ML, 1989, J MEM LANG, V28, P127, DOI 10.1016/0749-596X(89)90040-5; Unsworth N, 2014, COGNITIVE PSYCHOL, V71, P1, DOI 10.1016/j.cogpsych.2014.01.003; Unsworth N, 2010, INTELLIGENCE, V38, P111, DOI 10.1016/j.intell.2009.08.002	15	3	5	0	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1097-6256	1546-1726		NAT NEUROSCI	Nat. Neurosci.	MAR	2015	18	3					327	328		10.1038/nn.3962	http://dx.doi.org/10.1038/nn.3962			2	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	CC2SO	25710832	Green Accepted			2023-01-03	WOS:000350195100007
J	Watanabe, S; Sato, K; Hasegawa, N; Kurihara, T; Matsutani, K; Sanada, K; Hamaoka, T; Fujita, S; Iemitsu, M				Watanabe, Shinya; Sato, Koji; Hasegawa, Natsuki; Kurihara, Toshiyuki; Matsutani, Kenji; Sanada, Kiyoshi; Hamaoka, Takafumi; Fujita, Satoshi; Iemitsu, Motoyuki			Serum C1q as a novel biomarker of sarcopenia in older adults	FASEB JOURNAL			English	Article						aging; fibrosis; skeletal muscle; resistance training	SKELETAL-MUSCLE; SATELLITE CELLS; EXERCISE; AGE; INFLAMMATION; EXPRESSION; RESPONSES; PATHWAY; FRAILTY; HEALTH	Aging-induced elevation in C1q secretion activates the Wnt signaling pathway in muscles, leading to the development of muscle fibrosis. However, the association between serum C1q level and muscle mass and strength remains unclear in humans. The aim of the study was to elucidate whether serum C1q level is associated with aging-and resistance training-induced changes in muscle mass and strength. First, in a cross-sectional study, we investigated the association between serum C1q level and muscle mass and strength in 131 healthy subjects, aged 20-81 yr. Second, in an intervention study, we examined the association between the effects of serum C1q level and muscle mass and strength on 12wk resistance training in 11 healthy older adults (60-81 yr). In the cross-sectional study, serum C1q level increased with aging and was negatively correlated with muscle mass and strength. Furthermore, 12 wk resistance training in older adults reduced the age-associated elevation in serum C1q levels. The training effect of serum C1q level significantly correlated with the change in the cross-sectional area of the thigh (r = -0.703; P < 0.01). Serum C1q level may reflect loss of muscle mass; therefore, C1q may be a novel biomarker of sarcopenia.	[Watanabe, Shinya; Sato, Koji; Hasegawa, Natsuki; Kurihara, Toshiyuki; Matsutani, Kenji; Sanada, Kiyoshi; Hamaoka, Takafumi; Fujita, Satoshi; Iemitsu, Motoyuki] Ritsumeikan Univ, Fac Sport & Hlth Sci, Kusatsu, Shiga 5258577, Japan	Ritsumeikan University	Iemitsu, M (corresponding author), Ritsumeikan Univ, Fac Sport & Hlth Sci, 1-1-1 Nojihigashi, Kusatsu, Shiga 5258577, Japan.	iemitsu@fc.ritsumei.ac.jp		Sanada, Kiyoshi/0000-0003-3703-4098; WATANABE, SHINYA/0000-0003-1369-9001	Ministry of Education, Culture, Sports, Science and Technology of Japan (KAKENHI) [26282199, 25560378, 22680050]; Grants-in-Aid for Scientific Research [25560378] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan (KAKENHI)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (KAKENHI #26282199 and #25560378 to M.I. and #22680050 to S.F.). The authors declare no conflicts of interest.	Adamo ML, 2006, AGEING RES REV, V5, P310, DOI 10.1016/j.arr.2006.05.001; Arnold AS, 2011, GERONTOLOGY, V57, P37, DOI 10.1159/000281883; Arthur ST, 2012, INT J BIOL SCI, V8, P731, DOI 10.7150/ijbs.4262; Bandeen-Roche K, 2006, J GERONTOL A-BIOL, V61, P262, DOI 10.1093/gerona/61.3.262; Brack AS, 2007, SCIENCE, V317, P807, DOI 10.1126/science.1144090; Caron AZ, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-185; Day K, 2010, DEV BIOL, V340, P330, DOI 10.1016/j.ydbio.2010.01.006; Ensrud KE, 2007, J GERONTOL A-BIOL, V62, P744, DOI 10.1093/gerona/62.7.744; Faulkner JA, 2007, CLIN EXP PHARMACOL P, V34, P1091, DOI 10.1111/j.1440-1681.2007.04752.x; Fujita S, 2009, DIABETOLOGIA, V52, P1889, DOI 10.1007/s00125-009-1430-8; Gasier HG, 2011, ACTA PHYSIOL, V201, P381, DOI 10.1111/j.1748-1716.2010.02183.x; Goodpaster BH, 2001, J APPL PHYSIOL, V90, P2157, DOI 10.1152/jappl.2001.90.6.2157; Haddad F, 2002, J APPL PHYSIOL, V93, P394, DOI 10.1152/japplphysiol.01153.2001; Kadi F, 2004, J PHYSIOL-LONDON, V558, P1005, DOI 10.1113/jphysiol.2004.065904; Legoedec J, 1997, MOL IMMUNOL, V34, P735, DOI 10.1016/S0161-5890(97)00093-X; Liu HJ, 2007, SCIENCE, V317, P803, DOI 10.1126/science.1143578; Lynch GS, 2007, PHARMACOL THERAPEUT, V113, P461, DOI 10.1016/j.pharmthera.2006.11.004; Montero-Fernandez N, 2013, EUR J PHYS REHAB MED, V49, P131; Naito AT, 2012, CELL, V149, P1298, DOI 10.1016/j.cell.2012.03.047; Peake J, 2010, AM J PHYSIOL-REG I, V298, pR1485, DOI 10.1152/ajpregu.00467.2009; PETRY F, 1991, J IMMUNOL, V147, P3988; Ryall JG, 2008, BIOGERONTOLOGY, V9, P213, DOI 10.1007/s10522-008-9131-0; Sato K, 2008, AM J PHYSIOL-ENDOC M, V294, pE961, DOI 10.1152/ajpendo.00678.2007; Sato K, 2014, FASEB J, V28, P1891, DOI 10.1096/fj.13-245480; Schaap LA, 2009, J GERONTOL A-BIOL, V64, P1183, DOI 10.1093/gerona/glp097; Schrager MA, 2007, J APPL PHYSIOL, V102, P919, DOI 10.1152/japplphysiol.00627.2006; Sousa-Victor P, 2014, NATURE, V506, P316, DOI 10.1038/nature13013; TENNER AJ, 1986, BIOCHEM J, V233, P451, DOI 10.1042/bj2330451; Verdijk LB, 2014, AGE, V36, P545, DOI 10.1007/s11357-013-9583-2; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406	30	36	40	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2015	29	3					1003	1010		10.1096/fj.14-262154	http://dx.doi.org/10.1096/fj.14-262154			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CC8QK	25491308				2023-01-03	WOS:000350633000024
J	Collins, FS; Varmus, H				Collins, Francis S.; Varmus, Harold			A New Initiative on Precision Medicine	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Collins, Francis S.] NIH, Bethesda, MD 20892 USA; [Varmus, Harold] NCI, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Collins, FS (corresponding author), NIH, Bldg 10, Bethesda, MD 20892 USA.							ABRAMS J, 2014, AM SOC CLIN ONCOL ED, V34, P71; Committee on a Framework for Developing a New Taxonomy of Disease, 2011, PREC MED BUILD KNOWL; de Bono JS, 2010, NATURE, V467, P543, DOI 10.1038/nature09339; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498	4	2902	3067	17	597	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 26	2015	372	9					793	795		10.1056/NEJMp1500523	http://dx.doi.org/10.1056/NEJMp1500523			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CB8SQ	25635347	Bronze, Green Published			2023-01-03	WOS:000349901700001
J	You, HZ; Rideau, E; Sidera, M; Fletcher, SP				You, Hengzhi; Rideau, Emeline; Sidera, Mireia; Fletcher, Stephen P.			Non-stabilized nucleophiles in Cu-catalysed dynamic kinetic asymmetric allylic alkylation	NATURE			English	Article							CONJUGATE ADDITION; SUBSTITUTION-REACTIONS; GRIGNARD-REAGENTS; ACID; IDENTIFICATION; RESOLUTION; LIGANDS	The development of new reactions forming asymmetric carbon-carbon bonds has enabled chemists to synthesize a broad range of important carbon-containing molecules, including pharmaceutical agents, fragrances and polymers(1). Most strategies to obtain enantiomerically enriched molecules rely on either generating new stereogenic centres from prochiral substrates or resolving racemic mixtures of enantiomers. An alternative strategy dynamic kinetic asymmetric transformation involves the transformation of a racemic starting material into a single enantiomer product, with greater than 50 per cent maximum yield(2,3). The use of stabilized nudeophiles (pK(a) < 25, where K-a is the acid dissociation constant) in palladium-catalysed asymmetric allylic alkylation reactions has proved to be extremely versatile in these processes(4,5). Conversely, the use of non-stabilized nudeophiles in such reactions is difficult and remains a key challenge'. Here we report a copper-catalysed dynamic kinetic asymmetric transformation using racemic substrates and alkyl nudeophiles. These nudeophiles have a pK(a) of >= 50, more than 25 orders of magnitude more basic than the nudeophiles that are typically used in such transformations. Organometallic reagents are generated in situ from alkenes by hydrometallation and give highly enantioenriched products under mild reaction conditions. The method is used to synthesize natural products that possess activity against tuberculosis and leprosy, and an inhibitor of para-aminobenzoate biosynthesis. Mechanistic studies indicate that the reaction proceeds through a rapidly isomerizing intermediate. We anticipate that this approach will be a valuable complement to existing asymmetric catalytic methods.	[You, Hengzhi; Rideau, Emeline; Sidera, Mireia; Fletcher, Stephen P.] Univ Oxford, Dept Chem, Chem Res Lab, Oxford OX1 3TA, England	University of Oxford	Fletcher, SP (corresponding author), Univ Oxford, Dept Chem, Chem Res Lab, 12 Mansfield Rd, Oxford OX1 3TA, England.	stephen.fletcher@chem.ox.ac.uk	Rideau, Emeline/AAR-1123-2020; Sidera, Mireia/N-3309-2015	Sidera, Mireia/0000-0002-7238-8433; You, Hengzhi/0000-0001-8904-5050; Rideau, Emeline/0000-0003-2940-1169	EPSRC [EP/H003711/1]; Engineering and Physical Sciences Research Council [EP/H003711/1] Funding Source: researchfish	EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	We acknowledge financial support from the EPSRC (EP/H003711/1, a Career Acceleration Fellowship to S.P.F.). B. Odell and T. Claridge are thanked for assistance with the NMR experiments.	Alexakis A, 2008, CHEM REV, V108, P2796, DOI 10.1021/cr0683515; CABOT MC, 1981, LIPIDS, V16, P146, DOI 10.1007/BF02535690; Geurts K, 2008, PURE APPL CHEM, V80, P1025, DOI 10.1351/pac200880051025; Giacomina F, 2013, EUR J ORG CHEM, V2013, P6710, DOI 10.1002/ejoc.201300971; Harutyunyan SR, 2008, CHEM REV, V108, P2824, DOI 10.1021/cr068424k; Huerta FF, 2001, CHEM SOC REV, V30, P321, DOI 10.1039/b105464n; Jacobsen E. N., 2004, COMPREHENSIVE ASY S2; JACOBSEN PL, 1973, ANTIMICROB AGENTS CH, V3, P373, DOI 10.1128/AAC.3.3.373; Langlois JB, 2012, CHEM SCI, V3, P1062, DOI 10.1039/c2sc00868h; Langlois JB, 2012, TOP ORGANOMETAL CHEM, V38, P235, DOI 10.1007/3418_2011_12; Langlois JB, 2009, CHEM COMMUN, P3868, DOI 10.1039/b907722g; Lu Z, 2008, ANGEW CHEM INT EDIT, V47, P258, DOI 10.1002/anie.200605113; Maksymowicz RM, 2012, NAT CHEM, V4, P649, DOI [10.1038/NCHEM.1394, 10.1038/nchem.1394]; MATSUSHITA H, 1982, CHEM COMMUN, P160; Misale A, 2014, ANGEW CHEM INT EDIT, V53, P7068, DOI 10.1002/anie.201309074; Norinder J, 2007, CHEM-EUR J, V13, P4094, DOI 10.1002/chem.200601684; Pfaltz A., 1999, COMPREHENSIVE ASYMME, P833, DOI DOI 10.1021/CR0683515; Seemann M, 2003, EUR J ORG CHEM, V2003, P2122, DOI 10.1002/ejoc.200200700; Sha SC, 2013, J AM CHEM SOC, V135, P17602, DOI 10.1021/ja409511n; Sidera M, 2013, ANGEW CHEM INT EDIT, V52, P7995, DOI 10.1002/anie.201303202; Streitwieser A, 2008, J ORG CHEM, V73, P9426, DOI 10.1021/jo8020743; Teichert JF, 2010, ANGEW CHEM INT EDIT, V49, P2486, DOI 10.1002/anie.200904948; Trost BM, 2008, J AM CHEM SOC, V130, P14092, DOI 10.1021/ja806781u; Trost BM, 2007, ALDRICHIM ACTA, V40, P59; Trost BM, 1996, CHEM REV, V96, P395, DOI 10.1021/cr9409804; TROST BM, 1976, J ORG CHEM, V41, P3215, DOI 10.1021/jo00881a039; TROST BM, 1994, J AM CHEM SOC, V116, P4089, DOI 10.1021/ja00088a059; Vedejs E, 2005, ANGEW CHEM INT EDIT, V44, P3974, DOI 10.1002/anie.200460842; Wang JF, 2010, CHEM BIODIVERS, V7, P2046, DOI 10.1002/cbdv.201000072; Zhang HX, 2006, ANGEW CHEM INT EDIT, V45, P6391, DOI 10.1002/anie.200601880	30	76	76	6	136	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 15	2015	517	7534					351	355		10.1038/nature14089	http://dx.doi.org/10.1038/nature14089			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AY8NK	25592541				2023-01-03	WOS:000347810300042
J	Overwijk, WW				Overwijk, Willem W.			Human CD4(+) T cells spontaneously detect somatic mutations in cancer cells	NATURE MEDICINE			English	Editorial Material									Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Overwijk, WW (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA.	woverwijk@mdanderson.org			NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA016672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cobbold M, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006061; Hailemichael Y, 2013, NAT MED, V19, P465, DOI 10.1038/nm.3105; Hunuel N.N., 2000, NEW ENGL J MED, V558, P2698; Kim HJ, 2014, CANCER IMMUNOL RES, V2, P91, DOI 10.1158/2326-6066.CIR-13-0216; Linnemann C, 2015, NAT MED, V21, P81, DOI 10.1038/nm.3773; Robbins PF, 2013, NAT MED, V19, P747, DOI 10.1038/nm.3161; Rosenberg SA, 2014, NAT REV CLIN ONCOL, V11, P630, DOI 10.1038/nrclinonc.2014.174; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Tran E, 2014, SCIENCE, V344, P641, DOI 10.1126/science.1251102	9	9	11	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2015	21	1					12	14		10.1038/nm.3783	http://dx.doi.org/10.1038/nm.3783			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	AZ7OM	25569544	Green Accepted			2023-01-03	WOS:000348408000006
J	Mercy, KM; Gordon, KB; Paller, AS				Mercy, Katherine M.; Gordon, Kenneth B.; Paller, Amy S.			Patient Satisfaction and Quality of Life in Psoriasis and Psoriatic Arthritis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SYMPTOMS; THERAPY	JAMA DERMATOLOGY Undertreatment, Treatment Trends, and Treatment Dissatisfaction Among Patients With Psoriasis and Psoriatic Arthritis in the United States: Findings From the National Psoriasis Foundation Surveys, 2003-2011 April W. Armstrong, MD, MPH; Andrew D. Robertson, PhD; Julie Wu, BS; Clayton Schupp, PhD; Mark G. Lebwohl, MD IMPORTANCE Psoriasis and psoriatic arthritis inflict significant morbidity. Data on undertreatment, treatment use, and treatment satisfaction are paramount to identify priority areas for advocacy, education, and research to improve patient outcomes. OBJECTIVES To determine the extent of nontreatment and undertreatment of psoriatic diseases, trends in treatment use, treatment satisfaction, and reasons for medication discontinuation among patients with psoriasis and psoriatic arthritis. DESIGN, SETTING, AND PARTICIPANTS We used the national survey data collected by the National Psoriasis Foundation via biannual surveys conducted from January 1, 2003, through December 31, 2011, in the United States. Survey data were collected from randomly sampled patients with psoriasis and psoriatic arthritis in the US population from a database of more than 76 000 patients with psoriatic diseases. MAIN OUTCOMES AND MEASURES Nontreatment, undertreatment, and treatment trends determined by the use of prescription medication (topical, phototherapeutic, oral systemic, and biologic), as well as treatment satisfaction and reasons for medication discontinuation. RESULTS A total of 5604 patients with psoriasis or psoriatic arthritis completed the survey. From 2003 through 2011, patients who were untreated ranged from 36.6% to 49.2% of patients with mild psoriasis, 23.6% to 35.5% of patients with moderate psoriasis, and 9.4% to 29.7% of patients with severe psoriasis. Among those receiving treatment, 29.5% of patients with moderate psoriasis and 21.5% of patients with severe psoriasis were treated with topical agents alone. The most frequently used phototherapy modality is UV-B, whereas methotrexate is the most commonly used oral agent. Although adverse effects and a lack of effectiveness were primary reasons for discontinuing biological agents, the inability to obtain adequate insurance coverage was among the top reasons for discontinuation. Overall, 52.3% of patients with psoriasis and 45.5% of patients with psoriatic arthritis were dissatisfied with their treatment. CONCLUSIONS AND RELEVANCE Nontreatment and undertreatment of patients with psoriasis and psoriatic arthritis remain a significant problem in the United States. While various treatment modalities are available for psoriasis and psoriatic arthritis, widespread treatment dissatisfaction exists. Efforts in advocacy and education are necessary to ensure that effective treatments are accessible to this patient population. JAMA Dermatol. 2013; 149(10): 1180-1185. doi: 10.1001/jamadermatol.2013.5264.	[Mercy, Katherine M.; Gordon, Kenneth B.; Paller, Amy S.] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Paller, AS (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Dermatol, 676 N St Clair,Ste 1600, Chicago, IL 60611 USA.	apaller@northwestern.edu		Paller, Amy/0000-0001-6187-6549	Abbott; Amgen; Celgene; Eli Lilly; Janssen; Novartis; Pfizer; Merck	Abbott(Abbott Laboratories); Amgen(Amgen); Celgene(Bristol-Myers SquibbCelgene Corporation); Eli Lilly(Eli Lilly); Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Novartis(Novartis); Pfizer(Pfizer); Merck(Merck & Company)	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Gordon reported having received grants, personal fees, or both from Abbott, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and Merck. Dr Paller reported having received an honorarium for consultating for Abbvie and having been an investigator without personal compensation for Amgen. No other disclosures were reported.	Armstrong AW, 2013, JAMA DERMATOL, V149, P1180, DOI 10.1001/jamadermatol.2013.5264; Duffin KC, 2014, BRIT J DERMATOL, V170, P672, DOI 10.1111/bjd.12745; Finlay AY, 2004, J CUTAN MED SURG, V8, P310, DOI 10.1007/s10227-005-0030-6; Gordon KB, 2014, BRIT J DERMATOL, V170, P705, DOI 10.1111/bjd.12636; Langley RG, 2010, J AM ACAD DERMATOL, V63, P457, DOI 10.1016/j.jaad.2009.09.014; Prodanowich S, 2005, J AM ACAD DERMATOL, V52, P262, DOI 10.1016/j.jaad.2004.06.017; van Cranenburgh OD, 2013, BRIT J DERMATOL, V169, P398, DOI 10.1111/bjd.12372; Wu JJ, 2012, ARCH DERMATOL, V148, P1244, DOI 10.1001/archdermatol.2012.2502	8	8	9	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 24	2014	312	24					2676	2677		10.1001/jama.2014.12494	http://dx.doi.org/10.1001/jama.2014.12494			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AX5KW	25536259				2023-01-03	WOS:000346966100020
J	Arora, R; Bhushan, S; Kumar, R; Mannan, R; Kaur, P; Singh, AP; Singh, B; Vig, AP; Sharma, D; Arora, S				Arora, Rohit; Bhushan, Sakshi; Kumar, Rakesh; Mannan, Rahul; Kaur, Pardeep; Singh, Amrit Pal; Singh, Bikram; Vig, Adarsh P.; Sharma, Deepika; Arora, Saroj			Hepatic Dysfunction Induced by 7, 12-Dimethylbenz(alpha) anthracene and Its Obviation with Erucin Using Enzymatic and Histological Changes as Indicators	PLOS ONE			English	Article							POLYCYCLIC AROMATIC-HYDROCARBONS; OXIDATIVE STRESS; RAT-LIVER; DMBA; ISOTHIOCYANATES; CANCER; SULFORAPHANE; BINDING; CHEMOPREVENTION; PRODUCTS	The toxicity induced by 7, 12-dimethylbenz(alpha) anthracene (DMBA) has been widely delineated by a number of researchers. This potent chemical damages many internal organs including liver, by inducing the production of reactive oxygen species, DNA-adduct formation and affecting the activities of phase I, II, antioxidant and serum enzymes. Glucosinolate hydrolytic products like isothiocyanates (ITCs) are well known for inhibiting the DNA-adduct formation and modulating phase I, II enzymes. Sulforaphane is ITC, currently under phase trials, is readily metabolized and inter-converted into erucin upon ingestion. We isolated erucin from Eruca sativa (Mill.) Thell. evaluated its hepatoprotective role in DMBA induced toxicity in male wistar rats. The rats were subjected to hepatic damage by five day regular intraperitoneal doses of DMBA. At the end of the protocol, the rats were euthanized, their blood was collected and livers were processed. The liver homogenate was analyzed for phase I (NADPH-cytochrome P450 reductase, NADH-cytochrome b5 reductase, cytochrome P450, cytochrome P420 and cytochrome b5), phase II (DT diaphorase, glutathione-S-transferase and gamma-glutamyl transpeptidase) and antioxidant enzymes (superoxide dismutase, catalase, guaiacol peroxidise, ascorbate peroxidise, glutathione reductase and lactate dehydrogenase). The level of thiobarbituric acid reactive substances, lipid hydroperoxides, conjugated dienes and reduced glutathione in the liver homogenate was also analyzed. The serum was also analyzed for markers indicating hepatic damage (alkaline phosphatase, serum glutamic oxaloacetic transaminase, serum glutamic pyruvic transaminase, direct bilirubin and total bilirubin). Erucin provided significant protection against DMBA induced damage by modulating the phase I, II and antioxidant enzymes. The histological evaluation of liver tissue was also conducted, which showed the hepatoprotective role of erucin.	[Arora, Rohit; Bhushan, Sakshi; Kumar, Rakesh; Kaur, Pardeep; Vig, Adarsh P.; Arora, Saroj] Guru Nanak Dev Univ, Dept Bot & Environm Sci, Amritsar, Punjab, India; [Mannan, Rahul] Sri Guru Ram Inst Med Sci & Res, Amritsar, Punjab, India; [Singh, Amrit Pal] Guru Nanak Dev Univ, Dept Pharmaceut Sci, Amritsar, Punjab, India; [Singh, Bikram; Sharma, Deepika] Inst Himalayan Bioresource & Technol, CSIR, Nat Plant Prod Div, Palampur, Himachal Prades, India	Guru Nanak Dev University; Guru Nanak Dev University; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Himalayan Bioresource Technology (IHBT)	Arora, S (corresponding author), Guru Nanak Dev Univ, Dept Bot & Environm Sci, Amritsar, Punjab, India.	sarojarora.gndu@gmail.com	Mannan, Rahul/AAQ-2608-2021; Kaur, Pardeep/N-7224-2019; Arora, Rohit/AAF-8162-2020; Vig, Adarsh Pal/AAI-1312-2020; Singh, Amrit Pal/ABI-8109-2020; Arora, Saroj/AAV-3682-2021; Kumar, Rakesh/ABD-1065-2020	Mannan, Rahul/0000-0002-6642-0468; Kaur, Pardeep/0000-0001-7350-7839; Vig, Adarsh Pal/0000-0003-1419-2501; Singh, Amrit Pal/0000-0002-7658-241X; Arora, Saroj/0000-0002-4086-5653; Kumar, Rakesh/0000-0001-7664-0803; SHARMA, DEEPIKA/0000-0001-7627-6458; Arora, Rohit/0000-0001-6447-5628	Department of Science and Technology (DST) & University Grants Commission (UGC), New Delhi; Guru Nanak Dev University, Amritsar	Department of Science and Technology (DST) & University Grants Commission (UGC), New Delhi; Guru Nanak Dev University, Amritsar	The authors thank financial support of Department of Science and Technology (DST) & University Grants Commission (UGC), New Delhi and Guru Nanak Dev University, Amritsar. Authors are thankful to UPE (under the university with potential for excellence), BSR and CPEPA programme. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AEBI H, 1984, METHOD ENZYMOL, V105, P121; Agca CA, 2012, PHARM BIOL, V50, P1513, DOI 10.3109/13880209.2012.688057; Ahmed HA, 2006, J EGYPT SOC TOXICOL, V35, P97; ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; Anzenbacherova E, 2008, PHYSIOL RES, V57, P761, DOI 10.33549/physiolres.931319; Arora R, 2014, J FOOD SCI, V79, pC1964, DOI 10.1111/1750-3841.12579; ASADA K, 1992, PHYSIOL PLANTARUM, V85, P235, DOI 10.1111/j.1399-3054.1992.tb04728.x; Blazevic I, 2009, FOOD CHEM, V113, P96, DOI 10.1016/j.foodchem.2008.07.029; Boghori M, 2014, J ORAL BIOL CRANIOFA; Carlberg I, 1975, METHOD ENZYMOL, P484; Chatterjee M, 2010, CHEM-BIOL INTERACT, V188, P102, DOI 10.1016/j.cbi.2010.06.007; Cho HJ, 2013, INT J MOL SCI, V14, P20564, DOI 10.3390/ijms141020564; Choi SJ, 2003, J BIOCHEM MOL BIOL, V36, P332; Clarke JD, 2008, CANCER LETT, V269, P291, DOI 10.1016/j.canlet.2008.04.018; Cornblatt BS, 2007, CARCINOGENESIS, V28, P1485, DOI 10.1093/carcin/bgm049; Danson S, 2004, CANCER TREAT REV, V30, P437, DOI 10.1016/j.ctrv.2004.01.002; Devasagayam TPA, 2003, INDIAN J BIOCHEM BIO, V40, P300; Dimitrova-Shumkovska J, 2010, TOXICOL PATHOL, V38, P957, DOI 10.1177/0192623310379137; Ernster, 1967, METHOD ENZYMOL, V10, P309, DOI [DOI 10.1016/0076-6879(67)10059-1, 10.1016/0076-6879(67)10059-1]; Ganin H, 2013, MEDCHEMCOMM, V4, P175, DOI 10.1039/c2md20196h; Gao J, 2005, TOXICOL SCI, V86, P68, DOI 10.1093/toxsci/kfi176; Gnaiger E., 2010, MITO PHYSL NET, V08, P1; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hanlon N, 2009, MOL NUTR FOOD RES, V53, P836, DOI 10.1002/mnfr.200800292; Harmeet Singh, 2011, European Journal of Medicinal Plants, V1, P162; Her JL, 2013, SENSOR ACTUAT B-CHEM, V182, P396, DOI 10.1016/j.snb.2013.03.026; HUBERMAN E, 1979, P NATL ACAD SCI USA, V76, P862, DOI 10.1073/pnas.76.2.862; ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6; Izzotti A, 1999, CANCER RES, V59, P4285; JIANG ZY, 1992, ANAL BIOCHEM, V202, P384, DOI 10.1016/0003-2697(92)90122-N; Kaur R, 2013, FREE RADICAL BIO MED, V65, P131, DOI 10.1016/j.freeradbiomed.2013.06.016; Keum YS, 2004, MUTAT RES-FUND MOL M, V555, P191, DOI 10.1016/j.mrfmmm.2004.05.024; KONO Y, 1978, ARCH BIOCHEM BIOPHYS, V186, P189, DOI 10.1016/0003-9861(78)90479-4; Kumagai A, 2013, CELL, V153, P1602, DOI 10.1016/j.cell.2013.05.038; Kumar R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090083; MORSE MA, 1987, CANCER LETT, V37, P25, DOI 10.1016/0304-3835(87)90142-X; OMURA T, 1964, J BIOL CHEM, V239, P2370; OMURA T, 1970, J BIOCHEM-TOKYO, V67, P249, DOI 10.1093/oxfordjournals.jbchem.a129248; Putter J., 1974, METHODS ENZYMATIC AN, VSecond, P685, DOI [10.1016/B978-0-12- 091302-2.50033-5, 10.1016/B978-0-12-091302-2.50033-5, DOI 10.1016/B978-0-12-091302-2.50033-5]; Ravindra K, 2008, ATMOS ENVIRON, V42, P2895, DOI 10.1016/j.atmosenv.2007.12.010; Rohit Arora, 2014, International Journal of Life Sciences Biotechnology and Pharma Research, V3, P42; Schenkman JB, 2003, PHARMACOL THERAPEUT, V97, P139, DOI 10.1016/S0163-7258(02)00327-3; SCHWARTZ JH, 1963, P NATL ACAD SCI USA, V49, P871, DOI 10.1073/pnas.49.6.871; Strasak AM, 2008, CANCER RES, V68, P3970, DOI 10.1158/0008-5472.CAN-07-6686; Szaefer H, 2014, DRUG CHEM TOXICOL, V37, P472, DOI 10.3109/01480545.2014.893442; SZASZ G, 1976, CLIN CHEM, V22, P2051; Veyrand B, 2013, ENVIRON INT, V54, P11, DOI 10.1016/j.envint.2012.12.011; WONG LK, 1983, APPL ENVIRON MICROB, V46, P1239, DOI 10.1128/AEM.46.5.1239-1242.1983; YANG SK, 1975, P NATL ACAD SCI USA, V72, P2601, DOI 10.1073/pnas.72.7.2601; Yu H, 2005, INT J ENV RES PUB HE, V2, P114; Zhang YS, 2004, MUTAT RES-FUND MOL M, V555, P173, DOI 10.1016/j.mrfmmm.2004.04.017; Zhang YS, 2010, MOL NUTR FOOD RES, V54, P127, DOI 10.1002/mnfr.200900323	52	19	20	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2014	9	11							e112614	10.1371/journal.pone.0112614	http://dx.doi.org/10.1371/journal.pone.0112614			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA8CP	25390337	gold, Green Published, Green Submitted			2023-01-03	WOS:000349144400109
J	Dai, LL; Mao, YY; Luo, XM; Shen, YP				Dai, Lin-Lin; Mao, Yuan-Yuan; Luo, Xiao-Ming; Shen, Yue-Ping			Prenatal Care in Combination with Maternal Educational Level Has a Synergetic Effect on the Risk of Neonatal Low Birth Weight: New Findings in a Retrospective Cohort Study in Kunshan City, China	PLOS ONE			English	Article							PRETERM BIRTH; ASSOCIATION; OUTCOMES; INEQUALITIES; ADEQUACY; INDEXES; VISITS	Objectives: To investigate the dose-response relationship and synergetic effect of the maternal educational level and two measures of prenatal care on neonatal low birth weight (LBW) risk. Methods: Data were derived from the Perinatal Health Care Surveillance System (PHCSS) from January 2001 to September 2009 in Kunshan City, Jiangsu province, eastern China, which included data on 31412 women with a normal birth weight delivery and 640 women with a LBW delivery. Logistic modelling was performed to estimate the association including the joint effects with odds ratio (OR) and 95% confidence interval (CI) between the prenatal care measures and LBW risk after adjusting for the potential confounders. The dose-response relationship between the number of prenatal care visits and the risk of LBW was investigated by modeling the quantitative exposure with restricted cubic splines (RCS). Results: There was a significant synergetic effect on the LBW risk between maternal educational attainment and the number of prenatal care visits (chi(2)=4.98, P=0.0257), whereas no significant maternal educational attainment interaction was found with the week of initiation of prenatal care after adjusting for relevant confounding factors (chi(2)=2.04, P=0.1530), and the LBW risk displayed a 'U-shape' curve tendency among the different number of prenatal care visits (P for nonlinearity=0.0002) using RCS. In particular, the ORs were approaching the curve's bottom when the women had 9 or 10 prenatal care visits. Comparing with 5 prenatal care visits, the ORs and 95% CI of LBW risk for 7, 9, 11 and >= 13 visits were 0.92 (0.82-1.03), 0.50 (0.38-0.66), 0.62 (0.47-0.82), and 0.99 (0.61-1.60), respectively. Conclusions: Our findings suggest that appropriate prenatal care, in combination with a higher maternal educational level, can produce a protective interaction effect on LBW risk. Reasonable health resource assignment for different social statuses should be taken into account by policy-makers in developing countries.	[Dai, Lin-Lin; Shen, Yue-Ping] Soochow Univ, Dept Epidemiol & Biostat, Sch Publ Hlth, Coll Med, Suzhou, Jiangsu, Peoples R China; [Mao, Yuan-Yuan] Kunshan First Peoples Hosp, Suzhou, Jiangsu, Peoples R China; [Luo, Xiao-Ming] Kunshan Fourth Peoples Hosp, Suzhou, Jiangsu, Peoples R China	Soochow University - China	Shen, YP (corresponding author), Soochow Univ, Dept Epidemiol & Biostat, Sch Publ Hlth, Coll Med, Suzhou, Jiangsu, Peoples R China.	shenyueping@suda.edu.cn	Dai, Yun/AAG-4040-2019	Dai, Yun/0000-0003-2285-0818; Orlowski, Robert/0000-0002-5723-4129; Takabatake, Yukie/0000-0003-0540-3610	Priority Academic Program Development of Jiangsu Higher Education Institutions; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA100866, R01CA093738, P50CA142509] Funding Source: NIH RePORTER	Priority Academic Program Development of Jiangsu Higher Education Institutions; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to gratefully acknowledge the work and support of the leaders and health care professionals at all levels responsible for the operation of the Perinatal Health Care Surveillance System in Kunshan City, Jiangsu Province, China. This study was supported by a Project of the Priority Academic Program Development of Jiangsu Higher Education Institutions.	Alexander GR, 2001, PUBLIC HEALTH REP, V116, P306; Alibekova R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084237; Barker DJP, 2002, INT J EPIDEMIOL, V31, P1235, DOI 10.1093/ije/31.6.1235; Barros H, 1996, J PUBLIC HEALTH MED, V18, P321, DOI 10.1093/oxfordjournals.pubmed.a024513; Blumenshine P, 2010, AM J PREV MED, V39, P263, DOI 10.1016/j.amepre.2010.05.012; Breslow NE, 1980, IARC SCI PUBL, P5; Cano-Serral Gemma, 2006, Gac Sanit, V20, P25, DOI 10.1157/13084124; Collins JW, 1997, J NATL MED ASSOC, V89, P198; Goldani MZ, 2004, AM J PUBLIC HEALTH, V94, P1366, DOI 10.2105/AJPH.94.8.1366; HACK M, 1995, FUTURE CHILD, V5, P176, DOI 10.2307/1602514; Hien NT, 2005, TROP DOCT, V35, P103, DOI 10.1258/0049475054036823; Jefferis BJMH, 2002, BRIT MED J, V325, P305, DOI 10.1136/bmj.325.7359.305; Jewell RT, 2006, HEALTH ECON, V15, P1245, DOI 10.1002/hec.1121; Khan-Neelofur D, 1998, PAEDIATR PERINAT EP, V12, P7, DOI 10.1046/j.1365-3016.12.s2.6.x; KOTELCHUCK M, 1994, AM J PUBLIC HEALTH, V84, P1486, DOI 10.2105/AJPH.84.9.1486; Krans EE, 2012, AM J OBSTET GYNECOL, V206, P398, DOI 10.1016/j.ajog.2011.06.082; Lauderdale Diane S, 2010, Med Care Res Rev, V67, P609, DOI 10.1177/1077558709351530; Li CY, 2008, PUBLIC HEALTH, V122, P243, DOI 10.1016/j.puhe.2007.05.011; Liu Ying-hui, 2006, Zhonghua Liu Xing Bing Xue Za Zhi, V27, P1029; Liu YH, 2008, AM J PUBLIC HEALTH, V98, P687, DOI 10.2105/AJPH.2006.088716; Lu M C, 2003, J Matern Fetal Neonatal Med, V13, P362, DOI 10.1080/713605924; Nwaru BI, 2012, EUR J PUBLIC HEALTH, V22, P776, DOI 10.1093/eurpub/ckr182; Orsini N, 2011, STATA J, V11, P1; PANETH NS, 1995, FUTURE CHILD, V5, P19, DOI 10.2307/1602505; Pathak PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013593; Petrou S, 2003, EUR J OBSTET GYN R B, V106, P40, DOI 10.1016/S0301-2115(02)00215-4; RUTTER DR, 1990, SOC SCI MED, V30, P553, DOI 10.1016/0277-9536(90)90154-K; VanderWeele TJ, 2009, J CLIN EPIDEMIOL, V62, P438, DOI 10.1016/j.jclinepi.2008.08.001; Wehby GL, 2009, HEALTH POLICY PLANN, V24, P175, DOI 10.1093/heapol/czp005	29	63	66	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 26	2014	9	11							e113377	10.1371/journal.pone.0113377	http://dx.doi.org/10.1371/journal.pone.0113377			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CA8CZ	24594907	Green Submitted, Green Published, gold			2023-01-03	WOS:000349145400046
J	Solomon, BJ; Mok, T; Kim, DW; Wu, YL; Nakagawa, K; Mekhail, T; Felip, E; Cappuzzo, F; Paolini, J; Usari, T; Iyer, S; Reisman, A; Wilner, KD; Tursi, J; Blackhall, F; Boyer, M; Ganju, V; Hughes, B; Pavlakis, N; Solomon, B; Varma, S; Berghmans, T; Canon, JL; Demedts, I; Janssens, A; Louis, R; Pieters, T; Schallier, D; Surmont, V; da Silva, CM; Ferreira, CGM; Hirsh, V; Joy, A; Laberge, F; Morzycki, W; Wierzbicki, R; Han, B; Liu, X; Qin, S; Shi, Y; Wang, Y; Wu, G; Wu, YL; Zhou, C; Ahvonen, J; Barlesi, F; Cadranel, J; Dansin, E; Fayette, J; Morere, JF; Moro-Sibilot, D; Pujol, JL; Quoix, E; Zalcman, G; Frickhofen, N; Schneider, CP; Wehler, T; Mok, T; So, P; Cuffe, S; Bearz, A; Boni, C; Cappuzzo, F; Cognetti, F; De Braud, F; De Pas, T; Galetta, D; Migliorino, M; Rocco, D; Scagliotti, G; Tagliaferri, P; Tiseo, M; Aoe, K; Hida, T; Kato, T; Kozuki, T; Nakagawa, K; Niho, S; Nishio, M; Nokihara, H; Satouchi, M; Seto, T; Takahashi, T; Ahn, JS; Kim, DW; Kim, SW; Berchem, G; Rodriguez, OA; Biesma, B; Dingemans, AM; Smit, E; Helland, A; Barata, F; Gorbunova, V; Manikhas, G; Orlov, S; Leong, S; Lim, HL; Soo, R; Tan, EH; Nosworthy, A; Villena, MC; Felip, E; Lopez, PG; Casado, DI; Banaclocha, NM; Aix, SP; Aransay, NR; Abreu, DR; Perez, JT; Gautschi, O; Pless, M; Zippelius, A; Chang, GC; Tsai, YH; Shparyk, Y; Blackhall, F; Steele, N; Armenio, V; Dragnev, K; Dugan, M; Gadgeel, S; Gerber, D; Graziano, S; Gurubhagavatula, S; Horn, L; Jalal, S; Lauer, R; Mehra, R; Mekhail, T; Mirshahidi, H; Pakkala, S; Polikoff, J; Raftopoulos, H; Saleh, M; Salgia, R; Waqar, S				Solomon, Benjamin J.; Mok, Tony; Kim, Dong-Wan; Wu, Yi-Long; Nakagawa, Kazuhiko; Mekhail, Tarek; Felip, Enriqueta; Cappuzzo, Federico; Paolini, Jolanda; Usari, Tiziana; Iyer, Shrividya; Reisman, Arlene; Wilner, Keith D.; Tursi, Jennifer; Blackhall, Fiona; Boyer, M.; Ganju, V.; Hughes, B.; Pavlakis, N.; Solomon, B.; Varma, S.; Berghmans, T.; Canon, J-L; Demedts, I.; Janssens, A.; Louis, R.; Pieters, T.; Schallier, D.; Surmont, V.; da Silva, C. Maciel; Ferreira, C-G Moreira; Hirsh, V.; Joy, A.; Laberge, F.; Morzycki, W.; Wierzbicki, R.; Han, B.; Liu, X.; Qin, S.; Shi, Y.; Wang, Y.; Wu, G.; Wu, Y-L; Zhou, C.; Ahvonen, J.; Barlesi, F.; Cadranel, J.; Dansin, E.; Fayette, J.; Morere, J-F; Moro-Sibilot, D.; Pujol, J-L; Quoix, E.; Zalcman, G.; Frickhofen, N.; Schneider, C-P; Wehler, T.; Mok, T.; So, P.; Cuffe, S.; Bearz, A.; Boni, C.; Cappuzzo, F.; Cognetti, F.; De Braud, F.; De Pas, T.; Galetta, D.; Migliorino, M.; Rocco, D.; Scagliotti, G.; Tagliaferri, P.; Tiseo, M.; Aoe, K.; Hida, T.; Kato, T.; Kozuki, T.; Nakagawa, K.; Niho, S.; Nishio, M.; Nokihara, H.; Satouchi, M.; Seto, T.; Takahashi, T.; Ahn, J-S; Kim, D-W; Kim, S-W; Berchem, G.; Rodriguez, O. Arrieta; Biesma, B.; Dingemans, A-M; Smit, E.; Helland, A.; Barata, F.; Gorbunova, V.; Manikhas, G.; Orlov, S.; Leong, S.; Lim, H-L; Soo, R.; Tan, E-H; Nosworthy, A.; Villena, M. Codes; Felip, E.; Lopez, P. Garrido; Casado, D. Isla; Banaclocha, N. Martinez; Aix, S. Ponce; Aransay, N. Reguart; Abreu, D. Rodriguez; Perez, J. Trigo; Gautschi, O.; Pless, M.; Zippelius, A.; Chang, G-C; Tsai, Y-H; Shparyk, Y.; Blackhall, F.; Steele, N.; Armenio, V.; Dragnev, K.; Dugan, M.; Gadgeel, S.; Gerber, D.; Graziano, S.; Gurubhagavatula, S.; Horn, L.; Jalal, S.; Lauer, R.; Mehra, R.; Mekhail, T.; Mirshahidi, H.; Pakkala, S.; Polikoff, J.; Raftopoulos, H.; Saleh, M.; Salgia, R.; Waqar, S.		PROFILE 1014 Investigators	First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANAPLASTIC LYMPHOMA; PHASE-III; CISPLATIN; PLUS; ADENOCARCINOMA; GEFITINIB; CRITERIA; THERAPY; QLQ-C30; KINASE	BACKGROUND The efficacy of the ALK inhibitor crizotinib as compared with standard chemotherapy as first-line treatment for advanced ALK-positive non-small-cell lung cancer (NSCLC) is unknown. METHODS We conducted an open-label, phase 3 trial comparing crizotinib with chemotherapy in 343 patients with advanced ALK-positive nonsquamous NSCLC who had received no previous systemic treatment for advanced disease. Patients were randomly assigned to receive oral crizotinib at a dose of 250 mg twice daily or to receive intravenous chemotherapy (pemetrexed, 500 mg per square meter of body-surface area, plus either cisplatin, 75 mg per square meter, or carboplatin, target area under the curve of 5 to 6 mg per milliliter per minute) every 3 weeks for up to six cycles. Crossover to crizotinib treatment after disease progression was permitted for patients receiving chemotherapy. The primary end point was progression-free survival as assessed by independent radiologic review. RESULTS Progression-free survival was significantly longer with crizotinib than with chemotherapy (median, 10.9 months vs. 7.0 months; hazard ratio for progression or death with crizotinib, 0.45; 95% confidence interval [CI], 0.35 to 0.60; P<0.001). Objective response rates were 74% and 45%, respectively (P<0.001). Median overall survival was not reached in either group (hazard ratio for death with crizotinib, 0.82; 95% CI, 0.54 to 1.26; P = 0.36); the probability of 1-year survival was 84% with crizotinib and 79% with chemotherapy. The most common adverse events with crizotinib were vision disorders, diarrhea, nausea, and edema, and the most common events with chemotherapy were nausea, fatigue, vomiting, and decreased appetite. As compared with chemotherapy, crizotinib was associated with greater reduction in lung cancer symptoms and greater improvement in quality of life. CONCLUSIONS Crizotinib was superior to standard first-line pemetrexed-plus-platinum chemotherapy in patients with previously untreated advanced ALK-positive NSCLC.	[Solomon, Benjamin J.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Mok, Tony] Chinese Univ Hong Kong, State Key Lab South China, Hong Kong Canc Inst, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China; [Wu, Yi-Long] Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China; [Kim, Dong-Wan] Seoul Natl Univ Hosp, Seoul 110744, South Korea; [Nakagawa, Kazuhiko] Kinki Univ, Osaka, Japan; [Mekhail, Tarek] Florida Hosp, Inst Canc, Orlando, FL USA; [Felip, Enriqueta] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain; [Cappuzzo, Federico] Ist Toscano Tumori, Livorno, Italy; [Paolini, Jolanda; Usari, Tiziana; Tursi, Jennifer] Pfizer Oncol, Milan, Italy; [Iyer, Shrividya] Pfizer Oncol, New York, NY USA; [Reisman, Arlene] Pfizer Global Innovat Pharma Business, New York, NY USA; [Wilner, Keith D.] Pfizer Oncol, La Jolla, CA USA; [Blackhall, Fiona] Univ Manchester, Christie Hosp, Manchester, Lancs, England; [Blackhall, Fiona] Univ Manchester, Inst Canc Sci, Manchester, Lancs, England	Peter Maccallum Cancer Center; Chinese University of Hong Kong; Seoul National University (SNU); Seoul National University Hospital; Kindai University (Kinki University); Adventist Health Services; AdventHealth; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO); ISPRO Istituto per lo studio, la prevenzione e la rete oncologica; Pfizer; Pfizer; Pfizer; Pfizer; Christie NHS Foundation Trust; Christie Hospital; University of Manchester; University of Manchester	Solomon, BJ (corresponding author), Peter MacCallum Canc Ctr, Dept Med Oncol, St Andrews Pl, East Melbourne, Vic 3002, Australia.	ben.solomon@petermac.org	Wu, Yi-Long/AAB-9137-2022; Cappuzzo, federico/R-2827-2016; Wu, Yi-Long/AAW-9832-2020; Galetta, Domenico/J-4082-2018; Cognetti, Francesco/AAC-2637-2019; GARRIDO, PILAR/D-5187-2017; Boyer, Michael/GZG-2105-2022; Kim, Dong-Wan/J-5391-2012; Mok, Tony Shu Kam/B-2310-2019; Berchem, Guy/C-9364-2014; Hughes, Brett/A-4546-2015; Blackhall, Fiona H/N-2186-2015; Orlov, Sergey/AAC-8379-2022; Wu, Yi-Long/C-3396-2008; FELIP, ENRIQUETA/AAG-6316-2019; ZALCMAN, Gerard/M-8113-2019; Wehler, Thomas Christian/AAY-6362-2020; Tagliaferri, Pierosandro/K-9546-2016; Wu, Yi-Long/GRJ-9238-2022; Helland, Åslaug/H-3910-2015; Tiseo, Marcello/K-6119-2016; De Pas, tommaso/K-4879-2018	Cappuzzo, federico/0000-0002-6295-6767; Galetta, Domenico/0000-0002-4878-5906; GARRIDO, PILAR/0000-0002-5899-6125; Boyer, Michael/0000-0002-0452-2987; Mok, Tony Shu Kam/0000-0002-8251-0551; Berchem, Guy/0000-0003-0157-2257; Hughes, Brett/0000-0002-1811-0537; Blackhall, Fiona H/0000-0001-8716-3395; Wu, Yi-Long/0000-0002-3611-0258; Wu, Yi-Long/0000-0002-3611-0258; Helland, Åslaug/0000-0002-5520-0275; Tiseo, Marcello/0000-0002-9553-8465; Smit, Egbert/0000-0002-7329-6995; MORO-SIBILOT, Denis/0000-0001-6776-8610; Rodriguez-Abreu, Delvys/0000-0003-0506-1366; Balmana, Judith/0000-0002-0762-6415; Solomon, Benjamin/0000-0003-3059-5730; Iyer, shrividya/0000-0002-1770-2311; FELIP, ENRIQUETA/0000-0002-7620-0098	Pfizer	Pfizer(Pfizer)	Supported by Pfizer.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; *ABB MOL, 2011, VYS ALK BREAK AP FIS; BERGMAN B, 1994, EUR J CANCER, V30A, P635, DOI 10.1016/0959-8049(94)90535-5; Blackhall FH, 2014, J CLIN ONCOL, V32, P2780, DOI 10.1200/JCO.2013.54.5921; Camidge DR, 2012, LANCET ONCOL, V13, P1011, DOI 10.1016/S1470-2045(12)70344-3; Camidge DR, 2012, NAT REV CLIN ONCOL, V9, P268, DOI 10.1038/nrclinonc.2012.43; Camidge DR, 2011, J THORAC ONCOL, V6, P774, DOI 10.1097/JTO.0b013e31820cf053; Christensen JG, 2007, MOL CANCER THER, V6, P3314, DOI 10.1158/1535-7163.MCT-07-0365; Cortes JE, 2012, J CLIN ONCOL, V30; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Fayers P, 2002, EUR J CANCER, V38, pS125; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X; Mok T, 2013, J CLIN ONCOL, V31, P1081, DOI 10.1200/JCO.2012.43.0652; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Paz-Ares L, 2012, LANCET ONCOL, V13, P247, DOI 10.1016/S1470-2045(12)70063-3; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; ROBINS JM, 1991, COMMUN STAT THEORY, V20, P2609, DOI 10.1080/03610929108830654; ROBINS JM, 1992, EPIDEMIOLOGY, V3, P319, DOI 10.1097/00001648-199207000-00007; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Scagliotti GV, 2008, J CLIN ONCOL, V26, P3543, DOI 10.1200/JCO.2007.15.0375; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; Sequist LV, 2013, J CLIN ONCOL, V31, P3327, DOI 10.1200/JCO.2012.44.2806; Shaw AT, 2013, ANN ONCOL, V24, P59, DOI 10.1093/annonc/mds242; Shaw AT, 2013, NEW ENGL J MED, V368, P2385, DOI 10.1056/NEJMoa1214886; Shaw AT, 2009, J CLIN ONCOL, V27, P4247, DOI 10.1200/JCO.2009.22.6993; SHAW AT, 2013, 15 WORLD C LUNG CANC; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Temple R, 2006, PHARMACOEPIDEM DR S, V15, P241, DOI 10.1002/pds.1211; White IR, 1999, STAT MED, V18, P2617, DOI 10.1002/(SICI)1097-0258(19991015)18:19<2617::AID-SIM187>3.0.CO;2-E; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	33	2194	2311	8	186	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 4	2014	371	23					2167	2177		10.1056/NEJMoa1408440	http://dx.doi.org/10.1056/NEJMoa1408440			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AW0IY	25470694	Green Published, Bronze			2023-01-03	WOS:000345976700005
J	Pei, XY; Dai, Y; Felthousen, J; Chen, S; Takabatake, Y; Zhou, L; Youssefian, LE; Sanderson, MW; Bodie, WW; Kramer, LB; Orlowski, RZ; Grant, S				Pei, Xin-Yan; Dai, Yun; Felthousen, Jessica; Chen, Shuang; Takabatake, Yukie; Zhou, Liang; Youssefian, Leena E.; Sanderson, Michael W.; Bodie, Wesley W.; Kramer, Lora B.; Orlowski, Robert Z.; Grant, Steven			Circumvention of Mcl-1-Dependent Drug Resistance by Simultaneous Chk1 and MEK1/2 Inhibition in Human Multiple Myeloma Cells	PLOS ONE			English	Article							DOWN-REGULATION; BONE-MARROW; INDUCE APOPTOSIS; UP-REGULATION; FACTOR-I; MCL-1; PHOSPHORYLATION; SURVIVAL; PROTEIN; BIM	The anti-apoptotic protein Mcl-1 plays a major role in multiple myeloma (MM) cell survival as well as bortezomib- and microenvironmental forms of drug resistance in this disease. Consequently, there is a critical need for strategies capable of targeting Mcl-1-dependent drug resistance in MM. The present results indicate that a regimen combining Chk1 with MEK1/2 inhibitors effectively kills cells displaying multiple forms of drug resistance stemming from Mcl-1 up-regulation in association with direct transcriptional Mcl-1 down-regulation and indirect disabling of Mcl-1 anti-apoptotic function through Bim up-regulation and increased Bim/Mcl-1 binding. These actions release Bak from Mcl-1, accompanied by Bak/Bax activation. Analogous events were observed in both drug-naive and acquired bortezomib-resistant MM cells displaying increased Mcl-1 but diminished Bim expression, or cells ectopically expressing Mcl-1. Moreover, concomitant Chk1 and MEK1/2 inhibition blocked Mcl-1 up-regulation induced by IL-6/IGF-1 or co-culture with stromal cells, effectively overcoming microenvironment-related drug resistance. Finally, this regimen down-regulated Mcl-1 and robustly killed primary CD138(+) MM cells, but not normal hematopoietic cells. Together, these findings provide novel evidence that this targeted combination strategy could be effective in the setting of multiple forms of Mcl-1-related drug resistance in MM.	[Pei, Xin-Yan; Dai, Yun; Felthousen, Jessica; Chen, Shuang; Takabatake, Yukie; Zhou, Liang; Youssefian, Leena E.; Sanderson, Michael W.; Bodie, Wesley W.; Kramer, Lora B.; Grant, Steven] Virginia Commonwealth Univ, Dept Med, Div Hematol Oncol, Richmond, VA 23298 USA; [Pei, Xin-Yan; Dai, Yun; Felthousen, Jessica; Chen, Shuang; Takabatake, Yukie; Zhou, Liang; Youssefian, Leena E.; Sanderson, Michael W.; Bodie, Wesley W.; Kramer, Lora B.; Grant, Steven] Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Richmond, VA 23298 USA; [Orlowski, Robert Z.] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA; [Grant, Steven] Virginia Commonwealth Univ, Dept Biochem, Richmond, VA USA; [Grant, Steven] Inst Mol Med, Richmond, VA USA	Virginia Commonwealth University; Virginia Commonwealth University; University of Texas System; UTMD Anderson Cancer Center; Virginia Commonwealth University	Grant, S (corresponding author), Virginia Commonwealth Univ, Dept Med, Div Hematol Oncol, Med Coll Virginia Campus, Richmond, VA 23298 USA.	stgrant@vcu.edu	Dai, Yun/AAG-4040-2019	Dai, Yun/0000-0003-2285-0818; Orlowski, Robert/0000-0002-5723-4129; Takabatake, Yukie/0000-0003-0540-3610	National Institutes of Health [CA100866, CA93738, P50 CA142509-01]; MMRF; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA100866, R01CA093738, P50CA142509] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MMRF; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by awards CA100866, CA93738, and P50 CA142509-01 from the National Institutes of Health and the MMRF. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bhat UG, 2010, LEUKEMIA, V24, P851, DOI 10.1038/leu.2010.3; Bhat UG, 2010, MOL CANCER THER, V9, P1688, DOI 10.1158/1535-7163.MCT-09-0919; Bhat UG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006593; Chen S, 2007, CANCER RES, V67, P782, DOI 10.1158/0008-5472.CAN-06-3964; Chen S, 2012, CANCER RES, V72, P4225, DOI 10.1158/0008-5472.CAN-12-1118; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Dai Y, 2002, BLOOD, V100, P3333, DOI 10.1182/blood-2002-03-0940; Dai Y, 2008, BLOOD, V112, P2439, DOI 10.1182/blood-2008-05-159392; Dai Y, 2011, J BIOL CHEM, V286, P34036, DOI 10.1074/jbc.M111.284216; Dai Y, 2011, BLOOD, V117, P1947, DOI 10.1182/blood-2010-06-291146; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Eichhorn JM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.411; Ewings KE, 2007, CELL CYCLE, V6, P2236, DOI 10.4161/cc.6.18.4728; Ewings KE, 2007, EMBO J, V26, P2856, DOI 10.1038/sj.emboj.7601723; Fulda S, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00121; Gomez-Bougie P, 2007, CANCER RES, V67, P5418, DOI 10.1158/0008-5472.CAN-06-4322; Gores GJ, 2012, GENE DEV, V26, P305, DOI 10.1101/gad.186189.111; Han J, 2004, J BIOL CHEM, V279, P22020, DOI 10.1074/jbc.M313234200; Hazlehurst LA, 2003, ONCOGENE, V22, P7396, DOI 10.1038/sj.onc.1206943; Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hu JS, 2012, BLOOD, V119, P826, DOI 10.1182/blood-2011-07-366492; Jourdan M, 2003, ONCOGENE, V22, P2950, DOI 10.1038/sj.onc.1206423; Kale AJ, 2012, J MED CHEM, V55, P10317, DOI 10.1021/jm300434z; Kawabata T, 2012, J BIOL CHEM, V287, P10289, DOI 10.1074/jbc.M111.319426; Khoury JD, 2003, J PATHOL, V199, P90, DOI 10.1002/path.1254; Kim KH, 2010, BIOMAT PROP PROD DEV, P149; Konopleva M, 2012, LEUKEMIA, V26, P778, DOI 10.1038/leu.2011.287; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Kuhn DJ, 2012, BLOOD, V120, P3260, DOI 10.1182/blood-2011-10-386789; Laubach JP, 2011, J NATL COMPR CANC NE, V9, P1209, DOI 10.6004/jnccn.2011.0098; Le Gouill S, 2004, CELL CYCLE, V3, P1259; Le Gouill S, 2004, BLOOD, V104, P2886, DOI 10.1182/blood-2004-05-1760; Ley R, 2004, J BIOL CHEM, V279, P8837, DOI 10.1074/jbc.M311578200; MacCallum DE, 2005, CANCER RES, V65, P5399, DOI 10.1158/0008-5472.CAN-05-0233; Mahindra A, 2012, NAT REV CLIN ONCOL, V9, P135, DOI 10.1038/nrclinonc.2012.15; Manier S, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/157496; Mazumder S, 2012, CANCER RES, V72, P3069, DOI 10.1158/0008-5472.CAN-11-4106; McMillin DW, 2010, NAT MED, V16, P483, DOI 10.1038/nm.2112; Mitsiades CS, 2006, EUR J CANCER, V42, P1564, DOI 10.1016/j.ejca.2005.12.025; MOALLI PA, 1993, CANCER RES, V53, P3877; Morales AA, 2011, BLOOD, V118, P1329, DOI 10.1182/blood-2011-01-327197; Nair RR, 2012, ADV PHARMACOL, V65, P143, DOI 10.1016/B978-0-12-397927-8.00006-3; Nefedova Y, 2003, LEUKEMIA, V17, P1175, DOI 10.1038/sj.leu.2402924; Nencioni A, 2005, BLOOD, V105, P3255, DOI 10.1182/blood-2004-10-3984; Nguyen M, 2007, P NATL ACAD SCI USA, V104, P19512, DOI 10.1073/pnas.0709443104; Nifoussi SK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047060; Pagnucco G, 2004, ANN NY ACAD SCI, V1028, P390, DOI 10.1196/annals.1322.047; Pei XY, 2007, BLOOD, V110, P2092, DOI 10.1182/blood-2007-04-083204; Pei XY, 2011, BLOOD, V118, P5189, DOI 10.1182/blood-2011-02-339432; Perez-Galan P, 2007, BLOOD, V109, P4441, DOI 10.1182/blood-2006-07-034173; Rahmani M, 2005, J BIOL CHEM, V280, P35217, DOI 10.1074/jbc.M506551200; Schmidmaier R., 2006, Experimental Oncology, V28, P12; Schmidmaier R, 2004, BLOOD, V104, P1825, DOI 10.1182/blood-2003-12-4218; Senderowicz AM, 2000, ONCOGENE, V19, P6600, DOI 10.1038/sj.onc.1204085; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Tai YT, 2007, BLOOD, V110, P1656, DOI 10.1182/blood-2007-03-081240; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Wuilleme-Toumi S, 2005, LEUKEMIA, V19, P1248, DOI 10.1038/sj.leu.2403784; Yang-Yen HF, 2006, J BIOMED SCI, V13, P201, DOI 10.1007/s11373-005-9064-4; Yasui H, 2006, BRIT J HAEMATOL, V132, P385, DOI 10.1111/j.1365-2141.2005.05860.x; Zhang B, 2003, ONCOGENE, V22, P1848, DOI 10.1038/sj.onc.1206358; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; Zhang J, 2003, ONCOGENE, V22, P6289, DOI 10.1038/sj.onc.1206718	64	63	66	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 4	2014	9	3							e89064	10.1371/journal.pone.0089064	http://dx.doi.org/10.1371/journal.pone.0089064			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC4FD	24594907	Green Published, Green Submitted, gold			2023-01-03	WOS:000332475500008
J	Dart, RC; Surratt, HL; Cicero, TJ; Parrino, MW; Severtson, SG; Bucher-Bartelson, B; Green, JL				Dart, Richard C.; Surratt, Hilary L.; Cicero, Theodore J.; Parrino, Mark W.; Severtson, S. Geoff; Bucher-Bartelson, Becki; Green, Jody L.			Trends in Opioid Analgesic Abuse and Mortality in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EXTENDED-RELEASE OXYCODONE; COLLEGE-STUDENTS; NONMEDICAL USE; PRESCRIPTION; DIVERSION; IMPACT	Background The use of prescription opioid medications has increased greatly in the United States during the past two decades; in 2010, there were 16,651 opioid-related deaths. In response, hundreds of federal, state, and local interventions have been implemented. We describe trends in the diversion and abuse of prescription opioid analgesics using data through 2013. Methods We used five programs from the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS) System to describe trends between 2002 and 2013 in the diversion and abuse of all products and formulations of six prescription opioid analgesics: oxycodone, hydrocodone, hydromorphone, fentanyl, morphine, and tramadol. The programs gather data from drug-diversion investigators, poison centers, substance-abuse treatment centers, and college students. Results Prescriptions for opioid analgesics increased substantially from 2002 through 2010 in the United States but then decreased slightly from 2011 through 2013. In general, RADARS System programs reported large increases in the rates of opioid diversion and abuse from 2002 to 2010, but then the rates flattened or decreased from 2011 through 2013. The rate of opioid-related deaths rose and fell in a similar pattern. Reported nonmedical use did not change significantly among college students. Conclusions Postmarketing surveillance indicates that the diversion and abuse of prescription opioid medications increased between 2002 and 2010 and plateaued or decreased between 2011 and 2013. These findings suggest that the United States may be making progress in controlling the abuse of opioid analgesics. Copyright (C) 2015 Massachusetts Medical Society.	[Dart, Richard C.; Severtson, S. Geoff; Bucher-Bartelson, Becki; Green, Jody L.] Denver Hlth & Hosp Author, Rocky Mt Poison & Drug Ctr, Denver, CO 80204 USA; [Surratt, Hilary L.] Nova SE Univ, Ctr Appl Res Subst Use & Hlth Dispar, Ft Lauderdale, FL 33314 USA; [Cicero, Theodore J.] Washington Univ, Dept Psychiat, Sch Med, St Louis, MO 63130 USA; [Parrino, Mark W.] Amer Assoc Treatment Opioid Dependence, New York, NY USA	Denver Health Medical Center; Nova Southeastern University; Washington University (WUSTL)	Dart, RC (corresponding author), Denver Hlth & Hosp Author, Rocky Mt Poison & Drug Ctr, 777 Bannock St,Mailcode 0180, Denver, CO 80204 USA.	richard.dart@rmpdc.org		Dart, Richard/0000-0001-5989-9354; Surratt, Hilary/0000-0003-4027-7840	Denver Health and Hospital Authority	Denver Health and Hospital Authority	Funded by the Denver Health and Hospital Authority.	[Anonymous], 2012, MULT CAUS DEATH FIL; [Anonymous], HOM RECR SAF LAWS ST; [Anonymous], 2013, BHSIS SER S; [Anonymous], 2002, PRESCR DRUGS STAT MO; Cicero TJ, 2007, DRUG ALCOHOL DEPEN, V91, P115, DOI 10.1016/j.drugalcdep.2007.05.008; Cicero TJ, 2012, NEW ENGL J MED, V367, P187, DOI 10.1056/NEJMc1204141; Dart RC, 2014, CLIN J PAIN, V30, P685, DOI 10.1097/AJP.0000000000000001; Dart RC, 2009, DRUG ALCOHOL DEPEN, V105, pS26, DOI 10.1016/j.drugalcdep.2009.08.011; Dasgupta N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041181; Davis JM, 2014, PHARMACOEPIDEM DR S, V23, P18, DOI 10.1002/pds.3533; Doherty C, 2013, AM SEE US LOSING GRO; Drug Abuse Warning Network, 2013, 2011 NAT EST DRUG RE; Franklin GM, 2012, AM J IND MED, V55, P325, DOI 10.1002/ajim.21998; IMS Institute for Healthcare Informatics, 2011, HSRN DAT BRIEF XPON; Inciardi James A, 2009, J Opioid Manag, V5, P81; McCabe SE, 2014, ADDICT BEHAV, V39, P1176, DOI 10.1016/j.addbeh.2014.03.008; Mowry JB, 2013, CLIN TOXICOL, V51, P949, DOI 10.3109/15563650.2013.863906; Muhuri PK, 2013, CBHSQ CTR BEHAV HLTH; Office of National Drug Control Policy US Executive Office of the President, 2011, EP RESP AM PRESCR DR; Reifler LM, 2012, PAIN MED, V13, P434, DOI 10.1111/j.1526-4637.2012.01327.x; Rosenblum A, 2007, DRUG ALCOHOL DEPEN, V90, P64, DOI 10.1016/j.drugalcdep.2007.02.012; Severtson SG, 2013, J PAIN, V14, P1122, DOI 10.1016/j.jpain.2013.04.011; Substance Abuse and Mental Health Services Administration, 2013, NSDUH SER H, VH-46; Substance Abuse and Mental Health Services Administration, 2013, NAT SURV DRUG US HLT; Substance Abuse Mental Health Services Administration, 2012, NSDUH SER H, V44; Surratt HL, 2014, PHARMACOEPIDEM DR S, V23, P314, DOI 10.1002/pds.3553; Unick GJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054496	27	867	868	6	223	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 15	2015	372	3					241	248		10.1056/NEJMsa1406143	http://dx.doi.org/10.1056/NEJMsa1406143			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AZ3HX	25587948	Bronze, Green Published			2023-01-03	WOS:000348119200008
J	Yuan, QL; Guo, TM; Liu, L; Sun, F; Zhang, YG				Yuan, Qi-ling; Guo, Tuan-mao; Liu, Liang; Sun, Fu; Zhang, Yin-gang			Traditional Chinese Medicine for Neck Pain and Low Back Pain: A Systematic Review and Meta-Analysis	PLOS ONE			English	Article							RANDOMIZED CLINICAL-TRIAL; CHRONIC SPINAL PAIN; TERM-FOLLOW-UP; ACUPUNCTURE TREATMENT; COMPARING ACUPUNCTURE; THERAPY; EXERCISE; ACUPRESSURE; EFFICACY; PLACEBO	Background Neck pain (NP) and low back pain (LBP) are common symptoms bothering people in daily life. Traditional Chinese medicine (TCM) has been used to treat various symptoms and diseases in China and has been demonstrated to be effective. The objective of the present study was to review and analyze the existing data about pain and disability in TCM treatments for NP and LBP. Methods Studies were identified by a comprehensive search of databases, such as MEDLINE, EMBASE, and Cochrane Library, up to September 1, 2013. A meta-analysis was performed to evaluate the efficacy and safety of TCM in managing NP and LBP. Results Seventy five randomized controlled trials (n = 11077) were included. Almost all of the studies investigated individuals experiencing chronic NP (CNP) or chronic LBP (CLBP). We found moderate evidence that acupuncture was more effective than sham-acupuncture in reducing pain immediately post-treatment for CNP (visual analogue scale (VAS) 10 cm, mean difference (MD) = -0.58 (-0.94, -0.22), 95% confidence interval, p = 0.01), CLBP (standardized mean difference = -0.47 (-0.77, -0.17), p = 0.003), and acute LBP (VAS 10 cm, MD = -0.99 (-1.24, -0.73), p < 0.001). Cupping could bemore effective than waitlist in VAS (100mm) (MD = -19.10 (-27.61, -10.58), p < 0.001) for CNP or medications (e.g. NSAID) for CLBP (MD = -5.4 (-8.9, -0.19), p = 0.003). No serious or life-threatening adverse effects were found. Conclusions Acupuncture, acupressure, and cupping could be efficacious in treating the pain and disability associated with CNP or CLBP in the immediate term. Gua sha, tai chi, qigong, and Chinese manipulation showed fair effects, but we were unable to draw any definite conclusions, and further research is still needed. The efficacy of tuina and moxibustion is unknown because no direct evidence was obtained. These TCM modalities are relatively safe.	[Yuan, Qi-ling; Liu, Liang; Sun, Fu; Zhang, Yin-gang] Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 1, Dept Orthopaed, Xian 710061, Peoples R China; [Guo, Tuan-mao] Xianyang Cent Hosp, Dept Orthopaed 2, Xianyang 712000, Shaanxi, Peoples R China; [Sun, Fu] Xian Med Coll, Affiliated Hosp, Dept Orthopaed, Xian 710077, Peoples R China	Xi'an Jiaotong University; Xi'an Medical University	Zhang, YG (corresponding author), Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 1, Dept Orthopaed, Xian 710061, Peoples R China.	zyingang@mail.xjtu.edu.cn	Yuan, Qiling/AGX-7768-2022	Yuan, Qiling/0000-0002-4822-2513; Guo, Meiting/0000-0002-1497-7053	Natural Scientific Fund of China [81371987, 81171761]	Natural Scientific Fund of China	The authors are grateful for the support of the Natural Scientific Fund of China (no. 81371987, 81171761). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersson G, 1997, ADULT SPINE PRINCIPL; Birch S, 1998, CLIN J PAIN, V14, P248, DOI 10.1097/00002508-199809000-00012; Braun M, 2011, PAIN MED, V12, P362, DOI 10.1111/j.1526-4637.2011.01053.x; Brinkhaus B, 2006, ARCH INTERN MED, V166, P450; Chen J, 2009, CHIN J TRADIT MED TR, V17, P32; Cherkin DC, 2009, ARCH INTERN MED, V169, P858, DOI 10.1001/archinternmed.2009.65; Cherkin DC, 2001, ARCH INTERN MED, V161, P1081, DOI 10.1001/archinte.161.8.1081; Cho YJ, 2013, SPINE, V38, P549, DOI 10.1097/BRS.0b013e318275e601; Chou R, 2010, JAMA-J AM MED ASSOC, V303, P1295, DOI 10.1001/jama.2010.344; COAN RM, 1981, AM J CHINESE MED, V9, P326, DOI 10.1142/S0192415X81000433; COAN RM, 1980, AM J CHINESE MED, V8, P181, DOI 10.1142/S0192415X80000141; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cote P, 1998, SPINE, V23, P1689, DOI 10.1097/00007632-199808010-00015; Cramer H, 2011, FORSCH KOMPLEMENTMED, V18, P327, DOI 10.1159/000335294; D'Sylva J, 2010, MANUAL THER, V15, P415, DOI 10.1016/j.math.2010.04.003; Farhadi K, 2009, COMPLEMENT THER MED, V17, P9, DOI 10.1016/j.ctim.2008.05.003; Fejer R, 2006, EUR SPINE J, V15, P834, DOI 10.1007/s00586-004-0864-4; Fu LM, 2009, J ALTERN COMPLEM MED, V15, P133, DOI 10.1089/acm.2008.0135; Fu WB, 2009, CHIN J INTEGR MED, V15, P426, DOI 10.1007/s11655-009-0426-z; Furlan AD, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/953139; Furlan AD, 2009, SPINE, V34, P1929, DOI 10.1097/BRS.0b013e3181b1c99f; Gao S, 1993, ZHONG YI YAO DONG TA, V4, P25, DOI 1016/j.math.2010.04.003; Geng M, 1989, ZHEN JIU XUE BAO, V3, P29; Giles LGF, 2003, SPINE, V28, P1490, DOI 10.1097/00007632-200307150-00003; Giles LGF, 1999, J MANIP PHYSIOL THER, V22, P376, DOI 10.1016/S0161-4754(99)70082-5; Grant DJ, 1999, PAIN, V82, P9, DOI 10.1016/S0304-3959(99)00027-5; Gross A, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004249.pub3; Haake M, 2007, ARCH INTERN MED, V167, P1892, DOI 10.1001/archinte.167.17.1892; Hall AM, 2011, ARTHRIT CARE RES, V63, P1576, DOI 10.1002/acr.20594; Hasegawa TM, 2013, ACUPUNCT MED; Hayden J, 2011, COCHRANE DB SYST REV; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; [洪永锋 HONG Yongfeng], 2006, [中国康复医学杂志, Chinese Journal of Rehabilitation Medicine], V21, P340; Hsieh LLC, 2006, BMJ-BRIT MED J, V332, P696, DOI 10.1136/bmj.38744.672616.AE; Hsieh LLC, 2004, PREV MED, V39, P168, DOI 10.1016/j.ypmed.2004.01.036; Hunter RF, 2012, CLIN J PAIN, V28, P259, DOI 10.1097/AJP.0b013e3182274018; Inoue Motohiro, 2006, Acupunct Med, V24, P103; Irnich D, 2001, BMJ-BRIT MED J, V322, P1574, DOI 10.1136/bmj.322.7302.1574; Itoh K, 2007, COMPLEMENT THER MED, V15, P172, DOI 10.1016/j.ctim.2006.05.003; Itoh Kazunori, 2006, Acupunct Med, V24, P5; Itoh Kazunori, 2004, Acupunct Med, V22, P170; Itoh Kazunori, 2009, Complement Ther Clin Pract, V15, P22, DOI 10.1016/j.ctcp.2008.09.003; Jacobs WCH, 2013, EUR SPINE J, V22, P1936, DOI 10.1007/s00586-013-2823-4; Kennedy S, 2008, COMPLEMENT THER MED, V16, P139, DOI 10.1016/j.ctim.2007.03.001; Kim JI, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-146; Kim TH, 2012, J OCCUP HEALTH, V54, P416, DOI 10.1539/joh.12-0133-OA; Lam M, 2013, SPINE, V38, P2124, DOI 10.1097/01.brs.0000435025.65564.b7; Lansinger B, 2007, SPINE, V32, P2415, DOI 10.1097/BRS.0b013e3181573b4b; Lao L., 2012, INTEGRATIVE PEDIAT O, P125; Lauche R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065378; Lauche R, 2012, AM J CHINESE MED, V40, P905, DOI 10.1142/S0192415X1250067X; Lauche R, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/429718; Lauche R, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-63; Lee JH, 2013, CLIN J PAIN, V29, P172, DOI 10.1097/AJP.0b013e31824909f9; Leibing E, 2002, PAIN, V96, P189, DOI 10.1016/S0304-3959(01)00444-4; Li DZ, 2006, FLORA CHINA, V22, P7; Li JY, 2009, NEI MONGOL J TRADIT, V14, P31; Li Q, 2007, CHIN J CLIN REHABIL, V11, P4531; Liang ZH, 2011, COMPLEMENT THER MED, V19, pS26, DOI 10.1016/j.ctim.2010.11.005; Lin JH, 2013, MANUAL THER, V18, P308, DOI 10.1016/j.math.2012.11.005; Liu BX, 2008, CHINESE J REHABILITA, V14, P572; Macedo LG, 2013, PHYS THER, V93, P1587, DOI 10.2522/ptj.20120464; MAKELA M, 1991, AM J EPIDEMIOL, V134, P1356; Meng CF, 2003, RHEUMATOLOGY, V42, P1508, DOI 10.1093/rheumatology/keg405; Miyazaki S, 2009, CLIN J PAIN, V25, P438, DOI 10.1097/AJP.0b013e318193a6e1; Molsberger AF, 2002, PAIN, V99, P579, DOI 10.1016/S0304-3959(02)00269-5; Moore RA, 1998, PAIN, V78, P209, DOI 10.1016/S0304-3959(98)00140-7; Moreno SG, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2981; Muller R, 2005, J MANIP PHYSIOL THER, V28, P3, DOI 10.1016/j.jmpt.2004.12.004; Nabeta T, 2002, COMPLEMENT THER MED, V10, P217, DOI 10.1016/S0965-2299(02)00082-1; Nuesch E, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c3515; Owens DK, 2010, J CLIN EPIDEMIOL, V63, P513, DOI 10.1016/j.jclinepi.2009.03.009; PETRIE JP, 1986, BRIT J RHEUMATOL, V25, P271; Rendant D, 2011, SPINE, V36, P419, DOI 10.1097/BRS.0b013e3181d51fca; Roelofs PD, 2011, COCHRANE DB SYST REV; Sahin N, 2010, ACUPUNCTURE ELECTRO, V35, P17, DOI 10.3727/036012910803860959; Sator-Katzenschlager SM, 2004, ANESTH ANALG, V98, P1359, DOI 10.1213/01.ANE.0000107941.16173.F7; Shankar Nilima, 2011, Indian J Physiol Pharmacol, V55, P25; Sherwin D C, 1992, Rehabil Nurs, V17, P253; Su Jiang-tao, 2010, Zhongguo Zhen Jiu, V30, P617; Suen Lorna K P, 2007, Complement Ther Clin Pract, V13, P63, DOI 10.1016/j.ctcp.2006.10.005; THOMAS M, 1991, AM J CHINESE MED, V19, P95, DOI 10.1142/S0192415X91000156; Trinh K, 2007, SPINE, V32, P236, DOI 10.1097/01.brs.0000252100.61002.d4; Tsui MLK, 2004, J ALTERN COMPLEM MED, V10, P803; Vas J, 2006, PAIN, V126, P245, DOI 10.1016/j.pain.2006.07.002; Vas J, 2012, PAIN, V153, P1883, DOI 10.1016/j.pain.2012.05.033; Vas Jorge, 2006, BMC Complement Altern Med, V6, P14, DOI 10.1186/1472-6882-6-14; von Trott P, 2009, J PAIN, V10, P501, DOI 10.1016/j.jpain.2008.11.004; Wang B. X., 2004, CHINESE J CLIN REHAB, V8, P3413; Weiss J, 2013, J ALTERN COMPLEMENT; White P, 2004, ANN INTERN MED, V141, P911, DOI 10.7326/0003-4819-141-12-200412210-00007; Witt CM, 2006, AM J EPIDEMIOL, V164, P487, DOI 10.1093/aje/kwj224; Xu M, 2009, LIAONING J TRADITION, V36, P1007; Xu M, 2013, AM J CHINESE MED, V41, P1, DOI 10.1142/S0192415X13500018; Xu Y, 1977, CHI JIAO YI SHENG ZA, V1, P34; Yang BH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035032; Yeh CH, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/196978; Yeung CKN, 2003, J ALTERN COMPLEM MED, V9, P479, DOI 10.1089/107555303322284767; Yip Y B, 2006, Complement Ther Clin Pract, V12, P18, DOI 10.1016/j.ctcp.2005.09.005; Yip YB, 2004, COMPLEMENT THER MED, V12, P28, DOI 10.1016/j.ctim.2003.12.003; Yun MD, 2012, J ALTERN COMPLEM MED, V18, P130, DOI 10.1089/acm.2010.0779; Zaringhalam Jalal, 2010, Chin Med, V5, P15, DOI 10.1186/1749-8546-5-15; [张洪来 Zhang Honglai], 2003, [中国针灸, Chinese Acupuncture and Moxibustion], V23, P637; Zhu LG, 2005, CHIN J ORTHOP TRAUMA, V18, P489; Zhu XM, 2002, AM J CHINESE MED, V30, P13, DOI 10.1142/S0192415X02000028	105	176	193	8	92	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 24	2015	10	2							e0117146	10.1371/journal.pone.0117146	http://dx.doi.org/10.1371/journal.pone.0117146			37	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CC9IY	25738838	Green Published, Green Submitted, gold			2023-01-03	WOS:000350683900024
